As filed with the Securities and Exchange Commission on October 22, 2021

 

Registration No. 333-    

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Synergy CHC Corp.

(Exact name of registrant as specified in its charter)

 

Nevada   2833   99-0379440

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

 

865 Spring Street

Westbrook, Maine 04092

(615) 939-9004

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

 

 

 

Jack Ross

Chief Executive Officer

c/o Synergy CHC Corp.

865 Spring Street

Westbrook, Maine 04092

(615) 939-9004

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

W. David Mannheim

E. Peter Strand

Michael K. Bradshaw, Jr.

Nelson Mullins Riley & Scarborough LLP

4140 Parklake Avenue, Suite 200

Raleigh, NC 27612

(919) 329-3800

 

C. Brophy Christensen, Jr., Esq.

Jeeho M. Lee, Esq.

O’Melveny & Myers LLP

Two Embarcadero Center, 28th Floor

San Francisco, CA 94111

(415) 984-8793

 

 

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer  
Non-accelerated filer     Smaller reporting company  
        Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

CALCULATION OF REGISTRATION FEE

 

Title of Each Class of Securities to be Registered  

Proposed

Maximum

Aggregate

Offering Price(1)

   

Amount of

Registration Fee

 
Common stock, par value $0.00001 per share   $ 69,000,000     $ 6,396.3  

 

  (1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the offering price of any additional shares of common stock that the underwriters have the right to purchase to cover over-allotments.

 

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.

 

 

 

 
   

 

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED OCTOBER 22, 2021

 

                Shares

Common Stock

 

 

Synergy CHC Corp.

 

 

 

Synergy CHC Corp. is offering             shares of our common stock, par value $0.00001 per share. We currently estimate that the initial public offering price of our common stock will be between $     and $     .

 

Prior to September 28, 2021, shares of our common stock were quoted on the OTC Markets Group, Inc. Pink tier under the symbol “SNYR.” As a result of amendments to Exchange Act Rule 15c2-11, because we do not presently make current information publicly available, our common stock was shifted to the OTC Expert Market on September 28, 2021, which means that there are no longer publicly-available quotations of our common stock. We have applied to list our common stock on the Nasdaq Capital Market under the symbol “SNYR.”

 

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 8.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

    Per Share     Total  
Public offering price   $            $    
Underwriting discounts and commissions(1)   $       $            
Proceeds to us, before expenses   $       $    

 

(1) The underwriters will receive compensation in addition to the discounts and commissions. See “Underwriting” beginning on page 56 for a description of compensation payable to the underwriters.

 

We have granted a 30-day option to the representative of the underwriters to purchase up to                additional shares of common stock solely to cover over-allotments, if any.

 

The underwriters are offering the shares for sale on a firm commitment basis. The underwriters expect to deliver the shares to purchasers on or about            , 2021.

 

B. Riley Securities

 

The date of this prospectus is         , 2021

 

 

 

 
   

 

TABLE OF CONTENTS

 

PROSPECTUS SUMMARY 1
THE OFFERING 6
SUMMARY HISTORICAL CONSOLIDATED FINANCIAL AND OTHER DATA 7
RISK FACTORS 8
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 18
USE OF PROCEEDS 19
MARKET FOR OUR COMMON STOCK 20
DIVIDEND POLICY 21
CAPITALIZATION 22
DILUTION 23
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 24
BUSINESS 31
MANAGEMENT 40
EXECUTIVE AND DIRECTOR COMPENSATION 45
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 47
PRINCIPAL STOCKHOLDERS 49
DESCRIPTION OF CAPITAL STOCK 50
SHARES ELIGIBLE FOR FUTURE SALE 53
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 54
UNDERWRITING 56
LEGAL MATTERS 61
EXPERTS 61
WHERE YOU CAN FIND MORE INFORMATION 61
INDEX TO FINANCIAL STATEMENTS F-1

 

 

 

You should rely only on the information contained in this prospectus or in any free writing prospectus that we may provide to you in connection with this offering. Neither we nor any of the underwriters has authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus or in any such free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We can provide no assurance as to the reliability of any other information that others may give you. Neither we nor any of the underwriters is making an offer to sell or seeking offers to buy these securities in any jurisdiction where or to any person to whom the offer or sale is not permitted. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of such free writing prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates.

 

Trademarks

 

We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks and trade names or products in this prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.

 

Market and Industry Data

 

Unless otherwise indicated, information contained in this prospectus concerning our industry, competitive position and the markets in which we operate is based on information from independent industry and research organizations, other third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third-party sources, as well as data from our internal research, and are based on assumptions we made upon reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

 

i
 

 

 

PROSPECTUS SUMMARY

 

This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of the information that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes included in this prospectus, before making an investment decision. Some of the statements in this prospectus constitute forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.” Unless otherwise indicated in this prospectus, “Synergy CHC,” “we,” “us” and “our” refer to Synergy CHC Corp. and, where appropriate, its subsidiaries.

 

Our Company

 

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a patented brain health supplement that has been clinically shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals, and a developing brand, Hand MD, consisting of a full range of preventative, restorative, and anti-aging skin care products designed for the hands. During the year ended December 31, 2020, FOCUSfactor represented 62% of our net revenue, Flat Tummy was 17%, and Hand MD was 17%. During the six months ended June 30, 2021, FOCUSfactor represented 71% of our net revenue, Flat Tummy was 29%, and Hand MD was 0.2%. Our products are sold through some of the nation’s leading club, mass drug, and other retailers such as Costco, Amazon.com, Walmart, Walgreens, CVS, The Vitamin Shoppe, Target.com, H-E-B, and SuperValu.

 

We built our brand portfolio through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including earnout. Our Hand MD brand was acquired for $1.5 million of our stock in August 2015. In November 2015, we acquired our second marquee brand – Flat Tummy – for AUD 10.0 million (or approximately $7.0 million), using a mix of cash and stock. Our capital structure following the acquisition of our key brands in 2015 was highly levered, and our focus was on paying our debt as we did not have the resources to grow our business. We have grown our FOCUSfactor brand from 2 SKUs at acquisition to 16 SKUs, and our Flat Tummy Brand from 1 SKU to 18 SKUs.

 

With the outbreak of the COVID-19 pandemic in North America during the first three months of 2020, we extended our Hand MD brand to produce and market a range of hand sanitizers. We deployed the cash flow from hand sanitizer sales for a television advertising strategy to drive growth in our flagship FOCUSfactor brand products. Our FOCUSfactor advertising campaigns have aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT, targeting adults 45 years of age and older. As a result, net revenue for the year ended December 31, 2020 was $40.2 million, an increase of $10.9 million, or 37.0%, over net revenue for the year ended December 31, 2019. Net revenue for the six months ended June 30, 2021 was $24.8 million, an increase of $6.9 million, or 38.3% over net revenue for the six months ended June 30, 2020. In particular, FOCUSfactor net revenue continued to benefit from our advertising strategy, increasing to $17.5 million for the six months ended June 30, 2021, a 124% increase over the same period in 2020.

 

Following the completion of this offering, we intend to use the proceeds to repay in full our outstanding debt, to accelerate the growth of our current brands through advertising and otherwise, and to drive our acquisition strategy as we have a pipeline of potential near-term acquisition targets that we are eager to pursue. Given the success of our FOCUSfactor advertising campaigns – in which we have achieved approximately a $4 increase in gross revenue for each incremental $1 of advertising spend – we believe that we can meaningfully expand our FOCUSfactor campaigns. In addition, we have tailored strategies for our Flat Tummy and Hand MD brands to maximize our return on investment and leverage our experience with both traditional and digital marketing. Our asset-light business model, in which we partner with third-party manufacturers to produce our brand offerings, allows us to scale quickly and profitably while satisfying growing demand.

 

For the six months ended June 30, 2021, our net revenues, net income and Adjusted EBITDA were $24.8 million, $2.6 million and $3.5 million, respectively, representing an increase of 38.3%, 139.7%, and 13.4% over the same period in the prior fiscal year. During the year ended December 31, 2020, our net revenues, net income (loss) and Adjusted EBITDA were $40.2 million, $1.4 million and $4.7 million, respectively, as compared to $29.4 million, $(9.2) million and $4.2 million for the prior year.

 

Our Brands

 

Our flagship brand, FOCUSfactor, is a brain health nutritional supplement with over 15 years of heritage and a patented formula comprised of a proprietary blend of key brain supporting ingredients along with vitamins, minerals, and other nutrients. We believe FOCUSfactor is the only product in its category whose entire patented formula has been clinically shown to support memory, concentration and focus. Our FOCUSfactor brand consists of 16 SKUs and is sold primarily through leading retailers in the United States, including Costco, Walmart, Amazon.com, Walgreens, and CVS, in addition to selling direct to consumer through the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the retailer from the single SKU available at the beginning of our relationship in 2015 or 2016. In addition, we have increased our presence in retail locations for these key partners, resulting in a significant increase in retail doors, being the number of SKUs multiplied by the number of retail locations for each retailer.

 

Our second marquee brand, Flat Tummy, consists of a range of lifestyle products and accessories including tea, shakes, lollipops, supplements, apparel, and exercise accessories. We also provide a Flat Tummy mobile app, which as of June 30, 2021 had 1.3 million unique downloads and is intended as a tool to promote the Flat Tummy lifestyle centered around general wellness and health. Our Flat Tummy brand consists of 18 SKUs and is sold direct to consumer through the Flat Tummy website and application, as well as through retailers such as Amazon.com and CVS.

 

 

1
 

 

 

Our developing brand, Hand MD, is a beauty-focused brand consisting of an anti-aging skincare line formulated specifically for the hands. The product line includes serums and creams for exfoliating, skin repair and rehydration as well as hand soaps and hand sanitizers. The Hand MD brand consists of 8 SKUs and is sold online through the Hand MD website as well as through Amazon.com.

 

We also own five additional, non-core brands. While we may elect to promote these brands and commercialize their products in the future, we have prioritized our key FOCUSfactor, Flat Tummy, and Hand MD brands, and management is focused on the growth of these core products.

 

Our net revenues by brand for the six months ended June 30, 2021 are below:

 


Net Revenue by Brand for the Six Months Ended June 30, 2021(1)

 

 

 

(1) Hand MD represented 0.2% of our net revenue for the six months ended June 30, 2021.

 

In the United States, the U.S. Food and Drug Administration (the “FDA”) has regulatory oversight over our FOCUSfactor, Flat Tummy and Hand MD products. However, no formal FDA approval or registration is required because our products are classified as dietary supplements (all FOCUSfactor products and some Flat Tummy products), foods (some Flat Tummy products) or cosmetics (all Hand MD products except hand sanitizer, which must follow the OTC monograph). Hand MD hand sanitizer, provided it follows the conditions, uses, doses, labeling and testing in the OTC monograph, is generally recognized as safe and effective and can be marketed without FDA approval.

 

In Canada, Health Canada (“HC”) has oversight over our FOCUSfactor, Flat Tummy and Hand MD products. Our FOCUSfactor and Flat Tummy products are considered natural health products by HC so they each have a natural product number that was assigned by HC upon its review and approval. Hand MD products are considered cosmetics by HC, so notification filings are required which are not subject to review and approval, with the exception of hand sanitizer, which is considered a natural health product and has been assigned a natural product number by HC. This natural product number represents the product license that enables us to distribute hand sanitizer in Canada.

 

In the United Kingdom, both FOCUSfactor and Flat Tummy are considered food supplements that are regulated by the Food Standards Agency. There is no requirement for licensing or registering food supplement products in the United Kingdom, and products must comply with relevant food law. Hand MD products are not currently sold in the United Kingdom.

 

In Australia, FOCUSfactor products are “Listed Medicines” that are regulated by the Therapeutic Goods Administration (“TGA”) and require an AUST L (Australia Listed Medicine) number. Flat Tummy products are classified as either Listed Medicines or meal replacements. Listed Medicines are regulated by the TGA while meal replacements are regulated under the Australia New Zealand Food Standards Code. Hand MD products are not currently sold in Australia.

 

Our Competitive Strengths

 

We believe that we have attributes that differentiate us from our competitors and provide us with significant competitive advantages. Our key competitive strengths include:

 

Well-Positioned in Growing Categories Driven by Favorable Consumer Trends

 

An increased focus on health, beauty and wellness by consumers has served as a tailwind for our brands. The nutritional supplement market has experienced significant growth across a range of areas including immune health, brain health, heart health, sleep/stress, and overall nutrition and wellness as a result of an aging population, increased obesity, pandemic concerns and a desire for more natural solutions and treatments over prescription medication. Additionally, there is an increased demand on hand cleansing and hand sanitizing products due to the COVID-19 pandemic, which is also driving demand for hand moisturizing products to soothe dried, chapped hands due to frequent hand washing and sanitizing. We believe that we are well positioned to benefit from these favorable trends. Our FOCUSfactor, Flat Tummy and Hand MD brands have seen strong growth with net revenues up 38% year-over-year in the six months ended June 30, 2021. We believe our focus on lifestyle products has also benefited from the growth and prevalence of social media.

 

Clinically Shown Results Backed by Independent Study for FOCUSfactor

 

We believe FOCUSfactor is the only product in its category with both a patent and a clinical study to support the product claims for improved memory, concentration, and focus. FOCUSfactor has been tested in a single-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate its effect on memory, concentration, and focus in healthy adults.

 

In this study, FOCUSfactor was tested on its entire 52-ingredient formulation rather than testing one or two ingredients within a formulation. FOCUSfactor was shown to provide a 44% increase in recall memory after six weeks of use versus placebo. This differentiates FOCUSfactor from other brain-health supplements and is a prime reason why FOCUSfactor has been placed in premier retailers. See “Business — FOCUSfactor Clinical Study” for additional information.

 

 

2
 

 

 

Experienced Management Team with Proven Track Record of Value Creation

 

Our executive team has a combined 90 years of experience in consumer marketing and distribution and has been instrumental in acquiring and building our core brands. Management has exercised strong financial discipline in its acquisition strategy, with a focus on acquiring brands at attractive valuations. For example, we acquired FOCUSfactor for approximately 3x trailing EBITDA. For the six months ended June 30, 2021, the year ended December 31, 2020 and the year ended December 31, 2019, FOCUSfactor generated net revenue of $17.5 million, $24.9 million and $18.9 million, respectively. Management’s philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our proven marketing and distribution strategies to develop brands to their full potential. We believe we are adept at identifying promising opportunities that build out and complement our core brand portfolio.

 

Premier Retail Partners

 

Our premier retail partners include Costco, Walmart, Amazon.com, Walgreens, and CVS. We sell products to these partners under their standard arrangements, which do not include a term or duration as sales under each vendor agreement are generally made on a purchase order basis, and do not include any termination provisions. Our partners provide a platform to expand the breadth of our current offerings through product line extensions and new product innovation. We continue to introduce new SKUs to our current retail partners, such as the addition of FOCUSfactor Gummies to our membership club channel. Additionally, the international footprint of certain of our various retail partners facilitates our geographic expansion plans.

 

Scalable and Flexible Asset-Light Model to Support Growth

 

Our focus is on brand management, marketing, product development and distribution, and we utilize contract manufacturing partners in order to produce our various brand offerings. The use of third-party manufacturing partners allows us to scale quickly, as we ensure that our partners have sufficient capacity to meet our demand needs. We also maintain multiple relationships with different contract manufactures, ensuring diversification of our manufacturing base and reducing the likelihood of supply bottlenecks or deficits that could potentially slow our growth.

 

Our Growth Strategy

 

We intend to drive growth and increased profitability in our business through these key elements of our strategy:

 

Broaden Media Advertising Strategy

 

We have experienced a significant acceleration in sales growth for the FOCUSfactor brand as a result of our television advertising. We launched a national advertising campaign in August 2020, which has aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT, targeting adults 45 years of age and older. Since initiating our advertising strategy, FOCUSfactor net revenue has nearly doubled at key retailers. Based on these recent television campaigns, we estimate that we have experienced approximately $4 of gross revenue growth for every incremental $1 of advertising spend. We believe that we have significant growth potential through increased advertising budgets, and we expect to deploy a portion of the proceeds from this offering to expand our advertising campaigns. In particular, we anticipate a coordinated expansion of our television advertising strategy as we focus on pushing additional SKUs within our retail sales partner network to continue to build brand awareness and increase reach for FOCUSfactor. We also plan to invest in online marketing to promote all of our brands, including social media and influencer driven marketing.

 

Acquire Brands which Complement Our Existing Portfolio

 

We will continue to evaluate acquisition opportunities that we believe fit well within our brand portfolio and create value for our stockholders, such as further retail expansion in nutraceuticals and market expansion in health and beauty. In spite of historical capital constraints, our opportunistic approach to acquisitions has resulted in a successful track record of identifying promising targets that align with our overall brand strategy in the health, beauty and lifestyle segments. With the proceeds from this offering, we expect to accelerate our acquisition strategy, focusing on acquisition targets that management believes have the greatest synergistic potential, enabling us to significantly grow our product offerings and reach.

 

Partner with Additional Leading Retailers to Expand the Reach of Our Products

 

We have established distribution relationships with premier retail partners, including Costco, Walmart, Amazon.com, Walgreens, CVS, The Vitamin Shoppe, Target.com, H-E-B and SuperValu. Based on the success of our products with these leading retail partners, we believe that we are well positioned to add new retailers that will enhance our distribution footprint. We believe we have expansion opportunities with food retailers, including those focused on health foods. We intend to introduce seven new SKUs across three potential retailers, which would potentially result in the addition of approximately 50,000 retail doors.

 

Diversify Our Geographic Presence through Entry into New Markets

 

We seek to accelerate our sales growth by expanding and further diversifying our geographic footprint. In the year ended December 31, 2020, markets outside of North America represented 0.5% of our total net revenues. Our goal is to increase our net revenues generated from new markets. As we target new international markets, our strategy is to develop highly competitive and differentiated products that are produced in-country for ease of entry, with support from our regulatory group and an in-country regulatory consultant to help expedite the approval process. We currently plan to enter the United Kingdom and Australia markets in 2022, initially with FOCUSfactor, followed by Flat Tummy and Hand MD. We then plan to expand our brands into Asian markets and Mexico in late 2022 and 2023.

 

 

3
 

 

 

Use Innovative Strategies to Boost Consumer Engagement

 

We have made investments in promoting apps for Flat Tummy and view this as a key aspect of growing our customer base and maintaining high levels of engagement. We have also focused on developing our social media presence, in particular through Instagram, in order to foster and grow our relationship with customers. Our brands appeal to both specific consumer needs as well as lifestyle choices and we seek to deepen our understanding of our customers and boost recognition of our brands through increased engagement.

 

Continue to Develop and Expand Our Current Brands

 

Our plan is to further develop and expand our brands by reaching a broader set of customers through advertising and product expansion. More specifically, we look to develop new products for our brands to satisfy the various customer segment opportunities (i.e. baby boomers, millennials, etc.) and satisfy various consumer needs as they relate to new and improved formulations, expanded and improved product benefits, alternative delivery formats and sizes. As we increase the product line-up behind our brands, we leverage our current retail distribution network by expanding our presence as well as adding incremental distribution with new retail partners. With a broader brand presence, we believe our advertising becomes even more efficient at driving sales velocity.

 

This is evidenced by our expanded FOCUSfactor product line, including gummies that are marketed to both adults and children and liquid energy and focus shots for a younger adult audience. Beginning in 2022, we plan to introduce additional FOCUSfactor products, including a “maximum strength” formula, an “ultimate” formula, ready-to-drink beverages and a nootropic line. The Flat Tummy brand has strategically added complementary products such as new shake options and supplements to appeal to a broader consumer group. In the fourth quarter of 2021, we plan to introduce a Flat Tummy superfruits gummy and an ashwagandha/calming gummy. Beginning in 2022, we plan to introduce additional Flat Tummy products, including three new protein shakes, a protein ready-to-drink beverage, hydration powder and preworkout powder. Additionally, we plan to employ this strategy of expanding our brands into international markets that include the United Kingdom, Australia and Asia, among others.

 

Marketing and Sales

 

Our targeted, consumer-driven marketing strategy has been key to building our brands and driving revenue growth. We manage dedicated marketing strategies for each of our brands in order to build deep connections with our customers.

 

FOCUSfactor. Our marketing strategy for FOCUSfactor is primarily focused on television advertising campaigns with leading national networks that appeal to the demographics of our wellness focused customer base. Our television advertising campaigns, launched in 2020, have coincided with strong sales results for the brand, with FOCUSfactor net revenue increasing 124% in the six months ended June 30, 2021 compared with the same period in 2020. In the year ended December 31, 2020, FOCUSfactor net revenue increased 38.1% year-over-year, to $24.9 million. As our flagship brand, FOCUSfactor accounted for 71% of our net revenue in the six months ended June 30, 2021, compared with 44% in the six months ended June 30, 2020, 62% in the year ended December 31, 2020 and 64% in the year ended December 31, 2019.

 

Flat Tummy. We employ a primarily online and social media driven strategy for our Flat Tummy brand. The brand is focused primarily on women. We employ campaigns to reach our core target segments through a mix of traditional online advertising as well as influencer-based marketing. In the six months ended June 30, 2021, Flat Tummy accounted for 29% of our net revenue, compared with 25% in the six months ended June 30, 2020, 17% in the year ended December 31, 2020 and 34% in the year ended December 31, 2019.

 

Hand MD. We mainly rely on social media and online advertising for our Hand MD brand. In the six months ended June 30, 2021, Hand MD accounted for 0.2% of our net revenue, compared with 28% in the six months ended June 30, 2020, 17% in the year ended December 31, 2020 and 1% for the year ended December 31, 2019.

 

Competition

 

The U.S. nutritional supplements retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies, and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products.

 

Recent Developments

 

Certain Preliminary Estimated Financial Data

 

The following presents preliminary estimates of certain of our consolidated financial data for the three months ended September 30, 2021. Our consolidated financial statements as of and for the three months ended September 30, 2021 are not yet available and are subject to completion of our financial closing procedures. The following information reflects our preliminary estimates based on currently available information and is subject to change. We have provided ranges, rather than specific amounts, for the preliminary estimated results for net income, EBITDA (a non-GAAP financial measure) and Adjusted EBITDA (a non-GAAP financial measure) described below primarily because we are still in the process of finalizing our financial and operating results as of and for the three months ended September 30, 2021 and, as a result, our final reported results may vary from the preliminary estimates. The preliminary estimated financial data set forth below have been prepared by, and are the responsibility of, our management. Our auditors have not audited, reviewed, compiled or applied agreed-upon procedures with respect to the preliminary estimated financial data. Accordingly, our auditors do not express an opinion or any other form of assurance with respect thereto. We expect to complete our interim financial statements as of and for the three months ended September 30, 2021 subsequent to the completion of this offering. Our preliminary estimated results also include non-GAAP financial measures. Neither such measures nor our estimates of GAAP results should be viewed as a substitute for interim financial statements prepared in accordance with GAAP. Please refer to “—Non-GAAP Financial Measures” for the reasons we believe non-GAAP measures may be useful to investors, as well as a discussion of the limitations of such measures. You should not place undue reliance on the preliminary estimates, and the preliminary estimates are not necessarily indicative of the results to be expected in the future. The preliminary estimates should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and the consolidated financial statements and related notes thereto included elsewhere in this prospectus.

 

   

Three Months Ended

September 30, 2021

 
(Unaudited; in thousands of dollars)   Low
(Estimated)
    High
(Estimated)
 
             
Net income   $     $    
EBITDA*   $       $    
Adjusted EBITDA*   $       $    

 

 

 

* A non-GAAP financial measure. See reconciliation to net income below.

 

The below table reconciles expected net income to expected EBITDA and expected Adjusted EBITDA for the three months ended September 30, 2021.

 

   

Three Months Ended

September 30, 2021

 
(Unaudited; in thousands of dollars)   Low (Estimated)     High (Estimated)  
                 
Net income (loss)   $       $    
Interest income                
Interest expense                
Taxes                
Depreciation and amortization                
EBITDA   $       $    
Impairment of intangible assets                
Stock-based compensation                
Non-recurring expenses                
Bad debts                
Obsolete inventory                
Loss on foreign currency translation and transaction                
Adjusted EBITDA   $       $    

 

  (1)  
  (2)  
  (3)  
  (4)  

 

Summary Risk Factors

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in the section titled “Risk Factors” following this prospectus summary. These risks include, but are not limited to, the following:

 

 

We operate in a highly competitive industry and our failure to compete effectively could materially and adversely affect our sales and growth prospects;

     
  Our failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could significantly harm our relationship with customers and our product sales, as well as our financial condition and operating results;
     
 

Our sales growth is dependent upon maintaining our relationships with a small number of existing large customers, and the loss of any one such customer could materially adversely affect our business and financial performance;

 

 

4
 

 

 

 

If our outside suppliers and manufacturers fail to supply products in sufficient quantities and in a timely fashion, our business could suffer;

     
 

The COVID-19 pandemic and associated responses could materially adversely affect our business, operating results, financial condition and prospects;

     
 

Adverse or negative publicity could cause our business to suffer;

     
 

We continue to explore new strategic initiatives, but we may not be able to successfully execute on, or realize the expected benefits from, the implementation of our strategic initiatives, and our pursuit of new strategic initiatives may pose significant costs and risks;

     
 

The nutritional supplement industry increasingly relies on intellectual property rights and although we seek to ensure that we do not infringe the intellectual property rights of others, there can be no assurance that third parties will not assert intellectual property infringement claims against us;

     
 

We plan to expand into additional international markets, which will expose us to significant operational risks;

     
 

We may experience product recalls, withdrawals or seizures, which could materially and adversely affect our business, financial condition and results of operations;

     
  We and our suppliers are subject to numerous laws and regulations that apply to the manufacturing and sale of nutritional supplements, and compliance with these laws and regulations, as they currently exist or as modified in the future, may increase our costs, limit or eliminate our ability to sell certain products, subject us or our suppliers to the risk of enforcement action or litigation, or otherwise adversely affect our business, results of operations and financial condition; and
     
  The other factors described in “Risk Factors.”

 

Our Corporate Information

 

We were organized as a corporation under the laws of the State of Nevada on December 29, 2010 under the name “Oro Capital Corporation.” In April 2014, Synergy Strips Corp., a Delaware corporation, became our wholly-owned subsidiary, and we changed our name from “Oro Capital Corporation” to “Synergy Strips Corp.” In August 2015, we changed our name to “Synergy CHC Corp.” In January 2019, our other U.S. subsidiaries, Neuragen Corp., Sneaky Vaunt Corp., The Queen Pegasus Corp. and Breakthrough Products Inc., merged with and into the Company. In July 2021, we acquired Hand MD Corp. as a wholly-owned subsidiary.

 

We were a public reporting company until July 17, 2020, the date on which we filed a Form 15 to voluntarily suspend our duty to file reports under Sections 13 and 15(d) of the Exchange Act. As a result of this offering, we will become subject again to the information and reporting requirements of the Exchange Act and we will file periodic reports, proxy statements and other information with the SEC.

 

The address of our principal executive offices is currently 865 Spring Street, Westbrook, Maine 04092 and our phone number is (615) 939-9004. Our website is www.synergychc.com. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus.

 

1-for-     Reverse Stock Split

 

Prior to the effective date of the registration statement of which this prospectus is a part, we will effect a 1-for-     reverse stock split with respect to our common stock. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus gives effect to this reverse stock split.

 

Implications of Being a Smaller Reporting Company

 

We are a “smaller reporting company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

 

 

5
 

 

 

THE OFFERING

 

Common stock offered                  shares.
   
Common stock to be outstanding after this offering                  shares (or             shares if the underwriters exercise their over-allotment option in full).
   
Over-allotment option We have granted the underwriters a 30-day option to purchase up to an additional             shares of our common stock at the public offering price to cover over-allotments, if any.
   
Use of proceeds

We estimate that the net proceeds to us from this offering will be approximately $     million, or approximately $     million if the underwriters exercise their over-allotment option in full, assuming a public offering price of $     per share, the midpoint of the price range set forth on the cover page of this prospectus.

 

We intend to use the net proceeds of this offering to repay indebtedness, to support our organic growth, for advertising and for other general corporate purposes, including for unidentified potential acquisitions. See “Use of Proceeds.”

   
Risk factors You should read the “Risk Factors” section of this prospectus beginning on page 8 for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.
   
Proposed Nasdaq Capital Market symbol SNYR
   
Insider Participation

Certain of our officers, directors and stockholders, including                  , and certain of their respective affiliates, have indicated an interest in participating in this offering at the public offering price. We anticipate that such persons will purchase in the aggregate approximately                  shares of common stock offered hereby. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to them than they indicated an interest in purchasing or sell no shares to them, and they could determine to purchase fewer shares than they indicated an interest in purchasing or purchase no shares in this offering.

 

As of October 8, 2021, 89,889,074 shares of our common stock were outstanding. Unless we indicate otherwise or the context otherwise requires, all information in this prospectus:

 

  assumes no exercise by the underwriters of their over-allotment option;
  excludes 3,466,667 shares of common stock issuable upon the exercise of outstanding options at a weighted exercise price of $0.54 per share;
  gives effect to a 1-for-     reverse stock split with respect to our common stock, which will occur prior to the effective date of the registration statement of which this prospectus is a part; and
  excludes 12,058,333 shares of common stock reserved for future issuance pursuant to our 2014 Stock Incentive Plan.

 

 

6
 

 

 

SUMMARY HISTORICAL CONSOLIDATED FINANCIAL AND OTHER DATA

 

The following tables set forth our summary historical consolidated financial data as of, and for the periods ended on, the dates indicated.

 

The summary consolidated statements of operations data for the years ended December 31, 2020 and 2019 are derived from our audited consolidated financial statements and notes that are included elsewhere in this prospectus.

 

The summary condensed consolidated statements of operations data for the six months ended June 30, 2021 and 2020 and the summary consolidated balance sheet data as of June 30, 2021 are derived from our unaudited interim condensed consolidated financial statements and notes that are included elsewhere in this prospectus. We have prepared the unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles (GAAP) and on the same basis as the audited consolidated financial statements. Our historical results are not necessarily indicative of our results in any future period and results from our interim period may not necessarily be indicative of the results of the entire year.

 

    For the six months ended     For the six months ended     For the year ended     For the year ended  
    June 30,
2021
    June 30,
2020
    December 31,
2020
    December 31,
2019
 
    (Unaudited)     (Unaudited)              
Statement of operations data:                                
Revenue   $ 24,761,974     $ 17,906,767     $ 40,226,865     $ 29,357,546  
Cost of sales (including related party purchases of $0, $0, $0 and $4,847,626, respectively)     6,794,344       6,593,446       14,578,865       9,137,602  
Gross profit     17,967,630       11,313,321       25,648,000       20,219,944  
Total operating expenses     14,505,045       8,736,985       22,609,745       28,176,054  
Income (loss) from operations     3,462,585       2,576,336       3,038,255       (7,956,110 )
Total other expenses     717,619       1,345,990       1,627,123       1,119,800  
Net income (loss) before income taxes     2,744,966       1,230,346       1,411,132       (9,075,910 )
Income tax expense     (104,537 )     (128,996 )     -       (131,537 )
Net income (loss) after tax   $ 2,640,429     $ 1,101,350     $ 1,411,132     $ (9,207,447 )
Net income (loss) per share – basic and diluted   $ 0.03     $ 0.01     $ 0.02     $ (0.10 )
Weighted average common shares outstanding, basic and diluted     89,889,044       89,889,044       89,889,044       89,883,194  
Adjusted EBITDA   $ 3,507,083     $ 3,093,940     $ 4,680,161     $ 4,205,741  

 

Non-GAAP Financial Measures

 

We currently focus on Adjusted EBITDA to evaluate our business relationships and our resulting operating performance and financial position. Adjusted EBITDA is defined as EBITDA (net income plus interest expense, income tax expense, depreciation and amortization), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We present Adjusted EBITDA because we consider it an important measure of our performance and a meaningful financial metric in assessing our operating performance from period to period by excluding certain items that we believe are not representative of our core business, such as certain non-cash items and other adjustments. We believe that Adjusted EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), provides useful information to investors.

 

   

Six Months Ended

June 30, 2021

   

Six Months Ended

June 30, 2020

    Year Ended December 31, 2020     Year Ended December 31, 2019  
      (Unaudited)       (Unaudited)                  
Net income (loss)   $ 2,640,429     $ 1,101,350     $ 1,411,132     $ (9,207,447 )
Interest income     (24 )     (79 )     (104 )     (414 )
Interest expense     627,883       497,992       1,186,034       981,105  
Taxes     104,537       128,996             131,537  
Depreciation and amortization           95,686       148,697       1,342,689  
EBITDA   $ 3,372,825     $ 1,823,945     $ 2,745,759     $ (6,752,530 )
Impairment of intangible assets                 47,002       9,715,137  
Stock-based compensation           77,358       128,929       201,155  
Non-recurring expenses     393,965 (1)     1,014,846 (2)     1,263,427 (3)     493,924 (4)
Bad debts                 74,068       283,972  
Obsolete inventory                 527,737       257,111  
Loss on foreign currency translation and transaction     (259,707 )     177,791       (106,761 )     6,972  
Adjusted EBITDA   $ 3,507,083     $ 3,093,940     $ 4,680,161     $ 4,205,741  

 

  (1) Consists of acquisition expenses with customers for shelf placement of $393,965.
  (2) Consists of loan fees of $1,000,000 and acquisition expenses with customers for shelf placement of $14,846.
  (3) Consists of loan fees of $1,000,000 and related financing costs of $61,000, leasehold renovations of $174,215 and acquisition expenses with customers for shelf placement of $28,212.
  (4) Consists of acquisition expenses with customers for shelf placement of $261,801, customer return of $215,189 and inventory write off of $16,934.

 

EBITDA and Adjusted EBITDA are considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA represents EBITDA further adjusted to exclude the impact of higher-than-normal revenue change order activity and certain expenses and transactions that we believe are not representative of our core operating results; stock-based compensation; non-recurring expenses for acquisitions, such as one-time expenses with customers for shelf placement, and other fees and costs; and loss on foreign currency translation and transaction. Our definitions of EBITDA and Adjusted EBITDA might not be comparable to similarly titled measures reported by other companies.

 

 

   

June 30,

2021

    December 31, 2020     December 31, 2019  
    (Unaudited)              
Balance sheet data:                        
Current assets   $ 15,921,408     $ 12,587,089     $ 5,047,095  
Total assets     15,921,408       12,587,089       5,190,629  
Current liabilities     15,717,469       14,739,196       10,147,064  
Total liabilities     17,258,150       16,271,192       10,393,980  
Total stockholders’ deficit     (1,336,742 )     (3,684,103 )     (5,203,351 )
Total liabilities and stockholders’ deficit   $ 15,921,408     $ 12,587,089     $ 5,190,629  

 

7
 

 

RISK FACTORS

 

An investment in our common stock involves a high degree of risk. You should carefully consider the following risks and all of the other information contained in this prospectus before deciding whether to invest in our common stock. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose all or part of your investment in our common stock. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations. Some statements in this prospectus, including such statements in the following risk factors, constitute forward-looking statements. See the section entitled “Cautionary Note Regarding Forward-Looking Statements.”

 

Risks Related to Our Business, Strategy and Industry

 

We operate in a highly competitive industry and our failure to compete effectively could materially and adversely affect our sales and growth prospects.

 

The U.S. nutritional supplements retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies, and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. As certain products become more mainstream, with broader distribution, we experience increased competition for those products. Increased competition from companies that distribute through retail, e-commerce or wholesale channels could have a material adverse effect on our financial condition and results of operations. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products. Furthermore, if we fail to maximize the efficiency of our ship direct to customers strategies, or fail to provide our customers with an attractive omni-channel experience, our business and results of operations could be materially and adversely affected. We may not be able to compete effectively, and any of the factors listed above may cause price reductions, reduced margins and losses of our market share.

 

Our failure to appropriately respond to changing consumer preferences and demand for new products or product enhancements could significantly harm our relationship with customers and our product sales, as well as our financial condition and operating results.

 

Our business is subject to changing consumer trends and preferences, including rapid and frequent changes in demand for products, new product introductions and enhancements. Our failure to accurately predict these trends could negatively impact consumer opinion of our products, which in turn could harm our customer relationships and cause the loss of sales. The success of our new product offerings and enhancements depends upon a number of factors, including our ability to:

 

accurately anticipate consumer needs;
innovate and develop new products or product enhancements that meet these needs;
successfully commercialize new products or product enhancements in a timely manner;
price our products competitively;
manufacture and deliver our products in sufficient volumes and in a timely manner; and
differentiate our product offerings from those of our competitors.

 

If we do not introduce new products or make enhancements to meet the changing needs of our customers in a timely manner, some of our products could be rendered obsolete, which could negatively impact our revenues, financial condition, and operating results.

 

We depend on a small number of large retailers for a significant portion of our sales. Our sales growth is dependent upon maintaining our relationships with existing customers, and the loss of any one such customer could materially adversely affect our business and financial performance.

 

Certain retailers make up a significant percentage of our products’ retail volume. For the year ended December 31, 2020, our top two customers, Costco and Walmart, accounted for 47% of our net revenue. We sell products to each of Costco and Walmart under their standard vendor agreements. These vendor agreements do not include a term or duration as sales under each vendor agreement are generally made on a purchase order basis, and do not include any termination provisions. The loss of sales of any of our products in a major retailer, or the reduction of purchasing levels or the cancellation of any business from a major retailer, could have a material adverse effect on our business and financial performance. In addition, if we were to lose one or more of these retailers as a distribution channel for our products, we can make no assurances that we will be able to find a comparable retailer to replace such relationship or that we will be able to find a replacement at all, which could negatively impact our revenues, financial condition, and operating results.

 

8
 

 

If our outside suppliers and manufacturers fail to supply products in sufficient quantities and in a timely fashion, our business could suffer.

 

Contract manufacturers produce all of our products. Our contract manufacturers acquire all of the raw materials for manufacturing our products from third-party suppliers. We also depend on outside suppliers for the packaging materials for our products. In the event we were to lose any significant suppliers or contract manufacturers and have trouble in finding or transitioning to alternative suppliers or manufacturers, it could result in product shortages or product back orders, which could harm our business. There can be no assurance that suppliers will be able to provide our contract manufacturers the raw materials in the quantities and at the appropriate level of quality that we request or at a price that we are willing to pay. We are also subject to delays caused by any interruption in the production of these materials including weather, disease, crop conditions, climate change, transportation interruptions and natural disasters or other catastrophic events. Our profit margins and timely product delivery are dependent upon the ability of our suppliers and contract manufacturers to supply us with products in a timely and cost-efficient manner. Our ability to enter new markets and sustain satisfactory levels of sales in each market depends on the ability of our suppliers and contract manufacturers to provide required levels of ingredients and products and to comply with all applicable regulations. The failure of our outside suppliers or manufacturers to supply ingredients or produce our products could materially adversely affect our business operations. We believe we have dependable suppliers for all of our ingredients and we have identified alternative suppliers and manufacturers for all of our ingredients and products. If our suppliers are unable to perform, any delay in replacing or substituting such ingredients could adversely affect our business.

 

A downturn in the economy, including as a result of COVID-19, could affect consumer purchases of discretionary items such as the health and wellness products that we offer, which could have an adverse effect on our business, financial condition, profitability, and cash flows.

 

We offer a broad selection of health and wellness products. A downturn in the economy, including as a result of COVID-19, could adversely impact consumer purchases of discretionary items such as health and wellness products. The United States and global economies may slow dramatically as a result of a variety of factors, including turmoil in the credit and financial markets, concerns regarding the stability and viability of major financial institutions, the state of the housing markets, and volatility in worldwide stock markets. In the event of such economic downturn, the U.S. and global economies could become significantly challenged in a recessionary state for an indeterminate period of time. Inflation or other changes in economic conditions that negatively affect demand for discretionary items could adversely affect our revenue. These economic conditions could cause many of our existing and potential customers to delay or reduce purchases of our products for some time, which in turn could harm our business by adversely affecting our revenues, results of operations, cash flows and financial condition. We cannot predict these economic conditions or the impact they would have on our consumers or business.

 

Adverse or negative publicity could cause our business to suffer.

 

Our business depends, in part, on the public’s perception of our integrity and the safety and quality of our products. Any adverse publicity could negatively affect the public’s perception about our industry, our products, or our reputation and could result in a significant decline in our operations. Specifically, we are susceptible to adverse or negative publicity regarding:

 

the nutritional supplements industry;
skeptical consumers;
competitors;
the safety and quality of our products and/or our ingredients;
any recalls or adverse health consequences of our competitors’ products;
regulatory investigations of our products or our competitors’ products; and
scandals or regulatory investigations regarding the business practices or products of our competitors.

 

We continue to explore new strategic initiatives, but we may not be able to successfully execute on, or realize the expected benefits from, the implementation of our strategic initiatives, and our pursuit of new strategic initiatives may pose significant costs and risks.

 

Our strategic initiatives are focused on, among other things, new product acquisition, new customer acquisition, improving the customer experience through the roll-out of initiatives including increasing customer engagement and personalization, improving the omni-channel experience (including in stores as well as through the internet and mobile devices), providing a relevant and inspiring product assortment and improving customer loyalty and retention. We also continually evaluate acquisition opportunities that we believe fit well within our brand portfolio and create value for our stockholders. Our future operating results are dependent, in part, on our management’s success in implementing these and other strategic initiatives, and as a result could divert management’s attention from our existing business as management focuses on developing these initiatives and related operations. Also, our short-term operating results could be unfavorably impacted by the opportunity and financial costs associated with the implementation of our strategic plans or the completion of any acquisitions, and we might not realize the benefits from such strategies. In addition, we may not be successful in achieving the intended objectives of the strategic initiatives (including acquisitions) in a timely manner or at all. We may choose to fund any acquisitions by way of (i) debt, which would subject us to additional covenant obligations and liquidity constraints, (ii) cash, which could divert working capital away from our existing business, or (iii) equity, which would result in dilution for existing stockholders, or any combination of the foregoing. There can also be no guarantee that we will be able to obtain debt on favorable terms, or at all.

 

As has been the case with our historical acquisition transactions, future business combinations could involve the acquisition of significant tangible and intangible assets, which could require us to record ongoing amortization expense with respect to identified intangible assets acquired. In addition, we may need to record write-downs from future impairments of identified tangible and intangible assets and goodwill. These and other similar accounting charges would reduce any future earnings or increase any losses. In future acquisitions, we could also incur debt to pay for acquisitions or issue additional equity securities as consideration, either of which could cause our stockholders to suffer significant dilution. Additionally, our ability to utilize net operating loss carryforwards, if any, acquired in any acquisitions may be significantly limited or unusable by us under Section 382 or other sections of the Internal Revenue Code (as has been the case with our net operating loss carryforwards attributable to the acquisition of Breakthrough Products, Inc.).

 

9
 

 

The nutritional supplement industry increasingly relies on intellectual property rights and although we seek to ensure that we do not infringe the intellectual property rights of others, there can be no assurance that third parties will not assert intellectual property infringement claims against us, which claims may result in substantial costs and diversion of management and other resources and could have a material adverse effect on our business, financial condition and operating results. Our inability to acquire, protect or maintain our intellectual property could harm our ability to compete or grow.

 

Recently it has become more and more common for suppliers and competitors to apply for patents or develop proprietary technologies and processes. We seek to ensure that we do not infringe the intellectual property rights of others, but there can be no assurance that third parties will not assert intellectual property infringement claims against us. These developments could prevent us from offering or supplying competitive products or ingredients in the marketplace. They could also result in litigation or threatened litigation against us related to alleged or actual infringement of third-party rights. If an infringement claim is asserted or litigation is pursued, we may be required to obtain a license of rights, pay royalties on a retrospective or prospective basis or terminate our manufacturing and marketing of our products that are alleged to have infringed. Litigation with respect to such matters could result in substantial costs and diversion of management and other resources and could have a material adverse effect on our business, financial condition and results of operations.

 

We have numerous United States and foreign trademarks and service marks. There can be no assurance that the protection afforded by these trademarks and service marks will provide us with a competitive advantage or that we will be able to assert our intellectual property rights in infringement actions. We may be required to defend our intellectual property against such infringement, which could result in substantial costs and diversion of management and other resources. In addition, results of such litigation are difficult to predict and if we are not successful in defending our intellectual property rights, this could have a material adverse effect on our business, financial condition and results of operations.

 

If we are not able to adequately prevent disclosure of proprietary knowledge, the value of our products could be materially diminished.

 

Trade secrets are difficult to protect. We rely on trade secrets to protect our proprietary knowledge, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce. We rely in part on confidentiality agreements to protect our trade secrets and other proprietary knowledge. We cannot guarantee that we have entered into such agreements with each party that may have had access to our proprietary knowledge, or that such agreements, even if in place, will not be circumvented. These agreements may not effectively prevent disclosure of proprietary knowledge and may not provide an adequate remedy in the event of unauthorized disclosure of such information. In addition, others may independently discover our trade secrets and proprietary knowledge, in which case we may have no right to prevent them from using such trade secrets or proprietary knowledge to compete with us. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could materially adversely affect our business, financial condition and results of operations.

 

International expansion will subject our business to additional economic and operational risks that could increase our costs and make it difficult to operate profitably.

 

One of our key growth strategies is to pursue international expansion. Expansion of our international operations may require significant expenditure of financial and management resources and result in increased administrative and compliance costs. As a result of such expansion, we will be increasingly subject to the risks inherent in conducting business internationally, including:

 

foreign currency fluctuations, which could result in reduced revenues and increased operating expenses;
longer or less predictable payment and sales cycles;
difficulty in collecting accounts receivable;
applicable foreign tax structures, including tax rates that may be higher than tax rates in the United States or taxes that may be duplicative of those imposed in the United States;
tariffs and trade barriers;
general economic and political conditions in each country;
inadequate intellectual property protection in foreign countries;
uncertainty regarding liability for information retrieved and replicated in foreign countries;
the difficulties and increased expenses of complying with a variety of foreign laws, regulations and trade standards; and
unexpected changes in regulatory requirements.

 

As a result of these risks, we may be required to incur higher than expected costs to implement or we may not be able to achieve the expected benefits of our international strategy. If we are unsuccessful in this international expansion, we would be required to reevaluate our growth strategy, and we may have incurred substantial expenses and devoted significant management time and resources in pursuing international growth.

 

10
 

 

We may experience product recalls, withdrawals or seizures, which could materially and adversely affect our business, financial condition and results of operations.

 

We may be subject to product recalls, withdrawals or seizures if any of the products we sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacturing, labeling, promotion, sale or distribution of those products. A significant recall, withdrawal or seizure of any of the products we manufacture or sell may require significant management attention, would likely result in substantial and unexpected costs and may materially and adversely affect our business, financial condition or results of operations. Furthermore, a recall, withdrawal or seizure of any of our products may adversely affect consumer confidence in our brands and thus decrease consumer demand for our products. As is common in the nutritional supplements industry, we rely on our contract manufacturers and suppliers to ensure that the products they manufacture and sell to us comply with all applicable regulatory and legislative requirements. In general, we seek representations and warranties, indemnification and/or insurance from our contract manufacturers and suppliers. However, even with adequate insurance and indemnification, any claims of non-compliance could significantly damage our reputation and consumer confidence in our products. In addition, the failure of those products to comply with applicable regulatory and legislative requirements could prevent us from marketing the products or require us to recall or remove such products from the market, which in certain cases could materially and adversely affect our business, financial condition and results of operations.

 

Increases in the price or shortages of supply of key raw materials could materially and adversely affect our business, financial condition and results of operations.

 

Our products are composed of certain key raw materials. If the prices of these raw materials were to increase significantly, it could result in a significant increase to us in the prices charged to us. Raw material prices may increase in the future and we may not be able to pass on those increases to customers who purchase our products. A significant increase in the price of raw materials that cannot be passed on to customers could have a material adverse effect on our business, financial condition and results of operations.

 

We are subject to credit risk.

 

We are exposed to credit risk primarily on our accounts receivable. We provide credit to our customers in the ordinary course of our business and perform ongoing credit evaluations. While we believe that our exposure to concentrations of credit risk with respect to accounts receivable is mitigated by our large retail partner base, and we make allowances for doubtful accounts, we nevertheless run the risk of our customers not being able to meet their payment obligations, particularly in a future economic downturn. For instance, in 2019, payments from one of our customers were delayed, and in 2020, one of our customers entered Chapter 11 bankruptcy. If a material number of our customers were not able to meet their payment obligations, our results of operations could be harmed.

 

Natural disasters and unusually adverse weather conditions could cause permanent or temporary damage to our distribution centers, impair our ability to purchase, receive or replenish inventory or cause customer traffic to decline, all of which could result in lost sales and otherwise materially and adversely affect our results of operations.

 

The occurrence of one or more natural disasters, such as hurricanes, fires, floods, earthquakes, tornadoes, high winds and other severe weather, could materially and adversely affect our operations and results of operations. To the extent these events result in the suspension of shipping by our distributors, closure of our corporate headquarters, or a significant number of the stores in which our products are sold, or to the extent they adversely affect one or more of our key suppliers, our operations and results of operations could be materially and adversely affected through an inability to make deliveries to stores and through lost sales. In addition, these events could result in increases in fuel (or other energy) prices or a fuel shortage, the temporary lack of an adequate work force in a market, the temporary or long-term disruption in the supply of products from suppliers, delay in the delivery of goods to our distribution centers or stores, the temporary reduction in the availability of products in our stores and disruption to our information systems, as noted above. These events also could have indirect consequences, such as increases in the cost of insurance, if they were to result in significant loss of property or other insurable damage.

 

Our e-commerce business is dependent on certain third parties. Changes in business practices or terms by such third parties could have a material adverse effect on our results of operations.

 

Our e-commerce business has several third-party relationships that contribute to our ability to generate revenue from a variety of online sources. These relationships may be dependent upon third-party tools, such as search engines, established business terms negotiated by us, or utilization of third-party marketplaces. If the economics of these relationships or the use of the third-party tools used to drive revenue change materially, this could affect our decision to maintain these relationships, and could result in lost sales and otherwise materially and adversely affect our financial performance.

 

11
 

 

If we do not successfully develop and maintain a relevant omni-channel experience for our customers, our business and results of operations could be materially and adversely affected.

 

Omni-channel retailing is rapidly evolving, and we must keep pace with changing customer expectations and new developments by our competitors. Our customers are increasingly using computers, tablets, mobile phones, and other devices to shop online. As part of our omni-channel strategy, we have made and will continue to make technology investments to expand our online distribution. If we are unable to make, improve, or develop relevant customer-facing technology in a timely manner, our ability to compete and our business and results of operations could be materially and adversely affected. In addition, if our e-commerce businesses or our other customer-facing technology systems do not function as designed, we may experience a loss of customer confidence, lost sales, or data security breaches, any of which could materially and adversely affect our business and results of operations.

 

Our principal stockholders have the ability to significantly influence or control matters requiring a stockholder vote and other stockholders may not have the ability to influence corporate transactions.

 

Currently, our principal stockholders beneficially own approximately 77% of our outstanding common stock, and following this offering, assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, will beneficially own approximately     % of our outstanding common stock. As a result, they have the ability to determine the outcome on all matters requiring approval of our stockholders, including the election of directors and approval of significant corporate transactions.

 

We are highly dependent on our management team, and the loss of our senior executive officers or other key employees could harm our ability to implement our strategies, impair our relationships with customers and adversely affect our business, results of operations and growth prospects.

 

Our success depends, in large degree, on the skills of our management team and our ability to retain, recruit and motivate key officers and employees. Our active senior executive leadership team, including Jack Ross, Brendan Horning and Alfred Baumeler, have significant experience, and their knowledge and relationships would be difficult to replace. Leadership changes will occur from time to time, and we cannot predict whether significant resignations will occur or whether we will be able to recruit additional qualified personnel. Competition for senior executives and skilled personnel in our industry is intense, which means the cost of hiring, paying incentives and retaining skilled personnel may continue to increase.

 

We need to continue to attract and retain key personnel and to recruit qualified individuals to succeed existing key personnel to ensure the continued growth and successful operation of our business. In addition, we must attract and retain qualified personnel to continue to grow our business, and competition for such personnel can be intense. Our ability to effectively compete for senior executives and other qualified personnel by offering competitive compensation and benefit arrangements may be restricted by cash flow and other operational restraints. The loss of the services of any senior executive or other key personnel, or the inability to recruit and retain qualified personnel in the future, could have a material adverse effect on our business, financial condition or results of operations. In addition, to attract and retain personnel with appropriate skills and knowledge to support our business, we may offer a variety of benefits, which could reduce our earnings or have a material adverse effect on our business, financial condition or results of operations.

 

System security risks, data protection breaches, cyber-attacks and systems integration issues could disrupt our internal operations.

 

Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate or compromise our confidential information or that of third parties, create system disruptions or cause shutdowns. Computer programmers and hackers also may be able to develop and deploy viruses, worms, and other malicious software programs that attack or otherwise exploit any security vulnerabilities of the products that we may sell in the future. Such disruptions could adversely impact our ability to fulfill orders and interrupt other processes. Delayed sales, lower profits, or lost customers resulting from these disruptions could adversely affect our financial results, stock price and reputation.

 

Legal and Regulatory Risks

 

Our products are subject to government regulation, both in the United States and abroad, which could increase our costs significantly and limit or prevent the sale of our products.

 

The manufacture, packaging, labeling, advertising, promotion, distribution and sale of our products are subject to regulation by numerous national and local governmental agencies in the United States and other countries. The primary regulatory bodies in the United States are the FDA and FTC, and we are also subject to similar regulatory bodies in all the countries in which we do business. Failure to comply with regulatory requirements may result in various types of penalties or fines. These include injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. Individual U.S. states also regulate nutritional supplements. A state may seek to interpret claims or products presumptively valid under federal law as illegal under that state’s regulations. For example, in February 2015, the New York Attorney General issued cease and desist letters to several national retailers regarding certain herbal supplements, and since that time both the New York Attorney General and other states’ Attorneys General have engaged in inquiries regarding the manufacture and sale of various supplements, and pursuant to such inquiries could seek to take actions against industry participants or amend applicable regulations in their state. In markets outside the United States, we are usually required to obtain approvals, licenses, or certifications from a country’s ministry of health or comparable agency, as well as labeling and packaging regulations, all of which vary from country to country. Approvals or licensing may be conditioned on reformulation of products or may be unavailable with respect to certain products or product ingredients. Any of these government agencies, as well as legislative bodies, can change existing regulations, or impose new ones, or could take aggressive measures, causing or contributing to a variety of negative consequences, including:

 

  requirements for the reformulation of certain or all products to meet new standards;

 

12
 

 

  the recall or discontinuance of certain or all products;
  additional record keeping;
  expanded documentation of the properties of certain or all products;
  expanded or different labeling;
  adverse event tracking and reporting; and
  additional scientific substantiation.

 

Any or all of these requirements could have a material adverse effect on us. There can be no assurance that the regulatory environment in which we operate will not change or that such regulatory environment, or any specific action taken against us, will not result in a material adverse effect on us.

 

Congress and/or regulatory agencies may impose additional laws or regulations or change current laws or regulations, and state attorneys general may increase enforcement of existing or new laws, and compliance with new or changed governmental regulations, or any state attorney proceeding, could increase our costs significantly and materially and adversely affect our business, financial condition and results of operations.

 

From time to time, Congress, the FDA, the FTC, or other federal, state, local or foreign legislative and regulatory authorities may impose additional laws or regulations that apply to us, repeal laws or regulations that we consider favorable to us or impose more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals or interpretations or to predict the effect that additional governmental regulation, when and if it occurs, would have on our business in the future. Those developments could require reformulation of certain products to meet new standards, recalls or discontinuance of certain products (including products that we sell) not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, adverse event reporting or other new requirements. For example, in recent years, the FDA has issued warning letters to several cosmetic companies alleging improper claims regarding their cosmetic products. If the FDA determines that we have disseminated inappropriate drug claims for our products intended to be sold as cosmetics, we could receive a warning or untitled letter, be required to modify our product claims or take other actions to satisfy the FDA. Any developments of this nature could increase our costs significantly and could have a material adverse effect on our business, financial condition and results of operations.

 

Our failure to comply with regulations could result in substantial monetary penalties and could adversely affect our operating results.

 

The marketing and labeling of any food product in recent years has brought increased risk that consumers will bring class action lawsuits and that the FTC and/or state attorneys general will bring legal action concerning the truth and accuracy of the marketing and labeling of the product, seek removal of a product from the marketplace, and/or impose fines and penalties. Products that we sell carry express or implied statements relating to the ingredients or health and wellness related attributes of our products. For example, in May 2017, we were one of 45 brands that were warned by the FTC regarding influencer promotion of products on Instagram. The FTC warned the companies and influencers that any sponsored posts for a product must use clear language indicating that the post is a paid sponsorship. The lack of regulatory definition for many label statements has contributed to legal challenges against many supplements companies, and plaintiffs have commenced legal actions against several nutritional supplement companies, asserting false, misleading and deceptive advertising and labeling claims. As a result of such legal or regulatory challenges, consumers may avoid purchasing products from us or seek alternatives, even if the basis for the claim is unfounded.

 

The FTC has instituted numerous enforcement actions against dietary supplement companies for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading advertising claims. Failure by us to comply with applicable regulations could result in substantial monetary penalties, which could have a material adverse effect on our financial condition or results of operations.

 

Even when unmerited, class claims, action by the FTC or state attorneys general enforcement actions can be expensive to defend and adversely affect our reputation with existing and potential customers and consumers and our corporate and brand image, which could have a material and adverse effect on our business, financial condition or results of operations. The number of private consumer class actions relating to false or deceptive advertising against nutritional supplement companies has increased in recent years. In addition, the FDA has aggressively enforced its regulations with respect to different types of product claims that may or may not be made for food products. These events could interrupt the marketing and sales of our products, severely damage our brand reputation and public image, increase our legal expenses, result in product recalls or litigation, and impede our ability to deliver our products in sufficient quantities or quality, which could result in a material adverse effect on our business, financial condition, results of operations and cash flows.

 

13
 

 

We may experience product liability claims and litigation to prosecute such claims, and although we maintain product liability insurance, which we believe to be adequate for our needs, there can be no assurance that our insurance coverage will be adequate or that we will be able to obtain adequate insurance coverage in the future. In addition, we may be subject to consumer fraud claims, including consumer class action claims regarding product labeling and advertising, and litigation to prosecute such claims; these claims are generally not covered by insurance.

 

We could face financial liability from product liability claims if the use of our products results in significant loss or injury. We can make no assurances that we will not be exposed to any future product liability claims. Such claims may include claims that our products contain contaminants or that we fail to provide or provide inadequate warnings concerning side effects or interactions of our products with other substances. Such claims may result in substantial settlement amounts or judgments against us, and may also require us to incur additional costs to change the packaging of our products to include adequate warning language or subject our products to additional testing. A product liability claim, regardless of its merit or ultimate outcome, could result in:

 

  injury to our reputation;
  decreased demand for our products;
  diversion of management’s attention;
  a change in the design, manufacturing process or the indications for which our marketed products may be used;
  loss of revenue; and
  an inability to commercialize product candidates.

 

In addition, consumer fraud claims, including consumer class action claims regarding product labeling and advertising, are increasingly common as to food and dietary supplement products. If we face such claims, we may be forced to defend the action in the applicable courts. If such claims are found to be correct, this would have a material adverse effect on us and our reputation.

 

We carry insurance coverage in the types and amounts that we consider reasonably adequate to cover the risks we face from product liability claims. If insurance coverage is inadequate or unavailable or premium costs continue to rise, we may face additional claims not covered by insurance, and claims that exceed coverage limits or that are not covered could have a material adverse effect on us. Moreover, liability claims arising from a serious adverse event may in addition to increasing our costs through higher insurance premiums and deductibles, make it more difficult to secure adequate insurance coverage in the future. Because insurance is generally hard to obtain for such claims, these could have a material adverse effect on us.

 

We may experience Lanham Act claims by competitors, and litigation to prosecute such claims.

 

The Lanham Act empowers competitors to file suit regarding any promotional statements that the competitor believes to be false or misleading. If a competitor prevails, it could obtain monetary damages, including potentially treble damages and attorneys’ fees. A court can also order corrective advertising, or even a product recall if the offending claims are found on the product’s packaging and labeling. If we experience a Lanham Act claim filed against us, this could have a material adverse effect on us and on our products’ reputation.

 

If we fail to protect the integrity and security of customer-related and other confidential information, we could be exposed to litigation, increased costs and reputational damage, and our business, results of operations and financial condition could be materially and adversely affected.

 

The use of individually identifiable data by us, our customers, and others is regulated at the state, federal and international levels. Privacy and information security laws and regulations change from time to time, and there may not always be clear guidance from the respective governments and regulators regarding the interpretation of these laws and regulations, which may create the risk of an inadvertent violation. In addition, the increasing costs of compliance with those laws and regulations and related technology investments could materially and adversely affect our business and results of operations. Additionally, the success of our e-commerce operations depends upon the secure transmission of confidential information over public networks, including the use of cashless payments, and we use computers in substantially all other aspects of our business operations. Such uses give rise to cybersecurity risks, including security breach, espionage, system disruption, theft and inadvertent release of information. While we have taken significant steps to protect customers’ personal information, consumer preferences and credit card information, and other confidential information, including our employees’ private information and financial and strategic data about the Company and our business partners, our suppliers or others may undermine our security measures. As a result, unauthorized parties may obtain access to our data systems and misappropriate confidential data. Furthermore, because the methods used to obtain unauthorized access change frequently and may not be immediately detected, we may be unable to anticipate these methods or implement preventative measures, and our incident response efforts may not be entirely effective. Any preventative measures we implement may have the potential to negatively affect our relations with our customers or decrease activity on our websites or apps by making them less user-friendly. If our data security is compromised, it could have a material adverse effect on our reputation, results of operations and financial condition, materially increase the costs we incur to protect against those events in the future and subject us to additional legal risk and a competitive disadvantage and damage to our brand reputation. In addition, our customers could lose confidence in our ability to protect their personal information, which could cause them to stop using our websites or apps. We are reliant on third-party electronic payment systems and platforms, such as PayPal, Stripe, Amazon Pay, Afterpay and Shopify Payments, not only to protect the security of the information stored, but also to appropriately track and record data. Any failures or inadequacies in these third-party systems, even if unrelated to our business, could result in significant liability, could materially and adversely affect our reputation and business and could cause government agencies to enact additional regulatory requirements or to modify their enforcement or investigation activities.

 

14
 

 

Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results.

 

U.S. generally accepted accounting principles and related pronouncements, implementation guidelines and interpretations with regard to a wide variety of matters that are relevant to our business, such as, but not limited to, revenue recognition, stock-based compensation, trade promotions, and income taxes are highly complex and involve many subjective assumptions, estimates and judgments by our management. Changes to these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported results.

 

Risks Related to this Offering and Ownership of Our Common Stock

 

An active, liquid trading market for our common stock does not currently exist and may not develop after this offering, and as a result, you may not be able to sell your common stock at or above the public offering price, or at all.

 

Prior to September 28, 2021, shares of our common stock were quoted on the OTC Markets Group, Inc. Pink tier under the symbol “SNYR.” Trading on the OTC Pink marketplace was infrequent and in limited volume. As a result of amendments to Exchange Act Rule 15c2-11, because we do not presently make current information publicly available, our common stock was shifted to the OTC Expert Market on September 28, 2021, which means that there are no longer publicly-available quotations of our common stock. Although we have applied to list our shares of common stock on Nasdaq in connection with this offering, an active trading market for shares of our common stock may never develop or be sustained following this offering. If an active trading market does not develop, you may have difficulty selling your shares of common stock at an attractive price, or at all. The public offering price for our common stock will be determined by negotiations between us and the representative of the underwriters and may not be indicative of prices that will prevail in the open market following this offering. Consequently, you may not be able to sell your common stock at or above the public offering price or at any other price or at the time that you would like to sell. An inactive market may also impair our ability to raise capital by selling our common stock and may impair our ability to expand our business by using our common stock as consideration in an acquisition.

 

You may be diluted by future issuances of common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price.

 

Our certificate of incorporation authorizes us to issue shares of our common stock and options, rights, warrants and appreciation rights relating to our common stock for the consideration and on the terms and conditions established by our Board of Directors (the “Board”) in its sole discretion. We could issue a significant number of shares of common stock in the future in connection with investments or acquisitions. Any of these issuances could dilute our existing stockholders, and such dilution could be significant. Moreover, such dilution could have a material adverse effect on the market price for the shares of our common stock.

 

A significant number of our total outstanding shares are restricted from immediate resale, but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.

 

Subject to certain exceptions, without the prior written consent of B. Riley Securities, Inc., as representative of the underwriters, we, and our officers and directors and our 1% and greater stockholders, during the period ending 180 days after the date of this prospectus, have agreed not to: (1) offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock; (2) file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or (3) enter into any swap or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of common stock, subject to certain exceptions. B. Riley Securities, Inc., in its sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time with or without notice. See “Underwriting.”

 

The market price of our common stock may decline significantly when the restrictions on resale by our existing stockholders lapse. A decline in the market price of our common stock might impede our ability to raise capital through the issuance of additional shares of common stock or other equity securities.

 

15
 

 

You will incur immediate dilution in the net tangible book value of the shares you purchase in this offering.

 

The public offering price of our common stock will be higher than the net tangible book value per share of outstanding common stock prior to completion of this offering. Based on our net tangible book value as of June 30, 2021 and upon the issuance and sale of shares of common stock by us at the assumed public offering price of $     per share (the mid-point of the range set forth on the cover page of this prospectus), if you purchase our common stock in this offering, you will suffer immediate dilution of approximately $     per share in net tangible book value. Dilution is the amount by which the offering price paid by purchasers of our common stock in this offering will exceed the as adjusted net tangible book value per share of our common stock upon completion of this offering. If the underwriters exercise their option to purchase additional shares, you will experience future dilution. A total of 15,525,000 shares of common stock have been reserved for future issuance under our 2014 Stock Incentive Plan. You may experience additional dilution upon future equity issuances or the exercise of stock options to purchase common stock granted to our directors, officers and employees under our current and future stock-based compensation plans.

 

There are material limitations with making preliminary estimates of our financial results for the period ended September 30, 2021 prior to the completion of our and our auditors’ financial review procedures for such period.

 

The preliminary financial estimates contained in “Prospectus Summary — Recent Developments” are not a comprehensive statement of our financial results for the period ended September 30, 2021, and our auditors have not yet completed their review of such financial results. Our financial statements for the period ended September 30, 2021 will not be available until after this offering is completed and, consequently, will not be available to you prior to investing in this offering. Our actual financial results for the period ended September 30, 2021 may differ materially from the preliminary financial estimates we have provided as a result of the completion of our financial closing procedures, final adjustments, and other developments arising between now and the time that our financial results for such periods are finalized. Our preliminary estimated results also include non-GAAP financial measures. Neither such measures nor our estimates of GAAP results should be viewed as a substitute for interim financial statements prepared in accordance with GAAP. You should not place undue reliance on the preliminary estimates, and the preliminary estimates are not necessarily indicative of the results to be expected in the future. The preliminary financial data included herein has been prepared by, and are the responsibility of, management. RBSM LLP, our independent registered public accounting firm, has not audited, reviewed, compiled, or performed any procedures with respect to such preliminary estimates. Accordingly, RBSM LLP does not express an opinion or any other form of assurance with respect thereto.

 

We do not anticipate paying any cash dividends on our common stock in the foreseeable future.

 

We currently intend to retain our future earnings, if any, for the foreseeable future, to repay indebtedness and to fund the development and growth of our business. We do not intend to pay any dividends to holders of our common stock in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our Board taking into account various factors, including our business, operating results and financial condition, current and anticipated cash needs, plans for expansion, any legal or contractual limitations on our ability to pay dividends under our loan agreements or otherwise. As a result, if our Board does not declare and pay dividends, the capital appreciation in the price of our common stock, if any, will be your only source of gain on an investment in our common stock, and you may have to sell some or all of your common stock to generate cash flow from your investment.

 

If securities or industry analysts do not publish research or reports about our business, or if they downgrade their recommendations regarding our common stock, its trading price and volume could decline.

 

We expect the trading market for our common stock to be influenced by the research and reports that industry or securities analysts publish about us, our business or our industry. As a new public company, we do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock may be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline and our common stock to be less liquid. Moreover, if one or more of the analysts who cover us downgrades our stock or publishes inaccurate or unfavorable research about our business, or if our results of operations do not meet their expectations, our stock price could decline.

 

The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.

 

We were a public reporting company until July 17, 2020, the date on which we filed a Form 15 to voluntarily suspend our duty to file reports under Sections 13 and 15(d) of the Exchange Act. At that time, because our common stock was not listed on a national securities exchange, we believed that the significant cost reductions associated with ceasing to be a reporting company would benefit us and our stockholders. After review, we felt that being on the over the counter market was not valuable due to the illiquidity and limited investor base. We now believe that listing our common stock on a national securities exchange, although accompanied by reporting requirements, is in our best interest because we expect such listing to improve the liquidity of our common stock, broaden the pool of investors that may be interested in investing in us, improve the attractiveness of using our stock as consideration for acquisitions and make our common stock a more attractive investment for institutional investors.

 

As a result of this offering, we will become subject to the reporting requirements of the Exchange Act, as amended, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations. Compliance with these rules and regulations involves significant legal and financial compliance costs, may make some activities more difficult, time-consuming or costly and may increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants, which will increase our costs and expenses.

 

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us, and our business may be adversely affected.

 

Furthermore, although we are permitted to purchase and maintain insurance on behalf of our directors and officers, we do not currently do so and may have to expend significant funds to cover our commitments to indemnify our directors and officers. However, we are considering obtaining such insurance coverage with terms of coverage appropriate for a company of our size and nature.

 

16
 

 

We may be subject to additional regulatory burdens resulting from our public listing.

 

We are working with our legal, accounting and financial advisors to identify those areas in which changes should be made to our financial management control systems to manage our obligations as a public company listed on Nasdaq. These areas include corporate governance, corporate controls, disclosure controls and procedures and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas, including our internal controls over financial reporting. However, we cannot assure holders of our common stock that these and other measures that we might take will be sufficient to allow us to satisfy our obligations as a public company listed on Nasdaq on a timely basis. In addition, compliance with reporting and other requirements applicable to public companies listed on Nasdaq will create additional costs for us and will require the time and attention of management. We cannot predict the amount of the additional costs that we might incur, the timing of such costs or the impact that management’s attention to these matters will have on our business.

 

Anti-takeover effects of certain provisions of Nevada state law hinder a potential takeover of us.

 

Though not now, we may be or in the future we may become subject to Nevada’s control share law. A corporation is subject to Nevada’s control share law if it has more than 200 stockholders, at least 100 of whom are stockholders of record and residents of Nevada, and it does business in Nevada or through an affiliated corporation. The law focuses on the acquisition of a “controlling interest,” which means the ownership of outstanding voting shares sufficient, but for the control share law, to enable the acquiring person to exercise the following proportions of the voting power of the corporation in the election of directors: (i) one-fifth or more but less than one-third; (ii) one-third or more but less than a majority; or (iii) a majority or more. The ability to exercise such voting power may be direct or indirect, as well as individual or in association with others.

 

The effect of the control share law is that the acquiring person, and those acting in association with it, obtains only such voting rights in the control shares as are conferred by a resolution of the stockholders of the corporation, approved at a special or annual meeting of stockholders. The control share law contemplates that voting rights will be considered only once by the other stockholders. Thus, there is no authority to strip voting rights from the control shares of an acquiring person once those rights have been approved. If the stockholders do not grant voting rights to the control shares acquired by an acquiring person, those shares do not become permanent non-voting shares. The acquiring person is free to sell its shares to others. If the buyers of those shares themselves do not acquire a controlling interest, their shares do not become governed by the control share law.

 

If control shares are accorded full voting rights and the acquiring person has acquired control shares with a majority or more of the voting power, any stockholder of record, other than an acquiring person, who has not voted in favor of approval of voting rights is entitled to demand fair value for the redemption of such stockholder’s shares.

 

Nevada’s control share law may have the effect of discouraging takeovers of the corporation.

 

In addition to the control share law, Nevada has a business combination law, which prohibits certain business combinations between Nevada corporations and “interested stockholders” for two years after the “interested stockholder” first becomes an “interested stockholder,” unless the corporation’s board of directors approves the combination in advance or thereafter by both the board of directors and 60% of the disinterested stockholders. For purposes of Nevada law, an “interested stockholder” is any person who is (i) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (ii) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding shares of the corporation. The definition of the term “business combination” is sufficiently broad to cover virtually any kind of transaction that would allow a potential acquiror to use the corporation’s assets to finance the acquisition or otherwise to benefit its own interests rather than the interests of the corporation and its other stockholders.

 

The effect of Nevada’s business combination law is to potentially discourage parties interested in taking control of us from doing so if it cannot obtain the approval of our board of directors.

 

We may experience fluctuations in our tax obligations and effective tax rate, which could materially and adversely affect our results of operations.

 

We are subject to U.S. federal and state income taxes and taxes in certain other non-U.S. jurisdictions. Tax laws, regulations and administrative practices in various jurisdictions may be subject to significant change, with or without advance notice, due to economic, political and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. There are many transactions that occur during the ordinary course of business for which the ultimate tax determination is uncertain. Our effective tax rates could be affected by numerous factors, such as changes in tax, accounting and other laws, regulations, administrative practices, principles and interpretations, the mix and level of earnings in a given taxing jurisdiction or our ownership or capital structures. For example, the United States government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate, an increase in the tax rate applicable to certain income earned overseas and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. No specific United States tax legislation has been proposed at this time and the likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. We urge investors to consult with their legal and tax advisers regarding implications of potential changes in U.S. tax laws on an investment in our common stock.

 

Our reverse stock split may not result in a proportional increase in the per share price of our common stock.

 

The effect of the reverse stock split on the market price for our common stock cannot be accurately predicted. In particular, we cannot assure you that the prices for shares of the common stock after the reverse stock split will increase proportionately to prices for shares of our common stock immediately before the reverse stock split. The market price of our common stock may also be affected by other factors which may be unrelated to the reverse stock split or the number of shares issued and outstanding.

 

Furthermore, even if the market price of our common stock does rise following the reverse stock split, we cannot assure you that the market price of our common stock immediately after the proposed reverse stock split will be maintained for any period of time. Moreover, because some investors may view the reverse stock split negatively, we cannot assure you that the reverse stock split will not adversely impact the market price of our common stock. There is also the possibility that liquidity may be adversely affected by the reduced number of shares which would be issued and outstanding when the reverse stock split is effected, particularly if the price per share of our common stock begins a declining trend after the reverse stock split is affected. Accordingly, our total market capitalization after the reverse stock split may be lower than the market capitalization before the reverse stock split.

 

17
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” All statements other than statements of historical facts contained in this prospectus may be forward-looking statements. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “continues,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” “would” or “should” or, in each case, their negative or other variations or comparable terminology. They appear in a number of places throughout this prospectus, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, future acquisitions and the industry in which we operate.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but are not limited to, those described in the “Risk Factors” section of this prospectus, which include, but are not limited to, risks related to the following:

 

our ability to compete in our industry, including against competitors that have significantly greater financial, technical and marketing resources than we do;
our ability to respond to customer preferences and successfully develop new and innovative products in a timely manner and effectively manage the introduction of new or enhanced products;
risks related to a loss of, or material cancellation, reduction, or delay in purchases by, one or more of our largest customers;
our outside suppliers and manufacturers failing to supply products in sufficient quantities and in a timely fashion;
the impact of the COVID-19 pandemic and associated responses on our business, operating results, financial condition and prospects;
our ability to execute on our strategic initiatives (including acquisitions);
our ability to maintain the reputation of our brands;
the risks related to consumers’ perception of the safety and quality of our products as well as similar products distributed by other companies in our industry;
the risks related to third parties asserting intellectual property infringement claims against us;
the risks related to our planned expansion into additional international markets;
the risks related to adverse economic conditions;
the risks related to catastrophic events;
our ability to retain key personnel, manage our business effectively, and continue to grow;
the impact of numerous laws and regulations that apply to the manufacture, sale, and manufacturing of nutritional supplements, and compliance with these laws and regulations, as they currently exist or as modified in the future, on us and our suppliers;
the risks related to product recalls;
the risks related to product liability claims and litigation to prosecute such claims; and
the other factors described in “Risk Factors.”

 

These factors should not be construed as exhaustive and should be read with the other cautionary statements in this prospectus.

 

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ materially from statements made in or suggested by the forward-looking statements contained in this prospectus. The matters summarized under “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and elsewhere in this prospectus could cause our actual results to differ significantly from those contained in our forward-looking statements. In addition, even if our results of operations, financial condition and liquidity, and industry developments are consistent with the forward-looking statements contained in this prospectus, those results or developments may not be indicative of results or developments in subsequent periods.

 

In light of these risks and uncertainties, we caution you not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this prospectus speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those statements to reflect future events or developments, except as required by applicable law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

 

18
 

 

USE OF PROCEEDS

 

Assuming a public offering price of $     per share, the midpoint of the range set forth on the cover page of this prospectus, we estimate that the net proceeds to us from the sale of our common stock in this offering will be $     million (or $     million if the underwriters exercise their over-allotment option in full), after deducting underwriting discounts and commissions and the estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed public offering price would increase (decrease) the net proceeds to us from this offering by approximately $     million (or $     million if the underwriters exercise their over-allotment option in full), assuming the number of shares we sell, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and the estimated offering expenses payable by us.

 

We intend to use approximately $6,925,000 of the net proceeds as follows:

 

  approximately $6,500,000 to repay a portion of amounts owed under our amended and restated loan agreement, as amended, with Knight Therapeutics (Barbados) Inc. (an owner of greater than 10% of our common stock), which bears interest at a rate of 12.5% per annum and has a maturity date of December 31, 2021, and to pay associated fees; and
  approximately $425,000 to repay amounts due to Knight Therapeutics Inc. in connection with our acquisition of Neuragen in 2015, which amounts do not bear interest and have a maturity date of June 30, 2029.

 

We intend to use the remaining net proceeds (which will be approximately $     million, or $     million if the underwriters exercise their over-allotment option in full) to support our organic growth, for advertising and for other general corporate purposes, including to fund potential future investments and acquisitions of companies that we believe are complementary to our business and consistent with our growth strategy. Although we may, from time to time, evaluate potential strategic investments and acquisitions, we do not have any agreements, commitments or plans for any specific acquisitions at this time.

 

The amounts and timing of our use of net proceeds from this offering will vary depending on numerous factors. As a result, our management will have broad discretion over how these proceeds are used.

 

19
 

 

MARKET FOR OUR COMMON STOCK

 

As a result of amendments to Exchange Act Rule 15c2-11, because we do not presently make current information publicly available, our common stock was shifted from the OTC Markets Group, Inc. Pink tier to the OTC Expert Market on September 28, 2021, which means that there are no longer publicly-available quotations of our common stock. Prior to September 28, 2021, shares of our common stock were quoted on the OTC Pink under the symbol “SNYR.” Although our shares were quoted on the OTC Pink from July 2020 to September 2021, because trading on the OTC Pink was infrequent and limited in volume, the prices at which such transactions occurred may not necessarily reflect the price that would be paid for our common stock in a more liquid market. From April 2014 to July 2020, our common stock was quoted on the OTC Markets Group, Inc. OTCQB under the symbol “SNYR.” As of October 8, 2021, there were approximately 37 record holders of our common stock.

 

We have applied to list our common stock on the Nasdaq Capital Market under the symbol “SNYR.” However, we cannot assure you that a liquid trading market for our common stock will develop or be sustained after this offering. You may not be able to sell your shares quickly or at the market price if trading in our common stock is not active. See “Underwriting” for more information regarding our arrangements with the underwriters and the factors considered in setting the public offering price.

 

The following table sets forth, for the fiscal quarters indicated, the high and low sale prices per share of our common stock, without giving effect to our proposed reverse stock split. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.

 

    High     Low  
Year Ending December 31, 2021            
3rd Quarter (through September 27, 2021)   $ 0.170     $ 0.047  
2nd Quarter   $ 0.100     $ 0.030  
1st Quarter   $ 0.183     $ 0.034  
                 
Year Ended December 31, 2020                
4th Quarter   $ 0.080     $ 0.028  
3rd Quarter   $ 0.111     $ 0.040  
2nd Quarter   $ 0.199     $ 0.025  
1st Quarter   $ 0.150     $ 0.030  
                 
Year Ended December 31, 2019                
4th Quarter   $ 0.190     $ 0.040  
3rd Quarter   $ 0.270     $ 0.150  
2nd Quarter   $ 0.290     $ 0.150  
1st Quarter   $ 0.270     $ 0.135  

 

20
 

 

DIVIDEND POLICY

 

Since our inception, we have not paid any dividends on our common stock, and we currently expect that, for the foreseeable future, all earnings, if any, will be retained for use in the development and operation of our business. In the future, our Board may decide, at its discretion, whether dividends may be declared and paid to holders of our common stock.

 

21
 

 

CAPITALIZATION

 

The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2021:

 

  on an actual basis; and

 

  on an as adjusted basis to give effect to our 1-for-     reverse stock split, the issuance and sale by us in this offering of            shares of our common stock at an assumed public offering price of $     per share (the midpoint of the range set forth on the cover page of this prospectus), after deducting the estimated underwriting discounts and commissions and estimated offering expenses that we expect to pay, and the application of the net proceeds from this offering as described under “Use of Proceeds.”

 

This table should be read in conjunction with, and is qualified in its entirety by reference to, “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes appearing elsewhere in this prospectus.

 

    As of June 30, 2021  
    Actual     As Adjusted  
Cash and cash equivalents   $ 966,398          
                 
Capitalization:                
Current debt:                
Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party   $ 5,524,450        

Short term loan

   

393,754

       
Total current debt     5,918,204        
Long-term debt:                
Note payable, net of debt discount and debt issuance cost, related party     1,239,908        
Total long-term debt     1,239,908        
Stockholders’ deficit:                
Common stock, $0.00001 par value; 300,000,000 shares authorized; 89,889,074 and          , shares issued and outstanding, respectively     899          
Additional paid in capital     19,147,884          
Accumulated other comprehensive (loss) income     (302,517 )        
Accumulated deficit     (20,183,008 )        
Total stockholders’ deficit     (1,336,742 )        
Total Capitalization   $ 5,821,370          

 

Unless we indicate otherwise, all information in this Capitalization section:

 

  assumes no exercise by the underwriters of their over-allotment option;
     
  excludes 3,466,667 shares of common stock issuable upon the exercise of outstanding options at a weighted exercise price of $0.54 per share; and
     
  excludes 12,058,333 shares of common stock reserved for future issuance pursuant to our 2014 Stock Incentive Plan.

 

22
 

 

DILUTION

 

If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after the closing of this offering.

 

Our historic net tangible book value of our common stock as of June 30, 2021 was approximately $(1.3 million), or $(0.01) per share, based on the number of shares of our common stock outstanding as of June 30, 2021. Historic net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of outstanding shares of common stock.

 

After giving effect to the 1-for-     reverse stock split and the receipt of the net proceeds from our sale of         shares of common stock in this offering at an assumed public offering price of $     per share (the midpoint of the range set forth on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2021, would have been $     million, or $     per share. This represents an immediate increase in as adjusted net tangible book value of $     per share to our existing stockholders and an immediate dilution of $     per share to investors purchasing common stock in this offering.

 

We calculate dilution per share to new investors by subtracting the historic net tangible book value per share from the public offering price paid by the new investor. The following table illustrates the dilution to new investors on a per share basis:

 

Assumed public offering price per share         $    
Historic net tangible book value per share as of June 30, 2021   $ (0.01 )        
Increase in net tangible book value per share attributable to new investors in this offering              
As adjusted net tangible book value per share after this offering              
Dilution in net tangible book value per share to new investors in this offering         $    

 

Each $1.00 increase (decrease) in the assumed public offering price of $     would increase (decrease) our as adjusted net tangible book value per share after this offering by $     per share and the dilution to new investors by $     per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us would increase (decrease) the as adjusted net tangible book value by $     per share and the dilution to new investors by $     per share, assuming the assumed public offering price remains the same and after deducting underwriting discounts and commissions.

 

If the underwriters’ option to purchase additional shares to cover over-allotments is exercised in full, the as adjusted net tangible book value per share after giving effect to this offering would be $     per share, representing an immediate increase to existing stockholders of $     per share, and immediate dilution to new investors in this offering of $     per share.

 

The following table summarizes, as of June 30, 2021, on the as adjusted basis described above:

 

  the total consideration paid to us by our existing stockholders and by new investors purchasing common stock in this offering, assuming a public offering price of $     per share (the midpoint of the range set forth on the cover page of this prospectus), before deducting underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering; and
     
  the average price per share paid by existing stockholders and by new investors purchasing shares in this offering.

 

    Shares Purchased     Total Consideration     Average Price  
    Number     Percent     Amount     Percent     Per Share  
Existing stockholders           %   $       %   $  
New investors                  %                  %        
Total             100.0 %   $       100.0 %   $         

 

A $1.00 increase (decrease) in the assumed public offering price of $     per share would increase (decrease) total consideration paid by new investors by $     million and increase (decrease) the total consideration paid to us by new investors by     %, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

If the underwriters’ option to purchase additional shares to cover over-allotments is exercised in full, the number of shares held and the percentage of total consideration paid by the existing stockholders after this offering would be reduced to     % and     %, respectively, and the number of shares held and the percentage of total consideration paid by new investors would increase to     % and     %, respectively.

 

The foregoing calculations exclude:

 

  3,466,667 shares of common stock issuable upon the exercise of outstanding options at a weighted exercise price of $0.54 per share; and
  12,058,333 shares of common stock reserved for future issuance pursuant to our 2014 Stock Incentive Plan.

 

23
 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our results of operations and financial condition should be read together with “Summary Historical Consolidated Financial and Other Data” and the financial statements and related notes included elsewhere in this prospectus. Such discussion and analysis reflects our historical results of operations and financial position and does not give effect to the completion of this offering. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” and elsewhere in this prospectus.

 

Overview

 

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of three core brands: FOCUSfactor, a patented brain health supplement that has been clinically shown to improve memory, concentration and focus; Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals; and Hand MD, a full range of preventative, restorative, and anti-aging skin care products designed for the hands.

 

Our management’s discussion and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction with our audited Consolidated Financial Statements and accompanying notes thereto included elsewhere in this prospectus. Key factors affecting our results of operations include revenues, cost of sales, operating expenses and income and taxation.

 

Non-GAAP Financial Measures

 

We currently focus on Adjusted EBITDA to evaluate our business relationships and our resulting operating performance and financial position. Adjusted EBITDA is defined as EBITDA (net income plus interest expense, income tax expense, depreciation and amortization), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We present Adjusted EBITDA because we consider it an important measure of our performance and a meaningful financial metric in assessing our operating performance from period to period by excluding certain items that we believe are not representative of our core business, such as certain non-cash items and other adjustments.

 

We believe that Adjusted EBITDA, viewed in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), provides useful information to investors.

 

    Six Months Ended June 30, 2021     Six Months Ended June 30, 2020     Year Ended December 31, 2020     Year Ended December 31, 2019  
    (Unaudited)     (Unaudited)              
Net income (loss)   $ 2,640,429     $ 1,101,350     $ 1,411,132     $ (9,207,447 )
Interest income     (24 )     (79 )     (104 )     (414 )
Interest expense     627,883       497,992       1,186,034       981,105  
Taxes     104,537       128,996             131,537  
Depreciation and amortization           95,686       148,697       1,342,689  
EBITDA   $ 3,372,825     $ 1,823,945     $ 2,745,759     $ (6,752,530 )
Impairment of intangible assets                 47,002       9,715,137  
Stock-based compensation           77,358       128,929       201,155  
Non-recurring expenses     393,965 (1)     1,014,846 (2)     1,263,427 (3)     493,924 (4)
Bad debts                 74,068       283,972  
Obsolete inventory                 527,737       257,111  
Loss on foreign currency translation and transaction     (259,707 )     177,791       (106,761 )     6,972  
Adjusted EBITDA   $ 3,507,083     $ 3,093,940     $ 4,680,161     $ 4,205,741  

 

  (1) Consists of acquisition expenses with customers for shelf placement of $393,965.
  (2) Consists of loan fees of $1,000,000 and acquisition expenses with customers for shelf placement of $14,846.
  (3) Consists of loan fees of $1,000,000 and related financing costs of $61,000, leasehold renovations of $174,215 and acquisition expenses with customers for shelf placement of $28,212.
  (4) Consists of acquisition expenses with customers for shelf placement of $261,801, customer return of $215,189 and inventory write off of $16,934.

 

EBITDA and Adjusted EBITDA are considered non-GAAP financial measures. EBITDA represents earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA represents EBITDA further adjusted to exclude the impact of higher-than-normal revenue change order activity and certain expenses and transactions that we believe are not representative of our core operating results; stock-based compensation; non-recurring expenses for acquisitions, such as one-time expenses with customers for shelf placement, and other fees and costs; and loss on foreign currency translation and transaction. Our definitions of EBITDA and Adjusted EBITDA might not be comparable to similarly titled measures reported by other companies.

 

24
 

 

Results of Operations for the Six Months Ended June 30, 2021 and June 30, 2020

 

During both the six months ended June 30, 2021 and 2020, we focused on developing our currently owned brands into new markets and by product extensions. Our objective is to grow all four of our targeted verticals (Nutraceuticals, Over the Counter (OTC), Consumer Goods and Cosmeceuticals) to provide a balanced and synergistic portfolio that drives consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor and Flat Tummy consumables, Over the Counter (OTC) consists of Neuragen products, Consumer Goods consists of Sneaky Vaunt and app revenue, and Cosmeceuticals consists of Hand MD products.

 

Revenue

 

For the six months ended June 30, 2021, we had revenue of $24,761,974 from sales of our products, as compared to revenue of $17,906,767 for the six months ended June 30, 2020. The revenue is comprised of the following categories:

 

    June 30, 2021     June 30, 2020  
Nutraceuticals   $ 24,549,101     $ 12,361,201  
Over the Counter (OTC)     -       22,311  
Consumer Goods     168,047       565,756  
Cosmeceuticals     44,826       4,957,499  
    $ 24,761,974     $ 17,906,767  

 

We had an increase in Nutraceuticals revenue in the six months ended June 30, 2021 as compared to the six months ended June 30, 2020 due to higher consumer sales across all of our distribution channels driven by our advertising campaigns and new products entering the market. The increase was due solely to sales volume increases, as prices for our products did not increase year-over-year. We had a decrease in Over the Counter revenue in 2021 as compared to 2020 due to a supply issue with Neuragen during the period. We had a decrease in Consumer Goods revenue in 2021 as compared to 2020 due to a shift in business focus away from our Sneaky Vaunt brand. We had a decrease in Cosmeceuticals revenue in 2021 as compared to 2020 due to sales of a hand sanitizer product to a retailer in 2020 that was not repeated in 2021. The sales to the retailer in 2020 were as a result of excessive demand and insufficient supply of hand sanitizers as a result of the COVID-19 outbreak. As the supply of hand sanitizers increased in 2021, the pricing to customers and resulting margins decreased and we decided to no longer pursue the sale of the product.

 

Cost of Revenue

 

For the six months ended June 30, 2021, our cost of revenue was $6,794,344. Our cost of revenue for the six months ended June 30, 2020, was $6,593,446. The cost of revenue is comprised of the following categories:

 

    June 30, 2021     June 30, 2020  
Nutraceuticals   $ 6,762,231     $ 3,633,453  
Over the Counter (OTC)     -       -  
Consumer Goods     29,986       161,821  
Cosmeceuticals     2,127       2,798,172  
    $ 6,794,344     $ 6,593,446  

 

We had an increase in Nutraceuticals in 2021 as compared to 2020 due to higher sales. We had a decrease in Consumer Goods in 2021 as compared to 2020 due to a decrease in sales. We had a decrease in Cosmeceuticals in 2021 as compared to 2020 due to sale of a hand sanitizer product to a retailer in 2020 that was not repeated in 2021.

 

Gross Profit

 

Gross profit was $17,967,631, or 73% of revenue, for the six months ended June 30, 2021, as compared to gross profit of $11,313,321, or 63% of revenue, for the same period in 2020, an increase of $6,654,309, or 59%. The increase in gross profit is directly related to the increase in net sales. The increase in gross profit margin in total is directly related to the mix of products being sold. Our Nutraceuticals gross profit margin remained largely stable with a slight increase in 2021 to 72% from 71%. Our Cosmeceuticals gross profit increased in 2021 to 95% from 44%, which is directly attributable to the high volume of hand sanitizer sales during 2020 at a lower margin.

 

Operating Expenses

 

Selling and Marketing Expenses

 

For the six months ended June 30, 2021, our selling and marketing expenses were $11,507,769 as compared to $5,640,397 for the six months ended June 30, 2020, which is primarily due to an increase in promotions and advertising, which had been reduced in response to COVID-19 during the six months ended June 30, 2020.

 

General and Administrative Expenses

 

For the six months ended June 30, 2021, our general and administrative expenses were $2,997,276. For the six months ended June 30, 2020, our general and administrative expenses were $3,043,044. The decrease is primarily due to improved management of operating costs.

 

Depreciation and Amortization Expenses

 

For the six months ended June 30, 2021, our depreciation and amortization expenses were $0 as compared to $53,544 for the six months ended June 30, 2020. The decrease is due to impairment of assets in 2020.

 

Other Income and Expenses

 

For the six months ended June 30, 2021 and 2020 we had other (income) and expense items of the following:

 

    Six months
ended
June 30, 2021
    Six months
ended
June 30, 2020
 
Interest income   $ (24 )   $ (79 )
Other income           (181,849 )
Other expense (loan success fee)           1,000,000  
Interest expense     627,883       497,992  
Remeasurement loss (gain) on translation of foreign subsidiary     89,760       (12,216 )
Amortization of debt issuance cost           42,142  
Total other expense   $ 717,619     $ 1,345,990  

 

For the six months ended June 30, 2021, we had interest expense of $627,883 as compared to $497,992 for the six months ended June 30, 2020 due to interest on the Knight loan success fee during the entire period ended June 30, 2021 and our entry into the $500,000 working capital loan with Shopify Capital.

 

Net Income

 

For the six months ended June 30, 2021, our net income was $2,640,429 as compared to a net income of $1,101,350 for the six months ended June 30, 2020 due to higher revenue.

 

Results of Operations for the Years Ended December 31, 2020 and December 31, 2019

 

During both 2020 and 2019, we focused on developing our currently owned brands into new markets and by product extensions.

 

Revenue

 

For the year ended December 31, 2020, we had revenues of $40,226,865 from sales of our products, as compared to revenue of $29,357,546 for the year ended December 31, 2019. This is comprised of the following categories:

 

   

December 31,

2020

   

December 31,

2019

 
Nutraceuticals   $ 31,902,291     $ 28,149,938  
Over the Counter (OTC)     22,310       62,359  
Consumer Goods     1,201,317       706,688  
Cosmeceuticals     7,100,947       438,561  
    $ 40,226,865     $ 29,357,546  

 

The increase in our Nutraceutical category was due to higher sales. The decrease in the Over the Counter (OTC) category was due to a supply issue with Neuragen during the year. The increase in the Consumer Goods category is due to normalization of business after the 2019 launch of our online application. The increase in the Cosmeceuticals category was due to the launch of a new Hand MD hand sanitizer product.

 

Cost of Sales

 

For the year ended December 31, 2020, our cost of sales was $14,578,865. Our cost of sales for the year ended December 31, 2019, was $9,137,602. This is comprised of the following categories:

 

   

December 31,

2020

   

December 31,

2019

 
Nutraceuticals   $ 9,948,690     $ 8,943,967  
Over the Counter (OTC)     24,082       -  
Consumer Goods     494,591       78,109  
Cosmeceuticals     4,111,502       115,526  
    $ 14,578,865     $ 9,137,602  

 

The increase in our Nutraceutical category was due to higher revenue and a write off of obsolete inventory. The increase in Consumer Goods was due to the write off of obsolete inventory. The increase in Cosmeceuticals was due to higher Hand MD revenue and a write off of obsolete inventory. Management reviews inventory periodically and determines if any products have a limited useful life or are otherwise obsolete and should be written off.

 

Gross Profit

 

Gross profit was $25,648,000, or 64% of revenue for the year ended December 31, 2020, as compared to gross profit of $20,219,944 or 69% of revenue for the same period in 2019, an increase of $5,428,056 or 27%. The increase in gross profit is directly related to the increase in net sales. The decrease in gross profit margin is directly related to the mix of products being sold.

 

Operating Expenses

 

Selling and Marketing Expenses

 

For the year ended December 31, 2020, our selling and marketing expenses were $15,889,066 as compared to $11,471,652 for the year ended December 31, 2019. The increase is due to an increase in promotions and advertising, including $2,674,000 in media spending related to the launch of our national television advertising campaign for FOCUSfactor, with the balance representing in-store promotional and advertising support to drive sales at our retailers.

 

25
 

 

Bad debts

 

For the year ended December 31, 2020, our bad debts expenses were $74,068. For the year ended December 31, 2019, our bad debts expenses were $283,971. The decrease is due to the write off of a single customer in each of 2020 and 2019 as a result of a customer entering Chapter 11 bankruptcy and slow payment, respectively.

 

General and Administrative Expenses

 

For the year ended December 31, 2020, our general and administrative expenses were $6,499,344. For the year ended December 31, 2019, our general and administrative expenses were $5,493,433. The increase is due to higher operating costs, which correlate with an increase in revenue.

 

Impairment of Intangible Assets

 

For the year ended December 31, 2020, our impairment of intangible assets expenses were $47,002 as compared to $9,715,137 for the year ended December 31, 2019. The decrease is due to the impairment of goodwill and indefinite life intangible assets in 2019 as a result of management’s reevaluation of such intangible assets arising out of the purchase of FOCUSfactor and Flat Tummy.

 

Depreciation and Amortization Expenses

 

For the year ended December 31, 2020, our depreciation and amortization expenses were $100,265 as compared to $1,211,861 for the year ended December 31, 2019. The decrease is due to the impairment of intangible assets during 2019, thus lower amortization costs during 2020.

 

Other Income and Expenses

 

For the years ended December 31, 2020 and December 31, 2019, we had other (income) and expense items of the following:

 

    Year
ended
December 31, 2020
    Year
ended
December 31, 2019
 
Interest income   $ (104 )   $ (414 )
Interest expense     1,186,034       981,105  
Remeasurement (gain) loss on translation of foreign subsidiary     (457,955 )     8,280  
Amortization of debt issuance cost     48,432       130,829  
Other income     (210,284 )      
Other expense (loan success fee)     1,000,000        
Finance expense     61,000        
Total   $ 1,627,123     $ 1,119,800  

 

The increase in interest expense in 2020 was due to our May 2020 working capital loan. In 2020 we received SBA PPP Loan proceeds from the United States government and Cash Flow Boost from the Australian government related to COVID-19 relief payments, which are included in other income.

 

Income tax expense

 

For the year ended December 31, 2020, we incurred income tax expense of $0. For the year ended December 31, 2019 we incurred income tax expense of $131,537 relating to an accrual of estimated future taxes.

 

Net Income (Loss)

 

For the year ended December 31, 2020, our net income was $1,411,132. For the year ended December 31, 2019 our net loss was $9,207,447. This was due to increase in impairment of intangible assets during 2019.

 

26
 

 

Liquidity and Capital Resources

 

Overview

 

As of June 30, 2021, we had $966,398 cash on hand. In addition, we had $20,000,000 available for certain future acquisitions under our credit facility with Knight, and restricted cash of $100,000 which is held for credit card collateral.

 

Our sources of cash have historically consisted of proceeds from issuances of loans from related parties and revenues generated from operations. We believe the existing cash and cash equivalents and cash provided by sales of our products will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months. Our future capital requirements will depend on many factors, including growth rate, the timing and extent of spending to support development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product offerings, and the continuing market acceptance of our products. In the future, we may enter into arrangements to acquire or invest in complementary businesses, services and technologies, including intellectual property rights.

 

We may be required to seek additional equity or debt financing, including to fund these acquisitions or investments. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to expand operations and invest in new products, our ability to compete successfully could be reduced and our results of operations may be adversely impacted.

 

Short- and Long-Term Borrowings

 

On January 22, 2015, we entered into a Loan and Security Agreement (“Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan us $6,000,000, and which amount was borrowed at closing for the purpose of acquiring the FOCUSfactor business. At closing, we paid Knight an origination fee of $120,000 and a work fee of $60,000 and also paid $40,000 of Knight’s expenses associated with the loan. The loan bore interest at a rate of 15% per year; provided, however, that upon the occurrence of an equity or convertible equity offering by us of at least $1,000,000, the interest rate will drop to 13% per year. Interest accrues quarterly and is payable in arrears on March 31, June 30, September 30 and December 31 in each year, beginning on March 31, 2015. This loan was fully repaid in 2018.

 

On June 26, 2015, the Company, through its wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000 in connection with an asset purchase agreement. The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the security agreement, which will be released upon receipt of total payments of $1,200,000. The balance at June 30, 2021 was $425,000.

 

On November 12, 2015, we entered into a First Amendment to Loan Agreement (“First Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $5,500,000, and which amount was borrowed at closing for the purpose of acquiring Breakthrough Products, Inc. and NomadChoice Pty Limited through stock purchase agreements. At closing, we paid Knight an origination fee of $110,000 and a work fee of $55,000 and also paid $24,000 of Knight’s expenses associated with the loan. The loan bears interest at a rate of 15% per year. The interest rate will decrease to 13% if we meet certain equity fundraising targets. The First Amendment matured on November 11, 2017. This loan was fully repaid in 2017.

 

On August 9, 2017, we entered into an Amended and Restated Loan Agreement with Knight, pursuant to which Knight agreed to loan us an additional $10,000,000, which amount was borrowed at closing for working capital purposes, and an ongoing credit facility of up to $20,000,000 for use in connection with future mergers and acquisitions. At closing, we paid Knight an origination fee of $200,000 and a work fee of $100,000 and also paid $100,000 of Knight’s expenses associated with the loan.

 

On May 8, 2020, we entered into a Third Amendment Agreement (the “Third Amendment”) to the Amended and Restated Loan Agreement with Knight, pursuant to which Knight agreed to loan us an additional $2,500,000 (the “Additional Loan”). We paid Knight a work fee of $36,000, and $25,000 for Knight’s legal costs and expenses incurred in connection with the Third Amendment. The Additional Loan had a maturity date of May 8, 2021 and bears interest at 12.5% per annum compounding quarterly. During the six months ended June 30, 2021, $2,000,000 of the Additional Loan was repaid and the remaining balance has been extended to a maturity date of December 31, 2021. The loan balance of the Additional Loan at June 30, 2021 was $500,000.

 

The terms of the $10,000,000 loaned in connection with the Amended and Restated Loan Agreement were modified by the Third Amendment. This tranche bears interest from May 8, 2020 at a rate equal to 12.5% per annum compounded quarterly. We agreed to pay a success fee in the amount of $1,000,000 with respect to this tranche, which shall be fully earned on May 8, 2020 and payable no later than August 31, 2022. The success fee shall bear interest at 12.5% per annum compounding quarterly. The loan has been extended to a maturity date of December 31, 2021. The loan balance at June 30, 2021 was $5,000,000.

 

As amended, the Amended and Restated Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics (including maintenance at all times of a cash balance of $600,000, Adjusted EBITDA of at least $3,000,000 for the 12 months ending on June 30, 2020, Adjusted EBITDA of at least $4,000,000 for each 12 month period ending on the last day of each fiscal quarter thereafter), and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to our business, provided that the aggregate consideration to be paid does not exceed $100,000 and the acquired business guarantees our obligations under the Amended and Restated Loan Agreement, or for qualifying acquisitions financed under our $20,000,000 credit facility for future mergers and acquisitions, among other permitted acquisitions) or make capital expenditures in excess of $500,000. The Amended and Restated Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect defaults. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of all loans under the Amended and Restated Loan Agreement will bear a default interest rate of an additional 5%.

 

27
 

 

During the year ended December 31, 2020, we received funding (the “PPP Loan”) through the U.S. Small Business Administration’s Paycheck Protection Program (“PPP”) of $163,542, which bears interest at 1% per annum, with monthly installments commencing on May 5, 2020 for 60 months through its maturity on May 5, 2025. We used all proceeds from the PPP Loan to maintain payroll and other allowable expenses. In July 2021, the PPP Loan was forgiven in full. Our subsidiary, Nomad Choice Pty Ltd, received the Cash Flow Boost from the Australian government. This assistance was received from March 2020 through September 2020 in the amount of $46,742 and does not need to be repaid.

 

On May 16, 2021, we entered into a loan agreement in the amount of $565,000 with Shopify Capital Inc. for an advancement of working capital from our online processing account. We received $500,000 from Shopify Capital Inc. and $65,000 of original issue discount. The loan bears a repayment rate of 14% of daily sales and we shall pay $94,167 every 60 days with a final payment due on May 12, 2022. The payment of such amounts is secured by a security interest in (i) all accounts and balances in such accounts owned by us; (ii) all general intangibles, all payment intangibles, all rights to payment, all accounts receivable; (iii) all money, cash equivalents and other assets that come into the control of Shopify; and (iv) all of the proceeds of the foregoing pursuant to a Security Agreement, which will be released upon receipt of total payments of $565,000. This security agreement takes second priority behind the security agreement for our loan with Knight. We recognized amortization original issue discount of $11,877, which is included in interest expense in the statement of income during the six months ended June 30, 2021. The outstanding loan balance at June 30, 2021 was $393,754. 

 

Operating Activities

 

For the six months ended June 30, 2021, net cash provided by operating activities was $1,312,136, compared to net cash used in operating activities of $2,521,575 for the six months ended June 30, 2020. This increase in net cash provided by operating activities for the six months ended June 30, 2021 was primarily attributable to a decrease in accounts receivable and an increase in accounts payable and accrued expenses.

 

For the six months ended June 30, 2021, net cash provided by operating activities of $1,312,136 consisted of our net income of $2,640,429 adjusted by:

  

Amortization of debt issuance cost   $  11,877  
Foreign currency transaction loss     (348,208 )
Remeasurement loss on translation of foreign subsidiary     89,760  
Non cash implied interest     17,442  
Changes in operating assets and liabilities:        
Accounts receivable     1,326,856  
Loan receivable, related party     (783,293 )
Inventory     (4,717,766 )
Prepaid expense     (80,210 )
Prepaid expense, related party     44,545  
Income taxes receivable     116,074  
Contract liabilities     (73,139 )
Accounts payable and accrued liabilities     3,125,110  
Accounts payable, related party     (217,761 )

 

For the six months ended June 30, 2020, net cash used by operating activities of $2,521,575 consisted of our net income of $1,101,350 adjusted by:

 

Amortization of debt issuance cost   $ 42,141  
Depreciation and amortization     53,544  
Stock based compensation expense     77,358  
Foreign currency transaction loss     190,007  
Remeasurement loss on translation of foreign subsidiary     (12,216 )
Non cash implied interest     9,298  
Reversal of allowance for doubtful accounts     (170,309 )
Gain on write-off of payables     (180,000 )
Accrual of loan success fee     1,000,000  
Changes in operating assets and liabilities:        
Accounts receivable     (3,610,852 )
Loan receivable, related party     (45,179 )
Inventory     (337,369 )
Prepaid expense     (344,414 )
Prepaid expense, related party      
Income taxes receivable     226,686  
Contract liabilities     9,250  
Accounts payable and accrued liabilities     (791,573 )
Accounts payable, related party     170,345

 

For the year ended December 31, 2020, we had net cash used in operating activities of $1,588,248 as compared to $2,946,350 of net cash provided by operating activities for the year ended December 31, 2019. The decrease was attributable to a decision in 2020 to purchase inventory and ship through a third party rather than shipping directly from our manufacturers, and the increase in accounts receivable and the increase in a related party loan receivable in 2020 due to higher revenues in the normal course of our growth.

 

For 2020, net cash used in operating activities of $1,588,248 consisted of our net income of $1,411,132 adjusted by:

 

Amortization of debt issuance cost   $ 48,432  
Depreciation and amortization     100,265  
Stock based compensation expense     128,929  
Impairment of intangible assets     47,002  
Foreign currency transaction loss     351,194  
Bad debts     74,068  
Remeasurement loss on translation of foreign subsidiary     (457,955 )
Non cash implied interest     36,455  
Reversal of allowance for doubtful accounts     (237,768 )
Gain on write-off of payables     (180,000 )
Accrual of loan success fee     1,000,000  
Write-off of inventory     527,737  
Changes in operating assets and liabilities:        
Accounts receivable     (2,070,032 )
Loan and accounts receivable, related party     (2,028,524 )
Inventory     (2,133,145 )
Prepaid expenses     (558,346 )
Prepaid expense, related party     (492,741 )
Income taxes receivable     (280,304 )
Income taxes payable     300,773  
Contract liabilities     113,916  
Accounts payable and accrued liabilities     3,251,816  
Accounts payable, related party     (541,152 )

 

For 2019, net cash provided by operating activities of $2,946,350 consisted of our net loss of $9,207,447 adjusted by:

 

Amortization of debt issuance cost   $ 130,829  
Depreciation and amortization     1,211,860  
Stock based compensation     201,155  
Impairment of intangible assets     9,715,137  
Foreign currency transaction loss     (1,308 )
Bad debts     283,972  
Remeasurement loss on translation of foreign subsidiary     8,280  
Non cash implied interest     38,310  
Write-off of inventory     257,111  
Changes in operating assets and liabilities:        
Accounts receivable     3,027,900  
Accounts receivable, related party     (277,432 )
Inventory     552,158  
Prepaid expenses     642,704  
Income taxes receivable     135,072  
Contract liabilities     (41,823 )
Accounts payable and accrued expenses     (2,910,949 )
Accounts payable, related party     (819,179 )

 

28
 

 

Investing Activities

For the six months ended June 30, 2021, net cash used in investing activities was $0, compared to net cash used in investing activities of $130,528 for the six months ended June 30, 2020.

 

For the years ended December 31, 2020 and 2019, we used net cash of $0 in investing activities.

 

Financing Activities

 

For the six months ended June 30, 2021, net cash used in financing activities was $1,618,123, compared to net cash used in financing activities of $1,975,000 for the six months ended June 30, 2020.

 

Financing activities during the six months ended June 30, 2021 and June 30, 2020:

 

    Six months
ended
June 30, 2021
    Six months
ended
June 30, 2020
 
Advances from related party   $     $ 70,490  
Repayments of advances to related party           (70,490 )
Proceeds of note payable, related party    

     

2,500,000

 
Proceeds of short term debt     500,000        
Repayment of short term debt     (118,123 )      
Repayment of notes payable, related party     (2,000,000 )     (525,000 )

 

For the year ended December 31, 2020, financing activities provided $1,950,000, as compared to $2,050,000 used in financing activities for the year ended December 31, 2019. The increase was attributable to the issuance of a new note in 2020.

 

Financing activities during 2020:

 

Proceeds of notes payable   $ 2,500,000  
Repayment of notes payable     (550,000 )
Advances from related party     74,629  
Repayments of advances to related party     (74,629 )

 

Financing activities during 2019:

 

Repayment of notes payable   $ (2,050,000 )
Advances from related party     324,102  
Repayments of advances to related party     (324,102 )

 

Key Near-Term Initiatives

 

During the remainder of 2021 and through 2022, we intend to organically grow our current product lines by developing and launching new products and expanding into new markets. Specifically, for Flat Tummy we are expecting to launch a superfruits gummy and an ashwagandha/calming gummy in the fourth quarter of 2021, and three new protein shakes, a protein ready-to-drink beverage, hydration powder and preworkout powder in 2022. For FOCUSfactor, we are working on developing four new products targeted to launch beginning in 2022, including a “maximum strength” formula, an “ultimate” formula, ready-to-drink beverages and a nootropic line. Another major initiative is increasing investment in our TV advertising campaign for our FOCUSfactor brand. Additionally, in the fourth quarter of 2021, we are planning the launch of three core FOCUSfactor products in the United Kingdom and Australia. Lastly, we intend to grow further through additional strategic acquisitions and we continue to evaluate opportunities and candidates that we believe fit well with our brand portfolio. With the proceeds from this offering, we expect to accelerate our acquisition strategy, in particular with candidates with whom we are in discussions. Certain of these acquisitions, if consummated, would require us to incur additional debt.

 

Off-Balance Sheet Arrangements

 

During the six months ended June 30, 2021, and during the years ended December 31, 2020 and 2019, we had no off-balance sheet arrangements.

 

Inflation

 

The effect of inflation on our operating results was not significant in the six months ended June 30, 2021 or the years ended December 31, 2020 and 2019.

 

29
 

 

Critical Accounting Policies

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures of contingent assets and liabilities. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition and allowance for doubtful accounts. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

 

Management believes the following critical accounting policies, among others, affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

 

Use of Estimates

 

In preparing the consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the statements of financial condition, and revenues and expenses for the years then ended. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, the assumptions used to calculate stock-based compensation, derivative liabilities and common stock issued for services. Significant estimates are assumptions about collection of accounts receivable, current income taxes, deferred income taxes valuation allowance, useful life of fixed and intangible assets, and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary.

 

Revenue recognition

 

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration we expect to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

 

We recognize revenue upon shipment from our fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. We recognize revenue for our digital products in the month the download by the customer occurs.

 

Revenues from sale of Hand MD hand sanitizers in 2020 were recognized in accordance with our revenue recognition policies which are based upon ASC 606. All product sales were initiated based upon the retailer’s purchase orders at a fixed transaction price and revenues recognized when the products were delivered and accepted by the customer.

 

Contract Liabilities - Deferred Revenue

 

Our contract liabilities consist of advance customer payments and deferred revenue. Deferred revenue results from transactions in which we have been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the deferred revenues are recognized.

 

Income Taxes

 

We utilize FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

We generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of our realization of the net operating loss carry forward prior to its expiration.

 

NomadChoice Pty Ltd, our wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. We recognize liabilities for anticipated tax audit issues based on our current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Synergy CHC Inc. is a wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. We recognize liabilities for anticipated tax audit issues based on our current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Effect of Exchange Rate on Results

 

The functional currency of one of our foreign subsidiaries (NomadChoice Pty Ltd.) is the U.S. Dollar. This foreign subsidiary maintains its records using local currency (Australian Dollar – “AUD”). All monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates, non-monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary.

 

The functional currency of our other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). This foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income.

 

The exchange rates used to translate amounts in AUD and CAD into USD for the purposes of preparing the consolidated financial statements were as follows:

 

Balance sheet:

 

    December 31,     December 31,  
    2020     2019  
Period-end AUD: USD exchange rate   $ 0.7708     $ 0.7030  
Period-end CAD: USD exchange rate   $ 0.7854     $ 0.7699  

 

Income statement:

 

    December 31,     December 31,  
    2020     2019  
Average Yearly AUD: USD exchange rate   $ 0.6902     $ 0.6954  
Average Yearly CAD: USD exchange rate   $ 0.7463     $ 0.7537  

 

Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred.

 

30
 

 

BUSINESS

 

Our Company

 

We are a provider of consumer health care, beauty, and lifestyle products. Our current brand portfolio consists of two marquee brands, FOCUSfactor, a patented brain health supplement that has been clinically shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals, and a developing brand, Hand MD, consisting of a full range of preventative, restorative, and anti-aging skin care products designed for the hands. During the year ended December 31, 2020, FOCUSfactor represented 62% of our net revenue, Flat Tummy was 17%, and Hand MD was 17%. During the six months ended June 30, 2021, FOCUSfactor represented 71% of our net revenue, Flat Tummy was 29%, and Hand MD was 0.2%. Our products are sold through some of the nation’s leading club, mass drug, and other retailers such as Costco, Amazon.com, Walmart, Walgreens, CVS, The Vitamin Shoppe, Target.com, H-E-B, and SuperValu.

 

We built our brand portfolio through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including earnout. Our Hand MD brand was acquired for $1.5 million of our stock in August 2015. In November 2015, we acquired our second marquee brand – Flat Tummy – for AUD 10.0 million (or approximately $7.0 million), using a mix of cash and stock. Our capital structure following the acquisition of our key brands in 2015 was highly levered, and our focus was on paying our debt as we did not have the resources to grow our business. We have grown our FOCUSfactor brand from 2 SKUs at acquisition to 16 SKUs, and our Flat Tummy Brand from 1 SKU to 18 SKUs.

 

With the outbreak of the COVID-19 pandemic in North America during the first three months of 2020, we extended our Hand MD brand to produce and market a range of hand sanitizers. We deployed the cash flow from hand sanitizer sales for a television advertising strategy to drive growth in our flagship FOCUSfactor brand products. Our FOCUSfactor advertising campaigns have aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT, targeting adults 45 years of age and older. As a result, net revenue for the year ended December 31, 2020 was $40.2 million, an increase of $10.9 million, or 37.0%, over net revenue for the year ended December 31, 2019. Net revenue for the six months ended June 30, 2021 was $24.8 million, an increase of $6.9 million, or 38.3% over net revenue for the six months ended June 30, 2020. In particular, FOCUSfactor net revenue continued to benefit from our advertising strategy, increasing to $17.5 million for the six months ended June 30, 2021, a 124% increase over the same period in 2020.

 

Following the completion of this offering, we intend to use the proceeds to repay in full our outstanding debt, to accelerate the growth of our current brands through advertising and otherwise, and to drive our acquisition strategy as we have a pipeline of potential near-term acquisition targets that we are eager to pursue. Given the success of our FOCUSfactor advertising campaigns – in which we have achieved approximately a $4 increase in gross revenue for each incremental $1 of advertising spend – we believe that we can meaningfully expand our FOCUSfactor campaigns. In addition, we have tailored strategies for our Flat Tummy and Hand MD brands to maximize our return on investment and leverage our experience with both traditional and digital marketing. Our asset-light business model, in which we partner with third-party manufacturers to produce our brand offerings, allows us to scale quickly and profitably while satisfying growing demand.

 

For the six months ended June 30, 2021, our net revenues, net income and Adjusted EBITDA were $24.8 million, $2.6 million and $3.5 million, respectively, representing an increase of 38.3%, 139.7%, and 13.4% over the same period in the prior fiscal year. During the year ended December 31, 2020, our net revenues, net income (loss) and Adjusted EBITDA were $40.2 million, $1.4 million and $4.7 million, respectively, as compared to $29.4 million, $(9.2) million and $4.2 million for the prior year.

 

Our Brands

 

Our flagship brand, FOCUSfactor, is a brain health nutritional supplement with over 15 years of heritage and a patented formula comprised of a proprietary blend of key brain supporting ingredients along with vitamins, minerals, and other nutrients. We believe FOCUSfactor is the only product in its category whose entire patented formula has been clinically shown to support memory, concentration and focus. Our FOCUSfactor brand consists of 16 SKUs and is sold primarily through leading retailers in the United States, including Costco, Walmart, Amazon.com, Walgreens, and CVS, in addition to selling direct to consumer through the FOCUSfactor website. Across three of our key partners, we have increased the number of SKUs sold through the retailer from the single SKU available at the beginning of our relationship in 2015 or 2016. In addition, we have increased our presence in retail locations for these key partners, resulting in a significant increase in retail doors, being the number of SKUs multiplied by the number of retail locations for each retailer.

 

Our second marquee brand, Flat Tummy, consists of a range of lifestyle products and accessories including tea, shakes, lollipops, supplements, apparel, and exercise accessories. We also provide a Flat Tummy mobile app, which as of June 30, 2021 had 1.3 million unique downloads and is intended as a tool to promote the Flat Tummy lifestyle centered around general wellness and health. Our Flat Tummy brand consists of 18 SKUs and is sold direct to consumer through the Flat Tummy website and application, as well as through retailers such as Amazon.com and CVS.

 

31
 

 

Our developing brand, Hand MD, is a beauty-focused brand consisting of an anti-aging skincare line formulated specifically for the hands. The product line includes serums and creams for exfoliating, skin repair and rehydration as well as hand soaps and hand sanitizers. The Hand MD brand consists of 8 SKUs and is sold online through the Hand MD website as well as through Amazon.com.

 

We also own five additional, non-core brands. While we may elect to promote these brands and commercialize their products in the future, we have prioritized our key FOCUSfactor, Flat Tummy, and Hand MD brands, and management is focused on the growth of these core products.

 

Our net revenues by brand for the six months ended June 30, 2021 are below:

 

Net Revenue by Brand for the Six Months Ended June 30, 2021(1)

 

 

 

(1) Hand MD represented 0.2% of our net revenue for the six months ended June 30, 2021.

 

Our Competitive Strengths

 

We believe that we have attributes that differentiate us from our competitors and provide us with significant competitive advantages. Our key competitive strengths include:

 

Well-Positioned in Growing Categories Driven by Favorable Consumer Trends

 

An increased focus on health, beauty and wellness by consumers has served as a tailwind for our brands. The nutritional supplement market has experienced significant growth across a range of areas including immune health, brain health, heart health, sleep/stress, and overall nutrition and wellness as a result of an aging population, increased obesity, pandemic concerns and a desire for more natural solutions and treatments over prescription medication. Additionally, there is an increased demand on hand cleansing and hand sanitizing products due to the COVID-19 pandemic, which is also driving demand for hand moisturizing products to soothe dried, chapped hands due to frequent hand washing and sanitizing. We believe that we are well positioned to benefit from these favorable trends. Our FOCUSfactor, Flat Tummy and Hand MD brands have seen strong growth with net revenues up 38% year-over-year in the six months ended June 30, 2021. We believe our focus on lifestyle products has also benefited from the growth and prevalence of social media.

 

Clinically Shown Results Backed by Independent Study for FOCUSfactor

 

We believe FOCUSfactor is the only product in its category with both a patent and a clinical study to support the product claims for improved memory, concentration, and focus. FOCUSfactor has been tested in a single-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate its effect on memory, concentration, and focus in healthy adults.

 

In this study, FOCUSfactor was tested on its entire 52-ingredient formulation rather than testing one or two ingredients within a formulation. FOCUSfactor was shown to provide a 44% increase in recall memory after six weeks of use versus placebo. This differentiates FOCUSfactor from other brain-health supplements and is a prime reason why FOCUSfactor has been placed in premier retailers. See “ — FOCUSfactor Clinical Study” for additional information.

 

Experienced Management Team with Proven Track Record of Value Creation

 

Our executive team has a combined 90 years of experience in consumer marketing and distribution and has been instrumental in acquiring and building our core brands. Management has exercised strong financial discipline in its acquisition strategy, with a focus on acquiring brands at attractive valuations. For example, we acquired FOCUSfactor for approximately 3x trailing EBITDA. For the six months ended June 30, 2021, the year ended December 31, 2020 and the year ended December 31, 2019, FOCUSfactor generated net revenue of $17.5 million, $24.9 million and $18.9 million, respectively. Management’s philosophy is to acquire promising brands that fit within our health, beauty and lifestyle offerings, and apply our proven marketing and distribution strategies to develop brands to their full potential. We believe we are adept at identifying promising opportunities that build out and complement our core brand portfolio.

 

32
 

 

Premier Retail Partners

 

Our premier retail partners include Costco, Walmart, Amazon.com, Walgreens, and CVS. We sell products to these partners under their standard arrangements, which do not include a term or duration as sales under each vendor agreement are generally made on a purchase order basis, and do not include any termination provisions. Our partners provide a platform to expand the breadth of our current offerings through product line extensions and new product innovation. We continue to introduce new SKUs to our current retail partners, such as the addition of FOCUSfactor Gummies to our membership club channel. Additionally, the international footprint of certain of our various retail partners facilitates our geographic expansion plans.

 

Scalable and Flexible Asset-Light Model to Support Growth

 

Our focus is on brand management, marketing, product development and distribution, and we utilize contract manufacturing partners in order to produce our various brand offerings. The use of third-party manufacturing partners allows us to scale quickly, as we ensure that our partners have sufficient capacity to meet our demand needs. We also maintain multiple relationships with different contract manufactures, ensuring diversification of our manufacturing base and reducing the likelihood of supply bottlenecks or deficits that could potentially slow our growth.

 

Our Growth Strategy

 

We intend to drive growth and increased profitability in our business through these key elements of our strategy:

 

Broaden Media Advertising Strategy

 

We have experienced a significant acceleration in sales growth for the FOCUSfactor brand as a result of our television advertising. We launched a national advertising campaign in August 2020, which has aired on major news and entertainment networks such as Fox News, CNN, MSNBC, TLC, and TNT, targeting adults 45 years of age and older. Since initiating our advertising strategy, FOCUSfactor net revenue has nearly doubled at key retailers. Based on these recent television campaigns, we estimate that we have experienced approximately $4 of gross revenue growth for every incremental $1 of advertising spend. We believe that we have significant growth potential through increased advertising budgets, and we expect to deploy a portion of the proceeds from this offering to expand our advertising campaigns. In particular, we anticipate a coordinated expansion of our television advertising strategy as we focus on pushing additional SKUs within our retail sales partner network to continue to build brand awareness and increase reach for FOCUSfactor. We also plan to invest in online marketing to promote all of our brands, including social media and influencer driven marketing.

 

Acquire Brands which Complement Our Existing Portfolio

 

We will continue to evaluate acquisition opportunities that we believe fit well within our brand portfolio and create value for our stockholders, such as further retail expansion in nutraceuticals and market expansion in health and beauty. In spite of historical capital constraints, our opportunistic approach to acquisitions has resulted in a successful track record of identifying promising targets that align with our overall brand strategy in the health, beauty and lifestyle segments. With the proceeds from this offering, we expect to accelerate our acquisition strategy, focusing on acquisition targets that management believes have the greatest synergistic potential, enabling us to significantly grow our product offerings and reach.

 

Partner with Additional Leading Retailers to Expand the Reach of Our Products

 

We have established distribution relationships with premier retail partners, including Costco, Walmart, Amazon.com, Walgreens, CVS, The Vitamin Shoppe, Target.com, H-E-B and SuperValu. Based on the success of our products with these leading retail partners, we believe that we are well positioned to add new retailers that will enhance our distribution footprint. We believe we have expansion opportunities with food retailers, including those focused on health foods. We intend to introduce seven new SKUs across three potential retailers, which would potentially result in the addition of approximately 50,000 retail doors.

 

Diversify Our Geographic Presence through Entry into New Markets

 

We seek to accelerate our sales growth by expanding and further diversifying our geographic footprint. In the year ended December 31, 2020, markets outside of North America represented 0.5% of our total net revenues. Our goal is to increase our net revenues generated from new markets. As we target new international markets, our strategy is to develop highly competitive and differentiated products that are produced in-country for ease of entry, with support from our regulatory group and an in-country regulatory consultant to help expedite the approval process. We currently plan to enter the United Kingdom and Australia markets in 2022, initially with FOCUSfactor, followed by Flat Tummy and Hand MD. We then plan to expand our brands into Asian markets and Mexico in late 2022 and 2023. In the United Kingdom and Australia, we have established relationships with manufacturers who will be producing FOCUSfactor in each country by December 2021. In addition, we are developing our marketing plans in compliance with applicable law, and are initiating retailer meetings as we seek to gain distribution across retail channels. In Mexico, we are currently awaiting regulatory review of our FOCUSfactor labels by the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). Following approval, we will establish in-country production with local manufacturers and begin connecting with retailers in Mexico. Our planned expansion into Asian markets is in early stages, and we are working with regulatory consultants to develop our plans.

 

33
 

 

Use Innovative Strategies to Boost Consumer Engagement

 

We have made investments in promoting apps for Flat Tummy and view this as a key aspect of growing our customer base and maintaining high levels of engagement. We have also focused on developing our social media presence, in particular through Instagram, in order to foster and grow our relationship with customers. Our brands appeal to both specific consumer needs as well as lifestyle choices and we seek to deepen our understanding of our customers and boost recognition of our brands through increased engagement.

 

Continue to Develop and Expand Our Current Brands

 

Our plan is to further develop and expand our brands by reaching a broader set of customers through advertising and product expansion. More specifically, we look to develop new products for our brands to satisfy the various customer segment opportunities (i.e. baby boomers, millennials, etc.) and satisfy various consumer needs as they relate to new and improved formulations, expanded and improved product benefits, alternative delivery formats and sizes. As we increase the product line-up behind our brands, we leverage our current retail distribution network by expanding our presence as well as adding incremental distribution with new retail partners. With a broader brand presence, we believe our advertising becomes even more efficient at driving sales velocity.

 

This is evidenced by our expanded FOCUSfactor product line, including gummies that are marketed to both adults and children and liquid energy and focus shots for a younger adult audience. Beginning in 2022, we plan to introduce additional FOCUSfactor products, including a “maximum strength” formula, an “ultimate” formula, ready-to-drink beverages and a nootropic line. The Flat Tummy brand has strategically added complementary products such as new shake options and supplements to appeal to a broader consumer group. In the fourth quarter of 2021, we plan to introduce a Flat Tummy superfruits gummy and an ashwagandha/calming gummy. Beginning in 2022, we plan to introduce additional Flat Tummy products, including three new protein shakes, a protein ready-to-drink beverage, hydration powder and preworkout powder. Additionally, we plan to employ this strategy of expanding our brands into international markets that include the United Kingdom, Australia and Asia, among others.

 

Marketing and Sales

 

Our targeted, consumer-driven marketing strategy has been key to building our brands and driving revenue growth. We manage dedicated marketing strategies for each of our brands in order to build deep connections with our customers.

 

FOCUSfactor. Our marketing strategy for FOCUSfactor is primarily focused on television advertising campaigns with leading national networks that appeal to the demographics of our wellness focused customer base. Our television advertising campaigns, launched in 2020, have coincided with strong sales results for the brand, with FOCUSfactor net revenue increasing 124% in the six months ended June 30, 2021 compared with the same period in 2020. In the year ended December 31, 2020, FOCUSfactor net revenue increased 38.1% year-over-year, to $24.9 million. As our flagship brand, FOCUSfactor accounted for 71% of our net revenue in the six months ended June 30, 2021, compared with 44% in the six months ended June 30, 2020, 62% in the year ended December 31, 2020 and 64% in the year ended December 31, 2019. The following charts demonstrate the significant growth in FOCUSfactor sales following the launch of our television advertising campaigns in August 2020, at a mass retailer (FOCUSfactor 90-count), a club store (FOCUSfactor 180-count) and a drug store (FOCUSfactor 60-count and FOCUSfactor Extra 60-count).

 

 

 

 

We also utilize in-store promotions along with online and social media advertising to promote our FOCUSfactor brand. We leverage the following online and social media assets as part of our marketing strategy:

 

Website: Our FOCUSfactor website helps to educate and inform consumers on our line of products. The website also serves as a direct-to-consumer sales channel for most FOCUSfactor products.

 

Instagram: Our main social media platform is Instagram. As of June 30, 2021, we had 14,300 followers.

 

FOCUSfactor – Brain Hub App: Early in 2021 we launched our Brain Hub app on the Android and Apple iOS platforms to provide an additional point of engagement with customers. The app contains a library of brain games and guided meditation sessions on topics related to mindfulness and brain health in order to keep consumers engaged.

 

Flat Tummy. We employ a primarily online and social media driven strategy for our Flat Tummy brand. The brand is focused primarily on women. We employ campaigns to reach our core target segments through a mix of traditional online advertising as well as influencer-based marketing. In the six months ended June 30, 2021, Flat Tummy accounted for 29% of our net revenue, compared with 25% in the six months ended June 30, 2020, 17% in the year ended December 31, 2020 and 34% in the year ended December 31, 2019.

 

Website: Our Flat Tummy website acts as a platform for engagement with our customers. In addition to offering a direct-to-consumer sales channel for our products, we also host a lifestyle blog on our website with a focus on health and fitness.

 

Instagram: Our primary social media platform is Instagram. As of June 30, 2021, we had 1.6 million followers. Our marketing strategy for Flat Tummy seeks to leverage our large online following to promote products from across the Flat Tummy brand. More recently we have engaged with social media influencers as a new strategy to promote our products.

 

Facebook: As of June 30, 2021, we had 552,000 followers. We mainly use the platform to share promotions and to relay content and advertisements.

 

34
 

 

Flat Tummy App: Our Flat Tummy app had 1.3 million unique downloads as of June 30, 2021, across both the Apple and Android platforms. The app provides customized workouts, nutrition information, and diet plans. The app is currently free to customers; however, we are exploring different strategies to monetize our large user base.

 

Hand MD. We mainly rely on social media and online advertising for our Hand MD brand. In the six months ended June 30, 2021, Hand MD accounted for 0.2% of our net revenue, compared with 28% in the six months ended June 30, 2020, 17% in the year ended December 31, 2020 and 1% for the year ended December 31, 2019.

 

Website: We primarily sell Hand MD products direct to consumer through our website www.handmd.com. We also host a blog on our website to drive consumer engagement and education on our various product offerings. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus.

 

Instagram: We mainly utilize Instagram as our social medial platform for engaging with Hand MD customers.

 

FOCUSfactor Clinical Study

 

FOCUSfactor has been tested in a single-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate its effect on memory, concentration, and focus in healthy adults. A total of 96 subjects were enrolled and randomized to one of the two treatment groups (FOCUSfactor and placebo). The study was sponsored by Factor Nutrition Labs, LLC, the developer of FOCUSfactor, and was conducted in 2011 at Cognitive Research Corporation (“CRC”) in Saint Petersburg, Florida. The sponsor, in consultation with CRC, was responsible for study design including selection of dose, eligibility criteria, efficacy and safety assessments, and vitamin/nutraceutical supply. CRC, a contract research organization, was responsible for data collection, database preparation, overall project management, site monitoring, data management, statistical analyses, and preparation of the final clinical study report.

 

The primary endpoint was sum recall for five trials of the Rey Auditory Verbal Learning Test (RAVLT), a standardized neuropsychological test of memory. The RAVLT is one of the most commonly used tests of memory in psychopharmacology research. The test was originally developed in the 1940s and has proven useful in evaluating verbal learning and memory, including proactive inhibition, retroactive inhibition, retention, encoding versus retrieval, and subjective organization. The standard RAVLT begins with a subject being read a list of 15 unrelated words at the rate of one word per second. The examiner then asks the subject to recall as many words as possible. This procedure is then repeated four more times with the same list of words and the number of correct responses is summed. This summed score was chosen as the primary outcome measure, or endpoint, for the current study.

 

The study demonstrated that, compared to placebo, FOCUSfactor improved abilities referred to as memory (i.e., short term memory), attention (e.g., focus), concentration and working memory in healthy adults. Following six weeks of treatment, subjects who received FOCUSfactor had a mean increase in recall of 6.5 words compared to 4.5 words for those who received placebo (t = -4.32, df = 87, p <0.001). The total words recalled over the five trials following six weeks of treatment (corrected for baseline score) was 51.9 words for subjects receiving FOCUSfactor compared to 49.7 words for subjects receiving placebo (t = -2.98, df = 87, p = 0.002). The significant effect on the RAVLT summed score supports the hypothesis that FOCUSfactor improves memory, attention (e.g. focus), and concentration. In addition, FOCUSfactor was found to be very well tolerated.

 

Hand MD Daily Dual Repair Clinical Study

 

Hand MD Daily Dual Repair has been tested in a single-center, single arm study to evaluate its effects on skin hydration, the appearance of hyperpigmentation/age spots, the appearance of skin radiance, and the appearance of fine lines and wrinkles of the hand area, among other objectives. A total of 51 healthy female subjects, 35 to 65 years of age, completed the clinical study. We sponsored the study, which was conducted in 2017 at BioScreen Testing Services, Inc. in Phoenix, Arizona. The experimental techniques used were: corneometer readings to measure electrical capacitance/hydration of the skin, cutometer readings to measure viscoelastic properties of the skin, software analysis of very high resolution images of the skin to measure roughness and smoothness, standardized photographs of the skin to evaluate fine lines and wrinkles, hyperpigmentation/age spots and skin radiance using the R.W. Johnson Pharmaceutical Research Scale for Evaluation of Photodamage, and self-assessment questionnaires. Baseline evaluations were made at the start of the study, after a five-day “washout” period. Subjects were instructed to use the test products as indicated, and evaluations were made after four weeks and eight weeks.

 

The tested product regimen provided the following statistically significant improvements after eight weeks of use: 100% of subjects demonstrated an increase in skin hydration, 71% demonstrated a decrease in appearance of hyperpigmentation/age spots, 88% of subjects demonstrated an increase in appearance of skin radiance, and 86% of subjects demonstrated a decrease in appearance of fine lines and wrinkles of the hand area. There were no adverse events reported during the study period.

 

Our History

 

We were organized as a corporation under the laws of the State of Nevada on December 29, 2010 under the name “Oro Capital Corporation.” In April 2014, Synergy Strips Corp., a Delaware corporation, became our wholly-owned subsidiary, and we changed our name from “Oro Capital Corporation” to “Synergy Strips Corp.” In August 2015, we changed our name to “Synergy CHC Corp.” In January 2019, our other U.S. subsidiaries, Neuragen Corp., Sneaky Vaunt Corp., The Queen Pegasus Corp. and Breakthrough Products Inc., merged with and into the Company. In July 2021, we acquired Hand MD Corp. as a wholly-owned subsidiary.

 

We were a public reporting company until July 17, 2020, the date on which we filed a Form 15 to voluntarily suspend our duty to file reports under Sections 13 and 15(d) of the Exchange Act. As a result of this offering, we will become subject again to the information and reporting requirements of the Exchange Act and we will file periodic reports, proxy statements and other information with the SEC.

 

Our Industry

 

The global nutritional supplement market is expected to grow at a compound annual growth rate (CAGR) of approximately 9.3% from 2018 to 2028 according to Inkwood Research. One of the drivers of this growth is the increasing availability of over-the-counter products as an alternative to prescription medication.

 

FOCUSfactor competes in the brain health supplement category. The global brain health supplements market was estimated to be $7.2 billion in 2020 and is expected to grow at a compound annual growth rate of 8.0% from 2021 to 2028, according to Grand View Research. FOCUSfactor’s growth in the year ended December 31, 2020 was 31% year-over-year, significantly outpacing the overall brain health supplement market. The industry is fragmented, with both global and domestic competitors, which gives us an opportunity to scale and continue to take market share.

 

Our Flat Tummy brand competes in the weight management and wellbeing market, which in 2019 was estimated to be a $20.6 billion global market, with forecasted growth of 7.0% annually from 2020 to 2025, according to ResearchAndMarkets.com.

 

Demographic trends and changing consumer habits, including a focus on reducing obesity prevalence, have been drivers of this market. We expect these trends will benefit the Flat Tummy brand and allow for new and innovative products to appeal to the changing market demographics.

 

COVID-19 has raised awareness of hand hygiene, which we view as supportive of our line of Hand MD products, including hand sanitizer. The global hand care market was estimated to be $12.4 billion in 2018, and it is expected to grow at a compound annual growth rate of 4.5% from 2019 to 2025, according to Grand View Research.

 

Research and Development

 

The development of new products is comprised of two distinct steps. First, our marketing team reviews new product opportunities by analyzing trends in the market as well as products offered by our competition and then develops preliminary new product concepts which include claims/benefits, delivery form, packaging, and pricing targets, among others. We then work with our third-party manufacturers and leverage their research and development to finalize our new product initiative (including formula and specifications), as these partners are experienced in product development and formulation. When we acquire a brand, we typically further expand the SKUs under that brand, through internal development and with our existing partners. Generally, we take ownership of the formulas and related intellectual property, unless the products use a generic formulation.

 

35
 

 

Manufacturing and Related Operations

 

We currently outsource the manufacturing of our products to third parties who have the necessary equipment and technology to provide the significant quantities required. The FOCUSfactor line is manufactured by Atrium Innovations and Vit-Best Nutrition and we have recently added Protab as a third source to support the growth of the brand. The Flat Tummy line uses various manufacturers such as Caraway Tea Company to make our teas, Vit-Best Nutrition to make our shakes and supplement capsules, Supplement Manufacturing Partner, Inc. to make our gummies, and Primrose Candy Company to make appetite suppression lollipops. Hand MD is manufactured by HealthSpecialty.

 

Distribution

 

Most of our revenues are generated through the retail channel, primarily due to our FOCUSfactor brand which is sold mainly through leading retailers. These retailers include club, mass, drug and other retailers such as Costco, Walmart, Amazon.com, Walgreens and CVS. All of our brands are also sold direct to consumer through their respective brand websites.

 

Competition

 

The U.S. nutritional supplements retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies, and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market. Certain of our competitors may have significantly greater financial, technical and marketing resources than we do, and may be able to adapt to changes in consumer preferences more quickly, devote greater resources to the marketing and sale of their products, or generate greater brand recognition. In addition, our competitors may be more effective and efficient in introducing new products.

 

Although there are many competing products on the market across our product categories, FOCUSfactor is the only brain-health formulation with both a patent and clinical study to support its claim of improving memory, concentration and focus. FOCUSfactor’s competitors include a wide range of products, from targeted brain-enhancement supplements to indirect competitors such as energy drinks that claim to improve concentration. Our Flat Tummy and Hand MD brands all compete in well-established segments with a diverse range of competition both domestically and internationally.

 

Government Regulation

 

Domestic

 

The processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of our products are subject to regulation by one or more federal agencies, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture and the Environmental Protection Agency, and by various agencies of the states and localities in which our products are sold. However, no formal FDA approval or registration is required because our products are classified as dietary supplements (all FOCUSfactor products and some Flat Tummy products), foods (some Flat Tummy products) or cosmetics (all Hand MD products except hand sanitizer, which must follow the OTC monograph).

 

Food and Drug Administration

 

Dietary Supplements

 

The Dietary Supplement Health and Education Act of 1994 (“DSHEA”) amended the Federal Food, Drug, and Cosmetic Act (the “FDC Act”) to establish a new framework governing the composition, safety, labeling, manufacturing and marketing of dietary supplements. Generally, under the FDC Act, dietary ingredients (i.e., vitamins; minerals; herbs or other botanicals; amino acids; or dietary substances for use by humans to supplement diet by increasing total dietary intake; or any concentrate, metabolite, constituent, extract or combination of any of the above) that were marketed in the United States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. “New” dietary ingredients (i.e., dietary ingredients that were not marketed in the United States before October 15, 1994) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been “present in the food supply as an article used for food” without being “chemically altered.” A new dietary ingredient notification must provide the FDA evidence of a “history of use or other evidence of safety” establishing that use of the dietary ingredient “will reasonably be expected to be safe.” A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe.

 

Such a determination could prevent the marketing of such dietary ingredient. In 2011 and 2016, the FDA issued draft guidance setting forth recommendations for complying with the new dietary ingredient notification requirement. Although FDA guidance is non-binding and does not establish legally enforceable responsibilities, and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations, FDA guidance is a strong indication of the FDA’s view on the topic discussed in the guidance, including its position on enforcement. At this time, it is difficult to determine whether the 2016 draft guidance (which replaced the 2011 draft guidance), if finalized, would have a material impact on our operations. However, if the FDA were to enforce the applicable statutes and regulations in accordance with the draft guidance as written, such enforcement could require us to incur additional expenses, which could be significant, and negatively impact our business in several ways, including, but not limited to, enjoining the manufacturing of our products until the FDA determines that we are in compliance and can resume manufacturing, increasing our liability and reducing our growth prospects.

 

36
 

 

The FDA or other agencies could take actions against products or product ingredients that, in their determination, present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products that we sell. Such actions or warnings could be based on information received through FDC Act-mandated reporting of serious adverse events.

 

We take a number of actions to ensure the products we sell comply with the FDC Act. As is common in our industry, we rely on our third-party vendors to ensure that the products they manufacture and sell to us comply with all applicable regulatory and legislative requirements. In general, we seek representations and warranties, indemnification and/or insurance from our vendors. However, even with adequate insurance and indemnification, any claims of non-compliance could significantly damage our reputation and consumer confidence in our products. In addition, the failure of such products to comply with applicable regulatory and legislative requirements could prevent us from marketing the products or require us to recall or remove such products from the market, which in certain cases could materially and adversely affect our business, financial condition and results of operations. A removal or recall could also result in negative publicity and damage to our reputation that could reduce future demand for our products. In such case, we may attempt to offset any losses related to recalls and removals with reformulated or alternative products; however, there can be no assurance that we would be able to offset all or any portion of losses related to any future removal or recall.

 

The FDC Act permits structure/function claims to be included in labels and labeling for dietary supplements without FDA pre-market approval. However, companies must have substantiation that the claims are “truthful and not misleading,” and must submit a notification with the text of the claims to the FDA no later than 30 days after marketing the dietary supplement with the claims. Permissible structure/function claims may describe how a particular nutrient or dietary ingredient affects the structure, function or general well-being of the body, or characterize the documented mechanism of action by which a nutrient or dietary ingredient acts to maintain such structure or function. The label or labeling of a product marketed as a dietary supplement may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat or prevent a disease (i.e. a disease claim). If the FDA determines that a particular structure/function claim is an unacceptable disease claim that causes the product to be regulated as a drug, a conventional food claim or an unauthorized version of a “health claim,” or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading in any particular way, we would be prevented from using the claim and would have to update our product labels and labeling accordingly.

 

In addition, DSHEA provides that so-called “third-party literature,” e.g., “a publication, including an article, a chapter in a book, or an official abstract of a peer-reviewed scientific publication that appears in an article and was prepared by the author or the editors of the publication” supplements, when reprinted in its entirety, may be used “in connection with the sale of a dietary supplement to consumers” without the literature being subject to regulation as labeling. Such literature: (1) must not be false or misleading; (2) may not “promote” a particular manufacturer or brand of dietary supplement; (3) must present a balanced view or is displayed or presented with other such items on the same subject matter so as to present a balanced view of the available scientific information; (4) if displayed in an establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or any other method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any continued dissemination could subject our product to regulatory action as an illegal drug.

 

In June 2007, pursuant to the authority granted by the FDC Act as amended by DSHEA, the FDA published detailed current Good Manufacturing Practice (“cGMP”) regulations that govern the manufacturing, packaging, labeling and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all dietary supplement manufacturers, and the FDA conducts inspections of dietary supplement manufacturers pursuant to these requirements. There remains considerable uncertainty with respect to the FDA’s interpretation of the regulations and their actual implementation in manufacturing facilities.

 

In addition, the FDA’s interpretation of the regulations governing dietary supplements will likely change over time as the agency becomes more familiar with the industry and the regulations. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility “adulterated,” and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act (“FSMA”), which was enacted in January 2011, the manufacturing of dietary ingredients contained in dietary supplements will be subject to similar or even more burdensome manufacturing requirements, which will likely increase the costs of dietary ingredients and will subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA will also require importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.

 

The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue a public warning or notice of violation letter to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, require a recall of illegal or unsafe products from the market, and request the Department of Justice to initiate a seizure action, an injunction action or a criminal prosecution in United States courts.

 

37
 

 

The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA’s ability to order mandatory recalls, administratively detain domestic products, and require certification of compliance with domestic requirements for imported foods associated with safety issues. FSMA also gave the FDA the authority to administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.

 

Hand Sanitizers

 

Hand sanitizers are classified as over-the-counter (“OTC”) drugs, which have specific regulatory requirements, including ingredient and manufacturing requirements. Under the OTC monograph system, selected OTC drugs are generally recognized as safe and effective and do not require the submission and approval of a new drug application. The FDA OTC monographs include well-known ingredients and specific requirements for permitted indications, required warnings and precautions, allowable combinations of ingredients and dosage levels. Products marketed under the OTC monograph system must conform to specific quality, formula and labeling requirements.

 

Cosmetics

 

The FDC Act, defines cosmetics as articles or components of articles intended for application to the human body to cleanse, beautify, promote attractiveness, or alter the appearance, with the exception of soap. The labeling of cosmetic products is subject to the requirements of the FDC Act, the Fair Packaging and Labeling Act, the Poison Prevention Packaging Act and other FDA regulations. Cosmetics are not subject to pre-market approval by the FDA; however, certain ingredients, such as color additives, must be pre-approved for the specific intended use of the product and are subject to certain restrictions on their use. If a company has not adequately substantiated the safety of its products or ingredients by, for example, performing appropriate toxicological tests or relying on already available toxicological test data, then a specific warning label is required. The FDA may, by regulation, require other warning statements on certain cosmetic products for specified hazards associated with such products. FDA regulations also prohibit or otherwise restrict the use of certain types of ingredients in cosmetic products.

 

In addition, the FDA requires that cosmetic labeling and claims be truthful and not misleading. Moreover, cosmetics may not be marketed or labeled for their use in treating, preventing, mitigating, or curing disease or other conditions or in affecting the structure or function of the body, as such claims would render the products to be a drug and subject to regulation as a drug. The FDA has issued warning letters to cosmetic companies alleging improper drug claims regarding their cosmetic products, including, for example, product claims regarding hair growth or preventing hair loss. In addition to FDA requirements, the FTC as well as state consumer protection laws and regulations can subject a cosmetics company to a range of requirements and theories of liability, including similar standards regarding false and misleading product claims, under which FTC or state enforcement or class-action lawsuits may be brought.

 

In the United States, the FDA has not promulgated regulations establishing cGMPs for cosmetics. However, FDA’s draft guidance on cosmetic cGMPs, most recently updated in June 2013, provides recommendations related to process documentation, recordkeeping, building and facility design, equipment maintenance and personnel, and compliance with these recommendations can reduce the risk that FDA finds such products have been rendered adulterated or misbranded in violation of applicable law. FDA also recommends that manufacturers maintain product complaint and recall files and voluntarily report adverse events to the agency. The FDA monitors compliance of cosmetic products through market surveillance and inspection of cosmetic manufacturers and distributors to ensure that the products are not manufactured under unsanitary conditions, or labeled in a false or misleading manner. Inspections also may arise from consumer or competitor complaints filed with the FDA. In the event the FDA identifies unsanitary conditions, false or misleading labeling, or any other violation of FDA regulation, FDA may request or a manufacturer may independently decide to conduct a recall or market withdrawal of product or to make changes to its manufacturing processes or product formulations or labels.

 

Federal Trade Commission

 

The FTC exercises jurisdiction over the advertising of dietary supplements and cosmetics and requires that all advertising to consumers be truthful and non-misleading. The FTC actively monitors the dietary supplement space and has instituted numerous enforcement actions against dietary supplement companies for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading advertising claims. These enforcement actions have resulted in consent decrees and significant monetary judgments against the companies and/or individuals involved. Regulators require a company to convey product claims clearly and accurately and further require marketers to maintain adequate substantiation for their claims. More specifically, the FTC requires such substantiation to be competent and reliable scientific evidence and requires a company to have a reasonable basis for the expressed and implied product claim before it disseminates an advertisement. A reasonable basis is determined based on the claims made, how the claims are presented in the context of the entire advertisement, and how the claims are qualified. The FTC’s standard for evaluating substantiation is designed to ensure that consumers are protected from false and/or misleading claims by requiring scientific substantiation of product claims at the time such claims are first made. The failure to have this substantiation violates the Federal Trade Commission Act.

 

Foreign

 

Our products sold in foreign countries are also subject to regulation under various national, local and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and distribution of dietary supplements and over-the-counter drugs. Government regulations in foreign countries may prevent or delay the introduction, or require the reformulation, of certain of our products.

 

In foreign markets, our regulatory department works with an in-country regulatory consultant group to guide us through the regulatory process needed to launch our product in a particular country such as Canada, the United Kingdom and Australia. For example, Canada and Australia require a product submission packet and approval from Health Canada (“HC”) and the Therapeutic Goods Administration (“TGA”), respectively. In the United Kingdom, on the other hand, no formal regulatory approval is needed. Launch timing varies by country. In the United States and United Kingdom, once a formula is established and labeling has been approved by our regulatory and legal advisors, the product can be launched upon production. The Australian approval process generally takes one to two weeks from the time the packet is submitted, while in Canada the approval process can take from two months to six months from submission.

 

In Canada, HC has oversight over our FOCUSfactor, Flat Tummy and Hand MD products. Our FOCUSfactor and Flat Tummy products are considered natural health products by HC so they each have a natural product number that was assigned by HC upon its review and approval. Hand MD products are considered cosmetics by HC, so notification filings are required which are not subject to review and approval, with the exception of hand sanitizer, which has been assigned a natural product number by HC.

 

In the United Kingdom, both FOCUSfactor and Flat Tummy are considered food supplements that are regulated by the Food Standards Agency. There is no requirement for licensing or registering food supplement products in the United Kingdom, and products must comply with relevant food law. Hand MD products are not currently sold in the United Kingdom.

 

In Australia, FOCUSfactor products are “Listed Medicines” that are regulated by the TGA and require an AUST L (Australia Listed Medicine) number. Flat Tummy products are classified as either Listed Medicines or meal replacements. Listed Medicines are regulated by the TGA while meal replacements are regulated under the Australia New Zealand Food Standards Code. Hand MD products are not currently sold in Australia.

 

New Legislation or Regulation

 

Legislation may be introduced which, if passed, would impose substantial new regulatory requirements on dietary supplements. We cannot determine what effect additional domestic or international governmental legislation, regulations, or administrative orders, when and if promulgated, would have on our business in the future. New legislation or regulations may require the reformulation of certain products to meet new standards, require the recall or discontinuance of certain products not capable of reformulation, impose additional record keeping or require expanded documentation of the properties of certain products, expanded or different labeling or scientific substantiation.

 

Intellectual Property

 

We own 18 trademarks that have been registered with the United States Patent and Trademark Office and have filed applications to register additional trademarks. In addition, we claim domestic trademark and service mark rights in numerous additional marks that we use. We own a number of trademark registrations in countries outside the United States. Federally registered trademarks in the United States have a perpetual life, as long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. Most foreign trademark offices use similar trademark renewal processes. We regard our trademarks and other proprietary rights as valuable assets and believe they make a significant positive contribution to the marketing of our products.

 

38
 

 

We protect our legal rights concerning our trademarks by appropriate measures, which may include legal action. We possess a portfolio of both registered and unregistered (i.e., common law) trademarks. In certain circumstances, we seek and obtain registrations for our trademarks, which may confer certain advantages, and the decision to register a trademark is made on a case by case basis. We have registered and intend to register certain trademarks in certain limited jurisdictions outside the United States where our products are sold, but we may not register all or even some of our trademarks in every country in which we conduct business or intend to conduct business.

 

We own U.S. Patent 8,329,227 covering FOCUSfactor’s proprietary formulation “for enhanced mental function.” This patent was issued by the United States Patent and Trademark Office in December 2012 and expires in April 2025.

 

In addition to this intellectual property, we also rely on our proprietary knowledge and ongoing technological innovation to develop a competitive position in the market for our products. Each of our patents and know-how are integral to the conduct of our business and the loss of any could have a material adverse effect on our business.

 

Human Capital Management

 

We recognize that attracting, motivating and retaining passionate talent at all levels is vital to continuing our success. By improving employee retention and engagement, we also improve our ability to support our customers and protect the long-term interests of our stakeholders and stockholders. We invest in our employees through continuously improving benefits and various health and wellness initiatives, and offer competitive compensation packages, working to continuously improve fairness in internal compensation practices.

 

As of October 1, 2021, we had 39 full-time employees. We intend to grow our employee base in response to the demands and requirements of the business. We believe that the employer-employee relationships in our Company are positive. We have no labor union contracts.

 

Properties

 

The following table describes our principal properties leased as of October 20, 2021:

 

Purpose   Location   Square Footage
Technology Center (1)   Halifax, NS   8,500
Main Office (2)   Westbrook, ME   3,510

 

(1) Monthly rental payments are $25,000 Canadian Dollars per month on a month-to-month basis.

(2) Monthly rental payments are $4,290 per month on a month-to-month basis.

 

Legal Proceedings

 

From time to time, we are involved in various litigation matters arising in the ordinary course of our business. We do not believe that any of these matters, individually or in the aggregate, are currently material to us.

 

39
 

 

MANAGEMENT

 

The following table sets forth certain information as of October 20, 2021 about our executive officers and members of our Board.

 

Name   Age   Position  
Jack Ross   56   Chief Executive Officer and Chairman  
Brendan Horning   38   Chief Financial Officer  
Alfred Baumeler(1)   56   President and Director Nominee  
Jaime Fickett   43   Senior Vice President of Finance and Operations  
J. Paul SoRelle   65   Director  
Stephen Fryer   83   Director  
Nitin Kaushal   56   Director Nominee  

 

(1) Alfred Baumeler will be appointed to the Board effective upon the closing of the offering described in this prospectus.

 

Executive Officers

 

Jack Ross has served as our Chief Executive Officer and Chairman since October 2014, served as our Chief Financial Officer from August 2018 until July 2021 and from October 2014 until October 2017, and served as our President from May 2020 until January 2021 and from October 2014 until October 2017. Mr. Ross has also served as the Chief Executive Officer of Kenek Brands Inc., an executive consulting firm, since January 2014. In addition, Mr. Ross has served as the Chairman and Chief Executive Officer of Gowan Capital Inc. since May 2011. Mr. Ross’ significant leadership experience at various private and public companies led to the conclusion that he should serve as a member of our Board of Directors, in light of our business and structure.

 

Brendan Horning was appointed our Chief Financial Officer in July 2021. Since November 2019, Mr. Horning has also served as the President and director of Brendan Horning Incorporated. Prior to being appointed our Chief Financial Officer, Mr. Horning served as our Vice President of Investor Relations from February 2021 until July 2021 and from September 2016 until October 2019. From February 2013 to September 2016, Mr. Horning served as a partner of an accounting firm. Mr. Horning received a Bachelor of Commerce in Finance and Accounting from St. Mary’s University. Mr. Horning is also a chartered professional accountant in Canada and has completed the three-year Canadian Institute of Chartered Accountants in-depth tax program.

 

Alfred Baumeler has served as our President since January 2021 and has agreed to serve on our Board of Directors upon the completion of this offering. From August 2015 to December 2020, Mr. Baumeler served as our Executive Vice President of Sales and Marketing. From September 2012 to August 2015, Mr. Baumeler served as Senior Vice President of Marketing for Healthy Natural Systems/Core Science Medica (CSM)/Lifeagen, a nutritional supplement company. From January 2012 to August 2012, Mr. Baumeler was self-employed as a marketing consultant. From November 2009 to November 2011, Mr. Baumeler was the Senior Vice President and Chief Marketing Officer for Natrol, Inc., a manufacturer of vitamins, minerals and supplements. Mr. Baumeler earned his Bachelor of Science from Rutgers University in Engineering and his Master of Business Administration in Marketing and Finance from Columbia Business School. Mr. Baumeler’s 30 years of experience in consumer goods, of which 20 were in the nutritional supplement industry, led to the conclusion that he should serve as a member of our Board of Directors.

 

Jaime Fickett has served as our Senior Vice President of Finance and Operations since January 2015. From August 2006 to January 2015, Ms. Fickett served as Chief Financial Officer of Factor Nutrition Labs, LLC, a company that developed dietary supplements. From 1999 to 2006, Ms. Fickett was employed in the public accounting sector as an auditor. Ms. Fickett earned a Bachelor of Science in Accounting from the University of Maine. Ms. Fickett earned her Master of Science in Accounting from Southern New Hampshire University.

 

Directors and Director Nominees

 

J. Paul SoRelle was appointed as a director in December 2014. From 1999 to April 2020, Mr. SoRelle served as the President and Chief Executive Officer of Pioneer Press of Greeley, Inc., a commercial printing company. Since April 2020, Mr. SoRelle has continued to consult for Pioneer Press. Prior to joining Pioneer Press, Mr. SoRelle acquired RamStar, Inc. in November 1988 and served as President and CEO, as well as in other roles. RamStar, Inc. was acquired by International Thunderbird Gaming Corporation in 1994, where Mr. SoRelle served on the board of directors and as Executive Vice President until October 1996. In November 1982, Mr. SoRelle acquired three convenience stores, expanded to eight stores and sold them in 1988. Mr. SoRelle’s significant leadership experience at Pioneer Press of Greeley, Inc. led to the conclusion that he should serve as a member of our Board of Directors, in light of our business and structure.

 

40
 

 

Nitin Kaushal has agreed to serve on our Board of Directors upon the completion of this offering. Since March 2020, Mr. Kaushal has served as President of Anik Capital Corp. He retired from PricewaterhouseCoopers LLP (Canada), where he was a Managing Director in the Corporate Finance Practice from April 2012 until February 2020. He has over thirty years of experience in the financial services industry and has held senior roles in investment banking, venture capital and consulting firms including Desjardins Securities Inc., Orion Securities Inc., Vengate Capital, HSBC Securities Inc. and Gordon Capital and in the venture capital industry with MDS Capital Corp. Mr. Kaushal serves on the board of VieMed Healthcare, Inc., FSD Pharma, Inc., High Tide Inc., Delta 9 Cannabis Inc., PsyBio Therapeutics Corp. and Flower One Holdings Inc. Mr. Kaushal earned his Bachelor of Science in Chemistry from the University of Toronto and is a Chartered Accountant in Canada. Mr. Kaushal’s experience as a member of various boards of directors and as a Chartered Accountant provides the Board with additional perspective on financial reporting, governance and management issues and led to the conclusion that he should serve as a member of our Board of Directors.

 

Stephen Fryer was appointed as a director in December 2014. Since June 2003, Mr. Fryer has been the Chief Executive Officer and Managing Partner of SC Capital Partners, Inc., a private micro-market investment banking and private equity intermediary. Prior to joining SC Capital Partners, Inc., Mr. Fryer was Chief Executive Officer of Pen Interconnect from March 1998 to September 2002. From May 1989 to August 1997, Mr. Fryer was Managing Director of Ventana International, Ltd., a venture capital and private investment banking firm with operations and investors in the United States, Latin America, Europe and Asia. Mr. Fryer earned a B.S. in Mechanical Engineering, with a minor in Economics, from the University of Southern California. Mr. Fryer’s substantial experience in the investment banking industry, and his demonstrated skill in corporate finance, led to the conclusion that he should serve as a member of our Board of Directors, in light of our business and structure.

 

Corporate Governance

 

Composition of our Board of Directors

 

Our business and affairs are managed under the direction of our Board. The number of directors will be fixed by our Board, subject to the terms of our certificate of incorporation and amended and restated bylaws. Our Board currently consists of three directors (Mr. Ross, Mr. SoRelle and Mr. Fryer), and will consist of five directors (Mr. Ross, Mr. Baumeler, Mr. SoRelle, Mr. Fryer and Mr. Kaushal) upon the completion of this offering.

 

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable our Board to satisfy its oversight responsibilities effectively in light of our business and structure, the Board focuses primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business.

 

Corporate Governance Profile

 

We intend to structure our corporate governance in a manner we believe closely aligns our interests with those of our stockholders. Notable features of our corporate governance structure will include the following:

 

  our Board will not be classified, with each of our directors subject to re-election annually;
  we expect that a majority of our directors will satisfy the Nasdaq listing standards for independence;
  generally, all matters to be voted on by stockholders will be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all stockholders present in person or represented by proxy, voting together as a single class;
  we intend to comply with the requirements of the Nasdaq marketplace rules, including having committees comprised solely of independent directors; and
  we do not have a stockholder rights plan.

 

Our directors will stay informed about our business by attending meetings of our Board and its committees and through supplemental reports and communications. Our independent directors will meet regularly in executive sessions without the presence of our corporate officers or non-independent directors.

 

Role of the Board in Risk Oversight

 

The Board actively manages the Company’s risk oversight process and receives periodic reports from management on areas of material risk to the Company, including operational, financial, legal, and regulatory risks. The Board committees assist the Board in fulfilling its oversight responsibilities in certain areas of risk. The Audit Committee assists the Board with its oversight of the Company’s major financial risk exposures. The Compensation Committee assists the Board with its oversight of risks arising from the Company’s compensation policies and programs. The Corporate Governance and Nominating Committee assists the Board with its oversight of risks associated with board organization, board independence, and corporate governance. While each committee is responsible for evaluating certain risks and overseeing the management of those risks, the entire Board is regularly informed about the risks.

 

41
 

 

Director Independence

 

The Nasdaq marketplace rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominations committees be independent, or, if a listed company has no nominations committee, that director nominees be selected or recommended for the board’s selection by independent directors constituting a majority of the board’s independent directors. The Nasdaq marketplace rules further require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act.

 

Prior to the completion of this offering, our Board undertook a review of the independence of our directors and considered whether any director has a material relationship with us that could compromise that director’s ability to exercise independent judgment in carrying out that director’s responsibilities. Our Board has affirmatively determined that each of Messrs. SoRelle, Fryer and Kaushal qualify as an independent director, as defined under the applicable corporate governance standards of Nasdaq. These rules require that our Audit Committee be composed of at least three members, one of whom must be independent on the date of listing on Nasdaq, a majority of whom must be independent within 90 days of the effective date of the registration statement containing this prospectus, and all of whom must be independent within one year of the effective date of the registration statement containing this prospectus.

 

Board Leadership

 

The offices of the chairman of the Board and chief executive officer are currently combined. Mr. Ross serves as the Company’s chairman and chief executive officer. The Board believes that this structure is the most appropriate structure at this time for several reasons. Mr. Ross is responsible for the day-to-day operations of the Company and the execution of its strategies. Since these topics are an integral part of Board discussions, Mr. Ross is the director best qualified to chair those discussions. In addition, Mr. Ross’ experience and knowledge of the Company and the industry are critical to Board discussions and the Company’s success. The Board believes that Mr. Ross is well qualified to serve in the combined roles of chairman and chief executive officer and that Mr. Ross’ interests are sufficiently aligned with the stockholders he represents.

 

The Board does not have a lead independent director. To help ensure the independence of the Company’s Board, the independent directors of the Board intend to meet without members of management at various times during the year.

 

Board Committees

 

Our Board of Directors will establish an audit committee, a compensation committee, and a nominating and corporate governance committee, each of which will operate pursuant to a charter to be adopted by our Board of Directors and will be effective upon the effectiveness of the registration statement of which this prospectus is a part. Upon the effectiveness of the registration statement of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, Nasdaq and SEC rules and regulations.

 

Following the completion of this offering, the full text of our audit committee charter, compensation committee charter, and nominating and corporate governance charter will be posted on the investor relations portion of our website at www.synergychc.com. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus, and you should not consider it a part of this prospectus.

 

Audit Committee

 

Upon completion of this offering, Messrs. SoRelle, Fryer and Kaushal will serve on the Audit Committee, which will be chaired by Mr. Kaushal. The committee’s primary duties are to:

 

  review and discuss with management and our independent auditor our annual and quarterly financial statements and related disclosures, including disclosure under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the results of the independent auditor’s audit or review, as the case may be;
  review our financial reporting processes and internal control over financial reporting systems and the performance, generally, of our internal audit function;
  oversee the audit and other services of our independent registered public accounting firm and be directly responsible for the appointment, independence, qualifications, compensation and oversight of the independent registered public accounting firm, which reports directly to the Audit Committee;
  provide an open means of communication among our independent registered public accounting firm, management, our internal auditing function and our Board;
  review any disagreements between our management and the independent registered public accounting firm regarding our financial reporting;
  prepare the Audit Committee report for inclusion in our proxy statement for our annual stockholder meetings;
  establish procedures for complaints received regarding our accounting, internal accounting control and auditing matters; and
  approve all audit and permissible non-audit services conducted by our independent registered public accounting firm.

 

42
 

 

All members of our Audit Committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq listing rules. Our Board of Directors has determined that Mr. Kaushal qualifies as an “audit committee financial expert” within the meaning of applicable SEC regulations. In making this determination, our Board of Directors considered the nature and scope of experience that Mr. Kaushal has previously had with public reporting companies. Our Board of Directors has determined that all of the directors that will become members of our audit committee upon the effectiveness of the registration statement of which this prospectus forms a part satisfy the relevant independence requirements for service on the Audit Committee set forth in the rules of the SEC and the Nasdaq listing rules. Both our independent registered public accounting firm and management will periodically meet privately with our Audit Committee.

 

Compensation Committee

 

Upon completion of this offering, Messrs. SoRelle, Fryer and Kaushal will serve on the Compensation Committee, which will be chaired by Mr. Kaushal. The committee’s primary duties are to:

 

  approve corporate goals and objectives relevant to chief executive officer compensation and evaluate performance in light of those goals and objectives;
  determine and approve executive officer compensation, including base salary and incentive awards;
  make recommendations to the Board regarding compensation plans; and
  administer our stock plan.

 

Our Compensation Committee determines and approves all elements of executive officer compensation. It also provides recommendations to the Board with respect to non-employee director compensation. The Compensation Committee may not delegate its authority to any other person, other than to a subcommittee.

 

Our Board of Directors has determined that each member of the Compensation Committee is “independent” as defined in the applicable Nasdaq rules. Each member of our Compensation Committee will be a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended.

 

Nominating and Corporate Governance Committee

 

Upon completion of this offering, Messrs. SoRelle, Fryer and Kaushal will serve on the Nominating and Corporate Governance Committee, which will be chaired by Mr. Kaushal. The committee’s primary duties are to:

 

  consider director nominees recommended by stockholders and recommend nominees for election as directors;
  oversee the evaluation of the Board;
  review our Board’s committee structure and composition and make recommendations; and
  develop, recommend and oversee our corporate governance principles, including our Code of Business Ethics and Conduct.

 

Code of Business Ethics and Conduct

 

Prior to the effectiveness of the registration statement of which this prospectus is a part, we will adopt a written code of business ethics and conduct that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following the effectiveness of the registration statement of which this prospectus is a part, a current copy of the code will be posted on the investor relations section of our website, which is located at www.synergychc.com. If we make any substantive amendments to, or grant any waivers from, the code of business ethics and conduct for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a Current Report on Form 8-K.

 

43
 

 

Legal Proceedings

 

To our knowledge, (i) no director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years; (ii) no director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past ten years; (iii) no director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past ten years; and (iv) no director or officer has been found by a court to have violated a federal or state securities or commodities law during the past ten years.

 

44
 

 

EXECUTIVE AND DIRECTOR COMPENSATION

 

We are a “smaller reporting company” under applicable SEC rules and are providing disclosure regarding our executive compensation arrangements pursuant to the rules applicable to emerging growth companies, which means that we are not required to provide a compensation discussion and analysis and certain other disclosures regarding our executive compensation. The following discussion relates to the compensation of our named executive officers for 2020, consisting of Jack Ross, our Chief Executive Officer, Chairman and former President and Chief Financial Officer, and our two other most highly compensated executive officers as of December 31, 2020, Alfred Baumeler, our President and former Executive Vice President – Sales and Marketing, and Jaime Fickett, our Senior Vice President of Finance and Operations.

 

Fiscal Year 2020 and 2019 Summary Compensation Table

 

The following Fiscal Year 2020 and 2019 Summary Compensation Table contains information regarding compensation for 2020 and 2019 that we paid to Mr. Ross and our two other most highly compensated executive officers as of December 31, 2020.

 

Name and Principal Position   Year     Salary
($)
    Bonus
($)
    All other
compensation
($)
    Total
($)
 
Jack Ross     2020       1,080,000 (3)           30,000 (4)     1,110,000  
Chief Executive Officer, Chairman, Former President and Former Chief Financial Officer (1)     2019       824,413             18,000 (5)     842,413  
                                         
Alfred Baumeler     2020       275,000       25,000       14,700 (6)     314,700  
President and Former Executive Vice President – Sales and Marketing (2)     2019       250,000       75,000       11,100 (7)     336,100  
                                         
Jaime Fickett     2020       255,000       25,000             280,000  
Senior Vice President of Finance and Operations     2019       255,000       76,580             331,580  

 

(1) Mr. Ross serves as our Chief Executive Officer and Chairman, served as our Chief Financial Officer from October 2014 until July 2021 and served as our President from May 2020 until January 2021. Mr. Ross is not an employee of the Company.
(2) Mr. Baumeler served as our Executive Vice President – Sales and Marketing until January 2021, when he was promoted to President.
(3) Consists of amounts paid to Kenek Brands Inc. pursuant to a consulting agreement. See “Consulting Agreement” below.
(4) Consists of a vehicle allowance of $2,500 per month.
(5) Consists of a vehicle allowance of $1,500 per month.
(6) Consists of a vehicle allowance of $600 per month and retirement allowance of $7,500.
(7) Consists of a vehicle allowance of $300 per month and retirement allowance of $7,500.

 

Consulting Agreement

 

The following discussion relates to compensation arrangements on behalf of, and compensation paid by us to an entity controlled by Mr. Ross. We do not have an employment agreement with Mr. Baumeler or Ms. Fickett.

 

We are party to a Sales and Marketing Consultant and Distribution Agreement dated April 2, 2014 (the “Consulting Agreement”) with Kenek Brands Inc. (“Kenek”). Mr. Ross is the owner of Kenek and its sole officer and director. Pursuant to the Consulting Agreement, Kenek has been retained to serve as a consultant and advisor to us, including developing, expanding and managing sales, marketing and distribution and aiding in strategic direction of our sales and planning. As compensation for Kenek’s services, we pay Kenek $9,000 per month plus a 2% commission on all product sales on products that Kenek or its agents or brokers introduce to us. In addition, on April 2, 2014, we granted Kenek fully-vested options to purchase 1,000,000 shares of our common stock at an exercise price of $0.25 per share, which have expired. We have also agreed to reimburse Kenek for all out of pocket expenses incurred to perform the duties set out in the Consulting Agreement, including travel, meals and lodging. The Consulting Agreement had an initial period of one year and automatically renews for successive one-year periods unless terminated by either party upon 90 days’ prior written notice. For two years following termination, we have agreed to pay to Kenek a 1% commission on all product sales on products that Kenek or its agents or brokers introduced to us. See “Certain Relationships and Related Party Transactions” for additional information.

 

45
 

 

Fiscal Year 2020 Outstanding Equity Awards at Fiscal Year-End Table

 

The following table lists all of the outstanding equity awards held on December 31, 2020 by each of the Company’s named executive officers, before adjusting for the proposed 1-for-        reverse stock split.

 

      Option Awards         Stock Awards  
Name    

Number of
securities
underlying
unexercised
options
exercisable

(#)

     

Number of
securities
underlying
unexercised
options
unexercisable

(#)

     

Equity
incentive
plan
awards:
Number of
securities
underlying
unexercised
unearned
options

(#)

     

Option
exercise
price

($)

      Option
expiration
date
     

Number
of
shares
or units
of stock
that
have not
vested

(#)

      Market
value of
shares of
units of
stock that
have not
vested
($)
     

Equity

incentive

plan
awards:
Number
of

unearned

shares,
units or
other
rights
that
have not
vested

(#)

      Equity
incentive
plan
awards:
Market
or payout value of
unearned
shares,
units or
other
rights
that have
not
vested
($)
 
Jack Ross                                                      
Alfred Baumeler     1,000,000                   0.65       12/14/2025                          
Jaime Fickett     1,000,000                   0.65       12/14/2025                          

 

Equity Incentive Plans

 

The following table summarizes information about our equity compensation plans as of December 31, 2020. All outstanding awards relate to our common stock.

 

Plan category   Number of
securities
to be issued
upon vesting
of grants
and exercise
of outstanding
options, warrants
and rights
    Weighted-
average
exercise
price of
outstanding
options, warrants
and rights
    Number of
securities
remaining
available for
future issuance
under equity
compensation
plans
 
Equity compensation plan approved by stockholders(1)     3,466,667     $ 0.54       12,058,333  
Equity compensation plan not approved by stockholders         $        
Total     3,466,667     $ 0.54       12,058,333  

 

(1) The Company’s 2014 Stock Incentive Plan was approved by stockholders in July 2015.

 

Fiscal Year 2020 Director Compensation

 

Our named executive officer and director, Mr. Ross, did not receive any compensation for his service as a director for the year ended December 31, 2020. All compensation paid to Mr. Ross is set forth above under “—Fiscal Year 2020 and 2019 Summary Compensation Table.” The following table provides information regarding all compensation paid to our non-employee directors during the fiscal year ended December 31, 2020.

 

Name   Fees
earned
or paid
in cash
    Stock
awards
    Option
awards
    Non-equity
incentive
plan
compensation
    Nonqualified
deferred
compensation
earnings
    All other
compensation
    Total  
Stephen Fryer   $ 20,000       -       -       -       -       -     $ 20,000  
Paul SoRelle   $ -       -       -       -       -       -     $ -  

 

Director Compensation

 

We do not currently have a formal policy with respect to compensating non-employee directors for service as directors. Following the consummation of this offering, we anticipate that directors who are not also our officers or employees will receive compensation for their service on our board and committees thereof. The amount and form of such compensation has not yet been determined. Each non-employee director will be reimbursed for out-of-pocket expenses incurred in connection with attending board and committee meetings.

 

46
 

 

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

Following is a description of transactions since January 1, 2018, including currently proposed transactions to which we have been or are to be a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors (including nominees), executive officers or beneficial holders of more than 5% of our capital stock, or any immediate family members of and any entities affiliated with any such person, had or will have a direct or indirect material interest.

 

We may encounter business arrangements or transactions with businesses and other organizations in which one of our directors or executive officers, significant stockholders or their immediate families is a participant and the amount exceeds $120,000. We refer to these transactions as related party transactions. Related party transactions have the potential to create actual or perceived conflicts of interest between us and our directors, officers and significant stockholders or their immediate family members. All services listed below are provided at cost.

 

On April 2, 2014, we entered into a Sales and Marketing Consultant and Distribution Agreement, with Kenek Brands, Inc. (“Kenek”), a company owned by Jack Ross, our Chief Executive Officer. For the years ended December 31, 2020, 2019 and 2018, we accrued and paid consulting fees of $82,917, $57,917 and $57,917, respectively, per month to Kenek. We also pay a vehicle allowance of $2,500 per month (or $30,000 per year) to Mr. Ross. We expensed $1,110,000, $824,413 and $648,944, respectively, during the years ended December 31, 2020, 2019 and 2018 as consulting fees, advanced $425,000 in the manner of a prepaid bonus in the year ended December 31, 2020, and made payments totaling $1,110,000, $852,626 and $648,944 towards services to Kenek for the years ended December 31, 2020, 2019 and 2018, respectively. We expensed $862,296 during the six months ended June 30, 2021. As of June 30, 2021, December 31, 2020, December 31, 2019 and December 31, 2018, the total outstanding balance was $32,500, $0, $0 and $28,213, respectively.

 

On January 22, 2015, we entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc. (“Knight”) (an owner of greater than 10% of our common stock), for the purchase of the FOCUSfactor assets. The loan bore interest at a rate of 15% per year; provided, however, that upon the occurrence of an equity or convertible equity offering by us of at least $1,000,000, the interest rate would drop to 13% per year. During the year ended December 31, 2018, the highest aggregate principal amount outstanding under this loan was $562,500. During the year ended December 31, 2018, $562,500 of principal and $4,611 of interest was paid, resulting in full repayment of this loan.

 

On June 26, 2015, we entered into a Security Agreement with Knight Therapeutics, Inc. (“Knight Therapeutics”) (an affiliate of an owner of greater than 10% of our outstanding common stock) through its wholly owned subsidiary Neuragen Corp., for the purchase of the assets of Knight Therapeutics, Inc. At June 30, 2021, December 31, 2020, December 31, 2019 and December 31, 2018, we owed $425,000, $425,000, $475,000 and $525,000, respectively, in relation to this agreement.

 

On August 18, 2015, we entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she provided marketing and sales related services. Under the terms of the Consulting Agreement, we paid $120,000, $120,000 and $120,000 to Ms. Harshbarger for the years ended December 31, 2020, 2019 and 2018, respectively, and $60,000 for the six months ended June 30, 2021.

 

On August 9, 2017, we entered into an Amended and Restated Loan Agreement with Knight for a working capital loan. The loan bears interest at a rate of 10.5% per year. At December 31, 2020, 2019 and 2018, we owed Knight $5,000,000, $5,451,568 and $7,320,739, respectively, on this loan, net of debt issuance cost. Since January 1, 2018, the highest aggregate principal amount outstanding under this loan was $9,500,000 during the year ended December 31, 2018. During the years ended December 31, 2020, 2019 and 2018, $500,000, $2,000,000 and $500,000 of principal was paid, respectively. During the years ended December 31, 2020, 2019 and 2018, $737,595, $912,486 and $325,803 of interest was paid, respectively. During 2021, through June 30, 2021, no principal and $473,958 of interest was paid. As of October 20, 2021, the outstanding principal balance was $5,000,000.

 

On May 8, 2020, we entered into a Third Amendment Agreement to the Amended and Restated Loan Agreement with Knight, pursuant to which Knight agreed to loan us an additional $2.5 million for working capital. The loan bears interest at a rate of 12.5% per year. Pursuant to the Third Amendment Agreement, a loan success fee of $1,000,000 was earned by Knight and is payable in August 2022. The loan success fee bears interest at a rate of 12.5% per year. At December 31, 2020, we owed Knight $2,500,000 on this loan. Since May 8, 2020, the highest aggregate principal amount outstanding under this loan was $2,500,000. During the year ended December 31, 2020, no principal and $125,868 of interest was paid. During 2021, through June 30, 2021, no principal and $203,646 of interest was paid. As of October 20, 2021, the outstanding principal balance was $500,000.

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics, Inc. for the distribution rights of FOCUSfactor in Canada. In conjunction with this agreement, we are required to pay Knight Therapeutics a distribution fee equal to 30% of gross sales for sales achieved through a direct sales channel and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $100,000 Canadian dollars. On and after February 15, 2021, the agreement automatically renews for additional one-year terms unless either party gives notice of nonrenewal at least 180 days prior to the end of the then-current term. During the year ended December 31, 2020, we expensed $178,341 Canadian dollars ($133,094 U.S. Dollars). As of December 31, 2020, 2019 and 2018, the total outstanding balance was $178,341, $100,000 and $200,000 Canadian dollars, respectively. In U.S. Dollars, the total outstanding balance was $140,069, $70,295 and $152,834 as of December 31, 2020, 2019 and 2018, respectively. As of June 30, 2021, the total outstanding balance was $178,341 Canadian dollars ($143,885 U.S. Dollars).

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics, Inc. for the distribution rights of Hand MD in Canada. In conjunction with this agreement, we are required to pay Knight Therapeutics a distribution fee equal to 60% of gross sales for sales achieved through a direct sales channel until the sales in the calendar year equal the threshold amount and then 40% of all such gross sales in such calendar year in excess of the threshold amount and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight Therapeutics under this agreement is $25,000 Canadian dollars. On and after February 15, 2021, the agreement automatically renews for additional one-year terms unless either party gives notice of nonrenewal at least 180 days prior to the end of the then-current term. During the year ended December 31, 2020, we expensed $385,689 Canadian dollars ($287,836 U.S. Dollars). As of December 31, 2020, 2019 and 2018, the total outstanding balance was $110,637, $25,000 and $25,000 Canadian dollars, respectively. In U.S. Dollars, the total outstanding balance was $86,894, $17,574 and $18,325 as of December 31, 2020, 2019 and 2018, respectively. As of June 30, 2021, the total outstanding balance was $110,637 Canadian dollars ($89,263 U.S. Dollars).

 

47
 

 

On January 1, 2017, we entered into agreements with Knight Therapeutics, Inc. for the distribution rights of Sneaky Vaunt in Canada, and with Knight Therapeutics (Barbados) Inc. for the distribution rights of Sneaky Vaunt in Israel, Romania, Russia and Sub-Saharan Africa. In conjunction with these agreements, for sales in Canada, we are required to pay Knight Therapeutics a distribution fee equal to 60% of gross sales until the sales in the calendar year equal the threshold amount and then 40% of gross sales in such calendar year in excess of the threshold amount. For sales in Israel, Romania, Russia and Sub-Saharan Africa, we are required to pay Knight Therapeutics (Barbados) a distribution fee equal to 60% of gross sales. On and after February 15, 2021, the agreements automatically renew for additional one-year terms unless either party gives notice of nonrenewal at least 180 days prior to the end of the then-current term. We expensed royalties under the agreements of $1,055, $4,867 and $16,066 for the years ended December 31, 2020, 2019 and 2018, respectively, related to Sneaky Vaunt. At December 31, 2020, 2019 and 2018, we owed $0, $246 and $5,906, respectively, in connection with the royalty distribution agreements. We expensed royalties under the agreements of $1,184 during the six months ended June 30, 2021. At June 30, 2021, we owed $1,079 in connection with the royalty distribution agreements.

 

We expensed royalties to Knight Therapeutics of $0 and $2,361 for the years ended December 31, 2019 and 2018, respectively, related to The Queen Pegasus, a former product. At December 31, 2019 and 2018, we owed Knight Therapeutics $0 and $193, respectively, in connection with a royalty distribution agreement.

 

We expensed $145,356, $14,801 and $250,000 for the years ended December 31, 2020, 2019 and 2018, respectively, and $631 for the six months ended June 30, 2021, to Hand MD Corp, related to a royalty agreement. As of June 30, 2021, December 31, 2020, December 31, 2019 and December 31, 2018, the Company owed Hand MD Corp. $0 in minimum future royalties.

 

On February 15, 2016, Nomad Choice Pty Ltd entered into agreements with Knight Therapeutics, Inc. for the distribution rights of Flat Tummy in Canada and with Knight Therapeutics (Barbados) Inc. for the distribution rights of Flat Tummy in Israel, Romania, Russia and Sub-Saharan Africa. In conjunction with these agreements, for sales in Canada, we are required to pay Knight Therapeutics a distribution fee equal to 60% of gross sales. For sales in Israel, Romania, Russia and Sub-Saharan Africa, we are required to pay Knight Therapeutics (Barbados) a distribution fee equal to 60% of gross sales. On and after February 15, 2021, the agreements automatically renew for additional one-year terms unless either party gives notice of nonrenewal at least 180 days prior to the end of the then-current term. We expensed royalties under the agreements of $169,552, $192,700 and $392,589 for the years ended December 31, 2020, 2019 and 2018, respectively, related to Flat Tummy. At December 31, 2020, 2019 and 2018, we owed $11,026, $5,528 and $109,329, respectively, in connection with the royalty distribution agreements. We expensed royalties under the agreements of $84,465 during the six months ended June 30, 2021. At June 30, 2021, we owed $25,576 in connection with the royalty distribution agreements.

 

Gale Bensussen, a former member of our Board of Directors, was an executive officer of a supplier to us during 2019. During the years ended December 31, 2019 and 2018, we acquired $4,847,626 and $4,392,245, of products from the supplier, respectively. We owed the supplier $956,438 and $1,775,617, respectively, at December 31, 2019 and 2018.

 

We entered into transactions with Black Otter, Inc., a related party 100% indirectly owned by Jack Ross, our Chief Executive Officer, during the years ended December 31, 2020 and 2019. The transactions were a pass through of expenses and reimbursements related to marketing. During the years ended December 31, 2020 and 2019, we received advances of $74,629 ($100,000 Canadian Dollars) and $324,102 ($430,000 Canadian Dollars), respectively, which were fully repaid. As of each of December 31, 2020 and 2019, there was $0 due or payable.

 

We entered into transactions with BoomBod Ltd., a related party 100% indirectly owned by Jack Ross, our Chief Executive Officer, during the six months ended June 30, 2021 and years ended December 31, 2020 and 2019. The transactions were a pass through and allocation of expenses and reimbursements related to marketing. As of June 30, 2021, December 31, 2020 and December 31, 2019 we were owed $3,089,249, $2,305,956 and $277,432, respectively.

 

We entered into transactions with Gowan Properties Inc., a related party 100% indirectly owned by Jack Ross, our Chief Executive Officer, during the year ended December 31, 2020. The transactions are related to rent expense of $25,000 Canadian Dollars per month for our Halifax, Nova Scotia technology center. During the year ended December 31, 2020, we expensed $275,000 Canadian Dollars ($205,485 U.S. Dollars) for rent expense. As of December 31, 2020, we had advanced $86,250 Canadian Dollars ($67,741 U.S. Dollars) for prepaid rent relating to 2021. During the six months ending June 30, 2021, we expensed $150,000 Canadian Dollars ($120,329 U.S. Dollars) for rent expense. As of June 30, 2021 we had advanced $28,750 Canadian Dollars ($23,196 U.S. Dollars) for prepaid rent.

 

48
 

 

PRINCIPAL STOCKHOLDERS

 

Our only outstanding class of voting securities is our common stock. The following table sets forth information known to us about the beneficial ownership of our common stock on October 8, 2021 by (i) each current director and director nominee; (ii) each named executive officer; and (iii) all of our executive officers and directors as a group. Other than as set forth below, no person known to us beneficially owns 5% or more of the outstanding common stock as of October 8, 2021.

 

Unless otherwise indicated in the footnotes, each person listed in the following table has sole voting power and investment power over the common stock listed as beneficially owned by that person. The percentages reflect beneficial ownership immediately prior to and immediately after the completion of this offering and are based on 89,889,074 shares of our common stock outstanding as of October 8, 2021 and          shares of our common stock outstanding after the completion of this offering after taking into account the reverse stock split described below. The percentages assume the underwriters do not exercise their option to purchase any additional shares. Unless otherwise indicated in the footnotes, the address for each listed person is Synergy CHC Corp., 865 Spring Street, Westbrook, Maine 04092. The information in the table gives effect to the 1-for-             reverse stock split with respect to our common stock, which will occur prior to the effective date of the registration statement of which this prospectus is a part.

 

          After this Offering
    Prior to this Offering     If Underwriters’ Option is Not Exercised   If Underwriters’ Option is Exercised in Full  
    Shares Beneficially Owned(1)     Shares Beneficially Owned   Shares Beneficially Owned  
Name of Beneficial Owner   Number     Percent     Number   Percent   Number   Percent  
5% Stockholders:                              
Gowan Private Equity Inc. (2)     43,780,750       48.7 %            
Knight Therapeutics (Barbados) Inc. (3)     17,645,812       19.6 %                  
Named executive officers, directors and director nominees:                                  
Jack Ross (4)     51,993,005       57.8 %                  
Alfred Baumeler (5)     1,000,000       1.1 %                  
Jaime Fickett (6)     1,000,000       1.1 %                  
J. Paul SoRelle (7)     2,296,658       2.5 %                  
Stephen Fryer     500       *                    
Nitin Kaushal                              
All executive officers and directors as a group (6 persons)     56,290,163       60.6 %                  

 

* Less than 1% of the outstanding common stock.

 

  (1) Beneficial ownership as reported in the table has been determined in accordance with Rule 13d-3 under the Exchange Act and is not necessarily indicative of beneficial ownership for any other purpose. The number of shares of common stock shown as beneficially owned includes shares of common stock which may not be beneficially owned but over which a person would be deemed to exercise control or direction. The number of shares of common stock shown as beneficially owned includes shares of common stock subject to stock options exercisable and restricted stock units that were outstanding on October 8, 2021 and that will vest within 60 days of October 8, 2021. Shares of common stock subject to stock options exercisable and restricted stock units that will vest within 60 days after October 8, 2021 are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.
  (2) This stockholder’s address is 156 Heddas Way, Fall River NS B2T 0J4, Canada. Consists of 43,780,750 shares of common stock owned by Gowan Private Equity Inc. Jack Ross is the Chief Executive Officer of Gowan Private Equity Inc. Decisions regarding the voting or disposition of the shares held by Gowan Private Equity Inc. are made by Mr. Ross.
  (3) Consists of 17,645,812 shares of common stock. This stockholder’s address is Chancery House, High Street, Bridgetown, Barbados. Decisions regarding the voting or disposition of the shares held by Knight Therapeutics (Barbados) Inc. are made by Michel Loustric.
  (4) This stockholder’s address is 156 Heddas Way, Fall River NS B2T 0J4, Canada. Consists of 3,378,572 shares of common stock owned by Jack Ross, 43,780,750 shares of common stock owned by Gowan Private Equity Inc., 3,208,649 shares of common stock owned by Dunhill Distribution Group and 1,625,034 shares of common stock owned by Gowan Capital Inc. Jack Ross is the Chief Executive Officer of Gowan Private Equity Inc., Dunhill Distribution Group, Inc. and Gowan Capital Inc. Decisions regarding the voting or disposition of the shares held by Gowan Private Equity Inc., Dunhill Distribution Group, Inc. and Gowan Capital Inc. are made by Mr. Ross.
  (5) Consists of options to purchase 1,000,000 shares of common stock.
  (6) Consists of options to purchase 1,000,000 shares of common stock.
  (7) Consists of 1,296,658 shares of common stock owned by the SoRelle Family Partnership LLLP and an option to purchase 1,000,000 shares of common stock held by Mr. SoRelle. Decisions regarding the voting or disposition of the shares held by the SoRelle Family Partnership LLLP are made by its general partners, Mr. SoRelle, Carroll V. SoRelle, Carol S. Pederson and Merrie S. Foreman, and each general partner individually has voting and dispositive power over such shares.

 

49
 

 

DESCRIPTION OF CAPITAL STOCK

 

The following descriptions are summaries of the material terms of our certificate of incorporation and amended and restated bylaws as proposed to be in effect upon consummation of the offering. Reference is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, the certificate of incorporation and amended and restated bylaws, forms of which are filed with the SEC as exhibits to the registration statement of which this prospectus is a part, and applicable law.

 

General

 

Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share, of which 89,889,074 shares are issued and outstanding as of October 8, 2021, held by approximately 37 stockholders of record, before giving effect to the 1-for-         reverse stock split. Upon completion of this offering, there will be              shares of common stock outstanding, after giving effect to the 1-for-          reverse stock split.

 

Common Stock

 

Dividend Rights

 

The holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our Board of Directors may determine.

 

Voting Rights

 

Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Cumulative voting for the election of directors is not provided for in our articles of incorporation, which means that the holders of a majority of our shares of common stock voted can elect all of the directors then standing for election.

 

Preemptive or Similar Rights

 

Our common stock is not entitled to preemptive rights and is not subject to conversion or redemption.

 

Liquidation Rights

 

Upon our liquidation, dissolution, or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock outstanding at that time after payment of other claims of creditors.

 

Anti-Takeover Effects of Certain Provisions of Nevada Law

 

Effect of Nevada Anti-takeover Statute. We are subject to Section 78.438 of the Nevada Revised Statutes, an anti-takeover law. In general, Section 78.438 prohibits a Nevada corporation from engaging in any business combination with any interested stockholder for a period of two years following the date that the stockholder became an interested stockholder, unless prior to that date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder, or if after the date that the stockholder becomes an interested stockholder the business combination is approved by the board of directors and by 60% of the voting power of all disinterested stockholders at either an annual or special meeting of the stockholders of the corporation. Section 78.439 provides that business combinations after the two-year period following the date that the stockholder becomes an interested stockholder may also be prohibited unless either approved by the corporation’s directors before the stock acquisition, or by a majority of the disinterested stockholders or unless the price and terms of the transaction meet other criteria set forth in the statute.

 

Section 78.416 defines “business combination” to include the following:

 

  any merger or consolidation involving the corporation and the interested stockholder or any other corporation which is an affiliate or associate of the interested stockholder;
     
  any sale, transfer, pledge or other disposition of the assets of the corporation involving the interested stockholder or any affiliate or associate of the interested stockholder if the assets transferred have a market value equal to 5% or more of all of the assets of the corporation or 5% or more of the value of the outstanding shares of the corporation or represent 10% or more of the earning power of the corporation;

 

50
 

 

  subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to an interested stockholder, with a market value of 5% or more of the value of the outstanding shares of the corporation;
     
  the adoption of a plan of liquidation proposed by or under any arrangement with the interested stockholder or any affiliate or associate of the interested stockholder;
     
  any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of voting shares of securities convertible into voting shares of the corporation beneficially owned by the interested stockholder or any affiliate or associate of the interested stockholder; or
     
  the receipt by the interested stockholder or any affiliate or associate of the interested stockholder of the benefit, except proportionately as a stockholder of the corporation, of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 78.423 defines an interested stockholder as any entity or person beneficially owning, directly or indirectly, 10% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by any of these entities or persons.

 

Control Share Acquisitions. Sections 78.378 through 78.3793 of the Nevada Revised Statutes limit the voting rights of certain acquired shares in a corporation. The provisions apply to any acquisition of outstanding voting securities of a Nevada corporation that has 200 or more stockholders, at least 100 of which are Nevada residents, and conducts business in Nevada (an “issuing corporation”) resulting in ownership of one of the following categories of an issuing corporation’s then outstanding voting securities: (i) twenty percent or more but less than thirty-three percent; (ii) thirty-three percent or more but less than fifty percent; or (iii) fifty percent or more. The securities acquired in such acquisition are denied voting rights unless a majority of the security holders approve the granting of such voting rights. Unless an issuing corporation’s articles of incorporation or bylaws then in effect provide otherwise: (i) voting securities acquired are also redeemable in part or in whole by an issuing corporation at the average price paid for the securities within 30 days if the acquiring person has not given a timely information statement to an issuing corporation or if the stockholders vote not to grant voting rights to the acquiring person’s securities, and (ii) if outstanding securities and the security holders grant voting rights to such acquiring person, then any security holder who voted against granting voting rights to the acquiring person may demand the purchase from an issuing corporation, for fair value, all or any portion of his securities. These provisions do not apply to acquisitions made pursuant to the laws of descent and distribution, the enforcement of a judgment, or the satisfaction of a security interest, or made in connection with certain mergers or reorganizations.

 

Indemnification of Directors and Officers

 

Neither our articles of incorporation, nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statutes (“NRS”). NRS Section 78.7502, provides that a corporation may indemnify any director, officer, employee or agent of a corporation against expenses, including fees, actually and reasonably incurred by him in connection with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.

 

NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

 

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

 

51
 

 

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

 

Our amended and restated bylaws will provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.

 

We will enter into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our articles of incorporation and amended and restated bylaws.

 

We do not currently carry directors’ and officers’ insurance. However, we may in the future purchase a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

 

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

 

We believe that these provisions and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

 

Listing

 

We have applied to list our common stock on the Nasdaq Capital Market under the symbol “SNYR.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, New York 11598.

 

52
 

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Prior to this offering, there are no publicly-available quotations of our common stock. Future sales of substantial amounts of our common stock in the public market, or the perception that such sales may occur, could adversely affect market prices prevailing from time to time. Further, because only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the future.

 

Upon completion of this offering,                shares of common stock will be outstanding. Of these shares,                shares of our common stock (or                shares if the underwriters exercise in full their option to purchase additional shares) sold in this offering will be freely transferable without restriction or further registration under the Securities Act, except for any shares purchased by our “affiliates,” as that term is defined in Rule 144 under the Securities Act. The remaining                 shares of our common stock outstanding are “restricted shares” as defined in Rule 144. Restricted shares may be sold in the public market only if registered under the Securities Act or if they qualify for an exemption from registration under Rule 144. As a result of the contractual 180-day lock-up period described below, the shares subject to lock-up agreements will be available for sale in the public market only after 180 days from the date of this prospectus (generally subject to resale limitations).

 

Rule 144

 

In general, a person who has beneficially owned restricted shares of our common stock for at least six months would be entitled to sell such securities, provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, the sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares of our common stock for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, the sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of the following:

 

  1% of the number of shares of our common stock then outstanding, which will equal approximately                 shares immediately after this offering; or

 

  the average weekly trading volume of our common stock on the Nasdaq Capital Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale;

 

provided, in each case, that we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale and notice provisions of Rule 144 to the extent applicable.

 

Lock-up Agreements

 

The Company, each of our directors and executive officers following this offering, and our 1% and greater stockholders, have agreed, subject to certain limited exceptions, not to offer, pledge, sell, contract to sell, grant any option to purchase, or otherwise dispose of our common stock or any securities convertible into or exchangeable or exercisable for common stock, or to enter into any hedge or other arrangement or any transaction that transfers, directly or indirectly, the economic consequence of ownership of the shares of our common stock for a period of 180 days after the date of this prospectus, without the prior written consent of B. Riley Securities, Inc., as representative of the underwriters. See “Underwriting—Lock-up Agreements.” The underwriters do not have any present intention or arrangement to release any shares of our common stock subject to lock-up agreements prior to the expiration of the 180-day lock-up period.

 

53
 

 

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS

 

The following is a summary of the material U.S. federal income tax consequences relating to the acquisition, ownership, and disposition of common stock acquired pursuant to this offering by non-U.S. holders (as defined below). This summary deals only with common stock held as a capital asset (within the meaning of Section 1221 of the Code) and does not discuss the U.S. federal income tax consequences applicable to a non-U.S. holder that is subject to special treatment under U.S. federal income tax laws, including, but not limited to: a dealer in securities or currencies; a broker-dealer; a financial institution; a qualified retirement plan, individual retirement plan, or other tax-deferred account; a regulated investment company; a real estate investment trust; a tax-exempt organization; an insurance company; a person holding common stock as part of a hedging, integrated, conversion, or straddle transaction or a person deemed to sell common stock under the constructive sale provisions of the Code; a trader in securities that has elected the mark-to-market method of tax accounting; an accrual method taxpayer subject to special tax accounting rules under Section 451(b) of the Code; an entity that is treated as a partnership for U.S. federal income tax purposes; a person that received such common stock in connection with services provided; qualified foreign pension funds as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds; a corporation that is subject to the accumulated earnings tax; a person that owns or has owned, actually or constructively, more than 5% of our common stock; a corporation organized outside the United States, any state thereof or the District of Columbia that is nonetheless treated as a U.S. taxpayer for U.S. federal income tax purposes; a person that is not a non-U.S. holder; a “controlled foreign corporation;” a “passive foreign investment company;” or a U.S. expatriate and former citizens or long-term residents of the United States.

 

This summary is based upon provisions of the Code, its legislative history, applicable U.S. Treasury regulations promulgated thereunder, published rulings, and judicial decisions, all as in effect as of the date hereof. We have not sought, and will not seek, any ruling from the Internal Revenue Service, or IRS, with respect to the tax consequences discussed herein, and there can be no assurance that the IRS will not take a position contrary to the tax consequences discussed below or that any position taken by the IRS would not be sustained. Those authorities may be repealed, revoked, or modified, perhaps retroactively, or may be subject to differing interpretations, which could result in U.S. federal income tax consequences different from those discussed below. This summary does not address all aspects of U.S. federal income tax, does not deal with all tax considerations that may be relevant to stockholders in light of their personal circumstances, and does not address any state, local, foreign, gift, Medicare, estate (except to the limited extent set forth herein), or alternative minimum tax considerations.

 

For purposes of this discussion, a “U.S. holder” is a beneficial holder of common stock that is for U.S. federal income tax purposes: an individual citizen or resident of the United States; a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia; an estate the income of which is subject to U.S. federal income taxation regardless of its source; or a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (2) was in existence on August 20, 1996 and has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.

 

For purposes of this discussion, a “non-U.S. holder” is a beneficial owner of common stock that is neither a U.S. holder nor a partnership (or any other entity or arrangement that is treated as a partnership) for U.S. federal income tax purposes regardless of its place of organization or formation. If a partnership (or an entity or arrangement that is treated as a partnership for U.S. federal income tax purposes) holds common stock, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. A partner of a partnership holding common stock is urged to consult its own tax advisors.

 

THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME, ESTATE, AND OTHER TAX CONSEQUENCES OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR SPECIFIC SITUATIONS, AS WELL AS THE TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, OR NON-U.S. TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS (INCLUDING THE U.S. FEDERAL ESTATE AND GIFT TAX LAWS) OR UNDER ANY APPLICABLE INCOME TAX TREATY.

 

Distributions on Our Common Stock

 

Distributions with respect to common stock, if any, generally will constitute dividends for U.S. federal income tax purposes to the extent paid out of current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. Any portion of a distribution in excess of current or accumulated earnings and profits will be treated as a return of capital and will first be applied to reduce the holder’s tax basis in its common stock, but not below zero. Any remaining amount will then be treated as gain from the sale or exchange of the common stock and will be treated as described under “—Disposition of Our Common Stock” below.

 

54
 

 

Distributions treated as dividends that are paid to a non-U.S. holder, if any, with respect to shares of our common stock, will be subject to U.S. federal withholding tax at a rate of 30% (or such lower rate as may be specified in an applicable income tax treaty, provided the non-U.S. Holder furnishes a valid IRS Form W-8BEN or IRS Form W-8BEN-E (or applicable successor form or other documentation) to us or our paying agent certifying qualification for the lower treaty rate) of the gross amount of the dividends unless the dividends are effectively connected with the non-U.S. holder’s conduct of a trade or business in the United States subject to the discussion below regarding foreign accounts and backup withholding. A non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaties.

 

If a non-U.S. holder is engaged in a trade or business in the United States and dividends with respect to the common stock are effectively connected with the conduct of that trade or business and, if required by an applicable income tax treaty, are attributable to a U.S. permanent establishment, then although the non-U.S. holder will generally be exempt from the 30% U.S. federal withholding tax, provided certain certification requirements are satisfied, the non-U.S. holder will be subject to U.S. federal income tax on those dividends on a net income basis at regular graduated U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. Any such effectively connected income received by a foreign corporation may, under certain circumstances, be subject to an additional branch profits tax equal to 30% (or lower applicable income tax treaty rate) of its effectively connected earnings and profits for the taxable year, as adjusted under the Code. To claim the exemption from withholding with respect to any such effectively connected income, the non-U.S. holder must generally furnish to us or our paying agent a properly executed IRS Form W-8ECI (or applicable successor form). In the case of a non-U.S. holder that is an entity, Treasury regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If a non-U.S. holder holds stock through a financial institution or other agent acting on the holder’s behalf, the holder will be required to provide appropriate documentation to such agent. Such holder’s agent will then be required to provide certification to us or our paying agent.

 

Disposition of Our Common Stock

 

Subject to the discussion below regarding backup withholding, a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain from a sale, exchange or other disposition of our stock unless:

 

  (a) that gain is effectively connected with the non-U.S. holder’s conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment maintained by the non-U.S. holder);
     
  (b) the non-U.S. holder is a nonresident alien individual who is present in the United States for 183 days or more in the taxable year of that disposition, and certain other conditions are met; or
     
  (c) we are or have been a “United States real property holding corporation” within the meaning of Code Section 897(c)(2) for U.S. federal income tax purposes at any time during the shorter of the five-year period preceding the date of disposition or the holder’s holding period for our common stock, and certain other requirements are met.

 

If a non-U.S. holder is described in clause (a) of the preceding paragraph, the non-U.S. holder will generally be subject to tax on the net gain derived from the disposition at the regular graduated U.S. federal income tax rates in the same manner as if such non-U.S. holder were a U.S. person, unless an applicable income tax treaty provides otherwise. In addition, a non-U.S. holder that is a corporation may be subject to the branch profits tax at a rate equal to 30% (or lower applicable income tax treaty rate) of its effectively connected earnings and profits, as adjusted for certain items.

 

If the non-U.S. holder is an individual described in clause (b) of the preceding paragraph, the non-U.S. holder will generally be subject to a flat 30% tax on the gain derived from the disposition, which may be offset by U.S.-source capital losses even though the non-U.S. holder is not considered a resident of the United States, provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses.

 

If the non-U.S. holder is described in clause (c) of the preceding paragraph, the non-U.S. holder will generally be subject to U.S. federal income tax in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. Although there can be no assurance, we believe that we are not, and we do not anticipate becoming, a United States real property holding corporation for U.S. federal income tax purposes. Even if we are treated as a United States real property holding corporation, gain realized by a non-U.S. holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1) the non-U.S. holder owned, directly, indirectly and constructively, no more than five percent of our common stock at all times within the shorter of (x) the five-year period preceding the disposition, or (y) the holder’s holding period, and (2) our common stock is regularly traded on an established securities market. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your disposition is taxable because we are a United States real property holding corporation and your ownership of our common stock exceeds five percent, you will be taxed on such disposition generally in the manner applicable to U.S. persons and in addition, a purchaser of your common stock may be required to withhold tax with respect to that obligation. Such withheld tax is not an additional tax but merely an advance payment, which may be credited against the tax liability of persons subject to such withholding or refunded to the extent it results in an overpayment of tax and the appropriate information is timely supplied to the IRS.

 

Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.

 

U.S. Federal Estate Tax

 

The estate of a nonresident alien individual is generally subject to U.S. federal estate tax on property it is treated as the owner of, or has made certain life transfers of, having a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent for U.S. federal estate tax purposes, unless an applicable estate tax treaty between the United States and the decedent’s country of residence provides otherwise.

 

Information Reporting and Backup Withholding Tax

 

We report to our non-U.S. holders and the IRS certain information with respect to any dividends we pay on our common stock, including the amount of dividends paid during each fiscal year, the name and address of the recipient, and the amount, if any, of tax withheld. All distributions to holders of common stock are subject to any applicable withholding. Information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the non-U.S. holder’s conduct of a U.S. trade or business or withholding was reduced by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established. Under U.S. federal income tax law, interest, dividends, and other reportable payments may, under certain circumstances, be subject to “backup withholding” at the then applicable rate (currently, 24%). Backup withholding, however, generally will not apply to distributions on our common stock to a non-U.S. holder, provided the non-U.S. holder furnishes to us or our paying agent the required certification as to its non-U.S. status, such as by providing a valid IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-8ECI, or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if either we or our paying agent has actual knowledge, or reason to know, that the holder is a U.S. person that is not an exempt recipient. Backup withholding is not an additional tax but merely an advance payment, which may be credited against the tax liability of persons subject to backup withholding or refunded to the extent it results in an overpayment of tax and the appropriate information is timely supplied to the IRS.

 

Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, information reporting but not backup withholding will apply in a manner similar to dispositions effected through a U.S. office of a broker, if a non-U.S. holder sells our common stock through a non-U.S. office of a broker that has certain connections with the United States.

 

Withholding on Payments to Foreign Accounts

 

Certain withholding taxes may apply under Section 1471 through 1472 of the Code (which are commonly referred to as the Foreign Account Tax Compliance Act (“FATCA”)) to certain types of payments made to “foreign financial institutions” (as specially defined under these rules) and certain other non-U.S. entities if certification, information reporting and other specified requirements are not met. A 30% withholding tax may apply to “withholdable payments” if they are paid to a foreign financial institution or to a non-financial foreign entity, unless (a) the foreign financial institution undertakes certain diligence and reporting obligations and other specified requirements are satisfied, (b) the non-financial foreign entity either certifies it does not have any substantial U.S. owners or furnishes identifying information regarding each substantial U.S. owner and other specified requirements are satisfied or (c) the foreign financial institution or non-financial foreign entity otherwise qualified for an exemption from these rules.

 

“Withholdable payment” generally means any payment of interest, dividends, rents, and certain other types of generally passive income if such payment is from sources within the United States. U.S. Treasury Regulations proposed in December 2018 (and upon which taxpayers and withholding agents are entitled to rely until final regulations are issued) eliminate possible withholding under these rules on the gross proceeds from any sale or other disposition of our common stock, previously scheduled to apply beginning January 1, 2019. If the payee is a foreign financial institution, it must enter into an agreement with the U.S. Treasury requiring, among other things, that it undertake to identify accounts held by certain U.S. persons or U.S.-owned foreign entities, annually report certain information about such accounts and withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and other requirements, or comply with comparable requirements under an applicable inter-governmental agreement between the United States and the foreign financial institution’s home jurisdiction. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. If an investor does not provide us with the information necessary to comply with these rules, it is possible that distributions to such investor that are attributable to withholdable payments, such as dividends, will be subject to the 30% withholding tax.

 

Holders should consult their own tax advisers regarding the implications of FATCA on their investment in our common stock.

 

55
 

 

UNDERWRITING

 

We have entered into an underwriting agreement, dated                , 2021, with B. Riley Securities, Inc., acting as the sole book-running manager (sometimes referred to as the “Representative”). Subject to the terms and conditions of the underwriting agreement, each of the underwriters named below has agreed to purchase, and we have agreed to sell to it, the number of shares of common stock listed next to its name at the public offering price, less the underwriting discounts and commissions, as set forth on the cover page of this prospectus and as indicated below:

 

Underwriters     Number of Shares  
B. Riley Securities, Inc.        
         
         
         
Total        

 

The underwriting agreement provides that the obligation of the underwriters to purchase all of the shares being offered to the public is subject to approval of legal matters by counsel and the satisfaction of other conditions. These conditions include, among others, the continued accuracy of representations and warranties made by us in the underwriting agreement, delivery of legal opinions and the absence of any material changes in our assets, business or prospects after the date of this prospectus. The underwriters are obligated to purchase all of our shares in this offering, other than those covered by the over-allotment option described below, if they purchase any of our shares.

 

The Representative of the underwriters has advised us that the underwriters propose to offer the common stock directly to the public at the public offering prices listed on the cover page of this prospectus and to selected dealers, who may include the underwriters, at the public offering price less a selling concession not in excess of $     per share for the common stock. After the completion of this offering, the underwriters may change the offering price and other selling terms.

 

Pursuant to the underwriting agreement, we have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments which the underwriters or other indemnified parties may be required to make in respect of any such liabilities.

 

Over-Allotment Option

 

We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 30 days after the date of this prospectus, permits the underwriters to purchase a maximum of additional shares from us to cover over-allotments, if any. If the underwriters exercise all or part of this option, each underwriter will be obligated to purchase its proportionate number of shares covered by the option at the public offering price that appears on the cover page of this prospectus, less the underwriting discounts and commissions.

 

Commissions and Expenses

 

The following table provides information regarding the amount of the underwriting discounts and commissions to be paid to the underwriters by us. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase additional shares to cover over-allotments, if any.

 

      Per Share     Total Without Over-Allotment     With Over-Allotment
Underwriting discounts and commissions paid by us   $   $   $
Proceeds, before expenses, to us   $   $   $

 

The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $      million, which includes our legal, accounting and printing costs and various other fees associated with registration and listing of our common stock. We have agreed to reimburse the Representative for its reasonable out-of-pocket expenses actually incurred in the offering, other than fees and disbursements of legal counsel to the representative. We have agreed to reimburse reasonable fees and disbursements of the Representative’s legal counsel actually incurred up to $300,000 if the offering is not consummated. If the offering is not consummated within a specified period agreed to by and between B. Riley Securities, Inc. and us and any person purchases securities from us in a public offering pursuant to a registration statement filed with the SEC within six months thereafter, we will pay B. Riley Securities, Inc. a termination fee equal to 7.0% of the price paid by the purchaser of such securities, subject to FINRA Rule 5110(g)(5).

  

56
 

 

Discretionary Accounts

 

The underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

 

Lock-Up Agreements

 

Each of our directors and executive officers following this offering, and our 1% and greater stockholders have agreed to a 180-day “lock-up” from the date of this prospectus relating to shares of our common stock that they beneficially own. This means that, for a period of 180 days following the date of this prospectus, such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of the representative, subject to certain exceptions.

 

The Representative may, in their sole discretion and at any time or from time to time, release all or any portion of the common stock or other securities subject to the lock-up agreement. Any determination to release any common stock would be based upon a number of factors at the time of determination, which may include the market price of the common stock, the liquidity of the trading market of the common stock, general market conditions, the number of shares of common stock or other securities proposed to be sold or otherwise transferred and the timing, purposes and terms of the proposed sale or other transfer. The Representative does not have any present intention, agreement or understanding, implicit or explicit, to release any of the shares of common stock or other securities subject to the lock-up agreements prior to the expiration of the lock-up period described above.

 

In addition, the underwriting agreement provides that, subject to certain exceptions, we will not, for a period of 180 days following the date of this prospectus, offer, sell or distribute any of our securities, without the prior written consent of the underwriters.

 

Right of First Refusal

 

We have agreed to grant the Representative, for the 12-month period following the closing of this offering, a right of first refusal to act as (i) lead underwriter and sole book runner in connection with any public offering of equity or equity-linked securities, sole placement agent in any private offering of equity, equity-linked securities, debt or debt-like securities or other capital markets financings and (ii) financial advisor in connection with any sale of all or a significant portion of our assets or capital stock, regardless of how structured and whether in one transaction or a series of transactions, as well as any transaction or disposition that results in the effective sale, transfer or other disposition of ownership or control over a significant portion of one or more of our principal businesses or operations (the “Right of First Refusal”), which right is exercisable in the representative’s sole discretion. In accordance with Financial Industry Regulation Authority (“FINRA”) Rule 5110(g)(6), such Right of First Refusal does not have a duration of more than three years from the commencement of sales in this offering or the termination date of the engagement between us and the representative.

 

Nasdaq Capital Market

 

We have applied to have our shares of common stock listed on the Nasdaq Capital Market under the symbol “SNYR.” Our application might not be approved and the completion of this offering is contingent upon such approval.

 

Stabilization

 

Until the distribution of the securities offered by this prospectus is completed, rules of the SEC may limit the ability of the underwriters to bid for and to purchase our common stock. As an exception to these rules, the underwriters may engage in transactions effected in accordance with Regulation M under the Exchange Act that are intended to stabilize, maintain or otherwise affect the price of our common stock. The underwriters may engage in over-allotment sales, syndicate covering transactions, stabilizing transactions and penalty bids in accordance with Regulation M:

 

  Stabilizing transactions permit bids or purchases for the purpose of pegging, fixing or maintaining the price of the common stock, so long as stabilizing bids do not exceed a specified maximum.

 

  Over-allotment involves sales by the underwriters of securities in excess of the number of securities the underwriters are obligated to purchase, which creates a short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares of common stock over-allotted by the underwriters is not greater than the number of shares of common stock that they may purchase in the over-allotment option. In a naked short position, the number of shares of common stock involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option or purchasing shares of our common stock in the open market.

 

57
 

 

  Covering transactions involve the purchase of securities in the open market after the distribution has been completed in order to cover short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which they may purchase securities through the over-allotment option. If the underwriters sell more shares of common stock than could be covered by the over-allotment option, creating a naked short position, the position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in this offering.

 

  Penalty bids permit the underwriters to reclaim a selling concession from a selected dealer when the securities originally sold by the selected dealer are purchased in a stabilizing or syndicate covering transaction.

 

These stabilizing transactions, covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market.

 

Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the prices of our common stock. These transactions may occur on any trading market. If any of these transactions are commenced, they may be discontinued without notice at any time.

 

Electronic Prospectus

 

This prospectus may be made available in electronic format on Internet sites or through other online services maintained by the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. Other than this prospectus in electronic format, any information on the underwriters’ or their affiliates’ websites and any information contained in any other website maintained by the underwriters or any affiliate of the underwriters is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors.

 

Notice to Prospective Investors in Canada (Alberta, British Columbia, Manitoba, Ontario and Québec Only)

 

This document constitutes an “exempt offering document” as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of shares of common stock described herein (the “Securities”). No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this document or on the merits of the Securities and any representation to the contrary is an offence.

 

Canadian investors are advised that this document has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts (“NI 33-105”). Pursuant to section 3A.3 of NI 33-105, this document is exempt from the requirement that the issuer and the underwriters in the offering provide Canadian investors with certain conflicts of interest disclosure pertaining to “connected issuer” and/or “related issuer” relationships as may otherwise be required pursuant to subsection 2.1(1) of NI 33-105.

 

Resale Restrictions

 

The offer and sale of the Securities in Canada are being made on a private placement basis only and are exempt from the requirement that the issuer prepare and file a prospectus under applicable Canadian securities laws. Any resale of Securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the Securities outside of Canada.

 

Representations of Purchasers

 

Each Canadian investor who purchases the Securities will be deemed to have represented to the issuer, the underwriters and each dealer from whom a purchase confirmation is received, as applicable, that the investor (i) is purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii) is an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii) is a “permitted client” as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.

 

58
 

 

Taxation and Eligibility for Investment

 

Any discussion of taxation and related matters contained in this document does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the Securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the Securities or with respect to the eligibility of the Securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.

 

Rights of Action for Damages or Rescission

 

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

 

Personal Information

 

We and the representative hereby notify prospective Canadian purchasers that: (a) we may be required to provide personal information pertaining to the purchaser as required to be disclosed in Schedule I of Form 45-106F1 under NI 45-106 (including its name, address, telephone number, email address, if provided, and the number and type of securities purchased, the total purchase price paid for such securities, the date of the purchase and specific details of the prospectus exemption relied upon under applicable securities laws to complete such purchase) (“personal information”), which Form 45-106F1 may be required to be filed by us under NI 45-106, (b) such personal information may be delivered to the securities regulatory authority or regulator in accordance with NI 45-106, (c) such personal information is being collected indirectly by the securities regulatory authority or regulator under the authority granted to it under the securities legislation of the applicable legislation, (d) such personal information is collected for the purposes of the administration and enforcement of the securities legislation of the applicable jurisdiction, and (e) the purchaser may contact the applicable securities regulatory authority or regulator by way of the contact information provided in Schedule 2 to Form 45-106F1. Prospective Canadian purchasers that purchase securities in this offering will be deemed to have authorized the indirect collection of the personal information by each applicable securities regulatory authority or regulator, and to have acknowledged and consented to such information being disclosed to the Canadian securities regulatory authority or regulator, and to have acknowledged that such information may become available to the public in accordance with requirements of applicable Canadian laws.

 

Language of Documents

 

Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the Securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu’il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d’achat ou tout avis) soient rédigés en anglais seulement.

 

Notice to Prospective Investors in the European Economic Area and the United Kingdom

 

In relation to the Member States of the European Economic Area and the United Kingdom (each, a “Relevant State”), no offer of shares of our common stock which are the subject of the offering contemplated by this prospectus to the public may be made in that Relevant State other than:

 

  to any legal entity that is a qualified investor as defined in the Prospectus Regulation;

 

  to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the relevant representative or representatives nominated by us for any such offer; or

 

  in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

 

provided that no such offer of shares of our common stock described in this prospectus shall result in a requirement for the publication of a prospectus, by us or any of the underwriters, pursuant to Article 3 of the Prospectus Regulation.

 

59
 

 

Each purchaser of shares of our common stock described in this prospectus located within a Relevant State will be deemed to have represented, acknowledged and agreed that (1) it is a “qualified investor” within the meaning of the Prospectus Regulation; and (2) in the case of any shares of common stock acquired by it as a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, as that term is defined in the Prospectus Regulation, or in circumstances in which the prior consent of the underwriters has been given to the offer or resale; or where shares of common stock have been acquired by it on behalf of persons in any Relevant State other than qualified investors, the offer of those shares of common stock to it is not treated under the Prospectus Regulation as having been made to such persons. For purposes of this provision, the expression an “offer to the public” in relation to the shares of our common stock in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of our common stock to be offered so as to enable an investor to decide to purchase or subscribe to the shares and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129.

 

We and the underwriters have not authorized and do not authorize the making of any offer of shares of our common stock through any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final placement of the shares as contemplated in this prospectus. Accordingly, no purchaser of the shares of our common stock, other than the underwriters, is authorized to make any further offer of the shares on behalf of us or the underwriters. References to the Prospectus Regulation includes, in relation to the UK, the Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

The above selling restriction is in addition to any other selling restrictions set out below.

 

Additional Notice to Prospective Investors in the United Kingdom

 

The communication of this prospectus and any other document or materials relating to the issue of the shares of our common stock offered hereby is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom’s Financial Services and Markets Act 2000, as amended, or the FSMA. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom who have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Financial Promotion Order), or who fall within Article 49(2)(a) to (d) of the Financial Promotion Order, or who are any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, the shares of our common stock offered hereby are only available to, and any investment or investment activity to which this prospectus relates will be engaged in only with, relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this prospectus or any of its contents. Any invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) in connection with the issue or sale of the shares of our common stock may only be communicated or caused to be communicated in circumstances in which Section 21(1) of the FSMA does not apply to us.

 

All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the shares of our common stock in, from or otherwise involving the United Kingdom.

 

Notice to Prospective Investors in Switzerland

 

This document is not intended to constitute an offer or solicitation to purchase or invest in the securities. The securities may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (“FinSA”) and no application has or will be made to admit the securities to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this document nor any other offering or marketing material relating to the securities constitutes a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.

 

Neither this document nor any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (“CISA”). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of the securities.

 

60
 

 

LEGAL MATTERS

 

The validity of the shares of common stock offered hereby will be passed upon for us by Nelson Mullins Riley & Scarborough LLP, Raleigh, North Carolina. O’Melveny & Myers LLP is acting as counsel for the underwriters.

 

EXPERTS

 

The consolidated financial statements of Synergy CHC Corp. as of December 31, 2020 and 2019 and for the years then ended included in this prospectus have been so included in reliance on the reports of RBSM LLP, an independent registered public accounting firm, which are included herein, given on the authority of said firm as experts in auditing and accounting.

 

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement.

 

Upon completion of this offering, we will be subject to the information and periodic requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is www.sec.gov. We also maintain a website at www.synergychc.com. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.

 

61
 

 

INDEX TO FINANCIAL STATEMENTS

 

    Page
     
Unaudited Interim Financial Statements:    
     
Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020   F-2
     
Condensed Consolidated Statements of Income and Comprehensive Income for the Six Months Ended June 30, 2021 and 2020   F-3
     
Condensed Consolidated Statement of Stockholders’ Deficit for the Six Months Ended June 30, 2021 and 2020   F-4
     
Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2021 and 2020   F-5
     
Audited Annual Financial Statements:    
     
Report of Independent Registered Accounting Firm   F-23
     
Consolidated Balance Sheets as of December 31, 2020 and 2019   F-24
     
Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the Years Ended December 31, 2020 and 2019   F-25
     
Consolidated Statement of Changes in Stockholders’ (Deficit) Equity for the Years Ended December 31, 2020 and 2019   F-26
     
Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019   F-27
     
Notes to the Consolidated Financial Statements   F-28

 

F-1
 

 

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

 

    June 30, 2021     December 31, 2020  
      (Unaudited)          
Assets                
Current Assets:                
Cash and cash equivalents   $ 966,398     $ 1,565,453  
Restricted cash     100,000       100,000  
Accounts receivable, net     2,053,230       3,380,086  
Loan receivable (related party)     3,089,249       2,305,956  
Prepaid expenses including related party amount of $448,196 and $492,741, respectively)     1,112,475       1,237,230  
Income taxes receivable     415,844       531,918  
Inventory, net     8,184,212       3,466,446  
Total Current Assets     15,921,408       12,587,089  
Total Assets   $ 15,921,408     $ 12,587,089  
                 
Liabilities and Stockholders’ Deficit                
Current Liabilities:                
Accounts payable and accrued liabilities (including related party payable of $292,303 and $510,064, respectively)   $ 9,750,601     $ 7,101,700  
Contract liabilities     48,664       121,803  
Short term loans payable, net of debt discount     393,754       -  
Current portion of long-term debt, net of debt discount and debt issuance cost, related party     5,524,450       7,515,693  
Total Current Liabilities     15,717,469       14,739,196  
                 
Long-term Liabilities:                
Note payable, net of debt discount and debt issuance cost, related party     1,239,908       1,231,223  
Income taxes payable     300,773       300,773  
Total Long-term Liabilities     1,540,681       1,531,996  
Total Liabilities     17,258,150       16,271,192  
                 
Commitments and contingencies                
                 
Stockholders’ Deficit:                
Common stock, $0.00001 par value; 300,000,000 shares authorized; 89,889,074 shares issued and outstanding     899       899  
Additional paid in capital     19,147,884       19,147,884  
Accumulated other comprehensive loss     (302,517 )     (9,449 )
Accumulated deficit     (20,183,008 )     (22,823,437 )
Total stockholders deficit     (1,336,742 )     (3,684,103 )
Total Liabilities and Stockholders’ Deficit   $ 15,921,408     $ 12,587,089  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

F-2

 

 

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Income and Comprehensive Income

 

    For the six months ended  
    June 30, 2021     June 30, 2020  
Revenue   $ 24,761,974     $ 17,906,767  
Cost of sales     6,794,344       6,593,446  
Gross profit     17,967,630       11,313,321  
                 
Operating expenses                
Selling and marketing     11,507,769       5,640,397  
General and administrative     2,997,276       3,043,044  
Depreciation and amortization     -       53,544  
Total operating expenses     14,505,045       8,736,985  
                 
Income from operations     3,462,585       2,576,336  
                 
Other (income) expenses                
Interest income     (24 )     (79 )
Other income     -       (181,849 )
Other expense (loan success fee)     -       1,000,000  
Interest expense     627,883       497,992  
Remeasurement loss on translation of foreign subsidiary     89,760       (12,216 )
Amortization of debt issuance cost     -       42,142  
                 
Total other expenses     717,619       1,345,990  
                 
Net income before income taxes     2,744,966       1,230,346  
Income tax expense     104,537       128,996  
Net income after tax   $ 2,640,429     $ 1,101,350  
                 
Net income per share – basic   $ 0.03     $ 0.01  
Net income per share – diluted   $ 0.03     $ 0.01  
                 
Weighted average common shares outstanding                
Basic     89,889,044       89,889,044  
Diluted     89,889,044       89,889,044  
                 
Comprehensive income:                
Net income   $ 2,640,429     $ 1,101,350  
Foreign currency translation adjustment     (293,068 )    

174,191

 
Comprehensive income (loss)   $ 2,347,361     $

1,275,541

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

F-3

 

 

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Stockholders’ Deficit

 

    Common stock     Additional Paid in     Accumulated Other Comprehensive     Accumulated     Total Stockholders’  
    Shares     Amount     Capital     Income     Deficit     Deficit  
Balance as of December 31, 2019     89,889,074     $ 899     $ 19,018,955     $ 11,364     $ (24,234,569 )   $ (5,203,351 )
                                                 
Fair value of vested stock options                     77,358                       77,358  
Foreign currency translation gain                             174,191               174,191  
Net income                                     1,101,350       1,101,350  
Balance as of June 30, 2020     89,889,074     $ 899     $ 19,096,313     $ 185,555     $ (23,133,219 )   $ (3,850,452 )

 

    Common stock     Additional Paid in     Accumulated Other Comprehensive     Accumulated     Total Stockholders’  
    Shares     Amount     Capital     Loss     Deficit     Deficit  
Balance as of December 31, 2020     89,889,074     $ 899     $ 19,147,884     $ (9,449 )   $ (22,823,437 )   $ (3,684,103 )
                                                 
Foreign currency translation loss                             (293,068 )             (293,068 )
Net income                                     2,640,429       2,640,429  
Balance as of June 30, 2021     89,889,074     $ 899     $ 19,147,884     $ (302,517 )   $ (20,183,008 )   $ (1,336,742 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

F-4

 

 

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of Cash Flows

 

    For the six months ended  
    June 30, 2021     June 30, 2020  
Cash Flows from Operating Activities                
Net income   $ 2,640,429     $ 1,101,350  
Adjustments to reconcile net income to net cash provided by operating activities:                
Depreciation and amortization           53,544  
Amortization of debt issuance cost     11,877       42,141  
Stock based compensation expense           77,358  
Remeasurement loss (gain) on translation of foreign subsidiary     89,760       (12,216 )
Foreign currency transaction gain (loss)     (348,208 )     190,007  
Non cash implied interest     17,442       9,298  
Reversal of allowance for doubtful accounts           (170,309 )
Gain on write-off of payables           (180,000 )
Accrual of loan success fee           1,000,000  
Changes in operating assets and liabilities:                
Accounts receivable     1,326,856       (3,610,852 )
Loan receivable, related party     (783,293 )     45,179  
Inventory     (4,717,766 )     (337,369 )
Prepaid expense     80,210       (344,414 )
Prepaid expense, related party     44,545        
Income taxes receivable     116,074       226,686  
Accounts payable and accrued liabilities     3,125,110       (791,573 )
Accounts payable, related party     (217,761 )     170,345  
Contract liabilities     (73,139 )     9,250  
Net cash provided by (used in) operating activities     1,312,136       (2,521,575 )
                 
Cash Flows from Investing Activities                
Payments for acquisition of fixed assets           (130,528 )
Net cash used in investing activities           (130,528 )
                 
Cash Flows from Financing Activities                
Advances from related party           70,490  
Repayments of advances to related party           (70,490 )
Proceeds from notes payable, related party           2,500,000  
Proceeds from short term debt     500,000        
Repayment of short term debt     (118,123 )      
Repayment of notes payable, related party     (2,000,000 )     (525,000 )
Net cash (used in) provided by financing activities     (1,618,123 )     1,975,000  
                 
Effect of exchange rate on cash, cash equivalents and restricted cash     (293,068 )    

174,191

 
                 
Net decrease in cash, cash equivalents and restricted cash     (599,055 )     (502,912 )
                 
Cash, Cash Equivalents and restricted cash, beginning of year     1,665,453       1,324,514  
                 
Cash, Cash Equivalents and restricted cash, end of period   $ 1,066,398     $ 821,602  
                 
Supplemental Disclosure of Cash Flow Information:                
Cash paid during the period for:                
Interest   $

873,564

    $ 466,245  
Income taxes   $     $  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

F-5

 

 

 

Synergy CHC Corp.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1 – Nature of the Business

 

Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.”

 

The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisition.

 

Effective January 1, 2019 the Company has merged the U.S. Subsidiaries (Neuragen Corp., Breakthrough Products Inc., Sneaky Vaunt Corp., and The Queen Pegasus Corp.) into the parent company.

 

Synergy is the sole owner of two subsidiaries: NomadChoice Pty Ltd. and Synergy CHC Inc. and the results have been consolidated in these statements.

 

Note 2 – Summary of Significant Accounting Policies

 

General

 

The accompanying condensed consolidated financial statements as of June 30, 2021 and December 31, 2020 and for the six months ended June 30, 2021 and 2020 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2020 and footnotes thereto.

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

F-6

 

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates are assumptions about collection of accounts receivable, current income taxes, deferred income taxes valuation allowance, useful life of fixed and intangible assets, and assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary.

 

Reclassification

 

Certain amounts in prior periods have been reclassified to conform to current period presentation. These reclassifications had no effect on the previously reported net loss.

 

Cash and Cash Equivalents

 

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of June 30, 2021, the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2021, the uninsured balance amounted to $722,362.

 

Restricted Cash

 

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows.

 

    June 30, 2021    

December 31, 2020

    June 30, 2020  
                   
Cash and cash equivalents   $ 966,398     $ 1,565,453     $ 721,602  
Restricted cash     100,000       100,000       100,000  
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows   $ 1,066,398     $ 1,665,453     $ 821,602  

 

Amounts included in restricted cash represent amounts held for credit card collateral.

 

Capitalization of Fixed Assets

 

The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) ASC 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

 

F-7

 

 

The Company recognizes revenue upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. The Company recognizes revenue for its digital products in the month the download by the customer occurs.

 

Contract Assets

 

The Company does not have any contract assets such as work-in-process. All trade receivables on the Company’s condensed consolidated balance sheet are from contracts with customers.

 

Contract Costs

 

Costs incurred to obtain a contract are capitalized unless short term in nature. As a practical expedient, costs to obtain a contract that are short term in nature are expensed as incurred. The Company does not have any contract costs capitalized as of June 30, 2021 or December 31, 2020.

 

Contract Liabilities

 

The Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized.

 

    June 30, 2021    

December 31, 2020

 
             
Beginning balance   $ 121,803     $ 7,887  
Additions     48,664       121,803  
Recognized as revenue     (121,803 )     (7,887 )
Ending balance   $ 48,664     $ 121,803  

 

Accounts receivable

 

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of both June 30, 2021 and December 31, 2020 the allowance for doubtful accounts was $46,204.

 

Advertising Expense

 

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling expense in the accompanying unaudited condensed consolidated statements of income.

 

Research and Development

 

Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred.

 

Income Taxes

 

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

F-8

 

 

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

 

NomadChoice Pty Ltd, the Company’s wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Synergy CHC Inc. is a wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Net Earnings (Loss) Per Common Share

 

The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted earnings per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net loss per share is anti-dilutive. As of June 30, 2021, and 2020, options to purchase 3,466,667 and 4,666,667 shares of common stock, respectively, were outstanding.

 

The following is a reconciliation of the number of shares used in the calculation of basic earnings per share and diluted earnings per share for the six months ended June 30, 2021 and 2020:

 

    For the six months ended  
    June 30, 2021     June 30, 2020  
             
Net income after tax   $ 2,640,429     $ 1,101,350  
                 
Weighted average common shares outstanding     89,889,074       89,889,074  
Incremental shares from the assumed exercise of dilutive stock options     -       -  
Dilutive potential common shares     89,889,074       89,889,074  
                 
Net earnings per share:                
Basic   $ 0.03     $ 0.01  
Diluted   $ 0.03     $ 0.01  

 

The following securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive:

 

    2021     2020  
Options to purchase common stock     3,466,667       4,666,667  

 

F-9

 

 

Fair Value Measurements

 

The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure.

 

ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value:

 

Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

 

Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level 3 - Unobservable inputs for the asset or liability.

 

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

As of June 30, 2021, the Company has determined that there were no assets or liabilities measured at fair value.

 

Inventory

 

Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value. Finished goods include the cost of labor to assemble the items.

 

Stock-Based Compensation

 

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

Foreign Currency Translation

 

The functional currency of one of the Company’s foreign subsidiaries (Nomadchoice Pty Ltd.) is the U.S. Dollar. The Company’s foreign subsidiary maintains its records using local currency (Australian Dollar). All monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at quarter end exchange rates, non-monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments were recorded in statements of income as Remeasurement gain or loss on translation of foreign subsidiary.

 

F-10

 

 

The functional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income.

 

The exchange rates used to translate amounts in AUD and CAD into USD for the purposes of preparing the consolidated financial statements were as follows:

 

Balance sheet:

 

    June 30, 2021     December 31, 2020  
Period-end AUD: USD exchange rate   $ 0.7495     $ 0.7708  
Period-end CAD: USD exchange rate   $ 0.8068     $ 0.7854  

 

Income statement:

 

    June 30, 2021     June 30, 2020  
Average Quarterly AUD: USD exchange rate   $ 0.7712     $ 0.6572  
Average Quarterly CAD: USD exchange rate   $ 0.8022     $ 0.7331  

 

Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred.

 

Concentrations of Credit Risk

 

In the normal course of business, the Company provides credit terms to its customers; however, collateral is not required. Accordingly, the Company performs credit evaluations of its customers and maintains allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk exists on outstanding accounts receivable for a select number of customers due to individual buying patterns.

 

Warehousing costs

 

Warehouse costs include all third party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales.

 

Product display costs

 

All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred.

 

Cost of Sales

 

Cost of sales includes the purchase cost of products sold and all costs associated with getting the products into the retail stores including buying and transportation costs.

 

Debt Issuance Costs

 

Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs are netted off with the related loan and are being amortized to interest expense over the term of the related debt facilities.

 

F-11

 

 

Gain (Loss) on Modification/Extinguishment of Debt

 

In accordance with ASC 470, a modification or an exchange of debt instruments that adds or eliminates a conversion option that was substantive at the date of the modification or exchange is considered a substantive change and is measured and accounted for as extinguishment of the original instrument along with the recognition of a gain or loss. Additionally, under ASC 470, a substantive modification of a debt instrument is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. A substantive modification is accounted for as an extinguishment of the original instrument along with the recognition of a gain or loss.

 

Shipping Costs

 

Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses.

 

Related parties

 

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

 

Segment Reporting

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

 

Presentation of Financial Statements – Going Concern

 

Going Concern Evaluation

 

In connection with preparing unaudited condensed consolidated financial statements for the six months ended June 30, 2021, management evaluated whether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company’s ability to continue as a going concern within one year from the date that the financial statements are issued.

 

The Company considered the following:

 

  At June 30, 2021, the Company had an accumulated deficit of $20,183,008.
  During 2021, the Company extended the due date of its outstanding loans of $5,500,000 to December 31, 2021.

 

Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.

 

F-12

 

 

The Company evaluated its ability to meet its obligations as they become due within one year from the date that the financial statements are issued by considering the following:

 

  The Company received $500,000 through a working capital loan.
  During the six months ended June 30, 2021, the Company repaid $2,000,000 of loans.
  The Company generated net income of $2,640,429 for the six months ended June 30, 2021.
  At June 30, 2021, the Company had working capital surplus of $203,939, which includes loans receivable from related party of $3,089,249, prepaid expenses to related party of $448,196 offset by loans payable to related party of $5,524,450 and contract liabilities of $48,664.
  Revenue increase in 2021 as compared to 2020 of $6,855,207.
  During the six months ended June 30, 2021, the Company’s operating activities provided cash of $1,312,136.
  The Company has a line of credit facility of $20 million available from its current lender for future mergers and acquisitions.
  The Company may sell its common stock to raise additional capital. The offering price would be determined between the Company and the underwriters based on market conditions at the time of the offering.

 

Management concluded that above factors alleviates doubts about the Company’s ability to generate enough cash from operations and other available sources to satisfy its obligations for the next twelve months from the issuance date.

 

The Company will take the following actions if it starts to trend unfavorably to its internal profitability and cash flow projections, in order to mitigate conditions or events that would raise substantial doubt about its ability to continue as a going concern:

 

  Raise additional capital through line of credit and/or loans financing for future mergers and acquisition, which may be impacted by the recent outbreak of COVID-19.
  Implement additional restructuring and cost reductions.
  Raise additional capital through a private placement, which may be impacted by the recent outbreak of COVID-19.

 

As of September 14, 2021 and June 30, 2021, the Company had $796,985 and $1,066,398, respectively, in cash and cash equivalents.

 

Impact of COVID-19

 

The outbreak of COVID-19, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. A pandemic, including COVID-19, or other public health epidemic poses the risk that the Company or its employees, suppliers, and other partners may be prevented from conducting business activities at full capacity for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact that COVID-19 could have on the Company’s business, the continued spread of COVID-19 and the measures taken by the governments of countries affected and in which the Company operates could disrupt the operation of the Company’s business. The COVID-19 outbreak and mitigation measures may also have an adverse impact on global economic conditions, which could have an adverse effect on the Company’s business and financial condition, including on its potential to conduct financings on terms acceptable to the Company, if at all. In addition, the Company may take temporary precautionary measures intended to help minimize the risk of the virus to its employees, including temporarily requiring all employees to work remotely, and discouraging employee attendance at in-person work-related meetings, which could negatively affect the Company’s business. The extent to which the COVID-19 outbreak impacts the Company’s results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 did not have a material effect on the Consolidated Statements of Operations or the Consolidated Balance Sheets included in this prospectus.

 

The CARES Act includes, among other things, provisions relating to payroll tax credits and deferrals, net operating loss carryback periods, alternative minimum tax credits and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established a Paycheck Protection Program (“PPP”), whereby certain small business are eligible for a loan to fund payroll expenses, rent and related costs. We had received funding under the PPP, and all of that as indicated in our Consolidated Statement of Operations has been forgiven. Our subsidiary, Nomad Choice Pty Ltd received the cash flow boost from the Australian Government due to the global pandemic. This assistance was received from March 2020 through to September 2020 (refer to Note 10).

 

F-13

 

 

Recent Accounting Pronouncements

 

ASU 2019-12

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which provides guidance in certain areas of accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements and related disclosures. The adoption of the new standard did not have any impact on the Company’s consolidated financial statements.

 

ASU 2016-13

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendment to the initial guidance: ASU 2018-19 (collectively, Topic 326). ASU 2016-13 amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The adoption of the new standard is not expected to have any impact on the Company’s consolidated financial statements.

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

 

Note 3 – Inventory

 

Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value.

 

The carrying value of inventory consisted of the following:

 

    June 30, 2021     December 31, 2020  
Finished goods   $ 7,621,780     $ 3,205,557  
Components     88,666       63,910  
Inventory in transit     355,641       171,861  
Raw materials     118,125       25,118  
Total inventory   $ 8,184,212     $ 3,466,446  

 

On January 22, 2015, inventory was pledged to Knight Therapeutics under the Loan Agreement (see note 10). As of June 30, 2021 and December 31, 2020, $355,641 and $171,861, respectively, of the Company’s inventory was in transit. During the year ended December 31, 2020 $527,737 of expiring and slow-moving inventory was written off to cost of sales.

 

Note 4 – Accounts Receivable

 

Accounts receivable, net of allowances for sales returns and doubtful accounts, consisted of the following:

 

    June 30, 2021     December 31, 2020  
Trade accounts receivable   $ 2,099,434     $ 3,426,290  
Less allowances     (46,204 )     (46,204 )
Total accounts receivable, net   $ 2,053,230     $ 3,380,086  

 

During the year ended December 31, 2020, the Company charged $74,068 to bad debt expense and created an allowance for doubtful accounts. During the year ended December 31, 2020, the Company wrote-off accounts receivable of $74,068. During 2020, the Company has reduced the allowance for doubtful accounts by $237,768 relating to allowance for doubtful accounts created in 2019.

 

F-14

 

 

Note 5 – Prepaid Expenses

 

Prepaid expenses consisted of the following:

 

    June 30, 2021     December 31, 2020  
Advances for inventory   $ 363,389     $ 362,310  
Media     67,647       46,749  
Insurance     8,234       22,951  
Deposits     16,397       12,099  
Rent, related party     23,196       67,741  
Promotion - Bloggers     66,970       113,887  
License agreement     89,444       51,111  
Software subscriptions     22,149       -  
Components     9,156       73,305  
Prepaid bonus, related party     425,000       425,000  
Miscellaneous     20,893       62,077  
Total   $ 1,112,475     $ 1,237,230  

 

Note 6 – Concentration of Credit Risk

 

Cash and cash equivalents

 

The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At June 30, 2021 and December 31, 2020, the uninsured balances amounted to $722,362 and $1,386,413, respectively.

 

Accounts receivable

 

As of June 30, 2021, three customers accounted for 77% of the Company’s accounts receivable. As of December 31, 2020, four customers accounted for 86% of the Company’s accounts receivable.

 

Major customers

 

For the six months ended June 30, 2021, three customers accounted for approximately 67% of the Company’s net revenue. For the six months ended June 30, 2020, four customers accounted for approximately 58% of the Company’s net revenue. For the year ended December 31, 2020, two customers accounted for approximately 47% of the Company’s net revenue. Substantially all of the Company’s business is with companies in North America.

 

Accounts payable

 

As of June 30, 2021 and December 31, 2020, two vendors accounted for 64% and 59%, respectively, of the Company’s accounts payable.

 

Major suppliers

 

For the six months ended June 30, 2021, two suppliers accounted for approximately 42% of the Company’s purchases. For the six months ended June 30, 2020, two suppliers accounted for approximately 49% of the Company’s purchases. For the year ended December 31, 2020, three suppliers accounted for approximately 46% of the Company’s purchases. Substantially all of the Company’s business is with suppliers in the United States.

 

F-15

 

 

Note 8 – Related Party Transactions

 

The Company accrued and paid consulting fees of $125,000 for five months to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company expensed $862,296 during the six months ended June 30, 2021. The Company also paid six months of a vehicle allowance of $2,500 per month. As of June 30, 2021, the total outstanding balance was $32,500 for consulting fees and reimbursements.

 

On June 26, 2015, the Company entered into a Security Agreement with Knight Therapeutics, Inc., (owner of greater than 10% shares of the Company) through its wholly owned subsidiary Neuragen Corp., for the purchase of Knight Therapeutics, Inc.’s assets. At both June 30, 2021 and December 31, 2020, the Company owed Knight $425,000 in relation to this agreement. The Company recorded present value of future payments of $264,358 as of June 30, 2021 (see Note 10).

 

On August 18, 2015, the Company entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related service. The Company pays Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. The Company has extended this agreement on a month to month basis. Hand MD, LLC is a 50% owner in Hand MD Corp. The Company expensed $60,000 through payroll for the six months ended June 30, 2021. As of June 30, 2021, the total outstanding balance was $0.

 

The Company has entered into transactions with a related party controlled by the CEO. The transactions were a pass through and allocation of expenses and reimbursements. As of June 30, 2021 and December 31, 2020 the Company was owed $3,089,249 and $2,305,956, respectively.

 

On August 9, 2017, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party (owner of greater than 10% shares of the Company), for a working capital loan. At June 30, 2021 and December 31, 2020, the Company owed Knight $5,000,000 on this loan. During the year ended December 31, 2020 a loan success fee of $1,000,000 was earned by Knight and recorded as a long-term liability, payable in August 2022.

 

On May 8, 2020, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for working capital loan. At June 30, 2021 and December 31, 2020, the Company owed Knight $500,000 and $2,500,000, respectively, on this loan (see Note 10).

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics for the distribution rights of FOCUSfactor in Canada. In conjunction with this agreement, we are required to pay Knight a distribution fee equal to 30% of gross sales for sales achieved through a direct sales channel and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $100,000 Canadian dollars and is calculated and accrued for annually. During the year ended December 31, 2020, the Company expensed was $178,341 Canadian dollars (US Dollars $133,094). As of both June 30, 2021 and December 31, 2020, the outstanding balance was $178,341 Canadian dollars. In US Dollars, the total outstanding balance was $140,069 as of December 31, 2020. In US Dollars the total outstanding balance was $143,885 as of June 30, 2021.

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics for the distribution rights of Hand MD into Canada. In conjunction with this agreement, we are required to pay Knight a distribution fee equal to 60% of gross sales for sales achieved through a direct sales channel until the sales in the calendar year equal the threshold amount and then 40% of all such gross sales in such calendar year in excess of the threshold amount and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $25,000 Canadian dollars and is calculated and accrued for annually. During the year ended December 31, 2020, the Company expensed was $385,689 Canadian dollars (US Dollars $287,836). As of both June 30, 2021 and December 31, 2020, the total outstanding balance was $110,637 Canadian dollars. In US Dollars, the total outstanding balance was $86,894 as of December 31, 2020. In US Dollars, the total outstanding balance was $89,263 as of June 30, 2021.

 

The Company expensed royalty of $84,465 during the six months ended June 30, 2021. At June 30, 2021, the Company, owed Knight Therapeutics $25,576 in connection with a royalty distribution agreement.

 

The Company expensed royalty of $1,184 during the six months ended June 30, 2021. At June 30, 2021 the Company owed Knight Therapeutics $1,079 in connection with a royalty distribution agreement for Sneaky Vaunt.

 

F-16

 

 

The Company expensed and paid $631 during the six months ended June 30, 2021 to Hand MD, Corp, related to a royalty agreement. At June 30, 2021, the Company owed Hand MD Corp. $0 in minimum future royalties.

 

The Company entered into transactions with a related party controlled by the CEO during the six months ended June 30, 2020. The transactions were a pass through of expenses and reimbursements. During the six months ended June 30, 2020, the Company received advances of $70,490 ($100,000 Canadian Dollars), which was fully repaid. As of June 30, 2020, there was $0 due or payable.

 

The Company entered into transactions with a related party controlled by the CEO during the six months ended June 30, 2021 and 2020. The transactions are related to rent expense of $25,000 Canadian Dollars per month. During the six months ended June 30, 2021, the Company expensed $150,000 Canadian Dollars ($120,329 US Dollars) for rent expense. During the six months ended June 30, 2020, the Company expensed $75,000 Canadian Dollars ($54,984 US Dollars) for rent expense. As of June 30, 2021, the Company has advanced $28,750 Canadian Dollars ($23,196 US Dollars) for prepaid rent. As of December 31, 2020, the Company has advanced $86,250 Canadian Dollars ($67,741 US Dollars) for prepaid rent relating to 2021.

 

Note 9 – Accounts Payable and Accrued Liabilities

 

As of June 30, 2021, and December 31, 2020, accounts payable and accrued liabilities consisted of the following:

 

    June 30, 2021     December 31, 2020  
Accrued payroll   $ 232,144     $ 180,374  
Legal/Professional fees     11,616       17,924  
Commissions     881,681       516,491  
Manufacturers     5,933,732       3,149,773  
Promotions     639,669       1,292,262  
Accounting Fees     9,121       2,926  
Interest, related party           271,528  
Management fee, related party     32,500        
Customers     80,168       144,142  
Royalties, related party     259,803       238,536  
Warehousing     63,061       64,140  
Sales taxes     738,271       899,852  
Payroll taxes     25,669       31,703  
Severance Accrual     270,333       270,333  
Inventory     512,476        
Others     60,357       21,716  
Total   $ 9,750,601     $ 7,101,700  

 

The Company has not filed its State & Local Income/Franchise tax returns in States it is required to file. The Company has estimated and accrued for its sales tax liability at $140,519 and $197,483 for the parent entity as of June 30, 2021 and December 31, 2020, respectively.

 

Note 10 – Notes Payable

 

The Company’s loans payable at June 30, 2021 and December 31, 2020 are as follows:

 

    June 30, 2021     December 31, 2020  
             
Loans payable   $ 7,211,235     $ 8,746,916  
Unamortized debt issuance cost and original issuance discount     (53,123 )      
Total     7,158,112       8,746,916  
Less: Current portion, related party     (5,524,450 )     (7,515,693 )
Less: Current portion, other     (393,754 )      
Long-term portion, related party   $ 1,239,908     $ 1,231,223  

 

F-17

 

 

$950,000 June 26, 2015 Security Agreement:

 

On June 26, 2015, the Company issued a 0% promissory note in a principal amount of $950,000 in connection with an Asset Purchase Agreement. The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ended September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million.

 

The Company recorded present value of future payments of $264,358 and $246,916 as of June 30, 2021 and December 31, 2020, respectively. At June 30, 2021 and December 31, 2020, the Company owed Knight $425,000 in relation to this agreement. The Company recorded imputed interest expense of $17,442 and $9,298 for the six months ended June 30, 2021 and 2020, respectively.

 

$10,000,000 August 9, 2017 Loan:

 

On August 9, 2017, we entered into a Second Amendment to Loan Agreement (“Second Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $10 million, and an ongoing credit facility of up to $20 million, and which amount was borrowed at closing (the “Financing”) for working capital purposes. At closing, we paid Knight an origination fee of $200,000 and a work fee of $100,000 and also paid $100,000 of Knight’s expenses associated with the Loan.

 

Additional Tranches under the Loan Agreement are available to the Company until August 9, 2022 provided that no event of default exists. Each Additional Tranche must be for a minimum amount of $1.0 million, may only be used to finance qualified acquisitions (as defined in the Loan Agreement), and can be denied in Knight’s absolute discretion. If an Additional Tranche is denied, the Company can effect a qualified acquisition through a special purpose entity with such special purpose entity being entitled to obtain financing from third parties so long as such financing does not adversely affect Knight or Knight’s rights under the Loan Agreement. Upon the closing of any Additional Tranche, the Company will pay Knight an origination fee equal to 2% of the Additional Tranche, a work fee equal to 1% of the amount of the Additional Tranche, and reimburse Knight for its expenses incurred in connection with its consideration of any Additional Tranche (whether or not advanced).

 

The Loan bears interest at 10.5% per annum. The amended Loan Agreement matures on August 8, 2020 and (b) the date that Knight, in its discretion, accelerates the Company’s obligations due to an event of default.

 

On the Maturity Date of the Third Tranche and every Additional Tranche (or upon the acceleration of each such loan), the Company must pay Knight a success fee (the “Success Fee”) of that number of Company common shares equal to 10% of the loan, divided by the lesser of (a) $1.50, (b) the lowest price at which any common shares were issued by the Company in any offering or equity financing or other transaction between the Closing Date and the date the Success Fee is due, and (c) the current market price on the date the Success Fee is due. The Company may also pay the Success Fee in cash pursuant to the terms of the Loan Agreement.

 

The Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to the Company’s business, and provided that the aggregate consideration to be paid does not exceed $100,000 and the acquired business guarantees the Company’s obligations under the Loan Agreement) or make capital expenditures in excess of $500,000. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect defaults. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of all loans under the Loan Agreement will bear a default interest rate of an additional 5%.

 

The Company’s obligations and liabilities under the Loan Agreement are secured and unconditionally guaranteed by certain of the Company’s wholly owned subsidiaries as provided in the Loan Agreement.

 

F-18

 

 

We have met all the covenants except for the TTM EBITDA of $5 million during the period ending March 31, 2018. Default Interest rate of 5% (from 10.5% to 15.5%) applies in accordance to our current agreement and will be in effect starting April 1, 2018 and will be in effect until the $5 million TTM EBITDA covenant is achieved. We entered into Loan Amendment Agreement on May 14, 2018, the interest rate was reduced to 13% due to reducing payroll expenses. Also, Synergy will maintain Focus Factor Net Sales as measured on a year-end basis of at least USD $15 million for each fiscal year starting with December 31, 2017.

 

We have amended our covenants under our loan agreement on March 27, 2019. The new covenants are as follows: we will maintain a minimum EBITDA of $1,900,000 for the twelve months ending on December 31, 2018, $2,500,000 for the twelve months ending March 31, 2019, $3,500,000 for the twelve months ending June 30, 2019 and $5,000,000 for the twelve months period ending on last day of each fiscal quarters thereafter. We shall maintain a net debt to TTM EBITDA ratio of no more than 8:1 for the twelve month period ending on December 31, 2018 until March 31, 2019 and shall maintain a net debt to TTM EBITDA ratio of no more than 6:1 thereafter. We shall maintain at all times a positive cash balance of $575,000 for the three month period ending December 31, 2018, $750,000 for the three month period ending March 31, 2019 and $1,000,000 thereafter. The default interest rate of 2.5% applies (from 13% to 15.5%) in accordance to our current agreement and will be in effect as of October 1, 2018 to June 30, 2019. Effective June 30, 2019 the interest rate reverted back to 10.5%.

 

The Company also recorded deferred financing costs of $452,869 with respect to the above loan. The Company recognized amortization of deferred financing costs of $0 and $42,141 during the six months ended June 30, 2021 and 2020, respectively. Unamortized debt issuance cost as of both June 30, 2021 and December 31, 2020 amounted to $0.

 

On May 8, 2020, the Company entered into a Third Amendment Agreement (the “Third Amendment”) to the Amended and Restated Loan Agreement (the “Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan the Company an additional $2.5 million (the “Additional Loan”). That same day (the “Closing”), the Company paid Knight a work fee of $36,000, and $25,000 for Knight’s legal costs and expenses incurred in connection with the Third Amendment. The Third Amendment amends the original loan agreement that the Company and Knight entered into in January 2015 and subsequently amended (as amended, the “Original Loan Agreement”). The Additional Loan matures on May 8, 2021 (the “TA Maturity Date”) and bears interest at 12.5% per annum compounding quarterly. On the TA Maturity Date, the Company will pay Knight a success fee (the “Success Fee”) of $83,250. The Success Fee is payable in cash or stock as set forth in the Loan Agreement. The Third Amendment includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, including an undertaking to maintain at all times a cash balance of $600,000 and EBITDA of $3,000,000 for the twelve months ended June 30, 2020 and $4,000,000 for the twelve month period ending on the last day of each fiscal quarter thereafter.

 

Terms of the $10,000,000 August 9, 2017 loan (Third Tranche) (see note 10) were modified in the Third amendment. Third tranche shall bear interest from May 8, 2020 at a rate equal to 12.5% per annum compounded quarterly. The Company shall pay success fee in the amount of $1,000,000 with respect to the Third Tranche, which shall be fully earned on May 8, 2020 and payable no later than August 31, 2022. Third Tranche success fee shall bear interest at 12.5% per annum compounding quarterly. The loan has been extended to a maturity date of December 31, 2021. Because these amendments were considered not substantive changes, the Company accounted for the modifications as modification of debt.

 

The Company recognized interest expense of $500,868 and $466,246 during the six months ended June 30, 2021 and 2020, respectively. Accrued interest was $0 and $271,528 as of June 30, 2021 and December 31, 2020, respectively. The loan balances, including success fee, at June 30, 2021 and December 31 2020 were $6,500,000 and $8,500,000, respectively.

 

F-19

 

 

The PPP Loan and Financial Assistance:

 

In June 2020, the American Institute of Certified Public Accountants in conjunction with the Financial Accounting Standards Board developed Technical Question and Answer (“TQA”) 3200.18, “Borrower Accounting for a Forgivable Loan Received Under the Small Business Administration Paycheck Protection Program”, which is intended to provide clarification on how to account for loans received from the PPP. TQA 3200.18 states that an entity may account for PPP loans under ASC 470, “Debt” or, if the entity is expected to meet PPP eligibility criteria and the PPP loan is expected to be forgiven, the entity may account for the loans under IAS 20, “Accounting for Government Grants and Disclosure of Government Assistance”. The Company has elected to account for PPP loan proceeds under IAS 20 as allowed by TQA 3200.18.

 

The CARES Act includes, among other things, provisions relating to payroll tax credits and deferrals, net operating loss carryback periods, alternative minimum tax credits and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established a Paycheck Protection Program (“PPP”), whereby certain small business are eligible for a loan to fund payroll expenses, rent and related costs. We had received funding under the PPP of $163,542 and bears interest at 1% per annum, with monthly installments commencing on May 5, 2020 for 60 months through its maturity on May 5, 2025. The Company used all proceeds from the PPP Loan to maintain payroll and other allowable expenses. As a result, management believes that the Company has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven in its entirety. As such, in accordance with International Accounting Standards (“IAS”) 20, “Accounting for Government Grants and Disclosure of Government Assistance,” the Company has recognized the entire PPP Loan amount of $163,542 as other income, which is included in other non-operating income (expense) in the consolidated statement of income for the six months ended June 30, 2020. Our subsidiary, Nomad Choice Pty Ltd received the cash flow boost from the Australian Government due to the global pandemic. This assistance was received from March 2020 through to June 2020 of $18,307 which is included in other non-operating income (expense) in the consolidated statement of income for the six months ending June 30, 2020.

 

$565,000 May 16, 2021 Loan:

 

On May 16, 2021, the Company entered into a loan agreement of $565,000 with Shopify Capital Inc. for an advancement of working capital from its online processing account. The Company received $500,000 from Shopify Capital Inc. and $65,000 was an original issue discount. The loan bears a repayment rate of 14% of daily sales and the Company shall pay $94,167 every 60 days with a final payment due on May 12, 2022.

 

The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security Agreement, which will be released upon receipt of total payments of $565,000.

 

The Company recognized amortization original issue discount of $11,877, which is included in interest expense in the statement of income during the six months ended June 30, 2021. The outstanding loan balance at June 30, 2021 was $393,754.

 

Note 11 – Stockholders’ Equity

 

The total number of shares of all classes of capital stock which the Company is authorized to issue is 300,000,000 shares of common stock with $0.00001 par value.

 

As of both June 30, 2021 and December 31, 2020, there were 89,889,074 shares of the Company’s common stock issued and outstanding.

 

Note 12 – Commitments & Contingencies

 

Litigation:

 

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

 

F-20

 

 

Note 13 – Stock Options

 

The following table summarizes the options outstanding, option exercisability and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at June 30, 2021:

 

      Options Outstanding   Options Exercisable
Exercise
Prices ($)
    Number
Outstanding
  Weighted
Average
Remaining
Contractual
Life
(Years)
    Weighted
Average
Exercise
Price ($)
    Number
Exercisable
  Weighted
Average
Exercise
Price ($)
 
 $ 0.25 – 0.70     3,466,667     3.96     $ 0.54     3,446,667   $ 0.54  

 

The stock option activity for the six months ended June 30, 2021 is as follows:

 

    Options
Outstanding
    Weighted Average
Exercise Price
 
Outstanding at December 31, 2020     3,466,667     $ 0.54  
Granted     -       -  
Exercised     -       -  
Expired or canceled     -       -  
Outstanding at June 30, 2021     3,466,667     $ 0.54  

 

Stock-based compensation expense related to vested options was $0 and $77,358 during the six months ended June 30, 2021 and 2020, respectively, which is a component of general and administrative expense in the statement of operations. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2017 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.48-0.50, risk-free interest rate of 1.95-1.99%, volatility of 116-117%, expected lives of 10 years, and dividend yield of 0%. Stock options outstanding as of June 30, 2021, as disclosed in the above table, have an intrinsic value of $0. As of June 30, 2021, unamortized stock-based compensation costs related to options was $0.

 

Note 14 – Segments

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregate basis.

 

Net sales attributed to customers in the United States and foreign countries for the six months ended June 30, 2021 and 2020 were as follows:

 

    June 30, 2021     June 30, 2020  
United States   $ 23,928,636     $ 12,737,461  
Foreign countries     833,338       5,169,306  
    $ 24,761,974     $ 17,906,767  

 

Foreign countries primarily consist of sales in Canada.

 

F-21

 

 

The Company’s net sales by product group for the six months ended June 30, 2021 and 2020 were as follows:

 

    June 30, 2021     June 30, 2020  
Nutraceuticals   $ 24,549,101     $ 12,361,201  
Over the Counter (OTC)     -       22,311  
Consumer Goods     168,047       565,756  
Cosmeceuticals     44,826       4,957,499  
    $ 24,761,974     $ 17,906,767  

 

(1) Net sales for any other product group of similar products are less than 10% of consolidated net sales.

 

The Company’s net sales by major sales channel for the six months ended June 30, 2021 and 2020 were as follows:

 

      June 30, 2021     June 30, 2020  
Online     $ 10,163,673     $ 6,538,289  
Retail       14,598,301       11,368,478  
      $ 24,761,974     $ 17,906,767  

 

Note 15 – Income Taxes

 

Income tax expense was $104,537 for the six months ended June 30, 2021, compared to $128,996 for the same period in 2020. The current provision is attributable to Australian operations and the current tax rate in effect in that country.

 

The total deferred tax asset is calculated by multiplying a domestic federal (US) 21% marginal tax rate by the cumulative net operating loss carryforwards (“NOL”). The domestic marginal tax rate does not include any state & local marginal tax rate attributable to the Company. The Company currently has estimated NOLs, which expire through 2035. Management has determined based on all the available information that a 100% valuation reserve is required.

 

For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOLs would be limited or eliminated, as to the amount that could be utilized each year, based on the Code. NOLs attributable to Breakthrough Products, Inc., which are the majority of the Company’s domestic NOLs are Separate Return Limitation Year (SRLY) NOLs. Such losses may generally not be available for use (limited or eliminated).

 

The Company has not filed its State & Local Income/Franchise tax returns in States it is required to file for the last few years, so such returns and liability remain open. The Company does not expect this to be a significant liability.

 

Note 16 – Subsequent Events

 

Management evaluated all activities of the Company through the issuance date of the Company’s unaudited condensed consolidated financial statements and concluded that except as noted below, no subsequent events have occurred that would require adjustment or disclosure into the unaudited condensed consolidated financial statements.

 

Subsequent to June 30, 2021 the Company has entered into an agreement to acquire the outstanding 50% of Hand MD Corp. whereby Synergy will become the 100% owner. The consideration of $1,700,000 will be disbursed as follows: $500,000 within 10 business days of the execution of the agreement, $400,000 on or before the six month anniversary of the agreement, $400,000 on or before the twelve month anniversary of the agreement and $400,000 on or before the eighteen month anniversary of the agreement. The first payment of $500,000 was made in July 2021.

 

F-22

 

 

Report of Independent Registered Public Accounting Firm

 

To the Board of Directors and Shareholders of

Synergy CHC Corp. and subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Synergy CHC Corp. and subsidiaries (the Company) as of December 31, 2020 and 2019, and the related statements of operations, other comprehensive income (loss), stockholders’ (deficit) equity, and cash flows for each of the years in the two year period ended December 31, 2020, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

 

/s/ RBSM LLP  
We have served as the Company’s auditor since 2014.  
New York, NY  
August 5, 2021  

 

F-23

 

 

Synergy CHC Corp.

Consolidated Balance Sheets

 

    December 31, 2020     December 31, 2019  
Assets                
Current Assets                
Cash and cash equivalents   $ 1,565,453     $ 1,224,514  
Restricted cash     100,000       100,000  
Accounts receivable, net     3,380,086       1,146,354  
Loan receivable (related party)     2,305,956       277,432  
Prepaid expenses (including related party amount of $492,741 and $0, respectively)     1,237,230       186,143  
Income taxes receivable     531,918       251,614  
Inventory, net     3,466,446       1,861,038  
Total Current Assets     12,587,089       5,047,095  
                 
Fixed assets, net     -       135,898  
Intangible assets, net     -       7,636  
                 
Total Assets   $ 12,587,089     $ 5,190,629  
                 
Liabilities and Stockholders’ Deficit                
Current Liabilities:                
Accounts payable and accrued liabilities (including related party payable of $510,064 and $1,051,216, respectively)   $ 7,101,700     $ 4,674,064  
Contract liabilities     121,803       7,887  
Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party     7,515,693       5,465,113  
Total Current Liabilities     14,739,196       10,147,064  
                 
Long-term Liabilities:                
Notes payable, net of debt discount and debt issuance cost, related parties     1,231,223       246,916  
Income taxes payable     300,773        
Total long-term liabilities     1,531,996       246,916  
Total Liabilities     16,271,192       10,393,980  
                 
Commitments and contingencies                
                 
Stockholders’ Deficit:                
Common stock, $0.00001 par value; 300,000,000 shares authorized; 89,889,074 and 89,889,074, shares issued and outstanding, respectively     899       899  
Additional paid in capital     19,147,884       19,018,955  
Accumulated other comprehensive (loss) income     (9,449 )     11,364  
Accumulated deficit     (22,823,437 )     (24,234,569 )
Total stockholders’ deficit     (3,684,103 )     (5,203,351 )
Total Liabilities and Stockholders’ Deficit   $ 12,587,089     $ 5,190,629  

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-24

 

 

Synergy CHC Corp.

Consolidated Statements of Operations and Other Comprehensive Income (Loss)

 

    For the year Ended     For the year ended  
    December 31, 2020     December 31, 2019  
Revenue   $ 40,226,865     $ 29,357,546  
                 
Cost of Sales (including related party purchases of $0 and $4,847,626, respectively)     14,578,865       9,137,602  
                 
Gross Profit     25,648,000       20,219,944  
                 
Operating expenses                
Selling and marketing     15,889,066       11,471,652  
General and administrative     6,499,344       5,493,433  
Reserve for bad debts     74,068       283,971  
Impairment of assets     47,002       9,715,137  
Depreciation and amortization     100,265       1,211,861  
Total operating expenses     22,609,745       28,176,054  
                 
Income (loss) from operations     3,038,255       (7,956,110 )
                 
Other (income) expenses                
Interest income     (104 )     (414 )
Interest expense     1,186,034       981,105  
Remeasurement (gain) loss on translation of foreign subsidiary     (457,955 )     8,280  
Amortization of debt issuance cost     48,432       130,829  
Other income     (210,284 )     -  
Other expenses (loan success fee)     1,000,000       -  
Finance expenses     61,000       -  
                 
Total other expenses     1,627,123       1,119,800  
                 
Net income (loss) before income taxes     1,411,132       (9,075,910 )
Income tax expense           (131,537 )
                 
Net income (loss) after tax   $ 1,411,132     $ (9,207,447 )
                 
Net income (loss) per share – basic and diluted   $ 0.02     $ (0.10 )
                 
Weighted average common shares outstanding                
Basic and Diluted     89,889,044       89,883,194  
Comprehensive income (loss):                
Net income (loss)   $ 1,411,132     $ (9,207,447 )
Foreign currency translation adjustment     (20,813 )     (167,752 )
Comprehensive income (loss)   $ 1,390,319     $ (9,375,199 )

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-25

 

 

Synergy CHC Corp.

Consolidated Statements of Stockholders’ (Deficit) Equity

 

    Common stock     Additional
Paid in
    Accumulated
Other
Comprehensive
    Accumulated     Total
Stockholders’
Equity
 
    Shares     Amount     Capital     Income (Loss)     Deficit     (Deficit)  
Balance as of December 31, 2018     89,862,683     $ 899     $ 18,817,800     $ 179,116     $ (15,027,122 )   $ 3,970,693  
Fair value of vested stock options                     161,570                       161,570  
Common stock issued for Per-fekt settlement     26,391               39,585                       39,585  
Foreign currency translation loss                             (167,752 )             (167,752 )
Net loss                                     (9,207,447 )     (9,207,447 )
Balance as of December 31, 2019     89,889,074     $ 899     $ 19,018,955     $ 11,364     $ (24,234,569 )   $ (5,203,351 )
Fair value of vested stock options                     128,929                       128,929  
Foreign currency translation loss                             (20,813 )             (20,813 )
Net income                                     1,411,132       1,411,132  
Balance as of December 31, 2020     89,889,074     $ 899     $ 19,147,884     $ (9,449 )   $ (22,823,437 )   $ (3,684,103 )

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-26

 

 

Synergy CHC Corp.

Consolidated Statements of Cash Flows

 

    For the year Ended     For the year ended  
    December 31, 2020     December 31, 2019  
Cash Flows from Operating Activities                
Net income (loss)   $ 1,411,132     $ (9,207,447 )
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:                
Amortization of debt issuance cost     48,432       130,829  
Depreciation and amortization     100,265       1,211,860  
Stock based compensation expense     128,929       201,155  
Impairment of intangible assets     47,002       9,715,137  
Foreign currency transaction loss     351,194       (1,308 )
Bad debts     74,068       283,972  
Remeasurement loss on translation of foreign subsidiary     (457,955 )     8,280  
Non cash implied interest     36,455       38,310  
Reversal of allowance for doubtful accounts     (237,768 )     -  
Gain on write-off of payables     (180,000 )     -  
Accrual of loan success fee     1,000,000       -  
Write-off of inventory     527,737       257,111  
Changes in operating assets and liabilities:                
Accounts receivable     (2,070,032 )     3,027,900  
Loan and accounts receivable, related party     (2,028,524 )     (277,432 )
Inventory     (2,133,145 )     552,158  
Prepaid expenses     (558,346 )     642,704  
Prepaid expense, related party     (492,741 )     -  
Income taxes receivable     (280,304 )     135,072  
Income taxes payable     300,773       -  
Contract liabilities     113,916       (41,823 )
Accounts payable and accrued liabilities     3,251,816       (2,910,949 )
Accounts payable, related party     (541,152 )     (819,179 )
Net cash (used in) provided by operating activities     (1,588,248 )     2,946,350  
                 
Cash Flows from Investing Activities                
Net cash used in investing activities     -       -  
                 
Cash Flows from Financing Activities                
Advances from related party     74,629       324,102  
Repayments of advances to related party     (74,629 )     (324,102 )
Proceeds from notes payable     2,500,000       -  
Repayment of notes payable     (550,000 )     (2,050,000 )
Net cash provided by (used in) financing activities     1,950,000       (2,050,000 )
                 
Effect of exchange rate on cash, cash equivalents and restricted cash     (20,813 )     (167,752 )
Net increase in cash, cash equivalents and restricted cash     340,939       728,598  
                 
Cash, Cash Equivalents and restricted cash, beginning of year     1,324,514       595,916  
                 
Cash, Cash Equivalents and restricted cash, end of year   $ 1,665,453     $ 1,324,514  
                 
Supplemental Disclosure of Cash Flow Information:                
Cash paid during the period for:                
Interest   $ 805,048     $ 939,711  
Income taxes   $ -     $ 38,919  
                 
Supplemental Disclosure of Non-cash Investing and Financing Activities:                
Accrual of loan success fee   $ 1,000,000     $ -  

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-27

 

 

SYNERGY CHC CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1 – Nature of the Business

 

Synergy CHC Corp. (“Synergy”, “we”, “us”, “our” or the “Company”) (formerly Synergy Strips Corp.) was incorporated on December 29, 2010 in Nevada under the name “Oro Capital Corporation.” On April 21, 2014, the Company changed its fiscal year end from July 31 to December 31. On April 28, 2014, the Company changed its name to “Synergy Strips Corp.”. On August 5, 2015, the Company changed its name to “Synergy CHC Corp.”

 

The Company is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands. Synergy’s strategy is to grow its portfolio both organically and by further acquisition.

 

Effective January 1, 2019 the Company has merged the U.S. Subsidiaries (Neuragen Corp., Breakthrough Products Inc., Sneaky Vaunt Corp., and The Queen Pegasus Corp.) into the parent company.

 

Synergy is the sole owner of two subsidiaries: NomadChoice Pty Ltd. and Synergy CHC Inc. and the results have been consolidated in these statements.

 

Note 2 – Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

 

All amounts referred to in the notes to the consolidated financial statements are in United States Dollars ($) unless stated otherwise.

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain amounts in prior periods have been reclassified to conform to current period presentation. These reclassifications had no effect on the previously reported net loss.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. At December 31, 2020 and 2019 significant estimates included are assumptions about collection of accounts receivable, current income taxes, deferred income taxes valuation allowance, useful life of fixed and intangible assets, impairment analysis of goodwill and intangible assets, estimates used in the fair value calculation of stock based compensation, assumptions used in Black-Scholes-Merton, or BSM, valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate. The results of any changes in accounting estimates are reflected in the financial statements in the period in which the changes become evident. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary.

 

Cash and Cash Equivalents

 

The Company considers all cash on hand and in banks, including accounts in book overdraft positions, certificates of deposit and other highly-liquid investments with maturities of three months or less, when purchased, to be cash and cash equivalents. As of December 31, 2020, and 2019, the Company had no cash equivalents. The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2020 and 2019, the uninsured balances amounted to $1,386,413 and $947,312, respectively.

 

F-28

 

 

Restricted Cash

 

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows.

 

    December 31, 2020     December 31, 2019  
Cash and cash equivalents   $ 1,565,453     $ 1,224,514  
Restricted cash     100,000       100,000  
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows   $ 1,665,453     $ 1,324,514  

 

Amount included in restricted cash represents the amount held for credit card collateral.

 

Capitalization of Fixed Assets

 

The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one year for: (1) assets purchased; (2) existing assets that are replaced, improved or the useful lives have been extended; or (3) all land, regardless of cost. Acquisitions of new assets, additions, replacements and improvements (other than land) costing less than the minimum rule in addition to maintenance and repair costs, including any planned major maintenance activities, are expensed as incurred.

 

Intangible Assets

 

We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization except intellectual property of $1,450,000 acquired as part of an Asset Purchase Agreement entered into with Factor Nutrition Labs LLC on January 22, 2015, $10,000 acquired as part of an Asset Purchase Agreement entered into with Perfekt Beauty Holdings LLC and CDG Holdings, LLC (“Perfekt”) on June 21, 2017 and $50,000 acquired as an Asset Purchase entered into with Cocowhite on May 22, 2018. Intangible assets are amortized on a straight line basis over the useful lives. During the year ended December 31, 2019, the Company fully impaired intellectual property related to Focus Factor and charged to operations impairment loss of $1,450,000.

 

Long-lived Assets

 

Long-lived assets include equipment and intangible assets other than those with indefinite lives. We assess the carrying value of our long-lived asset groups when indicators of impairment exist and recognize an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset.

 

Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in our use of the assets or in our business strategy, loss of or changes in customer relationships and significant negative industry or economic trends. When indications of impairment arise for a particular asset or group of assets, we assess the future recoverability of the carrying value of the asset (or asset group) based on an undiscounted cash flow analysis. If carrying value exceeds projected, net, undiscounted cash flows, an additional analysis is performed to determine the fair value of the asset (or asset group), typically a discounted cash flow analysis, and an impairment charge is recorded for the excess of carrying value over fair value. During the year ended December 31, 2019, the Company fully impaired intangible assets and charged to operations impairment loss of $471,897.

 

Goodwill

 

An asset purchase is accounted for under the purchase method of accounting. Under that method, assets and liabilities of the business acquired are recorded at their estimated fair values as of the date of the acquisition, with any excess of the cost of the acquisition over the estimated fair value of the net tangible and intangible assets acquired recorded as goodwill. As of December 31, 2019 our qualitative analysis of goodwill indicated potential impairment, thus the Company chose to fully impair goodwill and charged to operations impairment loss of $7,793,240.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification (“ASC”) ASC 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

 

F-29

 

 

The Company recognizes revenue upon shipment from its fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf. In such cases, ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors, passes to such distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished goods. Freight billed to customers is presented as revenues, and the related freight costs are presented as cost of goods sold. Cancelled orders are refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered with specific promotions and orders will be refilled if lost in transit. The Company recognizes revenue for its digital products in the month the download by the customer occurs.

 

Contract Assets

 

The Company does not have any contract assets such as work-in-process. All trade receivables on the Company’s consolidated balance sheet are from contracts with customers.

 

Contract Costs

 

Costs incurred to obtain a contract are capitalized unless short term in nature. As a practical expedient, costs to obtain a contract that are short term in nature are expensed as incurred. The Company does not have any contract costs capitalized as of December 31, 2020 or 2019.

 

Contract Liabilities

 

The Company’s contract liabilities consist of advance customer payments. Contract liability results from transactions in which the Company has been paid for products by customers, but for which all revenue recognition criteria have not yet been met. Once all revenue recognition criteria have been met, the contract liabilities are recognized.

 

    December 31, 2020     December 31, 2019  
             
Beginning balance   $ 7,887     $ 49,709  
Additions     121,803       7,887  
Recognized as revenue     (7,887 )     (49,709 )
Ending balance   $ 121,803     $ 7,887  

 

Accounts receivable

 

Accounts receivable are generally unsecured. The Company establishes an allowance for doubtful accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability. Accounts are written off after all reasonable collection efforts have been exhausted and management concludes that likelihood of collection is remote. Any future recoveries are applied against the allowance for doubtful accounts. As of December 31, 2020 and 2019, allowance for doubtful accounts was $46,204 and $283,971, respectively.

 

Advertising Expense

 

The Company expenses marketing, promotions and advertising costs as incurred. Such costs are included in selling and marketing expense in the accompanying consolidated statements of operations.

 

Research and Development

 

Costs incurred in connection with the development of new products and processing methods are charged to general and administrative expenses as incurred.

 

Income Taxes

 

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

F-30

 

 

The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% has been established due to the uncertainty of the Company’s realization of the net operating loss carry forward prior to its expiration.

 

NomadChoice Pty Ltd, the Company’s wholly-owned subsidiary is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Synergy CHC Inc. is a wholly-owned foreign subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognizes liabilities for anticipated tax audit issues based on the Company’s current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

 

Net Earnings (Loss) Per Common Share

 

The Company computes earnings per share under ASC subtopic 260-10, Earnings Per Share. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during the reporting periods. Diluted earnings per share is computed by increasing the denominator by the weighted average number of additional shares that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless their effect on net income per share is anti-dilutive. As of December 31, 2020, and 2019, options to purchase 3,466,667 and 6,166,667 shares of common stock, respectively, were outstanding.

 

The following is a reconciliation of the number of shares used in the calculation of basic and diluted earnings (loss) per share for the years ending December 31, 2020, and 2019:

 

    For the year ending  
    December 31, 2020     December 31, 2019  
             
Net income (loss) after tax   $ 1,411,132     $ (9,207,447 )
                 
Weighted average common shares outstanding     89,889,044       89,883,194  
Incremental shares from the assumed exercise of dilutive stock options     -       -  
Dilutive potential common shares     89,889,044       89,883,194  
                 
Net earnings (loss) per share:                
Basic   $ 0.02     $ (0.10 )
Diluted   $ 0.02     $ (0.10 )

 

The following securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive:

 

    For the year ending  
    December 31, 2020     December 31, 2019  
                 
Options to purchase common stock     3,466,667       6,166,667  

 

Fair Value Measurements

 

The Company measures and discloses the fair value of assets and liabilities required to be carried at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value, establishes a framework for measuring fair value, and enhances fair value measurement disclosure.

 

F-31

 

 

ASC 825 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes three levels of inputs that may be used to measure fair value:

 

– Level 1 - Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

– Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly.

– Level 3 - Unobservable inputs for the asset or liability.

 

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

As of both December 31, 2020 and 2019, the Company has determined that there were no assets or liabilities measured at fair value.

 

Inventory

 

Inventory consists of raw materials, components and finished goods. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value. Finished goods include the cost of labor to assemble the items.

 

Stock-Based Compensation

 

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

Foreign Currency Translation

 

The functional currency of one of the Company’s foreign subsidiaries (NomadChoice Pty Ltd.) is the U.S. Dollar. The Company’s foreign subsidiary maintains its records using local currency (Australian Dollar – “AUD”). All monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates, non-monetary assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at transaction day exchange rates. Income and expense items related to non-monetary items were translated at exchange rates prevailing during the transaction date and other incomes and expenses were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, were recorded in statements of operations as Remeasurement gain or loss on translation of foreign subsidiary.

 

The functional currency of the Company’s other foreign subsidiary (Synergy CHC Inc.) is the Canadian Dollar (CAD). The Company’s foreign subsidiary maintains its records using local currency (CAD). All assets and liabilities of the foreign subsidiary were translated into U.S. Dollars at period end exchange rates and stockholders’ equity is translated at the historical rates. Income and expense items were translated using average exchange rate for the period. The resulting translation adjustments, net of income taxes, are reported as other comprehensive income and accumulated other comprehensive income in the stockholder’s equity in accordance with ASC 220 – Comprehensive Income.

 

The exchange rates used to translate amounts in AUD and CAD into USD for the purposes of preparing the consolidated financial statements were as follows:

 

Balance sheet:

 

    December 31, 2020     December 31, 2019  
Period-end AUD: USD exchange rate   $ 0.7708     $ 0.7030  
Period-end CAD: USD exchange rate   $ 0.7854     $ 0.7699  

 

F-32

 

 

Income statement:

 

    December 31, 2020     December 31, 2019  
Average Yearly AUD: USD exchange rate   $ 0.6902     $ 0.6954  
Average Yearly CAD: USD exchange rate   $ 0.7463     $ 0.7537  

 

Translation gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are translated into either Australian Dollars or Canadian Dollars, as the case may be, at the rate on the date of the transaction and included in the results of operations as incurred.

 

Concentrations of Credit Risk

 

In the normal course of business, the Company provides credit terms to its customers; however, collateral was not required. Accordingly, the Company performed credit evaluations of its customers and maintained allowances for possible losses which, when realized, were within the range of management’s expectations. From time to time, a higher concentration of credit risk existed on outstanding accounts receivable for a select number of customers due to individual buying patterns.

 

Warehousing costs

 

Warehouse costs include all third party warehouse rent fees and are charged to selling and marketing expenses as incurred. Any additional costs relating to assembly or special pack-outs of the Company’s products are charged to cost of sales.

 

Product display costs

 

All displays manufactured and purchased by the Company are for placement of product in retail stores. This also includes all costs for display execution and setup and retail services are charged to cost of sales and expensed as incurred.

 

Cost of Sales

 

Cost of sales includes the purchase cost of products sold, all costs associated with getting the products into the retail stores including buying and transportation costs and the hosting of our online Application.

 

Debt Issuance Costs

 

Debt issuance costs consist primarily of arrangement fees, professional fees and legal fees. These costs were netted off with the related loan and were being amortized to interest expense over the term of the related debt facilities.

 

Gain (Loss) on Modification/Extinguishment of Debt

 

In accordance with ASC 470, a modification or an exchange of debt instruments that adds or eliminates a conversion option that was substantive at the date of the modification or exchange is considered a substantive change and is measured and accounted for as extinguishment of the original instrument along with the recognition of a gain or loss. Additionally, under ASC 470, a substantive modification of a debt instrument is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. A substantive modification is accounted for as an extinguishment of the original instrument along with the recognition of a gain or loss.

 

Shipping Costs

 

Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in selling and marketing expenses.

 

Related parties

 

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

 

F-33

 

 

Segment Reporting

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregated basis.

 

Presentation of Financial Statements – Going Concern

 

Going Concern Evaluation

 

In connection with preparing consolidated financial statements for the year ended December 31, 2020, management evaluated whether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company’s ability to continue as a going concern within one year from the date that the consolidated financial statements are issued.

 

The Company considered the following:

 

At December 31, 2020, the Company had an accumulated deficit of $22,823,437.
At December 31, 2020, the Company had working capital deficit of $2,152,107.
During 2020, the Company extended the due date of its outstanding loan to December 31, 2020 and subsequently extended it until December 31, 2021.

 

Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.

 

The Company evaluated its ability to meet its obligations as they become due within one year from the date that the financial statements are issued by considering the following:

 

Revenue increased in 2020 by $10,869,319.
The Company had net income of $1,411,132 in 2020 as opposed to a net loss of $9,207,447 in 2019.
The Company raised $2.5 million via debt financing during the year ended December 31, 2020.
In 2020, the Company repaid $0.5 million of loans.
Working capital deficit of $2,152,107 at December 31, 2020, includes loans payables to related party of $7,515,693 and deferred revenue of $121,803.
The Company has line of credit facility of $20 million available from its current lender for future mergers and acquisition.
The Company has the option of selling its common stock to raise additional capital. The offering price will be determined between us and the underwriters based on market conditions at the time of the offering.

 

Management concluded that above factors alleviates doubts about the Company’s ability to generate enough cash from operations and other available sources to satisfy its obligations for the next twelve months from the issuance date.

 

The Company will take the following actions if it starts to trend unfavorably to its internal profitability and cash flow projections, in order to mitigate conditions or events that would raise substantial doubt about its ability to continue as a going concern:

 

Raise additional capital through line of credit and/or loans financing for future mergers and acquisition, which may be impacted by the outbreak of COVID-19.
Implement additional restructuring and cost reductions.
Raise additional capital through a private placement, which may be impacted by the outbreak of COVID-19.

 

At July 27, 2021 and December 31, 2020, the Company had $2,700,863 and $1,665,453, respectively in cash and cash equivalents and restricted cash.

 

Impact of COVID-19

 

The outbreak of COVID-19, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. A pandemic, including COVID-19, or other public health epidemic poses the risk that the Company or its employees, suppliers, and other partners may be prevented from conducting business activities at full capacity for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact that COVID-19 could have on the Company’s business, the continued spread of COVID-19 and the measures taken by the governments of countries affected and in which the Company operates could disrupt the operation of the Company’s business. The COVID-19 outbreak and mitigation measures may also have an adverse impact on global economic conditions, which could have an adverse effect on the Company’s business and financial condition, including on its potential to conduct financings on terms acceptable to the Company, if at all. In addition, the Company may take temporary precautionary measures intended to help minimize the risk of the virus to its employees, including temporarily requiring all employees to work remotely, and discouraging employee attendance at in-person work-related meetings, which could negatively affect the Company’s business. The extent to which the COVID-19 outbreak impacts the Company’s results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 did not have a material effect on the consolidated statements of operations or the consolidated balance sheets included in this prospectus.

 

F-34

 

 

The CARES Act includes, among other things, provisions relating to payroll tax credits and deferrals, net operating loss carryback periods, alternative minimum tax credits and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established a Paycheck Protection Program (“PPP”), whereby certain small business are eligible for a loan to fund payroll expenses, rent and related costs. We had received funding under the PPP, and all of that as indicated in our Consolidated Statement of Operations has been forgiven. Our subsidiary, Nomad Choice Pty Ltd received the cash flow boost from the Australian Government due to the global pandemic. This assistance was received from March 2020 through to September 2020 (refer to Note 12).

 

Recent Accounting Pronouncements

 

ASU 2019-12

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which provides guidance in certain areas of accounting for income taxes. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is in the process of evaluating the impact of this standard on its consolidated financial statements and related disclosures. The adoption of the new standard is not expected to have any impact on the Company’s consolidated financial statements.

 

ASU 2018-13

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes in Disclosure Requirements for Fair Value Measurement, which removes, modifies and adds certain disclosure requirements in Topic 820 “Fair Value Measurement”. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements.

 

ASU 2017-04, Intangibles - Goodwill and other (Topic 350)

 

In January 2017, the FASB issued Accounting Standards Update (“ASU”) 2017-04 Intangibles - Goodwill and other, which simplifies the test for goodwill impairment. This Update eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of the assets acquired and liabilities assumed in a business combination. Instead an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, however the loss recognized should not exceed the total amount of goodwill allocated to the reporting unit. The amendments in this Update are effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements.

 

ASU 2016-15

 

In August 2016, the FASB issued AS 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The effective date for ASU 2016-15 is for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted. Adoption of this new standard did not have any impact on the Company’s consolidated financial statements.

 

ASU 2016-13

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendment to the initial guidance: ASU 2018-19 (collectively, Topic 326). ASU 2016-13 amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The adoption of the new standard is not expected to have any impact on the Company’s consolidated financial statements.

 

F-35

 

 

ASU 2016-02

 

In February 2016, the FASB issued ASU 201602, “Leases” (“ASU 201602”). This guidance, as amended by subsequent ASU’s on the topic, improves transparency and comparability among companies by recognizing right of use (ROU) assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements. ASU No. 2016-02 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, with early adoption permitted. We adopted ASU No. 2016-02 in our fiscal year beginning January 1, 2019 and used the optional transition method provided by the FASB in ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements”, with no restatement of comparative periods. The Company notes there was no impact on adoption as the leases entered into by the Company were for less than 12 month terms.

 

The new standard provides optional practical expedients in transition. We will only elect the package of practical expedients where, under the new standard, prior conclusions about lease identification, lease classification and initial direct costs do not need to be reassessed. The new standard also provides practical expedients for ongoing accounting where we elected the practical expedients on adoption and did not record any ROU asset with terms of less than 12 months.

 

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

 

Note 3 – Income Taxes

 

The Company utilizes FASB ASC 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized.

 

Deferred income taxes arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or noncurrent depending on the periods in which the temporary differences are expected to reverse. The Company does not have any uncertain tax positions.

 

For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOLs would be limited or eliminated, as to the amount that could be utilized each year, based on the Code. NOLs attributable to Breakthrough Products, Inc., which are the majority of the Company’s domestic NOLs are Separate Return Limitation Year (SRLY) NOLs. Such losses may generally not be available for use (limited or eliminated).

 

The Company has not filed its State & Local Income/Franchise tax returns in States it is required to file, as such returns and liability remain open. The Company does not expect this to be a significant liability.

 

The table below summarizes the differences between the U.S. statutory federal rate and the Company’s estimated effective tax rate for the years ended December 31, 2020 and 2019:

 

    December 31, 2020     December 31, 2019  
U.S. Statutory Rate     21 %     (21 )%
Impairment of intangible assets     -       23 %
Amortization of intangible assets     -       3 %
AU/CA rate in excess of U.S. effective rate     22 %     - %
Carryback of Australian tax loss     -       (2 )%
Utilization of U.S. net operating losses     -       (2 )%
Increase in valuation allowance     13 %     -  
Other     16 %     -  
Utilization of Australian and Canadian NOL     (72 )%     -  
Total provision for income taxes     -       1 %

 

F-36

 

 

The Company has deferred tax assets, which have been fully reserved, as follows as of December 31, 2020 and 2019:

 

    December 31, 2020     December 31, 2019  
Net operating Losses   $ 6,404,580     $ 8,275,000  
Accrued severance (from 2019 still unpaid)     56,700       -  
Obsolete inventory     110,880       -  
Nonstatutory stock options     515,319       -  
Success fee     210,000       -  
Other     24,150       -  
True up of prior year nonstatutory stock options     -       916,673  
True up of prior year net operating loss     -       (2,055,690 )
Deferred tax asset     7,321,629       7,135,983  
Valuation allowance for deferred tax assets     (7,321,629 )     (7,135,983 )
Net deferred tax assets   $ -     $ -  

 

Tax expense was $0 and $131,537 for 2020 and 2019, respectively.

 

The Company also has net operating loss carryforwards of approximately $30,000,000 and approximately $33,000,000 (United States and Canada) included in the deferred tax asset table above for 2020 and 2019, respectively, the majority attributable to the acquisition of Breakthrough Products, Inc. However, due to limitations of carryover attributes and separate return limitation year rules, it is unlikely the company will benefit from the NOLs and thus Management has determined a 100% valuation reserved is required. Further, the Company has not completed an evaluation of the NOLs attributable to Breakthrough Products, Inc. at the date of this report.

 

Note 4 – Accounts Receivable

 

Accounts receivable, net of allowances for doubtful accounts, consisted of the following:

 

    December 31, 2020     December 31, 2019  
Trade accounts receivable   $ 3,426,290     $ 1,430,326  
Less allowances     (46,204 )     (283,972 )
Total accounts receivable, net   $ 3,380,086     $ 1,146,354  

 

During the years ended December 31, 2020 and 2019, the Company charged $74,068 and $283,972, respectively, to bad debt expense and created an allowance for doubtful accounts. During the year ended December 31, 2020, the Company wrote-off accounts receivable of $74,068. During 2020, the Company has reduced the allowance for doubtful accounts by $237,768 relating to allowance for doubtful accounts created in 2019.

 

Note 5 – Prepaid Expenses

 

At December 31, 2020 and 2019, prepaid expenses consisted of the following:

 

    December 31, 2020     December 31, 2019  
Advances for inventory   $ 362,310     $ 9,071  
Media     46,749       -  
Insurance     22,951       16,763  
Deposits     12,099       10,234  
Rent, related party     67,741       -  
Promotion - Bloggers     113,887       -  
License agreement     51,111       -  
Software subscriptions     -       9,536  
Components     73,305       -  
Prepaid bonus, related party     425,000       -  
Promotions     -       122,626  
Miscellaneous     62,077       17,913  
Total   $ 1,237,230     $ 186,143  

 

F-37

 

 

Note 6 – Concentration of Credit Risk

 

Cash and cash equivalents

 

The Company maintains its cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (FDIC) in accounts that at times may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with major financial institutions. At December 31, 2020 and 2019, the uninsured balance amounted to $1,386,413 and $947,312, respectively.

 

Accounts receivable

 

As of December 31, 2020 and 2019, four and two customers accounted for 86% and 52%, respectively, of the Company’s accounts receivable.

 

Major customers

 

For the year ended December 31, 2020, two customers accounted for approximately 47% of the Company’s net revenue. For the year ended December 31, 2019, two customers accounted for approximately 51% of the Company’s net revenue. Substantially all of the Company’s business is with companies in the United States.

 

Accounts payable

 

As of December 31, 2020 and 2019, two vendors accounted for 59% and 73%, respectively, of the Company’s accounts payable. This includes a related party vendor in 2019.

 

Major suppliers

 

For the year ended December 31, 2020, three suppliers accounted for approximately 46% of the Company’s purchases. For the year ended December 31, 2019, two suppliers accounted for approximately 40% of the Company’s purchases. Substantially all of the Company’s business is with suppliers in the United States. This includes purchases from related party supplier for 2019.

 

Note 7 – Inventory

 

Inventory consists of finished goods, components and raw materials. The Company’s inventory is stated at the lower of cost (FIFO cost basis) or net realizable value.

 

The carrying value of inventory consisted of the following:

 

    December 31, 2020     December 31, 2019  
Finished goods   $ 3,205,557     $ 1,554,013  
Components     63,910       264,518  
Inventory in transit     171,861       42,507  
Raw materials     25,118       -  
                 
Total inventory   $ 3,466,446     $ 1,861,038  

 

As of January 22, 2015, inventory was pledged to Knight under the Loan Agreement (see note 12). As of December 31, 2020 and 2019, $171,861 and $42,507, respectively, of the Company’s inventory was in transit. During the years ended December 31, 2020 and 2019, $527,737 and $257,111, respectively, of expiring and slow-moving inventory was written off to cost of sales.

 

Note 8 – Fixed Assets and Intangible Assets

 

As of December 31, 2020 and 2019, fixed assets and intangible assets consisted of the following:

 

    December 31, 2020     December 31, 2019  
             
Property and equipment   $ 566,445     $ 566,445  
Less accumulated depreciation     (525,617 )     (430,547 )
Less accumulated impairment     (40,828 )     -  
Fixed assets, net   $ -     $ 135,898  

 

F-38

 

 

Depreciation expense for the years ended December 31, 2020 and 2019 was $98,230 and $133,873, respectively. During the year ended December 31, 2020, the Company fully impaired remaining assets of $40,828.

 

    December 31, 2020     December 31, 2019  
             
FOCUSfactor intellectual property   $ 1,450,000     $ 1,450,000  
Per-fekt intellectual property     -       -  
Cocowhite intellectual property     -       -  
Intangible assets subject to amortization     5,388,230       5,388,230  
Less accumulated amortization     (4,910,159 )     (4,908,696 )
Less accumulated impairment     (1,928,071 )     (1,921,898 )
Intangible assets, net   $ -     $ 7,636  

 

Amortization expense for the years ended December 31, 2020 and 2019 was $2,035 and $1,077,987, respectively. Impairment of intangible assets for the years ended December 31, 2020 and 2019 related to intangible assets from brands purchased in 2015.

 

During the year ended December 31, 2019, the Company fully impaired goodwill of $7,793,240. During the year ended December 31, 2020, the Company fully impaired remaining intangible assets of $6,173.

 

Note 9 – Related Party Transactions

 

The Company accrued and paid consulting fees of $82,917 per month through December 2020 to a company owned by Mr. Jack Ross, Chief Executive Officer of the Company. The Company also paid twelve months of a vehicle allowance of $2,500 per month. The Company expensed $1,110,000 and $824,413, respectively during 2020 and 2019 as consulting fees, advanced $425,000 in the manner of a prepaid bonus, and made payments totaling $1,110,000 and $852,626 towards services to an entity owned and controlled by an officer and shareholder of the Company for the year ended December 31, 2020 and 2019, respectively. As of both December 31, 2020 and 2019, the total outstanding balance was $0.

 

On June 26, 2015, the Company entered into a Security Agreement with Knight Therapeutics, Inc., a related party (owner of greater than 10% shares of the Company), through its wholly owned subsidiary Neuragen Corp., for the purchase of Knight Therapeutics, Inc.’s assets. At December 31, 2019 and 2018, the Company owed Knight $425,000 and $475,000 in relation to this agreement (see Note 11). The Company recorded present value of future payments of $246,916 and $260,461 as of December 31, 2020 and 2019, respectively.

 

On August 18, 2015, the Company entered into a Consulting Agreement with Kara Harshbarger, the co-founder of Hand MD, LLC, pursuant to which she will provide marketing and sales related service. The Company will pay Ms. Harshbarger $10,000 a month for one year unless the Consulting Agreement is terminated earlier by either party. The Company decided to extend the contract on a month to month basis. Hand MD, LLC is a 50% owner in Hand MD Corp. The Company expensed $120,000 through payroll for each of the years ended December 31, 2020 and 2019. As of December 31, 2020 and 2019, the total outstanding balance was $0.

 

The Company entered into transactions with a related party controlled by the CEO during the years ended December 31, 2020 and 2019. The transactions were a pass through and allocation of expenses and reimbursements. As of December 31, 2020 and 2019 the Company was owed $2,305,956 and $277,432, respectively.

 

On August 9, 2017, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party (owner of greater than 10% shares of the Company), for a working capital loan. At December 31, 2020 and 2019, the Company owed Knight $5,000,000 and $5,451,568, respectively, on this loan, net of debt issuance cost (see Note 11). During the year ended December 31, 2020 a loan success fee of $1,000,000 was earned by Knight and recorded as a long-term liability, payable in August 2022.

 

On May 8, 2020, the Company entered into a Loan Agreement with Knight Therapeutics (Barbados) Inc., a related party, for working capital loan. At December 31, 2020, the Company owed Knight $2,500,000 on this loan (see Note 11).

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics for the distribution rights of FOCUSFactor in Canada. In conjunction with this agreement, we are required to pay Knight a distribution fee equal to 30% of gross sales for sales achieved through a direct sales channel and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $100,000 Canadian dollars. During the year ended December 31, 2020, the Company expensed was $178,341 Canadian dollars (US Dollars $133,094). As of December 31, 2020 and 2019, the total outstanding balance was $178,341 and $100,000 Canadian dollars, respectively. In US Dollars, the total outstanding balance was $140,069 and $70,295 as of December 31, 2020 and 2019, respectively.

 

F-39

 

 

On December 23, 2016, we entered into an agreement with Knight Therapeutics for the distribution rights of Hand MD into Canada. In conjunction with this agreement, we are required to pay Knight a distribution fee equal to 60% of gross sales for sales achieved through a direct sales channel until the sales in the calendar year equal the threshold amount and then 40% of all such gross sales in such calendar year in excess of the threshold amount and 5% of gross sales for sales achieved through retail sales. The minimum due to Knight under this agreement is $25,000 Canadian dollars. During the year ended December 31, 2020, the Company expensed was $385,689 Canadian dollars (US Dollars $287,836). As of December 31, 2020 and 2019, the total outstanding balance was $110,637 and $25,000 Canadian dollars, respectively. In US Dollars, the total outstanding balance was $86,894 and $17,574 as of December 31, 2020 and 2019, respectively.

 

The Company expensed royalty of $1,055 and $4,867 for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020 and 2019, the Company owed Knight Therapeutics $0 and $246, respectively in connection with a royalty distribution agreement.

 

The Company expensed commissions of $0 and $9,065 for the years ended December 31, 2020 and 2019, respectively. At both December 31, 2020 and 2019, the Company owed Founded Ventures, owned by a shareholder in the Company, $0 in connection with a commission agreement.

 

The Company expensed commissions of $0 and $644 for the years ended December 31, 2020 and 2019, respectively. At both December 31, 2020 and 2019, the Company owed Founded Ventures $0 in connection with a commission agreement.

 

The Company expensed and paid $145,356 and $14,801 for the years ended December 31, 2020 and 2019, respectively, to Hand MD, Corp, related to a royalty agreement. As of both December 31, 2020 and 2019, the Company owed Hand MD Corp. $0 in minimum future royalties.

 

The Company expensed royalty of $169,552 and $192,700 for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020 and 2019, the Company owed Knight Therapeutics $11,026 and $5,528, respectively, in connection with a royalty distribution agreement.

 

A member of the Company’s Board of Directors was an executive officer of a supplier to the Company during 2019. During the year ended December 31, 2019, the Company acquired $4,847,626 of products from the supplier and is included in cost of sales. The Company owed the supplier $956,438 December 31, 2019.

 

The Company entered into transactions with a related party controlled by the CEO during the years ended December 31, 2020 and 2019. The transactions were a pass through of expenses and reimbursements. During the years ended December 31, 2020 and 2019, the Company received advances of $74,629 ($100,000 Canadian Dollars) and $324,102 ($430,000 Canadian Dollars), respectively, which were fully repaid. As of both December 31, 2020 and 2019, there was $0 due or payable.

 

The Company entered into transactions with a related party controlled by the CEO during the year ended December 31, 2020. The transactions are related to rent expense of $25,000 Canadian Dollars per month. During the year ended December 31, 2020 the Company expensed $275,000 Canadian Dollars ($205,485 US Dollars) for rent expense. As of December 31, 2020 the Company has advanced $86,250 Canadian Dollars ($67,741 US Dollars) for prepaid rent relating to 2021.

 

Note 10 – Accounts Payable and Accrued Liabilities

 

As of December 31, 2020 and 2019, accounts payable and accrued liabilities consisted of the following:

 

    December 31, 2020     December 31, 2019  
Accrued payroll   $ 180,374     $ 110,536  
Legal fees     17,924       68,098  
Commissions     516,491       229,657  
Manufacturers (including related party payable of $0 and $956,438, respectively)     2,447,404       2,082,256  
Promotions     1,292,262       1,312,541  
Accounting Fees     2,926       10,873  
Interest, related party     271,528       -  
Customers     144,142       26,206  
Royalties, related party     238,536       93,643  
Warehousing     64,140       13,746  
Sales taxes     899,852       313,985  
Payroll taxes     734,072       90,500  
Severance Accrual     270,333       270,333  
Related Party Reimbursements     -       1,135  
Others     21,716       50,555  
Total   $ 7,101,700     $ 4,674,064  

 

F-40

 

 

The Company has not filed its State & Local Income/Franchise tax returns in States it is required to file. The Company has estimated and accrued for its sales tax liability at $197,483 and $273,855 for the parent entity as of December 31, 2020 and 2019, respectively.

 

Note 11 – Notes Payable, related party

 

The Company’s notes payable at December 31, 2020 and 2019 are as follows:

 

    December 31, 2020     December 31, 2019  
             
Notes payable   $ 8,746,916     $ 5,760,461  
Unamortized debt issuance cost     -       (48,432 )
Total     8,746,916       5,712,029  
Less: Current portion     (7,515,693 )     (5,465,113 )
Long-term portion   $ 1,231,223     $ 246,916  

 

$950,000 June 26, 2015 Security Agreement:

 

On June 26, 2015, the Company, through its wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000 in connection with an Asset Purchase Agreement. The note requires $250,000 to be paid on or before June 30, 2016, and $700,000 to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5% of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts is secured by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which will be released upon receipt of total payments of $1.2 million.

 

Company recorded present value of future payments of $246,916 and $260,461 as of December 31, 2020 and 2019, respectively. At December 31, 2020 and 2019, the Company owed Knight $425,000 and $475,000 in relation to this agreement. The Company recorded interest expense of $36,455 and $38,310 for the year ended December 31, 2020 and 2019, respectively. The Company made payments of $50,000 during both 2020 and 2019.

 

$10,000,000 August 9, 2017 Loan:

 

On August 9, 2017, we entered into a Second Amendment to Loan Agreement (“Second Amendment”) with Knight, pursuant to which Knight agreed to loan us an additional $10 million, and an ongoing credit facility of up to $20 million, and which amount was borrowed at closing (the “Financing”) for working capital purposes. At closing, we paid Knight an origination fee of $200,000 and a work fee of $100,000 and also paid $100,000 of Knight’s expenses associated with the Loan.

 

Additional Tranches under the Loan Agreement are available to the Company until August 9, 2022 provided that no event of default exists. Each Additional Tranche must be for a minimum amount of $1.0 million, may only be used to finance qualified acquisitions (as defined in the Loan Agreement), and can be denied in Knight’s absolute discretion. If an Additional Tranche is denied, the Company can effect a qualified acquisition through a special purpose entity with such special purpose entity being entitled to obtain financing from third parties so long as such financing does not adversely affect Knight or Knight’s rights under the Loan Agreement. Upon the closing of any Additional Tranche, the Company will pay Knight an origination fee equal to 2% of the Additional Tranche, a work fee equal to 1% of the amount of the Additional Tranche, and reimburse Knight for its expenses incurred in connection with its consideration of any Additional Tranche (whether or not advanced).

 

The Loan bears interest at 10.5% per annum. The amended Loan Agreement matures on August 8, 2020 and (b) the date that Knight, in its discretion, accelerates the Company’s obligations due to an event of default.

 

On the Maturity Date of the Third Tranche and every Additional Tranche (or upon the acceleration of each such loan), the Company must pay Knight a success fee (the “Success Fee”) of that number of Company common shares equal to 10% of the loan, divided by the lesser of (a) $1.50, (b) the lowest price at which any common shares were issued by the Company in any offering or equity financing or other transaction between the Closing Date and the date the Success Fee is due, and (c) the current market price on the date the Success Fee is due. The Company may also pay the Success Fee in cash pursuant to the terms of the Loan Agreement.

 

F-41

 

 

The Loan Agreement includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, and to not merge or dispose of assets, acquire other businesses (except for businesses substantially similar or complementary to the Company’s business, and provided that the aggregate consideration to be paid does not exceed $100,000 and the acquired business guarantees the Company’s obligations under the Loan Agreement) or make capital expenditures in excess of $500,000. The Loan Agreement also includes customary events of default, including payment defaults, breaches of covenants, change of control and material adverse effect defaults. Upon the occurrence of an event of default and during the continuation thereof, the principal amount of all loans under the Loan Agreement will bear a default interest rate of an additional 5%.

 

The Company’s obligations and liabilities under the Loan Agreement are secured and unconditionally guaranteed by certain of the Company’s wholly-owned subsidiaries as provided in the Loan Agreement.

 

We have met all the covenants except for the TTM EBITDA of $5 million during the period ending March 31, 2018. Default Interest rate of 5% (from 10.5% to 15.5%) applies in accordance to our current agreement and will be in effect starting April 1, 2018 and will be in effect until the $5 million TTM EBITDA covenant is achieved. We entered into Loan Amendment Agreement on May 14, 2018, the interest rate was reduced to 13% due to reducing payroll expenses. Also, Synergy will maintain Focus Factor Net Sales as measured on a year-end basis of at least USD $15 million for each fiscal year starting with December 31, 2017.

 

We have amended our covenants under our loan agreement on March 27, 2019. The new covenants are as follows: we will maintain a minimum EBITDA of $1,900,000 for the twelve months ending on December 31, 2018, $2,500,000 for the twelve months ending March 31, 2019, $3,500,000 for the twelve months ending June 30, 2019 and $5,000,000 for the twelve months period ending on last day of each fiscal quarters thereafter. We shall maintain a net debt to TTM EBITDA ratio of no more than 8:1 for the twelve month period ending on December 31, 2018 until March 31, 2019 and shall maintain a net debt to TTM EBITDA ratio of no more than 6:1 thereafter. We shall maintain at all times a positive cash balance of $575,000 for the three month period ending December 31, 2018, $750,000 for the three month period ending March 31, 2019 and $1,000,000 thereafter. The default interest rate of 2.5% applies (from 13% to 15.5%) in accordance to our current agreement and was in effect as of October 1, 2018 to June 30, 2019. Effective June 30, 2019 the interest rate referred back to 10.5%.

 

The Company also recorded deferred financing costs of $452,869 with respect to the above loan. The Company recognized amortization of deferred financing costs of $48,432 and $130,829 during the years ended December 31, 2020 and 2019, respectively. Unamortized debt issuance cost as of December 31, 2020 and 2019 amounted to $0 and $48,432, respectively.

 

On May 8, 2020, the Company entered into a Third Amendment Agreement (the “Third Amendment”) to the Amended and Restated Loan Agreement (the “Loan Agreement”) with Knight Therapeutics (Barbados) Inc. (“Knight”), pursuant to which Knight agreed to loan the Company an additional $2.5 million (the “Additional Loan”). That same day (the “Closing”), the Company paid Knight a work fee of $36,000, and $25,000 for Knight’s legal costs and expenses incurred in connection with the Third Amendment. The Third Amendment amends the original loan agreement that the Company and Knight entered into in January 2015 and subsequently amended (as amended, the “Original Loan Agreement”). The Additional Loan matures on May 8, 2021 (the “TA Maturity Date”) and bears interest at 12.5% per annum compounding quarterly. On the TA Maturity Date, the Company will pay Knight a success fee (the “Success Fee”) of $83,250. The Success Fee is payable in cash or stock as set forth in the Loan Agreement. The Third Amendment includes customary representations, warranties, and affirmative and restrictive covenants, including covenants to attain and maintain certain financial metrics, including an undertaking to maintain at all times a cash balance of $600,000 and EBITDA of $3,000,000 for the twelve months ended June 30, 2020 and $4,000,000 for the twelve month period ending on the last day of each fiscal quarter thereafter.

 

Terms of the $10,000,000 August 9, 2017 loan (Third Tranche) (see note 10) was modified in the Third amendment. Third tranche shall bear interest from May 8, 2020 at a rate equal to 12.5% per annum compounded quarterly. The Company shall pay success fee in the amount of $1,000,000 with respect to the Third Tranche, which shall be fully earned on May 8, 2020 and payable no later than August 31, 2022. Third Tranche success fee shall bear interest at 12.5% per annum compounding quarterly. The loan has been extended to a maturity date of December 31, 2021. Because these amendments were considered not substantive changes, the Company accounted for the modifications as modification of debt.

 

The Company recognized interest expense of $995,760 and $912,486 during the years ended December 31, 2020 and 2019, respectively. Accrued interest was $271,528 and $0 as of December 31, 2020 and 2019, respectively. The loan balances, including success fee, at December 31, 2020 and 2019 were $8,500,000 and $5,500,000, respectively.

 

F-42

 

 

The PPP Loan and Financial Assistance:

 

In June 2020, the American Institute of Certified Public Accountants in conjunction with the Financial Accounting Standards Board developed Technical Question and Answer (“TQA”) 3200.18, “Borrower Accounting for a Forgivable Loan Received Under the Small Business Administration Paycheck Protection Program”, which is intended to provide clarification on how to account for loans received from the PPP. TQA 3200.18 states that an entity may account for PPP loans under ASC 470, “Debt” or, if the entity is expected to meet PPP eligibility criteria and the PPP loan is expected to be forgiven, the entity may account for the loans under IAS 20, “Accounting for Government Grants and Disclosure of Government Assistance”. The Company has elected to account for PPP loan proceeds under IAS 20 as allowed by TQA 3200.18.

 

The CARES Act includes, among other things, provisions relating to payroll tax credits and deferrals, net operating loss carryback periods, alternative minimum tax credits and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established a Paycheck Protection Program (“PPP”), whereby certain small business are eligible for a loan to fund payroll expenses, rent and related costs. We had received funding under the PPP of $163,542 and bears interest at 1% per annum, with monthly installments commencing on May 5, 2020 for 60 months through its maturity on May 5, 2025. The Company used all proceeds from the PPP Loan to maintain payroll and other allowable expenses. As a result, management believes that the Company has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven in its entirety. As such, in accordance with International Accounting Standards (“IAS”) 20, “Accounting for Government Grants and Disclosure of Government Assistance,” the Company has recognized the entire PPP Loan amount of $163,542 as other income, which is included in other non-operating income (expense) in the consolidated statement of operations for the year ended December 31, 2020. Our subsidiary, Nomad Choice Pty Ltd received the cash flow boost from the Australian Government due to the global pandemic. This assistance was received from March 2020 through to September 2020 of $46,742 which is included in other non-operating income (expense) in the consolidated statement of operations for the year ended December 31, 2020.

 

Note 12 – Stockholders’ Equity

 

The total number of shares of all classes of capital stock which the Company is authorized to issue is 300,000,000 shares of common stock with $0.00001 par value.

 

During the year ended December 31, 2019, the Company issued 26,391 shares of its common stock valued at $39,585 in full and final settlement on the Perfekt transaction.

 

As of both December 31, 2020, and 2019, there were 89,889,074 shares of the Company’s common stock issued and outstanding.

 

Note 13 – Commitments and Contingencies

 

Litigation:

 

From time to time the Company may become a party to litigation in the normal course of business. Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.

 

Other Commitments

 

During the year ended December 31, 2019 the Company received a 60 day Proposition 65 letter that one of its products did not have California’s Proposition 65 label. The Company has settled the matter and made a one-time payment of $85,000 in full satisfaction of the matter.

 

Note 14 – Stock Options

 

The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees and consultants under a stock option plan at December 31, 2020:

 

          Options Outstanding       Options Exercisable  
  Exercise Price ($)       Number
Outstanding
      Weighted
Average
Remaining
Contractual Life
(Years)
      Weighted
Average
Exercise
Price ($)
      Number
Exercisable
      Weighted
Average
Exercise
Price ($)
 
$ 0.25 – 0.70       3,466,667       4.46     $ 0.54       3,466,667     $ 0.54  

 

F-43

 

 

The stock option activity for the year ended December 31, 2020 is as follows:

 

    Options
Outstanding
    Weighted
Average
Exercise Price
 
Outstanding at December 31, 2018     7,166,667     $ 0.50  
Granted     -       -  
Exercised     -       -  
Expired or canceled     (1,000,000 )     (0.25 )
Outstanding at December 31, 2019     6,166,667       0.54  
Granted                
Exercised                
Expired or canceled     (2,700,000 )     (0.53 )
Outstanding at December 31, 2020     3,466,667     $ 0.54  

 

Stock-based compensation expense related to vested options was $128,929 and $161,570 during the years ended December 31, 2020 and 2019, respectively. The Company determined the value of share-based compensation for options vesting during the year ended December 31, 2017 using the Black-Scholes fair value option-pricing model with the following weighted average assumptions: estimated fair value of Company’s common stock of $0.48-0.50, risk-free interest rate of 1.95-1.99%, volatility of 116-117%, expected lives of 10 years, and dividend yield of 0%. Stock options outstanding as of December 31, 2020, as disclosed in the above table, have an intrinsic value of $0. As of December 31, 2020, unamortized stock-based compensation costs related to options was $0.

 

Note 15 – Segments

 

Segment identification and selection is consistent with the management structure used by the Company’s chief operating decision maker to evaluate performance and make decisions regarding resource allocation, as well as the materiality of financial results consistent with that structure. Based on the Company’s management structure and method of internal reporting, the Company has one operating segment. The Company’s chief operating decision maker does not review operating results on a disaggregated basis; rather, the chief operating decision maker reviews operating results on an aggregated basis.

 

Net sales attributed to customers in the United States and foreign countries for the years ended December 31, 2020 and 2019 were as follows:

 

    December 31, 2020     December 31, 2019  
United States   $ 30,683,330     $ 27,295,126  
Foreign countries     9,543,535       2,062,420  
    $ 40,226,865     $ 29,357,546  

 

Foreign country sales primarily consist of sales in Canada.

 

The Company’s net sales by product group for the years ended December 31, 2020 and 2019 were as follows:

 

    December 31, 2020     December 31, 2019  
Nutraceuticals   $ 31,902,291     $ 28,149,938  
Over the Counter (OTC)     22,310       62,359  
Consumer Goods     1,201,317       706,688  
Cosmeceuticals     7,100,947       438,561  
    $ 40,226,865     $ 29,357,546  

 

(1) Net sales for any other product group of similar products are less than 10% of consolidated net sales.

 

The Company’s net sales by major sales channel for the years ended December 31, 2020 and 2019 were as follows:

 

    December 31, 2020     December 31, 2019  
Online   $ 9,923,825     $ 10,382,593  
Retail     30,303,040       18,974,953  
    $ 40,226,865     $ 29,357,546  

 

Long-lived assets (net) attributable to operations in the United States and foreign countries as of December 31, 2020 and 2019 were as follows:

 

    December 31, 2020     December 31, 2019  
United States   $                    -     $ -  
Foreign countries     -       7,636  
    $ -     $ 7,636  

 

Note 16 – Subsequent Events

 

The Company evaluated its December 31, 2020 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.

 

Subsequent to December 31, 2020, the Company has made $2,000,000 in payments on the outstanding loans.

 

Subsequent to December 31, 2020, the Company has received verification of full forgiveness of their disbursement under the PPP Loan program.

 

Subsequent to December 31, 2020, the Company has entered into an agreement to acquire the outstanding 50% of Hand MD Corp. whereby Synergy will become the 100% owner. The consideration of $1,700,000 will be disbursed as follows: $500,000 within 10 business days of the execution of the agreement, $400,000 on or before the six month anniversary of the agreement, $400,000 on or before the twelve month anniversary of the agreement and $400,000 on or before the eighteen month anniversary of the agreement. The first payment of $500,000 was made in July 2021.

 

F-44

 

 

                 Shares of Common Stock

 

 

 

Synergy CHC Corp.

 

 

 

PRELIMINARY PROSPECTUS

 

 

 

B. Riley Securities

 

                , 2021

 

Through and including              , 2021 (25 days after the date of this prospectus), all dealers that effect transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions.

 

 
 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 13. Other Expenses of Issuance and Distribution

 

The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by us in connection with the sale of the common stock being registered. All amounts shown are estimates except for the SEC registration fee, the FINRA filing fee and the listing fee for the Nasdaq Capital Market.

 

   

Amount Paid

or to be Paid

 
SEC registration fee   $ 7,995  
FINRA filing fee     13,438  
Nasdaq listing fee     75,000  
Printing and engraving expenses     *  
Legal fees and expenses     *  
Accounting fees and expenses     *  
Blue sky fees and expenses     *  
Transfer agent and registrar fees and expenses     *  
Miscellaneous expenses     *  
Total   $ *  

 

 

* To be provided by amendment.

 

Item 14. Indemnification of Directors and Officers

 

Neither our articles of incorporation, nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statutes (“NRS”). NRS Section 78.7502, provides that a corporation may indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.

 

NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

 

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

 

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

 

II-1
 

 

Our amended and restated bylaws will provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.

 

We will enter into indemnification agreements with each of our officers and directors a form of which is filed as an exhibit to this Registration Statement.

 

These agreements will require us to indemnify these individuals to the fullest extent permitted under Nevada law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

 

The proposed form of underwriting agreement filed as Exhibit 1.1 to this Registration Statement provides for indemnification of directors and officers of the Registrant by the underwriter against certain civil liabilities that may be incurred in connection with this offering, including certain liabilities under the Securities Act.

 

Item 15. Recent Sales of Unregistered Securities

 

In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act:

 

On January 28, 2019, we issued 26,391 shares of our common stock to Malk Group, Inc. in full and final settlement of our purchase of all of the assets and the assumption of certain liabilities of Perfekt Beauty Holdings LLC (“Perfekt Beauty”), pursuant to the Asset Purchase Agreement dated June 21, 2017 by and among us, Perfekt Beauty and CDG Holdings, LLC. The shares of common stock were sold in a transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a)(2) thereof. The shares of our common stock may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and any applicable state securities laws.

 

Item 16. Exhibits and Financial Statement Schedules

 

(a) Exhibits

 

The following documents are filed as exhibits to this registration statement:

 

Exhibit No.   Description
1.1*   Form of Underwriting Agreement.
2.1*   Agreement and Plan of Merger, dated April 7, 2014, by and among Oro Capital Corporation, Synergy Merger Sub, Inc. and Synergy Strips Corp.
2.2*   Asset Purchase Agreement, dated January 22, 2015, by and among Synergy Strips Corp.; Factor Nutrition Labs, LLC; Vita Partners, LLC, RPR Partners, LLC, and Thor Associates, Inc.
2.3*   Asset Purchase Agreement, dated June 26, 2015, by and between Neuragen Corp. and Knight Therapeutics, Inc.
3.1*   Articles of Incorporation, as amended.
3.2*   Bylaws.
3.3*   Amendment to Bylaws.
3.4*   Form of Amended and Restated Bylaws, to be in effect upon consummation of this offering.
5.1**   Opinion of Nelson Mullins Riley & Scarborough LLP.
10.1#*   Sales and Marketing Consultant and Distribution Agreement, dated April 2, 2014, between Synergy Strips Corp. and Kenek Brands Inc.
10.2*   Loan Agreement, dated January 22, 2015, between Knight Therapeutics (Barbados) Inc. and Synergy Strips Corp.
10.3*  

Distribution, License and Supply Agreement, dated January 22, 2015, by and between Synergy Strips Corp. and Knight Therapeutics (Barbados) Inc.

10.4#*   Synergy Strips Corp. 2014 Stock Incentive Plan.
10.5*   Contribution Agreement, dated August 18, 2015, between Synergy CHC Corp. and Hand MD Corp.
10.6*   Contribution Agreement, dated August 18, 2015, among Hand MD, LLC, Principal Owners as listed therein, Synergy CHC Corp. and Hand MD Corp.
10.7*   Intellectual Property License Agreement, dated August 18, 2015, by and between Synergy CHC Corp. and Hand MD. Corp.
10.8*   Consulting Agreement, dated August 18, 2015, by and between Synergy CHC Corp. And Kara Harshbarger.
10.9*   Stock Purchase Agreement, dated November 12, 2015, by and among Breakthrough Products, Inc., URX ACQUISITION TRUST, Jordan Eisenberg, other shareholders as listed therein and Synergy CHC Corp.
10.10*   Share Purchase Agreement, dated November 15, 2015, between TPR Investments Pty Ltd CAN 128 396 654 as trustee for Polmear Family Trust, Timothy Polmear and Rebecca Polmear, NomadChoice Pty Limited ACN 160 729 939 trading as Flat Tummy Tea and Synergy CHC Corp.

 

II-2
 

 

10.11*   First Amendment to Loan Agreement, dated November 12, 2015, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.12*   Amendment to First Amendment Agreement, dated December 3, 2015, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.13*   Amendment and Confirmation Agreement, dated December 3, 2015, by and among Knight Therapeutics (Barbados) Inc., Nomad Choice Pty Ltd, Synergy CHC Corp. and Breakthrough Products, Inc.
10.14*   Settlement and Release Agreement, dated December 17, 2015, by and between Synergy CHC Corp., the former shareholders of Breakthrough Products, Inc. and URX ACQUISITION TRUST and as representative of certain shareholders.
10.15*   Hand MD Distribution Agreement (Canada), dated December 23, 2016, between Knight Therapeutics Inc. and Synergy CHC Corp.
10.16*   FOCUSfactor Distribution Agreement (Canada), dated December 23, 2016, between Knight Therapeutics Inc. and Synergy CHC Corp.
10.17*   Asset Purchase Agreement, dated June 21, 2017, among Synergy CHC Corp., Perfekt Beauty Holdings LLC and CDG Holdings, LLC.
10.18*   Amended and Restated Loan Agreement, dated August 9, 2017, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.19*   First Amendment to Amended and Restated Loan Agreement, dated May 14, 2018, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.20*   Second Amendment to Amended and Restated Loan Agreement, dated March 27, 2019, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.21*   Third Amendment Agreement, dated May 8, 2020, between Knight Therapeutics (Barbados) Inc. and Synergy CHC Corp.
10.22*   Distribution Agreement (Canada), dated February 15, 2016, between Knight Therapeutics Inc. and Nomad Choice Pty Ltd.
10.23*   Distribution Agreement (Remaining Territories), dated February 15, 2016, between Knight Therapeutics (Barbados) Inc. and Nomad Choice Pty Ltd.
10.24*   Distribution Agreement (Canada), dated January 1, 2017, between Knight Therapeutics Inc. and Sneaky Vaunt Corp.
10.25*   Distribution Agreement (Remaining Territories), dated January 1, 2017, between Knight Therapeutics (Barbados) Inc. and Sneaky Vaunt Corp.
10.26+*   Costco Wholesale Basic Vendor Agreement, dated October 9, 2009, between Factor Nutrition Labs LLC and Costco Wholesale Corporation.
10.27+*   Supplier Agreement by and among Factor Nutrition Labs LLC and Wal-Mart Stores, Inc., Wal-Mart Stores East, LP, Wal-Mart Stores East, Inc., Wal-Mart Stores Texas, LP, Sam’s West, Inc., and Sam’s East, Inc.  
10.28*   Shopify Capital Agreement, effective May 16, 2021, by and between Shopify Capital Inc. and Synergy CHC Corp.
10.29*   Form of Indemnity Agreement.
14.1*   Code of Business Ethics and Conduct.
21.1*   List of subsidiaries of the Registrant.
23.1*   Consent of RBSM LLP.
23.2**   Consent of Nelson Mullins Riley & Scarborough LLP (included in Exhibit 5.1).
24.1*   Power of Attorney (included on signature page).
99.1*   Consent of Nitin Kaushal.

 

 

# Denotes a management contract or compensatory plan or arrangement.
+ Certain confidential information contained in this agreement has been omitted because it is not material and would be competitively harmful if publicly disclosed.
* Filed herewith.
** To be filed by amendment.

 

(b) Financial Statement Schedules

 

All schedules have been omitted because the information required to be set forth in the schedules is either not applicable or is shown in the financial statements or notes thereto.

 

Item 17. Undertakings

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

The undersigned registrant hereby undertakes:

 

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westbrook, State of Maine, on the 22nd day of October, 2021.

 

  SYNERGY CHC CORP.
     
  By: 

/s/ Jack Ross

    Jack Ross
    Chief Executive Officer and Chairman

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jack Ross and Brendan Horning and each of them, his or her true and lawful attorneys-in-fact and agents with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by the registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, his, hers or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

SIGNATURE   TITLE   DATE
         
/s/ Jack Ross   Chief Executive Officer and Chairman   October 22, 2021
Jack Ross    (principal executive officer)    
         
/s/ Brendan Horning   Chief Financial Officer   October 22, 2021
Brendan Horning    (principal financial officer)    
         
/s/ Alfred Baumeler   President and Director Nominee   October 22, 2021
Alfred Baumeler        
         
/s/ Jaime Fickett   Senior Vice President of Finance and Operations   October 22, 2021
Jaime Fickett    (principal accounting officer)    
         
/s/ J. Paul SoRelle   Director   October 22, 2021
J. Paul SoRelle        
         
/s/ Stephen Fryer   Director   October 22, 2021
Stephen Fryer        

 

II-4

 

Exhibit 1.1

 

Synergy CHC Corp.

[●] Shares of Common Stock

 

UNDERWRITING AGREEMENT

 

 

[●], 2021

 

B. Riley Securities, Inc.

as Representative of the

several Underwriters

 

c/o B. Riley Securities, Inc.

299 Park Avenue

New York, NY 10171

 

Ladies and Gentlemen:

 

Synergy CHC Corp., a Nevada corporation (the “Company”), confirms its agreement with each of the Underwriters listed on Schedule I hereto (collectively, the “Underwriters”), for whom B. Riley Securities, Inc. is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company of [●] shares (the “Initial Shares”) of Common Stock, par value $0.00001 per share, of the Company (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the number of shares of Common Stock set forth opposite the names of the Underwriters in Schedule I hereto, and (ii) the grant of the option described in Section 1(b) hereof to purchase all or any part of [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Shares”), from the Company, to the Underwriters, acting severally and not jointly, in the respective numbers of shares of Common Stock set forth opposite the names of each of the Underwriters listed in Schedule I hereto. The Initial Shares to be purchased by the Underwriters and the Option Shares, if and to the extent such option described in Section 1(b) hereof is exercised are hereinafter called, collectively, the “Shares.”

 

The Company understands that the Underwriters propose to make a public offering of the Shares as soon as the Underwriters deem advisable after this Underwriting Agreement (the “Agreement”) has been executed and delivered.

 

The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1 (No. 333-[●]), including a related preliminary prospectus, for the registration of the Shares under the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Securities Act”). The Company has prepared and filed such amendments to the registration statement and such amendments or supplements to the related preliminary prospectus as may have been required to the date hereof, and will file such additional amendments or supplements as may hereafter be required. The registration statement has been declared effective under the Securities Act by the Commission. The registration statement, as amended at the time it was declared effective by the Commission (and, if the Company files a post-effective amendment to such registration statement that becomes effective prior to the Closing Time (as defined below), such registration statement as so amended) and including all information deemed to be a part of the registration statement pursuant to incorporation by reference, Rule 430A of the Securities Act or otherwise, is hereinafter called the “Registration Statement.” Any registration statement filed pursuant to Rule 462(b) of the Securities Act is hereinafter called the “Rule 462(b) Registration Statement,” and after such filing the term “Registration Statement” shall include the Rule 462(b) Registration Statement. Each prospectus describing the Shares and the offering thereof included in the Registration Statement before it was declared effective by the Commission under the Securities Act, and any preliminary form of prospectus filed with the Commission by the Company with the consent of the Underwriters pursuant to Rule 424(a) of the Securities Act, including all information incorporated by reference in either such prospectus, is hereinafter called the “Preliminary Prospectus.” The term “Prospectus” means the final prospectus, as first filed with the Commission pursuant to paragraph (1) or (4) of Rule 424(b) of the Securities Act, and any amendments thereof or supplements thereto, including all information incorporated by reference therein.

 

 
 

 

The Commission has not issued any order preventing or suspending the use of any Preliminary Prospectus.

 

The term “Disclosure Package” means (i) the Preliminary Prospectus, as most recently amended or supplemented immediately prior to the Initial Sale Time (as defined herein); (ii) the Issuer Free Writing Prospectuses (as defined below), if any, identified in Schedule II hereto; (iii) the pricing information set forth on Schedule III hereto; and (iv) any other Free Writing Prospectus (as defined below) that the parties hereto shall hereafter expressly agree to treat as part of the Disclosure Package.

 

The term “Issuer Free Writing Prospectus” means any issuer free writing prospectus, as defined in Rule 433 of the Securities Act. The term “Free Writing Prospectus” means any free writing prospectus, as defined in Rule 405 of the Securities Act.

 

The Company and the Underwriters agree as follows:

 

1. Sale and Purchase:

 

(a) Initial Shares. Upon the basis of the representations and warranties and other terms and conditions and agreements herein set forth, at the purchase price per share of Common Stock of $[●], the Company agrees to sell to each Underwriter, and each Underwriter, severally and not jointly, agrees to purchase from the Company, that number of Initial Shares set forth in Schedule I opposite such Underwriter’s name, plus any additional number of Initial Shares which such Underwriter may become obligated to purchase pursuant to the provisions of Section 8 hereof, subject in each case, to such adjustments among the Underwriters as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares.

 

  - 2 -  

 

 

(b) Option Shares. In addition, upon the basis of the representations and warranties and other terms and conditions and agreements herein set forth, at the purchase price per share of Common Stock set forth in paragraph (a) above less an amount equal to any dividend or distribution payable on Initial Shares that is not also payable on the Option Shares, the Company hereby grants an option to the Underwriters, acting severally and not jointly, to purchase from the Company, all or any part of the Option Shares, plus any additional number of Option Shares which such Underwriter may become obligated to purchase pursuant to the provisions of Section 8 hereof. The option hereby granted will expire 30 days after the date hereof and may be exercised in whole or in part from time to time within such 30-day period only for the purpose of covering over-allotments in connection with the offering and distribution of the Initial Shares upon notice by the Representative to the Company, setting forth the number of Option Shares as to which the several Underwriters are then exercising the option and the time and date of payment and delivery for such Option Shares. Any such time and date of delivery (an “Option Closing Time”) shall be determined by the Representative, but shall not be later than five full business days (or earlier, without the consent of the Company, than two full business days) after the exercise of such option, nor in any event prior to the Closing Time, as hereinafter defined. If the option is exercised as to all or any portion of the Option Shares, the Company will sell that number of Option Shares then being purchased and each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Shares then being purchased which the number of Initial Shares set forth in Schedule I opposite the name of such Underwriter bears to the total number of Initial Shares, subject in each case to such adjustments among the Underwriters as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares. The Representative may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.

 

2. Payment and Delivery

 

(a) Initial Shares. The Initial Shares to be purchased by each Underwriter hereunder, in definitive form, and in such authorized denominations and registered in such names as the Representative may request upon at least forty-eight hours’ prior notice to the Company shall be delivered by or on behalf of the Company to the Representative, including, at the option of the Representative, through the facilities of The Depository Trust Company (“DTC”) for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the account specified to the Representative by the Company upon at least forty-eight hours’ prior notice. The time and date of such delivery and payment shall be 9:30 a.m., New York City time, on the second (third, if the determination of the purchase price of the Initial Shares occurs after 4:30 p.m., New York City time) business day after the date hereof (unless another time and date shall be agreed to by the Representative and the Company). The time and date at which such delivery and payment are actually made is hereinafter called the “Closing Time.”

 

(b) Option Shares. Any Option Shares to be purchased by each Underwriter hereunder, in definitive form, and in such authorized denominations and registered in such names as the Representative may request upon at least forty-eight hours’ prior notice to the Company shall be delivered by or on behalf of the Company to the Representative, including, at the option of the Representative, through the facilities of DTC for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the account specified to the Representative by the Company upon at least forty-eight hours’ prior notice. The time and date of such delivery and payment shall be 9:30 a.m., New York City time, on the date specified by the Representative in the notice given by the Representative to the Company of the Underwriters’ election to purchase such Option Shares or on such other time and date as the Company and the Representative may agree upon in writing.

 

  - 3 -  

 

 

3. Representations and Warranties of the Company:

 

The Company represents and warrants to each of the Underwriters as of the date hereof, the Initial Sale Time (as defined below), as of the Closing Time and as of any Option Closing Time (if any), and agrees with each Underwriter, that:

 

(a) the Company has the authorized capitalization as set forth in the Registration Statement, the Prospectus and the Disclosure Package; the outstanding shares of capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable, and are as set forth in the Registration Statement, the Disclosure Package and the Prospectus under the caption “Capitalization” (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Disclosure Package and the Prospectus). None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Disclosure Package and the Prospectus. The descriptions of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Disclosure Package and the Prospectus accurately and fairly present the information required to be shown with respect to such plans, arrangements, options and rights. All of the outstanding shares of capital stock, partnership interests and membership interests, as the case may be, of the Subsidiaries (as defined below) of the Company have been duly authorized and are validly issued, fully paid and non-assessable securities thereof and, except as disclosed in each of the Registration Statement, the Disclosure Package and the Prospectus, all of the outstanding shares of capital stock, partnership interests or membership interests, as the case may be, of the Subsidiaries are directly or indirectly owned of record and beneficially by the Company, free and clear of any pledge, lien, encumbrance, security interest or other claim; except as disclosed in each of the Registration Statement, the Prospectus and the Disclosure Package, there are no outstanding (i) securities or obligations of the Company or any of the Subsidiaries convertible into or exchangeable for any capital stock of the Company or any such Subsidiary; (ii) warrants, rights or options to subscribe for or purchase from the Company or any such Subsidiary any such capital stock or any such convertible or exchangeable securities or obligations; or (iii) obligations of the Company or any such Subsidiary to issue any shares of capital stock, any such convertible or exchangeable securities or obligation, or any such warrants, rights or options; and none of the outstanding interests of any of the Subsidiaries, if any, were issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary;

 

(b) each of the Company and the subsidiaries named in Exhibit 21 to the Registration Statement (which are the only significant subsidiaries as defined in Rule 1-02 of Regulation S-X of the Company) (the “Subsidiaries”) has been duly incorporated, formed or organized and is validly existing as a corporation or limited liability company in good standing under the laws of its respective jurisdiction of incorporation, formation or organization, as applicable, with full power and authority to own, lease, and operate its respective properties and to conduct its respective businesses as described in each of the Registration Statement, the Prospectus and the Disclosure Package, and, in the case of the Company, to execute and deliver this Agreement and to consummate the transactions contemplated herein;

 

  - 4 -  

 

 

(c) the Company and all of the Subsidiaries are duly qualified or licensed to transact business and are in good standing in each jurisdiction in which they conduct their respective businesses, or in which they own or lease real property or otherwise maintain an office, and in which the failure, individually or in the aggregate, to be so qualified or licensed could have a material adverse effect on the (A) assets, liabilities, business, operations, earnings, operating results, properties or condition (financial or otherwise), present or prospective, of the Company and the Subsidiaries taken as a whole, or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such effect or change referred to in subclause (A) or (B), where the context so requires, is hereinafter called a “Material Adverse Effect” or “Material Adverse Change”); and except as disclosed in each of the Registration Statement, the Disclosure Package, and the Prospectus, (i) the Company and the Subsidiaries, taken as a whole, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its Subsidiaries, taken as a whole, and have not entered into any transactions (whether or not in the ordinary course of business) that is material; (ii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its Subsidiaries; (iii) no Subsidiary is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such Subsidiary’s capital stock or from repaying to the Company or any other Subsidiary any amounts which may from time to time become due under any loans or advances to such Subsidiary from the Company or such other Subsidiary, or from transferring any such Subsidiary’s property or assets to the Company or to any other Subsidiary; and (iv) the Company does not own, directly or indirectly, any capital stock or other equity securities of any other corporation or any ownership interest in any partnership, joint venture or other association;

 

(d) the Company and the Subsidiaries have at all times been, and currently are, in compliance in all material respects with all applicable laws, rules, regulations, orders, decrees and judgments, including those relating to transactions with affiliates;

 

(e) neither the Company nor any Subsidiary is in breach or violation of or in default under (nor has any event occurred which with notice, lapse of time, or both would constitute a breach or violation of, or default under) (i) its respective charter, bylaws, limited partnership agreement, operating agreement or other similar organizational documents (the “organizational documents”); (ii) the performance or observance of any obligation, agreement, covenant or condition contained in any contract, lease, license, indenture, mortgage, deed of trust, loan, note or credit agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which any of them or their respective properties is bound; or (iii) any federal, state, local or foreign law, regulation or rule or any decree, judgment, permit or order (each, a “Law”) applicable to the Company, except, in the case of (ii) and (iii) above, for such breaches, violations or defaults which could not, individually or in the aggregate, have a Material Adverse Effect;

 

  - 5 -  

 

 

(f) the execution, delivery and performance of this Agreement, and consummation of the transactions contemplated herein and in the Registration Statement, the Disclosure Package and the Prospectus and the issuance and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement, the Disclosure Package and the Prospectus under the caption “Use of Proceeds”) and the compliance by the Company with its obligations hereunder, have been duly authorized by all necessary corporate action and do not and will not (i) conflict with, or result in any breach or violation of, or constitute a default or any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its Subsidiaries (a “Repayment Event”) under (nor constitute any event which with notice, lapse of time, or both would constitute a breach or violation of, or default or a Repayment Event under), (A) any provision of the organizational documents of the Company or any Subsidiary, or (B) any provision of any license, indenture, mortgage, deed of trust, loan, note or credit agreement or other agreement or instrument to which the Company or any Subsidiary is a party or by which any of them or their respective properties may be bound or affected, or under any federal, state, local or foreign law, regulation or rule or any decree, judgment, writ or order applicable to the Company or any Subsidiary, except in the case of this clause (B) for such breaches, violations or defaults which could not, individually or in the aggregate, have a Material Adverse Effect; or (ii) result in the creation or imposition of any lien, charge, claim or encumbrance upon any property or asset of the Company or any Subsidiary;

 

(g) this Agreement has been duly authorized, executed and delivered by the Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally, and by general equitable principles, and except to the extent that the indemnification and contribution provisions of Section 9 hereof may be limited by federal or state securities laws and public policy considerations in respect thereof;

 

(h) no approval, authorization, consent or order of or filing with any federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency is required in connection with the Company’s execution, delivery and performance of this Agreement, its consummation of the transactions contemplated herein and in the Registration Statement, the Disclosure Package and the Prospectus, and its sale and delivery of the Shares, and the compliance by the Company with its obligations hereunder, other than (i) such as have been obtained, under the Securities Act and the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the “Exchange Act”); (ii) such approvals as have been obtained in connection with the approval of the quotation of the Shares on the Nasdaq Stock Market (“Nasdaq”); and (iii) any necessary qualification under the securities or blue sky laws of the various jurisdictions in which the Shares are being offered by the Underwriters or by the rules of the Financial Industry Regulatory Authority (“FINRA”);

 

  - 6 -  

 

 

(i) each of the Company and the Subsidiaries has all necessary permits, licenses, authorizations, consents and approvals (the “Permits”) and has made all necessary filings required under any federal, state, local or foreign law, regulation or rule, and has obtained all necessary authorizations, consents and approvals from other persons, required to conduct its business as described in each of the Registration Statement, the Prospectus and the Disclosure Package, except to the extent that any failure to have any such Permits, to make any such filings or to obtain any such authorizations, consents or approvals could not, individually or in the aggregate, have a Material Adverse Effect; except as described in each of the Registration Statement, the Prospectus and the Disclosure Package, neither the Company nor any of the Subsidiaries is required by any applicable law to obtain accreditation or certification from any governmental agency or authority to provide the products and services which it currently provides or which it proposes to provide as set forth in each of the Registration Statement, the Prospectus and the Disclosure Package; none of the Company or any of the Subsidiaries is not in compliance with, or is in violation of, in default under, or has received any notice regarding a possible violation, default, modification or revocation of, any such Permit or any federal, state, local or foreign law, regulation or rule or any decree, order or judgment applicable to the Company or any of the Subsidiaries, the effect of which, individually or in the aggregate, could result in a Material Adverse Change; and no such Permit contains a materially burdensome restriction that is not adequately disclosed in each of the Registration Statement, the Prospectus and the Disclosure Package;

 

(j) each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto has become effective under the Securities Act, and no stop order suspending the effectiveness of the Registration Statement, any Rule 462(b) Registration Statement or any post-effective amendment thereto has been issued under the Securities Act and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission; to the knowledge of the Company, the Company is not the subject of a proceeding under Section 8A of the Securities Act in connection with the offering of the Shares; and the Company has complied, to the Commission’s satisfaction, with any request on the part of the Commission for additional or supplemental information;

 

(k) the Preliminary Prospectus and Prospectus, each when filed, and the Registration Statement as of the effective date and as of the date hereof, and any further amendments or supplements to the Preliminary Prospectus, Prospectus or the Registration Statement complied or will comply, when they become effective or are filed with the Commission, as the case may be, in all material respects with the requirements of the Securities Act;

 

(l) each of the Registration Statement, any Rule 462(b) Registration Statement, and any post-effective amendments thereto, as of its respective effective date and as of the date hereof, did not, does not and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; and the Preliminary Prospectus (including any wrapper thereof) does not, and the Prospectus or any amendment or supplement thereto (including any wrapper thereof) will not, as of the applicable filing date, the date hereof and at the Closing Time and on each Option Closing Time (if any), contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no warranty or representation with respect to any statement contained in or omitted from the Registration Statement, the Preliminary Prospectus or the Prospectus in reliance upon and in conformity with the information concerning the Underwriters furnished in writing by or on behalf of the Underwriters through the Representative to the Company expressly for use therein (that information being limited to that described in Section 9(b) hereof);

 

  - 7 -  

 

 

(m) as of [●] [a.m.] [p.m.] (Eastern time) on the date of this Agreement (the “Initial Sale Time”), the Disclosure Package did not, and at the time of each sale of Shares and at the Closing Time and each Option Closing Time, the Disclosure Package will not, contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; as of its issue date or date of first use and at all subsequent times through the Initial Sale Time, each Issuer Free Writing Prospectus did not, and at the time of each sale of Shares and at the Closing Time and each Option Closing Time, each such Issuer Free Writing Prospectus will not, contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no warranty or representation with respect to any statement contained in or omitted from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendments thereto and the Disclosure Package in reliance upon and in conformity with the information concerning the Underwriters and furnished in writing by or on behalf of the Underwriters through the Representative to the Company expressly for use therein (that information being limited to that described in Section 9(b) hereof);

 

(n) each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Preliminary Prospectus, or the Prospectus including any document incorporated by reference therein that has not been superseded or modified;

 

(o) prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any “prospectus” (within the meaning of the Securities Act) or used any “prospectus” (within the meaning of the Securities Act) in connection with the offer or sale of the Shares, in each case other than the Preliminary Prospectus or an Issuer Free Writing Prospectus, if any; the Company has not, directly or indirectly, prepared, used or referred to any Free Writing Prospectus except in compliance with Rules 164 and 433 under the Securities Act; the Company is eligible to use Free Writing Prospectuses in connection with this offering pursuant to Rules 164 and 433 under the Securities Act; any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act; the Company was not, is not or will not be (as applicable) an “ineligible issuer” (as defined in Rule 405 under the Securities Act) as of the eligibility determination date for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares contemplated by the Registration Statement and the Prospectus, without taking into account any determination by the Commission pursuant to Rule 405 under the Securities Act that it is not necessary under the circumstances that the Company be considered an “ineligible issuer”; and each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of the Securities Act;

 

  - 8 -  

 

 

(p) except for the Issuer Free Writing Prospectuses identified in Schedule II hereto, and any electronic road show relating to the public offering of shares contemplated herein furnished to you before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of the Representative, prepare, use or refer to, any Free Writing Prospectus; and each electronic road show, when considered together with the Disclosure Package, did not, as of the Initial Sale Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(q) the Preliminary Prospectus, the Prospectus and any Issuer Free Writing Prospectuses (to the extent any such Issuer Free Writing Prospectus was required to be filed with the Commission) delivered to the Underwriters for use in connection with the public offering of the Shares contemplated herein have been and will be identical to the versions of such documents transmitted to the Commission for filing via the Electronic Data Gathering Analysis and Retrieval System (“EDGAR”), except to the extent permitted by Regulation S-T;

 

(r) the Company filed the Registration Statement with the Commission before using any Issuer Free Writing Prospectus; and each Issuer Free Writing Prospectus was preceded or accompanied by the most recent Preliminary Prospectus satisfying the requirements of Section 10 under the Securities Act, which Preliminary Prospectus included an estimated price range;

 

(s) the Company (i) has not engaged in any oral or written communication made in reliance upon Section 5(d) of the Securities Act or Rule 163B under the Securities Act (each, a “Testing-the-Waters Communication”) other than Testing-the-Waters Communications with the consent of the Representative with entities that are, or that the Company reasonably believes are, “qualified institutional buyers” within the meaning of Rule 144A under the Securities Act or institutions that are “accredited investors” within the meaning of Rule 501 under the Securities Act; (ii) has not authorized anyone other than the Representative to engage in Testing-the-Waters Communications; and (iii) reconfirms that the Representative has been authorized to act on its behalf in undertaking materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Shares, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically) (“Marketing Materials”) or Testing-the-Waters Communications. As of its issue date or date of first use and at all subsequent times through the Initial Sale Time, each of the Testing-the-Waters Communications and the Marketing Materials, if any, when considered together with the Disclosure Package, did not, and at the time of each sale of Shares and at the Closing Time and each Option Closing Time, include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading and does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus;

 

  - 9 -  

 

 

(t) there are no actions, suits, proceedings, inquiries or investigations pending or, to the knowledge of the Company, threatened against or affecting the Company or any Subsidiary or any of their respective officers and directors or to which the properties, assets or rights of any such entity are subject, at law or in equity, before or by any federal, state, local or foreign governmental or regulatory commission, board, body, authority, arbitral panel or agency which, individually or in the aggregate, could result in a Material Adverse Effect;

 

(u) the financial statements, including the notes thereto, included in (or incorporated by reference into) each of the Registration Statement, the Prospectus and the Disclosure Package present fairly the consolidated financial position of the entities to which such financial statements relate (the “Covered Entities”) as of the dates indicated and the consolidated results of operations and changes in financial position and cash flows of the Covered Entities for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States (“GAAP”) and on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto, and in accordance with Regulation S-X promulgated by the Commission; the financial statement schedules included in (or incorporated by reference into) the Registration Statement and the amounts in both the Prospectus and the Disclosure Package under the captions “Prospectus Summary—Summary Historical Consolidated Financial and Other Data” and “Capitalization” have been compiled on a basis consistent with the financial statements included in each of the Registration Statement, the Prospectus and the Disclosure Package; no other financial statements or supporting schedules are required to be included in the Registration Statement, the Prospectus or the Disclosure Package; the Company and its Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), the Prospectus and the Disclosure Package; and all disclosures contained in the Registration Statement, the Prospectus and the Disclosure Package that constitute non-GAAP financial measures (as defined by the rules and regulations under the Securities Act and the Exchange Act) comply with Regulation G under the Exchange Act and Item 10 of Regulation S-K under the Securities Act, as applicable; and the interactive data in eXtensible Business Reporting Language (“XBRL”) included in the Registration Statement, the Prospectus, and the Disclosure Package fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto;

 

(v) RBSM LLP, whose reports on the consolidated financial statements (including the notes and schedules thereto) of the Company and the Subsidiaries are filed with the Commission as part of each of the Registration Statement, the Prospectus and the Disclosure Package or are incorporated by reference therein, and any other accounting firm that has certified Company financial statements and delivered its reports with respect thereto, are, and were during the periods covered by their reports, (i) independent public accountants as required by the Securities Act and the rules of the Public Company Accounting Oversight Board (the “PCAOB”); (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act; and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn; and to the Company’s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Disclosure Package and the Prospectus;

 

  - 10 -  

 

 

(w) subsequent to the respective dates as of which information is given in each of the Registration Statement, the Prospectus and the Disclosure Package, and except as may be otherwise stated in such documents, there has not been (i) any Material Adverse Change or any development that could reasonably be expected to result in a Material Adverse Change, whether or not arising in the ordinary course of business; (ii) any transaction that is material to the Company and the Subsidiaries taken as a whole, contemplated or entered into by the Company or any of the Subsidiaries; (iii) any obligation, contingent or otherwise (including off-balance sheet obligations), directly or indirectly incurred by the Company or any Subsidiary (including, without limitation, any losses or interference with their respective businesses from fire, explosion, flood, earthquakes, accident, war, terrorism, epidemic or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree) that is material to the Company and Subsidiaries taken as a whole; (iv) any change in the capital stock or outstanding indebtedness of the Company or any Subsidiaries; or (v) any dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock;

 

(x) the Shares conform in all material respects to the description thereof contained in the Registration Statement, the Prospectus and the Disclosure Package; and no holder of the Shares will be subject to personal liability by reason of being such a holder;

 

(y) except as disclosed in each of the Registration Statement, the Prospectus and the Disclosure Package, there are no persons with registration or other similar rights to have any equity or debt securities, including securities which are convertible into or exchangeable for equity securities, registered pursuant to the Registration Statement or otherwise registered by the Company under the Securities Act, except for those registration or similar rights which have been validly waived with respect to the offering contemplated by this Agreement; and all of such registration or similar rights are fairly summarized in the Registration Statement, the Prospectus and the Disclosure Package;

 

(z) the Shares have been duly authorized and, when issued and duly delivered by the Company against payment therefor as contemplated by this Agreement, will be validly issued, fully paid and non-assessable, free and clear of any pledge, lien, encumbrance, security interest or other claim, and the issuance and sale of the Shares by the Company is not subject to preemptive or other similar rights (whether arising by operation of law, under the organizational documents of the Company or under any agreement to which the Company or any Subsidiary is a party or otherwise);

 

(aa) the Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and have been approved for listing on Nasdaq, subject to official notice of issuance; the Company has taken all necessary actions to ensure that, as of the Closing Time and each Option Closing Time, it will be in compliance with all applicable corporate governance requirements set forth in Nasdaq’s listing rules then in effect;

 

  - 11 -  

 

 

(bb) none of the Company, the Subsidiaries, or any of their respective directors, officers, representatives or affiliates has taken, nor will take, directly or indirectly, (i) any action which is designed to, has constituted or might reasonably be expected to cause or result in stabilization or manipulation of the price of any security of the Company (including the Shares and any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Shares), whether to facilitate the sale or resale of the Shares or otherwise and (ii) any action which would directly or indirectly violate Regulation M;

 

(cc) none of the Company or any of the Subsidiaries is required to register as a “broker” or “dealer” in accordance with the provisions of the Exchange Act; and all of the information provided to the Underwriters or to counsel for the Underwriters by the Company and, to the knowledge of the Company, its officers and directors and the holders of any securities of the Company in connection with the review of the offering of the Shares by FINRA is true, complete, correct and compliant with FINRA’s rules;

 

(dd) the Company has furnished to the Underwriters a letter agreement in the form attached hereto as Exhibit A (the “Lock-up Agreement”) from each of the persons listed on Exhibit B (each a “Lock-up Person”). If any additional persons shall become officers or directors of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as an officer or director of the Company, to execute and deliver to the Representative a Lock-up Agreement.

 

(ee) any certificate signed by any officer of the Company or any Subsidiary delivered to the Representative or to counsel for the Underwriters pursuant to or in connection with this Agreement or the offer, issuance, and sale of the Shares hereunder shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby;

 

(ff) the form of certificate used to evidence the Common Stock complies in all material respects with all applicable statutory requirements, with any applicable requirements of the organizational documents of the Company and the requirements of Nasdaq;

 

(gg) each of the Company and the Subsidiaries have good and marketable title to all real property owned by them, if any, and good and marketable title to all personal property and other assets reflected as owned by them in the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Disclosure Package and the Prospectus, in each case free and clear of all liens, security interests, pledges, charges, encumbrances, mortgages, equities, adverse claims and other defects, except such as are disclosed in the Registration Statement, the Disclosure Package and the Prospectus or such as those that do not, singly or in the aggregate, materially and adversely affect the value of such property and do not interfere with the use made or proposed to be made of such property by the Company and the Subsidiaries; and any real property, improvements, buildings, equipment and personal property held under lease by the Company or any Subsidiary are held under valid, existing and enforceable leases, with such exceptions as are disclosed in the Registration Statement, the Prospectus and the Disclosure Package or are not material and do not interfere with the use made or proposed to be made of such real property, improvements, buildings, equipment and personal property by the Company or such Subsidiary;

 

  - 12 -  

 

 

(hh) the descriptions in each of the Registration Statement, the Prospectus and the Disclosure Package of the legal or governmental proceedings, contracts, leases and other legal documents therein described present fairly the information required to be shown, and there are no legal or governmental proceedings, contracts, leases, or other documents of a character required to be described in the Registration Statement, the Prospectus or the Disclosure Package or to be filed as exhibits thereto which are not described or filed as required; all agreements between the Company or any of the Subsidiaries and third parties expressly referenced in any of the Registration Statement, the Prospectus and the Disclosure Package are legal, valid and binding obligations of the Company or one or more of the Subsidiaries, enforceable in accordance with their respective terms, except to the extent enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles;

 

(ii) the Company and each Subsidiary owns or possesses adequate licenses or other rights to use all patents, trademarks, service marks, trade names, copyrights, software and designs, trade secrets, manufacturing processes, other intangible property rights and know-how (collectively “Intangibles”) necessary to entitle the Company and each Subsidiary to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus, and neither the Company nor any Subsidiary has received notice of infringement of or conflict with (and neither the Company nor any Subsidiary knows of any such infringement of or conflict with) asserted rights of others with respect to any Intangibles which could, individually or in the aggregate, have a Material Adverse Effect;

 

  - 13 -  

 

 

(jj) the Company owns, possesses, licenses or has other rights to use, on reasonable terms, all patents, trade and service marks, trade and service mark registrations, trade names, copyrights, inventions, trade secrets, technology, know-how and other intellectual property (collectively, the “Intellectual Property”) described in the Registration Statement, Disclosure Package, and Prospectus as being owned or licensed by them or which are reasonably necessary for the conduct of the Company’s business as now conducted or as proposed in the Registration Statement, the Disclosure Package, and the Prospectus to be conducted; the conduct of the respective businesses of the Company and the Subsidiaries does not and the Company does not expect it will, infringe, misappropriate or otherwise conflict in any material respect with any such rights of others; and (i) to the Company’s knowledge, there is no material infringement by third parties of any such Intellectual Property owned by or exclusively licensed to the Company; (ii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (iii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of Intellectual Property owned by or exclusively licensed to the Company, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding, or claim which could have a Material Adverse Effect; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others asserting that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for concluding that any such claim will be asserted, or if asserted, would be successful, or if successfully asserted, could have a Material Adverse Effect; (v) to the Company’s knowledge, the Company and the Subsidiaries do not in the conduct of their business as now conducted or as proposed to be conducted as described in the Registration Statement, the Disclosure Package, or the Prospectus infringe or conflict with any patent right of any third party, or any discovery, invention, product or process which is the subject of a patent issued to any third party, which such infringement or conflict could result in a Material Adverse Change; (vi) there is no prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or any U.S. patent application held by the Company unpatentable which has not been disclosed, or will not be disclosed in the required time period, to the U.S. Patent and Trademark Office; (vii) the Company or a Subsidiary has paid or will pay all maintenance and issue fees that are due or will be due, within the required time period, and has claimed small entity status only as appropriate with respect to all Intellectual Property owned by the Company and the Subsidiaries that is the subject of any application or registration with a governmental body or agency; (viii) to the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property owned by the Company and the Subsidiaries or any facts or circumstances which would render any such Intellectual Property invalid or unenforceable; (ix) the Company and its Subsidiaries have taken reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and to Company’s knowledge no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company; (x) none of the Company-owned Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its Subsidiaries has been obtained or is being used by the Company or any of its Subsidiaries in violation of any contractual obligation binding on the Company or its Subsidiaries; and (xi) the Company and each of its Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any Subsidiary, and all such agreements are in full force and effect;

 

  - 14 -  

 

 

(kk) the Company has established and maintains disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities in a timely manner, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared, (ii) have been evaluated for effectiveness as of the end of the last fiscal period covered by the Registration Statement; and (iii) except as disclosed in each of the Registration Statement, the Disclosure Package and the Prospectus, are effective in all material respects to perform the functions for which they were established;

 

(ll) the Company and each of its Subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; since the end of the Company’s most recent audited fiscal year, except as disclosed in each of the Registration Statement, the Disclosure Package and the Prospectus, there has been (A) no significant deficiency or material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (B) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and the Company is not aware of (x) any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting or (y) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting;

 

  - 15 -  

 

 

(mm) each of the Company and the Subsidiaries has filed or caused to be filed on a timely basis all necessary and material federal, state, local and foreign income and franchise tax returns required to be filed through the date hereof or have properly requested extensions thereof and have timely paid all taxes shown as due thereon and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings and as to which adequate reserves have been provided and will be maintained; and no material tax deficiency has been asserted against any such entity, nor does any such entity know of any material tax deficiency which is likely to be asserted against any such entity; all tax liabilities, accruals and reserves with respect to any income and corporation tax liability for any years not finally determined are adequately provided for to meet any assessments or re-assessments for additional income tax on the respective books of such entities, except to the extent of any inadequacy that would not result in a Material Adverse Effect;

 

(nn) each of the Company and the Subsidiaries maintains insurance (issued by insurers of recognized financial responsibility) of the types, in the amounts and with such deductibles and covering such risks generally deemed adequate for their respective businesses and consistent with insurance coverage maintained by similar companies in similar businesses, including, but not limited to, insurance covering real and personal property owned or leased by the Company and the Subsidiaries against theft, damage, destruction, acts of vandalism and all other risks customarily insured against, all of which insurance is in full force and effect; the Company has no reason to believe that it or any of its Subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material Adverse Change; and neither the Company nor any of its Subsidiaries has been denied any insurance coverage which it has sought or for which it has applied;

 

(oo) except as could, individually or in the aggregate, result in a Material Adverse Change, (i) neither the Company nor any of the Subsidiaries is in violation, or has received notice of any violation with respect to, any applicable environmental, safety or similar law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof applicable to the business of the Company or any of the Subsidiaries; (ii) the Company and the Subsidiaries have received all permits, licenses or other approvals required of them under applicable federal and state occupational safety and health and environmental laws and regulations to conduct their respective businesses, and the Company and the Subsidiaries are in compliance with all terms and conditions of any such permit, license or approval; (iii) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any applicable environmental, safety or similar laws and regulations against the Company or any of its Subsidiaries; and (iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its Subsidiaries relating to any environmental laws;

 

  - 16 -  

 

 

(pp) neither the Company nor any Subsidiary is in violation of or has received notice of any violation with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable federal or state wages and hours law, nor any state law precluding the denial of credit due to the neighborhood in which a property is situated, the violation of any of which could have a Material Adverse Effect;

 

(qq) the Company and each of the Subsidiaries and any “employee benefit plan” (as defined under ERISA (as defined below)) established or maintained by the Company, its Subsidiaries or their respective ERISA Affiliates (as defined below) are in compliance in all material respects with all presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”) and the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”), and no such plan is under audit or investigation by any Governmental Authority; no “reportable event” (as defined in ERISA) has occurred or is reasonably likely to occur with respect to any “pension plan” (as defined in ERISA) for which the Company or any of the Subsidiaries or their respective ERISA Affiliates would have any liability; the Company and each of the Subsidiaries and each of their respective ERISA Affiliates have not incurred and are not reasonably likely to incur liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “pension plan” or (ii) Section 412, 4971, 4975, or 4980B of the Code; and each “pension plan” for which the Company and each of its Subsidiaries and their respective ERISA Affiliates would have any liability, or established or maintained by any such entity, that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; and, for the purposes of this paragraph, “ERISA Affiliate” means, with respect to the Company or any of its Subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Code of which the Company or such Subsidiary is a member;

 

(rr) none of the Company, any of its Subsidiaries, any officer or director purporting to act on behalf of the Company or any of the Subsidiaries or, to the Company’s knowledge, any of their respective employees or agents has at any time (i) made any contributions to any candidate for political office, or failed to disclose fully any such contributions, in violation of law; (ii) made any payment to any state, federal or foreign governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments required or allowed by applicable law; or (iii) engaged in any transactions, maintained any bank account or used any corporate funds except for transactions, bank accounts and funds which have been and are reflected in the normally maintained books and records of the Company and the Subsidiaries;

 

  - 17 -  

 

 

(ss) there are no outstanding loans, extensions of credit or advances or guarantees of indebtedness by the Company or any of the Subsidiaries to or for the benefit of any of the officers or directors of the Company or any of the Subsidiaries or any immediate family members of such officers or directors;

 

(tt) each “forward-looking statement” (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Disclosure Package or the Prospectus, (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement; and no such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading;

 

(uu) all statistical, demographic and market-related data included in the Registration Statement, the Disclosure Package or the Prospectus is based on or derived from sources that the Company believes to be reliable and accurate in all material respects; and to the extent required, the Company has obtained the written consent to the use of such data from such sources;

 

(vv) neither the Company nor any of the Subsidiaries nor, to the knowledge of the Company, any employee or agent of the Company or any of the Subsidiaries has made any payment of funds of the Company or of any Subsidiary or received or retained any funds in violation of any law, rule or regulation or of a character required to be disclosed in the Registration Statement, the Prospectus or the Disclosure Package;

 

(ww) all securities issued by the Company or any of the Subsidiaries have been issued and sold in compliance with (i) all applicable federal and state securities laws; (ii) the laws of the applicable jurisdiction of incorporation of the issuing entity; and (iii) to the extent applicable to the issuing entity, the requirements of Nasdaq;

 

(xx) neither the Company nor any Subsidiary knows of any violation of any municipal, state or federal law, rule or regulation (including those pertaining to environmental matters) concerning any property owned by the Company or any of the Subsidiaries (the “Properties”) thereof which could have a Material Adverse Effect; each of the Properties complies with all applicable zoning laws, ordinances, regulations and deed restrictions or other covenants in all material respects and, if and to the extent there is a failure to comply, such failure does not materially impair the value of any of the Properties and will not result in a forfeiture or reversion of title; neither the Company nor any Subsidiary has received from any governmental authority any written notice of any condemnation of or zoning change affecting the Properties or any part thereof, and neither the Company nor any Subsidiary knows of any such condemnation or zoning change which is threatened and which if consummated could have a Material Adverse Effect; and all liens, charges, encumbrances, claims, or restrictions on or affecting the properties and assets (including the Properties) the Company or any of the Subsidiaries that are required to be described in the Registration Statement, the Disclosure Package or Prospectus are disclosed therein;

 

  - 18 -  

 

 

(yy) except as otherwise disclosed in each of the Registration Statement, the Disclosure Package and the Prospectus, (i) neither the Company nor any of the Subsidiaries nor, to the best knowledge of Company, any other owners of the property at any time or any other party has at any time, handled, stored, treated, transported, manufactured, spilled, leaked, or discharged, dumped, transferred or otherwise disposed of or dealt with, Hazardous Materials (as hereinafter defined) on, to or from the Properties, other than by any such action taken in compliance with all applicable Environmental Statutes or by the Company, any of the Subsidiaries or any other party in connection with the ordinary use of residential, retail or commercial properties owned by the Company and the Subsidiaries; (ii) the Company does not intend to use the Properties or any subsequently acquired properties for the purpose of handling, storing, treating, transporting, manufacturing, spilling, leaking, discharging, dumping, transferring or otherwise disposing of or dealing with Hazardous Materials other than by any such action taken in compliance with all applicable Environmental Statutes or by the Company, any of the Subsidiaries or any other party in connection with the ordinary use of residential, retail or commercial properties owned by the Company and the Subsidiaries; (iii) neither the Company nor any of the Subsidiaries knows of any seepage, leak, discharge, release, emission, spill, or dumping of Hazardous Materials into waters on or adjacent to the Properties or any other real property owned or occupied by any such party, or onto lands from which Hazardous Materials might seep, flow or drain into such waters; (iv) neither the Company nor any of the Subsidiaries has received any notice of, or has any knowledge of any occurrence or circumstance which, with notice or passage of time or both, would give rise to a claim under or pursuant to any federal, state or local environmental statute or regulation or under common law, pertaining to Hazardous Materials on or originating from any of the Properties or any assets described in the Registration Statement, Disclosure Package or the Prospectus, or any other real property owned or occupied by any such party or arising out of the conduct of any such party, including without limitation a claim under or pursuant to any Environmental Statute (hereinafter defined); or (v) neither the Properties nor any other land owned by the Company or any of the Subsidiaries is included or, to the best of the Company’s knowledge, proposed for inclusion on the National Priorities List issued pursuant to CERCLA (as hereinafter defined) by the United States Environmental Protection Agency (the “EPA”) or, to the best of the Company’s knowledge, proposed for inclusion on any similar list or inventory issued pursuant to any other Environmental Statute or issued by any other Governmental Authority (as hereinafter defined);

 

As used herein, “Hazardous Material” shall include, without limitation any flammable explosives, radioactive materials, hazardous materials, hazardous wastes, toxic substances, or related materials, asbestos or any hazardous material as defined by any federal, state or local environmental law, ordinance, rule or regulation including without limitation the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, 42 U.S.C. Sections 9601-9675 (“CERCLA”), the Hazardous Materials Transportation Act, as amended, 49 U.S.C. Sections 1801-1819, the Resource Conservation and Recovery Act, as amended, 42 U.S.C. Sections 6901-6992K, the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Sections 11001-11050, the Toxic Substances Control Act, 15 U.S.C. Sections 2601-2671, the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. Sections 136-136y, the Clean Air Act, 42 U.S.C. Sections 7401-7642, the Clean Water Act (Federal Water Pollution Control Act), 33 U.S.C. Sections 1251-1387, the Safe Drinking Water Act, 42 U.S.C. Sections 300f-300j-26, and the Occupational Safety and Health Act, 29 U.S.C. Sections 651-678, as any of the above statutes may be amended from time to time, and in the regulations promulgated pursuant to each of the foregoing (individually, an “Environmental Statute”) or by any federal, state or local governmental authority having or claiming jurisdiction over the properties and assets described in the Prospectus (a “Governmental Authority”);

 

  - 19 -  

 

 

(zz) in connection with this offering, the Company has not offered and will not offer its Common Stock or any other securities convertible into or exchangeable or exercisable for Common Stock in a manner in violation of the Securities Act; and the Company has not distributed and will not distribute any offering material in connection with the offer and sale of the Shares except for the Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus or the Registration Statement;

 

(aaa) except pursuant to this Agreement, the Company has not incurred any liability for, and there is no broker, finder or other party that is entitled to receive from the Company, any brokerage, finder’s or other fee or commission or similar payment in connection with the transactions herein contemplated;

 

(bbb) no relationship, direct or indirect, exists between or among the Company or any of the Subsidiaries on the one hand, and any other person on the other hand, which is required by the Securities Act to be described in the Registration Statement, the Prospectus or the Disclosure Package, which is not so described;

 

(ccc) none of the Company or any of the Subsidiaries is and, after giving effect to the offering and sale of the Shares or the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the Disclosure Package or the Prospectus, will be, or will be required to register as an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”); and neither the Company nor any of the Subsidiaries is required to register as an “investment adviser” as such term is term is defined in the Investment Advisers Act of 1940, as amended (the “Investment Advisers Act”);

 

(ddd) there are no existing or, to the knowledge of the Company, threatened or imminent labor disputes with, or other work stoppages of, the employees of the Company or any of its Subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company or any of its Subsidiaries, which could have, individually or in the aggregate, a Material Adverse Effect;

 

(eee) the Company, the Subsidiaries and any of the officers and directors of the Company and the Subsidiaries, in their capacities as such, are, and at the Closing Time and any Option Closing Time will be, in compliance with the provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder or implementing the provisions thereof, including Section 402 related to loans and Sections 302 and 906 related to certifications;

 

  - 20 -  

 

 

(fff) except as disclosed in each of the Registration Statement, the Disclosure Package and the Prospectus, (i) to the knowledge of the Company, there has been no security breach or incident, unauthorized access or disclosure, or other compromise of the Company’s or its Subsidiaries’ information technology and computer systems, networks, hardware, software, data and databases (including the data and information of their respective borrowers, customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its Subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its Subsidiaries), equipment or technology (collectively, “IT Systems and Data”) except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; (ii) neither the Company nor its Subsidiaries have been notified of, or have knowledge of any event or condition that would result in, any security breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data; and (iii) the Company and its Subsidiaries have implemented and maintained appropriate controls, policies, procedures, and technological safeguards to protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards, including without limitation, Data Protection Requirements and the Payment Card Industry Data Security Standard (“PCI-DSS”), except with respect to (i) and (ii), for any such security breach or incident, unauthorized access or disclosure, or other compromises, as would not, individually or in the aggregate, result in a Material Adverse Change, or with respect to (iii), where the failure to do so would not, individually or in the aggregate, result in a Material Adverse Change. The Company and its Subsidiaries are presently in material compliance with all applicable laws and statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations and applicable industry standards, including but not limited to, PCI-DSS, relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data, including, but not limited to Personal Data, from unauthorized use, access, misappropriation or modification (collectively, “Data Protection Requirements”); the Company and its Subsidiaries’ IT Systems and Data are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, security deficiencies or vulnerabilities, Trojan horses, time bombs, malware, ransomware, and other corruptants;

 

(ggg) the Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including, but not limited to the California Consumer Privacy Act (“CCPA”), HIPAA, the CAN SPAM Act, the Telephone Consumer Protection Act, the Children’s Online Privacy Protection Act, the European Union e-Privacy Directive, the United Kingdom Data Protection Act, and the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their external and internal policies and procedures relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, transfer (including any cross-border transfers), and analysis (collectively, “Processing”) of Personal Data and for handling and responding to requests from data subjects relating to their Personal Data (the “Policies”). The Company and its Subsidiaries have at all times had a privacy policy for all website and mobile applications operated by or behalf of the Company and its Subsidiaries, and made all disclosures to and obtained all consents from users or customers required by applicable laws and regulatory rules or requirements for the Processing of Personal Data, and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company has at all times been in material compliance with all Policies and consents relating to the Processing of Personal Data. The Company further certifies that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any audit, investigation, remediation, or other corrective action pursuant to any Privacy Law or any contract relating to the Processing of Personal Data; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. “Personal Data” for the purpose hereof means (a) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (b) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (c) “personal data” as defined by GDPR; (d) “personal information” as defined by the CCPA; (e) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (“HIPAA”); and (f) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation or that would be protected as personal data or personal information or similar term under Privacy Laws;

 

  - 21 -  

 

 

(hhh) none of the Company or any of the Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of such entities is in violation of or is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and the Subsidiaries and, to the knowledge of the Company, their affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith;

 

(iii) none of the Company or any of its Subsidiaries, or, to the Company’s knowledge, any of their respective affiliates or any director, officer, agent or employee of, or other person associated with or acting on behalf of, the Company or any of its Subsidiaries, has violated the Bank Secrecy Act, as amended, the Uniting and Strengthening of America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act (USA PATRIOT ACT) of 2001 or the rules and regulations promulgated under any such law or any successor law;

 

(jjj) the operations of the Company and its Subsidiaries and, to the Company’s knowledge, its affiliates are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Money Laundering Control Act of 1986, as amended, any other money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries, or, to the Company’s knowledge, any of its affiliates, with respect to the Money Laundering Laws is pending or, to the Company’s knowledge, threatened;

 

(kkk) each of the Company and its Subsidiaries, and, to the Company’s knowledge, each of their affiliates and any director, officer, agent or employee of, or other person associated with or acting on behalf of, the Company has acted at all times in compliance with applicable Export and Import Laws (as defined below) and there are no claims, complaints, charges, investigations or proceedings pending or expected or, to the knowledge of the Company, threatened between the Company or any of its Subsidiaries and any governmental authority under any Export or Import Laws. The term “Export and Import Laws” means the Arms Export Control Act, the International Traffic in Arms Regulations, the Export Administration Act of 1979, as amended, the Export Administration Regulations, and all other laws and regulations of the United States government regulating the provision of services to non-U.S. parties or the export and import of articles or information from and to the United States of America, and all similar laws and regulations of any foreign government regulating the provision of services to parties not of the foreign country or the export and import of articles and information from and to the foreign country to parties not of the foreign country;

 

  - 22 -  

 

 

(lll) none of the Company or any of its Subsidiaries, or, to the knowledge of the Company, any director, officer, employee, agent, affiliate or other person associated with or acting on behalf of the Company or any of its Subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury of the United Kingdom (“HMT”) or any other relevant sanctions authority (collectively, “Sanctions”), nor is the Company, any of its Subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the Crimea, Cuba, Iran, North Korea, Sudan and Syria (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions; (ii) to fund or facilitate any activities of or business in any Sanctioned Country; or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country;

 

(mmm) the Company and its Subsidiaries have no securities rated by any “nationally recognized statistical rating organization,” as such term is defined in Section 3(a)(62) of the Exchange Act;

 

(nnn) the Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively, “Health Care Authorizations”) issued or required by the appropriate local, state, federal, national, supranational or other foreign regulatory agencies or bodies necessary to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus, including, without limitation, all such Health Care Authorizations required by the U.S. Food and Drug Administration, the Australian Therapeutic Goods Administration, Health Canada or any other comparable state, federal or foreign agencies or bodies to which it is subject, and the Company has not received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization, except for such Health Care Authorizations, the lack of which would not, individually or in the aggregate, result in a Material Adverse Effect;

 

(ooo) the Company and its subsidiaries are, and at all times have been, in compliance with all Health Care Laws applicable to the Company. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.); (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), and the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h); (iii) all other comparable local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries; and (iv) the regulations promulgated pursuant to such statutes. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws in any material respect nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission), except as would not be expected, individually or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or, to the Company’s knowledge, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the Company’s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion; and

 

  - 23 -  

 

 

(ppp) the preclinical tests and clinical study (collectively, “studies”) that are referenced in, or the results of which are referred to in, the Registration Statement, the Disclosure Package or the Prospectus were conducted in all respects in accordance with the applicable Health Care Laws; and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results referenced in the Registration Statement, the Disclosure Package or the Prospectus.

 

The Company has a reasonable basis for making each of the representations set forth in this Section 3. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to ‎Section 6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.

 

4. Certain Covenants:

 

The Company hereby covenants and agrees with each Underwriter:

 

(a) to furnish such information as may be required and otherwise to cooperate in qualifying the Shares for offering and sale under (or otherwise obtaining exemptions from the application of) the securities or blue sky laws of such jurisdictions (both domestic and foreign) as the Representative may designate and to maintain such qualifications, registrations, and exemptions, as applicable, in effect as long as requested by the Representative for the distribution of the Shares, provided that the Company shall not be required to qualify as a foreign corporation or to consent to the service of process under the laws of any such jurisdiction (except service of process with respect to the offering and sale of the Shares) where it is not presently qualified; and to promptly advise the Representative of the receipt by the Company of any notification with respect to the suspension of the qualification, registration, or exemption of the Shares for offer or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment;

 

(b) if, at the time this Agreement is executed and delivered, it is necessary for (i) a post-effective amendment to the Registration Statement or (ii) a Rule 462(b) Registration Statement to be filed with the Commission and become effective before the offering of the Shares may commence, the Company will use its reasonable best efforts to cause such post-effective amendment or Rule 462(b) Registration Statement to become effective and will pay any applicable fees in accordance with the Securities Act as soon as possible and will advise the Representative promptly and, if requested by the Representative, will confirm such advice in writing, (i) when such post-effective amendment or Rule 462(b) Registration Statement has become effective and (ii) if Rule 430A under the Securities Act is used, when the Prospectus has been filed with the Commission pursuant to Rule 424(b) under the Securities Act (which the Company agrees to file in a timely manner in accordance with such Rules);

 

  - 24 -  

 

 

(c) to prepare the Prospectus in a form approved by the Underwriters and file such Prospectus with the Commission pursuant to Rule 424(b) under the Securities Act not later than 10:00 a.m. (New York City time), on the day following the execution and delivery of this Agreement or on such other day as the parties may mutually agree and to furnish promptly (and with respect to the initial delivery of such Prospectus, not later than 10:00 a.m. (New York City time) on the day following the execution and delivery of this Agreement or on such other day as the parties may mutually agree), and for so long as a prospectus relating to the Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), to the Underwriters copies of the Prospectus (or of the Prospectus as amended or supplemented if the Company shall have made any amendments or supplements thereto after the effective date of the Registration Statement) in such quantities and at such locations as the Underwriters may reasonably request for the purposes contemplated by the Securities Act, which Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the version transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T;

 

(d) to advise the Representative promptly and (if requested by the Representative) to confirm such advice in writing, when the Registration Statement has become effective and when any post-effective amendment thereto becomes effective under the Securities Act;

 

(e) to furnish a copy of each proposed Free Writing Prospectus (or any amendment or supplement thereto) to the Representative and counsel for the Underwriters for review, a reasonable amount of time prior to the proposed time of filing or use thereof, and obtain the consent of the Representative prior to referring to, using or filing with the Commission any Free Writing Prospectus (or any amendment or supplement thereto) pursuant to Rule 433(d) under the Securities Act, other than the Issuer Free Writing Prospectuses, if any, identified in Schedule II hereto;

 

(f) to comply with the requirements of Rules 164 and 433 of the Securities Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission, legending and record keeping, as applicable;

 

(g) to advise the Representative immediately, confirming such advice in writing, of (i) the receipt of any comments from, or any request by, the Commission for amendments or supplements to the Registration Statement, the Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus, or for additional information with respect thereto; (ii) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending the use of the Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus, or of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes and, if the Commission or any other government agency or authority should issue any such order, to make every reasonable effort to obtain the lifting or removal of such order as soon as possible; (iii) any examination pursuant to Section 8(e) of the Securities Act concerning the Registration Statement; or (iv) if the Company becomes subject to a proceeding under Section 8A of the Securities Act in connection with the public offering of Shares contemplated herein; to advise the Representative promptly of any proposal to amend or supplement the Registration Statement, the Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus and to file no such amendment or supplement to which the Representative shall reasonably object in writing;

 

  - 25 -  

 

 

(h) to furnish to the Underwriters for a period of five years from the date of this Agreement (i) as soon as available, copies of all annual, quarterly and current reports, proxy statements, or other communications supplied to holders of shares of Common Stock; (ii) as soon as practicable after the filing thereof, copies of all reports filed by the Company with the Commission, FINRA or any securities exchange; and (iii) such other information as the Underwriters may reasonably request regarding the Company and the Subsidiaries, provided, however, that the requirements of this Section shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR;

 

(i) to advise the Underwriters promptly of the happening of any event or development known to the Company within the time during which a Prospectus relating to the Shares (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is required to be delivered under the Securities Act which, in the judgment of the Company or in the reasonable opinion of the Representative or counsel for the Underwriters, (i) would require the making of any change in the Prospectus or the Disclosure Package so that the Prospectus or the Disclosure Package would not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; (ii) as a result of which any Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement relating to the Shares; or (iii) if it is necessary at any time to amend or supplement the Prospectus or the Disclosure Package to comply with any law and, during such time, to promptly prepare and furnish to the Underwriters copies of the proposed amendment or supplement before filing any such amendment or supplement with the Commission and thereafter promptly furnish at the Company’s own expense to the Underwriters and to dealers, copies in such quantities and at such locations as the Representative may from time to time reasonably request of an appropriate amendment or supplement to the Prospectus or the Disclosure Package so that the Prospectus or the Disclosure Package as so amended or supplemented will not, in the light of the circumstances when it (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is so delivered, be misleading or, in the case of any Issuer Free Writing Prospectus, conflict with the information contained in the Registration Statement, or so that the Prospectus or the Disclosure Package will comply with the law;

 

(j) to file promptly with the Commission any amendment or supplement to the Registration Statement, any Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus that may, in the judgment of the Company or the Representative, be required by the Securities Act or requested by the Commission;

 

(k) prior to filing with the Commission any amendment or supplement to the Registration Statement, any Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus, to furnish a copy thereof to the Representative and counsel for the Underwriters and obtain the consent of the Representative to the filing;

 

  - 26 -  

 

 

(l) to furnish promptly to the Representative a signed copy of the Registration Statement, as initially filed with the Commission, and of all amendments or supplements thereto (including all exhibits filed therewith or incorporated by reference therein) and such number of conformed copies of the foregoing as the Representative may reasonably request;

 

(m) to furnish to the Representative, not less than two business days before filing with the Commission, during the period referred to in paragraph (i) above, a copy of any document proposed to be filed with the Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act and during the period of five years hereafter to file all such documents in the manner and within the time periods required by the Exchange Act;

 

(n) to refrain from taking any action that would result in an Underwriter or the Company being required to file with the Commission a Free Writing Prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder;

 

(o) to apply the net proceeds of the sale of the Shares in accordance with its statements under the caption “Use of Proceeds” in the Registration Statement, the Prospectus and the Disclosure Package;

 

(p) to make generally available to its security holders and to deliver to the Representative as soon as practicable, but in any event not later than the end of the fiscal quarter first occurring after the first anniversary of the effective date of the Registration Statement an earnings statement complying with the provisions of Section 11(a) of the Securities Act and of Rule 158 under the Securities Act covering a period of 12 months beginning after the effective date of the Registration Statement; provided, however, that the requirements of this section shall be satisfied to the extent such statement is available on EDGAR;

 

(q) to use its best efforts to maintain the quotation of the Shares on Nasdaq and to file with Nasdaq all documents and notices required by Nasdaq of companies that have securities that are traded and quotations for which are reported by Nasdaq;

 

(r) to comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Shares as contemplated by this Agreement, the Registration Statement, the Disclosure Package and the Prospectus;

 

(s) to engage and maintain, at its expense, a registrar and transfer agent for the Shares;

 

(t) to invest or otherwise use the proceeds received by the Company from its sale of the Shares, and to continue to operate its business, in such a manner as would not require the Company or any of its Subsidiaries to register as (i) an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act or (ii) an “investment adviser” as such term is term is defined in the Investment Advisers Act;

 

  - 27 -  

 

 

(u) to refrain, from the date hereof until 180 days after the date of the Prospectus (such period, the “Company Lock-up Period”), without the prior written consent of the Representative (which consent may be withheld in the Representative’s sole discretion), from, directly or indirectly, (i) offering, pledging, selling, contracting to sell, selling any option or contract to purchase, purchasing any option or contract to sell, granting any option for the sale of, or otherwise disposing of or transferring, (or entering into any transaction or device which is designed to, or could be expected to, result in the disposition by any person at any time in the future of), any share of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or filing or confidentially submitting any registration statement under the Securities Act with respect to any of the foregoing; or (ii) entering into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the Shares to be sold hereunder, (B) any shares of Common Stock issued by the Company upon the exercise or settlement of an equity award, or the exercise of a warrant, outstanding on the date hereof and referred to in the Prospectus, or (C) any issuance of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Disclosure Package and the Prospectus, but only if the holders of such securities agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such Company Lock-up Period without the prior written consent of the Representative (which consent may be withheld in its sole discretion);

 

(v) not to, to cause its Subsidiaries not to, and to ensure its officers, directors and affiliates not to, (i) take, directly or indirectly, any action designed to stabilize or manipulate the price of any security of the Company, or which may cause or result in, or which might in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the Company, to facilitate the sale or resale of any of the Shares; (ii) sell, bid for, purchase or pay anyone any compensation for soliciting purchases of the Shares; or (iii) pay or agree to pay to any person any compensation for soliciting any order to purchase any other securities of the Company and shall, and shall cause each of its officers, directors and affiliates to, comply with all applicable provisions of Regulation M;

 

(w) During the Company Lock-up Period, (i) to enforce all Lock-up Agreements that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or other securities or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such Lock-up Agreements for the duration of the periods contemplated in such agreements and (ii) to announce the Underwriters’ intention to release any director or “officer” (within the meaning of Rule 16a-1(f) under the Exchange Act) of the Company from any of the restrictions imposed by any Lock-up Agreement, by issuing, through a major news service, a press release in form and substance satisfactory to the Representative or, if consented to by the Representative, in a registration statement that is publicly filed in connection with a secondary offering of the Company’s shares promptly following the Company’s receipt of any notification from the Representative in which such intention is indicated, but in any case not later than the close of the third business day prior to the date on which such release or waiver is to become effective; provided, however, that nothing shall prevent the Representative, on behalf of the Underwriters, from announcing the same through a major news service, irrespective of whether the Company has made the required announcement; and provided, further, that no such announcement shall be made of any release or waiver granted solely to permit a transfer of securities that is not for consideration and where the transferee has agreed in writing to be bound by the terms of a Lock-up Agreement;

 

  - 28 -  

 

 

(x) that the Company will comply with all of the provisions of any undertakings in the Registration Statement; and

 

(y) prior to the Closing Time and each applicable Option Closing Time, to furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement, the Disclosure Package, and the Prospectus.

 

The Representative, on behalf of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance.

 

5. Payment of Expenses:

 

(a) The Company agrees to pay all costs and expenses incident to the performance of its obligations under this Agreement, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, including expenses, fees and taxes in connection with (i) the preparation and filing of the Registration Statement, each Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus and any amendments or supplements thereto, and the printing and furnishing of copies of each thereof to the Underwriters and to dealers (including costs of mailing and shipment); (ii) the registration, preparation, issuance and delivery of the Shares to the Underwriters, including any stock, stamp or other transfer taxes or duties payable upon the sale, issuance, and delivery of the Shares to the Underwriters; (iii) the printing of this Agreement, any agreement among the Underwriters, any dealer agreements and any closing documents and furnishing of copies of each to the Underwriters and to dealers (including costs of mailing and shipment); (iv) the qualification or registration (or obtaining exemptions from the qualification or registration) of the Shares for offering and sale under state or foreign laws that the Company and the Representative have mutually agreed are appropriate and the determination of their eligibility for investment under state or foreign law as aforesaid (including the reasonable legal fees and filing fees and other reasonable disbursements of counsel for the Underwriters relating thereto) and the preparation, printing and furnishing of copies of any blue sky surveys or legal investment surveys and a “Canadian Wrapper,” if applicable, to the Underwriters and to dealers; (v) the determination of compliance with the rules and regulations of, and any filing for review of the public offering of the Shares by, FINRA (including the reasonable legal fees and filing fees and other reasonable disbursements of counsel for the Underwriters relating thereto); (vi) the fees and expenses of any transfer agent or registrar for the Shares and miscellaneous expenses referred to in the Registration Statement; (vii) the fees and expenses incurred in connection with the inclusion of the Shares in Nasdaq; (viii) making road show presentations or holding road show meetings with prospective investors and the Underwriters’ sales forces with respect to the offering of the Shares, including, without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the officers of the Company and any such consultants, and, the pro rata cost of any aircraft chartered in connection with the road show, and the costs of all Marketing Materials; (ix) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors; (x) preparing and distributing bound volumes of transaction documents for the Representative and its legal counsel; and (xi) the performance of the Company’s other obligations hereunder. Upon the request of the Representative, the Company will provide funds in advance for filing fees.

 

  - 29 -  

 

 

(b) The Company agrees to reimburse the Representative for (i) its reasonable out-of-pocket expenses in connection with the performance of its activities under this Agreement, including, but not limited to, costs such as printing, facsimile, courier service, direct computer expenses, accommodations and travel, but excluding the fees and expenses of the Underwriters’ outside legal counsel and any other advisors, accountants, appraisers, etc. (other than the fees and expenses of counsel with respect to state securities or blue sky laws and obtaining the filing for review of the public offering of the Shares by FINRA, all of which shall be reimbursed by the Company pursuant to the provisions of Section 5(a) above) and (ii) up to $300,000 of documented legal fees and disbursements of counsel for the Underwriters actually incurred if the public offering of the Shares contemplated by this Agreement is consummated.

 

(c) If this Agreement shall be terminated by the Underwriters, or any of them, because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such Underwriters as have so terminated this Agreement with respect to themselves, severally, upon demand for all fees and disbursements of Underwriters’ counsel and any other advisors, accountants, appraisers, etc. reasonably incurred by such Underwriters in connection with this Agreement or the transactions contemplated herein.

 

6. Conditions of the Underwriters’ Obligations:

 

The obligations of the Underwriters hereunder to purchase Shares at the Closing Time or on each Option Closing Time, as applicable, are subject to the accuracy of the representations and warranties on the part of the Company hereunder on the date hereof and at the Closing Time and on each Option Closing Time, as applicable, the performance by the Company of its obligations hereunder and to the satisfaction of the following further conditions at the Closing Time or on each Option Closing Time, as applicable:

 

(a) The Company shall furnish to the Underwriters at the Closing Time and at each Option Closing Time (if applicable) an opinion and 10b-5 statement of Nelson Mullins Riley & Scarborough LLP, counsel for the Company, addressed to the Underwriters and dated the Closing Time or the applicable Option Closing Time, as the case may be, and in form and substance satisfactory to the Representative.

 

  - 30 -  

 

 

(b) On the date of this Agreement and at the Closing Time and at each Option Closing Time (if applicable), the Representative shall have received from RBSM LLP letters addressed to the Representative and dated the respective dates of delivery thereof and in form and substance satisfactory to the Representative, containing statements and information of the type customarily covered by an accountant’s “comfort letters” to underwriters delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin) issued in connection with underwritten public offerings including, without limitation, the audited and unaudited financial statements and the various other financial disclosures including any pro forma financial statements contained in the Registration Statement, the Disclosure Package and the Prospectus; provided, that the letters delivered at the Closing Time and each Option Closing Time (if applicable) shall use a “cut-off” date no more than three business days prior to such Closing Time or such Option Closing Time, as the case may be.

 

(c) The Representative shall have received at the Closing Time and at each Option Closing Time (if applicable) an opinion and 10b-5 statement of O’Melveny & Myers LLP, counsel to the Underwriters, addressed to the Representative and dated the Closing Time or the applicable Option Closing Time, as the case may be, and in form and substance satisfactory to the Representative.

 

(d) The Representative shall have received at the Closing Time and at each Option Closing Time (if applicable) an opinion of Nevada counsel to the Underwriters, addressed to the Representative and dated the Closing Time or the applicable Option Closing Time, as the case may be, and in form and substance satisfactory to the Representative.

 

(e) The Registration Statement shall have become effective not later than 5:30 p.m., New York City time, on the date of this Agreement, or such later time and date as the Representative shall approve. If Rule 430A under the Securities Act is used, the Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Securities Act at or before 5:30 p.m., New York City time, on the second full business day after the date of this Agreement (or such earlier time as may be required under the Securities Act).

 

(f) Any Rule 462(b) Registration Statement required to be filed prior to the sale of the Shares under the Securities Act shall have been filed on the date hereof and shall have become automatically effective upon such filing.

 

(g) No amendment or supplement to the Registration Statement, the Prospectus or any document in the Disclosure Package shall have been filed to which the Underwriters shall have objected in writing.

 

(h) Prior to the Closing Time and each Option Closing Time, (i) no stop order suspending the effectiveness of the Registration Statement or any order preventing or suspending the use of the Prospectus or any document in the Disclosure Package shall have been issued, and no proceedings for such purpose shall have been initiated or, to the Company’s knowledge, threatened by the Commission, and no suspension of the qualification of the Shares for offering or sale in any jurisdiction, or the initiation or, to the Company’s knowledge, threatening of any proceedings for any of such purposes, has occurred; (ii) all requests for additional information on the part of the Commission shall have been complied with to the reasonable satisfaction of the Representative; (iii) the Registration Statement shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (iv) the Prospectus and the Disclosure Package shall not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and (v) the Company shall not have become the subject of a proceeding under Section 8A of the Securities Act in connection with the offering of the Shares.

 

  - 31 -  

 

 

(i) All filings with the Commission required by Rule 424 under the Securities Act (including the information required by Rule 430A under the Securities Act) to have been filed by the Closing Time shall have been made in the manner and within the applicable time period prescribed for such filing by such Rule.

 

(j) Between the time of execution of this Agreement and the Closing Time or the relevant Option Closing Time, (i) there shall not have been any Material Adverse Change; and (ii) no transaction which is material and unfavorable to the Company shall have been entered into by the Company or any of the Subsidiaries, in each case, which in the Representative’s sole judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares as contemplated by the Registration Statement.

 

(k) The Shares shall have been approved for listing on Nasdaq.

 

(l) FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms or other arrangements of the transactions contemplated hereby.

 

(m) On or prior to the date hereof, the Representative shall have received Lock-up Agreements from the Lock-Up Persons, and such letter agreements shall be in full force and effect.

 

(n) The Company shall furnish to the Underwriters, at the Closing Time and at each Option Closing Time (if applicable), a certificate of its Chief Executive Officer or President and its Chief Financial Officer, dated the Closing Time or the applicable Option Closing Time, to the effect that:

 

(i) the representations, warranties, and covenants of the Company in this Agreement are true and correct, with the same force and effect as if made on and as of such date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed under this Agreement or satisfied at or prior to such date;

 

(ii) no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued and no proceedings for that purpose have been instituted or are pending or threatened by the Commission under the Securities Act; and

 

(iii) for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change.

 

  - 32 -  

 

 

(o) The Company shall furnish to the Underwriters, as of the date hereof, at the Closing Time and at each Option Closing Time (if applicable), a certificate of its Chief Financial Officer, dated the Closing Time or the applicable Option Closing Time, with respect to certain financial data contained in the Disclosure Package and the Prospectus, providing “management comfort” with respect to such information, in form and substance satisfactory to the Representative.

 

(p) The Company shall have furnished to the Underwriters and counsel for the Underwriters such other information, documents, opinions and certificates as to the accuracy and completeness of any statement in the Registration Statement, the Prospectus and the Disclosure Package, the representations, warranties and statements of the Company contained herein, and the performance by the Company of its covenants contained herein, and the fulfillment of any conditions contained herein, as of the Closing Time or any Option Closing Time, as the Underwriters or their counsel may reasonably request, and all proceedings taken by the Company in connection with the issuance and sale of the Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representative and counsel for the Underwriters.

 

If any condition specified in this ‎Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representative by notice from the Representative to the Company at any time on or prior to the Closing Time and, with respect to the Option Shares, at any time on or prior to the applicable Option Closing Time, which termination shall be without liability on the part of any party to any other party, except that ‎Sections 5, 7, ‎and 9 shall at all times be effective and shall survive such termination.

 

7. Termination:

 

The obligations of the several Underwriters hereunder shall be subject to termination in the absolute discretion of the Representative, at any time prior to the Closing Time or any Option Closing Time, (i) if any of the conditions specified in Section 6 hereof shall not have been fulfilled when and as required by this Agreement to be fulfilled; (ii) if there has been, in the judgment of the Representative, since the respective dates as of which information is given in the Registration Statement, the Prospectus or the Disclosure Package, any Material Adverse Change, or any development involving a prospective Material Adverse Change, or material change in management of the Company or any Subsidiary, whether or not arising in the ordinary course of business;(iii) if there has occurred any outbreak or escalation of hostilities or other national or international calamity or crisis or change in economic, political, health or other conditions, the effect of which on the United States or international financial markets is such as to make it, in the judgment of the Representative, impracticable or inadvisable to market the Shares or enforce contracts for the sale of the Shares; (iv) if trading in any securities of the Company has been suspended by the Commission or by Nasdaq, or if trading generally on the New York Stock Exchange or Nasdaq has been suspended or halted (including an automatic halt in trading pursuant to market-decline triggers, other than those in which solely program trading is temporarily halted), or limitations on prices for trading (other than limitations on hours or numbers of days of trading) have been fixed, or maximum ranges for prices for securities have been required, by such exchange or FINRA or the over-the-counter market or by order of the Commission or any other governmental authority; (v) any federal, state, local or foreign statute, regulation, rule or order of any court or other governmental authority has been enacted, published, decreed or otherwise promulgated which, in the reasonable opinion of the Representative, materially adversely affects or will materially adversely affect the business or operations of the Company; or (vi) any action has been taken by any federal, state, local or foreign government or agency in respect of its monetary or fiscal affairs which, in the reasonable opinion of the Representative, could reasonably be expected to have a material adverse effect on the securities markets in the United States.

 

  - 33 -  

 

 

If the Representative elects to terminate this Agreement as provided in this Section 7, the Company and the Underwriters shall be notified promptly by telephone, promptly confirmed by facsimile or e-mail.

 

If the sale to the Underwriters of the Shares, as contemplated by this Agreement, is not carried out by the Underwriters for any reason permitted under this Agreement or if such sale is not carried out because the Company shall be unable to comply in all material respects with any of the terms of this Agreement, the Company shall not be under any obligation or liability under this Agreement (except to the extent provided in Sections 5 and 9 hereof) and the Underwriters shall be under no obligation or liability to the Company under this Agreement (except to the extent provided in Section 9 hereof) or to one another hereunder.

 

8. Increase in Underwriters’ Commitments:

 

Subject to Sections 6 and 7 hereof, if any Underwriter shall fail, refuse, or default at the Closing Time or at any Option Closing Time in its obligation to take up and pay for the Shares to be purchased by it under this Agreement on such date, the Representative shall have the right, within 36 hours after such default, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Shares which such Underwriter shall have agreed but failed to take up and pay for (the “Defaulted Shares”). Absent the completion of such arrangements within such 36-hour period, (i) if the total number of Defaulted Shares does not exceed 10% of the total number of Shares to be purchased on such date, each non-defaulting Underwriter, severally and not jointly, shall take up and pay for (in addition to the number of Shares which it is otherwise obligated to purchase on such date pursuant to this Agreement) the portion of the total number of Shares agreed to be purchased by the defaulting Underwriter on such date in the proportion that its underwriting obligations hereunder bears to the underwriting obligations of all non-defaulting Underwriters; and (ii) if the total number of Defaulted Shares exceeds 10% of such total, the Representative may terminate this Agreement by notice to the Company, without liability of any party to any other party except that the provisions of Sections 5 and 9 hereof shall at all times be effective and shall survive such termination.

 

Without relieving any defaulting Underwriter from its obligations hereunder, the Company agrees with the non-defaulting Underwriters that it will not sell any Shares hereunder on such date unless all of the Shares to be purchased on such date are purchased on such date by the Underwriters (or by substituted Underwriters selected by the Representative with the approval of the Company or selected by the Company with the approval of the Representative).

 

If a new Underwriter or Underwriters are substituted for a defaulting Underwriter in accordance with the foregoing provision, the Company or the non-defaulting Underwriters shall have the right to postpone the Closing Time or the relevant Option Closing Time for a period not exceeding five business days in order that any necessary changes in the Registration Statement and Prospectus and other documents may be effected.

 

  - 34 -  

 

 

The term “Underwriter” as used in this Agreement shall refer to and include any Underwriter substituted under this Section 8 with the same effect as if such substituted Underwriter had originally been named in this Agreement.

 

9. Indemnity and Contribution by the Company and the Underwriters:

 

(a) The Company agrees to indemnify, defend and hold harmless each Underwriter and any person who controls any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, any “affiliate” (within the meaning of Rule 405 under the Act) of any Underwriter, and the respective directors, officers, employees, members and agents of each Underwriter, and the successors and assigns of all of the foregoing persons, from and against, and to reimburse any and all expenses incurred in connection with, any loss, expense, liability, damage or claim (including the reasonable cost of investigation) which, jointly or severally, any such Underwriter or other person may incur under the Securities Act, the Exchange Act or otherwise, insofar as such loss, expense, liability, damage or claim arises out of or is based upon (i) any breach of any representation, warranty or covenant of the Company contained herein; (ii) any failure on the part of the Company to comply with any applicable law, rule or regulation relating to the offering of securities being made pursuant to the Prospectus; (iii) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment), any Issuer Free Writing Prospectus that the Company has filed or was required to file with the Commission or is otherwise required to retain, the Prospectus (the term Prospectus for the purpose of this Section 9 being deemed to include any Preliminary Prospectus, the Prospectus and the Prospectus as amended or supplemented by the Company) or the Disclosure Package; (iv) any application or other document, or any amendment or supplement thereto, executed by the Company or based upon written information furnished by or on behalf of the Company filed in any jurisdiction (domestic or foreign) to qualify the Shares under the securities or blue sky laws thereof or filed with the Commission or any securities association or securities exchange (each an “Application”); (v) any omission or alleged omission to state a material fact required to be stated in any such Registration Statement, or necessary to make the statements made therein, in the light of the circumstances under which they were made, not misleading; (vi) any omission or alleged omission from any such Issuer Free Writing Prospectus, Prospectus, Disclosure Package, Testing-the-Waters Communication or Marketing Material, or any Application, of a material fact necessary to make the statements made therein, in the light of the circumstances under which they were made, not misleading; (vii) any untrue statement or alleged untrue statement of any material fact contained in any audio or visual materials used in connection with the marketing of the Shares, including, without limitation, slides, videos, films and tape recordings, the Testing-the-Waters Communications and the Marketing Materials; and (viii) any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by the foregoing clauses; except, in the case of (iii), (v) and (vi) above only, insofar as any such loss, expense, liability, damage or claim arises out of or is based upon any untrue statement or alleged untrue statement or omission or alleged omission of a material fact contained in and in conformity with information furnished in writing by the Underwriters through the Representative to the Company expressly for use in such Registration Statement, Prospectus or Application. The indemnity agreement set forth in this Section 9(a) shall be in addition to any liability which the Company may otherwise have.

 

  - 35 -  

 

 

If any action, suit or proceeding (a “Proceeding”) is brought against an Underwriter or other person in respect of which indemnity may be sought against the Company pursuant to the foregoing paragraph, such indemnified party shall promptly notify the Company in writing of the institution of such Proceeding and the Company shall assume the defense of such Proceeding including the employment of counsel reasonably satisfactory to the indemnified party and payment of any and all expenses related to such Proceeding or incurred in connection with such indemnified party’s successful enforcement of this Section 9(a); provided, however, that any failure or delay to so notify the Company will not relieve the Company of any obligation hereunder, except to the extent that its ability to defend is actually impaired by such failure or delay. Such indemnified party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless the employment of such counsel shall have been authorized in writing by the Company in connection with the defense of such action, or the Company shall not have employed counsel to have charge of the defense of such action within a reasonable time or such indemnified party or parties shall have reasonably concluded (based on the advice of counsel) that there may be defenses available to it or them which are different from or additional to those available to the Company (in which case the Company shall not have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events such fees and expenses shall be borne by the Company and paid as incurred (it being understood, however, that the Company shall not be liable for the expenses of more than one separate firm of attorneys for the Underwriters or controlling persons in any one action or series of related actions in the same jurisdiction (other than local counsel in any such jurisdiction) representing the indemnified parties who are parties to such action). Anything in this paragraph to the contrary notwithstanding, the Company shall not be liable for any settlement of any such Proceeding effected without its consent, and the Company shall not, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened Proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such Proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.

 

(b) Each Underwriter agrees, severally and not jointly, to indemnify, defend and hold harmless the Company, the Company’s directors, the Company’s officers that signed the Registration Statement, and any person who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, and the successors and assigns of all of the foregoing persons, from and against any loss, expense, liability, damage or claim (including the reasonable cost of investigation) which the Company or any such person may incur under the Securities Act, the Exchange Act or otherwise, insofar as such loss, expense, liability, damage or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any Testing-the-Waters Communication or any Marketing Material that the Company has filed or was required to file with the Commission or is otherwise required to retain, or any Application or (ii) any omission or alleged omission to state a material fact required to be stated in any such Registration Statement, Prospectus, Issuer Free Writing Prospectus, Disclosure Package, Testing-the-Waters Communication or Marketing Material, or necessary to make the statements made therein, in the light of the circumstances under which they were made, not misleading, but in each case only insofar as such untrue statement or alleged untrue statement or omission or alleged omission was made in such Registration Statement, Issuer Free Writing Prospectus, Prospectus or Application in reliance upon and in conformity with information furnished in writing by the Underwriters through the Representative to the Company expressly for use therein. The statements set forth in the paragraphs [●] under the caption “Underwriting” in the Preliminary Prospectus, the Disclosure Package and the Prospectus (to the extent such statements relate to the Underwriters) constitute the only information furnished by or on behalf of any Underwriter through the Representative to the Company for purposes of Section 3(l) and Section 3(m) and this Section 9.

 

  - 36 -  

 

 

If any Proceeding is brought against the Company, or any such person in respect of which indemnity may be sought against any Underwriter pursuant to the foregoing paragraph, the Company, or such person shall promptly notify the Representative in writing of the institution of such Proceeding and the Representative, on behalf of the Underwriters, shall assume the defense of such Proceeding, including the employment of counsel reasonably satisfactory to the indemnified party and payment of any and all expenses related to such Proceeding or incurred in connection with such indemnified party’s successful enforcement of this Section 9(b). Such indemnified party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless the employment of such counsel shall have been authorized in writing by the Representative in connection with the defense of such action or the Representative shall not have employed counsel to have charge of the defense of such action within a reasonable time or such indemnified party or parties shall have reasonably concluded (based on the advice of counsel) that there may be defenses available to it or them which are different from or additional to those available to the Underwriters (in which case the Representative shall not have the right to direct the defense of such action on behalf of the indemnified party or parties), in any of which events such fees and expenses shall be borne by such Underwriter and paid as incurred (it being understood, however, that the Underwriters shall not be liable for the expenses of more than one separate firm of attorneys in any one action or series of related actions in the same jurisdiction (other than local counsel in any such jurisdiction) representing the indemnified parties who are parties to such action). Anything in this paragraph to the contrary notwithstanding, no Underwriter shall be liable for any settlement of any such Proceeding effected without its written consent, and the Underwriters shall not, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened Proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such Proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.

 

  - 37 -  

 

 

(c) If the indemnification provided for in this Section 9 is, for any reason, unavailable or insufficient to hold harmless an indemnified party under Sections 9(a) and (b) in respect of any losses, expenses, liabilities, damages or claims referred to therein, then each applicable indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, expenses, liabilities, damages or claims (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Shares or (ii) if (but only if) the allocation provided by (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in (i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, expenses, liabilities, damages or claims, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other hand shall be deemed to be in the same proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company bear to the underwriting discounts and commissions received by the Underwriters. The relative fault of the Company on the one hand and of the Underwriters on the other hand shall be determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, expenses, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating, preparing to defend or defending any Proceeding. The provisions set forth in ‎Sections 9(a) and 9(b) with respect to notice of commencement of any Proceeding shall apply if a claim for contribution is to be made under this ‎Section 9(c); provided, however, that no additional notice shall be required with respect to any action for which notice has been duly given under Sections 9(a) or 9(b) for purposes of indemnification.

 

(d) The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 9 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in Section 9(c)(i) and, if applicable, Section 9(c)(ii) above. Notwithstanding the provisions of this Section 9, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions applicable to the Shares purchased by such Underwriter. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 9 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on Schedule I hereto.

 

10. Survival:

 

The indemnity and contribution agreements contained in Section 9 and the covenants, warranties and representations of the Company contained in Sections 3 and 4 of this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of any Underwriter, or any person who controls any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, and the respective directors, officers, employees and agents of each Underwriter or by or on behalf of the Company, its directors and officers, or any person who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, and shall survive any termination of this Agreement and the sale and delivery of the Shares. The Company and each Underwriter agree promptly to notify the others of the commencement of any litigation or proceeding against it and, in the case of the Company, against any of the Company’s officers and directors, in connection with the sale and delivery of the Shares, or in connection with the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, or the Prospectus.

 

  - 38 -  

 

 

11. Duties:

 

Nothing in this Agreement shall be deemed to create a partnership, joint venture or agency relationship between the parties. The Underwriters undertake to perform such duties and obligations only as expressly set forth herein. Such duties and obligations of the Underwriters with respect to the Shares shall be determined solely by the express provisions of this Agreement, and the Underwriters shall not be liable except for the performance of such duties and obligations with respect to the Shares as are specifically set forth in this Agreement. The Company acknowledges and agrees that: (i) the purchase and sale of the Shares pursuant to this Agreement, including the determination of the public offering price of the Shares and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (ii) in connection with each transaction contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the financial advisor, agent or fiduciary of the Company or its affiliates, stockholders, creditors or employees or any other party; (iii) no Underwriter has assumed or will assume an advisory, agency or fiduciary responsibility in favor of the Company with respect to any of the transactions contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters); (iv) the several Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and that the several Underwriters have no obligation to disclose any of such interests; and (v) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. The Company acknowledges that the Underwriters disclaim any implied duties (including any fiduciary duty), covenants or obligations arising from the Underwriters’ performance of the duties and obligations expressly set forth herein. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the several Underwriters with respect to any breach or alleged breach of agency, advisory, fiduciary or similar duty.

 

12. Notices:

 

Except as otherwise herein provided, all statements, requests, notices and agreements shall be in writing and effective only on receipt and, if sent to the Representative, will be mailed, delivered or e-mailed to: B. Riley Securities, Inc., 299 Park Avenue, New York, NY 10171, Attention: Syndicate Department, with a copy (which shall not constitute notice) to the Representative’s counsel at O’Melveny & Myers LLP, Two Embarcadero Center, 28th Floor, San Francisco, California 94111, Attention: C. Brophy Christensen, Jr., Esq and Jeeho M. Lee, Esq, or, if sent the Company, will be mailed, delivered or e-mailed to Synergy CHC Corp., 865 Spring Street, Westbrook, Maine 04092, Attention: Jack Ross, with a copy (which shall not constitute notice) to the Company’s counsel at Nelson Mullins Riley & Scarborough LLP, 4140 Parklake Avenue, Suite 200, Raleigh, North Carolina 27612, Attention: W. David Mannheim. Any party hereto may change the address for receipt of communications by giving written notice to the others.

 

  - 39 -  

 

 

13. Governing Law:

 

This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to conflicts of laws principles. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in the (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan and (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and the Company and each Underwriter irrevocably submit to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. The Company and each Underwriter irrevocably and unconditionally waives any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

 

14. Parties at Interest:

 

The Agreement herein set forth has been and is made solely for the benefit of the Underwriters, the Company, and the controlling persons, directors, officers, and other persons referred to in Section 9 hereof, and their respective successors, assigns, executors and administrators. No other person, partnership, association or corporation (including a purchaser, as such purchaser, from any of the Underwriters) shall acquire or have any right under or by virtue of this Agreement.

 

15. Successors and Assigns:

 

This Agreement shall be binding upon each of the Underwriters and the Company and their respective successors and assigns and any successor or assign of any substantial portion of the Company’s and any of the Underwriters’ respective businesses and/or assets.

 

16. Counterparts and Facsimile Signatures:

 

This Agreement may be signed by the parties in counterparts which together shall constitute one and the same agreement among the parties. A facsimile or .pdf signature shall constitute an original signature for all purposes.

 

17. Partial Unenforceability:

 

The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

  - 40 -  

 

 

18. Recognition of the U.S. Special Resolution Regimes:

 

(a) In the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

 

(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined below) of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

 

For purposes of this Agreement, (A) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

 

19. General Provisions:

 

This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings in this Agreement have been inserted as a matter of convenience of reference and shall not affect the construction or interpretation of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

  - 41 -  

 

 

If the foregoing correctly sets forth the understanding among the Company and the Underwriters, please so indicate in the space provided below for the purpose, whereupon this Agreement shall constitute a binding agreement among the Company and the Underwriters.

 

  Very truly yours,
     
  SYNERGY CHC CORP.
     
  By:       
  Name:  
  Title:  

 

Accepted and agreed to as
of the date first above written:

 

B. RILEY SECURITIES, INC.  
     
By:              
Name:    
Title:    

 

For itself and as Representative of the other
Underwriters named on Schedule I hereto.

 

 

 

 

Schedule I

 

Underwriter    

Number of Initial

Shares to be Purchased

 
B. Riley Securities, Inc.     [●]  
[●]     [●]  
[●]     [●]  
Total     [●]  

 

I-1

 

 

Schedule II

 

Issuer Free Writing Prospectuses

 

[●]

 

II-1

 

 

Schedule III

 

      Pricing Terms  
Number of Initial Shares:     [●]  
         
Number of Option Shares:     [●]  
         
Public Offering Price per Share:     $[●]  
         
[Underwriting Discount:     [●]]  

 

III-1

 

 

EXHIBIT A

 

Form of Lock-up Agreement

 

A-1

 

 

                   , 2021

 

B. Riley Securities, Inc.
As representative of the several Underwriters

 

c/o B. Riley Securities, Inc.
299 Park Avenue
New York, NY 10171

 

Re: SYNERGY CHC CORP. - Initial Public Offering

 

Ladies and Gentlemen:

 

The undersigned understands that you, as representative (the “Representative”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule A to such agreement (collectively, the “Underwriters”), with Synergy CHC Corp, a Nevada corporation (the “Company”), providing for a public offering (the “Offering”) of shares (the “Shares”) of common stock of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 filed or to be filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.

 

In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this letter agreement (this “Letter Agreement”) and continuing to and including the date 180 days after the date of the final prospectus (the “Prospectus”) with respect to the Offering (the “Restricted Period”), the undersigned will not offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company, whether now owned or hereinafter acquired, owned directly by the undersigned (including holding as a custodian) or with respect to which the undersigned has beneficial ownership within the rules and regulations of the SEC (collectively, the “Lock-Up Shares”). The foregoing restriction is expressly agreed to preclude the undersigned from engaging in any hedging or other transaction that is designed to or that reasonably could be expected to lead to or result in a sale or disposition of the Lock-Up Shares even if such Lock-Up Shares would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the Lock-Up Shares or with respect to any security that includes, relates to, or derives any significant part of its value from such Lock-Up Shares.

 

A-2

 

 

If the undersigned is an officer or director of the issuer, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed Shares the undersigned may purchase in the Offering.

 

In addition, the undersigned agrees that, without the prior written consent of the Representative, it will not, during the Restricted Period, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock.

 

Notwithstanding the foregoing, the undersigned may, without the consent of the Representative:

 

(A) transfer or dispose of the Lock-Up Shares as a bona fide gift or gifts, provided that the donee or donees thereof agree to be bound in writing by the restrictions set forth herein;

 

(B) transfer or dispose of the Lock-Up Shares to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein and any such transfer shall not involve a disposition for value;

 

(C) transfer or dispose of the Lock-Up Shares if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (i) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or to any investment fund or other entity controlled or managed by the undersigned or (ii) as part of a distribution, transfer or disposition by the undersigned to its stockholders, partners, members, beneficiaries or other equity holders, provided, in each case, that the transferees thereof agree to be bound in writing by the restrictions set forth herein and any such transfer shall not involve a disposition for value;

 

(D) transfer or dispose of the Lock-Up Shares by will, other testamentary document or intestate succession upon the death of the undersigned, provided that the legatee, heir or other transferee agrees to be bound in writing by the restrictions on transfer set forth herein and any such transfer shall not involve a disposition for value, and provided further that any required filing made pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shall include a footnote noting the circumstances described in this clause (D) and no other public filing or announcement shall be required or shall be made voluntarily in connection with such transfer or disposition;

 

A-3

 

 

(E) transfer or dispose of the Lock-Up Shares by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or other court order, provided that the recipient agrees to be bound in writing by the restrictions set forth herein, provided further that any required filing made pursuant to Section 16(a) of the Exchange Act, shall include a footnote noting the circumstances described in this clause (E) and no other public filing or announcement shall be required or shall be made voluntarily in connection with such transfer or disposition;

 

(F) enter into a trading plan providing for the sale of the Lock-Up Shares by the undersigned, which trading plan meets the requirements of Rule 10b5-1(c) under the Exchange Act, provided, however, that such plan does not provide for, or permit, the sale of any Lock-Up Shares during the Restricted Period and no filing under Section 16(a) of the Exchange Act or other public announcement is voluntarily made or required regarding such plan during the Restricted Period;

 

(G) transfer or dispose of the Lock-Up Shares to the Company solely to satisfy tax withholding obligations pursuant to the Company’s equity incentive plans or arrangements disclosed in the Prospectus, provided that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be required or shall be voluntarily made during the period beginning on the date hereof and continuing to and including the date that is 30 days after the date of the Prospectus (the “30 Day Period”), and after the 30 Day Period, if the undersigned is required to file a report under Section 16(a) of the Exchange Act during the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (G) and no other public filing or announcement shall be required or shall be made voluntarily in connection with such transfer or disposition;

 

(H) transfer the Lock-Up Shares to the Company pursuant to agreements in effect on the date of the Prospectus and as described in the Prospectus under which the Company has the option to repurchase shares or forfeit the Lock-Up Shares upon termination of service of the undersigned, provided that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be required or shall be voluntarily made during the period beginning on the date hereof and continuing to and including the date that is 60 days after the date of the Prospectus (the “60 Day Period”), and after the 60 Day Period, if the undersigned is required to file a report under Section 16(a) of the Exchange Act during the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (H) and no other public filing or announcement shall be required or shall be made voluntarily in connection with such repurchase or forfeiture;

 

(I) dispose of the Lock-Up Shares solely in connection with the “cashless” exercise of stock options or warrants to acquire shares of Common Stock described in the Prospectus or issued pursuant to an equity plan or arrangement described in the Prospectus (the term “cashless” exercise being intended to include the sale of a portion of the shares issuable upon exercise of the stock options or warrants or previously owned shares to the Company to cover payment of the exercise price) for the purpose of exercising such stock options or warrants, in any event, solely if such stock options or warrants would otherwise expire during the Restricted Period, provided that any shares of Common Stock received upon such exercise shall be subject to all of the restrictions set forth in this Letter Agreement and provided, further, that any filing required under Section 16(a) of the Exchange Act shall clearly indicate in the codes and footnotes thereto that any disposition of shares in connection with a “cashless” exercise was made solely to the Company and no other public filing or announcement shall be made voluntarily in connection with such exercise; and

 

A-4

 

 

(J) transfer or dispose of any Lock-Up Shares acquired in open market transactions after completion of the Offering, provided that no such transaction is required to be, or is, publicly announced (whether on Form 4, Form 5 or otherwise) during the Restricted Period and no other public filing or announcement shall be made voluntarily in connection with such transfer or disposition.

 

The undersigned now has, and, except as contemplated by clauses (A) through (J) above, for the duration of the Restricted Period will have, good and marketable title to the Lock-Up Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Shares except in compliance with the foregoing restrictions.

 

If the undersigned is an officer or director of the Company, (i) B. Riley Securities, Inc. agrees that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock of the Company, B. Riley Securities, Inc. will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by B. Riley Securities, Inc. hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described herein to the extent and for the duration that such terms remain in effect at the time of the transfer.

 

Notwithstanding anything to the contrary contained herein, this Agreement will automatically terminate and the undersigned will be released from all of his, her or its obligations hereunder upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreement, the Company advises the Representative in writing that it has determined not to proceed with the Offering, (ii) the Company files an application to withdraw the registration statement related to the Offering, (iii) the Underwriting Agreement is executed but is terminated (other than the provisions thereof which survive termination) prior to payment for and delivery of the Shares to be sold thereunder, or (iv) December 31, 2021, in the event that the Underwriting Agreement has not been executed by such date; provided, however, that the Company may, by written notice to you prior to such date, extend such date for a period of up to three additional months.

 

This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.

 

The undersigned understands that the Company and the Underwriters are relying upon this Agreement in proceeding toward consummation of the Offering. The undersigned further understands that this Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, and assigns.

 

[signature page follows]

 

A-5

 

 

  Very truly yours,
   
   
  Name of Security Holder (Print exact name)
     
  By:  
    Signature
     
  If not signing in an individual capacity:
     
   
  Name of Authorized Signatory (Print)
     
   
  Title of Authorized Signatory (Print)
     
  (indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)

 

A-6

 

 

EXHIBIT B

 

Lock-up Persons

 

1. Jack Ross
2. Brendan Horning
3. Alfred Baumeler
4. Jaime Fickett
5. J. Paul SoRelle
6. Nitin Kaushal
7. Stephen Fryer
8. BlackDog Marketing & Advertising
9. CastleHill Capital Inc
10. Dunhill Distribution Group Inc.
11. Gowan Capital Inc
12. Gowan Private Equity Inc
13. Hand MD Corp.
14. Knight Therapeutics (Barbados) Inc
15. SoRelle Family Partnership LLLP
16. TPR Investments PTY Limited
17. Mark Richards

 

A-7

 

 

Exhibit 2.1

 

AGREEMENT AND PLAN OF MERGER

 

by and among

 

Oro Capital Corporation

 

Synergy Merger Sub, Inc.,

 

and

 

Synergy Strips Corp.

 

dated as of April 7, 2014

 

 
 

 

Table of Contents

 

  Page
     
ARTICLE 1 THE MERGER 1
1.1. The Merger 1
1.2. Closing 1
1.3. Effective Time of the Merger 2
1.4. Effects of the Merger 2
1.5. Certificate of Incorporation and Bylaws of the Surviving Corporation 2
1.6. Directors and Officers 2
ARTICLE 2 EFFECT OF THE MERGER ON THE CAPITAL STOCK OF COMPANY AND MERGER SUB 2
2.1. Effect on Capital Stock 2
2.2. Intentionally Omitted 3
2.3. Issuance and Reservation of Shares 3
2.4. Dissenting Shares 4
2.5. Additional Actions 4
ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY 4
3.1. Organization, Standing and Corporate Power 4
3.2. Subsidiaries 4
3.3. Capital Structure of the Company 5
3.4. Corporate Authority; Noncontravention 5
3.5. Governmental Authorization 5
3.6. Financial Statements 6
3.7. Absence of Certain Changes or Events 6
3.8. Certain Fees 6
3.9. Litigation; Labor Matters; Compliance with Laws 6
3.10. Benefit Plans 7
3.11. Tax Returns and Tax Payments 7
3.12. Environmental Matters 8
3.13. Material Contract Defaults 8
3.14. Accounts Receivable 8
3.15. Properties 8
3.16. Intellectual Property 9
3.17. Board Recommendation 9
3.18. Undisclosed Liabilities 9
3.19. No Registration of Securities 9
3.20. Parent Information 9
3.21. Licenses. 9
3.22. FDA and Related Matters. 10
3.23. Questionable Payments. 11
3.24. Full Disclosure 12

 

 
 

 

ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB 12
4.1. Organization, Standing and Corporate Power 12
4.2. Subsidiaries 12
4.3. Capital Structure of Parent and Merger Sub 12
4.4. Corporate Authority; Noncontravention 13
4.5. Government Authorization 14
4.6. SEC Documents; Undisclosed Liabilities; Financial Statements 14
4.7. Absence of Certain Changes 15
4.8. Certain Fees 15
4.9. Litigation; Labor Matters; Compliance with Laws 15
4.10. Benefit Plans 16
4.11. Certain Employee Payments 16
4.12. Tax Returns and Tax Payments 16
4.13. Intentionally Omitted 16
4.14. Material Contract Defaults 16
4.15. Accounts Receivable 17
4.16. Properties 17
4.17. Intellectual Property 17
4.18. Board Determination 17
4.19. Required Parent Share Issuance Approval 17
4.20. Undisclosed Liabilities 17
4.21. Full Disclosure 17
ARTICLE 5 CONDUCT OF BUSINESSES PENDING THE MERGER 18
5.1. Conduct of Business by the Company Pending the Merger. 18
5.2. Conduct of Business by Parent and Merger Sub Pending the Merger. 18
ARTICLE 6 COVENANTS OF PARENT OR COMPANY 19
6.1. Director and Officer Appointments 19
6.2. Private Placement. . 19
6.3. Parent Name Change.. 20
6.4. NASDAQ. 20
ARTICLE 7 COVENANTS OF PARENT AND THE COMPANY 20
7.1. Public Announcements 20
7.2. Transfer Taxes 20
7.3. Fees and Expenses 20
7.4. Transfer Restrictions 20
7.5. Current Report 21
7.6. Access and Information. 21
ARTICLE 8 INDEMNIFICATION 22
8.1. Indemnification of Parent and Merger Sub 22
8.2. Indemnification of the Company 22
8.3. Claims Procedure 22
8.4. Exclusive Remedy 23
ARTICLE 9 CONDITIONS TO MERGER 23
9.1. Condition to Obligation of Each Party to Effect the Merger 23
9.2. Additional Conditions to Obligations of Parent and Merger Sub 23
9.3. Additional Conditions to Obligations of the Company 24
ARTICLE 10 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS 25

 

 
 

 

ARTICLE 11 TERMINATION 25
11.1. Termination 25
11.2. Notice of Termination 26
11.3. Effect of Termination 26
ARTICLE 12 GENERAL PROVISIONS 26
12.1. Notices 26
12.2. Amendment 27
12.3. Waiver 27
12.4. Failure or Indulgence Not Waiver; Remedies Cumulative 27
12.5. Headings 27
12.6. Severability 27
12.7. Entire Agreement 27
12.8. Assignment 28
12.9. Parties In Interest 28
12.10. Governing Law 28
12.11. Counterparts 28
12.12. Attorneys Fees 28
12.13. Representation 28
12.14. Drafting 28
12.15. Interpretation 28

 

Signatures 29
Exhibit A - Certain Definitions A-1
Exhibit B - Delaware Certificate of Merger B-1
Exhibit C - Form of Stockholder Representation Letter C-1
Exhibit D - Form of Indemnification Agreement D-1

 

 
 

 

AGREEMENT AND PLAN OF MERGER

 

THIS AGREEMENT AND PLAN OF MERGER (the “Agreement”), is made and entered into as of April 7, 2014, by and among Oro Capital Corporation, a Nevada corporation (“Parent”), Synergy Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and Synergy Strips Corp., a Delaware corporation (the “Company”). Certain other capitalized terms used in this Agreement are defined in Exhibit A attached hereto.

 

RECITALS

 

WHEREAS, the respective Boards of Directors of Parent, Merger Sub, and the Company have determined that it is in the best interest of each company and their respective stockholders to consummate the merger transaction provided for herein in which Merger Sub would merge with and into the Company (the “Merger”), with the Company surviving the Merger, upon the terms and subject to the conditions set forth herein;

 

WHEREAS, the respective Boards of Directors of Parent, Merger Sub, and the Company have approved this Agreement, the Merger, and the other transactions contemplated by this Agreement, upon the terms and subject to the conditions set forth in this Agreement in accordance with the Nevada Revised Statutes (“NRS”), the Delaware General Corporation Law (“DGCL”) and their respective charter documents;

 

WHEREAS, each of Parent, Merger Sub, and the Company desires to make certain representations, warranties, covenants and agreements in connection with the Merger and the other transactions contemplated by this Agreement and also to prescribe various conditions to the consummation thereof; and

 

WHEREAS, for federal income tax purposes, the parties intend that the Merger shall qualify as reorganization under the provisions of Section 368(a)(1)(B) of the Code.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises, representations, warranties, covenants and agreements herein contained, the parties hereto, intending to be legally bound, hereby agree as follows:

 

ARTICLE 1

 

THE MERGER

 

1.1. The Merger. Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, Merger Sub shall be merged with and into the Company at the Effective Time of the Merger (as defined in Section 1.3). Also at the Effective Time, the separate corporate existence of Merger Sub shall cease, and the Company shall continue as the surviving corporation (the “Surviving Corporation”) and shall succeed to and assume all the rights, properties, liabilities and obligations of Merger Sub in accordance with the DGCL.

 

1.2. Closing. Upon the terms and subject to the conditions set forth herein and unless this Agreement has been terminated pursuant to its terms, the closing of the Merger (the “Closing”) shall take place at the offices of Greenberg Traurig LLP located at 1201 K Street, Suite 1100, Sacramento, CA 95814 at the date on or before thirty (30) days following the date upon which the conditions to Closing set forth in Article 9 of this Agreement shall have been satisfied or, to the extent permitted hereunder, waived by the appropriate party (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted hereunder, waiver of all such conditions) or at such other time, date or location as the parties hereto agree. The date on which the Closing actually occurs and the transactions contemplated hereby become effective is hereinafter referred to as the “Closing Date.” At the time of the Closing, Parent, Merger Sub and the Company shall deliver the certificates and other documents and instruments required to be delivered hereunder.

 

1
 

 

1.3. Effective Time of the Merger. Subject to the provisions of this Agreement, at the Closing, the parties hereto shall (a) cause a certificate of merger in substantially the form of Exhibit B (the “Delaware Certificate of Merger”) to be executed and filed with the Secretary of State of the State of Delaware, as provided in Section 252 of the DGCL and (b) take all such other and further actions as may be required by the DGCL or other applicable Law to make the Merger effective. The Merger shall become effective as of the date and time of the filing of the Delaware Certificate of Merger or at such later date or time as may be agreed by the Company and Parent in writing and specified in the Delaware Certificate of Merger in accordance with relevant provisions of the DGCL. The date and time of such effectiveness are referred to herein as the “Effective Time.”

 

1.4. Effects of the Merger. Subject to the foregoing, the effects of the Merger shall be as provided in the applicable provisions of the DGCL.

 

1.5. Certificate of Incorporation and Bylaws of the Surviving Corporation. The Certificate of Incorporation of the Company as in effect immediately prior to the Effective Time and as amended by the Delaware Certificate of Merger shall, from and after the Effective Time, be the Certificate of Incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or in accordance with applicable Law. The Bylaws of the Company as in effect immediately prior to the Effective Time shall, from and after the Effective Time, be the Bylaws of the Surviving Corporation until thereafter changed or amended as provided therein or in accordance with applicable Law.

 

1.6. Directors and Officers. The directors and officers of the Company immediately prior to the Effective Time shall, from and after the Effective Time, be the directors and officers, respectively, of the Surviving Corporation until their successors shall have been duly elected or appointed and qualified in accordance with applicable Law or until their earlier death, resignation or removal in accordance with the Surviving Corporation’s Certificate of Incorporation and Bylaws.

 

ARTICLE 2

 

EFFECT OF THE MERGER ON THE CAPITAL STOCK

OF COMPANY AND MERGER SUB

 

2.1. Effect on Capital Stock. At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub or the Company or any holder of capital stock of Parent, Merger Sub or the Company:

 

(a) Capital Stock of Merger Sub. Each issued and outstanding share of capital stock of Merger Sub shall by virtue of the Merger and without any action on the part of any holder thereof, be converted into one share of the Company’s common stock. Such newly issued share shall thereafter constitute all of the issued and outstanding capital stock of the Surviving Corporation.

 

2
 

 

(b) Conversion of the Company Stock. Subject to other provisions of this Article 2:

 

(i) The shares of the Company Common Stock issued and outstanding immediately prior to the Effective Time (individually a “Share” and collectively the “Shares”), but excluding (A) Shares held by the Company, and (B) Shares held by Parent, Merger Sub or any other Subsidiary or parent of Parent or Merger Sub, if any, and (C) Dissenting Shares, shall, by virtue of the Merger, be converted automatically into the right to receive 16,000,000 shares of Common Stock of Parent (the “Merger Consideration”).

 

(ii) The Shares and the holders thereof shall be set forth on a Merger Consideration certificate that has been delivered by the Company to the Parent prior to the Closing (the “Merger Consideration Certificate”). Parent and the Surviving Corporation shall be entitled to rely on the Merger Consideration Certificate in connection with issuance of certificates representing the Merger Consideration pursuant to Section 2.3.

 

(iii) At the Effective Time, all Shares shall no longer be outstanding and shall automatically be canceled and retired and shall cease to exist, and subject to Section 2.4, each holder of a certificate formerly representing any Shares shall cease to have any rights with respect thereto, except the right to receive, upon the surrender of any certificates representing such holder’s Shares, a certificate or certificates representing the Merger Consideration to which such holder is entitled.

 

(iv) At the Effective Time, each Share held by the Company as treasury stock or held by Parent, Merger Sub or any Subsidiary or parent of Parent, Merger Sub or the Company immediately prior to the Effective Time shall, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holder thereof, be canceled, retired and cease to exist, and no consideration shall be delivered with respect thereto.

 

2.2. Intentionally Omitted

 

2.3. Issuance and Reservation of Shares.

 

(a) Promptly after the Effective Time, Parent shall distribute the Merger Consideration to holders of Shares by issuance of certificates in accordance with the Merger Consideration Certificate and the applicable provisions of the NRS.

 

(b) If any portion of the Merger Consideration is to be issued to a Person other than the registered holder of the Shares represented by the certificates surrendered in exchange therefor, it shall be a condition to such issuance that the certificates so surrendered shall be properly endorsed or otherwise be in proper form for transfer and that the Person requesting such issuance shall pay to Parent any transfer or other taxes required as a result of such issuance to a Person other than the registered holder of such Shares or establish to the satisfaction of Parent that such tax has been paid or is not payable.

 

(c) Notwithstanding anything to the contrary in this Section 2.3, Parent shall not be liable to any holder of Shares for any amount paid to a public official pursuant to and in accordance with the requirements of applicable abandoned property, escheat or similar Laws.

 

3
 

 

2.4. Dissenting Shares.

 

(a) Notwithstanding Section 2.1, Shares outstanding immediately prior to the Effective Time and held by a holder who has not voted in favor of, or consented in writing to, the Merger and who has properly exercised appraisal rights of such Shares in accordance with Section 262 of the DGCL (such Shares being referred to collectively as the “Dissenting Shares” until such time as such holder fails to perfect or otherwise loses such holder’s appraisal rights under the DGCL with respect to such Shares) shall not be converted into the right to receive any portion of the Merger Consideration as provided in Section 2.1(b) of this Agreement, but instead shall be entitled to only such rights as are granted by Section 262 of the DGCL; provided, however, that if, after the Effective Time, such holder fails to perfect, withdraws or loses such holder’s right to an appraisal pursuant to Section 262 of the DGCL or if a court of competent jurisdiction shall determine that such holder is not entitled to the relief provided by Section 262 of the DGCL, such Shares shall thereupon be treated as if they had been converted as of the Effective Time into the right to receive the Merger Consideration to which such holder is entitled pursuant to Section 2.1(b), upon surrender of such holder’s certificate formerly representing such Shares.

 

(b) The Company shall give Parent prompt notice of any demands received by the Company for the appraisal of Shares, and Parent shall have the right to consult with the Company regarding all negotiations and proceedings with respect to such demands. The Company shall not make any such payment without Parent’s prior written consent (not to be unreasonably withheld, delayed, denied, or conditioned).

 

2.5. Additional Actions. If, at any time after the Effective Time, the Surviving Corporation shall consider or be advised that any deeds, bills of sale, assignments, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm of record or otherwise in the Surviving Corporation its right, title or interest in, to or under any of the rights, properties or Assets of Merger Sub or the Company or otherwise to carry out this Agreement, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name and on behalf of Merger Sub and the Company, all such deeds, bills of sale, assignments and assurances and to take and do, in the name and on behalf of Merger Sub or the Company, all such other actions and things as may be necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and under such rights, properties or Assets in the Surviving Corporation or otherwise carry out the transactions contemplated by this Agreement.

 

ARTICLE 3

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to Parent and Merger Sub that, except as set forth in the disclosure schedules delivered by the Company to Parent and Merger Sub (the “Company Disclosure Schedule”) which have been provided to Parent prior to the date hereof:

 

3.1. Organization, Standing and Corporate Power. The Company is duly organized, validly existing and in good standing under the Laws of the State of Delaware and has the requisite corporate power and authority and all government licenses, authorizations, Permits, consents and approvals required to own, lease and operate its properties and carry on its business as now being conducted. The Company is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect.

 

3.2. Subsidiaries. The Company does not own directly or indirectly, any equity or other ownership interest in any company, corporation, partnership, joint venture or otherwise.

 

4
 

 

3.3. Capital Structure of the Company. As of the date of this Agreement, the number of shares and type of all authorized, issued and outstanding capital stock of the Company, and all shares of capital stock reserved for issuance under the Company’s various option and incentive plans is specified on Schedule 3.3. Except as set forth in Schedule 3.3, no shares of capital stock or other equity securities of the Company are issued, reserved for issuance or outstanding. All outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights. Except as set forth on Schedule 3.3, there are no outstanding bonds, debentures, notes or other indebtedness or other securities of the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters. Except as set forth in Schedule 3.3, there are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which the Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity or voting securities of the Company or obligating the Company to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking. There are no outstanding contractual obligations, commitments, understandings or arrangements of the Company to repurchase, redeem or otherwise acquire or make any payment in respect of any shares of capital stock of the Company. Except as set forth on Schedule 3.3, there are no agreements or arrangements pursuant to which the Company is or could be required to register shares of Company Common Stock or other securities under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”) or other agreements or arrangements with or among any security holders of the Company with respect to securities of the Company.

 

3.4. Corporate Authority; Noncontravention. The Company has all requisite corporate and other power and authority to enter into this Agreement and, subject to receipt of the approval of its stockholders, to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been (or at Closing will have been) duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and when delivered by the Company shall constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of creditors’ rights generally or by general principles of equity. The execution and delivery of this Agreement do not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation of, or Default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to a loss of a material benefit under, or result in the creation of any Lien upon any of the properties or Assets of the Company under, (a) the certificate or articles of incorporation, bylaws or other organizational or charter documents of the Company, (b) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, Permit, concession, franchise or license applicable to the Company, its properties or Assets, or (c) subject to the governmental filings and other matters referred to in Section 3.5, any judgment, Order, decree, statute, Law, ordinance, rule, regulation or arbitration award applicable to the Company, its properties or Assets, other than, in the case of clauses (b) and (c), any such conflicts, breaches, violations, Defaults, rights, losses or Liens that individually or in the aggregate could not have a Material Adverse Effect with respect to the Company or could not prevent, hinder or materially delay the ability of the Company to consummate the transactions contemplated by this Agreement.

 

3.5. Governmental Authorization. No consent, approval, Order or authorization of, or registration, declaration or filing with, or notice to, any Governmental Entity, is required by or with respect to the Company in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions contemplated hereby, except, with respect to this Agreement, any filings under the DGCL, the NRS, the Securities Act or Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”).

 

5
 

 

3.6. Financial Statements.

 

(a) At Closing, Parent has received a copy of the audited consolidated financial statements of the Company for the fiscal years ended December 31, 2012 and December 31, 2013 (collectively, the “Company Financial Statements”). The Company Financial Statements fairly present the financial condition of the Company at the dates indicated and its results of operations and cash flows for the periods then ended and, except as indicated therein, reflect all claims against, debts and liabilities of the Company, fixed or contingent, and of whatever nature, as of the dates indicated.

 

(b) Since January 1, 2014 (the “Company Balance Sheet Date”), there has been no Material Adverse Effect with respect to the Company.

 

(c) Except as set forth on Schedule 3.6, since the Company Balance Sheet Date, the Company has not suffered any damage, destruction or loss of physical property (whether or not covered by insurance) affecting its condition (financial or otherwise) or operations (present or prospective).

 

3.7. Absence of Certain Changes or Events. Except as set forth on Schedule 3.7, since the Company Balance Sheet Date, the Company has conducted its business only in the ordinary course consistent with past practice, and there is not and has not been any:

 

(a) Material Adverse Effect with respect to the Company;

 

(b) condition, event or occurrence which could reasonably be expected to prevent, hinder or materially delay the ability of the Company to consummate the transactions contemplated by this Agreement;

 

(c) creation or other incurrence by the Company of any Lien on any asset other than in the ordinary course consistent with past practices;

 

(d) labor dispute, other than routine, individual grievances, or, to the Knowledge of the Company, any activity or proceeding by a labor union or representative thereof to organize any employees of the Company or any lockouts, strikes, slowdowns, work stoppages or threats by or with respect to such employees;

 

(e) damage, destruction or loss having, or reasonably expected to have, a Material Adverse Effect on the Company;

 

(f) other condition, event or occurrence which individually or in the aggregate could reasonably be expected to have a Material Adverse Effect or give rise to a Material Adverse Effect with respect to the Company; or

 

(g) agreement or commitment to do any of the foregoing.

 

3.8. Certain Fees. Except as set forth on Schedule 3.8, no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by this Agreement.

 

3.9. Litigation; Labor Matters; Compliance with Laws.

 

(a) There is no suit, action or proceeding or investigation pending or, to the Knowledge of the Company, threatened against or affecting the Company or any basis for any such suit, action, proceeding or investigation that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect with respect to the Company or prevent, hinder or materially delay the ability of the Company to consummate the transactions contemplated by this Agreement.

 

6
 

 

(b) The Company is not a party to, or bound by, any collective bargaining agreement, Contract or other agreement or understanding with a labor union or labor organization, nor is it the subject of any proceeding asserting that it has committed an unfair labor practice or seeking to compel it to bargain with any labor organization as to wages or conditions of employment nor is there any strike, work stoppage or other labor dispute involving it pending or, to its Knowledge, threatened, any of which could have a Material Adverse Effect with respect to Company.

 

(c) The conduct of the business of the Company complies with all statutes, Laws, regulations, ordinances, rules, judgements, Orders, decrees or arbitration awards applicable thereto.

 

3.10. Benefit Plans. Except as set forth on Schedule 3.10, the Company is not a party to any Benefit Plan under which the Company currently has an obligation to provide benefits to any current or former employee, officer or director of the Company. As used herein, “Benefit Plan” shall mean any employee benefit plan, program, or arrangement of any kind, including any defined benefit or defined contribution plan, stock ownership plan, executive compensation program or arrangement, bonus plan, incentive compensation plan or arrangement, profit sharing plan or arrangement, deferred compensation plan, agreement or arrangement, supplemental retirement plan or arrangement, vacation pay, sickness, disability, or death benefit plan (whether provided through insurance, on a funded or unfunded basis, or otherwise), medical or life insurance plan providing benefits to employees, retirees, or former employees or any of their dependents, survivors, or beneficiaries, employee stock option or stock purchase plan, severance pay, termination, salary continuation, or employee assistance plan.

 

3.11. Tax Returns and Tax Payments.

 

(a) The Company has timely filed with the appropriate taxing authorities all Tax Returns required to be filed by it (taking into account all applicable extensions). All such Tax Returns are true, correct and complete in all respects. All Taxes due and owing by the Company have been paid (whether or not shown on any Tax Return and whether or not any Tax Return was required). The unpaid Taxes of the Company did not, as of the Company Balance Sheet Date, exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the Company Financial Statements (rather than in any notes thereto). Since the Company Balance Sheet Date, the Company has not incurred any liability for Taxes outside the ordinary course of business consistent with past custom and practice. As of the Closing Date, the unpaid Taxes of the Company will not exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the books and records of the Company.

 

(b) No material claim for unpaid Taxes has been made or become a Lien against the property of the Company or is being asserted against the Company, and no extension of the statute of limitations on the assessment of any Taxes has been granted by the Company and is currently in effect.

 

(c) As used herein, “Taxes” shall mean all taxes of any kind, including, without limitation, those on or measured by or referred to as income, gross receipts, sales, use, ad valorem, franchise, profits, license, withholding, payroll, employment, excise, severance, stamp, occupation, premium value added, property or windfall profits taxes, customs, duties or similar fees, assessments or charges of any kind whatsoever, together with any interest and any penalties, additions to tax or additional amounts imposed by any governmental authority, domestic or foreign. As used herein, “Tax Return” shall mean any return, report or statement required to be filed with any governmental authority with respect to Taxes.

 

7
 

 

3.12. Environmental Matters. The Company is in compliance with all Environmental Laws in all material respects. The Company holds all Permits and authorizations required under applicable Environmental Laws, unless the failure to hold such Permits and authorizations would not have a Material Adverse Effect on the Company, and is in compliance with all terms, conditions and provisions of all such Permits and authorizations in all material respects. No releases of Hazardous Materials have occurred at, from, in, to, on or under any real property currently or formerly owned, operated or leased by the Company or any predecessor thereof and no Hazardous Materials are present in, on, about or migrating to or from any such property which could result in any liability to the Company. The Company has not transported or arranged for the treatment, storage, handling, disposal, or transportation of any Hazardous Material to any off-site location which could result in any liability to the Company. The Company has no liability, absolute or contingent, under any Environmental Law that if enforced or collected would have a Material Adverse Effect on the Company.

 

3.13. Material Contract Defaults. The Company is not, or has not received any notice or has any Knowledge that any other party is, in Material Contract Default under any Company Material Contract; and there has not occurred any event that with the lapse of time or the giving of notice or both would constitute such a Material Contract Default. For purposes of this Agreement, a “Company Material Contract” means any Contract that is effective as of the Closing Date to which the Company is a party (a) with expected receipts or expenditures in excess of $25,000, (b) requiring the Company to indemnify any person, (c) granting exclusive rights to any party, or (d) evidencing indebtedness for borrowed or loaned money in excess of $25,000, including guarantees of such indebtedness.

 

3.14. Accounts Receivable. All of the accounts receivable of the Company that are reflected on the Company Financial Statements or the accounting records of the Company as of the Closing (collectively, the “Accounts Receivable”) represent or will represent valid obligations arising from sales actually made or services actually performed in the ordinary course of business and are not subject to any defenses, counterclaims, or rights of set off other than those arising in the ordinary course of business and for which adequate reserves have been established. The Accounts Receivable are fully collectible to the extent not reserved for on the balance sheet on which they are shown.

 

3.15. Properties.

 

(a) The Company has valid land use rights for all real property that is material to its business and good, clear and marketable title to all the tangible properties and tangible Assets reflected in the latest balance sheet as being owned by the Company or acquired after the date thereof which are, individually or in the aggregate, material to the Company’s business (except properties sold or otherwise disposed of since the date thereof in the ordinary course of business), free and clear of all Material Liens, claims, options and restrictions of any nature whatsoever. Any real property and facilities held under lease by the Company is held by it under valid, subsisting and enforceable leases of which the Company is in compliance, except as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

(b) The Company has good and marketable title to, or in the case of leased property, a valid leasehold interest in, the office space, computers, machinery, equipment and other material tangible Assets which are material to its business.

 

8
 

 

3.16. Intellectual Property.

 

(a) As used in this Agreement, the term “Trademarks” means trademarks, service marks, trade names, internet domain names, designs, slogans, and general intangibles of like nature; the term “Trade Secrets” means technology; trade secrets and other confidential information, know-how, proprietary processes, formulae, algorithms, models, and methodologies; the term “Intellectual Property” means patents, copyrights, Trademarks, applications for any of the foregoing, and Trade Secrets; the term “License Agreements” means any license agreements granting any right to use or practice any rights under any Intellectual Property, and any written settlements relating to any Intellectual Property, to which any Person is a party or otherwise bound; and the term “Software” means any and all computer programs, including any and all software implementations of algorithms, models and methodologies, whether in source code or object code.

 

(b) The Company owns or has valid rights to use the Intellectual Property and Software that are necessary for the conduct of its business as now being conducted. All of the Company’s licenses to use Software are current and have been paid for the appropriate number of users. To the knowledge of the Company, none of the Company’s Intellectual Property or the Company’s License Agreements infringe upon the rights of any third party that may give rise to a cause of action or claim against the Company or its successors.

 

3.17. Board Recommendation. The Board of Directors of the Company has determined that the terms of the Merger are fair to and in the best interests of the stockholders of the Company and recommended that the Company’s stockholders approve the Merger.

 

3.18. Undisclosed Liabilities. The Company has no liabilities or monetary obligations of any nature (whether fixed or unfixed, secured or unsecured, known or unknown and whether absolute, accrued, contingent, or otherwise) except for such liabilities or obligations reflected or reserved against in the Company Financial Statements, incurred in the ordinary course of business after the Company Balance Sheet Date, or disclosed in Schedule 3.18.

 

3.19. No Registration of Securities. The Company understands and acknowledges that the offering, exchange and issuance of the Merger Consideration pursuant to this Agreement will not be registered under the Securities Act on the grounds that the offering, sale, exchange and issuance of securities contemplated by this Agreement are exempt from registration pursuant to Section 4(a)(2) and/or Section 3(b) of the Securities Act, and that Parent’s reliance upon such exemption is predicated in part upon the Company’s representations herein and upon the representations contained in the Stockholder Representation Letters, the form of which is attached as Exhibit C to this Agreement.

 

3.20. Parent Information. The Company acknowledges that it has had access to the documents filed by Parent under the Exchange Act, since the end of its most recently completed fiscal year to the date hereof, and has carefully reviewed the same (“Exchange Act Documents”). The Company further acknowledges that Parent has made available to it the opportunity to ask questions of and receive answers from Parent’s officers and directors concerning the terms and conditions of this Agreement and the business and financial condition of Parent, and the Company has received to its satisfaction, such information about the business and financial condition of Parent and the terms and conditions of the Agreement as it has requested. The Company has carefully considered the potential risks relating to Parent and investing in the Merger Consideration, and fully understands that such securities are speculative investments, which involve a high degree of risk of loss of the Company and its stockholders’ entire investment. Among others, the Company has carefully considered each of the risks identified under the caption “Risk Factors” in the Exchange Act Documents, which are incorporated herein by reference. The Company has made available all such information to its stockholders in considering the terms and conditions of the Merger.

 

3.21. Licenses. The Company possesses from all appropriate governmental authorities all licenses, permits, authorizations, approvals, franchises and rights necessary for the Company to engage in the business currently conducted by it, all of which are in full force and effect.

 

9
 

 

3.22. FDA and Related Matters.

 

(a) The Company is and at all times has been in compliance in all respects with (i) all laws, rules, regulations and policies of the Food and Drug Administration (“FDA”) , Health Canada (“HC”) and other Healthcare Regulatory Authorities (as defined below) and (ii) all Healthcare Regulatory Authorizations (as defined below), including all requirements of the FDA, HC, and all other Healthcare Regulatory Authorities, that are applicable to the Company or by which any property, product, or other asset of the Company (including, without limitation, any Product Candidate (as defined below)) is bound or affected. As of the date of this Agreement, the Company has not received any written notification of any pending or, to the knowledge of the Company, threatened, claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action from any Healthcare Regulatory Authority. As used herein, “Healthcare Regulatory Authorities” means any entities that are concerned with or regulate the marketing, sale, use, handling and control, safety, efficacy, reliability or manufacturing of food, drug or biological products or medical devices or are concerned with or regulate public health care programs. As used herein, “Healthcare Regulatory Authorizations” means all approvals, clearances, authorizations, registrations, certifications, licenses and permits granted by any Healthcare Regulatory Authority, including all investigational new drug applications and new drug applications. As used herein, “Product Candidates” means foods, supplements, biologics, compounds or other products under development, current, active or otherwise, or consideration by the Company or any of its licensees.

 

(b) The Company holds and at all relevant times has held all Healthcare Regulatory Authorizations required for the conduct of its business, and all such Healthcare Regulatory Authorizations are in full force and effect. No event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other impairment of the rights of the holder of any such Healthcare Regulatory Authorization.

 

(c) There are no facts or circumstances that the Company has concluded are reasonably likely to have a material adverse effect on the continued supply (either for clinical or commercial purposes) of the active ingredients or raw materials necessary to produce the Product Candidates currently used in clinical trials.

 

(d) The Company has not received any material written information from any Healthcare Regulatory Authority with jurisdiction over the marketing, sale, use, handling and control, safety, efficacy, reliability, or manufacturing of any of the Company’s products or services which would reasonably be expected to lead to the revocation, withdrawal, or denial of any application for marketing approval before such Healthcare Regulatory Authority.

 

(e) The Company has made available to Parent all reports, documents, claims, notices, filings, minutes, transcripts, recordings and other material correspondence between the Company and any Healthcare Regulatory Authority.

 

(f) All material reports, documents, claims, applicable product registration files and dossiers, notices and similar filings required to be filed, maintained, or furnished to any Healthcare Regulatory Authority by the Company have been so filed, maintained or furnished and, to the knowledge of the Company, were complete and correct in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing).

 

(g) The Company has not voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued, any investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of any Product Candidate being administered in a human clinical trial sponsored by the Company. The Company has not received any written notice that the FDA or any other governmental or regulatory authority has (i) commenced, or threatened to initiate, any action to request the recall of any Product Candidate, (ii) commenced, or threatened to initiate, any action to enjoin the manufacture or distribution of any Product Candidate, or (iii) commenced, or threatened to initiate, any action to enjoin the manufacture or distribution of any Product Candidate produced at any facility where any Product Candidate is manufactured, tested, processed, packaged or held for sale.

 

10
 

 

(h) All manufacturing operations conducted by or for the benefit of the Company, whether domestic or foreign, have been, and are being conducted in material compliance with the FDA’s current Good Manufacturing Practice regulations for drug and biological products, including, without limitation, the relevant current International Conference on Harmonization (ICH) guidance documents (including, without limitation, the ICH Guidance Q7A Good Manufacturing Practices Guidance for Active Pharmaceutical Ingredients), 21 C.F.R. Parts 210, 211, 606 and 610, and all similar local, state, federal, EU and other foreign laws or regulatory requirements.

 

(i) The Company has not received any FDA Form 483, notice of adverse finding, warning letters, untitled letters or other notices alleging a lack of safety from any Healthcare Regulatory Authority, and there is no action or proceeding pending or, to the knowledge of the Company, threatened by any such Healthcare Regulatory Authority, contesting the approval of, the uses of, or the labeling or promotion of, or otherwise alleging any violation of law with respect to, any product manufactured, distributed or marketed by or on behalf of the Company.

 

(j) The Company is not the subject of any pending or, to the knowledge of the Company, threatened investigation regarding the Company or its products, by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (Sept. 10, 1991) and any amendments thereto, or otherwise. Neither the Company nor, to the knowledge of the Company, any officer, employee, agent or distributor of the Company, has committed or been convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar law or authorized by 21 U.S.C. § 335a(b) or any similar law. Neither the Company nor, to the knowledge of the Company, any officer, employee, agent or distributor of the Company, has been convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in the federal health care programs under Section 1128 of the Social Security Act or any similar law. As of the date hereof, no claims, actions, proceedings or investigations that would reasonably be expected to result in a material debarment or exclusion of the Company is pending or, to the knowledge of the Company, threatened, against the Company or, to the knowledge of the Company, any of its directors, officers, employees or agents.

 

(k) Neither the Company nor any Affiliate thereof has taken or agreed to take any action or has any knowledge of any fact or circumstance that the Company believes is reasonably likely to materially impede or delay receipt of any approval or consent from any Healthcare Regulatory Authority that is necessary to consummate the Merger or the other transactions contemplated by this Agreement.

 

3.23. Questionable Payments. Neither the Company nor any director, officer or, to the best knowledge of the Company, agent, employee or other Person associated with or acting on behalf of the Company, has used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful payments to government officials or employees from corporate funds; established or maintained any unlawful or unrecorded fund of corporate monies or other assets; made any false or fictitious entries on the books of record of any such corporations; or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.

 

11
 

 

3.24. Full Disclosure. All of the representations and warranties made by the Company in this Agreement, including the Company Disclosure Schedules attached hereto, and all statements set forth in the certificates delivered by the Company at the Closing pursuant to this Agreement, are true, correct and complete in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make such representations, warranties or statements, in light of the circumstances under which they were made, misleading. The copies of all documents furnished by the Company pursuant to the terms of this Agreement are complete and accurate copies of the original documents. The schedules, certificates, and any and all other statements and information, whether furnished in written or electronic form, to Parent or its representatives by or on behalf of any of the Company or its Affiliates in connection with the negotiation of this Agreement and the transactions contemplated hereby do not contain any material misstatement of fact or omit to state a material fact or any fact necessary to make the statements contained therein not misleading.

 

ARTICLE 4

 

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

 

Parent and Merger Sub, jointly and severally, represent and warrant to the Company that, except as set forth in Parent Disclosure Schedule:

 

4.1. Organization, Standing and Corporate Power. Each of Parent and Merger Sub is duly organized, validly existing and in good standing under the Laws of the States of Nevada and Delaware, respectively, and has the requisite corporate power and authority and all government licenses, authorizations, Permits, consents and approvals required to own, lease and operate its properties and carry on its business as now being conducted. Each of Parent and Merger Sub is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect with respect to Parent. Shares of common stock of Parent, par value $0.00001 (“Parent Common Stock”), trade on the OTC Bulletin Board under the symbol “OCAP.”

 

4.2. Subsidiaries. Other than Merger Sub, Parent does not own directly or indirectly, any equity or other ownership interest in any company, corporation, partnership, joint venture or otherwise.

 

4.3. Capital Structure of Parent and Merger Sub.

 

(a) Immediately prior to the issuance of the Merger Consideration at Closing, the authorized capital stock of Parent will consist of 75,000,000 shares of Parent Common Stock, $0.00001 par value, of which no more than approximately 49,000,000 shares of Parent Common Stock will be issued and outstanding, and no shares of Parent Common Stock will be issuable upon the exercise of outstanding warrants, convertible notes, options or otherwise. All outstanding shares of capital stock of Parent are, and all shares which may be issued pursuant to this Agreement will be, when issued, duly authorized, validly issued, fully paid and nonassessable, not subject to preemptive rights, and issued in compliance with all applicable state and federal Laws concerning the issuance of securities. Except for the Parent Common Stock, there are no outstanding bonds, debentures, notes or other indebtedness or other securities of Parent having the right to vote (or convertible into, or exchangeable for, securities having the right to vote), and there are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which Parent is a party or by which Parent is bound obligating Parent to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity securities of Parent or obligating Parent to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity securities of Parent or obligating Parent to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking. There are no outstanding contractual obligations, commitments, understandings or arrangements of Parent or any of its subsidiaries to repurchase, redeem or otherwise acquire or make any payment in respect of any shares of capital stock of Parent or any of its subsidiaries. There are no agreements or arrangements pursuant to which Parent is or could be required to register shares of Parent Common Stock or other securities under the Securities Act or other agreements or arrangements with or among any security holders of Parent with respect to securities of Parent.

 

12
 

 

(b) Immediately prior to the Closing, the authorized capital stock of Merger Sub will consist of 1,000 shares of Merger Sub Common Stock, $0.001 par value, of which no more than 100 shares of Merger Sub Common Stock will be issued and outstanding, and no shares of Merger Sub Common Stock will be issuable upon the exercise of outstanding warrants, convertible notes, options or otherwise. All outstanding shares of capital stock of Merger Sub are owned by Parent and are duly authorized, validly issued, fully paid and nonassessable, not subject to preemptive rights, and issued in compliance with all applicable state and federal Laws concerning the issuance of securities. Except for the Merger Sub Common Stock, there are no outstanding bonds, debentures, notes or other indebtedness or other securities of Merger Sub having the right to vote (or convertible into, or exchangeable for, securities having the right to vote). There are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which Merger Sub is a party or by which Merger Sub is bound obligating Merger Sub to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity securities of Merger Sub or obligating Merger Sub to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity securities of Merger Sub or obligating Merger Sub to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking. There are no outstanding contractual obligations, commitments, understandings or arrangements of Merger Sub to repurchase, redeem or otherwise acquire or make any payment in respect of any shares of capital stock of Merger Sub. There are no agreements or arrangements pursuant to which Merger Sub is or could be required to register shares of Merger Sub Common Stock or other securities under the Securities Act or other agreements or arrangements with or among any security holders of Merger Sub with respect to securities of Merger Sub. Merger Sub does not own directly or indirectly, any equity or other ownership interest in any company, corporation, partnership, joint venture or otherwise. Merger Sub has not conducted any operations and does not have any assets, liabilities or employees.

 

4.4. Corporate Authority; Noncontravention. Each of Parent and Merger Sub has all requisite corporate and other power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by each of Parent and Merger Sub and the consummation by each of Parent and Merger Sub of the transactions contemplated hereby have been (or at Closing will have been) duly authorized by all necessary corporate action on the part of each of Parent and Merger Sub. This Agreement has been duly executed and when delivered by each of Parent and Merger Sub, shall constitute a valid and binding obligation of each of Parent and Merger Sub, enforceable against Parent and Merger Sub in accordance with its terms, except as such enforcement may be limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of creditors’ rights generally or by general principles of equity. The execution and delivery of this Agreement do not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions hereof will not, conflict with, or result in any breach or violation of, or Default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to loss of a material benefit under, or result in the creation of any Lien upon any of the properties or Assets of Parent and Merger Sub under, (a) the articles of incorporation, bylaws, or other charter documents of each of Parent and Merger sub, (b) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, Permit, concession, franchise or license applicable to each of Parent or Merger Sub, each of its properties or Assets, or (c) subject to the governmental filings and other matters referred to in Section 4.5, any judgment, Order, decree, statute, Law, ordinance, rule, regulation or arbitration award applicable to each of Parent and Merger Sub, each of its properties or Assets, other than, in the case of clauses (b) and (c), any such conflicts, breaches, violations, Defaults, rights, losses or Liens that individually or in the aggregate could not have a Material Adverse Effect with respect to Parent or could not prevent, hinder or materially delay the ability of Parent to consummate the transactions contemplated by this Agreement.

 

13
 

 

4.5. Government Authorization. No consent, approval, Order or authorization of, or registration, declaration or filing with, or notice to, any Governmental Entity, is required by or with respect to each of Parent and Merger Sub in connection with the execution and delivery of this Agreement by Parent and Merger Sub, or the consummation by Parent and Merger Sub of the transactions contemplated hereby, except, with respect to this Agreement, any filings under the DGCL, the NRS, the Securities Act or the Exchange Act.

 

4.6. SEC Documents; Undisclosed Liabilities; Financial Statements.

 

(a) Parent has timely filed all reports, schedules, forms, statements and other documents as required by the Securities and Exchange Commission (the “SEC”) and Parent has delivered or made available to the Company all reports, schedules, forms, statements and other documents filed with the SEC (collectively, and in each case including all exhibits and schedules thereto and documents incorporated by reference therein, the “Parent SEC Documents”). As of their respective dates, the Parent SEC Documents complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to such Parent SEC Documents. Except to the extent revised or superseded by a subsequent filing with the SEC (a copy of which has been provided to the Company prior to the date of this Agreement), none of the Parent SEC Documents (including any and all consolidated financial statements included therein) contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The consolidated financial statements of Parent included in such Parent SEC Documents comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with GAAP (except, in the case of unaudited consolidated quarterly statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly present the consolidated financial position of Parent and its consolidated subsidiaries as of the dates thereof and the consolidated results of operations and changes in cash flows for the periods then ended (subject, in the case of unaudited quarterly statements, to normal year-end audit adjustments as determined by Parent’s independent accountants). Except as set forth in the Parent SEC Documents, at the date of the most recent financial statements of Parent included in the Parent SEC Documents, Parent has not incurred any liabilities or monetary obligations of any nature (whether accrued, absolute, contingent or otherwise), which, individually, or in the aggregate, could reasonably be expected to have a Material Adverse Effect on Parent.

 

(b) Except as disclosed in the Parent SEC Documents filed prior to the date hereof or as set forth in this Agreement, since January 31, 2014 (the “Parent Balance Sheet Date”), there has been no Material Adverse Effect with respect to Parent.

 

(c) Except as disclosed in the Parent SEC Documents filed prior to the date hereof or as provided in this Agreement, since the Parent Balance Sheet Date, Parent has not issued, sold or otherwise disposed of, or agreed to issue, sell or otherwise dispose of, any capital stock or any other security of Parent and has not granted or agreed to grant any option, warrant or other right to subscribe for or to purchase any capital stock or any other security of Parent or has incurred or agreed to incur any indebtedness for borrowed money.

 

14
 

 

4.7. Absence of Certain Changes. Except as disclosed in the Parent SEC Documents filed prior to the date hereof or as set forth on Schedule 4.7, since the Parent Balance Sheet Date, Parent has conducted its business only in the ordinary course consistent with past practice in light of its current business circumstances, and there is not and has not been any:

 

(a) Material Adverse Effect with respect to Parent;

 

(b) condition, event or occurrence which could reasonably be expected to prevent, hinder or materially delay the ability of Parent to consummate the transactions contemplated by this Agreement;

 

(c) incurrence, assumption or guarantee by Parent of any indebtedness for borrowed money other than in the ordinary course and in amounts and on terms consistent with past practices;

 

(d) creation or other incurrence by Parent of any Lien on any asset other than in the ordinary course consistent with past practices;

 

(e) labor dispute, other than routine, individual grievances, or, to the Knowledge of Parent, any activity or proceeding by a labor union or representative thereof to organize any employees of Parent or any lockouts, strikes, slowdowns, work stoppages or threats by or with respect to such employees;

 

(f) payment, prepayment or discharge of liability other than in the ordinary course of business or any failure to pay any liability when due;

 

(g) material write-offs or write-downs of any Assets of Parent;

 

(h) damage, destruction or loss having, or reasonably expected to have, a Material Adverse Effect on Parent;

 

(i) other condition, event or occurrence which individually or in the aggregate could reasonably be expected to have a Material Adverse Effect or give rise to a Material Adverse Effect with respect to Parent; or

 

(j) agreement or commitment to do any of the foregoing.

 

4.8. Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by Parent or Merger Sub to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other person with respect to the transactions contemplated by this Agreement.

 

4.9. Litigation; Labor Matters; Compliance with Laws.

 

(a) There is no suit, action or proceeding or investigation pending or, to the Knowledge of each of Parent and Merger Sub, threatened against or affecting Parent or Merger Sub or any basis for any such suit, action, proceeding or investigation that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect with respect to each of Parent or Merger Sub or prevent, hinder or materially delay the ability of each of Parent and Merger Sub to consummate the transactions contemplated by this Agreement, nor is there any judgment, decree, injunction, rule or Order of any Governmental Entity or arbitrator outstanding against Parent or Merger Sub having, or which, insofar as reasonably could be foreseen by Parent or Merger Sub, in the future could have, any such effect.

 

15
 

 

(b) Each of Parent and Merger Sub is not a party to, or bound by, any collective bargaining agreement, Contract or other agreement or understanding with a labor union or labor organization, nor is it the subject of any proceeding asserting that it has committed an unfair labor practice or seeking to compel it to bargain with any labor organization as to wages or conditions of employment nor is there any strike, work stoppage or other labor dispute involving it pending or, to its Knowledge, threatened, any of which could have a Material Adverse Effect with respect to Parent.

 

(c) The conduct of the business of each of Parent and Merger Sub complies with all statutes, Laws, regulations, ordinances, rules, judgments, Orders, decrees or arbitration awards applicable thereto.

 

4.10. Benefit Plans. Each of Parent and Merger Sub is not a party to any Benefit Plan under which Parent or Merger Sub currently has an obligation to provide benefits to any current or former employee, officer or director of Parent or Merger Sub.

 

4.11. Certain Employee Payments. Parent is not a party to any employment agreement which could result in the payment to any current, former or future director or employee of Parent of any money or other property or rights or accelerate or provide any other rights or benefits to any such employee or director as a result of the transactions contemplated by this Agreement, whether or not (a) such payment, acceleration or provision would constitute a “parachute payment” (within the meaning of Section 280G of the Code), or (b) some other subsequent action or event would be required to cause such payment, acceleration or provision to be triggered.

 

4.12. Tax Returns and Tax Payments.

 

(a) Parent has timely filed with the appropriate taxing authorities all Tax Returns required to be filed by it (taking into account all applicable extensions). All such Tax Returns are true, correct and complete in all respects. All Taxes due and owing by Parent have been paid (whether or not shown on any Tax Return and whether or not any Tax Return was required). Parent is not currently the beneficiary of any extension of time within which to file any Tax Return or pay any Tax. No claim has ever been made in writing or otherwise addressed to Parent by a taxing authority in a jurisdiction where Parent does not file Tax Returns that it is or may be subject to taxation by that jurisdiction. The unpaid Taxes of Parent did not, as of the Parent Balance Sheet Date, exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the financial statements (rather than in any notes thereto). Since the Parent Balance Sheet Date, neither the Parent nor any of its subsidiaries has incurred any liability for Taxes outside the ordinary course of business consistent with past custom and practice. As of the Closing Date, the unpaid Taxes of Parent and its subsidiaries will not exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the books and records of Parent.

 

(b) No material claim for unpaid Taxes has been made or become a Lien against the property of Parent or is being asserted against Parent, no audit of any Tax Return of Parent is being conducted by a tax authority, and no extension of the statute of limitations on the assessment of any Taxes has been granted by Parent and is currently in effect. Parent has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.

 

4.13. Intentionally Omitted.

 

4.14. Material Contract Defaults. Parent is not, or has not received any notice or has any Knowledge that any other party is, in Material Contract Default under any Parent Material Contract; and there has not occurred any event that with the lapse of time or the giving of notice or both would constitute such a Material Contract Default. For purposes of this Agreement, a “Parent Material Contract” means any Contract that is effective as of the Closing Date to which the Parent is a party (a) with expected receipts or expenditures in excess of $25,000, (b) requiring the Parent to indemnify any person, (c) granting exclusive rights to any party, or (d) evidencing indebtedness for borrowed or loaned money in excess of $25,000, including guarantees of such indebtedness.

 

16
 

 

4.15. Accounts Receivable. All of the accounts receivable of Parent that are reflected in the Parent SEC Documents or the accounting records of Parent as of the Closing (collectively, the “Parent Accounts Receivable”) represent or will represent valid obligations arising from sales actually made or services actually performed in the ordinary course of business and are not subject to any defenses, counterclaims, or rights of set off other than those arising in the ordinary course of business and for which adequate reserves have been established. The Parent Accounts Receivable are fully collectible to the extent not reserved for on the balance sheet on which they are shown.

 

4.16. Properties. Each of Parent and Merger Sub has valid land use rights for all real property that is material to its business and good, clear and marketable title to all the tangible properties and tangible Assets reflected in the latest balance sheet as being owned by Parent or Merger Sub or acquired after the date thereof which are, individually or in the aggregate, material to Parent’s business (except properties sold or otherwise disposed of since the date thereof in the ordinary course of business), free and clear of all Material Liens, claims, options and restrictions of any nature whatsoever. Any real property and facilities held under lease by Parent or Merger Sub are held by them under valid, subsisting and enforceable leases of which each of Parent and Merger Sub is in compliance, except as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

4.17. Intellectual Property. Each of Parent and Merger Sub owns or has valid rights to use the Intellectual Property and Software that are necessary for the conduct of its business as now being conducted. All of Parent’s and Merger Sub’s licenses to use Software are current and have been paid for the appropriate number of users. To the Knowledge of each of Parent and Merger Sub, none of Parent’s or Merger Sub’s Intellectual Property or Parent’s or Merger Sub’s License Agreements infringe upon the rights of any third party that may give rise to a cause of action or claim against Parent or Merger Sub or each of its successors.

 

4.18. Board Determination. The Board of Directors of each of Parent and Merger Sub has unanimously determined that the terms of the Merger are fair to and in the best interests of Parent and Merger Sub and each of its stockholders.

 

4.19. Required Parent Share Issuance Approval. Parent represents that the issuance of the Merger Consideration will be in compliance with the NRS and the Articles of Incorporation and Bylaws of Parent.

 

4.20. Undisclosed Liabilities. Parent has no liabilities or obligations of any nature (whether fixed or unfixed, secured or unsecured, known or unknown and whether absolute, accrued, contingent, or otherwise) except for liabilities or obligations reflected or reserved against in the Parent SEC Documents filed prior to the date hereof or incurred in the ordinary course of business since the Parent Balance Sheet Date.

 

4.21. Full Disclosure. All of the representations and warranties made by each of Parent and Merger Sub in this Agreement, including the Parent Disclosure Schedules attached hereto, and all statements set forth in the certificates delivered by each of Parent and Merger Sub at the Closing pursuant to this Agreement, are true, correct and complete in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make such representations, warranties or statements, in light of the circumstances under which they were made, misleading. The copies of all documents furnished by each of Parent and Merger Sub pursuant to the terms of this Agreement are complete and accurate copies of the original documents. The schedules, certificates, and any and all other statements and information, whether in written or electronic form, to the Company or its representatives by or on behalf of any of the Parent or Merger Sub or their Affiliates in connection with the negotiation of this Agreement and the transactions contemplated hereby do not contain any material misstatement of fact or omit to state a material fact or any fact necessary to make the statements contained therein not misleading.

 

17
 

 

ARTICLE 5

 

CONDUCT OF BUSINESSES PENDING THE MERGER

 

5.1. Conduct of Business by the Company Pending the Merger. Prior to the Effective Time, unless Parent or Merger Sub shall otherwise agree in writing or as otherwise contemplated by this Agreement or the other agreements contemplated hereby:

 

(a) the business of the Company shall be conducted only in the ordinary course;

 

(b) the Company shall not (i) directly or indirectly redeem, purchase or otherwise acquire or agree to redeem, purchase or otherwise acquire any shares of its capital stock; (ii) amend its Certificate of Incorporation or Bylaws except to effectuate the transactions contemplated herein; or (iii) split, combine or reclassify the outstanding Shares or declare, set aside or pay any dividend payable in cash, stock or property or make any distribution with respect to any such stock;

 

(c) the Company shall not (i) issue or agree to issue any additional Shares, or options, warrants or rights of any kind to acquire any Shares, except in connection with the Financing, (ii) acquire or dispose of any fixed assets or acquire or dispose of any other substantial assets other than in the ordinary course of business; (iii) incur additional indebtedness or any other liabilities or enter into any other transaction other than in the ordinary course of business; (iv) enter into any contract, agreement, commitment or arrangement with respect to any of the foregoing; or (v) except as contemplated by this Agreement, enter into any contract, agreement, commitment or arrangement to dissolve, merge, consolidate or enter into any other material business combination;

 

(d) the Company shall use its best efforts to preserve intact the business organization of the Company, to keep available the service of its present officers and key employees, and to preserve the good will of those having business relationships with it; and

 

(e) the Company will not, nor will it authorize any director or authorize or permit any officer or employee or any attorney, accountant or other representative retained by it to, make, solicit, encourage any inquiries with respect to, or engage in any negotiations concerning, any Acquisition Proposal (as defined below for purposes of this paragraph). The Company will promptly advise Parent orally and in writing of any such inquiries or proposals (or requests for information) and the substance thereof. As used in this paragraph, “Acquisition Proposal” shall mean any proposal for a merger or other business combination involving the Company or for the acquisition of a substantial equity interest in it or any material assets of it other than as contemplated by this Agreement. The Company will immediately cease and cause to be terminated any existing activities, discussions or negotiations with any Person conducted heretofore with respect to any of the foregoing.

 

5.2. Conduct of Business by Parent and Merger Sub Pending the Merger. Prior to the Effective Time, unless the Company shall otherwise agree in writing or as otherwise contemplated by this Agreement or the other agreements contemplated hereby:

 

(a) the business of Parent and Merger Sub shall be conducted only in the ordinary course; provided, however, that Parent shall take the steps necessary to have discontinued its existing business without liability to Parent or Merger Sub or the Surviving Corporation immediately following the Effective Time;

 

18
 

 

(b) neither Parent nor Merger Sub shall (i) directly or indirectly redeem, purchase or otherwise acquire or agree to redeem, purchase or otherwise acquire any shares of its capital stock; (ii) amend its charter or by-laws other than to effectuate the transactions contemplated hereby; or (iii) split, combine or reclassify its capital stock or declare, set aside or pay any dividend payable in cash, stock or property or make any distribution with respect to such stock;

 

(c) neither Parent nor Merger Sub shall (i) issue or agree to issue any additional shares of, or options, warrants or rights of any kind to acquire shares of, its capital stock; (ii) acquire or dispose of any assets other than in the ordinary course of business; (iii) incur additional indebtedness or any other liabilities or enter into any other transaction except in the ordinary course of business; (iv) enter into any contract, agreement, commitment or arrangement with respect to any of the foregoing or (v) except as contemplated by this Agreement, enter into any contract, agreement, commitment or arrangement to dissolve, merge, consolidate or enter into any other material business contract or enter into any negotiations in connection therewith;

 

(d) neither the Parent nor Merger Sub will, nor will they authorize any director or authorize or permit any officer or employee or any attorney, accountant or other representative retained by them to, make, solicit, encourage any inquiries with respect to, or engage in any negotiations concerning, any Acquisition Proposal (as defined below for purposes of this paragraph). Parent will promptly advise the Company orally and in writing of any such inquiries or proposals (or requests for information) and the substance thereof. As used in this paragraph, “Acquisition Proposal” shall mean any proposal for a merger or other business combination involving the Parent or Merger Sub or for the acquisition of a substantial equity interest in either of them or any material assets of either of them other than as contemplated by this Agreement. Parent will immediately cease and cause to be terminated any existing activities, discussions or negotiations with any Person conducted heretofore with respect to any of the foregoing; and

 

(e) neither Parent nor Merger Sub will enter into any new employment agreements with any of their officers or employees or grant any increases in the compensation or benefits of their officers and employees.

 

ARTICLE 6

 

COVENANTS OF PARENT OR COMPANY

 

6.1. Director and Officer Appointments. As of the Effective Time, Parent shall have taken all action to cause the persons as set forth on Schedule 6.1 to be appointed Parent’s directors and officers, and the current officers and directors of Parent on Schedule 6.1 shall have resigned from Parent. Parent shall use its best efforts to have a majority of its board members be independent by the director independence standards established by the NASDAQ Stock Market.

 

6.2. Disclosure. Concurrently with the execution of this Agreement, the Company shall deliver to Parent and Merger Sub all schedules and exhibits to be attached hereto. Such schedules and exhibits, and all updates thereto shall be prepared in good faith and contain accurate, true, correct and complete information. From the date of execution of this Agreement through the Closing, the Company will promptly notify Parent and Merger Sub if the Company becomes aware of any fact, circumstance or condition that causes or constitutes a breach of any of the Company’s representations or warranties (with each such fact, circumstance or condition, an “Update”).

 

19
 

 

6.3. Private Placement. The Company shall commence a private placement offering (the “Financing”) for the issuance of up to 5,000,000 Shares (such amount subject to adjustment upon the approval of both Parent and the Company) to investors in connection with the transactions contemplated by the Agreement.

 

6.4. Parent Name Change. Prior to the Effective Time, Parent shall have taken all required legal actions to change its corporate name to a name to be agreed upon by Parent and the Company. The parties acknowledge and agree that Parent has authorization for such name change, and to the extent the Company holds any rights in or to such name the Company hereby grants to Parent a non-exclusive right to use such name, including without limitation any trade name, service name, service mark or trade dress rights of the Company therein or thereto.

 

6.5. NASDAQ. After the Effective Time, Parent shall use its best efforts to cause the Parent Common Stock to be listed on the NASDAQ Stock Market.

 

ARTICLE 7

 

COVENANTS OF PARENT AND THE COMPANY

 

7.1. Public Announcements. No party shall have the right to issue any press release or other public statement with respect to this Agreement or the transactions contemplated herein without the prior written consent of each other party (not to be unreasonably withheld, delayed, denied or conditioned), except as required by Law.

 

7.2. Transfer Taxes. Parent, Merger Sub and the Company agree that the Company (prior to the Merger) and the Surviving Corporation (following the Merger) will pay any real property, transfer or gains tax, stamp tax, stock transfer tax, or other similar tax imposed on the Merger or the surrender of the Shares pursuant to the Merger (collectively, “Transfer Taxes”), excluding any Transfer Taxes as may result from the transfer of beneficial interests in the Shares other than as a result of the Merger, and any penalties or interest with respect to the Transfer Taxes. The Company agrees to cooperate with Parent in the filing of any returns with respect to the Transfer Taxes.

 

7.3. Fees and Expenses. All of the legal, accounting and other expenses incurred by any party hereto in connection with the transactions contemplated by this Agreement shall be paid by the Company simultaneously at, or immediately after, Closing.

 

7.4. Transfer Restrictions.

 

(a) The Company realizes that the Merger Consideration is not registered under the Securities Act, or any foreign or state securities Laws. The Company agrees that the Merger Consideration will and may not be sold, offered for sale, pledged, hypothecated, or otherwise transferred (collectively, a “Transfer”) except in compliance with the Securities Act, if applicable, and applicable foreign and state securities Laws, and with an opinion of Parent’s counsel. The Company understands that the Merger Consideration can only be Transferred pursuant to registration under the Securities Act or pursuant to an exemption therefrom. The Company understands that to Transfer the Merger Consideration may require in some jurisdictions specific approval by the appropriate governmental agency or commission in such jurisdiction.

 

20
 

 

(b) To enable Parent to enforce the transfer restrictions contained in Section 7.4(a), the Company hereby consents to the placing of legends upon, and stop-transfer orders with the transfer agent of the Parent Common Stock with respect to the Merger Consideration, including, without limitation, the following:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, MORTGAGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF, EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER THE ACT, OR (II) IN COMPLIANCE WITH RULE 144 PROMULGATED UNDER THE ACT, OR (III) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY AND ITS COUNSEL.”

 

7.5. Current Report. Parent shall file a Current Report on Form 8-K with the SEC on the Closing Date containing information about the Merger and pro forma financial statements of Parent and the Company and audited financial statements of the Company as required by Regulation S-K under the Securities Act (the “8-K Report”).

 

7.6. Access and Information. The Company, on the one hand, and Parent and Merger Sub, on the other hand, shall each afford to the other and to the other’s accountants, counsel and other representatives full access during normal business hours throughout the period prior to the Effective Time to all of its properties, books, contracts, commitments and records (including but not limited to tax returns) and during such period, each shall furnish promptly to the other all information concerning its business, properties and personnel as such other party may reasonably request. Each party shall hold, and shall cause its employees and agents to hold, in confidence all such information and shall use such information only to effect the transactions contemplated hereby and as otherwise expressly permitted herein (other than such information that (a) is already in such party’s possession or (b) becomes generally available to the public other than as a result of a disclosure by such party or its directors, officers, managers, employees, agents or advisors, or (c) becomes available to such party on a non-confidential basis from a source other than the other party hereto or its advisors, provided that such source is not known by such party to be bound by a confidentiality agreement with or other obligation of secrecy to the other party hereto until such time as such information is otherwise publicly available; provided, however, that (i) any such information may be disclosed to such party’s directors, officers, employees and representatives of such party’s advisors who need to know such information for the purpose of evaluating the transactions contemplated hereby (it being understood that such directors, officers, employees and representatives shall be informed by such party of the confidential nature of such information and bound by confidentiality and non-use obligations no less restrictive than those set forth herein), (ii) any disclosure of such information may be made as to which the party hereto furnishing such information has consented in writing, and (iii) any such information may be disclosed pursuant to a judicial, administrative or governmental order or request or applicable laws or rules of the SEC; provided, however, that the requested party will promptly so notify the other party so that the other party may seek a protective order or appropriate remedy and/or waive compliance with this Agreement and if such protective order or other remedy is not obtained or the other party waives compliance with this provision, the requested party will furnish only that portion of such information that is legally required and will exercise its best efforts to obtain a protective order or other reliable assurance that confidential treatment will be accorded the information furnished). If this Agreement is terminated, each party will deliver to the other all documents and other materials (including copies) obtained by such party or on its behalf from the other party as a result of this Agreement or in connection herewith, whether so obtained before or after the execution hereof.

 

21
 

 

ARTICLE 8

 

INDEMNIFICATION

 

8.1. Indemnification of Parent and Merger Sub.

 

(a) Subject to the limitations contained in this Article 8, the Company shall defend, indemnify and hold harmless Parent and Merger Sub and their respective officers, directors, stockholders, employees and agents from and against any and all losses, claims, judgments, liabilities, demands, charges, suits, penalties, costs or expenses, including court costs and attorneys’ fees (“Claims and Liabilities”) with respect to or arising from (i) the breach of any warranty or any inaccuracy of any representation made by the Company in this Agreement, or (ii) the breach of any covenant or agreement made by the Company in this Agreement.

 

(b) In addition to the obligations set forth in Section 8.1(a) above, the Company shall defend, indemnify and hold harmless Parent and Merger Sub and their respective officers, directors, stockholders, employees and agents against any and all Claims and Liabilities with respect to or arising from any claims for any right to receive Merger Consideration made by any Person who is not a holder of Company Stock at the Effective Time or is a holder of Company Stock and claiming a right to Merger Consideration inconsistent with the Merger Consideration Certificate.

 

8.2. Indemnification of the Company. Parent shall defend, indemnify and hold harmless the Company, and its officers, directors, stockholders, employees and agents from and against any and all Claims and Liabilities with respect to or arising from (a) breach of any warranty or any inaccuracy of any representation made by Parent or Merger Sub, or (b) breach of any covenant or agreement made by Parent or Merger Sub in this Agreement.

 

8.3. Claims Procedure. Promptly after the receipt by any indemnified party (the “Indemnitee”) of notice of the commencement of any action or proceeding against such Indemnitee, such Indemnitee shall, if a claim with respect thereto is or may be made against any indemnifying party (the “Indemnifying Party”) pursuant to this Article 8, give such Indemnifying Party written notice of the commencement of such action or proceeding and give such Indemnifying Party a copy of such claim and/or process and all legal pleadings in connection therewith. The failure to give such notice shall not relieve any Indemnifying Party of any of its indemnification obligations contained in this Article 8, except where, and solely to the extent that, such failure actually and Materially prejudices the rights of such Indemnifying Party. Such Indemnifying Party shall have, upon request within thirty (30) days after receipt of such notice, but not in any event after the settlement or compromise of such claim, the right to defend, at its own expense and by its own counsel reasonably acceptable to the Indemnitee, any such matter involving the asserted liability of the Indemnitee; provided, however, that if the Indemnitee determines that there is a reasonable probability that a claim may Materially and adversely affect it, other than solely as a result of money payments required to be reimbursed in full by such Indemnifying Party under this Article 8 or if a conflict of interest exists between Indemnitee and the Indemnifying Party, the Indemnitee shall have the right to defend, compromise or settle such claim or suit; and, provided, further, that such settlement or compromise shall not, unless consented to in writing by such Indemnifying Party, which shall not be unreasonably withheld, be conclusive as to the liability of such Indemnifying Party to the Indemnitee. In any event, the Indemnitee, such Indemnifying Party and its counsel shall cooperate in the defense against, or compromise of, any such asserted liability, and in cases where the Indemnifying Party shall have assumed the defense, the Indemnitee shall have the right to participate in the defense of such asserted liability at the Indemnitee’s own expense. In the event that such Indemnifying Party shall decline to participate in or assume the defense of such action, prior to paying or settling any claim against which such Indemnifying Party is, or may be, obligated under this Article 8 to indemnify an Indemnitee, the Indemnitee shall first supply such Indemnifying Party with a copy of a final court judgment or decree holding the Indemnitee liable on such claim or, failing such judgment or decree, the terms and conditions of the settlement or compromise of such claim. An Indemnitee’s failure to supply such final court judgment or decree or the terms and conditions of a settlement or compromise to such Indemnifying Party shall not relieve such Indemnifying Party of any of its indemnification obligations contained in this Article 8, except where, and solely to the extent that, such failure actually and Materially prejudices the rights of such Indemnifying Party. If the Indemnifying Party is defending the claim as set forth above, the Indemnifying Party shall have the right to settle the claim only with the consent of the Indemnitee.

 

22
 

 

8.4. Exclusive Remedy. Each of the parties hereto acknowledges and agrees that, from and after the Closing Date, its sole and exclusive monetary remedy with respect to any and all claims relating to the subject matter of this Agreement shall be pursuant to the indemnification provisions set forth in this Article 8, except that nothing in this Agreement shall be deemed to constitute a waiver of any injunctive or other equitable remedies or any tort claims of, or causes of action arising from, intentionally fraudulent misrepresentation, willful breach or deceit. The parties’ obligations under this Article 8 shall terminate twelve (12) months from the Closing Date.

 

ARTICLE 9

 

CONDITIONS TO MERGER

 

9.1. Condition to Obligation of Each Party to Effect the Merger. The respective obligations of Parent, Merger Sub and the Company to consummate the transactions contemplated herein are subject to the satisfaction or waiver in writing at or prior to the Effective Time of the following conditions.

 

(a) No Injunctions. No temporary restraining Order, preliminary or permanent injunction issued by any court of competent jurisdiction preventing or prohibiting the consummation of the Merger or the other transactions contemplated herein shall be in effect; provided, however, that each party shall have used its commercially reasonable efforts to prevent the entry of such Orders or injunctions and to appeal as promptly as possible any such Orders or injunctions and to appeal as promptly as possible any such Orders or injunctions that may be entered.

 

(b) Company Stockholder Approval. This Agreement and the Merger shall have been approved and adopted by the requisite vote of the Company, the Company’s stockholders in accordance with the Company’s Certificate of Incorporation and the DGCL.

 

(c) Parent and Merger Sub Approval. This Agreement and the Merger shall have been approved and adopted by the requisite vote of Parent’s board of directors in accordance with the Parent’s Articles of Incorporation and the NRS. This Agreement and the Merger shall have been approved and adopted by the requisite vote of Merger Sub’s stockholder in accordance with Merger Sub’s Certificate of Incorporation and the DGCL.

 

9.2. Additional Conditions to Obligations of Parent and Merger Sub. The obligations of Parent and the Merger Sub to consummate the transactions contemplated herein are also subject to the satisfaction or waiver in writing at or prior to the Effective Time of the following conditions.

 

(a) Representations and Warranties. The representations and warranties of the Company contained in this Agreement and in any certificate or other writing delivered to Parent pursuant hereto shall be true and correct on and as of the Effective Time with the same force and effect as if made on and as of the Effective Time, and Parent and Merger Sub shall have received a certificate to such effect signed by the President and the Chief Executive Officer of the Company.

 

23
 

 

(b) Agreements and Covenants. The Company shall have performed or complied with all agreements and covenants required by this Agreement to be performed or complied with by them on or prior to the Effective Time, and Parent shall have received a certificate to such effect signed by the President and Chief Executive Officer of the Company.

 

(c) Certificate of Secretary. The Company shall have delivered to Parent a certificate executed by the Secretary of the Company certifying: (i) resolutions duly adopted by the Board of Directors and stockholders of the Company authorizing this Agreement and the Merger; (ii) the Certificate of Incorporation and Bylaws of the Company as in effect immediately prior to the Effective Time, including all amendments thereto; (iii) the Merger Consideration Certificate; and (iv) the incumbency of the officers of the Company executing this Agreement and all agreements and documents contemplated hereby.

 

(d) Consents Obtained. All consents, waivers, approvals, authorizations or Orders required to be obtained, and all filings required to be made, by the Company for the authorization, execution and delivery of this Agreement and the consummation by it of the transactions contemplated hereby shall have been obtained and made by the Company, except for such consents, waivers, approvals, authorizations and Orders, and such filings, which would not be reasonably likely to have a Material Adverse Effect on the Company or the Surviving Corporation.

 

(e) Absence of Material Adverse Effect. There shall not have been any Material Adverse Effect with respect to the Company.

 

(f) Merger Consideration Certificate. Parent shall have received the Merger Consideration Certificate from the Company.

 

(g) Audited Financial Statements. Parent shall have received from the Company the Company Financial Statements, the audited consolidated financial statements of the Company for the fiscal years ended December 31, 2013 and 2012 and pro forma financial statements as of the day prior to the Closing Date in form and content required to be included in the 8-K Report.

 

(h) Stockholder Representation Letters. Each stockholder of the Company shall have executed and delivered to Parent a stockholder representation letter in substantially the form attached hereto as Exhibit C, and Parent shall be reasonably satisfied that the issuance of Parent Common Stock pursuant to the Merger is exempt from the registration requirements of the Securities Act.

 

9.3. Additional Conditions to Obligations of the Company. The obligations of the Company to consummate the transactions contemplated herein are also subject to the satisfaction or waiver in writing at or prior to the Effective Time of the following conditions.

 

(a) Representations and Warranties. The representations and warranties of Parent and Merger Sub contained in this Agreement and in any certificate or other writing delivered to the Company pursuant hereto shall be true and correct on and as of the Effective Time with the same force and effect as if made on and as of the Effective Time, and the Company shall have received a certificate to such effect signed by the President and the Chief Executive Officer of Parent.

 

(b) Agreements and Covenants. Parent and Merger Sub shall have performed or complied with all agreements and covenants required by this Agreement to be performed or complied with by them on or prior to the Effective Time, and the Company shall have received a certificate to such effect signed by the President and Chief Executive Officer of Parent.

 

24
 

 

(c) Certificate of Secretary. Parent shall have delivered to the Company a certificate executed by the Secretary of Parent certifying: (i) resolutions duly adopted by the Board of Directors of Parent and Merger Sub, respectively, authorizing this Agreement and the Merger and resolutions duly adopted by the sole stockholder of Merger Sub authorizing this Agreement and the Merger; (ii) the Articles of Incorporation and Bylaws of Parent as in effect immediately prior to the Effective Time, including all amendments thereto; and (iii) the incumbency of the officers of Parent executing this Agreement and all agreements and documents contemplated hereby.

 

(d) Consents Obtained. All consents, waivers, approvals, authorizations or Orders required to be obtained, and all filings required to be made, by Parent or Merger Sub for the authorization, execution and delivery of this Agreement and the consummation by it of the transactions contemplated hereby shall have been obtained and made by Parent and Merger Sub, respectively, except for such consents, waivers, approvals, authorizations and Orders, and such filings, which would not be reasonably likely to have a Material Adverse Effect on Parent or Merger Sub.

 

(e) Absence of Material Adverse Effect. There shall not have been any Material Adverse Effect on Parent or Merger Sub, other than any change that shall result from general economic conditions or conditions generally affecting the industry in which Parent conducts operations.

 

(f) Post-Merger Capitalization. At the Effective Time, the authorized capital stock of Parent shall consist of 75,000,000 shares of Parent Common Stock, of which 60,000,000 shares shall be issued and outstanding (including the Merger Consideration), not including any shares of Parent Common Stock issued in connection with the Financing.

 

(g) Officers and Directors. Parent shall deliver to the Company evidence of appointment of those new directors and officers as further described in Section 6.1. Parent shall have delivered to each new director an executed indemnification agreement in substantially the form attached hereto as Exhibit D. Parent shall also have delivered to the Company a letter of resignation executed by each Parent officer and director further described in Section 6.1 to be effective upon the Closing Date.

 

(h) Financing. The Company shall have consummated the initial closing of the Financing.

 

ARTICLE 10

 

SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS

 

All representations, warranties and covenants of the parties contained in this Agreement will remain operative and in full force and effect, regardless of any investigation made by or on behalf of the parties to this Agreement, until the date that is the first anniversary of the Closing Date, whereupon such representations, warranties and covenants will expire (except for covenants that by their terms survive for a longer period).

 

ARTICLE 11

 

TERMINATION

 

11.1. Termination. This Agreement may be terminated at any time prior to the Effective Time, whether before or after approval of the Merger by the stockholders of the Company:

 

(a) by mutual written agreement of the Company and Parent duly authorized by the Boards of Directors of the Company and Parent;

 

25
 

 

(b) by either the Company or Parent, if the other party (which, in the case of Parent, shall mean Parent and Merger Sub) has breached any representation, warranty, covenant or agreement of such other party set forth in this Agreement and such breach has resulted or can reasonably be expected to result in a Material Adverse Effect on such other party or would prevent or materially delay the consummation of the Merger;

 

(c) by either party, if the required approval of the stockholders of the Company shall not have been obtained by reason of the failure to obtain the required vote;

 

(d) by either party, if all the conditions to the obligations of such party for Closing the Merger shall not have been satisfied or waived on or before the Final Date (as defined below) other than as a result of a breach of this Agreement by the terminating party;

 

(e) by either party if the initial closing of the Financing has not been successfully consummated on or before the Final Date; or

 

(f) by either party, if a permanent injunction or other Order by any Federal or state court which would make illegal or otherwise restrain or prohibit the consummation of the Merger shall have been issued and shall have become final and nonappealable;

 

As used herein, the “Final Date” shall be April 30, 2014.

 

11.2. Notice of Termination. Any termination of this Agreement under Section 11.1 above will be effective immediately upon by the delivery of written notice of the terminating party to the other party hereto specifying with reasonable particularity the reason for such termination.

 

11.3. Effect of Termination. In the case of any termination of this Agreement as provided in this Section 10, this Agreement shall be of no further force and effect and nothing herein shall relieve any party from liability for any breach of this Agreement.

 

ARTICLE 12

 

GENERAL PROVISIONS

 

12.1. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) two days after deposit with a nationally recognized overnight courier, specifying not later than two day delivery, with written verification of receipt. All communications shall be sent to the parties at the following addresses or facsimile numbers specified below (or at such other address or facsimile number for a party as shall be designated by ten days advance written notice to the other parties hereto):

 

(a) If to Parent or Merger Sub:

 

Oro Capital Corporation

Dassan Island Drive

Plettenberg Bay, 6600

South Africa

Attn: Danny Aaron, President & CEO

 

with a copy to (which shall not constitute notice):

 

Greenberg Traurig, LLP

1201 K Street, Suite 1100

Sacramento, California 95814

Attn: Mark C. Lee

Ph: (916) 442-1111

Fax: (916) 448-1709

 

26
 

 

(b) If to the Company:

 

Synergy Strips Corp.

2105 Burton Branch Road

Algood, TN 38506

Attn: Jack Ross, President & CEO

Ph: (615) 939-9004

Fax: (888) 389-3036

 

12.2. Amendment. To the extent permitted by Law, this Agreement may be amended by a subsequent writing signed by each of the parties upon the approval of the Boards of Directors of each of the parties, whether before or after any stockholder approval of the issuance of the Merger Consideration has been obtained; provided, that after any such approval by the holders of Shares, there shall be made no amendment that pursuant to the DGCL requires further approval by such stockholders without the further approval of such stockholders.

 

12.3. Waiver. At any time prior to the Closing, any party hereto may with respect to any other party hereto (a) extend the time for performance of any of the obligations or other acts, (b) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto, or (c) waive compliance with any of the agreements or conditions contained herein. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the party or parties to be bound thereby.

 

12.4. Failure or Indulgence Not Waiver; Remedies Cumulative. No failure or delay on the part of any party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude other or further exercise thereof or of any other rights. Except as otherwise provided hereunder, all rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.

 

12.5. Headings. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

12.6. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible, in a mutually acceptable manner, to the end that transactions contemplated hereby are fulfilled to the extent possible.

 

12.7. Entire Agreement. This Agreement (including the Company Disclosure Schedule and the Parent Disclosure Schedule together with the Transaction Documents and the exhibits and schedules attached hereto and thereto and the certificates referenced herein) constitutes the entire agreement and supersedes all prior agreements and undertakings both oral and written, among the parties, or any of them, with respect to the subject matter hereof and, except as otherwise expressly provided herein.

 

27
 

 

12.8. Assignment. No party may assign this Agreement or assign its respective rights or delegate their duties (by operation of Law or otherwise), without the prior written consent of the other party. This Agreement will be binding upon, inure to the benefit of and be enforceable by the parties and their respective successors and permitted assigns.

 

12.9. Parties In Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto and their permitted assigns and respective successors, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, including, without limitation, by way of subrogation.

 

12.10. Governing Law. This Agreement will be governed by, and construed and enforced in accordance with the Laws of the State of Nevada as applied to Contracts that are executed and performed in Nevada, without regard to the principles of conflicts of Law thereof.

 

12.11. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together will constitute one and the same Agreement. This Agreement, to the extent delivered by means of a facsimile machine or electronic mail (any such delivery, an “Electronic Delivery”), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute original forms hereof and deliver them in person to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

12.12. Attorneys Fees. If any action or proceeding relating to this Agreement, or the enforcement of any provision of this Agreement is brought by a party hereto against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled).

 

12.13. Representation. The parties to this Agreement, and each of them, acknowledge, agree, and represent that it: (a) has been represented in connection with the negotiation and preparation of this Agreement by counsel of that party’s choosing; (b) has read the Agreement and has had it fully explained by its counsel; (c) it is fully aware of the contents and legal effect of this Agreement; (d) has authority to enter into and sign the Agreement; and (e) enters into and signs the same by its own free will.

 

12.14. Drafting. The parties to this Agreement acknowledge that each of them have participated in the drafting and negotiation of this Agreement. For purposes of interpreting this Agreement, each provision, paragraph, sentence and word herein shall be deemed to have been jointly drafted by both parties. The parties intend for this Agreement to be construed and interpreted neutrally in accordance with the plain meaning of the language contained herein, and not presumptively construed against any actual or purported drafter of any specific language contained herein.

 

12.15. Interpretation. For purposes of this Agreement, references to the masculine gender shall include feminine and neuter genders and entities. Where a reference in this Agreement is made to a Section, Exhibit or Schedule, such reference shall be to a Section of, Exhibit to or Schedule of this Agreement unless otherwise indicated. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” References to a “party” or “parties” shall mean Parent and/or Merger Sub, on the one hand, and the Company, on the other hand, as applicable. The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. References to “this Agreement” shall include the Company Disclosure Schedule and the Parent Disclosure Schedule.

 

[Remainder of Page Intentionally Left Blank; Signature Page to Follow]

 

28
 

 

IN WITNESS WHEREOF, the parties have caused this Agreement and Plan of Merger to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

  ORO CAPITAL CORPORATION, a Nevada corporation
     
  By:  
  Name: Danny Aaron
  Title: President & Chief Executive Officer
     
  SYNERGY MERGER SUB, INC. a Delaware corporation
     
  By:  
  Name: Danny Aaron
  Title: President
     
  SYNERGY STRIPS CORP., a Delaware corporation
     
  By:  
  Name: Jack Ross
  Title: President & Chief Executive Officer

 

29
 

 

EXHIBIT A

 

CERTAIN DEFINITIONS

 

The following terms, as used in the Agreement, have the following meanings:

 

Accounts Receivable” shall have the meaning as set forth in Section 3.14 of the Agreement.

 

Affiliate(s)” shall have the meaning set forth in Rule 12b-2 of the regulations promulgated under the Exchange Act.

 

Agreement” shall have the meaning as set forth in the Preamble.

 

Assets” of a Person shall mean all of the assets, properties, businesses and rights of such Person of every kind, nature, character and description, whether real, personal or mixed, tangible or intangible, accrued or contingent, or otherwise relating to or utilized in such Person’s business, directly or indirectly, in whole or in part, whether or not carried on the books and records of such Person, and whether or not owned in the name of such Person or any Affiliate of such Person and wherever located.

 

Benefit Plans” shall have the meaning as set forth in Section 3.10 of the Agreement.

 

Claims and Liabilities” shall have the meaning as set forth in Section 8.1(a) of the Agreement.

 

Closing” shall have the meaning as set forth in Section 1.2 of the Agreement.

 

Closing Date” shall have the meaning as set forth in Section 1.2 of the Agreement.

 

Code” means the Internal Revenue Code of 1986, as amended.

 

Company” shall have the meaning as set forth in the Preamble.

 

Company Balance Sheet Date” shall have the meaning as set forth in Section 3.6(b) of the Agreement.

 

Company Disclosure Schedule” shall have the meaning as set forth in the opening paragraph of Article 3 of the Agreement.

 

Company Financial Statements” shall have the meaning as set forth in Section 3.6(a) of the Agreement.

 

Company Material Contract” shall have the meaning as set forth in Section 3.13 of the Agreement.

 

Company Common Stock” means the total outstanding capital stock of the Company as of the Closing Date.

 

Contract” means any written or oral agreement, arrangement, commitment, contract, indenture, instrument, lease, obligation, plan, restriction, understanding or undertaking of any kind or character, or other document to which any Person is a party or by which such Person is bound or affecting such Person’s capital stock, Assets or business.

 

Default” means (a) any breach or violation of or default under any Contract, Order or Permit, (b) any occurrence of any event that with the passage of time or the giving of notice or both would constitute a breach or violation of or default under any Contract, Order or Permit, or (c) any occurrence of any event that with or without the passage of time or the giving of notice would give rise to a right to terminate or revoke, change the current terms of, or renegotiate, or to accelerate, increase, or impose any Liability under, any Contract, Order or Permit.

 

Delaware Certificate of Merger” shall have the meaning as set forth in Section 1.3 of the Agreement.

 

DGCL” shall have the meaning as set forth in the Recitals of the Agreement.

 

Dissenting Shares” shall have the meaning as set forth in Section 2.4 of the Agreement.

 

Effective Time” shall have the meaning as set forth in Section 1.3 of the Agreement.

 

  A-1  
     

 

Electronic Delivery” shall have the meaning as set forth in Section 11.11 of the Agreement.

 

Environmental Laws” mean any and all federal, state, local and foreign statutes, laws, judicial decisions, regulations, ordinances, rules, judgments, orders, decrees, codes, plans, injunctions, Permits, concessions, grants, franchises, licenses, agreements and governmental restrictions, relating to human health, the environment or to emissions, discharges or releases of pollutants, contaminants or other Hazardous Material or wastes into the environment, including without limitation ambient air, surface water, ground water or land, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of pollutants, contaminants or other Hazardous Material or wastes or the clean-up or other remediation thereof.

 

Exchange Act” has the meaning set forth in Section 3.5 of the Agreement.

 

Exchange Act Documents” has the meaning set forth in Section 3.20 of the Agreement.

 

FINRA” means The Financial Industry Regulatory Authority.

 

GAAP” means U.S. generally accepted accounting principles.

 

Governmental Entity” shall mean any government or any agency, bureau, board, directorate, commission, court, department, official, political subdivision, tribunal, or other instrumentality of any government, whether federal, state or local, domestic or foreign.

 

Hazardous Material” means any toxic, radioactive, corrosive or otherwise hazardous substance, including petroleum, its derivatives, by-products and other hydrocarbons, or any substance having any constituent elements displaying any of the foregoing characteristics, which in any event is regulated under any Environmental Law.

 

Indemnitee” shall have the meaning as set forth in Section 8.3 of the Agreement.

 

Indemnifying Party” shall have the meaning as set forth in Section 8.3 of the Agreement.

 

Intellectual Property” shall have the meaning as set forth in Section 3.16(a) of the Agreement.

 

Knowledge” means the actual knowledge of the officers of a party.

 

Law” means any code, law, ordinance, regulation, reporting or licensing requirement, rule, or statute applicable to a Person or its Assets, liabilities or business, including those promulgated, interpreted or enforced by any Regulatory Authority.

 

License Agreements” shall have the meaning as set forth in Section 3.16(a) of the Agreement.

 

Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect to such asset.

 

Material” and “Materially” for purposes of this Agreement shall be determined in light of the facts and circumstances of the matter in question; provided that any specific monetary amount stated in this Agreement shall determine materiality in that instance.

 

Material Adverse Effect” means, with respect to any Person, any change or effect that either individually or in the aggregate with all such other changes or effects is materially adverse to the business, assets, properties or condition of such party and its Subsidiaries taken as a whole.

 

  A-2  
     

 

Material Contract Default” means a default under any Contract which would (a) permit any other party to cancel or terminate the same (with or without notice of passage of time) or (b) provide a basis for any other party to claim money damages in excess of $50,000 (either individually or in the aggregate with all other such claims under that contract) or (c) give rise to a right of acceleration of any material obligation or loss of any material benefit under any such Contract.

 

Merger” shall have the meaning as set forth in the Recitals of the Agreement.

 

Merger Consideration” shall have the meaning as set forth in Section 2.1(b)(ii) of the Agreement.

 

Merger Consideration Certificate” shall have the meaning as set forth in Section 2.1(b)(iii) of the Agreement.

 

Merger Sub” shall have the meaning as set forth in the Preamble.

 

NRS” shall have the meaning as set forth in the Recitals of the Agreement.

 

Order” means any administrative decision or award, decree, injunction, judgment, order, quasi-judicial decision or award, ruling, or writ of any federal, state, local or foreign or other court, arbitrator, mediator, tribunal, administrative agency or Regulatory Authority.

 

Parent” shall have the meaning as set forth in the Preamble.

 

Parent Accounts Receivable” shall have the meaning as set forth in Section 4.15 of the Agreement.

 

Parent Balance Sheet” shall have the meaning as set forth in Section 4.6(b) of the Agreement.

 

Parent Common Stock” shall have the meaning as set forth in Section 4.1 of the Agreement.

 

Parent Disclosure Schedule” shall mean the written disclosure schedule delivered on or prior to the date hereof by Parent to the Company that is arranged in paragraphs corresponding to the numbered and lettered paragraphs corresponding to the numbered and lettered paragraphs contained in the Agreement.

 

Parent Material Contract” shall have the meaning as set forth in Section 4.14 of the Agreement.

 

Parent SEC Documents” shall have the meaning as set forth in Section 4.6(a) of the Agreement.

 

Person” means an individual, a corporation, a partnership, an association, a trust, a limited liability company or any other entity or organization, including a government or political subdivision or any agency or instrumentality thereof.

 

Permit” shall mean any federal, state, local, and foreign governmental approval, authorization, certificate, consent, easement, filing, franchise, letter of good standing, license, notice, permit, qualification, registration or right of or from any Governmental Entity (or any extension, modification, amendment or waiver of any of these) to which any Person is a party or that is or may be binding upon or inure to the benefit of any Person or its securities, Assets or business, or any notice, statement, filing or other communication to be filed with or delivered to any Governmental Entity.

 

Regulatory Authorities” means, collectively, the Federal Trade Commission, the United States Department of Justice, United States Department of Transportation, Federal Railroad Administration, United States Environmental Protection Agency, and all foreign, federal, state and local regulatory agencies and other Governmental Entities or bodies having jurisdiction over the parties and their respective Assets, employees, businesses and/or Subsidiaries, including FINRA and the SEC.

 

  A-3  
     

 

SEC” shall have the meaning as set forth in Section 4.6(a) of the Agreement.

 

Securities Act” shall have the meaning as set forth in Section 3.3 of the Agreement.

 

Share” or “Shares” shall have the meaning as set forth in Section 2.1(b)(ii) of the Agreement.

 

Software” shall have the meaning as set forth in Section 3.16(a) of the Agreement.

 

Subsidiary” means, with respect to any Person, (i) any corporation, limited liability company, association or other business entity of which more than 50% of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person (or a combination thereof) and (ii) any partnership (a) the sole general partner or managing general partner of which is such Person or a Subsidiary of such Person or (b) the only general partners of which are such Person or of one or more Subsidiaries of such Person (or any combination thereof).

 

Surviving Corporation” shall have the meaning as set forth in Section 1.1 of the Agreement.

 

Tax” or “Taxes” shall have the meaning as set forth in Section 3.11(c) of the Agreement.

 

Tax Return” shall have the meaning as set forth in Section 3.11(c) of the Agreement.

 

Trademarks” shall have the meaning as set forth in Section 3.16(a) of the Agreement.

 

Trade Secrets” shall have the meaning as set forth in Section 3.16(a) of the Agreement.

 

Transaction Documents” means the Agreement, and any other document executed and delivered pursuant hereto together with any exhibits or schedules to such documents.

 

Transfer” shall have the meaning as set forth in Section 7.4(a) of the Agreement.

 

Transfer Taxes” shall have the meaning as set forth in Section 7.3 of this Agreement.

 

8-K Report” shall have the meaning as set forth in Section 7.5 of the Agreement.

 

  A-4  
     

 

EXHIBIT B

 

CERTIFICATE OF MERGER

 

OF

 

SYNERGY MERGER SUB, INC.

 

INTO

 

SYNERGY STRIPS CORP.

 

(UNDER SECTION 8-252 OF THE GENERAL

 

CORPORATION LAW OF THE STATE OF DELAWARE)

 

Synergy Strips Corp., a corporation organized and existing under the laws of the State of Delaware, and Synergy Merger Sub, Inc. a corporation organized and existing under the laws of the State of Delaware, each do hereby certify that:

 

  1. The name and state of incorporation of each of the constituent corporations are:

 

  a. Synergy Strips Corp., a Delaware corporation; and
  b. Synergy Merger Sub, Inc., a Delaware corporation.

 

  2. An Agreement and Plan of Merger has been approved, adopted, certified, executed, and acknowledged by Synergy Strips Corp and Synergy Merger Sub, Inc. in accordance with Section 8-252(c) of the General Corporation Law of the State of Delaware.
  3. The name of the surviving corporation is Synergy Strips Corp. (the “Surviving Corporation”).
  4. The Certificate of Incorporation of Synergy Strips Corp. shall be the Certificate of Incorporation of the Surviving Corporation.
  5. The merger is to become effective on [______], 2014.
  6. The executed Agreement and Plan of Merger is on file at the principal place of business of the Surviving Corporation at 2105 Burton Branch Road, Algood, TN 38506.
  7. A copy of the Agreement and Plan of Merger will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of Synergy Strips Corp. or Synergy Merger Sub, Inc..
  8. The authorized capital stock of Synergy Merger Sub, Inc., a Delaware corporation, is 1,000 shares of common stock, $0.001 par value per share.
  9. The Surviving Corporation agrees that it may be served with process in the State of Delaware in any proceeding for enforcement of any obligation of the Surviving Corporation arising from this merger, including any suit or other proceeding to enforce the rights of stockholders as determined in appraisal proceedings pursuant to the provisions of Section 262 of the General Corporation Law of the State of Delaware, and irrevocably appoints the Secretary of State of Delaware as its agent to accept services of process in any such suit or proceeding. The Secretary of State shall mail any such process to the Surviving Corporation at 2105 Burton Branch Road, Algood, TN 38506.

 

  B-1  
     

 

IN WITNESS WHEREOF, the undersigned officers, for and on behalf of their respective corporations, have executed this Certificate of Merger this ___ day of ________, 2014 and hereby acknowledge, under penalties of perjury, that this Certificate of Merger is the act and deed of their respective corporations and that the facts stated in this Certificate of Merger are true.

 

  SYNERGY STRIPS CORP.,
  a Delaware corporation
     
  By:  
  Name: Jack Ross
  Title: Chief Executive Officer and President
     
  SYNERGY MERGER SUB, INC.,
  a Delaware corporation
     
  By:  
  Name: Danny Aaron
  Title: President

 

[Signature Page to Delaware Certificate of Merger]

 

  B-2  
     

 

EXHIBIT C

 

FORM OF STOCKHOLDER REPRESENTATION LETTER

 

__________, 2014

 

Oro Capital Corporation

Dassan Island Drive

Plettenberg Bay, 6600

South Africa

 

Shareholder Representation Letter

 

Ladies and Gentlemen:

 

Pursuant to an Agreement and Plan of Merger (the “Agreement”) dated as of April 7, 2014 (the “Agreement Date”) by and among Oro Capital Corporation, a Nevada corporation (“Pubco”), Synergy Merger Sub, Inc. a Delaware corporation, and Synergy Strips Corp. (“Synergy”), the undersigned (the “Shareholder”) expects to receive shares of Pubco Common Stock (the “Securities”) pursuant to a merger transaction in accordance with the Delaware General Corporation Law (the “Merger”). Capitalized terms used herein but not defined will have the meanings ascribed to them in the Agreement. The Shareholder whose signature appears below, represents and warrants to Pubco that, as of the date first written above and as of the Closing Date, the statements contained in this Shareholder Representation Letter are, and will be, correct and complete:

 

1. REPRESENTATIONS AND WARRANTIES OF SHAREHOLDER.

 

1.1. “Accredited” Investor. The Merger pursuant to the Agreement, and the distribution of the Securities to the Shareholder at the Closing, are intended to be exempt from registration under the Securities Act of 1933, as amended (the “Act”). Unless the Shareholder checks the “no” box on the signature page hereof indicating that the Shareholder is not an Accredited Investor, the Shareholder represents and warrants that the Shareholder falls within one of the following definitions of Accredited Investor:

 

(Please initial the category that applies)

 

  _______ (a) The Shareholder is a natural person whose individual net worth, or joint net worth with spouse, exceeds $1,000,000.
     
    Explanation. In calculating net worth, you include all of your assets (other than your primary residence) whether liquid or illiquid, such as cash, stock, securities, personal property and real estate based on the fair market value of such property MINUS all debts and liabilities (other than a mortgage or other debt secured by your primary residence). In the event that the amount of any mortgage or other indebtedness secured by your primary residence exceeds the fair market value of the residence, that excess liability should also be deducted from your net worth. Any mortgage or indebtedness secured by your primary residence incurred within 60 days before the time of the sale of the Securities offered hereunder, other than as a result of the acquisition of the primary residence, shall also be deducted from your net worth.
     
  _______ (b) The Shareholder is a natural person who had an individual income in excess of $200,000 in each of the last two years or joint income with spouse in excess of $300,000 in each of those years and reasonably expects to reach the same income level in the current year.

 

  C-1  
     

 

  _______ (c) The Shareholder is either a director or executive officer of Pubco.
     
  _______ (d) The Shareholder is a corporation or other entity with total assets in excess of US$5,000,000, not formed for the specific purpose of acquiring the Securities.
     
  _______ (e) The Shareholder is an entity, all of the equity owners of which are as specified in (a) or (b) above.

 

The Shareholder further certifies that: (i) the Shareholder has the capacity to protect the Shareholder’s interests in this investment; (ii) the Shareholder is able to bear the economic risks of this investment; and (iii) the amount of the investment does not exceed 10% of the Shareholder’s net worth or joint net worth with spouse.

 

1.2. Regulation S; Non-U.S. Person Status. For purposes of compliance with the Regulation S exemption for the acquisition of the Securities by non-U.S. Persons, the Shareholder makes the following representations, warranties and covenants:

 

(a) The Shareholder is a person or entity that is outside the United States and is not a “US Person,” as such term is defined in Rule 902(k) of Regulation S.[1]

 

(b) The Shareholder is not acquiring the Securities for the account or benefit of a US Person.

 

(c) The Shareholder has been independently advised as to the applicable holding period imposed in respect of the Securities by securities legislation in the jurisdiction in which it resides and confirms that no representation has been made respecting the applicable holding periods for the Securities in such jurisdiction and it is aware of the risks and other characteristics of the Securities and of the fact that holders of Securities may not be able to resell the Securities except in accordance with applicable securities legislation and regulatory policy.

 

(d) To the knowledge of the Shareholder, without having made any independent investigation, neither Pubco or Synergy nor any person acting for Pubco or Synergy, has conducted any “directed selling efforts” in the United States as the term “directed selling efforts” is defined in Rule 902 of Regulation S, which, in general, means any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the marketing in the United States for any of the Securities being offered. Such activity includes, without limitation, the mailing of printed material to investors residing in the United States, the holding of promotional seminars in the United States, and the placement of advertisements with radio or television stations broadcasting in the United States or in publications with a general circulation in the United States, which discuss the offering of the Securities. To the knowledge of the Shareholder, the Securities were not offered to the Shareholder through, and the Shareholder is not aware of, any form of general solicitation or general advertising, including without limitation, (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

(e) The Shareholder will offer, sell or otherwise transfer the Securities, only (i) pursuant to a registration statement that has been declared effective under the Act, (ii) pursuant to offers and sales that occur outside the United States within the meaning of Regulation S in a transaction meeting the requirements of Rule 904 (or other applicable Rule) under the Act, or (iii) pursuant to another available exemption from the registration requirements of the Act, subject to Pubco’s right prior to any offer, sale or transfer pursuant to clauses (ii) or (iii) to require the delivery of an opinion of counsel, certificates or other information reasonably satisfactory to Pubco for the purpose of determining the availability of an exemption.

 

  C-2  
     

 

(f) The Shareholder will not engage in hedging transactions involving the Securities unless such transactions are in compliance with the Act.

 

(g) The Shareholder represents and warrants that the Shareholder is not a citizen of the United States and is not, and has no present intention of becoming, a resident of the United States (defined as being any natural person physically present within the United States for at least 183 days in a 12-month consecutive period or any entity who maintained an office in the United States at any time during a 12-month consecutive period). The Shareholder understands that Pubco may rely upon the representations and warranty of this paragraph as a basis for an exemption from registration of the Securities under the Act, and the provisions of relevant state securities laws.

 

(h) The Shareholder hereby represents that he, she or it has satisfied and fully observed the laws of the jurisdiction in which he, she or it is located or domiciled, in connection with the acquisition of the Securities, including (i) the legal requirements of the Shareholder’s jurisdiction for the acquisition of the Securities, (ii) any foreign exchange restrictions applicable to such acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, which may be relevant to the holding, redemption, sale, or transfer of the Securities; and further, the Shareholder agrees to continue to comply with such laws as long as he, she or it shall hold the Securities.

 

1.3. Holding For Own Account. The Shareholder is acquiring an interest in the Securities for the Shareholder’s own account, for investment purposes only, and not with a view toward the resale or distribution thereof within the meaning of the Act, except pursuant to effective registrations or qualifications relating thereto under the Act and applicable state securities or blue sky laws or pursuant to an exemption therefrom.

 

1.4. Unregistered Securities; Restrictions on Transfer. The Shareholder understands that: (a) the Securities have not been registered under the Act or the securities laws of any state or other jurisdiction in reliance upon exemptions from such registration requirements for non-public offerings; (b) the Securities may not be sold, pledged or otherwise transferred except pursuant to effective registrations or qualifications relating thereto under the Act and other applicable securities laws or pursuant to an exemption therefrom; and (c) neither Pubco or Synergy are under any obligation to register or qualify the Securities under the Act or any other applicable securities laws, or to take any action to make any exemption from any such registration provisions available. The Shareholder understands that the Shareholder may not transfer any Securities unless such Securities are registered under the Act or qualified under applicable state securities laws or unless with respect to the Securities, in the reasonable opinion of counsel to Pubco, exemptions from such registration and qualification requirements are available. Pubco may require an opinion to such effect from counsel to the Shareholder reasonably satisfactory to Pubco. The Shareholder has also been advised that exemptions from registration and qualification may not be available or may not permit the Shareholder to transfer all or any of the Securities in the amounts or at the times proposed by the Shareholder.

 

1.5. Securities Law Restrictions. The Shareholder will not sell, assign or transfer any of the Securities received by the Shareholder in connection with the Agreement except (a) pursuant to an effective registration statement under the Act, (b) in conformity with the volume and other limitations of Securities and Exchange Commission Rule (“SEC”) Rule 144 promulgated under the Act (“Rule 144”), or (c) in a transaction which, in the opinion of independent counsel to the Shareholder delivered to Pubco and satisfactory to Pubco, is not required to be registered under the Act. Pubco shall not have any obligation to effect a transfer of any Securities that is not in compliance with applicable federal and state securities laws.

 

  C-3  
     

 

1.6. Rule 144; Legends. The Shareholder has been advised and acknowledges that Rule 144, which permits certain limited sales of unregistered securities, is not presently available with respect to the Securities and, in any event, requires that the Securities be held for a minimum of six months (and the sale thereof may be subject to certain volume and other limitations under Rule 144), after they have been purchased and paid for (within the meaning of Rule 144), before they may be resold under Rule 144. The Shareholder understands that Rule 144 may indefinitely apply to and restrict transfer of the Securities if the Shareholder is an “affiliate” of Pubco and “current public information” about Pubco (as defined in Rule 144) is not publicly available. The Shareholder further understands that, if applicable, sales under Rule 144 are not available to the Shareholder during such time as Pubco remains a “shell company” (as defined in Rule 405 promulgated under the 1933 Act).

 

Pubco may place any legend contemplated by the Agreement, one or more of the legends below, or such other legends as it may reasonably deem appropriate, on each certificate or instrument representing Securities:

 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES OR BLUE SKY LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR IN A TRANSACTION WHICH IS NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THE ACT OR ANY APPLICABLE SECURITIES OR BLUE SKY LAWS AND, IN THE CASE OF A TRANSACTION NOT SUBJECT TO SUCH REGISTRATION REQUIREMENTS, UNLESS THE ISSUER HAS RECEIVED AN OPINION OF COUNSEL TO THE HOLDER REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE ACT.

 

1.7. Shareholder’s Business Experience. The Shareholder has, alone or together with the Shareholder’s representative, if any, such knowledge and experience in financial and business matters so that the Shareholder is capable of evaluating the relative merits and risks of the investment in the Securities that is represented by the Agreement and the transactions contemplated thereby. The Shareholder has adequate means of providing for its, his or her current economic needs and possible personal contingencies, has no need for liquidity in its, his or her investment in Pubco and is able financially to bear the risks of such investment.

 

1.8. Availability of Information. The Shareholder acknowledges that the Shareholder has had access to all information regarding Pubco and its present and prospective business, assets, liabilities and financial condition that the Shareholder reasonably considers important in making the decision to acquire the Securities pursuant to the Merger, and that all documents, records and books pertaining to the investment in Pubco resulting from the Agreement and requested by the Shareholder or the Shareholder’s representative, if any, have been made available or delivered to the Shareholder, to the extent that Pubco possesses such information or can obtain such information without unreasonable efforts or expense.

 

1.9. Opportunity to Ask Questions. The Shareholder or the Shareholder’s representative, if any, has had an opportunity to discuss Pubco’s business, management and financial affairs with Pubco’s management and to ask questions of and receive answers from Pubco, or a person or persons acting on behalf of Pubco, concerning the business of Pubco. The Shareholder acknowledges that all such questions, if any, have been answered to the Shareholder’s satisfaction.

 

  C-4  
     

 

1.10. Shareholder Representation Letter. The Shareholder has carefully read this Shareholder Representation Letter and, to the extent the Shareholder believes necessary, has discussed with the Shareholder’s counsel the representations, warranties and agreements that the Shareholder makes herein and the applicable limitations upon the Shareholder’s resale of the Securities.

 

1.11. Pubco Information. The Shareholder is also aware of and acknowledges the following:

 

(a) that no federal or state agency has made any finding or determination regarding the fairness of this investment, or any recommendation or endorsement of the Securities;

 

(b) that neither the officers, directors, agents, affiliates or employees of Pubco or Synergy, nor any other person, has expressly or by implication, made any representation or warranty to the Shareholder concerning Pubco or Synergy; and

 

(c) that the past performance or experience of Pubco or Synergy or their respective officers, directors, agents or employees will not in any way indicate or predict the results of the ownership of Securities or of Pubco’s activities.

 

1.12. Stop Transfer Instructions; No Requirement to Transfer. The Shareholder agrees that, in order to ensure compliance with the restrictions referred to herein, Pubco may issue appropriate “stop transfer” instructions to its transfer agent. Pubco shall not be required (a) to transfer or have transferred on its books any Securities that have been sold or otherwise transferred in violation of any of the provisions of this Shareholder Representation Letter or the Agreement or (b) to treat as owner of such Securities or to accord the right to vote or pay dividends to any shareholder or other transferee to whom such Securities shall have been so transferred in violation of any provision of this Shareholder Representation Letter or the Agreement.

 

1.13. No Public Solicitation. The Shareholder represents that at no time was the Shareholder presented with or solicited by any general mailing, leaflet, public promotional meeting, newspaper or magazine article, radio or television advertisement, or any other form of general advertising or general solicitation in connection with the transactions contemplated by the Agreement.

 

1.14. Principal Residence. The address shown under the Shareholder’s signature on the signature page hereof is the Shareholder’s principal residence.

 

1.15. Indemnification. The Shareholder will indemnify and hold harmless Pubco and Synergy and their respective officers, directors, managers and counsel, from and against any and all damages, losses, liabilities or expenses (including all legal fees and costs) directly or indirectly incurred, resulting or arising out of the breach of any of the representations, warranties or covenants given or made in this Shareholder Representation Letter.

 

1.16. Authorization of Transaction. The Shareholder has full power and authority to execute and deliver this Shareholder Representation Letter and to perform the Shareholder’s obligations hereunder.

 

1.17. Disposition of Securities. The Shareholder is not a party to any option, warrant, purchase right, or other contract or commitment that could require the Shareholder to sell, transfer, or otherwise dispose of any of the Securities.

 

2. MERGER AGREEMENT. The Shareholder agrees that the Securities will be subject to and bound by, all of the provisions of the Agreement relating to the Securities.

 

  C-5  
     

 

3. ENTIRE AGREEMENT. The Agreement and this Shareholder Representation Letter constitute the entire agreement and understanding of the parties with respect to the subject matter of this Shareholder Representation Letter, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof.

 

4. COUNTERPARTS. This Shareholder Representation Letter may be executed in several counterparts, each of which shall be an original, but all of which together shall constitute one and the same agreement.

 

5. EFFECT OF HEADINGS. The section headings herein are for convenience only and shall not affect the construction or interpretation of this Shareholder Representation Letter.

 

6. GOVERNING LAW; CONSENT TO JURISDICTION. This Shareholder Representation Letter shall be governed by, and construed in accordance with, the internal laws of the State of Nevada applicable to contracts executed in and to be performed by residents of Nevada within that State.

 

7. NO TAX REPRESENTATIONS. The Shareholder represents, warrants and acknowledges that the Shareholder is not relying on Pubco or Synergy for any tax advice concerning the federal or state income or other tax consequences of the transactions contemplated by the Agreement or the Shareholder’s receipt of the Securities, and that the Shareholder has consulted such advisors as the Shareholder deems necessary or appropriate to understand the tax consequences of the investment represented by the Securities.

 

[Signature Page Follows]

 

  C-6  
     

 

  SHAREHOLDER
   
  Signature
  Name (Please Type or Print)
  Title (Please Type or Print) (if applicable)
  Street Address
  City, State, Zip Code
  Country
  Social Security Number
  (or tax I.D. Number, if an entity)
  Accredited Investor:
   
  (Please Check One of the Following Boxes)
  [  ] Yes [  ] No

 

  C-7  
     

 

EXHIBIT D

 

FORM OF INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (this “Agreement”), dated as of March __, 2014, is made by and between Oro Capital Corporation, a Nevada corporation (the “Company”), and the undersigned, who is either a director or an officer (or both) of the Company (the “Indemnitee”), with this Agreement to be deemed effective as of the date that the Indemnitee first assumed either such capacity at the Company.

 

RECITALS

 

A. The Company is aware that competent and experienced persons are reluctant to serve as directors or officers of corporations unless they are protected by comprehensive liability insurance and indemnification, due to the exposure to litigation costs and risks resulting from their service to such corporations, and due to the fact that the exposure frequently bears no reasonable relationship to the compensation of such directors and officers;

 

B. The Board of Directors of the Company (the “Board”) has concluded that, to retain and attract talented and experienced individuals to serve as officers or directors of the Company, it is necessary for the Company contractually to indemnify certain of such persons and to assume for itself maximum liability for expenses and damages in connection with claims against such persons in connection with their service to the Company;

 

C. Section 7502 of Chapter 78 of the Nevada General Corporation Law, under which the Company is organized (“Section 7502”), empowers the Company to indemnify by agreement its present and former officers and directors and persons who serve, at the request of the Company, as directors or officers of other corporations, partnerships, joint ventures, trusts, or other enterprises and expressly provides that the indemnification provided by Section 7502 is not exclusive; and

 

D. The Company desires and has requested the Indemnitee to serve or continue to serve as a director or an officer of the Company free from undue concern for claims for damages arising out of or related to such services to the Company.

 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

 

1. Definitions

 

1.1 Agent. For the purposes of this Agreement, “agent” of the Company means any person who is or was a director or an officer of the Company or a subsidiary of the Company; or is or was serving at the request of the Company or a subsidiary of the Company as a director or an officer of another foreign or domestic corporation, partnership, joint venture, trust, or other enterprise or an affiliate of the Company. The term “enterprise” includes any employee benefit plan of the Company, its subsidiaries, affiliates, and predecessor corporations.

 

1.2 Company. For purposes of this Agreement, the “Company” includes, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger that, if its separate existence had continued, would have had power and authority to indemnify its directors or officers so that any person who is or was a director or an officer of such constituent corporation, or is or was serving at the request of such constituent corporation as a director or an officer of another corporation, partnership, joint venture, trust, or other enterprise, shall stand in the same position under this Agreement with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

 

1.3 Expenses. For the purposes of this Agreement, “expenses” includes all direct and indirect costs of any type or nature whatsoever (including, without limitation, all attorneys’ fees and related disbursements and other out-of-pocket costs) actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, or appeal of a proceeding or establishing or enforcing a right to indemnification or advancement of expenses under this Agreement, Section 7502 or otherwise; provided, however, that expenses shall not include any judgments, fines, ERISA excise taxes or penalties, or amounts paid in settlement of a proceeding.

 

  D-1  
     

 

1.4 Fines. For purposes of this Agreement, references to “fines” includes any excise taxes assessed on a person with respect to any employee benefit plan.

 

1.5 Liabilities. For purposes of this Agreement, “liabilities” means judgments, fines, ERISA execute taxes or penalties, and amounts paid in settlement in connection with a proceeding.

 

1.6 Other Enterprises. For purposes of this Agreement, “other enterprises” includes employee benefit plans.

 

1.7 Proceeding. For the purposes of this Agreement, “proceeding” means any threatened, pending, or completed action, suit, or other proceeding, whether civil, criminal, administrative, or investigative.

 

1.8 Subsidiary. For purposes of this Agreement, “subsidiary” means any corporation of which more than 50% of the outstanding voting securities is owned directly or indirectly by the Company, by the Company and one or more of its subsidiaries, or by one or more of the Company’s subsidiaries.

 

1.9 Serving at the Request of the Company. For purposes of this Agreement, “serving at the request of the Company” includes any service as a director or an officer of the Company that imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

2. Agreement to Serve. The Indemnitee agrees to serve and/or continue to serve as an agent of the Company, at the will of the Company (or under separate agreement, if such agreement exists), in the capacity the Indemnitee currently serves as an agent of the Company, faithfully and to the best of his ability, so long as he is duly appointed or elected and qualified in accordance with the applicable provisions of the charter documents of the Company or any subsidiary of the Company; provided, however, that the Indemnitee may at any time and for any reason resign from such position (subject to any contractual obligation that the Indemnitee may have assumed apart from this Agreement), and the Company and any subsidiary shall have no obligation under this Agreement to continue the Indemnitee in any such position.

 

3. Directors’ and Officers’ Insurance. The Company shall, to the extent that the Board determines it to be economically reasonable, maintain a policy of directors’ and officers’ liability insurance (“D&O Insurance”), on such terms and conditions as may be approved by the Board.

 

4. Mandatory Indemnification. Subject to Section 9 below, the Company hereby agrees to hold harmless and indemnify the Indemnitee to the fullest extent permitted by law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof:

 

4.1 Third-Party Actions. If the Indemnitee is a person who was or is a party or is threatened to be made a party to any proceeding (except an action by or in the right of the Company) by reason of the fact that the Indemnitee is or was an agent of the Company, or by reason of anything done or not done by the Indemnitee in any such capacity, against any and all expenses and liabilities of any type whatsoever incurred by the Indemnitee in connection with such proceeding if (a) the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe the Indemnitee’s conduct was unlawful, or (b) the Indemnitee, if a director or an officer of the Company, did not act or fail to act in a manner that constituted a breach of the Indemnitee’s fiduciary duties as a director or an officer or such Indemnitee’s breach of those duties did not involve intentional misconduct, fraud, or a knowing violation of law; and

 

  D-2  
     

 

4.2 Derivative Actions. If the Indemnitee is a person who was or is a party or is threatened to be made a party to any proceeding by or in the right of the Company to procure a judgment in its favor by reason of the fact that the Indemnitee is or was an agent of the Company, or by reason of anything done or not done by the Indemnitee in any such capacity, against any and all expenses and liabilities incurred by the Indemnitee in connection with such proceeding if (a) the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company, or (b) the Indemnitee, if a director or an officer of the Company, did not act or fail to act in a manner that constituted a breach of the Indemnitee’s fiduciary duties as a director or an officer or such Indemnitee breach of those duties involved intentional misconduct, fraud, or a knowing violation of law; except that no indemnification under this subsection shall be made in respect of any claim, issue, or matter as to which the Indemnitee shall have been adjudged by a court of competent jurisdiction, after the exhaustion of all appeals therefrom, to be liable to the Company or for amounts paid in settlement to the Company, unless and only to the extent that the court in which such proceeding was brought or another court of competent jurisdiction determines upon application that, in view of all the circumstances of the case, the Indemnitee is fairly and reasonable entitled to indemnity for such expenses as the court deems proper; and

 

4.3 Exception for Amounts Covered by Insurance. Notwithstanding the foregoing, the Company shall not be obligated to indemnify the Indemnitee for expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent such have been paid to the Indemnitee by D&O Insurance.

 

4.4 Indemnification for Expenses as a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of the Indemnitee’s status as an agent of the Company, a witness, or is made (or asked) to respond to discovery requests, in any proceeding to which Indemnitee is not a party, the Indemnitee shall be indemnified against all expenses and liabilities of any type whatsoever actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

 

5. Partial Indemnification and Contribution.

 

5.1 Partial Indemnification. If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of any expenses or liabilities of any type whatsoever incurred by the Indemnitee in connection with a proceeding but is not entitled, however, to indemnification for all of the total amount thereof, then the Company shall nevertheless indemnify the Indemnitee for such total amount except as to the portion thereof to which the Indemnitee is not entitled to indemnification.

 

5.2 Contribution. If the Indemnitee is not entitled to the indemnification provided in Section 4 for any reason other than the statutory limitations set forth in the Nevada General Corporation Law, then in respect of proceeding in which the Company is jointly liable with the Indemnitee (or would be if joined in such proceeding), the Company shall contribute to the amount of expenses and liabilities paid or payable by the Indemnitee in such proportion as is appropriate to reflect (a) the relative benefits received by the Company on the one hand and the Indemnitee on the other hand from the transaction from which such proceeding arose and (b) the relative fault of the Company on the one hand and of the Indemnitee on the other hand in connection with the events that resulted in such expenses, as well as any other relevant equitable considerations. The relative fault of the Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent the circumstances resulting in such expenses, judgments, fines, or settlement amounts. The Company agrees that it would not be just and equitable if contribution pursuant to this Section 5 were determined by pro rata allocation or any other method of allocation which does not take account of the foregoing equitable considerations.

 

  D-3  
     

 

6. Mandatory Advancement of Expenses.

 

6.1 Advancement. Subject to Section 9 below, the Company shall pay as incurred and in advance of the final disposition of a civil or criminal proceeding all expenses incurred by the Indemnitee in connection with defending any such proceeding to which the Indemnitee is a party or is threatened to be made a party by reason of the fact that the Indemnitee is or was an agent of the Company or by reason of anything done or not done by the Indemnitee in any such capacity. The Indemnitee hereby undertakes to promptly repay such amounts advanced only if, and to the extent that, it shall ultimately by determined that the Indemnitee is not entitled to be indemnified by the Company under the provisions of this Agreement, the Articles of Incorporation or Bylaws of the Company, the Nevada General Corporation Law, or otherwise. The advances to be made hereunder shall be paid by the Company to the Indemnitee within thirty (30) days following delivery of a written request therefor by the Indemnitee to the Company.

 

6.2 Exception. Notwithstanding the foregoing provisions of this Section 6, the Company shall not be obligated to advance any expenses to the Indemnitee arising from a lawsuit filed directly by the Company against the Indemnitee if an absolute majority of the members of the Board reasonably determines in good faith, within thirty (30) days of the Indemnitee’s request to be advanced expenses, that the facts known to them at the time such determination is made demonstrate clearly and convincingly that the Indemnitee acted in bad faith. If such a determination is made, the Indemnitee may have such decision reviewed in the manner set forth in Section 8.5 hereof, with all references therein to “indemnification” being deemed to refer to “advancement of expenses,” and the burden of proof shall be on the Company to demonstrate clearly and convincingly that, based on the facts known at the time, the Indemnitee acted in bad faith. The Company may not avail itself of this Section 6.2 as to a given lawsuit if, at any time after the occurrence of the activities or omissions that are the primary focus of the lawsuit, the Company has undergone a change in control. For this purpose, a “change in control” shall mean a given person of group of affiliated persons or groups increasing their beneficial ownership interest in the Company by at least twenty (20) percentage points without advance Board approval.

 

7. Notice and Other Indemnification Procedures.

 

7.1 Notification. Promptly after receipt by the Indemnitee of notice of the commencement of or the threat of commencement of any proceeding, the Indemnitee shall, if the Indemnitee believes that indemnification with respect thereto may be sought from the Company under this Agreement, notify the Company of the commencement or threat of commencement thereof.

 

7.2 Insurance. If, at the time of the receipt of a notice of the commencement of a proceeding pursuant to Section 7.1 hereof, the Company has D&O Insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such D&O Insurance policies.

 

  D-4  
     

 

7.3 Defense. In the event the Company shall be obligated to advance the expenses for any proceeding against the Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by the Indemnitee (which approval shall not be unreasonably withheld), upon the delivery to the Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by the Indemnitee and the retention of such counsel by the Company, the Company will not be liable to the Indemnitee under this Agreement for any fees of counsel subsequently incurred by the Indemnitee with respect to the same proceeding, provided that (a) the Indemnitee shall have the right to employ the Indemnitee’s own counsel in any such proceeding at the Indemnitee’s expense; (b) the Indemnitee shall have the right to employ the Indemnitee’s own counsel in connection with any such proceeding, at the expense of the Company, if such counsel serves in a review, observer, advice, and counseling capacity and does not otherwise materially control or participate in the defense of such proceeding; and (c) if (i) the employment of counsel by the Indemnitee has been previously authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be conflict of interest between the Company and the Indemnitee in the conduct of any such defense, or (iii) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company.

 

8. Determination of Right to Indemnification.

 

8.1 Success on Merits. To the extent the Indemnitee has been successful on the merits or otherwise in defense of any proceeding referred to in Section 4.1 or 4.2 of this Agreement or in the defense of any claim, issue, or matter described therein, the Company shall indemnify the Indemnitee against expenses actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, or appeal of such proceeding, or such claim, issue, or matter, as the case may be.

 

8.2 Proof by Company. In the event that Section 8.1 is inapplicable, or does not apply to the entire proceeding, the Company shall nonetheless indemnify the Indemnitee unless the Company shall prove by clear and convincing evidence to a forum listed in Section 8.4 below that the Indemnitee has not met the applicable standard of conduct required to entitle the Indemnitee to such indemnification.

 

8.3 Termination of Proceeding. The termination of any proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere its equivalent, does not, of itself, create a presumption that a person (a) did not act in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, (b) with respect to any criminal action or proceeding, that the person had reasonable cause to believe that the person’s conduct was unlawful, or (c) the person’s act or failure to act constituted a breach of the person’s fiduciary duties as a director or an officer or the person’s breach of those duties involved intentional misconduct, fraud, or a knowing violation of law.

 

8.4 Applicable Forums. The Indemnitee shall be entitled to select the forum in which the validity of the Company’s claim under Section 8.2 hereof that the Indemnitee is not entitled to indemnification will be heard from among the following, except that the Indemnitee can select a forum consisting of the stockholders of the Company only with the approval of the Company and, if the Indemnitee is a director or an officer at the time of such determination, the determination shall be made in accordance with (a), (b), (c) or (d) below at the election of the Company:

 

(a) A majority vote of the directors who are not parties to the proceeding for which indemnification is being sought even though less than a quorum;

 

(b) By a committee of directors who are not parties to the proceeding for which indemnification is being sought designated by a majority vote of such directors, even though less than a quorum;

 

(c) If there are no directors who are not parties to the proceeding for which indemnification is sought, or if such directors so direct, by independent legal counsel in a written opinion;

 

  D-5  
     

 

(d) The stockholders of the Company;

 

(e) A panel of three arbitrators, one of whom is selected by the Company, another of whom is selected by the Indemnitee and the last of whom is selected by the first two arbitrators so selected; or

 

(f) A court having jurisdiction of subject matter and the parties.

 

8.5 Submission. As soon as practicable, and in no event later than thirty (30) days after the forum has been selected pursuant to Section 8.4 above, the Company shall, at its own expense, submit to the selected forum its claim that the Indemnitee is not entitled to indemnification, and the Company shall act in the utmost good faith to assure the Indemnitee a complete opportunity to defend against such claim.

 

8.6 Appeals. If the forum selected in accordance with Section 8.4 hereof is not a court, then after the final decision of such forum is rendered, the Company or the Indemnitee shall have the right to apply to a court of Nevada, the court in which the proceeding giving rise to the Indemnitee’s claim for indemnification is or was pending, or any other court of competent jurisdiction, for the purpose of appealing the decision of such forum, provided that such right is executed within sixty (60) days after the final decision of such forum is rendered. If the forum selected in accordance with Section 8.4 hereof is a court, then the rights of the Company or the Indemnitee to appeal any decision of such court shall be governed by the applicable laws and rules governing appeals of the decision of such court.

 

8.7 Expenses for Interpretation. Notwithstanding any other provision in this Agreement to the contrary, the Company shall indemnify the Indemnitee against all expenses incurred by the Indemnitee in connection with any hearing or proceeding under this Section 8 involving the Indemnitee and against all expenses incurred by the Indemnitee in connection with any other proceeding between the Company and the Indemnitee involving the interpretation or enforcement of the rights of the Indemnitee under this Agreement unless a court of competent jurisdiction finds that each of the material claims and/or defenses of the Indemnitee in any such proceeding was frivolous or not made in good faith.

 

9. Exceptions. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement in the following circumstances:

 

9.1 Claims Initiated by Indemnitee. To indemnify or advance expenses to the Indemnitee with respect to proceedings or claims initiated or brought voluntarily by the Indemnitee and not by way of defense, except with respect to proceedings specifically authorized by the Board or brought to establish or enforce a right to indemnification and/or advancement of expenses arising under this Agreement, the charter documents of the Company or any subsidiary, or any statute or law or otherwise, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board finds it to be appropriate; or

 

9.2 Unauthorized Settlements. To indemnify the Indemnitee hereunder for any amounts paid in settlement of a proceeding unless the Company consents in advance in writing to such settlement, which consent shall not be unreasonably withheld; or

 

9.3 Securities Law Actions. To indemnify the Indemnitee on account of any suit in which judgment is rendered against the Indemnitee for an accounting of profits made from the purchase or sale by the Indemnitee of securities of the company pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934 and amendments thereto or similar provisions of any federal, state, or local statutory law; or

 

  D-6  
     

 

9.4 Unlawful Indemnification. To indemnify the Indemnitee if a final decision by a court having jurisdiction in the mater shall determine that such indemnification is not lawful. In this respect, the Company and the Indemnitee have been advised that the Securities and Exchange Commission takes the position that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication.

 

10. Non-Exclusivity. The provisions for indemnification and advancement of expenses set forth in this Agreement shall not be deemed exclusive of any other rights that the Indemnitee may have under any provision of law, the Company’s Certificate of Incorporation or Bylaws, the vote of the Company’s stockholders or disinterested directors, other agreements, or otherwise, both as to action in the Indemnitee’s official capacity and to action in another capacity while occupying the Indemnitee’s position as an agent of the Company, and the Indemnitee’s rights hereunder shall continue after the Indemnitee has ceased acting as an agent of the Company and shall inure to the benefit of the heirs, executors, and administrators of the Indemnitee.

 

11. General Provisions.

 

11.1 Interpretation of Agreement. It is understood that the parties hereto intend this Agreement to be interpreted and enforced so as to provide indemnification and advancement of expenses to the Indemnitee to the fullest extent now or hereafter permitted by law, except as expressly limited herein.

 

11.2 Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable for any reason whatsoever, then: (a) the validity, legality, and enforceability of the remaining provisions of this Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal, or unenforceable that are not themselves invalid, illegal, or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal, or unenforceable, that are not themselves invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal, or unenforceable and to give effect to Section 11.1 hereof.

 

11.3 Modification and Waiver. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver.

 

11.4 Subrogation. In the event of full payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all documents required and shall do all acts that may be necessary or desirable to secure such rights and to enable the Company effectively to bring suit to enforce such rights.

 

11.5 Counterparts. This Agreement may be executed in one or more counterparts, which shall together constitute one agreement.

 

11.6 Successors and Assigns. The terms of this Agreement shall bind, and shall inure to the benefit of, the successors and assigns of the parties hereto. The indemnification and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director or an officer and shall inure to the benefit of the heirs, executors, and administrators of such a person.

 

  D-7  
     

 

11.7 Notice. All notices, requests, demands, and other communications under this Agreement shall be in writing and shall be deemed duly given if (a) delivered by hand and receipted for by the party addressee, or (b) mailed by certified or registered mail, with postage prepaid, on the third business day after the mailing date. Addresses for notice to either party are as shown on the signature page of this Agreement or as subsequently modified by written notice.

 

11.8 Governing Law. This Agreement shall be governed exclusively by and construed according to the laws of the State of Nevada, as applied to contracts between Nevada residents entered into and to be performed entirely within Nevada .

 

11.9 Consent to Jurisdiction. The Company and the Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of Nevada for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement.

 

11.10 Attorneys’ Fees. In the event Indemnitee is required to bring any action to enforce rights under this Agreement (including, without limitation, the expenses of any proceeding described in Section 4), the Indemnitee shall be entitled to all reasonable fees and expenses in bringing and pursuing such action, unless a court of competent jurisdiction finds each of the material claims of the Indemnitee in any such action was frivolous and not made in good faith.

 

  D-8  
     

 

IN WITNESS WHEREOF, the parties hereto have entered into this Indemnification Agreement effective as of the date first written above.

 

ORO CAPITAL CORPORATION INDEMNITEE:  
     
By:                  
Name:    
Title:    

 

  D-9  
     

 

SCHEDULE 6.1

 

Directors to be Appointed to Parent

 

1. Mark Suponitsky

2. Jordin Mendelsohn

 

Director to Resign from Parent

 

1. Danny Aaron

 

Officers to be Appointed to Parent

 

1. Mark Suponitsky, President, CEO, Secretary, Treasurer

 

Officer to Resign from Parent

 

1. Danny Aaron, President, Secretary and Treasurer

 

 

 

Exhibit 2.2

 

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT (the “Agreement”) dated as of January 22, 2015, is by and among Synergy Strips Corp. (the “Buyer”); Factor Nutrition Labs, LLC, a Delaware limited liability company (the “Seller”); Vita Partners, LLC, RPR Partners, LLC, and Thor Associates, Inc. (each a “Principal Owner”); and, for purposes of Article XIV hereof. Jack Ross (“Guarantor”). The Buyer, Seller, Principal Owners and Guarantor are sometimes referred to collectively as “Parties” and individually as a “Party”.

 

W I T N E S S E T H :

 

WHEREAS, among Seller’s several ingestible dietary supplement lines of business is a line of business and products called FOCUS Factor (the “Product,” and the Product plus the business related to the Product is collectively the “Focus Factor Business”);

 

WHEREAS, the Principal Owners, either directly or indirectly, collectively own all of the equity of Seller; and

 

WHEREAS, Buyer desires to purchase all of the assets of the Focus Factor Business, and the Seller desires to sell such assets to the Buyer, in each case upon the terms and subject to the conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements hereinafter contained, the Parties hereto hereby agree as follows:

 

SECTION 1. DEFINITIONS.

 

As used in this Agreement (including the recitals and Disclosure Schedules hereto), the following terms shall have the following meanings (such meanings to be applicable equally to both singular and plural forms of the terms defined):

 

“Accounts Receivable” shall mean all accounts and notes receivable relating to sales of the Product, as set forth on Schedule A hereto;

 

“Action” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether formal or informal, whether public or private and whether at law or in equity;

 

“Actual Proceeds” means the amount of the Purchase Price the applicable Principal Owner actually receives in cash.

 

“Additional Payment” shall have the meaning set forth in Section 3.1(b) hereof;

 

“Adverse Event” means any untoward medical occurrence in a consumer or clinical investigation subject administered Products and which does not necessarily have to have a causal relationship with such treatment.

 

“Affiliate” shall mean, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by Contract or otherwise) of such Person;

 

“Assigned Contracts” shall mean all Contracts, licenses, instruments, obligations, promises, undertaking, and equipment leases and other agreements, whether written or oral, which are used in, support the production and sale of the Product or are related to the Focus Factor Business;

 

 
 

 

“Assumed Liabilities” shall have the meaning set forth in Section 2.4 hereof;

 

“Bad Conduct” shall have the meaning set forth in Section 11.1 hereof;

 

“Business Day” shall mean days other than Saturdays, Sundays and other legal holidays or days on which banks in New York City are closed;

 

“Business Intellectual Property” shall have the meaning set forth in Section 5.9 hereof;

 

“Buyer” shall have the meaning set forth in the Preamble hereto;

 

“Buyer Indemnitees” shall have the meaning set forth in Section 11.1 hereof;

 

“Buyer Losses” shall have the meaning set forth in Section 11.1 hereof;

 

“Cap” shall have the meaning set forth in Section 11.1 hereof;

 

“Clients” means all of the clients of Seller during each of Seller’s 2012 and 2013 fiscal years and during the period ended as of December 31, 2014;

 

“Closing” shall mean the consummation of the transactions contemplated by this Agreement;

 

“Closing Date” shall have the meaning set forth in Section 4 hereof;

 

“Closing Payment” shall have the meaning set forth in Section 3.1(a) hereof;

 

“Code” means the Internal Revenue Code of 1986, as amended.

 

“Commercially Reasonable Efforts” means the commercially reasonable efforts that a prudent Person desirous of achieving a result and having an incentive to and interest in achieving such result would use to achieve that result as expeditiously as reasonably possible under the circumstances;

 

“Confidentiality Agreement” means that certain confidentiality agreement dated as of August 22, 2014, between Buyer and Seller;

 

“Contract” means any agreement, contract, indenture, instrument, obligation, promise or undertaking (whether written or oral and whether express or implied) that is legally binding;

 

“Disputed Claim” shall have the meaning set forth in Section 11.2(b) hereof;

 

“Domain Names” shall have the meaning set forth in Section 5.9(a) hereof;

 

“Employee” means an employee of Seller employed in connection with the Focus Factor Business;

 

“Employee Benefit Plan” means any pension, profit sharing, 401(k), retirement, deferred compensation, stock purchase, stock option or other equity based compensation plans, incentive, bonus, vacation, employment, independent contractor, severance, disability, hospitalization, sickness, death, medical insurance, dental insurance, life insurance and any other employee benefit plan (whether provided on a funded or unfunded basis, or through insurance or otherwise), agreement, program, policy, trust, fund, Contract or arrangement;

 

“Environmental Laws” means all Laws concerning pollution or protection of the environment and natural resources, including without limitation all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, control or cleanup of any hazardous materials, substances or wastes, pesticides, pollutants or by products, asbestos, polychlorinated biphenyls, or radiation, each as amended and as now or hereafter in effect;

 

 
 

 

“Excluded Seller Assets” any asset of Seller that is not included in the definition of Purchased Property and specifically including, without limitation, any of the following Seller assets:

 

(i) cash and cash equivalents;

 

(ii) all tangible personal property of every kind owned or leased by Seller other than the Purchased Property;

 

(iii) all Contracts, licenses, IT vendor services Contracts and equipment leases and other agreements, whether written or oral, other than the Assigned Contracts, the IP Assets, the Intellectual Property and the Licensed Intellectual Property;

 

(iv) all files and records, other than the Files and Records;

 

(v) all of the other intangible rights and property of Seller, including any intellectual property rights, going concern value, goodwill, telephone, domains, and email addresses and listing, in each case other than the Assigned Contracts, the IP Assets, the Licensed Intellectual Property and the Intellectual Property; and

 

(vi) the assets of Seller set forth in Schedule B hereto.

 

“Excluded Liabilities” shall have the meaning set forth in Section 2.5 hereof;

 

“Files and Records” shall mean all files and records, whether in hard copy or digital, electronic, data, magnetic or other format, of the Seller relating to or used in connection with the Focus Factor Business or otherwise relating to the Purchased Property;

 

“Financial Statements” shall have the meaning set forth in Section 5.5 hereof;

 

“Fundamental Representations” shall mean the representations and warranties set forth in Sections 5.1 (Corporate Organization), 5.2 (Qualification to Do Business), 5.3 (Authorization and Validity of Agreement), 5.4 (No Conflict or Violation), 5.7 (Tax Matters), and 5.14 (Brokerage);

 

“GAAP” shall mean United States generally accepted accounting principles as in effect on the date on which the document or calculation to which it refers relates, applied on a consistent basis throughout the periods covered thereby;

 

“General Intellectual Property” shall have the meaning set forth in Section 5.9 hereof;

 

“Government” shall mean any agency, division, subdivision, audit group or procuring office of the Government of the United States, any state of the United States, including the employees or agents thereof;

 

“Guarantee” means any Contract of guarantee, indemnification, assumption or endorsement or any other like commitment of the obligations, liabilities (fixed, contingent or otherwise) or indebtedness of another Person;

 

“Guaranteed Obligations” shall have the meaning set forth in Section 14(a);

 

“Guarantor” shall have the meaning set forth in the Preamble hereto.

 

“Indemnifiable Claim” shall have the meaning set forth in Section 11.2(b) hereof;

 

“Intellectual Property” “ means all intellectual property rights whether protected, created or arising under the Laws of the United States or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, Linkedln, Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, software or computer programs, and data base.

 

 
 

 

“IP Assets” shall have the meaning set forth in Section 5.9 hereof;

 

“IT Contracts” shall mean (i) all information technology vendor services Contracts used in the operations of the Focus Factor Business and (ii) any and all rights to the warranties received from IT vendors and suppliers to the Focus Factor Business with respect to the foregoing and any and all related claims, credits, rights of recovery and set-off with respect thereto;

 

“IT Vendors” shall mean all information technology vendors, suppliers, contractors and consultants who are parties to IT Contracts;

 

“Knowledge of the Seller” or “Seller’s Knowledge” or a similar phrase shall mean, with respect to any matter, the actual knowledge of the officers or managers of the Seller or the Principal Owners, or facts regarding such matter which reasonably should have been known by such persons after making a diligent inquiry with respect to such matter;

 

“Laws” means all statutes, laws, codes, ordinances, regulations, rules, orders, judgments, writs, injunctions, acts or decrees of any Government entity;

 

“Liability” means any liability or obligation of whatever kind or nature (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), including without limitation any liability for Taxes;

 

“Lien” shall mean any mortgage, pledge, security interest, encumbrance, lien (statutory or other) or conditional sale agreement, and including claims on title and liens in favor of contractors, carriers, warehousemen, mechanics, materialmen, and subcontractors and statutory or common law liens to secure claims for labor, materials or supplies, and other similar liens and encumbrances;

 

“Licensed Intellectual Property” shall have the meaning set forth in Section 5.10(c) hereof;

 

“Marketing Materials of Focus Factor” shall have the meaning set forth in Section 5.10(a) hereof;

 

“Person” shall mean and include any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, any other unincorporated organization or Government;

 

“Pledge Agreement” shall have the meaning set forth in Section 14.

 

“Purchase Price” shall have the meaning set forth in Section 3 hereof;

 

“Purchased Property” means all of the assets of Seller relating to the Focus Factor Business including, without limitation:

 

(i) the Product and all formulations related thereto;

 

(ii) all of Seller’s rights existing under all the Assigned Contracts, commitments, purchase orders and other agreements related to the Focus Factor Business, including all confidentiality, assignment of inventions, non-competition and/or non-solicitation covenants or any other Contract between each Transferred Employee and Seller, including the Assigned Contracts listed in Schedule 5.12:

 

(iii) the Accounts Receivable;

 

 
 

 

(iv) the Business Intellectual Property (including the Trademarks, and Patents); the IP Assets (including the Domain Names, the Web Site Content and the Marketing Materials); and the Licensed Intellectual Property, including the Intellectual Property, IP Assets, and Licensed Intellectual Property listed on Schedule 5.9:

 

(v) the proprietary formulation for the Product;

 

(vi) the Files and Records, including the Files and Records listed on Schedule C:

 

(vii) all Focus Factor Business and Product inventory, finished goods, raw materials, work in progress, packaging, parts or other inventories, including the inventory listed on Schedule D (the “Inventory”);

 

(viii) the goodwill and going concern value with respect to the Focus Factor Business and the Product, including without limitation all relationships with the clients and the right for Buyer to represent itself as the successor to Seller in respect of The Focus Factor Business;

 

(ix) all prepayments, prepaid expenses, claims, deposits, warranties. Guarantees, refunds. Actions, rights of recovery, rights of set-off, rights of indemnification, and rights of recoupment related to the Focus Factor Business and similar assets relating to the Focus Factor Business, including those listed on Schedule E;

 

(x) all fixed assets relating to the Focus Factor Business, including all equipment, machinery, furniture, vehicles, spare parts, trade fixtures, leasehold improvements, computers, computer systems, telephones, telephone systems, and all related equipment and all other tangible personal property relating to the Focus Factor Business, including those set forth on Schedule F. which schedule reflects the location of any fixed assets as of the Closing that are not located on Sellers’ premises;

 

(xi) all assignable licenses, permits, certificates of authority, authorizations, approvals, registrations, qualifications, waivers and similar instruments granted or issued by any Government entity, and all pending applications therefor or renewals thereof (“Permits”) relating to the Focus Factor Business, including those set forth on Schedule 5.10;

 

(xii) all personnel files for Transferred Employees;

 

(xiii) all insurance, warranty and condemnation net proceeds received after the Closing Date with respect to damage, non conformance of or loss to the Purchased Property;

 

(xiv) all claims of Seller against third parties relating to the Purchased Property and the Assumed Liabilities, whether known or unknown, choate or inchoate, contingent or non-contingent; and

 

(xv) all other assets of any kind or nature of the Seller related to the Focus Factor Business, other than the Excluded Assets;

 

“Regulations” means the Treasury Regulations (including Temporary Regulations) promulgated by the United States Department of Treasury with respect to the code;

 

“Seller” shall have the meaning set forth in the Preamble hereto;

 

“Seller’s Events of Breach” shall have the meaning set forth in Section 12.1 hereof;

 

“Serious Adverse Event” or means an Adverse Event that at any dose (i) results in death, (ii) is life-threatening, (iii) requires inpatient hospitalization or prolongation of existing hospitalization, (iv) results in persistent or significant disability/incapacity, or (v) is a congenital anomaly/birth defect. The term “life-threatening” in this definition refers to an event in which the consumer was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it had been more severe. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other outcomes listed above should also be included in this definition to the extent reasonable medical and scientific judgement indicates that expedited reporting is appropriate under applicable Laws.

 

 
 

 

“Taxes” shall mean (i) all federal, state, local or foreign taxes, including, but not limited to, income, gross income, gross receipts, capital, production, excise, employment, sales, use, transfer, transfer gain, ad valorem, premium, profits, license, capital stock, franchise, severance, stamp, withholding, Social Security, employment, unemployment, disability, worker’s compensation, payroll, utility, windfall profit, custom duties, personal property, real property, environmental, registration, alternative or add-on minimum, estimated and other taxes, governmental fees or like charges of any kind whatsoever, (ii) any interest, penalties, fines, loss, damages, liability, expense or additions thereto whether disputed or not, and (iii) any transference liability in respect of any items described in clauses (i) or (ii) payable by reason of contract assumption, transference liability, operation of law, or otherwise;

 

“Tax Return” means any return, declaration, report, claim for refund, FBAR Report, information return or statement relating to any Taxes, including any schedule or attachment thereto and including any amendment thereof;

 

“Third Party Proceeding” shall have the meaning set forth in Section 11.2 hereof;

 

“Threshold” shall have the meaning set forth in Section 11.1 hereof;

 

“Trademarks” shall have the meaning set forth in Section 5.10(a) hereof;

 

“Transaction Documents” shall mean this Agreement, the Bill of Sale, the Pledge Agreement, and the other exhibits and schedules hereto and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in connection with the transactions contemplated to be consummated pursuant to any of the foregoing;

 

“Transfer Taxes” shall have the meaning set forth in Section 12.3 hereof; and

 

“Vendor” means the top five (5) production vendors and subcontractors of Seller in terms of amounts paid to such vendors during each of Seller’s 2012 and 2013 fiscal years and during the period ended as of December 31, 2014.

 

SECTION 2. PURCHASE AND SALE OF THE PURCHASED PROPERTY.

 

SECTION 2.1. Transfer of Assets. Upon the terms and subject to the conditions herein set forth, the Seller shall sell, convey, transfer, assign and deliver to the Buyer and/or its designated Affiliates, free and clear of any Liens (other than any Liens constituting a part of the Assumed Liabilities and specifically identified on Schedule 2.4 hereto), and the Buyer and/or its designated Affiliates shall purchase and accept from the Seller, on the Closing Date, all of Seller’s right, title and interest in and to the Purchased Property. For the avoidance of doubt, the Parties acknowledge that the Excluded Seller Assets are not part of the Purchased Property being conveyed to Buyer hereunder, and such Excluded Seller Assets shall remain the property of Seller after Closing.

 

SECTION 2.2. Sale at Closing Date. The sale, transfer, assignment and delivery by the Seller of the Purchased Property to the Buyer, as herein provided, shall be effected on the Closing Date by this Agreement and the Bill of Sale, and such other deeds, bills of sale, endorsements, assignments and other instruments of transfer and conveyance as counsel for the Buyer may reasonably require in order to provide for the proper legal transfer of the Purchased Property to Buyer.

 

SECTION 2.3. Subsequent Conveyance Documentation & Reconciliations

 

(a) The Seller shall, at any time and from time to time after the Closing Date, upon the request of the Buyer, execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, all such further authorizations, deeds, assignments, consents, transfers, conveyances and related documentation as may be reasonably required for the better assigning, transferring, granting, conveying and confirming to the Buyer or its successors and assigns, or for aiding and assisting in collecting and reducing to possession, any or all of the Purchased Property; including any documentation reasonably required to collect for the account of the Buyer all Accounts Receivable and any other item of Purchased Property. The Seller agrees to hold in trust for the account of the Buyer all Accounts Receivable and any other items of Purchased Property received by Seller on or after the Closing Date and further agree to promptly deliver such items of Purchased Property to the Buyer.

 

 
 

 

(b) Seller shall conduct a reconciliation of its books and records relating to the Focus Factor Accounts Receivable as well as the Accounts Payable (as defined in Section 2.4) and accrued expenses (including those arising under any Assigned Contracts) on the day prior to the Closing Date and will provide it to the Buyer at Closing. At the Closing, or as soon as reasonably possible thereafter. Buyer and Seller will, respectively, use Commercially Reasonable Efforts to do the following: (i) Seller will promptly transfer to Buyer all Accounts Receivable that are or come into Seller’s possession; (ii) Buyer will promptly transfer to Seller all cash and cash equivalents that do not constitute cash and cash equivalents of the Focus Factor Business related to post-Closing periods that are or come into Buyer’s possession; and (iii) Seller shall pay all accounts payable and accrued expenses not arising under the Focus Factor Business (i.e., any accounts payable relating to the Excluded Assets).

 

SECTION 2.4. Assumed Liabilities. Upon the terms and subject to the conditions set forth in this Agreement, from and after the Closing, the Buyer will assume and pay, perform, discharge and be responsible for the following obligations and liabilities of the Seller: (i) the accounts payable of Seller set forth on Schedule 2.4(i) (the “Accounts Payable”), (ii) the obligations and liabilities of the Seller under the Assigned Contracts incurred after the Closing Date (and specifically excluding any obligations or liabilities under and breaches thereof arising prior to the Closing Date) which obligations and liabilities being assumed under such certain Assigned Contracts are specifically set forth on Schedule 2.4(ii) hereto, and (iii) the Liabilities set forth on Schedule 5.8 (the “Assumed Liabilities”); provided, however, the Assumed Liabilities shall not include any obligations or liabilities that were not incurred in the ordinary course of business. Assumed Liabilities shall include any liabilities for (a) Taxes relating to or arising out of the Focus Factor Business accruing on and after the Closing Date (including, without limitation, sales taxes), (b) Taxes payable by the Buyer resulting from payments made pursuant to this Agreement, (c) one-half of the Transfer Taxes, if applicable, and (d) Taxes of Buyer or any other Person, relating to the Focus Factor Business on and after the Closing Date, whether pursuant to an agreement, by operation law or transferee or successor liability, or otherwise. Seller shall retain, and Buyer shall not assume, any liability of Seller, direct or indirect, known or unknown, absolute or contingent, not expressly included in the Assumed Liabilities.

 

SECTION 2.5. Excluded Liabilities. Purchaser shall not assume and shall not be responsible to pay, perform or discharge any of the following Liabilities or obligations of Seller (collectively, the “Excluded Liabilities”): (i) Liabilities relating to or arising out of the ownership or leasing of the Purchased Property prior to the Closing Date; (ii) any liability arising out of any Action pending as of the Closing Date; (iii) Liabilities for Taxes relating to or arising out of the Focus Factor Business accruing prior to the Closing Date (including, without limitation, accrued sales taxes); (iv) liabilities for Taxes of the Seller, whether or not relating to or arising out of the Focus Factor business and whether or not incurred prior to the Closing date, including, without limitation, any Taxes payable by the Seller resulting from payments made pursuant to this Agreement; (v) any deferred Taxes of any nature; (vi) one-half of the Transfer Taxes, if applicable; (vii) any liability of Seller having to do with a business other than the Focus Factor Business; (viii) any liability with respect to any Employee or former employee of Seller, or any consultant retained by Seller; (ix) any liability to any Governmental entity arising out of or resulting from Seller’s compliance or noncompliance with any law, regulation, order, injunction, judgment, decree, ruling, assessment or award (an “Order”) of any Government entity (i.e., the liability is imposed by the Government entity); (x) any liability of Seller under this Agreement or any other document executed in connection with the transactions contemplated by this Agreement; and (xi) any liability of Seller based on Seller’s actions or omissions occurring after the Closing Date.

 

SECTION 3. CONSIDERATION.

 

SECTION 3.1. Purchase Price. Upon the terms and subject to the conditions set forth in this Agreement, in reliance on the representations, warranties, covenants and agreements of the Seller contained herein, the aggregate purchase price of the Purchased Property shall be six million dollars and no cents ($6,000,000.00) (the “Purchase Price”). The Purchase Price will be paid by the Buyer (such payment secured by a pledge agreement between Buyer and Seller), for the sale and transfer of the Purchased Property, to or (as directed by Seller) for the benefit of the Seller as follows:

 

(a) At the Closing, four million five hundred thousand dollars ($4,500,000) (the “Closing Payment”); and

 

 
 

 

(b) An additional payment of one million five hundred thousand dollars ($1,500,000), payable as follows (the “Additional Payment”):

 

(i) seven hundred fifty thousand dollars ($750,000) on or before January 20, 2016; and

 

(ii) seven hundred fifty thousand dollars ($750,000) on or before January 20, 2017.

 

SECTION 3.2. Allocation of Purchase Price. Seller and Buyer shall cooperate in the preparation of a joint schedule (the “Allocation Schedule”) allocating the Purchase Price (including for purposes of this Section 3.2 the Assumed Liabilities) among the Assets purchased pursuant to this Agreement. Seller and Buyer each agree to file IRS Form(s) 8594 and all federal, state and local income Tax Returns in accordance with the Allocation Schedule, and none of them shall thereafter take an income Tax Return position inconsistent with such allocation unless such inconsistent position shall arise out of or through an audit or other inquiry or examination by the IRS or other Tax authority. Seller and Buyer each agree to provide the other promptly with any other information required to complete the Allocation Schedule. If, however, Seller and Buyer are unable to complete such schedule within one hundred and twenty (120) days following the Closing Date, or such later date as agreed to by Buyer and Seller, then Buyer and Seller shall file IRS Form(s) 8594 and any federal, state and local income Tax Returns allocating the Final Purchase Price among the Assets in the manner each believes is appropriate; provided, however, that such allocation must be reasonable and in accordance with Code section 1060 and the Regulations thereunder and provided, further, that the portion of the Purchase Price allocated to Accounts Receivable shall not exceed the net amount of Accounts Receivable included in the Purchased Property.

 

SECTION 4. CLOSING. The Closing shall take place at the offices of Williams & Connolly LLP, at 10:00 a.m., local time on or before January 23, 2015, after the conditions in Section 9 and Section 10 have been met or waived, or at such other place and time as may be mutually agreed to by the Parties hereto, provided, however, that the Closing may occur virtually, such that copies of signatures may be exchanged via electronic mail (with originals to follow in the mail) (the date of Closing is “Closing Date”). The Closing shall be deemed to occur and be effective as of 12:01 AM on the Closing Date.

 

SECTION 5. REPRESENTATIONS AND WARRANTIES OF THE SELLER. Asa material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, Seller and each of the Principal Owners (other than Thor Associates, Inc., which is making only the representations and warranties set forth in Sections 5.3, 5.4, 5.22, and 5.25 and only with respect to Thor Associates, Inc.) hereby jointly and severally (other than Thor Associates, Inc., which is making these representations and warranties severally and not jointly) represent and warrant as of the date hereof, except as set forth on the disclosure schedules (the “Disclosure Schedules”) attached to this Agreement, to Buyer as follows:

 

SECTION 5.1. Corporate Organization. The Seller is a limited liability company duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The organizational documents which have been furnished to Buyer reflect all amendments made thereto at any time prior to the date of this Agreement and are correct and complete. The minute books and other books and records of Seller, to the extent such minutes exist, have been furnished to Buyer. The Principal Owners do not, whether in their individual capacities or through any other entity, engage in any other business that competes with the Focus Factor Business.

 

SECTION 5.2. Qualification to Do Business. Seller has the requisite power and authority and all necessary governmental authority to own, operate or lease all the items of Purchased Property that it purports to own, operate or lease and to carry on the Focus Factor Business as it is now being conducted, and is duly qualified to do business as a foreign company, and is in good standing, in each jurisdiction where the character of its assets owned, operated or leased or the nature of its activities makes such qualification necessary (except where failure to so qualify would not have a material adverse effect on the ability of Seller to execute, deliver and perform the Transaction Documents and consummate the transactions contemplated thereunder).

 

SECTION 5.3. Authorization and Validity of Agreement. Seller and the Principal Owners each has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Seller’s or each Principal Owner’s obligations thereunder have been duly authorized by all necessary corporate, shareholder or member action of Seller and the Principal Owners, and no other proceedings on the part or in respect of the Seller or any Principal Owner is necessary to authorize such execution, delivery and performance. The Transaction Documents have been duly executed by Seller and the Principal Owners and constitute its valid and binding obligations, enforceable against each in accordance with their respective terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

 
 

 

SECTION 5.4. No Conflict or Violation. Subject to obtaining any consents and approvals set forth in Schedule 5.4. the execution, delivery and performance by the Seller and the Principal Owners of the Transaction Documents and all Assigned Contracts (including the transfer of the Purchased Property to Buyer and Buyer’s use thereof following the Closing) does not and will not (a)(i) conflict with or result in a breach of the terms, conditions, or provisions of, (ii) constitute a default under (whether with or without the passage of time, the giving of notice or both), (iii) give any third party the right to modify, terminate or accelerate any obligation under, (iv) result in a violation of, or (v) require any consent, exemption or other action by or notice or declaration to, or filing with, any third party of any Government entity pursuant to (A) any organizational documents of the Seller or Principal Owners; (B) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (C) any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Seller or any of the Principal Owners is a party or by which Seller or any of the Principal Owners is bound or to which any of the Seller’s or any of the Principal Owners’ properties or assets is subject; or (D) the Assigned Contracts or other rights, agreements or licenses constituting the Purchased Property; (b) result in the creation of any Lien or Tax upon the equity or assets of Seller or the Principal Owners (including the Purchased Property); or (c) otherwise interfere in any material manner with the operation of the Focus Factor Business or the Purchased Property or have any material adverse effect thereon.

 

SECTION 5.5. Financial Statements. Attached hereto as Schedule 5.5 are the financial statements of the Seller (the “Financial Statements”). The Financial Statements have been prepared using consistent accounting principles, presentations, methods, standards, policies, practices, classifications, estimation and adjustment methodologies, assumptions, and procedures. Seller’s books of account and records are complete and correct and fairly reflect all of the assets, liabilities, transactions, and results of operations of the business of Seller and the Focus Factor Business in all material respects. Seller has delivered to the Buyer or its representatives copies of the Financial Statements.

 

SECTION 5.6. Absence of Certain Changes or Events.

 

(a) Except as set forth in Schedule 5.6. since December 31, 2014, there has not been:

 

(i) any adverse change in the business, operations, properties, assets, or condition (financial or other) of the Purchased Property or Seller in any material respect, and, to Seller’s Knowledge, no fact or condition exists and no event has occurred that would be reasonably likely to result in any such change; or

 

(ii) any material loss, damage, destruction or other casualty to the Purchased Property (whether or not covered by insurance).

 

(b) Since December 31, 2014, the Seller has operated the Focus Factor Business in the ordinary course of business and consistent with past practice and, except as set forth on Schedule 5.6 hereto, has not:

 

(i) incurred any obligation or liability (whether absolute, accrued, contingent or otherwise) relating to the operations of the Focus Factor Business, in an amount greater than $10,000 that will not have been paid in full by the Closing Date or having a term or duration of more than one year;

 

(ii) discharged or satisfied any Lien or paid or satisfied any obligation or Liability (whether absolute, accrued, contingent or otherwise);

 

(iii) mortgaged, pledged or subjected to any Lien any of the Purchased Property;

 

 
 

 

(iv) sold, licensed, assigned, or transferred any of its assets or canceled any debts or claims or waived any material right or claim;

 

(v) disposed of, relinquished or allowed to lapse any patents, trademarks, service marks, domain names, web addresses or copyrights (or any interest therein) or any patent, trademark, service mark, domain name or web address or copyright applications (or any interest therein) used (or that were, or are intended to be used) in the operations of the Focus Factor Business;

 

(vi) defaulted on any material obligation relating to the operations of the Focus Factor Business;

 

(vii) written off as uncollectible any accounts receivable with respect to any products to be delivered to customers after the Closing Date;

 

(viii) amended any term of, or waived any right under, any Contract that is in the Purchased Property;

 

(ix) sold, assigned, transferred, abandoned, or permitted to lapse any Permits;

 

(x) entered into any agreement or made any commitment to do any of the foregoing;

 

(xi) commenced any litigation or binding dispute resolution process or settled or compromised any pending or threatened suit. Action or claim; or

 

(xii) entered into any other material Contract or material transaction.

 

SECTION 5.7. Tax Matters.

 

(a) The Seller and its subsidiaries has timely filed all material Tax Returns that it was required to file. All such Tax Returns as so filed disclose all Taxes required to be paid for the periods covered thereby. All material Taxes due and owing by the Seller (whether or not shown on any Tax Return) have been paid.

 

The Seller is not currently is the beneficiary of any extension of time within which to file any Tax Return. There are no Liens for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Seller. The Seller has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party, and all Tax Returns and form required with respect thereto have been properly completed and timely filed. Upon and after the acquisition of the Purchased Property by Buyer, Buyer will have no, and will not be subject to any, liability, as a successor or otherwise, for or with respect to any Taxes of or pertaining to (i) Seller or (ii) Focus Factor for any period or transactions arising on or before the Closing.

 

(b) There is no material dispute or claim concerning any Tax liability of the Seller either (A) claimed or raised by any authority in writing or (B) to the knowledge of the Seller.

 

(c) Section 5.7 of the Disclosure Schedule lists all federal, state, local, and foreign income Tax Returns filed with respect to the Seller for taxable periods ended on or after December 31, 2010, indicates those Tax Returns that have been audited, and indicates those Tax Returns that currently are the subject of audit. The Seller has delivered to Buyer correct and complete copies of all federal income Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Seller since December 31, 2010. The Seller has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

 

 
 

 

(d) The Seller has not made any material payments, is not obligated to make any material payments, and is not a party to any agreement that under certain circumstances could obligate it to make any material payments that will not be deductible under Code section 280G. The Seller is not a party to any Tax allocation or sharing agreement. The Seller (A) has not been a member of an affiliated group (within the meaning of Code section 1504(a)) filing a consolidated federal income Tax Return (other than a group the common parent of which was the Seller) and (B) does not have any liability for the Taxes of any Person under Regulations section 1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, by contract, or otherwise.

 

(e) The unpaid Taxes of the Seller (A) did not, as of the most recent fiscal month end, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the most recent Financial Statements (rather than in any notes thereto) and (B) will not exceed that reserve as adjusted for operations and transactions through the Closing Date in accordance with the past custom and practice of the Seller in filing its Tax Returns.

(f) The Seller does not have any subsidiaries.

 

(g) The Seller has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Code section 355 or Code section 361.

 

(h) At all times since its formation, Seller has been classified as a partnership for federal income Tax purposes.

 

SECTION 5.8. Absence of Undisclosed Liabilities: Indebtedness. Except as set forth on Schedule 5.8. Seller has no indebtedness or Liabilities, absolute or contingent, involving, affecting or relating to the Focus Factor Business, the Purchased Property, or the transactions contemplated by the Transaction Documents (other than any liabilities which constitute Excluded Liabilities hereunder).

 

SECTION 5.9. Intellectual Property.

 

(a) Definitions.

 

(i) “IP Assets” shall mean all of the following materials owned or licensed by Seller with respect to the Focus Factor Business: (A) the proprietary formulas for the Product; (B) the domain names listed on Schedule 5.9(a) (collectively, the “Domain Names”); (C) all the content on and accessible through the websites associated with the Domain Names, including demos (collectively, the “Website Content”); and (D) the entire Focus Factor Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Focus Factor Business marketing materials (whether in draft or final form) (collectively, the “Marketing Materials”).

 

(ii) Schedule 5.9(a) lists all patented, registered, applied-for, and other Intellectual Property used in the Focus Factor Business, and all Intellectual Property of Seller licensed to any third Person (collectively, the “Business Intellectual Property”), including the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by Seller from a third party is “Licensed Intellectual Property”).

 

(b) Seller owns all right, title and interest in and to, or has a valid and enforceable license to use, all IP Assets, Business Intellectual Property, and the Licensed Intellectual Property, free and clear of all Liens, and all patented or registered Business Intellectual Property is valid and enforceable. Seller has taken commercially reasonable steps to maintain the confidentiality of all information that constitutes a trade secret of the Focus Factor Business. Seller has the valid right to transfer the Intellectual Property included in the Purchased Property to Buyer as contemplated hereunder.

 

 
 

 

(c) (i) The conduct of the Focus Factor Business, including the delivery and distribution of the Product, has not infringed and does not infringe on any Intellectual Property or any other proprietary rights of any Person, including but not limited to the rights of privacy or publicity; (ii) to Seller’s Knowledge, no Person is infringing, violating or misappropriating any Business Intellectual Property; (iii) Seller has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to result in the invalidation or unenforceability of any registered Business Intellectual Property; (iv) Seller is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (v) Seller has not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of Intellectual Property or the Product; (vi) Seller has not entered into any Contract that includes a forbearance to sue or settlement Contract with respect to any Intellectual Property; and (vii) Seller has not received any written notice of any claim within the prior three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of. Seller’s ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Product. Seller has secured and has in place a policy to secure valid written confidentiality Contracts and assignments of Intellectual Property from all consultants, contractors. Employees and customers who contribute or have contributed to the creation, conception, reduction to practice or other development of any Intellectual Property developed on behalf of Seller.

 

(d) No Product provided or distributed by Seller in its conduct of the Business: (i) violates any Law; (ii) includes any information or material that is defamatory; or (iii) infringes any right of privacy of any Person. Each Person whose name, image, voice or likeness is incorporated into any Marketing Materials or other Purchased Property has executed a written release consenting to Seller’s use of such Person’s name, image, voice and/or likeness (as applicable) and releasing Seller from any claims with respect thereto (a “Release”), each of such Releases are fully assignable to Buyer without further consent of any Person and each of such Releases are included within the Purchased Property.

 

(e) Seller has operated the Focus Factor Business and provided all Products in compliance with any posted privacy policies and all applicable Laws relating to privacy, data protection, anti-spam, telemarketing, personally identifiable information and similar consumer protection Laws (“Information Privacy Laws”). Seller has not received written notice of any claims or been charged with violation of any Information Privacy Law. To the Knowledge of Seller, Seller is not under investigation with respect to any violation of any Information Privacy Laws.

 

SECTION 5.10. Compliance with Law. Except as set forth in Schedule 5.10. the manufacture and sale of the Product, the operation of the Focus Factor Business, and the business of Seller has been conducted in material compliance with all applicable Laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Seller and its assets, properties and operations. Except as set forth in Schedule 5.10. the Seller has not received notice of any violation (or possible violation) of any such Law or other legal requirement, and the Seller is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or Governmental or regulatory authority, applicable to Seller, the Focus Factor Business, or the Purchased Property. Without limiting the foregoing. Seller has not received any warning letter or untitled letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the FDA or any other similar Governmental entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any Laws. No “bulk sales” or similar Law applies to the transactions contemplated by this Agreement. Seller holds all Permits required for the conduct of the Focus Factor Business and the ownership of its properties. All such Permits are set forth on Schedule 5.10. No written notices have been received by Seller alleging the failure to hold any Permit. Seller is in compliance with all terms and conditions of all such Permits. All of such Permits shall be available for use by Seller immediately after the Closing.

 

SECTION 5.11. Litigation. There are no claims. Actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of the Seller, threatened, before any federal, state, provincial or local court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Seller or any of its officers, directors, employees, agents or Affiliates involving, affecting or relating to Seller, any Principal Owner, the Focus Factor Business, the Purchased Property, or the transactions contemplated by the Transaction Documents.

 

 
 

 

SECTION 5.12. Assigned Contracts. Each Assigned Contract is valid, binding and enforceable against the parties thereto in accordance with its terms, and in full force and effect on the date hereof, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity. Each Assigned Contract will remain in full force and effect without penalty in accordance with its terms upon consummation of the Closing. The Seller has performed all payment and other obligations required to be performed by it to date hereunder, and is not in default or delinquent in performance, status or any other respect (claimed or actual) in connection with, any Assigned Contract, and, to the Knowledge of the Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. To the Knowledge of the Seller, no other party to any Assigned Contract is in default in respect thereof, and, to the Knowledge of the Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. To the Knowledge of Seller, there is no breach or cancellation or anticipated breach or cancellation by the other parties to any Assigned Contract. Schedule 5.12 sets forth a list all Assigned Contracts and, a list of all other written Contracts that are material to the Focus Factor Business, and a summary of all other oral Contracts that are material to the Focus Factor Business. The Seller has delivered to the Buyer or its representatives true and complete originals or copies of all written Contracts required to be listed on Schedule 5.12.

 

SECTION 5.13. Title to Purchased Property. Except as set forth on Schedule 5.13. Seller has good and valid title to, or a valid leasehold interest in, the Purchased Property, free and clear of all Liens. Such Purchased Property, taken as a whole, are free from any material defects, have been maintained in accordance with normal industry practice and are in good operating condition and repair (subject to normal wear and tear). The Purchased Property is sufficient for the continued operation of the Focus Factor Business after the Closing in substantially the same manner as conducted prior to the Closing and constitute all of the rights, property and assets used in or necessary to conduct the Focus Factor Business. None of the Excluded Seller Assets are material to the Focus Factor Business.

 

SECTION 5.14. Brokerage. Except as set forth on Schedule 5.14. neither Seller nor any of the Principal Owners have incurred, or will incur, a brokerage, finder’s, or similar fee in connection with the transactions contemplated by this Agreement.

 

SECTION 5.15. Insurance. Seller is currently insured by insurers unaffiliated with Seller with respect to its properties, assets and operation of the Focus Factor Business in such amounts and against such risks which are appropriate and customary for the type of business conducted by Seller with customary deductibles and retained amounts. In addition, Seller has maintained comparable insurance for all prior periods. With respect to each insurance policy held by Seller (the “Insurance Policies”) (a) such Insurance Policy is legal, valid, binding and in full force and effect; (b) Seller is not in default under such Insurance Policy; and (c) Seller has delivered a true and correct copy of any such Insurance Policy requested by Buyer. There are no claims by Seller pending under any such Insurance Policies and Seller has not been informed that coverage has been questioned, denied or disputed by the underwriters of such Insurance Policies with respect to any such claims.

 

SECTION 5.16. Employment Matters.

 

(a) Schedule 5.16(a) separately sets forth all of the Employees as of the date hereof, including for each such Employee: name, job title, FLSA designation, work location (identified by street address), current compensation paid or payable, all wage arrangements, fringe benefits (other than Employee benefits applicable to all Employees, which benefits are set forth on a separate list on Schedule 5.16(a)) and visa and green card application status. To the Knowledge of Seller, no Employee is a party to, or is otherwise bound by, any Contract or arrangement, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Employee’s duties.

 

(b) Except as set forth on Schedule 5.16(b). to the Knowledge of Seller, each Employee is (i) a United States citizen, (ii) a lawful permanent resident of the United States, or (iii) an alien authorized to work in the United States either specifically for Seller or for any United States employer. Seller is in compliance in all material respects with applicable Law, has completed a Form 1-9 (Employment Eligibility Verification) for each Employee and each such Form 1-9 has since been updated as required by applicable Law and is correct and complete as of the date hereof. With respect to each Employee, an authorized official of Seller has reviewed the original documents relating to the employment eligibility and authorization of such Employee to be employed in the United States in compliance with applicable Law and such documents appeared, to such official, to be genuine on their face.

 

 
 

 

(c) Seller has, or will have no later than the Closing Date, paid all accrued salaries, bonuses, commissions, wages, severance and accrued vacation pay of the Employees due to be paid through the Closing Date. Seller is in compliance, in all material respects, with all Laws governing the employment of labor, including but not limited to, all contractual commitments and all such Laws relating to wages, hours, affirmative action, collective bargaining, discrimination, civil rights, safety and health, workers’ compensation and the collection and payment of withholding and/or Social Security Taxes and similar Taxes, including, but not limited to, the Age Discrimination in Employment Act, as amended. Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Fair Labor Standards Act (29 U.S.C. 201, et seq.) (“FLSA”), the Americans with Disabilities Act, the Sarbanes-Oxley Act of 2002, the Worker Adjustment and Retraining Notification Act, as amended, the Occupational Safety and Health Act, as amended, the Family and Medical Leave Act (29 U.S.C. 2601, et seq.), as amended, the National Labor Relations Act of 1935, as amended. Executive Order 11246 and any other executive orders or regulations governing affirmative action, EEO and VETS-100 reporting obligations, the Immigration Nationality Act (8 U.S.C. 1324a, et seq.), as amended, and all similar applicable Laws (collectively the “Labor Laws”). Seller has, during the three (3) year period prior to the date hereof, conducted the Focus Factor Business in compliance with all applicable Labor Laws. Seller has withheld all amounts required by Law or Contract to be withheld from the wages or salaries of its Employees and is not liable for the payment of any arrears of wages or other Taxes, penalties, fines or other compensation of any kind, however designated, for failure to comply with any of the foregoing. Seller has maintained adequate and suitable records regarding the service of each Employee including records of working time. Except as set forth on Schedule 5.16(c). the Seller has properly classified its Employees pursuant to the FLSA. The Seller is not, and in the last three years has not been, a government contractor.

 

(d) Seller has not at any time during the last three (3) years had, nor to the Knowledge of Seller, is there now threatened, any walkout, strike, union activity, picketing, work stoppage, work slowdown, any effort to organize or any other similar occurrence or any attempt to organize or represent the labor force of Seller. There are no controversies pending or threatened between Seller, on the one hand, and any of its Employees (or former Employees), or any labor union or other collective bargaining unit representing any of their Employees, on the other hand. No investigation, review, complaint or proceeding by any Government entity or Employee or former Employee with respect to Seller in relation to any actual or alleged violation of any Labor Laws is pending or, to the Knowledge of Seller, threatened, nor has Seller received any notice from any Government entity indicating an intention to conduct the same. No union or other collective bargaining unit or Employee organizing entity has been certified or recognized by Seller as representing any of its Employees.

 

(e) Schedule 5.16(e) contains a true and compete list of any and all employment, change in control, severance, retention, termination, non-competition, nonsolicitation and other similar employment Contracts, arrangements or policies, whether written or oral, between the Seller and any individual other than at-will employment arrangements but including all Contracts, arrangements or policies that affect at-will Employees.

 

SECTION 5.17. Contractor Matters. Schedule 5.17 contains a complete and accurate listing of the name (if an entity, including the name of the individuals employed by or providing service on behalf of such entity) and contact information of each independent contractor, consultant, freelancer or other service provider (collectively, “Contractors”) used by Seller at any point during the prior one (1) year. A copy of each Contract relating to the services any Contractor provides to the Focus Factor Business has been provided to Seller. To the Knowledge of Seller, no Contractor used by Seller is a party to, or is otherwise bound by, any Contract or arrangement with any third party, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Contractor’s duties for Seller. Each Contractor ever retained by Seller to create, modify or work with respect to the Business Intellectual Property has executed a nondisclosure and assignment-of-rights Contract for the benefit of Seller and Seller is the owner of all rights in and to all Intellectual Property created by each Contractor in performing services for Seller vesting all rights in work product created in Seller. To the Knowledge of Seller, no current Contractor used by Seller intends to terminate his or her or its relationship with Seller. Seller has no obligation or Liability with respect to any Taxes (or the withholding thereof) in connection with any Contractor. Seller has properly classified, pursuant to the Code, Labor Laws and any other applicable Law, all Contractors used by Seller at any point.

 

 
 

 

SECTION 5.18. Employee Benefits.

 

(a) Schedule 5.18(a)SECTION 5.18. (all contains a true and complete list of all Employee Benefit Plans maintained or contributed to by Seller or under which Seller has or could have any obligations (other than obligations to make current wage or salary payments or sales commissions terminable on notice of 30 days or less) or liabilities, actual or contingent, whether or not legally binding, in respect of, or which otherwise cover, any of the current or former officers, Employees or independent contractors of Seller who provide(d) services in respect of the Focus Factor Business or their dependents or beneficiaries (the items required to be disclosed on Schedule 5.18(a) and Schedule 5.16 (61 may be hereinafter individually referred to as a “Seller Benefit Plan” and collectively referred to as the “Seller Benefit Plans”). Seller has delivered or made available to Buyer true and complete copies of all documents, as they may have been amended through the date hereof, embodying or relating to the Seller Benefit Plans, including but not limited to Forms 5500 and actuarial valuations for the last three plan years, plan documents, trust agreements, insurance Contracts, administrative services agreements, most recent determination letters and other documents required under ERISA.

 

(b) Each Seller Benefit Plan has been established, maintained and administered in accordance with its terms and with all provisions of (including rules and regulations thereunder) ERISA, the Code and other applicable Law, and neither Seller nor any “party in interest” or any “disqualified person” with respect to any Seller Benefit Plan has engaged in a “prohibited transaction” within the meaning of Section 4975 of the Code or Section 406 of ERISA or engaged in a similar transaction with respect to any Seller Benefit Plan. Each Seller Benefit Plan that is intended to be qualified within the meaning of Section 401(a) of the Code is so qualified and has received a favorable determination letter from the Internal Revenue Service (or, if such plan is a prototype or volume submitter plan document, such prototype or volume submitter plan document has received a favorable opinion from the IRS that the form meets the tax qualification requirements) to the effect that such Seller Benefit Plan satisfies the requirements of Section 401(a) of the Code and that its related trust is exempt from taxation under Section 501(a) of the Code and there are no facts or circumstances that could reasonably be expected to cause the loss of such qualification or the imposition of Liability, penalty or Tax under ERISA, the Code or other applicable Laws (including the rules and regulations under any of them).

 

(c) No Seller Benefit Plan is, and neither Seller nor any of its ERISA Affiliates has ever sponsored an Employee Benefit Plan that is or was, subject to Title IV of ERISA. No Seller Benefit Plan is, and neither the Seller nor any of its ERISA Affiliates has ever contributed, or been obligated to contribute, to any “multiemployer plan” (within the meaning of Sections 3(37) or 4001(a)(3) of ERISA) under Subtitle E of ERISA.

 

(d) Schedule 5.18(d). sets forth each Seller Benefit Plan that is a “nonqualified deferred compensation plan”, within the meaning of Section 409A of the Code (each, a “Section 409A Plan”), and identifies each Section 409A Plan in connection with which Seller or it successors may have Liability with respect to Employees, Contractors or directors. No such plan has assets set aside directly or indirectly in the manner described in Section 409A(b)(l) of the Code or contains a provision that would be subject to Section 409A(b)(2) of the Code. Each Section 409A Plan (i) was, since the date of the inception of such Seller Benefit Plan, administered in good faith compliance with the requirements of Section 409A of the Code and applicable guidance issued thereunder, (ii) has been, since the date of inception of such Seller Benefit Plan, administered in compliance, in all material respects, with the requirements of Section 409A of the Code and the final regulations issued and outstanding thereunder. In the event of an audit by the IRS of either the Company or any individual participating in such Seller Benefit Plan, the additional Tax described in Section 409A(a)(l)(B) would not be assessed against any such participant with respect to benefits due or accruing under such Seller Benefit Plan.

 

(e) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in combination with another event): (i) result in any payment becoming due, or increase the amount of any compensation due, to any Employee; (ii) increase any benefits otherwise payable under any Seller Benefit Plan; or (iii) result in the acceleration of the time of payment or vesting of any such compensation or benefits.

 

 
 

 

SECTION 5.19. Environmental and Safety Matters. Seller has complied and is in compliance with all Environmental Laws, including but not limited to all Permits required by Environmental Laws for the conduct of the business operations of Seller and the disposition of all hazardous materials in accordance with all applicable Environmental Laws. Seller has not received any outstanding and unresolved written or oral notices, reports or other information regarding any actual or alleged violation of Environmental Laws by Seller, or any Liabilities or potential Liabilities, including any remedial obligations, relating to any of them or their facilities arising under Environmental Laws. Seller is not a potentially responsible party under the federal Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, or any analogous state, local or foreign applicable Laws arising out of events occurring prior to the Closing Date. To Seller’s Knowledge, no facts, events or conditions relating to the past or present facilities, properties or operations of Seller, or any geologically or hydrologically adjoining properties, shall prevent, hinder or limit Seller’s continued compliance with Environmental Laws, give rise to any remedial obligations of Seller pursuant to Environmental Laws, or give rise to any other Liabilities of Seller pursuant to Environmental Laws, including, without limitation, any relating to onsite or offsite releases or threatened releases of hazardous materials, personal injury, property damage or natural resources damage. To Seller’s Knowledge, there have not been in the past and are not now any underground tanks or underground improvements, including treatment or storage tanks, sumps, or water, gas or oil wells; polychlorinated biphenyls; or asbestos or asbestos-containing materials at, on or under any of the Leased Real Property. Seller has delivered to Buyer true and complete copies and results of any reports, studies, analyses, tests, or monitoring possessed or initiated by Seller pertaining to hazardous materials in, on, under, or migrating to or from any of the Leased Real Property, or concerning compliance by Seller, or any other Person for whose conduct Seller is or may be held responsible, with Environmental Laws.

 

SECTION 5.20. Real Property.

 

(a) Schedule 5.20 (all sets forth the address of each leased real property of Seller (the “Leased Real Property”), and a true and complete list of all leases (including all amendments, extensions, renewals, Guarantees and other Contracts with respect thereto) for each such Leased Real Property (including the date and name of the parties to such lease or license document) (the “Leases”). Seller has delivered to Buyer a true and complete copy of each Lease, and in the case of any oral Lease, a written summary of the material terms of such Lease. With respect to each of the Leases: (i) such Lease is legal, valid, binding, enforceable and in full force and effect; (ii) the transactions set forth in this Agreement do not require the consent of any other Person to such Lease, or such consent has been obtained, shall not result in a breach of or default under such Lease, or otherwise cause such Lease to cease to be legal, valid, binding, enforceable and in full force and effect on identical terms following the Closing; (iii) Seller’s possession and quiet enjoyment of the Leased Real Property under such Lease has not been disturbed, and there are no disputes with respect to such Lease; (iv) Seller, and to Seller’s Knowledge any other party to the Lease, is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, the passage of time or both, would constitute such a breach or default, or permit the termination, modification or acceleration of rent under such Lease; (v) no security deposit or portion thereof deposited with respect to such Lease has been applied in respect of a breach or default under such Lease which has not been redeposited in full; (vi) Seller does not owe, or shall owe in the future, any brokerage commissions or finder’s fees with respect to such Lease; (vii) the other party to such Lease is not an Affiliate of, and otherwise does not have any economic interest in, Seller; (viii) Seller has not subleased, licensed or otherwise granted any Person the right to use or occupy such Leased Real Property or any portion thereof; (ix) Seller has not collaterally assigned or granted any other security interest in such Lease or any interest therein; (x) there are no Liens on the estate or interest created by such Lease; and (xi) all buildings, structures, improvements, fixtures, building systems and equipment, and all components thereof, included in the applicable Leased Real Property are in good condition and repair (fair wear and tear excepted) and sufficient for the operation of the Focus Factor Business as conducted thereon.

 

(b) Seller does not own any real property.

 

SECTION 5.21. Affiliate Transactions. No shareholder, officer, director, member or Affiliate of Seller or any individual related by blood, marriage or adoption to any such individual or any entity in which any such Person or individual owns any beneficial interest, is a party to any Contract or transaction with Seller or has any interest in any real, tangible or intangible asset or property used by Seller.

 

 
 

 

SECTION 5.22. Solvency.

 

(a) Each of Seller and the Principal Owners is not now insolvent and will not be rendered insolvent by any of the transactions contemplated by this Agreement. As used in this section, “insolvent” means that the sum of the debts and other probable Liabilities of Seller exceeds the present fair saleable value of Seller’s assets.

 

(b) Immediately after giving effect to the consummation of the transactions contemplated by this Agreement: (i) Seller will be able to pay its Liabilities as they become due in the ordinary course of its business; (ii) Seller will not have unreasonably small capital with which to conduct its present or proposed business; (iii) Seller will have assets (calculated at fair market value) that exceed its Liabilities; and (iv) taking into account all pending and threatened litigation, final judgments against Seller in Actions for money damages are not reasonably anticipated to be rendered in such amounts that Seller will be unable to satisfy any such judgments promptly in accordance with their terms (taking into account the maximum probable amount of such judgments in any such Actions and the earliest reasonable time at which such judgments might be rendered) as well as all other obligations of Seller. The cash available to Seller, after taking into account all other anticipated uses of the cash, will be sufficient to pay all such debts and judgments promptly in accordance with their terms.

 

(c) Notwithstanding Section 5.22(b). Seller shall have the right to contest and resolve non-material debts and obligations outstanding as at Closing such as utilities and other non-material payments and Liabilities; provided, however, that no such non-material debts, obligations and Liabilities shall affect the Purchased Property or Buyer’s payment of the Purchase Price.

 

SECTION 5.23. Client and Vendor Relations. Schedule 5.23 contains a correct and complete list of the names of the Clients and Vendors, and the amount of revenues to or purchases from each such Client or Vendor during the 2013 fiscal year and the period ended as of December 31, 2014. Seller maintains commercially reasonable relations with each of the Clients and Vendors and to Seller’s Knowledge no event has occurred that could materially and adversely affect Seller’s relations with any Client or Vendor. Except as set forth on Schedule 5.23. no Client or Vendor has during the last twelve (12) months cancelled, terminated, materially decreased the rate of, materially altered the terms with respect to or, to the Knowledge of Seller, made any threat to cancel or otherwise terminate any of its Contracts with Seller or to decrease its usage or supply of Seller’s services or products, excluding for avoidance of doubt, discrete projects performed by the Seller for Clients, for which the Seller’s services terminated solely by virtue of the Seller’s having completed the project to the Clients’ satisfaction. To the Knowledge of Seller, no current Client or Vendor may terminate or materially alter its business relations with Seller, either as a result of the transactions contemplated hereby or otherwise except as set forth on Schedule 5.23.

 

SECTION 5.24. Product and Service Warranties: Adverse Events. Seller has made no express warranty or Guarantee to any customer or Client as to services or goods provided by Seller. There is no pending or, to the Knowledge of Seller, threatened claim alleging any breach of any warranty or Guarantee. Seller has not been required to pay direct, incidental, or consequential damages to any Person in connection with any services or goods provided at any time since January 1, 2010. There have not been any Adverse Events or Serious Adverse Events with respect to the Product of the Focus Factor Business.

 

SECTION 5.25. Disclosure.

 

(a) No representation or warranty by Seller or any of the Principal Owners contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of Seller or any of the Principal Owners pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.

 

(b) Seller does not have Knowledge of any fact that has specific application to Seller (other than general economic or industry conditions) and that may materially adversely affect the Purchased Property, that has not been set forth in this Agreement or the Disclosure Schedules.

 

 
 

 

SECTION 5.26. Accounts Receivable; Inventories. Except as set forth on Schedule 5.26. all accounts receivable reflected in the Financial Statements are valid receivables and represent arm’s length transactions in the ordinary course of business and are collectible in full net of the reserve for doubtful accounts, discounts, and/or promotional expenses set forth in the Financial Statements and assuming that the Buyer uses commercially reasonable and good faith efforts to collect such accounts receivable. The reserve for doubtful accounts, if any, set forth in the Financial Statements is accurate. Except as set forth on Schedule 5.26. Seller maintains no inventory, finished goods, raw materials, work in progress, packaging, parts or other inventories in the Focus Factor Business. All such inventory set forth on Schedule 5.26. whether or not reflected in the Financial Statements, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory is owned by Seller free and clear of all Liens, and no such inventory is held on a consignment basis. The quantities of each such item of inventory (whether raw materials, work-in-process or finished goods) are not excessive, but are reasonable in the present circumstances of Seller.

 

SECTION 6. REPRESENTATIONS AND WARRANTIES OF THE BUYER. The Buyer hereby represents and warrants to the Seller as follows:

 

SECTION 6.1. Corporate Organization. The Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Nevada, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its businesses as now conducted. The Buyer is duly qualified to do business as a foreign company, and is in good standing in each jurisdiction where the character of its properties owned, operated or leased or the nature of its activities makes such qualification necessary.

 

SECTION 6.2. Authorization and Validity of Agreement. The Buyer has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of the Buyer’s obligations thereunder have been duly authorized by all necessary company action by the Buyer, and no other proceedings on the part of the Buyer are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed by the Buyer and constitutes its valid and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

SECTION 6.3. No Conflict or Violation. Subject to obtaining all consents and approvals set forth on Schedule 6.3 the execution, delivery and performance by the Buyer of the Transaction Documents (i) does not and will not violate or conflict with any provision of the organizational documents of the Buyer (ii) does not and will not violate any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any acceleration of remedies or any right of termination under, any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Buyer is a party or by which Buyer is bound or to which any of the Buyers’ properties or assets is subject, except for such breaches, defaults and accelerations as would not have a material adverse effect on the ability of the Buyer to consummate the transactions contemplated hereby.

 

SECTION 7. COVENANTS OF THE SELLER.

 

The Seller covenants as follows:

 

SECTION 7.1. Conduct of Business Before the Closing Date.

 

(a) Without the prior written consent of the Buyer, between the date hereof and the Closing Date, the Seller shall not, except as required or expressly permitted pursuant to the terms hereof:

 

(i) make any material change in the conduct of the Focus Factor Business or enter into any transaction relating to or affecting the Focus Factor Business in an amount greater than $10,000 or having a term or duration of more than one year;

 

(ii) make any sale, assignment, transfer, abandonment or other conveyance of the Purchased Property or any part thereof;

 

(iii) subject any of the Purchased Property, or any part thereof, to any Lien or suffer such to exist;

 

 
 

 

(iv) fail to keep in full force and effect insurance comparable in amount and scope of coverage maintained in respect of the Focus Factor Business;

 

(v) take any other action that would cause any of the representations and warranties made by them in the Transaction Documents not to remain true and correct in all material respects (except as to representations and warranties which are qualified as to materiality, which representations and warranties must remain true and correct in all respects);

 

(vi) make, enter into, modify, amend in any material respect, renew, extend or terminate any Assigned Contract; or

 

(vii) agree or commit to do any of the foregoing.

(b) From and after the date hereof and until the Closing Date, the Seller shall:

 

(i) continue to maintain, in all material respects, the Purchased Property in accordance with prudent practice in a condition suitable for its continued future use that is consistent with its current use;

 

(ii) continue to manufacture and sell the Product in the ordinary course of business consistent with existing practice;

 

(iii) keep the Files and Records in the ordinary course of business and in accordance with existing practice; and

 

(iv) use Commercially Reasonable Efforts to maintain existing business relationships with customers, suppliers and contractors with respect to the Focus Factor Business in accordance with existing practice.

 

SECTION 7.2. Consents and Approvals. The Seller shall, at its cost and expense, use Commercially Reasonable Efforts to obtain all necessary consents, waivers, authorizations and approvals of all governmental and regulatory authorities, and of all other Persons required to be obtained in connection with the execution, delivery and performance by it of the Transaction Documents, which shall include the use by Seller of Commercially Reasonable Efforts to obtain all consents and approvals necessary to assign to Buyer all rights under any Contracts that are included in the Purchased Property. Access to Properties and Records. Subject to the terms of the Confidentiality Agreement, between Seller and the Buyer, the Seller shall afford to the Buyer, and to the accountants, counsel and representatives of the Buyer, access during normal business hours throughout the period prior to the Closing Date (or the earlier termination of this Agreement pursuant to Section 12 hereof) to all properties, books, Contracts, commitments, Employees, vendors and records of the Seller relating to the Focus Factor Business, the Purchased Property, and the Assumed Liabilities.

 

SECTION 7.3. Negotiations. From and after the date hereof until the Closing Date or termination of the Agreement pursuant to Section 12 hereof, none of the Seller, any Affiliate, nor any of their respective officers or directors nor any agent nor anyone else acting on behalf of the Seller or such persons shall, directly or indirectly, encourage, facilitate, solicit, engage in negotiations with, respond to inquiries or provide any information to, any Person, firm, or other entity or group (other than the Buyer or its representatives) concerning any merger, sale of substantial assets, purchase or sale of shares of capital stock or similar transaction involving the Focus Factor Business or any other transaction inconsistent with the transactions contemplated hereby. The Seller shall promptly communicate to the Buyer any inquiries or communications concerning any such transaction which it may receive or of which it may become aware.

 

 
 

 

SECTION 7.4. Assignment of Contracts and Warranties. At the Closing and effective as of the Closing Date, the Seller shall assign to the Buyer all of its rights under the Assigned Contracts. No liabilities under any Contract shall be included as Assumed Liabilities except and unless as expressly provided in Section 2.4. Seller and the Principal Owners shall advise Buyer promptly in writing with respect to any Contract under which it knows or has reason to believe it will not receive the required consent. Seller and the Principal Owners shall take all actions reasonably requested by Buyer and cooperate with Buyer to obtain any new Contract (if necessary) on substantially similar terms and conditions as those under the existing Contract and/or to provide the economic benefit of such Contract to Buyer. Notwithstanding the foregoing, and without affecting the Buyer’s closing conditions hereunder, to the extent that any Assigned Contracts cannot be assigned to the Buyer at the Closing Date, the Seller shall maintain such Contracts in effect and, as agent for Buyer, the performance obligations of the Seller, as the case may be, thereunder shall be deemed to be subleased or subcontracted to the Buyer until such Assigned Contract has been assigned. Seller shall (i) use all Commercially Reasonable Efforts to obtain all necessary consents, (ii) cooperate with the Buyer in any arrangement designed to provide to the Buyer the benefits (including the exercise of rights) under any such Assigned Contracts that Buyer designates that it wishes to be assigned, including enforcement for the benefit of the Buyer of any and all rights of Seller against a third party thereto arising out of the breach or cancellation by such third party or otherwise, (iii) hold all monies paid thereunder in trust for the account of the Buyer (unless otherwise agreed to in this Agreement), and (iv) remit all such money without set-off of any kind whatsoever to the Buyer as promptly as possible (unless otherwise agreed to in this Agreement).

 

SECTION 7.5. Post-Closing Matters. The Principal Owners shall cause Seller to preserve and maintain its organizational existence and remain in good standing for a period of at least twenty-four (24) months after the date hereof. As soon as practicable after the Closing Date but in any event no later than 30 days after the Closing, Seller shall take all action necessary to remove all Product and Seller names and logos and color schemes and any other Intellectual Property or IP Assets from their respective signage at all locations, letterhead, stationary, advertising, websites and other marketing materials and other content available for viewing by the public, and will change its name with the Delaware Secretary of State and all other jurisdictions in which Seller has made registrations to transact business, any other, any other registrations and/or name filings (including the amendment or withdrawal of any registrations and/or assumed name filings with the State of Delaware or any cities and counties within the State of Delaware and all applicable jurisdictions) such that Seller’s name does not include the words “Factor” or “Focus”, any derivative thereof, or any name which sounds or looks similar thereto, or any trademarks or trade names used in the Focus Factor Business, and Seller shall otherwise cease to use such names for all purposes, other than as necessary for the winding up of its business affairs. Seller herby covenants and agrees that it shall, no later than fifteen (15) days following the Closing Date, provide documentation to Buyer, in the form and substance satisfactory to Buyer, evidencing the filing of such amendments or withdrawals with such jurisdictions. Seller also agrees to execute any documentation necessary to give Buyer the right to collect payments related to the Purchased Property (including accounts receivable) in Seller’s name following Closing.

 

SECTION 7.6. Post-Closing Operation of Business. Following the Closing, Seller and each of the Principal Owners shall fully cooperate with Buyer to transfer the Focus Factor Business to Buyer in such a manner as to preserve the value thereof.

 

SECTION 7.7. Post-Closing Audit. Following the Closing, Seller and the Principal Owners shall reasonably cooperate in Buyer’s preparation and audit of GAAP financial statements for all periods in which Seller’s financial statements were not prepared in accordance with GAAP and audited, so that GAAP financial statements can be prepared no later than sixty (60) days following the Closing.

 

SECTION 7.8. Noncompetition. Nonsolicitation and Non disparagement.

 

(a) Noncompetition. Seller and the Principal Owners acknowledge that (i) Buyer would not have entered into this Agreement but for the agreements and covenants contained in this Section 7.8; and (ii) the agreements and covenants contained in this Section 7.8 are essential to protect the business and goodwill of the Focus Factor Business and are reasonable and appropriate in scope; (iii) the Focus Factor Business is national in scope; and (iv) the business of Buyer is worldwide in scope. To induce Buyer to enter into this Agreement, each of Seller and the Principal Owners (other than Thor Associates, Inc.) covenants and agrees that during the period commencing on the Closing Date and ending on the fifth (5th) anniversary of the Closing Date (the “Restricted Period”), Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (A) engage in any business or activity that competes with the Focus Factor Business; (B) render any services to any Person for use in competing with Buyer in connection with the Focus Factor Business; (C) have an interest in any Person engaged in any business that competes with Buyer in connection with the Focus Factor Business, directly or indirectly, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee or consultant or any other relationship or capacity; provided, however. Seller or any of the Principal Owners may own, directly or indirectly, solely as an investment, securities of any Person which are publicly traded if Seller or such Principal Owner, as the case may be (I) is not a controlling Person of, or a member of a group which controls, such Person and (II) does not, directly or indirectly, own two percent (2%) or more of any class of securities of such Person; or (D) interfere with business relationships (whether formed heretofore or hereafter) between Buyer or any of its Affiliates and customers, suppliers or prospects of the Focus Factor Business.

 

 
 

 

(b) Employees of the Business. During the Restricted Period, Seller, the Principal Owners (other than Thor Associates, Inc.) and their respective Affiliates shall not, directly or indirectly, (i) solicit or encourage any Employee or consultant performing services in connection with the Focus Factor Business to leave the employment or retention of Buyer or any of its Affiliates, or (ii) hire any such Employee or consultant who was performing services in connection with the Focus Factor Business and who has left the employment or retention of Buyer or any of its Affiliates within one (1) year of the termination of such Employee’s employment or consultant’s retention with Buyer or any of its Affiliates.

 

(c) Customers of the Business. During the Restricted Period, Seller, its employees, officers, directors, the Principal Owners (other than Thor Associates, Inc.), and their respective Affiliates shall not, directly or indirectly, (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client, supplier or vendor of Buyer or any of its Affiliates not to hire or do business with Buyer or any of its Affiliates or any successor thereto; (ii) solicit for himself or any Person other than Buyer or any of its Affiliates, the business of any Person who is a customer, client, supplier or vendor of Buyer or any of its Affiliates, or was its customer or supplier within two (2) years prior to the time of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Buyer.

 

(d) Confidential Information. From and after the Closing, Seller, its stockholders, employees, officers, directors, the Principal Owners and their respective Affiliates shall keep secret and retain in strictest confidence, and shall not use for the benefit of itself or others, all confidential matters relating to the Focus Factor Business or Buyer and its Affiliates, including, but not limited to, “know how”, trade secrets, customer lists, supplier lists, details of consultant and employment Contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Buyer and its Affiliates; provided, however, this covenant shall not apply to any information which is or becomes generally available to the public other than as a result of disclosure by the Seller, the Principal Owners or their respective Affiliates. Seller, the Principal Owners and their respective Affiliates may disclose Confidential Information if required to do so in any legally required government or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that Seller (A) provides Buyer with prompt notice of such required disclosure so that Buyer may attempt to obtain a protective order, (B) cooperates with Buyer, at Buyer’s expense, in obtaining such protective order, and (C) only discloses that Confidential Information which it is absolutely required to disclose as advised by counsel. This subsection (d) shall not affect or amend the Confidentiality Agreement.

 

(e) Non disparagement. After the Closing Date, Seller and the Principal Owners will not disparage Buyer, any of Buyer’s Affiliates or any of such parties’ shareholders, directors, officers, employees or agents.

 

(f) Tolling of Covenant Periods. The Restricted Period provided in this Section 7.8 shall not include and shall be extended beyond, any time during which a party is failing to comply with any provision of this Section 7.8 with respect to such party.

 

(g) Blue Penciling. If any term or other provision of this Section 7.8 is invalid, illegal, or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions of this Section 7.8 shall nevertheless remain in full force and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 7.8 so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

 
 

 

SECTION 7.9. Employees.

 

(a) Buyer agrees to offer employment as of the Closing Date, on an “at will” basis to substantially all the Employees of Seller including all management Employees, and if any such Employee accepts Buyer’s offer of employment, he or she shall become an employee of Buyer after the Closing Date (such Employees are referred to hereinafter as the “Transferred Employees”). Transferred Employees shall be credited for past service toward Buyer’s then- current benefits offered by Buyer for purposes of determining eligibility (but not benefit accrual).

 

(b) Seller shall make all salary, commission, bonus, incentive, vacation pay or other benefit accrual payments, in each case that relate to periods prior to and through the Closing, to Employees as they become due. Buyer shall not be required to provide continuations of any of Seller’s salary arrangements, bonus or incentive pay or other plans, commission arrangements or commission agreements or wage or salary or compensation incentives after the Closing Date.

 

(c) Seller and Buyer shall cooperate to take whatever reasonable steps are necessary to effect the distribution and direct rollover to Buyer’s qualified retirement plan that includes a cash or deferred arrangement under Section 401(k) of the Code (“Buyer’s 401(k) Plan”) of the account balance of each Transferred Employee, if eligible in the Seller Benefit Plan that is a qualified retirement plan that includes a cash or deferred arrangement under Section 401(k) of the Code (“Seller’s 401(k) Plan”) as soon as administratively practicable following the Closing Date and after such Transferred Employee elects such a distribution and direct rollover, in accordance with and to the extent permitted by the terms of Seller’s 401(k) Plan, Buyer’s 401(k) Plan and applicable Law.

 

(d) The parties acknowledge and agree that it is their intention that all existing Contracts of non-competition between Seller and any Employee or any Contractor providing services to Seller in respect of the Business as of immediately prior to the Closing Date shall be transferred to or assumed by Buyer as a result of the transactions described herein and that such Contracts shall constitute Purchased Contracts hereunder. If any such Contract may not be so assigned. Seller agrees that it will cooperate with Buyer to enforce such Contracts as Buyer may reasonably request.

 

(e) Buyer and Seller (and their Affiliates) hereby agree to follow the “Alternate Procedure,” as such procedure is described in Section 5 of Rev. Proc. 2004-53, 2004- 34 I.R.B. 320 (Aug. 18, 2004), for preparing and filing Forms W-2, and 941, and transferring of Forms W-4 and W-5, with respect to Transferred Employees.

 

(f) This Section 7.9 shall operate exclusively for the benefit of the parties to this Agreement and not for the benefit of any other Person, including the Transferred Employees or any other Employee, Contractor, former Employee or other Person who performs or performed services to the Company.

 

SECTION 7.10. Claims Assistance.

 

(a) Seller and the Principal Owners provide such assistance, support and information as reasonably required by Buyer from time to time to assist in (i) the defense of claims made by third parties against Buyer in respect of Assumed Liabilities, and (ii) any claim by Buyer or Seller against third parties in respect of Assumed Liabilities.

 

(b) Seller and the Principal Owners shall provide such assistance, support and information as reasonably required by Buyer from time to time to assist Buyer to obtain any Permits that are necessary or useful to carry on the Business to the extent that such Permits are not assignable from Seller to Buyer.

 

SECTION 7.11. Post-Closing Receipts. If at any time following the Closing Date, Seller or any Principal Owner receives, or comes into possession of, any of the Purchased Property or any receipts, proceeds, checks, securities or other property of any kind comprising, arising out of or derived from the Purchased Property, then Seller or such Principal Owner shall immediately deliver it to the Seller with such endorsements, transfers or assignments as may be necessary or useful to ensure that the Seller receives the immediate and full benefit thereof.

 

 
 

 

SECTION 8. COVENANTS OF THE BUYER.

 

SECTION 8.1. Consents and Approvals. The Buyer (i) shall, at its cost and expense, use all Commercially Reasonable Efforts to obtain all necessary consents, waivers, authorizations and approvals of all governmental and regulatory authorities, and all other Persons required to be obtained by the Buyer in connection with the execution, delivery and performance by it of the Transaction Documents, and (ii) shall diligently assist and cooperate with the Seller in preparing and filing all documents required to be submitted by the Seller to any governmental or regulatory authority, domestic or foreign, in connection with such transactions and in obtaining any governmental consents, waivers, authorizations or approvals which may be required to be obtained by the Seller in connection with such transactions (which assistance and cooperation shall include, without limitation, timely furnishing to the Seller all information concerning the Buyer that counsel to the Seller determines is required to be included in such documents or would be helpful in obtaining any such required consent, waiver, authorization or approval).

 

SECTION 8.2. Post-Closing Efforts. On and after the Closing Date and until payment in full of the Additional Payment, the Buyer shall use its Commercially Reasonable Efforts to maintain the Focus Factor Business and operations consistent with current levels, including without limitation acting in good faith to maintain current levels of distribution by Costco of the Product.

 

SECTION 9. CONDITIONS TO OBLIGATIONS OF THE SELLERS. The obligations of the Seller to effect the Closing and to consummate the transactions contemplated by the Transaction Documents are subject to the fulfillment, at or before the Closing Date, of each of the following conditions, any one or more of which may be waived by the Seller in its sole discretion:

 

SECTION 9.1. Representations and Warranties of the Buyer. All representations and warranties made by the Buyer in this Agreement shall be true and correct in all material respects (except as to representations and warranties which are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of the date of this Agreement and on and as of the Closing Date as if again made by the Buyer on and as of such date.

 

SECTION 9.2. Performance of the Obligations of the Buyer. The Buyer shall have performed in all material respects all obligations required under this Agreement to be performed by it on or before the Closing Date.

 

SECTION 9.3. Financing. Buyer has delivered to Seller evidence of financing to Buyer in an aggregate amount sufficient to consummate the transactions contemplated by this Agreement.

 

SECTION 9.4. Distribution of Cash. Immediately prior to Closing, Seller shall have distributed all cash in its accounts to its members.

 

SECTION 9.5. Due Diligence. Prior to Closing, Buyer shall have provided evidence to Seller by which Seller can reasonably conclude after due diligence that the assets securing Buyer’s obligations hereunder will cover such obligations.

 

SECTION 9.6. Buyer Closing Deliverables.

 

At the Closing, Buyer will:

 

(a) Execute and deliver a duly executed counterpart of the bill of sale in the form attached hereto as Exhibit A (the “Bill of Sale”);

 

(b) Deliver to the Seller the Closing Payment in immediately available funds;

 

(c) Deliver a certificate executed by the authorized person of the Buyer certifying as to the truthfulness, completeness and accuracy of attached copies of resolutions of the directors of the Buyer authorizing this Agreement and the transactions contemplated hereby;

 

(d) Deliver to Seller a certificate of the Secretary of the State of Nevada, dated reasonably close to the Closing Date, as to the legal existence and good standing of the Buyer in Nevada;

 

(e) Deliver to Seller an executed promissory note constituting the Additional Payment; and

 

(f) Execute and deliver the Pledge Agreement.

 

 
 

 

SECTION 9.7. Board. The board of directors of Buyer shall have approved the transactions contemplated hereby.

 

SECTION 10. CONDITIONS TO OBLIGATIONS OF THE BUYER. The obligations of the Buyer to consummate the transactions contemplated by the Transaction Documents are subject to the fulfillment, at or before the Closing Date, of each of the following conditions, any one or more of which may be waived by the Buyer in its sole discretion:

 

SECTION 10.1. Representations and Warranties of the Seller. All representations and warranties made by the Seller in this Agreement shall be true and correct in all material respects (except as to representations and warranties which are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of the date of this Agreement and on and as of the Closing Date as if again made by the Seller on and as of such date.

 

SECTION 10.2. Performance of the Obligations of the Seller. The Seller has performed in all material respects all agreement, covenants, and obligations required under this Agreement to be performed by it on or before the Closing Date.

 

SECTION 10.3. Liability for Outstanding Sums. Buyer shall have no liability with respect to outstanding sums owed to Seller’s existing officers and Employees, including, without limitation, with respect to any previous loans made by such officers or Employees.

 

SECTION 10.4. Seller Closing Documents. The Seller shall have delivered to the Buyer the following documents:

 

(a) the Files and Records forming a part of the Purchased Property;

 

(b) a duly executed Bill of Sale;

 

(c) physical possession and control of the Purchased Property;

 

(d) all consents that are required to transfer the Assigned Contracts and the other items of Purchased Property;

 

(e) a certificate executed by the appropriate officers of the Seller, certifying the satisfaction by the Seller of the conditions specified in Sections 10.1, 10.2, and 10.7;

 

(f) a certificate executed by the authorized person of the Seller certifying as to the truthfulness, completeness and accuracy of attached copies of resolutions of the directors and members of the Seller authorizing this Agreement and the transactions contemplated hereby;

 

(g) evidence of satisfaction and termination of all liens applicable to the Purchased Property (other than permitted liens, as may be mutually agreed upon by the Parties);

 

(h) such other documents relating to the transactions contemplated by the Transaction Documents to be consummated at the Closing as counsel to the Buyer shall reasonably request in order to convey unencumbered title to the Purchased Property to Buyer;

 

(i) (i) a certificate of the Secretary of the State of Delaware and Maine, dated reasonably close to the Closing Date, as to the legal existence and good standing of the Seller in Delaware and Maine; and

 

(k) appropriate assignments of the Intellectual Property included in the Purchased Property, in a form acceptable to Buyer.

 

 
 

 

SECTION 10.5. Filing of Required Notices. Seller shall have filed any and all applicable “bulk sale” and related notices with the appropriate authorities, and paid any and all sales taxes assessed in connection therewith.

 

SECTION 10.6. Amounts Due to Creditors. Seller shall pay at Closing out of the Closing Payment any and all amounts due and owing to creditors, other than those amounts expressly assumed by Buyer.

 

SECTION 10.7. Board and Stockholder Approval. The board of directors and the stockholders of Seller shall have approved the transactions contemplated hereby.

 

SECTION 10.8. No Proceeding or Litigation. No Action, suit or proceeding brought by or on behalf of any Person or Governmental entity challenging the legality of, or seeking to restrain, prohibit, materially modify or rescind the transactions contemplated by this agreement shall have been instituted and not settled or otherwise terminated.

 

SECTION 11. INDEMNIFICATION.

 

SECTION 11.1. Indemnification by the Seller. The Seller and each of the Principal Owners, jointly and severally, up to their respective Actual Proceeds, shall indemnify and save and hold the Buyer, any Affiliate of the Buyer and their respective directors, officers, managers, employees, successors, and assigns (the “Buyer Indemnitees”), harmless from and against any and all damages, claims, demands, obligations, liabilities, losses, costs, expenses (including all reasonable attorneys’ fees and expenses of investigation incurred by the Buyer Indemnitees in any Action or proceeding between the Seller and the Buyer Indemnitees or between the Buyer Indemnitees and any third party or otherwise), deficiencies, interests, penalties, impositions, assessments and/ or fines (collectively, “Buyer Losses”), whether or not in connection with a third-party claim, arising out of, resulting from or related to any and/or all of the Seller’s Events of Breach. As used herein, “Seller’s Events of Breach” shall be and mean any one or more of the following:

 

(a) any breach of any representation or warranty made by Seller or the Principal Owners in this Agreement or the other Transaction Documents;

 

(b) any liabilities arising out of the ownership or operation of the Purchased Property prior to the Closing Date other than the Assumed Liabilities;

 

(c) any brokerage or finder’s fees or commissions or similar payments based upon any agreement or understanding made, or alleged to have been made, by any Person with Seller or the Principal Owners (or any person acting on their behalf) in connection with any of the transactions contemplated by this Agreement;

 

(d) any Seller Benefit Plan in existence prior to the Closing Date, whether such Liability arises before, on or after the Closing Date, including, without limitation, unfunded Liabilities, Liability with respect to the termination of any such plan, any retiree from employment with Seller, any unfunded Liability under any such plan, or any accrued but unpaid claim under such Seller Benefit Plan;

 

(e) any Liability relating to compliance with any Environmental Law arising out of or relating to operation of the Business prior to the Closing Date or Seller’s leasing, ownership or operation of real property

 

(f) the employment (including the initial hiring and all terms, conditions, and events relating to the ongoing employment prior to the Closing Date) or termination of employment (including constructive termination) by Seller of any individual (including without limitation any current or former employee of the Seller), including any compensation due to the employees or contractors relating to periods ending on or prior to the Closing Date, including, without limitation, severance, salary, commission, bonus, incentives, vacation pay or other benefit accruals or any termination liability

 

 
 

 

(g) all Liabilities and commitments with respect to eligible persons and their eligible dependants, in respect of health insurance under COBRA;

 

(h) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of the shareholders of Seller;

 

(i) any breach of any covenant or other agreement made by Seller or the Principal Owners in this Agreement or the other Transaction Documents, or any failure of the Seller or the Principal Owners to duly perform or observe any term, provision, covenant, agreement contained in this Agreement or the other Transaction Documents on the part of the Seller or the Principal Owners to be performed or observed; and

 

(j) any claim or cause of Action by any Party against any Buyer Indemnitee, with respect to any liabilities of the Seller and Affiliates of the Seller other than the Assumed Liabilities; provided, however, that neither Seller nor the Principal Owners shall be liable to make any payment in respect of a claim for indemnification in respect of any Seller’s Events of Breach until the aggregate of such Buyer Losses shall exceed $50,000 (“Threshold”), but once such Buyer Losses shall exceed such $50,000 Threshold (“Basket”), the Buyer Indemnitees shall have the right to indemnification hereunder, and the Seller and/or its members shall be required to make payment to the Buyer Indemnitees in respect of such claims, to the full extent of such Buyer Losses without reference to or deduction for the $50,000 Threshold up to an aggregate liability cap equal to the Purchase Price (“Cap”), provided, however, that the Basket and Cap shall not apply (and Seller and the Principal Owners shall be fully liable) in the case of any claims based on (i) a breach of any Fundamental Representations, (ii) fraud, bad faith, criminal conduct, intentional misrepresentation, or willful misconduct (“Bad Conduct”), or (iii) indemnification under Section 11.1(b), 11. l(i), or 11.10, provided, further, that the liability of each Principal Owner under (i) through (iii) shall not exceed such Principal Owner’s pro rata share of such liability (“pro rata share” shall mean the Principal Owner’s percentage ownership of Seller).

 

All representations, warranties, covenants and obligations of Seller and the Principal Owners herein, and all other agreements or instruments contemplated hereby to which Buyer, Seller or any Principal Owner is a party, shall survive the Closing Date for eighteen (18) months, except that: (i) all covenants and agreements which by their terms contemplate performance after the Closing Date shall survive the Closing indefinitely, unless specified otherwise by their terms; and (ii) for breaches of any Fundamental Representations or Bad Conduct, the survival period shall be indefinite. Any claim for indemnification made in accordance with this Section 11, prior to the expiration of the applicable indemnification period set forth in this paragraph shall survive until such matter is resolved.

 

Following the Closing, the indemnification afforded by this Section 11 shall be the sole and exclusive remedy of the Buyer Indemnitees in respect of claims for Seller’s Events of Breach.

 

SECTION 11.2. Procedures for Indemnification by the Seller.

 

(a) Notice of Claims. If a Seller’s Event of Breach occurs or is alleged and a Buyer Indemnitee asserts that the Seller has become obligated to such Buyer Indemnitee pursuant to Section 11.1 hereof (“Direct Claim”), or if any suit, Action, investigation, claim or proceeding (a “Third Party Proceeding”) is threatened, begun, made or instituted by a third party as a result of which the Seller may become obligated to a Buyer Indemnitee hereunder, such Buyer Indemnitee shall give written notice thereof to the Seller (the “Buyer’s Claims Notice”). The Buyer’s failure or delay in providing a Buyer’s Claims Notice shall not relieve Seller of its obligations under this Section 11 except to the extent that the Seller is materially prejudiced as a result thereof.

 

(b) Response to Direct Claims. The Seller shall have thirty (30) calendar days after receipt of the Buyer’s Claim Notice for a Direct Claim to reject or accept the claim as an indemnifiable claim for Buyer Losses under this Section 11. If, within thirty (30) calendar days after receipt by the Seller of such a Buyer’s Claim Notice, Seller delivers notice to the Buyer Indemnitee containing a written objection to the claim (or a portion thereof) by the Buyer Indemnitee, stating the nature of and grounds for such objection in reasonable detail, then such claim (or portion thereof) shall be deemed to be a “Disputed Claim” and such claim shall be resolved in accordance with Section 11.2(c) hereof. If, within thirty (30) calendar days after actual receipt by the Seller’s of the Buyer’s Claim Notice for a Direct Claim, the Seller delivers notice to the Buyer Indemnitee containing a written acceptance of the claim, (or a portion thereof) then such claim (or portion thereof) shall be deemed an indemnifiable claim under this Section 11 (the “Indemnifiable Claim”), and the Seller will be conclusively deemed to have consented to recovery by the Buyer Indemnitee of the full amount of Buyer Losses in connection with the claim.

 

 
 

 

(c) Dispute Resolution. Any disputes arising under this Section 11 shall be resolved as follows: (i) first, the Parties shall attempt in good faith for 30 days to resolve the dispute, and (ii) if the dispute remains unresolved after such 30 day period, the Parties agree that any Party may file suit in any court or other adjudicative body having jurisdiction in order to resolve the dispute.

 

(d) Third Party Proceeding.

 

(i) Seller shall have twenty (20) days from receipt of a Buyer’s Claim Notice for a Third Party Proceeding to provide the Buyer Indemnitee with notice that it wishes to assume the defense in the Third Party Proceeding and acknowledges liability for such damages, in which event the Buyer Indemnitee shall have the right to participate in the defense at its own expense; provided, however, that the Buyer Indemnitee is hereby authorized prior to and during such time to file any motion, answer or other pleading that it shall deem necessary or appropriate to protect its interests and that is not prejudicial to Seller. If Seller fails to give the Buyer Indemnitee timely notice as provided herein, the Buyer Indemnitee shall have the right to defend against such Third Party Proceeding.

 

(ii) If Seller assumes the defense in a Third Party Proceeding, the Indemnifying Party shall not agree to any settlement, compromise or discharge of a Third-Party Claim that involves any consideration other than the payment of money without the Indemnified Party’s prior written consent, which shall not be unreasonably withheld. If the Indemnifying Party does not assume the defense of a Third-Party Claim, the Indemnified Party shall be entitled to undertake any settlement, compromise or discharge of such Third-Party Claim without the Indemnifying Party’s prior consent.

 

(iii) Notwithstanding anything herein to the contrary. Seller and the Principal Owners shall not be entitled to assume control of the defense in a Third Party Proceeding, and shall pay the reasonably documented fees and expenses of legal counsel retained by the Buyer Indemnitee, if a court of competent jurisdiction rules that Seller or the Principal Owners have failed or are failing to prosecute or defend such claim.

 

(iv) Notwithstanding the provisions of Section 13.2, Seller hereby consents to the nonexclusive jurisdiction of any court in which an Action or claim in respect of a Third Party Proceeding is brought against any Buyer Indemnitee for purposes of any claim that a Buyer Indemnitee may have under this Agreement with respect to such Action or claim or the matters alleged therein and agrees that process may be served on Seller with respect to such a claim anywhere in the world.

 

SECTION 11.3. Indemnification Binds Successors and Assigns. All of the indemnification rights of the Buyer and obligations of the Seller arising pursuant to this Section 11 shall survive any sale, assignment or other transfer by the Buyer or any Seller of all or part of their respective title to or interest in all or part of the Transaction Documents or the Purchased Property and shall apply to and bind each and every successor and assign of the Buyer and each Seller.

 

SECTION 11.4. Dispute Resolution Costs. Each Party shall bear all its own costs of any court Action or other dispute resolution proceeding hereunder, including without limitation, the fees and expenses of its own legal counsel and other filing fees and expenses of such Party for such proceeding.

 

SECTION 12. TERMINATION.

 

SECTION 12.1. Conditions of Termination. Notwithstanding anything to the contrary contained herein, this Agreement may be terminated at any time before the Closing:

 

(a) By mutual consent of the Seller and the Buyer,

 

(b) By either the Seller or the Buyer if the other Party shall have breached this Agreement in any material respect and such breach continues for a period of ten (10) days after the receipt of written notice of the breach from the non-breaching Party, or

 

 
 

 

(c) By either the Seller or Buyer if the Closing has not occurred on or before 5:00 p.m. eastern time on January 23, 2015 (regardless of the pendency of any cure period provided for in Section 12.1(b).

 

SECTION 12.2. Effect of Termination. If this Agreement is terminated in accordance with Section 12.1 hereof, this Agreement shall become null and void and have no effect, with no liability on the part of the Seller or the Buyer, or their Affiliates and their respective directors, managers, officers, agents, members or shareholders, except for the obligations set forth in this Section 12.2, Section 7.9(d), Section 13, and the Confidentiality Agreement both of which shall survive any termination; and provided, however, that notwithstanding the foregoing, nothing herein and no termination hereof shall relieve any Party from liability for any breach of any of its representations, warranties, covenants or agreements set forth in this Agreement which arise prior to termination.

 

SECTION 13. MISCELLANEOUS.

 

SECTION 13.1. Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Parties hereto.

 

SECTION 13.2. Governing Law: Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of Delaware, without giving effect to the principles of conflicts of laws thereof. The Parties hereto irrevocably consent to the jurisdiction of, the federal and state courts of the State of Delaware located in Wilmington, Delaware for such purpose.

 

SECTION 13.3. Expenses. Except as otherwise provided herein, each of the Parties hereto shall pay all its own expenses in connection with this Agreement and the transactions contemplated hereby, including, without limitation, any legal and accounting fees, whether or not the transactions contemplated hereby are consummated. The Seller and the Buyer shall each pay one-half of any applicable state and local sales, transfer, excise, value-added or other similar Taxes, and all recording and filing fees that may be imposed by reason of the sale, transfer, assignment and delivery of the Purchased Property (collectively, the “Transfer Taxes”). Each party agrees to cooperate with such other party in the timely completion, execution and filing of any documentation required by any local, state, federal or other Tax authority in connection with the Transfer Taxes, including any documentation as may be requested to establish an exemption from (or otherwise reduce) or make a report with respect to the Transfer Taxes.

 

SECTION 13.4. Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

SECTION 13.5. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, (ii) on the day of transmission if sent via facsimile transmission or email to the facsimile number or email given below, and telephonic confirmation of receipt is obtained promptly after completion of transmission, or (iii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the Party as follows:

 

If to the Seller or any Principal Owner:

Factor Nutrition Labs, LLC, do Michael O’Connor, Esq. Williams & Connolly, 725 Twelfth Street, N.W., Washington, D.C., 20005.

With a copy to:

Thor Associates, Inc.

Thor Associates, Inc., do Sanford H. Greenberg Greenberg Freeman LLP 110 East 59th Street 22nd Floor

New York, New York 10022

 

If to the Buyer:

Jack Ross

865 Spring Street

Westbrook, Maine 04092

With a copy to:

Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, NC 27607 Attention: W. David Mannheim, Esq.

 

Any Party may change its address for the purpose of this Section by giving the other Party written notice of its new address in the manner set forth above.

 

 
 

 

SECTION 13.6. Amendments: Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

SECTION 13.7. Public Announcements. The Parties will reasonably cooperate concerning the public announcement of the transactions contemplated herein, but no Party hereto shall make any public statement regarding this Agreement or the transactions contemplated herein without Buyer’s prior written approval.

 

SECTION 13.8. Entire Agreement. This Agreement, the Exhibits and schedules hereto and the Confidentiality Agreement contain the entire understanding between the Parties hereto with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein. This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.

 

SECTION 13.9. Parties in Interest. Nothing in this Agreement is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the Seller and the Buyer and their respective successors and permitted assigns. Nothing in this Agreement is intended to relieve or discharge the obligations or liability of any third persons to the Seller or the Buyer. No provision of this Agreement shall give any third persons any right as a third party beneficiary of this Agreement or provide any right of subrogation or Action over or against the Seller or the Buyer.

 

SECTION 13.10. Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

SECTION 13.11. Counterparts. This Agreement may be executed in counterparts and via pdf, each of which shall be deemed an original, but all of which shall constitute the same instrument.

 

SECTION 13.12. Fulfillment of Obligations. Any obligation of any Party to any other Party under this Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such Party, shall be deemed to have been performed, satisfied, or fulfilled by such Party.

 

SECTION 13.13. Remedies. Except as expressly provided in this Agreement, any Person having any rights under any provision of this Agreement, including, without limitation, Section 7.9, shall be entitled to enforce such rights specifically (without posting a bond or other security), to require Seller and their respective Affiliates to account for and pay over to Buyer all payments, profits, monies, accruals, increments or other benefits derived by such party by reason of any breach of any provision of this Agreement, to recover damages and to exercise all other rights granted by Laws. Except as expressly provided in this Agreement, all such rights and remedies shall be cumulative and non-exclusive, and may be exercised singularly or concurrently. The Parties acknowledge that any breach of this Agreement may cause substantial irreparable harm to the other Party. Therefore, this Agreement may be enforced in equity by specific performance, temporary restraining order and/or injunction. The rights to such equitable remedies shall be in addition to all other rights or remedies which a Party may have under this Agreement or under applicable law.

 

 
 

 

SECTION 13.14. FURTHER ACTIONS. In case at any time after the Closing any further action is necessary to carry out the purposes of this Agreement, each of the parties shall take such further action (including the execution and delivery of such further instruments and documents) as any other party reasonably may request, all at the sole cost and expense of the requesting party (unless the requesting party is entitled to indemnification therefore under Section 11).

 

SECTION 14. GUARANTY

 

(a) The Guarantor hereby guarantees to the Seller the Additional Payment obligations of the Buyer under Section 3.1(b) of this Agreement and no other obligations (the Guaranteed Obligations”), subject to the terms and conditions of this Section 14. This guaranty is an absolute, unconditional and continuing guaranty of the full and punctual payment and performance of the Guaranteed Obligations, not only collectability, and is in no way conditioned upon any requirement that the Seller first attempt to collect any of the Guaranteed Obligations from the Buyer or resort to any security or other means of obtaining its payment or performance, except to the extent otherwise set forth in this Section 14. Should the Buyer default in the performance of any of the Guaranteed Obligations, or in the event that the Buyer or the Guarantor shall (i) apply for or consent to the appointment of a receiver, trustee or liquidator of it or a material portion of its or their property, (ii) admit in writing its or their inability to pay or fail generally to pay its or their debts as they mature, (iii) make a general assignment for the benefit of creditors, (iv) be adjudicated a bankrupt, or (v) file a voluntary petition in bankruptcy or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any bankruptcy, reorganization, arrangement, insolvency, readjustment of debts, dissolution or liquidation statute, or an answer admitting the material allegations of a petition filed against it or any of them in a proceeding under any such law, the obligations of the Guarantor hereunder shall become immediately due and payable to the Seller, without demand or notice of any nature, all of which are expressly waived by the Guarantor. Notwithstanding the foregoing or anything to the contrary in this Agreement or any of the Transaction Documents, in the event that Seller desires to collect any of the Guaranteed Obligations from Guarantor, Seller is required to first proceed against the assets of Guarantor that are secured by the Stock Pledge and Security Agreement attached hereto as Exhibit B (the “Pledge Agreement”), and if, and only if, the Guaranteed Obligations are not satisfied by the assets of Guarantor under Pledge Agreement, then Seller can proceed against Guarantor’s other assets.

 

(b) The Guarantor further agrees, as the principal obligor and not as a guarantor only, to pay to the Seller, on demand, all reasonable costs and expenses (including court costs and legal fees and expenses) incurred or expended by the Seller in connection with the enforcement of the Guaranteed Obligations and this guaranty, together with interest on amounts recoverable under this guaranty from the time of such demand until payment thereof at a rate equal to the sum of (i) the base rate as quoted in The Wall Street Journal (Eastern Edition) as of the date of any demand under this guaranty, plus (ii) 5%.

 

(c) Except as otherwise provided for herein, the Guarantor waives presentment, demand, protest, notice of acceptance, notice of Guaranteed Obligations incurred and all other notices of any kind, all defenses which may be available by virtue of any valuation, stay, moratorium law or other similar law now or hereafter in effect, any right to require the marshaling of assets of the Buyer or of the Guarantor, and all suretyship defenses generally. Without limiting the generality of the foregoing, the Guarantor agrees to the provisions of any instrument evidencing, securing or otherwise executed in connection with any Guaranteed Obligation and agrees that the obligations of the Guarantor hereunder shall not be released or discharged, in whole or in part, or otherwise affected by (i) the failure of the Seller to assert any claim or demand or to enforce any right or remedy against the Buyer; (ii) any extensions or renewals of any Guaranteed Obligation; (iii) any rescissions, waivers, amendments or modifications of any of the terms or provisions of any agreement evidencing, securing or otherwise executed in connection with any Guaranteed Obligation; (iv) the substitution or release of any entity primarily or secondarily liable for any Guaranteed Obligation; (v) the adequacy of any rights the Seller may have against any collateral or other means of obtaining repayment of the Guaranteed Obligations; (vi) the impairment of any collateral securing the Guaranteed Obligations, including the failure to perfect or preserve any rights the Seller might have in such collateral or the substitution, exchange, surrender, release, loss or destruction of any such collateral; or (vii) any other act or omission that might in any manner or to any extent vary the risk of the Guarantor or otherwise operate as a release or discharge of the Guarantor, all of which may be done without notice to the Guarantor except as otherwise set forth herein.

 

 
 

 

(d) If for any reason the Buyer has no legal existence or is under no legal obligation to discharge any of the Guaranteed Obligations, or if any of the Guaranteed Obligations have become irrecoverable from the Buyer by operation of law or for any other reason, this guaranty nevertheless shall be binding on the Guarantor to the same extent as if the Guarantor at all times had been the principal obligor on all such Guaranteed Obligations. In the event that acceleration of the time for payment of the Guaranteed Obligations is stayed upon the insolvency, bankruptcy or reorganization of the Buyer, or for any other reason, all such amounts otherwise due under the terms of any agreement, document or instrument evidencing, securing or otherwise executed in connection with any Guaranteed Obligation shall be immediately due and payable by the Guarantor.

 

(e) Until the payment and performance in full of all Guaranteed Obligations: (i) the Guarantor shall not exercise any rights against the Buyer arising as a result of payment by the Guarantor hereunder, by way of subrogation or otherwise, and will not prove any claim in competition with the Seller in respect of any payment hereunder in bankruptcy or insolvency proceedings of any nature; and (ii) the Guarantor will not claim any set-off or counterclaim against the Buyer in respect of any liability of the Guarantor to the Seller. The payment of any amounts due with respect to any indebtedness of the Buyer for money now or hereafter borrowed from Guarantor or now or hereafter held by the Guarantor is hereby subordinated to the prior payment in full of the Guaranteed Obligations. The Guarantor agrees that for so long as any Guaranteed Obligation is due and payable to the Seller, the Guarantor will not demand, sue for or otherwise attempt to collect any such indebtedness of the Buyer to the Guarantor until such Guaranteed Obligations shall have been paid in full.

 

This guaranty shall remain in full force and effect until payment in full of any and all Guaranteed Obligations of the Buyer to the Seller, at which time it shall terminate. This guaranty shall continue to be effective or be reinstated, notwithstanding the foregoing, if at any time any payment made or value received with respect to the Guaranteed Obligations is rescinded, invalidated, declared to be fraudulent or preferential, or set aside or is required to be repaid to a trustee, receiver or any other party under any case or proceeding, voluntary or involuntary, for the distribution, division or application of all or part of the assets of the Buyer or the Guarantor or the proceeds thereof, whether such case or proceeding be for the liquidation, dissolution or winding up of the Buyer or the Guarantor or their respective businesses, a receivership, insolvency or bankruptcy case or proceeding, an assignment for the benefit of creditors or a proceeding by or against the Buyer or the Guarantor for relief under the federal Bankruptcy Code or any other bankruptcy, reorganization or insolvency law or any other law relating to the relief of debtors, readjustment of indebtedness, reorganization, arrangement, composition or extension or marshaling of assets or otherwise, all as though such payment had not been made or value received.

 

[Signature page follows.]

 

 
 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.

 

BUYER: SYNERGY STRIPS CORP.  
   
By: /s/ Jack Ross  
Name: Jack Ross  
Title: CEO  
     
SELLER: FACTOR NUTRITION LABS, LLC  
   
By: /s/ Paul Levinsohn  
Name: Paul Levinsohn  
Title: Principal/CEO  
     
PRINCIPAL OWNERS:  
   
VITA PARTNERS, LLC  
   
By: /s/Jack Dushey  
Name: Jack Dushey  
Title:    
     
RPR PARTNERS, LLC  
   
By: /s/ Paul Levinsohn  
Name: Paul Levinsohn  
Title: Manager  
     
THOR ASSOCIATES, INC.  
     
By: /s/ Fern Lee  
Name: Fern Lee  
Title: CEO  
     
GUARANTOR  
     
By: /s/ Jack Ross  
Name: Jack Ross  

 

 
 

 

Omitted Exhibits and Schedules*

 

EXHIBITS

Exhibit A – Bill of Sale

Exhibit B – Pledge Agreement

SCHEDULES

Schedule A – Aged Receivables By Customer Code

Schedule B – Excluded Seller Assets

Schedule C – Files and Records

Schedule D – Inventory

Schedule E – Fixed Assets

Schedule F – Tangible Personal Property

Schedule 2.4 – Permitted Liens

Schedule 2.4(i) – Accounts Payable

Schedule 2.4(ii) – Assigned Contracts

Schedule 5.4 – Consents and Approvals

Schedule 5.5 – Financial Statements

Schedule 5.6 – Absence of Certain Changes or Events

Schedule 5.7 – Tax Returns

Schedule 5.8 – Assumed Liabilities

Schedule 5.9 – Licensed Intellectual Property

Schedule 5.9(a) – Domain Names

Schedule 5.10 – Permits

Schedule 5.12 – Assigned Contracts

Schedule 5.13 – Title to Purchased Property

Schedule 5.14 – Brokerage

Schedule 5.16(a) – Employee List

Schedule 5.16(b) – Employees

Schedule 5.16(c) – FLSA

Schedule 5.16(e) – Employment Contracts

Schedule 5.17 – Contractor Matters

Schedule 5.18(a) – Employee Benefit Plans

Schedule 5.18(d) – Section 409A Plans

Schedule 5.20(a) – Leased Real Property

Schedule 5.23 – Clients and Vendors

Schedule 5.26 – Accounts Receivable; Inventories

Schedule 6.3 – Buyer’s Consents and Approvals

* The listed exhibits and schedules have been omitted from this Exhibit 2.3 pursuant to Item 601(b)(2) of Regulation S-K. Synergy Strips Corp. hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC.

 

 

 

 

Exhibit 2.3

 

ASSET PURCHASE AGREEMENT

 

THIS AGREEMENT is made and dated as of June 26, 2015.

 

BETWEEN: Neuragen Corp., a corporation formed under the laws of the State of Delaware;
   
  (the “Purchaser”)
   
AND: KNIGHT THERAPEUTICS INC., a corporation formed under the laws of Canada;
   
  (“Knight”)

RECITALS

 

(A) WHEREAS Knight was a secured creditor of Origin Biomed Inc. (“Origin”);
   
(B) WHEREAS on April 7, 2015 by Order of the Supreme Court of Nova Scotia (the “Court”) and on the application of Knight, Grant Thornton Limited (“GTL”) was appointed Receiver of Origin;
   
(C) WHEREAS by Order dated June 4, 2015, the Court authorized GTL to convey the right, title and interest in certain of the property of Origin to Knight (a copy of the said Order and any related receiver reports being attached hereto as Schedule A);
   
(D) WHEREAS by agreement dated June 24, 2015, GTL conveyed such property, including the Purchased Assets, to Knight (a copy of the said agreement being attached hereto as Schedule B);
   
(E) WHEREAS the Purchaser desires to purchase and Knight desires to sell the Purchased Assets as herein defined;
   
(F) WHEREAS the Parties wish to enter into this Agreement, all on the terms and conditions set out herein.

 

NOW, THEREFORE, in consideration of these premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby covenant, contract and agree as follows:

 

1. DEFINED TERMS

 

1.1 For the purposes of this Agreement, unless the context otherwise requires, the following terms shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:

 

Affiliate” means any corporation or entity which is directly or indirectly controlled by, or controls or is under common control with, another corporation or entity, provided that “control” shall mean ownership as to more than fifty percent (50%) of another corporation or entity or the power to direct decisions of another corporation or entity, including, without limitation, the power to direct management and policies of another corporation or entity, whether by reason of ownership, by contract or otherwise;

 

Agreement” means this Asset Purchase Agreement and all schedules, exhibits and instruments supplemental hereto or in amendment or confirmation hereof.

 

Confidential Information” shall mean, with respect to a Party (the “Receiving Party”), all information, which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, licensees or sublicensees (“Representatives”), except to the extent that such information, (i) as of the date of disclosure is demonstrably known to the Receiving Party or its Representatives, as shown by written documentation, other than by virtue of a prior confidential disclosure to such Party or its Representatives by the Disclosing Party; (ii) as of the date of disclosure is in, or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (iii) is obtained by the Receiving Party or its Representatives from a third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing Party; or (iv) is independently developed by or for the Receiving Party or its Representatives without reference to or reliance upon any Confidential Information of the Disclosing Party as demonstrated by competent written records.

 

     
 

 

Effective Date” shall mean the date hereof.

 

Know How” means any and all technical information, trade secrets, formulas, prototypes, specifications, directions, instructions, test protocols, procedures and results, studies, analyses, raw material sources, data, manufacturing data, formulation or production technology, conceptions, ideas, innovations, discoveries, inventions, processes, methods, materials, machines, devices, formulae, equipment, enhancements, modifications, technological developments, techniques, systems, tools, designs, drawings, plans, software, documentation, data, programs and other knowledge, information, skills and materials controlled or owned by Knight as at the date hereof and pertaining to the Products, and any modifications, variations, derivative works and improvements of or relating to any of the foregoing owned and controlled by Knight as at the date hereof.

 

IP Agreement” means that certain agreement dated October 18, 2009 between Neuroquest and Origin, as amended, copies of which are attached in Schedule I.

 

Liens” shall mean any security, interest, mortgage, pledge or other encumbrance.

 

“Losses” means losses, damages, liabilities, deficiencies, actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers.

 

LSU Agreement” means that certain agreement dated March 26, 2004 between Origin and the Louisiana State University Agricultural and Mechanical College, copy of which is attached in Schedule I.

 

Net Sales” means the gross amounts invoiced by or on behalf of the Purchaser and its Affiliates for sales of the Products to third parties that are not Affiliates of the Purchaser in bona fide, arm’s-length transactions, less the following deductions if and to the extent they are (i) determined in accordance with the Purchaser’s accounting standards which are in accordance with IFRS, (ii) actually taken by the Purchaser or its Affiliates, and (iii) included in the gross invoiced sales price of the Products or otherwise directly paid or incurred by the Purchaser or its Affiliates with respect to the sale of the Products:

 

  (a) cash discounts;
     
  (b) rebates;
     
  (c) direct to customer discounts and coupons;
     
  (d) charge-backs;
     
  (e) bad debt;
     
  (f) amounts repaid or credited by reasons of defects, rejections, recalls, returns; and
     
  (g) tariffs, duties, excise, sales, value-added and other similar taxes (other than taxes based on income).

 

Neuroquest” means Neuroquest Inc.

 

Parties” means Knight and the Purchaser, collectively, and “Party” means either of them.

 

Products” means the products and formulas listed in Schedule C.

 

     
 

 

Purchased Assets” means and comprises, as of the Effective Date, all right, title and interest of Knight in, to and under the following properties, assets and rights to the extent that such properties, assets and rights relate to the manufacturing (if applicable), marketing, promotion, sale and distribution of the Products exclusively in the Territory:

 

  (a) rights to the registered marks listed on Schedule D, and to the patents pending listed on Schedule D and all goodwill appurtenant thereto, applications, renewals and registrations thereof and all common law rights relating to the Territory therein;
     
  (b) any and all domain names and addresses and websites related exclusively to the Products in the Territory, including the domain names listed on Schedule D;
     
  (c) all finished goods, raw materials, and packaging material inventory of the Products to be used exclusively for sale in the Territory;
     
  (d) all accounts receivable relating to the sales of the Products in the Territory, as listed on Schedule E;
     
  (e) all prepaid expenses or deposits that would be to the benefit of the Purchaser in respect of the sale of the Products in the Territory, as listed on Schedule F;
     
  (f) all books and records (including customer lists) pertaining to the sale of the Products in the Territory in Knight’s possession or control, provided that where such books and records are not exclusive to the Territory, copies shall be provided;
     
  (g) the rights to the clinical trials in respect of the Products described in Schedule G, it being acknowledged and agreed by the Purchaser that Knight shall retain corresponding rights to such clinical trials for outside of the Territory;
     
  (h) those orders for the purchase of Products for the Territory that have been shipped but not yet invoiced, being those listed in Schedule H;
     
  (i) all data and know-how (including relating to formulation of the Products) and other intellectual property rights in Knight’s possession and control to the extent that these are exclusively related to the manufacture, use or sale of the Products in the Territory;
     
  (j) all personnel files related to the individuals described in Section 3.4 to the extent in Knight’s possession or control and to the extent such individuals are hired by the Purchaser;
     
  (k) all claims of Knight against third parties related to the Products in the Territory and the assets described in this definition, whether known or unknown, choate or inchoate, contingent or non-contingent; and
     
  (l) the goodwill and going concern value with respect to the assets described in subsections (a) through (k) above.

 

Royalty Payment” has the meaning ascribed thereto in Section 2.3.

 

Share Agreement” means that certain agreement dated December 21, 2011 between Origin, Neuroquest and Neurodyn Inc., as amended, copies of which are attached in Schedule I.

 

Territory” means the United States, including all states contained therein and Puerto Rico and the U.S. Virgin Islands.

 

     
 

 

1.2 Schedules

 

  Schedule A Court Order
  Schedule B Purchase Agreement
  Schedule C Products
  Schedule D Patents Pending
  Schedule E Accounts Receivable
  Schedule F Prepaid Expenses or Deposits
  Schedule G Clinical Trials
  Schedule H Orders of Products
  Schedule I License Agreements
  Schedule J Current Assets and Liabilities

 

2. PURCHASE AND SALE

 

2.1 Purchased Assets: Subject to the provisions of this Agreement, Knight hereby sells, assigns and transfers to the Purchaser and the Purchaser hereby purchases from Knight, as of the Effective Date, the Purchased Assets.
   
2.2 Consideration. The consideration payable by the Purchaser for the Purchased Assets shall be:

 

  2.2.1 the amount of US$250,000 payable upon the execution of this Agreement;
     
  2.2.2 the amount of US$250,000 payable on or before June 30, 2016;
     
  2.2.3 the amount of US$700,000 payable in installments (i) in respect of the period ending September 30, 2015 and (ii) for each three month period thereafter (December 31, March 31, June 30, September 30) equal to the greater of (x) five percent (5%) of Net Sales for that period, and (y) US$12,500; and
     
  2.2.4 commencing from the payment in full of the amount of US$700,000 as set forth in Section 2.2.3 above, and for the sixty (60) months thereafter, an amount equal to two percent (2%) of Net Sales for that sixty (60) month period. Payments under this Section 2.2.4 shall accrue and be payable on a quarterly basis;

(collectively, the “Total Consideration”)

 

2.3 Royalty Payment: The obligations set forth in Sections 2.2.3 and 2.2.4 (the “Royalty Payments”), together with the reporting obligations set forth in Section 6 below, shall bind all sublicensees, assignees and other successors and assigns of the Purchaser.
   
2.4 Rights Reserved by Knight: Knight reserves to itself the right to market, sell, and distribute the Products outside the Territory. Knight recognizes and agrees that it has no right, title or license to market, sell or distribute the Products in the Territory, and that it will not grant any party the right, title or license to market, sell or distribute the Products in the Territory. To the extent required, the Purchaser hereby acknowledges that Knight may have the Products manufactured in the Territory for sale outside the Territory and Knight acknowledges that the Purchaser may have the Products manufactured outside the Territory for sale in the Territory.
   
2.5 Allocation of Purchase Price. Knight and the Purchaser shall cooperate in the preparation of a joint schedule allocating the purchase price among the Purchased Assets.

 

     
 

 

2.6 Closing. Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of Wyrick Robbins Yates & Ponton LLP, Raleigh, NC, at 10:00 a.m. EST, on June 26, 2015. At the Closing, Knight shall deliver to the Purchaser the following:

 

  2.6.1 A bill of sale in a form and substance satisfactory to the Purchaser, duly executed by Knight, transferred the tangible personal property in the Purchased Assets to the Purchaser; and
     
  2.6.2 Intellectual property assignments in form and substance satisfactory to the Purchaser and duly executed by Knight, transferring all of Knight’s right, title and interest in and to the intellectual property assets included in the Purchased Assets to the Purchaser.

 

3. LICENCE
   
3.1 Knight hereby grants to the Purchaser an exclusive, transferable, irrevocable, royalty-free (excluding any Royalty Payments required by this Agreement and the LSU Royalty), fully paid up perpetual right and licence or sublicense (as applicable) (with the right to sublicense), limited in all respects to the Territory, for and in respect to (i) the assets and rights described in paragraphs (a), (g) and (i) of the definition of Purchased Assets, (ii) the rights that Knight holds under the IP Agreement, the Share Agreement and/or the LSU Agreement, and (iii) all Know How, necessary for the manufacture, marketing, import, export, sale, distribution, and other exploitation of the Products in the Territory, including the distribution of the Products under private or non-Neuragen labels.
   
3.2 The Purchaser acknowledges that the Products are subject to the license obligations set forth in the agreements attached hereto as Schedule I and, to the extent applicable, agrees to assume such obligations in connection with the marketing, sale and distribution of the Products in the Territory, specifically excluding any royalty or payment obligations thereunder other than with respect to the LSU Agreement (the “LSU Royalty”). The Purchaser agrees to assume the royalty obligations (if any) payable to Louisiana State Agricultural and Mechanical College pursuant to the LSU Agreement. The LSU Royalty will be remitted by the Purchaser to Knight for payment to LSU.

 

4. Assumption of Liabilities AND OTHER MATTERS
   
4.1 Upon the terms and subject to the conditions set forth in this Agreement, with effect as of the Effective Date, the Purchaser hereby assumes, and agrees to pay, perform and discharge when due, and shall indemnify Knight and/or its Affiliates, as the case may be, from and against the following liabilities (the “Assumed Liabilities”):

 

  4.1.1 the accounts payable owing to C-Care in the amount of US$51,795;
     
  4.1.2 the liabilities described in Section 3.2 with respect to the contracts listed on Schedule I, to the extent applicable, but only to the extent such liabilities thereunder are required to be performed after the Closing and do not arise from any failure to perform, improper performance, warranty or other breach, default or violation by Knight on or prior to the Closing; and
     
  4.1.3 all allowances for customer returns in respect of Products sold in the Territory prior to the Effective Date and credits and other amounts owed to customers in respect of the sale of Products in the Territory prior to the Effective Date, not to exceed US$100,000.

 

Notwithstanding anything to the contrary in this Agreement, the Purchaser shall not assume and shall not be responsible to pay, perform, or discharge any liabilities of Knight or its Affiliates of any kind or nature whatsoever other than the Assumed Liabilities (the “Excluded Liabilities”), and Knight shall pay and satisfy in due course all Excluded Liabilities which they are obligated to pay and satisfy. Excluded Liabilities include, without limitation, any royalties payable to Neuroquest Inc. (other than the LSU Royalty).

 

     
 

 

4.2 The Parties agree that the aggregate book value of the assets described in paragraphs (c), (d) and (e) of the definition of “Purchased Assets” shall exceed the liabilities assumed and paid by the Purchaser under Section 4.1 by not less than US$75,000 as set forth on Schedule J hereto. To the extent that the finished goods inventory included in the Purchased Assets cannot be sold solely as a result of those finished goods being stale-dated, then Knight shall provide to the Purchaser raw materials of the Products with an equivalent book value to the stale-dated goods but only to the extent necessary to meet the said US$75,000 threshold. The Purchaser shall use reasonable commercial efforts to sell such inventory prior to selling new inventory. If, as of the date two hundred seventy (270) days from the date hereof, the US$75,000 threshold has not been met, then Knight shall pay the Purchaser the amount of the shortfall or at its option provide the Purchaser with raw materials of the Products with an equivalent book value.
   
4.3 Origin employed two (2) employees in the Territory, namely Mike Herb and Angela MacIntosh. The Purchaser shall indicate by notice in writing to Knight to be sent by July 15, 2015 whether or not it wishes to hire one, both or neither of such employees. For each such employee in respect of which the Purchaser declines to hire, Knight shall indemnify the Purchaser with respect to any severance or other costs arising from the termination of such employees’ employment with Origin or Knight. Should the Purchaser or its Affiliates rehire any such employee within one (1) year of the date hereof, it shall reimburse to Knight any severance or other termination costs incurred by Knight.
   
5. security
   
5.1 As security for the payment of the Total Consideration, the Purchaser shall, contemporaneously herewith, grant to Knight on terms and conditions satisfactory to Knight, an enforceable security charge and interest over certain of its assets, undertakings and property pursuant to a Security Agreement substantially in the form attached hereto as Exhibit A.
   
6. PAYMENT TERMS
   
6.1 Payment of Royalties. The Purchaser shall make the Royalty Payments owed to Knight hereunder within forty-five (45) days from the end of each quarterly period in which such payment accrues. For greater certainty, the Parties agree that Royalty Payments shall accrue on the date of shipment of the Products by or on behalf of the Purchaser. Each Royalty Payment shall be accompanied by a report setting forth the sales of the Products in the Territory in the quarter covered by such statement, specifying the Net Sales, if any and the royalties payable with respect thereto.
   
6.2 Accounting. All payments hereunder shall be made in United States dollars.
   
6.3 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one percent (1%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
6.4 Taxes. All payments paid by the Purchaser to Knight under this Agreement are exclusive of, and the Purchaser shall pay any sales, use, rental, custom, value added, consumption or other taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement, provided, however, that the Purchaser shall in no event be responsible or liable for any income taxes attributable to Knight. All payments contemplated under this Section 6.4 shall be supported by a valid receipt for any tax withholding from the appropriate taxing authorities, as well as any other documentation required by the Canada Revenue Agency, the Internal Revenue Service, or any other taxing authority, for the purpose of obtaining an income tax deduction and/or tax credit for Knight. The Parties shall cooperate with each other by providing information to the other Party, as may be reasonably requested by the other Party, for use in connection with making any withholdings and/or in obtaining any tax deduction and/or tax credits hereunder. Without limiting the generality of the foregoing, the Parties agree to execute certain forms required by the States of Maryland and New Jersey to be presented at Closing.

 

     
 

 

6.5 Records Retention; Review

 

  6.5.1 Payments. The Purchaser and its Affiliates shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate records of sales by the Purchaser or its Affiliates, as the case may be, of the Products and in sufficient detail to allow the accuracy of the payments hereunder to be confirmed.
     
  6.5.2 Review. At the request of Knight, upon at least ten (10) business days’ prior written notice from Knight, and at the expense of Knight (except as otherwise provided herein), the Purchaser shall permit Knight or its representative to inspect (during regular business hours) the relevant records required to be maintained by the Purchaser and its Affiliates under this Section 6.5. Knight shall be entitled to review the then-preceding four (4) years of records required to be maintained by the Purchaser and its Affiliates under this Section 6.5 solely for purposes of verifying the Purchaser’s calculations. If any review reveals a deficiency in the calculation of payments resulting in an underpayment by the Purchaser, the Purchaser shall promptly pay Knight the amount remaining to be paid and, if such underpayment is by five percent (5%) or more for any one-year period, the Purchaser shall pay the reasonable documented out-of-pocket expenses of the review.
     
  6.5.3 Other Parties. Each Party shall include in any agreement with its Affiliates or third parties, terms requiring such party to assume the Royalty Payments and LSU Royalty and to retain records as required in this Section 6.5 and to permit the other Party to inspect such records as required by this Section 6.5.

 

7. MANUFACTURING AND FORMULATION
   
7.1 The Purchaser acknowledges that the Products are currently sourced through C-Care Company of Linthicum Heights, MD, as contract manufacturer, and that there is no formal manufacturing or supply agreement in place with C-Care. Each of the Purchaser and Knight agree to use reasonable commercial efforts to coordinate with one another in respect of sourcing the Products (through C-Care or otherwise) with the intention of obtaining volume and other discounts and efficiencies (batch sizes, validation charges, etc.), provided that neither Party is obliged to source Products together.
   
7.2 The Parties agree that at Knight’s request the Products shall be reformulated in a manner that excludes the use of geraniol. Knight shall initiate and lead such reformulation process in consultation with the Purchaser. Knight and the Purchaser shall share all of the costs of such reformulation equally. For greater certainty, the Purchaser will be entitled to such reformulated Products and the rights thereto solely in respect to the Territory and Knight will be so entitled everywhere outside the Territory. Upon any reformulation described in this Section 7.2, Knight and the Purchaser agree to enter into a separate agreement regarding the details of such reformulation. The Parties further agree to consult with one another with respect to any additional reformulation of the Products with the intention that they will cost share and have exclusive rights to the reformulated Product in their respective territories as above.
   
7.3 Should either Party at any time or from time to time wish to extend or add to the products sold under the “Neuragen” trademark (such as a line extension) (a “New Product”) for their respective territories, they shall offer the opportunity to the other to market and sell the New Product in its own territory, which offer shall include the proposed details (including proposed cost sharing or other financial terms for the new offering). The Parties shall negotiate in good faith for a period of not less than thirty (30) days after which the offering party may withdraw the offer.

 

     
 

 

8. REPRESENTATIONS AND WARRANTIES OF SYNERGY
   
8.1 The Purchaser represents and warrants to Knight that, as of the Effective Date:

 

  8.1.1 The Purchaser is duly organized, validly existing, and in good standing under the laws of the State of Delaware.
     
  8.1.2 The Purchaser has all necessary power, authority and capacity and is properly authorized to enter into this Agreement and to perform its obligations hereunder. The execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by it and its directors and the Agreement is a legal and binding obligation of the Purchaser, enforceable against the Purchaser by Knight in accordance with its terms except as enforcement may be limited by bankruptcy, insolvency and other laws affecting the rights of creditors generally and except that equitable remedies may be granted only in the discretion of a court of competent jurisdiction;
     
  8.1.3 The execution, delivery, and performance of this Agreement by the Purchaser does not, and the consummation of the transactions contemplated herein will not, violate any provisions of the Purchaser’s organizational documents, any Law or regulation applicable to the Purchaser, or any agreement, mortgage, lease, instrument, order, judgment, or decree to which the Purchaser is a party or is bound.
     
  8.1.4 No consent or approval of, or filing with or notice to, any federal, state, provincial, or local regulatory authority, agency, or department or any other person not a party to this Agreement to which the Purchaser is a party is required or necessary to be obtained by the Purchaser or on its behalf in connection with the execution, delivery, and performance of this Agreement or to consummate the transactions contemplated hereby or thereby.

 

9. REPRESENTATIONS AND WARRANTIES OF KNIGHT
   
9.1 Knight represents and warrants to the Purchaser that, as of the Effective Date:

 

  9.1.1 Knight is duly organized, validly existing, and in good standing under the laws of Canada.
     
  9.1.2 Knight has all necessary corporate power, authority and capacity and is properly authorized to enter into this Agreement and to perform its obligations hereunder. The execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all necessary actions of it, its shareholders, and its directors and the Agreement is a legal and binding obligation of Knight, enforceable against Knight by the Purchaser in accordance with its terms except as enforcement may be limited by bankruptcy, insolvency and other laws affecting the rights of creditors generally and except that equitable remedies may be granted only in the discretion of a court of competent jurisdiction;
     
  9.1.3 The execution, delivery, and performance of this Agreement by Knight, including the sale and assignment of the Purchased Assets to the Purchaser, does not, and the consummation of the transactions contemplated herein will not (a) violate any provisions of Knight’s organizational documents, bylaws, any Law or regulation applicable to Knight, or any agreement, mortgage, lease, instrument, order, judgment, or decree to which Knight is a party or is bound; or (b) require the consent, notice or other action by any person under, conflict with, result in a violation or breach of, constitute a default under or result in the acceleration of any contract.
  9.1.4 To the best of Knight’s knowledge, no consent or approval of, or filing with or notice to, any federal, state, provincial, or local regulatory authority, agency, or department or any other person not a party to this Agreement is required or necessary to be obtained by Knight or on its behalf in connection with the execution, delivery, and performance of this Agreement or to consummate the transactions contemplated hereby or thereby.

 

     
 

 

  9.1.5 Knight is the owner of and has good, valid, and marketable legal title to the Purchased Assets free and clear of all Liens. The Purchaser acknowledges that Knight’s title thereto is derived from and limited by the proceedings and agreements referred to in the Recitals hereto.
     
  9.1.6 Except as described in the Recitals hereto, there are no claims, actions, suits, proceedings, complaints, or investigations pending, or to the knowledge of Knight, threatened, before any federal, state, provincial or local court or government or regulatory authority, or before any arbitrator of any nature, brought by or against Knight or any of its Affiliates involving, affecting, or related to the Purchased Assets.
     
  9.1.7 The Purchased Assets, along with the licenses granted in Section 3.2, constitute all of the rights, property and assets in Knight’s possession or control with respect to the manufacture and distribution of the Products in the Territory.
     
  9.1.8 To the best of Knight’s knowledge, no action, suit, proceeding, or audit is pending against or with respect to the any of the Purchased Assets regarding taxes.

 

10. DISCLAIMER OF WARRANTIES.
   
10.1 EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, EACH OF the Purchaser AND Knight HEREBY DISCLAIMS ALL CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT OF THE SUBJECT MATTER OF THIS AGREEMENT, WHETHER EXPRESS OR IMPLIED, BY STATUTE, CUSTOM OF THE TRADE OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF ANY PURCHASED ASSETS, THE PRODUCTS, THEIR MERCHANTABILITY OR THEIR FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS) AND ANY SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY DISCLAIMED BY EACH OF SYNERGY AND KNIGHT AND EXCLUDED.
   
11. INDEMNIFICATION. The representations and warranties contained herein shall survive the Closing and shall remain in full force and effect for a period of twelve (12) months. Knight shall indemnify and defend each of the Purchaser and its Affiliates and their respective representatives (collectively, the “Synergy Indemnitees”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Synergy Indemnitees based upon, arising out of, with respect to or by reason of:
   
  (a) any inaccuracy in or breach of any of the representations or warranties of Knight contained in this Agreement, the other transaction documents related to this Agreement or in any certificate or instrument delivered by or on behalf of Knight pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
   
  (b) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Knight pursuant to this Agreement, the other transaction documents related to this Agreement or any certificate or instrument delivered by or on behalf of Knight pursuant to this Agreement;
   
  (c) The Purchaser agrees that Knight’s liability for any breach of any condition, warranty or statement in respect of this Agreement or at law shall not exceed the consideration actually received by it pursuant to Section 2.2 above. The Purchaser shall be permitted any offset any Losses payable to it under this Section 11 against amounts otherwise payable by the Purchaser to Knight hereunder.

 

     
 

 

12. GENERAL
   
12.1 Other Expenses. Each of Knight and Purchaser will bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the transactions contemplated hereby.
   
12.2 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether written or oral. There are no conditions, covenants, agreements, representations, warranties or other provisions, express or implied, collateral, statutory or otherwise, relating to the subject matter hereof except as herein provided.
   
12.3 Governing Law; Exclusive Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State New York applicable to contracts made and to be performed wholly within the State of New York, without regard to the conflict of laws principles thereof. The Parties expressly reject the application of the United Nations Convention on Contracts for the International Sale of Goods and all implementing legislation thereunder. The Parties hereby consent to the exclusive jurisdiction of the Federal and New York State courts located in Manhattan, New York and hereby waive any objection to venue or forum laid therein. The Parties hereby agree that service of process by certified mail, return receipt requested, shall constitute personal service for all purposes hereof.

 

12.4 Counterparts; Facsimile Signature. This Agreement may be executed in one or more counterparts, and all such counterparts shall be deemed to be part of one and the same original. One or more counterparts of this Agreement may be delivered via electronic means, with the intention that they shall have the same effect as an original counterpart hereof.
   
12.5 Confidentiality. Knight and the Purchaser acknowledge that each Party will be exposed to certain Confidential Information of the other Party. Knight and the Purchaser agree that Knight and its Affiliates, employees, agents and consultants, and the Purchaser and its Affiliates, employees, agents and consultants, will not use and will not disclose any Confidential Information of the other Party except in accordance with the provisions and for the purposes of this Agreement. In addition, neither Party will disclose any Confidential Information of the other Party to any Affiliate, employee, agent or consultant who does not have a need to know such Confidential Information.
   
12.6 Assignment. Neither party shall assign this Agreement or any part thereof without the prior written consent of the other party (which consent shall not be unreasonably withheld); provided, however, that the Purchaser and Knight, without such consent, may assign this Agreement to an Affiliate or in connection with the transfer or sale of substantially all of its business or assets to which this Agreement pertains, in the event of its merger or consolidation with another company. No such permitted assignment or other permitted transfer shall relieve the assigning or transferring party from its obligations hereunder. A change in ownership of either party shall not be construed as an assignment of this Agreement.
   
12.7 Successors in Interest. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their subsidiaries, affiliates, successors and permitted assigns. Assignment to an affiliate or subsidiary shall not release the party making such assignment from responsibility for its obligations under this Agreement.

 

(Signatures on next page)

 

     
 

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.

 

  Neuragen Corp.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: President and Chief Executive Officer
     
  Knight therapeutics inc.
     
  By: /s/ Jeffrey Kadanoff
  Name: Jeffrey Kadanoff
  Title: Chief Financial Officer

 

     
 

 

Omitted Exhibits and Schedules*

 

EXHIBITS

 

  Exhibit A Security Agreement

 

SCHEDULES

 

  Schedule A Court Order
  Schedule B Purchase Agreement
  Schedule C Products
  Schedule D Patents Pending
  Schedule E Accounts Receivable
  Schedule F Prepaid Expenses or Deposits
  Schedule G Clinical Trials
  Schedule H Orders of Products
  Schedule I License Agreements
  Schedule J Current Assets and Liabilities

 

* The listed exhibits and schedules have been omitted from this Exhibit 2.4 pursuant to Item 601(b)(2) of Regulation S-K. Synergy Strips Corp. hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC.

 

     

 

 

Exhibit 3.1

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

Exhibit 3.2

 

BYLAWS

OF

ORO CAPITAL CORPORATION

 

I. SHAREHOLDER’S MEETING.

 

.01 Annual Meetings.

 

The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may come before it, shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notice of the meeting, on the first week in November of each and every year, at 1:00 p.m., commencing in 2009 but in case such day shall be a legal holiday, the meeting shall be held at the same hour and place on the next succeeding day not a holiday.

 

.02 Special Meeting.

 

Special meetings of the shareholders of this Corporation may be called at any time by the holders of ten percent (10%) of the voting shares of the Corporation, or by the President, or by the Board of Directors or a majority thereof. No business shall be transacted at any special meeting of shareholders except as is specified in the notice calling for said meeting. The Board of Directors may designate any place, either within or without the State of Nevada, as the place of any special meeting called by the president or the Board of Directors, and special meetings called at the request of shareholders shall be held at such place in the State of Nevada, as may be determined by the Board of Directors and placed in the notice of such meeting.

 

.03 Notice of Meeting.

 

Written notice of annual or special meetings of shareholders stating the place, day, and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called shall be given by the secretary or persons authorized to call the meeting to each shareholder of record entitled to vote at the meeting. Such notice shall be given not less than ten (10) nor more than fifty (50) days prior to the date of the meeting, and such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his/her address as it appears on the stock transfer books of the Corporation.

 

.04 Waiver of Notice.

 

Notice of the time, place, and purpose of any meeting may be waived in writing and will be waived by any shareholder by his/her attendance thereat in person or by proxy. Any shareholder so waiving shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.

 

.05 Quorum and Adjourned Meetings.

 

A majority of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. A majority of the shares represented at a meeting, even if less than a quorum, may adjourn the meeting from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. The shareholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.

 

.06 Proxies.

 

At all meetings of shareholders, a shareholder may vote by proxy executed in writing by the shareholder or by his/her duly authorized attorney in fact. Such proxy shall be filed with the secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven (11) months from the date of its execution, unless otherwise provided in the proxy.

 

 
 

 

.07 Voting of Shares.

 

Except as otherwise provided in the Articles of Incorporation or in these Bylaws, every shareholder of record shall have the right at every shareholder’s meeting to one (1) vote for every share standing in his/her name on the books of the Corporation, and the affirmative vote of a majority of the shares represented at a meeting and entitled to vote thereat shall be necessary for the adoption of a motion or for the determination of all questions and business which shall come before the meeting.

 

II. DIRECTORS.

 

.01 General Powers.

 

The business and affairs of the Corporation shall be managed by its Board of Directors.

 

.02 Number, Tenure and Qualifications.

 

The number of Directors of the Corporation shall be not less than one nor more than thirteen. Each Director shall hold office until the next annual meeting of shareholders and until his/her successor shall have been elected and qualified. Directors need not be residents of the State of Nevada or shareholders of the Corporation.

 

.03 Election.

 

The Directors shall be elected by the shareholders at their annual meeting each year; and if, for any cause the Directors shall not have been elected at an annual meeting, they may be elected at a special meeting of shareholders called for that purpose in the manner provided by these Bylaws.

 

.04 Vacancies.

 

In case of any vacancy in the Board of Directors, the remaining Directors, whether constituting a quorum or not, may elect a successor to hold office for the unexpired portion of the terms of the Directors whose place shall be vacant, and until his/her successor shall have been duly elected and qualified. Further, the remaining Directors may fill any empty seats on the Board of Directors even if the empty seats have never been occupied.

 

.05 Resignation.

 

Any Director may resign at any time by delivering written notice to the secretary of the Corporation.

 

.06 Meetings.

 

At any annual, special or regular meeting of the Board of Directors, any business may be transacted, and the Board may exercise all of its powers. Any such annual, special or regular meeting of the Board of Directors of the Corporation may be held outside of the State of Nevada, and any member or members of the Board of Directors of the Corporation may participate in any such meeting by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other at the same time; the participation by such means shall constitute presence in person at such meeting.

 

A. Annual Meeting of Directors.

 

Annual meetings of the Board of Directors shall be held immediately after the annual shareholders’ meeting or at such time and place as may be determined by the Directors. No notice of the annual meeting of the Board of Directors shall be necessary.

 

 
 

 

B. Special Meetings.

 

Special meetings of the Directors shall be called at any time and place upon the call of the president or any Director. Notice of the time and place of each special meeting shall be given by the secretary, or the persons calling the meeting, by mail, radio, telegram, or by personal communication by telephone or otherwise at least one (1) day in advance of the time of the meeting. The purpose of the meeting need not be given in the notice. Notice of any special meeting may be waived in writing or by telegram (either before or after such meeting) and will be waived by any Director in attendance at such meeting.

 

C. Regular Meetings of Directors.

 

Regular meetings of the Board of Directors shall be held at such place and on such day and hour as shall from time to time be fixed by resolution of the Board of Directors. No notice of regular meetings of the Board of Directors shall be necessary.

 

.07 Quorum and Voting.

 

A majority of the Directors presently in office shall constitute a quorum for all purposes, but a lesser number may adjourn any meeting, and the meeting may be held as adjourned without further notice. At each meeting of the Board at which a quorum is present, the act of a majority of the Directors present at the meeting shall be the act of the Board of Directors. The Directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough Directors to leave less than a quorum.

 

.08 Compensation.

 

By resolution of the Board of Directors, the Directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as Director. No such payment shall preclude any Director from serving the Corporation in any other capacity and receiving compensation therefor.

 

.09 Presumption of Assent.

 

A Director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless his/her dissent shall be entered in the minutes of the meeting or unless he/she shall file his/her written dissent to such action with the person acting as the secretary of the meeting before the adjournment thereof or shall forward such dissent by registered mail to the secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favor of such action.

 

.10 Executive and Other Committees.

 

The Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members an executive committee and one of more other committees, each of which, to the extent provided in such resolution, shall have and may exercise all the authority of the Board of Directors, but no such committee shall have the authority of the Board of Directors, in reference to amending the Articles of Incorporation, adoption a plan of merger or consolidation, recommending to the shareholders the sale, lease, exchange, or other disposition of all of substantially all the property and assets of the dissolution of the Corporation or a revocation thereof, designation of any such committee and the delegation thereto of authority shall not operate to relieve any member of the Board of Directors of any responsibility imposed by law.

 

 
 

 

.11 Chairman of Board of Directors.

 

The Board of Directors may, in its discretion, elect a chairman of the Board of Directors from its members; and, if a chairman has been elected, he/she shall, when present, preside at all meetings of the Board of Directors and the shareholders and shall have such other powers as the Board may prescribe.

 

.12 Removal.

 

Directors may be removed from office with or without cause by a vote of shareholders holding a majority of the shares entitled to vote at an election of Directors.

 

III. ACTIONS BY WRITTEN CONSENT.

 

Any corporate action required by the Articles of Incorporation, Bylaws, or the laws under which this Corporation is formed, to be voted upon or approved at a duly called meeting of the Directors or shareholders may be accomplished without a meeting if a written memorandum of the respective Directors or shareholders, setting forth the action so taken, shall be signed by all the Directors or shareholders, as the case may be.

 

IV. OFFICERS.

 

.01 Officers Designated.

 

The Officers of the Corporation shall be a president, one or more vice presidents (the number thereof to be determined by the Board of Directors), a secretary and a treasurer, each of whom shall be elected by the Board of Directors. Such other Officers and assistant officers as may be deemed necessary may be elected or appointed by the Board of Directors. Any Officer may be held by the same person, except that in the event that the Corporation shall have more than one director, the offices of president and secretary shall be held by different persons.

 

.02 Election, Qualification and Term of Office.

 

Each of the Officers shall be elected by the Board of Directors. None of said Officers except the president need be a Director, but a vice president who is not a Director cannot succeed to or fill the office of president. The Officers shall be elected by the Board of Directors. Except as hereinafter provide, each of said Officers shall hold office from the date of his/her election until the next annual meeting of the Board of Directors and until his/her successor shall have been duly elected and qualified.

 

.03 Powers and Duties.

 

The powers and duties of the respective corporate Officers shall be as follows:

 

A. President.

 

The president shall be the chief executive Officer of the Corporation and, subject to the direction and control of the Board of Directors, shall have general charge and supervision over its property, business, and affairs. He/she shall, unless a Chairman of the Board of Directors has been elected and is present, preside at meetings of the shareholders and the Board of Directors.

 

B. Vice President.

 

In the absence of the president or his/her inability to act, the senior vice president shall act in his place and stead and shall have all the powers and authority of the president, except as limited by resolution of the Board of Directors.

 

 
 

 

C. Secretary.

 

The secretary shall:

 

  1. Keep the minutes of the shareholder’s and of the Board of Directors meetings in one or more books provided for that purpose;
 
  2. See that all notices are duly given in accordance with the provisions of these Bylaws or as required by law;
 
  3. Be custodian of the corporate records and of the seal of the Corporation and affix the seal of the Corporation to all documents as may be required;
 
  4. Keep a register of the post office address of each shareholder which shall be furnished to the secretary by such shareholder;
 
  5. Sign with the president, or a vice president, certificates for shares of the Corporation, the issuance of which shall have been authorized by resolution of the Board of Directors;
 
  6. Have general charge of the stock transfer books of the corporation; and,
 
  7. In general perform all duties incident to the office of secretary and such other duties as from time to time may be assigned to him/her by the president or by the Board of Directors.

 

D. Treasurer.

 

Subject to the direction and control of the Board of Directors, the treasurer shall have the custody, control and disposition of the funds and securities of the Corporation and shall account for the same; and, at the expiration of his/her term of office, he/she shall turn over to his/her successor all property of the Corporation in his/her possession.

 

E. Assistant Secretaries and Assistant Treasurers.

 

The assistant secretaries, when authorized by the Board of Directors, may sign with the president or a vice president certificates for shares of the Corporation the issuance of which shall have been authorized by a resolution of the Board of Directors. The assistant treasurers shall, respectively, if required by the Board of Directors, give bonds for the faithful discharge of their duties in such sums and with such sureties as the Board of Directors shall determine. The assistant secretaries and assistant treasurers, in general, shall perform such duties as shall be assigned to them by the secretary or the treasurer, respectively, or by the president or the Board of Directors.

 

.04 Removal.

 

The Board of Directors shall have the right to remove any Officer whenever in its judgment the best interest of the Corporation will be served thereby.

 

.05 Vacancies.

 

The Board of Directors shall fill any office which becomes vacant with a successor who shall hold office for the unexpired term and until his/her successor shall have been duly elected and qualified.

 

.06 Salaries.

 

The salaries of all Officers of the Corporation shall be fixed by the Board of Directors.

 

 
 

 

V. SHARE CERTIFICATES

 

.01 Form and Execution of Certificates.

 

Certificates for shares of the Corporation shall be in such form as is consistent with the provisions of the Corporation laws of the State of Nevada. They shall be signed by the president and by the secretary, and the seal of the Corporation shall be affixed thereto. Certificates may be issued for fractional shares.

 

.02 Transfers.

 

Shares may be transferred by delivery of the certificates therefor, accompanied either by an assignment in writing on the back of the certificates or by a written power of attorney to assign and transfer the same signed by the record holder of the certificate. Except as otherwise specifically provided in these Bylaws, no shares shall be transferred on the books of the Corporation until the outstanding certificate therefor has been surrendered to the Corporation.

 

.03 Loss or Destruction of Certificates.

 

In case of loss or destruction of any certificate of shares, another may be issued in its place upon proof of such loss or destruction and upon the giving of a satisfactory bond of indemnity to the Corporation. A new certificate may be issued without requiring any bond, when in the judgment of the Board of Directors it is proper to do so.

 

VI. BOOKS AND RECORDS.

 

.01 Books of Accounts, Minutes and Share Register.

 

The Corporation shall keep complete books and records of accounts and minutes of the proceedings of the Board of Directors and shareholders and shall keep at its registered office, principal place of business, or at the office of its transfer agent or registrar a share register giving the names of the shareholders in alphabetical order and showing their respective addresses and the number of shares held by each.

 

.02 Copies of Resolutions.

 

Any person dealing with the Corporation may rely upon a copy of any of the records of the proceedings, resolutions, or votes of the Board of Directors or shareholders, when certified by the president or secretary.

 

VII. CORPORATE SEAL.

 

The Corporation is not required to have a corporate seal.

 

VIII. LOANS.

 

No loans shall be made by the Corporation to its Officers or Directors

 

IX. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

 

.01 Indemnification.

 

The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that such person is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgment, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action proceeding, had reasonable cause to believe that such person’s conduct was unlawful.

 

 
 

 

.02 Derivative Action

 

The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in the Corporation’s favor by reason of the fact that such person is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees) and amount paid in settlement actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to amounts paid in settlement, the settlement of the suit or action was in the best interests of the Corporation; provided, however, that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable for gross negligence or willful misconduct in the performance of such person’s duty to the Corporation unless and only to the extent that, the court in which such action or suit was brought shall determine upon application that, despite circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as such court shall deem proper. The termination of any action or suit by judgment or settlement shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation.

 

.03 Successful Defense.

 

To the extent that a Director, Trustee, Officer, employee or Agent of the Corporation has been successful on the merits or otherwise, in whole or in part in defense of any action, suit or proceeding referred to in Paragraphs .01 and .02 above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

 

.04 Authorization.

 

Any indemnification under Paragraphs .01 and .02 above (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the Director, Trustee, Officer, employee or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth in Paragraphs .01 and .02 above. Such determination shall be made (a) by the Board of Directors of the Corporation by a majority vote of a quorum consisting of Directors who were not parties to such action, suit or proceeding, or (b) is such a quorum is not obtainable, by a majority vote of the Directors who were not parties to such action, suit or proceeding, or (c) by independent legal counsel (selected by one or more of the Directors, whether or not a quorum and whether or not disinterested) in a written opinion, or (d) by the Shareholders. Anyone making such a determination under this Paragraph .04 may determine that a person has met the standards therein set forth as to some claims, issues or matters but not as to others, and may reasonably prorate amounts to be paid as indemnification.

 

.05 Advances.

 

Expenses incurred in defending civil or criminal action, suit or proceeding shall be paid by the Corporation, at any time or from time to time in advance of the final disposition of such action, suit or proceeding as authorized in the manner provided in Paragraph .04 above upon receipt of an undertaking by or on behalf of the Director, Trustee, Officer, employee or agent to repay such amount unless it shall ultimately be by the Corporation is authorized in this Section.

 

 
 

 

.06 Nonexclusivity.

 

The indemnification provided in this Section shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any law, bylaw, agreement, vote of shareholders or disinterested Directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a Director, Trustee, Officer, employee or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.

 

.07 Insurance.

 

The Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability assessed against such person in any such capacity or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability.

 

.08 “Corporation” Defined.

 

For purposes of this Section, references to the “Corporation” shall include, in addition to the Corporation, an constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had the power and authority to indemnify its Directors, Trustees, Officers, employees or agents, so that any person who is or was a Director, Trustee, Officer, employee or agent of such constituent corporation or of any entity a majority of the voting stock of which is owned by such constituent corporation or is or was serving at the request of such constituent corporation as a Director, Trustee, Officer, employee or agent of the corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section with respect to the resulting or surviving Corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

 

X. AMENDMENT OF BYLAWS.

 

.01 By the Shareholders.

 

These Bylaws may be amended, altered, or repealed at any regular or special meeting of the shareholders if notice of the proposed alteration or amendment is contained in the notice of the meeting.

 

.02 By the Board of Directors.

 

These Bylaws may be amended, altered, or repealed by the affirmative vote of a majority of the entire Board of Directors at any regular or special meeting of the Board.

 

XI. FISCAL YEAR.

 

The fiscal year of the Corporation shall be set by resolution of the Board of Directors.

 

XII. RULES OF ORDER.

 

The rules contained in the most recent edition of Robert’s Rules or Order, Newly Revised, shall govern all meetings of shareholders and Directors where those rules are not inconsistent with the Articles of Incorporation, Bylaws, or special rules or order of the Corporation.

 

XIII. REIMBURSEMENT OF DISALLOWED EXPENSES.

 

If any salary, payment, reimbursement, employee fringe benefit, expense allowance payment, or other expense incurred by the Corporation for the benefit of an employee is disallowed in whole or in part as a deductible expense of the Corporation for Federal Income Tax purposes, the employee shall reimburse the Corporation, upon notice and demand, to the full extent of the disallowance. This legally enforceable obligation is in accordance with the provisions of Revenue Ruling 69-115, 1969-1 C.B. 50, and is for the purpose of entitling such employee to a business expense deduction for the taxable year in which the repayment is made to the Corporation. In this manner, the Corporation shall be protected from having to bear the entire burden of disallowed expense items.

 

 

 

Exhibit 3.3

 

AMENDMENT TO

BYLAWS OF SYNERGY STRIPS CORP.

 

THIS AMENDMENT to the Bylaws of Synergy Strips Corp. (the “Corporation”) is dated as of the 22nd day of June 2015.

 

WHEREAS, the Board of Directors and shareholders of the Corporation have adopted the Bylaws of Synergy Strips Corp. (as amended, the “Bylaws”); and

 

WHEREAS, pursuant to Article X.01 of the Bylaws, the Bylaws may be amended by a majority of the Corporation’s Board of Directors (the “Board”) and the Board has approved amending the Bylaws to allow action by written consent of a majority of the shareholders.

 

NOW, THEREFORE, the Bylaws have been amended as follows:

 

  1. Article III shall be amended as follows:
     
    “Any corporate action required by the Articles of Incorporation, Bylaws, or the laws under which this Corporation is formed, to be voted upon or approved at a duly called meeting of the Directors or shareholders may be accomplished without a meeting if a written memorandum of the respective Directors or shareholders, setting forth the action so taken, shall be signed by all the Directors or shareholders holding a majority of the voting capital stock, as the case may be.”

 

IN WITNESS WHEREOF, the undersigned hereby certifies that this Amendment was duly adopted by the Board of Directors.

 

  SYNERGY STRIPS CORP.
   
  /s/ Jack Ross
  Jack Ross, President, Chief Executive Officer, Chief Financial Officer, Secretary

 

 

 

 

Exhibit 3.4

 

AMENDED AND RESTATED

BYLAWS

 

OF

 

SYNERGY CHC CORP.

f/k/a

SYNERGY STRIPS CORP.

 

I. SHAREHOLDER’S MEETING.

 

.01 Annual Meetings.

 

The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may come before it, shall be held at the registered office of the Corporation, or such other places, either within or without the State of Nevada, as may be designated by the notice of the meeting, on the first day of November of each and every year, at 1:00 p.m., commencing in 2009 but in case such day shall be a legal holiday, the meeting shall be held at the same hour and place on the next succeeding day not a holiday.

 

.02 Special Meeting.

 

Special meetings of the shareholders of this Corporation may be called at any time by the holders of ten percent (10%) of the voting shares of the Corporation, or by the President, or by the Board of Directors or a majority thereof. No business shall be transacted at any special meeting of shareholders except as is specified in the notice calling for said meeting. The Board of Directors may designate any place, either within or without the State of Nevada, as the place of any special meeting called by the president or the Board of Directors, and special meetings called at the request of shareholders shall be held at such place in the State of Nevada, as may be determined by the Board of Directors and placed in the notice of such meeting.

 

.03 Notice of Meeting.

 

Written notice of annual or special meetings of shareholders stating the place, day, and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called shall be given by the secretary or persons authorized to call the meeting to each shareholder of record entitled to vote at the meeting. Such notice shall be given not less than ten (10) nor more than fifty (50) days prior to the date of the meeting, and such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his/her address as it appears on the stock transfer books of the Corporation.

 

Page 1 of 12
 

 

.04 Waiver of Notice.

 

Notice of the time, place, and purpose of any meeting may be waived in writing and will be waived by any shareholder by his/her attendance thereat in person or by proxy. Any shareholder so waiving shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.

 

.05 Quorum and Adjourned Meetings.

 

A majority of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. A majority of the shares represented at a meeting, even if less than a quorum, may adjourn the meeting from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. The shareholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.

 

.06 Proxies.

 

At all meetings of shareholders, a shareholder may vote by proxy executed in writing by the shareholder or by his/her duly authorized attorney in fact. Such proxy shall be filed with the secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven (11) months from the date of its execution, unless otherwise provided in the proxy.

 

.07 Voting of Shares.

 

Except as otherwise provided in the Articles of Incorporation or in these Bylaws, every shareholder of record shall have the right at every shareholder’s meeting to one (1) vote for every share standing in his/her name on the books of the Corporation, and the affirmative vote of a majority of the shares represented at a meeting and entitled to vote thereat shall be necessary for the adoption of a motion or for the determination of all questions and business which shall come before the meeting.

 

II. DIRECTORS.

 

.01 General Powers.

 

The business and affairs of the Corporation shall be managed by its Board of Directors.

 

Page 2 of 12
 

 

.02 Number, Tenure and Qualifications.

 

The number of Directors of the Corporation shall be not less than one nor more than thirteen. Each Director shall hold office until the next annual meeting of shareholders and until his/her successor shall have been elected and qualified. Directors need not be residents of the State of Nevada or shareholders of the Corporation. The Board of Directors shall consist of two persons; however, the number of Directors may be changed at any time by shareholders holding at least a majority of the voting capital stock.

 

.03 Election.

 

The Directors shall be elected by the shareholders at their annual meeting each year; and if, for any cause the Directors shall not have been elected at an annual meeting, they may be elected at a special meeting of shareholders called for that purpose in the manner provided by these Bylaws.

 

.04 Vacancies.

 

In case of any vacancy in the Board of Directors, and such vacancy is not filled by the shareholders within 90 days after the vacancy shall occur, the remaining Directors, whether constituting a quorum or not, may elect a successor to hold office for the unexpired portion of the terms of the Directors whose place shall be vacant, and until his/her successor shall have been duly elected and qualified. Further, the remaining Directors may fill any empty seats on the Board of Directors even if the empty seats have never been occupied.

 

.05 Resignation.

 

Any Director may resign at any time by delivering written notice to the secretary of the Corporation.

 

.06 Meetings.

 

At any annual, special or regular meeting of the Board of Directors, any business may be transacted, and the Board may exercise all of its powers. Any such annual, special or regular meeting of the Board of Directors of the Corporation may be held outside of the State of Nevada, and any member or members of the Board of Directors of the Corporation may participate in any such meeting by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other at the same time; the participation by such means shall constitute presence in person at such meeting.

 

Page 3 of 12
 

 

A. Annual Meeting of Directors.

 

Annual meetings of the Board of Directors shall be held immediately after the annual shareholders’ meeting or at such time and place as may be determined by the Directors. No notice of the annual meeting of the Board of Directors shall be necessary.

 

B. Special Meetings.

 

Special meetings of the Directors shall be called at any time and place upon the call of the president or any Director. Notice of the time and place of each special meeting shall be given by the secretary, or the persons calling the meeting, by mail, radio, email, or by personal communication by telephone or otherwise at least one (1) day in advance of the time of the meeting. The purpose of the meeting need not be given in the notice. Notice of any special meeting may be waived in writing or by telegram (either before or after such meeting) and will be waived by any Director in attendance at such meeting.

 

C. Regular Meetings of Directors.

 

Regular meetings of the Board of Directors shall be held at such place and on such day and hour as shall from time to time be fixed by resolution of the Board of Directors. No notice of regular meetings of the Board of Directors shall be necessary.

 

.07 Quorum and Voting.

 

A majority of the Directors presently in office shall constitute a quorum for all purposes, but a lesser number may adjourn any meeting, and the meeting may be held as adjourned without further notice. At each meeting of the Board at which a quorum is present, the act of a majority of the Directors present at the meeting shall be the act of the Board of Directors. The Directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough Directors to leave less than a quorum.

 

.08 Compensation.

 

By resolution of the Board of Directors, the Directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as Director. No such payment shall preclude any Director from serving the Corporation in any other capacity and receiving compensation therefor.

 

Page 4 of 12
 

 

.09 Presumption of Assent.

 

A Director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless his/her dissent shall be entered in the minutes of the meeting or unless he/she shall file his/her written dissent to such action with the person acting as the secretary of the meeting before the adjournment thereof or shall forward such dissent by certified mail, return receipt requested, to the secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favor of such action.

 

.10 Executive and Other Committees.

 

The Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members an executive committee and one of more other committees, each of which, to the extent provided in such resolution, shall have and may exercise all the authority of the Board of Directors, but no such committee shall have the authority of the Board of Directors, in reference to amending the Articles of Incorporation, adoption a plan of merger or consolidation, recommending to the shareholders the sale, lease, exchange, or other disposition of all of substantially all the property and assets for the dissolution of the Corporation or a revocation thereof, designation of any such committee and the delegation thereto of authority shall not operate to relieve any member of the Board of Directors of any responsibility imposed by law.

 

.11 Chairman of Board of Directors.

 

The Board of Directors may, in its discretion, elect a chairman of the Board of Directors from its members; and, if a chairman has been elected, he/she shall, when present, preside at all meetings of the Board of Directors and the shareholders and shall have such other powers as the Board may prescribe.

 

.12 Removal.

 

Directors may be removed from office with or without cause by a vote of shareholders holding a majority of the shares entitled to vote at an election of Directors.

 

III. ACTIONS BY WRITTEN CONSENT.

 

Any corporate action required by the Articles of Incorporation, Bylaws, or the laws under which this Corporation is formed, to be voted upon or approved at a duly called meeting of the Directors or shareholders may be accomplished without a meeting if a written memorandum of the respective Directors or shareholders, setting forth the action so taken, shall be signed by all the Directors or by shareholders holding a majority of the voting capital stock, as the case may be.

 

Page 5 of 12
 

 

IV. OFFICERS.

 

.01 Officers Designated.

 

The Officers of the Corporation shall be a president, one or more vice presidents (the number thereof to be determined by the Board of Directors), a secretary and a treasurer, each of whom shall be elected by the Board of Directors. Such other Officers and assistant officers as may be deemed necessary may be elected or appointed by the Board of Directors. Any Officer may be held by the same person, except that in the event that the Corporation shall have more than one director, the offices of president and secretary shall be held by different persons.

 

.02 Election, Qualification and Term of Office.

 

Each of the Officers shall be elected by the Board of Directors. None of said Officers except the president need be a Director, but a vice president who is not a Director cannot succeed to or fill the office of president. The Officers shall be elected by the Board of Directors. Except as hereinafter provide, each of said Officers shall hold office from the date of his/her election until the next annual meeting of the Board of Directors and until his/her successor shall have been duly elected and qualified.

 

.03 Powers and Duties.

 

The powers and duties of the respective corporate Officers shall be as follows:

 

A. President.

 

The president shall be the chief executive Officer of the Corporation and, subject to the direction and control of the Board of Directors, shall have general charge and supervision over its property, business, and affairs. He/she shall, unless a Chairman of the Board of Directors has been elected and is present, preside at meetings of the shareholders and the Board of Directors.

 

B. Vice President.

 

In the absence of the president or his/her inability to act, the senior vice president shall act in his place and stead and shall have all the powers and authority of the president, except as limited by resolution of the Board of Directors.

 

Page 6 of 12
 

 

C. Secretary.

 

The secretary shall:

 

 

1. Keep the minutes of the shareholder’s and of the Board of Directors meetings in one or more books provided for that purpose;

 

2. See that all notices are duly given in accordance with the provisions of these Bylaws or as required by law;

 

3. Be custodian of the corporate records and of the seal of the Corporation and affix the seal of the Corporation to all documents as may be required;

 

4. Keep a register of the post office address of each shareholder which shall be furnished to the secretary by such shareholder;

 

5. Sign with the president, or a vice president, certificates for shares of the Corporation, the issuance of which shall have been authorized by resolution of the Board of Directors;

 

6. Have general charge of the stock transfer books of the corporation; and,

 

7. In general perform all duties incident to the office of secretary and such other duties as from time to time may be assigned to him/her by the president or by the Board of Directors.

 

D. Treasurer.

 

Subject to the direction and control of the Board of Directors, the treasurer shall have the custody, control and disposition of the funds and securities of the Corporation and shall account for the same; and, at the expiration of his/her term of office, he/she shall turn over to his/her successor all property of the Corporation in his/her possession.

 

E. Assistant Secretaries and Assistant Treasurers.

 

The assistant secretaries, when authorized by the Board of Directors, may sign with the president or a vice president certificates for shares of the Corporation the issuance of which shall have been authorized by a resolution of the Board of Directors. The assistant treasurers shall, respectively, if required by the Board of Directors, give bonds for the faithful discharge of their duties in such sums and with such sureties as the Board of Directors shall determine. The assistant secretaries and assistant treasurers, in general, shall perform such duties as shall be assigned to them by the secretary or the treasurer, respectively, or by the president or the Board of Directors.

 

Page 7 of 12
 

 

.04 Removal.

 

The Board of Directors shall have the right to remove any Officer whenever in its judgment the best interest of the Corporation will be served thereby.

 

.05 Vacancies.

 

The Board of Directors shall fill any office which becomes vacant with a successor who shall hold office for the unexpired term and until his/her successor shall have been duly elected and qualified.

 

.06 Salaries.

 

The salaries of all Officers of the Corporation shall be fixed by the Board of Directors.

 

V. SHARE CERTIFICATES

 

.01 Form and Execution of Certificates.

 

Certificates for shares of the Corporation shall be in such form as is consistent with the provisions of the Corporation laws of the State of Nevada. They shall be signed by the president and by the secretary, and the seal of the Corporation shall be affixed thereto. Certificates may be issued for fractional shares.

 

.02 Transfers.

 

Shares may be transferred by delivery of the certificates therefor, accompanied either by an assignment in writing on the back of the certificates or by a written power of attorney to assign and transfer the same signed by the record holder of the certificate. Except as otherwise specifically provided in these Bylaws, no shares shall be transferred on the books of the Corporation until the outstanding certificate therefor has been surrendered to the Corporation.

 

.03 Loss or Destruction of Certificates.

 

In case of loss or destruction of any certificate of shares, another may be issued in its place upon proof of such loss or destruction and upon the giving of a satisfactory bond of indemnity to the Corporation. A new certificate may be issued without requiring any bond, when in the judgment of the Board of Directors it is proper to do so.

 

Page 8 of 12
 

 

VI. BOOKS AND RECORDS.

 

.01 Books of Accounts, Minutes and Share Register.

 

The Corporation shall keep complete books and records of accounts and minutes of the proceedings of the Board of Directors and shareholders and shall keep at its registered office, principal place of business, or at the office of its transfer agent or registrar a share register giving the names of the shareholders in alphabetical order and showing their respective addresses and the number of shares held by each.

 

.02 Copies of Resolutions.

 

Any person dealing with the Corporation may rely upon a copy of any of the records of the proceedings, resolutions, or votes of the Board of Directors or shareholders, when certified by the president or secretary.

 

VII. CORPORATE SEAL.

 

The Corporation is not required to have a corporate seal.

 

VIII. LOANS.

 

No loans shall be made by the Corporation to its Officers or Directors

 

IX. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

 

.01 Indemnification.

 

The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that such person is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgment, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action proceeding, had reasonable cause to believe that such person’s conduct was unlawful.

 

Page 9 of 12
 

 

.02 Derivative Action

 

The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in the Corporation’s favor by reason of the fact that such person is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees) and amount paid in settlement actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to amounts paid in settlement, the settlement of the suit or action was in the best interests of the Corporation; provided, however, that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable for gross negligence or willful misconduct in the performance of such person’s duty to the Corporation unless and only to the extent that, the court in which such action or suit was brought shall determine upon application that, despite circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as such court shall deem proper. The termination of any action or suit by judgment or settlement shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation.

 

.03 Successful Defense.

 

To the extent that a Director, Trustee, Officer, employee or Agent of the Corporation has been successful on the merits or otherwise, in whole or in part in defense of any action, suit or proceeding referred to in Paragraphs .01 and .02 above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith.

 

Page 10 of 12
 

 

.04 Authorization.

 

Any indemnification under Paragraphs .01 and .02 above (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the Director, Trustee, Officer, employee or agent is proper in the circumstances because such person has met the applicable standard of conduct set forth in Paragraphs .01 and .02 above. Such determination shall be made (a) by the Board of Directors of the Corporation by a majority vote of a quorum consisting of Directors who were not parties to such action, suit or proceeding, or (b) if such a quorum is not obtainable, by a majority vote of the Directors who were not parties to such action, suit or proceeding, or (c) by independent legal counsel (selected by one or more of the Directors, whether or not a quorum and whether or not disinterested) in a written opinion, or (d) by the Shareholders. Anyone making such a determination under this Paragraph .04 may determine that a person has met the standards therein set forth as to some claims, issues or matters but not as to others, and may reasonably prorate amounts to be paid as indemnification.

 

.05 Advances.

 

Expenses incurred in defending civil or criminal action, suit or proceeding shall be paid by the Corporation, at any time or from time to time in advance of the final disposition of such action, suit or proceeding as authorized in the manner provided in Paragraph .04 above upon receipt of an undertaking by or on behalf of the Director, Trustee, Officer, employee or agent to repay such amount unless it shall ultimately be determined that such expenses are properly payable by the Corporation as authorized in this Section.

 

.06 Nonexclusivity.

 

The indemnification provided in this Section shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any law, bylaw, agreement, vote of shareholders or disinterested Directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a Director, Trustee, Officer, employee or agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.

 

.07 Insurance.

 

The Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a Director, Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee, Officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability assessed against such person in any such capacity or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability.

 

Page 11 of 12
 

 

.08 “Corporation” Defined.

 

For purposes of this Section, references to the “Corporation” shall include, in addition to the Corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had the power and authority to indemnify its Directors, Trustees, Officers, employees or agents, so that any person who is or was a Director, Trustee, Officer, employee or agent of such constituent corporation or of any entity a majority of the voting stock of which is owned by such constituent corporation or is or was serving at the request of such constituent corporation as a Director, Trustee, Officer, employee or agent of the corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Section with respect to the resulting or surviving Corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

 

X. AMENDMENT OF BYLAWS.

 

.01 By the Shareholders.

 

These Bylaws may be amended, altered, or repealed at any regular or special meeting of the shareholders if notice of the proposed alteration or amendment is contained in the notice of the meeting.

 

.02 By the Board of Directors.

 

These Bylaws may be amended, altered, or repealed by the affirmative vote of a majority of the entire Board of Directors at any regular or special meeting of the Board, except for the number of Directors set forth in Article II.02, which may only be changed by the shareholders.

 

XI. FISCAL YEAR.

 

The fiscal year of the Corporation shall be set by resolution of the Board of Directors.

 

XII. RULES OF ORDER.

 

The rules contained in the most recent edition of Robert’s Rules or Order, Newly Revised, shall govern all meetings of shareholders and Directors where those rules are not inconsistent with the Articles of Incorporation, Bylaws, or special rules or order of the Corporation.

 

XIII. REIMBURSEMENT OF DISALLOWED EXPENSES.

 

If any salary, payment, reimbursement, employee fringe benefit, expense allowance payment, or other expense incurred by the Corporation for the benefit of an employee is disallowed in whole or in part as a deductible expense of the Corporation for Federal Income Tax purposes, the employee shall reimburse the Corporation, upon notice and demand, to the full extent of the disallowance. This legally enforceable obligation is in accordance with the provisions of Revenue Ruling 69-115, 1969-1 C.B. 50, and is for the purpose of entitling such employee to a business expense deduction for the taxable year in which the repayment is made to the Corporation. In this manner, the Corporation shall be protected from having to bear the entire burden of disallowed expense items.

 

Page 12 of 12

 

 

 

 

 

Exhibit 10.1

 

SALES AND MARKETING CONSULTANT AND DISTRIBUTION AGREEMENT

 

April 2, 2014

 

This will confirm the arrangement, terms and conditions pursuant to which Kenek Brands Inc (“Consultant”) has been retained to serve as a consultant and advisor to Synergy Strips Corp. (“the Company”). The undersigned hereby agree to the following terms and conditions:

 

1. Duties of Consultant The Consultant will provide such consulting services and advice pertaining to the Company’s business affairs as the Company may from time to time reasonably request. Consulting and advisory services shall take place at the mutual convenience of the Company and the Consultant. Without limiting the generality of the foregoing, Consultant will primarily assist the Company in developing, expanding and managing an extensive network of Broker/Sales/Retailers groups and aid in the strategic direction of the Company’s sales and planning.
   
2. Term of the Agreement The effective date of this Agreement shall be as of April 2, 2014. The term of this Agreement shall be for a one (1) year period and will be self-renewing at the end of the one (1) year period for an additional term unless otherwise terminated as set forth in this agreement prior to. Termination (as in paragraph 12) of this Agreement shall not affect the Company’s agreement to not circumvent Consultant or to indemnify Consultant (as in paragraphs 9 and 10).
   
3. Available Time Consultant shall make available such time as, in its sole discretion, it shall deem appropriate for the performance of its obligations under this Agreement. The Company acknowledges and agrees that Consultant will perform consulting or other services for other companies, subject to confidentiality agreement herein (paragraph 8).
   
4. Compensation As compensation for Consultant’s services hereunder, the Company shall pay to the Consultant as follows:

 

  a. Monthly Retainer Upon execution of the Agreement, the Company will advance the Consultant $9,000 USD on the 1st of each month until this agreement is mutually terminated subject to paragraph 12 herein.
     
  b. Sales Commission A two percent (2%) commission override will be paid on all product sales on products that Consultant or his sales agents or brokers introduce to the Company.
     
  c. Agreement Termination The termination of this Agreement (as in paragraph 11), shall not affect the payment of success compensation to Consultant as well as the share options described below in subparagraph (e) herein.
     
  d. Payment of Compensation At the end of each month, Consultant sales commission will be paid by the Company based on all sales generated as provided for in Section 4 (b).
     
  e. Share Options The Consultant will receive one (1) Million share options of the Company at a strike price of $0.25/per share which will vest in full upon signing of this agreement

 

5. Expenses The Company will reimburse the Consultant for all out of pocket expenses incurred to perform the duties set out in this agreement, specifically but not limited to travel, meals and lodging as required. The Company will establish an expense policy which will include that the Company will be required to reimburse Consultant at a minimum on a monthly basis or within seven days of receiving the Consultant’s expenses, whichever is earlier.

 

 
 

 

6. Relationship Nothing herein shall constitute Consultant as an employee or agent of the Company. It is understood that Consultant will be an independent contractor. Except to such extent as may hereinafter be expressly agreed for a specific purpose, Consultant shall not have the authority to obligate or commit the Company in any manner whatsoever. All decisions relating to products sold remain the sole responsibility of the Company (ingredients, packaging, pricing, shipping, financial, promotion, etc.)
   
7. Information The Company acknowledges the Consultant will rely on information furnished by the Company concerning the Company’s business affairs without independent certification, and the Company represents that such information will be materially complete and correct.
   
8.

Confidentiality Except in the course of the performance of duties hereunder, Consultant and the Company agree that both parties shall not disclose any trade secrets, know-how, or other proprietary information not in the public domain, learned as a result of this Agreement unless and until such information becomes generally known.

 

a. Unless Consultant or the Company comes under direct subpoena to disclose this information to a court.

 

9. Mutual Non-circumvention The Company and the Consultant agree to a mutual non-circumvention on all aspects of the business. The Company, its representatives, and other consultants agree not to approach parties introduced by Consultant, on behalf of other companies with which they may be involved, without permission and involvement of Consultant. The Company agrees that the list of contacts introduced by Consultant shall be deemed confidential, and shall not be disclosed in part or in whole by another party without Consultant’s express permission. The Consultant agrees to the exact same non-circumvention provisions as it pertains to anyone that the Company introduces to the Consultant and the Consultant is bound by the same non-circumvention provisions that the Company has agreed to as described in this paragraph.

 

10. Mutual Indemnification The Company and the Consultant agree to a mutual indemnification. The Consultant agrees to indemnify and hold harmless the Company, its partners, officers, directors, and employees, from the and against any losses, claims, damages, liabilities, and expenses whatsoever (including reasonable costs of investigation or defending any action) to which they or any of them may become subject under any applicable law arising out of Consultant’s performance under this Agreement. The Company agrees to indemnify the Consultant for all of the same issues and provisions described in this paragraph, which results in a mutual indemnification.
   
11. Title The Consultant shall operate its duties as set out in this agreement with the title of “Global Business Development”.
   
12. Termination Upon the happening of any one or more of the following events, in addition to any other rights and remedies available, either party may cancel and terminate this Agreement by giving ninety (90) days prior written notice to the other party.

 

a. Upon termination or non-renewal of this Agreement, the Company shall pay to the Consultant, during the first two (2) years only following termination; 50 percent(%) or (1%) of all sales commissions earned on all product sales from products that the Consultant or his sales agents or brokers introduce to the Company.

 

 
 

 

13. Assignment This Agreement shall not be assignable without the written consent of the other party. Notwithstanding the foregoing, either party may assign this Agreement to an affiliated company or to a successor company by merger or sale.
   
14. Standard of Care Consultant shall at all times faithfully, industriously and to the best of Consultant’s abilities, experience and talents, provide Services that may be required pursuant to the express and implied terms and provisions of this Agreement.
   
15. Entire Agreement This Agreement sets forth the entire agreement of the parties hereto with regard of the subject matter hereof and thereof and supersedes and replaces all prior or contemporaneous agreements, understandings and representations, oral or written, with regard to such matters.
   
16. Other Provisions

 

  (a) Notices. All legal notices, consents or other communications shall be in writing and shall be delivered personally or by messenger, or mailed by registered or certified mail, return receipt requested, postage prepaid, or via an email, in all cases addressed to the party for whom intended at its address set forth below:

 

If to the Company:

If to the Consultant: Kenek Brands Inc

275 Canterburry Lane

Fall River, Nova Scotia B2T 1A4

 

or such other address as a party has designated by notice in writing to the other party given in the manner provided by this section 8(a). Without limiting any other means by which a party may be able to prove that a notice has been received by the other party, a notice shall be deemed to be duly received (i) if sent by hand, overnight courier or telegram, the date when left at the address of the recipient; (ii) if sent by registered or certified mail, the date of the return receipt; or (iii) if sent by email, upon receipt by the sender of an acknowledgement or transmission report generated by the machine from which the email was sent indicating that the email was sent in its entirety to the recipient’s email address.

 

17. Governing Law This Agreement shall be deemed to be a contract made under the laws of the State of California, and for all purposes shall be construed in accordance with the laws of said State.

 

 
 

 

18. Arbitration In the event of any dispute arising out of or related to this Agreement or any parties’ conduct or performance under this Agreement, each of the parties agrees to resolve any such dispute by confidential and binding arbitration before JAMS from its offices in Los Angeles, California and pursuant to the Comprehensive Arbitration Rules and Procedures. Judgment upon the award rendered by the arbitrator(s) must be entered and/or confirmed in state or federal courts located in the County of Los Angeles, State of California and Consultant and Company agree to submit to the exercise of jurisdiction over them by said state or federal courts in the County of Los Angeles, State of California. The prevailing party in such arbitration shall be entitled to recover costs and attorneys’ fees incurred in arbitrating the dispute and in preparing for such arbitration.

 

IN WITNESS WHEREOF, the parties have affixed their hands and seals the day and year provided below

 

Kenek Brands Inc.

 

    Date: April 2, 2014
Per: Jack Ross    
Synergy Strips Corp.    
    Date: April 2, 2014
Per: Mark Suponitsky    

 

 

 

Exhibit 10.2

 

LOAN AGREEMENT

 

Dated as of January 22, 2015

between

KNIGHT THERAPEUTICS (BARBADOS) INC.

as Lender

- and -

SYNERGY STRIPS CORP.

as Borrower

 

 
 

 

Table of Contents

 

    Page
ARTICLE 1 - DEFINITIONS 1
1.1 General Definitions 1
1.2 Schedules and Exhibits 11
1.3 Accounting Terms and Definitions 12
1.4 Currency Conversion 12
1.5 Supplements, Re-enactments, Etc 12
1.6 Headings of Subdivisions 12
1.7 Gender and Number 12
1.8 Monetary References 12
1.9 Actions on Days Other Than Business Days 12
ARTICLE 2 - TERMS OF THE LOAN 13
2.1 The Loan 13
2.2 Maturity Date 13
ARTICLE 3 - PAYMENT 13
3.1 Payments on Principal 13
3.2 Optional Prepayments 13
3.3 General Matters 14
ARTICLE 4 - INTEREST. FEES AND CHARGES 14
4.1 Rate of Interest 14
4.2 Payment of Interest 14
4.3 Default Rate of Interest 14
4.4 Computation of Interest and Fees 14
4.5 Maximum Interest 14
4.6 Origination Fee 14
4.7 Work Fee 14
4.8 Lender’s Expenses 15
4.9 Illegality 15
4.10 Increased Costs 15
ARTICLE 5 - TERMINATION AND REDUCTION 15
5.1 Termination 15
5.2 Continuing Obligations 16
ARTICLE 6 - SECURITY AND COLLATERAL 16
6.1 Security Delivered on the Closing Date 16
6.2 Further Assurances 16
6.3 Security Effective Notwithstanding Date of Loan 16
6.4 No Merger 17
6.5 Release of Security 17

 

 
 

 

Table of Contents (continued)

 

    Page
ARTICLE 7 - REPRESENTATIONS AND WARRANTIES 17
7.1 Representations and Warranties 17
7.2 Survival of Representations and Warranties 22
ARTICLE 8 - schedules AND REPORTS 22
8.1 Financial Information 22
8.2 Compliance Certificate 23
8.3 Other Matters 23
ARTICLE 9 - COVENANTS 23
9.1 Covenants 23
9.2 Negative Covenants 27
9.3 Entitled to Perform Covenants 29
ARTICLE 10 - CONDITIONS PRECEDENT 29
10.1 Conditions Precedent to Loan 29
ARTICLE 11 - EVENTS OF DEFAULT 31
11.1 Events of Default 31
11.2 Acceleration and Termination of Rights 33
11.3 Remedies Cumulative and Waivers 33
11.4 Saving 33
11.5 Third Parties 34
11.6 Set-Off or Compensation 34
ARTICLE 12 - INDEMNIFICATION, ETC 34
12.1 General Indemnity 34
12.2 Taxes 35
ARTICLE 13 - GENERAL PROVISIONS 35
13.1 Notice 35
13.2 Choice of Governing Law and Construction 36
13.3 Attornment 36
13.4 Press Releases 36
13.5 Modification and Benefit of Agreement 36
13.6 Power of Attorney 36
13.7 Waivers, Confidentiality, Information Sharing 37
13.8 Timing of Payments 37
13.9 Judgment Currency 37
13.1 Severability 37
13.11 Conflicts 37
13.12 Entire Agreement 37
13.13 Counterpart Execution/Electronic Delivery 37
13.14 English Language 37

 

 
 

 

LOAN AGREEMENT

 

THIS LOAN AGREEMENT is made with effect as of the 21st day of January, 2015, by and between SYNERGY STRIPS CORP., a corporation formed under the laws of the State of Nevada (the “Borrower’ ) and KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados, and one or more Persons to whom the foregoing or their permitted assigns may from time to time assign an interest in the Loan Documents (as defined below) (collectively, the “Lender”);

 

RECITALS:

 

WHEREAS the Borrower desires that the Lender extend the Loan (as defined below) to the Borrower for the purpose of financing the acquisition of FNL, and the Lender has indicated its willingness to lend on the terms and conditions set forth herein;

 

AND WHEREAS the parties wish to provide for the terms and conditions upon which the Loan shall be made;

 

NOW THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE 1 – DEFINITIONS

 

1.1 General Definitions.

 

In this Agreement the following terms shall have the following meanings:

 

“Acquisition” means, with respect to any Person, any purchase or other acquisition by such Person, regardless of how accomplished or effected (including any such purchase or other acquisition effected by way of amalgamation, merger, arrangement, business combination or other form of corporate reorganization or by way of purchase, lease or other acquisition arrangements), of (i) any other Person (including any purchase or acquisition of such number of the issued and outstanding securities of, or such portion of an Equity Interest in, such other Person so that such other Person becomes a Subsidiary of the purchaser or of any of its Affiliates) or of all or substantially all of the Property of any other Person, or (ii) any division, business, operation or undertaking of any other Person or of all or substantially all of the Property of any division, business, operation or undertaking of any other Person.

 

“Action Request” means any request from any Governmental Authority under any Environmental Law whereby such body or agency requests that the Person requested takes action or steps or does acts or things in respect of any Property in its charge, management or control to remediate a matter which is not or is alleged not to be in compliance with all Environmental Laws, except where such non-compliance would not reasonably be expected to have a Material Adverse Effect.

 

“Affiliate” means: (i) any Person which, directly or indirectly, controls, is controlled by or is under common control with any other Person; (ii) any Person which beneficially owns or holds, directly or indirectly, fifty percent (50%) or more of any class of voting stock or Equity Interest (including partnership interests) of any other Person; or (iii) any Person, fifty percent (50%) or more of any class of the voting stock (or if such Person is not a corporation, fifty percent (50%) or more of the Equity Interest, including partnership interests) of which is beneficially owned or held, directly or indirectly, by any other Person. For the purposes of this definition, control of any Person (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to elect or appoint a majority of the board of directors of, or persons performing similar functions in respect of, such Person, whether through the ownership of voting securities, by contract, or otherwise.

 

1
 

 

“Agreement” means this agreement and all schedules attached hereto; the expressions “hereof’, “herein”, “hereto”, “hereunder”, “hereby” and similar expressions refer to this Agreement, as amended, restated or supplemented from time to time, as a whole and not to any particular Article, Section, Schedule, or other portion hereof or thereof.

 

“Annual Business Plan” means the annual business plan of the Borrower, prepared on a Consolidated basis, with detailed financial projections and budgets on a quarter to quarter basis for the following one (1) Fiscal Year, in each case consisting of a balance sheet, statement of income, retained earnings, statement of cash flows, proposed Capital Expenditures and a list of assumptions upon which such projections are based.

 

“Applicable Law” means (i) any domestic or foreign statute, law (including common and civil law), treaty, code, ordinance, rule, regulation, restriction or by-law (zoning or otherwise); (ii) any judgment, order, writ, injunction, decision, ruling, decree or award; (iii) any regulatory policy, practice, guideline or directive; or (iv) any franchise, licence, qualification, authorization, consent, exemption, waiver, right, permit or other approval of any Governmental Authority, binding on or affecting the Person referred to in the context in which the term is used or binding on or affecting the property of such Person, in each case whether or not having the force of law.

 

“Arm’s Length” has the meaning specified in the definition of “Non-Arm’s Length”.

 

“Associate” with respect to Lender means an “associate” as defined in the Canada Business Corporations Act.

 

“Audited Financial Statements” means the audited Consolidated statement of financial position of the Borrower for the Fiscal Year ended December 31, including, without limitation, balance sheet, statement of income and retained earnings and statements of cash flows for such Fiscal Year prepared in accordance with IFRS.

 

“Auditor” means the Borrower’s auditor and includes its successor which needs be an auditor of recognized national standing from time to time.

 

“Board” means the Borrower’s board of directors.

 

“Borrower” means Synergy Strips Corp., a corporation incorporated under the laws of the State of Nevada, and its permitted successors and assigns.

 

“Business” means the manufacture, distribution and sale of ingestible dietary supplements, including the product known as Synergy Strips.

“Business Day” means a day (other than Saturday or Sunday) on which banks are generally open for business in Montreal, Quebec and New York, New York.

 

“Capital Expenditures” means, for any period, any expenditure made by any Person for the purchase, lease, acquisition, licence, erection, development, improvement, construction, repair or replacement of capital assets, and any expenditure related to a Capital Lease or any other expenditure required to be capitalized, all as determined in accordance with IFRS.

 

“Capital Lease” means, with respect to any Person, any lease of (or other agreement conveying the right to use) any real or personal property by such Person that, in conformity with IFRS, is or should be accounted for as a capital lease on the balance sheet of that Person.

 

“Cash Balance Statement” shall have the meaning ascribed to it in Section 9.1(x)(iii).

 

2
 

 

“Change of Control” means, with respect to the Borrower, the acquisition by any Person or group of Persons who act together in concert for such purpose of (i) shares or other voting Equity Interests of the Borrower to which are attached more than fifty percent (50%) of the votes that may be cast to elect directors or other Persons charged with the direction of the management of the Borrower and which, if exercised, are sufficient to elect a majority of such directors or other management Persons, or (ii) any other right to appoint a majority of such directors or other management Persons or with respect to any Person who from time to time has previously met the foregoing test the further acquisition by such Person or group of Persons who act together in concert for such purpose of any further units or other voting Equity Interests of the Borrower.

 

“Closing Date” means January 21, 2015 or such other date on which the Loan is made concurrently with the closing of the FNL Transaction.

 

“Collateral” means all of the undertaking and Property, present and future, real, immovable, personal and movable, of Borrower, now or hereafter pledged, hypothecated, granted or assigned to the Lender to secure, either directly or indirectly, repayment on account of payment of any of the Obligations.

 

“Compliance Certificate” means the certificate required pursuant to Section 8.2, substantially in the form annexed as Schedule 8.2 and signed by the President and Chief Financial Officer of the Borrower.

 

“Consolidated” means, when used to modify a financial term, test, statement, or report of a Person, the application or preparation of such term, test, statement or report (as applicable) based upon the consolidation, in accordance with IFRS, of the financial condition or operating results of such Person.

 

“Consolidated Net Income” means, for any period, the Consolidated net income after tax of the Borrower for such period.

 

“Contingent Obligation” means, as to any Person, any obligation, whether secured or unsecured, of such Person guaranteeing or indemnifying, or in effect guaranteeing or indemnifying, any indebtedness, leases, dividends, letters of credit or other monetary obligations (the “primary obligations”) of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, including any obligation of such Person as an account party in respect of a letter of credit or letter of guarantee issued to assure payment by the primary obligor of any such primary obligation and any obligations of such Person, whether or not contingent, (i) to purchase any such primary obligation or any Property constituting direct or indirect security therefor, (ii)to advance or supply funds for the purchase or payment of any such primary obligation or to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (iii) to purchase Property, Equity Interests or services primarily for the purpose of assuring the obligee under any such primary obligation of the ability of the primary obligor to make payment of such primary obligation, or (iv) otherwise to assure or hold harmless the obligee under such primary obligation against loss in respect of such primary obligation; provided, however, that the term “Contingent Obligation” shall not include endorsements of instruments for deposit or collection in the ordinary course of business.

 

“Control Agreement” means a control agreement, in form and substance satisfactory to the Lender, executed and delivered by the Borrower, the Lender and the applicable securities intermediary with respect to a Securities Account or a deposit-taking institution with respect to a Deposit Account.

 

“Controlled Group” means, in respect of Borrower operating in the United States, all members of a controlled group of corporations and all trades or businesses (whether or not incorporated) under common control which, together with Borrower or any of its Subsidiaries, are treated as a single employer under Section 414(b) or (c) of the Revenue Code.

 

“Debt” means, with respect to any Person, without duplication, the aggregate of the following amounts, at the date of determination: (i) all indebtedness of such Person for borrowed money; (ii) all obligations of such Person for the deferred purchase price of Property or services which constitute indebtedness; (iii) all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments; (iv) all obligations of such Person created or arising under any conditional sale or other title retention agreement with respect to Property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such Property); (v) all obligations of such Person as lessee under leases that have been or should be, in accordance with IFRS, recorded as Capital Leases; (vi) all reimbursement obligations, contingent or otherwise, of such Person under acceptance, letter of credit and similar facilities; (vii) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any partnership or shareholder or other equity interests of such Person (for greater certainty, not including obligations with respect to unexercised options and rights of first refusal and where conditions precedent to the purchase, redemption, retirement, defeasance or other acquisition of such obligations have not occurred); (viii) all Contingent Obligations of such Person in respect of Debt of another Person; and (ix) any other obligation arising under arrangements or agreements that, in substance, provide financing to such Person.

 

3
 

 

“Deemed Interest Rate” means the interest rate applicable to the Loan as set out in Section 4.1 or 4.3, as the case may be, from time to time.

 

“Default” means any event or condition which, with the giving of notice, the lapse of time or both, would constitute an Event of Default.

 

“Deposit Account” means any “deposit account” as such term is defined in the UCC.

 

“Depreciation Expense” means, for any period with respect to any Person, depreciation, amortization, depletion and other like reductions to income of such Person for such period not involving any outlay of cash, determined, without duplication and determined on a consolidated basis, in accordance with IFRS.

 

“Disposition” means any sale, assignment, transfer, conveyance, lease or other disposition of any asset of Borrower in a single transaction or a series of related transactions and the word “Dispose” shall have a correlative meaning.

 

“Distribution” means, with respect to any Person, any payment, directly or indirectly, by such Person: (i) of any dividends on any shares of its capital, other than dividends payable in shares; (ii) on account of, or for the purpose of setting apart any property for a sinking or other analogous fund for, the purchase, redemption, retirement or other acquisition of any Equity Interests; (iii) of any other distribution in respect of any Equity Interests; or (iv) of any management, consulting or similar fee or compensation or any bonus payment or comparable payment, or by way of gift or other gratuity, to any Affiliate of such Person or to any director, officer or member of the management of such Person or an Affiliate of such Person or to any Person not dealing at Arm’s Length with such first Person (for greater certainty, compensation (including bonuses) paid by Borrower in the course of its business to directors, officers and members of management of Borrower shall not constitute Distributions hereunder).

 

EBITDA” means, for any period, Consolidated Net Income for the Borrower earned during such period, plus, to the extent deducted in calculating Consolidated Net Income (without duplication):

 

  (i) Interest Expense for such period;
     
  (ii) Income Tax Expense for such period; and
     
  (iii) Depreciation Expense for such period;
     

decreased by the sum (without duplication) of:

 

  (iv) extraordinary, unusual or non-recurring items for such period; and
     
  (v) dividend and interest income earned or received for such period.
     

“Environmental Laws” means all Applicable Laws relating to Materials of Environmental Concern, pollution or protection of health, safety or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including without limitation, laws and regulations relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern, or otherwise relating to the manufacturing, processing, distribution, use, treatment, storage, disposal or transport of Materials of Environmental Concern.

 

“Equipment” means all machinery, apparatus, equipment, fittings, furniture, fixtures, motor vehicles and other tangible personal or movable Property (other than Inventory) of every kind and description used in a Person’s operations or owned by such Person or in which such Person has an interest, whether now owned or hereafter acquired by such Person and wherever located, and all parts, accessories and tools and all increases and accessories thereto and substitutions and replacements therefor.

 

4
 

 

“Equity Financing” means the completion of an offering or offerings of the Borrower’s equity securities or securities convertible into equity securities of at least $1,000,000 in the aggregate.

 

“Equity Interests” means (i) in the case of any corporation or company, all shares or capital stock and any securities exchangeable for or convertible into shares or capital stock, (ii) in the case of an association or business entity, any and all shares, interests, participation rights or other equivalents of corporate stock (however designated) in or to such association or entity, (iii) in the case of a partnership, limited liability company or unlimited liability company, partnership or membership interests (whether general or limited), as applicable, and (iv) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distribution of assets of, the issuing Person, and including, in all of the foregoing cases described in clauses (i), (ii), (iii) or (iv), any warrants, rights or other options to purchase or otherwise acquire any of the interests described in any of the foregoing cases.

 

“Equivalent” means with respect to any two currencies, the amount obtained in one currency when an amount in the other currency is translated into the first currency in accordance with Section 1.4 hereof.

 

“ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, together with the regulations thereunder as the same may be amended from time to time.

 

“ERISA Plan” means any employee pension benefit plan covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Revenue Code (other than a multiemployer plan) that either (i) is maintained by Borrower (including after giving effect to the FNL Transaction), or (ii) with respect to which Borrower has or may have liability (including after giving effect to the FNL Transaction).

 

“Event of Default” shall have the meaning ascribed to it in Article 11 hereof.

 

“Financial Statements” means the statements of financial position of the Borrower, including without limitation, the balance sheet, statement of income and retained earnings and statement of cash flows of the Borrower, the Cash Balance Statement, all prepared in accordance with IFRS and consistent with the approach used by the Borrower in its Audited Financial Statements.

 

“Fiscal Quarter” means any of the quarterly accounting periods of the Borrower ending on March 31, June 30, September 30, and December 31 of each year.

 

“Fiscal Year” means any period of twelve consecutive months ending on December 31 of any calendar year.

 

“FNL” means Factor Nutrition Labs, LLC, a Delaware limited liability company and its permitted successors and assigns.

 

“FNL Asset Acquisition” means the acquisition by Borrower of the FOCUSFactor assets of FNL pursuant to the FNL Asset Purchase Agreement.

 

“FNL Asset Purchase Agreement” means that certain Agreement for Purchase and Sale of Assets dated as of January , 2015, by and among FNL and Borrower.

 

“FNL Business” means the business of manufacturing, distribution and sale of FOCUSFactor, an ingestible dietary supplement.

 

“FNL Transaction” means the transactions contemplated by the FNL Asset Purchase Agreement.

 

“Governmental Authority” means the government of Canada, the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including any supranational bodies such as the European Union or the European Central Bank and including a Minister of the Crown, Superintendent of Financial Institutions or other comparable authority or agency.

 

5
 

 

“IFRS” means, at any time, the International Financial Reporting Standards, promulgated by the International Accounting Standards Board, as amended, supplemented or replaced from time to time.

 

“Income Tax Expense” means, with respect to the Borrower, for any period, the aggregate, without duplication and on a consolidated basis, of all current Taxes on the income of the Borrower for such period, determined in accordance with IFRS.

 

“Intellectual Property” means the intellectual property in patents, patent applications, trade-marks, trade-mark applications, trade names, service marks, copyrights, copyright registrations and trade secrets including, without limitation, customer lists and information and business opportunities, industrial designs, proprietary software, technology, recipes and formulae and other similar intellectual property rights.

 

“Interest Expense” of the Borrower means, for any period, without duplication and on a consolidated basis, the aggregate amount of interest and other financing charges paid or payable by the Borrower, on account of such period with respect to Debt including interest, amortization of discount and financing fees, commissions, discounts, the interest or time value of money component of costs related to factoring or securitizing receivables or monetizing inventory and other fees and charges payable with respect to letters of credit, letters of guarantee and bankers’ acceptance financing, standby fees, the interest component of Capital Leases, all as determined in accordance with IFRS.

 

“Interest Payment Date” means March 31, June 30, September 30 and December 31 in each year.

 

“Inventory” means, with respect to any Person, all inventory of such Person, whether now owned or hereafter acquired including, but not limited to, all goods intended for sale or lease by such Person, or for display or demonstration; all work in process; all raw materials and other materials and supplies of every nature and description used or which might be used in connection with the manufacture, printing, packing, shipping, advertising, selling, leasing or furnishing of such goods or otherwise used or consumed in such Person’s business.

 

“Lender Distribution Agreement” means the proposed license and distribution agreement between the Borrower and the Lender by which the Lender shall have the exclusive Canadian distribution rights to FOCUSFactor, FOCUSFactor Kids and Synergy Strips.

 

“Lender Option” means the option granted to the Lender pursuant to that certain distribution option agreement dated as of the date of this Agreement whereby the Lender will acquire the option to negotiate an exclusive distribution agreement for the Borrower’s Products for Canada, Russia, Sub-Sahara Africa and Israel.

 

“Lender’s Additional Equity” means the issuance to the Lender of a ten (10) year warrant to purchase 5% of the common shares of the Borrower, on a fully diluted basis, at a price per share equal to $0.34, being 80% of the current trading price, provided that should the share price remain at or above $1.00 for six (6) consecutive months, the Lender shall forfeit the difference between the number of (i) shares acquired under the said warrant prior to the expiry of the ninety (90) days after the said six (6) month period and (ii) 25% of the shares purchasable under the said warrant.

 

“Lender’s Equity” means the issuance to the Lender, for no additional consideration, of such number of common shares of the Borrower that will result in the Lender receiving, on a fully diluted basis and after giving effect to the issuance referred to in Section 10.1(v), of 6.5% of the common shares of the Borrower, on a fully diluted basis, which shares will not be subject to any trading restrictions, other than as required under Applicable Law.

 

“Lender’s Nominee” shall have the meaning ascribed to it in Section 9. l(y) hereof.

 

6
 

 

“Lien” means: (i) any interest in Property securing an obligation owed to, or a claim by, a Person, whether such interest is based on the common law, civil law, statute, or contract, and including, without limitation, a security interest, charge, claim, hypothec or lien arising from a mortgage, deed of trust, hypothec, encumbrance, pledge, hypothecation, assignment, deposit arrangement, agreement, security agreement, conditional sale or trust receipt or a lease, consignment or bailment for security purposes; and (ii) to the extent not included under clause (i), (A) any rights of repossession or similar rights of unpaid suppliers, (B) any reservation, exception, encroachment, easement, right-of-way, covenant, condition, restriction, lease or other title exception or encumbrance affecting Property, and (C) any other lien, hypothec, charge, privilege, secured claim, title retention, garnishment right, deemed trust, encumbrance or other right affecting Property, choate or inchoate, whether or not crystallized or fixed, whether or not for amounts due or accruing due, arising by any statute or law of any jurisdiction, at law, in equity or by any agreement.

 

“Loan” shall have the meaning ascribed to it in Section 2.1 hereof.

 

“Loan Documents” means (i) this Agreement and the Security Agreement delivered by Borrower pursuant to this Agreement, and (ii) all present and future security, agreements and documents labelled by the parties thereto as a Loan Document, in each case as the same may from time to time be supplemented, amended or restated, and “Loan Document” shall mean any one of the Loan Documents.

 

“Losses” shall have the meaning ascribed to it in Section 12.1 hereof.

 

“Material Adverse Effect” shall mean (i) a material adverse effect on the business, prospects, operations, properties, assets, or condition (financial or otherwise) of the Borrower on a consolidated basis, (ii) an adverse effect on the legality, validity or enforceability of any of the Loan Documents which could reasonably be considered material having regard to the Loan Documents considered as a whole, including the validity, enforceability, perfection or priority of any Lien created under any of the Security which could reasonably be considered material having regard to the Security considered as a whole, (iii) a material adverse effect on the ability of Borrower, to pay or perform any of its debts, liabilities or obligations under any of the Loan Documents, which could reasonably be considered material having regard to Borrower as a whole, or (iv) an adverse effect on the right, entitlement or ability of the Lender to enforce their rights or remedies under any of the Loan Documents which could reasonably be considered material having regard to the Loan Documents taken as a whole.

 

“Material Contracts” means, collectively, each written agreement (or multiple agreements with the same Person), arrangement or understanding entered into by Borrower or to be assigned to the Borrower pursuant to the FNL Transaction, which if not complied with, or expires, or is terminated, could reasonably be expected to have a Material Adverse Effect.

 

“Material Licences” means, collectively, each licence, permit or approval issued by any Governmental Authority or any applicable stock exchange or securities commission to Borrower or to be assigned to the Borrower pursuant to the FNL Transaction, the breach or default of which, or termination of, could reasonably be expected to result in a Material Adverse Effect.

 

“Materials of Environmental Concern” means any chemicals, pollutants, contaminants, wastes, toxic substances, petroleum, petroleum products, together with any hazardous, toxic or dangerous substances, materials and wastes, including, without limitation, hydrocarbons (including naturally occurring or man-made petroleum and hydrocarbons), flammable explosives, asbestos, urea formaldehyde insulation, radioactive materials, biological substances, polychlorinated biphenyls, pesticides, herbicides and any other kind and/or type of pollutants or contaminants (including, without limitation, materials which include hazardous constituents), sewage, sludge, industrial slag, solvents and/or any other similar substances, materials or wastes and including any other substances, materials or wastes that are or become regulated under any laws relating to the protection of the environment or maintenance of occupational safety (including, without limitation, any that are or become classified as hazardous or toxic under any such laws).

 

“Maturity Date” shall have the meaning ascribed to it in Section 2.2.

 

“Measurement Period” shall have the meaning ascribed to it in Section 2.2.

 

“Net Debt” means, as of any date of determination, (i) Consolidated Debt of the Borrower outstanding on such date minus (ii) the aggregate amount of cash and cash equivalents included in the cash accounts listed on the Consolidated statement of financial position of the Borrower as of such date, to the extent the use thereof for application to payment of Debt is not prohibited by law or contract.

 

7
 

 

“Non-Arm’s Length” and similar phrases have the meaning attributed thereto for the purposes of the Income Tax Act (Canada); and “Arm’s Length” shall have the opposite meaning.

 

“Obligations” means all present and future obligations and indebtedness, of any and every kind and nature, of Borrower to the Lender arising under this Agreement and the other Loan Documents, whether now or hereafter existing, whether now due or to become due, whether primary, secondary, direct, indirect, absolute, contingent or otherwise (including without limitation, obligations of performance), whether several or joint or joint and several.

 

“OFAC” means The Office of Foreign Assets Control of the US Department of the Treasury.

 

“Organizational Documents” means, with respect to any applicable Person, such Person’s articles or other charter or constitutional documents, by-laws, shareholder agreement, partnership agreement, joint venture agreement, limited liability company agreement or trust agreement, as applicable, and any and all other similar agreements, documents and instruments relative to such Person.

 

“PBGC” means the Pension Benefit Guaranty Corporation or any Person succeeding to any or all of its functions under ERISA.

 

“Pension Plan” means (i) a “pension plan” or “plan” which is subject to the funding requirements of applicable pension benefit legislation in any jurisdiction as is applicable to the employees of Borrower (after giving effect to the FNL Transaction); or (ii) any pension benefit plan or similar agreement applicable to employees of Borrower (after giving effect to the FNL Transaction, other than a plan sponsored by a Governmental Authority) which, for greater certainty, includes an ERISA Plan.

 

“Perfection Certificate” means a certificate in the form of Exhibit 1. or any other form approved by the Lender.

 

“Permitted Cash Investments” means an investment in any of the following:

 

(i) direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the Government of the United States or of any state thereof, as applicable (or by any agency or instrumentality of any of the foregoing to the extent such obligations are backed by the full faith and credit of the Government of the United States or of such state, as applicable);

 

(ii) investments in certificates of deposit, bankers’ acceptances and time deposits maturing within 180 days from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the United States or or federal state in the United States having combined capital and surplus of not less than $300,000,000 or the Equivalent in any other currency; and

 

(iii) commercial paper of an issuer rated at least A-1+ or the equivalent thereof by a rating agency satisfactory to the Lender, and in each case maturing within six months from the date of acquisition.

 

“Permitted Debt” means:

 

(i) Debt under this Agreement;

 

(ii) Debt in respect of Purchase Money Security Interests and Capital Leases in an outstanding amount not to exceed $100,000 in aggregate at any time;

 

(iii) Debt consented to in writing by the Lender from time to time and subject to the terms imposed by the Lender in connection with such consent;

 

8
 

 

(iv) to the extent included as Debt, accounts payable that arise, and accrued expenses incurred in, the ordinary course of business; and

 

(v) Debt of $1,500,000 owed to FNL pursuant to the FNL Asset Purchase Agreement.

 

“Permitted Disposition” means (i) the Disposition of Inventory in the ordinary course of business; (ii) the Disposition of used, worn-out or surplus Equipment in the ordinary course of business; (iii) other Dispositions to the extent that no Default or Event of Default exists and the fair market value of the assets Disposed of pursuant to this clause (iii) does not exceed during any Fiscal Year $150,000; and (iv) a Disposition under a distribution agreement contemplated by the Lender Option.

 

“Permitted Distribution” means (i) directors’ fees paid by the Borrower in an aggregate amount in any Fiscal Year not to exceed $50,000 so long as there exists no Default or Event of Default and such directors’ fees are customary and reasonable for directors in a similar business to the Business; and (ii) bonuses paid or other comparable payments made to its officers and members of management by the Borrower in an aggregate amount in respect of any Fiscal Year not to exceed $100,000 (the “Management Bonus Limit”), provided that such bonuses and comparable payments are customary and reasonable for officers and members of management in a business similar to the Business.

 

“Permitted Liens” means, with respect to any Person, the following:

 

(i) liens for Taxes not yet due or for which installments have been paid based on reasonable estimates pending final assessments, or if due, the validity of which is being contested diligently and in good faith by appropriate proceedings by that Person for which reasonable reserves under IFRS are maintained;

 

(ii) undetermined or inchoate liens, rights of distress and charges incidental to current operations which have not at such time been filed or exercised and of which the Lender has been given notice, or which relate to obligations not due or payable, or if due, the validity of which is being contested diligently and in good faith by appropriate proceedings by that Person;

(iii) reservations, limitations, provisos and conditions expressed in any original grants from the Crown or other grants of real or immovable property, or interests therein;

 

(iv) zoning, land use and building restrictions, by-laws, regulations and ordinances of federal, provincial, state, municipal and other Governmental Authorities, licences, easements, servitudes, rights-of-way and rights in the nature of easements (including, without limiting the generality of the foregoing, licences, easements, servitudes, rights-of-way and rights in the nature of easements for railways, sidewalks, public ways, sewers, drains, gas, steam and water mains or electric light and power, or telephone and telegraph conduits, poles, wires and cables) which do not materially impair the use of the affected land for the purpose for which it is used by that Person;

 

(v) title defects, encroachments or irregularities or other matters relating to title which are of a minor nature and which in the aggregate do not materially impair the use of the affected property for the purpose for which it is used by that Person;

 

(vi) the right reserved to or vested in any municipality or governmental or other public authority by the terms of any lease, licence, contract, franchise, grant or permit acquired by that Person or by any statutory provision to terminate any such lease, licence, contract, franchise, grant or permit, or to require annual or other payments as a condition to the continuance thereof;

 

(vii) the Lien resulting from the deposit of cash or securities in connection with contracts, tenders or expropriation proceedings, or to secure workers compensation, employment insurance, surety or appeal bonds, costs of litigation when required by law not to exceed $100,000 in aggregate outstanding at any time, liens and claims incidental to current construction, mechanics’, warehousemen’s, carriers’ and other similar liens, and public, statutory and other like obligations incurred in the ordinary course of business;

 

9
 

 

(viii) security given to a public utility or any municipality or Governmental Authority when required by such utility or authority in connection with the operations of that Person in the ordinary course of its business provided that such security does not materially impair the use of the affected property for the purpose for which it is used by that Person;

 

(ix) the Lien created by a judgment of a court of competent jurisdiction, as long as the judgment is being contested diligently and in good faith by appropriate proceedings by that Person and does not result in an Event of Default;

 

(x) the Security;

 

(xi) Purchase Money Security Interests and Capital Leases, provided that such Liens secure Permitted Debt;

 

(xii) such other Liens as agreed to in writing by the Lender in accordance with this Agreement; and

 

(xiii) any other Liens securing Debt the principal amount of which (when aggregated with the outstanding principal of any other such Debt secured by Borrower) does not exceed $100,000 (or its equivalent)).

 

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, institution, entity, party or foreign or local government (whether federal, provincial, state, county, city, municipal or otherwise), including, without limitation, any instrumentality, division, agency, body or department thereof.

 

“Prepayment Fee” shall have the meaning ascribed to it in Section 3.2 hereof.

 

“Product” means each current and future product, process or service under development, developed, manufactured, licensed, distributed, marketed or sold by Borrower and any other current or future products or services in which Borrower has any proprietary rights or beneficial interests and includes all products and product rights to be acquired pursuant to the FNL Transaction.

 

“Prohibited Transaction” means any transaction set forth in Section 406 of ERISA, or Section 4975 of the Revenue Code, to the extent that such transaction is not otherwise exempt by Applicable Law.

 

“Property” means, with respect to any Person, all or any portion of its undertaking, property or asset, whether real, immovable, personal, movable, or mixed, tangible or intangible, including for greater certainty any Equity Interests of a corporation or ownership interest in any other Person.

 

“Purchase Money Security Interest” means a Lien created or assumed by Borrower securing Debt incurred to finance the unpaid acquisition price of personal Property provided that

 

“Regulatory Authority” means any Governmental Authority that has responsibility in any country or group of countries over the development, manufacture or commercialization of a Product, including the U.S. Food and Drug Administration, Health Canada and the European Medicines Agency, and any successor agency thereof.

 

“Repayment Schedule” means the Schedule of repayment of principal of the Loan attached hereto as Schedule 3.1(b).

 

“Reportable Event” means any of the events set forth in Section 4043 of ERISA, other than an event for which the provision of notice has been waived.

 

“Requirements of Law” means, as to any Person, the Organizational Documents of such Person and any Applicable Law, or determination of a Governmental Authority, in each case, applicable to or binding upon such Person or any of its business or Property or to which such Person or any of its business or Property is subject.

 

10
 

 

“Revenue Code” means the United States Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and the regulations and published interpretations thereof.

 

“Revenues” means, for any period, consolidated gross income for such period.

 

“Sanctioned Entity” means (i) a country or a government of a country, (ii) an agency of the government of a country, (iii) an organization directly or indirectly controlled by a country or its government, (iv) a Person resident in, or determined to be resident in, a country, in each case, that is subject to a country sanctions program administered and enforced by OF AC.

 

“Sanctioned Person” means a person named on the list of Specially Designated Nationals maintained by OF AC (including on account of its membership in a Controlled Group).

 

“Securities Account” means any “securities account” as such term is defined in the STA and the UCC.

 

“Security” means the Liens created by the Security Documents.

 

“Security Documents” means the documents set out in Section 6.1.

 

“Subsidiary” means, with respect to a Person, any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether at the time stock of any other class of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned by the Person or by any partnership or other corporate entity of which more than fifty percent (50%) of the outstanding equity interests are at the time, directly or indirectly, owned by the Person.

 

“Taxes” shall have the meaning ascribed to it in Section 12.2 hereof.

 

“TTM EBITDA” means, at any date, EBITDA for the twelve (12) months immediately preceding such date.

 

“Violation Notice” means any notice received by a Person, from any Governmental Authority under any Environmental Law that such Person or any of its Property is not in compliance with the requirements of any Environmental Law, if such non-compliance would reasonably be expected to have a Material Adverse Effect.

 

“Warrant” means that certain common share stock purchase warrant to be executed by the Borrower and the Lender to give effect to the Lender’s Equity issuance.

 

“Welfare Plan” means any medical, health, hospitalization, insurance or other employee benefit or welfare plan, agreement or arrangement subject to ERISA and applicable to employees of Borrower (including after giving effect to the FNL Transaction) and includes a “welfare plan” as defined in Section 3(1) of ERISA.

 

1.2 Schedules and Exhibits.

 

The following are the Schedules and Exhibits to this Agreement, which are deemed to be a part of this Agreement:

 

  Exhibit 1 Schedule 3.1(b)   Perfection Certificate Repayment Schedule
  Schedule 7.1(f) - Intellectual Property
  Schedule 7.1(i) - Litigation
  Schedule 7.1(j) - Material Contracts and Material Licences
  Schedule 7.1(o) - Taxes
  Schedule 7.1(r) - Location of Collateral
  Schedule 7.1(s) - Owned Real Property
  Schedule 7. l(t) - Leased Real Property
  Schedule 7.1(v) - Labor Matters
  Schedule 7.1(w) - Pension Plans
  Schedule 7.1(z) - Insurance
  Schedule 7.1(hh) - Regulatory Matters
  Schedule 8.2 - Officer’s Compliance Certificate

 

11
 

 

1.3 Accounting Terms and Definitions.

 

Unless otherwise defined or specified herein, all defined terms in Section 1.1 as used in this Agreement shall have the meanings set out in such paragraph, and all accounting terms used in this Agreement shall be construed in accordance with IFRS, applied on a basis consistent in all material respects with the annual Audited Financial Statements, except as otherwise specifically prescribed herein. All accounting determinations for purposes of determining compliance with the financial covenants contained herein shall be made in accordance with IFRS as in effect on the Closing Date (unless and to the extent otherwise stipulated herein) and applied on a basis consistent in all material respects with the Audited Financial Statements, except as otherwise specifically prescribed herein. Except as otherwise specified herein, the financial statements required to be delivered hereunder from and after the Closing Date, and all financial records, shall be maintained in accordance with sound accounting practices including, if applicable, IFRS. If IFRS shall change from the basis used in preparing the Audited Financial Statements, the Compliance Certificates required to be delivered pursuant to Section 8.2 demonstrating compliance with the covenants contained herein shall include, at the election of the Borrower or upon the request of the Lender, calculations setting forth the adjustments necessary to demonstrate how the Borrower is in compliance with the financial covenants based upon IFRS as in effect on the Closing Date.

 

1.4 Currency Conversion.

 

Whenever in this Agreement there is a need to convert Canadian dollars to U.S. dollars, or vice versa, or any other foreign currency, for the purpose of any valuation, calculation or determination (including the determination of an Equivalent for the purpose of expressing an amount in one currency as an amount in another currency), the rate of exchange to be used shall be the Bank of Canada noon spot rate (or any other rate to which the parties agree) on such day, and if that day is not a Business Day, on the immediately preceding Business Day.

 

1.5 Supplements, Re-enactments, Etc.

 

References herein to any document or legislation are, unless otherwise stated, to be construed as references to such document or legislation as amended, restated or supplemented from time to time and references to any enactment include re-enactments, amendments and extensions thereof.

 

1.6 Headings of Subdivisions.

 

The headings of subdivisions in this Agreement are for convenience of reference only, and shall not govern the interpretation of any of the provisions of this Agreement.

 

1.7 Gender and Number.

Words importing the singular include the plural and vice versa and words importing gender include all genders.

 

1.8 Monetary References.

 

Any reference in this Agreement to “Dollars”, “dollars” or the sign shall be deemed to be a reference to lawful money of the United States, unless otherwise expressly stated.

 

1.9 Actions on Days Other Than Business Days.

 

Except as otherwise specifically provided herein, where any payment is required to be made or any other action is required to be taken on a particular day and such day is not a Business Day and, as a result, such payment cannot be made or action cannot be taken on such day, then this Agreement shall be deemed to provide that such payment shall be made or such action shall be taken on the first Business Day after such day.

 

12
 

 

ARTICLE 2 - TERMS OF THE LOAN

 

2.1 The Loan.

 

Subject to the terms and conditions of this Agreement and the other Loan Documents, the Lender agrees to loan to the Borrower in lawful money of the United States the principal amount of $6,000,000 to or for the account of the Borrower (the “Loan”) on the Closing Date and the Borrower hereby irrevocably authorizes the Lender to make the Loan on the Closing Date.

 

2.2 Maturity Date

 

The maturity date (the “Maturity Date”) shall be January 20, 2017; provided, however, that if the Borrower’s Revenues exceed USD$13,000,000 and the Borrower’s EBITDA exceeds $2,000,000 for the twelve (12) month period from April 1 to March 31 (the “Measurement Period”) commencing with the period ending March 31, 2016, the Borrower shall have the option to extend the Maturity Date for up to two (2) successive additional twelve (12) month period until no later than January 20, 2019. On or prior to May 15, in each year (starting with May 15, 2016), the Borrower shall provide the Lender with a certificate of the Auditor certifying that the Borrower’s Revenues and EBITDA for the Measurement Period have surpassed the said thresholds. If such thresholds have been surpassed and provided that there is then no Default or Event of Default then occurring, the Borrower may indicate in such notice that it wishes to extend the Maturity Date for an additional twelve (12) month period. In the event that the Borrower fails to send such notice, the Maturity Date shall not be extended.

 

ARTICLE 3 – PAYMENT

 

3.1 Payments on Principal.

 

(a) The Borrower shall pay in full to the Lender the outstanding principal amount on the Loan, together with all accrued and unpaid interest thereon and any other accrued and unpaid Obligations (including, in the case of clause (ii) below, any Prepayment Fee), on the earliest to occur of: (i) the Maturity Date; and (ii) the date of the acceleration of the Obligations pursuant to Section 11.2 of this Agreement.

 

(b) On each Interest Repayment Date, commencing with the Interest Repayment Date falling on June 30, 2015 and in addition to the interest payments set forth in Section 4.2, the Borrower shall pay to the Lender on account of principal of the Loan the amount set forth on the Repayment Schedule.

 

(c) All payments to be made by the Borrower to the Lender hereunder shall be made to the Lender by wire transfer in accordance with the wire instructions given by the Lender to the Borrower in writing from time to time.

 

3.2 Optional Prepayments.

 

(a) Subject to the terms hereof, the Borrower may prepay the outstanding principal of the Loan (in whole but not in part) at any time following the Closing Date, subject to the concurrent payment to the Lender of a prepayment fee calculated in accordance with Section 3.2(b) (the “Prepayment Fee”), together with all accrued and unpaid interest thereon, provided that the Lender receives not less than 10 Business Days’ notice of such prepayment.

 

(b) The Prepayment Fee shall be equal to the greater of (i) the total unpaid annual Interest Expense that would have been payable during the year in which the prepayment in accordance with Section 3.2(a) is made if such prepayment is made prior to the first anniversary of the Closing; and (ii) $300,000.

 

(c) Any amounts prepaid or repaid shall not be re-borrowed. All amounts prepaid or repaid shall be applied (i) firstly in reduction of accrued and unpaid interest and all other amounts then outstanding (other than the principal amount of the Loan), and (ii) thereafter, in reduction of the principal amount of the Loan being prepaid or repaid.

 

13
 

 

3.3 General Matters.

 

All payments made by the Borrower shall be made without set-off, recoupment or counterclaim. The Loan shall, if requested by the Lender, in the Lender’s sole discretion, be evidenced by one or more promissory notes in form and substance satisfactory to the Lender. However, if such Loan is not so evidenced, the Loan made by the Lender, including rates of interest, fees and other charges, may be evidenced by entries upon the books and records maintained by the Lender which books and records shall constitute conclusive evidence thereof in the absence of manifest error.

 

ARTICLE 4 - INTEREST, FEES AND CHARGES

 

4.1 Rate of Interest.

 

Subject to Section 4.3, the principal amount of the Loan and other outstanding Obligations shall bear interest from the Closing Date to the date paid, and at a rate equal to 15% per annum compounded quarterly; provided, however, that upon the occurrence of an Equity Financing interest shall thereafter be calculated at a rate equal to 13% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4.

 

4.2 Payment of Interest.

 

The Borrower shall pay the Lender all accrued and unpaid interest on the principal amount of the Loan and the outstanding amount of other Obligations quarterly in arrears in cash on each Interest Payment Date, starting with the Interest Payment Date falling on March 31, 2015.

 

4.3 Default Rate of Interest.

 

Upon and after the occurrence of an Event of Default under Section 11.1, and during the continuation thereof, the principal amount of the Loan and the other Obligations shall bear interest at a rate per annum equal to the interest rate otherwise payable pursuant to Section 4.1 plus five percent (5%) and such interest shall be calculated daily and compounded quarterly and shall be payable on demand by the Lender.

 

4.4 Computation of Interest and Fees.

 

Interest hereunder shall be determined daily and compounded quarterly not in advance, both before and after demand, default and judgment and shall be computed on the actual number of days elapsed over a year of three hundred and sixty-five (365) days or three hundred and sixty- six (366) days, as the case may be.

 

4.5 Maximum Interest.

 

It is the intent of the parties that the rate of interest and the other charges to the Borrower under this Agreement shall be lawful; therefore, if for any reason the interest or other charges payable under this Agreement are found by a court of competent jurisdiction, in a final determination, to exceed the limit which the Lender may lawfully charge the Borrower, then the obligation to pay interest and other charges shall automatically be reduced with retroactive effect to such limit and, if any amount in excess of such limit shall have been paid, then such amount shall be refunded to the Borrower.

 

4.6 Origination Fee.

 

The Borrower will pay to the Lender an origination fee equal to $120,000, being 2% of the Loan amount, which will be payable at Closing.

 

4.7 Work Fee.

 

The Borrower will pay to the Lender a work fee equal to $60,000, being 1% of the Loan amount, which will be payable at the earlier of January 23, 2015 and Closing. For greater certainty, the said fee is payable whether or not Closing occurs.

 

14
 

 

4.8 Lender’s Expenses.

 

The Borrower shall reimburse the Lender for all reasonable costs and expenses (including without limitation, reasonable consultant’s fees and expenses and reasonable legal fees and expenses in each applicable jurisdiction) incurred by the Lender in connection with: (a) the documentation and consummation of this transaction (whether or not this transaction is consummated) including, without limitation, security and other public record searches, lien filings, express mail or similar express or messenger delivery, due diligence costs and expenses, (b) and in seeking to collect, protect or enforce any rights in or to the Collateral or incurred by the Lender in seeking to collect any Obligations and to administer and enforce any of its rights under this Agreement and the other Loan Documents. All such costs, expenses and charges incurred after the Closing Date will constitute Obligations hereunder, shall by payable by the Borrower to the Lender on demand and, if overdue by 30 days or more, until paid, will bear interest at the Deemed Interest Rate.

 

4.9 Illegality.

 

If any Applicable Law coming into force after the Closing Date, or if any change in any existing Applicable Law or in the interpretation or application thereof by any court or Governmental Authority, now or hereafter makes it unlawful for the Lender to have advanced or acquired interest in the Loan or to give effect to its obligations in respect thereof, the Lender may, by written notice thereof to the Borrower, declare its obligations under this Agreement to be terminated, and the Borrower shall prepay, within the time required by such law, the principal amount of the Loan together with accrued interest thereon and any other amounts owing under this Agreement as may be applicable to the date of such payment (excluding for the avoidance of doubt, any amount of the Prepayment Fee). If any such event shall, in the opinion of the Lender, only affect part of its obligations under this Agreement, the remainder of this Agreement shall be unaffected and the obligations of the Borrower under the Loan Documents shall continue.

 

4.10 Increased Costs.

 

Notwithstanding any other provision herein, in the event that the introduction of or any change in any Applicable Law or in the interpretation or application thereof, or compliance by the Lender with any request or directive (whether or not having the force of law) from any Governmental Authority:

 

(a) subjects the Lender to any new tax of any kind whatsoever with respect to this Agreement, the other Loan Documents or the Loan, or changes the basis of taxation of payments to the Lender of principal, interest or any other amount payable hereunder (except for changes in the rate of tax imposed on the overall net income of the Lender); or

 

(b) imposes, modifies, holds applicable any reserve, special deposit, compulsory loan or similar requirement against Property held by, or deposits or other obligations in or for the account of, advances or loans by, or other credit extended by, or any other acquisition of funds by, any office of the Lender; and the result of any of the foregoing is to materially increase the cost to the Lender of agreeing to make, making, continuing or maintaining or participating in the Loan, or to materially reduce any amount receivable thereunder or to materially increase the withholding taxes payable then, in any such case, the Borrower shall pay the Lender, after demand by the Lender, any additional amounts necessary to compensate the Lender on an after-tax basis for such additional cost or reduced amount receivable or increased withholding taxes payable with respect to any Loan Document or the Loan made hereunder.

 

ARTICLE 5 - TERMINATION AND REDUCTION

 

5.1 Termination.

 

This Agreement shall be in effect from the date hereof until the indefeasible repayment and performance in full of the Obligations upon the Maturity Date (unless the Obligations become due and payable pursuant to Article 11 hereof in which case the Borrower shall immediately pay all of the Obligations, or are prepaid in accordance with Section 3.2). If the due date of the Obligations is accelerated pursuant to Article 11 hereof or if the Borrower prepays the Loan in accordance with Section 3.2 hereof, this Agreement shall terminate on the date that all such Obligations are indefeasibly paid in full. At such time as the Borrower has repaid all of the Obligations and this Agreement has terminated:

 

(a) the Borrower shall provide a release of any obligations and obligations of the Lender and its Affiliates, in form and substance reasonably satisfactory to the Lender; and

 

15
 

 

(b) the Lender shall, at the Borrower’s cost and expense, deliver to the Borrower a termination, discharge and release of all security in form and substance reasonably satisfactory to the Borrower and such other documents and instruments as the Borrower may reasonably request in order to effect or evidence the termination of this Agreement and the security.

 

5.2 Continuing Obligations.

 

Nothing in Section 5.1 shall affect any liabilities and obligations of Borrower or the Lender set out in this Agreement or in any other Loan Document which are stated to survive payment of the Obligations and termination of this Agreement or the Loan Documents, as the case may be.

 

ARTICLE 6 - SECURITY AND COLLATERAL

 

6.1 Security Delivered on the Closing Date.

 

On the Closing Date, as continuing collateral security for the payment and satisfaction of all Obligations of the Borrower to the Lender, the Borrower shall deliver or cause to be delivered to the Lender Security on the Collateral, including the following Security Documents, all of which shall be in form and substance satisfactory to the Lender:

 

(a) a general security agreement from Borrower in favour of the Lender constituting a first-priority Lien (subject only to Permitted Liens) on all of the present and future Property of Borrower;

 

(b) a collateral assignment from Borrower of its interests in all Material Contracts and Material Licenses;

 

(c) Subordination Agreement with FNL in favour of the Lender;

 

(d) Control Agreement;

 

(e) Intellectual Property Security Agreement; and

 

(f) such other agreements as the Lender may require from time to time.

 

6.2 Further Assurances.

 

The Borrower shall take or cause to be taken such action and execute and deliver or cause to be executed and delivered to the Lender such agreements, documents and instruments as the Lender shall request, and register, file or record the same (or a notice or financing statement in respect thereof) in all offices where such registration, filing or recording is, in the opinion of the Lender or Lender’s counsel, necessary or advisable to constitute, perfect and maintain the Security Documents referred to in Section 6.1 as first-ranking Liens of Borrower or the Person granting such Liens, subject only to the Permitted Liens, in all jurisdictions reasonably required by the Lender, in each case within a reasonable time after the request therefor by the Lender or Lender’s counsel, and in each case in form and substance satisfactory to the Lender and Lender’s counsel, acting reasonably.

 

6.3 Security Effective Notwithstanding Date of Loan.

 

The Security shall be effective and the undertakings in this Agreement and the other Loan Documents with respect thereto shall be continuing, whether the monies hereby or thereby secured or any part thereof shall be advanced before or after or at the same time as the creation of any such Security or before or after or upon the date of execution of this Agreement. The Security shall not be affected by any payments on this Agreement or any of the other Loan Documents, but shall constitute continuing security to and in favour of the Lender for the Obligations from time to time.

 

16
 

 

6.4 No Merger.

 

The Security shall not merge in any other security. No judgment obtained by or on behalf of the Lender shall in any way affect any of the provisions of this Agreement, the other Loan Documents or the Security. For greater certainty, no judgment obtained by or on behalf of the Lender shall in any way affect the obligation of the Borrower to pay interest or other amounts at the rates, times and in the manner provided in this Agreement.

 

6.5 Release of Security.

 

Following due payment and performance in full of all Obligations of the Borrower under this Agreement and the other Loan Documents, the Lender will, at the cost and expense of the Borrower, release and discharge the right and interest of the Lender in the Collateral, following indefeasible payment and performance in full of all Obligations of the Borrower under this Agreement and the other Loan Documents.

 

In addition, if any Property of Borrower is Disposed of as permitted by this Agreement or is otherwise released from the Security at the direction or with the consent of the Lender, at the request, cost and expense of the Borrower (on satisfaction, or on being assured of concurrent satisfaction, of any condition to or obligation imposed with respect to such Disposition), the Lender shall discharge such Property from the Security and deliver and re-assign to the Borrower or its Subsidiaries (without any representation or warranty) any of such Property as is then in the possession of the Lender.

 

ARTICLE 7 - REPRESENTATIONS AND WARRANTIES

 

7.1 Representations and Warranties.

 

The Borrower hereby makes the following representations, warranties and covenants:

 

(a) Existence and Qualification. The Borrower (i) has been duly incorporated, amalgamated, formed, merged or continued, as the case may be, and is validly subsisting and in good standing as a corporation, company or partnership, under the laws of its jurisdiction of incorporation, amalgamation, merger, formation or continuance, as the case may be, (ii) is duly qualified to carry on its business in each jurisdiction in which it carries on business or will carry on business after giving effect to the FNL Transaction except for nonqualification which has no adverse effect on the Business or the FNL Transaction, and (iii) has all required Material Licences.

 

(b) Power and Authority. The Borrower has the corporate, company or partnership power, capacity and authority, as the case may be, (i) to enter into, and to exercise its rights and perform its obligations under, the Loan Documents to which it is a party and all other instruments and agreements delivered by it pursuant to any of the Loan Documents, and (ii) to own its Property and carry on its business as currently conducted or as will be conducted after giving effect to the FNL Transaction.

 

(c) Execution, Delivery, Performance and Enforceability of Documents. The execution, delivery and performance of each of the Loan Documents to which Borrower is a party, and every other instrument or agreement delivered by Borrower pursuant to the FNL Transaction has been duly authorized by all corporate or limited liability company, as the case may be, actions required, and each of such documents has been duly executed and delivered by it. Each Loan Document to which Borrower is a party constitutes the legal, valid and binding obligation of Borrower, enforceable against Borrower in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity).

 

(d) Compliance with Applicable Laws, Organizational Documents and Contractual Obligations. None of the execution or delivery of, the consummation of the transactions contemplated in, or the compliance with the terms, conditions and provisions of any of, the Loan Documents or any of the agreements or documents delivered in connection with the FNL Transaction by Borrower conflicts with or will conflict with, or results or will result in any breach of, or constitutes a default under or contravention of, any Requirement of Law in any material respect, Borrower’s Organizational Documents or any Material Contract or Material Licence, or results or will result in the creation or imposition of any Liens upon any of its Property except for Permitted Liens.

 

17
 

 

(e) Consent Respecting Loan Documents. The Borrower has obtained, made or taken all consents, approvals, authorizations, declarations, registrations, filings, notices and other actions whatsoever required (except for registrations or filings which may be required in respect of the Security Documents) to enable it to execute and deliver each of the Loan Documents to which it is a party and to consummate the transactions contemplated in the Loan Documents, and to complete and implement the FNL Transaction and to execute and deliver each of the instruments and agreements delivered by it in connection with the FNL Transaction and to consummate the transactions contemplated in such instruments and agreements except where the failure to do so is immaterial considering the nature of the FNL Transaction and the Loan Documents.

 

(f) Intellectual Property.

 

(i) The Borrower possesses, and shall continue to possess, adequate Intellectual Property to continue to conduct its Business as heretofore conducted by it, details of all of which as of the Closing Date are described on Schedule 7.1(f). After completion of the FNL Transaction, Borrower shall possess and shall continue to possess adequate Intellectual Property to conduct the FNL Business as did FNL prior to the said completion.

 

(ii) Except as set forth in Schedule 7.1(f). Borrower will be entitled to continue to use, practice and exercise rights in, all of the Intellectual Property including that acquired as part of the FNL Transaction.

 

(g) Current and Prior Names. The Borrower’s current and prior names, trade-names and division names and those proposed to be used after giving effect to the FNL Transaction are described on Schedule 7.1(g).

 

(h) Corporate Structure. The Borrower has no Subsidiaries. The Borrower is not engaged in any joint venture or partnership with any other Person.

 

(i) Litigation. Except as described in Schedule 7.1(i). to the best of Borrower’s knowledge after due inquiry, there are no actions, suits, counterclaims or proceedings which are pending or threatened against Borrower which if adversely determined would have a Material Adverse Effect.

 

(j) Material Contracts and Licences. Schedule 7.1(j) (as amended from time to time and updated in accordance with delivery of a Compliance Certificate pursuant to Section 8.2), accurately sets out all Material Contracts and Material Licences, including after giving effect to the FNL Transaction. A true and complete certified copy of each Material Contract and Material Licence existing at the Closing Date, including after giving effect to the FNL Transaction, has been delivered to the Lender and each Material Contract and Material Licence is in full force and effect. No event has occurred and is continuing which would constitute a material breach of or a default under any such Material Contract or Material Licence. Each Material Contract to which Borrower is a party is binding upon Borrower and, to its knowledge, is a binding agreement of each other Person who is a party to the Material Contract. It has obtained, as of the Closing Date, all necessary consents, including consents of landlords to the granting of a security interest in each Material Contract and Material Licence pursuant to the Security Documents.

 

(k) No Liens. No security agreement, financing statement or analogous instrument exists as at the Closing Date with respect to any of the Collateral other than any security agreement, financing statement or analogous instrument evidencing Permitted Liens.

 

(l) Title to Collateral. The Borrower is the lawful owner of all Collateral now purportedly owned or hereafter purportedly acquired by it (including, without limitation, pursuant to the FNL Transaction), free from all Liens, whether voluntarily or involuntarily created and whether or not perfected, other than Permitted Liens.

 

(m) Financial Information. All of the quarterly and annual Financial Statements or other financial information which have been furnished to the Lender, in connection with this Agreement or the FNL Transaction are complete in all material respects and such Financial Statements or other financial information fairly present the results of operations and financial position of the Borrower or the FNL Business (as applicable) as of the dates referred to therein and have been prepared in accordance with IFRS. All other financial information (including, without limitation, the Annual Business Plan) provided to the Lender are complete in all material respects and based on reasonable assumptions and expectations.

 

18
 

 

(n) Permitted Debt. As of the Closing Date (giving effect to the making of the Loan), the Borrower is not obligated, whether directly or indirectly, for any Debt other than the Permitted Debt.

 

(o) Taxes. Except as disclosed in Schedule 7.1(o). the Borrower has duly and timely filed all Tax returns required to be filed by it and has paid or made adequate provision for the payment of all Taxes levied on its Property or income which are showing therein as due and payable, including interest and penalties, or has accrued such amounts in its financial statements for the payment of such Taxes except for Taxes which are not material in amount or which are not delinquent or if delinquent are being contested, and there is no material action (except, after the date of this Agreement, as is disclosed to the Lender in writing), suit, proceeding, investigation, audit or claim now pending, or to its knowledge, threatened by any Governmental Authority regarding any Taxes nor has it agreed to waive or extend any statute of limitations with respect to the payment or collection of Taxes. There is no material Tax liability to the Borrower that will arise as a result of the completion of the FNL Transaction.

 

(p) Full Disclosure. All information provided or to be provided to the Lender by or on behalf of Borrower in connection with the Loan and the FNL Transaction is, to Borrower’s knowledge, true and correct in all material respects and none of the documentation furnished to the Lender by or on behalf of it, to Borrower’s knowledge, omits or will omit as of such time, a material fact necessary to make the statements contained therein not misleading in any material way, and all expressions of expectation, intention, belief and opinion contained therein were honestly made on reasonable grounds (and any other Person who furnished such material on behalf of it).

 

(q) Insolvency. The Borrower (i) has not committed any act of bankruptcy, (ii) is not insolvent, nor has proposed, nor given notice of its intention to propose, a compromise or arrangement to its creditors generally, nor (iii) has any petition for a receiving order in bankruptcy filed against it, made a voluntary assignment in bankruptcy, taken any proceeding with respect to any compromise or arrangement, taken any proceeding to have itself declared bankrupt or wound-up, taken any proceeding to have a receiver appointed of any part of its Property.

 

(r) Location of Collateral. The offices where Borrower keeps its books, records and accounts (or copies thereof) concerning the Collateral, Borrower’s principal place of business and all of Borrower’s other significant places of business and significant locations of Collateral, all after giving effect to the FNL Transaction, are as set forth in Schedule 7.1(r).

 

(s) Owned Real Property. A list of Borrower’s owned real property after giving effect to the FNL Transaction is as set forth in Schedule 7.1(s).

 

(t) Leased Real Property. A list of Borrower’s leased real property after giving effect to the FNL Transaction is as set forth in Schedule 7.1(t).

 

(u) Environmental Laws. The Borrower complied with all Environmental Laws applicable to the construction and operation of its Property and businesses, except where any non-compliance would not reasonably be expected to have a Material Adverse Effect; the Borrower has no material contingent liability with respect to non-compliance with Environmental Laws or the generation, handling, use, storage, or disposal of Materials of Environmental Concern; and, without limiting the generality of the foregoing, except as would not reasonably be expected to have a Material Adverse Effect, the Borrower:

 

(i) has not received any Action Request, Violation Notice, summons, complaint, order or other notice that it is not in compliance with, or that any Governmental Authority is investigating its compliance with. Environmental Laws:

 

(ii) has no knowledge or reason to believe that operations or any Property of or occupied by the Borrower or in the Borrower’s charge, management or control are not in compliance with all applicable Environmental Laws and each of its Properties is free:

 

(A) from contamination by, and there has not been thereon a release, discharge or emission of, any Materials of Environmental Concern which is prohibited, controlled or regulated under any Environmental Law; and

 

19
 

 

(B) of underground storage tanks, landfills, land disposals and dumps;

 

(iii) has not filed any notice, or received notice, under any Applicable Law, including any Environmental Law, indicating past or present treatment, storage or disposal of a Material of Environmental Concern or reporting any spill or release of a Material of Environmental Concern into the environment;

 

(iv) has no contingent liability of which the Borrower has knowledge or reasonably should have knowledge in connection with any release of any Material of Environmental Concern;

 

(v) does not generate, transport, treat or dispose of any Material of Environmental Concern in any manner which is not in compliance with all applicable Environmental Laws; and

 

(vi) has not disposed of any Material of Environmental Concern in or on the ground of Borrower’s real properties or premises leased by Borrower.

 

(v) Labor Matters. Except as provided on Schedule 7.1(v) and after giving effect to the FNL Transaction:

 

(i) there is no collective bargaining agreement or other labour contract covering employees of Borrower;

 

(ii) there is no pending or, to the best of its knowledge, threatened strike, work stoppage, material unfair labour practice claims, or other material labour dispute against or affecting Borrower or its employees which would reasonably be expected to have a Material Adverse Effect;

 

(iii) there are no controversies pending or threatened between Borrower and any of its employees, other than employee grievances arising in the ordinary course of business which would not reasonably be expected to have a Material Adverse Effect; and

 

(iv) the Borrower is in compliance in all material respects with all Applicable Laws respecting employment and employment terms, conditions and practices, except where the failure to so comply would not reasonably be expected to have a Material Adverse Effect.

 

(w) Pension Plans. Except as disclosed on Schedule 7.1(w) and after giving effect to the FNL Transaction, the Borrower does not sponsor or maintain or contribute to a Pension Plan. With respect to any Pension Plan adopted or to which Borrower may become obliged to contribute (including after giving effect to the FNL Transaction), no failure to remit contributions (other than immaterial amounts) has occurred with respect to any such Pension Plan, that is sufficient to give rise to a Lien under any Applicable Laws of any jurisdiction (other than a Permitted Lien), and no condition exists and no event or transaction has occurred with respect to any such Pension Plan which could result in the incurrence by Borrower of any material liability, fine or penalty. Each Pension Plan is in compliance in all material respects with all Applicable Laws pertaining to pension benefits and Tax laws, (i) all contributions (including employee contributions made by authorized payroll deductions or other withholdings) required to be made to the appropriate funding agency in accordance with all Applicable Laws and the terms of such Pension Plan have been made in accordance with all Applicable Laws and the terms of such Pension Plan, except for amounts which are immaterial, (ii) all liabilities under such Pension Plan are fully funded, on a going concern and solvency basis, in accordance with the terms of the respective Pension Plans, the requirements of applicable pension benefits laws and of applicable regulatory authorities and the most recent actuarial report filed with respect to the Pension Plan. No event has occurred and no conditions exist with respect to any such Pension Plan that has resulted or could reasonably be expected to result in such Pension Plan having its registration revoked or refused for the purposes of any applicable pension benefits or tax laws or being placed under the administration of any relevant pension benefits regulatory authority or being required to pay any taxes or penalties under any applicable pension benefits or tax laws.

 

20
 

 

(x) ERISA, (i) With respect to each ERISA Plan, it and each other member of its Controlled Group has fulfilled its obligations under the minimum funding standards of and is in compliance in all material respects with ERISA and the Revenue Code to the extent applicable to it and has not incurred any liability to the PBGC or under Title IV of ERISA, other than a liability to the PBGC for premiums under Section 4007 of ERISA; (ii) it does not have any contingent liabilities with respect to any post-retirement benefits under a Welfare Plan, other than liability for continuation coverage described in Part 6 of Title I of ERISA or as required under Applicable Law requirements for health continuation coverage, (iii) neither a Reportable Event nor a Prohibited Transaction has occurred and is continuing with respect to any ERISA Plan; (iv) no notice of intent to terminate an ERISA Plan has been filed, nor has any ERISA Plan been terminated; (v) no circumstances exist which constitute grounds entitling the PBGC to institute proceedings to terminate, or appoint a trustee to administer, ERISA Plan, nor has the PBGC instituted any such proceedings; (vi) neither it nor any member of its Controlled Group has completely or partially withdrawn from a multiemployer plan; (vii) it and all members of its Controlled Group have met their minimum funding requirements under ERISA with respect to all of their ERISA Plans and the present value of all vested benefits under each ERISA Plan exceeds the fair market value of all such ERISA Plan assets allocable to such benefits, as determined on the most recent valuation date of such ERISA Plan and in accordance with the provisions of ERISA; and neither it nor any member of its Controlled Group has incurred any liability to the PBGC under ERISA.

 

(y) Computer Software. The Borrower owns or has licensed for use or otherwise has the right to use or to acquire or licence all of the material software necessary to conduct its businesses and the FNL Business. All computer equipment owned or used by Borrower or to be acquired pursuant to the FNL Transaction and necessary for the conduct of business and the FNL Business has been properly maintained and is in good working order for the purposes of on-going operation, subject to ordinary wear and tear for computer equipment of comparable age.

 

(z) Insurance. The Borrower has maintained and maintains insurance which is in full force and effect that complies with all of the requirements of this Agreement. The Borrower has maintained and maintains product liability insurance which is in full force and effect covering at least $1,000,000 per claim and $3,000,000 in the aggregate. Schedule 7.1(z) lists all existing insurance policies maintained by Borrower as of the Closing Date.

 

(aa) OF AC. The Borrower is not in violation of any of the country or list based economic and trade sanctions administered and enforced by OF AC. The Borrower (i) is not a Sanctioned Person or a Sanctioned Entity, (ii) has no more than ten percent (10%) of its assets located in Sanctioned Entities, or (iii) derives no more than ten percent (10%) of its revenues from investments in, or transactions with Sanctioned Persons or Sanctioned Entities.

 

(bb) Investment Company. The Borrower is not an “investment company” nor a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940 of the United Sates, as amended.

 

(cc) No Margin Stock. The Borrower is not engaged in the business of extending credit for the purpose of purchasing or carrying margin stock. None of the proceeds of the Loan shall be used to purchase or carry, or to reduce or retire or refinance any credit incurred to purchase or carry, any margin stock (within the meaning of Regulations U and X of the Board of Governors of the Federal Reserve System of the United States) or to extend credit to others for the purpose of purchasing or carrying any margin stock.

 

(dd) Perfection Certificate. The information set forth in the Perfection Certificate (and each Perfection Certificate delivered in accordance herewith) is true, correct and complete as of the date set forth therein and will be true, correct and complete on the Closing Date.

 

(ee) FNL Asset Purchase Agreement. The accuracy and completeness of each of the representations and warranties set out in Section 5 of the FNL Asset Purchase Agreement, including the definitions used in such sections of the FNL Asset Purchase Agreement (whether defined in Section 5 of the FNL Asset Purchase Agreement or elsewhere) and all such representations, warranties and definitions are hereby incorporated into this Agreement by reference as if same were herewith recited at length and made directly by the Borrower for the benefit of the Lender. Such representations and warranties shall survive for so long as the Obligations remain outstanding, notwithstanding any shorter survival period under the Purchase Agreement.

 

(ff) No Material Adverse Effect. No event has occurred which has had or could reasonably be expected to have a Material Adverse Effect.

 

(gg) No Default or Event of Default. No Default or Event of Default has occurred and is continuing.

 

21
 

 

(hh) Regulatory Matters.

 

(i) Except as set out in Schedule 7.1(i). each Product that is subject to the Applicable Laws promulgated by a Regulatory Authority, is manufactured, packaged, labelled, imported, exported, stored, distributed, sold (whether or not for consideration), advertised and marketed in compliance with all such Applicable Laws, (except for immaterial non-compliance) as well as all material terms and conditions imposed in any licences and permits issued in respect of the Products.

 

(ii) Neither the Borrower nor, to the knowledge of the Borrower, any officer, employee, contractor or agent of the Borrower has ever made an untrue statement of material fact or fraudulent statement to a Regulatory Authority or failed to disclose a material fact required to be disclosed to a Regulatory Authority.

 

(iii) Except as set out in Schedule 7.1 (iii) no Product has been recalled, withdrawn, suspended or discontinued (other than for commercial or business reasons) by Borrower at any time, and Borrower have not received any information or report from any Governmental Authority, indicating that any of the Products, or ingredients therein, are unsafe or unsuitable for its intended use or pose an unacceptable health risk.

 

(iv) To the knowledge of Borrower after due inquiry, none of the Products or ingredients therein have been the subject of a warning, consumer alert or other cautionary statement issued by any Governmental Authority nor is there any ongoing complaint or investigation by any Governmental Authority relating to the advertising or marketing practices used for any Product. Other than as provided for in Schedule 7.1(hh). Borrower are not aware of any facts that would indicate that any Governmental Authority has or will prohibit or materially restrict the marketing, sale, distribution or use in the United States, Canada or Europe of any Product or the operation or use of any facility currently used to produce, manufacture or distribute the Products.

 

(ii) None of the foregoing representations and warranties and no document furnished by or on behalf of Borrower to the Lender in connection with the negotiation of the transactions contemplated by this Agreement contain any untrue statement of a material fact or omit to state any material fact necessary to make any such statement or representation (taken as a whole) not materially misleading at such time in light of the circumstances under which such information or data was furnished.

 

7.2 Survival of Representations and Warranties.

 

The Borrower, for itself and on behalf of Borrower, represents, warrants and covenants that all representations, warranties and covenants contained in this Agreement (whether appearing in Article 7 or elsewhere) shall be true, correct and complete at the time of the Borrower’s execution of this Agreement, shall survive the execution, delivery and acceptance hereof by the parties hereto and the closing of the transactions described herein or related hereto, shall, except for representations and warranties that relate solely to an earlier date, remain true, correct and complete until the indefeasible repayment and performance in full of all of the Obligations and termination of this Agreement.

 

ARTICLE 8 - SCHEDULES AND REPORTS

 

8.1 Financial Information.

 

The Borrower shall deliver to the Lender the following financial information:

 

(a) no later than forty-five (45) days after the end of the Borrower’s first three Fiscal Quarters each year, copies of internally prepared Consolidated Financial Statements of the Borrower;

 

(b) no later than ninety (90) days after the end of each Fiscal Year of the Borrower, copies of annual Consolidated Audited Financial Statements of the Borrower, along with a comparison to the budget set forth in the Annual Business Plan and the previous year;

 

22
 

 

(c) no later than thirty (30) days prior to the commencement of each Fiscal Year of the Borrower, a copy of the Annual Business Plan (in form and substance satisfactory to the Lender) approved by the board of directors of the Borrower, and, within twenty (20) days of any material modification thereto, a copy of the Annual Business Plan previously delivered, as modified; provided, however, the parties acknowledge that a copy of the Annual Business Plan for Fiscal Year 2015 will only be delivered to the Lender on or before January 31, 2015; and

 

(d) no later than twenty-five (25) days after the end of each calendar month, copies of the Cash Balance Statements.

 

8.2 Compliance Certificate.

 

With each Financial Statement delivered pursuant to Sections 8.1(a), 8.1(b) and 8.1(d), the Borrower shall deliver to the Lender a Compliance Certificate. For greater certainty, the Compliance Certificate with respect to the Cash Balance Statement will be delivered monthly when due under Section 8.1(d).

 

8.3 Other Matters.

 

At such times as may be requested by the Lender from time to time hereafter, the Borrower shall deliver to the Lender (i) such additional schedules, certificates, reports and information with respect to the Collateral as the Lender may from time to time reasonably require, including, but not limited to, non-consolidated Financial Statements of the Borrower; (ii) a collateral assignment of any or all items of property held by Borrower, from time to time, to the Lender or as the Lender may direct in order to perfect and further establish the security interests in favour of the Lender (or the Collateral Agent in the discretion of the Lender) in such property in accordance with this Agreement (to the extent not otherwise previously perfected under a Loan Document). All schedules, certificates, reports and assignments and other items delivered by the Borrower to the Lender hereunder shall be executed by an authorized representative of the Borrower, and shall be in such form and contain such information as the Lender shall reasonably request. The Lender, through its officers, employees or agents, shall have the right, upon reasonable notice at any time and from time to time in the Lender’s name, in the name of a nominee of the Lender or in Borrower’s name, to verify the validity, amount or any other matter relating to any of the Collateral, by mail, telephone, telegraph or otherwise. The Borrower shall reimburse the Lender, on demand, for all reasonable receipted costs, fees and expenses incurred by the Lender in this regard.

 

ARTICLE 9 – COVENANTS

 

9.1 Covenants.

 

Until indefeasible payment and performance in full of all Obligations and termination of this Agreement, unless the Borrower obtains the prior written consent of the Lender waiving or modifying any covenants hereunder in any specific instance, the Borrower shall:

 

(a) Timely Payment. Make due and timely payment of the Obligations required to be paid by it hereunder.

 

(b) Conduct of Business, Maintenance of Existence, Compliance with Laws. Carry on and conduct its business and operations in a proper, efficient and businesslike manner, in accordance with good business practice except for non-compliance which would not have a Material Adverse Effect; preserve, renew and keep in full force and effect its existence; and take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business and to comply in all material respects with all Material Contracts, Material Licences and Requirements of Law.

 

(c) Further Assurances. Provide the Lender with such other documents, opinions, consents, acknowledgements and agreements as are reasonably necessary to implement this Agreement and the other Loan Documents from time to time.

 

23
 

 

(d) Access to Information. Promptly provide the Lender with all information reasonably requested by the Lender from time to time concerning its financial condition and Property, and during normal business hours and from time to time upon reasonable notice, permit representatives of the Lender to inspect any of its Property and to examine and take extracts from its financial books, accounts and records including but not limited to accounts and records stored in computer data banks and computer software systems, and to discuss its financial affairs, its business or any part of its Property with its senior officers and (in the presence of such of its representatives as it may designate) its Auditor. Provided that a Default or Event of Default is then continuing (or the Lender reasonably expects that that is the case), the Borrower will pay all reasonable expenses incurred by such representatives in order to visit Borrower’s premises or attend at the Borrower’s principal office, as applicable, for such purposes.

 

(e) Obligations and Taxes. Pay or discharge or cause to be paid or discharged, before the same shall become delinquent (i) all Taxes imposed upon it or upon its income or profits or in respect of its business or Property and file all tax returns in respect thereof; (ii) all lawful claims for labour, materials and supplies; (iii) all required payments under any of its Debt, and (iv) all other obligations; provided, however that it shall not be required to pay or discharge or to cause to be paid or discharged any such amount so long as the validity or amount thereof shall be contested in good faith by appropriate proceedings and, in the case of clause (i) above, an adequate reserve in accordance with IFRS has been established in its books and records.

 

(f) Use of Loan. Use the proceeds of the Loan only to finance the FNL Transaction and the expenses related thereto or related to this Agreement and the Loan Documents and for working capital for the Business.

 

(g) Insurance. Maintain or cause to be maintained with reputable insurers coverage against risk of loss or damage to its Property (including public liability and damage to property of third parties) and business interruption insurance of such types as is customary for and would be maintained by a corporation with an established reputation engaged in the same or similar business in similar locations and provide to the Lender, as requested (acting reasonably), evidence of such coverage. The Borrower shall, prior to the expiry or replacement of any insurance policy, notify the Lender of the replacement and at the Lender’s request send copies of all replacement policies to the Lender. Without limiting the generality of the foregoing, the Borrower will maintain product liability insurance covering at least $1,000,000 per claim and $3,000,000 in the aggregate. Without limiting the generality of the foregoing, the Borrower shall maintain in effect all insurance coverage reasonable and prudent for a business similar to the Business conducted in similar locations. The Lender shall be indicated in all insurance policies, as applicable, as first loss payee and additional insured, and all policies shall contain such standard mortgage clauses as the Lender shall reasonably require for the Lender’s protection.

 

(h) Notice of Default or Event of Default. Promptly and, in any event within two (2) Business Days, notify the Lender of any Default or Event of Default that would apply to it or to Borrower of which it becomes aware along with the action to be taken by Borrower to remedy any such Default or Event of Default.

 

(i) Notice of Material Adverse Effect. Promptly notify the Lender of any Material Adverse Effect of which it becomes aware.

 

(j) Notice of Litigation. Promptly notify the Lender on becoming aware of the occurrence of any litigation, dispute, arbitration, proceeding or other circumstance the result of which if determined adversely would or could reasonably be expected to result in (a) a judgment or award against it in excess of $100,000 or (b) a Material Adverse Effect, and from time to time provide the Lender with all reasonable information requested by it concerning the status of any such proceeding.

 

(k) Other Notices. Promptly, upon having knowledge, give notice to the Lender of:

 

(i) any notice of expropriation affecting Borrower;

 

(ii) any Action Request or Violation Notice;

 

(iii) any violation of any Applicable Law which does or may have a Material Adverse Effect on Borrower;

 

24
 

 

(iv) any default under any Debt in a principal amount greater than $100,000 of Borrower;

 

(v) any termination prior to maturity of or default under a Material Contract or any termination, lapse, rescission or default under a Material Licence;

 

(vi) any damage to or destruction of any Property, of Borrower having a replacement cost in excess of $100,000;

 

(vii) the acquisition of any real property by Borrower;

 

(viii) the receipt of insurance proceeds by Borrower in excess of $100,000;

 

(ix) any Lien registered against any Property of Borrower, other than a Permitted Lien;

 

(x) the occurrence of any event referred to in Section 7. l(w);

 

(xi) a Product being recalled, withdrawn, suspended or discontinued or is under consideration of being recalled, withdrawn, suspended or discontinued;

 

(xii) a Product being the subject of a warning, consumer alert or other cautionary statement issued by any Governmental Authority;

 

(xiii) any information or report from any Governmental Authority, indicating that any of the Products are, unsafe or unsuitable for its intended use or pose an unacceptable health risk;

 

(xiv) a default under the FNL Asset Purchase Agreement;

 

(xv) any entering into of a Material Contract or Material Licence; and

 

(xvi) any material adverse change in, or material adverse amendment to, or termination of a Material Contract or Material Licence.

 

(1) Environmental Compliance. Operate its business in compliance with Requirements of Environmental Laws (except where the failure to do so would not have a Material Adverse Effect) and operate all Property owned, leased or otherwise used by it such that no obligation, including a clean-up or remedial obligation, will arise under any Requirements of Environmental Law; provided, however, that if any such claim is made or any such obligation arises, the Borrower shall promptly satisfy, address or contest such claim or obligation at its own cost and expense. It shall promptly notify the Lender upon: (i) learning of the existence of any Materials of Environmental Concern located on, above or below the surface of any land which it owns, leases, operates, occupies or controls (except those being stored, used or otherwise handled in compliance with Requirements of Environmental Law), or contained in the soil or water constituting such land; and (ii) the occurrence of any reportable release, spill, leak, emission, discharge, leaching, dumping or disposal of Materials of Environmental Concern that has occurred on or from such land, which, in either the case of (i) or (ii), is likely to result in liability under Requirements of Environmental Law in excess of $100,000.

 

(m) Security. With respect to the Security:

 

(i) provide to the Lender the Security required from time to time pursuant to Article 6 in accordance with the provisions of such Article, accompanied by supporting resolutions, certificates and opinions in form and substance satisfactory to the Lender; and

 

(ii) do, execute and deliver all such things, documents, security, agreements and assurances as may from time to time be requested by the Lender to ensure that the Lender holds at all times valid, enforceable, perfected first-priority Liens (subject only to Permitted Liens) on the Collateral from Borrower meeting the requirements of Article 6.

 

25
 

 

(n) Maintenance of Property. Keep all Property useful and necessary in its business in good working order and condition, normal wear and tear excepted, and maintain all Intellectual Property necessary to carry on its business.

 

(o) Landlord Consents. Use its best commercial efforts to obtain, in favour of the Lender, a consent agreement from a landlord of premises that are leased at any time and from time to time by Borrower.

 

(p) Material Contracts. Ensure that any Material Contract is specifically assigned by way of security in favour of the Lender by the Borrower and to obtain, in favour of the Lender, if necessary to assign properly such Material Contract, an acknowledgement of a Person or Governmental Authority to such assignment.

 

(q) Employee Benefit and Welfare Plans. Maintain all employee benefit. Pension Plans and Welfare Plans relating to its business in compliance with all Applicable Laws except for immaterial non-compliance.

 

(r) Additional Information. Promptly provide the Lender, after the sending or filing thereof, with copies of all reports, notices, prospectuses and registration statements which Borrower files with a securities commission or securities regulatory authority in any Province of Canada or any other securities commission.

 

(s) Material Contracts and Material Licences. At the request of the Lender from time to time, provide to the Lender certified copies of all Material Contracts and Material Licences.

 

(t) Regulatory Matters. Ensure that (i) all non-compliance (other than immaterial non-compliance) with regulatory matters as identified in Schedule 7.1(t) is remedied within a reasonable period of time following the Closing Date, and (ii) all existing and future Products are licensed and/or registered, as applicable, in compliance with Applicable Laws.

 

(u) ERISA. Promptly pay and discharge all obligations and liabilities arising under ERISA of a character which if unpaid or unperformed could result in the imposition of a Lien other than a Permitted Lien against any of its Properties; promptly notify the Lender of (i) the occurrence of any Reportable Event with respect to an ERISA Plan that could reasonably be expected to result in material liability, (ii) receipt of any notice from the PBGC of its intention to seek termination of any ERISA Plan or appointment of a trustee therefor, (iii) its intention to terminate or withdraw from any ERISA Plan or multiemployer plan that could reasonably be expected to result in material liability, and (iv) the occurrence of any event with respect to any ERISA Plan or multiemployer plan which would result in the incurrence by it or any Subsidiary of any material liability, fine or penalty, and (v) any material increase in its contingent liability with respect to any post-retirement Welfare Plan benefit.

 

(v) Patriot Act. In the case of Borrower, the Borrower acknowledges and agrees that pursuant to the provisions of the USA Patriot Act (Title HE of the Pub. L. 107-56) signed into law October 26, 2001 (the “Patriot Act”), the Lender may be required to obtain, verify and record information with respect to Borrower; and the Borrower hereby agrees to cooperate with the Lender and provide them with all information that may be required in order to fulfil their obligations under the Patriot Act; and without limiting the generality of the foregoing, the Borrower agrees to use commercially reasonable efforts to obtain the consent of any of their respective officers, directors and employees whose consent to the disclosure of any such information is required under applicable privacy legislation in Canada.

 

(w) Books and Records. At all times keep accurate and complete books, records and accounts with respect to all of its business activities, in accordance with sound accounting practices and, where applicable, IFRS consistently applied, and shall keep such books, records and accounts, and any copies thereof, only at the addresses indicated for such purpose on Schedule 7.1(f):

 

(x) Financial Covenants.

 

  (i) Minimum EBITDA. The Borrower shall maintain a minimum EBITDA of $500,000 for the six (6) months ending on September 30, 2015 and for the six (6) month period ending on the last day of each Fiscal Quarter thereafter.
     
  (ii) Net Debt to TTM EBITDA Ratio. For the Fiscal Quarter ending on March 31, 2016 and at all times thereafter, the Borrower shall maintain a Net Debt to TTM EBITDA Ratio of no more than 6:1.
     
  (iii) Cash Balance. The Borrower will maintain at all times a minimum positive cash balance equal to $750,000 or such lower amount as is agreed to by the Lender acting reasonably (the “Cash Balance Statement”).

 

26
 

 

(y) Board of Directors. Until the repayment and performance in full of all of the Obligations and the termination of this Agreement the Lender shall be entitled to designate one individual (the “Lender’s Nominee”), to be an observer to or, if so determined by Lender, to be nominated and, if elected, to serve as a member of the Borrower’s board of directors (the “Board”), and so long as the Lender’s Nominee serves as a member of the Board, to serve on the Board’s Audit and Compensation Committee or, at Lender’s option, to serve as an observer to such Committees. The Lender acknowledges that any appointment to the Borrower’s Board must be ratified annually by a shareholder vote at the Borrower’s annual general or special meetings of shareholders and the Borrower shall use commercially reasonable efforts to cause the election of the Lender’s Nominee, including soliciting proxies in favour of the election of the Lender’s Nominee in the event the Borrower intends to solicit any such proxies in connection with a meeting of its shareholders. The Borrower shall notify the Lender in writing immediately upon determining the date of any meeting of its shareholders at which directors of the Borrower are to be elected and the Lender shall advise the Borrower and the Board of the name of the Lender’s Nominee within 14 Business Days after receiving such notice. The Lender will provide the Board with reasonable notice of the person it proposes to nominate to the Board, and the Board will give due consideration to the view of the independent members of the Board as to whether such person is an appropriate addition to the Board given his or her skill set. The Borrower shall not be entitled to veto the Lender’s Nominee unless such Lender’s Nominee has previously been removed by a resolution of its shareholders or such Lender Nominee is a director who retired by rotation and was not re-elected by the Borrower’s shareholders. If the Lender’s Nominee ceases to hold office as a director of the Borrower for any reason, the Lender shall be entitled to nominate an individual to replace him or her and the Borrower shall promptly take all steps as may be necessary to appoint such individual to the Board to replace the Lender’s Nominee who has ceased to hold office. The number of persons acting as directors of the Board shall not exceed five (5) persons without the Lender’s prior consent. The Lender’s Nominee shall be entitled, if acting as an observer or a director, to the same number of options to purchase common shares in the capital of the Borrower and on the same terms and conditions as would a director of the Borrower, but not fewer than 1,000,000 options.

 

9.2 Negative Covenants.

 

So long as this Agreement is in force and except as otherwise permitted by the prior written consent of the Lender, the Borrower shall not and shall ensure that Borrower shall not:

 

(a) Disposition of Property. Except for Permitted Dispositions, dispose of, in one transaction or a series of transactions, all or any part of its Property, whether now owned or hereafter acquired.

 

(b) No Consolidation, Amalgamation, etc. Consolidate, amalgamate or merge with any other Person, export a corporation into a jurisdiction outside of the United States, enter into any corporate reorganization or other transaction intended to effect or otherwise permit a change in its existing corporate or capital structure, liquidate, wind-up or dissolve itself, or permit any liquidation, winding-up or dissolution unless prior written approval has been received by the Lender and such documentation as is required by counsel to the Lender is delivered concurrently with such transaction.

 

(c) No Change of Name. Change its name or change its jurisdiction of incorporation or formation in each case without providing the Lender with fifteen (15) days’ prior written notice thereof.

 

(d) No Debt. Create, incur, assume or permit any Debt to remain outstanding, other than Permitted Debt.

 

(e) Operating Leases. Create, incur, assume or permit obligations outstanding in respect to operating leases (which, for greater certainty, does not include leases of real property) such that the aggregate annual payments due on such leases exceeds $100,000.

 

(f) No Distributions. Make any Distribution except Permitted Distributions.

 

27
 

 

(g) No Lien. Create, incur, assume or permit to exist any Lien upon any of its Property except a Permitted Lien.

 

(h) Acquisitions. Make any Acquisitions except:

 

(i) the FNL Transaction;

 

(ii) provided that no Event of Default has occurred and is continuing (or would result from such Acquisition), an Acquisition of any other Person or of all or part of the Property of any other Person or of all or part of any division, business, operation or undertaking of any other Person where the business of such Person is the same or substantially the same as, similar, complementary or related to, the Business or the business of the Borrower and the aggregate consideration payable in respect of such Acquisition (including, without limitation, any deferred consideration) is not more than $100,000, and further provided that any property acquired pursuant to such Acquisition becomes Collateral subject to the Security (including, without limitation, any shares of any Subsidiary); or

 

(iii) exercise of the Borrower’s right to repurchase the Lender Option as permitted under the Lender Option.

 

(i) No Change to Year End. Make any change to its Fiscal Year.

 

(j) Location of Assets in Other Jurisdictions. Except for any Property in transit in the ordinary course of business, acquire any Property outside of the jurisdictions identified in Schedule 7.1(r) or move any Property from one jurisdiction to another jurisdiction where the movement of such Property would cause the Lien of the Security over such Property to cease to be perfected under Applicable Law, or suffer or permit in any other manner any of its Property to not be subject to the Lien of the Security or to be or become located in a jurisdiction as a result of which the Lien of Security over such Property is not perfected, unless (i) Borrower has first given thirty (30) days’ prior written notice thereof to the Lender, and (ii) the Borrower has first executed and delivered to the Lender all Security and all financing or registration statements in form and substance satisfactory to the Lender which the Lender or its counsel, acting reasonably, from time to time deem necessary or advisable to ensure that the Security at all times constitutes a perfected first-priority Lien (subject only to Permitted Liens) over such Property notwithstanding the movement or location of such Property as aforesaid together with such supporting certificates, resolutions, opinions and other documents as the Lender may deem necessary or desirable in connection with such security and registrations.

 

(k) Amendments to Organizational Documents. Amend any of its Organizational Documents in a manner that would be materially prejudicial to the interests of the Lender under the Loan Documents.

 

(l) Amendments to other Documents. Amend, vary or alter any Material Contract or Material Licence in a manner that would reasonably be expected to have a Material Adverse Effect.

 

(m) Non-Arm’s Length Transactions. Except as contemplated by Section 9.2(f), effect any transactions with any Person not dealing at Arm’s Length unless such transaction is on market terms and consistent with transactions with Persons at Arm’s Length.

 

(n) Sale and Leaseback. Enter into any arrangement with any Person providing for the leasing by Borrower, as lessee, of Property which has been or is to be sold or transferred by Borrower to such Person or to any other Person to whom funds have been or are to be advanced by such Person on the security of such Property or the lease obligation of Borrower.

 

(o) Employee Loans. Make any loans or advances to an employee of Borrower other than loans in an aggregate amount not to exceed $100,000 provided that such loans are used to purchase Equity Interests in Borrower and at the time of the loan no Default or Event of Default exists.

 

28
 

 

(p) Deposit Accounts and Securities Accounts. The Borrower will not have any Permitted Cash Investments, cash or Equity Interests in any single Deposit Account or Securities Account located in the United States (other than payroll accounts), where the balance in such Deposit Account or Securities Account is in excess of $100,000 at any one time unless the Borrower and the applicable securities intermediary or deposit-taking institution have entered into a Control Agreement or similar agreement governing such Deposit Account or Securities Account in order to perfect (and further establish) the security interests in favour of the Lender under the Security Documents in such Permitted Cash Investments, cash or Equity Interests, except that (i) in the case of any Permitted Cash Investments, cash or Equity Interests in any single Deposit Account or Securities Account in existence on the Closing Date, the Borrower will within sixty (60) days of the Closing Date enter into a Control Agreement or similar agreement governing such Deposit Account or Securities Account in order to perfect (and further establish) the security interests in favour of the Lender under the Security Documents in such Permitted Cash Investments, cash or Equity Interests; and (ii) the requirements of this proviso will not apply to any Deposit Account or Securities Account that is required in connection with a Permitted Acquisition until sixty (60) days following the date such acquisition is consummated. The aggregate amount of all Permitted Cash Investments, cash and Equity Interests in all Deposit Accounts and all Securities Accounts owned by the Borrower for which a Control Agreement has not been delivered shall not exceed $200,000 at any time.

 

(q) New Subsidiaries. Create or acquire any Subsidiary after the date of this Agreement, including in respect of any Subsidiaries acquired as part of an Acquisition permitted under this Agreement, unless: (i) such Subsidiary exists pursuant to the laws of a state of the United States of America; (ii) all of the issued and outstanding Equity Interests of such Subsidiary is owned by the Borrower; (iii) such new Subsidiary provides a legal, valid and enforceable guarantee in favour of the Lender and first-ranking security in form and substance satisfactory to the Lender; and in each case appropriate legal opinions are delivered by Borrower’s counsel to the Lender.

 

(r) Capital Expenditures. Without prior written consent of the Lender, which consent will not be unreasonably withheld, the Borrower may not make any Capital Expenditures which exceed in any Fiscal Year an aggregate of $100,000 over the aggregate amount of Capital Expenditures included in the Annual Business Plan for such Fiscal Year.

 

(s) Compensation. Make any material changes to employee or management compensation practices other than changes which are customary and reasonable in a business similar to the Business.

 

9.3 Entitled to Perform Covenants

 

If the Borrower fails to perform any covenant contained in this Article 9, or in any other provision hereof or of any of the other Loan Documents, the Lender may perform in any manner deemed fit by it without thereby waiving any rights to enforce this Agreement or the other Loan Documents, any such covenant capable of being performed by it and if any such covenant requires the payment of money, the Lender may make such payments. All sums so expended by the Lender shall be deemed to form part of the Obligations, shall bear interest at the same rate as the Loan and shall be payable by the Borrower on demand.

 

ARTICLE 10 - CONDITIONS PRECEDENT

 

10.1 Conditions Precedent to Loan.

 

The obligations of the Lender to fund the Loan are subject to the satisfaction or waiver on or before the Closing Date of the following conditions precedent:

 

(a) this Agreement shall have been executed and delivered by all parties hereto;

 

(b) the Lender shall have received certified copies of the Organizational Documents of Borrower, the resolutions authorizing the execution, delivery and performance of Borrower’s respective obligations under the Loan Documents and the transactions contemplated herein, and the incumbency of the officers of Borrower;

 

(c) copies of all shareholder agreements and partnership agreements, if any, applicable to Borrower, certified by Borrower to be true, shall have been delivered to the Lender’s satisfaction;

 

29
 

 

(d) certificates of status or good standing, as applicable, for all relevant jurisdictions of Borrower shall have been delivered to the Lender;

 

(e) Borrower shall be in compliance in all material respects with all (if any) Material Contracts and Material Licences to the satisfaction of the Lender and copies of all Material Contracts and Material Licences if any, applicable to Borrower, shall have been delivered to the Lender;

 

(f) evidence of repayment in full of all Debt that is not Permitted Debt owing by Borrower to any third party lenders to Borrower concurrent with the Loan shall have been delivered to the Lender;

 

(g) evidence that all necessary or required consents or approvals of any Governmental Authority or other Person in connection with the completion of the FNL Transaction and the delivery of the Loan Documents have been obtained;

 

(h) releases, discharges, estoppels and postponements with respect to all Liens which are not Permitted Liens, if any, shall have been delivered to the Lender;

 

(i) payment of all amounts and fees payable to the Lender;

 

(j) duly executed copies of the Security shall have been delivered to the Lender and such financing statements or other registrations of such Security, or notice thereof, shall have been filed, registered, entered or recorded in all offices of public record necessary or desirable in the opinion of the Lender to preserve or protect the charges and security interests created thereby;

 

(k) a currently dated letter of opinion of counsel to the Borrower along with the opinions of local counsel for Borrower shall have been delivered to the Lender;

 

(l) the Borrower shall have delivered to the Lender certificates of insurance acceptable to the Lender showing, inter alia, the Lender as a first loss payee as its interest may appear on all insurance policies that insure the assets to be secured by the Security;

 

(m) no Default or Event of Default has occurred and is continuing on the Closing Date or would result from making the Loan and a senior officer of the Borrower shall have certified the same to the Lender;

 

(n) all representations and warranties made by Borrower in the Loan Documents are true and correct in all material respects;

 

(o) no Material Adverse Effect has occurred;

 

(p) a source and use of funds statement and an outline of the flow of funds from the Loan shall have been delivered to the Lender evidencing that the Loan will be used solely for the purpose provided for in Section 9.1(f);

 

(q) the Lender shall have received such additional evidence, documents or undertakings as the Lender shall reasonably request to establish the consummation of the transactions contemplated hereby and the FNL Transaction and be satisfied, acting reasonably, as to the taking of all proceedings in connection herewith in compliance with the conditions set forth in this Agreement;

 

(r) the Lender shall have completed all due diligence which it considers necessary or appropriate in its discretion in regard to Borrower and its Property, the FNL Transaction, books and records, operations, prospects and condition (financial or otherwise), including, without limitation, in regards to past and ongoing compliance with Applicable Laws (including Environmental Laws), union and labour relations and pension matters;

 

(s) the Lender and the Borrower will have entered into, executed and delivered, the Lender’s Option and the Lender’s Distribution Agreement, all on terms satisfactory to the parties, acting reasonably;

 

30
 

 

(t) concurrently therewith, the Borrower shall complete the FNL Transaction on terms and conditions satisfactory to the Lender;

 

(u) the Lender shall have received the Origination Fee (Section 4.6) and the Work Fee (Section 4.7);

 

(v) on or prior to Closing, Borrower will have completed an offering of Borrower’s equity securities or securities convertible into equity securities of at least $250,000;

 

(w) that certain agreement dated between FNL and inLife Business Development Group LLC shall and have been amended in a manner satisfactory to Lender;

 

(x) the execution and delivery of the Warrant by the Borrower;

 

(y) the execution and delivery by the Borrower of a warrant agreement giving effect to the Lender’s Additional Equity, on terms satisfactory to the Parties; and

 

(z) the Closing Date occurs by no later than January 23, 2015.

 

ARTICLE 11 - EVENTS OF DEFAULT

 

11.1 Events of Default.

 

The occurrence of any one or more of the following events shall constitute an “Event of Default” hereunder:

 

(a) the failure of the Borrower to pay any principal hereunder when due; or

 

(b) the failure of the Borrower to pay any interest or other Obligations (other than principal hereunder) when due, which failure continues unremedied for three (3) Business Days; or

 

(c) the failure of (i) Borrower to perform, keep or observe in a material respect any of the financial covenants in Section 9.1 (x) of this Agreement, (ii) Borrower to perform, keep or observe any of the other covenants, conditions, promises, agreements or obligations under this Agreement (other than as described in Sections 11.1(a) and (b) and other than those covenants, conditions, promises, agreements or obligations referred to in (i) above) or in any of the Loan Documents, in each case which failure is not cured within thirty (30) days of receipt of written notice from the Lender of such failure; or

 

(d) the making or furnishing by Borrower or any director or officer thereof to the Lender of any representation, warranty, certificate, schedule, report or other communication of a material nature within or in connection with this Agreement or the Loan Documents, which is untrue or misleading in any material respect when made; provided that, no Event of Default under this Section 11.1(d) will occur if such representation, warranty or other communication was not intentionally untrue or misleading, is capable of being corrected within thirty (30) days of being made and is diligently corrected within such thirty (30) day period; or

 

(e) if Borrower ceases or threatens to cease to carry on business generally or admits it inability or fails to pay its debts generally; or

 

(f) if (i) the Borrower fails to make any payment when such payment is due and payable to any Person in relation to any indebtedness for borrowed money or other indebtedness or liabilities arising in respect of any other Debt which in the aggregate principal amount then outstanding is in excess of $100,000 and such payment is not made within any applicable cure or grace period; or (ii) the Borrower defaults in the observance or performance of any other agreement or condition in relation to any such indebtedness to any Person which in the aggregate principal amount then outstanding is in excess of $100,000 or contained in any instrument or agreement evidencing, securing or relating thereto and such default is not waived or cured within any applicable cure or grace period; or

 

(g) if Borrower denies its obligations under any Loan Document or claims any of the Loan Documents to be invalid or withdrawn in whole or in part; or

 

31
 

 

(h) any of the Loan Documents or any material provision of any of them becomes unenforceable, unlawful or is changed by virtue of legislation or by a court, statutory board or commission, in each case in a manner that is adverse to the Lender, if Borrower does not, within fifteen (15) Business Days of receipt of notice of such Loan Document or material provision becoming unenforceable, unlawful or being changed and being provided with any required new agreement or amendment for execution by the Lender (acting reasonably), replace such Loan Document with a new agreement that is in form and substance satisfactory to the Lender or amend such Loan Document to the satisfaction of the Lender; or

 

(i) if a decree or order of a court of competent jurisdiction is entered adjudging Borrower a bankrupt or insolvent or approving a petition seeking the winding-up of Borrower under the United States Bankruptcy Code or any other bankruptcy, insolvency or analogous laws or issuing sequestration or process of execution against any substantial part of the Property of Borrower or ordering the winding up or liquidation of its affairs; or

 

(j) if Borrower becomes insolvent, makes any assignment in bankruptcy or makes any other similar assignment for the benefit of creditors, makes any proposal under the United States Bankruptcy Code or any comparable law, seeks relief under any other bankruptcy, insolvency or analogous law, is adjudged bankrupt, files a petition or proposal to take advantage of any act of insolvency, consents to or acquiesces in the appointment of a trustee, receiver, receiver and manager, interim receiver, custodian, sequestrator or other Person with similar powers of itself or of all or any substantial portion of its assets, or files a petition or otherwise commences any proceeding seeking any reorganization, arrangement, composition or readjustment under any applicable bankruptcy, insolvency, moratorium, reorganization or other similar law affecting creditors’ rights or consents to, or acquiesces in, the filing of such a petition; or

 

(k) if any proceeding or filing shall be instituted or made against Borrower seeking to have an order for relief entered against Borrower as debtor or to adjudicate it bankrupt or insolvent, or seeking liquidation, winding-up, reorganization, arrangement, adjustment or composition under any law relating to bankruptcy, insolvency, reorganization or relief or debtors (including, without limitation, the United States Bankruptcy Code or seeking appointment of a receiver, trustee, custodian or other similar official for Borrower or for any substantial part of its properties or assets unless the same is being contested actively and diligently in good faith by appropriate and timely proceedings and is dismissed, vacated or permanently stayed within thirty (30) days of institution; or

 

(l) if a Person takes possession by appointment of a receiver, receiver and manager, or otherwise of any material portion of the Property of Borrower; or

 

(m) if a final judgment, execution, writ of seizure and sale, sequestration or decree for the payment of money due shall have been obtained or entered against the Borrower in an amount in excess of $100,000 and such judgment, execution, writ of seizure and sale, sequestration or decree shall not have been and remain vacated, satisfied, discharged or stayed pending appeal within the applicable appeal period; or

 

(n) if any of the Security shall cease to be a valid and perfected first-priority security interest subject only to Permitted Liens and the Borrower shall have failed to remedy such default within fifteen (15) Business Days of the Borrower becoming aware of such fact; or

 

(o) if an event of default occurs under any Material Contract or Material Licence of Borrower and which is committed by Borrower (other than an event of default specifically dealt with in this Section) and such event of default has or would reasonably be expected to have a Material Adverse Effect and is not remedied within fifteen (15) days after the Borrower becomes aware of such event of default; or

 

(p) if any of the following events shall occur with respect to any Pension Plan:

 

(i) the institution of any steps by Borrower or any member of its Controlled Group or any applicable regulatory authority to terminate a Pension Plan (wholly or in part) if, as a result of such termination, Borrower may be required to make an additional contribution to such Pension Plan, or to incur an additional liability or obligation to such Pension Plan or ERISA Plan, equal to or in excess of $100,000 or the equivalent thereof in another currency; or

 

32
 

 

(ii) any Reportable Event or Prohibited Transaction occurs; or

 

(iii) a contribution failure occurs with respect to any ERISA Plan maintained by the Borrower or any member of its Controlled Group sufficient to give rise to a lien or charge under Section 302(f) of ERISA or under any applicable pension benefits legislation in any other jurisdiction; or

 

(q) if a Change of Control occurs; or

 

(r) all or any material part of the Property of Borrower shall be nationalized, expropriated or condemned, seized or otherwise appropriated, or custody or control of such Property of Borrower shall be assumed by any Governmental Authority or any court of competent jurisdiction at the instance of any Governmental Authority, in each case which has or would reasonably be expected to have a Material Adverse Effect except where contested in good faith by proper proceedings diligently pursued where a stay of enforcement is in effect;

 

(s) if any order is made by any Governmental Authority in relation to the Borrower, or there is any change of law, or the interpretation or administration therefore, in each case, which in the reasonable opinion of the Lender, operates to prevent or restrict the trading of the common shares of the Borrower;

 

(t) if the Lender’s Equity is not issued to Lender within the ten (10) days following Closing; or (u) if the Borrower fails to make either of the “Additional Payments” as defined in and pursuant to the FNL Asset Purchase Agreement on the due dates thereof.

 

11.2 Acceleration and Termination of Rights.

 

If any Event of Default shall occur and be continuing, all Obligations owing by the Borrower under the Loan Documents shall, at the option of the Lender, become immediately due and payable, all without notice, presentment, protest, demand, notice of dishonour or any other demand or notice whatsoever, all of which are hereby expressly waived by Borrower; provided, if any Event of Default described in Section 11.1(e), 11.1 (i) through 11.1 (k) with respect to the Borrower shall occur, the outstanding principal amount of the Loan and all other Obligations shall automatically be and become immediately due and payable. In such event the Lender may, in its discretion, exercise any right or recourse and/or proceed by any action, suit, remedy or proceeding against Borrower authorized or permitted by law for the recovery of all the Obligations of the Borrower to the Lender and proceed to exercise any and all rights hereunder and under the Security and no such remedy for the enforcement of the rights of the Lender shall be exclusive of or dependent on any other remedy but any one or more of such remedies may from time to time be exercised independently or in combination.

 

11.3 Remedies Cumulative and Waivers.

 

For greater certainty, it is expressly understood and agreed that the rights and remedies of the Lender hereunder or under any other Loan Document or instrument executed pursuant to this Agreement are cumulative and are in addition to and not in substitution for any rights or remedies provided by law or by equity; and any single or partial exercise by the Lender of any right or remedy for a default or breach of any term, covenant, condition or agreement contained in this Agreement or any other Loan Document shall not be deemed to be a waiver of or to alter, affect or prejudice any other right or remedy or other rights or remedies to which the Lender may be lawfully entitled for such default or breach. Any waiver by the Lender of the strict observance, performance or compliance with any term, covenant, condition or other matter contained herein and any indulgence granted, either expressly or by course of conduct, by the Lender shall be effective only in the specific instance and for the purpose for which it was given and shall be deemed not to be a waiver of any rights and remedies of the Lender under this Agreement or any other Loan Document as a result of any other default or breach hereunder or thereunder.

 

11.4 Saving.

 

The Lender shall not be under any obligation to the Borrower or any other Person to realize any Collateral or enforce the Security or any part thereof or to allow any of the Collateral to be sold. dealt with or otherwise disposed of. The Lender shall not be responsible or liable to Borrower or any other Person for any loss or damage upon the realization or enforcement of, the failure to realize or enforce the Collateral or any part thereof or the failure to allow any of the Collateral to be sold, dealt with or otherwise disposed of or for any act or omission on their respective parts or on the part of any director, officer, agent, servant or adviser in connection with any of the foregoing, except that the Lender may be responsible or liable for any loss or damage arising from the wilful misconduct or gross negligence of Lender.

 

33
 

 

11.5 Third Parties.

 

No Person dealing with the Lender or any agent of the Lender shall be required to inquire whether the Security has become enforceable, or whether the powers which the Lender is purporting to exercise have been exercisable, or whether any Obligations remain outstanding upon the security thereof, or as to the necessity or expediency of the stipulations and conditions subject to which any sale shall be made, or otherwise as to the propriety or regularity of any sale or other disposition or any other dealing with the Collateral charged by such Security or any part thereof.

 

11.6 Set-Off or Compensation.

 

In addition to and not in limitation of any rights now or hereafter granted under Applicable Law, if repayment is accelerated pursuant to Section 11.2, the Lender may at any time and from time to time without notice to the Borrower or any other Person, any notice being expressly waived by the Borrower, set-off and compensate and apply any and all deposits, general or special, time or demand, provisional or final, matured or unmatured, and any other indebtedness at any time owing by the Lender, to or for the credit of or the account of the Borrower, against and on account of the Obligations notwithstanding that any of them are contingent or unmatured.

 

ARTICLE 12 - INDEMNIFICATION, ETC.

 

12.1 General Indemnity.

 

The Borrower agrees to defend (with counsel satisfactory to the Lender), protect, indemnify and hold harmless the Lender, and each of its Affiliates, and Subsidiaries, and its respective officers, directors, employees, legal counsel and agents (each an “Indemnified Party”) from and against any and all obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature (including, without limitation, the disbursements and the fees (on a solicitor-client basis) of one legal counsel (unless it would be inappropriate for one counsel to represent all Indemnified Parties due to a conflict of interest or otherwise in which case, all legal counsel for each Indemnified Party) in connection with any investigative, administrative or judicial proceedings, whether or not any Indemnified Party shall be designated a party thereto), (collectively, “Losses”) which may be imposed on, incurred by, or asserted against, any Indemnified Party (whether direct, indirect or consequential and whether based on any federal, provincial, state or local laws or regulations, including, without limitation, securities, environmental and commercial laws and regulations, under common law or in equity, or based on contract or otherwise) in any manner relating to or arising out of this Agreement or any other Loan Document, or any act, event or transaction related or attendant thereto, the making and/or the management of the Loan or the use or intended use of the proceeds of the Loan; provided, however that the Borrower shall have no obligation hereunder to any Indemnified Party to the extent that such Losses were caused by or resulted from the wilful misconduct or gross negligence of such Indemnified Party. To the extent that the undertaking to indemnify set forth in the preceding sentence may be unenforceable against the Borrower because it violates any law or public policy, the Borrower shall satisfy such undertaking to the maximum extent permitted by Applicable Law. Any Losses covered by this indemnity shall be paid to each Indemnified Party on demand, and, failing prompt payment, shall, together with interest thereon at the Deemed Interest Rate from the date incurred by each Indemnified Party until paid in full, be added to the Obligations and be secured by the Collateral. The provisions of this Section 12.1 shall survive the satisfaction and payment of all Obligations and the termination of this Agreement.

 

34
 

 

12.2 Taxes.

 

All payments made by the Borrower under this Agreement and the Loan Documents shall be made free and clear of, and without deduction or withholding for or on account of, any present or future income, stamp or other taxes, levies, assessments, imposts, deductions, charges, or withholdings imposed by any foreign, federal, provincial, state, local or other jurisdiction or any Governmental Authority thereof or political subdivision or taxing authority therein, excluding taxes imposed on the net income or the capital of the Lender (all such non-excluded taxes being hereinafter called “Taxes”)- If any Taxes are required to be withheld from any amounts so payable to the Lender hereunder or under any Loan Documents the amounts so payable shall be increased to the extent necessary to yield to the recipient (after payment of all Taxes) interest or any such other amounts payable hereunder at the rates or in the amounts specified in this Agreement or any other Loan Documents. If the Borrower is required by Applicable Law to make any deduction or withholding on account of any Taxes or other amount from any sum paid or expressed to be payable to the Lender under this Agreement or any other Loan Document, then: (i) the Borrower shall notify the Lender of any such requirement or any change in any such requirement as soon as it becomes aware of it; (ii) the Borrower shall pay any such Taxes or other amount before the date on which penalties attached thereto become due and payable; (iii) the sum payable by the Borrower in respect of which the relevant deduction, withholding or payment is required shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding or payment, the recipient receives on the due date and retains (free from any liability in respect of any such deduction, withholding or payment) a sum equal to that which it would have received and so retained had no such deduction, withholding or payment been required or made; and (iv) within thirty (30) days after payment of any sum from which the Borrower is required by Applicable Law to make any deduction or withholding, and within thirty (30) days after the due date of payment of any Taxes or other amount which it is required by clause (ii) above to pay, it shall deliver to the Lender all such certified documents and other evidence as to the making of such deduction, withholding or payment as (A) are reasonably satisfactory to the Lender as proof of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other authority and (B) are reasonably required by the Lender to enable it to claim a tax credit with respect to such deduction, withholding or payment. If the Borrower fails to pay any Taxes when due to the appropriate taxing authority, the Borrower shall indemnify the Lender for any incremental taxes, interest or penalties that may become payable by the Lender as a result of any such failure. The provisions of this Section 12.2 shall survive the satisfaction and payment of all Obligations and the termination of this Agreement.

 

ARTICLE 13 - GENERAL PROVISIONS

 

13.1 Notice.

 

Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.1. Notices and other communications shall be addressed as follows:

 

  (a) if to the Borrower:
     
   

Synergy Strips Corp. c/o

Jack Ross 865 Spring

Street Westbrook, Maine 04092 Fax:

     
    E-mail: jack.ross@purebrands.ca
     
    with a copy to:
     
   

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

    Attention: W. David Mannheim, Esq.
    Fax No. (919)781-4865
    E-mail: dmannheim@wyrick.com

 

35
 

 

  (b) if to the Lender:
     
    Knight Therapeutics (Barbados) Inc.
    Chancery
    House High
    Street
    Bridgetown, St. Michael
    BB11128
    Barbados, WI
    Attention: Andrew C. Ferreira
    Telecopier: 1-246-431-0076
     
    with a copy to:
     
    Davies Ward Phillips & Vineberg LLP 900
    New York, NY 10022 U.S.A.
     
    Attention: Hillel W. Rosen
    Telecopier: (212)308-0132

 

13.2 Choice of Governing Law and Construction.

 

Except as expressly set forth therein, this Agreement and the other Loan Documents (unless expressly stated otherwise in the other Loan Documents) shall be governed by the laws of the State of New York therein as to interpretation, enforcement, validity, construction, effect, and in all other respects, including, without limitation, the legality of the interest rate and other charges, but excluding perfection and realization of the security interests and hypothecs in the Collateral, which shall be governed and controlled by the laws of the relevant jurisdiction.

 

13.3 Attornment.

 

The Parties hereto irrevocably submit and attorn to the non-exclusive jurisdiction of the courts of the State of New York for all matters arising out of, or in connection with, this Agreement and the other Loan Documents.

 

13.4 Press Releases.

 

Each party hereto agrees that it will promptly provide the other party with drafts of any press releases relating to the subject matter hereof, including the entering into of this Agreement, for review and comment prior to the issuance thereof, such review and comments not to be unreasonably withheld or delayed.

 

13.5 Modification and Benefit of Agreement.

 

This Agreement and the other Loan Documents may not be modified, altered or amended except by an agreement in writing signed by the Borrower and the Lender. The Borrower may not sell, assign or transfer this Agreement, or the other Loan Documents or any portion thereof including, without limitation, the Borrower’s right, tide, interest, remedies, powers or duties thereunder. The sale, assignment, transfer or other disposition by the Lender, at any time and from time to time hereafter, of this Agreement, or the other Loan Documents, or of any portion thereof, or participation therein including, without limitation, the right, title, interest, remedies, powers and/or duties of the Lender thereunder will require the prior written consent of the Borrower (not to be unreasonably withheld or delayed), unless an Event of Default is continuing or unless such sale, assignment, transfer or other disposition is to an Affiliate or Associate of the Lender. The Borrower agrees that it shall execute and deliver such documents as the Lender may request in connection with any such sale, assignment, transfer or other disposition. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their successors and permitted assigns.

 

13.6 Power of Attorney.

 

The Borrower acknowledges and agrees that its appointment of the Lender as its attorney and agent for the purposes specified in this Agreement is an appointment coupled with an interest and shall be irrevocable until all of the Obligations are paid in full and this Agreement is terminated.

 

36
 

 

13.7 Waivers, Confidentiality, Information Sharing.

 

(a) In no event shall any party hereto be liable for lost profits or other special or consequential damages.

 

(b) To the maximum extent permitted by Applicable Law, the Borrower hereby waives all rights to a hearing of any kind prior to the exercise by the Lender of its rights to repossess the Collateral without judicial process or to reply, attach or levy upon such Collateral without prior notice or hearing.

 

(c) To the maximum extent permitted by Applicable Law, the Borrower hereby waives demand, presentment, protest and notice of nonpayment.

 

(d) Failure of the Lender, at any time or times hereafter, to require strict performance by the Borrower of any provision of this Agreement or any of the other Loan Documents shall not waive, affect or diminish any right of the Lender thereafter to demand strict compliance and performance therewith. Any suspension or waiver by the Lender of a Default or Event of Default under this Agreement or any default under any of the Loan Documents shall not suspend, waive or affect any other Default or Event of Default under this Agreement or any other default under any of other Loan Documents, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. No delay on the part of the Lender in the exercise of any right or remedy under this Agreement or any other Loan Documents shall preclude any other or further exercise thereof or the exercise of any right or remedy. None of the undertakings, agreements, warranties, covenants and representations of the Borrower contained in this Agreement or any of the other Loan Documents and no Default or Event of Default under this Agreement or default under any of the other Loan Documents shall be deemed to have been suspended or waived by the Lender unless such suspension or waiver is in writing, signed by duly authorized officer(s) of the Lender and directed to the Borrower specifying such suspension or waiver.

 

(e) The Borrower hereby agrees and acknowledges that the Lender shall be permitted to share with any of its Affiliates, any information concerning the Borrower, Borrower, this Agreement and all other Loan Documents, and the subject matter thereof, that the Lender has or will have in its possession.

 

13.8 Timing of Payments.

 

Any payment received by the Lender after 3:00 p.m. (Montreal time) on a Business Day, or on any day that is not a Business Day, shall be credited to the account of the Borrower on the following Business Day.

 

13.9 Judgment Currency.

 

If in the recovery by the Lender of any amount owing hereunder in any currency, judgment can only be obtained in another currency and because of changes in the exchange rate of such currencies between the date of judgment and payment in full of the amount of such judgment, the amount of recovery under the judgment differs from the full amount owing hereunder, the Borrower shall pay any such shortfall to the Lender, and such shortfall can be claimed by the Lender against the Borrower as an alternative or additional cause of action and any surplus received by the Lender will be repaid to the Borrower.

 

13.10 Severability.

 

If any provision of this Agreement is held to be prohibited by or invalid under Applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or remaining provisions of this Agreement.

 

13.11 Conflicts.

 

In the event there occurs any conflict or inconsistency between any provision hereof and any provision of the other Loan Documents, the provision hereof, to the extent of any such conflict or inconsistency, shall govern.

 

13.12 Entire Agreement.

 

This Agreement and the other Loan Documents embody the entire agreement and understanding between the parties hereto and thereto and supersede all prior agreements and understandings between such parties relating to the subject matter hereof and thereof and may not be contradicted by evidence of prior or contemporaneous agreements of the parties. There are no unwritten oral agreements between the parties related to the subject matter of this Agreement and the other Loan Documents.

 

13.13 Counterpart Execution/Electronic Delivery.

 

This Agreement may be executed in counterpart and delivered by fax or other electronic means of delivery.

 

13.14 English Language.

 

At the request of the parties, this Agreement and the other Loan Documents have been negotiated in the English language and will be or have been executed in the English language. Les soussignes ont expressement demande que ce document et tous les documents annexes soient rediges en langue anglaise.

 

37
 

 

IN WITNESS WHEREOF, the Borrower has duly executed this Agreement as of the date set out on the first page hereof.

 

 

  SYNERGY STRIPS CORP.
     
  Per: /s/ Jack Ross
  Name: Jack Ross
  Title: CFO and Corporate Secretary
     
  KNIGHT THERAPEUTICS (BARBADOS) INC.
     
  Per: /s/ [Unintelligible]
  Name: Chancery Corporate Services Limited
  Title: Secretary

 

Signature Page- Loan Agreement

 

38
 

 

SCHEDULE 8.2

 

COMPLIANCE CERTIFICATE

 

TO: KNIGHT THERAPEUTICS (BARBADOS) INC.
  Chancery House, High Street Bridgetown, St. Michael BB 11128, Barbados WI
  Attention: Andrew C. Ferreira
  Telecopier: 1-246-431-0076
FROM: SYNERGY STRIPS CORP.
DATE: ●, 2015
   

1. This Compliance Certificate is delivered to you, as Lender, pursuant to the Loan Agreement made as of January 21, 2015 between the Borrower and the Lender, as amended, supplemented, restated or replaced from time to time (the “Loan Agreement”). All defined terms set forth, but not otherwise defined, in this notice shall have the respective meanings set forth in the Loan Agreement, unless the context requires otherwise.

 

2. I am the duly appointed ● of the Borrower and am providing this Certificate pursuant to the Loan Agreement.

 

3. Iam familiar with the Loan Agreement for purposes of delivering this Certificate.

 

4. The Borrower is in compliance with the Financial Covenants set forth in Section 9. l(x) of the Loan Agreement, namely:

 

  (a) EBITDA for the six (6) months ending ● was $●;
     
  (b) for the Fiscal Quarter ending ●, Net Debt to TTM EBITDA Ratio was ●;
     
  (c) as at ●, the cash balance was $●.

 

5. Attached as Schedule A is a list of additional Material Contracts and Material Licenses entered into since the date of the prior Compliance Certificate.

 

6. All rent payable to any landlord of leased real premises is up to date and there is no default by the Borrower under any such lease.

 

7. As of the date hereof, the Borrower is and will be in compliance with all of the terms and conditions of the Loan Agreement to which it is a party and no Default or Event of Default is continuing under the Loan Agreement.

 

IN WITNESS WHEREOF, I have signed this Certificate.

 

  SYNERGY STRIPS CORP.
     
  Per:                
  Name:  
  Title:  

 

     
     

 

Schedule A

 

MATERIAL CONTRACTS AND LICENSES

 

     

 

Exhibit 10.3

 

DISTRIBUTION, LICENSE AND SUPPLY AGREEMENT

 

THIS AGREEMENT, effective January 22, 2015, by and between SYNERGY STRIPS CORP., a corporation formed under the laws of the State of Nevada (“Synergy”) and KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation incorporated under the laws of Barbados (“Knight )

 

RECITALS

 

WHEREAS Synergy owns or licenses all right, title and interest in and to certain patents, trademark(s) and Know-How relating to an ingestible dietary supplement product known as FOCUSFactor and including FOCUSFactor Kids;

 

WHEREAS Synergy owns or licenses all right, title and interest in and to certain patents, trademark(s) and Know-How relating to an ingestible dietary supplement product known as Synergy Strips;

 

WHEREAS Knight wishes to be appointed by Synergy as exclusive distributor, to offer to sell and sell the Licensed Products in the Territory and Synergy is willing to grant such exclusive appointment;

 

WHEREAS Knight wishes to procure the Licensed Products from Synergy and Synergy wishes to supply the Licensed Products to Knight;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS

 

1.1 Definitions. The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:

 

“Additional Territory” has the meaning set forth in Section 11.

 

“Adverse Drug Reaction” means a noxious and unintended response to a drug, which occurs at doses normally used or tested for the diagnosis, treatment, or prevention of a disease or the modification of an organic function.

 

“Adverse Drug Event” means any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

 

“Affiliate” means any corporation, firm, partnership or other entity that directly or indirectly controls, is controlled by or is under common control with a Party, with “control” meaning ownership of greater than fifty percent (50%) of the voting stock or other voting interests in the Party or the right to receive over fifty percent (50%) of the profits or earnings of the Party. Such other relationship as in fact results in actual control over the management, business, and affairs of a Party shall also be deemed to constitute control.

 

“Agreement”, “hereto”, “hereunder”, “herein” and similar expressions mean this License, Development and Supply Agreement.

 

“Applicable Laws” means any law, regulation, rule, guidance, order, judgment or decree having the force of law in the Territory.

 

“Business Day” means any day other than (i) Saturday or Sunday or (ii) a day that is a legal holiday in either of Barbados or New York, New York, or (iii) any other day on which banks in either of Barbados or New York, New York are required to be closed.

 

“Calendar Quarter” means the three (3) month periods ending on March 31, June 30, September 30 and December 31 in each Calendar Year.

 

 

 

 

“Calendar Year” means, in respect of any particular year, the one (1) year period beginning on January 1 and ending on December 31.

 

“Commercial Sale” means any shipment of the Licensed Products in the Territory pursuant to an arm’s length sale by Knight or its Affiliates to a Third Party.

 

“Commercialize” means marketing, using, distributing, promoting, offering for sale, and selling the Licensed Products.

 

“Cost of Goods” means, with respect to the Licensed Products, the production cost of such Licensed Products (for the avoidance of doubt, including, without limitation, manufacturing oversight and quality assurance) calculated in accordance with internal cost accounting methods consistently applied by Synergy for its other similar pharmaceutical products; provided, that such methods comply with IFRS. Cost of Goods shall include direct labor, direct materials (including taxes and duties), but exclude corporate administrative overhead, any costs associated with excess capacity, any royalties or license fees payable to third parties and any other indirect costs. Notwithstanding the foregoing, in the event a Licensed Product is manufactured by a Third Party supplier and procured by Synergy, the “Cost of Goods” shall include the costs charged for such Licensed Product by such Third Party supplier to Synergy.

 

“Effective Date” means the date specified in the initial paragraph of this Agreement.

 

“Force Majeure” has the meaning set forth in Section 12.6.

 

“GMP” means good manufacturing practices as required under the rules of the applicable Governmental Authority in the Territory.

 

“Governmental Authority” means any federal, state, provincial, or municipal government body, commission, agency, board, court or tribunal in the Territory and having jurisdiction in the particular circumstances.

 

“IFRS” means, at any time, the International Financial Reporting Standards, promulgated by the International Accounting Standards Board, as amended, supplemented or replaced from time to time.

 

“Improvements” means any new indications, dosage strengths, reformulations, line extensions or other advances in, modifications or improvements to the Licensed Products.

 

“Initial Term” has the meaning set forth in Section 9.1.

 

“Know-How” means all scientific, technical, manufacturing, marketing, production, sales and other information relating to the Licensed Products that is known to or controlled by Synergy and which is reasonably necessary for the Commercialization of the Licensed Products in accordance with the terms of this Agreement.

 

“Launch” means the date of the first Commercial Sale in the Territory of the applicable Licensed Product.

 

“Licensed Products” means each of FOCUSFactor, FOCUSFactor Kids and Synergy Strip and all Improvements thereto. “Licensed Product” means either of them.

 

“Long Term Inability to Supply” shall mean the inability to supply at least seventy percent (70%) of the volumes of a Licensed Product indicated in the current forecast that exceeds one hundred and twenty (120) days.

 

“Knight Indemnified Party” has the meaning set forth in Section 8.5.

 

 

 

 

“Net Sales” means the gross amounts invoiced by or on behalf of Knight and its Affiliates for sales of Products to third parties that are not Affiliates of Knight in bona fide, arm’s-length transactions, less the following deductions if and to the extent they are (i) determined in accordance with Knight’s accounting standards which are in accordance with IFRS, (ii) actually taken by Knight or its Affiliates and (iii) included in the gross invoiced sales price of any Licensed Products or otherwise directly paid or incurred by Knight or its Affiliates with respect to the sale of Licensed Products:

 

  (a) cash discounts;
     
  (b) rebates;
     
  (c) direct to customer di scounts;
     
  (d) charge-backs;
     
  (e) bad debt;
     
  (f) amounts repaid or credited by reasons of defects, rejections, recalls, returns; and
     
  (g) tariffs, duties, excise, sales, value-added and other similar taxes (other than taxes based on income).

 

“Non-Renewal Fee” has the meaning set forth in Section 9.7.

 

“Non-Renewal Notice” has the meaning set forth in Section 9.1.

 

“Party” means either Synergy or Knight and “Parties” means both Synergy and Knight.

 

“Regulatory Approval” means any and all approvals, marketing authorizations, registrations and licenses (including amendments and supplements thereto) necessary from a Governmental Authority for the Commercialization or manufacture of the Licensed Products in or for the Territory.

 

“Regulatory Submissions” means all applications, filings, dossiers and the like submitted to a Governmental Authority for the purpose of obtaining Regulatory Approval.

 

“Renewable Term” has the meaning set forth in Section 9.1.

 

“SDEA” means the Safety Data Exchange Agreement to be entered into by the Parties within ninety (90) days after the Effective Date.

 

“Short Term Inability to Supply” shall mean the inability to supply at least seventy percent (70%) of the volumes of a Licensed Product indicated in the current forecast that continues for more than sixty (60) days but less than one hundred and twenty (120) days.

 

“Specifications” means the finished product specifications for each Licensed Product as required by the applicable Regulatory Approval and as may be modified from time to time in accordance with the provisions of this Agreement.

 

“Supply Price” has the meaning set forth in Section 6.2.

 

“Synergy Indemnified Party” has the meaning set forth in Section 8.6.

 

“Synergy Marks” means the trade-marks “FOCUSFactor”, and any other marks Synergy may adopt for use for the Licensed Products.

 

“Synergy Patents” means all patents in the Territory, including patent applications, continuations, divisional patents, re-examined patents, reissued patents, and foreign equivalents thereof, that are owned by or licensed to Synergy which claim inventions reasonably necessary for the Commercialization of the Licensed Products in the Territory.

 

 

 

 

“Term” means the Initial Term or a Renewal Term.

 

“Territory” means Canada and, subject to Section 12, may also include one or more of the Additional Territories.

 

“Third Party” means any person other than the Parties and their Affiliates.

 

1.2 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof

 

1.3 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.4 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.5 Canadian Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of the United States, unless otherwise noted.
   
1.6 Date References. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.
   
1.7 Gender. Words of one gender include the other gender.
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.
   
1.9 Solidary Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are solidary (joint and several).
   
1.10 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party.
   
1.11 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.12 Party References. Reference to any Party includes the successors and permitted assigns of that Party.
   
1.13 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.

 

2. GRANT OF RIGHTS

 

2.1 Appointment. Subject to the terms of this Agreement, Synergy, on behalf of itself and its Affiliates, hereby appoints Knight as its exclusive distributor of Licensed Products in the Territory for the Term and further grants to Knight and Knight hereby accepts, for the Term, and for the Territory only, an exclusive license under the Synergy Patents and Know-How to Commercialize the Licensed Products.
   
2.2 Sublicensing. Knight may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Knight assumes full responsibility for any actions taken by or omissions by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.

 

 

 

 

2.3 No Implied Licenses. Neither Party grants to the other Party any right or license to use any of its intellectual property, Know-How or other proprietary information, materials or technology, or to practice any of its patent, trademark, or trade dress rights, except as expressly set forth in this Agreement.
   
2.4 Restriction on Knight Sales. Knight shall not: (i) knowingly solicit or accept orders for distribution of Licensed Products to a Third Party outside the Territory; (ii) knowingly distribute any Licensed Products for sale or use outside the Territory; or (iii) supply any Third Party that has distributed or offered to distribute Licensed Products outside the Territory after Knight has actual knowledge that said Third Party has distributed or offered to distribute Licensed Products obtained from Knight outside of the Territory.
   
2.5 Restriction on Synergy Sales. Synergy shall not: (i) knowingly solicit or accept orders for distribution of Licensed Products to a Third Party for sale or distribution in the Territory; (ii) knowingly distribute any Licensed Products for sale or use in the Territory; or (iii) supply any Third Party that has distributed or offered to distribute Licensed Products in the Territory after Synergy has actual knowledge that said Third Party has distributed or offered to distribute Licensed Products obtained from Synergy in the Territory.
   
2.6 Performance by Affiliates. The Parties agree that their respective rights and obligations may be exercised or performed by any of their Affiliates; provided, however, that each Party shall be fully responsible and liable for the actions of such Affiliates in the performance of such obligations and shall ensure that such Affiliate complies with the terms of this Agreement.
   
3 REGULATORY AND DEVELOPMENT
   
3.1 Regulatory Submissions. Knight shall be solely responsible, at its expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the Licensed Products in the Territory. Synergy shall provide reasonable assistance to Knight in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Knight. Knight shall notify Synergy of all Regulatory Submissions that it submits.
   
3.2 Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in the Territory. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.
3.3 Other Covenants of Knight. In addition to its other obligations, commitments and undertakings set out in this Agreement, Knight agrees to:

 

  (a) assume the reasonable costs of intellectual property fdings, procurement and maintenance for all intellectual property applications and registrations associated with the Licensed Products in the Territory, provided that all intellectual property rights relating to the Licensed Products shall remain the exclusive property of Synergy ;
     
  (b) assume all marketing, sales and distribution expenses related to the commercialization of the Licensed Products in the Territory; and
     
  (c) prepare an annual marketing and sales plan relating to the Licensed Products in the Territory.

 

 

 

 

3.4 Other Covenants of Synergy. In addition to its other obligations, commitments and undertakings set out in this Agreement, Synergy agrees to:

 

  (a) provide Knight with all documentation relating to the submissions for Regulatory Approval to the U S. Food and Drug Administration or the European Medicines Agency for the Licensed Products within one (1) month from submission;
     
  (b) where applicable, provide reasonable assistance to Knight with the Regulatory Submission of the Licensed Products in the Territory;
     
  (c) provide full assistance and cooperation with respect to securing intellectual property protection in the Territory for the Licensed Products;
     
  (d) not assign the intellectual property associated with Licensed Products to any Third Party;
     
  (e) coordinate Launch activities with Knight, including pharmacovigilence, pricing, reimbursement, positioning and health care conferences;
     
  (f) promptly provide United States international marketing and sales materials used for the Licensed Products.

 

4 TRADEMARKS
   
4.1 Trade-Mark License. Synergy hereby grants to Knight, for the Term, an exclusive, royalty-free license to use the Synergy Marks in the Territory in association with the Licensed Products.
   
4.2 Ownership. Knight acknowledges that the Synergy Marks are owned by Synergy. The Synergy Marks shall be and remain the sole and exclusive property of Synergy. Knight shall not contest the ownership of the Synergy Marks or the validity of any registration relating thereto. Knight agrees, at the request of Synergy, to execute any and all proper documents appropriate to assist Synergy in obtaining and maintaining Synergy’s rights in and to the Synergy Marks.
   
4.3 Licensed Products to Bear Mark. Licensed Products distributed by Knight under this Agreement shall bear the Synergy Marks together with a notice that the Synergy Marks are used under license from Synergy, subject to the approval of such labeling by appropriate Governmental Authorities. Knight shall submit to Synergy, for prior approval, which shall not be unreasonably withheld, a representative sample of any marketing or promotional materials prepared by Knight, bearing the Synergy Marks.
   
4.4 No Similar Mark. Knight will not, without Synergy’s prior written consent, register or use in connection with any product, any trade-mark that is confusingly similar to the Synergy Marks.
   
5 COMMERCIALIZATION
   
5.1 Safety Data Exchange Agreement. The parties agree to develop and commit to a Safety Data Exchange Agreement (“SDEA”) that allows them to fulfill their respective regulatory and pharmacovigilence obligations relating to Adverse Drug Event and Adverse Drug Reaction reporting. Such SDEA will be completed within ninety (90) days after the Effective Date.
   
5.2 Quality Complaint Reporting. Knight shall be solely responsible for collecting and responding to any product quality complaint relating to the Licensed Products received from a customer in the Territory. Synergy shall investigate and provide Knight, in a timely manner, with reports resulting from such investigations. If Synergy receives a product quality complaint relating to the Licensed Products from a customer in the Territory, it shall investigate and promptly report the investigation results to Knight, who will be solely responsible for communication and response, if any, to the customer in the Territory. Furthermore, Synergy shall be responsible for investigating and submitting reports to Knight respecting any product quality complaints related to the manufacturing of the Licensed Products.

 

 

 

 

5.3

Other Information. In addition to the foregoing information to be provided, each Party shall provide to the other Party with any: (i) information relating to the efficacy and/or safety of the Licensed Products, including any recall of the Licensed Products; (ii) complaints from customers, healthcare professionals or competitors in the Territory relating to the Licensed Products; (iii) information relating to any potential liability to any Third Party in the Territory that is reasonably likely to arise for either Party in connection with the manufacture, or Commercialization of the Licensed Products in the Territory; (iv) information relating to any inspections, inquiries, issues raised or actions taken by any Governmental Authority in the Territory; and (v) any other information necessary or reasonably desirable to enable each Party to comply with any Applicable Law in the Territory or elsewhere.

     
5.4 Recall. Knight shall advise Synergy of any Governmental Authority initiated mandatory recall of Licensed Products in the Territory. Knight shall not initiate any voluntary recall of Licensed Products in the Territory without prior notice to and consultation with Synergy. Prior to executing any recall of Licensed Products in the Territory, Knight shall review with Synergy the proposed manner in which the recall is to be carried out. Knight will give due consideration to any reasonable recommendation from Synergy as to the manner of conducting the recall, provided that it is agreeable to the applicable Governmental Authority. Knight shall communicate directly with the applicable Governmental Authorities in relation to a Licensed Products recall in the Territory. If any Licensed Products recall in the Territory results from improper handling, shipping or storage of Licensed Products by Knight, and in no way results from the manufacture, control, handling, shipping or storage of the Licensed Products before receipt by Knight, the costs associated with the recall shall be paid by Knight and Knight shall indemnify Synergy against any Third Party claims in connection with the recall. If the recall results from any cause or issue other than ones for which Knight is responsible as set forth in the prior sentence, all costs and expenses arising from the recall, including any costs associated with replacing recalled Licensed Products, shall be paid for by Synergy and Synergy shall indemnify Knight against any Third Party Claims in connection therewith.
   
6 MANUFACTURE AND SUPPLY
   
6.1 Manufacture by Synergy. During the Term, Knight agrees to obtain exclusively from Synergy all Knight’s requirements of the Licensed Products for the Territory. Synergy agrees to supply Knight with all of its requirements of Licensed Products as set forth in each order submitted by Knight. Synergy may, at its discretion, use the services of a contract manufacturer to manufacture and package the Licensed Products.
   
6.2 Price. Synergy shall supply Licensed Products at a cost to Knight equal to Synergy’s Cost of Goods plus ten percent (10%), plus applicable sales taxes. Payment of such amounts shall be made by Knight to Synergy within thirty-five (35) days following Knight’s receive of an invoice from Synergy.
   
6.3 Orders. Knight shall order Licensed Products from Synergy by submitting purchase orders to Synergy. Such purchase order shall specify, at a minimum, the desired delivery date, unit quantity, place of delivery and an order number. Knight shall order Licensed Products. The initial purchase order will have a lead time of between sixty (60) and ninety (90) days between the time when an order for Licensed Products is submitted to Synergy until the Licensed Products is delivered to Knight. Thereafter, the purchase order will have not less than five (5) Business Days lead time
   
6.4 Delivery Terms. Licensed Products will, at Knight’s direction, be shipped directly to Knight or to a Third Party in the Territory designated by Knight. The terms for delivery of orders of Licensed Products shall be FOB (Incoterms 2010) Synergy’s manufacturer’s facility in the United States.
   
6.5 Packaging and Labeling. Knight shall determine the artwork and design for the packaging and labelling in the Territory in consultation with Synergy. Knight shall be entitled to have its trade-marks displayed on the packaging for the Licensed Products. Knight shall be responsible for the costs associated with the development of Knight’s artwork for the packaging and labeling of the Licensed Products for Launch and for any changes thereto made at Knight’s request or for any special packaging required by Knight or a Governmental Authority.

 

 

 

 

6.6 Specifications. Licensed Products manufactured and supplied to Knight hereunder shall conform to the Specifications which may be changed from time to time upon mutual agreement, or as required by any Governmental Authority.
   
6.7 GIMP. All manufacture and quality control operations by Synergy or its designee shall be in compliance with GMP.
   
6.8 Shelf Life. All Licensed Products supplied by Synergy hereunder shall have not less than eighty-five percent (85%) of its shelf life remaining upon delivery to Knight.
   
6.9 Quality Agreement. The Parties shall enter into a quality agreement regarding supply of Licensed Products by Synergy to Knight, incorporating provisions that are standard in the pharmaceutical field within ninety (90) days of the Effective Date.
   
6.10 Changes. A Party shall promptly notify the other Party in writing of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority, concerning the quality of Licensed Products and/or documentation or other items for such changes relating to the quality of the Licensed Products. The Parties shall negotiate in good faith towards an appropriate response to a Governmental Authority in respect of each proposed change in the quality of the Licensed Products including any costs associated with implementing said changes. Synergy shall notify Knight of any proposed change in manufacturing facility or manufacturing procedures.
   
6.11 Minor Changes. Minor changes in the procedures for manufacture or quality control that do not require approval from a Governmental Authority or that will not affect Regulatory Approvals will be communicated by Synergy to Knight in an annual review.
   
6.12 Release to Knight. Synergy, or its designee, shall only release for shipment to Knight, finished batches of Licensed Products that have been examined by Synergy for compliance with the Specifications. Synergy is responsible for conducting, or having conducted, all required stability and release testing to ensure that the finished batches of Licensed Products are in compliance with the Specifications.
   
6.13 Quality Audit. During normal working hours and upon reasonable notice, Knight shall be entitled to inspect areas within Synergy’s or its contract manufacturer’s establishment where Licensed Products are manufactured or stored, and to inspect the manufacturing, packaging, and quality control records relating to the Licensed Products.
   
6.14

Government Inspections. Synergy shall make its internal practices, and its manufacturing, packaging, and quality control records relating to the Licensed Products available to Governmental Authorities and will allow access to all facilities used for manufacturing the Licensed Products to the applicable Governmental Authorities for the purposes of determining Synergy’s compliance with Applicable Laws. Synergy agrees to advise Knight immediately of any proposed or announced visit or inspection, and as soon as possible but in any case within three (3) Business Days after any unannounced visit or inspection, by a Governmental Authority in the Territory relating to the Licensed Products. Synergy shall provide Knight with a reasonable description in writing of each such visit or inspection promptly thereafter, and with copies of any letters, reports or other documents issued by any such Governmental Authorities that relate to the Licensed Products.

 

6.15 Defects. Any claim by Knight regarding an apparent failure of the Licensed Products to comply with the Specifications must be made in writing with full particulars within thirty (30) days after receipt of the Licensed Products by Knight. In the case of latent defects, such defects shall be reported to Synergy within thirty (30) days of Knight having actual notice of the defect. In case of a justifiable claim for defect because of a failure of the Licensed Products to conform to the Specifications, Synergy or its designee shall, without charge, promptly replace the defective portion with supplies that are in compliance with such Specifications. Synergy shall assume all costs associated with transportation of replacement Licensed Products. Knight shall follow any reasonable instructions to return to Synergy or dispose of, in either event at Synergy’s expense, any quantities of Licensed Products as aforesaid that are not in compliance with the Specifications.

 

 

 

 

6.16 Independent Lab. If Synergy does not agree with Knight that the Licensed Products rejected by Knight fails to conform to the Specifications, the matter will be submitted for analysis to an independent laboratory agreed between the Parties. The decision of such independent laboratory following its analysis of the Licensed Products shall be final. The cost of the analysis, as well as the costs associated with reasonable shipping, handling, and storage of any Licensed Products under dispute as to compliance with the Specifications, shall be borne by the Party who was in error.
   
6.17 Short Shipment. If Knight determines that there is a shortage in the quantity of any shipment of Licensed Products (from quantities specified in the relevant bill of lading or other shipping documents), and it is determined that discrepancy existed at the time it was delivered to Knight from Synergy, Knight shall notify Synergy in writing as soon as reasonably possible, and Synergy shall make up the shortage within thirty (30) days of such notification at no additional cost to Knight.
   
6.18 Failure.

 

  (a) In the event of any Short Term Inability to Supply the Product in the Territory, Synergy shall be liable for payments to Knight as follows: (i) reimbursement for Knight’s share of all Licensed Products lost sales attributable to the Short Term Inability to Supply and quantified by Knight using commercially reasonable methods and (ii) all reasonable direct expenses incurred by Knight in dealing with and attempting to manage and resolve such Short Term Inability to Supply in the Territory, including but not limited to bona fide sales and marketing expenses and penalties imposed by distributors and wholesalers. Knight shall attempt to quantify the financial impact of any Short Term Inability to Supply, in writing, as soon as reasonably possible to Synergy and shall use all reasonable efforts to mitigate such impact. Payments due under this Section 6.18 shall be payable within thirty (30) days of receipt of said claim. In the event that two (2) Short Term Inability to Supply events occur within twenty four (24) month period, then Synergy shall, upon Knight’s request and Synergy’s expense, be required to enter into a contract manufacturing agreement with a Third Party for the manufacture in the Territory and supply of the Licensed Products to the Knight.
     
  (b) In the event of a Long Term Inability to Supply, Knight shall be entitled to all of the rights and recourses set forth in Section 6.18(a). In addition, Knight shall be entitled by notice in writing to terminate the supply arrangements contemplated in this Agreement, in which event:

 

  (i) Knight shall be entitled to purchase the Licensed Products from a Third Party. For greater certainty. Synergy shall grant to a Third Party designated by the Knight the non-exclusive license to use all relevant intellectual property for or in respect of the manufacture of the Licensed Products for commercialization in the Territory.
     
  (ii) Synergy shall provide such assistance as is required by Knight acting reasonably, from time to time to assist in sourcing the Licensed Products from a third party.
     
  (iii) Without limiting the generality of the foregoing. Synergy shall enter into a technology transfer agreement with a Third Party manufacturer selected by Knight under which Synergy shall transfer to the selected manufacturer all technical information necessary to manufacture the Licensed Products and supply the Licensed Products in the Territory.

 

6.19 Shortfall. In the event of an interruption or shortfall in supply of Licensed Products, for whatever reason, that exceeds ninety (90) days in duration, such that not all purchase orders for Licensed Products hereunder can be met, then Synergy shall immediately notify Knight and shall allocate a prorated share of its available sources and supplies among Knight and Synergy’s other partners (distributors, licensees, agents,) and internal needs, based on the respective forecasted commercial supply requirements of each of the parties for that allocation period. In any case, the Parties will discuss and agree in good faith on acceptable delivery dates and measures to mitigate the effects of the interruption or shortfall. Synergy shall use commercially reasonable efforts to eliminate, cure or overcome such shortage and to resume performance of its obligations hereunder as soon as reasonably possible.

 

 

 

 

6.20 Capacity and Supply. Synergy will maintain sufficient manufacturing time in its production schedule to provide consistent availability of Licensed Products to meet Knight’s firm orders. Synergy shall maintain or cause its contract manufacturer to maintain sufficient volumes of Licensed Products as Knight and Synergy, each acting reasonably and based on the then current and anticipated sales, from time to time determine.
   
6.21 Payment Method. All payment due to Synergy hereunder will be paid in United States Dollars by wire transfer to an account designated by Synergy.
   
6.22 Record Retention. Synergy will maintain complete and accurate books, records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.
   
6.23 Audit. During the Term of this Agreement and for three (3) years thereafter, Knight will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Synergy as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Synergy is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section 6 as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.
   
6.24 Payment of Additional Amounts. If, based on the results of any audit under Section 6.23, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.
   
7. INTELLECTUAL PROPERTY
   
7.1 Notification of Third Party Infringement. Each Party shall promptly disclose to the other in writing within ten (10) Business Days, any actual, alleged, or threatened Third Party infringement or misappropriation in the Territory of any Synergy Patent and any actual, alleged or threatened infringement or passing off of the Synergy Mark, of which such Party becomes aware.

 

 

 

 

7.2 Response to Third Party Infringement. Synergy shall have the first right, but not any obligation, to respond to any actual or threatened infringement of an Synergy Patent, the Synergy Mark or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory relating to the Licensed Products. If Synergy elects to respond to any actual or threatened infringement by initiating a proceeding. Synergy shall use legal counsel of its choice at its expense and shall have full control over the conduct of such proceeding. Synergy may settle or compromise any such proceeding without the consent of Knight; provided, however, that if such settlement affects Knight’s rights under this Agreement, or Knight’s ability to Commercialize the Licensed Products within the Territory, or otherwise requires Knight to admit wrongdoing, fault, or liability. Synergy will not settle or compromise any such proceeding without the consent of Knight, such consent not to be unreasonably withheld, conditioned, or delayed. If Synergy elects not to respond to any actual or threatened infringement of an Synergy Patent, the Synergy Mark or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory relating to the Licensed Products, then Knight shall have the right, but not the obligation, to take action, at its sole expense, in which case Knight shall have full control over the conduct of such proceeding and Knight may settle or compromise any such proceeding without the consent of Synergy; provided, however, that if such settlement affects Synergy’s intellectual property rights or its rights under this Agreement, or Synergy’s ability to Commercialize the Licensed Products outside the Territory, or otherwise requires Synergy to admit wrongdoing, fault, or liability, Knight will not settle or compromise any such proceeding without the consent of Synergy, such consent not to be unreasonably withheld, conditioned, or delayed. Knight shall be solely responsible for any legal costs or damages awards made in any proceeding that is initiated by Knight in the event that Synergy elects not to respond to any actual or threatened infringement.
   
7.3 Cooperation. Each Party shall cooperate reasonably, at its expense, in any enforcement effort initiated by the other Party. The Parties nor their Affiliates shall contest any joinder in any proceeding sought to be brought by the other Party if such joinder is required by Law.
   
7.4 Recovery. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any monetary award recovered from a Third Party in connection with any proceeding initiated to protect, maintain, defend, or enforce any intellectual property in the Territory or recovered from a Third Party in connection with any proceeding initiated for infringement or misappropriation of intellectual property shall first be used to reimburse the Parties for any out-of-pocket legal expenses relating to such proceeding and the balance being retained by the Party that brought and controlled such litigation.
   
7.5 Infringement of Third Party IP. If either Party becomes aware that its activities performed hereunder may constitute actual or alleged infringement or misappropriation of the intellectual property rights of a Third Party, it shall promptly notify the other Party and the Parties shall discuss a strategy to defend or mitigate against any actual or alleged infringement.
   
8. REPRESENTATION AND WARRANTIES
   
8 1 Synergy Covenants, Representations and Warranties Synergy covenants, represents and warrants (as the case may be) to Knight that:

 

  (a) Synergy is a corporation duly organized, validly existing and in good standing under the laws of Nevada;
     
  (b) Synergy has the legal right and authority to enter into this Agreement;
     
  (c) Synergy has taken all necessary actions to authorize the execution, delivery and performance of this Agreement;

 

 

 

 

  (d) Synergy has obtained all consents, licenses and authorizations that are necessary to perform its obligations under this Agreement;
     
  (e) Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Synergy, enforceable against Synergy in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and remedies or equitable principles;
     
  (f) The performance of Synergy’s obligations under this Agreement will not conflict with its organizational documents, as amended, or result in a breach of any material agreements or contracts to which it is a party;
     
  (g) Synergy has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would conflict with its obligations under this Agreement;
     
  (h) Synergy owns or licenses all of the Synergy Patents licensed to Knight pursuant to this Agreement and the Synergy Patents licensed to Knight pursuant to this Agreement are all of the patents owned or licensed by Synergy that are reasonably necessary for Knight to carry out its obligations and exercise its rights under this Agreement;
     
  (i) Synergy has not received any notice that the manufacture, sale, or use of the Licensed Products in the Territory infringes upon any intellectual property rights of any Third Parties in the Territory;
     
  (j) Synergy has not received any notice from a Third Party that any issued Synergy Patent is invalid or unenforceable for any reason;
     
  (k) To the knowledge of Synergy, there are no activities being carried out by Third Parties in the Territory that would constitute infringement or misappropriation of the Synergy Patents or the Synergy Mark;
     
  (l) Licensed Products manufactured by Synergy and provided to Knight pursuant to this Agreement will meet the Specifications at the time of delivery to Knight and will have been manufactured in accordance with the requirements of GMP.

 

8.2 Knight Representations and Warranties. Knight covenants, represents and warrants to
   
  Synergy (as the case may be) as follows:

 

  (a) Knight is a corporation duly organized, validly existing and in good standing, under the laws of Barbados.

 

  (b) Knight has the legal right, authority, and power to enter into this Agreement.
     
  (c) Knight has taken all necessary action to authorize the execution, delivery, and performance of this Agreement.
     
  (d) Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Knight, enforceable against Knight in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and remedies or equitable principles.
     
  (e) The performance of Knight’s obligations under this Agreement will not conflict with its organizational documents or result in a breach of any material agreements or contracts to which any is a party.
     
  (f) Knight has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would be inconsistent with its obligations under this Agreement.
     
  (g) Neither Knight nor its Affiliates will initiate a proceeding to challenge the validity or enforceability of any Synergy Patent or the Synergy Marks, or directly or indirectly assist any Third Party with respect to any such proceeding.

 

 

 

 

8.3 WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE LICENSED PRODUCTS OR ANY TECHNOLOGY OR ANY LICENSE GRANTED BY EITHER PARTY HEREUNDER. SYNERGY DOES NOT WARRANT NOR REPRESENT THAT ANY OF THE SYNERGY PATENTS ARE VALID OR ENFORCEABLE
   
8.4 LIMITATIONS OF LIABILITY. WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER
   
8.5

Indemnification by Synergy. Synergy hereby agrees to defend, indemnify, and hold Knight, its Affiliates and their respective officers, directors, employees and agents, (each a “Knight Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Synergy or an Affiliate of Synergy; (ii) any violation of Applicable Law by Synergy or its Affiliates; and (iii) any negligent act or omission or willful misconduct of Synergy or its Affiliates; (iv) any claim that the sale by Knight or its Affiliates, of the Licensed Products infringes on intellectual property rights in the Territory of any other person; (v) any claim arising from any use, within the approved labelling, made by any person of any of the Licensed Products; in all cases, except to the extent such Third Party’s claim for loss, damage or liability is the result of: (i) any breach of this Agreement by Knight or a Knight Indemnified Party, (ii) any violation of Applicable Law by Knight or a Knight Indemnified Party, or (iii) any negligent act or omission or willful misconduct of Knight or a Knight Indemnified Party.

 

8.6 Indemnification by Knight. Knight hereby agrees to defend, indemnify, and hold Synergy, its Affiliates and their respective officers, directors, employees and agents, (each a “Synergy Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Knight or an Affiliate of Knight; (ii) any violation of Applicable Law by Knight or its Affiliates; and (iii) any negligent act or omission or willful misconduct of Knight or its Affiliates; in all cases, except to the extent such Third Party’s claim for loss, damage or liability is the result of: (i) any breach of this Agreement by Synergy or an Synergy Indemnified Party, (ii) any violation of Applicable Law by Synergy or an Synergy Indemnified Party, or (iii) any negligent act or omission or willful misconduct of Synergy or an Synergy Indemnified Party.

 

 

 

 

8.7 Indemnification Procedure. If an indemnified party intends to claim indemnification under this Section 8, such party shall promptly notify the other party of any loss, claim, damage, liability or action in respect of which the indemnified party intends to claim such indemnification, and the indemnifying party shall have a first opportunity to assume the sole defense thereof with counsel selected by the indemnifying party and approved by the indemnified party acting reasonably; provided, however, that an indemnified party shall have the right to retain its own counsel and participate fully in the defense, with the fees and expenses to be paid by the indemnified party. The failure or delay to deliver notice to the indemnifying party, within a reasonable time after the commencement of any such proceeding, if irreparably prejudicial to the indemnifying party’s ability to defend such proceeding, shall relieve the indemnifying party of any and all liability to the indemnified party under this Section 8. The indemnified party shall cooperate fully with the indemnifying party and their legal representatives in the investigation of any loss, claim, damage, or liability covered by this indemnification, and shall mitigate such loss and damages. Any amount payable in order to satisfy an indemnity hereunder shall be paid as soon as reasonably possible after the indemnified party has incurred an indemnified expense and notified the indemnifying party thereof.
   
8.8 Compliance with Law. Each Party shall comply, and shall require their Affiliates and permitted sublicensees to comply, with all Applicable Laws relative to their obligations hereunder.
   
8.9 Insurance. The Parties shall maintain insurance, including product liability insurance, that is adequate to cover their obligations hereunder and that is consistent with normal business practices of prudent corporations engaged in the same or a similar business. The Parties acknowledge and agree that such insurance shall not be construed to create a limit with respect to their indemnification obligations.
9. TERM AND TERMINATION
   
9.1 Term. This Agreement will take effect from the Effective Date and, unless earlier terminated in accordance with the terms herein, will continue in full force and effect for fifteen (15) years from the Launch (the “Initial Term”). This Agreement shall automatically renew for successive fifteen (15) year periods (each a “Renewal Term”) unless, at least one (1) year prior to the expiry of the Initial Term or Renewal Term, either Party provides the other with written notice of its intention not to renew the Agreement (a “Non-Renewal Notice”) at the end of the applicable period, and further provided that if the notifying Party is Synergy, it shall be obliged to pay to Knight the Non-Renewal Fee set out in Section 9.7 below.
   
9.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:

 

  (a) In the event of a petition in bankmptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Knight’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

9.3 Termination of Knight. Knight may terminate this Agreement in whole or in part (with respect to a particular Licensed Product Territory or Additional Territory) by notice in writing given no less than sixty (60) days prior to the intended termination date.
   
9.4 Effect of Termination. Upon expiry or termination of this Agreement, all licenses and rights granted by Synergy hereunder shall terminate and Knight undertakes to:

 

  (a) except as provided for in Section 9.6, cease any Commercialization of the Licensed Products in the Territory; and
     
  (b) within thirty (30) days or expiry or termination, transfer title to all current and pending Regulatory Approvals for the Licensed Products to Synergy and assist Synergy, at Synergy’s cost, in submitting appropriate documents to transfer the Regulatory Approvals for the Licensed Products to Synergy or its designee.

 

 

 

 

9.5 Survival. In the event of the termination of this Agreement for any reason, the following provisions of this Agreement shall survive Sections 1, 7, 9, 10 and 12 and any other terms which, by their nature, require or contemplate performance by the Parties after expiry or termination. In any event, termination of this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such termination.
   
9.6 Sell-Off of Inventory. Upon termination of this Agreement, Knight shall be entitled to sell off any inventory of the Licensed Products in Knight’s possession or control or which are subject to binding purchase orders on the date such termination is effective.
   
9.7 Non-Renewal Fee. In the event that Synergy issues a Non-Renewal Notice, it shall be obliged to pay to Knight an amount equal to the Net Sales of the Licensed Products as achieved by Knight in the Territory during the eight (8) Calendar Quarters preceding the date of such notice, plus all applicable taxes (the “Non-Renewal Fee”). Within sixty (60) days of its receipt of the Non-Renewal Notice, Knight shall issue an invoice for the payment of the Non-Renewal Fee which shall include reasonable details as to the calculation of the said amount. The Non-Renewal Fee shall be payable by Synergy within thirty (30) days of the issuance of the said invoice.
   
10. DISPUTE RESOLUTION
   
10.1 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the simplified rules of the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held in New York New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision.
   
10.2 Irreparable Harm. Notwithstanding anything to the contrary in Section 10.2, if either Party in its sole judgment, acting reasonably, believes that any such dispute could cause it irreparable harm, such Party (i) will be entitled to seek equitable relief in order to avoid such irreparable harm and (ii) will not be required to follow the procedures set forth in Section 10.2.

 

 

 

 

11. KNIGHT OPTION FOR ADDITIONAL TERRITORIES
   
  Knight (directly or through one of its Affdiates) shall have the option to become Synergy’s exclusive distribution partner for either or both of the Licensed Products in any one or more of Israel, Russia and Sub-Saharan Africa (each an “Additional Territory”) under the same terms and conditions as this Agreement. Knight shall inform Synergy of its intention to exercise such right (directly or through one of its Affdiates) at any time or from time to time by notice in writing. If Knight exercises such right, then the said Additional Territories and the Licensed Product(s) referred to in such Territory shall be deemed to be part of the “Territory” for all purposes of this Agreement. Where the option is exercised on behalf of a Knight Affiliate, the parties shall enter into a separate and identified agreement concerning the particular Licensed Product and Additional Territory.

 

12. OTHER PROVISIONS
   
12.1 Withholding Tax. Knight will make all payments to Synergy under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Knight under this Agreement will be timely paid by Knight on behalf of Synergy to the appropriate Governmental Authority, and Knight will furnish Synergy with the corresponding proof of payment of such tax, as may be required in order to enable Synergy to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Knight and Synergy agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
12.2 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
12.3 Independent status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
12.4 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall enure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.

 

12.5 Compliance with law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of the Territory.
   
12.6 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.

 

 

 

 

12.7 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 12.7. Notices and other communications shall be addressed as follows:

 

  (a) In the case of Synergy:
     
    Synergy Strips Corp.
c/o Jack Ross 865 Spring
Street Westbrook, Maine 04092
Fax:
     
  E-mail: jack.ross@purebrands.ca
     
  with a copy to:
  Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail, Suite 300
Raleigh, North Carolina 27607 U.S.A.
  Attention: W. David Mannheim, Esq.
  Fax: (919) 781-4865
  E-mail: dmann heim@ wy ri ck. c om

 

  Knight Therapeutics (Barbados) Inc.
  Chancery House High Street
  Bridgetown, St. Michael
  BB11128  
  Barbados, WI
  Attention: Andrew C. Ferreira
  Fax: 1-246-431-0076
     
  With a copy to:
     
  Davies Ward Phillips & Vineberg LLP 900 Third Avenue 24th Floor
  New York, NY 10022
  LJ.S.A.  
  Attention: Hillel W. Rosen
  Fax: (212)308-0132

 

12.8 Complete Agreement. This Agreement together with the SDEA, and the Quality Agreement, embodies all of the understandings and obligations between the Parties with respect to the Licensed Products and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
12.9 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances.
   
12.10 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

 

 

 

12.11 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.

 

12.12 Public Announcements. Neither Party shall originate any publicity, news release, or public announcements relating to this Agreement (including, without limitation, its existence, its subject matter, the Parties’ performance, any amendment hereto, or performance hereunder), whether to the public or press, stockholders, or otherwise, without the prior written consent of the other Party, save only such announcements that are required by law or the rules of any relevant stock exchange to be made or that are otherwise agreed to by the Parties. If a Party decides to make an announcement, whether required by law or otherwise, it shall give the other Party reasonable notice of the text of the announcement so that the other Party shall have an opportunity to comment upon the announcement. To the extent that the receiving Party reasonably requests the deletion of any information in any such announcement, the disclosing Party shall delete such information unless, in the opinion of the disclosing Party’s legal counsel, such information is required by law or the rules of any relevant stock exchange to be disclosed. The timing and content of the initial press release relating to this Agreement, if any, including its existence, the subject matter to which it relates and the transactions contemplated herein will, except as otherwise required by law or any stock exchange rules, be determined jointly by the Parties.
   
12.13 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
12.14 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof.
   
12.15 English Language. At the request of the parties, this Agreement and the other Loan Documents have been negotiated in the English language and will be or have been executed in the English language. Les soussignes out expressement demande que ce document et tons les documents annexes soient rediges en langue anglaise.

 

(Signature page follows)

 

 

 

 

IN WITNESS WHEREOF, the parties have signed this Agreement

 

By: /s/ Jack Ross   By: /s/ [Unintelligible]
Name: JACK ROSS   Name: CHANCERY CORPORATE SERVICES LIMITED
Title: CEO   Title: SECRETARY

 

 

 

 

Exhibit 10.4

 

Synergy Strips Corp. 2014

Equity Incentive Plan

 

1. ESTABLISHMENT OF PLAN; DEFINITIONS

 

1.1 Purpose. The purpose of the Synergy Strips Corp. 2014 Equity Incentive Plan is to encourage certain officers, employees, directors, and consultants of Synergy Strips Corp., a Nevada corporation (the “Company”), to acquire and hold stock in the Company as an added incentive to remain with the Company and increase their efforts in promoting the interests of the Company, and to enable the Company to attract and retain capable individuals.

 

1.2 Definitions. Unless the context clearly indicates otherwise, the following terms shall have the meanings set forth below:

 

1.2.1 “Award” shall mean, individually or collectively, a grant under this Plan of Stock Options or Stock Awards.

 

1.2.2 “Award Agreement” shall mean a written agreement containing the terms and conditions of an Award, not inconsistent with this Plan.

 

1.2.3 “Beneficiary” and “Beneficial Ownership” shall mean the person, persons, trust, or trusts that have been designated by a Grantee in his or her most recent written beneficiary designation filed with the Committee to receive the benefits specified under this Plan upon such Grantee’s death or to which Awards or other rights are transferred if and to the extent permitted under Section 7.2.4 hereof. If, upon a Grantee’s death, there is no designated Beneficiary or surviving designated Beneficiary, then the term Beneficiary shall mean the person, persons, trust, or trusts entitled by will or the laws of descent and distribution to receive such benefits.

 

1.2.4 “Beneficial Owner” shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act and any successor to such Rule.

 

1.2.5 “Board” shall mean the board of directors of the Company.

 

1.2.6 “Change in Control” shall mean a Change in Control as defined in Section 7.1.1(b).

 

1.2.7 “Code” shall mean the Internal Revenue Code of 1986, as it may be amended from time to time.

 

1.2.8 “Committee” shall mean the Board or a committee of the Board appointed pursuant to Section 1.4 of this Plan.

 

1.2.9 “Common Stock” shall mean the Company’s common stock, par value $0.00001 per share.

 

1.2.10 “Company” shall mean Synergy Strips Corp., a Nevada corporation.

 

1.2.11 “Consultants” shall mean individuals who provide services to the Company and any Subsidiary who are not also Employees or Directors and which services are not in connection with the offer or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

 

1.2.12 “Covered Employee” shall mean a Grantee who, as of the date of vesting and/or payout of an Award, or the date the Company or any of its Subsidiaries is entitled to a tax deduction as a result of the Award, as applicable, is one of the group of “covered employees,” as defined in the regulations promulgated under Code Section 162(m), or any successor statute.

 

1.2.13 “Designated Officer” shall mean any executive officer of the Company to whom duties and powers of the Board or Committee hereunder have been delegated pursuant to Section 1.4.3.

 

 
 

 

1.2.14 “Directors” shall mean those members of the Board or the board of directors of any Subsidiary who are not also Employees.

 

1.2.15 “Disability” shall mean a medically determinable physical or mental condition that causes an Employee, Director, or Consultant to be unable to engage in any substantial gainful activity and that can be expected to result in death or to be of long-continued and indefinite duration.

 

1.2.16 “Effective Date” shall mean the effective date of this Plan, which shall be the Stockholder Approval Date.

 

1.2.17 “Employee” shall mean any common law employee, including Officers, of the Company or any Subsidiary as determined under the Code and the Treasury Regulations thereunder.

 

1.2.18 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.

 

1.2.19 “Fair Market Value” shall mean (i) if the Common Stock is listed on a national securities exchange or the NASDAQ system, the mean between the highest and lowest sales prices for the Common Stock on such date, or, if no such prices are reported for such day, then on the next preceding day on which there were reported prices; (ii) if the Common Stock is not listed on a national securities exchange or the NASDAQ system, the mean between the bid and asked prices for the shares on such date, or if no such prices are reported for such day, then on the next preceding day on which there were reported prices; or (iii) as determined in good faith by the Board.

 

1.2.20 “Grantee” shall mean an Officer, Employee, Director, or Consultant granted an Award.

 

1.2.21 “Incentive Stock Option” shall mean a Stock Option that meets the requirements of Code Section 422 and is granted pursuant to the Incentive Stock Option provisions as set forth in Section 2.

 

1.2.22 “Incumbent Board” shall mean the Incumbent Board as defined in Section 7.1.1(b)(ii).

 

1.2.23 “Non-Statutory Stock Option” shall mean a Stock Option that does not meet the requirements of Code Section 422 and is granted pursuant to the Non-Statutory Stock Option provisions as set forth in Section 3.

 

1.2.24 “Officer” shall mean a person who is an officer of the Company or a Subsidiary within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.

 

1.2.25 “Performance Award” shall mean an Award under Section 6 hereof.

 

1.2.26 “Performance Measure” shall mean one or more of the following criteria, or such other operating objectives, selected by the Committee to measure performance of the Company or any Subsidiary for a Performance Period, whether in absolute or relative terms: basic or diluted earnings per share of Stock; earnings per share of Common Stock growth; revenue; operating income; net income (either before or after taxes); earnings and/or net income before interest and taxes; earnings and/or net income before interest, taxes, depreciation, and amortization; return on capital; return on equity; return on assets; net cash provided by operations; free cash flow; Common Stock price; economic profit; economic value; total stockholder return; and gross margins and costs. Each such measure shall be determined in accordance with generally accepted accounting principles as consistently applied and, as determined by the independent accountants of the Company in the case of a Performance Award to a Covered Employee, to the extent intended to meet the performance-based compensation exception under Code Section 162(m), or as determined by the Committee for other Performance Awards, adjusted to omit the effects of extraordinary items, gain or loss on the disposal of a business segment, unusual or infrequently occurring events and transactions, and cumulative effects of changes in accounting principles.

 

1.2.27 “Performance Period” shall mean a period of not less than one (1) year over which the achievement of targets for Performance Measures is determined.

 

 
 

 

1.2.28 “Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, and shall include a “group” as defined in Section 13(d) thereof.

 

1.2.29 “Plan” shall mean the Synergy Strips Corp. 2014 Equity Incentive Plan as set forth herein and as amended from time to time.

 

1.2.30 “Related Entity” shall mean any Subsidiary, and any business, corporation, partnership, limited liability company, or other entity designated by the Board, in which the Company or a Subsidiary holds a substantial ownership interest, directly or indirectly.

 

1.2.31 “Restricted Stock” shall mean Common Stock that is issued pursuant to the Restricted Stock provisions as set forth in Section 4.

 

1.2.32 “Restricted Stock Units” shall mean Common Stock that is issued pursuant to the Restricted Stock Unit provisions as set forth in Section 5.

 

1.2.33 “Rule 16b-3” shall mean Rule 16b-3 promulgated under the Exchange Act or any successor thereto.

 

1.2.34 “Stockholder Approval Date” shall mean the date on which this Plan is approved by the stockholders of the Company eligible to vote in the election of directors, by a vote sufficient to meet the requirements of Code Sections 162(m) (if applicable) and 422, Rule 16b-3 under the Exchange Act (if applicable), applicable requirements under the rules of any stock exchange or automated quotation system on which the Common Stock may be listed on quoted, and other laws, regulations, and obligations of the Company applicable to this Plan.

 

1.2.35 “Stock Award” shall mean an award of Restricted Stock or Restricted Stock Units granted pursuant to this Plan.

 

1.2.36 “Stock Option” shall mean an option granted pursuant to this Plan to purchase shares of Common Stock.

 

1.2.37 “Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with and including the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

 

1.3 Shares of Common Stock Subject to this Plan.

 

1.3.1 Subject to the provisions of Section 7.1, the shares of Common Stock that may be issued pursuant to Stock Options and Stock Awards granted under this Plan shall not exceed fifteen million five hundred twenty five thousand (15,525,000) shares in the aggregate. If a Stock Option shall expire and terminate for any reason, in whole or in part, without being exercised or, if Stock Awards are forfeited because the restrictions with respect to such Stock Awards shall not have been met or have lapsed, the number of shares of Common Stock that are no longer outstanding as Stock Awards or subject to Stock Options may again become available for the grant of Stock Awards or Stock Options. There shall be no terms and conditions in a Stock Award or Stock Option that provide that the exercise of an Incentive Stock Option reduces the number of shares of Common Stock for which an outstanding Non-Statutory Stock Option may be exercised; and there shall be no terms and conditions in a Stock Award or Stock Option that provide that the exercise of a Non-Statutory Stock Option reduces the number of shares of Common Stock for which an outstanding Incentive Stock Option may be exercised.

 

1.3.2 The maximum number of shares of Common Stock subject to Awards that may be granted during any one calendar year to any one Covered Employee shall be limited to five million one hundred seventy five thousand (5,175,000) shares. To the extent required by Code Section 162(m) and so long as Code Section 162(m) is applicable to persons eligible to participate in this Plan, shares of Common Stock subject to the foregoing maximum with respect to which the related Award is terminated, surrendered, or cancelled shall nonetheless continue to be taken into account with respect to such maximum for the calendar year in which granted.

 

 
 

 

1.4 Administration of this Plan.

 

1.4.1 The Plan shall be administered by the Board. In the alternative, the Board may delegate authority to a Committee to administer this Plan on behalf of the Board, subject to such terms and conditions as the Board may prescribe. Such Committee shall consist of not less than two (2) members of the Board each of whom is a “non-employee director” within the meaning of Rule 16b-3, or any successor rule of similar import, and an “outside director” within the meaning of Section 162(m) of the Code and the regulations promulgated thereunder. Once appointed, the Committee shall continue to serve until otherwise directed by the Board. From time to time, the Board may increase the size of the Committee and appoint additional members thereof, remove members (with or without cause) and appoint new members in substitution therefor, fill vacancies, however caused, and remove all members of the Committee and, thereafter, directly administer this Plan. In the event that the Board is the administrator of this Plan in lieu of a Committee, the term “Committee” as used herein shall be deemed to mean the Board.

 

1.4.2 The Committee shall meet at such times and places and upon such notice as it may determine. A majority of the Committee shall constitute a quorum. Any acts by the Committee may be taken at any meeting at which a quorum is present and shall be by majority vote of those members entitled to vote. Additionally, any acts reduced to writing or approved in writing by all of the members of the Committee shall be valid acts of the Committee.

 

1.4.3 The Board may, in its sole discretion, divide the duties and powers of the Committee by establishing one or more secondary Committees to which certain duties and powers of the Board hereunder are delegated (each of which shall be regarded as a “Committee” under this Plan with respect to such duties and powers), or delegate all of its duties and powers hereunder to a single Committee. Additionally, if permitted by applicable law, the Board or Committee may delegate any or all of its duties and powers hereunder to a Designated Officer subject to such conditions and limitations as the Board or Committee shall prescribe. However, only the Committee described under Section 1.4.1 may designate and grant Awards to Grantees who are subject to Section 16 of the Exchange Act or Section 162(m) of the Code. The Committee shall also have the power to establish sub-plans (which may be included as appendices to this Plan or the respective Award Agreement), which may constitute separate programs, for the purpose of establishing programs that meet any special tax or regulatory requirements of jurisdictions other than the United States and its subdivisions. Any such interpretations, rules, administration and sub-plans shall be consistent with the basic purposes of this Plan.

 

1.4.4 Powers of the Committee. The Committee shall have all the powers vested in it by the terms of this Plan, such powers to include authority, in its sole and absolute discretion, to grant Awards under this Plan, prescribe Award Agreements and establish programs for granting Awards. The Committee shall have full power and authority to take all other actions necessary to carry out the purpose and intent of this Plan, including, but not limited to, the authority to:

(a) determine the Grantees to whom, and the time or times at which, Awards shall be granted;

 

(b) determine the types of Awards to be granted;

 

(c) determine the number of shares of Common Stock and/or amount of cash to be covered by or used for reference purposes for each Award;

 

(d) impose such terms, limitations, vesting schedules, restrictions, and conditions upon any such Award as the Committee shall deem appropriate, including without limitation establishing, in its discretion, Performance Measures that must be satisfied before an Award vests and/or becomes payable, the term during which an Award is exercisable, the purchase price, if any, under an Award, and the period, if any, following a Grantee’s termination of employment or service with the Company or any Subsidiary during which the Award shall remain exercisable;

 

 
 

 

(e) modify, extend, or renew outstanding Awards, accept the surrender of outstanding Awards, and substitute new Awards, provided that no such action shall be taken with respect to any outstanding Award that would materially and adversely affect the Grantee without the Grantee’s consent, or constitute a repricing of stock options without the consent of the holders of the Company’s voting securities under Section 1.4.4(f) below;

 

(f) only with the approval of the holders of the voting securities of the Company to the extent that such approval is required by applicable law, regulation, or the rules of a national securities exchange or automated quotation system to which the Company is subject, reprice Incentive Stock Options and Non-Statutory Stock Options either by amendment to lower the exercise price or by accepting such stock options for cancellation and issuing replacement stock options with a lower exercise price or through any other mechanism;

 

(g) accelerate the time in which an Award may be exercised or in which an Award becomes payable and waive or accelerate the lapse, in whole or in part, of any restriction or condition with respect to an Award;

 

(h) establish objectives and conditions, including targets for Performance Measures, if any, for earning Awards and determining whether Awards will be paid after the end of a Performance Period; and

 

(i) permit the deferral of, or require a Grantee to defer such Grantee’s receipt of or the delivery of Stock and/or cash under an Award that would otherwise be due to such Grantee and establish rules and procedures for such payment deferrals, provided the requirements of Code Section 409A are met with respect to any such deferral.

 

The Committee shall have full power and authority to administer and interpret this Plan and to adopt such rules, regulations, agreements, guidelines, and instruments for the administration of this Plan as the Committee deems necessary, desirable or appropriate in accordance with the bylaws of the Company.

 

1.4.5 To the maximum extent permitted by law, no member of the Board or Committee or a Designated Officer shall be liable for any action taken or decision made in good faith relating to this Plan or any Award thereunder.

 

1.4.6 The members of the Board and Committee and any Designated Officer shall be indemnified by the Company in respect of all their activities under this Plan in accordance with the procedures and terms and conditions set forth in the Certificate of Incorporation and bylaws of the Company as in effect from time to time. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s Certificate of Incorporation and bylaws, as a matter of law, or otherwise.

 

1.4.7 All actions taken and decisions and determinations made by the Committee or a Designated Officer on all matters relating to this Plan pursuant to the powers vested in it hereunder shall be in the Committee’s or Designated Officer’s sole and absolute discretion and shall be conclusive and binding on all parties concerned, including the Company, its stockholders, any Grantees, and any other Employee, and their respective successors in interest.

 

1.5 Amendment or Termination.

 

1.5.1 The Committee, without further approval of the Company’s stockholders, may amend or terminate this Plan or any portion thereof at any time, except that no amendment shall become effective without prior approval of the stockholders of the Company to increase the number of shares of Common Stock subject to this Plan or if stockholder approval is necessary to comply with any tax or regulatory requirement or rule of any national securities exchange or national automated quotation system upon which the Common Stock is listed or quoted (including for this purpose stockholder approval that is required for continued compliance with Rule 16b-3 or stockholder approval that is required to enable the Committee to grant Incentive Stock Options pursuant to this Plan).

 

1.5.2 The Committee shall be authorized to make minor or administrative amendments to this Plan as well as amendments to this Plan that may be dictated by the requirements of U.S. federal or state laws applicable to the Company or that may be authorized or made desirable by such laws. The Committee may amend any outstanding Award in any manner as provided in Section 1.4.4 and to the extent that the Committee would have had the authority to make such Award as so amended.

 

 
 

 

 

1.5.3 No amendment to this Plan or any Award may be made that would materially adversely affect any outstanding Award previously made under this Plan without the approval of the Grantee. Further, no amendment to this Plan or an Award shall be made that would cause any Award to fail to either comply with or meet an exception from Code Section 409A.

 

1.6 Effective Date and Duration of this Plan. This Plan shall become effective on the Effective Date. This Plan shall terminate at such time as may be determined by the Board, and no Stock Award or Stock Option may be issued or granted under this Plan thereafter, but such termination shall not affect any Stock Award or Stock Option theretofore issued or granted.

 

2. INCENTIVE STOCK OPTION PROVISIONS

 

2.1 Granting of Incentive Stock Options.

 

2.1.1 Only Employees of the Company shall be eligible to receive Incentive Stock Options under this Plan. Officers, Directors, and Consultants of the Company who are not also Employees shall not be eligible to receive Incentive Stock Options.

 

2.1.2 The purchase price of each share of Common Stock subject to an Incentive Stock Option shall not be less than 100% of the Fair Market Value of a share of the Common Stock on the date the Incentive Stock Option is granted. If an Employee owns or is deemed to own (by reason of the attribution rules applicable under Section 424(d) of the Code) more than 10% of the combined voting power of all classes of stock of the Company (or any parent corporation or subsidiary corporation of the Company, as those terms are defined in Sections 424(e) and (f) of the Code, respectively) and an Incentive Stock Option is granted to such Employee, the exercise price of such Incentive Stock Option (to the extent required by the Code at the time of grant) shall be no less than 110% of the Fair Market Value of a Share on the date such Incentive Stock Option is granted.

 

2.1.3 No Incentive Stock Option shall be exercisable more than ten (10) years from the date the Incentive Stock Option was granted; provided however, that if a Grantee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10% of the combined voting power of all classes of stock of the Company (or any parent corporation or subsidiary corporation of the Company, as those terms are defined in Sections 424(e) and (f) of the Code, respectively) and the Incentive Stock Option is granted to such Grantee, the term of the Incentive Stock Option shall be (to the extent required by the Code at the time of the grant) for no more than five (5) years from the date of grant.

 

2.1.4 The Committee shall determine and designate from time to time those Employees who are to be granted Incentive Stock Options and specify the number of shares subject to each Incentive Stock Option.

 

2.1.5 The Committee, in its sole discretion, shall determine whether any particular Incentive Stock Option shall become exercisable in one or more installments, specify the installment dates, and, within the limitations herein provided, determine the total period during which the Incentive Stock Option is exercisable. Further, the Committee may make such other provisions as may appear generally acceptable or desirable to the Committee or necessary to qualify its grants under the provisions of Section 422 of the Code.

 

2.1.6 The Committee may grant at any time new Incentive Stock Options to an Employee who has previously received Incentive Stock Options or other options whether such prior Incentive Stock Options or other options are still outstanding, have previously been exercised in whole or in part, or are cancelled in connection with the issuance of new Incentive Stock Options. The purchase price of the new Incentive Stock Options may be established by the Committee without regard to the existing Incentive Stock Options or other options.

 

 
 

 

2.1.7 Notwithstanding any other provisions hereof, the aggregate Fair Market Value (determined at the time the option is granted) of the Common Stock with respect to which Incentive Stock Options are exercisable for the first time by the Employee during any calendar year (under all such plans of the Grantee’s employer corporation and its parent corporation or subsidiary corporation as those terms are defined in Sections 424(e) and (f) of the Code, respectively) shall not (to the extent required by the Code at the time of the grant) exceed One Hundred Thousand Dollars ($100,000). To the extent that such aggregate Fair Market Value shall exceed One Hundred Thousand Dollars ($100,000), or other applicable amount, such Stock Options to the extent of the Common Stock in excess of such limit shall be treated as Non-Statutory Stock Options. In such case, the Company may designate the shares of Common Stock that are to be treated as Stock acquired pursuant to the exercise of an Incentive Stock Option.

 

2.2 Exercise of Incentive Stock Options. The exercise price of an Incentive Stock Option shall be payable on exercise of the option (i) in cash or by check, bank draft, or postal or express money order, (ii) ) if provided in the written Award Agreement and permitted by applicable law, by the surrender of Common Stock then owned by the Grantee, which Common Stock such Grantee has held for at least six (6) months, (iii) the proceeds of a loan from an independent broker-dealer whereby the loan is secured by the option or the stock to be received upon exercise, or (iv) any combination of the foregoing; provided, that each such method and time for payment and each such borrowing and terms and conditions of repayment shall then be permitted by and be in compliance with applicable law. Shares of Common Stock so surrendered in accordance with clause (ii) or (iv) shall be valued at the Fair Market Value thereof on the date of exercise, surrender of such Common Stock to be evidenced by delivery of the certificate(s) representing such shares in such manner, and endorsed in such form, or accompanied by stock powers endorsed in such form, as the Committee may determine.

 

2.3 Termination of Employment.

 

2.3.1 If a Grantee’s employment with the Company is terminated other than by Disability or death, the terms of any then outstanding Incentive Stock Option held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise expire or three (3) months after such termination of employment, and such Stock Option shall be exercisable to the extent it was exercisable as of such last date of employment.

 

2.3.2 If a Grantee’s employment with the Company is terminated by reason of Disability, the term of any then outstanding Incentive Stock Option held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise expire or twelve (12) months after such termination of employment, and such Stock Option shall be exercisable to the extent it was exercisable as of such last date of employment.

 

2.3.3 If a Grantee’s employment with the Company is terminated by reason of death, the representative of his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right during the period ending on the earlier of the date on which such Stock Option would otherwise expire or twelve (12) months after such date of death, to exercise any then outstanding Incentive Stock Options in whole or in part. If a Grantee dies without having fully exercised any then outstanding Incentive Stock Options, the representative of his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right to exercise such Stock Options in whole or in part.

 

3. NON-STATUTORY STOCK OPTION PROVISIONS

 

3.1 Granting of Stock Options.

 

3.1.1 Officers, Employees, Directors, and Consultants shall be eligible to receive Non-Statutory Stock Options under this Plan.

 

3.1.2 The Committee shall determine and designate from time to time those Officers, Employees, Directors, and Consultants who are to be granted Non-Statutory Stock Options and the amount subject to each Non-Statutory Stock Option.

 

3.1.3 The Committee may grant at any time new Non-Statutory Stock Options to an Employee, Director, or Consultant who has previously received Non-Statutory Stock Options or other Stock Options, whether such prior Non-Statutory Stock Options or other Stock Options are still outstanding, have previously been exercised in whole or in part, or are cancelled in connection with the issuance of new Non-Statutory Stock Options.

 

 
 

 

3.1.4 The Committee shall determine the purchase price of each share of Common Stock subject to a Non-Statutory Stock Option. Such price shall not be less than 100% of the Fair Market Value of such Common Stock on the date the Non-Statutory Stock Option is granted.

 

3.1.5 The Committee, in its sole discretion, shall determine whether any particular Non-Statutory Stock Option shall become exercisable in one or more installments, specify the installment dates, and, within the limitations herein provided, determine the total period during which the Non-Statutory Stock Option is exercisable. Further, the Committee may make such other provisions as may appear generally acceptable or desirable to the Committee, including the extension of a Non-Statutory Stock Option, provided that such extension does not extend the option beyond the period specified in Section 3.1.6 below.

 

3.1.6 No Non-Statutory Stock Option shall be exercisable more than ten (10) years from the date such option is granted.

 

3.2 Exercise of Stock Options. The exercise price of a Non-Statutory Stock Option shall be payable on exercise of the Stock Option (i) in cash or by check, bank draft, or postal or express money order, (ii) if provided in the written Award Agreement and permitted by applicable law, by the surrender of Common Stock then owned by the Grantee, which Common Stock such Grantee has held for at least six (6) months, (iii) the proceeds of a loan from an independent broker-dealer whereby the loan is secured by the option or the stock to be received upon exercise, or (iv) any combination of the foregoing; provided, that each such method and time for payment and each such borrowing and terms and conditions of repayment shall then be permitted by and be in compliance with applicable law. Shares of Common Stock so surrendered in accordance with clause (ii) or (iv) shall be valued at the Fair Market Value thereof on the date of exercise, surrender of such Common Stock to be evidenced by delivery of the certificate(s) representing such shares in such manner, and endorsed in such form, or accompanied by stock powers endorsed in such form, as the Committee may determine.

 

3.3 Termination of Relationship.

 

3.3.1 If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases to be a Consultant, other than by reason of Disability or death, the terms of any then outstanding Non-Statutory Stock Option held by the Grantee shall extend for a period ending on the earlier of the date established by the Committee at the time of grant or three (3) months after the Grantee’s last date of employment or cessation of being a Director or Consultant, and such Stock Option shall be exercisable to the extent it was exercisable as of the date of termination of employment or cessation of being a Director or Consultant.

 

3.3.2 If a Grantee’s employment is terminated by reason of Disability, a Director Grantee ceases to be a Director by reason of Disability or a Consultant Grantee ceases to be a Consultant by reason of Disability, the term of any then outstanding Non-Statutory Stock Option held by the Grantee shall extend for a period ending on the earlier of the date on which such Stock Option would otherwise expire or twelve (12) months after the Grantee’s last date of employment or cessation of being a Director or Consultant, and such Stock Option shall be exercisable to the extent it was exercisable as of such last date of employment or cessation of being a Director or Consultant.

 

3.3.3 If a Grantee’s employment is terminated by reason of death, a Director Grantee ceases to be a Director by reason of death or a Consultant Grantee ceases to be a Consultant by reason of death, the representative of his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right during the period ending on the earlier of the date on which such Stock Option would otherwise expire or twelve (12) months following his death to exercise any then outstanding Non-Statutory Stock Options in whole or in part. If a Grantee dies without having fully exercised any then outstanding Non-Statutory Stock Options, the representative of his estate or beneficiaries thereof to whom the Stock Option has been transferred shall have the right to exercise such Stock Options in whole or in part.

 

 
 

 

4. RESTRICTED STOCK AWARDS

 

4.1 Grant of Restricted Stock.

 

4.1.1 Officers, Employees, Directors and Consultants shall be eligible to receive grants of Restricted Stock under this Plan.

 

4.1.2 The Committee shall determine and designate from time to time those Officers, Employees, Directors and Consultants who are to be granted Restricted Stock and the number of shares of Common Stock subject to such Stock Award.

 

4.1.3 The Committee, in its sole discretion, shall make such terms and conditions applicable to the grant of Restricted Stock as may appear generally acceptable or desirable to the Committee.

 

4.2 Termination of Relationship.

 

4.2.1 If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases to be a Consultant, prior to the lapse of any restrictions applicable to the Restricted Stock, then such Common Stock shall be forfeited and the Grantee shall return the certificates representing such Common Stock to the Company.

 

4.2.2 If the restrictions applicable to a grant of Restricted Stock shall lapse, then the Grantee shall hold such Common Stock free and clear of all such restrictions except as otherwise provided in this Plan.

 

5. RESTRICTED STOCK UNIT AWARDS

 

5.1 Grant of Restricted Stock Units.

 

5.1.1 Officers, Employees, Directors, and Consultants shall be eligible to receive grants of Restricted Stock Units under this Plan.

 

5.1.2 The Committee shall determine and designate from time to time those Officers, Employees, Directors and Consultants who are to be granted Restricted Stock Units and number of shares of Common Stock subject to such Stock Award.

 

5.1.3 The Committee, in its sole discretion, shall make such terms and conditions applicable to the grant of Restricted Stock Units as may appear generally acceptable or desirable to the Committee.

 

5.2 Termination of Relationship.

 

5.2.1 If a Grantee’s employment with the Company is terminated, a Director Grantee ceases to be a Director, or a Consultant Grantee ceases to be a Consultant, prior to the lapse of any restrictions applicable to the Restricted Stock Units, then such Common Stock shall be forfeited and the Grantee shall return the certificates representing such Common Stock to the Company.

 

5.2.2 If the restrictions applicable to a grant of Restricted Stock Units shall lapse, then the Grantee shall hold such Common Stock free and clear of all such restrictions except as otherwise provided in this Plan.

 

6. PERFORMANCE AWARDS

 

6.1 The Committee, in its discretion, may establish targets for Performance Measures for selected Grantees and authorize the granting, vesting, payment, and/or delivery of Performance Awards in the form of Incentive Stock Options, Non-Statutory Stock Options, Restricted Stock, and Restricted Stock Units to such Grantees upon achievement of such targets for Performance Measures during a Performance Period. The Committee, in its discretion, shall determine the Grantees eligible for Performance Awards, the targets for Performance Measures to be achieved during each Performance Period, and the type, amount, and terms and conditions of any Performance Awards. Performance Awards may be granted either alone or in addition to other Awards made under this Plan.

 

 
 

 

6.2 After the Company is subject to Code Section 162(m), in connection with any Performance Awards granted to a Covered Employee that are intended to meet the performance-based compensation exception under Code Section 162(m), the Committee shall (i) establish in the applicable Award Agreement the specific targets relative to the Performance Measures that must be attained before the respective Performance Award is granted, vests, or is otherwise paid or delivered, (ii) provide in the applicable Award Agreement the method for computing the portion of the Performance Award that shall be granted, vested, paid, and/or delivered if the target or targets are attained in full or part, and (iii) at the end of the relevant Performance Period, and prior to any such grant, vesting, payment, or delivery, certify the extent to which the applicable target or targets were achieved and whether any other material terms were in fact satisfied. The specific targets and the method for computing the portion of such Performance Award that shall be granted, vested, paid, or delivered to any Covered Employee shall be established by the Committee prior to the earlier to occur of (A) ninety (90) days after the commencement of the Performance Period to which the Performance Measure applies and (B) the elapse of twenty-five percent (25%) of the Performance Period and in any event while the outcome is substantially uncertain. In interpreting Plan provisions applicable to Performance Measures and Performance Awards that are intended to meet the performance-based compensation exception under Code Section 162(m), it is the intent of this Plan to conform with the standards of Section 162(m) of the Code and Treasury Regulations Section 1.162-27(e)(2), and the Committee in interpreting this Plan shall be guided by such provisions.

 

7. GENERAL PROVISIONS

 

7.1 Adjustment Provisions.

 

7.1.1 Change of Control.

 

(a) Effect of “Change in Control.” If and only to the extent provided in the Award Agreement, or to the extent otherwise determined by the Committee, upon the occurrence of a “Change in Control,” as defined in Section 7.1.1(b):

 

(i) The Committee shall take such action as it deems appropriate and equitable to effectuate the purposes of this Plan and to protect the grantees of Awards, which action may include, without limitation, any one or more of the following, provided such action is in compliance with Code Section 409A if applicable: (i) acceleration or change of the exercise and/or expiration dates of any Award to require that exercise be made, if at all, prior to the Change in Control; and (ii) cancellation of any Award upon payment to the holder in cash of the Fair Market Value of the Stock subject to such Award as of the date of (and, to the extent applicable, as established for purposes of) the Change in Control, less the aggregate exercise price, if any, of the Award.

 

(ii) Notwithstanding the foregoing or any provision in any Award Agreement to the contrary, if in the event of a Change in Control, the successor company assumes or substitutes for a Stock Option or Stock Award, then each such outstanding Stock Option or Stock Award shall not be accelerated as described in Sections 7.1.1(a)(i). For the purposes of this Section 7.1.1(a)(ii), such Stock Option or Stock Award shall be considered assumed or substituted for if following the Change in Control the Award confers the right to purchase or receive, for each share of Common Stock subject to the Stock Option or Stock Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in the transaction constituting a Change in Control by holders of Common Stock shares for each Common Stock share held on the effective date of such transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration received in the transaction constituting a Change in Control is not solely common stock of the successor company or its parent or subsidiary, the Committee may, with the consent of the successor company or its parent or subsidiary, provide that the consideration to be received upon the exercise or vesting of a Stock Option or Stock Award, for each Common Stock share subject thereto, will be solely common stock of the successor company or its parent or subsidiary substantially equal in fair market value to the per share consideration received by holders of Common Stock shares in the transaction constituting a Change in Control. The determination of such substantial equality of value of consideration shall be made by the Committee in its sole discretion and its determination shall be conclusive and binding.

 

 
 

 

(b) Definition of “Change in Control”. Unless otherwise specified in an Award Agreement, a “Change in Control” shall mean the occurrence of any of the following:

 

(i) The acquisition by any Person of Beneficial Ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than fifty percent (50%) of either (A) the value of then outstanding equity securities of the Company (the “Outstanding Company Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”) (the foregoing Beneficial Ownership hereinafter being referred to as a “Controlling Interest”); provided, however, that for purposes of this Section 7.1.1, the following acquisitions shall not constitute or result in a Change in Control: (v) any acquisition directly from the Company; (w) any acquisition by the Company; (x) any acquisition by any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Related Entity; or (z) any acquisition by any entity pursuant to a transaction that complies with clauses (A), (B), and (C) of subsection 7.1.1(b)(iii) below; or

 

(ii) During any period of two (2) consecutive years (not including any period prior to the Effective Date) individuals who constitute the Board on the Effective Date (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

 

(iii) Consummation of a reorganization, merger, statutory share exchange, or consolidation or similar transaction involving the Company or any of its Related Entities, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or equity of another entity by the Company or any of its Related Entities (each a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the Beneficial Owners, respectively, of the Outstanding Company Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the value of the then outstanding equity securities and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of members of the board of directors (or comparable governing body of an entity that does not have such a board), as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity that as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any employee benefit plan (or related trust) of the Company or such entity resulting from such Business Combination or any Person that as of the Effective Date owns Beneficial Ownership of a Controlling Interest) beneficially owns, directly or indirectly, fifty percent (50%) or more of the value of the then outstanding equity securities of the entity resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such entity except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the Board or other governing body of the entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or

 

(iv) Approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

 

7.1.2 Adjustments to Awards. In the event that any extraordinary dividend or other distribution (whether in the form of cash, Common Stock, or other property), recapitalization, forward or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange, liquidation, dissolution or other similar corporate transaction or event affects the Common Stock and/or such other securities of the Company or any other issuer such that a substitution, exchange, or adjustment is determined by the Committee to be appropriate, then the Committee shall, in such manner as it may deem equitable, substitute, exchange, or adjust any or all of (A) the number and kind of Shares that may be delivered in connection with Awards granted thereafter, (B) the number and kind of Shares by which annual per-person Award limitations are measured under this Plan’s provisions, (C) the number and kind of Shares subject to or deliverable in respect of outstanding Awards, (D) the exercise price, grant price or purchase price relating to any Award and/or make provision for payment of cash or other property in respect of any outstanding Award, and (E) any other aspect of any Award that the Committee determines to be appropriate.

 

 
 

 

7.1.3 Adjustments in Case of Certain Transactions. In the event of any merger, consolidation or other reorganization in which the Company does not survive, or in the event of any Change in Control, any outstanding Awards may be dealt with in accordance with any of the following approaches, as determined by the agreement effectuating the transaction or, if and to the extent not so determined, as determined by the Committee: (a) the continuation of the outstanding Awards by the Company, if the Company is a surviving entity, (b) the assumption or substitution for, as those terms are defined in Section 7.1.1(b)(iv), the outstanding Awards by the surviving entity or its parent or subsidiary, (c) full exercisability or vesting and accelerated expiration of the outstanding Awards, or (d) settlement of the value of the outstanding Awards in cash or cash equivalents or other property followed by cancellation of such Awards (which value, in the case of Stock Options, shall be measured by the amount, if any, by which the Fair Market Value of a share of Common Stock exceeds the exercise or grant price of the Stock Option as of the effective date of the transaction). The Committee shall give written notice of any proposed transaction referred to in this Section 7.1.3 a reasonable period of time prior to the closing date for such transaction (which notice may be given either before or after the approval of such transaction), in order that Grantees may have a reasonable period of time prior to the closing date of such transaction within which to exercise any Awards that are then exercisable (including any Awards that may become exercisable upon the closing date of such transaction). A Grantee may condition his exercise of any Awards upon the consummation of the transaction.

 

7.1.4 Other Adjustments. The Committee (and the Board if and only to the extent such authority is not required to be exercised by the Committee to comply with Section 162(m) of the Code) is authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards (including Performance Awards, or performance goals relating thereto) in recognition of unusual or nonrecurring events (including, without limitation, acquisitions and dispositions of businesses and assets) affecting the Company, any Related Entity or any business unit, or the financial statements of the Company or any Related Entity, or in response to changes in applicable laws, regulations, accounting principles, tax rates and regulations or business conditions or in view of the Committee’s assessment of the business strategy of the Company, any Related Entity or business unit thereof, performance of comparable organizations, economic and business conditions, personal performance of a Grantee, and any other circumstances deemed relevant; provided that no such adjustment shall be authorized or made if and to the extent that such authority or the making of such adjustment would cause Stock Options or Stock Awards granted pursuant to Section 6 to Grantees designated by the Committee as Covered Employees and intended to qualify as “performance-based compensation” under Code Section 162(m) and the regulations thereunder to otherwise fail to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder.

 

7.1.5 Fractional Shares. No adjustment or substitution provided for in this Section 7.1 shall require the Company to sell a fractional share, and the total substitution or adjustment with respect to each outstanding Stock Option shall be limited accordingly.

 

7.1.6 Adjustment Certificates. Upon any adjustment made pursuant to this Section 7.1 the Company will, upon request, deliver to the Grantee a certificate setting forth the exercise price thereafter in effect and the number and kind of shares or other securities thereafter purchasable on the exercise of such Stock Option.

 

7.2 General.

 

7.2.1 Each Stock Option and Stock Award shall be evidenced by an Award Agreement containing such terms and conditions, not inconsistent with this Plan, as the Committee shall approve.

 

7.2.2 The granting of a Stock Option or Stock Award in any year shall not give the Grantee any right to similar grants in future years or any right to be retained in the employ of the Company, and all Employees shall remain subject to discharge to the same extent as if this Plan were not in effect.

 

7.2.3 No Officer, Employee, Director, or Consultant and no beneficiary or other person claiming under or through him, shall have any right, title or interest by reason of any Stock Option or any Stock Award to any particular assets of the Company, or any shares of Common Stock allocated or reserved for the purposes of this Plan or subject to any Stock Option or any Stock Award except as set forth herein. The Company shall not be required to establish any fund or make any other segregation of assets to assure the payment of any Stock Option or Stock Award.

 

 
 

 

7.2.4 Limits on Transferability.

 

(a) Except to the extent otherwise provided in the respective Award Agreement, no Award, other right, or interest granted under this Plan shall be pledged, hypothecated, or otherwise encumbered or subject to any lien, obligation, or liability of such Grantee to any party, or assigned or transferred by such Grantee otherwise than by will or the laws of descent and distribution or to a Beneficiary upon the death of a Grantee. Unless otherwise determined by the Committee in accordance with the provisions of the immediately preceding sentence, an Award may be exercised during the lifetime of the Grantee only by the Grantee or, during the period the Grantee is under a Disability, by the Grantee’s guardian or legal representative.

 

(b) Notwithstanding Section 7.2.4(a), an Award other than an Incentive Stock Option may, in the Committee’s sole discretion, be transferable by gift or domestic relations order to (i) the Grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, daughter-in-law, son-in-law, brother-in-law, or sister-in-law, including adoptive relationships (such persons, “Family Members”), (ii) a corporation, partnership, limited liability company, or other business entity whose only stockholders, partners, or members, as applicable are the Grantee and/or Family Members, or (iii) a trust in which the Grantee and/or Family Members have all of the beneficial interests, and subsequent to any such transfer any Award may be exercised by any such transferee, provided, however, no Award may be transferred for value (as defined in the General Instructions to Form S-8 Registration Statement).

 

(c) Notwithstanding Sections 7.2.4(a) and 7.2.4(b), an Award may be transferred pursuant to a domestic relations order that would satisfy Section 414(p)(1)(A) of the Code if such Section applied to an Award under this Plan, but only if the tax consequences flowing from the assignment or transfer are specified in said order, the order is accompanied by signed agreement by both or all parties to the domestic relations order, and, if requested by the Committee, an opinion is provided by qualified counsel for the Grantee that the order is enforceable by or against this Plan under applicable law, and said opinion further specifies the tax consequences flowing from the order and the appropriate tax reporting procedures for this Plan.

 

7.2.5 Notwithstanding any other provision of this Plan or agreements made pursuant thereto, the Company’s obligation to issue or deliver any certificate or certificates for shares of Common Stock under a Stock Option or Stock Award, and the transferability of Common Stock acquired by exercise of a Stock Option or grant of a Stock Award, shall be subject to all of the following conditions:

 

(a) Any registration or other qualification of such shares under any state or federal law or regulation, or the maintaining in effect of any such registration or other qualification that the Board shall, in its absolute discretion upon the advice of counsel, deem necessary or advisable; and

 

(b) The obtaining of any other consent, approval, or permit from any state or federal governmental agency that the Board shall, in its absolute discretion upon the advice of counsel, determine to be necessary or advisable.

 

The Company may, to the extent deemed necessary or advisable by the Committee, postpone the issuance or delivery of Common Stock or payment of other benefits under any Award until completion of such registration or qualification of such Common Stock (including, but not limited to, the conditions described in Sections 7.2.5(a) and 7.2.5(b) above) or other required action under any federal or state law, rule or regulation, listing, or other required action with respect to any stock exchange or automated quotation system upon which the Shares or other Company securities are listed or quoted, or compliance with any other obligation of the Company, as the Committee, may consider appropriate, and may require any Grantee to make such representations, furnish such information and comply with or be subject to such other conditions as it may consider appropriate in connection with the issuance or delivery of Shares or payment of other benefits in compliance with applicable laws, rules, and regulations, listing requirements, or other obligations.

 

7.2.6 All payments to Grantees or to their legal representatives shall be subject to any applicable tax, community property, or other statutes or regulations of the United States or of any state or country having jurisdiction over such payments. The Grantee may be required to pay to the Company the amount of any withholding taxes that the Company is required to withhold with respect to a Stock Option or its exercise or a Stock Award. In the event that such payment is not made when due, the Company shall have the right to deduct, to the extent permitted by law, from any payment of any kind otherwise due to such person all or part of the amount required to be withheld.

 

 
 

 

7.2.7 In the case of a grant of a Stock Option or Stock Award to any Employee of a Subsidiary, the Company may, if the Committee so directs, issue or transfer the shares, if any, covered by the Stock Option or Stock Award to such Subsidiary, for such lawful consideration as the Committee may specify, upon the condition or understanding that such Subsidiary will transfer the shares to the Employee in accordance with the terms of the Stock Option or Stock Award specified by the Committee pursuant to the provisions of this Plan.

 

7.2.8 A Grantee entitled to Common Stock as a result of the exercise of a Stock Option or grant of a Stock Award shall not be deemed for any purpose to be, or have rights as, a stockholder of the Company by virtue of such exercise, except to the extent that a stock certificate is issued therefor and then only from the date such certificate is issued. No adjustments shall be made for dividends or distributions or other rights for which the record date is prior to the date such stock certificate is issued. The Company shall issue any stock certificates required to be issued in connection with the exercise of a Stock Option with reasonable promptness after such exercise.

 

7.2.9 The grant or exercise of Stock Options granted under this Plan or the grant of a Stock Award under this Plan shall be subject to, and shall in all respects comply with, applicable law relating to such grant or exercise, or to the number of shares of Common Stock that may be beneficially owned or held by any Grantee.

 

7.2.10 The Company intends that this Plan shall comply with the requirements of Rule 16b-3 (the “Rule”) under the Securities Exchange Act of 1934, as amended, during the term of this Plan. Should any additional provisions be necessary for this Plan to comply with the requirements of the Rule, the Board may amend this Plan to add to or modify the provisions of this Plan accordingly.

 

7.2.11 Code Section 409A.

 

(a) If any Award constitutes a “nonqualified deferred compensation plan” under Section 409A of the Code (a “Section 409A Plan”), then the Award shall be subject to the following additional requirements, if and to the extent required to comply with Section 409A of the Code:

 

(i) Payments under the Section 409A Plan may not be made earlier than (u) the Grantee’s separation from service, (v) the date the Grantee becomes disabled, (w) the Grantee’s death, (x) a specified time (or pursuant to a fixed schedule) specified in the Award Agreement at the date of the deferral of such compensation, (y) a change in the ownership or effective control of the corporation, or in the ownership of a substantial portion of the assets of the corporation, or (z) the occurrence of an unforeseeable emergency;

 

(ii) The time or schedule for any payment of the deferred compensation may not be accelerated, except to the extent provided in applicable Treasury Regulations or other applicable guidance issued by the Internal Revenue Service;

 

(iii) Any elections with respect to the deferral of such compensation or the time and form of distribution of such deferred compensation shall comply with the requirements of Section 409A(a)(4) of the Code; and

 

(iv) In the case of any Grantee who is specified employee, a distribution on account of a separation from service may not be made before the date that is six (6) months after the date of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death).

 

 
 

 

For purposes of the foregoing, the terms “separation from service”, “disabled,” and “specified employee”, all shall be defined in the same manner as those terms are defined for purposes of Section 409A of the Code, and the limitations set forth herein shall be applied in such manner (and only to the extent) as shall be necessary to comply with any requirements of Section 409A of the Code that are applicable to the Award.

 

(b) The Award Agreement for any Award that the Committee reasonably determines to constitute a Section 409A Plan, and the provisions of this Plan applicable to that Award, shall be construed in a manner consistent with the applicable requirements of Section 409A, and the Committee, in its sole discretion and without the consent of any Grantee, may amend any Award Agreement (and the provisions of this Plan applicable thereto) if and to the extent that the Committee determines that such amendment is necessary or appropriate to comply with the requirements of Section 409A of the Code. No Section 409A Plan shall be adjusted, modified, or substituted for, pursuant to any provision of this Plan, without the consent of the Grantee if any such adjustment, modification, or substitution would cause the Section 409A Plan to violate the requirements of Section 409A of the Code.

 

(c) The Company intends that this Plan shall comply with the requirements of Section 409A of the Code, to the extent applicable. Should any changes to this Plan be necessary for this Plan to comply with the requirements of Section 409A, the Board may amend this Plan to add to or modify the provisions of this Plan accordingly.

 

7.2.12 The validity, construction, and effect of this Plan, any rules and regulations under this Plan, and any Award Agreement shall be determined in accordance with the laws of the State of Nevada without giving effect to principles of conflict of laws, and applicable federal law. Unless otherwise provided in the Award Agreement, recipients of an Award under this Plan are deemed to submit to the exclusive jurisdiction and venue of the federal or state courts whose jurisdiction covers California to resolve any and all issues that may arise out of or relate to this Plan or any related Award Agreement.

 

7.2.13 The Board shall have the authority to adopt such modifications, procedures, and subplans as may be necessary or desirable to comply with provisions of the laws of foreign countries in which the Company or its Related Entities may operate to assure the viability of the benefits from Awards granted to Grantees performing services in such countries and to meet the objectives of this Plan.

 

7.2.14 The Company will seek stockholder approval in the manner and to the degree required under applicable laws. If the Company fails to obtain any required stockholder approval of this Plan within twelve (12) months after the date this Plan is adopted by the Board, pursuant to Section 422 of the Code, any Option granted as an Incentive Stock Option at any time under this Plan will not qualify as an Incentive Stock Option within the meaning of the Code and will be deemed to be a Non-Statutory Stock Option.

 

 

 

 

 

Exhibit 10.5

 

CONTRIBUTION AGREEMENT

 

This Contribution Agreement (the “Agreement”) is made effective as of the 18th day of August, 2015 (the “Effective Date”) among Hand MD, LLC, a California limited liability company (“Seller”); Kara Harshbarger, Alex Khadavi and Afshin Shargani (each a “Principal Owner”); Synergy CHC Corp., a Nevada corporation (“Synergy”); and Hand MD Corp., a Delaware corporation (“Hand MD”). Hand MD, Synergy, Principal Owners and Seller are sometimes referred to collectively as the “Parties” and individually as a “Party”.

 

BACKGROUND

 

A. Seller is engaged in the business of developing, manufacturing, and selling skincare, nail care and nail polish products (the “Products”) (the Products and the business related to the Products is collectively the “Seller Business”).

 

B. The Principal Owners, either directly or indirectly, collectively own all of the equity of Seller.

 

C. Seller holds all right, title and interest in and to all Intellectual Property used in the Seller Business.

 

D. Seller wishes to contribute the Intellectual Property, together with certain other assets, to Hand MD under the terms and conditions set forth below in exchange for shares of the capital stock of Hand MD. Hand MD will be jointly owned by Synergy and Seller.

 

AGREEMENT

 

NOW, THEREFORE, for and in consideration of the mutual promises, covenants, and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties agree as follows:

 

1. Definitions.

 

Affiliate” means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise) of such Person;

Assigned Contracts” means all contracts, licenses, instruments, obligations, promises, undertaking, and equipment leases and other agreements, whether written or oral, which are used in, support the production and sale of the Products or are related to the Seller Business;

 

Closing” means the consummation of the transactions contemplated by this Agreement;

 

Files and Records” shall mean all files and records, whether in hard copy or digital, electronic, data, magnetic or other format, of Seller relating to or used in connection with the Seller Business or otherwise relating to the Contributed Assets;

 

Intellectual Property” means all intellectual property rights whether protected, created or arising under the laws of the United States or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, LinkedIn, Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, software or computer programs, and data base.

 

 
 

 

IP Assets” has the meaning set forth in Section 5;

 

Knowledge of Seller” or “Seller’s Knowledge” or a similar phrase means, with respect to any matter, the actual knowledge of the members, officers or managers of Seller or the Principal Owners, or facts regarding such matter which reasonably should have been known by such persons after making a diligent inquiry with respect to such matter;

 

Person” means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, any other unincorporated organization or government;

 

Transaction Documents” means this Agreement, the Bill of Sale, the IP Assignment Agreement, and the other exhibits and schedules hereto and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in connection with the transactions contemplated to be consummated pursuant to any of the foregoing.

 

2. Contribution of Assets. In exchange for the issuance of the Hand MD Securities (as defined below), Seller hereby grants, conveys, assigns, transfers and delivers to Hand MD all rights, title and interest in and to all of its intellectual property assets, including, without limitation, those specific assets set forth on Exhibit A attached hereto, and its Files and Records (collectively, the “Contributed Assets”).

 

3. Issuance of Hand MD Securities. In exchange for the contribution of the Contributed Assets and Seller’s execution of this Agreement, Hand MD hereby agrees to issue to Seller 1,000,000 shares of its Common Stock (the “Hand MD Securities”), representing fifty percent (50%) of Hand MD’s issued and outstanding capital stock on a fully-diluted basis as of the Closing.

 

4. Hand MD Representations. Hand MD hereby represents and warrants to Seller as follows:

 

(a) Corporate Organization. Hand MD is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its businesses as now conducted.

 

(b) Authorization and Validity of Agreement. Hand MD has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Hand MD’s obligations thereunder have been duly authorized by all necessary company action by Hand MD, and no other proceedings on the part of Hand MD are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed by Hand MD and constitutes its valid and binding obligation, enforceable against it in accordance with its terms.

 

(c) No Conflict or Violation. The execution, delivery and performance by Hand MD of the Transaction Documents (i) does not and will not violate or conflict with any provision of the organizational documents of Hand MD (ii) does not and will not violate any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any acceleration of remedies or any right of termination under, any contract, or other agreement or instrument to which Hand MD is a party.

 

5. Seller Representations. Seller and each of the Principal Owners hereby jointly and severally represent and warrant as follows:

 

(a) Organization. Seller is a limited liability company duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The members of Seller do not, whether in their individual capacities or through any other entity, engage in any other business that competes with the Seller Business.

 

(b) Qualification to Do Business. Seller has the requisite power and authority and all necessary governmental authority to own, operate or lease the Contributed Assets, and is in good standing in each jurisdiction where the character of its assets owned, operated or leased or the nature of its activities makes such qualification necessary.

 

 
 

 

(c) Authorization and Validity of Agreement. Seller and the Principal Owners each have all requisite power and authority to enter into the Transaction Documents and to carry out their obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Seller’s and the Principal Owners’ obligations thereunder have been duly authorized by all necessary corporate or member action of Seller, and no other proceedings on the part or in respect of Seller or the Principal Owners is necessary to authorize such execution, delivery and performance. The Transaction Documents have been duly executed by Seller and the Principal Owners and constitute valid and binding obligations, enforceable against Seller and the Principal Owners in accordance with their respective terms.

 

(d) No Conflict or Violation. The execution, delivery and performance by Seller and the Principal Owners of the Transaction Documents does not and will not (a)(i) conflict with or result in a breach of the terms, conditions, or provisions of, (ii) constitute a default under (whether with or without the passage of time, the giving of notice or both), (iii) give any third party the right to modify, terminate or accelerate any obligation under, (iv) result in a violation of, or (v) require any consent, exemption or other action by or notice or declaration to, or filing with, any third party of any government entity pursuant to (A) any organizational documents of Seller; (B) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (C) any contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Seller is a party or by which Seller is bound or to which any of Seller’s properties or assets is subject; or (D) the Assigned Contracts or other rights, agreements or licenses constituting the Contributed Assets; or (b) otherwise interfere in any material manner with the operation of the Seller Business or the Contributed Assets or have any material adverse effect thereon.

 

(e) QVC Statements. Attached hereto are financial statements regarding sale of the Products on QVC. The statements are complete and correct and accurately reflect sales of the Products.

 

(f) Absence of Undisclosed Liabilities; Indebtedness. Seller has no indebtedness or liability, absolute or contingent, involving, affecting or relating to the Seller Business, the Contributed Assets, or the transactions contemplated by the Transaction Documents.

 

(g) Intellectual Property.

 

  i. IP Assets” means all of the following materials owned or licensed by Seller with respect to the Seller Business: (A) all Intellectual Property used in the Seller Business, including, but not limited to, the proprietary formulas for the Products; (B) all domain names used by the Seller Business; (C) all the content on and accessible through the websites associated with such domain names; and (D) the entire Seller Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Seller Business marketing materials (whether in draft or final form).
     
  ii. Exhibit A lists all patented, registered, applied-for, and other Intellectual Property used in the Seller Business, and all Intellectual Property of Seller licensed to any third Person (collectively, the “Business Intellectual Property”), including the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by Seller from a third party is “Licensed Intellectual Property”).

 

 
 

 

  iii. Seller owns all right, title and interest in and to, or has a valid and enforceable license to use, all IP Assets, Business Intellectual Property, and the Licensed Intellectual Property, free and clear of all liens, and all patented or registered Business Intellectual Property is valid and enforceable. Seller has taken commercially reasonable steps to maintain the confidentiality of all information that constitutes a trade secret of the Seller Business. Seller has the valid right to transfer the Intellectual Property included in the Contributed Assets to Hand MD as contemplated hereunder.
     
  iv. (a) the conduct of the Seller Business, including the delivery and distribution of the Products has not infringed and does not infringe on any Intellectual Property or any other proprietary rights of any individual or entity, including but not limited to the rights of privacy or publicity; (b) no Person is infringing, violating or misappropriating any Business Intellectual Property; (c) Seller has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to result in the invalidation or unenforceability of any registered Business Intellectual Property; (d) Seller is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (e) Seller has not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of Intellectual Property or the Products; (f) Seller has not entered into any contract that includes a forbearance to sue or settlement contract with respect to any Intellectual Property; and (g) Seller has not received any written notice of any claim within the prior three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of, Seller’s ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Products. Seller has secured and has in place a policy to secure valid written confidentiality contracts and assignments of Intellectual Property from all consultants, contractors, employees and customers who contribute or have contributed to the creation, conception, reduction to practice or other development of any Intellectual Property developed on behalf of Seller.

 

(h) Compliance with Law. The manufacture and sale of the Products, the operation of the Seller Business, and the business of Seller has been conducted in material compliance with all applicable laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Seller and its assets, properties and operations. Seller has not received notice of any violation (or possible violation) of any such law or other legal requirement, and the Seller is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or governmental or regulatory authority, applicable to Seller, the Seller Business, or the Contributed Assets. Without limiting the foregoing, Seller has not received any warning letter or untitled letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the FDA or any other similar governmental entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any laws. No “bulk sales” or similar law applies to the transactions contemplated by this Agreement. Seller holds all permits required for the conduct of the Seller Business and the ownership of its properties.

 

(i) Litigation. There are no claims, actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of the Seller, threatened, before any federal, state, provincial or local court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Seller or any of its members, managers, officers, directors, employees, agents or Affiliates involving, affecting or relating to Seller, any member or manager of Seller, the Seller Business, the Contributed Assets, or the transactions contemplated by the Transaction Documents.

 

 
 

 

(j) Assigned Contracts. Each contract assigned to Hand MD is valid, binding and enforceable against the parties thereto in accordance with its terms, and in full force and effect on the date hereof, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity. Each Assigned Contract will remain in full force and effect without penalty in accordance with its terms upon consummation of the Closing. Seller has performed all payment and other obligations required to be performed by it to date hereunder, and is not in default or delinquent in performance, status or any other respect (claimed or actual) in connection with, any Assigned Contract, and, to the Knowledge of the Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. To the Knowledge of Seller, no other party to any Assigned Contract is in default in respect thereof, and, to the Knowledge of Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. There is no breach or cancellation or anticipated breach or cancellation by the other parties to any Assigned Contract.

 

(k) Title to Contributed Assets. Seller has good and valid title to, or a valid leasehold interest in, the Contributed Assets, free and clear of all liens.

 

(l) Product and Service Warranties; Adverse Events. Seller has made no express warranty or guarantee to any customer as to services or goods provided by Seller. There is no pending or, to the Knowledge of Seller, threatened claim alleging any breach of any warranty or guarantee. There have not been any adverse events with respect to the Products of the Seller Business.

 

(m) Clients and Vendors. Seller maintains commercially reasonable relations with each of its clients and vendors, and no event has occurred that could materially and adversely affect Seller’s relations with any client or vendor.

 

(n) Status. Seller and the Principal Owners each represent and warrant that (a) it has had an opportunity to discuss the business, management and financial affairs of Hand MD, has had access to, the management of Hand MD, and has had the opportunity to review any other information requested by Seller, and (b) Hand MD will be relying upon Seller’s and the Principal Owners’ representations and warranties set forth herein in offering the Hand MD Securities to it. Seller and the Principal Owners further each represent and warrant that: (i)(A) it has adequate net worth and means of providing for its current needs and possible contingencies to sustain a complete loss in the Hand MD Securities, and has no need for liquidity of the Hand MD Securities; (B) it recognizes that ownership of the Hand MD Securities involves substantial risks, including a risk of total loss of the value of the Hand MD Securities, and has taken full cognizance of and understands all of the risk factors related to the ownership of the Hand MD Securities; and (C) it has sufficient knowledge and experience in business and investments, including financial, business and tax matters, to be capable of evaluating the merits and risks of ownership in Hand MD and making an informed decision about ownership in Hand MD; or (ii) is an “accredited investor” as such term is defined in Rule 501 of Regulation D.

 

(o) Acquisition for Own Account. This Agreement is made with Seller and the Principal Owners in reliance upon such parties’ representations Hand MD, which by its execution hereof Seller and the Principal Owners hereby confirm, that the Hand MD Securities to be received by it will be acquired for investment for Seller’s own account, not as a nominee or agent, and not with a view to the sale or distribution of any part thereof, and that it has no present intention of selling, granting participation in, or otherwise distributing the same. By executing this Agreement, Seller further represents that it does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Hand MD Securities.

 

(p) No Intention to Distribute. Seller and the Principal Owners understand that the Hand MD Securities have not been registered under the Securities Act of 1933, as amended (the “1933 Act) on the grounds that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the 1933 Act, and that Hand MD’s reliance on such exemption is predicated in part on the representations set forth herein. Sellers and the Principal Owners realize that the basis for the exemption may not be present if, notwithstanding such representations, Seller has in mind merely acquiring the Hand MD Securities for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. Seller and the Principal Owners do not have any such intention.

 

 
 

 

(q) No Registration. Seller and the Principal Owners understand that the Hand MD Securities may not be sold, transferred or otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Hand MD Securities or an available exemption from registration under the 1933 Act, the Hand MD Securities must be held indefinitely. In particular, Seller and the Principal Owners are aware that the Hand MD Securities may not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about Hand MD. Seller and the Principal Owners represent that, in the absence of an effective registration statement covering the Hand MD Securities, it will sell, transfer, or otherwise dispose of such shares only in a manner consistent with its representations set forth herein and the Bylaws of Hand MD, as the same may be amended from time to time.

 

(r) Restrictions on Transfer. Seller agrees that in no event will it make a transfer or disposition of any of the Hand MD Securities (other than pursuant to an effective registration statement under the 1933 Act, or Rule 144 sale in compliance with the terms of such Rule or, to Hand MD’s reasonable satisfaction, pursuant to an exemption from the 1933 Act), unless and until (i) Seller shall have notified Hand MD of the proposed disposition and shall have furnished Hand MD with a statement of the circumstances surrounding the disposition, and (ii) if requested by Hand MD, at the expense of Seller or transferee, it shall have furnished to Hand MD an opinion of counsel, reasonably satisfactory to Hand MD, to the effect that such transfer may be made without registration under the 1933 Act.

 

(s) No representation or warranty by Seller or the Principal Owners contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of Seller or the Principal Owners pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading. Seller does not have Knowledge of any fact that has specific application to Seller (other than general economic or industry conditions) and that may materially adversely affect the Contributed Assets, that has not been set forth in this Agreement or the Disclosure Schedules.

 

6. Execution and Delivery of Instruments. In addition to any other documents to be delivered under other provisions of this Agreement, on the Effective Date the Parties will execute and deliver (a) the IP Assignment Agreement, in substantially the form attached hereto as Exhibit B (the “IP Assignment Agreement”), and (b) a bill of sale substantially in the form attached hereto as Exhibit C (the “Bill of Sale”). Following the Effective Date, Seller agrees to duly execute and deliver or cause to be executed and delivered all instruments of sale, conveyance, transfer and assignment, and all notices, releases, acquittances and other documents that may be necessary to more fully grant, convey, transfer and assign, and deliver to, and vest in, Hand MD the Contributed Assets hereby granted, conveyed, transferred and assigned.

 

7. Post-Closing Matters. Seller shall preserve and maintain its organizational existence and remain in good standing for a period of at least twenty-four (24) months after the Effective Date. As soon as practicable after the Effective Date, Seller shall take all action necessary to remove all Product and Seller names and logos and color schemes and any other Intellectual Property or IP Assets from their respective signage at all locations, letterhead, stationary, advertising, websites and other marketing materials and other content available for viewing by the public, and will change its name with the California Secretary of State and all other jurisdictions in which Seller has made registrations to transact business, and any other registrations and/or name filings such that Seller’s name does not include the words “Hand MD” or any derivative thereof, or any name which sounds or looks similar thereto, or any trademarks or trade names used in the Seller Business, and Seller shall otherwise cease to use such names for all purposes, other than as necessary for the winding up of its business affairs.

 

8. Noncompetition, Nonsolicitation and Nondisparagement.

 

(a) Noncompetition. Seller and the Principal Owners each acknowledge that (i) Hand MD and Synergy would not have entered into this Agreement but for the agreements and covenants contained in this Section 8; and (ii) the agreements and covenants contained in this Section 8 are reasonable and appropriate in scope; (iii) the Seller Business is worldwide in scope; and (iv) the business of Hand MD is worldwide in scope. To induce Hand MD to enter into this Agreement, each of Seller and the Principal Owners covenants and agrees that during the period commencing on the Effective Date and ending on the fifth (5th) anniversary of the Effective Date (the “Restricted Period”), Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (A) engage in any business or activity that competes with the Seller Business; (B) render any services to any Person for use in competing with Hand MD in connection with the Seller Business; (C) have an interest in any Person engaged in any business that competes with Hand MD in connection with the Seller Business, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee or consultant or any other relationship or capacity; provided, however, Seller or any of the Principal Owners may own, solely as an investment, securities of any Person which are publicly traded if Seller or such Principal Owner, as the case may be (I) is not a controlling Person of, or a member of a group which controls, such Person and (II) does not own two percent (2%) or more of any class of securities of such Person; or (D) interfere with business relationships (whether formed heretofore or hereafter) between Hand MD or any of its Affiliates and customers, suppliers or prospects of the Seller Business. For purposes of this Section 8(a), with respect only to Alex Khadavi, the “Seller Business” shall be defined as the business of developing, manufacturing, and selling hand care, nail care and nail polish products.

 

 
 

 

(b) Employees of the Business. During the Restricted Period, Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (i) solicit or encourage any employee or consultant performing services in connection with the Seller Business to leave the employment or retention of Hand MD or any of its Affiliates, or (ii) hire any such employee or consultant who was performing services in connection with the Seller Business and who has left the employment or retention of Hand MD or any of its Affiliates within one (1) year of the termination of such employee’s employment or consultant’s retention with Hand MD or any of its Affiliates.

 

(c) Customers of the Business. During the Restricted Period, Seller, its employees, officers, directors, the Principal Owners, and their respective Affiliates shall not (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client, supplier or vendor of Hand MD or any of its Affiliates not to hire or do business with Hand MD or any of its Affiliates or any successor thereto; (ii) solicit for himself or any Person other than Hand MD or any of its Affiliates, the business of any Person who is a customer, client, supplier or vendor of Hand MD or any of its Affiliates, or was its customer or supplier within two (2) years prior to the time of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Hand MD.

 

(d) Confidential Information. From and after the Closing, Seller, its members, employees, officers, managers, the Principal Owners and their respective Affiliates shall keep secret and retain in strictest confidence, and shall not use for the benefit of itself or others, all confidential matters relating to the Seller Business or Hand MD and its Affiliates, including, but not limited to, “know how”, trade secrets, customer lists, supplier lists, details of consultant and employment contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Hand MD and its Affiliates; provided, however, this covenant shall not apply to any information which is or becomes generally available to the public other than as a result of disclosure by the Seller, the Principal Owners or their respective Affiliates. Seller, the Principal Owners and their respective Affiliates may disclose Confidential Information if required to do so in any legally required government or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that Seller (A) provides Hand MD with prompt notice of such required disclosure so that Hand MD may attempt to obtain a protective order, (B) cooperates with Hand MD, at Hand MD’s expense, in obtaining such protective order, and (C) only discloses that Confidential Information which it is absolutely required to disclose as advised by counsel.

 

(e) Nondisparagement. After the Effective Date, Seller and the Principal Owners will not disparage Hand MD, any of Hand MD’s Affiliates or any of such parties’ shareholders, directors, officers, employees or agents.

 

(f) Tolling of Covenant Periods. The Restricted Period provided in this Section 8 shall not include and shall be extended beyond, any time during which a party is failing to comply with any provision of this Section 8 with respect to such party.

 

(g) Blue Penciling. If any term or other provision of this Section 8 is invalid, illegal, or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Section 8 shall nevertheless remain in full force and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 8 so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

 
 

 

9. Indemnification.

 

(a) Survival. All representations, warranties, covenants and agreements contained herein and all related rights to indemnification shall survive the Closing.

 

(b) Indemnification by Seller. Seller shall defend, indemnify and hold harmless Synergy, its affiliates and their respective stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including attorneys’ fees and disbursements, arising from or relating to:

 

  i. any inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement or any document to be delivered hereunder; or
     
  ii. any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement or any document to be delivered hereunder.

 

(c) Indemnification Procedures. Whenever any claim shall arise for indemnification hereunder, Synergy shall promptly provide written notice of such claim to Seller. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any action by a person or entity who is not a party to this Agreement, Seller, at its sole cost and expense and upon written notice to Synergy, may assume the defense of any such action with counsel reasonably satisfactory to Synergy. Synergy shall be entitled to participate in the defense of any such action, with its counsel and at its own cost and expense. If Seller does not assume the defense of any such action, Synergy may, but shall not be obligated to, defend against such action in such manner as it may deem appropriate, including, but not limited to, settling such action, after giving notice of it to Seller, on such terms as Synergy may deem appropriate and no action taken by Synergy in accordance with such defense and settlement shall relieve Seller of its indemnification obligations herein provided with respect to any damages resulting therefrom. Seller shall not settle any action without Synergy’s prior written consent (which consent shall not be unreasonably withheld or delayed).

 

10. Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

11. Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of Delaware, without giving effect to the principles of conflicts of laws thereof. The Parties hereto irrevocably consent to the exclusive jurisdiction of, the federal and state courts of the State of Delaware located in Wilmington, Delaware for such purpose.

 

12. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, or (ii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the Party as follows:

 

  If to the Seller or any Principal Owner: Hand MD, LLC
    12121 Wilshire Boulevard #1012
    Los Angeles, CA 90025
    Attention: Advanced Skin and Care
     
  Copy to: Klehr Harrison Harvey Branzberg LLP
    1835 Market Street, Suite 1400
    Philadelphia, PA 19103
    Attention: William W. Matthews, III
     
  If to Hand MD: Hand MD Corp.
    865 Spring Street
    Westbrook, ME 04092
    Attention: President

 

  Copy to: Wyrick Robbins Yates & Ponton LLP
    4101 Lake Boone Trail, Suite 300
    Raleigh, North Carolina 27607
    Attention: Zachary R. Bishop

 

 
 

 

Any Party may change its address for the purpose of this Agreement by giving the other Party written notice of its new address in the manner set forth above.

 

13. Execution of Documents; Counterparts; Delivery by Facsimile or E-Mail. Each party agrees to execute all documents necessary to carry out the purpose of this Agreement and to cooperate with each other for the expeditious filing of any and all documents and the fulfillment of the terms of this Agreement. This Agreement may be executed in any number of counterparts with the same effect as if all parties hereto had signed the same document. All counterparts shall be construed together and shall constitute one agreement. This Agreement and any signed agreement or instrument entered into in connection with this Agreement or contemplated hereby, to the extent signed and delivered by facsimile transmission or email (in PDF format), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

 

14. Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Parties hereto.

 

15. Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

16. Entire Agreement. This Agreement, the Exhibits and schedules hereto contain the entire understanding between the Parties hereto with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein. This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.

 

[THE NEXT PAGE IS THE SIGNATURE PAGE]

 

 
 

 

IN WITNESS WHEREOF, each of the undersigned parties has duly executed this Contribution Agreement, effective as of the date first set forth above.

 

  HAND MD, LLC
     
  By: /s/ Kara Harshbarger
  Name: Kara Harshbarger
  Title: President
     
  HAND MD CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: President
     
  SYNERGY CHC CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO
   
  /s/ Kara Harshbarger
  Kara Harshbarger
   
  /s/ Alex Khadavi
  Alex Khadavi
   
  /s/ Afshin Shargani
  Afshin Shargani

 

 

 

Exhibit 10.6

 

CONTRIBUTION AGREEMENT

 

This Contribution Agreement (the “Agreement”) is made effective as of the 18th day of August, 2015 (the “Effective Date”) among Hand MD, LLC, a California limited liability company (“Seller”); Kara Harshbarger, Alex Khadavi and Afshin Shargani (each a “Principal Owner”); Synergy CHC Corp., a Nevada corporation (“Synergy”); and Hand MD Corp., a Delaware corporation (“Hand MD”). Hand MD, Synergy, Principal Owners and Seller are sometimes referred to collectively as the “Parties” and individually as a “Party”.

 

BACKGROUND

 

A. Seller is engaged in the business of developing, manufacturing, and selling skincare, nail care and nail polish products (the “Products”) (the Products and the business related to the Products is collectively the “Seller Business”).

 

B. The Principal Owners, either directly or indirectly, collectively own all of the equity of Seller.

 

C. Seller holds all right, title and interest in and to all Intellectual Property used in the Seller Business.

 

D. Seller wishes to contribute the Intellectual Property, together with certain other assets, to Hand MD under the terms and conditions set forth below in exchange for shares of the capital stock of Hand MD. Hand MD will be jointly owned by Synergy and Seller.

 

AGREEMENT

 

NOW, THEREFORE, for and in consideration of the mutual promises, covenants, and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties agree as follows:

 

1. Definitions.

 

Affiliate” means, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise) of such Person;

 

Assigned Contracts” means all contracts, licenses, instruments, obligations, promises, undertaking, and equipment leases and other agreements, whether written or oral, which are used in, support the production and sale of the Products or are related to the Seller Business;

 

Closing” means the consummation of the transactions contemplated by this Agreement;

 

Files and Records” shall mean all files and records, whether in hard copy or digital, electronic, data, magnetic or other format, of Seller relating to or used in connection with the Seller Business or otherwise relating to the Contributed Assets;

 

 
 

 

Intellectual Property” means all intellectual property rights whether protected, created or arising under the laws of the United States or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, LinkedIn, Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, software or computer programs, and data base.

 

IP Assets” has the meaning set forth in Section 5;

 

Knowledge of Seller” or “Seller’s Knowledge” or a similar phrase means, with respect to any matter, the actual knowledge of the members, officers or managers of Seller or the Principal Owners, or facts regarding such matter which reasonably should have been known by such persons after making a diligent inquiry with respect to such matter;

 

Person” means any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, any other unincorporated organization or government;

 

Transaction Documents” means this Agreement, the Bill of Sale, the IP Assignment Agreement, and the other exhibits and schedules hereto and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in connection with the transactions contemplated to be consummated pursuant to any of the foregoing.

 

2. Contribution of Assets. In exchange for the issuance of the Hand MD Securities (as defined below), Seller hereby grants, conveys, assigns, transfers and delivers to Hand MD all rights, title and interest in and to all of its intellectual property assets, including, without limitation, those specific assets set forth on Exhibit A attached hereto, and its Files and Records (collectively, the “Contributed Assets”).

 

3. Issuance of Hand MD Securities. In exchange for the contribution of the Contributed Assets and Seller’s execution of this Agreement, Hand MD hereby agrees to issue to Seller 1,000,000 shares of its Common Stock (the “Hand MD Securities”), representing fifty percent (50%) of Hand MD’s issued and outstanding capital stock on a fully-diluted basis as of the Closing.

 

4. Hand MD Representations. Hand MD hereby represents and warrants to Seller as follows:

 

(a) Corporate Organization. Hand MD is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its businesses as now conducted.

 

(b) Authorization and Validity of Agreement. Hand MD has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Hand MD’s obligations thereunder have been duly authorized by all necessary company action by Hand MD, and no other proceedings on the part of Hand MD are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed by Hand MD and constitutes its valid and binding obligation, enforceable against it in accordance with its terms.

 

2
 

 

(c) No Conflict or Violation. The execution, delivery and performance by Hand MD of the Transaction Documents (i) does not and will not violate or conflict with any provision of the organizational documents of Hand MD (ii) does not and will not violate any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any acceleration of remedies or any right of termination under, any contract, or other agreement or instrument to which Hand MD is a party.

 

5. Seller Representations. Seller and each of the Principal Owners hereby jointly and severally represent and warrant as follows:

 

(a) Organization. Seller is a limited liability company duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The members of Seller do not, whether in their individual capacities or through any other entity, engage in any other business that competes with the Seller Business.

 

(b) Qualification to Do Business. Seller has the requisite power and authority and all necessary governmental authority to own, operate or lease the Contributed Assets, and is in good standing in each jurisdiction where the character of its assets owned, operated or leased or the nature of its activities makes such qualification necessary.

 

(c) Authorization and Validity of Agreement. Seller and the Principal Owners each have all requisite power and authority to enter into the Transaction Documents and to carry out their obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Seller’s and the Principal Owners’ obligations thereunder have been duly authorized by all necessary corporate or member action of Seller, and no other proceedings on the part or in respect of Seller or the Principal Owners is necessary to authorize such execution, delivery and performance. The Transaction Documents have been duly executed by Seller and the Principal Owners and constitute valid and binding obligations, enforceable against Seller and the Principal Owners in accordance with their respective terms.

 

(d) No Conflict or Violation. The execution, delivery and performance by Seller and the Principal Owners of the Transaction Documents does not and will not (a)(i) conflict with or result in a breach of the terms, conditions, or provisions of, (ii) constitute a default under (whether with or without the passage of time, the giving of notice or both), (iii) give any third party the right to modify, terminate or accelerate any obligation under, (iv) result in a violation of, or (v) require any consent, exemption or other action by or notice or declaration to, or filing with, any third party of any government entity pursuant to (A) any organizational documents of Seller; (B) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (C) any contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Seller is a party or by which Seller is bound or to which any of Seller’s properties or assets is subject; or (D) the Assigned Contracts or other rights, agreements or licenses constituting the Contributed Assets; or (b) otherwise interfere in any material manner with the operation of the Seller Business or the Contributed Assets or have any material adverse effect thereon.

 

(e) QVC Statements. Attached hereto are financial statements regarding sale of the Products on QVC. The statements are complete and correct and accurately reflect sales of the Products.

 

3
 

 

(f) Absence of Undisclosed Liabilities; Indebtedness. Seller has no indebtedness or liability, absolute or contingent, involving, affecting or relating to the Seller Business, the Contributed Assets, or the transactions contemplated by the Transaction Documents.

 

(g) Intellectual Property.

 

  i. IP Assets” means all of the following materials owned or licensed by Seller with respect to the Seller Business: (A) all Intellectual Property used in the Seller Business, including, but not limited to, the proprietary formulas for the Products; (B) all domain names used by the Seller Business; (C) all the content on and accessible through the websites associated with such domain names; and (D) the entire Seller Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Seller Business marketing materials (whether in draft or final form).
     
  ii. Exhibit A lists all patented, registered, applied-for, and other Intellectual Property used in the Seller Business, and all Intellectual Property of Seller licensed to any third Person (collectively, the “Business Intellectual Property”), including the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by Seller from a third party is “Licensed Intellectual Property”).
     
  iii. Seller owns all right, title and interest in and to, or has a valid and enforceable license to use, all IP Assets, Business Intellectual Property, and the Licensed Intellectual Property, free and clear of all liens, and all patented or registered Business Intellectual Property is valid and enforceable. Seller has taken commercially reasonable steps to maintain the confidentiality of all information that constitutes a trade secret of the Seller Business. Seller has the valid right to transfer the Intellectual Property included in the Contributed Assets to Hand MD as contemplated hereunder.
     
  iv. (a) the conduct of the Seller Business, including the delivery and distribution of the Products has not infringed and does not infringe on any Intellectual Property or any other proprietary rights of any individual or entity, including but not limited to the rights of privacy or publicity; (b) no Person is infringing, violating or misappropriating any Business Intellectual Property; (c) Seller has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to result in the invalidation or unenforceability of any registered Business Intellectual Property; (d) Seller is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (e) Seller has not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of Intellectual Property or the Products; (f) Seller has not entered into any contract that includes a forbearance to sue or settlement contract with respect to any Intellectual Property; and (g) Seller has not received any written notice of any claim within the prior three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of, Seller’s ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Products. Seller has secured and has in place a policy to secure valid written confidentiality contracts and assignments of Intellectual Property from all consultants, contractors, employees and customers who contribute or have contributed to the creation, conception, reduction to practice or other development of any Intellectual Property developed on behalf of Seller.

 

4
 

 

(h) Compliance with Law. The manufacture and sale of the Products, the operation of the Seller Business, and the business of Seller has been conducted in material compliance with all applicable laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Seller and its assets, properties and operations. Seller has not received notice of any violation (or possible violation) of any such law or other legal requirement, and the Seller is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or governmental or regulatory authority, applicable to Seller, the Seller Business, or the Contributed Assets. Without limiting the foregoing, Seller has not received any warning letter or untitled letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the FDA or any other similar governmental entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any laws. No “bulk sales” or similar law applies to the transactions contemplated by this Agreement. Seller holds all permits required for the conduct of the Seller Business and the ownership of its properties.

 

(i) Litigation. There are no claims, actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of the Seller, threatened, before any federal, state, provincial or local court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Seller or any of its members, managers, officers, directors, employees, agents or Affiliates involving, affecting or relating to Seller, any member or manager of Seller, the Seller Business, the Contributed Assets, or the transactions contemplated by the Transaction Documents.

 

(j) Assigned Contracts. Each contract assigned to Hand MD is valid, binding and enforceable against the parties thereto in accordance with its terms, and in full force and effect on the date hereof, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity. Each Assigned Contract will remain in full force and effect without penalty in accordance with its terms upon consummation of the Closing. Seller has performed all payment and other obligations required to be performed by it to date hereunder, and is not in default or delinquent in performance, status or any other respect (claimed or actual) in connection with, any Assigned Contract, and, to the Knowledge of the Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. To the Knowledge of Seller, no other party to any Assigned Contract is in default in respect thereof, and, to the Knowledge of Seller, no event has occurred which, with due notice or lapse of time or both, would constitute such a default. There is no breach or cancellation or anticipated breach or cancellation by the other parties to any Assigned Contract.

 

5
 

 

(k) Title to Contributed Assets. Seller has good and valid title to, or a valid leasehold interest in, the Contributed Assets, free and clear of all liens.

 

(l) Product and Service Warranties; Adverse Events. Seller has made no express warranty or guarantee to any customer as to services or goods provided by Seller. There is no pending or, to the Knowledge of Seller, threatened claim alleging any breach of any warranty or guarantee. There have not been any adverse events with respect to the Products of the Seller Business.

 

(m) Clients and Vendors. Seller maintains commercially reasonable relations with each of its clients and vendors, and no event has occurred that could materially and adversely affect Seller’s relations with any client or vendor.

 

(n) Status. Seller and the Principal Owners each represent and warrant that (a) it has had an opportunity to discuss the business, management and financial affairs of Hand MD, has had access to, the management of Hand MD, and has had the opportunity to review any other information requested by Seller, and (b) Hand MD will be relying upon Seller’s and the Principal Owners’ representations and warranties set forth herein in offering the Hand MD Securities to it. Seller and the Principal Owners further each represent and warrant that: (i)(A) it has adequate net worth and means of providing for its current needs and possible contingencies to sustain a complete loss in the Hand MD Securities, and has no need for liquidity of the Hand MD Securities; (B) it recognizes that ownership of the Hand MD Securities involves substantial risks, including a risk of total loss of the value of the Hand MD Securities, and has taken full cognizance of and understands all of the risk factors related to the ownership of the Hand MD Securities; and (C) it has sufficient knowledge and experience in business and investments, including financial, business and tax matters, to be capable of evaluating the merits and risks of ownership in Hand MD and making an informed decision about ownership in Hand MD; or (ii) is an “accredited investor” as such term is defined in Rule 501 of Regulation D.

 

(o) Acquisition for Own Account. This Agreement is made with Seller and the Principal Owners in reliance upon such parties’ representations Hand MD, which by its execution hereof Seller and the Principal Owners hereby confirm, that the Hand MD Securities to be received by it will be acquired for investment for Seller’s own account, not as a nominee or agent, and not with a view to the sale or distribution of any part thereof, and that it has no present intention of selling, granting participation in, or otherwise distributing the same. By executing this Agreement, Seller further represents that it does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Hand MD Securities.

 

(p) No Intention to Distribute. Seller and the Principal Owners understand that the Hand MD Securities have not been registered under the Securities Act of 1933, as amended (the “1933 Act) on the grounds that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the 1933 Act, and that Hand MD’s reliance on such exemption is predicated in part on the representations set forth herein. Sellers and the Principal Owners realize that the basis for the exemption may not be present if, notwithstanding such representations, Seller has in mind merely acquiring the Hand MD Securities for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. Seller and the Principal Owners do not have any such intention.

 

(q) No Registration. Seller and the Principal Owners understand that the Hand MD Securities may not be sold, transferred or otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Hand MD Securities or an available exemption from registration under the 1933 Act, the Hand MD Securities must be held indefinitely. In particular, Seller and the Principal Owners are aware that the Hand MD Securities may not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about Hand MD. Seller and the Principal Owners represent that, in the absence of an effective registration statement covering the Hand MD Securities, it will sell, transfer, or otherwise dispose of such shares only in a manner consistent with its representations set forth herein and the Bylaws of Hand MD, as the same may be amended from time to time.

 

6
 

 

(r) Restrictions on Transfer. Seller agrees that in no event will it make a transfer or disposition of any of the Hand MD Securities (other than pursuant to an effective registration statement under the 1933 Act, or Rule 144 sale in compliance with the terms of such Rule or, to Hand MD’s reasonable satisfaction, pursuant to an exemption from the 1933 Act), unless and until (i) Seller shall have notified Hand MD of the proposed disposition and shall have furnished Hand MD with a statement of the circumstances surrounding the disposition, and (ii) if requested by Hand MD, at the expense of Seller or transferee, it shall have furnished to Hand MD an opinion of counsel, reasonably satisfactory to Hand MD, to the effect that such transfer may be made without registration under the 1933 Act.

 

(s) No representation or warranty by Seller or the Principal Owners contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of Seller or the Principal Owners pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading. Seller does not have Knowledge of any fact that has specific application to Seller (other than general economic or industry conditions) and that may materially adversely affect the Contributed Assets, that has not been set forth in this Agreement or the Disclosure Schedules.

 

6. Execution and Delivery of Instruments. In addition to any other documents to be delivered under other provisions of this Agreement, on the Effective Date the Parties will execute and deliver (a) the IP Assignment Agreement, in substantially the form attached hereto as Exhibit B (the “IP Assignment Agreement”), and (b) a bill of sale substantially in the form attached hereto as Exhibit C (the “Bill of Sale”). Following the Effective Date, Seller agrees to duly execute and deliver or cause to be executed and delivered all instruments of sale, conveyance, transfer and assignment, and all notices, releases, acquittances and other documents that may be necessary to more fully grant, convey, transfer and assign, and deliver to, and vest in, Hand MD the Contributed Assets hereby granted, conveyed, transferred and assigned.

 

7. Post-Closing Matters. Seller shall preserve and maintain its organizational existence and remain in good standing for a period of at least twenty-four (24) months after the Effective Date. As soon as practicable after the Effective Date, Seller shall take all action necessary to remove all Product and Seller names and logos and color schemes and any other Intellectual Property or IP Assets from their respective signage at all locations, letterhead, stationary, advertising, websites and other marketing materials and other content available for viewing by the public, and will change its name with the California Secretary of State and all other jurisdictions in which Seller has made registrations to transact business, and any other registrations and/or name filings such that Seller’s name does not include the words “Hand MD” or any derivative thereof, or any name which sounds or looks similar thereto, or any trademarks or trade names used in the Seller Business, and Seller shall otherwise cease to use such names for all purposes, other than as necessary for the winding up of its business affairs.

 

7
 

 

8. Noncompetition, Nonsolicitation and Nondisparagement.

 

(a) Noncompetition. Seller and the Principal Owners each acknowledge that (i) Hand MD and Synergy would not have entered into this Agreement but for the agreements and covenants contained in this Section 8; and (ii) the agreements and covenants contained in this Section 8 are reasonable and appropriate in scope; (iii) the Seller Business is worldwide in scope; and (iv) the business of Hand MD is worldwide in scope. To induce Hand MD to enter into this Agreement, each of Seller and the Principal Owners covenants and agrees that during the period commencing on the Effective Date and ending on the fifth (5th) anniversary of the Effective Date (the “Restricted Period”), Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (A) engage in any business or activity that competes with the Seller Business; (B) render any services to any Person for use in competing with Hand MD in connection with the Seller Business; (C) have an interest in any Person engaged in any business that competes with Hand MD in connection with the Seller Business, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee or consultant or any other relationship or capacity; provided, however, Seller or any of the Principal Owners may own, solely as an investment, securities of any Person which are publicly traded if Seller or such Principal Owner, as the case may be (I) is not a controlling Person of, or a member of a group which controls, such Person and (II) does not own two percent (2%) or more of any class of securities of such Person; or (D) interfere with business relationships (whether formed heretofore or hereafter) between Hand MD or any of its Affiliates and customers, suppliers or prospects of the Seller Business. For purposes of this Section 8(a), with respect only to Alex Khadavi, the “Seller Business” shall be defined as the business of developing, manufacturing, and selling hand care, nail care and nail polish products.

 

(b) Employees of the Business. During the Restricted Period, Seller, the Principal Owners and their respective Affiliates shall not, directly or indirectly, (i) solicit or encourage any employee or consultant performing services in connection with the Seller Business to leave the employment or retention of Hand MD or any of its Affiliates, or (ii) hire any such employee or consultant who was performing services in connection with the Seller Business and who has left the employment or retention of Hand MD or any of its Affiliates within one (1) year of the termination of such employee’s employment or consultant’s retention with Hand MD or any of its Affiliates.

 

(c) Customers of the Business. During the Restricted Period, Seller, its employees, officers, directors, the Principal Owners, and their respective Affiliates shall not (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client, supplier or vendor of Hand MD or any of its Affiliates not to hire or do business with Hand MD or any of its Affiliates or any successor thereto; (ii) solicit for himself or any Person other than Hand MD or any of its Affiliates, the business of any Person who is a customer, client, supplier or vendor of Hand MD or any of its Affiliates, or was its customer or supplier within two (2) years prior to the time of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Hand MD.

 

(d) Confidential Information. From and after the Closing, Seller, its members, employees, officers, managers, the Principal Owners and their respective Affiliates shall keep secret and retain in strictest confidence, and shall not use for the benefit of itself or others, all confidential matters relating to the Seller Business or Hand MD and its Affiliates, including, but not limited to, “know how”, trade secrets, customer lists, supplier lists, details of consultant and employment contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Hand MD and its Affiliates; provided, however, this covenant shall not apply to any information which is or becomes generally available to the public other than as a result of disclosure by the Seller, the Principal Owners or their respective Affiliates. Seller, the Principal Owners and their respective Affiliates may disclose Confidential Information if required to do so in any legally required government or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that Seller (A) provides Hand MD with prompt notice of such required disclosure so that Hand MD may attempt to obtain a protective order, (B) cooperates with Hand MD, at Hand MD’s expense, in obtaining such protective order, and (C) only discloses that Confidential Information which it is absolutely required to disclose as advised by counsel.

 

8
 

 

(e) Nondisparagement. After the Effective Date, Seller and the Principal Owners will not disparage Hand MD, any of Hand MD’s Affiliates or any of such parties’ shareholders, directors, officers, employees or agents.

 

(f) Tolling of Covenant Periods. The Restricted Period provided in this Section 8 shall not include and shall be extended beyond, any time during which a party is failing to comply with any provision of this Section 8 with respect to such party.

 

(g) Blue Penciling. If any term or other provision of this Section 8 is invalid, illegal, or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Section 8 shall nevertheless remain in full force and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, the parties hereto shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 8 so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

9. Indemnification.

 

(a) Survival. All representations, warranties, covenants and agreements contained herein and all related rights to indemnification shall survive the Closing.

 

(b) Indemnification by Seller. Seller shall defend, indemnify and hold harmless Synergy, its affiliates and their respective stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including attorneys’ fees and disbursements, arising from or relating to:

 

  i. any inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement or any document to be delivered hereunder; or
     
  ii. any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement or any document to be delivered hereunder.

 

9
 

 

(c) Indemnification Procedures. Whenever any claim shall arise for indemnification hereunder, Synergy shall promptly provide written notice of such claim to Seller. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any action by a person or entity who is not a party to this Agreement, Seller, at its sole cost and expense and upon written notice to Synergy, may assume the defense of any such action with counsel reasonably satisfactory to Synergy. Synergy shall be entitled to participate in the defense of any such action, with its counsel and at its own cost and expense. If Seller does not assume the defense of any such action, Synergy may, but shall not be obligated to, defend against such action in such manner as it may deem appropriate, including, but not limited to, settling such action, after giving notice of it to Seller, on such terms as Synergy may deem appropriate and no action taken by Synergy in accordance with such defense and settlement shall relieve Seller of its indemnification obligations herein provided with respect to any damages resulting therefrom. Seller shall not settle any action without Synergy’s prior written consent (which consent shall not be unreasonably withheld or delayed).

 

10. Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

11. Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of Delaware, without giving effect to the principles of conflicts of laws thereof. The Parties hereto irrevocably consent to the exclusive jurisdiction of, the federal and state courts of the State of Delaware located in Wilmington, Delaware for such purpose.

 

12. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, or (ii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the Party as follows:

 

  If to the Seller or any Principal Owner: Hand MD, LLC
    12121 Wilshire Boulevard #1012
    Los Angeles, CA 90025
    Attention: Advanced Skin and Care
     
  Copy to: Klehr Harrison Harvey Branzberg LLP
    1835 Market Street, Suite 1400
    Philadelphia, PA 19103
    Attention: William W. Matthews, III
     
  If to Hand MD: Hand MD Corp.
    865 Spring Street
    Westbrook, ME 04092
    Attention: President
     
  Copy to: Wyrick Robbins Yates & Ponton LLP
    4101 Lake Boone Trail, Suite 300
    Raleigh, North Carolina 27607
    Attention: Zachary R. Bishop

 

10
 

 

Any Party may change its address for the purpose of this Agreement by giving the other Party written notice of its new address in the manner set forth above.

 

13. Execution of Documents; Counterparts; Delivery by Facsimile or E-Mail. Each party agrees to execute all documents necessary to carry out the purpose of this Agreement and to cooperate with each other for the expeditious filing of any and all documents and the fulfillment of the terms of this Agreement. This Agreement may be executed in any number of counterparts with the same effect as if all parties hereto had signed the same document. All counterparts shall be construed together and shall constitute one agreement. This Agreement and any signed agreement or instrument entered into in connection with this Agreement or contemplated hereby, to the extent signed and delivered by facsimile transmission or email (in PDF format), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

 

14. Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Parties hereto.

 

15. Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

16. Entire Agreement. This Agreement, the Exhibits and schedules hereto contain the entire understanding between the Parties hereto with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein. This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.

 

[THE NEXT PAGE IS THE SIGNATURE PAGE]

 

11
 

 

 

IN WITNESS WHEREOF, each of the undersigned parties has duly executed this Contribution Agreement, effective as of the date first set forth above.

 

  HAND MD, LLC
     
  By: /s/ Kara Harshbarger
  Name: Kara Harshbarger
  Title: President
     
  HAND MD CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: President
     
  SYNERGY CHC CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO
   
  /s/ Kara Harshbarger
  Kara Harshbarger
   
  /s/ Alex Khadavi
  Alex Khadavi
   
  /s/ Afshin Shargani
  Afshin Shargani

 

12

 

 

Exhibit 10.7

 

INTELLECTUAL PROPERTY LICENSE AGREEMENT

 

THIS AGREEMENT, effective August 18, 2015 (the “Effective Date”), is entered into by and between Synergy CHC Corp., a corporation formed under the laws of the State of Nevada (“Synergy”) and HAND MD CORP., a corporation incorporated under the laws of Delaware (“Hand”).

 

RECITALS

 

WHEREAS, Hand owns or licenses all right, title and interest in and to certain trademark(s), Know-How, and other intellectual property relating to a skincare product known as Hand MD; and

 

WHEREAS, the Parties desire to enter into an agreement whereby Hand will license to Synergy the exclusive right to manufacture and distribute the Licensed Products (as defined below), pursuant to the terms and conditions herein.

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

DEFINITIONS

 

Definitions. The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:

 

Adverse Drug Reaction” means a noxious and unintended response to a drug, which occurs at doses normally used or tested for the diagnosis, treatment, or prevention of a disease or the modification of an organic function.

 

Adverse Drug Event” means any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

 

Affiliate” means any corporation, firm, partnership or other entity that directly or indirectly controls, is controlled by or is under common control with a Party, with “control” meaning ownership of greater than fifty percent (50%) of the voting stock or other voting interests in the Party or the right to receive over fifty percent (50%) of the profits or earnings of the Party. Such other relationship as in fact results in actual control over the management, business, and affairs of a Party shall also be deemed to constitute control.

 

Agreement”, “hereto”, “hereunder”, “herein” and similar expressions mean this Intellectual Property License Agreement.

 

Applicable Laws” means any law, regulation, rule, guidance, order, judgment or decree having the force of law in the Territory.

 

Business Day” means any day other than (i) Saturday or Sunday or (ii) a day that is a legal holiday in New York, New York, or (iii) any other day on which banks in New York, New York are required to be closed.

 

Commercial Sale” means any shipment of the Licensed Products in the Territory pursuant to an arm’s length sale by Synergy or its Affiliates to a Third Party.

 

Commercialize” means marketing, using, distributing, promoting, offering for sale, and selling the Licensed Products.

 

Effective Date” means the date specified in the initial paragraph of this Agreement.

 

Force Majeure” has the meaning set forth in Section 0.

 

GMP” means good manufacturing practices as required under the rules of the applicable Governmental Authority in the Territory.

 

 
 

 

Governmental Authority” means any federal, state, provincial, or municipal government body, commission, agency, board, court or tribunal in the Territory and having jurisdiction in the particular circumstances.

 

Hand Indemnified Party” has the meaning set forth in Section 0.

 

Hand Marks” means the trade-marks “Hand MD”, and any other marks Hand may adopt for use for the Licensed Products.

 

Improvements” means any new indications, dosage strengths, reformulations, line extensions or other advances in, modifications or improvements to the Licensed Products.

 

Know-How” means all scientific, technical, manufacturing, marketing, production, sales and other information relating to the Licensed Products, as well as any other intellectual property for or related to the Licensed Products, that is known to or controlled by Hand and which is reasonably necessary for the Commercialization of the Licensed Products in accordance with the terms of this Agreement.

 

Launch” means the date of the first Commercial Sale in the Territory of the applicable Licensed Product.

 

Licensed Products” means the Hand MD skincare products and all Improvements thereto.

 

Minimum Royalty” means $0 for the first 12 months following the Effective Date; $250,00 for months 13 through 24 following the Effective Date; and $500,000 for months 25 through 36 following the Effective Date.

 

Net Sales” means the gross amounts invoiced by or on behalf of Synergy and its Affiliates for sales of Products to third parties that are not Affiliates of Synergy in bona fide, arm’s-length transactions, plus any amounts not invoiced in connection with any wholesale or retail level discounted prices, less the following deductions if and to the extent they are (i) determined in accordance with Synergy’s accounting standards, (ii) actually taken by Synergy or its Affiliates and (iii) included in the gross invoiced sales price of any Licensed Products or otherwise directly paid or incurred by Synergy or its Affiliates with respect to the sale of Licensed Products:

 

  (a) charge-backs;
  (b) bad debt; and
  (c) amounts repaid or credited by reasons of defects, rejections, recalls, returns.

 

Party” means either Hand or Synergy and “Parties” means both Hand and Synergy.

 

Regulatory Approval” means any and all approvals, marketing authorizations, registrations and licenses (including amendments and supplements thereto) necessary from a Governmental Authority for the Commercialization or manufacture of the Licensed Products in or for the Territory.

 

Regulatory Submissions” means all applications, filings, dossiers and the like submitted to a Governmental Authority for the purpose of obtaining Regulatory Approval.

 

SDEA” means the Safety Data Exchange Agreement to be entered into by the Parties within ninety (90) days after the Effective Date.

 

Specifications” means the finished product specifications for each Licensed Product as required by the applicable Regulatory Approval and as may be modified from time to time in accordance with the provisions of this Agreement.

 

Synergy Indemnified Party” has the meaning set forth in Section 0.

 

 
 

 

“Territory” means worldwide.

 

Third Party” means any person other than the Parties and their Affiliates.

 

Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.

 

Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

 

Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.

 

Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of the United States, unless otherwise noted.

 

Date References. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.

 

Gender. Words of one gender include the other gender.

 

Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

 

Solidary Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are solidary (joint and several).

 

No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party.

 

Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.

 

Party References. Reference to any Party includes the successors and permitted assigns of that Party.

 

Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.

 

GRANT OF RIGHTS

 

License. Subject to the terms of this Agreement, Hand hereby grants to Synergy and Synergy hereby accepts, for the Term, and for the Territory, an exclusive license under the Know-How to Commercialize the Licensed Products.

 

Sublicensing. Synergy may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its rights or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Synergy assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.

 

No Implied Licenses. Neither Party grants to the other Party any right or license to use any of its intellectual property, Know-How or other proprietary information, materials or technology, or to practice any of its patent, trademark, or trade dress rights, except as expressly set forth in this Agreement.

 

 
 

 

Restriction on Hand. During the Term of this Agreement, Hand shall not: (i) solicit or accept orders for distribution of Licensed Products to a Third Party for sale or distribution in the Territory; (ii) distribute any Licensed Products for sale or use in the Territory; or (iii) grant any license or right with respect to the Licensed Products in the Territory.

 

Performance by Affiliates. The Parties agree that their respective rights and obligations may be exercised or performed by any of their Affiliates; provided, however, that each Party shall be fully responsible and liable for the actions of such Affiliates in the performance of such obligations and shall ensure that such Affiliate complies with the terms of this Agreement.

 

REGULATORY AND DEVELOPMENT

 

Regulatory Submissions. Synergy shall be solely responsible, at its expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the Licensed Products in the Territory. Hand shall provide reasonable assistance to Synergy in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Synergy. Synergy shall notify Hand of all Regulatory Submissions that it submits.

 

Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in the Territory. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.

 

Other Covenants of Synergy. In addition to its other obligations, commitments and undertakings set out in this Agreement, Synergy agrees to:

 

assume the reasonable costs of intellectual property filings, procurement and maintenance for all intellectual property applications and registrations associated with the Licensed Products in the Territory; and

 

assume all marketing, sales and distribution expenses related to the commercialization of the Licensed Products in the Territory.

 

Other Covenants of Hand. In addition to its other obligations, commitments and undertakings set out in this Agreement, Hand agrees to:

 

provide Synergy with all documentation relating to the submissions for Regulatory Approval to the U.S. Food and Drug Administration or the European Medicines Agency or any other Governmental Authority for the Licensed Products within one (1) month from submission;

 

where applicable, provide reasonable assistance to Synergy with the Regulatory Submission of the Licensed Products in the Territory;

 

provide full assistance and cooperation with respect to securing intellectual property protection in the Territory for the Licensed Products;

 

not assign the intellectual property associated with Licensed Products to any Third Party;

 

coordinate Launch activities with Synergy, including pharmacovigilence, pricing, reimbursement, positioning and health care conferences; and

 

promptly provide United States and international marketing and sales materials used for the Licensed Products.

 

 
 

 

TRADEMARKS

 

Trade-Mark License. Hand hereby grants to Synergy, for the Term, an exclusive, royalty-free license to use the Hand Marks in the Territory in association with the Licensed Products.

 

Ownership. Synergy acknowledges that the Hand Marks are owned by Hand. The Hand Marks shall be and remain the sole and exclusive property of Hand. Synergy shall not contest the ownership of the Hand Marks or the validity of any registration relating thereto. Synergy agrees, at the request of Hand, to execute any and all proper documents appropriate to assist Hand in obtaining and maintaining Hand’s rights in and to the Hand Marks.

 

Licensed Products to Bear Mark. Licensed Products distributed by Synergy under this Agreement shall bear the Hand Marks, subject to the approval of such labeling by appropriate Governmental Authorities.

 

No Similar Mark. Synergy will not, without Hand’s prior written consent, register or use in connection with any product, any trade-mark that is confusingly similar to the Hand Marks.

 

COMMERCIALIZATION

 

Safety Data Exchange Agreement. The parties agree to develop and commit to a Safety Data Exchange Agreement (“SDEA”) that allows them to fulfill their respective regulatory and pharmacovigilence obligations relating to Adverse Drug Event and Adverse Drug Reaction reporting. Such SDEA will be completed within ninety (90) days after the Effective Date.

 

Quality Complaint Reporting. Synergy shall be solely responsible for collecting and responding to any product quality complaint relating to the Licensed Products received from a customer in the Territory. Synergy shall investigate and provide Hand, in a timely manner, with reports resulting from such investigations. If Hand receives a product quality complaint relating to the Licensed Products from a customer in the Territory, it shall investigate and promptly report the investigation results to Synergy, who will be solely responsible for communication and response, if any, to the customer in the Territory. If Synergy does not or is unable to respond to any product quality complaints related to the Licensed Products in a timely manner, Hand shall have the right to do so.

 

Other Information. In addition to the foregoing information to be provided, each Party shall provide to the other Party with any: (i) information relating to the efficacy and/or safety of the Licensed Products, including any recall of the Licensed Products; (ii) complaints from customers, healthcare professionals or competitors in the Territory relating to the Licensed Products; (iii) information relating to any potential liability to any Third Party in the Territory that is reasonably likely to arise for either Party in connection with the Commercialization of the Licensed Products in the Territory; (iv) information relating to any inspections, inquiries, issues raised or actions taken by any Governmental Authority in the Territory; and (v) any other information necessary or reasonably desirable to enable each Party to comply with any Applicable Law in the Territory or elsewhere.

 

Recall. Synergy shall advise Hand of any Governmental Authority initiated mandatory recall of Licensed Products in the Territory. Prior to executing any recall of Licensed Products in the Territory, Synergy shall review with Hand the proposed manner in which the recall is to be carried out. Synergy will give due consideration to any reasonable recommendation from Hand as to the manner of conducting the recall, provided that it is agreeable to the applicable Governmental Authority. Synergy shall communicate directly with the applicable Governmental Authorities in relation to a Licensed Products recall in the Territory.

 

ROYALTIES

 

Earned Royalty. In consideration of its license to the Know-How under this Agreement, Synergy shall pay to Hand a royalty of 5% of the Net Sales Price of each Licensed Product sold, transferred or otherwise disposed of by or for Synergy in the Territory during Term pursuant to Section 2.1, not including Sublicensing Royalty (“Earned Royalty”), and 5% of all amounts received by Synergy from any sublicenses granted pursuant to Section 2.2 (“Sublicensing Royalty; the Earned Royalty and Sublicensing Royalty shall be collectively the “Royalties”).

 

 
 

 

Minimum Royalty. If the total Royalties for any calendar quarter is less than the Minimum Royalty, Synergy shall pay Hand the Earned Royalty plus the difference between the Minimum Royalty and the Earned Royalty for that calendar quarter. For clarity, the Minimum Royalty (if any) is calculated quarterly (i.e., for months 13 through 24 following the Effective Date, it is $62,500 per calendar quarter). The Minimum Royalty terminates upon the 3 year anniversary of the Effective Date.

 

Taxes. Synergy will make all payments to Hand under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Synergy under this Agreement will be timely paid by Synergy on behalf of Hand to the appropriate Governmental Authority, and Synergy will furnish Hand with the corresponding proof of payment of such tax, as may be required in order to enable Hand to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Synergy and Hand agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.

 

Payment Terms and Royalty Statements

 

Synergy shall pay all Royalties (and Minimum Royalties, if applicable) for each calendar quarter within 60 days of the end of such calendar quarter. Synergy shall make all payments in US dollars by wire transfer of immediately available funds to a bank account to be designated in writing by Hand.

 

On or before the due date for all payments to Hand pursuant to this Section 6, Synergy shall provide Hand with a statement (“Payment Statement”) showing:

 

the total Net Sales Price of all Licensed Products sold, transferred or otherwise disposed of by Synergy and the total Sublicensing Revenue accrued in the relevant calendar quarter;

 

the calendar quarter for which the Earned Royalties and the Sublicensing Royalties were calculated; and

 

such other particulars as are reasonably necessary or as may be reasonably requested by Hand for an accurate accounting of the payments made pursuant to this Agreement.

 

6.4 Records. During the Term of the Agreement and for a period of 2 years from the termination of this Agreement, Synergy shall keep complete and accurate records of its and its records that are reasonably necessary for the calculation of payments to be made to Hand hereunder.

 

Audit

 

Hand, at its own expense, may at any time within 1 year after receiving any Payment Statement from Synergy, nominate an independent Certified Public Accountant (“Auditor”) who shall have access to Synergy’s applicable records during Synergy’s normal business hours for the purpose of verifying all payments made under this Agreement.

 

Hand shall provide to Synergy a copy of the Auditor’s audit report within 5 days of Hand’s receipt of the report. If the report shows that payments made by Synergy are deficient by more than five percent (5%) of the amount that was reported under this Agreement, Synergy shall pay Hand the deficient amount and the fees and expenses of the Auditor in connection with such audit within 30 days after Synergy’s receipt of the audit report.

 

INTELLECTUAL PROPERTY

 

Notification of Third Party Infringement. Each Party shall promptly disclose to the other in writing within ten (10) Business Days, any actual, alleged, or threatened Third Party infringement or misappropriation in the Territory of any Know-How and any actual, alleged or threatened infringement or passing off of the Hand Mark, of which such Party becomes aware.

 

 
 

 

Response to Third Party Infringement. Hand shall have the first right, but not any obligation, to respond to any actual or threatened infringement of Know-How, the Hand Mark or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory relating to the Licensed Products. If Hand elects to respond to any actual or threatened infringement by initiating a proceeding, Hand shall use legal counsel of its choice at its expense and shall have full control over the conduct of such proceeding. Hand may settle or compromise any such proceeding without the consent of Synergy; provided, however, that if such settlement affects Synergy’s rights under this Agreement, or Synergy’s ability to Commercialize the Licensed Products within the Territory, or otherwise requires Synergy to admit wrongdoing, fault, or liability, Hand will not settle or compromise any such proceeding without the written consent of Synergy, such consent not to be unreasonably withheld, conditioned, or delayed. If Hand elects not to respond to any actual or threatened infringement of the Know-How, the Hand Mark or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses in the Territory relating to the Licensed Products, then Synergy shall have the right, but not the obligation, to take action, at its sole expense, in which case Synergy shall have full control over the conduct of such proceeding and Synergy may settle or compromise any such proceeding without the consent of Hand; provided, however, that if such settlement affects Hand’s intellectual property rights or its rights under this Agreement, or otherwise requires Hand to admit wrongdoing, fault, or liability, Synergy will not settle or compromise any such proceeding without the written consent of Hand, such consent not to be unreasonably withheld, conditioned, or delayed. Synergy shall be solely responsible for any legal costs or damages awards made in any proceeding that is initiated by Synergy in the event that Hand elects not to respond to any actual or threatened infringement.

 

Cooperation. Each Party shall cooperate reasonably, at its expense, in any enforcement effort initiated by the other Party. The Parties nor their Affiliates shall contest any joinder in any proceeding sought to be brought by the other Party if such joinder is required by Law.

 

Recovery. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any monetary award recovered from a Third Party in connection with any proceeding initiated to protect, maintain, defend, or enforce any intellectual property in the Territory or recovered from a Third Party in connection with any proceeding initiated for infringement or misappropriation of intellectual property shall first be used to reimburse the Parties for any out-of-pocket legal expenses relating to such proceeding and the balance being retained by the Party that brought and controlled such litigation.

 

Infringement of Third Party IP. If either Party becomes aware that its activities performed hereunder may constitute actual or alleged infringement or misappropriation of the intellectual property rights of a Third Party, it shall promptly notify the other Party and the Parties shall promptly discuss a strategy to defend or mitigate against any actual or alleged infringement.

 

REPRESENTATION AND WARRANTIES

 

Hand Covenants, Representations and Warranties. Hand covenants, represents and warrants (as the case may be) to Synergy that:

 

Hand is a corporation duly organized, validly existing and in good standing under the laws of Delaware;

 

Hand has the legal right and authority to enter into this Agreement;

 

Hand has taken all necessary actions to authorize the execution, delivery and performance of this Agreement;

 

Hand has obtained all consents, licenses and authorizations that are necessary to perform its obligations under this Agreement;

 

Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Hand, enforceable against Hand in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and remedies or equitable principles;

 

The performance of Hand’s obligations under this Agreement will not conflict with its organizational documents, as amended, or result in a breach of any material agreements or contracts to which it is a party;

 

 
 

 

Hand has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would conflict with its obligations under this Agreement;

 

Hand solely owns all of the Know-How and Hand Marks licensed to Synergy pursuant to this Agreement and the Know-How licensed to Synergy pursuant to this Agreement is all of the Know-How that is necessary for Synergy to carry out its obligations and exercise its rights under this Agreement;

 

Hand has not received any notice that the manufacture, sale, or use of the Licensed Products in the Territory infringes upon any intellectual property rights of any Third Parties in the Territory; and

 

To the knowledge of Hand, there are no activities being carried out by Third Parties in the Territory that would constitute infringement or misappropriation of the Know-How or the Hand Mark.

 

Synergy Representations and Warranties. Synergy covenants, represents and warrants to Hand (as the case may be) as follows:

 

Synergy is a corporation duly organized, validly existing and in good standing, under the laws of Nevada;

 

Synergy has the legal right, authority, and power to enter into this Agreement;

 

Synergy has taken all necessary action to authorize the execution, delivery, and performance of this Agreement;

 

Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of Synergy, enforceable against Synergy in accordance with its terms, except to the extent enforceability is limited by bankruptcy, insolvency or similar laws affecting creditors’ rights and remedies or equitable principles;

 

The performance of Synergy’s obligations under this Agreement will not conflict with its organizational documents or result in a breach of any material agreements or contracts to which it is a party; and

 

Synergy has not and will not, during the term of this Agreement, enter into any material agreements or contracts that would be inconsistent with its obligations under this Agreement.

 

WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED.

 

LIMITATIONS OF LIABILITY. WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.

 

Indemnification by Hand. Hand hereby agrees to defend, indemnify, and hold Synergy, its Affiliates and their respective officers, directors, employees and agents, (each a “Synergy Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Hand or an Affiliate of Hand; (ii) any violation of Applicable Law by Hand or its Affiliates; and (iii) any negligent act or omission or willful misconduct of Hand or its Affiliates; (iv) any claim that the sale by Synergy or its Affiliates, of the Licensed Products infringes on intellectual property rights in the Territory of any other person; (v) any claim arising from any use, within the approved labelling, made by any person of any of the Licensed Products; in all cases, except to the extent such Third Party’s claim for loss, damage or liability is the result of: (i) any breach of this Agreement by Synergy or a Synergy Indemnified Party, (ii) any violation of Applicable Law by Synergy or a Synergy Indemnified Party, or (iii) any negligent act or omission or willful misconduct of Synergy or a Synergy Indemnified Party.

 

 
 

 

Indemnification by Synergy. Synergy hereby agrees to defend, indemnify, and hold Hand, its Affiliates and their respective officers, directors, employees and agents, (each a “Hand Indemnified Party”) harmless from and against any Third Party’s claims for loss, damage, or liability resulting from: (i) any breach of this Agreement or any warranty or covenant provided in this Agreement by Synergy or an Affiliate of Synergy; (ii) any violation of Applicable Law by Synergy or its Affiliates; and (iii) any negligent act or omission or willful misconduct of Synergy or its Affiliates; in all cases, except to the extent such Third Party’s claim for loss, damage or liability is the result of: (i) any breach of this Agreement by Hand or a Hand Indemnified Party, (ii) any violation of Applicable Law by Hand or a Hand Indemnified Party, or (iii) any negligent act or omission or willful misconduct of Hand or a Hand Indemnified Party.

 

Indemnification Procedure. If an indemnified party intends to claim indemnification under this Section 0, such party shall promptly notify the other party of any loss, claim, damage, liability or action in respect of which the indemnified party intends to claim such indemnification, and the indemnifying party shall have a first opportunity to assume the sole defense thereof with counsel selected by the indemnifying party and approved by the indemnified party acting reasonably; provided, however, that an indemnified party shall have the right to retain its own counsel and participate fully in the defense, with the fees and expenses to be paid by the indemnified party. The failure or delay to deliver notice to the indemnifying party, within a reasonable time after the commencement of any such proceeding, if irreparably prejudicial to the indemnifying party’s ability to defend such proceeding, shall relieve the indemnifying party of any and all liability to the indemnified party under this Section 0. The indemnified party shall cooperate fully with the indemnifying party and their legal representatives in the investigation of any loss, claim, damage, or liability covered by this indemnification, and shall mitigate such loss and damages. Any amount payable in order to satisfy an indemnity hereunder shall be paid as soon as reasonably possible after the indemnified party has incurred an indemnified expense and notified the indemnifying party thereof.

 

Compliance with Law. Each Party shall comply, and shall require their Affiliates and permitted sublicensees to comply, with all Applicable Laws relative to their obligations hereunder.

 

Insurance. The Parties shall maintain insurance, including product liability insurance, that is adequate to cover their obligations hereunder and that is consistent with normal business practices of prudent corporations engaged in the same or a similar business. The Parties acknowledge and agree that such insurance shall not be construed to create a limit with respect to their indemnification obligations.

 

TERM AND TERMINATION

 

Term. This Agreement will take effect from the Effective Date and, unless earlier terminated in accordance with the terms herein, will continue in perpetuity (the “Term”).

 

Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:

 

In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.

 

If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) thirty (30) days after written notice thereof is delivered to the defaulting or breaching Party, or (ii) in the case of a breach that cannot be cured within thirty (30) days, within a reasonable period not exceeding sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party.

 

 
 

 

Effect of Termination. Upon expiry or termination of this Agreement, all licenses and rights granted by Hand hereunder shall terminate and Synergy will:

 

except as provided for in Section 0, cease any Commercialization of the Licensed Products in the Territory; and

 

within thirty (30) days or expiry or termination, transfer title to all current and pending Regulatory Approvals for the Licensed Products to Hand and assist Hand, at Hand’s cost, in submitting appropriate documents to transfer the Regulatory Approvals for the Licensed Products to Hand or its designee.

 

Survival. In the event of the termination of this Agreement for any reason, the following provisions of this Agreement shall survive: Sections 1, 7, 8.5, 8.7, 9.4, 9.5 and 10, and any other terms which, by their nature, require or contemplate performance by the Parties after expiry or termination. In any event, termination of this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such termination.

 

Sell-Off of Inventory. Upon termination of this Agreement, Synergy shall be entitled to sell off any inventory of the Licensed Products in Synergy’s possession or control on the date such termination is effective, provided such sales are in the normal course of business and consistent with sales of the License Products during the Term of this Agreement.

 

OTHER PROVISIONS

 

Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.

 

Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.

 

Assignment. Except in connection with the acquisition of Synergy or the sale of all or substantially all of the assets of Synergy, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall enure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.

 

Compliance with law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of the Territory.

 

Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations promptly advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than one (1) month, and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.

 

 
 

 

Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by internationally recognized international courier, and shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 0. Notices and other communications shall be addressed as follows:

 

In the case of Synergy:

 

Synergy CHC Corp.

c/o Jack Ross

865 Spring Street

Westbrook, Maine 04092

E-mail: jack@synergystrips.com

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim

E-mail: dmannheim@wyrick.com

 

In the case of Hand:

 

[____________]

Attention:

Fax:

E-mail:

 

with a copy to:

 

Klehr Harrison Harvey Branzberg LLP

1835 Market Street, Suite 1400

Philadelphia, Pennsylvania 19103

U.S.A.

Attention: William W. Matthews, III

E-mail: WMatthews@klehr.com

 

Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the Licensed Products and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.

 

Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances.

 

Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of Delaware. The Parties hereto irrevocably consent to the exclusive jurisdiction of, the federal and state courts of the State of Delaware located in Wilmington, Delaware for such purpose. If either Party in its sole judgment, acting reasonably, believes that any dispute could cause it irreparable harm, such Party will be entitled to seek equitable relief in order to avoid such irreparable harm.

 

 
 

 

Public Announcements. Neither Party shall originate any publicity, news release, or public announcements relating to this Agreement (including, without limitation, its existence, its subject matter, the Parties’ performance, any amendment hereto, or performance hereunder), whether to the public or press, stockholders, or otherwise, without the prior written consent of the other Party, save only such announcements that are required by law or the rules of any relevant stock exchange to be made or that are otherwise agreed to by the Parties. If a Party decides to make an announcement, whether required by law or otherwise, it shall give the other Party reasonable notice of the text of the announcement so that the other Party shall have an opportunity to comment upon the announcement. To the extent that the receiving Party reasonably requests the deletion of any information in any such announcement, the disclosing Party shall delete such information unless, in the opinion of the disclosing Party’s legal counsel, such information is required by law or the rules of any relevant stock exchange to be disclosed. The timing and content of the initial press release relating to this Agreement, if any, including its existence, the subject matter to which it relates and the transactions contemplated herein will, except as otherwise required by law or any stock exchange rules, be determined jointly by the Parties.

 

Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.

 

Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof.

 

[Signature page follows]

 

 
 

 

In witness whereof, the parties have signed this Agreement.

 

SYNERGY CHC CORP.   HAND MD CORP.
         
By: /s/ Jack Ross   By: /s/ Jack Ross
Name: Jack Ross   Name: Jack Ross
Title: President and Chief Executive Officer   Title: President

 

Signature Page – Intellectual Property License Agreement

 

 

 

Exhibit 10.8

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of August 18, 2015 (the “Effective Date”), by and between Synergy CHC Corp., a Nevada corporation (the “Company”), and Kara Harshbarger (the “Consultant”).

 

WITNESSETH

 

WHEREAS, the Company desires to engage Consultant to provide certain services on an independent contractor basis as outlined below, and Consultant wishes to provide such services to Company; and

 

WHEREAS, the Company and Consultant desire to establish and document the terms and conditions of the consulting relationship between them.

 

NOW, THEREFORE, in consideration of the mutual promises and obligations of the parties set forth herein and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows:

 

1. Appointment of Consultant; Services. Company appoints Consultant and Consultant hereby accepts appointment as an independent contractor to perform services related to marketing and sales as may be requested by the Company from time to time, which may include, without limitation, the services described on Exhibit A hereto (the “Services”).

 

2. Term; Termination. This Agreement will be effective as of the Effective Date and will continue in effect for one year, unless earlier terminated by either party upon written notice to the other party. If Company terminates Consultant other than for cause during the term, then the payments set forth in Section 5 will continue until the end of the term.

 

3. Duties of Consultant. Consultant agrees to diligently, competently, and to the best of her ability perform the Services, provided that Consultant will at all times retain sole and absolute discretion and judgment in the manner and means of carrying out the Services. Other than expenses that are preapproved by the Company in writing, Consultant will be responsible for her expenses incurred in connection with the performance of the services described herein, including, without limitation, the costs and expenses of any insurance, office space, and supplies, as well as any applicable taxes, withholdings, contributions, fees or charges levied or required by any governmental entity as a result of Consultant’s performance of the Services; provided, however, for the purposes of this Section 3, the Company hereby preapproves any and all QVC travel expenses as well as press travel expenses for two meetings annually in New York City with beauty editors. Consultant will obtain and maintain all licenses, permits and approvals necessary to perform the Services.

 

4. Services for Others. During Consultant’s engagement with the Company, Consultant will be free to perform services for other persons and entities, provided that performance of such services does not materially interfere with Consultant’s performance of the Services under this Agreement, and Consultant will comply with Sections 9, 10, and 12 of this Agreement with respect to her services for or on behalf of other persons and entities.

 

Page 1 of 8
 

 

5. Compensation of Consultant. As compensation for the performance of the Services, the Company will pay Consultant a consulting fee of ten thousand dollars ($10,000) per month while this Agreement remains in effect, prorated for any partial months. Consultant will be paid in advance in installments of ten thousand dollars ($10,000) on the 1st day of each month while this Agreement remains in effect, upon receipt of an invoice from Consultant. The initial payment of $10,000 shall be payable on August __, 2015.

 

6. Independent Contractor Status of Consultant.

 

(a) Consultant’s legal status is an independent contractor of Company. Nothing in this Agreement makes Consultant the agent, partner, joint venturer, employee, or legal representative of Company for any purpose whatsoever; nor shall Consultant hold herself out as such. Consultant will have no authority to bind Company in any manner or for any purpose.

 

(b) Consultant (and any employees or agents of Consultant) will not be employees of Company for any purpose, including for purposes of the Fair Labor Standards Act’s minimum wage and overtime provisions, nor any other provision of federal, state, or local law applicable to employees. Further, Consultant understands and agrees that Consultant (and any employees or agents of Consultant) will not be entitled to any employment benefits that may be made available by the Company to its employees, including but not limited to vacation pay, sick leave, retirement benefits, social security, workers’ compensation, health or disability benefits, and unemployment insurance benefits.

 

(c) Consultant acknowledges that Consultant has not relied on any statements or representations by the Company or its attorneys with respect to the tax treatment of any compensation due under this Agreement. Consultant understands that the Company will not be responsible for withholding or paying any federal, state, or local income, social security, or other taxes in connection with any compensation paid under this Agreement, and Consultant agrees that Consultant is solely responsible for any such tax payments.

 

7. Representations. Consultant hereby represents and warrants to Company that (a) Consultant is free to enter into this Agreement with Company and to perform the Services described herein; (b) the execution of this Agreement and the performance of the Services by Consultant will not result in the breach of any express or implied, oral or written, contract or agreement, to which Consultant is bound (including, without limitation, any non-competition agreement with a current or prior employer); and (c) the execution of this Agreement and the performance of the Services will not at any time interfere with or violate any third party rights (including, without limitation, the use, disclosure, misappropriation, or infringement of any confidential information, proprietary rights or intellectual property belonging to any other person or entity).

 

Page 2 of 8
 

 

8. Indemnification.

 

(a) Consultant agrees to indemnify and hold Company harmless from and against any and all third party liabilities, claims, causes of action, losses, costs, fees (including, without limitation, attorneys’ fees), expenses, damages and penalties arising out of or relating to the acts or omissions of Consultant or her agents in performing Consultant’s obligations under this Agreement (including, without limitation, any negligence or intentional misconduct in performing the Services, or any breach of any representation, warranty or other provision of this Agreement by Consultant).

 

(b) Company agrees to indemnify and hold Consultant harmless from and against any and all third party liabilities, claims, causes of action, losses, costs, fees (including, without limitation, attorneys’ fees), expenses, damages and penalties arising out of or relating to the acts or omissions of Company or its agents in performing Company’s obligations under this Agreement (including, without limitation, any breach of any representation, warranty or other provision of this Agreement by Company).

 

9. Ownership of Intellectual Property.

 

(a) Consultant will immediately and fully disclose in writing to the Company all intellectual property and other proprietary information, including without limitation, all inventions, methods, processes, innovations, discoveries, developments, ideas, technologies, computer code and programs, macros, trade secrets, know-how, formulae, designs, patterns, marks, names, improvements, industrial designs, mask works, works of authorship, technical materials relating to the business of the Company conceived or developed for the Company by the Consultant during her engagement by the Company (collectively, “Intellectual Property”) whether or not any such Intellectual Property is patentable, copyrightable, or otherwise protectable. Notwithstanding the foregoing, this Agreement shall not be construed to apply to, and shall not create any assignment of, any Intellectual Property of Consultant that Consultant developed entirely on Consultant’s own time without using the Company’s equipment, facilities, or trade secret information, except for Intellectual Property that results from any work performed by the Consultant for the Company. The Company acknowledges that Consultant, subject to the Non-competition provisions of Section 12, below, may create inventions, methods, processes, innovations, discoveries, developments, ideas, technologies, computer code and programs, macros, trade secrets, know-how, formulae, designs, patterns, marks, names, improvements, industrial designs, mask works, works of authorship, technical materials for third parties during the term of this Agreement.

 

(b) Consultant does hereby, and will from time to time immediately upon the conception or development of any Intellectual Property in the course of Consultant’s engagement with the Company assign to the Company all of her right, title and interest in and to all such Intellectual Property (whether or not patentable, registrable, recordable or protectable by copyright and regardless of whether the Company pursues any of the foregoing). If any Intellectual Property falls within the definition of “work made for hire,” as such term is defined in 17 U.S.C. § 101, such Intellectual Property will be considered “work made for hire,” and the copyright of such Intellectual Property will be owned solely and exclusively by the Company. If any Intellectual Property does not fall within such definition of “work made for hire” then the right, title, and interest in and to such Intellectual Property of Consultant will be assigned to the Company pursuant to the first sentence of this Section 9(b).

 

Page 3 of 8
 

 

(c) Consultant will execute and deliver any assignment instruments and do all other things reasonably requested by the Company (both during and after Consultant’s engagement with the Company) in order to more fully vest in the Company sole and exclusive right, title, and interest in and to all Intellectual Property. Consultant agrees to cooperate with and provide reasonable assistance to the Company in the preparation of applications for letters patent, copyright, and other forms of protection for Intellectual Property, including but not limited to the execution and delivery of any instruments reasonably requested by the Company (both during and after Consultant’s engagement with the Company), in order to protect the Company’s interest in and to all Intellectual Property. If the Company is unable for any reason to secure Consultant’s signature on any lawful and necessary document required to apply for or execute any patent, trademark, copyright or other applications with respect to any Intellectual Property (including renewals, extensions, continuations, divisions or continuations in part thereof), Consultant hereby irrevocably designates and appoints the Company and its then current Chief Executive Officer as Consultant’s agent and attorney-in-fact to act for and in behalf and instead of Consultant, to execute and file any such application and to do all other lawfully permitted acts to further the prosecution and issuance of patents, trademarks, copyrights or other rights thereon with the same legal force and effect as if executed by Consultant.

 

10. Confidential Information.

 

(a) Consultant acknowledges that during her engagement with Company, Consultant will have access to certain highly-sensitive, confidential, and proprietary information belonging to the Company or third parties who may have furnished such information under obligations of confidentiality, relating to and used in the Company’s business (collectively, “Confidential Information”). Consultant acknowledges that, unless otherwise available to the public, Confidential Information includes, but is not limited to, the following categories of information and material, including all copies, notes, or other reproductions or replicas thereof: financial statements and information; budgets, forecasts, and projections; business and strategic plans; marketing, sales, and distribution strategies; research and development projects; records relating to any intellectual property developed by, owned by, controlled, licensed, or maintained by the Company; information related to the Company’s inventions, research, products, designs, methods, know-how, formulae, techniques, systems, processes; customer lists; non-public information relating to the Company’s customers, suppliers, employees, distributors, or investors; the specific terms of the Company’s agreements or arrangements, whether oral or written, with any customer, supplier, vendor, or contractor with which the Company may be associated from time to time; and any and all information relating to the operation of the Company’s business which the Company may from time to time designate as confidential or proprietary or that Consultant reasonably knows should be, or has been, treated by the Company as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print, or any other form, including all originals, copies, notes, or other reproductions or replicas thereof.

 

(b) Confidential Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Consultant or other violation of this Agreement; or (iii) is disclosed to Consultant by a third party under no obligation to maintain the confidentiality of the information.

 

Page 4 of 8
 

 

(c) Consultant agrees that Consultant will maintain the confidentiality of the Confidential Information at all times during and following her engagement by the Company and will not, directly or indirectly, use or disclose any Confidential Information for any purpose other than to the extent necessary to perform the Services.

 

(d) The restrictions in Section 10(c) above will not apply to any information to the extent that Consultant is required to disclose such information by law, provided that the Consultant (i) notifies the Company of the existence and terms of such obligation (to the extent Consultant is not legally prohibited or restricted from doing to), (ii) gives the Company a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure (to the extent Consultant is not legally prohibited or restricted from doing to), and (iii) only discloses that information actually required to be disclosed.

 

11. Return of Property. Upon termination of Consultant’s engagement with the Company for any reason, or at any time upon request of the Company, Consultant will promptly deliver to the Company all Confidential Information in any form along with all personal property belonging to the Company that is in Consultant’s possession, custody, or control, including, without limitation, all files, memoranda, designs, correspondence, manuals, programs, data, records, notes, notebooks, reports, papers, equipment, computer software, proposals, or any other file, material, document or possession (whether in hard copy or any electronic format), however obtained, along with any reproductions or copies. Notwithstanding the foregoing, Consultant may retain Confidential Information to the extent required to demonstrate her compliance with any legal, fiduciary or professional obligations, as well as Confidential Information contained in deleted emails and electronic documents which are archived by or on her behalf but are not accessible by the individuals who created or received such emails or documents, provided that in each case any retained Confidential Information shall remain subject to the confidentiality and non-use obligations set forth herein in accordance with the terms of this Agreement.

 

12. Non-Competition and Non-Solicitation. The parties acknowledge and agree that Consultant, through her association with Company as an independent contractor, will acquire a considerable amount of knowledge and goodwill with respect to the business of Company (including but not limited to its customer relationships), which knowledge and good will are extremely valuable to Company and which would be extremely detrimental to Company if used by Consultant to compete with Company. It is therefore understood and agreed that it is necessary for Consultant to be bound by certain reasonable covenants in order to afford fair protection to Company from unfair competition by Consultant. Consequently, as a material inducement for Company to engage Consultant, Consultant agrees to the restrictive covenants described herein.

 

(a) Definitions. The following definitions are applicable to this Section 12:

 

(i) Business” means the marketing and sale of skincare, nail polish and nail care products, including but not limited to products under the brand name Hand MD.

 

(ii) Customer” means any person or entity who is or was a customer or client of the Company at the time of, or during the 12 month period prior to, the termination of Consultant’s engagement with the Company.

 

Page 5 of 8
 

 

(iii) Restricted Period” means the period commencing on the date of termination of Consultant’s engagement with the Company and ending twelve (12) months after such date; provided, however, that the period shall be tolled and shall not run during any time Consultant is in violation of this Section 12, it being the intent of the parties that the Company is entitled to a full twelve (12) months post-engagement free of Consultant’s competition and solicitation as described in this Section 12.

 

(iv) Territory” means the United States of America, it being understood that the business of the Company is nationwide in scope.

 

(b) Non-Competition. During Consultant’s engagement with the Company and during the Restricted Period, Consultant will not (i) engage in the Business in the Territory (other than on behalf of the Company), or (ii) hold a position based in or with responsibility for all or part of the Territory, with any person or entity engaging in the Business, whether as an employee, consultant, or otherwise, in which Consultant will have duties, or will perform or be expected to perform services for such person or entity, that is or are the same as or substantially similar to the services actually performed by Consultant for the Company within the twelve (12) month period immediately preceding the termination of Consultant’s engagement with the Company, or in which Consultant will use or disclose or be reasonably expected to use or disclose any confidential or proprietary information of the Company.

 

(c) Non-Solicitation. During Consultant’s engagement with the Company and during the Restricted Period, Consultant will not, directly or indirectly, on Consultant’s own behalf or on behalf of any other party (except on behalf of the Company):

 

(i) Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert, or encourage any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by the Company;

 

(ii) Accept as a customer any Customer for purposes of marketing, selling, or providing products or services to such Customer that are similar to or competitive with those offered by the Company;

 

(iii) Induce, encourage, or attempt to induce or encourage any Customer to reduce, limit, or cancel its business with the Company; or

 

(iv) Solicit, induce, or attempt to solicit or induce any employee or consultant of the Company to terminate his or her employment or engagement with the Company.

 

Page 6 of 8
 

 

(d) Reasonableness of Restrictions. Consultant acknowledges and agrees that (i) the restrictive covenants in this Agreement are essential elements of Consultant’s engagement by the Company and are reasonable given Consultant’s access to the Company’s confidential information and the substantial knowledge and goodwill Consultant will acquire with respect to the business of the Company as a result of Consultant’s engagement by the Company; (ii) the restrictive covenants contained in this Agreement are reasonable in time, territory, and scope, and in all other respects. Should any part or provision of this Section 12 be held invalid, void, or unenforceable in any court of competent jurisdiction, such invalidity, voidness, or unenforceability shall not render invalid, void, or unenforceable any other part or provision of this Agreement. The parties further agree that if any portion of this Section 12 is found to be invalid or unenforceable by a court of competent jurisdiction because its duration, territory, or other restrictions are deemed to be invalid or unreasonable in scope, the invalid or unreasonable terms shall be replaced by terms that are valid and enforceable and that come closest to expressing the intention of such invalid or unenforceable terms.

 

13. Remedies. Consultant acknowledges and agrees that Consultant’s breach or threatened breach of Sections 9, 10, 11, and/or 12 of this Agreement will result in immediate and irreparable injury to Company, which injury will not be subject to redress by monetary damages. Accordingly, Consultant agrees that Company is entitled to enforce this Agreement by seeking a temporary restraining order, preliminary and permanent injunction and/or any other appropriate equitable relief to prevent or retrain such breach. Nothing in this Section prohibits the Company from pursuing any other remedies available to it in law or equity, including but not limited to the recovery of monetary damages. The Company will be entitled to recover its costs incurred in connection with any action to enforce Sections 9, 10, 11, and/or 12 of this Agreement, including reasonable attorneys’ fees and expenses, to the maximum extent permitted by law.

 

14. Benefit; Assignment. The rights, duties and obligations of the parties under this Agreement shall inure to the benefit and shall be binding upon their respective successors and permitted assigns. Neither this Agreement nor the respective rights, duties, obligations and responsibilities of Consultant under this Agreement may be assigned or transferred, in whole or in part, by Consultant to any other person, association, organization, company or other entity (including subcontractors) without the prior written consent of Company.

 

15. Governing Law; Venue. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without regard to that body of law known as choice of law. Any litigation arising out of or related to this Agreement will be brought exclusively in the state or federal courts located in Wilmington, Delaware. Each party (a) consents to the personal jurisdiction of said courts, (b) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and (c) agrees not to bring any proceeding arising out of or relating to this Agreement in any other court.

 

16. Miscellaneous.

 

(a) The provisions of Sections 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16 will survive the termination of this Agreement for any reason.

 

(b) Should any provision of this Agreement or the application thereof, to any extent, be held invalid or unenforceable, the remainder of this Agreement and the application thereof, other than those provisions held invalid or unenforceable, shall not be affected thereby and shall continue valid and enforceable to the fullest extent permitted by law or equity.

 

(c) No waiver by either party of any breach of this Agreement shall be construed as a waiver of any succeeding breach of this Agreement.

 

(d) This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same agreement. Facsimile or PDF reproductions of original signatures will be deemed binding for the purpose of the execution of this Agreement.

 

(e) This Agreement represents the entire and integrated agreement between the parties and supersedes all prior negotiations, representations or agreements, either written or oral regarding the subject matter thereof.

 

(f) This Agreement may be amended only by a written instrument signed by both Company and Consultant.

 

Page 7 of 8
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first above written.

 

CONSULTANT:   COMPANY:
     
Kara Harshbarger   Synergy CHC Corp.
       
/s/ Kara Harshbarger   By: /s/ Jack Ross
Kara Harshbarger     Jack Ross, Chief Executive Officer

 

Page 8 of 8
 

 

Exhibit A

 

Sales, marketing, and product development other consulting services.

 

Assistance with development of at least two new products for the Company.

 

 

 

Exhibit 10.9

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT (the “Agreement”) dated as of November 12, 2015, by and among Breakthrough Products, Inc., a Delaware corporation (the “Company”), URX ACQUISITION TRUST, a Delaware statutory trust, (the “Trust”), Jordan Eisenberg, the chief executive officer and a shareholder of the Company (“Eisenberg”), the other shareholders of the Company listed on Exhibit A (Eisenberg and such other shareholders being sometimes collectively referred to as the “Sellers,” and individually as a “Seller”), and Synergy CHC Corp., a Nevada corporation (the “Buyer”). Company, Trust, Sellers, and Buyer are sometimes referred to collectively as the “Parties” and individually as a “Party”.

 

BACKGROUND

 

Sellers, either directly or indirectly, collectively own all of the issued and outstanding capital stock of the Company.

 

The Company, operating as UrgentRx, is engaged in the business of developing and selling medications for headache, heart burn, allergy attack, ache and pain, and upset stomach in the form of powders (the “Products”) (the Products and the business related to the manufacture, sale, marketing and distribution of the Products is collectively the “Business”).

 

Buyer desires to purchase all of the outstanding capital stock of the Company (the “Stock Purchase”), and Sellers desire to sell such outstanding capital stock to Buyer, in each case upon the terms and subject to the conditions set forth in this Agreement.

 

The Trust was formed for the sole purpose of holding, collecting, and managing the Purchase Consideration (as defined below) payable with respect to the Stock Purchase (including voting the shares issued as purchase price consideration and exercising all shareholder rights with respect thereto while being held by the Trust), enforcing the rights of the Sellers with respect to this Agreement, payment of any expenses and any liabilities of the Sellers under this Agreement, and distributing the assets of the Trust to the Sellers.

 

In consideration of the foregoing and the respective covenants and agreements hereinafter contained, the Parties hereto hereby agree as follows:

 

1. Definitions. As used in this Agreement (including the recitals and Disclosure Schedules hereto), the following selected terms shall have the following meanings (such meanings to be applicable equally to both singular and plural forms of the terms defined):

 

Action” means any claim, action, cause of action, demand, lawsuit, arbitration, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether formal or informal, whether public or private and whether at law or in equity;

 

Affiliate” shall mean, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by Contract or otherwise) of such Person;

 

Closing” shall mean the consummation of the transactions contemplated by this Agreement;

 

Code” means the Internal Revenue Code of 1986, as amended;

 

Commercially Reasonable Efforts” means the commercially reasonable efforts that a prudent Person desirous of achieving a result and having an incentive to and interest in achieving such result would use to achieve that result as expeditiously as reasonably possible under the circumstances;

 

 
 

 

Company Equityholder” means the holder of any capital stock of the Company or any options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of its capital stock;

 

Contract” means any agreement, contract, indenture, instrument, obligation, promise or undertaking (whether written or oral and whether express or implied) that is legally binding;

 

Customers” means all of the customers of Company during each of Company’s 2012, 2013, and 2014 fiscal years and during the period ended as of September 30, 2015;

 

Disclosure Schedules” means the disclosure letter delivered by Sellers concurrently with the execution and delivery of this Agreement;

 

Employee” means an employee of Company employed in connection with the Business;

 

Employee Benefit Plan” means any pension, profit sharing, retirement, deferred compensation, stock purchase, stock option or other equity based compensation plans, incentive, bonus, vacation, employment agreement, independent contractor agreement, severance, disability, hospitalization, sickness, death, medical insurance, dental insurance, life insurance and any other material employee benefit plan (whether provided on a funded or unfunded basis, or through insurance or otherwise), agreement, program, policy, trust, fund, Contract or arrangement;

 

Environmental Laws” means all Laws concerning pollution or protection of the environment and natural resources, including without limitation all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, control or cleanup of any hazardous materials, substances or wastes, pesticides, pollutants or byproducts, asbestos, polychlorinated biphenyls, or radiation, each as amended and as now or hereafter in effect;

 

Fundamental Representations” shall mean the representations and warranties set forth in (i) Sections 3(a), 3(b), 3(c), and 3(d); (ii) Sections 4(a), 4(c), 4(d), and 4(e); (iii) Sections 5(a), 5(b), 5(c), 5(d), 5(g), 5(h), (5(i) and 5(j); and Sections 6(a), 6(b), 6(c), and 6(d).

 

Government” shall mean any agency, division, subdivision, audit group or procuring office of the Government of the United States, any state of the United States, including the employees or agents thereof;

 

Guarantee” means any Contract of guarantee, indemnification, assumption or endorsement or any other like commitment of the obligations, liabilities (fixed, contingent or otherwise) or indebtedness of another Person;

 

Intellectual Property” means all intellectual property rights whether protected, created or arising under the Laws of the United States or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, LinkedIn, Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, software or computer programs, and data base;

 

Knowledge of Company” or “Company’s Knowledge” or a similar phrase shall mean, with respect to any matter, the actual knowledge the Eisenberg, Lynn Millheiser (COO), Kimber Ward (VP Marketing), and Genevieve Bucsek (Controller), or facts regarding such matter which reasonably should have been known by such persons after making a diligent inquiry with respect to such matter;

 

Laws” means all statutes, laws, codes, ordinances, regulations, rules, orders, judgments, writs, injunctions, acts or decrees of any Government entity;

 

 
 

 

Liability” means any liability or obligation of whatever kind or nature (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), including without limitation any liability for Taxes;

 

Lien” shall mean any mortgage, pledge, security interest, encumbrance, lien (statutory or other) or conditional sale agreement, and including claims on title and liens in favor of contractors, carriers, warehousemen, mechanics, materialmen, and subcontractors and statutory or common law liens to secure claims for labor, materials or supplies, and other similar liens and encumbrances;

 

Material Adverse Effect” shall mean, when used in connection with an entity means any change, event, circumstance, condition or effect that is or is reasonably likely to be, individually or in the aggregate, materially adverse to: (i) the condition (financial or otherwise), capitalization, properties, prospects, products, assets (including intangible assets), Intellectual Property, liabilities, business, operations or results of operations of such entity and its subsidiaries, taken as a whole, or (ii) such entity’s ability to consummate the Stock Purchase or to perform its obligations under this Agreement;

Material Adverse Event” means any untoward or negative occurrence (including, without limitation, physical injury) related to the Business or the use of the Products that would result in a Material Adverse Effect;

 

Person” shall mean and include any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, and any other unincorporated organization or Government;

 

Regulations” means the Treasury Regulations (including Temporary Regulations) promulgated by the United States Department of Treasury with respect to the Code;

 

Taxes” shall mean (i) all federal, state, local or foreign taxes, including, but not limited to, income, gross income, gross receipts, capital, production, excise, employment, sales, use, transfer, transfer gain, ad valorem, premium, profits, license, capital stock, franchise, severance, stamp, withholding, Social Security, employment, unemployment, disability, worker’s compensation, payroll, utility, windfall profit, custom duties, personal property, real property, environmental, registration, alternative or add-on minimum, estimated and other taxes, governmental fees or like charges of any kind whatsoever, and (ii) any interest, penalties, fines, loss, damages, liability, expense or additions thereto whether disputed or not; and (iii) any transference liability in respect of any items described in clauses (i) or (ii) payable by reason of contract assumption, transference liability, operation of law, or otherwise;

 

Tax Return” means any return, declaration, report, claim for refund, information return or statement relating to any taxes, including any schedule or attachment thereto and including any amendment therof;

 

Transaction Documents” shall mean this Agreement, the Share certificates, and the other exhibits and schedules hereto and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in connection with the transactions contemplated to be consummated pursuant to any of the foregoing.

 

2. Stock Purchase.

 

(a) Purchase and Sale of the Company’s Capital Stock. Upon the terms and subject to the conditions herein set forth, Sellers agree to sell, convey, transfer, assign and deliver to Buyer, and Buyer agrees to purchase and accept from Sellers, at the Closing, all of the issued and outstanding capital stock of the Company (the “Shares”).

 

(b) Consideration.

 

(i) Upon the terms and subject to the conditions set forth in this Agreement, in reliance on the representations, warranties, covenants and agreements of Sellers contained herein, the consideration payable to Sellers for the Stock Purchase shall be the right to receive the corpus of the Trust pursuant to the governing documents of the Trust.

 

(ii) In consideration of the Stock Purchase, Buyer shall:

 

 
 

 

  1. Issue and deliver to the Trust for the benefit of the Sellers Six Million (6,000,000) shares of the common stock of Buyer, with a deemed value of $0.85 per share (the “Equity Consideration”); and
     
  2. Following the first Five Million Dollars ($5,000,000) in gross sales of the Products by Buyer or its Affiliates (including the Company), on a quarterly basis for a period of seven (7) years from the date of this Agreement, pay a royalty to the Trust for the benefit of the Sellers equal to five percent (5%) of gross sales of the Products by Buyer or its Affiliates (including the Company) (the “Royalty Consideration” and together with the Equity Consideration, the “Purchase Consideration”). For purposes of clarity, the $5 million gross sales threshold before Royalty Consideration becomes due and payable shall only apply once during the seven year period when Royalty Consideration is or may become due and payable by Buyer.

 

(c) Closing. The Closing will take place contemporaneously with the execution of this Agreement at the offices of Smith, Gambrell & Russell, LLP, 1230 Peachtree Street, N.E., Suite 3100, Atlanta, Georgia 30309. The Parties agree that the Closing may occur electronically through the delivery of facsimile or electronic copies of any and all other ancillary documents or documents required to be delivered under the terms of this Agreement, unless specifically set forth herein.

 

(d) Closing Deliverables. At the Closing:

 

(i) Each Seller will deliver to Buyer either (i) the certificates representing all of the Shares owned by such Seller, duly endorsed in blank or with appropriate stock powers with respect thereto duly endorsed in blank, or (ii) if such certificates are not available at Closing, stock powers for such unavailable certificates, duly endorsed in blank. All certificates will be delivered to Buyer no later than ten (10) days following the Closing. If any certificates cannot be located, such Seller will deliver to the Buyer, no later than ten (10) days following the Closing, an affidavit of such Seller reasonably satisfactory to Buyer stating that the certificates representing all of the Shares owned by such Seller have been lost, stolen or otherwise cannot be located.

 

(ii) The Company will deliver to Buyer evidence that the officers and directors of the Company in office immediately prior to the Closing have resigned as officers and directors of the Company effective as of the Closing, unless otherwise requested by Buyer; excluding Jordan Eisenberg, who shall have entered into an employment agreement with the Company.

 

(iii) The Company will deliver to Buyer evidence that the Shares can be transferred from the Sellers to Buyer free from any rights of first refusal, registration rights, rights of co-sale or other restrictions or conditions relating to transfer of the Shares.

 

(iv) The Company will deliver to Buyer evidence that all options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of its capital stock have been terminated.

 

(v) The Company will deliver to Buyer a Release Agreement in the form of Exhibit B duly executed by each Company Equityholder who is not also a Seller.

 

(vi) The Company will deliver to Buyer a certificate executed by the authorized person of the Company certifying as to the truthfulness, completeness and accuracy of attached copies of resolutions of the directors and shareholders of the Company authorizing this Agreement and the transactions contemplated hereby; and such other documents relating to the transactions contemplated by the Transaction Documents to be consummated at the Closing as counsel to Buyer shall reasonably request in order to complete the Stock Purchase by Buyer.

 

(vii) The Company will deliver to Buyer a certificate of the State of Delaware dated reasonably close to the Closing Date, as to the legal existence and good standing of Company in Delaware.

 

 
 

 

(viii) The Trust will deliver to Buyer its duly executed governing instrument(s).

 

(ix) The Trust will deliver to Buyer a certificate executed by its trustee, certifying the satisfaction by the Company of the conditions specified in Section 5 and certifying as to the truthfulness, completeness and accuracy of attached copies the Trust Documents (as defined below) authorizing this Agreement and the transactions contemplated hereby; and such other documents relating to the transactions contemplated by the Transaction Documents to be consummated at the Closing as counsel to Buyer shall reasonably request in order to complete the Stock Purchase by Buyer.

 

(x) Buyer shall issue and deliver to the Trust for the benefit of the Sellers the Equity Consideration.

 

3. Representations And Warranties Of Sellers. As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, each Seller severally represents and warrants to the Buyer that the statements contained in this Section 3 are true and correct as of the date hereof, with respect to itself, except as set forth in the Disclosure Schedules.

 

(a) Authority of Sellers. Each Seller has all requisite power and authority to enter into the Transaction Documents to which such Seller is a party and to carry out such Seller’s obligations thereunder. The execution and delivery of the Transaction Documents and the performance of each Seller’s obligations thereunder have been duly authorized by all necessary corporate, shareholder, partnership or member action of such Seller (if such Seller is a corporation or an entity with shareholders, partners or members), and no other proceedings on the part or in respect of such Seller is necessary to authorize such execution, delivery and performance. The Transaction Documents to which a Seller is identified as a party thereto have been duly executed by or on behalf of such Seller and assuming due authorization, execution and delivery by the other parties thereto, constitute such Seller’s valid and binding obligations, enforceable against such Seller in accordance with their respective terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

(b) No Conflicts; Consents. The execution, delivery and performance by Seller of the Transaction Documents to which such Seller is a party does not and will not: (a) result in a violation or breach of any provision of the governing documents of Seller, if applicable; (b) result in a violation or breach of any provision of any Law or Governmental order, judgment or decree applicable to Seller; or (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default under, or result in the acceleration of any agreement to which Seller is a party. No consent, waiver, approval, order, or authorization of, or registration, declaration, or filing with, any court, administrative agency, or commission or other governmental authority or instrumentality (“Governmental Entity”), or any other Person, is required by or with respect to Seller in connection with the execution and delivery of the Transaction Documents to which Seller is a party or the consummation of the transactions contemplated hereby.

 

(c) Title to Shares. Seller is the legal owner of the number and class of the Shares listed on Exhibit A hereto with respect to such Seller, free and clear of all Encumbrances.

 

(d) Legal Proceedings. There are no actions, suits, claims, investigations or other legal proceedings pending or, to Seller’s knowledge, threatened against or by Seller that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.

 

(e) Brokers. Except for Creo Capital Advisors LLC, who was hired by the Company, no broker, finder, or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

4. Representations and Warranties of the Company. As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, the Company represents and warrants to the Buyer that the statements contained in this Section 4 are true and correct as of the date hereof, except as set forth in the Disclosure Schedules.

 

 
 

 

(a) Corporate Organization. The Company is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The organizational documents which have been furnished to Buyer reflect all amendments made thereto at any time prior to the date of this Agreement and are correct and complete. The minute books and other books and records of the Company, to the extent such minutes exist, have been furnished to Buyer. The Trust is a statutory trust duly organized, validly existing and in good standing under the laws of its jurisdiction of formation.

 

(b) Qualification to Do Business. The Company has full corporate power and authority to carry on its business as now being conducted and is entitled to own, lease, or operate the properties and assets now owned, leased, or operated by it. The Company is qualified to do business, is in good standing, and has all required and appropriate licenses in each jurisdiction except jurisdictions in which failure to obtain or maintain such qualification, good standing, or licensing would not, individually or in the aggregate, have a Material Adverse Effect. The Company is duly qualified to conduct the Business as presently conducted by the Company as a foreign corporation in the jurisdictions listed in the Disclosure Schedule. No consent, waiver, approval, order, or authorization of, or registration, declaration, or filing with, any Governmental Entity or any other Person, is required to be made or obtained by the Company in connection with the execution and delivery of this Agreement by the Company, or the consummation by the Company of the transactions contemplated hereby, except for such consents, authorizations, filings, approvals and registrations that, if not obtained or made, would not have a Material Adverse Effect on the Company.

 

(c) Authorization and Validity of Agreement. The Company has all requisite power and authority to enter into the Transaction Documents to which it is a party and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of the Company’s obligations thereunder have been duly authorized by all necessary corporate action of the Company, and no other proceedings on the part or in respect of the Company is necessary to authorize such execution, delivery and performance. The Transaction Documents to which the Company is a party have been duly executed by or on behalf of the Company and assuming due authorization, execution and delivery by the other parties thereto constitute the valid and binding obligations of, and enforceable in accordance with their respective terms against, the Company, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

(d) No Conflict or Violation. Subject to obtaining any consents and approvals identified in the Disclosure Schedules, the execution, delivery and performance by the Company of the Transaction Documents to which it is a party does not and will not (i)(A) conflict with or result in a breach of the terms, conditions, or provisions of, (B) constitute a default under (whether with or without the passage of time, the giving of notice or both), (C) give any third party the right to modify, terminate or accelerate any obligation under, (D) result in a violation of, or (E) require any consent, exemption or other action by or notice or declaration to, or filing with, any third party of any Government Entity pursuant to (1) any organizational documents of Company; (2) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; or (3) any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Company is a party or by which Company is bound or to which any of Company’s properties or assets is subject; (ii) result in the creation of any Lien or Tax upon the equity or assets of Company; or (iii) otherwise interfere in any material manner with the Business. All of the Contracts and Permits of Company will continue without penalty, adjustment, breach of any such Contract or Permit, or the right of the customer or any Governmental Entity to terminate or modify any such Contract or Permit as a result of the Stock Purchase.

 

(e) Capitalization. The authorized capital stock of the Company, the issued and outstanding shares of capital stock of the Company, and the par value per share of all of the authorized capital stock of the Company, are set forth in the Disclosure Schedule. All of the Shares are duly authorized, validly issued, fully paid and nonassessable. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of its capital stock. Except as set forth in the Disclosure Schedule, there is no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Company. Except as described in the Disclosure Schedule, there are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the capital stock of the Company. Following the Closing, Buyer may freely terminate any voting trusts, proxies, or other agreements or understandings with respect to the voting of the capital stock of the Company. All actions have been properly authorized such that the Shares can be transferred to Buyer free from any rights of first refusal, registration rights, rights of co-sale or other restrictions or conditions relating to transfer of the Shares. All holders of Company capital stock are able to receive the Equity Consideration by virtue of an exemption to the Securities Act of 1933, as amended (the “1933 Act”).

 

 
 

 

(f) Assets. The Company has good and marketable title to, or a valid leasehold interest in, all of its assets and properties, free and clear of all Encumbrances, except those identified in the Disclosure Schedule, and except for liens for Taxes not yet due and payable, and mechanics’ liens, materialmen’s liens, and other liens arising by operation of law, which liens do not in any case materially and adversely affect the Company’s title to its assets, the Company’s use of its assets or the value of such assets. Except as set forth on the Disclosure Schedule, the obligations giving rise to the Encumbrances identified in the Disclosure Schedule may be prepaid at any time by the Company without penalty, premium or other special charge Except as disclosed in the Disclosure Schedule, to the Company’s Knowledge, the Company’s assets which are tangible personal property are in reasonably good and serviceable condition, normal wear and tear excepted, have been maintained in accordance with normal industry practice, and are suitable for the purposes for which they are presently used. The Company owns or leases all equipment or other tangible assets that are necessary for the conduct of the Business as presently conducted. No assets are used in the Business that are not owned or leased or licensed by the Company and not included in the Assets. The Company operates no business other than the Business and related activities.

 

(g) Subsidiaries. The Company does not own, directly or indirectly, any stock or other interests in any other entity.

 

(h) Financial Statements. Set forth in the Disclosure Schedules and provided to the Buyer are the Company’s most recent unaudited balance sheet, and unaudited income statement, as of October 31, 2015 (the “Financial Statements”). The Financial Statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), are complete and fairly represent in all material respects all of the assets, liabilities, transactions, and results of operations of the Business and the Company as of the dates thereof; subject, however, to normal year-end adjustments consistent with past practice, and further subject to the absence of footnotes, statements of cash flow, and changes in equity. The Company shall have a minimum cash balance of One Million Five Hundred Seventy-Five Thousand Dollars ($1,575,000) at Closing after payment of, or reservation on the Financial Statements for, all debts, fees, liabilities, payables, Taxes, claims, costs and expenses of or against the Company including, without limitation, all costs, expenses, payables, debts and liabilities arising out of the operations of the Company incurred or arising prior to the Closing.

 

(i) Absence of Certain Changes or Events. Except as otherwise provided in the Disclosure Schedule, since October 31, 2015, the Company has conducted the Business only in the ordinary course consistent with past practices. Without limiting the generality of the foregoing, since October 31, 2015, except as disclosed pursuant to the Disclosure Schedule:

(i) there has been no increase in the compensation or benefits paid or payable by the Company, other than in the ordinary course of business and consistent with past practices, to any of its officers, directors, employees, agents, consultants or shareholders, including any grant of severance or termination pay to any director, officer or employee of the Company, or any deferred compensation or similar agreement (or any amendment to any such existing agreement) with any director, officer or employee of the Company;

 

(ii) there has been no declaration, setting aside, or payment of dividends or distributions in respect of the capital stock of the Company, any split up or other recapitalization in respect of the capital stock of the Company or any direct or indirect redemption, purchase by the Company, or other acquisition by the Company of any such capital stock, except dividends declared and paid, or distributions made, prior to the Closing Date to Seller in the ordinary course of business consistent with the past practices of the Company;

 

(iii) the Company has not waived or compromised any right of material value or any payment, direct or indirect, of any material debt, liability, or other obligation;

 

(iv) there has been no Material Adverse Effect on the Company;

 

 
 

 

(v) there has been no issuance, transfer, sale, or pledge by the Company of any shares of its capital stock or other securities or any commitment, option, right, or privilege under which the Company is or may become obligated to issue any shares of its capital stock or other securities; there has been no indebtedness for borrowed money incurred by the Company except such as may have been incurred or entered into in the ordinary course of business; no loan has been made or agreed to be made by the Company, nor has the Company become liable or agreed to become liable as a guarantor with respect to any loan or other indebtedness of the Company or Seller, or any third party;

 

(vi) the Company has not waived or compromised any right of material value or any payment, direct or indirect, of any material debt, liability, or other obligation;

 

(vii) there has been no sale, assignment, or transfer of, or royalty arrangement with respect to the Company’s trade names, trademarks, service marks, domain names, web addresses, copyrights (or any interest therein), patent, or logos of material value, or any patent, trademark, service mark, domain name or web address or copyright applications (or any interest therein) used (or that were, or are intended to be used) in the operations of the Business;

 

(viii) there has been no sale, lease or disposition of, any material property or asset, tangible or intangible, of the Company;

 

(ix) there has been no actual or, to the Company’s Knowledge, threatened termination or loss of any (A) material contract, lease, license, permit or other agreement to which the Company was or is a party other than terminations of contracts upon completion of work; (ii) certificate, license, or other authorization required for the continued operation by the Company of any material portion of the Business; or (B) customer or other revenue source, which termination or loss could reasonably be expected to result in loss or revenues to the Company in excess of Twenty-five Thousand Dollars ($25,000.00) per year, and there is no event known to the Company (including, without limitation, the transactions contemplated hereby) that could reasonably be expected to result in any such termination or loss;

 

(x) there has been no resignation or termination of employment of any key officer or employee of the Company or, to any Company’s Knowledge, any impending resignation or termination of employment of any such officer or employee;

 

(xi) there has been no agreement or commitment by the Company or Seller to do any of the things described in this Section 4(i).

 

(j) Tax Matters.

 

(i) The Company has timely filed all material Tax Returns that it was required to file. All such Tax Returns as so filed are materially accurate, and, to the Company’s Knowledge, disclose all Taxes required to be paid for the periods covered thereby. All material Taxes due and owing by the Company (whether or not shown on any Tax Return) have been paid. The Company is not currently the beneficiary of any extension of time within which to file any Tax Return. There are no Liens for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Company. The Company has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party, and all Tax Returns and forms required with respect thereto have been properly completed and timely filed.

 

(ii) There is no material dispute or claim concerning any Tax liability of the Company either (A) claimed or raised by any authority in writing or (B) to the Knowledge of Company.

 

(iii) The Disclosure Schedule identifies all federal, state, local and foreign income Tax returns filed with respect to the Company for taxable periods ended on or after December 31, 2011, indicates those Tax Returns that have been audited, and indicates those Tax Returns that currently are the subject of audit. The Company has delivered to Buyer correct and complete copies of all federal income Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Company since December 31, 2011. The Company has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

 

 
 

 

(iv) The Company has not made any material payments, is not obligated to make any material payments, and is not a party to any agreement that under certain circumstances (including without limitation the performance of the transactions contemplated by this Agreement) could obligate it to make any material payments that will not be deductible under Code section 280G. The Company is not a party to any Tax allocation or sharing agreement. The Company (A) has not been a member of an affiliated group (within the meaning of Code section 1504(a)) filing a consolidated federal income Tax Return (other than a group the common parent of which was the Company) and (B) does not have any liability for the Taxes of any Person under Regulations section 1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, by contract, or otherwise.

 

(v) The unpaid Taxes of the Company (A) did not, as of the most recent fiscal month end, exceed the reserve for Tax liability (rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of the most recent Financial Statements (rather than in any notes thereto) and (B) will not exceed that reserve as adjusted for operations and transactions through the Closing Date in accordance with the past custom and practice of the Company in filing its Tax Returns.

 

(vi) The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Code section 355 or Code section 361.

 

(vii) At all times since its formation, the Company has been classified as a corporation for federal, state, local and foreign income Tax purposes.

 

(viii) The Company is not a “foreign person” as that term is used in Regulations section 1.1445-2.

 

(k) Absence of Undisclosed Liabilities; Indebtedness. Except as identified pursuant to the Disclosure Schedule, or reflected on the Financial Statements, or incurred in the ordinary course of business, the Company has no indebtedness or liability, absolute or contingent, involving, affecting or relating to the Business or the Products.

 

(l) Intellectual Property.

 

(i) “IP Assets” shall mean all of the following materials owned or licensed by the Company with respect to the Business: (A) the proprietary formulas for the Products; (B) the domain names listed on Schedule 4(l) (collectively, the “Domain Names”); (C) all the content on and accessible through the websites associated with the Domain Names, including demos (collectively, the “Website Content”); and (D) the entire Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Business marketing materials (whether in draft or final form) (collectively, the “Marketing Materials”).

 

(ii) Schedule 4(l) lists all patented, registered, applied-for, and other Intellectual Property used in the Business and all Intellectual Property of the Company licensed to any third Person (collectively, the “Business Intellectual Property”), including the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by the Company from a third party is “Licensed Intellectual Property”.

 

(iii) The Company owns all right, title and interest in and to or has a valid and enforceable license to use, all IP Assets, Business Intellectual Property, and the Licensed Intellectual Property, free and clear of all Liens, and all patented or registered Business Intellectual Property is valid and enforceable. To the Company’s Knowledge, it has taken commercially reasonable steps to maintain the confidentiality of all information that constitutes a trade secret of the Business.

 

 
 

 

(iv) Except as set forth on Schedule 4(l), (A) the conduct of the Business, including the delivery and distribution of the Products, has not infringed and does not infringe on any Intellectual Property or any other proprietary rights of any Person, including but not limited to the rights of privacy or publicity; (B) to the Knowledge of the Company, no Person is infringing, violating or misappropriating any Business Intellectual Property; (C) the Company has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to result in the invalidation or unenforceability of any registered Business Intellectual Property; (D) the Company is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (E) the Company has not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of Intellectual Property or the Products; (F) the Company has not entered into any Contract that includes a forbearance to sue or settlement Contract with respect to any Intellectual Property and (G) the Company has not received any written notice of any claim within the prior three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of, the Company’s ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Products. The Company has secured, and has in place a policy to secure, valid written confidentiality Contracts and assignments of Intellectual Property from all consultants, contractors, Employees and customers who contribute or have contributed to the creation, conception, reduction to practice or other development of any Intellectual Property developed on behalf of Company.

 

(v) No Product provided or distributed by the Company in its conduct of the Business: (A) violates any material Law; (B) includes any information or material that, to the Knowledge of the Company, is defamatory; or (C) infringes any right of privacy of any Person. Each Person whose name, image, voice or likeness is incorporated into any Marketing Materials has executed a written release consenting to the Company’s use of such Person’s name, image, voice and/or likeness (as applicable) and releasing the Company from any claims with respect thereto (a “Release”), each of such Releases are fully assignable to Buyer without further consent of any Person.

 

(vi) The Company has operated the Business and provided all Products in compliance with any posted privacy policies and all applicable Laws relating to privacy, data protection, anti-spam, telemarketing, personally identifiable information and similar consumer protection Laws (“Information Privacy Laws”). The Company has not received written notice of any claims or been charged with violation of any Information Privacy Law. To the Knowledge of Company, the Company is not under investigation with respect to any violation of any Information Privacy Laws.

 

(m) Compliance with Law. Except as identified in the Disclosure Schedule, the manufacture and sale of the Products and the operation of the Business has been conducted in material compliance with all applicable material Laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Company and its assets, properties and operations. Except as set forth in the Disclosure Schedule, the Company has not received notice of any violation (or possible violation) of any such Law or other legal requirement, and the Company is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or Governmental Entity or regulatory authority, applicable to the Company, the Business, the Products or the Shares. Without limiting the foregoing, the Company has not received any warning letter or untitled letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the FDA or any other similar Governmental entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any Laws. The Company holds all Permits required for the conduct of the Business and the ownership of its properties except where the absence thereof would not result in a Material Adverse Effect. No written notices have been received by the Company alleging the failure to hold any Permit. The Company is in material compliance with all terms and conditions of all such Permits. All of such Permits shall be available for use by Buyer immediately after the Closing. Without limiting the foregoing, the Company has not received any warning letter or untitled letter, report of inspectional observations, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from any Governmental Entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any Laws. No “bulk sales” or similar Law applies to the transactions contemplated by this Agreement.

 

(n) Litigation. Except as set forth on Schedule 4(n), there are no claims, Actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of Company, threatened before any federal, state, provincial, court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Company or any of its officers, directors, employees, agents or Affiliates, or the Sellers, involving, affecting or relating to the Company, the Business, the Products, the Shares, or the transactions contemplated by the Transaction Documents.

 

 
 

 

(o) Brokers. Except for Creo Capital Advisors LLC, who was hired by the Company, no broker, finder, or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company.

 

(p) Insurance. The Company is currently insured by insurers unaffiliated with the Company with respect to its properties, assets and operation of the Business in such amounts and against such risks which to the Knowledge of Company are appropriate and customary for the type of business conducted by the Company with customary deductibles and retained amounts. In addition, the Company has maintained comparable insurance for all prior periods. With respect to each insurance policy held by the Company (the “Insurance Policies”) (i) to the Knowledge of Company such Insurance Policy is legal, valid, binding and in full force and effect; (ii) the Company is not in default under such Insurance Policy; and (iii) the Company has delivered a true and correct copy of such Insurance Policy to Buyer. There are no claims by the Company pending under any such Insurance Policies and the Company has not been informed that coverage has been questioned, denied or disputed by the underwriters of such Insurance Policies with respect to any such claims.

 

(q) Employment Matters.

 

(i) The Disclosure Schedule identifies all of the Employees as of the date hereof, including for each such Employee: name, job title, FLSA classification, work location (identified by street address), current compensation paid or payable, all wage and fringe benefit arrangements. Except as set forth on the Disclosure Schedule, each Employee is employed by the Company at will and may be terminated by the Company without cause on thirty (30) days or less notice without penalty or severance. To the Knowledge of Company, no Employee is a party to, or is otherwise bound by, any Contract or arrangement, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Employee’s duties. Each current Employee has executed a nondisclosure and assignment-of-rights Contract for the benefit of the Company vesting all rights in work product created by the Employee, during the Employee’s employment or affiliation with the Company, in the Company. To the Knowledge of Company and except as set forth in the Disclosure Schedule, no Employee intends to terminate his or her employment with the Company. In accordance with its normal payroll policies the Company has paid all salaries, bonuses, commissions, wages, and severance that are owed to the Employees as of the Closing and maintained adequate reserves, as reflected in the Financial Statements, for all salaries, bonuses, commissions, wages, and severance not yet due and payable as of the Closing. The Company is in compliance, in all material respects, with all Laws governing the employment of labor.

 

(ii) Except as identified in the Disclosure Schedule, to the Knowledge of Company, each Employee is (i) a United States citizen, (ii) a lawful permanent resident of the United States, or (iii) an alien authorized to work in the United States either specifically for the Company or for any United States employer. The Company is in compliance in all material respects with applicable Law, has completed a Form I-9 (Employment Eligibility Verification) for each Employee and each such Form I-9 has since been updated as required by applicable Law and, to the Knowledge of the Company, is correct and complete as of the date hereof.

 

 
 

 

(iii) The Company is in compliance, in all material respects, with all Laws governing the employment of labor, including but not limited to, all such Laws relating to wages, hours, leaves of absence, affirmative action, collective bargaining, discrimination, civil rights, safety and health, workers’ compensation and the collection and payment of withholding and/or Social Security Taxes and similar Taxes, including, but not limited to, the Age Discrimination in Employment Act, as amended, Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Fair Labor Standards Act (29 U.S.C. 201, et seq.) (“FLSA”), the Americans with Disabilities Act, the Sarbanes-Oxley Act of 2002, the Worker Adjustment and Retraining Notification Act, as amended, the Occupational Safety and Health Act, as amended, the Family and Medical Leave Act (29 U.S.C. 2601, et seq.), as amended, the National Labor Relations Act of 1935, as amended, Executive Order 11246 and any other executive orders or regulations governing affirmative action, EEO and VETS-100 reporting obligations, the Immigration Nationality Act (8 U.S.C. 1324a, et seq.), as amended, and all similar applicable Laws (collectively the “Labor Laws”). The Company has, during the five (5) year period prior to the date hereof, conducted the Business in material compliance with all applicable Labor Laws. The Company has withheld all amounts required by Law or Contract to be withheld from the wages or salaries of its Employees and is not liable for the payment of any arrears of wages or other Taxes, penalties, fines or other compensation of any kind, however designated, for failure to comply with any of the foregoing. The Company has maintained adequate and suitable records regarding the service of each Employee including records of working time, where available. Each Employee of the Company has been properly classified as “exempt” or “non-exempt” under the FLSA and all other applicable Laws. The Company is not, and in the last three (3) years has not been, a government contractor.

 

(iv) The Company has not at any time during the last three (3) years had, nor to the Knowledge of Company is there now threatened, any walkout, strike, union activity, picketing, work stoppage, work slowdown, any effort to organize or any other similar occurrence or any attempt to organize or represent the labor force of the Company. There are no controversies pending or overtly threatened between the Company, on the one hand, and any of its Employees (or former Employees) or any labor union or other collective bargaining unit representing or purporting to represent any of its Employees, on the other hand. The Company is not a party to, bound by, or subject to any collective bargaining agreement or other Contract, written or oral, with any union representing or purporting to represent the Company’s Employees. No union or other collective bargaining unit or Employee organizing entity has been certified or recognized by Seller as representing any of its Employees.

 

(v) No investigation, review, complaint or proceeding by any Government entity or Employee or former Employee with respect to the Company in relation to any actual or alleged violation of any Labor Laws is pending or, to the Knowledge of Company, threatened, nor has the Company or Seller received any notice from any Government entity indicating an intention to conduct the same.

 

(vi) Within the past five (5) years, the Company has not implemented any mass layoff, plant closing, or other termination of employees that could implicate the Worker Adjustment and Retraining Notification Act (WARN Act) or any similar state or local Law.

 

(vii) The Company has identified in the Disclosure Schedule and provided to Buyer all employment, change in control, severance, retention, termination, non-competition, non-solicitation and other similar Contracts, arrangements or policies, whether written or oral, between Seller and any individual other than at-will employment arrangements but including all Contracts, arrangements or policies that affect at-will Employees. The Company is in material compliance with its obligations under all such Contracts.

 

(r) Contractor Matters. The Company has identified in the Disclosure Schedule the name and contact information of each independent contractor, consultant, freelancer or other service provider (i) utilized by the Company as of the date hereof or (ii) utilized by the Company relating to the development, modification or creation of any proprietary formulas for the Products within the three (3) years immediately preceding such date (collectively, “Contractors”). A copy of each Contract relating to the services any Contractor provides or provided to the Business has been made available to the Buyer. To the Knowledge of Company, no Contractor used by the Company is a party to, or is otherwise bound by, any Contract or arrangement with any third party, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Contractor’s duties for Seller. Each Contractor ever retained by the Company to create, modify or develop with respect to the proprietary formulas for the Products has executed a nondisclosure and assignment-of-rights Contract for the benefit of the Company and the Company is the owner of all rights in and to all Intellectual Property created by such Contractor in performing services for the Company vesting all rights in work product created in the Company. All individuals who have been treated by the Company as independent contractors in the five (5) years immediately preceding the date hereof were, to the Knowledge of Company, correctly classified as such for purposes of the Code and all other applicable Laws.

 

 
 

 

(s) Employee Benefits.

 

(i) The Disclosure Schedule lists all Employee Benefit Plans maintained or contributed to by the Company or under which the Company has or could have any obligations (other than obligations to make current wage or salary payments or sales commissions terminable on notice of thirty (30) days or less) or liabilities, actual or contingent, whether or not legally binding, in respect of any of the current or former officers, Employees or independent contractors of the Company who provided services in respect of the Business or their dependents or beneficiaries (individually referred to as a “Company Benefit Plan” and collectively referred to as the “Company Benefit Plans”). The Company has delivered or provided to Buyer true and complete copies of the plan documents, as they may have been amended through the date hereof, for each company Employee Benefit Plan, as well as, to the extent applicable, Forms 5500 and actuarial valuations for the last three plan years, plan documents, trust agreements, insurance Contracts, administrative services agreements, most recent determination letters and other documents required under ERISA.

 

(ii) Each Company Benefit Plan has been established, maintained and administered in accordance with its terms and in material compliance with all applicable provisions of (including rules and regulations thereunder) ERISA, the Code and other applicable Law, and neither the Company nor any “party in interest” or any “disqualified person” with respect to any Company Benefit Plan has engaged in a “prohibited transaction” within the meaning of Section 4975 of the Code or Section 406 of ERISA with respect to any Company Benefit Plan. Each Company Benefit Plan that is intended to be qualified within the meaning of Section 401(a) of the Code has received a favorable determination letter from the Internal Revenue Service (or, if such plan is a prototype or volume submitter plan document, such prototype or volume submitter plan document has received a favorable opinion from the IRS that the form meets the tax qualification requirements) to the effect that such Company Benefit Plan satisfies the requirements of Section 401(a) of the Code and that its related trust is exempt from taxation under Section 501(a) of the Code and there are no facts or circumstances that could reasonably be expected to cause the loss of such qualification or the imposition of Liability, penalty or Tax under ERISA, the Code or other applicable Laws (including the rules and regulations under any of them).

 

(iii) No Company Benefit Plan is, and neither the Company nor any of its ERISA Affiliates has ever sponsored an Employee Benefit Plan that is or was, subject to Title IV of ERISA. No Company Benefit Plan is, and neither the Company nor any of its ERISA Affiliates has ever contributed, or been obligated to contribute, to any “multiemployer plan” (within the meaning of Sections 3(37) or 4001(a)(3) of ERISA) under Subtitle E of ERISA.

 

(iv) The Disclosure Schedule identifies each Company Benefit Plan that is a “non-qualified deferred compensation plan”, within the meaning of Section 409A of the Code (each, a “Section 409A Plan”), and identifies each Section 409A Plan in connection with which the Company or it successors may have Liability with respect to Employees, Contractors or directors. No such plan has assets set aside directly or indirectly in the manner described in Section 409A(b)(1) of the Code or contains a provision that would be subject to Section 409A(b)(2) of the Code. Each Section 409A Plan (i) was, since the date of the inception of such Company Benefit Plan, (or since January 1, 2005, if later) administered in good faith compliance with the requirements of Section 409A of the Code and applicable guidance issued thereunder, (ii) has been, since the date of inception of such Company Benefit Plan (or since January 1, 2005, if later), administered in compliance, in all material respects, with the requirements of Section 409A of the Code and the final regulations issued and outstanding thereunder. In the event of an audit by the IRS of either the Company or any individual participating in such Company Benefit Plan, the additional Tax described in Section 409A(a)(1)(B) would not be assessed against any such participant with respect to benefits due or accruing under such Company Benefit Plan.

 

(v) Except as identified in the Disclosure Schedule, neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in combination with another event): (i) result in any payment becoming due, or increase the amount of any compensation due, to any Employee; (ii) increase any benefits otherwise payable under any Company Benefit Plan; or (iii) result in the acceleration of the time of payment or vesting of any such compensation or benefits.

 

(vi) The Company does not currently sponsor any Company Benefit Plan that is intended to be qualified within the meaning of Section 401(a) of the Code, including but not limited to any 401(k) plan. Company Employees are currently able to participate in a 401(k) plan sponsored by a professional employer organization (TriNet Group, Inc., or one of its affiliates), subject to the terms of such plan.

 

 
 

 

(t) Environmental and Safety Matters. The Company has complied in all material respects and is in material compliance with all Environmental Laws, including but not limited to all Permits required by Environmental Laws for the conduct of the business operations of the Company and the disposition of all hazardous materials in accordance with all applicable Environmental Laws. The Company has not received any outstanding and unresolved written or oral notices, reports or other information regarding any actual or alleged violation of Environmental Laws by the Company, or any Liabilities or potential Liabilities, including any remedial obligations, relating to any of them or their facilities arising under Environmental Laws. The Company is not a potentially responsible party under the federal Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, or any analogous state, local or foreign applicable Laws arising out of events occurring prior to the Closing Date. To the Knowledge of Company, no facts, events or conditions relating to the past or present facilities, properties or operations of the Company, or any geologically or hydrologically adjoining properties, shall prevent, hinder or limit the Company’s continued compliance with Environmental Laws, give rise to any remedial obligations of the Company pursuant to Environmental Laws, or give rise to any other Liabilities of the Company pursuant to Environmental Laws, including, without limitation, any relating to onsite or offsite releases or threatened releases of hazardous materials, personal injury, property damage or natural resources damage. To the Knowledge of Company, there have not been in the past and are not now any underground tanks or underground improvements, including treatment or storage tanks, sumps, or water, gas or oil wells; polychlorinated biphenyls; or asbestos or asbestos-containing materials at, on or under any of the Leased Real Property. The Company has delivered to Buyer true and complete copies and results of any reports, studies, analyses, tests, or monitoring possessed or initiated by the Company pertaining to hazardous materials in, on, under, or migrating to or from any of the Leased Real Property, or concerning compliance by the Company, or any other Person for whose conduct the Company is or may be held responsible, under Environmental Law.

 

(u) Real Property. The Disclosure Schedule identifies the address of each leased real property of the Company (the “Leased Real Property”). Seller has provided to Buyer a true and complete copy of all leases and subleases (including all amendments, extensions, renewals, Guarantees and other Contracts with respect thereto) for each such Leased Real Property (the “Leases”), and in the case of any oral Lease, a written summary of the material terms of such Lease. With respect to each of the Leases except as disclosed pursuant to the Disclosure Schedule: (i) to the Knowledge of Company, such Lease is legal, valid, binding, enforceable and in full force and effect; (ii) the transactions set forth in this Agreement do not require the consent of any other Person to such Lease, or such consent has been obtained, shall not result in a breach of or default under such Lease, or otherwise cause such Lease to cease to be legal, valid, binding, enforceable and in full force and effect on identical terms following the Closing; (iii) Seller’s possession and quiet enjoyment of the Leased Real Property under such Lease has not been disturbed, and there are no disputes with respect to such Lease; (iv) the Company, and any other party to the Lease, is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, the passage of time or both, would constitute such a breach or default, or permit the termination, modification or acceleration of rent under such Lease; (v) no security deposit or portion thereof deposited with respect to such Lease has been applied in respect of a breach or default under such Lease which has not been redeposited in full; (vi) the Company does not owe, or shall owe in the future, any brokerage commissions or finder’s fees with respect to such Lease; (vii) the other party to such Lease is not an Affiliate of, and otherwise does not have any economic interest in, the Company; (viii) the Company has not subleased, licensed or otherwise granted any Person the right to use or occupy such Leased Real Property or any portion thereof; (ix) the Company has not collaterally assigned or granted any other security interest in such Lease or any interest therein; (x) there are no Liens on the estate or interest created by such Lease; and (xi) to the Knowledge of Company, all buildings, structures, improvements, fixtures, building systems and equipment, and all components thereof, included in the applicable Leased Real Property are in good condition and repair (reasonable wear and tear excepted). The Company does not own any real property, nor has it ever owned any real property.

 

(v) Affiliate Transactions. Except as identified in the Disclosure Schedule, to the Knowledge of Company, no shareholder, officer, director, member or Affiliate of a Seller or any individual related by blood, marriage or adoption to any such individual or any entity in which any such Person or individual owns any beneficial interest, is a party to any Contract or transaction with Seller or has any interest in any real, tangible or intangible asset or property used by Seller.

 

 
 

 

(w) Customer and Vendor Relations. The Disclosure Schedule identifies a correct and complete list of the names of the top ten (10) Customers and Vendors and the amount of net revenues to or purchases from each such Customer or Vendor during the each of the 2013 and 2014 fiscal years and the period ended as of September 30, 2015 (each a “Key Relationship”). The Company maintains commercially reasonable relations with each of its Key Relationships and no event has occurred that would reasonably be expected to affect materially and adversely the Company’s relations with any Key Relationship. Except as disclosed pursuant to the Disclosure Schedule, no Customer or Vendor has during the last twelve (12) months cancelled, terminated, materially decreased the rate of, materially altered the terms with respect to or, to the Knowledge of Company, made any threat to cancel or otherwise terminate any of its Contracts with the Company or to decrease its usage or supply of the Company’s services or products, excluding for avoidance of doubt, discrete projects performed by the Company for Customers, for which the Company’s services terminated solely by virtue of the Company’s having completed the project to the Customers’ satisfaction. To the Knowledge of Company, except as identified in the Disclosure Schedule no current Customer or Vendor may terminate or materially alter its business relations with the Company, either as a result of the transactions contemplated hereby or otherwise.

 

(x) Product and Service Warranties; Adverse Events. Except as set forth in the Disclosure Schedule, the Company has made no express warranty or Guarantee to any Customer (or end user of the Company’s goods) as to services or goods provided by the Company. There is no pending or, to the Knowledge of Company, threatened claim alleging any breach of any warranty or Guarantee. The Company does not have any Liability under any such a warranty or Guarantee that would reasonably be expected to result in Liability to the Company, individually or in the aggregate, in excess of $10,000. There have not been any Material Adverse Events with respect to the Products or the Business.

 

(y) Guaranties. The Company is not a guarantor or otherwise liable for any liability, indebtedness or other obligation of any other Person.

 

(z) Disclosure. No representation or warranty by the Company contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of the Company pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.

 

(aa) Inventory. All inventory of the Company, whether or not reflected in the Balance Sheet, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory is owned by the Company free and clear of all encumbrances, and no inventory is held on a consignment basis. The quantities of each item of inventory are not excessive, but are reasonable in the present circumstances of the Company.

 

(bb) Contracts; Agreements.

 

(i) Except as disclosed in the Disclosure Schedule, the Company is not a party to or bound by:

 

  1. any customer, license, sale, distribution, commission, marketing, agent, franchise, technical assistance or similar Contract relating to or providing for the marketing and/or sale of products or services to which the Company is a party or by which it is otherwise bound;
     
  2. any Contract involving the license of any patent, copyright, trade secret or other proprietary right constituting Intellectual Property to or from the Company;

 

 
 

 

  3. any Contract providing for the development of any software, content (including textual content and visual, photographic or graphics content), technology or intellectual property for (or for the benefit or use of) use by the Company, or providing for the purchase by or license to (or for the benefit or use of) it of any hardware, software, content (including textual content and visual, photographic or graphics content), technology or intellectual property, which hardware, integrated circuits, software, content, technology or intellectual property is in any manner used or incorporated (or is contemplated by it to be used or incorporated) in connection with any aspect or element of any product or service provided by or technology used by the Company;
     
  4. any agreement, contract or commitment relating to the acquisition or disposition of any business (whether by merger, sale of stock, sale of assets or otherwise);
     
  5. (A) any agreement relating to Indebtedness or (B) any mortgages, indentures, loans or credit agreements, security agreements or other agreements or instruments relating to indebtedness;
     
  6. any joint venture or partnership or other similar agreement;
     
  7. any agreement with any Affiliate of the Company, with any director or officer of the Company, or with any “associate” or any member of the “immediate family” (as such terms are respectively defined in Rules 12b-2 and 16a-1 of the 1934 Act) of any such director or officer, other than employment, invention assignment and equity-related agreements provided to Buyer;
     
  8. any employment or consulting agreement, contract or commitment with an employee or individual consultant or salesperson or consulting or sales agreement, contract or commitment with a firm or other organization not otherwise disclosed on the Disclosure Schedule or not cancellable on thirty (30) days notice or less without penalty;
     
  9. any agreement or plan, including, without limitation, any stock option plan, stock appreciation rights plan or stock purchase plan, any of the benefits of which will be increased, or the vesting of benefits of which will be accelerated, by the occurrence of any of the transactions contemplated by this Agreement or the value of any of the benefits of which will be calculated on the basis of any of the transactions contemplated by this Agreement not otherwise disclosed on the Disclosure Schedule;
     
  10. any other oral or written Contract or obligation that individually has a value in excess of $15,000 or is otherwise material to the Company or its businesses, operations, financial condition, properties or assets.

 

(ii) Each agreement, contract, plan, lease, arrangement or commitment required to be disclosed, and which would be required to be disclosed absent disclosure elsewhere, pursuant to Section 4(bb)(i) above (each, a “Material Contract”) is a valid and binding agreement the Company and is in full force and effect with respect to the Company and, to the Knowledge of Company, each other party thereto, and neither the Company, nor to the Knowledge of Company, any other party thereto, is in default or breach in any material respect under the terms of any such Material Contract, and, to the Knowledge of Company, no event or circumstance has occurred that, with notice or lapse of time or both, would reasonably be expected to constitute any event of default thereunder. True and complete copies of each such Material Contract have been provided to Buyer. The Company has fulfilled all material obligations required pursuant to each Material Contract to have been performed by the Company prior to the date hereof.

 

(iii) Except in the ordinary course of business, no Person is renegotiating or seeking to renegotiate, or, to the Knowledge of Company, has a right (absent any default or breach of a Material Contract) pursuant to the terms of any Material Contract to renegotiate, any material amount paid or payable to the Company under any Material Contract or any other material term or provision of any Material Contract. The Company has not received any written indication or, to the Knowledge of the Company, verbal indication of an intention to terminate or renegotiate the terms of any of the Material Contracts by any of the parties to any of the Material Contracts.

 

(cc) Trust. No representation or warranty by the Trust contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of the Trust pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.

 

 
 

 

5. Representations And Warranties of the Trust. As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, the Trust hereby represents and warrants to the Buyer that the statements contained in this Section 5 are true and correct as of the date hereof.

 

(a) Organization. The Trust is a statutory trust duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The Trust has provided to the Buyer duly executed copies of its organizational and governing documents (collectively, the “Trust Documents”).

 

(b) Authorization and Validity of Agreement. The Trust has full power and authority to carry out its purpose as now being conducted or contemplated and is entitled to own, lease, or operate the assets it will own in accordance with this Agreement. No consent, waiver, approval, order, or authorization of, or registration, declaration, or filing with, any Governmental Entity or other Person is required to be made or obtained by the Trust in connection with the execution and delivery of this Agreement by the Trust, or the consummation by the Trust of the transactions contemplated hereby, except for such consents, authorizations, filings, approvals and registrations that, if not obtained or made, would not have a Material Adverse Effect on the Trust. The Trust has all requisite power and authority to enter into the Transaction Documents to which it is a party and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of the Trust’s obligations thereunder have been duly authorized by all necessary trustee action of the Trust, and no other proceedings on the part or in respect of the Trust is necessary to authorize such execution, delivery and performance. The Transaction Documents to which the Trust is a party have been duly executed by or on behalf of the Trust and assuming due authorization, execution and delivery by the other parties thereto constitute the valid and binding obligations of, and enforceable in accordance with their respective terms against, the Trust, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

(c) No Conflict or Violation. The execution, delivery and performance by the Trust of the Transaction Documents to which it is a party does not and will not (i)(A) conflict with or result in a breach of the terms, conditions, or provisions of, (B) constitute a default under (whether with or without the passage of time, the giving of notice or both), (C) give any third party the right to modify, terminate or accelerate any obligation under, (D) result in a violation of, or (E) require any consent, exemption or other action by or notice or declaration to, or filing with, any third Person or any Government Entity pursuant to (1) any organizational documents of the Trust; (2) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; or (3) any Contract, security agreement, trust indenture or other agreement or instrument to which the Trust is a party or by which the Trust is bound or to which any of the Trust’s properties or assets is subject; (ii) result in the creation of any Lien or Tax upon the equity or assets of Trust; or (iii) otherwise interfere in any material manner with the Business.

 

(d) Governing Documents. The Trust Documents provide that the Equity Consideration will be held by the Trust and not distributed to the Sellers for a period of three (3) years from the Closing. The allocation scheme in the Trust documents for disbursement and distribution of the Purchase Consideration is identical in all respects to the current Certificate of Incorporation of the Company, as amended, such that all Sellers will receive the identical portion of the Purchase Consideration as would have been received had he Buyer paid the Purchase Consideration directly to the Sellers, after adjust for any expenses of the Trust and indemnification claims by Buyer.

 

(e) Assets. The assets held by the Trust, until such time as no further Royalty Consideration is due, will consist solely of the Purchase Consideration and remain free and clear of all Encumbrances.

 

(f) Legal Proceedings. There are no actions, suits, claims, investigations or other legal proceedings pending or, to the Trust’s knowledge, threatened against or by the Trust that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.

 

 
 

 

(g) Status of Trust and Its Beneficiaries. (i) The Trust and its beneficiaries have had an opportunity to discuss the business, management and financial affairs of Buyer, have had access to, the management of Buyer, and have had the opportunity to review the information set forth in Buyer’s public filings and any other information requested by the Trust or any beneficiary, (ii) Buyer will be relying upon the Trust’s representations and warranties set forth herein in offering the Equity Consideration to it in its own right and for the benefit of Sellers, and (iii) the Trust and its beneficiaries recognize that ownership of the Equity Consideration involves substantial risks, including a risk of total loss of the value of the Equity Consideration, and have taken full cognizance of and understand all of the risk factors related to the ownership of the Equity Consideration; (iv) the Trust and its beneficiaries have an adequate net worth and means of providing for its current needs and possible contingencies to sustain a complete loss in the Equity Consideration; and (v) the Trust and its beneficiaries are able to receive the Equity Consideration by virtue of an exemption to the 1933 Act.

 

(h) Acquisition for Sellers’ Account. This Agreement is made with the Trust in reliance upon the Trust’s representations to Buyer, that the Equity Consideration to be issued to and held by the Trust for the benefit of the Sellers (in accordance with the terms of the Trust), was acquired for investment, and not with a view to the sale or distribution of any part thereof other than as permitted under the 1933 Act and that the Trust has no present intention of selling, granting participation in, or otherwise distributing the same other than what is permitted under the 1933 Act. Except as set forth in the Trust Documents, the Trust does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Equity Consideration.

 

(i) No Intention to Distribute. The Trust and its beneficiaries understand that the Equity Consideration shares have not been registered under the 1933 Act on the grounds that the sale provided for in this Agreement and the issuance of the Equity Consideration is exempt from registration under the 1933 Act, and that Buyer’s reliance on such exemption is predicated in part on the representations set forth herein. The Trust and its beneficiaries realize that the basis for the exemption may not be present if, notwithstanding such representations, the Trust and its beneficiaries have in mind merely acquiring the Equity Consideration for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. The Trust and its beneficiaries do not have any such intention.

 

(j) No Registration. The Trust and its beneficiaries understand that the Equity Consideration may not be sold, transferred or otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the shares or an available exemption from registration under the 1933 Act, the Equity Consideration must be held indefinitely. In particular, the Trust and its beneficiaries are aware that the shares may not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about Buyer. The Trust represents that, in the absence of an effective registration statement covering the Equity Consideration shares, it will not sell, transfer, or otherwise dispose of such shares except in a manner consistent with its representations set forth herein.

 

(k) Brokers. Except for Creo Capital Advisors LLC, who was hired by the Company, no broker, finder, or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

 

(l) Disclosure. No representation or warranty by the Trust contained in this Agreement, and no statement contained in the Disclosure Schedules or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of the Trust pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.

 

6. Representations And Warranties of the Buyer. As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, Buyer hereby represents and warrants to Sellers and Trust as follows:

 

(a) Corporate Organization. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its businesses as now conducted. Buyer is duly qualified to do business as a foreign company, and is in good standing in each jurisdiction where the character of its properties owned, operated or leased or the nature of its activities makes such qualification necessary. Buyer’s capitalization is sufficient to satisfy is obligation to issue the Equity Consideration.

 

 
 

 

(b) Authorization and Validity of Agreement. Buyer has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Buyer’s obligations thereunder have been duly authorized by all necessary company action by Buyer, and no other proceedings on the part of Buyer are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed by Buyer and, assuming due authorization, execution and delivery by the other parties thereto, constitutes its valid and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

(c) No Conflict or Violation. The execution, delivery and performance by Buyer of the Transaction Documents (i) does not and will not violate or conflict with any provision of the organizational documents of Buyer; (ii) does not and will not violate any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any acceleration of remedies or any right of termination under, any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Buyer is a party or by which Buyer is bound or to which any of Buyer’s properties or assets is subject, except for such breaches, defaults and accelerations as would not have a Material Adverse Effect on the ability of Buyer to consummate the transactions contemplated hereby.

 

(d) Investment Purpose. Buyer is acquiring the Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof. Buyer acknowledges that the Shares are not registered under the Securities Act of 1933, as amended, or any state securities laws, and that the Shares may not be transferred or sold except pursuant to the registration provisions of the Securities Act of 1933, as amended or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable.

 

(e) Litigation. There are no claims, Actions, suits, proceedings, complaints or investigations pending or, to the knowledge of Buyer, threatened before any federal, state, provincial, court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Buyer or any of its officers, directors, employees, agents or Affiliates, involving, affecting or relating to the Buyer, its business, the Equity Consideration, or the transactions contemplated by the Transaction Documents. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action.

 

(f) SEC Documents; Financial Statements. (a) Since [December 31, 2012], Buyer has filed with or furnished to the Securities and Exchange Commission (the “SEC”) all reports, schedules, forms, statements and other documents required to be so filed or furnished (the “Buyer SEC Documents”). All of the Buyer SEC Documents (other than preliminary material), as of their respective filing dates, complied as to form in all material respects with all applicable requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and, in each case, the rules and regulations promulgated thereunder applicable to such the Buyer SEC Documents. None of the Buyer SEC Documents at the time of filing contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, except to the extent such statements have been modified or superseded by later Buyer SEC Documents. As of their respective dates, the consolidated financial statements of Buyer included in the Buyer SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly presented in all material respects in accordance with the applicable requirements of GAAP, the financial position of Buyer as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to notes and to normal and recurring year-end audit adjustments). There are no outstanding or unresolved comments from the SEC with respect to any of the Buyer SEC Documents. Buyer and its subsidiaries maintain systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that comply in all material respects with the requirements of the Exchange Act. No stop order suspending the sale of the Buyer’s securities in any jurisdiction has been issued within the previous year, and no investigation or proceeding for that purpose has been commenced or is pending or threatened.

 

 
 

 

(g) Disclosure. No representation or warranty by the Buyer contained in this Agreement, and no statement contained in the Buyer SEC Documents or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of the Buyer pursuant to this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading.

 

7. Post Closing Covenants.

 

(a) Noncompetition, Nonsolicitation and Nondisparagement.

 

(i) Noncompetition. Eisenberg acknowledge that (i) Buyer would not have entered into this Agreement but for the agreements and covenants contained in this Section 7; and (ii) the agreements and covenants contained in this Section 7 are essential to protect the Business and are reasonable and appropriate in scope; (iii) the Business is national in scope, and as such the “Territory” for purposes of this Section 7 is the United States of America; and (iv) the business of Buyer is worldwide in time, territory, scope and all other respects. To induce Buyer to enter into this Agreement, Eisenberg covenants and agrees that during the period commencing on the Closing Date and ending on the third (3rd) anniversary of the Closing Date (the “Restricted Period”), Eisenberg shall not (A) engage in any business or activity that competes with the Business in the Territory; (B) render any services to any Person for use in competing with Company in the Territory in connection with the Business; (C) have an interest in any Person engaged in any business that competes with Buyer in the Territory in connection with the Business, directly or indirectly, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee or consultant or any other relationship or capacity; or (D) interfere with business relationships (whether formed heretofore or hereafter) between Company and customers, suppliers or prospects of the Business; provided, however, Eisenberg may own, directly or indirectly, solely as an investment, securities of any Person which are publicly traded if Eisenberg (I) is not a controlling Person of, or a member of a group which controls, such Person; and (II) does not, directly or indirectly, own two percent (2%) or more of any class of securities of such Person.

 

(ii) Employees of the Business. During the Restricted Period, Eisenberg shall not, directly or indirectly, solicit or encourage any Employee or consultant performing services in connection with the Business to leave the employment or retention of the Company.

 

(iii) Customers of the Business. During the Restricted Period, Eisenberg shall not, directly or indirectly, (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client, supplier or vendor of Company not to hire or do business with Company or any successor thereto; or (ii) solicit for himself or any Person other than Company, the business of any Person who is a customer, client, supplier or vendor of Company, or was its customer or supplier within one (1) year prior to the time of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Company.

 

(iv) Confidential Information. From and after the Closing, Eisenberg shall keep secret and retain in strictest confidence, and shall not use for the benefit of himself or others, all confidential matters relating to the Business, the Buyer or Company, including, but not limited to, “know how”, trade secrets, customer lists, supplier lists, details of consultant and employment Contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Buyer and its Affiliates (including Company); provided, however, this covenant shall not apply to any information which is or becomes generally available to the public other than as a result of an improper disclosure by Eisenberg. Eisenberg may disclose Confidential Information if required to do so in any legally required government or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that the Eisenberg (i) provides Buyer with prompt notice of such required disclosure so that Buyer may attempt to obtain a protective order, (ii) cooperates with Buyer, at Buyer’s expense, in obtaining such protective order, and (iii) only discloses that Confidential Information which it is absolutely required to disclose as advised by counsel.

 

 
 

 

(v) Nondisparagement. After the Closing Date, Eisenberg will not disparage Buyer, any of Buyer’s Affiliates (including Company) or any of such parties’ shareholders, directors, officers, employees or agents.

 

(vi) Tolling of Covenant Periods. The Restricted Period provided in this Section 7 shall not include and shall be extended beyond, any time during which Eisenberg is failing to comply with any provision of this Section 7, as finally determined by a court of competent jurisdiction or arbitrator, with respect to such Party.

 

(vii) Blue Penciling. If any term or other provision of this Section 7 is invalid, illegal, or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions of this Section 7 shall nevertheless remain in full force and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, Eisenberg and Buyer shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 7 so as to effect the original intent of Eisenberg and Buyer as closely as possible to the maximum extent allowed by Law to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

(b) Employees. Buyer agrees to offer, or cause the Company to offer, continued employment, on an “at will” basis to all the Employees as of the Closing, including all management Employees, and if any such Employee accepts such offer of employment, he or she shall become an employee of Buyer or Company, as applicable, after the Closing Date (such Employees are referred to hereinafter as the “Retained Employees”). Retained Employees shall be credited for past service toward all benefits offered by Buyer or Company for purposes of determining eligibility and benefit accrual.

 

(c) Securities Law Compliance. The Trust agrees that it will not transfer or dispose of any of the Equity Consideration other than pursuant to an effective registration statement under the Securities Act or a Rule 144 sale in compliance with the terms of such Rule or pursuant to an exemption from the 1933 Act. Buyer shall file and maintain such additional Buyer SEC Documents as may be necessary such that the representations and warranties set forth in Section 6(f) continue to remain true for all periods that the Equity Consideration is held by the Trust or Sellers, and Buyer shall cooperate with the Trust (and any Seller receiving a distribution of the any Equity Consideration) and any applicable transfer agent, in the removal of any legend on the shares constituting the Equity Consideration to permit the trade or liquidation thereof in the marketplace as permitted under Rule 144 (as promulgated under the Securities Act and in effect as of the applicable time), if requested by the Trust or applicable Seller.

 

(d) Trust Operation. From and after the Closing, all undertakings and actions of the Trust will carried out as set forth in this Agreement and the Trust Documents.

 

(e) Return of Trust Property by Sellers. In the event the Trust distributes the assets of the Trust to the Sellers in violation of this Agreement or the Trust Documents, each Seller covenants to promptly return such assets to the Trust.

 

(f) Product Sales Information. Within thirty (30) days after the end of each calendar quarter, Buyer will furnish to Trust, a complete and accurate written statement in a form reasonably acceptable to Trust, certified by Buyer’s authorized financial officer, showing the total number of Products (the volume and sales of each Product expressed in dollars, volume, and SKUs) sold and distributed by Buyer during the preceding calendar quarter. Buyer will keep at a location within the continental United States, reasonably detailed, complete and accurate books of account and records covering all transactions relating to the Products. Upon at least five (5) Business Days prior notice to Buyer, Trust and/or its authorized representatives will have the right, during regular business hours, to examine and copy such books of account and records and all other documents and material in the possession or under the control of Buyer insofar as they relate to the Products sold in the last two (2) years, in order to determine the accuracy of the periodic statements delivered or which should have been delivered by Buyer to Trust as provided above. In the event such examination indicates any under or overpayment of Royalty Consideration, an appropriate credit or refund will be promptly issued. If any such examination reveals an underpayment of Royalty Consideration, of more than five percent (5%) of the amount paid by Buyer, or if such examination is in connection with Buyer’s failure to deliver any periodic statement or pay any amounts due hereunder, then Buyer will bear all costs and expenses incurred by Trust in connection with the examination and collection of any such unpaid amounts (including, without limitation, all reasonable attorney’s fees and expenses). The full amount of any underpayment of Royalty Consideration, and related costs and expenses will be due and payable upon demand by Trust. All books of account and records of Buyer relating to the Products will be kept available for inspection by or on behalf of Trust for at least two (2) years after the expiration or termination of the seven-year Royalty Consideration period. All information received, reviewed and copied by Trust or its representatives in connection with or pursuant to this Section 7(f) shall be kept confidential and not disclosed to any other Person.

 

 
 

 

(g) Adoption of Release. By its execution hereof, each of the Sellers hereby agrees that it is bound by the terms of the Release Agreement attached as Exhibit B, the terms of which are incorporated herein by this reference.

 

8. Indemnification.

 

(a) Indemnification with Respect to a Seller’s Breach.

 

(i) To the extent the assets of the Trust are sufficient but subject to Section 8(f), the Trust shall indemnify and save and hold the Buyer, any Affiliate of the Buyer and their respective directors, officers, managers, employees, successors, and assigns (the “Buyer Indemnitees”), harmless from and against any and all damages, claims, demands, obligations, Liabilities, losses, costs, expenses (including all reasonable attorneys’ fees and expenses of investigation incurred by the Buyer Indemnitees in any Action or proceeding between a Seller and the Buyer Indemnitees or between the Buyer Indemnitees and any other Person or otherwise), deficiencies, interests, penalties, impositions, assessments and/ or fines (collectively, “Buyer Losses”), whether or not in connection with a third-party claim, arising out of, resulting from, or related to (i) a breach of any representation or warranty made by a Seller in this Agreement or the other Transaction Documents to which a Seller is a party; or (ii) a Seller’s breach of any covenant made by a Seller in this Agreement or the other Transaction Documents to which such Seller is a party; or (iii) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of a Seller arising with respect to the transactions which are the subject of this Agreement; provided that such indemnification shall not extend to the Covenantors breach of Section 7(a), or the breach of any employment agreement or the like to which a Seller may be a party.

 

(ii) To the extent the assets of the Trust are not sufficient to indemnify the Buyer Indemnitees for any Buyer Losses under Section 8(a)(i) above, but subject to Section 8(f), each Seller shall, severally but not jointly, indemnify and save and hold the Buyer Indemnitees harmless from and against any and all Buyer Losses whether or not in connection with a third-party claim, arising out of, resulting from, or related to (i) a breach of any representation or warranty made by such Seller in this Agreement or the other Transaction Documents to which such Seller is a party; or (ii) such Seller’s breach of any covenant made by a Seller in this Agreement or the other Transaction Documents to which such Seller is a party; or (iii) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of such Seller arising with respect to the transactions which are the subject of this Agreement; provided that such indemnification shall not extend to Eisenberg’s breach of Section 7(a), or the breach of any employment agreement or the like to which such Seller may be a party.

 

(b) Indemnification with Respect to the Company’s Breach.

 

(i) To the extent the assets of the Trust are sufficient, but subject to Section 8(f), the Trust shall indemnify and save and hold the Buyer Indemnitees, harmless from and against any and all Buyer Losses, whether or not in connection with a third-party claim, arising out of, resulting from or related to (i) the Company’s breach of any representation or warranty made by the Company in this Agreement or the other Transaction Documents to which the Company is a party; or (ii) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of a Seller arising with respect to the transactions which are the subject of this Agreement or of any party other than a Seller claiming to be a shareholder arising with respect to the transactions which are the subject of this Agreement.

 

(ii) To the extent the assets of the Trust are not sufficient to indemnify the Buyer Indemnitees for any Buyer Losses under Section 8(b)(i) above, but subject to Section 8(f), each Seller shall, severally but not jointly, indemnify and save and hold the Buyer Indemnitees harmless from and against any and all Buyer Losses whether or not in connection with a third-party claim, arising out of, resulting from, or related to (i) the Company’s breach of any representation or warranty made by the Company in this Agreement or the other Transaction Documents to which the Company is a party; or (ii) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of a Seller arising with respect to the transactions which are the subject of this Agreement or of any party other than a Seller claiming to be a shareholder arising with respect to the transactions which are the subject of this Agreement.

 

 
 

 

(c) Indemnification with Respect to the Trust’s Breach. To the extent the assets of the Trust are sufficient, but subject to Section 8(f), the Trust shall indemnify and save and hold the Buyer Indemnitees, harmless from and against any and all Buyer Losses, whether or not in connection with a third-party claim, arising out of, resulting from or related to (i) the Trust’s breach of any representation or warranty made by the Trust in this Agreement or the other Transaction Documents to which the Trust is a party; or (ii) the Trust’s breach of any covenant made by the Trust in this Agreement or the other Transaction Documents to which the Trust is a party; or (iii) the Trust’s breach of the Trust Documents.

 

(d) Indemnification by Buyer. Buyer shall indemnify and save and hold the Sellers, the Trust, any Affiliate of a Seller or the Trust and their respective directors, officers, managers, trustees, employees, advisors, successors, and assigns (the “Seller Indemnitees”), harmless from and against any and all damages, claims, demands, obligations, liabilities, losses, costs, expenses (including all reasonable attorneys’ fees and expenses of investigation incurred by the Seller Indemnitees in any Action or proceeding between the Buyer and the Seller Indemnitees or between the Seller Indemnitees and any third party or otherwise), deficiencies, interests, penalties, impositions, assessments and/ or fines (collectively, “Seller Losses”), whether or not in connection with a third-party claim, arising out of, resulting from or related to (i) Buyer’s breach of any representation or warranty made by Buyer in this Agreement or the other Transaction Documents to which the Buyer is a party, or (ii) Buyer’s breach of any covenant made by Buyer in this Agreement or the other Transaction Documents to which the Buyer is a party; or (iii) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of a shareholder of Buyer arising with respect to the transactions which are the subject of this Agreement.

 

(e) Set-Off by Buyer. Amounts that (i) the Trust and the Buyer agree in writing are due or (ii) upon a final determination by a court of competent jurisdiction or arbitrator that such amounts are due to the Buyer Indemnities under Sections 8(a) , (b) and (c) may be satisfied by set-off by the Buyer Indemnities, at their sole election, against any Royalty Consideration then due or to become due in the future.

 

(f) Limitations. The indemnification provided for in Sections 8(a), (b) and (c) shall be subject to the following limitations and provisions:

 

(i) The Trust and the Sellers shall not be liable to the Buyer Indemnitees for indemnification (other than with respect to a claim for indemnification based upon, arising out of, with respect to, or by reason of any inaccuracy in or breach of a Fundamental Representation or fraud) until the aggregate amount of Buyer Losses in respect of indemnification exceeds $50,000 (the “Basket”), in which event Trust and the Sellers, as applicable, shall be required to pay or be liable for the Buyer Losses in excess of the Basket in accordance with this Section 8;

 

(ii) The Trust and the Sellers shall not be liable to the Buyer Indemnitees for indemnification (other than with respect to a claim for indemnification based upon, arising out of, with respect to or by reason of any inaccuracy in or breach of a Fundamental Representation or fraud) for any Buyer Losses that, in the aggregate, are in excess of fifty percent (50%) of the Purchase Consideration.

 

(iii) The Trust shall not be liable to the Buyer Indemnitees for indemnification (other than with respect to a claim for indemnification based upon, arising out of, with respect to, or by reason of fraud) for any Buyer Losses that, in the aggregate, are in excess of the Purchase Consideration.

 

(iv) Each Seller shall not be liable to the Buyer Indemnitees for indemnification (other than with respect to a claim for indemnification based upon, arising out of, with respect to, or by reason of fraud) for any Buyer Losses that, in the aggregate, are in excess of the Purchase Consideration received by such Seller through distributions from the Trust.

 

 
 

 

(v) All claims for indemnification shall be paid either from the Equity Consideration or the set-off in Section 8(e), if elected by Buyer, unless the Trust elects to pay such claim in cash. For purposes of the foregoing each share of Equity Consideration will be valued at the greater of $0.85, or its Fair Market Value on the date the claim is paid. For purposes hereof, the Fair Market Value means, as of any particular date, (A) the volume weighted average of the closing sales prices of a security of the type that comprises the Equity Consideration for such day on all domestic securities exchanges on which such security may at the time be listed, (B) if there have been no sales of such security on any such exchange on any such day, the average of the highest bid and lowest asked prices for such security on all such exchanges at the end of such day, (C) if on any such day such security is not listed on a domestic securities exchange, the closing sales price of such security as quoted on the Financial Industry Regulatory Authority OTC Bulletin Board electronic inter-dealer quotation system (the “OTC Bulletin Board”), the OTC Markets Group Inc. electronic inter-dealer quotation system, including OTCQX, OTCQB and OTC Pink (the “Pink OTC Markets”) or similar quotation system or association for such day or (D) if there have been no sales of such security on the OTC Bulletin Board, the Pink OTC Markets or similar quotation system or association on such day, the average of the highest bid and lowest asked prices for such security quoted on the OTC Bulletin Board, the Pink OTC Markets or similar quotation system or association at the end of such day; in each case, averaged over twenty (20) consecutive Business Days ending on the Business Day immediately prior to the day as of which “Fair Market Value” is being determined, and (ii) “Business Day” means any day, except a Saturday, Sunday or legal holiday, on which banking institutions in the city of New York, New York, are authorized or obligated by law or executive order to close; provided, that if such security is listed on any domestic securities exchange, the term “Business Day” as used herein means Business Days on which such exchange is open for trading. If at any time a security is not listed on any domestic securities exchange or quoted on the OTC Bulletin Board, the Pink OTC Markets or similar quotation system or association, the market value of such security shall be the fair market value per share as determined by mutual agreement of the Trust and Buyer; provided, that if the Trust and Buyer are unable to agree on the market value per share of such security within 14 calendar days, such market value shall be determined by a nationally recognized investment banking, accounting or valuation firm jointly selected by the Trust from a list of at least three (3) provided by the Buyer. The determination of such firm shall be final and conclusive, and the fees and expenses of such valuation firm shall be borne by the Party whose proposed valuation is furthest from that reach by the firm.

 

(vi) Prior to or contemporaneously with, and as a condition to, pursuing any claim for indemnification for Buyer Losses under this Section 8 against any Seller or the Trust, a Buyer Indemnitee shall assert and pursue a claim for recovery under any policy of insurance that provides coverage for such Buyer Losses. Any recovery by a Buyer Indemnitee under such policy of insurance shall offset and reduce the amount of Buyer Losses for which the Trust or any Seller must indemnify the Buyer Indemnitee under this Section 8. To the extent any Seller or the Trust pays a Buyer Indemnitee for any Buyer Losses or Buyer exercises its right of set-off under Section 8(e) and the Buyer Indemnitee also recovers under a policy of insurance for such Buyer Losses, the Buyer Indemnitee shall promptly pay to the Trust or such Seller, as applicable, the amount (if any) by which the total recovery by Buyer Indemnitee exceeds the amount of such Buyer Losses.

 

(vii) To the extent such Buyer Losses arise from or were caused by acts or omissions by any of the Buyer Indemnitees after the Closing. For purposes of clarity, the limitation of this Section 8(f)(vii) shall not apply to any products liability claims relating to inventory of the Products existing as of the Closing and sold by the Company following the Closing in the ordinary course of business and consistent with past practices.

 

(g) Survival. All representations, warranties, covenants and obligations contained in this Agreement and the other Transaction Documents shall survive the Closing for eighteen (18) months, except that: (i) all covenants and agreements which by their terms contemplate performance after the Closing shall survive the Closing indefinitely, unless specified otherwise by their terms; (ii) for breaches of Sections 4(j) or 4(s), the survival shall be the applicable statute of limitations; (iii) for breaches of any Fundamental Representations, the survival period shall be indefinite; and (iv) for breaches based upon, arising out of, with respect to, or by reason of fraud, the survival period shall be the applicable statute of limitations. Notwithstanding the above, any claim for indemnification made in accordance with this Section 8 prior to the expiration of the applicable indemnification period set forth in this paragraph shall survive until such matter is resolved.

 

(h) Exclusive Remedy. The indemnification afforded by this Section 8 shall be the sole and exclusive remedy of the Seller Indemnitees and Buyer Indemnitees in respect of claims for any misrepresentation, breach of warranty or nonfulfillment or failure to be performed of any covenant or agreement contained in this Agreement or the other Transaction Documents, except for (i) Eisenberg’s breach of Section 7(a); (ii) the breach of any employment agreement or the like to which a Seller may be a party; (iii) the Trust’s breach of any representations, warranties, covenants or obligations contained in this Agreement and the other Transaction Documents which by their terms contemplate performance after the Closing; (iv) any Seller’s breach of the covenants in Section 7(e); or (v) Buyer’s breach of the covenants in Section 7(f).

 

 
 

 

(i) Materiality. For purposes of determining the amount of Buyer Losses under this Section 8, and not for purposes of determining whether or not a breach has occurred, any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty.

 

(j) Procedures for Indemnification.

 

(i) Notice of Claims. If any misrepresentation, breach of warranty or nonfulfillment or failure to be performed of any covenant or agreement contained in this Agreement or the other Transaction Documents occurs or is alleged and either (i) a Buyer Indemnitee asserts that Trust or any Seller(s), has become obligated to such Buyer Indemnitee pursuant to Section 8 hereof, or (ii) a Seller Indemnitee asserts that Buyer, has become obligated to such Seller Indemnitee pursuant to Section 8 hereof (“Direct Claim”), or if any suit, Action, investigation, claim or proceeding is threatened, begun, made or instituted by a third party (a “Third Party Proceeding”) as a result of which the Trust or any Seller(s) may become obligated to a Buyer Indemnitee hereunder, or Buyer may become obligated to a Seller Indemnitee, such Buyer Indemnitee or Seller Indemnitee, as applicable, shall give written notice thereof to the Trust or Buyer, as the case may be (the “Claims Notice”). For purposes of this Section 8(j) a Buyer Indemnitee or Seller Indemnitee sending a Claims Notice shall be referred to as an “Indemnitee.” A failure or delay in providing a Claims Notice shall not relieve Buyer, any Seller(s) or Trust of its indemnification obligations under this Section 8 except to the extent that such Party is materially prejudiced as a result thereof.

 

(ii) Response to Direct Claims. Any Seller(s), the Trust or Buyer as the indemnifying party under this Section 8 (the “Indemnitor”) shall have thirty (30) days after receipt of the Claims Notice for a Direct Claim to reject or accept the claim as an indemnifiable claim under Section 8. If, within thirty (30) days after receipt by the Indemnitor of such a Claims Notice, the Indemnitor delivers notice to the Indemnitee containing a written objection to the claim (or a portion thereof) by the Indemnitee, stating the nature of and grounds for such objection in reasonable detail, then such claim (or portion thereof) shall be deemed to be a “Disputed Claim” and such claim shall be resolved in accordance with this Section 8(j). If, within thirty (30) days after actual receipt by an Indemnitor of a Claims Notice for a Direct Claim, Indemnitor delivers notice to the Indemnitee containing a written acceptance of the claim, (or a portion thereof) then such claim (or portion thereof) shall be deemed an indemnifiable claim under this Section 8 (the “Indemnifiable Claim”), and unless such notice includes a reservation of rights, Indemnitor will be conclusively deemed to have consented to recovery by the Indemnitee of the full amount of Buyer Losses or Seller Losses, as applicable, subject to the limitations set forth in the Section 8, as applicable.

 

(iii) Dispute Resolution. Any disputes arising under this Section 8 shall be resolved as follows: (i) first, the Buyer and the Trust shall attempt in good faith for thirty (30) days to resolve the dispute, and (ii) if the dispute remains unresolved after such thirty (30) day period, the Buyer and the Trust agree that either the Buyer or the Trust may file suit in any court or other adjudicative body having jurisdiction pursuant to this Agreement in order to resolve the dispute.

 

(iv) Third Party Proceeding. Indemnitor shall have twenty (20) days from receipt of a Claims Notice for a Third Party Proceeding to provide the Indemnitee with notice that it wishes to assume the defense in the Third Party Proceeding, in which event the Indemnitee shall have the right to participate in the defense at its own expense; provided, however, that the Indemnitee is hereby authorized prior to and during such time to file any motion, answer or other pleading that it shall deem necessary or appropriate to protect its interests and that is not prejudicial to Indemnitor. If Indemnitor fails to give the Indemnitee timely notice as provided herein, the Indemnitee shall have the right to defend against such Third Party Proceeding. If Indemnitor assumes the defense in a Third Party Proceeding, the Indemnitor shall not agree to any settlement, compromise or discharge of a Third-Party Claim without the Indemnitee’s prior written consent, which shall not be unreasonably withheld. If the Indemnitor does not assume the defense of a Third-Party Claim, the Indemnitee shall be entitled to undertake any settlement, compromise or discharge of such Third-Party Claim without the Indemnitor’s prior consent. Notwithstanding anything herein to the contrary, an Indemnitor shall not be entitled to assume control of the defense in a Third Party Proceeding, and shall pay the reasonably documented fees and expenses of legal counsel retained by the Indemnitee if: (i) Indemnitee reasonably believes that an adverse determination of such claim could be detrimental to its interests; (ii) Indemnitee reasonably believes that the Indemnitor lacks the financial capability to pay any adverse monetary judgment being sought in the Third Party proceeding; (iii) Indemnitee reasonably believes that a conflict of interest exists or could reasonably arise which, under applicable principles of legal ethics, could prohibit a single legal counsel from representing both the parties in such proceeding, other than a conflict which may exist due to the underlying nature of the duty to indemnify; (iv) a court of competent jurisdiction rules that Indemnitor has failed or is failing to prosecute or defend such claim; or (v) such claim seeks damages other than monetary damages.

 

 
 

 

(v) Consent to Jurisdiction. Notwithstanding any other provision of this Section 8, Indemnitor hereby consents to the nonexclusive jurisdiction of any court in which an Action or claim in respect of a Third Party Proceeding is brought against an Indemnitee for purposes of any claim that an Indemnitee may have under this Agreement with respect to such Action or claim or the matters alleged therein and agrees that process may be served on Indemnitor with respect to such a claim anywhere in the world.

 

(vi) Indemnification Binds Successors and Assigns. All of the indemnification rights of the Parties arising pursuant to this Section 8 shall survive any sale, assignment or other transfer by a Party of all or part of their respective title to or interest in all or part of the Transaction Documents and shall apply to and bind each and every successor and assign of a Party hereto.

 

(vii) Fraud. For purposes of this Section 8, the term “fraud” shall only be deemed to refer to willful and intentional misrepresentations or omissions made, or intentional concealment performed, with the intent to deceive and shall not be deemed to include negligent misrepresentation, omissions or similar claims.

 

9. Appointment of the Trust as Representative of Sellers.

 

(a) By approving this Agreement and the transactions contemplated hereby, each Seller shall have irrevocably authorized, directed and appointed the Trust to act as sole and exclusive agent, attorney-in-fact and representative of such Seller, with full power of substitution with respect to all matters under this Agreement and the transactions contemplated hereby, including, without limitation, determining, giving and receiving notices and processes hereunder, receiving distributions of the Purchase Consideration to or for the benefit of Sellers, contesting and settling any and all claims for indemnification pursuant to Article 8, resolving any other disputes hereunder, performing the duties expressly assigned to the Trust hereunder and under the Trust Documents and incur such other expenses as the Trust shall reasonably deem necessary or prudent in connection with the foregoing.

 

(b) The Trust shall have the sole and exclusive right on behalf of each Seller to take any action or provide any waiver, or receive any notice with respect to any claims for indemnification under Article 8 and to settle any claim or controversy arising with respect thereto. Any such actions taken, exercises of rights, power or authority, and any decision or determination made by the Trust, shall be absolutely and irrevocably binding on each Seller as if such Seller personally had taken such action, exercised such rights, power or authority or made such decision or determination in such Seller’s individual capacity, and no Seller shall have the right to object, dissent, protest or otherwise contest the same. Any action required to be taken by any Seller hereunder or any action that any Seller, at its election, has the right to take hereunder, shall be taken only by the Trust and no Seller acting on its own shall be entitled to take any such action. After Closing, Buyer shall be entitled to deal exclusively with the Trust on all matters relating to this Agreement and shall be entitled to rely conclusively (without further evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Seller by the Trust, and on any other action taken or purported to be taken on behalf of any Seller by the Trust, as being fully binding upon such Seller. Notices or communications to or from the Trust shall constitute notice to or from each Seller. Any decision or action by the Trust hereunder, including any agreement between the Trust and Buyer relating to the defense, payment or settlement of any claims for indemnification hereunder, shall constitute a decision or action of any or all Sellers, as applicable, and shall be final, binding and conclusive upon each such Seller. No Seller shall have the right to object to, dissent from, protest or otherwise contest the same. The provisions of this Section 9, including the power of attorney granted hereby, are independent and severable, are irrevocable and coupled with an interest and shall not be terminated by any act of any one or Sellers or by operation of Law.

 

(c) The Trust may resign at any time; provided, however, in no event shall the Trust resign without having first appointed a new representative to serve in the same capacity and with the same authority as the Trust, who shall assume such duties immediately upon the resignation or removal of the Trust. Notice of the appointment of such new representative shall be sent to Buyer, such appointment to be effective upon the later of the date indicated in such notice or the date such notice is received by Buyer; provided, that until such notice is received, Buyer shall be entitled to rely on the decisions and actions of the Trust as described in Sections 9(a) and (b) above.

 

 
 

 

(d) The Trust shall not be liable to any Seller for actions taken pursuant to this Agreement, except to the extent such actions shall have been determined by a court of competent jurisdiction to have constituted gross negligence or involved fraud, intentional misconduct or bad faith (it being understood that any act done or omitted pursuant to the advice of counsel, accountants and other professionals and experts retained by the Trust shall be conclusive evidence of good faith).

 

10. Miscellaneous.

 

(a) Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Parties hereto.

 

(b) Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of North Carolina, United States, without giving effect to the principles of conflicts of laws thereof. The Parties hereto irrevocably consent to the jurisdiction of, the federal and state courts of the State of North Carolina located in Wake County, North Carolina for such purpose.

 

(c) Expenses. Except as otherwise provided herein, each of the Parties hereto shall pay all its own expenses in connection with this Agreement and the transactions contemplated hereby, including, without limitation, any legal and accounting fees, whether or not the transactions contemplated hereby are consummated.

 

(d) Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

(e) Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, or (ii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the Party as follows:

 

  If to Trust: [Insert Address]
     
  Copy to: Smith, Gambrell & Russell, LLP
    Suite 3100, Promenade
    1230 Peachtree Street, NE
    Atlanta, Georgia 30309
    Attention: John C. Ethridge, Jr.
     
  If to Buyer: Synergy CHC Corp.
    865 Spring Street
    Westbrook, ME 04092
    Attn: President
     
  Copy to: Wyrick Robbins Yates & Ponton LLP
    4101 Lake Boone Trail, Suite 300
    Raleigh, North Carolina 27607
    Attention: W. David Mannheim

 

Any Party may change its address for the purpose of this Section by giving the other Party written notice of its new address in the manner set forth above.

 

(f) Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

 
 

 

(g) Public Announcements. Sellers and the Trust shall not make any public statement regarding this Agreement or the transactions contemplated herein without Buyer’s prior written approval. Buyer shall provide a copy of any public statement to the Trust prior to the information being made public.

 

(h) Entire Agreement. This Agreement, the exhibits and schedules hereto contains the entire understanding between the Parties hereto with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein. This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.

 

(i) Parties in Interest. Nothing in this Agreement is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the Parties hereto and their respective successors and permitted assigns. Nothing in this Agreement is intended to relieve or discharge the obligations or liability of any third persons to any of the Parties hereto. No provision of this Agreement shall give any third persons any right as a third party beneficiary of this Agreement or provide any right of subrogation or Action over or against a Party hereto.

 

(j) Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

(k) Counterparts. This Agreement may be executed in counterparts and via .pdf, each of which shall be deemed an original, but all of which shall constitute the same instrument.

 

(l) Fulfillment of Obligations. Any obligation of any Party to any other Party under this Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such Party, shall be deemed to have been performed, satisfied, or fulfilled by such Party.

 

(m) Remedies. Except as expressly provided in this Agreement, any Person having any rights under any provision of this Agreement, including, without limitation, Section 7, shall be entitled to enforce such rights specifically (without posting a bond or other security) and to exercise all other rights granted by Laws. Except as expressly provided in this Agreement, all such rights and remedies shall be cumulative and non-exclusive, and may be exercised singularly or concurrently. The Parties acknowledge that any breach of this Agreement may cause substantial irreparable harm to the other Party. Therefore, this Agreement may be enforced in equity by specific performance, temporary restraining order and/or injunction. The rights to such equitable remedies shall be in addition to all other rights or remedies which a Party may have under this Agreement or under applicable law.

 

(n) Further Actions. In case at any time after the Closing any further action is necessary to carry out the purposes of this Agreement, each of the Parties shall take such further action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request, all at the sole cost and expense of the requesting Party (unless the requesting Party is entitled to indemnification therefore under Section 8). Without limiting the foregoing, after the Closing each Seller will furnish Buyer with such information and documents in such Seller’s possession or under such Seller’s control or that such Seller can execute or cause to be executed to further evidence Buyer’s ownership of the Shares.

 

[Signature pages follow]

 

 
 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.

 

  /s/ Jordan Eisenberg
  JORDAN EISENBERG
     
  BREAKTHROUGH PRODUCTS, INC.
     
  By: /s/ Jordan Eisenberg
  Name: Jordan Eisenberg
  Title: Chief Executive officer
     
  SYNERGY CHC CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer
     
  URX ACQUISITION TRUST
     
  By: /s/ Michael Valentino
  Name: Michael Valentino
  Title: Trustee

 

Signature Page to Stock Purchase Agreement - 1

 

 
 

 

[Form of Seller Signature Page]

 

Seller:

 

(USE THIS BLOCK IF AN INDIVIDUAL)

   
(Signature)  

 

Address:    
     
     

(USE THIS BLOCK IF AN ENTITY)

By:    
Name:    
Title:    
Address:    
     
     

 

Signature Page to Stock Purchase Agreement - 2

 

 

 

Exhibit 10.10

 

SHARE PURCHASE AGREEMENT

 

THIS SHARE PURCHASE AGREEMENT (the “Agreement”) dated as of November 15, 2015, between TPR Investments Pty Ltd ACN 128 396 654 as trustee for Polmear Family Trust (the “Seller”), Timothy Polmear and Rebecca Polmear (collectively, the “Principal Owners”), NomadChoice Pty Limited ACN 160 729 939 trading as Flat Tummy Tea, an Australian proprietary limited company (the “Company”), and Synergy CHC Corp., a Nevada corporation (the “Buyer”). Buyer and Seller are sometimes referred to collectively as the “Parties” and individually as a “Party”.

 

BACKGROUND

 

Seller and the Principal Owners, either directly or indirectly, collectively own, all of the issued fully paid ordinary shares of the Company (the “Company Shares”).

 

The Company is engaged in the business of developing, manufacturing, and selling herbal detox tea (the “Products”) (the Products and the business related to the Products is collectively the “Business”). For the avoidance of doubt, the “Business” shall be limited to the business known as “Flat Tummy Tea” and operated by the Company.

 

Buyer desires to purchase all of the Company Shares (the “Share Purchase”), and Seller and the Principal Owners desire to sell such Company Shares to Buyer, in each case upon the terms and subject to the conditions set forth in this Agreement.

 

In consideration of the foregoing and the respective covenants and agreements hereinafter contained, the Parties hereto hereby agree as follows:

 

1. Definitions.

 

As used in this Agreement (including the recitals and Disclosure Schedules hereto), the following selected terms shall have the following meanings (such meanings to be applicable equally to both singular and plural forms of the terms defined):

 

Action” means any claim, action, cause of action, demand, lawsuit, arbitration, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether formal or informal, whether public or private and whether at law or in equity;

 

Adjusted EBITDA” shall mean, with respect to any applicable period, the net income before interest, taxes, depreciation and amortization less any capital expenditures of the Company for such period, all as calculated on a consistent basis with the accounting standards and general accounting principles applied in the financial statements attached as Schedule 4(h);

 

Affiliate” shall mean, as to any Person, any other Person which directly or indirectly controls, or is under common control with, or is controlled by, such Person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”) shall mean possession, directly or indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or partnership or other ownership interests, by Contract or otherwise) of such Person;

 

Calculation Period” means the period beginning on November 1, 2015 and ending on June 30, 2016;

 

Calculation Period EBITDA” means the Company’s Adjusted EBITDA during the Calculation Period;

 

Clients” means all of the clients of the Company during each of the Company’s 2012, 2013, and 2014 fiscal years and during the period ended as of October 31, 2015;

 

Closing” shall mean the consummation of the transactions contemplated by this Agreement which shall occur on the Closing Date;

 

 
 

 

“Closing Date” means 12 November 2015;

 

Code” means the Internal Revenue Code of 1986, as amended;

 

Commercially Reasonable Efforts” means the commercially reasonable efforts that a prudent Person desirous of achieving a result and having an incentive to and interest in achieving such result would use to achieve that result as expeditiously as reasonably possible under the circumstances;

 

Contract” means any agreement, contract, indenture, instrument, obligation, promise or undertaking (whether written or oral and whether express or implied) that is legally binding;

 

Disclosure Schedules” means the disclosure letter delivered by Seller concurrently with the execution and delivery of this Agreement;

 

Earn-Out Multiple” means two (2);

 

Employee” means an employee of the Company employed in connection with the Business;

 

Employee Benefit Plan” means any pension, profit sharing, retirement, deferred compensation, share purchase, share option or other equity based compensation plans, incentive, bonus, vacation, employment, independent contractor, severance, disability, hospitalization, sickness, death, medical insurance, dental insurance, life insurance and any other employee benefit plan (whether provided on a funded or unfunded basis, or through insurance or otherwise), agreement, program, policy, trust, fund, Contract or arrangement;

 

Environmental Laws” means all Laws concerning pollution or protection of the environment and natural resources, including without limitation all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, control or cleanup of any hazardous materials, substances or wastes, pesticides, pollutants or byproducts, asbestos, polychlorinated biphenyls, or radiation, each as amended and as now or hereafter in effect;

 

Files and Records” shall mean all files and records, whether in hard copy or digital, electronic, data, magnetic or other format, of the Company relating to or used in connection with the Business;

 

Event of Insolvency” means, in relation to a corporation:

 

  (a) receiver, manager, receiver and manager, trustee, administrator or similar officer is appointed in respect of a person or any material asset of a corporation;
     
  (b) a liquidator or provisional or interim liquidator is appointed in respect of a corporation;
     
  (c) any application (not being an application withdrawn or dismissed within 7 days) is made to a court for an order, or an order is made, or a meeting is convened, or a resolution is passed, for the purpose of:
       
    (i) appointing a person referred to in paragraphs (a) or (b);
       
    (ii) winding up the relevant corporation; or
       
    (iii) proposing or implementing a compromise with creditors (including a scheme of arrangement, other than to carry out a reconstruction or amalgamation while solvent);
       
  (d) a final order, judgment or award is made against the corporation which it fails to satisfy within 7 days of being required to do so; or
     
  (e) the corporation becomes, or admits in writing that it is, is declared to be, or is deemed under any applicable Law to be, insolvent or unable to pay its debts;

 

Fundamental Representations” shall mean the representations and warranties set forth in Sections 4(a), 4(b), 4(c), 4(d), 4(e), 4(f), 4(j), 4(l), and 4(o);

 

Government” shall mean any agency, division, subdivision, audit group or procuring office of the Government of Australia or the United States, any state of Australia or the United States, including the employees or agents thereof;

 

 
 

 

GST Act” means as A New Tax System (Goods and Services Tax) Act 1999 (Cth);

 

Guarantee” means any Contract of guarantee, indemnification, assumption or endorsement or any other like commitment of the obligations, liabilities (fixed, contingent or otherwise) or indebtedness of another Person;

 

Intellectual Property” means all intellectual property rights whether protected, created or arising under the Laws of the United States, Australia, or any other jurisdiction, including the following: (i) patents and patent applications; (ii) trademarks and service marks, including all applications and registrations and goodwill related to the foregoing; (iii) copyrights, including all applications and registrations related to the foregoing (including, without limitation, for all designs); (iv) Internet domain names; (v) telephone numbers, electronic mail addresses and social media accounts and registrations, including but not limited to accounts and registrations with Facebook, LinkedIn, Twitter, and other similar services; and (vi) trade secrets, know-how, ideas, creative works, inventions, discoveries, methods, processes, technical data, specifications, research and development information, technology, software or computer programs, and data base;

 

Knowledge of the Seller” or “Seller’s Knowledge” or a similar phrase shall mean, with respect to any matter, the actual knowledge of the Seller, or the Principal Owners as at the date of this agreement;

 

Laws” means all statutes, laws, codes, ordinances, regulations, rules, orders, judgments, writs, injunctions, acts or decrees of any Government entity;

 

Liability” means any liability or obligation of whatever kind or nature (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), including without limitation any liability for Taxes;

 

Lien” shall mean any mortgage, pledge, security interest, encumbrance, lien (statutory or other) or conditional sale agreement, and including claims on title and liens in favor of contractors, carriers, warehousemen, mechanics, materialmen, and subcontractors and statutory or common law liens to secure claims for labor, materials or supplies, and other similar liens and encumbrances;

 

Material Adverse Effect” when used in connection with an entity, means any change, event, circumstance, condition or effect that is or is reasonably likely to be, individually or in the aggregate, materially adverse to: (i) the condition (financial or otherwise), capitalization, properties, prospects, products, assets (including intangible assets), Intellectual Property, liabilities, business, operations or results of operations of such entity and its subsidiaries, taken as a whole, or (ii) such entity’s ability to consummate the Share Purchase or to perform its obligations under this Agreement;

 

Material Adverse Event” means any untoward or negative occurrence (including, without limitation, physical injury) related to the Business or the use of the Products and which has a Material Adverse Effect;

 

Person” shall mean and include any individual, corporation, limited liability company, partnership, joint venture, association, joint-stock company, trust, and any other unincorporated organization or Government;

 

Taxes” shall mean (i) all federal, state, local or foreign taxes, including, but not limited to, income, gross income, gross receipts, capital, production, excise, employment, sales, use, transfer, transfer gain, ad valorem, premium, profits, license, capital stock, franchise, severance, stamp, withholding, employment, unemployment, disability, worker’s compensation, payroll, utility, windfall profit, custom duties, personal property, real property, environmental, registration, alternative or add-on minimum, estimated and other taxes, governmental fees or like charges of any kind whatsoever, and (ii) any interest, penalties, fines, loss, damages, liability, expense or additions thereto whether disputed or not; and (iii) any transference liability in respect of any items described in clauses (i) or (ii) payable by reason of contract assumption, transference liability, operation of law, or otherwise;

 

Tax Return” means any return, declaration, report, claim for refund, information return or statement relating to any taxes, including any schedule or attachment thereto and including any amendment therof;

 

 
 

 

Transaction Documents” shall mean this Agreement, the Share certificates, and the other exhibits and schedules hereto and thereto, and all other agreements, instruments, certificates and other documents to be entered into or delivered by any Party in connection with the transactions contemplated to be consummated pursuant to any of the foregoing;

 

The parties agree that for the purposes of calculating the Australian to US dollar conversion, the exchange rate will be $1.00:US$0.70.

 

2. Share Purchase

 

  (a) Purchase and Sale of the Company Shares. Upon the terms and subject to the conditions herein set forth, Seller agrees to sell, convey, transfer, assign and deliver to Buyer and Buyer agrees to purchase and accept from Seller, on the Closing Date, the Company Shares as set forth on Schedule 2(a), being all of the fully paid ordinary shares in the capital of the Company.

 

  (b) Surrender of the Company’s Share Certificates; Further Cooperation. At the Closing, Seller will deliver to Buyer its certificates representing all of Company Shares owned by Seller. From time to time after the Closing Date, without further consideration, Seller will execute and deliver such other instruments of conveyance and transfer and take such other action as Buyer reasonably may request to effectuate the transaction contemplated by this Agreement. Seller will furnish Buyer with such information and documents in Seller’s possession or under Seller’s control or that Seller can execute or cause to be executed as will enable Buyer to prosecute any and all pending claims, applications and the like which that be assigned hereunder.

 

3. Consideration

 

  (a) Initial Consideration. Upon the terms and subject to the conditions set forth in this Agreement, in reliance on the representations, warranties, covenants and agreements of Seller contained herein, the consideration payable to Seller for the Share Purchase shall be an amount of (i) Three Million Four Hundred Fifty Thousand Australian dollars ($3,450,000 AUD), which will be paid by Buyer at Closing (the “Cash Consideration”); plus (ii) Three Million Five Hundred Seventy One Thousand Four Hundred and Twenty-Eight (3,571,428) shares of the Common Stock of Buyer (the “Equity Consideration”) (collectively, the “Purchase Price”).

 

  (b) Earn-out Payment. As additional consideration for the Company Shares, at such times as provided in this Section 3(b) if the Calculation Period EBITDA is $5,000,000 AUD or more, Buyer shall pay to Seller an amount, if any (the Earn-out Payment), equal to (i)(A) the Calculation Period EBITDA; multiplied by (B) the Earn-out Multiple; minus (ii) the total of $6,500,000 AUD plus the Top Up EBITDA. In the event that the number produced by the formula above is negative, no payment shall be made. In no event shall Buyer be obligated to pay Seller more than Three Million Five Hundred Thousand Dollars ($3,500,000 AUD) in the aggregate for Earn-out Payment. The parties agree to release the Earn-out Payment from the Escrow Account and pay this amount to Seller pursuant to the terms and conditions of this Agreement and the Escrow Agreement.

 

  (c) If the Calculation Period EBITDA is initially less than $5,000,000 AUD (“Initial Period EBITDA”), the parties agree that an amount equal to (A) $5,000,000 AUD, less (B) the Initial Period EBIDTA (“Top Up EBITDA”) will count towards the Calculation Period EBITDA for the purposes of the Earn-out Payment calculation in Section 3(b); provided, however, in no event will the Top Up EBITDA exceed $2,357,912 AUD.

 

  (d) Procedures Applicable to Determination of the Earn-out Payment.

 

    (i) On or before July 15, 2016 Buyer will prepare and deliver to Seller a written statement (an “Earn-out Calculation Statement”) setting forth in reasonable detail its determination of the Calculation Period EBITDA as of June 30, 2016 and its calculation of any resulting Earn-out Payment (an “Earn-out Calculation”).

 

 
 

 

    (ii) Seller will have twenty (20) days after receipt of the Earn-out Calculation Statement (the “Review Period”) to review the Earn-out Calculation Statement. During the Review Period, Seller will have the right to inspect the Company’s books and records for the purposes reasonably related to the determinations of Adjusted EBITDA and the resulting Earn-out Payment. Prior to the expiration of the Review Period, Seller may object to the Earn-out Calculation set forth in the Earn-out Calculation Statement by delivering a written notice of objection (an “Earn-out Calculation Objection Notice”) to Buyer. Any Earn-out Calculation Objection Notice must specify the items in the applicable Earn-Out Calculation disputed by Seller and must describe in reasonable detail the basis for such objection, as well as the amount in dispute. If Seller fails to deliver an Earn-out Calculation Objection Notice to Buyer prior to the expiration of the Review Period, then the Earn-out Calculation set forth in the Earn-out Calculation Statement will be final and binding on the Parties and:

 

  1. the Earn-Out Payment will be payable to the Seller within ten (10) days (or such other period agreed by the parties) of the expiration of the Review Period; and

 

  2. the Buyer and the Seller agree and undertake to immediately provide executed written instruct ions (in accordance with the requirements of the Escrow Agreement) to the Escrow Agent to disburse an amount equal to the Earn-out Payment (in Australian dollars) to the Seller.

 

    (iii) If Seller timely delivers an Earn-out Calculation Objection Notice, Buyer and Seller will negotiate in good faith to resolve the disputed items and agree upon the resulting amount of Adjusted EBITDA and the resulting Earn-out Payment. If Buyer and Seller are unable to reach an agreement within seven (7) days after such Earn-out Calculation Objection Notice has been given, all unresolved disputed items must be promptly referred to an impartial internationally recognized firm of independent certified public accountants, other than Seller’s and Buyer’s accountants (the “Independent Accountant”). The Independent Accountant must be directed to render a written report on the unresolved disputed items as promptly as practicable, but in no event greater than seven (7) days after such submission to the Independent Accountant, and to resolve only those unresolved disputed items set forth in the Earn-out Calculation Objection Notice. If unresolved disputed items are submitted to the Independent Accountant, Buyer and Seller must each furnish to the Independent Accountant such work papers, schedules and other documents and information relating to the unresolved disputed items as the Independent Accountant may reasonably request. The Independent Accountant must resolve the disputed items based solely on the applicable definitions and other terms in this Agreement and the presentations by Buyer and Seller, and not by independent review. The resolution of the dispute and the calculation of Adjusted EBITDA that is the subject of the applicable Earn-out Calculation Objection Notice by the Independent Accountant will be final and binding on the Parties and:

 

  1. the Earn-Out Payment will be payable to the Seller within 10 days (or such other period agreed by the parties) of the resolution of the dispute and calculation of the Adjusted EBITDA by the Independent Accountant; and

 

  2. the Buyer and the Seller agree and undertake to immediately provide executed written instruct ions (in accordance with the requirements of the Escrow Agreement) to the Escrow Agent to disburse an amount equal to the Earn-out Payment (in Australian dollars) to the Seller.

 

    (iv) The fees and expenses of the Independent Accountant will be borne equally by Seller and Buyer.

 

  (e) Post-closing Operation of the Company. The Buyer acknowledges that given the method in which the Earn-out Payment is calculated, it is critical that the Buyer preserves the essence and character of the Business during the Calculation Period.

 

 
 

 

  (f) Subject to the terms of this Agreement, subsequent to the Closing, Buyer will have sole discretion with regard to all matters relating to the operation of the Company; provided, that, during the Calculation Period (i) Buyer shall not change the name of the Company’s product “Flat Tummy Tea”; (ii) Buyer shall operate the Business in the ordinary course of business in the same or similar manner and style using methods, practices, approaches and policies as have been used (or similar to those that have been used) by the Seller and the Principal Owners in the period prior to Closing; (iii) Buyer shall notify Seller as soon as reasonably practicable of any Material Adverse Effect on the Company or the Business; (iv) Buyer shall not make any capital expenditure payments that are unnecessary or larger than necessary in the context of the needs of the Business; (v) the Buyer shall use all reasonable endeavours to manage and conduct the Business as a going concern with all due care and in accordance with normal and prudent practice (having regard to the nature of the Business and good commercial practice and so as to comply with all applicable Laws), in order to preserve the value of the Company; and (vi) Buyer shall protect and maintain the Business and the assets of the Company, in order to properly preserve and grow their value. Buyer shall not, directly or indirectly, take any actions in bad faith that would have the purpose of avoiding or reducing any of the Earn-out Payments hereunder.

 

  (g) Right to Set-off. Buyer will have the right to withhold and set off against any amount otherwise due to be paid pursuant to this Section 3 the amount of Buyer’s Losses to which any of the Buyer Indemnitees are finally determined to be entitled to under Section 12.

 

  (h) Security. The Parties understand and agree that (i) the contingent rights to receive any Earn-out Payment shall not be represented by any form of certificate or other instrument, are not transferable, except by operation of Laws relating to descent and distribution, divorce and community property, and do not constitute an equity or ownership interest in Buyer or the Company, (ii) Seller shall not have any rights as a security holder of Buyer or the Company as a result of Seller’s contingent right to receive any Earn-out Payment hereunder, and (iii) no interest is payable with respect to any Earn-out Payment. However, the Buyer agrees that the amount deposited into the Escrow Account pursuant to clause 3(i) must not be secured by or form part of any secured property in any security document or arrangement granted by either the Buyer or the Company. The Buyer also agrees that any security granted by the Company or the Buyer, and the enforcement of any such security, shall be subject to the Buyer’s obligations to pay the Earn-out Payment and to deposit the amounts in accordance with clause 3(i).

 

  (i) Earn-Out Account. During the Calculation Period the Buyer shall, in each month that the Company’s Adjusted EBITDA exceeds four hundred thousand Australian dollars ($400,000 AUD), deposit seventy percent (70%) of such month’s Adjusted EBITDA into an Australian dollar denominated escrow account (the “Escrow Account”) established pursuant to the terms and conditions of a customary escrow agreement (the “Escrow Agreement”) with Wyrick Robbins Yates & Ponton LLP (the “Escrow Agent”) and where the Escrow Agent, Seller and Buyer are parties thereto. Each monthly deposit shall be made within thirty (30) days after the end of such month. The parties agree that the Escrow Agreement shall be provided and executed at Closing. The Escrow Agreement shall reflect in all material respects the terms and conditions of release of the Escrow Amount to Seller or Buyer, as applicable, set forth in this Section 3. The Escrow Amount shall be held in the Escrow Account until the final determination of the Earn-Out Payment in accordance with this Section 3. To the extent that there is a shortfall between the Earn-out Payment and the amount in the Escrow Account, for any reason, including as a result of foreign currency exchange, the Buyer must pay the difference to the Seller at the same time as the Earn-out Payment is released by the Escrow Agent.

 

4. Representations and Warranties of Seller and the Company.

 

As a material inducement to Buyer to enter into this Agreement and to consummate the transactions contemplated hereby, Seller, the Principal Owners, and the Company jointly and severally represent and warrants as of the date hereof, except as set forth on the Disclosure Schedules (or as disclosed in any other section, subsection or clause of the Disclosure Schedule to the extent that the applicability to such other section, subsection or clause is reasonably apparent on its face) to Buyer as set forth below.

 

  (a) Corporate Organization. The Company is a proprietary limited company duly organized, validly existing and in good standing under the laws of its jurisdiction of formation. The organizational documents which have been furnished to Buyer reflect all amendments made thereto at any time prior to the date of this Agreement and are correct and complete. The minute books and other books and records of the Company, to the extent such minutes exist, have been furnished to Buyer.

 

 
 

 

  (b) Qualification to Do Business. The Company has full corporate power and authority to carry on its business as now being conducted and is entitled to own, lease, or operate the properties and assets now owned, leased, or operated by it. The Company is qualified to do business, is in good standing, and to the Seller’s Knowledge has all required and appropriate licenses in each jurisdiction except jurisdictions in which failure to obtain or maintain such qualification, good standing, or licensing (i) would not, individually or in the aggregate, have or reasonably could be expected to have a Material Adverse Effect or (ii) would result in a material breach of any of the other representations, warranties, or covenants set forth in this Agreement. The Company is duly qualified to conduct the Business as presently conducted by the Company as an Australian corporation. No consent, waiver, approval, order, or authorization of, or registration, declaration, or filing with, any court, administrative agency, or commission or other governmental authority or instrumentality (“Governmental Entity”), or any third party, is required to be made or obtained by Seller or the Company in connection with the execution and delivery of this Agreement by Seller or the consummation by Seller of the transactions contemplated hereby, except for such consents, authorizations, filings, approvals and registrations that, if not obtained or made, would not have a Material Adverse Effect on the Company or such consents, authorizations, filings, approvals and registrations that must occur following Closing.

 

  (c) Authorization and Validity of Agreement. Seller and the Principal Owners have all requisite power and authority to enter into the Transaction Documents and to carry out their obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Seller’s and the Principal Owners’ obligations thereunder have been duly authorized by all necessary corporate, shareholder or member action of Seller and the Principal Owners, and no other proceedings on the part or in respect of Seller or the Principal Owners is necessary to authorize such execution, delivery and performance. The Transaction Documents have been duly executed by Seller and the Principal Owners and constitute its valid and binding obligations, enforceable against Seller and the Principal Owners in accordance with their respective terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

  (d) No Conflict or Violation. Subject to obtaining any consents and approvals set forth in Schedule 4(d), the execution, delivery and performance by Seller of the Principal Owners of the Transaction Documents does not and will not to the Seller’s Knowledge (i)(A) conflict with or result in a breach of the terms, conditions, or provisions of, (B) constitute a default under (whether with or without the passage of time, the giving of notice or both), (C) give any third party the right to modify, terminate or accelerate any obligation under, (D) result in a violation of, or (E) require any consent, exemption or other action by or notice or declaration to, or filing with, any third party of any Government entity pursuant to (1) any organizational documents of the Company; (2) any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; or (3) any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the Seller’s or Principal Owners’ properties or assets is subject; (ii) result in the creation of any Lien or Tax upon the equity or assets of Seller or the Principal Owners; or (iii) otherwise interfere in any material manner with the Business.
     
  (e) Capitalization. The Company Shares are paid up. All of the Company Shares are duly authorized, validly issued and fully paid. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of its shares. There is no outstanding or authorized share appreciation, phantom shares, profit participation, or similar rights with respect to the Company. There are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the shares of the Company.

 

 
 

 

  (f) Assets. The Company has good and marketable title to, or a valid leasehold interest in, all of its assets and properties, free and clear of all Encumbrances, except for liens for Taxes not yet due and payable, and mechanics’ liens, materialmen’s liens, and other liens arising by operation of law, which liens do not in any case materially and adversely affect the Company’s title to its assets, the Company’s use of its assets or the value of such assets. The Company’s assets which are tangible personal property are in reasonably good and serviceable condition, normal wear and tear excepted, have been maintained in accordance with normal industry practice, and are suitable for the purposes for which they are presently used. The Company owns or leases all equipment or other tangible assets that are necessary for the conduct of the Business as presently conducted. No assets are used in the Business that are not owned or leased by the Company and not included in the Assets. The Company operates no business other than the Business and related activities.

 

  (g) Subsidiaries. The Company does not own, directly or indirectly, any shares or other interests in any other entity.

 

  (h) Financial Statements. Attached hereto as Schedule 4(h) are: the Company’s most recent balance sheet, and income statement as of October 31, 2015 (the “Financial Statements”). The Financial Statements have been prepared using consistent accounting principles, presentations, methods, standards, policies, practices, classifications, estimation and adjustment methodologies, assumptions, and procedures. The Company’s books of account and records are complete and correct and accurately reflect all of the assets, liabilities, transactions, and results of operations of the business of the Company. The Financial Statements fairly present in all material respects the results of operations of the Business as of the dates thereof. Seller has delivered to Buyer or its representatives copies of the Financial Statements.

 

  (i) Absence of Certain Changes or Events. Since October 31, 2015, the Company has conducted the Business only in the ordinary course consistent with past practices. Without limiting the generality of the foregoing, since October 31, 2015:

 

    (i) there has been no increase in the compensation or benefits paid or payable by the Company, other than in the ordinary course of business and consistent with past practices, to any of its officers, directors, employees, agents, consultants or shareholders, including any grant of severance or termination pay to any director, officer or employee of the Company, or any deferred compensation or similar agreement (or any amendment to any such existing agreement) with any director, officer or employee of the Company;
       
    (ii) there has been no declaration, setting aside, or payment of dividends or distributions in respect of the Company Shares, any split up or other recapitalization in respect of the Company Shares or any direct or indirect redemption, purchase by the Company, or other acquisition by the Company of any such shares, except dividends declared and paid, or distributions made, prior to the Closing Date to Seller in the ordinary course of business consistent with the past practices of the Company;

 

    (iii) the Company has not waived or compromised any right of material value or any payment, direct or indirect, of any material debt, liability, or other obligation;

 

    (iv) there has been no Material Adverse Effect on the Company;

 

    (v) there has been no issuance, transfer, sale, or pledge by the Company of any Company Shares or other securities or any commitment, option, right, or privilege under which the Company is or may become obligated to issue any shares or other securities; there has been no indebtedness for borrowed money incurred by the Company except such as may have been incurred or entered into in the ordinary course of business; no loan has been made or agreed to be made by the Company, nor has the Company become liable or agreed to become liable as a guarantor with respect to any loan or other indebtedness of the Company or Seller, or any third party;

 

    (vi) there has been no sale, assignment, or transfer of, or royalty arrangement with respect to the Company’s trade names, trademarks, service marks, domain names, web addresses, copyrights (or any interest therein), patent, or logos of material value, or any patent, trademark, service mark, domain name or web address or copyright applications (or any interest therein) used (or that were, or are intended to be used) in the operations of the Business;

 

    (vii) there has been no sale, lease or disposition of, any material property or asset, tangible or intangible, of the Company;

 

 
 

 

    (viii) there has been no actual or, to any Seller’s Knowledge, threatened termination or loss of any (A) material contract, lease, license, permit or other agreement to which the Company was or is a party other than terminations of contracts upon completion of work; (ii) certificate, license, or other authorization required for the continued operation by the Company of any material portion of the Business; or (B) customer or other revenue source, which termination or loss could reasonably be expected to result in loss or revenues to the Company in excess of Twenty-five Thousand Dollars ($25,000.00) per year, and there is no event known to Seller (including, without limitation, the transactions contemplated hereby) that could reasonably be expected to result in any such termination or loss;

 

    (ix) there has been no resignation or termination of employment of any key officer or employee of the Company or, to any Seller’s Knowledge, any impending resignation or termination of employment of any such officer or employee other than the Principal Owners which will resign following the Calculation Period;

 

    (x) there has been no agreement or commitment by the Company or Seller to do any of the things described in this Section 4(i).

 

  (j) Tax Matters

 

    (i) the Company has timely filed all material Tax Returns that it was required to file. All such Tax Returns as so filed disclose all Taxes required to be paid for the periods covered thereby. All material Taxes due and owing by the Company (whether or not shown on any Tax Return) have been paid or provided for in the Company’s balance sheet. The Company is not currently the beneficiary of any extension of time within which to file any Tax Return. There are no Liens for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Company. The Company has withheld and paid, or made provision in its balance sheet for, all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, shareholder, or other third party, and all Tax Returns and forms required with respect thereto have been properly completed and timely filed. Upon and after the acquisition of the Company Shares by Buyer, Buyer will have no, and will not be subject to any, liability, as a successor or otherwise, for or with respect to any Taxes of or pertaining to (i) the Company or (ii) the Business for any period or transactions arising before the Closing other than as provided for on its balance sheet. For the avoidance of doubt, the Seller and Principal Owners do not represent or warrant that there will not be any taxes payable or liabilities arising on or after Closing in relation to the Share Purchase.

 

    (ii) There is no material dispute or claim concerning any Tax liability of the Company either (A) claimed or raised by any authority in writing or (B) to the Knowledge of the Company.

 

  (k) Absence of Undisclosed Liabilities; Indebtedness. Except as set forth in the Company’s balance sheet, the Company has no indebtedness or liability, absolute or contingent, involving, affecting or relating to the Business, the Products, or the transactions contemplated by the Transaction Documents.

 

  (l) Intellectual Property.

 

    (i) IP Assets” shall mean all of the following materials owned or licensed by the Company with respect to the Business: (A) the proprietary formulas for the Products; (B) the domain names listed on Schedule 4(l) (collectively, the “Domain Names”); (C) all the content on and accessible through the websites associated with the Domain Names, including demos (collectively, the “Website Content”); and (D) the entire Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Business marketing materials (whether in draft or final form) (collectively, the “Marketing Materials”).

 

    (ii) Schedule 4(l) lists all patented, registered, applied-for, and other Intellectual Property used in the Business, and all Intellectual Property of the Company licensed to any third Person (collectively, the “Business Intellectual Property”), including the registration and application information, date of application or issuance and relevant jurisdiction as to each, and whether or not the Business Intellectual Property is owned or licensed. Business Intellectual Property that is licensed by the Company from a third party is “Licensed Intellectual Property”.

 

 
 

 

    (iii) The Company owns, or will own at Closing, all right, title and interest in and to or has a valid and enforceable license or right to use, all IP Assets, Business Intellectual Property, and the Licensed Intellectual Property, free and clear of all Liens, and all patented or registered Business Intellectual Property is valid and enforceable. The Company has taken commercially reasonable steps to maintain the confidentiality of all information that constitutes a trade secret of the Business. The Company has the valid right to transfer the Intellectual Property included in the Business to Buyer as contemplated hereunder.

 

    (iv) Except as set forth on Schedule 4(l), (A) to the Knowledge of the Seller, the conduct of the Business, including the delivery and distribution of the Products, has not infringed and does not infringe on any Intellectual Property or any other proprietary rights of any Person, including but not limited to the rights of privacy or publicity; (B) to the Knowledge of the Seller, no Person is infringing, violating or misappropriating any Business Intellectual Property; (C) to the Knowledge of the Seller the Company, has not taken any action, or failed to take any action, during prosecution of any application that could reasonably be expected to result in the invalidation or unenforceability of any registered Business Intellectual Property; (D) the Company is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of any Business Intellectual Property; (E) the Company has not received within the prior three (3) years any written notice, and is not currently a party to any pending suit, claiming any alleged infringement or misappropriation of the Intellectual Property rights of other Persons with respect to its or their use of Intellectual Property or the Products; (F) the Company has not entered into any Contract that includes a forbearance to sue or settlement Contract with respect to any Intellectual Property and (G) the Company has not received any written notice of any claim within the prior three (3) years, and is not currently a party to any pending suit, which challenges the validity or enforceability of, the Company’s ownership of or right to use, any Intellectual Property (excluding, for clarity, office actions) or the Products. With respect to the material Intellectual Property of the Company (e.g., product formulas, etc.), Seller has secured valid written confidentiality Contracts and assignments of Intellectual Property from all consultants, contractors, Employees, and customers who contribute or have contributed to the creation, conception, reduction to practice or other development of such Intellectual Property developed on behalf of Seller.

 

    (v) To the Knowledge of the Seller, no Product provided or distributed by Seller in its conduct of the Business: (A) violates any Law in any material respect; (B) includes any information or material that is defamatory in any material respect; or (C) infringes any right of publicity, privacy, or other right of any Person in any material respect.

 

  (m) Compliance with Law. To the Knowledge of the Seller, the manufacture and sale of the Products and the operation of the Business has been conducted in material compliance with all applicable Laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Company and its assets, properties and operations. The Company has not received notice of any violation (or possible violation) of any such Law or other legal requirement, and the Company is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or Governmental or regulatory authority, applicable to the Company, the Business, or the Company Shares. To the Seller’s Knowledge, the Company holds all Permits required for the conduct of the Business and the ownership of its properties. No written notices have been received by the Company alleging the failure to hold any Permit. To the Seller’s Knowledge, the Company is in compliance with all terms and conditions of all such Permits. All of such Permits shall be available for use by Buyer immediately after the Closing. Without limiting the foregoing, the Company has not received any warning letter or untitled letter, report of inspectional observations, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the any governmental entity or any institutional review board or independent ethics committee alleging a lack of material compliance by Company with any Laws. No “bulk sales” or similar Law applies to the transactions contemplated by this Agreement.

 

  (n) Litigation. There are no claims, Actions, suits, proceedings, complaints or investigations pending or, to the Knowledge of the Seller, threatened before any court or governmental or regulatory authority, domestic or foreign, or before any arbitrator of any nature, brought by or against the Company or any of its officers, directors, employees, agents or Affiliates, or the Principal Owners, involving, affecting or relating to the Company, the Business, the Company Shares, or the transactions contemplated by the Transaction Documents.

 

 
 

 

  (o) Brokerage. Except for payment to be made to Go Capital set forth on Schedule 4(o), the Company has not incurred, and shall not incur, any brokerage, finder’s or similar fee in connection with the transactions contemplated by this Agreement.

 

  (p) Insurance. The Company is currently insured by insurers unaffiliated with the Company with respect to its properties, assets and operation of the Business in such amounts and against such risks which are appropriate and customary for the type of business conducted by the Company with customary deductibles and retained amounts. With respect to each insurance policy held by the Company (the “Insurance Policies”) (i) such Insurance Policy is legal, valid, binding and in full force and effect; (ii) the Company is not in default under such Insurance Policy; and (iii) the Company has delivered a true and correct copy of such Insurance Policy to Buyer. There are no claims by the Company pending under any such Insurance Policies and the Company has not been informed that coverage has been questioned, denied or disputed by the underwriters of such Insurance Policies with respect to any such claims.

 

  (q) Employment Matters. Schedule 4(q) separately sets forth all of the Employees as of the date hereof, including for each such Employee: name, job title, designation, work location (identified by street address), current compensation paid or payable, all wage arrangements, fringe. No Employee is a party to, or is otherwise bound by, any Contract or arrangement, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Employee’s duties. Each current Employee has executed, or will have executed as of Closing, a nondisclosure and assignment-of-rights Contract for the benefit of the Company vesting all rights in work product created by the Employee, during the Employee’s employment or affiliation with the Company, in the Company. To the Knowledge of the Seller and except as set forth on Schedule 4(q), no Employee other than the Principal Owners intends to terminate his or her employment with the Company. The Company has, or will have no later than the Closing Date, included provision for all accrued salaries, bonuses, commissions, wages, severance and accrued vacation pay of the Employees due to be paid through the Closing Date in the Company’s accounts / financial statements. The Company is in compliance, in all material respects, with all Laws governing the employment of labor.

 

  (r) Contractor Matters. The Seller has or will, prior to the Closing Date, disclose a list of the name (if an entity, including the name of the individuals employed by or providing service on behalf of such entity) and contact information of each material independent contractor, consultant, freelancer or other service provider (collectively, “Contractors”) used by the Company at any point during the prior one (1) year. A copy of each Contract relating to the services any Contractor provides to the Business has been provided to the Company. To the Knowledge of the Seller, no Contractor used by the Company is a party to, or is otherwise bound by, any Contract or arrangement with any third party, including any confidentiality or non-competition Contract, that in any way adversely affects or restricts the performance of such Contractor’s duties for the Company. To the Knowledge of the Seller, no current Contractor used by the Company intends to terminate his or her or its relationship with the Company. The Company has no obligation or Liability with respect to any Taxes (or the withholding thereof) in connection with any Contractor. The Company has properly classified, pursuant to any applicable Law, all Contractors used by the Company at any point.

 

  (s) Employee Benefits. The Company does not maintain or contribute to any Employee Benefit Plans other than in respect to the bonus and incentives available to its Employees. .

 

  (t) Environmental and Safety Matters. The Company has complied and is in compliance with all Environmental Laws, including but not limited to all Permits required by Environmental Laws for the conduct of the business operations of the Company and the disposition of all hazardous materials in accordance with all applicable Environmental Laws in all material respects. The Company has not received any outstanding and unresolved written or oral notices, reports or other information regarding any actual or alleged violation of Environmental Laws by the Company, or any Liabilities or potential Liabilities, including any remedial obligations, relating to any of them or their facilities arising under Environmental Laws.

 

 
 

 

  (u) Real Property. Schedule 4(u) sets forth the address of each leased real property of the Company (the “Leased Real Property”), and a true and complete list of all leases (including all amendments, extensions, renewals, Guarantees and other Contracts with respect thereto) for each such Leased Real Property (including the date and name of the parties to such lease or license document) (the “Leases”). Seller has delivered to Buyer a true and complete copy of each Lease, and in the case of any oral Lease, a written summary of the material terms of such Lease. With respect to each of the Leases: (i) such Lease is legal, valid, binding, enforceable and in full force and effect; (ii) the transactions set forth in this Agreement do not require the consent of any other Person to such Lease, or such consent has been obtained, shall not result in a breach of or default under such Lease, or otherwise cause such Lease to cease to be legal, valid, binding, enforceable and in full force and effect on identical terms following the Closing; (iii) the Company’s possession and quiet enjoyment of the Leased Real Property under such Lease has not been disturbed, and there are no disputes with respect to such Lease; (iv) the Company, and any other party to the Lease, is not in breach or default under such Lease, and no event has occurred or circumstance exists which, with the delivery of notice, the passage of time or both, would constitute such a breach or default, or permit the termination, modification or acceleration of rent under such Lease; (v) no security deposit or portion thereof deposited with respect to such Lease has been applied in respect of a breach or default under such Lease which has not been redeposited in full; (vi) the Company does not owe, or shall not owe in the future, any brokerage commissions or finder’s fees with respect to such Lease; (vii) the other party to such Lease is not an Affiliate of, and otherwise does not have any economic interest in, the Company; (viii) the Company has not subleased, licensed or otherwise granted any Person the right to use or occupy such Leased Real Property or any portion thereof; (ix) the Company has not collaterally assigned or granted any other security interest in such Lease or any interest therein; (x) there are no Liens on the estate or interest created by such Lease; and (xi) all buildings, structures, improvements, fixtures, building systems and equipment, and all components thereof, included in the applicable Leased Real Property are in good condition and repair (fair wear and tear excepted). The Company does not own any real property, nor has it ever owned any real property.

 

  (v) Affiliate Transactions. No shareholder, officer, director, member or Affiliate of the Company or any individual related by blood, marriage or adoption to any such individual or any entity in which any such Person or individual owns any beneficial interest, is a party to any Contract or transaction with the Company or has any interest in any real, tangible or intangible asset or property used by the Company.

 

  (w) Product and Service Warranties; Adverse Events. The Company has made no express warranty or Guarantee to any customer or Client as to services or goods provided by the Company other than those required to be provided by Law. There is no pending or, to the Knowledge of the Seller, threatened claim alleging any breach of any warranty or Guarantee. There have not been any Material Adverse Events with respect to the Products or the Business.

 

  (x) Guaranties. The Company is not a guarantor or otherwise liable for any liability, indebtedness or other obligation of any other Person.

 

  (y) Status. Seller represents and warrants that (i) it has had an opportunity to discuss the business, management and financial affairs of Buyer, has had access to, the management of Buyer, and has had the opportunity to review the information set forth in Buyer’s public filings and any other information requested by Seller, (ii) Buyer will be relying upon Seller’s representations and warranties set forth herein in offering the Company Shares to it, and (iii) it has retained and consulted with a “Purchaser Representative,” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “1933 Act). Seller further represents and warrants that: (i)(A) it recognizes that ownership of the Equity Consideration involves substantial risks, including a risk of total loss of the value of the Equity Consideration, and has taken full cognizance of and understands all of the risk factors related to the ownership of the Equity Consideration; (B) it has sufficient knowledge and experience in business and investments, including financial, business and tax matters, to be capable of evaluating the merits and risks of ownership in the Buyer and making an informed decision about ownership in the Buyer, and (C) it has an adequate net worth and means of providing for its current needs and possible contingencies to sustain a complete loss in the Equity Consideration; or (ii) it is an “accredited investor” as such term is defined in Rule 501 of Regulation D.

 

 
 

 

  (z) Acquisition for Own Account. This Agreement is made with Seller and Principal Owners in reliance upon such parties’ representations to Buyer, which by its execution hereof Seller and the Principal Owners hereby confirm that the Equity Consideration to be received by it will be acquired for investment for Seller’s own account, not as a nominee or agent, and not with a view to the sale or distribution of any part thereof other than as permitted under the 1933 Act and that it has no present intention of selling, granting participation in, or otherwise distributing the same other than what is permitted under the 1933 Act. By executing this Agreement, Seller further represents that it does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Equity Consideration.

 

  (aa) No Intention to Distribute. Seller and the Principal Owners understand that the Equity Consideration shares have not been registered under the 1933 Act on the grounds that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the 1933 Act, and that Buyer’s reliance on such exemption is predicated in part on the representations set forth herein. Seller and the Principal Owners realize that the basis for the exemption may not be present if, notwithstanding such representations, Seller or the Principal Owners have in mind merely acquiring the Equity Consideration shares for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. Seller and the Principal Owners do not have any such intention.

 

  (bb) No Registration. Seller and the Principal Owners understand that the Equity Consideration may not be sold, transferred or otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the shares or an available exemption from registration under the 1933 Act, the Equity Consideration must be held indefinitely. In particular, Seller and the Principal Owners are aware that the shares may not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about Buyer. The Seller and Principal Owners represent that, in the absence of an effective registration statement covering the Equity Consideration shares, it will sell, transfer, or otherwise dispose of such shares only in a manner consistent with its representations set forth herein and then only in accordance with the provisions of this Agreement.

 

  (cc) Restrictions on Transfer. Seller agrees that in no event will it make a transfer or disposition of any of the Equity Consideration (other than pursuant to an effective registration statement under the 1933 Act or a Rule 144 sale in compliance with the terms of such Rule or pursuant to an exemption from the 1933 Act. Buyer shall cooperate with Seller and Seller’s transfer agent in the removal of any legend on the shares constituting the Equity Consideration to permit the trade or liquidation thereof in the marketplace as permitted under Rule 144 of the 1933, if requested by Seller.

 

  (dd) Inventory. All inventory of the Company, whether or not reflected in the Balance Sheet, consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such inventory is owned by the Company free and clear of all encumbrances, and no inventory is held on a consignment basis. The quantities of each item of inventory are not excessive, but are reasonable in the present circumstances of the Company.

 

  (ee) Customers. The due diligence materials provided by the Company to Buyer includes information regarding each customer who has paid consideration to the Company for goods or services rendered for each of the last two (2) most recent fiscal years, and the amount of consideration paid.

 

  (ff) Contracts; Agreements.

 

    (i) Except as disclosed in Schedule 4(ff), the Company is not a party to or bound by any oral or written Contract or obligation that individually has a value in excess of $15,000, has a term of greater than two (2) years or is otherwise material to the Company or its businesses, operations, financial condition, properties or assets.

 

 
 

 

    (ii) Each agreement, contract, plan, lease, arrangement or commitment required to be disclosed pursuant to this Section 4(ff) (each, a “Material Contract”) is a valid and binding agreement the Company and is in full force and effect with respect to the Company and, to the Knowledge of the Seller, each other party thereto, and neither the Company, nor to the Knowledge of the Seller, any other party thereto, is in default or breach in any material respect under the terms of any such Material Contract, and, to the Knowledge of the Seller, no event or circumstance has occurred that, with notice or lapse of time or both, would reasonably be expected to constitute any event of default thereunder. True and complete copies of each such Material Contract have been made available to Buyer. The Company has fulfilled all material obligations required pursuant to each Material Contract to have been performed by the Company prior to the date hereof, and, to the Knowledge of the Seller, without giving effect to the Share Purchase and the other transactions contemplated by this Agreement, the Company will be able to fulfill, when due, all of its obligations under the Material Contracts that remain to be performed after the date hereof.

 

    (iii) No Person is renegotiating or seeking to renegotiate, or, to the Knowledge of the Seller, has a right (absent any default or breach of a Material Contract) pursuant to the terms of any Material Contract to renegotiate, any material amount paid or payable to the Company under any Material Contract or any other material term or provision of any Material Contract. The Company has not received any written indication or, to the Knowledge of the Company, verbal indication of an intention to terminate or renegotiate the terms of any of the Material Contracts by any of the parties to any of the Material Contracts.

 

  (gg) Seller is a “non-U.S. Person” (as defined in Regulation S promulgated under the 1933 Act) and (i) the transaction contemplated by this Agreement constitutes an “offshore transaction” (as such term is defined in Regulation S) and (ii) the Equity Consideration will be for investment for the Seller’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof in the U.S. or to a U.S. resident, and that Seller has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, Seller further represents that it (A) does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer, or grant participations to such person, or to any third person in the U.S. or to a U.S. resident, with respect to any of the Equity Consideration; (B) agrees to resell the Equity Consideration only in accordance with the provisions of Regulation S of the 1933 Act, pursuant to registration under the 1933 Act, or pursuant to an available exemption from registration under the 1933 Act; and (iii) agrees not to engage in hedging transactions with respect to such Equity Consideration unless otherwise in compliance with the 1933 Act. Seller acknowledges that, to its knowledge, neither the Buyer, nor any of its affiliates, nor any person acting on its or their behalf has engaged in any directed selling efforts in violation of the requirements of Regulation S.

 

5. Limitations to representations and warranties of the Seller and the Company and Actions

 

  (a) The Buyer acknowledges and agrees that the Seller, the Principal Owners and the Company have disclosed or are deemed to have disclosed against the representations and warranties of Seller and the Company, and the Buyer is aware of, and will be treated as having actual knowledge of, all facts, matters and circumstances that:

 

    (i) are within the actual knowledge of the Buyer or its advisers in relation to the Share Purchase; and

 

    (ii) are fairly disclosed in the Disclosure Schedules and the due diligence material in relation to the Business and the Company that have been provided to the Buyer.

 

  (b) The warranties and representations of the Seller and Principal Owners are given subject to the disclosures or deemed disclosures described in Section 5(a). The Seller and the Principal Owners will have no liability under the representation and warranty of Seller and the Principal Owners to the extent that disclosure is made or is deemed to have been made against the representations and warranties given under Section 4.

 

  (c) It shall not be a breach of a representation and warranty of Seller and the Company, if the facts, matters or circumstances giving rise to such Action are fairly disclosed or are deemed to have been fairly disclosed under Section 5(a).

 

  (d) Neither the Seller nor the Principal Owners are liable under an Action for any Liability to the extent that the Buyer recovers, or is compensated for by any other means, from another source whether by way of contract, indemnity or otherwise (including under a policy of insurance or from a government agency).

 

 
 

 

  (e) This Section 5 does not prevent the Buyer being entitled to commence an Action under this Agreement or a Transaction Documents. However, if for any reason more than one amount is paid in respect of the same Liability, the Buyer must procure that the amount in excess of the amount of the Liability (less the costs and expenses of making the claim or commencing the Action) is immediately repaid to the Seller to give full effect to this Section 5.

 

  (f) The Buyer must:

 

    (i) take all reasonable actions (subject to being indemnified by Seller against all reasonable costs and expenses incurred) to mitigate any Liability that may give rise to an Action, including, if the Buyer is entitled to recover, or be compensated for by any other means, any Liability from another source the Buyer must use all reasonable endeavours to recover or be compensated for or procure that such Liability is recovered or compensated for as soon as practicable from that source. The Buyer must notify its insurers of this Section 5(f).

 

    (ii) not omit to take any reasonable action that would mitigate any Liability that may give rise to an Action.

 

  (g) Neither the Seller nor the Principal Owners are liable under any Action, other than Action in respect of Tax, for any Liability to the extent that Liability:

 

    (i) (provisions in accounts) has been included as a provision, allowance, reserve or accrual in the Company’s accounts or financial statements that have been provided to the Buyer or that arises in respect of a matter that has been noted in the Company’s accounts or financial statements that have been provided to the Buyer;

 

    (ii) (contingent losses): is contingent, unless and until the Liability becomes an actual Liability and is due and payable;

 

    (iii) (change of law or interpretation): arises from:

 

    (iv) the enactment or amendment of any legislation or regulations;

 

      (1) a change in the judicial or administrative interpretation of the law; or
         
      (2) a change in the practice or policy of any governmental agency,

 

after the date of Closing, including legislation, regulations, amendments, interpretation, practice or policy that has a retrospective effect;

 

    (v) (consequential loss): is special, indirect or consequential loss or damage including loss of profit or loss of reputation;

 

    (vi) (post Closing conduct):arises from anything done or not done after Closing by or on behalf of the Buyer or its Affiliates that is outside the ordinary course of the Business and the Buyer was aware or ought reasonably be aware would give rise to an Action against the Seller or the Principal Owners;

 

    (vii) (promoted claims): arises from an Action initiated by a third party that is attributable to anything done or not done after Closing by or on behalf of the Buyer or its Affiliates that was calculated or intended to cause the Action initiated by the third party to be made;

 

    (viii) (change in accounting policy): would not have arisen but for a change after Closing in any accounting policy or practice of the Buyer that applied before Closing;

 

    (ix) (change of Business): arises out of the cessation or alteration of the Business after Closing;

 

    (x) (legal costs): is not a reasonable legal cost; and

 

    (xi) (remediable loss): is remediable, provided it is remedied to the satisfaction of the Buyer, acting reasonably, within 45 days after the Seller or Principal Owners receives written notice of an Action or a Direct Claim in accordance with this Agreement.

 

6. Representations And Warranties Of The Buyer.

 

Buyer hereby represents and warrants to Seller as follows:

 

  (a) Corporate Organization. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada, and has all requisite power and authority and all necessary governmental authority to own, operate or lease the properties that it purports to own, operate or lease and to carry on its businesses as now conducted. Buyer is duly qualified to do business as a foreign company, and is in good standing in each jurisdiction where the character of its properties owned, operated or leased or the nature of its activities makes such qualification necessary.

 

 
 

 

  (b) Authorization and Validity of Agreement. Buyer has all requisite power and authority to enter into the Transaction Documents and to carry out its obligations thereunder. The execution and delivery of the Transaction Documents and the performance of Buyer’s obligations thereunder have been duly authorized by all necessary company action by Buyer, and no other proceedings on the part of Buyer are necessary to authorize such execution, delivery and performance. Each of the Transaction Documents has been duly executed by Buyer and constitutes its valid and binding obligation, enforceable against it in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights generally and except for the limitations imposed by general principles of equity.

 

  (c) No Conflict or Violation. Subject to obtaining all consents and approvals set forth herein, the execution, delivery and performance by Buyer of the Transaction Documents, to the knowledge of Buyer, (i) does not and will not violate or conflict with any provision of the organizational documents of Buyer; (ii) does not and will not violate any provision of law, rule or regulation, or any order, judgment or decree of any court or other governmental or regulatory authority; (iii) does not violate or will not result in a breach of or constitute (with due notice or lapse of time or both) a default under, or give rise to any acceleration of remedies or any right of termination under, any Contract, lease, sublease, occupancy agreement, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which Buyer is a party or by which Buyer is bound or to which any of Buyer’s properties or assets is subject, except for such breaches, defaults and accelerations as would not have a Material Adverse Effect on the ability of Buyer to consummate the transactions contemplated hereby.

 

  (d) No Event of Insolvency: no Event of Insolvency has occurred in relation to the Buyer, nor is there any act which has occurred or to the best of its knowledge, is anticipated to occur which is likely to result in an Event of Insolvency in relation to the Buyer.

 

  (e) No litigation: the Buyer is not a party to any investigation, prosecution, litigation, legal proceeding, arbitration, mediation or any other form of dispute resolution, and to the best of its knowledge no such proceedings are pending or threatened and there is no circumstance or fact that is likely to give rise to any such proceedings.

 

  (f) Compliance with Applicable Law: To the knowledge of Buyer, Buyer is in compliance in all material respects with the applicable Laws; and

 

  (g) Securities Law: the Buyer:

 

    (i) is a “reporting company” that is subject to the reporting requirements of the Securities Exchange Act of 1934;
       
    (ii) has complied with the periodic reporting requirements of the Securities Exchange Act of 1934; and
       
    (iii) has otherwise complied the requirements of Rule 144 promulgated under the 1933 Act so as to ensure that the Equity Consideration to be received by the Seller will be eligible for exemption from registration under Rule 144 of the 1933 Act and will be freely tradable on the date which is 6 months following the issue of the Equity Consideration, provided that Seller owns less than 10% of the voting securities of Buyer.

 

7. Covenants

 

  (a) Seller Covenants: The Seller covenants as follows:

 

    (i) Consents and Approvals. Seller shall, at its cost and expense, use Commercially Reasonable Efforts to obtain all necessary consents, waivers, authorizations and approvals of all governmental and regulatory authorities, and of all other Persons required to be obtained in connection with the execution, delivery and performance by it of the Transaction Documents.
       
    (ii) Post-Closing Operation of Business. Following the Closing, Seller shall fully cooperate with Buyer to transfer the Business assets and liabilities to Buyer in such a manner as to preserve the value thereof.

 

  (b) Buyer Covenants: The Buyer covenants as follows:

 

    (i) that on the date which is 6 months following the issue of the Equity Consideration, it will take such action as is required to ensure that the Equity Consideration is freely tradable, including, without limitation, requesting removal of any restrictive legend attaching to the Equity Consideration; and

 

    (ii) that the Buyer must pay all relevant taxes for which the Company is liable for and which relate to the period prior to Closing but which are due after Closing has occurred, on or before the due date, subject to the sufficient provision being made for the tax/es in the Company’s Financial Statements.

 

 
 

 

8. Noncompetition, Nonsolicitation and Nondisparagement.

 

  (a) Noncompetition. Seller and the Principal Owners acknowledge that (i) Buyer would not have entered into this Agreement but for the agreements and covenants contained in this Section 8; and (ii) the agreements and covenants contained in this Section 8 are essential to protect the Business and are reasonable and appropriate in scope; (iii) the Business is international in scope; and (iv) the business of Buyer is international in scope. To induce Buyer to enter into this Agreement, Seller and the Principal Owners covenant and agree that during the period commencing on the Closing Date and ending on the fifth (5th) anniversary of the Closing Date (the “Restricted Period”), Seller, the Principal Owners, and their respective Affiliates shall not, directly or indirectly, (A) engage in any business or activity that competes with the Business ; (B) render any services to any Person for use in competing with Buyer in connection with the Business; (C) have an interest in any Person engaged in any business that competes with Buyer in connection with the Business, directly or indirectly, in any capacity, including, without limitation, as a shareholder, officer, director, principal, agent, trustee or consultant or any other relationship or capacity but, for the avoidance of doubt, this shall not include the Seller or the Principal Owners’ engagement of a non-Employee blogger or any other service provider or person for a purpose not related to a business or activity that competes with the Business but who may promote a product for a business that competes with the Business; provided, however, Seller or the Principal Owners may own, directly or indirectly, solely as an investment, securities of any Person which are publicly traded if Seller or the Principal Owner (I) is not a controlling Person of, or a member of a group which controls, such Person and (II) does not, directly or indirectly, own two percent (2%) or more of any class of securities of such Person; or (III) interfere with business relationships (whether formed heretofore or hereafter) between Buyer or any of its Affiliates and customers, suppliers or prospects of the Business.

 

  (b) Employees of the Business. During the Restricted Period, Seller, and the Principal Owners, and their respective Affiliates shall not, directly or indirectly, (i) solicit or encourage any Employee or consultant performing services in connection with the Business to leave the employment or retention of Buyer or any of its Affiliates, or (ii) hire any such Employee or consultant who was performing services in connection with the Business and who has left the employment or retention of Buyer or any of its Affiliates within one (1) year of the termination of such Employee’s employment or consultant’s retention with Buyer or any of its Affiliates.

 

  (c) Customers of the Business. During the Restricted Period, the Principal Owners and Seller, its employees, officers, and directors shall not, directly or indirectly, (i) persuade or attempt to persuade any customer, prospective customer, client, prospective client, supplier or vendor of Buyer or any of its Affiliates not to hire or do business with Buyer or any of its Affiliates or any successor thereto; (ii) solicit for himself or any Person other than Buyer or any of its Affiliates, the business of any Person who is a customer, client, supplier or vendor of Buyer or any of its Affiliates, or was its customer or supplier within one (1) year prior to the time of such solicitation to the extent that such business is similar to the business conducted by such customer or supplier with Buyer. For the avoidance of doubt, this clause shall not prevent the Seller or the Principal Owners from conducting such advertising or marketing for a business that does not compete with the Business nor shall it prevent a previous customer, client, supplier or vendor of the Business from initiating contact with and utilizing the services of any business which is operated by the Seller or the Principal Owners which does not compete with the Business.

 

 
 

 

  (d) Confidential Information. From and after the Closing, the Principal Owners and Seller, its shareholders, employees, officers, and directors shall keep secret and retain in strictest confidence, and shall not use for the benefit of itself or others, all confidential matters relating to the Business or Buyer and its Affiliates, including, but not limited to, “know how”, trade secrets, customer lists, supplier lists, details of consultant and employment Contracts, pricing policies, operational methods, marketing plans or strategies, product development techniques or plans, business acquisition plans, technical processes, designs and design projects, processes, inventions, software, source codes, object codes, systems documentation and research projects and other business affairs (“Confidential Information”), and shall not disclose them to anyone outside of Buyer and its Affiliates; provided, however, this covenant shall not apply to any information which is or becomes generally available to the public other than as a result of disclosure by the Principal Owners or Seller or its respective Affiliates. The Principal Owners and Seller and its respective Affiliates may disclose Confidential Information if required to do so in any legally required government or securities filings, legal proceedings, subpoena, civil investigative demand or other similar process; provided, that Seller and the Principal Owners (i) provides Buyer with prompt notice of such required disclosure so that Buyer may attempt to obtain a protective order, (ii) cooperates with Buyer, at Buyer’s expense, in obtaining such protective order, and (iii) only discloses that Confidential Information which it is absolutely required to disclose as advised by counsel. Notwithstanding anything to the contrary in this Section 8(d), the Principal Owners and Seller, its shareholders, employees, officers, and directors shall be free to use for any purpose the residuals resulting from access to or work with the Confidential Information, provided that such party shall not disclose the Confidential Information except as expressly permitted pursuant to the terms of this Agreement. The term “residuals” means information in intangible form (i.e., not written or other documentary form, including tape or disk), which is incidentally and unintentionally retained in memory by persons who have had access to the Confidential Information, including ideas, concepts, know-how or techniques contained therein and where the source of the Confidential Information has become remote (e.g., as a result of the passage of time or the person’s subsequent exposure to information of a similar nature from other sources) such that the person can no longer identify the Confidential Information’s confidential source; provided, however, that no license to any Company intellectual property is granted under this Section, this Section 8(d) will not supersede or alter any separate agreement between such party and the Company, unless that agreement is acknowledged to be expressly subject to this clause, and residuals do not include any Product formulations.

 

  (e) Nondisparagement. After the Closing Date, Seller and the Principal Owners will not disparage Buyer, any of Buyer’s Affiliates or any of such parties’ shareholders, directors, officers, employees or agents.

 

  (f) Tolling of Covenant Periods. The Restricted Period provided in this Section 8 shall not include and shall be extended beyond, any time during which a party is failing to comply with any provision of this Section 8 with respect to such party.

 

  (g) Blue Penciling. If any term or other provision of this Section 8 is invalid, illegal, or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions of this Section 8 shall nevertheless remain in full force and effect. Upon determination that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties hereto shall negotiate in good faith to, or the arbitrator making such a determination shall, modify this Section 8 so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

9. Employees.

 

During the Calculation Period, the Buyer must retain all Employees including all management Employees with the Company and shall not terminate their employment without the prior written consent of the Seller, such consent shall not be unreasonably withheld, except that Buyer can terminate Employees for cause. Seller shall make all salary, commission, bonus, incentive, vacation pay or other benefit accrual payments, in each case that relate to periods prior to and through the Closing, to Employees as they become due. Buyer shall not be required to provide continuations of any of Seller’s salary arrangements, bonus or incentive pay or other plans, commission arrangements or commission agreements or wage or salary or compensation incentives after the Closing Date.

 

10. Conditions to Obligations of Seller.

 

The obligations of Seller to effect the Closing and to consummate the transactions contemplated by the Transaction Documents are subject to the fulfillment, at or before the Closing Date, of each of the following conditions, any one or more of which may be waived by Seller in its sole discretion:

 

  (a) Representations and Warranties of the Buyer. All representations and warranties made by Buyer in this Agreement shall be true and correct in all material respects (except as to representations and warranties which are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of the date of this Agreement and on and as of the Closing Date as if again made by Buyer on and as of such date.

 

 
 

 

  (b) Performance of the Obligations of the Buyer. Buyer shall have performed in all material respects all obligations required under this Agreement to be performed by it on or before the Closing Date.

 

  (c) Buyer Closing Deliverables. At the Closing, Buyer will:

 

    (i) Deliver to Seller the Cash Consideration in immediately available AUS funds;
       
    (ii) Deliver to Seller the Equity Consideration, including certificates therefor;
       
    (iii) Deliver a certificate executed by the authorized person of the Buyer certifying as to the truthfulness, completeness and accuracy of attached copies of resolutions of the directors of the Buyer authorizing this Agreement and the transactions contemplated hereby; and
       
    (iv) Deliver to the Seller the Escrow Agreement executed by the Buyer and the Escrow Agent.

 

  (d) Pay to Go Capital Pty Ltd the payment set forth on Schedule 4(o) in immediately available funds;
     
  (e) Deliver to Seller a certificate of the Secretary of the State of Nevada, dated reasonably close to the Closing Date, as to the legal existence and good standing of the Buyer in Nevada.

 

11. Conditions to Obligations of Buyer.

 

The obligations of Buyer to consummate the transactions contemplated by the Transaction Documents are subject to the fulfillment, at or before the Closing Date, of each of the following conditions, any one or more of which may be waived by Buyer in its sole discretion:

 

  (a) Representations and Warranties of Seller. All representations and warranties made by Seller in this Agreement shall be true and correct in all material respects (except as to representations and warranties which are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of the date of this Agreement and on and as of the Closing Date as if again made by Seller on and as of such date.
     
  (b) Performance of the Obligations of Seller. Seller has performed in all material respects all agreement, covenants, and obligations required under this Agreement to be performed by it on or before the Closing Date.
     
  (c) Satisfaction of Liabilities and Obligations. All debts, fees, liabilities, payables, Taxes, claims, costs and expenses of or against the Company including, without limitation, all costs, expenses, payables, debts and liabilities arising out of the operations of the Company incurred or arising prior to the Closing will be paid or satisfied by the Company at or before Closing or the Purchase Price will be adjusted therefor at the Closing, except with respect to creditors in the day-to-day operation of the Business with no Lien or security interest in any of the Company’s assets. All cash in excess of zero working capital requirements will have been paid into the Escrow Account established for the segregation of Adjusted EBITDA from July 1, 2015 to October 31, 2015.
     
  (d) Seller Closing Documents. Seller shall have delivered to Buyer the following documents:

 

    (i) all certificates representing all of the Company, duly endorsed in blank or with appropriate share powers;

 

    (ii) a certificate executed by the authorized person of Seller certifying as to the truthfulness, completeness and accuracy of attached copies of resolutions of the of Seller authorizing this Agreement and the transactions contemplated hereby;
       
    (iii) such other documents relating to the transactions contemplated by the Transaction Documents to be consummated at the Closing as counsel to Buyer shall reasonably request in order to complete the share purchase by Buyer;
       
    (iv) a extract of the register maintained by the Australian Securities and Investments Commission, dated reasonably close to the Closing Date, as to the legal existence and good standing of the Company in Australia;
       
    (v) resignations of the officers and directors of the Company in office immediately prior to the Closing; and
       
    (vi) deliver to the Buyer the Escrow Agreement executed by the Seller.

 

 
 

 

12. Indemnification.

 

  (a) Indemnification by Buyer. Buyer shall indemnify and save and hold the Seller and Principal Owners, successors, and assigns (the “Seller Indemnitees”), harmless from and against any and all damages, claims, demands, obligations, liabilities, losses, costs, expenses (including all reasonable attorneys’ fees and expenses of investigation incurred by the Seller Indemnitees in any Action or proceeding between Buyer and the Seller Indemnitees or between the Seller Indemnitees and any third party or otherwise), deficiencies, interests, penalties, impositions, assessments and/ or fines (collectively, “Seller Losses”), whether or not in connection with a third-party claim, arising out of, resulting from or related to (each “Buyer’s Events of Breach”):

 

    (i) any breach of any representation or warranty made by the Buyer in this Agreement or the other Transaction Documents; and
       
    (ii) all acts and omissions in the conduct of the Company and the Business on and after Closing and indemnifies, and must keep indemnified, the Seller Indemnitees against any loss arising in respect of any such acts or omissions after Closing including liability arising out of defects in products sold or services provided by the Buyer after Closing. This indemnity extends to liability that may arise as a result of any of the products so sold or advice given being defective;
       
    (iii) any breach of any covenant or other agreement made by Seller in Section 7(b) of this Agreement,

 

provided, however, that Buyer shall not be liable to make any payment in respect of a claim for indemnification in respect of any breach of any representation or warranty made by the Buyer in this Agreement or the other Transaction Documents until the aggregate of such Seller Losses shall exceed $5,000 (“Threshold”). Once such Seller Losses shall exceed such $5,000 Threshold (“Basket”), the Seller Indemnitees shall have the right to indemnification hereunder, and Buyer and/or its members shall be required to make payment to the Seller Indemnitees in respect of such claim to the full extent of such Seller Losses without reference to or deduction for the $5,000 Threshold up to an aggregate liability cap equal to the value of Cash Consideration as set out in this Agreement (“Cap”), provided, however, that the Basket and Cap shall not apply (and Buyer and its members shall be fully liable) in the case of any claims based on fraud, bad faith, criminal conduct, intentional misrepresentation, or willful misconduct (“Bad Conduct”) or (ii) indemnification under Sections 12(a)(ii) and 12(a)(iii). Notwithstanding anything to the contrary in this Agreement, Seller Indemnitees’ right to indemnification in this Section 12(a) will not apply to the extent that the Seller Losses arise out of or in connection with a Seller Event of Breach.

 

  (b) Indemnification by Seller. Seller and each of the Principal Owners, jointly and severally, shall indemnify and save and hold the Buyer, any Affiliate of the Buyer and their respective directors, officers, managers, employees, successors, and assigns (the “Buyer Indemnitees”), harmless from and against any and all damages, claims, demands, obligations, liabilities, losses, costs, expenses (including all reasonable attorneys’ fees and expenses of investigation incurred by the Buyer Indemnitees in any Action or proceeding between Seller and the Buyer Indemnitees or between the Buyer Indemnitees and any third party or otherwise), deficiencies, interests, penalties, impositions, assessments and/ or fines (collectively, “Buyer Losses”), whether or not in connection with a third-party claim, arising out of, resulting from or related to any and/or all of Seller’s Events of Breach.
     
  (c) As used herein, “Seller’s Events of Breach” shall be and mean any one or more of the following:

 

    (i) any breach of any representation or warranty made by Seller or the Principal Owners in this Agreement or the other Transaction Documents;
       
    (ii) any Seller employee benefit plan in existence prior to the Closing Date, whether such Liability arises before, on or after the Closing Date, including, without limitation, unfunded Liabilities, Liability with respect to the termination of any such plan, any retiree from employment with Seller, any unfunded Liability under any such plan, or any accrued but unpaid claim under such Seller employee benefit plan;
       
    (iii) the employment (including the initial hiring and all terms, conditions, and events relating to the ongoing employment prior to the Closing Date) or termination of employment (including constructive termination) by Seller of any individual (including without limitation the Principal Owners and any current or former employee of Seller), including any compensation due to the Employees or Contractors relating to periods ending on or prior to the Closing Date, including, without limitation, severance, salary, commission, bonus, incentives, vacation pay or other benefit accruals or any termination liability; and

 

 
 

 

    (iv) any Liability relating to common law or statutory dissenter’s rights, appraisal rights, or any similar rights of the shareholders or owners of Seller,
       
    (v) any breach of any covenant or other agreement made by Seller in Section 7(a) or Section 8 of this Agreement,

 

provided, however, that neither Seller nor the Principal Owners shall be liable to make any payment in respect of a claim for indemnification in respect of any Seller’s Events of Breach until the aggregate of such Buyer Losses shall exceed $5,000 (“Threshold”). Once such Buyer Losses shall exceed such $5,000 Threshold (“Basket”), the Buyer Indemnitees shall have the right to indemnification hereunder, and Seller and/or its members shall be required to make payment to the Buyer Indemnitees in respect of such claim to the full extent of such Buyer Losses without reference to or deduction for the $5,000 Threshold up to an aggregate liability cap equal to the Cash Consideration (“Cap”), provided, however, that the Basket and Cap shall not apply (and Seller and its members shall be fully liable) in the case of any claims based on (i) a breach of any Fundamental Representations, (ii) fraud, bad faith, criminal conduct, intentional misrepresentation, or willful misconduct (“Bad Conduct”), or (iii) indemnification under Sections 12(c)(ii) through 12(c)(v).

 

  (d) All representations, warranties, covenants and obligations of Buyer, Seller and/or the Principal Owners, and all other agreements or instruments contemplated hereby to which Buyer or Seller, or the Principal Owners, is a party shall survive the Closing Date for twelve (12) months, except that: (i) all covenants and agreements which by their terms contemplate performance after the Closing Date shall survive the Closing for a period of four (4) years, unless specified otherwise by their terms; and (ii) for breaches of any Fundamental Representations or Bad Conduct, the survival period shall be four (4) years. Notwithstanding the above, any claim for indemnification made in accordance with this Section 12 prior to the expiration of the applicable indemnification period set forth in this paragraph shall survive until such matter is resolved. For the avoidance of any doubt, a Buyer’s Claim Notice must have been received in accordance with clause 12(g)(i) prior to the expiration of the applicable indemnification period set forth in this paragraph in order for the claim to survive the applicable indemnification period.
     
  (e) Following the Closing, the indemnification afforded by this Section 12 shall be the sole and exclusive remedy of the Buyer Indemnitees in respect of claims for Seller’s Events of Breach.

 

  (f) For purposes of this Section 12, any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty.
     
  (g) Procedures for Indemnification by the Seller.

 

    (i) Notice of Claims. If a Seller’s Event of Breach occurs or is alleged and a Buyer Indemnitee asserts that Seller has become obligated to such Buyer Indemnitee pursuant to Section 12 hereof (“Direct Claim”), or if any suit, Action, investigation, claim or proceeding (a “Third Party Proceeding”) is threatened, begun, made or instituted by a third party as a result of which Seller may become obligated to a Buyer Indemnitee hereunder, such Buyer Indemnitee shall give written notice thereof to Seller which must contain full details of the Direct Claim or Third Party Proceeding then known to the Buyer of the events, matters or circumstances giving rise to the claim (the “Buyer’s Claims Notice”). The Buyer’s failure or delay in providing the Buyer’s Claim Notice shall not relieve Seller or its obligations under this Section except to the extent that Seller is materially prejudiced as a result thereof. If a Buyers’ Event of Breach occurs or is alleged and a Seller Indemnitee asserts that Buyer has become obligated to such Seller Indemnitee pursuant to Section 12 hereof (“Seller Direct Claim”), or if any Third Party Proceeding is threatened, begun, made or instituted by a third party as a result of which Buyer may become obligated to a Seller Indemnitee hereunder, such Seller Indemnitee shall give written notice thereof to Buyer which must contain full details of the Seller Direct Claim or Third Party Proceeding then known to the Seller of the events, matters or circumstances giving rise to the claim (the “Seller’s Claims Notice”). The Seller’s failure or delay in providing the Seller’s Claim Notice shall not relieve Buyer or its obligations under this Section except to the extent that Buyer is materially prejudiced as a result thereof.

 

 
 

 

    (ii) Response to Direct Claims. Seller shall have thirty (30) days after receipt of the Buyer’s Claim Notice for a Direct Claim to reject or accept the claim as an indemnifiable claim for Buyer Losses under Section 12. If, within thirty (30) days after receipt by Seller of such a Buyer’s Claim Notice, Seller delivers notice to the Buyer Indemnitee containing a written objection to the claim (or a portion thereof) by the Buyer Indemnitee, stating the nature of and grounds for such objection in reasonable detail, then such claim (or portion thereof) shall be deemed to be a “Disputed Claim” and such claim shall be resolved in accordance with Section 12. If, within thirty (30) days after actual receipt by Seller’s of the Buyer’s Claim Notice for a Direct Claim, Seller delivers notice to the Buyer Indemnitee containing a written acceptance of the claim, (or a portion thereof) then such claim (or portion thereof) shall be deemed an indemnifiable claim under this Section 12 (the “Indemnifiable Claim”), and Seller will be conclusively deemed to have consented to recovery by the Buyer Indemnitee of the full amount of Buyer Losses subject to offset for the Basket in connection with the claim, if applicable.

 

  (h) Dispute Resolution. Any disputes arising under this Section 12 shall be resolved as follows: (i) first, the Parties shall attempt in good faith for thirty (30) days to resolve the dispute, and (ii) if the dispute remains unresolved after such thirty (30) day period, the Parties agree that Section 14(c) will apply.
     
  (i) Third Party Proceeding. Seller shall have twenty (20) days from receipt of a Buyer’s Claim Notice for a Third Party Proceeding to provide the Buyer Indemnitee with notice that it wishes to assume the defense in the Third Party Proceeding and acknowledges liability for such damages, in which event the Buyer Indemnitee shall have the right to participate in the defense at its own expense; provided, however, that the Buyer Indemnitee is hereby authorized prior to and during such time to file any motion, answer or other pleading that it shall deem necessary or appropriate to protect its interests and that is not prejudicial to Seller. If Seller fails to give the Buyer Indemnitee timely notice as provided herein, the Buyer Indemnitee shall have the right to defend against such Third Party Proceeding. If Seller assumes the defense in a Third Party Proceeding, (i) the Indemnifying Party shall not agree to any settlement, compromise or discharge of a Third-Party Claim without the Indemnified Party’s prior written consent; and (ii) the Buyer must provide the Seller and the Principal Owners with all reasonable assistance requested by them in relation to the Third Party Proceeding, including providing access to witnesses and documentary or other evidence relevant to the Third Party Proceedings, allow them and their advisers to inspect and take copies of all relevant books, records, files and documents, and providing them with reasonable access to the personnel, premises and chattels of the Seller for the purposes of obtaining information in relation to the Third Party Proceeding.
     
  (j) If the Indemnifying Party does not assume the defense of a Third-Party Claim, the Indemnified Party shall be entitled to undertake any settlement, compromise or discharge of such Third-Party Claim without the Indemnifying Party’s prior consent. Notwithstanding anything herein to the contrary, Seller and the Principal Owners shall not be entitled to assume control of the defense in a Third Party Proceeding, and shall pay the reasonably documented fees and expenses of legal counsel retained by the Buyer Indemnitees if: (i) Buyer reasonably believes that an adverse determination of such claim could be detrimental to the Buyer’s business; (ii) Buyer reasonably believes that a conflict of interest exists or could reasonably arise which, under applicable principles of legal ethics, could prohibit a single legal counsel from representing both the parties in such proceeding, other than a conflict which may exist due to the underlying nature of the duty to indemnify; (iii) a court of competent jurisdiction rules that Seller has failed or is failing to prosecute or defend such claim; (iv) such claim seeks damages other than monetary damages; or (v) such claim involves conduct of the Business both before and after the Closing.

 

  (k) Notwithstanding the provisions of Section 12(g), Seller hereby consents to the nonexclusive jurisdiction of any court in which an Action or claim in respect of a Third Party Proceeding is brought against any Buyer Indemnitee for purposes of any claim that a Buyer Indemnitee may have under this Agreement with respect to such Action or claim or the matters alleged therein and agrees that process may be served on Seller with respect to such a claim anywhere in the world.
     
  (l) Indemnification Binds Successors and Assigns. All of the indemnification rights of the Buyer and obligations of Seller arising pursuant to this Section 12 shall apply to and bind each and every successor and assign of Buyer and Seller.
     
  (m) Dispute Resolution Costs. Each Party shall bear all its own costs of any court Action or other dispute resolution proceeding hereunder, including without limitation, the fees and expenses of its own legal counsel and other filing fees and expenses of such Party for such proceeding.

 

 
 

 

13. Termination.

 

  (a) Conditions of Termination. Notwithstanding anything to the contrary contained herein, this Agreement may be terminated at any time before the Closing:

 

    (i) By mutual consent of Seller and Buyer;
       
    (ii) By either Seller or Buyer if the other Party shall have breached this Agreement in any material respect and such breach continues for a period of ten (10) days after the receipt of written notice of the breach from the non-breaching Party; or

 

  (b) Effect of Termination. If this Agreement is terminated in accordance with Section 13 hereof, this Agreement shall become null and void and have no effect, with no liability on the part of Seller or Buyer, or their Affiliates and their respective directors, managers, officers, agents, members or shareholders, except for the obligations set forth in this Section 13, Section 11, which shall survive any termination; and provided, however, that notwithstanding the foregoing, nothing herein and no termination hereof shall relieve any Party from liability for any breach of any of its representations, warranties, covenants or agreements set forth in this Agreement which arise prior to termination.

 

14. Miscellaneous.

 

  (a) Successors and Assigns. Any Party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other Parties hereto; provided that this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Parties hereto.
     
  (b) Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of New York, United States, without giving effect to the principles of conflicts of laws thereof.
     
  (c) Dispute Resolution. Subject to Section 3(c)(iii), any dispute or Action arising in connection with this Agreement shall be referred to and finally resolved under the then applicable rules of the Singapore International Arbitration Centre (SIAC) , which SIAC Rules are deemed to be incorporated by reference into this clause. There shall be 3 (three) arbitrators. The seat of the arbitration shall be Singapore. The language to be used in the arbitral proceedings shall be English.
     
  (d) Expenses. Except as otherwise provided herein, each of the Parties hereto shall pay all its own expenses in connection with this Agreement and the transactions contemplated hereby, including, without limitation, any legal and accounting fees, whether or not the transactions contemplated hereby are consummated. Buyer shall be responsible for and shall pay all applicable state and local sales, transfer, excise, value-added or other similar Taxes, and all recording and filing fees that may be imposed by reason of the Share Purchase (collectively, the “Transfer Taxes”). Each party agrees to cooperate with such other party in the timely completion, execution and filing of any documentation required by any local, state, federal or other Tax authority in connection with the Transfer Taxes, including any documentation as may be requested to establish an exemption from (or otherwise reduce) or make a report with respect to the Transfer Taxes.
     
  (e) Goods and Services Tax.

 

    (i) In this Section 14(e), the expressions Input Tax Credit, Supply, Tax Invoice, Recipient and Taxable Supply have the meanings given to those expressions in the GST Act.
       
    (ii) With the exception of any amount payable under this Section 14(e), unless otherwise expressly stated, all amounts stated to be payable in this Agreement are exclusive of GST.
       
    (iii) If GST is imposed on any Supply made under or in accordance with this Agreement, the Recipient of the Taxable Supply must pay to the Supplier an additional amount equal to the GST payable on or for the Taxable Supply. Payment of the additional amount will be made at the same time as payment for the Taxable Supply is required to be made in accordance with this Agreement, subject to the provision of a Tax Invoice.
       
    (iv) If this Agreement requires a party to pay for, reimburse or contribute to any expense, loss, indemnity or outgoing (Reimbursable Expense) suffered or incurred by another party, the amount required to be paid, reimbursed or contributed by the first party will be the sum of:

 

      (1) the amount of the Reimbursable Expense less the Input Tax Credits (if any) to which the other party is entitled in respect of the Reimbursable Expense; and
         
      (2) if the other party’s recovery from the first party is a Taxable Supply, any GST payable in respect of that Supply.

 

  (f) Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

 
 

 

  (g) Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the Party to whom notice is to be given, or (ii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the Party as follows:

 

  If to Seller or any Principal Owner:  
     
    NomadChoice Pty Limited trading as Flat Tummy Tea
    LVI 330 Churchill Ave.
    Subiaco WA 6008 Australia
     
  Copy to: Steinepreis Paganin
    Level 4, the Read Buildings
    16 Milligan Street
    Perth, WA 6000 Australia
     
  If to Buyer: Synergy CHC Corp.
    865 Spring Street
    Westbrook, ME 04092
    Attn: President
     
  Copy to: Wyrick Robbins Yates & Ponton LLP
    4101 Lake Boone Trail, Suite 300
    Raleigh, North Carolina 27607
    Attention: W. David Mannheim

 

Any Party may change its address for the purpose of this Section by giving the other Party written notice of its new address in the manner set forth above.

 

  (h) Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the Parties hereto, or in the case of a waiver, by the Party waiving compliance. Any waiver by any Party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

    (i) Public Announcements. Seller shall not make any public statement regarding this Agreement or the transactions contemplated herein without Buyer’s prior written approval. Buyer shall provide a copy of any public statement to Seller prior to the information being made public.
       
    (ii) Entire Agreement. This Agreement, the exhibits and schedules hereto contains the entire understanding between the Parties hereto with respect to the transactions contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such transactions. All schedules and exhibits hereto and any documents and instruments delivered pursuant to any provision hereof are expressly incorporated herein and made a part of this Agreement as fully as though completely set forth herein. This Agreement shall only be binding on the Parties hereto upon execution and delivery of this Agreement by each of the Parties.
       
    (iii) Parties in Interest. Nothing in this Agreement is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than Seller and Buyer and their respective successors and permitted assigns. Nothing in this Agreement is intended to relieve or discharge the obligations or liability of any third persons to Seller or Buyer. No provision of this Agreement shall give any third persons any right as a third party beneficiary of this Agreement or provide any right of subrogation or Action over or against Seller or Buyer.
       
    (iv) Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.
       
    (v) Counterparts. This Agreement may be executed in counterparts and via .pdf, each of which shall be deemed an original, but all of which shall constitute the same instrument.
       
    (vi) Fulfillment of Obligations. Any obligation of any Party to any other Party under this Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such Party, shall be deemed to have been performed, satisfied, or fulfilled by such Party.

 

 
 

 

    (vii) Remedies. Except as expressly provided in this Agreement, any Person having any rights under any provision of this Agreement, including, without limitation, Section 8, shall be entitled to enforce such rights specifically (without posting a bond or other security), to require: (i) Seller and their respective Affiliates to account for and pay over to Buyer; and (ii) Buyer and its respective Affiliates to account for and pay over to Seller, all payments, profits, monies, accruals, increments or other benefits derived by such party by reason of any breach of any provision of this Agreement, to recover damages and to exercise all other rights granted by Laws. Except as expressly provided in this Agreement, all such rights and remedies shall be cumulative and non-exclusive, and may be exercised singularly or concurrently. The Parties acknowledge that any breach of this Agreement may cause substantial irreparable harm to the other Party. Therefore, this Agreement may be enforced in equity by specific performance, temporary restraining order and/or injunction. The rights to such equitable remedies shall be in addition to all other rights or remedies which a Party may have under this Agreement or under applicable law.
       
    (viii) Further Actions. In case at any time after the Closing any further action is necessary to carry out the purposes of this Agreement, each of the Parties shall take such further action (including the execution and delivery of such further instruments and documents) as any other Party reasonably may request, all at the sole cost and expense of the requesting Party (unless the requesting Party is entitled to indemnification therefore under Section 12).

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the date first above written.

 

EXECUTED by TPR INVESTMENTS
PTY LIMITED
ACN 128 396 654 AS TRUSTEE FOR
THE POLMEAR FAMILY TRUST
in accordance with section 127 of the
Corporations Act 2001 (Cth):
)
)
)
)
 

 

/s/ Tim Polmear  
Signature of director  
   
Tim Polmear  
Name of director  

 

*please delete as applicable

 

EXECUTED by NOMADCHOICE PTY
LIMITED
ACN 160 729 939
in accordance with section 127 of the
Corporations Act 2001 (Cth):
)
)
)
)
 

 

/s/ Timothy Polmear  
Signature of director  
   
Timothy Polmear  
Name of director  

 

[Signature Page to Stock Purchase Agreement]

 

 
 

 

SIGNED by TIMOTHY POLMEAR
in the presence of:
)
)
)
 
     
/s/ Matthew Hawtin   /s/ Timothy Polmear
Signature of witness   Signature
     
Matthew Hawtin    
Name of witness    

 

SIGNED by REBECCA POLMEAR
in the presence of:
)
)
)
 
     
/s/ Matthew Hawtin   /s/ Rebecca Polmear
Signature of witness   Signature
     
Matthew Hawtin    
Name of witness    

 

  SYNERGY CHC CORP.
     
  By: /s/ Jack Ross
  Name:  Jack Ross
  Title: Chief Executive Officer

 

 

 

Exhibit 10.11

 

FIRST AMENDMENT TO LOAN AGREEMENT entered into as of the 12th day of November, 2015 (the “First Amendment”),

 

BETWEEN: KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados;
   
  (hereinafter called the “Lender”)
   
AND: SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada;
   
  (hereinafter called the “Synergy”)

 

WHEREAS Synergy (then known as Synergy Strips Corp.) and the Lender are parties to that certain loan agreement (the “Loan Agreement”) made as of the 21st day of January, 2015, pursuant to which the Lender has extended a loan to Synergy in the principal amount of Six Million United States Dollars (US$6,000,000) (the “Original Loan”);

 

WHEREAS Synergy has requested an additional loan in the principal amount of Five Million Five Hundred Thousand United States Dollars (US$5,500,000) (the “Additional Loan”);

 

WHEREAS the Lender and Synergy desire to amend the Loan Agreement to, inter alia, provide for the Additional Loan on the terms and conditions set forth herein;

 

NOW, THEREFORE, IN CONSIDERATION of these presents and of the mutual covenants hereinafter contained, the parties have agreed as follows:

 

Article 1

interpretation

 

1.1 Capitalized Terms

 

In this First Amendment, capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement as if amended to include the amendments set out in this First Amendment.

 

Article 2

amendments

 

2.1 Amendments to the Loan Agreement

 

The Borrower and the Lender hereby agree to amend the Loan Agreement as follows:

 

  2.1.1 Section 1.1 of the Loan Agreement is amended by inserting or restating the following definitions (as the case may be).

 

2015 First Warrant” means that certain common share stock purchase warrant to be executed by the Borrower and the Lender to give effect to the Lender’s 2015 Immediate Equity issuance.

 

2015 Second Warrant” means that certain common share stock purchase warrant to be executed by the Borrower and the Lender to give effect to the Lender’s 2015 Equity.

 

Additional Loan” means the loan to the Borrower by the Lender in the principal amount of Five Million Five Hundred Thousand United States Dollars (US$5,500,000) pursuant to the First Amendment.

 

 
 

 

Borrower” means Synergy CHC Corp. (formerly known as Synergy Strips Corp.) a corporation incorporated under the laws of the State of Nevada together with all of its Subsidiaries and also includes their respective permitted successors and assigns.

 

Breakthrough” means Breakthrough Products, Inc.

 

Breakthrough Acquisition” means the acquisition by the Borrower of all the issued and outstanding shares of Breakthrough Products, Inc.

 

Business” means the business of the Borrower including the manufacture, distribution, sale of consumer health products, including the products known as Synergy Strips, Flat Tummy Tea and UrgentRX Products.

 

Equity Financing” means the completion, on or prior to the first anniversary of the Second Closing Date, of an offering or offerings of the Borrower’s equity securities or securities convertible into equity securities of at least Two Million Dollars in the aggregate.

 

First Amendment” means the First Amendment to this Agreement entered into as of the 12th day of November, 2015.

 

Lender’s 2015 Equity” means the issuance to the Lender of a ten (10) year warrant to purchase 5% of the common shares of the Borrower, on a fully diluted basis after giving effect to the Lender’s 2015 Immediate Equity and to both the Breakthrough Acquisition and the Nomad Acquisition, at a price per share equal to $0.70, including a full ratchet clause pegged at $0.70 a share.

 

Lender’s 2015 Immediate Equity” means the issuance to the Lender, for no additional consideration, of such number of common shares of the Borrower that will result in the Lender receiving, on a fully diluted basis and after giving effect to (i) the Breakthrough Acquisition, (ii) the Nomad Acquisition, and (iii) the Lender’s 2015 Equity, 6.5% of the common shares of the Borrower, which shares will not be subject to any trading restrictions, other than as required under Applicable Law. For clarity, these shares are in addition to shares of Borrower currently being held by Lender.

 

Lender’s Nomad Distribution Agreement” means the proposed license and distribution agreement among the Borrower, Nomad and the Lender by which (i) Lender shall have exclusive distribution rights to all products of Nomad including the “Flat Tummy Tea” products, in each of Canada, Israel, Romania, Russia and Sub Saharan Africa, and (ii) Lender shall sublicense the direct-to-consumer channel for the said territory back to Nomad for a royalty equal to sixty percent (60%) of Gross Sales.

 

Loan” means, as the context requires, both the Original Loan and the Additional Loan, collectively.

 

Maturity Date” means: (i) with respect to the Original Loan, January 17, 2017 and (ii) with respect to the Additional Loan, November 11, 2017.

 

Nomad” means Nomadchoice Pty Ltd (ABN 41 160 729 939).

 

Nomad Acquisition” means the acquisition by the Borrower of all the issued and outstanding shares of Nomad.

 

Nomad Guarantee” means a guarantee agreement satisfactory to the Lender executed by Nomad in respect of the Obligations.

 

 
 

 

Nomad Purchase Agreement” means that certain Stock Purchase Agreement dated November 12, 2015 among the Borrower, Nomad, TPR Investments Pty Ltd CAN 128 396 654, as trustee for Polmear Family Trust, Timothy Polmear and Rebecca Polmear, effecting the Nomad Acquisition.

 

Nomad Security Documents” means the Security Documents to be granted by Nomad in respect of the Nomad Guarantee.

 

Nomad Vendors” means the vendor’s of the shares of Nomad pursuant to the Nomad Acquisition.

 

Original Loan” means the loan to the Borrower by the Lender in the principal amount of Six Million United States Dollars (US$6,000,000) pursuant to this Agreement.

 

Repayment Schedule” means the Amended and Restated Schedule of Repayment of principal of the Original Loan and the Additional Loan attached this Amendment as Schedule A.

 

Second Closing Date” means November 12, 2015 or such other date on which the Additional Loan is made concurrently with the closing of the Nomad Acquisition.

 

Warrant” means the 2015 First Warrant and the 2015 Second Warrant, together or separately, as the context requires.

 

  2.1.2 The following definitions set forth in the Loan Agreement are amended:

 

Loan Documents” is hereby amended to include this First Amendment, any additional, amended or restated Loan Documents delivered to the Lender in connection with this First Amendment or otherwise in connection with the Loan Agreement, including any Loan Document delivered to the Lender as general continuing collateral security for the payment and performance of the present and future Obligations (including obligations relating to the Additional Loan), as well as any amendments, replacements, supplements or other modifications hereto or thereto or any other documents or instruments contemplated hereby or thereby.

 

Permitted Debt” is amended to include:

 

“(vi) Debt of a maximum of AUD$3,500,000 that may be owed to the Nomad Vendors pursuant to the Nomad Purchase Agreement.”

 

  2.1.3 Section 1 of the Loan Agreement as currently stated shall be renumbered as Section 2.1(a) and refer to the Original Loan only. The following shall be added as Section 2.1(b) in respect of the Additional Loan:

 

“Subject to the terms and conditions of this Agreement and the other Loan Documents, the Lender agrees to loan to the Borrower in lawful money of the United States the Additional Loan on the terms hereof and the Borrower hereby irrevocably authorizes the Lender to make the Additional Loan on the terms hereof. The Additional Loan shall bear interest as set forth in Section 4.1 of this Agreement.

 

The Additional Loan shall be disbursed in two tranches. The first tranche of Three Million Two Hundred Fifty Thousand United States Dollars (US$3,250,000) shall be disbursed upon the satisfaction of the conditions precedent set forth in Section 3.1 of this Agreement.

 

The balance of the Additional Loan, being Two Million Two Hundred Fifty Thousand United States Dollars (US$2,250,000) shall be disbursed upon satisfaction of the conditions precedent set forth in Section 3.2 of this Agreement.”

 

 
 

 

  2.1.4 Section 2.2 of the Loan Agreement as currently stated shall be renumbered as Section 2.2(a) and refers to the Original Loan only. The following shall be added as a new Section 2.2(b) in respect of the Additional Loan:

 

“The Maturity Date of the Additional Loan shall be November 11, 2017.”

 

  2.1.5 Sections 3.2(a) and (b) of the Loan Agreement as currently stated shall be renumbered as Sections 3.2(a)(i) and 3.2(a)(ii) and refer to the Original Loan only. The following shall be added as a new Section 3.2(b) in respect of the Additional Loan:

 

“Subject to the terms hereof, the Borrower may prepay the outstanding principal of the Additional Loan any time following the first anniversary of the Second Closing Date. Such prepayments may only be for a minimum amount of One Million Dollars ($1,000,000) and in additional increments of One Million Dollars ($1,000,000) unless the entire Additional Loan is being prepaid in full. Such prepayment must be accompanied by a prepayment fee of five percent (5%) of the amount of the Additional Loan being prepaid at that time.”

 

  2.1.6 Section 4.3 of the Loan Agreement is hereby amended by deleting the words:

 

“the interest rate otherwise payable pursuant to Section 4.1 plus five percent (5%)” and replacing same by “twenty percent (20%)”

 

  2.1.7 Section 6.1 of the Loan Agreement is hereby amended by adding the following:

 

  “(g) Guarantee Agreement of the Obligations from Breakthrough;
     
  (h) Nomad Guarantee;
     
  (i) General Security Agreement from each of Borrowers’ Subsidiaries including Breakthrough and Nomad;
     
  (j) a collateral assignment from each of Borrower’s Subsidiaries of its interest on all Material Contracts and Material Licenses;
     
  (k) Intellectual Property Security Agreement of each of Borrower’s Subsidiaries;
     
  (l) Subordination Agreement by Nomad Vendors in favour of Knight;
     
  (m) specific security agreement granted by the Borrower in respect of the issued share capital in Nomad.”

 

  2.1.8 Section 7 of the Loan Agreement is amended by adding the following:

 

  “(jj) Nomad Share Purchase Agreement. The accuracy and completeness of each of the representations and warranties set out in the Nomad Purchase Agreement and all such representations and warranties are hereby incorporated into this Agreement by reference as if same were herewith recited at length and made directly by the Borrower for the benefit of Lender. Such representations and warranties shall survive for so long as the Obligations remain outstanding notwithstanding any shorter survival period under the said share purchase agreement.

 

 
 

 

  (kk) Breakthrough Share Purchase Agreement. The accuracy and completeness of each of the representations and warranties set out in the share purchase agreement concerning the Breakthrough Acquisition and all such representations and warranties are hereby incorporated into this Agreement by reference as if same were herewith recited at length and made directly by the Borrower for the benefit of Lender. Such representations and warranties shall survive for so long as the Obligations remain outstanding notwithstanding any shorter survival period under the said share purchase agreement.”

 

  2.1.9 Section 9.1 of the Loan Agreement is amended by adding the following:

 

  “(z) Borrower must maintain separate financial records for the business conducted by Breakthrough (including a separate balance sheet, income statement and cash flow statement);
     
  (aa) following the release of Borrower’s financial statements for the quarter ended March 31, 2015 and at any time thereafter, Borrower shall promptly (and in any event within three (3) Business Days) notify Knight should either (i) the business being conducted by Breakthrough reflect negative EBITDA for the relevant quarter, or (ii) the working capital related to that business fall below Five Hundred Thousand Dollars ($500,000). In such event, Knight may, in its sole discretion, direct Borrower to immediately cease the UrgenRX business. For certainty, failure to do so upon receipt of such direction will be an Event of Default under this Agreement.
     
  (bb) Borrower must ensure that:

 

  (a) Nomad completes a financial assistance whitewash procedure in relation to the Nomad Guarantee and Nomad Security Documents granted in respect thereto in accordance with Section 260B of the Corporations Act 2001 (Cth) by no later than the date that is 30 days after the Second Closing Date; and
     
  (b) the Nomad Guarantee and Nomad Security Documents granted in respect thereto are effective no later than the date that is thirty (30) days after the Second Closing Date.

 

  Failure to comply with this clause will be an Event of Default if not cured within ten (10) Business Days of non-compliance.”

 

 

  2.1.10 Section 9.1(x)(i) of the Loan Agreement is hereby amended by adding the following at the end of that Section:

 

“Commencing with the six (6) month period ending on June 30, 2016, and for each six (6) month period ending on the last day of each Fiscal Quarter thereafter, Borrower shall maintain a minimum EBITDA of One Million Dollars ($1,000,000).”

 

  2.1.11 Section 9.1(x)(iii) of the Loan Agreement is hereby amended by requiring the amount of minimum cash balance to be One Million Dollars ($1,000,000) commencing on June 30, 2016.

 

  2.1.12 Section 9.2 of the Loan Agreement is amended by adding the following:

 

  “(t) Nomad. Make any payment under the Nomad Purchase Agreement if a Default or Event of Default has occurred and is continuing or would occur as a result of making such payment.”

 

 
 

 

  2.1.13 Article 11 of the Loan Agreement is amended by adding the following:

 

  “(u) If the Borrower fails to make any of the “earn-out payments” pursuant to the Nomad Acquisition.
     
  (w) If the Borrower does not complete the Equity Financing by the first anniversary of the Second Closing Date.”

 

  2.1.14 From and after the Second Closing Date, (i) all references in the Loan Agreement to “this Agreement” shall mean the Loan Agreement as amended by this First Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time, and (ii) all references in the other Loan Documents to the “Loan Agreement” (or words of similar import) shall be deemed to be references to the Loan Agreement as amended by this First Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time. All references in any of the Loan Documents to the “Loan Documents” shall mean the Loan Documents as amended by this First Amendment and as may otherwise be amended restated, supplemented or otherwise modified from time to time.

 

  2.1.15 Except as expressly amended by this First Amendment, all other provisions of the Loan Agreement and the Transaction Documents not specifically amended hereby shall remain unchanged and in full force and effect.

 

Article 3

 

CONDITIONS PRECEDENT & closing date

 

3.1 Conditions to Loan by the Lender

 

The effectiveness of this First Amendment and the Lender’s obligation to fund the Additional Loan amount shall be subject to following conditions precedent having been met to the satisfaction of the Lender, or, alternatively, waived in writing by the Lender:

 

  3.1.1 the Borrower will pay to the Lender an origination fee equal to One Hundred Ten Thousand United States Dollars (US$110,000), being two percent (2%) of the Additional Loan amount, on the Second Closing Date;
     
  3.1.2 the Borrower will pay to the Lender a work fee equal to Fifty Five Thousand United States Dollars (US$55,000), being one percent (1%) of the Additional Loan amount, at the earlier of November 12, 2015 and the Second Closing Date, whether or not the Additional Loan is advanced;
     
  3.1.3 this Agreement shall have been executed and delivered by all parties hereto;
     
  3.1.4 the Borrower and each of the Subsidiaries shall have executed and delivered to the Lender the Loan Documents to which each is a party including, without limitation, the Security Documents;
     
  3.1.5 the Lender shall have received certified copies of the resolutions authorizing the execution, delivery and performance of Borrower’s, Nomad’s and Breakthrough’s respective obligations under the Loan Documents to which they are a party and the transactions contemplated therein, and the incumbency of the officers of Borrower, Nomad and Breakthrough;
     
  3.1.6 certificates of status or good standing, as applicable, for all relevant jurisdictions of Borrower shall have been delivered to the Lender;
     
  3.1.7 certificate of incorporation and constituent documents of Nomad;

 

 
 

 

  3.1.8 Borrower shall be in compliance in all material respects with all (if any) Material Contracts and Material Licences to the satisfaction of the Lender and copies of all Material Contracts and Material Licences if any, applicable to Borrower, shall have been delivered to the Lender;
     
  3.1.9 evidence of repayment in full of all Debt that is not Permitted Debt owing by Borrower to any third party lenders to Borrower concurrent with the Loan shall have been delivered to the Lender;
     
  3.1.10 evidence that all necessary or required consents or approvals of any Governmental Authority or other Person in connection with the completion of the Breakthrough Acquisition and the Nomad Acquisition and the delivery of the Loan Documents have been obtained;

 

  3.1.11 releases, discharges, estoppels and postponements with respect to all Liens which are not Permitted Liens, if any, shall have been delivered to the Lender;
     
  3.1.12 payment of all amounts and fees payable to the Lender;
     
  3.1.13 duly executed copies of the Security shall have been delivered to the Lender and such financing statements or other registrations of such Security, or notice thereof, shall have been filed, registered, entered or recorded in all offices of public record necessary or desirable in the opinion of the Lender to preserve or protect the charges and security interests created thereby;
     
  3.1.14 the Borrower shall have delivered to the Lender original share certificates in respect of all of the issued share capital in Nomad together with share transfer forms in respect of the shares in Nomad duly executed by the Borrower;
     
  3.1.15 evidence satisfactory to the Lender that entry into the Security Documents to which Nomad is a party does not materially prejudice the interests of Nomad or its shareholders and does not materially prejudice the ability of Nomad to pay its creditors (and that the board of directors of Nomad have resolved that this is the case);
     
  3.1.16 evidence that immediately prior to the acquisition by the Borrower of all the issued share capital in Nomad, the directors of Nomad will be Jack Ross, Stephen Fryer and Timothy Polmeer and that appointment of such directors has been, or will be, notified to the Australian Securities and Investments Commission;
     
  3.1.17 a currently dated letter of opinion of counsel to the Borrower along with the opinions of local counsel for Borrower shall have been delivered to the Lender. Such opinions shall, amongst other things, confirm that the existing Security delivered in connection with the Original Loan is first ranking security in favour of the Lender in respect to all of the Obligations, including without limitation, the Additional Loan;
     
  3.1.18 the Borrower shall have delivered to the Lender certificates of insurance acceptable to the Lender showing, inter alia, the Lender as a first loss payee as its interest may appear on all insurance policies that insure the assets to be secured by the Security;
     
  3.1.19 no Default or Event of Default has occurred and is continuing on the Second Closing Date or would result from making the Additional Loan and a senior officer of the Borrower shall have certified the same to the Lender;
     
  3.1.20 all representations and warranties made by Borrower, Nomad and Breakthrough in the Loan Documents are true and correct in all material respects;

 

 
 

 

  3.1.21 no Material Adverse Effect has occurred;
     
  3.1.22 a source and use of funds statement and an outline of the flow of funds from the Loan shall have been delivered to the Lender evidencing that the Loan will be used solely for the Nomad Acquisition and for working capital purposes;
     
  3.1.23 the Lender shall have received such additional evidence, documents or undertakings as the Lender shall reasonably request to establish the consummation of the transactions contemplated hereby, and the Breakthrough Acquisition and the Nomad Acquisition and be satisfied, acting reasonably, as to the taking of all proceedings in connection herewith in compliance with the conditions set forth in this Agreement;
     
  3.1.24 the Lender shall have completed all due diligence which it considers necessary or appropriate in its discretion in regard to Borrower and its Property, the Breakthrough Acquisition and the Nomad Acquisition, books and records, operations, prospects and condition (financial or otherwise), including, without limitation, in regards to past and ongoing compliance with Applicable Laws (including Environmental Laws), union and labour relations and pension matters;
     
  3.1.25 the Lender and the Borrower will have entered into, executed and delivered the Lender’s Nomad Distribution Agreement, all on terms satisfactory to the parties, acting reasonably;
     
  3.1.26 concurrently therewith, the Borrower shall complete the Breakthrough Acquisition and the Nomad Acquisition on terms and conditions satisfactory to the Lender;
     
  3.1.27 the execution and delivery of the 2015 First Warrant and the 2015 Second Warrant by the Borrower; and
     
  3.1.28 the Second Closing Date occurs by no later than November 16, 2015;
     

provided that if and to the extent that any Loan Document or other condition precedent set forth in this Section 3.1 and relating specifically and solely to Breakthrough or the Breakthrough Acquisition is not delivered at or prior to the Second Closing Date, then same shall instead become a condition precedent to the Lender advancing the second tranche of the Additional Loan as set forth in Section 3.2 and shall not be a waiver of such unfulfilled condition.

 

3.2 Conditions of Second Tranche
   

The effectiveness of the Lender’s obligation to fund the second tranche of the Additional Loan amount, as set forth in Section 2.1.4 of this Agreement, shall be subject to following conditions precedent having been met to the satisfaction of the Lender, or, alternatively, waived in writing by the Lender:

 

  3.2.1 Borrower must ensure that:

 

  (a) Nomad completes a financial assistance whitewash procedure in relation to the Nomad Guarantee and Nomad Security Documents granted in respect thereto in accordance with Section 260B of the Corporations Act 2001 (Cth) by no later than the date that is thirty (30) days after the Second Closing Date; and
     
  (b) the Nomad Guarantee and Nomad Security Documents granted in respect thereto are effective no later than the date that is thirty (30) days after the Second Closing Date.

 

  3.2.2 Borrower shall have satisfied all those conditions precedent set forth in Section 3.1 that relate to Breakthrough and/or the Breakthrough Acquisition that were not satisfied on or prior to the Second Closing Date;

 

 
 

 

  3.2.3 no Default or Event of Default has occurred and is continuing on the date of disbursement or would result from making the second tranche of the Additional Loan and a senior officer of the Borrower shall have certified the same to the Lender;
     
  3.2.4 all representations and warranties made by Borrower in the Loan Documents are true and correct in all material respects;
     
  3.2.5 no Material Adverse Effect has occurred.

 

3.3 Termination

 

This First Amendment shall automatically be terminated on November 18, 2015 if the conditions precedent set forth under Section 3.1 have not been met.

 

Article 4

MISCELLANEOUS

 

4.1 Further Assurances

 

Each of the Borrower and the Lender shall, from time to time hereafter and upon any reasonable request of the other party, execute and deliver such further agreements and documents and do all such other acts and things as may be necessary or appropriate to give effect to the foregoing.

 

4.2 Time of the Essence

 

Time shall be of the essence of this First Amendment.

 

4.3 Severability

 

If any provision of this First Amendment is found by final judgment of a court of competent jurisdiction to be invalid or unenforceable in whole or in part, such provision (or part thereof, as the case may be) shall be severable and such finding shall not affect the validity or enforceability of the remainder of such provision or of any other provision hereof.

 

4.4 Enurement

 

This First Amendment shall enure to the benefit of and be binding upon the parties hereto and their permitted assigns.

 

4.5 Counterparts

 

This First Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

 

4.6 Paramountcy

 

In the event of any conflict or inconsistency between the terms and conditions of this First Amendment and the terms and conditions of any other Transaction Document, including the Loan Agreement, the terms and conditions of this First Amendment shall prevail and be paramount to the extent of such conflict or inconsistency.

 

4.7 Governing Law

 

This First Amendment will be governed by and construed in accordance with the laws of the Province of Quebec and the laws of Canada applicable therein.

 

4.8 Language

 

The parties acknowledge that they have requested that this First Amendment and all ancillary documents be drawn up in the English language only. Les parties reconnaissent avoir exigé que cette convention ainsi que tous les documents y reliés soient rédigés en anglais seulement.

 

(signature page follows)

 

 
 

 

IN WITNESS WHEREOF the parties hereto have duly executed this First Amendment as of the date and at the place first hereinabove set forth.

 

  KNIGHT THERAPEUTICS (BARBADOS) INC.
     
  by: /s/ Michael Loustric               
  Name: Michael Loustric
  Title: President

 

  SYNERGY CHC CORP.
     
  by: /s/ Jack Ross     
  Name: Jack Ross
  Title: Chief Executive Officer

 

 

 

Exhibit 10.12

 

AMENDMENT TO FIRST AMENDMENT AGREEMENT entered into as of the 3rd day of December, 2015 (the “Amendment”).

 

BETWEEN: KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados;
  (hereinafter called the “Lender”)
   
AND: SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada;
  (hereinafter called the “Synergy”)

 

WHEREAS Synergy (then known as Synergy Strips Corp.) and the Lender are parties to that certain loan agreement (as amended by the First Amendment, the “Loan Agreement”) made as of the 21st day of January, 2015, pursuant to which the Lender has extended a loan to Synergy in the principal amount of Six Million United States Dollars (US$6,000,000) as amended by a first amendment to the loan agreement made as of November 12, 2015 (the “First Amendment”) pursuant to which the Lender has extended an additional loan to Synergy in the principal amount of Five Million Five Hundred Thousand United States Dollars (US$5,500,000) (the “Additional Loan”);

 

WHEREAS the Lender and Synergy desire to amend the First Amendment to, inter alia, modify the conditions precedent for the second tranche of the Additional Loan;

 

NOW, THEREFORE, IN CONSIDERATION of these presents and of the mutual covenants hereinafter contained, the parties have agreed as follows:

 

Article 1

interpretation

 

1.1 Capitalized Terms

 

In this Amendment, capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement.

 

Article 2

amendments

 

2.1 Amendments to the First Amendment

 

The Borrower and the Lender hereby agree to amend the First Agreement as follows:

 

  2.1.1 Section 2.1.1 of the First Amendment is hereby amended by inserting the following definition:
     
    Amendment and Confirmation Agreement” means that certain agreement among the Lender, Synergy, Nomad and Breakthrough by which Nomad and Breakthrough confirm that the terms of the distribution, license and supply agreement dated January 22, 2015 between Synergy and the Lender apply to them and by which the parties amend certain provisions of such distribution, license and supply agreement;

 

  2.1.2 Section 2.1.1 of the First Amendment is hereby amended by deleting the definition of “Lender’s Nomad Distribution Agreement”.
     
  2.1.3 Section 3.2.5 of the First Amendment is hereby amended to replace “Lender’s Nomad Distribution Agreement” by “Amendment and Confirmation Agreement”.
     
  2.1.4 Article 3 of the First Amendment is hereby amended by adding the following:

 

 
 

 

  3.5 Distribution Agreement

 

    The Lender, Nomad and Borrower shall enter into, execute and deliver a distribution agreement within thirty (30) days of the disbursement of the second tranche of the Additional Loan with the following terms and conditions:
     
  (a) Lender and/or its affiliates shall grant to Nomad non-exclusive distribution rights for “Flat Tummy Tea” products in the Territory for direct to consumer sales; and
     
  (b) Nomad shall buy its “Flat Tummy Tea” products in the Territory for direct to consumer sales under the distribution agreement on an exclusive basis from the Lender and/or its affiliates at cost of goods plus 60% of gross sales.

 

  2.1.5 From and after the date hereof, (i) all references in the First Amendment to “this First Amendment” shall mean the First Amendment as amended by this Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time, and (ii) all references in the other Loan Documents to the “Loan Agreement” (or words of similar import) shall be deemed to be references to the Loan Agreement as amended by the First Amendment as amended by this Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time. All references in any of the Loan Documents to the “Loan Documents” shall mean the Loan Documents as amended by this Amendment and as may otherwise be amended restated, supplemented or otherwise modified from time to time.
     
  2.1.6 Except as expressly amended by this Amendment, all other provisions of the First Amendment and the Transaction Documents not specifically amended hereby shall remain unchanged and in full force and effect.

 

Article 3

MISCELLANEOUS

 

3.1 Further Assurances

 

Each of the Borrower and the Lender shall, from time to time hereafter and upon any reasonable request of the other party, execute and deliver such further agreements and documents and do all such other acts and things as may be necessary or appropriate to give effect to the foregoing.

 

3.2 Time of the Essence

 

Time shall be of the essence of this Amendment.

 

3.3 Severability

 

If any provision of this Amendment is found by final judgment of a court of competent jurisdiction to be invalid or unenforceable in whole or in part, such provision (or part thereof, as the case may be) shall be severable and such finding shall not affect the validity or enforceability of the remainder of such provision or of any other provision hereof.

 

3.4 Enurement

 

This Amendment shall enure to the benefit of and be binding upon the parties hereto and their permitted assigns.

 

3.5 Counterparts

 

This Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

 

3.6 Paramountcy

 

In the event of any conflict or inconsistency between the terms and conditions of this Amendment and the terms and conditions of any other Transaction Document, including the Loan Agreement and the First Amendment, the terms and conditions of this Amendment shall prevail and be paramount to the extent of such conflict or inconsistency.

 

3.7 Governing Law

 

This Amendment will be governed by and construed in accordance with the laws of the Province of Quebec and the laws of Canada applicable therein.

 

3.8 Language

 

The parties acknowledge that they have requested that this Amendment and all ancillary documents be drawn up in the English language only. Les parties reconnaissent avoir exigé que cette convention ainsi que tous les documents y reliés soient rédigés en anglais seulement.

 

 
 

 

IN WITNESS WHEREOF the parties hereto have duly executed this Amendment as of the date and at the place first hereinabove set forth.

 

  KNIGHT THERAPEUTICS (BARBADOS) INC.
   
  By: /s/ Michael Loustric
  Name: Michael Loustric
  Title: President
     
  SYNERGY CHC CORP.
   
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer

 

 

 

Exhibit 10.13

 

AMENDMENT AND CONFIRMATION AGREEMENT

 

THIS AGREEMENT, effective December 3rd, 2015, by and among KNIGHT THERAPEUTICS (BARBADOS) INC. (“Knight”), a corporation incorporated under the laws of Barbados, NOMAD CHOICE PTY LTD. (Nomad), a corporation formed under the laws of Australia, and SYNERGY CHC CORP. (Synergy), a corporation formed under the laws of the State of Nevada, and BREAKTHROUGH PRODUCTS, INC. (“Breakthrough”), a corporation formed under the laws of Delaware.

 

WHEREAS Synergy and Knight are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time (the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named Knight its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS Synergy has acquired all of the shares of Nomad effective November 16, 2015 and, as and from that date, Nomad became an Affiliate;

 

WHEREAS Synergy has acquired all of the shares of Breakthrough effective November 12, 2015 and as and from that date, Breakthrough became an Affiliate;

 

WHEREAS the parties wish to confirm that the terms and conditions of the DLS Agreement apply to Nomad and Breakthrough effective from the dates each became an Affiliate;

 

WHEREAS the parties wish to confirm certain amendments to the DLS Agreement;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS
   
1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
   
2 GRANT OF RIGHTS
   
2.1 Each of Nomad and Breakthrough hereby confirms that it is subject to the terms and conditions of the DLS Agreement, as hereby amended, as if it were an original signatory thereto.
   
2.2 The DLS Agreement is hereby amended by replacing the definition of “Licensed Product” as follows:

 

“(i) with respect to Synergy means FocusFactor, FocusFactor Kids, Synergy Strips and all Improvements thereto, and (ii) with respect to Nomad, Breakthrough and any other Subsidiary of Synergy means all of the their present and future products (including with respect to Nomad “Flat Tummy Tea” and with respect to Breakthrough “urgentRX”)”.

 

2.3 The DLS Agreement is hereby amended by replacing the definition of “Territory” as follows:

 

“Territory (i) means Canada, Israel, Romania, Russia and each of the countries within Sub-Saharan Africa.”

 

2.4 The DLS Agreement is hereby amended by deleting (i) Section 11 thereof and (ii) all references in the DLS Agreement to the defined term “Additional Territory”.
   
2.5 Section 9.3 of the DLS Agreement is deleted and replaced with the following:

 

“9.3 Termination of Knight. Knight may terminate this Agreement in whole or in part (including with respect to a particular Licensed Product and/or Territory or a particular Territory in respect of a particular Licensed Product) by notice in writing given not less than sixty (60) days prior to the intended termination date.”

 

 
 

 

3 OTHER PROVISIONS
   
3.1 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances.
   
3.2 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.
   
3.3 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
3.4 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
3.5 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof.

 

 
 

 

In witness whereof, the parties have signed this Agreement.

 

  KNIGHT THERAPEUTICS (BARBADOS) INC.

 

  By: /s/ Michael Loustric
  Name: Michael Loustric
  Title: President

 

  NOMAD CHOICE PTY LTD.

 

  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer

 

  SYNERGY CHC CORP.

 

  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer

 

  BREAKTHROUGH PRODUCTS, INC.

 

  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer

 

 

 

Exhibit 10.14

 

Settlement and Release AGREEMENT

 

This Settlement and Release Agreement (“Agreement”) by and between Synergy CHC Corp., a Nevada corporation (“Releasor”), the former shareholders (the “Shareholders”) of Breakthrough Products, Inc., a Delaware corporation (the “Company”), URX ACQUISITION TRUST, a Delaware statutory trust (the “Trust”), on its own behalf and as the representative of the Shareholders, David T. Leyrer (“Leyrer”), Michael Valentino (“Valentino”), Ron Fugate (“Fugate”), and Randall Kaplan (“Kaplan”, and collectively with Leyrer, Valentino, Fugate, the “Former Directors”) is dated and effective as of the 17th day of December, 2015.

 

WHEREAS, the Company, the Trust, Jordan Eisenberg, the former chief executive officer of the Company and a Shareholder, the Shareholders and Releasor are parties to that certain Stock Purchase Agreement (the “SPA”) dated November 12, 2015 (capitalized terms used herein but not otherwise defined have the meaning ascribed to them in the SPA);

 

WHEREAS, pursuant to the terms of the SPA, Releasor acquired all outstanding shares of capital stock of the Company (the “Transaction”);

 

WHEREAS, pursuant to the terms of the SPA, the Shareholders, the Company and the Trust made certain representations and warranties to Releasor regarding, among other things, the financial condition of the Company and the Company’s outstanding liabilities and obligations to third parties;

 

WHEREAS, following the Transaction, Releasor discovered certain irregularities in the financial information of the Company as well as conflicting information regarding the Company’s liabilities and obligations to third parties from what was previously provided by the Company;

 

WHEREAS, Releasor made a claim for indemnification against the Shareholders and the Trust pursuant to Section 8 of the SPA (the “Claim”);

 

WHEREAS, Releasor and the Trust, on its own behalf and on behalf of the Shareholders, have reached an agreement to resolve the Claim to the mutual satisfaction of all parties and wish to document such settlement in this Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:

 

1. Settlement Payments.

 

  a. The Trust will return Three Million (3,000,000) shares of Releasor’s common stock to Releasor. Upon execution of this Agreement, the Trust will return the certificate representing the Equity Consideration to Releasor’s transfer agent, VStock Transfer, with instructions to transfer Three Million (3,000,000) shares to Releasor and return a new certificate to the Trust for the balance of Three Million (3,000,000) shares of Releasor’s common stock.
     
  b. The time period under which Royalty Consideration is payable to the Trust by Releasor under the SPA is reduced from seven (7) years to five (5) years.
     
  c. Releasor will issue a warrant in the form of Exhibit A to the Trust.

 

 
 

 

2. Releases.

 

  a. Release of the Trust and Shareholders by Releasor. Except as set forth in Section 3 of this Agreement, in exchange for the payments outlined above, Releasor, on its own behalf and on behalf of its Affiliates, directors, officers, managers, employees, agents, representatives, successors, and assigns, forever releases and discharges the Trust and its trustees, the Shareholders and their respective agents, representatives, successors, and assigns from any and all claims, demands, and causes of action of every kind and nature, whether known or unknown, direct or indirect, accrued, contingent or potential, which Releasor ever had or now has and which arose from the beginning of time until the date of this Agreement.
     
  b. Release of the former Directors of the Company by Releasor. Except as set forth in Section 3 of this Agreement, in exchange for the payments outlined above, Releasor, on its own behalf and on behalf of its Affiliates, directors, officers, managers, employees, agents, representatives, successors, and assigns, forever releases and discharges the Former Directors and their agents, representatives, heirs and assigns from any and all claims, demands, and causes of action of every kind and nature, whether known or unknown, direct or indirect, accrued, contingent or potential, which Releasor ever had or now has and which arose from the beginning of time until the date of this Agreement.
     
  c. Release of Releasor by the Trust and the Former Directors. Except as set forth in Section 3 of this Agreement, in exchange for the payments outlined above, the Trust, on its own behalf and as the representative of the Shareholders, its trustees, agents, representatives, successors, and assigns and the Former Directors, their heirs and assigns, forever release and discharge Releasor, its Affiliates, and their respective directors, officers (other than the officers of the Company prior to November 12, 2015), managers, employees (other than employees of the Company who were employees prior to November 12, 2015, whether or not they remained employees after such date), agents, representatives, successors, and assigns from any and all claims, demands, and causes of action of every kind and nature, whether known or unknown, direct or indirect, accrued, contingent or potential, which such parties ever had or now have and which arose from the beginning of time until the date of this Agreement.
     
  d. With respect to the foregoing releases, Releasor, Trust and the Former Directors each expressly waive any and all provisions, rights and benefits conferred by any law of the United States or of any country, state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to Section 1542 of the California Civil Code, and including Section 1542 of the California Civil Code which provides:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

3. Future Claims. Each party to this Agreement specifically acknowledges and agrees that all rights of any party to pursue Jordan Eisenberg and any former officers and employees of the Company (the “Company Management Team”) are specifically reserved, except that no claim survives against Valentino notwithstanding his title as Chairman of the Company. Releasor hereby covenants and agrees not to bring or initiate any proceeding to assert any claims, rights or remedies against the Trust, any trustee of the Trust, any Former Director or any Shareholder (other than Shareholders who are also members of the Company Management Team) under the indemnification provisions of the SPA or otherwise that relate in any way to the Claim, to any other potential claims under the SPA or to the Transaction; provided, however, that all parties acknowledge and agree that any claims by Releasor against the Trust or any Shareholder for breach of any representation or warranty contained in Sections 3 and 4(e) of the SPA are specifically preserved (the “Preserved Claims”). For purposes of clarity, Releasor and its successors and assigns shall have no further rights to indemnification under Section 8 of the SPA other than claims against the Company Management Team and other than the Preserved Claims.

 

4. Authority. Each party to this Agreement, on its own behalf and on behalf of those it represents, represents and warrants to all other parties that such party has all requisite power and authority to enter into this Agreement and to carry out its obligations thereunder.

 

 
 

 

5. Successors and Assigns. This Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the parties hereto.

 

6. Governing Law; Jurisdiction. This Agreement shall be construed, performed and enforced in accordance with, and governed by, the laws of the State of North Carolina, United States, without giving effect to the principles of conflicts of laws thereof. The parties hereto irrevocably consent to the jurisdiction of, the federal and state courts of the State of North Carolina located in Wake County, North Carolina for such purpose.

 

7. Expenses. Except as otherwise provided herein, each of the parties hereto shall pay all its own expenses in connection with this Agreement and the transactions contemplated hereby, including, without limitation, any legal and accounting fees.

 

8. Severability. In the event that any part of this Agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this Agreement shall remain in full force and effect.

 

9. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of service if served personally on the party to whom notice is to be given, or (ii) on the day of delivery by Federal Express or similar overnight courier or the Express Mail service maintained by the U.S. Postal Service, to the party the addresses set forth in the SPA.

 

10. Amendments; Waivers. This Agreement may be amended or modified, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the parties hereto, or in the case of a waiver, by the party waiving compliance. Any waiver by any party of any condition, or of the breach of any provision, term, covenant, representation or warranty contained in this Agreement, in any one or more instances, shall not be deemed to be nor construed as further or continuing waiver of any such condition, or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.

 

11. Public Announcements. The Trust shall not make any public statement regarding this Agreement or the transactions contemplated herein without Releasor’s prior written approval. Releasor will be required to file a Form 8-K with the U.S. Securities and Exchange Commission regarding this Agreement

.

12. Entire Agreement. This Agreement and the exhibits hereto contain the entire understanding between the parties hereto with respect to the matters contemplated hereby and thereby and supersede and replace all prior agreements and understandings, oral or written, with regard to such matters.

 

13. Section and Paragraph Headings. The section and paragraph headings in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

14. Counterparts. This Agreement may be executed in counterparts and via .pdf, each of which shall be deemed an original, but all of which shall constitute the same instrument.

 

15. Independent Counsel; Mutual Drafting. Each party hereto consulted, or had the opportunity to consult, legal counsel or other advisors of its own choosing with respect to this Agreement and fully understands the meaning and intent of, this Agreement, including, but not limited to, the final and binding effect of this Agreement and the acknowledgments, releases, and waivers contained herein. Each party hereto shall be deemed to have consulted and assisted with the drafting of this Agreement such that any ambiguity herein shall not be construed in favor of one party over the other party.

 

[Signature Page Follows]

 

 
 

 

IN WITNESS WHEREOF, the parties have executed this Settlement and Release Agreement effective as of the day and year first above written.

 

  SYNERGY CHC CORP.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: Chief Executive Officer

 

  URX ACQUISITION TRUST,
  on its own behalf and as representative of the Shareholders
     
  KMJZ Investments, L.L.C., Voting Trustee
     
  By: /s/ Scott Peppett
  Name: Scott Peppett
  Title: Authorized Representative
     
  Arbicha Invesments, L.L.C., Voting Trustee
  By Arbicha, LLC, Sole Member
     
  By: /s/ Randall Kaplan
  Name: Randall Kaplan
  Title: Manager
     
  Casa Vicente, LLC, Voting Trustee
     
  By: /s/ David Leyrer
  Name: David Leyrer
  Title: Manager
     
  URX Acquisition Trustee, LLC
     
  By: /s/ Michael Valentino
  Name: Michael Valentino
  Title: Sole Member

 

[Signature Page to Settlement and Release Agreement]

 

 
 

 

  FORMER DIRECTORS:
   
  David T. Leyrer
   
  /s/ David T. Leyrer
   
  Michael Valentino
   
  /s/ Michael Valentino
   
  Ron Fugate
   
  /s/ Ron Fugate
   
  Randall Kaplan
   
  /s/ Randall Kaplan

 

[Signature Page to Settlement and Release Agreement]

 

 
 

 

Exhibit A

 

Form of Warrant

 

[Exhibit A to Settlement and Release Agreement]

 

 

 

Exhibit 10.15

 

HAND MD

DISTRIBUTION AGREEMENT

(Canada)

 

THIS AGREEMENT, effective December 23, 2016, by and among KNIGHT THERAPEUTICS INC. (“Knight”), a corporation incorporated under the laws of Canada, and SYNERGY CHC CORP. (“Synergy”), a corporation formed under the laws of Nevada.

 

WHEREAS Synergy and Knight Therapeutics (Barbados) Inc. (“KB”) are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named KB its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS KB assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight;

 

WHEREAS MD Products (as herein defined) are included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with Synergy in respect of Direct Channel Sales and of Retail Sales of MD Products in Canada;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS

 

1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
   
1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:

 

“Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of MD Products and supply of same to Synergy under this Agreement. For greater certainty, where Knight purchases MD Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer.

 

“Direct Channel Sales” means the Commercialization of MD Products in Canada directly to consumers from a website or any other direct-to-consumer sales channel.

 

“MD Products” means the “Hand MD” line of products as now or may in the future be Commercialized by Synergy or its Affiliates (including future line extensions relating thereto) and other skin care products and related accessories Commercialized from time to time by Synergy or any company or entity controlled by Synergy. For greater certainty, the “Hand MD” line of products shall include any products and accessories that are Commercialized under the “Hand MD” trademark and/or tradename (or any variations thereof).

 

 
2

 

“Gross Sales” means the gross invoiced sales price for MD Products sold by Synergy or its Affiliates, as applicable, to Third Parties throughout Canada during each Calendar Quarter, less only (i) the shipping and handling charges that are actually incurred by Synergy or its Affiliates in delivering such MD Products to Third Parties in Canada and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of MD Products. Sales between or among Synergy and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where (a) MD Products are sold by Synergy or its Affiliates other than in an arm’s length sale, (b) MD Products are sold as one of a number of items without a separate invoiced price; or (c) consideration for MD Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be Synergy’s average Gross Sales to Third Parties for the applicable quantity of MD Products at that time.

 

“Retail Sales” means the Commercialisation of MD Products in Canada, other than through Direct Channel Sales, and includes wholesale distribution and retail sales.

 

“Threshold Amount” means the aggregate gross sales in Canada for the four (4) successive Calendar Quarters ending December 31, 2016 of the Flat Tummy Tea products as determined pursuant to the Distribution Agreement between Knight and an affiliate of Synergy in respect to such product.

 

1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 Canadian Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of Canada, unless otherwise noted.
   
1.7 Gender. Words of one gender include the other gender,
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

 

 
3

 

1.9 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.
   
1.10 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.11 Party References. Reference to any Party includes the successors and permitted assigns of that Party.
   
1.12 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.

 

DISTRIBUTION TERMS

 

2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and its Affiliates, hereby appoints Synergy as its exclusive Third Party distributor of MD Products for Canada solely and exclusively in respect of Direct Channel Sales and Retail Sales and further grants to Synergy and Synergy hereby accepts for Canada and solely and exclusively in respect of Direct Channel Sales and Retail Sales a non-exclusive sublicense under the Synergy Marks used in association with MD Products to Commercialize MD Products through Direct Channel Sales and Retail Sales in Canada. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute MD Products in Canada through Direct Channel Sales and Retail Sales. Without limiting the generality of the forgoing, in the event that Knight determines to create and operate a website or uses other social media to promote and sell MD Products in Canada, it shall consult with Synergy and each of Synergy and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the MD Products in Canada through Direct Channel Sales or Retail Sales, Knight shall not pursue a brand strategy that Synergy, acting reasonably, determines is materially adverse to the brand equity of MD Products in Canada.
   
2.2 Sublicensing. Synergy may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Synergy assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.
   
2.3 Interim Period. Section 3.2 below contemplates that Knight may enter into an agreement with the Manufacturer. Knight shall advise Synergy by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, Synergy shall be permitted to source MD Products directly from the Manufacturer. In respect to inventory of MD Products sourced directly by Synergy as permitted by this Section 2.3, Synergy will make the following payments to Knight in each Calendar Year:

 

  2.3.1 In respect to MD Products Commercialized through Direct Channel Sales, sixty percent (60%) of Gross Sales until Gross Sales from Direct Channel Sales in such Calendar Year are equal to the Threshold Amount and then forty percent (40%) of all such Gross Sales in such Calendar Year in excess of the Threshold Amount.

 

 
4

 

  2.3.2 In respect to MD Products Commercialized through Retail Sales, five percent (5%) of Gross Sales from Retail Sales .

 

2.4 Payment. Payment shall be made on a monthly basis (on or before the fifteenth (15th) day of each month) for all Gross Sales of such inventory and until such inventory is exhausted.

 

3 SUPPLY

 

3.1 Exclusivity. Except as set forth otherwise in Section 2.3, Synergy will purchase all of its requirements of MD Products for Canada and in respect of Direct Channel Sales or Retail Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. Synergy acknowledges that Knight may from time to time enter into an agreement with contract manufacturer(s) (collectively, the “Manufacturer”) for the supply (which may include packaging) of MD Products under this Agreement. In such instances, Knight and Synergy shall determine mutually acceptable procedures that will allow Synergy to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that Synergy shall acquire MD Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at Synergy’s request, facilitate any claims, demands, complaints or similar actions that Synergy wishes to assert against the Manufacturer in respect of MD Products purchased by Synergy from Knight.
   
3.3 Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the packaging for the MD Products, Knight shall not be obliged to supply packaging to Synergy. Synergy will continue to source such packaging itself and will make arrangements with the Manufacturer to fill bulk product into the packaging provided.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of MD Products that are on order or unpaid from time to time.
   
3.5 Liability. Synergy acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of MD Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.
   
3.6 Regulatory Submissions. Knight shall be solely responsible, at its expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the MD Products in Canada. Synergy shall provide reasonable assistance to Knight in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Knight. Knight shall notify Synergy of all Regulatory Submissions that it submits.

 

 
5

 

3.7 Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in Canada. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.

 

3.8 Other Covenants. In addition to its other obligations, commitments and undertakings set out in this Agreement, Knight agrees to assume the reasonable costs of intellectual property filings, procurement and maintenance for all intellectual property applications and registrations associated with the MD Products in Canada.

 

3.9 Additional Terms.

 

  3.9.1 A Party shall promptly notify the other Party in writing of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority in Canada, concerning the quality of MD Products and/or documentation or other items for such changes relating to the quality of the MD Products. The Parties shall negotiate in good faith towards an appropriate response to such a Governmental Authority in respect of each proposed change in the quality of the MD Products including any costs associated with implementing said changes.
     
  3.9.2 Minor changes in the procedures for manufacture or quality control that do not require approval from a Governmental Authority in Canada or that will not affect Regulatory Approvals in Canada will be communicated by Knight to Synergy in an annual review.
     
  3.9.3 Knight will maintain complete and accurate books, records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.
     
  3.9.4 During the Term of this Agreement and for three (3) years thereafter, Synergy will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Knight as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit.

 

 
6

 

Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.

 

  3.9.5 If, based on the results of any audit under Section 3.9.4, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.
     
  3.9.6 With respect to the Commercialization of MD Products in Canada, Synergy shall comply with (i) the requirements of the Advertising Standards Canada, (ii) the Code of Ethical Practices adopted from time to time by Innovative Medicines Canada and (iii) all Applicable Laws.

 

3.10 Responsibility. Synergy acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of MD Products in Canada through Direct Channel Sales and Retail Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.

 

4 PAYMENT AND FINANCIAL TERMS

 

4.1 Product Price. Knight will supply MD Products to Synergy at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) in respect to MD Products sold through Direct Channel Sales, for each Calendar Year sixty percent (60%) of Gross Sales from Direct Channel Sales until the Gross Sales in such Calendar Year from Direct Channel Sales equal the Threshold Amount and then forty percent (40%) of all such Gross Sales in that same Calendar Year in excess of the Threshold Amount and (iii) in respect to MD Products sold thought Retail Sales, five percent (5%) of Gross Sales from Retail Sales. Knight shall initially invoice Synergy for the Cost of Goods for MD Products supplied hereunder. Synergy shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of MD Products relating thereto.

 

4.2 Report. Within twenty-five (25) days following the end of each Calendar Quarter, Synergy shall render a written report to Knight setting forth the following information and calculations in which sales of MD Products occurred in the Calendar Quarter covered by such report:

 

  4.2.1 the Gross Sales, if any, in Canadian dollars;
     
  4.2.2 the calculation of the balance of the Product Price for MD Products Commercialised through Direct Chanel Sales (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales; and

 

 
7

 

  4.2.3 the calculation of the balance of the Product Price for MD Products Commercialised through Retail Sales (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.

 

4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by Synergy within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.
   
4.4 Minimum. The minimum payment to be paid each full Calendar Year during the Term by Synergy to Knight in respect of Retail Sales pursuant to Sections 2.3.2 and 4.1(iii) shall be no less than $25,000 in the aggregate. Synergy shall, by no later than January 31 of the Calendar Year immediately following, make such payment (if any) as is required to meet such requirement. If the Agreement is terminated other than at the end of a Calendar Year, such minimum payment shall be pro-rated.
   
4.5 Currency. The Product Price shall be paid by Synergy in Canadian dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than Canadian dollars, the Cost of Goods shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to Synergy in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than Canadian dollars, Gross Sales shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.6 Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty-four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.
   
4.7 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
4.8 Withholding Tax. Synergy will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Synergy under this Agreement will be timely paid by Synergy on behalf of Knight to the appropriate Governmental Authority, and Synergy will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Synergy and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.

 

 
8

 

4.9 VAT and Similar Taxes. All amounts paid by Synergy to Knight under this Agreement are exclusive of, and Synergy shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.

 

5 TERM

 

5.1 Initial Term. The appointment set forth in Section 2.1 shall be for an initial period terminating on February 15, 2021, and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.
   
5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:

 

  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.

 

  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Synergy’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and Synergy undertakes to except as provided for in Section 5.4, cease any Commercialization of the MD Products in Canada.

 

5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, Synergy shall be entitled to sell off any inventory of the MD Products in Synergy’s possession or control or which are subject to binding purchase orders on the date such termination is effective.

 

 
9

 

6 LIMITATION OF LIABILITY

 

WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO

 

ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.

 

7 OTHER PROVISIONS

 

7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.
   
7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of Canada.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.

 

 
10

 

7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:

 

(a)      In the case of the Synergy:

 

SYNERGY CHC CORP.
865 Spring Street

Westbrook, Maine 04092
Attention: Jack Ross

E-mail: jack.ross@purebrands.ca

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LIP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax: (919) 781-4865

E-mail: dmannheim@wyrick.com

 

(b)      In the case of Knight:

 

KNIGHT THERAPEUTICS INC.

3400 de Mainsonneuve

Suite 1055

Westmount, Quebec H3Z 3B8

Attention: Jeff Kadanoff, Chief Financial Officer

Fax: (514) 481-4116

E-mail: jkadanoff@gud-knight.com

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

1501 McGill College Ave.

Suite 2600

Montreal, Quebec H3A 3N9

Attention: Hillel W. Rosen

Fax: (514) 841-6499

E-mail: hrosen@dwpv.com

 

 
11

 

7.7 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances

 

7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.

 

7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof
   
7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision..

 

[Signature page follows]

 

 

 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement.

 

  KNIGHT THERAPEUTICS INC.
  By: /s/ Jeffrey Kadanoff
  Name: Jeffrey Kadanoff
  Title: CFO

 

  SYNERGY CHC CORP.
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

 

Exhibit 10.16

 

FOCUSFactor

DISTRIBUTION AGREEMENT

(Canada)

 

THIS AGREEMENT, effective December 23, 2016, by and among KNIGHT THERAPEUTICS INC. (“Knight”), a corporation incorporated under the laws of Canada, and SYNERGY CHC CORP. (“Synergy”), a corporation formed under the laws of Nevada.

 

WHEREAS Synergy and Knight Therapeutics (Barbados) Inc. (“KB”) are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named KB its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS KB assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight;

 

WHEREAS FF Products (as herein defined) are included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with Synergy in respect of Direct Channel Sales and of Retail Sales of FF Products in Canada;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS

 

1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.

 

1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:

 

“Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of FF Products and supply of same to Synergy under this Agreement including without limitation, its internal and external costs related to quality assurance and stability procedures and processes undertaken with respect to the FF Products. For greater certainty, where Knight purchases FF Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer plus its internal and external costs related to quality assurance and stability procedures and processes undertaken with respect to the FF Products.

 

“Direct Channel Sales” means the Commercialization of FF Products in Canada directly to consumers from a website or any other direct-to-consumer sales channel.

 

“FF Products” means FOCUSFactor, FOCUSFactor Kids and all Improvements thereto.

 

 
 

 

“Gross Sales” means the gross invoiced sales price for FF Products sold by Synergy or its Affiliates, as applicable, to Third Parties throughout Canada during each Calendar Quarter, less only (i) the shipping and handling charges that are actually incurred by Synergy or its Affiliates in delivering such FF Products to Third Parties in Canada and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of FF Products. Sales between or among Synergy and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where (a) FF Products are sold by Synergy or its Affiliates other than in an arm’s length sale, (b) FF Products are sold as one of a number of items without a separate invoiced price; or (c) consideration for FF Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be Synergy’s average Gross Sales to Third Parties for the applicable quantity of FF Products at that time.

 

“Retail Sales” means the Commercialisation of FF Products in Canada, other than through Direct Channel Sales, and includes wholesale distribution and retail sales.

 

1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 Canadian Dollars. References in this Agreement to “Dollars” or “S” shall mean the legal tender of Canada, unless otherwise noted.
   
1.7 Gender. Words of one gender include the other gender.
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.
   
1.9 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.

 

1.10 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.

 

1.11 Party References. Reference to any Party includes the successors and permitted assigns of that Party.

 

 
-3-

 

1.12 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.

 

2 DISTRIBUTION TERMS
   
2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and its Affiliates, hereby appoints Synergy as its exclusive Third Party distributor of FF Products for Canada solely and exclusively in respect of Direct Channel Sales and Retail Sales and further grants to Synergy and Synergy hereby accepts for Canada and solely and exclusively in respect of Direct Channel Sales and Retail Sales a non-exclusive sublicense under the Synergy Marks and to the extent required under any Knight trademarks used in association with FF Products to Commercialize FF Products through Direct Channel Sales and Retail Sales in Canada. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute FF Products in Canada through Direct Channel Sales and Retail Sales. Without limiting the generality of the forgoing, in the event that Knight determines to create and operate a website or uses other social media to promote and sell FF Products in Canada, it shall consult with Synergy and each of Synergy and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the FF Products in Canada through Direct Channel Sales or Retail Sales, Knight shall not pursue a brand strategy that Synergy, acting reasonably, determines is materially adverse to the brand equity of FF Products in Canada.
   
2.2 Sublicensing. Synergy may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Synergy assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.
   
2.3 Interim Period. Section 3.2 below contemplates that Knight may enter into an agreement with the Manufacturer. Knight shall advise Synergy by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, Synergy shall be permitted to source FF Products directly from the Manufacturer. In respect to inventory of FF Products sourced directly by Synergy as permitted by this Section 23, Synergy will make the following payments to Knight:

 

  2.3.1 In respect to FF Products Commercialized through Direct Channel Sales, thirty percent (30%) of Gross Sales therefrom;

 

  2.3.2 In respect to FF Products Commercialized through Retail Sales, five percent (5%) of Gross Sales therefrom;

 

2.4 Payment. Payment shall be made on a monthly basis (on or before the fifteenth (15th) day of each month) for all Gross Sales of such inventory and until such inventory is exhausted.

 

 
-4-

 

3 SUPPLY
   
3.1 Exclusivity. Except as set forth otherwise in Section 2.3, Synergy will purchase all of its requirements of FF Products for Canada and in respect of Direct Channel Sales or Retail Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. Synergy acknowledges that Knight may from time to time enter into an agreement with contract manufacturer(s) (collectively, the “Manufacturer”) for the supply (which may include packaging) of FF Products under this Agreement. In such instances, Knight and Synergy shall determine mutually acceptable procedures that will allow Synergy to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that Synergy shall acquire FF Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at Synergy’s request, facilitate any claims, demands, complaints or similar actions that Synergy wishes to assert against the Manufacturer in respect of FF Products purchased by Synergy from Knight.
   
3.3 Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the packaging for the FF Products, Knight shall not be obliged to supply packaging to Synergy. Synergy will continue to source such packaging itself and will make arrangements with the Manufacturer to fill bulk product into the packaging provided.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of FF Products that are on order or unpaid from time to time.
   
3.5 Liability. Synergy acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of FF Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.
   
3.6 Regulatory Submissions. Knight shall be solely responsible, at Synergy’s expense, for preparing, filing, and managing any Regulatory Submission required after the date hereof and for maintaining at Synergy’s expense any Regulatory Approval for the FF Products in Canada. Each Party shall provide reasonable assistance to the other in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Knight. Knight shall notify Synergy of all Regulatory Submissions that it submits.
   
17 Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in Canada. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.

 

 
-5-

 

3.8 Other Covenants. In addition to its other obligations, commitments and undertakings set out in this Agreement, Knight agrees to assume the reasonable costs of intellectual property filings, procurement and maintenance for all intellectual property applications and registrations associated with the FF Products in Canada.
   
3.9 Additional Terms.

 

  3.9.1 A Party shall promptly notify the other Party in writing of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority in Canada, concerning the quality of FF Products and/or documentation or other items for such changes relating to the quality of the FF Products. The Parties shall negotiate in good faith towards an appropriate response to such a Governmental Authority in respect of each proposed change in the quality of the FF Products including any costs associated with implementing said changes.

 

  3.9.2 Minor changes in the procedures for manufacture or quality control that do not require approval from a Governmental Authority in Canada or that will not affect Regulatory Approvals in Canada will be communicated by Knight to Synergy in an annual review.

 

  3.9.3 Knight will maintain complete and accurate books, records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.

 

  3.9.4 During the Term of this Agreement and for three (3) years thereafter, Synergy will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Knight as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.

 

 
-6-

 

  3.9.5 If, based on the results of any audit under Section 3.9.4, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.

 

  3.9.6 With respect to the Commercialization of FF Products in Canada, Synergy shall comply with (i) the requirements of the Advertising Standards Canada, (ii) the Code of Ethical Practices adopted from time to time by Innovative Medicines Canada and (iii) all Applicable Laws.

 

3.10 Marketing. Synergy shall use reasonable commercial efforts to Commercialize the FF Products in Canada, including using its “Einstein” materials and through television advertising.

 

3.11 Responsibility. Synergy acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of FF Products in Canada through Direct Channel Sales and Retail Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.

 

4 PAYMENT AND FINANCIAL TERMS

 

4.1 Product Price. Knight will supply FF Products to Synergy at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) in respect to FF Products sold through Direct Channel Sales, thirty percent (30%) of Gross Sales from Direct Channel Sales and (iii) in respect to FF Products sold though Retail Sales, five percent (5%) of Gross Sales from Retail Sales. Knight shall initially invoice Synergy for the Cost of Goods for FF Products supplied hereunder. Synergy shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of FF Products relating thereto.

 

4.2 Report. Within twenty-five (25) days following the end of each Calendar Quarter, Synergy shall render a written report to Knight setting forth the following information and calculations in which sales of FF Products occurred in the Calendar Quarter covered by such report:

 

  4.2.1 the Gross Sales, if any, in Canadian dollars;

 

  4.2.2 the calculation of the balance of the Product Price for FF Products Commercialised through Direct Chanel Sales (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales; and

 

  4.2.3 the calculation of the balance of the Product Price for FF Products Commercialised through Retail Sales (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.

 

 
-7-

 

4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by Synergy within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.
   
4.4 Minimum. The minimum payment to be paid each full Calendar Year during the Term by Synergy to Knight in respect of Retail Sales pursuant to Sections 2.3.2 and 4.1(iii) shall be no less than $100,000 in the aggregate. Synergy shall, by no later than January 31 of the Calendar Year immediately following, make such payment (if any) as is required to meet such requirement. In the event that this Agreement is terminated other than at the end of a Calendar Year, the said minimum payment shall be pro-rated.
   
4.5 Currency. The Product Price shall be paid by Synergy in Canadian dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than Canadian dollars, the Cost of Goods shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to Synergy in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than Canadian dollars, Gross Sales shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.6 Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty-four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.
   
4.7 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
4.8 Withholding Tax. Synergy will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Synergy under this Agreement will be timely paid by Synergy on behalf of Knight to the appropriate Governmental Authority, and Synergy will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Synergy and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
4.9 Transition. Upon the execution of this Agreement, Synergy shall purchase Knights’ inventory of FF Products for a purchase price equal to Knight’s Cost of Goods for same.

 

 
-8-

 

4.10 VAT and Similar Taxes. All amounts paid by Synergy to Knight under this Agreement are exclusive of, and Synergy shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.

 

5 TERM

 

5.1 Initial Term. The appointment set forth in Section 2.1 shall be for an initial period terminating on February 15, 2021, and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.
   
5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:

 

  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Synergy’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and Synergy undertakes except as provided for in Section 5.4, to cease any Commercialization of the FF Products in Canada.
   
5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, Synergy shall be entitled to sell off any inventory of the FF Products in Synergy’s possession or control or which are subject to binding purchase orders on the date such termination is effective.

 

6 LIMITATION OF LIABILITY

 

WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.

 

 
-9-

 

7 OTHER PROVISIONS
   
7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.
   
7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of Canada.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.

 

 
-10-

 

7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:

 

  (a) In the case of the Synergy:

 

SYNERGY CHC CORP.

865 Spring Street

Westbrook, Maine 04092

Attention: Jack Ross

E-mail: jack.ross@purebrands.ca

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax: (919) 781-4865

E-mail: dmaimheim@wyrick.com

 

  (b) In the case of Knight:

 

KNIGHT THERAPEUTICS INC.

3400 de Maisonneuve West

Suite 1055

Westmount, Quebec H3Z 3B8

Attention: Jeff Kadanoff, Chief Financial Officer

Fax: (514)481-4116

E-mail: jkadanoff@gud-knight.com

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

1501 McGill College Ave.

Suite 2600

Montreal, Quebec H3A 3N9

Attention: Hillel W. Rosen

Fax: (514) 841-6499

E-mail: hrosen@dwpv.com

 

7.7 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances

 

 
-11-

 

7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.

 

7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.

 

7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof

 

7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision..

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement.

 

  KNIGHT THERAPEUTICS INC.

 

  By: /s/ Jeffrey Kadanoff
  Name: Jeffrey Kadanoff
  Title: CFO

 

  SYNERGY CHC CORP.

 

  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

 

 

Exhibit 10.17

 

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT is made and entered into this 21st day of June 2017, by and among the following parties: (A) Synergy CHC Corp., a Delaware corporation (“Buyer”); (B) Perfekt Beauty Holdings LLC, a Delaware limited liability company “Seller”); and (C) CDG Holdings, LLC, a Delaware limited liability company (the “Member”).

 

WITNESSETH:

 

WHEREAS, the Seller is engaged in the business of developing and selling skincare and cosmetics products under the brand Per-fekt (the “Products” and the business related to the manufacture, sale, marketing and distribution of the Products is, collectively, the “Business”);

 

WHEREAS, the Member owns 92.3% of all of the issued and outstanding equity interests of the Seller; and

 

WHEREAS, the Seller desires to sell, and Buyer desires to purchase, all or substantially all of Seller’s assets for the consideration payable by Buyer to Seller as set forth in this Agreement, on the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration of the above premises and of the mutual covenants, conditions and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows:

 

article 1: DEFINITIONS

 

1.1 Definitions. Unless the context shall otherwise require, terms used in this Agreement with initial capital letters shall have the meanings ascribed to them in Annex A, which is hereby incorporated by reference into this Agreement and made a part hereof.

 

1.2 Rules of Construction. For purposes of this Agreement: (a) whenever the context requires, any pronoun shall include the corresponding masculine, feminine and neuter forms; (b) where the context so requires or permits, the use of the singular form includes the plural, and the use of the plural form includes the singular; (c) the words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation”; (d) all references to “party” and “parties” shall be deemed references to parties to this Agreement, unless the context shall otherwise require; (e) except as specifically otherwise provided in this Agreement, a reference to an Article, Section, Schedule or Exhibit is a reference to an Article or Section of this Agreement or a Schedule or Exhibit of or to this Agreement; (f) the term “or” is used in its inclusive sense and shall be deemed to have the meaning “and/or”, and, together with the terms “either” and “any” shall not be exclusive; (g) the term “any” shall be deemed to have the meaning “any and/or all”; (h) when used in this Agreement, words such as “herein”, “hereinafter”, “hereby”, “hereof,” “hereto”, “hereunder” and words of similar import shall refer to this Agreement as a whole, including Schedules and Exhibits hereto, and not to any particular provision of this Agreement, unless the context clearly requires otherwise; (i) any reference to any Contract or other document or instrument or to any Law is to it as amended and supplemented from time to time through the date of the Closing (and in the case of any Law, to any successor provisions, and to any rules and regulations promulgated thereunder, in effect as of the date of this Agreement and as of the date of the Closing), unless the context requires otherwise; (j) any reference to a Person shall include the permitted successors and assigns of such Person; and (k) any reference to any materials, including any document, report, record, file or other data, shall, in each case, include any form or medium of such materials (including electronic form).

 

article 2: ASSET PURCHASE

 

2.1 Asset Purchase; Assumption of Liabilities.

 

(a) Asset Purchase. Upon the terms and subject to the conditions of this Agreement, and except for the assets set forth on Schedule 2.1(a) hereof, at the Closing, the Seller shall sell, assign, transfer and deliver to the Buyer, and the Buyer shall purchase, acquire and accept from Seller, one hundred percent (100%) of the assets of the Seller, tangible and intangible, wherever located, whether or not listed in the Financial Statements (the “Purchased Assets”). The Purchased Assets include, without limitation: (i) all accounts receivable of Seller; (ii) the Beauty Brands and Costco orders; (iii) all Seller customer relationships; and (iv) and all formulas related to the Per-fekt products. The Purchased Assets shall be sold, transferred and assigned free and clear of all Liens and Encumbrances, except for Permitted Encumbrances. Notwithstanding the foregoing, the Purchased Assets will not include any of the assets listed on Schedule 2.1(a) (collectively, the “Excluded Assets”).

 

 
 

 

(b) Documentation. At the Closing, the Seller shall deliver one or more assignment and transfer agreement(s) and bill(s) of sale to the Buyer, such assignment and transfer agreement(s) and bill(s) of sale to be in form and substance reasonably acceptable to the Buyer.

 

(c) Assumption of Liabilities. The Buyer shall assume and agree to pay, perform and discharge when due, only the following liabilities and obligations of Seller (the “Assumed Liabilities”): (i) the Liabilities of the Seller described in Schedule 2.1(c)(i); (ii) the Liabilities of Seller arising after the Closing under the Contracts included in the Purchased Assets, including those listed on Schedule 2.1(c)(ii) (the “Assumed Contracts”), provided that the Buyer shall not assume any Liabilities of the Seller arising out of or in connection with any breaches or defaults by the Seller under the Assumed Contracts arising prior to the Closing and that the Assumed Liabilities shall not include any obligations or liabilities that were not incurred in the ordinary course of business and shall not include Liabilities or obligations that are caused by the actions or inactions of the Seller with respect to the Purchased Assets on or prior to the Closing Date; and (iii) the Liabilities arising out of operation of the Business or ownership of the Purchased Assets after Closing.

 

(d) Non-Assumption of Other Liabilities. Unless specifically set forth and assumed in Sections 2.1(c) or (e), the Buyer will not assume or in any way undertake to pay, perform, satisfy or discharge any Liability or other obligation whatsoever of the Seller or the Business, including, without limitation, any and all Liabilities for, relating to, arising out of or resulting from (i) any Taxes (whether payable by or for the Seller, any member of Seller or any other Person), (ii) accounts payable of the Seller not listed in Schedule 2.1(c)(i), (iii) the services or products of the Seller (including the Products) to the extent sold, performed, or delivered prior to the Closing Date (including, without limitation, any product returns, which shall remain the sole and complete liability of the Seller), (iv) the ownership or leasing of the Purchased Assets prior to or on the Closing Date, (v) any Action arising out of events occurring prior to the Closing, regardless of when made or asserted, (vi) any Liability under any Assumed Contract incurred during or relating in any way to the period prior to the Closing, (vii) any Employee or former employee of the Seller, or any consultant retained by the Seller, (viii) any obligation to indemnify, reimburse or advance amounts to any officer, director, Employee or agent of the Seller, (ix) any Action pending as of the Closing Date, (x) any Action commenced after the Closing Date and arising out of or relating to any occurrence or event happening prior to the Closing Date, (xi) the Seller’s compliance or noncompliance with any Law or Governmental Order, (xii) any liability of the Seller or the Member under this Agreement or any other document executed in connection with the Transactions, (xiii) the Seller’s actions or omissions occurring before, on or after the Closing Date, and (xiv) employee benefits (including, without limitation, any and all Liabilities for offering and providing COBRA continuation coverage (and all required notices related thereto) and accrued vacation, sick leave and bonuses, with respect to Seller’s Employees and former employees and their respective dependents and other COBRA qualified beneficiaries under Seller’s group health plans for “qualifying events” (within the meaning of §4980B of the Code and applicable regulations) occurring prior to and including the Closing Date (including any “qualifying event” occurring by virtue of an Employee not being hired by Buyer in connection with the consummation of the Transactions)) (collectively, the “Excluded Liabilities”). The Seller shall promptly pay and discharge all Excluded Liabilities in the ordinary course of business.

 

(e) Ulta Liability. As of the Closing, the Excluded Liabilities includes the wholesale value of returns of the Product inventory held by Ulta as of the Closing (“Ulta Held Inventory”), which, as of Closing, has a wholesale value of approximately $1,010,000 (the “Ulta Liability Amount”). In the event of Product returns of the Ulta Held Inventory by Ulta, Buyer shall be obligated to purchase the returned Products (except those returned Products that are reasonably deemed to be damaged, expired or otherwise unsaleable) from Seller at Seller’s true cost of manufacturing for such returned Products. Excluded Liabilities shall not include, and Seller shall have no liability for, freight or transportation costs associated with such returns. Following Closing, Buyer agrees to use commercially reasonable efforts to sell Products to Ulta (such sales being “New Product Sales”) and to support the resale of Products sold to Ulta. The Ulta Liability Amount shall decrease by the amount of New Product Sales by Buyer, from time to time, and once New Product Sales (measured using the Net Sales definition) equal or exceed the Ulta Liability Amount, then all Liabilities associated with the Ulta Held Inventory shall become an Assumed Liability. Notwithstanding the foregoing, on the one-year anniversary of the Closing, all Liabilities associated with the Ulta Held Inventory shall become an Assumed Liability.

 

 
 

 

2.2 Payment of Consideration.

 

(a) Purchase Price. The total purchase price for the Purchased Assets (such amount, the “Purchase Price”) will be payable in accordance with the provisions of this Agreement and equal to the sum of:

 

(i) the Preliminary Adjustment Amount; minus

 

(ii) the Seller Indebtedness Amount (as defined in Section 2.2(b)(i) below); minus

 

(iii) the amount of any Final Adjustment Amount Underage (as determined in accordance with Section 2.3 below); plus

 

(iv) the amount of any Final Adjustment Amount Overage (as determined in accordance with Section 2.3 below); plus

 

(v) Any Royalty Consideration (as defined in Section 2.2(c) below).

 

(b) Payment of Closing Date Purchase Price. In consideration of the transfer of the Purchased Assets to Buyer, at the Closing, Buyer shall:

 

(i) direct payment of an amount equal to the Seller’s Indebtedness set forth on Schedule 2.2(b)(i) hereof as of the Closing Date pursuant to payoff letter(s) in form reasonably acceptable to Buyer which will cause the release of all Liens (if any) on the Purchased Assets (the “Seller Indebtedness Amount”); and

 

(ii) pay to the Seller the following (the “Closing Payment”): (A) the Preliminary Adjustment Amount, minus (B) the Seller Indebtedness Amount. The Closing Payment shall be paid to Seller in the form of shares of Common Stock of Buyer. The Buyer shall issue to Seller at the Closing a number of shares of Common Stock of Buyer equal to the Closing Payment divided by $1.50.

 

(c) Royalty Consideration. As additional consideration for the purchase of the Purchased Assets, the Buyer agrees to make the following payments to the Seller in accordance with, and subject to the conditions of, this Section 2.2(c) and Section 6.1 (the sum of any such payments, if any, the “Royalty Consideration”):

 

(i) A 5% royalty on a quarterly basis beginning on the Closing Date, and terminating on the ten (10) year anniversary of the Closing Date, on all Net Sales of Products.

 

(d) Closing Deliverables. At or prior to the Closing, the Seller will prepare and deliver to the Buyer a statement of the amount of the estimated Adjustment Amount as of 12:01 a.m. Eastern Time on the Closing Date without taking into account any of the transactions to be completed on the Closing Date in accordance with the terms of this Agreement (the “Preliminary Adjustment Amount”), together with a reasonably detailed supporting calculation thereof. The Seller shall conduct a physical inventory count in order to determine the wholesale value of the Inventory. The Seller shall not promote, remove or liquidate any Inventory through sales, bulk sales or shipments to another retailer or location prior to Closing.

 

2.3 Purchase Price Adjustment.

 

(a) Within 90 days following the Closing, the Buyer shall prepare and deliver, or cause to be prepared and delivered, to the Seller a statement (the “Closing Schedule”) setting forth:

 

(i) the Buyer’s determination of the actual amounts of (A) the Adjustment Amount, including the Final Adjustment Amount Overage or the Final Adjustment Amount Underage (the “Final Adjustment Amount”), and (B) the Seller Indebtedness Amount, in each case as of 12:01 a.m. Eastern Time on the Closing Date without taking into account any of the transactions to be completed on the Closing Date in accordance with the terms of this Agreement;

 

 
 

 

(ii) a calculation of any adjustments to the Closing Payment based on such calculations (the adjusted Closing Payment as a result of such calculation being the “Final Closing Payment”); and

 

(iii) a calculation of the accounts receivable contained in the Preliminary Adjustment Amount that were not collected by Buyer within the thirty (30) days immediately following the Closing and the accounts receivable existing at the Closing but not taken into account in calculating the Adjustment Amount (the “Excluded AR”).

 

(b) Within fifteen (15) days after delivery of the Closing Schedule, the Seller may deliver a notice to Buyer either: (i) concurring with the Closing Schedule (a “Notice of Concurrence”); or (ii) disagreeing therewith (a “Notice of Disagreement”). If the Seller delivers a Notice of Disagreement, then it shall be accompanied by the Seller’s proposed revisions to the Closing Schedule. If the Seller fails to deliver any notice within such 15-day period, the Seller shall be deemed to have delivered a Notice of Concurrence.

 

(c) If a Notice of Concurrence is delivered or deemed delivered, and if the Final Closing Payment is less than the Closing Payment, the Buyer shall be entitled to payment out of the Royalty Consideration in the full amount of such shortfall. If a Notice of Concurrence is delivered or deemed delivered, and the Final Closing Payment is greater than the Closing Payment, Buyer shall pay to the Seller the full amount of such excess (with such payment being in shares of Buyer Common Stock priced at $1.50 per share) within thirty (30) days of the delivery of the Notice of Concurrence.

 

(d) If a Notice of Disagreement is delivered, then the Seller and the Buyer shall, during the 15-day period following such delivery (the “Negotiation Period”), use commercially reasonable efforts to agree on the Final Adjustment Amount. If, during such period, the Seller and the Buyer are unable to reach agreement, they promptly shall engage a nationally recognized certified public accounting firm reasonably acceptable to each such party (the “Independent Auditor”) to resolve the disagreement, and any such resolution shall be final, conclusive and binding upon the parties hereto, absent fraud or manifest error. To the extent the Final Closing Payment as determined by the Independent Auditor is less than the Closing Payment, the Buyer shall be entitled to payment out of the Royalty Consideration in the full amount of such shortfall. To the extent the Final Closing Payment as determined by the Independent Auditor is more than the Closing Payment, the Buyer shall pay to the Seller the full amount of such excess (with such payment being in shares of Buyer Common Stock priced at $1.50 per share) within thirty (30) days of such resolution.

 

(e) Each of the Seller and the Buyer shall pay fifty percent (50%) of the fees and expenses of the Independent Auditor.

 

2.4 Allocation of Consideration. The parties will mutually agree upon an allocation of the consideration paid hereunder among the Purchased Assets in accordance with Section 1060 of the Code and the Treasury Regulations promulgated thereunder and consistent with the allocation set forth on Schedule 2.4 and agree to use the allocations therein for all filings, declarations and reports with the IRS. The parties each agree to complete and file IRS Form 8594 with its U.S. Federal Income Tax Return consistent with such allocation for the Tax year in which the Closing occurs.

 

2.5 Closing. The closing of the Transactions (the “Closing”) will take place remotely via the exchange of documents and signatures (the date of the Closing, the “Closing Date”). The Closing shall be effective as of 12:01 AM Eastern Time on the Closing Date.

 

2.6 Collection of Accounts Receivable. Buyer shall use commercially reasonable efforts to collect accounts receivable included in the Purchased Assets as of the Closing Date and shall permit Seller to assist in collection efforts, including permitting Seller to directly contact payors. Each of Buyer and Seller shall be responsible for the costs and expenses of their respective collection efforts. Any and all Excluded AR shall be the property of Seller and Seller may use its discretion in collecting all such Excluded AR for its benefit after the thirty (30) day period following Closing.

 

 
 

 

2.7 Financial Statement Preparation. Following the Closing Date, Seller and Member shall use its commercially reasonable efforts to assist Buyer in causing to be prepared, as promptly as practicable, and in any event no later than seventy (75) days following the Closing Date, any financial statements that Buyer is required to file pursuant to Form 8-K, Rule 3-05 or Article 11 of Regulation S-X under the Exchange Act, and shall use its commercially reasonable efforts to obtain the consents of its auditor(s) with respect thereto as may be required by applicable SEC regulations. Seller represents and warrants that it has secured and will secure the cooperation of its finance staff to assist Buyer with getting audited financial statements. All costs and expenses associated with this Section 2.7, including reasonable compensation for services provided by Seller’s finance staff and auditors, shall be paid by Buyer.

 

article 3: REPRESENTATIONS AND WARRANTIES
OF THE SELLER and the Members

 

As of the Closing Date, each of the Seller and Member, jointly and severally, hereby represents and warrants to the Buyer as to the matters specified in this Article 3 (other than the investment representations in Sections 3.31 to 3.35, which are made by Seller only) subject to the exceptions disclosed in the disclosure schedules delivered by the Seller and the Member to the Buyer (the “Schedules”) concurrently with the execution and delivery of this Agreement. The sections of the Schedules are numbered to correspond to the applicable Section of this Agreement. The Schedules set forth, among other things, items the disclosure of which is necessary either in response to an express disclosure requirement contained in a section of this Agreement or as an exception to one or more representations or warranties contained in the corresponding section of this Article 3. Information or disclosures set forth in one section of the Schedules shall qualify other sections in this Agreement to the extent that it is readily apparent on its face that such information or disclosures apply to such other sections.

 

3.1 Organization and Standing. The Seller has been duly formed and organized and is validly existing and in good standing under the Laws of the jurisdiction of its formation. The Seller has the requisite power and authority to own its properties and assets and to carry on its business as currently conducted. The Seller is duly qualified or licensed to do business and in good standing as a foreign entity (if applicable) in each jurisdiction in which it conducts business, except where failure to so qualify would not reasonably be expected to have a material adverse effect on the Seller. Schedule 3.1 contains a complete and accurate list of the Seller’s jurisdiction of organization and any other jurisdictions in which it is qualified to do business as a foreign entity. The Seller has furnished to Buyer true and correct copies of its Organizational Documents, as amended to date, and such Organizational Documents are in full force and effect. The Seller is not in violation of any of the provisions of its Organizational Documents. The Seller has no Subsidiaries.

 

3.2 Authorization; Enforceability . The Seller has all requisite power and authority to enter into this Agreement and the other agreements referenced herein or required hereby (the “Seller Related Agreements”), and to consummate the transactions contemplated hereby and thereby (the “Transactions”). The execution and delivery of this Agreement and the Seller Related Agreements and the consummation of the Transactions have been duly and validly authorized by all necessary action on the part of the Seller, and no further action is required on the part of the Seller to authorize this Agreement, the Seller Related Agreements, and the Transactions. This Agreement and the Seller Related Agreements have been duly executed and delivered by the Seller and, assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitute the valid and binding obligation of the Seller, enforceable against it in accordance with their respective terms, except as such enforceability may be subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies.

 

3.3 Absence of Conflicting Agreements; Consents. Neither the execution, delivery or performance by the Seller of this Agreement and any Seller Related Agreements to which the Seller is a party, nor the consummation of the Transactions, does or will, after the giving of notice, or the lapse of time or both, or otherwise:

 

(a) contravene, result in a breach of, or constitute a default under, the Seller’s Organizational Documents;

 

(b) contravene or violate any Law to which the Seller or the Business is subject or by which the Seller or the Business is bound;

 

 
 

 

(c) contravene or constitute a default under any Material Contract;

 

(d) contravene in any material respect, result in any material breach of or constitute a default in any material respect (or which with the giving of notice or lapse of time would become such a default) under, give rise to any right of termination, material amendment, material modification, acceleration or cancellation of any material obligation or loss of any material benefit under, result in the creation of any Lien or Encumbrance on any of the assets of the Seller (including the Purchased Assets) pursuant to or under any Law or Governmental Order applicable to the Seller; or

 

(e) require the Consent of any Person or any Governmental Authority, other than as set forth in Schedule 3.3.

 

3.4 Capitalization. Schedule 3.4 sets forth the number, class and ownership of the Seller’s outstanding equity securities immediately prior to Closing (the “Seller Equity Interests”). The Seller Equity Interests constitute all of the outstanding equity or voting interests of the Seller, and the Seller Equity Interests have been duly authorized and are validly issued, fully paid and nonassessable. There are no outstanding securities convertible, exercisable or exchangeable into equity of the Seller or any options, warrants, purchase rights, subscription rights, preemptive rights, conversion rights, exchange rights, calls, puts, rights of first refusal or other Contracts that could require the Seller to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any equity interest. There are no voting trusts, proxies or other Contracts relating to the voting of equity of the Seller.

 

3.5 Sufficiency of, Title to and Condition of the Assets.

 

(a) The Purchased Assets constitute all of the assets related to or used in or otherwise owned or leased by the Seller in connection with the Business as the Business is currently conducted, and are sufficient to permit operation of the Business from and immediately after the Closing Date in substantially the same manner as the Business is currently conducted. All items of tangible personal property, material to the operation of the Business, whether owned or leased by the Seller, have been maintained in accordance with normal industry practice, are adequate and suitable for the purposes for which they are presently being used or held for use, conform in all material respects to all applicable Laws and Permits relating to their use and operation, and are free from defects (patent and latent) and deferred maintenance obligations, subject to normal wear and tear. Without limiting the generality of the foregoing, the equipment included in the Purchased Assets has been properly maintained and is in good working condition, subject to normal wear and tear.

 

(b) The Seller has good and marketable title in and to (or in the case of leased assets, a valid leasehold interest in) all of the Purchased Assets (other than inventory and other assets sold or disposed of in the ordinary course of business), free and clear of all Liens and Encumbrances other than Permitted Encumbrances.

 

3.6 Contracts.

 

(a) Schedule 3.6(a) sets forth a true, complete and correct list of all of the following Contracts to which the Seller is a party (such Contracts together with any Contracts listed on Schedule 3.8(b), collectively the “Material Contracts”):

 

(i) any written employment or severance Contract with any current or former employee of the Seller whereby the Seller continues to have ongoing obligations thereunder;

 

(ii) any Contract (or group of related Contracts) related to the engagement of any consultant or other independent contractor that provides for payments or other consideration in excess of $2,000;

 

(iii) any Contract (or group of related Contracts) with a customer or client or purchase orders (or group of related purchase orders) for the purchase or sale of products or services (A) having remaining obligations on the part of the Seller to a customer or client by any party thereto in excess of $2,000 or having remaining obligations on the part of the Seller to a vendor or supplier with respect to purchase orders (or group of related purchase orders by any party thereto) in excess of $2,000, (B) containing provisions of the type commonly referred to as a “most favored nation” provision, or (C) requiring the Seller to purchase its total requirements of any product or service from any Person or containing “take or pay” provisions;

 

 
 

 

(iv) any note, bond, indenture and other similar instrument or Contract evidencing, creating or otherwise relating to Indebtedness;

 

(v) any Contract with any Related Party relating to or in any way affecting the Business;

 

(vi) any executory Contract or commitment (or group of related Contracts or commitments) for capital expenditures that has remaining obligations in excess of $2,000;

 

(vii) any Contract that limits or purports to limit the ability of the Seller to compete in any line of business or with any Person in any geographic area during any period of time, as well as any Contract that limits the ability of any Employee to compete with the Seller;

 

(viii) any Contract creating a partnership or joint venture or similar entity or venture or any corporate sponsorship;

 

(ix) any Contract that is a collective bargaining agreement;

 

(x) any Contract (or group of related Contracts) that is material to the Business, or the absence or termination of which could reasonably be expected to have a Material Adverse Effect;

 

(xi) any Contract that provides for the indemnification of any Person or the assumption of any Liability of any Person that could reasonably be expected to exceed $2,000; and

 

(xii) any other Contract (or group of related Contracts) the performance of which involves future payments or receipts by the Seller in excess of $2,000.

 

(b) The Seller has delivered to Buyer true, correct and complete copies of all Material Contracts, including all amendments, modifications and changes thereto, and any assignments thereof. The Material Contracts constitute all of the Contracts that are material to the Business. Except as set forth in Schedule 3.6(b): (i) the Seller has performed, in all material respects, all terms, covenants, conditions and agreements of each of the Material Contracts that are required to be performed by the Seller; (ii) the Seller is not in default, in any material respect, under any Material Contract, and, to the Knowledge of the Seller, no other Person that is a party to any such Material Contract is in default thereunder in any material respect; (iii) to the Knowledge of the Seller, no event has occurred that (before or after notice or lapse of time or both) would become a breach or default, in any material respect, by the Seller or, to the Knowledge of the Seller, any other Person that is a party thereto under any such Material Contract; and (iv) each of the Material Contracts is valid, binding, enforceable and in full force and effect and constitutes the legal and binding obligation of the Seller and, to the Knowledge of the Seller, each other Person that is a party thereto in accordance with its terms.

 

3.7 Intellectual Property.

 

(a) Except as set forth on Schedule 3.7(a)(i), the Seller is the exclusive owner of all Intellectual Property, or has the rights to use all Intellectual Property, that is material or necessary to operate the Business as now conducted, free and clear of any Liens and Encumbrances (collectively such owned and licensed Intellectual Property is referred to herein as the “Seller Intellectual Property”) other than Permitted Encumbrances. Schedule 3.7(a)(ii) sets forth a true, complete and correct list of all such Seller Intellectual Property, including, without limitation formulas used in the Business, and Seller Intellectual Property that has been registered with the United States Patent and Trademark Office or Copyright Office and pending applications for registration, in each case listing the title and current owner(s), the jurisdiction(s) in which such Seller Intellectual Property has been issued or registered, and the application, serial or registration number, all of which will be transferred to the Buyer hereunder.

 

 
 

 

(b) Except as set forth in Schedule 3.7(b), the Seller has not received notice from any Person, nor has any knowledge of any valid basis for any Person to be, claiming that the operation of the Business currently infringes or misappropriates the Intellectual Property rights of any Person or constitutes unfair competition or trade practices under the Laws of any jurisdiction. Schedule 3.7(b) lists any complaint, claim, or notice, or written threat thereof, received by the Seller alleging any currently existing infringement, violation or misappropriation of the Intellectual Property of any Person.

 

(c) With respect to each item of Seller Intellectual Property which is licensed to the Seller: (i) the Seller has the valid right to use such Intellectual Property pursuant to a valid and enforceable license agreement; and (ii) the Seller is not in breach of any applicable license agreement and is not aware of any party that is in breach of the applicable license agreement. Each license agreement to which the Seller is party will remain unchanged and unaffected by the Transactions and the consummation of the Transactions will not result in the loss or impairment or termination of any Seller Intellectual Property.

 

(d) The Seller has taken all commercially reasonable steps necessary or required to insure the privacy of its databases and the security against breach of its computer systems by any unauthorized third party.

 

(e) No Product provided or distributed by the Seller in its conduct of the Business: (A) materially violates any Law; (B) includes any information or material that, to the Knowledge of the Seller, is defamatory; or (C) to the Knowledge of the Seller, infringes any right of privacy of any Person. Each Person whose name, image, voice or likeness is incorporated into any Marketing Materials has executed a written release consenting to the Seller’s use of such Person’s name, image, voice and/or likeness (as applicable) and releasing the Seller from any claims with respect thereto, each of such releases are fully assignable to Buyer without further consent of any Person.

 

(f) The Seller has operated the Business and provided all Products in material compliance with any posted privacy policies and all applicable Laws relating to privacy, data protection, anti-spam, telemarketing, personally identifiable information and similar consumer protection Laws (“Information Privacy Laws”). The Seller has not received written notice of any claims or been charged with violation of any Information Privacy Law. To the Knowledge of the Seller, the Seller is not under investigation with respect to any violation of any Information Privacy Laws.

 

3.8 Real Property; Leases.

 

(a) The Seller does not own any real property.

 

(b) The leases, licenses and subleases listed on Schedule 3.8(b) (collectively, the “Leases”) constitute all of the current leases, licenses or subleases for the use or occupancy of real property by or from the Seller (the “Seller Leased Real Property”).

 

(c) With respect to each such Lease:

 

(i) the Seller is not in breach or in default in any material respect thereof, and to the Knowledge of the Seller, no other Person that is a party to any such Lease is in breach or default in any material respect thereunder;

 

(ii) each of the Leases constitutes the legal and binding obligations of the Seller, and to the Knowledge of the Seller, any other Person that is a party thereto in accordance with its terms;

 

(iii) the Seller has not assigned, transferred, conveyed, mortgaged, deeded in trust or caused any Lien or Encumbrance (other than any Permitted Encumbrance) to exist with respect to any interest of the Seller in such Lease;

 

(iv) the Seller has not received notice of any non-compliance with current zoning or land use Laws or of any pending condemnation or similar proceeding affecting such Seller Leased Real Property or any portion thereof, and, to the Knowledge of the Seller, no such action is presently threatened;

 

(v) the Seller is entitled to the right of quiet enjoyment of each parcel of Seller Leased Real Property and is in peaceful and undisturbed possession of the Seller Leased Real Property, and the Seller has not received notice of any uncured violation of any contractual or legal restrictions that preclude or restrict the ability to use the Seller Leased Real Property for the purposes for which it is currently being used;

 

 
 

 

(vi) the Seller Leased Real Property and any buildings, structures, improvements and fixtures thereon constitute the only real property, improvements and fixtures used by the Seller and are adequate for the conduct of the Business as it currently is conducted;

 

(vii) the Seller has delivered to Buyer true, correct and complete copies of all of the Leases, including all amendments, modifications and changes thereto, and any assignments thereof; and

 

(viii) the Seller has not granted any license, lease or sublease to use or occupy the Seller Leased Real Property.

 

3.9 Financial Statements.

 

(a) The Seller has delivered to Buyer true, correct and complete copies (a) of the unaudited balance sheet for the Seller, as of December 31, 2016, and the related statement of operations and members’ equity for the fiscal year then ended, including any notes thereto (collectively, the “Annual Financial Statements”), and (b) an unaudited balance sheet (the “Most Recent Balance Sheet”) for the Seller as of May 31, 2017 (the “Most Recent Fiscal Month End”), and the related unaudited statement of operations for the five (5) month period then ended (collectively, the “Interim Financial Statements” and, together with the Annual Financial Statements, the “Financial Statements”).

 

(b) Except as set forth on Schedule 3.9(b)(i), the Financial Statements: (i) are complete and correct in all material respects and are derived from and are in accordance with the books and Records of the Seller; (ii) fairly and accurately represent, in all material respects, the financial condition of the Seller, as applicable, at the respective dates specified therein and the results of operations for the respective periods specified therein; and (iii) have been prepared in accordance with GAAP applied on a consistent basis throughout the periods covered thereby, except (x) to the extent prepared on a cash basis, and in such event, the Financial Statements are complete and correct in all material respects and fairly and accurately represent, in all material respects, the financial condition of the Seller or (y) in the case of the Interim Financial Statements, subject to normal recurring year-end adjustments and absence of notes.

 

3.10 Absence of Changes. Except as disclosed in Schedule 3.10, since May 31, 2017, there has not been:

 

(a) any change in the assets, business, properties, condition (financial or otherwise), or results of operations of the Seller, taken as a whole, from that reflected in the Financial Statements, except changes in the ordinary course of business that have not had, or would not reasonably be expected to have, in the aggregate and with or without the lapse of time, a Material Adverse Effect;

 

(b) any significant damage, destruction or loss that could reasonably be expected to materially and adversely affect the Business or the assets and properties of the Seller, whether or not covered by insurance;

 

(c) any amendments or changes in the Organizational Documents, except as contemplated by this Agreement;

 

(d) any waiver or compromise by the Seller of a material right or of a material debt owed to or by the Seller, except in the ordinary course of business and that would not reasonably be expected to have a Material Adverse Effect;

 

(e) any satisfaction or discharge of any Lien or Encumbrance or payment of any obligation by the Seller, except in the ordinary course of business and that would not reasonably be expected to have a Material Adverse Effect;

 

 
 

 

(f) any indication by any material customer or any supplier of the Seller of an intention to discontinue or change the terms of its relationship with the Seller;

 

(g) any declaration or payment of any dividend or other distribution of the assets or properties of the Seller;

 

(h) any increase in or modification of the compensation or benefits payable by the Seller to any of its directors, officers or Employees, other than annual increases or consistent with past practice;

 

(i) any delay or postponement in the payment of trade payables and other Liabilities outside the ordinary course of business;

 

(j) any imposition of any Lien or Encumbrance (other than Permitted Encumbrances) upon any of the assets or properties of the Seller;

 

(k) any sale, lease or other disposition of any asset or property of the Seller (including Seller Intellectual Property) except in the ordinary course of business;

 

(l) any occurrence, event, incident, action, failure to act, or transaction that has had or could reasonably be expected to have, with or without the lapse of time, a Material Adverse Effect;

 

(m) any material change in the accounting methods used by the Seller; or

 

(n) any labor dispute involving the Seller.

 

3.11 Litigation. Except as set forth in Schedule 3.11, (a) there is no Action pending or, to the Knowledge of the Seller, threatened against the Seller or relating to or affecting any of its assets or properties or that seeks to prevent, enjoin or otherwise delay the Transactions and (b) the Seller is not subject to any Governmental Order. Except for claims for collections in the ordinary course of business or as set forth in Schedule 3.11, there is no Action or investigation by the Seller currently pending or that the Seller intends to initiate. To the Knowledge of the Seller, no event has occurred or circumstance exists, with or without the lapse of time, that is reasonably likely to give rise to or serve as a basis for the commencement of any such Action.

 

3.12 Compliance with Laws.

 

(a) The Seller is and has been in compliance in all material respects with all applicable Laws and Permits, and to the Knowledge of the Seller, no event has occurred and no condition or circumstance exists that could reasonably be expected (with or without notice or lapse of time) to constitute, or result directly or indirectly in, a default under, a breach or violation of, or a failure to comply, in any material respect, with any applicable Laws or Permits. The Seller has not received any written notice from any Person regarding any actual, alleged or potential violation of any Laws or Permits since January 1, 2016.

 

(b) Except as identified on Schedule 3.12, the operation of the Business has been conducted in material compliance with all applicable material Laws and other requirements of all courts and other governmental or regulatory authorities having jurisdiction over the Seller and its assets, properties and operations. Except as set forth on Schedule 3.12, the Seller has not received written notice of any violation (or possible violation) of any such Law or other legal requirement, and the Seller is not in default with respect to any order, writ, judgment, award, injunction or decree of any federal, state or local court or Governmental Authority or regulatory authority, applicable to the Seller, the Business, or the Products. Without limiting the foregoing, the Seller has not received any warning letter or untitled letter, report of inspectional observations, including FDA Form 483s, establishment inspection reports, notices of violation, clinical holds, enforcement notices or other documents from the United States Food and Drug Administration or any other similar Governmental Authority or any institutional review board or independent ethics committee alleging a lack of material compliance by Seller with any Laws. The Seller holds all Permits required for the conduct of the Business and the ownership of its properties except where the absence thereof would not result in a Material Adverse Effect. No written notices have been received by the Seller alleging the failure to hold any Permit. The Seller is in material compliance with all terms and conditions of all such Permits.

 

 
 

 

3.13 Taxes.

 

(a) The Seller has accurately prepared and timely filed all federal, state and local, foreign and other Tax Returns that are required to be filed by it, and has paid or made provision for the payment of all Taxes of the Seller, if any, that have become due and payable, whether or not shown on a Tax Return. No deficiency assessment or proposed adjustment of the Seller’s United States Tax or state, local or foreign Taxes is pending, and there is no Liability of the Seller for any Tax as of the date of the Interim Financial Statements for which there is not an adequate reserve reflected in the Most Recent Balance Sheet.

 

(b) All Taxes payable by, or due from, the Seller have been fully paid or adequately disclosed and fully provided for in the books and Financial Statements. The Seller has not received any notice of an examination of any Tax Return of the Seller by any Governmental Authority. There are no outstanding agreements or waivers extending the statutory period of limitation applicable to any Tax Return of the Seller.

 

(c) No claim has been made by (i) a Governmental Authority in a jurisdiction where the Seller does not file Tax Returns that the Seller is or may be subject to taxation by that jurisdiction or (ii) a Governmental Authority in any jurisdiction in which the Seller does file Tax Returns that the Seller is or may be subject to taxation for any type of Tax for which the Seller has not filed all such Tax Returns in that jurisdiction. There are no Liens or other Encumbrances for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Seller.

 

(d) The Seller has withheld and paid all Taxes required to have been withheld and paid in connection with any amounts paid or owing to any Employee, independent contractor, creditor, stockholder, member, equity holder or other Person.

 

(e) The Seller has not received from any foreign, federal, state, or local Tax authority (including jurisdictions where the Seller has not filed Tax Returns) any (i) written notice indicating an intent to open an audit or other review, (ii) request for information related to Tax matters, or (iii) notice of deficiency or proposed adjustment for any amount of Tax proposed, asserted, or assessed by any Tax authority against the Seller. The Seller has delivered to Buyer correct and complete copies of all United States federal, state, local or foreign income Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Seller filed or received since January 1, 2016.

 

(f) Except as set forth in Schedule 3.13(f), the Seller is not a party to any Contract, plan or other arrangement that, individually or collectively, could give rise to the payment of any amount that would be subject to withholding under sections 409A, 457A or 4999 of the Code (whether directly under such Code section or pursuant to Code section 3401).

 

(g) The Seller has not engaged, or is not currently engaging, in any “reportable transaction” within the meaning of Treasury Regulation section 1.6011-4(b).

 

(h) Except as set forth in Schedule 3.13(h), the Seller is not a party to or bound by any Tax allocation, indemnification or sharing agreement. The Seller (i) has not been a member of an “affiliated group” (within the meaning of Code section 1504(a)) filing a consolidated federal income Tax Return or (ii) does not have any Liability for the Taxes of any Person under Treasury Regulations section 1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, by contract, or otherwise.

 

(i) Seller (i) does not own, directly or indirectly, any interest in any entity that is organized outside of the United States and (ii) has not filed a Form 8832 with the IRS, or otherwise made a “classification” election under Treasury Regulations section 301.7701-3.

 

(j) The Seller has conducted all aspects of its business in accordance in all material respects with the terms and conditions of all Tax rulings, Tax concessions and Tax holidays that were provided by any relevant Tax authority.

 

 
 

 

3.14 Insurance. The Seller has in full force and effect, and has had in full force and effect since January 1, 2016, the liability and casualty insurance, errors and omissions insurance, workers compensation insurance, automobile insurance, and employee fidelity insurance insuring the Business, properties, assets, employees and officers and/or directors of the Seller as listed in Schedule 3.14. True, complete and correct copies of each such insurance policy (or certificate of insurance, if such insurance policy is unavailable) listed or required to be listed in Schedule 3.14 have been delivered to Buyer. Neither the Seller nor, to the Knowledge of the Seller, the insurance companies party thereto are in default, in any material respect, with respect to any such insurance policies, and the Seller has not failed to give any notice or present any material claim that is pending under any policies in due and timely fashion. Since January 1, 2016, no insurer has (a) denied or disputed (or otherwise reserved its rights with respect to) the coverage of any claim pending under any insurance policy or (b) threatened to cancel any insurance policy.

 

3.15 Guarantees. Except as set forth on Schedule 3.15, (a) the Seller is not a guarantor or otherwise responsible for any Liability (including Indebtedness) of any other Person other than endorsements of checks for deposit in the ordinary course of business and (b) no Person (other than the Seller) has guaranteed or is otherwise responsible for any Liability (including Indebtedness) of the Seller other than endorsements of checks for deposit in the ordinary course of business.

 

3.16 Employees; Independent Contractors.

 

(a) Schedule 3.16(a) sets forth a true, correct and complete list of all current employees, managers, and officers of the Seller (collectively, the “Employees”) showing each of their names, the identity of their employer, job titles, exemption classification under the Fair Labor Standards Act of 1938, as amended (“FLSA”), status (full-time or part-time, active or inactive), current annual compensation, bonuses, commissions, deferred or contingent compensation, pension, accrued and unused vacation and other paid leave, sick and paid time off, paid or payable (in cash or otherwise). Except as set forth in Schedule 3.16(a), the employment or term of service of all Employees is terminable at will, which means that their employment can be terminated at any time, with or without notice, for any reason or no reason at all without penalty or severance.

 

(b) Schedule 3.16(b) sets forth a true and correct list of all independent contractors (collectively, “Independent Contractors”) that are presently engaged by the Seller and an indication of which, if any, of such Independent Contractors cannot be terminated on thirty (30) days’ notice or less or at any time, without Liability other than fees, costs and remuneration accrued through the effective time of termination.

 

(c) To the Knowledge of the Seller, within the past one (1) year, no Employee or Independent Contractor has been in violation in any material respect of any employment contract, non-disclosure agreement, non-competition agreement or restrictive covenant to a former employer relating to the right of any such Person to be employed or retained by the Seller because of the nature of the business conducted by the Seller. To the Knowledge of the Seller, within the past one (1) year, no Employee, former employee or Independent Contractor has been in violation in any material respect of any enforceable employment contract, nondisclosure agreement, non-competition agreement or restrictive covenant in respect of an agreement or Contract between the Seller, on the one hand, and that Employee, former employee or Independent Contractor, on the other hand.

 

(d) The Seller is compliant in all material respects with the Immigration and Nationality Act, the Immigration Reform and Control Act of 1986, and other applicable Laws regarding work authorization and the employment of individuals who are not citizens of the United States, all as amended from time to time (collectively the “Immigration Laws”). To the Knowledge of the Seller, each Employee who is a resident alien and who works the Seller has obtained all required documentation to permit such Employee to work for the Seller under the Immigration Laws. To the Knowledge of the Seller, the Seller does not employ any Employee who is not authorized to work in the United States under the Immigration Laws. There are no pending or, to the Knowledge of the Seller, threatened investigations, audits, claims or proceedings relating in any way to compliance by the Seller with respect to the Immigration Laws.

 

(e) (i) The Seller is not party to, bound by, or subject to any collective bargaining agreement or other labor union contract covering any of the Employees, and to the Knowledge of the Seller, there exists no organizational effort presently being made or threatened by or on behalf of any labor union, work council, or other organization with respect to the Employees, and, to the Knowledge of the Seller, no such efforts have been made since January 1, 2016; (ii) the Seller has not been or is not engaged in any unfair labor practice or other unlawful wage and hour or employment practice since January 1, 2016, and there are no charges of any unfair labor practice, charge of discrimination or harassment or other unlawful wage and hour or employment practice pending against the Seller before the National Labor Relations Board, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Department of Labor or any other Governmental Authority; and (iii) since January 1, 2016, the Seller has not experienced any strikes, grievances, claims of unfair labor practices, or other collective bargaining disputes or other labor disputes or controversies and, to the Knowledge of the Seller, none of the foregoing are threatened.

 

 
 

 

(f) Other than as would not have a Material Adverse Effect, the Seller is in compliance, and has complied, with the FLSA and all other applicable Laws concerning the classification of Employees and Independent Contractors and have properly classified all such persons for purposes of participation in the Employee Benefit Plans and other applicable Laws. The Seller (i) is in compliance in all material respects, and have complied in all material respects, with all Laws concerning employment, employment practices, termination of employment, terms and conditions of employment, wages and hours, duration of work, overtime, collective bargaining, employment discrimination, leaves of absence, immigration, civil rights, safety and health, workers’ compensation, pay equity and classification of employees; (ii) has withheld and reported all Taxes or other amounts required by Law or by agreement to be withheld and reported from the wages, salaries and other payments to Employees and former employees; (iii) is not liable for any arrears of wages or other compensation, or any Taxes or any penalty for failure to comply with any of the foregoing; and (iv) is not liable for any payment to any trust or other fund or to any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits for Employees and former employees (other than routine payments to be made in the normal course of business and consistent with past practice). Except as set forth on Schedule 3.16(f), there are no pending or, to the Knowledge of the Seller, threatened or reasonably anticipated Actions against the Seller under any worker’s compensation policy or long-term disability policy.

 

(g) The Seller is in compliance with the Worker Readjustment And Notification Act, as amended (the “WARN Act”) and any applicable state laws or other applicable Laws regarding redundancies, reductions in force, mass layoffs, and plant closings, including all obligations to furnish promptly and correctly all notices required to be given thereunder in connection with any redundancy, reduction in force, mass layoff, or plant closing to affected employees, representatives, any state dislocated worker unit and local government officials, or any other Governmental Authority. No reduction in the notification period under the WARN Act is being relied upon by the Seller.

 

(h) The Seller is in compliance in all material respects with all Health and Safety Laws and any applicable foreign, state, provincial or other applicable Laws regarding employee and workplace safety.

 

(i) In connection with Closing, the Seller shall satisfy in cash payments to each Employee all obligations for accrued wages, bonuses, Employee Benefit Plans, independent contractor payments, accrued vacation and sick leave or similar benefits provided to such Employees.

 

3.17 Benefit Plans. The Seller does not have, and has never had, any (i) “employee benefit plans” as such term is defined in section 3(3) of ERISA (such as pension and 401(k) plans, and medical, life, and disability plans), or (ii) any bonus, stock option, stock purchase, restricted stock, incentive, deferred compensation, retiree medical or life insurance, cafeteria plan, dependent care plan, supplemental retirement or other benefit plan, program or arrangement or any employment, termination, severance, retention, stay bonus or other contract, agreement, plan, program or arrangement that provides or promises benefits or payments to any current Employee or former employee, Independent Contractor, officer, shareholder or director of the Seller that the Seller maintains or makes contributions to or has any responsibility or Liability for.

 

3.18 Environmental Compliance.

 

(a) The Seller is in compliance in all material respects with all Environmental Laws, and any past noncompliance by the Seller with Environmental Laws in any respect has been resolved without any ongoing or future Liabilities.

 

 
 

 

(b) The Seller has not received any written notice of any Action, and, to the Knowledge of the Seller, no such Action has been filed, commenced or threatened against the Seller that:

 

(i) asserts or alleges that the Seller violated any Environmental Laws;

 

(ii) asserts or alleges that the Seller is required to conduct any Remedial Action at the Seller Leased Real Property or in connection with the Business;

 

(iii) asserts or alleges that the Seller is required to pay all or a portion of the cost of any past, present or future Remedial Action at any of the Seller Leased Real Property or in connection with the Business; or

 

(iv) asserts or alleges that the Seller is liable in connection with the exposure of any persons to Hazardous Materials that are present at or Released at or from any Seller Leased Real Property or that relate to the Business.

 

(c) The Seller has not caused, permitted or suffered Hazardous Materials to be stored, deposited, treated, recycled, disposed of, or Released at any Seller Leased Real Property in violation of any applicable Environmental Laws in any material respect, and to the Knowledge of the Seller, there has been no Release at any of the Seller Leased Real Property, that would subject any owner or operator of such Seller Leased Real Property to Liability for any Remedial Action under any Environmental Laws. To the Knowledge of the Seller, there are no tanks or other facilities, equipment or transformers on, under, or at the Seller Leased Real Property that contain any Hazardous Materials that, if known to be present in soils or ground water, would subject any owner or operator of such Seller Leased Real Property to Liability for any Remedial Action under any Environmental Laws. The Seller is not subject, as a result of its interests in the Seller Leased Real Property or in connection with the Business, to any Governmental Order related to or arising out of any Environmental Laws, and, to the Knowledge of the Seller, the Seller has not been named or listed as a potentially responsible party in a matter related to or arising out of any Environmental Laws. The Seller is not conducting or funding any Remedial Action in connection with the Business or at any Seller Leased Real Property. The Seller has provided Buyer with true, correct and complete copies of all environmental assessments, audits, studies or other analyses of any Seller Leased Real Property in its possession or control. All amounts required to correct any issue related to compliance by the Seller with any and all Environmental Laws are reflected in the Financial Statements.

 

3.19 Brokers; Service Providers. Except as set forth on Schedule 3.19, neither the Seller nor any of its Affiliates have any Liability to pay any brokers’, finders’ or similar agents’ fees or commissions with respect to the Transactions. Except for third party service providers set forth on Schedule 3.19, neither the Seller nor any of its Affiliates have any Liability to pay any fees, commissions, expenses or reimbursements of any third party service provider with respect to the Transactions.

 

3.20 Transactions with Affiliates.

 

(a) Schedule 3.20(a) sets forth a true, correct and complete list of all Contracts and arrangements between or among the Seller, on the one hand, and (i) any of the Seller’s Affiliates, members, directors, or officers, or (ii) any Employees of the Seller’s members or family members of any Employee of the Seller’s members who own an equity interest in any of the Seller’s members or trusts created for the benefit of any such family member or employee (collectively, the “Related Parties”), on the other hand.

 

(b) Except as set forth in Schedule 3.20(a), no Related Party (i) has been involved in any business agreement, arrangement or relationship with, relating to or in any way affecting the Seller or the Business (including furnishing services to or receiving services from, renting or leasing equipment, real estate or other assets or properties to or from, or providing or receiving the benefit of properties or assets for non-arm’s length compensation) since January 1, 2016, or (ii) owns any asset, tangible or intangible, that is material to the operation of the Business and that is used by the Seller. All transactions with any of the Related Parties have been fully and completely and accurately reflected in the Financial Statements, including but not limited to payments to any of the Related Parties for services or products or other contributions to the Seller in connection with the operation of the Business.

 

3.21 Suppliers. Schedule 3.21 sets forth a true, correct and complete list of the ten (10) largest suppliers for the Seller who supplied products, materials or services to the Seller during the 2016 and 2017 fiscal years. No such supplier has given written notice to the Seller that it intends to stop supplying, or alter in any material respect its relationship with the Seller with respect to, such products, material or services to the from terms and conditions and quantities similar in all material respects to those used in its current sales or services to the Business.

 

 
 

 

3.22 Customers. Schedule 3.22 sets forth a true, correct and complete list of the ten (10) largest customers for the Seller who purchased Products, materials or services from the Seller during the 2016 and 2017 fiscal years. No such customer has given written notice to the Seller that it intends to stop purchasing, or alter in any material respect its relationship with the Seller with respect to, such Products, material or services from the Business from terms and conditions and quantities similar in all material respects to those used in its current purchases from the Business.

 

3.23 No Undisclosed Liabilities. The Seller has no Liability (and, to the Knowledge of the Seller, there is no basis for any present or future Action, charge, complaint, claim, or demand against the Seller or the Business giving rise to any Liability), except for (a) Liabilities required in accordance with GAAP to be set forth on the Most Recent Balance Sheet, (b) Liabilities that have arisen after the Most Recent Fiscal Month End in the ordinary course of business consistent with past practices (none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach of warranty, tort, infringement, or violation of Law), (c) Liabilities resulting from the obligations of the Seller under this Agreement or the Seller Related Agreements, and (d) the Liabilities set forth in Schedule 3.23.

 

3.24 Permits. Schedule 3.24 contains a true, complete and correct list of all Permits of the Seller. Such Permits constitute all material Permits required by applicable Laws to carry on the Business as currently conducted. All such Permits are valid, and in full force and effect and. The Seller is in compliance in all material respects with the requirements and limitations included in such Permits.

 

3.25 Disputed Accounts Payable. Except as set forth in Schedule 3.25, there are no (individually or in the aggregate) unpaid invoices or bills representing amounts alleged to be owed by the Seller that the Seller has disputed or determined to dispute or refuse to pay.

 

3.26 Minute Books. The Seller has made available to Buyer all of the Records of the Seller, all of which are complete and correct in all material respects and represent actual, bona fide transactions and have been maintained in accordance with sound business practices.

 

3.27 Computer Systems. Except as set forth in Schedule 3.27, none of the computer software, computer hardware (whether general or special purpose), telecommunications capabilities (including voice, data and video networks) and other similar or related items of automated, computerized, and/or software systems and any other networks or systems and related services that are used by or relied on by the Seller in the Business (i) has experienced bugs, failures, breakdowns, or continued substandard performance in the past twelve (12) months that has caused any material disruption or interruption in or to the use of any such systems by the Seller; or (ii) will require the consent or approval of any Person to be transferred to the Buyer in connection with the Closing.

 

3.28 Inventory. All inventories of the Seller, including, but not limited to, all raw materials, Products, finished product, samples, and Product components or ingredients (collectively, “Inventory”) consists of a quality and quantity usable and salable in the ordinary course of business consistent with past practice, except for obsolete, damaged or defective items that have been written off or written down to fair market value or for which a reasonable reserve has been established. At the Closing, the Inventory will include sufficient quantities as are reasonably necessary for the conduct of the Business in the ordinary course consistent with past practices. The term “Inventory” shall not include out of date, discontinued or non-approved Products set forth on Schedule 3.28. The Seller’s accounting practice with respect to Inventory is to expense the Inventory at the time of purchase.

 

3.29 Solvency. The Seller is not now insolvent nor will the Seller be rendered insolvent by any of the Transactions. As used in this section, “insolvent” means that the sum of the Seller’s debts and other probable Liabilities exceed the present fair saleable value of the Seller’s assets.

 

3.30 Product and Service Warranties . Except as set forth on Schedule 3.30 the Seller has made no express warranty to any customer (or end user of the Seller’s goods or Products) as to services or goods provided by the Seller. There is no pending or, to the Knowledge of the Seller, threatened claim alleging any breach of any warranty. The Seller does not have any Liability under any such a warranty that would reasonably be expected to result in Liability to the Seller, individually or in the aggregate, in excess of $5,000. To the Knowledge of the Seller, there have not been any Adverse Events with respect to the Products or the Business.

 

 
 

 

3.31 Status. The Seller represents and warrants that (a) it has had an opportunity to discuss the business, management and financial affairs of the Buyer, has had access to, the management of the Buyer, and has had the opportunity to review the information set forth in the Buyer’s public filings and any other information requested by the Seller, and (b) the Buyer will be relying upon the Seller’s representations and warranties set forth herein in issuing the shares of Common Stock of the Buyer as part of the Purchase Price (the “Equity Consideration”) to it, and it is not relying on the advice or recommendations of the Buyer and it has made its own independent decision that the Equity Consideration is suitable and appropriate for the Seller. The Seller further represents and warrants that: (i)(A) it recognizes that ownership of the Equity Consideration involves substantial risks, including a risk of total loss of the value of the Equity Consideration, and has taken full cognizance of and understands all of the risk factors related to the ownership of the Equity Consideration; and (B) it has sufficient knowledge and experience in business and investments, including financial, business and tax matters, to be capable of evaluating the merits and risks of ownership in the Buyer and making an informed decision about ownership in the Buyer; or (ii) it is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “1933 Act”).

 

3.32 Acquisition for Own Account. This Agreement is made with the Seller in reliance upon Seller’s representations to the Buyer, which by its execution hereof the Seller hereby confirms, that the Equity Consideration to be received by Seller will be acquired for investment for the Seller’s own account, not as a nominee or agent, and not with a view to the sale or distribution of any part thereof other than as permitted under the 1933 Act and that it has no present intention of selling, granting participation in, or otherwise distributing the same other than what is permitted under the 1933 Act. By executing this Agreement, the Seller further represents that it does not have any contract, undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person, or to any third person, with respect to the Equity Consideration.

 

3.33 No Intention to Distribute. The Seller understand that the Equity Consideration shares have not been registered under the 1933 Act on the grounds that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the 1933 Act, and that the Buyer’s reliance on such exemption is predicated in part on the representations set forth herein. The Seller realizes that the basis for the exemption may not be present if, notwithstanding such representations, the Seller has in mind merely acquiring the Equity Consideration shares for a fixed or determined period in the future, or for a market rise, or for sale if the market does not rise. The Seller does not have any such intention.

 

3.34 No Registration. The Seller understands that the Equity Consideration may not be sold, transferred or otherwise disposed of without registration under the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Equity Consideration shares or an available exemption from registration under the 1933 Act, the Equity Consideration must be held indefinitely. In particular, the Seller is aware that the Equity Consideration shares may not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about the Buyer.

 

3.35 Restrictions on Transfer. The Seller agrees that in no event will it make a transfer or disposition of any of the Equity Consideration other than pursuant to an effective registration statement under the 1933 Act or a Rule 144 sale in compliance with the terms of such Rule or pursuant to an exemption from the 1933 Act. Buyer shall cooperate with Seller and Seller’s transfer agent in the removal of any legend on the Equity Consideration shares constituting the Equity Consideration to permit the trade or liquidation thereof in the marketplace as permitted under Rule 144 of the 1933 Act, if requested by the Seller.

 

 
 

 

article 4: REPRESENTATIONS AND WARRANTIES OF THE BUYER

 

As of the date hereof and as of the Closing Date, the Buyer hereby represents and warrants to the Seller as follows:

 

4.1 Organization and Standing. The Buyer is duly organized, validly existing and in good standing under the Laws of the Governmental Body of its incorporation and is duly qualified or licensed to do business and in good standing in each jurisdiction in which the character of its properties owned, operated, or leased or the nature of its properties owned, operated or leased make such qualification necessary except as would not materially and adversely affect the Buyer. The Buyer has the requisite corporate power to own, lease, and operate its properties and to carry on its business as such is now conducted and as is contemplated to be conducted immediately after the Closing.

 

4.2 Authorization; Enforceability. The execution, delivery and performance of this Agreement and the agreements, documents, certificates and instruments contemplated under this Agreement to which the Buyer is or will be a party (collectively, “Buyer Related Agreements”) and the consummation by the Buyer of the Transactions, are within the power of the Buyer and have been duly authorized by all necessary corporate action by the Buyer and its shareholders and board of directors, and no approval from or notice to any of the shareholders and board of directors of the Buyer is required regarding the same that has not been obtained or given, as applicable. This Agreement and the Buyer Related Agreements have been duly executed and delivered by the Buyer and, assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitutes (or, if such agreement is to be executed and delivered at Closing, will constitute) the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as such enforceability may be subject to the laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies.

 

4.3 Absence of Conflicting Agreements; Consents. Neither the execution, delivery or performance of this Agreement and the Buyer Related Agreements, nor the consummation of the Transactions by the Buyer, does or will, after the giving of notice, or the lapse of time or both, or otherwise: (a) contravene, result in a breach of, or constitute a default under, the Organizational Documents of the Buyer; (b) contravene or violate in any material respect any material applicable Law to which the Buyer is a party or by which the Buyer or its assets are bound; (c) contravene in any material respect, or constitute a default in any material respect under, any contract or agreement to which the Buyer is a party or by which the Buyer or its assets are bound; or (d) require the Consent of or notice to any Governmental Authority.

 

4.4 Capitalization. As of the date hereof, the authorized capital stock of the Buyer consists of 300,000,000 shares of Common Stock, $0.00001 par value. As of the date hereof, approximately 88,764,357 shares of Common Stock are validly issued and outstanding, and each outstanding share of Common Stock is fully paid and nonassessable. As of the date hereof, Buyer has 9,225,000 shares of Common Stock available for future grant pursuant to the Buyer’s 2014 Equity Incentive Plan, (collectively, the “Equity Plan”), (ii) outstanding options to purchase 6,300,000 shares of Common Stock under the Equity Plan, and (iii) no outstanding shares of restricted stock under the Equity Plan. The issued and outstanding shares of Common Stock conform to the description thereof contained in the reports (the “Exchange Act Reports”) filed by the Buyer with the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Except for options issued under the Equity Plan, the Buyer does not have outstanding any options or warrants to purchase, or any preemptive rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or any contracts or commitments to issue or sell, shares of its capital stock, and there is no commitment, plan or arrangement to issue, any securities or obligations convertible into any shares of capital stock of the Buyer or any such options, rights convertible securities or obligations.

 

4.5 Issuance, Sale and Delivery of the Equity Consideration. The Equity Consideration has been duly authorized and, when issued, delivered and paid for in the manner set forth in this Agreement, will be duly authorized, validly issued, fully paid and nonassessable, free and clear of any Lien or Encumbrance, other than restrictions of transfer from federal or state securities laws. No preemptive rights or other rights (which have not been waived) to subscribe for or purchase exist with respect to the issuance and sale of the Equity Consideration by the Buyer pursuant to this Agreement.

 

 
 

 

4.6 Financials. The Buyer’s financial statements (including all notes and schedules thereto) included in the Exchange Act Reports relating to the two year period preceding the date hereof present fairly in all material respects the financial position, results of operations, statements of cash flows and statements of stockholders’ equity and other information purported to be shown therein of the Buyer at the respective dates and for the respective periods to which they apply (subject, in the case of unaudited statements, to normal year-end audit adjustments and the absence of footnotes) and such financial statements have been prepared in conformity with GAAP, consistently applied throughout the periods involved (except as may be indicated in the notes thereto). Since the date of the most recent financial statements included in the Exchange Act Reports, there has not been any event or condition of any character that, either individually or cumulatively, has or would have a Material Adverse Effect.

 

4.7 Exchange Act Reports. The Buyer has complied in all material respects with the filing requirements of the SEC under the Exchange Act and all rules and regulations thereunder for the two years preceding the date hereof. As of their respective filing dates, all documents filed by the Buyer with the SEC complied in all material respects with the requirements of the Exchange Act and all rules and regulations thereunder, and none of the Exchange Act Reports, when filed, contained any untrue statement of a material fact or omitted any fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

4.8 Offering Valid. Assuming the accuracy of the representations and warranties of the Seller contained in Article 3 hereof, the offer, sale and issuance of the Equity Consideration will be exempt from the registration requirements of the 1933 Act, and will have been registered or qualified (or exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws.

 

4.9 Brokers. Neither the Buyer nor any of its Affiliates has any Liability to pay any finders’, brokers’ or similar agents’ fees or commissions with respect to the Transactions.

 

4.10 Litigation. There is no material Action pending or, to the knowledge of the Buyer, threatened against the Buyer or its Affiliates with respect to the Transactions. Neither the Buyer nor any of its Affiliates is subject to any Governmental Order that would alone or in the aggregate materially and adversely affect the ability of the Buyer to close the Transactions or have a material adverse effect on the Business after the Closing Date.

 

4.11 No Other Representations. The Buyer acknowledges and agrees that except for the representations and warranties contained in Article 3, neither Seller nor Member, nor any of their respective directors, officers, employees, subsidiaries, controlling persons, agents or Affiliates, makes or has made any representation or warranty, either express or implied, as to the accuracy or completeness of any information relating to the Seller, Member, the Business, the Purchased Assets or the Assumed Liabilities, and the Buyer is not relying, and has not relied, on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties in Article 3.

 

article 5: CONDITIONS PRECEDENT TO CLOSING; CLOSING DELIVERABLES

 

5.1 General Conditions. Consummation of the Transactions shall be subject to the fulfillment on or before the Closing Date of each of the following conditions:

 

(a) No Proceedings. No Action or proceeding shall have been instituted or threatened prior to or on the Closing Date before any Governmental Authority pertaining to the Transactions, the result of which could prevent or make illegal the consummation of the Transactions.

 

 
 

 

(b) No Order. There shall not be in force any Governmental Order by any Governmental Authority of competent jurisdiction or any Law restraining, enjoining, prohibiting, invalidating or otherwise preventing the consummation of the Transactions.

 

5.2 Conditions to Closing in Favor of the Buyer . The obligation of the Buyer to consummate the Transactions is subject to the satisfaction, or the written waiver by Buyer, of each of the following conditions on or before the Closing Date:

 

(a) Representations, Warranties and Covenants. (i) Each representation and warranty of the Seller contained in this Agreement shall be true and correct on and as of the Closing Date in all material respects (except for those representations and warranties which address matters only as of a particular date, which shall have been true and correct as of such particular date and except for representations and warranties that contain “Material Adverse Effect” qualifications and other qualifications based on the word “material,” which shall be true and correct in all respects), and (ii) the Seller shall have performed and complied in all material respects with all covenants and obligations under this Agreement required to be performed and complied with by the Seller prior to or as of the Closing.

 

(b) No Material Adverse Effect. No event or events shall have occurred since the date of this Agreement which individually or in the aggregate has had, or is reasonably likely to have, a Material Adverse Effect on the Seller, the Business or the Purchased Assets.

 

(c) Officer’s Certificate of the Seller. Buyer shall have received a certificate, validly executed by an executive officer of the Seller for and on its behalf, to the effect that, as of the Closing, (i) the conditions to the obligations of the Buyer set forth in Sections 5.2(a) and (b) hereof have been satisfied to his or her actual knowledge, and (ii) each and every one of the other conditions to the obligations of the Buyer set forth in this Section 5.2 have been satisfied to his or her actual knowledge (unless otherwise waived in accordance with the terms hereof).

 

(d) FIRPTA Certificate. Buyer shall have received a properly executed certificate of non-foreign status substantially in the form specified in Section 1.1445-2 of the Treasury Regulations from the Seller.

 

(e) Consents. Prior to the Closing, the Seller shall obtain the Consents, waivers and approvals, and timely provide notices, under the Contracts, Leases, Permits, real estate leases and other arrangements set forth on Schedule 5.2(e), so as to preserve all rights of, and benefits to, the Buyer thereunder from and after the Closing. To the extent that the rights of the Seller under any Contract or other Purchased Asset to be assigned to Buyer hereunder may not be assigned without the Consent of another Person which has not been obtained as of the Closing, this Agreement will not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and the Seller, at its expense, will obtain any such required Consent(s) within sixty (60) days of Closing. If any such Consent has not been obtained as of the Closing or if any attempted assignment would be ineffective or would impair the Buyer’s rights under the Contract or Purchased Asset in question so that the Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law and the Contract or Purchased Asset, will act after the Closing as the Buyer’s agent for the limited purpose of obtaining for it the benefits thereunder and will cooperate, to the maximum extent permitted by Law and the Contract or Purchased Asset, with Buyer in any other reasonable arrangement satisfactory to all parties designed to provide such benefits to the Buyer, and the Buyer will be responsible for the costs and expenses of obtaining such benefits. Notwithstanding the foregoing, any failure to obtain any required Consent, whether or not disclosed by the Seller to the Buyer in the Schedules or otherwise, will not relieve the Seller of its obligation to obtain all such Consents as set forth herein.

 

(f) Delivery of Documents. The Seller shall have executed and delivered to Buyer all documents, certificates, instruments and schedules required hereunder.

 

(g) Release of Liens and Encumbrances. Buyer shall have received from the Seller duly and validly executed copies of all agreements, instruments, certificates and other documents, in form and substance acceptable to Buyer, that are necessary or appropriate to evidence the release of all Liens and Encumbrances and satisfy all Indebtedness identified on Schedule 5.2(g).

 

(h) Employee Matters.

 

(i) Immediately prior to the Closing, without penalty or Liability to the Buyer, the Seller shall terminate all Employees.

 

(ii) In connection with Closing, the Seller shall satisfy in cash payments to each Employee all obligations for accrued wages, bonuses, Employee Benefit Plans, independent contractor payments, accrued vacation and sick leave or similar benefits provided to such Employees.

 

 
 

 

(iii) Nothing in this Agreement or any other Transaction document shall be construed as an obligation of the Buyer to continue the employment of any Employee for any period following the Closing Date. Nothing contained in this Agreement: (i) shall be construed to limit in any way the ability of the Buyer or any of its Affiliates to terminate the employment of any Employee at any time and for any or no reason; (ii) shall be construed to establish, amend or modify any benefit or compensation plan, program, agreement or arrangement; (iii) shall alter or limit the Buyer or any of its Affiliates’ ability to amend, modify or terminate any benefit or compensation plan, program, agreement or arrangement at any time assumed, established, sponsored or maintained by the Buyer or any of its Affiliates; (iv) is intended to confer upon any current or former employee (including any Employee) or any other Person any right to a particular term or condition of employment; or (v) is intended to alter or impair any rights an Employee has or may have accrued under any Employee Benefit Plan or Contract. Without limiting the generality of the foregoing, nothing in this Agreement, express or implied, is intended to confer any rights, benefits, remedies, obligations or liabilities upon any Person other than the parties to this Agreement and their respective successors and assigns, including any current or former employees, retirees, or dependents or beneficiaries of employees or retirees.

 

(i) Name Change. At the Closing, the Seller will deliver to the Buyer a fully executed amendment to the Seller’s Organizational Documents to change its name to a name bearing no resemblance to its present name (including, without limitation, removal of the word “Per-fekt” from such name) and authorize the Buyer to file such amendments with the applicable Governmental Authority on the Seller’s behalf.

 

(j) Good Standing and Tax Clearance Certificates. The Seller shall have delivered to Buyer (i) a certificate or certificates dated within five (5) days of the Closing Date of the jurisdiction where the Seller is incorporated and any other jurisdictions where the Seller is qualified as a foreign corporation as to the good standing of the Seller, and (b) tax clearance certificates from applicable taxing authorities as reasonably requested by Buyer.

 

(k) Intellectual Property Assignment. The Seller shall have delivered to Buyer an executed Intellectual Property Assignment in the form attached hereto.

 

(l) Other Matters. The Seller shall have delivered to Buyer, in form and substance acceptable to Buyer, such certificates and other evidence as Buyer may reasonably request as to the satisfaction of the conditions contained in this Section 5.2.

 

5.3 Conditions to Closing in Favor of the Seller. The obligation of the Seller to consummate the transactions to be performed by it at the Closing is subject to the satisfaction, or the written waiver by the Seller, of each of the following conditions on or before the Closing Date:

 

(a) Representations, Warranties and Covenants. (i) Each representation and warranty of the Buyer contained in this Agreement shall be true and correct on and as of the Closing Date (except for those representations and warranties which address matters only as of a particular date, which shall have been true and correct as of such particular date and except for representations and warranties that contain “Material Adverse Effect” qualifications and other qualifications based on the word “material,” which shall be true and correct in all respects), and (ii) the Buyer shall have performed and complied in all material respects with all covenants and obligations under this Agreement required to be performed and complied with by the Buyer prior to or as of the Closing.

 

(b) Officer’s Certificate of the Buyer. The Seller shall have received a certificate, validly executed by an executive officer of the Buyer to the effect that, as of the Closing, (i) the condition to the obligations of the Seller set forth in Section 5.3(a) hereof have been satisfied to his actual knowledge, and (ii) each and every one of the other conditions to the obligations of the Seller set forth in this Section 5.3 have been satisfied to his actual knowledge (unless otherwise waived in accordance with the terms hereof).

 

(c) Delivery of Documents. The Buyer shall have executed and delivered all documents, certificates, instruments and schedules required hereunder to the Seller.

 

article 6: ROYALTY OBLIGATIONS

 

6.1 Reporting; Audit. Buyer will send Seller an accounting statement reflecting Buyer’s Net Sales for each calendar quarter, along with a computation and payment of Royalty Consideration due, within forty-five (45) days following each calendar quarter. No more than once every twelve (12) months, Seller may audit the books and records of Buyer to ensure that all accountings and payments are accurate, provided that Seller provides Buyer with written notice at least ten (10) days prior to conducting such audit. Seller may not conduct an audit of the same accounting statement more than once. In the event Seller discovers an underpayment following an audit, Buyer shall compensate Seller the total underpayment. Seller is responsible for paying along with the reasonable and verified costs and expenses of said audit, unless the audit uncovers an underpayment of 5% or more in which case Buyer will pay said expenses.

 

 
 

 

article 7: SURVIVAL; INDEMNIFICATION

 

7.1 Survival. All of the representations and warranties of the parties hereto contained in this Agreement shall survive the Closing and continue in full force and effect for a period of one (1) year from the Closing Date; provided, however, that (a) the representations and warranties set forth in Section 3.1 (Organization and Standing), Section 3.2 (Authorization; Enforceability), Section 3.4 (Capitalization), Section 3.19 (Brokers; Service Providers), Section 4.1 (Organization and Standing), Section 4.2 (Authorization; Enforceability), and Section 4.9 (Brokers) (such representations and warranties, collectively, the “Fundamental Representations”) shall survive the Closing and continue in full force and effect indefinitely, and (b) the representations and warranties contained in Section 3.13 (Taxes), Section 3.17 (Employee Benefit Plans) and Section 3.18 (Environmental Compliance) shall survive the Closing and continue in full force and effect for six (6) months following the expiration of the applicable statute of limitations with respect thereto. The covenants and agreements of the parties set forth in this Agreement shall survive the Closing until fully performed and discharged. The applicable period of survival set forth in this Section 7.1 is referred to as the “Survival Period.” Any claims as to a breach or default of a representation or warranty under Section 7.2 must be asserted with reasonable specificity in writing by the party making such claim within the applicable Survival Period; provided, that any claim made with reasonable specificity by the Person seeking to be indemnified within the time periods set forth in this Section 7.1 shall survive until such claim is finally and fully resolved.

 

7.2 Indemnification by the Seller and the Member. The Seller and the Member agree to defend, indemnify and hold harmless, jointly and severally, the Buyer and each of its Affiliates and their respective Affiliates, officers, managers, members, employees, agents, advisors, representatives, and the successors and assigns of the foregoing (each hereinafter referred to individually as a “Buyer Indemnified Person,” and collectively as “Buyer Indemnified Persons”), without duplication, from, against and in respect of all Losses resulting from, arising out of, or caused by any of the following (collectively, “Seller Indemnifiable Matters”):

 

(a) any breach of any representation or warranty made by the Seller or the Member herein;

 

(b) any breach by the Seller or the Member of, or failure by the Seller or the Member to perform, carry out or otherwise fulfill or comply with, any of the covenants, agreements, undertakings or obligations contained in this Agreement;

 

(c) any claim, demand or Action made or filed by any Person that such Person is or was entitled (by contract, employment, or otherwise) to receive any amount or property in such Person’s capacity (or asserted capacity) prior to the date hereof as a holder of equity interests or similar synthetic or contractual interests in the Seller or any predecessor of the Seller;

 

(d) the amount of any Taxes owed by the Seller or the members of Seller or that relate to the Business or to the Purchased Assets for any periods on or before the Closing Date;

 

(e) the amount of any Taxes owed by the Seller or the Shareholders or that relate to the Purchased Assets for any periods on or before the Closing Date;

 

(f) any Liability arising from the ownership or operation of the Purchased Assets or the Business on or prior to the Closing Date, subject to Sections 2.1(c) and (e);

 

(g) any Liability with respect to the Excluded Assets;

 

(h) any Liability with respect to the Excluded Liabilities; and

 

 
 

 

(i) any claim, demand or Action made or filed by Richard Anderson, or any of his successors, assigns, or Affiliates, that he or they were or are entitled (by contract, employment, or otherwise) to receive any amount or property in his or their capacity (or asserted capacity) prior to the date hereof as a holder of equity interests or similar synthetic or contractual interests in the Seller or any predecessor of the Seller, or arising out of his employment relationship with the Seller or any predecessor of the Seller.

 

7.3 Indemnification by the Buyer. The Buyer agrees to defend, indemnify and hold harmless, jointly and severally, the Seller and each of its Affiliates and their respective officers, managers, members, employees, agents, advisors, representatives, and the successors and assigns of the foregoing (each hereinafter referred to individually as a “Seller Indemnified Person,” and collectively as “Seller Indemnified Persons”), without duplication, from, against and in respect of all Losses resulting from, arising out of, or caused by any of the following (collectively, “Buyer Indemnifiable Matters”):

 

(a) any breach of any representation or warranty made by the Buyer herein; and

 

(b) any breach by the Buyer of, or failure by the Buyer to perform, carry out or otherwise fulfill or comply with, any of the covenants, agreements, undertakings or obligations contained in this Agreement.

 

7.4 Limitations on Indemnification .

 

(a) Notwithstanding the foregoing provisions of this Article 7 and except as set forth in Section 7.4(d), the Seller and the Member shall not be required to defend, indemnify or hold the Buyer Indemnified Persons harmless under Section 7.2 unless and until the aggregate Losses for which the Seller and the Member are liable thereunder exceed a cumulative aggregate amount of $20,000 (the “Basket”), in which event the Buyer Indemnified Persons (as a group) shall, subject to the other limitations herein, be indemnified by the Seller and the Member for all such Losses including the amount of the Basket. Except as set forth in Section 7.4(d), the aggregate liability of the Seller and the Member on account of any Seller Indemnifiable Matters shall be limited to an aggregate amount equal to the Purchase Price (the “Cap”).

 

(b) Notwithstanding the foregoing provisions of this Article 7 and except as set in Section 7.4(d), the Buyer shall not be required to defend, indemnify or hold the Seller Indemnified Persons harmless under Section 7.3 unless and until the aggregate Losses for which the Buyer is liable thereunder exceed the Basket, in which event the Seller Indemnified Persons (as a group) shall, subject to the other limitations herein, be indemnified by the Buyer for all such Losses including the amount of the Basket. Except as set forth in Section 7.4(d), the aggregate liability of the Buyer on account of Buyer Indemnifiable Matters shall be limited to an aggregate amount equal to the Cap.

 

(c) Notwithstanding the foregoing provisions of this Article 7 and except as set in Section 7.4(d), no party shall be entitled to indemnification under this Article 7 with respect to incidental damages, special damages, exemplary damages, or punitive damages (other than such incidental, special, exemplary, or punitive damages recoverable by a third party pursuant to a Third Party Claim).

 

(d) Notwithstanding the foregoing, (i) neither the Cap nor the Basket shall apply to Losses resulting from, arising out of, or caused by (1) a breach by the Buyer, the Seller or the Member of a Fundamental Representation or (2) the Seller and the Member’s indemnity obligations set forth in Sections 7.2(c), (d), (e), (f), (g), or (h), and (ii) none of the Cap, the Basket nor the limitations of Section 7.4(c) shall apply to Losses directly or indirectly incurred in connection with or as a result of fraud by any of the Buyer, the Seller or the Member.

 

(e) All references in this Agreement to “materiality,” “in all material respects,” “Material Adverse Effect” and other terms derived therefrom shall be disregarded for purposes of determining the amount of Losses for which a party shall be indemnified under this Article 7.

 

7.5 Indemnification Procedures. The procedures for indemnification under this Agreement shall be as follows:

 

(a) The Buyer Indemnified Person(s) or the Seller Indemnified Person(s), as applicable (either, a “Claimant”), shall promptly give notice to the party from which indemnification is claimed (the “Indemnifying Party”) of any demand, suit, assertion of liability, Action or claim (a “Claim”). If the Claim relates to an Action filed by another Person against the Claimant (a “Third Party Claim”), then such notice shall be given by the Claimant within five (5) Business Days after written notice of such Action was received by the Claimant and shall include true, correct and complete copies of all Claim notices and documents; provided, however, that the failure or delay of the Claimant to provide any such notice shall not release the Indemnifying Party from any of its obligations under this Article 7 unless (and then solely to the extent that) the Indemnifying Party is actually prejudiced by such delay.

 

 
 

 

(b) With respect to Claims solely between the parties, following receipt of written notice from the Claimant of a Claim, stating with reasonable specificity the factual basis of such Claim, the Indemnifying Party shall have forty-five (45) days to make such investigation of the Claim as the Indemnifying Party reasonably deems necessary or desirable, and the Claimant agrees to make available to the Indemnifying Party and its authorized representatives all information relevant and necessary to substantiate the Claim, except to the extent any attorney-client privilege would thereby be vitiated. If the Claimant and the Indemnifying Party agree at or prior to the expiration of such forty-five (45) day period to the validity and amount of such Claim, then, subject to Section 7.6, the Indemnifying Party shall promptly pay to the Claimant, or if applicable deduct from the Royalty Consideration, when due, the full amount of the Claim, subject to the terms and limitations hereof. If the Claimant and the Indemnifying Party agree at or prior to the expiration of such forty-five (45) day period to the validity and amount of such Claim, but (i) the Claim is subject to the Basket and (ii) the Claim, together with all previous valid Claims, does not cause the Basket to be met or exceeded, then the Indemnifying Party need not pay to the Claimant any monies with respect to such Claim, but the full amount of the Claim shall be added to the Basket, subject to the terms and limitations hereof. If the Claimant and the Indemnifying Party do not reach any such agreement within such forty-five (45) day period, then the Claimant may seek an appropriate remedy at law or in equity, as applicable, subject to the terms and limitations hereof.

 

(c) With respect to any Third Party Claim, the Indemnifying Party shall be entitled to assume and maintain control of the defense and settlement of such Third Party Claim; provided, however, that, the Claimant shall be entitled to reasonably participate in the defense of such Third Party Claim and to employ counsel, at its own expense, to assist in the handling of such Third Party Claim. So long as the Indemnifying Party is defending diligently and in good faith any such Third Party Claim, Claimant shall not settle or compromise such claim or demand. The Indemnifying Party shall have the power and authority to settle or consent to the entry of judgment of such Third Party Claim in its sole discretion, provided that the Indemnifying Party shall not settle or compromise any Third Party Claim without the consent of Claimant if the judgment or settlement (i) would result in the payment by Claimant of money damages for which Claimant is not entitled to indemnification hereunder or other equitable relief against Claimant, or (ii) does not include a full and complete release of Claimant from any and all liability thereunder.

 

7.6 Set-Off of Recovery by Buyer Indemnified Persons. The amount of any indemnifiable Loss that (x) the Seller or the Member agree in writing is due and payable to the Buyer Indemnified Persons pursuant to this Article 7 or (y) a court of competent jurisdiction or arbitrator finally determines is due and payable by the Seller or the Member to the Buyer Indemnified Persons pursuant to this Article 7, shall be paid or offset in the following order and priority:

 

(a) First, such indemnifiable Losses shall be paid out of amounts payable as Royalty Consideration, if any, payable in the next two installments (or, at the Buyer’s election, future installments); and

 

(b) Second, in the event that the amounts payable as Royalty Consideration in the next two installments (or, at the Buyer’s election, future installments) is not sufficient to fully pay all such indemnifiable Losses, any shortfall may be satisfied by payment from the Seller or the Member to the applicable Buyer Indemnified Persons.

 

7.7 Withholding Rights. Each party shall be entitled to deduct and withhold from any amounts payable pursuant to this Agreement such amount as it is required to deduct and withhold with respect to the making of such payment under the Code or other applicable Law. To the extent that amounts are so withheld, such withheld amounts shall be treated for purposes of this Agreement as having been paid to the relevant payee in respect of which such deduction and withholding was made.

 

7.8 Determination of Loss Net of Other Recoveries. The amount of Losses recoverable by any Claimant hereunder with respect to a particular Claim shall be net of any amounts actually recovered or recoverable from insurance recoveries with respect thereto, less any costs related to obtaining such recoveries.

 

 
 

 

7.9 Exclusive Remedy. Following the Closing, the indemnification and other remedies set forth under this Article 7 shall constitute the sole and exclusive remedies of the parties with respect to any matters arising under or relating to this Agreement, except in the case of fraud by any party or the right of any party to seek injunctive or other equitable relief pursuant to Section 8.13.

 

7.10 Tax Treatment. For purposes of Tax reporting, the parties shall treat all payments and set-off made by or deemed to be made by a party under this Article 7 as adjustments to the consideration paid by the Buyer, unless otherwise required by applicable Law.

 

article 8: MISCELLANEOUS

 

8.1 Entire Agreement; Amendment. This Agreement, the Schedules and Exhibits hereto and all documents and certificates executed and delivered pursuant to this Agreement constitute the entire agreement and understanding among the parties pertaining to the subject matter hereof, and supersede all prior and contemporaneous agreements (including any term sheet, letter of intent, or confidentiality or non-disclosure agreement between or among the parties or their respective Affiliates), understandings, negotiations and discussions of the parties, whether oral or written, and there are no warranties, representations or other covenants or agreements between or among the parties in connection with the subject matter hereof, except as specifically set forth herein. No amendment, supplement, modification, waiver or termination of this Agreement or provision hereof shall be binding unless executed in writing by the party to be bound thereby.

 

8.2 Extension; Waiver. At any time prior to the Closing, the Seller, on the one hand, and the Buyer, on the other hand, may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations of the other party hereto, (b) waive any inaccuracies in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto, and (c) waive compliance with any of the agreements or conditions for the benefit of such party contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party. Such extension or waiver shall not be deemed to apply to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any agreement or condition, as the case may be, other than that which is specified in the extension or waiver. The failure of any party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.

 

8.3 Benefit; Assignment. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. No party to this Agreement may, directly or indirectly, by merger, operation of law, or otherwise, assign either this Agreement or any of its rights, interests or obligations under this Agreement without the prior written consent of the other parties hereto; provided, however, that the Buyer or Seller may, without the consent of the other Party assign all or any portion of its rights under this Agreement and the related documents delivered at Closing at any time to an Affiliate, which for this purpose shall include any equity owner of Seller, or, on or after the Closing, any other Person in connection with a sale of all or substantially all of its assets, or the Business, however effected. Any purported assignment or delegation in violation of the preceding provisions of this Section 8.3 will be null and void.

 

8.4 Notices. All communications, notices, demands and requests required or permitted to be given under the provisions of this Agreement shall be (a) in writing, (b) sent by confirmed facsimile, electronic mail, delivered by personal delivery or sent by commercial delivery service or certified mail, return receipt requested, (c) deemed to have been given on the date sent by facsimile or electronic mail if sent on a Business Day before 5:00 p.m. local time of the recipient, and if not then on the next Business Day immediately thereafter; the date of personal delivery; or the date set forth in the records of the commercial delivery service or on the return receipt, and (d) addressed as follows, unless and until any of such parties notifies the other in accordance with this Section 8.4 of a change of address or change of facsimile number:

 

(i) If to the Seller:

Perfekt Beauty Holdings LLC

6059 Bristol Parkway

Culver City, California 90230 USA

Attention: Maurice Rasgon

Telephone No. (310) 397-9300

Facsimile No.: (310) 397-9399

E-mail: Maurice@cdgla.net

 

 
 

 

With a required copy that shall not constitute notice to:

 

Stradling Yocca Carlson & Rauth, P.C.

660 Newport Center Drive, Suite 1600

Newport Beach, CA 92660

Attention: Christopher D. Ivey

Telephone No.: (949) 725-4121

Facsimile No.: (949) 823-5121

E-mail: civey@sycr.com

 

(ii) If to the Member:

CDG Holdings, LLC

6059 Bristol Parkway

Culver City, California 90230 USA

Attention: Maurice Rasgon

Telephone No. (310) 397-9300

Facsimile No.: (310) 397-9399

E-mail: Maurice@cdgla.net

 

With a required copy that shall not constitute notice to:

Stradling Yocca Carlson & Rauth, P.C.

660 Newport Center Drive, Suite 1600

Newport Beach, CA 92660

Attention: Christopher D. Ivey

Telephone No.: (949) 725-4121

Facsimile No.: (949) 823-5121

E-mail: civey@sycr.com

 

(iii) If to the Buyer:

Synergy CHC Corp.

865 Spring Street

Westbrook, ME 04092

Attention; President

Telephone No.______________

Facsimile No.:_______________

E-mail:_________________________

 

With a required copy that shall not constitute notice to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

Attention: Zachary R. Bishop

Telephone No.: (919) 781-4000

Facsimile No.: (919) 781-4865

E-mail: zbishop@wyrick.com

 

8.5 Counterparts. This Agreement may be executed and delivered in several counterparts, each of which shall be deemed original, but such counterparts shall together (when executed and delivered) constitute but one and the same instrument. This Agreement may be executed and delivered in counterpart signature pages executed and delivered via facsimile or other electronic transmission in Adobe portable document format (also known as “PDF”), and any such counterpart executed and delivered via facsimile or other electronic transmission in PDF shall be deemed an original for all intents and purposes. Any party who delivers such a signature page agrees to later deliver an original executed counterpart to any party who requests it, promptly upon request.

 

 
 

 

8.6 Headings. The Table of Contents and Article, Section and other headings set forth in this Agreement and the Schedules and Exhibits hereto are inserted or used for convenience of reference only and shall not control or affect the meaning or construction of the provisions of this Agreement.

 

8.7 Severability. If any provision of this Agreement or the application thereof to any Person or circumstance shall be invalid, illegal or unenforceable to any extent, the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by applicable Law so long as the economic or legal substance of the Transactions is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the Transactions are fulfilled to the greatest extent possible.

 

8.8 No Reliance. Except as expressly set forth in this Agreement, no Person other than any party hereto is entitled to rely on any of the representations, warranties, covenants, agreements, rights or remedies of the parties under or by virtue of this Agreement. No party assumes any Liability to any such other Person because of any reliance on the representations, warranties, agreements, rights or remedies of the parties under or by virtue of this Agreement.

 

8.9 Governing Law; Waiver of Jury Trial.

 

(a) This Agreement shall be governed, construed and enforced in accordance with the Laws of the State of Delaware applicable to contracts made and performed in that State without giving effect to any choice or conflict of law principle, provision or rule, including all matters of construction, interpretation, validity and performance.

 

(b) Each party acknowledges and agrees that any Actions (in contract, in tort or otherwise) arising out of or relating to this Agreement, any transactions contemplated hereby, any relationships between or among the parties hereunder and any disputes with respect to any of the foregoing is likely to involve complicated and difficult issues, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUCH ACTION. NO PARTY TO THIS AGREEMENT OR ANY ASSIGNEE, SUCCESSOR, HEIR OR PERSONAL REPRESENTATIVE OF A PARTY MAY SEEK A JURY TRIAL IN ANY ACTION, LAWSUIT, PROCEEDING, COUNTERCLAIM OR ANY OTHER LITIGATION PROCEDURE BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE OTHER AGREEMENTS OR THE DEALINGS OR THE RELATIONSHIP BETWEEN THE PARTIES. NO PARTY WILL SEEK TO CONSOLIDATE ANY SUCH ACTION, IN WHICH A JURY TRIAL HAS BEEN WAIVED, WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT OR HAS NOT BEEN WAIVED. THE PROVISIONS OF THIS SECTION 8.9(b) HAVE BEEN FULLY DISCUSSED BY THE PARTIES HERETO, AND THESE PROVISIONS WILL BE SUBJECT TO NO EXCEPTIONS. NO PARTY HERETO HAS IN ANY WAY AGREED WITH OR REPRESENTED TO ANY OTHER PARTY HERETO THAT THE PROVISIONS OF THIS SECTION 8.9(b) WILL NOT BE FULLY ENFORCED IN ALL INSTANCES.

 

 
 

 

8.10 Consent to Jurisdiction and Service of Process. EACH PARTY HEREBY CONSENTS AND AGREES THAT THE STATE OR FEDERAL COURTS LOCATED IN THE STATE OF DELAWARE HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE PARTIES PERTAINING TO THIS AGREEMENT OR TO ANY MATTER ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS, EACH PARTY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND EACH PARTY HEREBY WAIVES ANY OBJECTION THAT SUCH PARTY MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS SUCH COURT DEEMS APPROPRIATE. EACH PARTY HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO SUCH PARTY AT THE ADDRESS SET FORTH IN SECTION 8.4 OF THIS AGREEMENT AND THAT SERVICE SO MADE WILL BE DEEMED COMPLETED UPON THE EARLIER OF SUCH PARTY’S ACTUAL RECEIPT THEREOF OR FIVE BUSINESS DAYS AFTER DEPOSIT IN THE UNITED STATES MAIL, PROPER POSTAGE PREPAID.

 

8.11 No Strict Construction. The parties have participated jointly in the negotiation and drafting of this Agreement, and the language used in this Agreement shall be deemed to be the language chosen by the parties to express their mutual intent. In the event an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties, and no presumption or burden of proof will arise favoring or disfavoring any Person by virtue of the authorship of any of the provisions of this Agreement.

 

8.12 Expenses. Each party shall bear his, her or its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the Transactions.

 

8.13 Specific Performance. The parties hereto acknowledge and agree that the failure of any party to perform its agreements and covenants hereunder, including such party’s failure to take all actions as are necessary on such party’s part in accordance with the terms and conditions of this Agreement, will cause irreparable injury to the other parties, for which damages, even if available, will not be an adequate remedy. Accordingly, each party hereby consents to the issuance of injunctive relief by any court of competent jurisdiction to compel performance of such party’s obligations and to the granting by any court of the remedy of specific performance of such party’s obligations hereunder.

 

8.14 Publicity. The Seller and the Member shall not issue any press release or make any public announcement relating to the subject matter of this Agreement without the prior written consent of Buyer. Notwithstanding the foregoing, nothing contained in this Agreement shall prevent any party, after notification to the other party to the extent legally permissible, from making any announcement or publication required by applicable Law or from making any filings with Governmental Authorities that, based on advice of legal counsel, is required in connection with the execution and delivery of this Agreement or the consummation of the Transactions.

 

8.15 Further Assurances. From time to time after the Closing Date, upon the reasonable request of any party hereto, the other party or parties hereto shall execute and deliver or cause to be executed and delivered such further instruments of conveyance, assignment, transfer, acceptance and assumption, and take such further action as the requesting party may reasonably request in order to fully effectuate the purposes, terms and conditions of this Agreement. Subject to the terms and conditions provided in this Agreement, following the Closing, each of the parties hereto shall use commercially reasonable efforts to take promptly, or cause to be taken, all actions, and to do promptly, or cause to be done, all things necessary, proper or advisable under applicable Laws and regulations to consummate and make effective the Transactions and to effect all necessary registrations and filings and to remove any injunctions or other impediments or delays, legal or otherwise, in order to consummate and make effective the Transactions for the purpose of securing to the parties hereto the benefits contemplated by this Agreement.

 

8.16 Sales, Transfer and Documentary Taxes, etc.. The Seller will pay all federal, state and local sales, documentary and other transfer taxes, if any, due as a result of the purchase, sale or transfer of the Purchased Assets in accordance herewith whether imposed by law on the Seller or the Buyer, and the Seller and the Members will indemnify, reimburse and hold harmless the Buyer in respect of the liability for payment of or failure to pay any such taxes or the filing of or failure to file any reports required in connection therewith.

 

* * * * *

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK;

THE SIGNATURE PAGES FOLLOW

 

 
 

 

IN WITNESS WHEREOF, the parties have executed this Asset Purchase Agreement as of the day and year first written above.

  SELLER:
   
  Perfekt Beauty Holdings LLC
     
  By:  
    _______________, President
     
  MEMBER:
   
  CDG Holdings LLC
     
  By:  
  Name:  
  Its:  
     
  BUYER:
   
  Synergy CHC Corp.
     
  By:  
    Jack Ross, Chief Executive Officer

 

Signature Page to Asset Purchase Agreement

 

 
 

 

ANNEX A

 

Defined Terms

 

Capitalized terms used in the Agreement to which this Annex A is attached shall have (unless the context shall otherwise require) the following respective meanings, and all references to Sections, Exhibits or Schedules in the following definitions shall refer to Sections, Exhibits or Schedules of or to the Agreement:

 

Action” shall mean any claim, demand, charge, complaint, notice, action, suit, litigation, arbitration, inquiry, proceeding or investigation of any matter by or before any Governmental Authority.

 

Adjustment Amount” means the aggregate value of the of the following items as of the close of business on the day prior to the Closing Date: (i) the wholesale value of the Seller’s useable, new and unsold Inventory; (ii) the dollar amount equal to $56,085.57; and (iii) the dollar amount (expressed as a positive number) of certain collectible accounts receivable of the Seller.

 

Adverse Event” means any untoward or negative occurrence (including, without limitation, physical injury) related to the Business or the use of the Products.

 

Affiliate” shall mean, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common Control with such Person.

 

Agreement” shall mean this Asset Purchase Agreement, together with the Schedules and Exhibits attached hereto, as the same shall be amended and/or supplemented from time to time in accordance with the terms hereof.

 

Annual Financial Statements” shall have the meaning set forth in Section 3.9(a).

 

Assumed Contracts” shall have the meaning set forth in Section 2.1(c).

 

Assumed Liabilities” shall have the meaning set forth in Section 2.1(c).

 

Basket” shall have the meaning set forth in Section 7.4(a).

 

Business” shall have the meaning set forth in the recitals.

 

Business Day” shall mean any day excluding Saturdays, Sundays and any day that banking institutions located in New York City are authorized or required by applicable Law or other action of a Governmental Authority to close.

 

Buyer” shall have the meaning set forth in the preamble.

 

Buyer Indemnifiable Matters” shall have the meaning set forth in Section 7.3.

 

Buyer Indemnified Person” shall have the meaning set forth in Section 7.2.

 

Buyer Related Agreements” shall have the meaning set forth in Section 4.2.

 

CDG” shall have the meaning set forth in the preamble.

 

Cap” shall have the meaning set forth in Section 7.4(a).

 

Claim” shall have the meaning set forth in Section 7.5(a).

 

Claimant” shall have the meaning set forth in Section 7.5(a).

 

 
 

 

Closing” shall have the meaning set forth in Section 2.5.

 

Closing Date” shall have the meaning set forth in Section 2.5.

 

Closing Payment” shall have the meaning set forth in Section 2.2(b)(ii).

 

Closing Schedule” shall have the meaning set forth in Section 2.3(a).

 

COBRA” shall have the meaning set forth in Section 3.17(b).

 

Code” shall mean the Internal Revenue Code of 1986, as amended from time to time.

 

Consents” shall mean the consents, permits or approvals of, and filings or notices to, Government Authorities and other Persons necessary to consummate the Transactions.

 

Contracts” shall mean all contracts, leases, arrangements, indentures, notes, bonds, mortgages, guarantees, loans, instruments, commitments or other agreements (including leases for personal or real property and employment agreements), written or oral (including any amendments, supplements, restatements, extensions and other modifications thereto), of the Seller or to which the Seller is a party and that are in effect as of the date of this Agreement.

 

Control” (including, with correlative meanings, the terms “controlled by,” “controlling” and “under common control with”), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

 

Employees” shall have the meaning set forth in Section 3.16(a).

 

Encumbrance” means any claim, charge, easement, encumbrance, lease, covenant, security interest, mortgage, Lien, option, pledge, rights of others, restriction (whether on voting, sale, transfer, disposition or otherwise), or other encumbrance whatsoever, whether imposed by agreement, understanding, Law, equity or otherwise, except for any restrictions on transfer generally arising under any applicable federal or state securities law.

 

Environmental Laws” shall mean any and all federal, state, provincial and local Laws, rules and regulations, including statutes, regulations, ordinances, codes, orders and rules, as amended, any judicial or administrative interpretation thereof, including any consent decree or judgment, relating to pollution or the protection of the environment, natural resources, or natural resource damages, including those relating to the Release, use, handling, transportation, treatment or storage of Hazardous Materials. Environmental Laws include the Federal Solid Waste Disposal Act, the Federal Clean Air Act, the Federal Clean Water Act, the Federal Resource Conservation and Recovery Act of 1976, the Federal Comprehensive Environmental Response, Compensation and Liability Act of 1980, the Federal Insecticide, Fungicide & Rodenticide Act, the Toxic Substances Control Act, the Federal Oil Pollution Act of 1990, the Federal Safe Drinking Water Act, the Federal Noise Control Act of 1972, the Federal Pollution Prevention Act of and 1990, and the Federal Emergency Planning & Community Right-To-Know Act, each as amended, and regulations of the Environmental Protection Agency, regulations of the Nuclear Regulatory Agency and regulations of any state department of natural resources or state environmental protection agency. Environmental Laws also include any permit, approval, license or other authorization required under any applicable Environmental Law.

 

Equity Plan” shall have the meaning set forth in Section 4.4.

 

ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended.

 

Estimated Purchase Price” shall have the meaning set forth in Section 2.2(a)(i).

 

Exchange Act” shall have the meaning set forth in Section 4.4.

 

 
 

 

Exchange Act Reports” shall have the meaning set forth in Section 4.4.

 

Excluded AR” shall have the meaning set forth in Section 2.3(a)(iii).

 

Excluded Assets” shall have the meaning set forth in Section 2.1(a).

 

Excluded Liabilities” shall have the meaning set forth in Section 2.1(d).

 

Exhibits” shall mean those exhibits referenced in this Agreement, which exhibits are hereby incorporated and made a part hereof.

 

Final Adjustment Amount” shall have the meaning set forth in Section 2.3(a)(i).

 

Final Adjustment Amount Overage” means the amount, if any, by which Final Adjustment Amount exceeds the Preliminary Adjustment Amount.

 

Final Adjustment Amount Underage” means the amount, if any, by which Final Adjustment Amount is less than Preliminary Adjustment Amount.

 

Final Closing Payment” shall have the meaning set forth in Section 2.3(a)(ii).

 

Financial Statements” shall have the meaning set forth in Section 3.9(a).

 

FLSA” shall have the meaning set forth in Section 3.16(a).

 

Fundamental Representations” shall have the meaning set forth in Section 7.1.

 

GAAP” shall mean generally accepted accounting principles as in effect in the United States.

 

Governmental Authority” means (i) any federal, state, provincial, regional, county, city, municipal or local government, whether foreign or domestic or (ii) governmental or quasi-governmental authority of any nature, including any regulatory or administrative agency, commission, department, board, bureau, court, tribunal, arbitrator, arbitral body, agency, branch, official entity or other administrative or regulatory body obtaining authority from any of the foregoing, including courts, public utilities, sewer authorities and any supra-national organization, state, county, city or other political subdivision.

 

Governmental Order” shall mean any order, writ, judgment, citation, injunction, decree, ruling, charge, stipulation, determination or award entered by any Governmental Authority.

 

Guarantee” means any Contract of guarantee, assumption or endorsement or any other like commitment of the obligations, liabilities (fixed, contingent or otherwise) or indebtedness of another Person.

 

Hazardous Material” shall mean (i) any material, substance or waste defined or regulated as hazardous or toxic or as a pollutant or contaminant, as those terms are defined in the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, 42 U.S.C. Sections 9601 et seq., or any other applicable Environmental Laws, including toxic materials or harmful physical agents, as defined in the Occupational Safety and Health Act of 1970, as amended, 29 U.S.C. Section 651 et seq., and (ii) petroleum and petroleum products, byproducts or breakdown products, radioactive materials, asbestos, and polychlorinated biphenyls and toxic mold.

 

Health and Safety Laws” shall mean any and all federal, state and local Laws, rules and regulations, including statutes, regulations, ordinances, codes, orders and rules, as amended, any judicial or administrative interpretation thereof, including any consent decree or judgment, relating to health and safety, including those relating to worker health and safety. Health and Safety Laws include the Occupational Safety and Health Act of 1970, as amended, and regulations of the Occupational Safety and Health Administration and of any similar state department or agency. Health and Safety Laws also include any permit, approval, license or other authorization required under any applicable Health and Safety Laws.

 

 
 

 

Immigration Laws” shall have the meaning set forth in Section 3.16(d).

 

Indebtedness” shall mean any of the following Liabilities: (i) any indebtedness for borrowed money or issued in substitution for or exchange of indebtedness for borrowed money, (ii) any indebtedness evidenced by any note, bond, debenture or other debt instrument, (iii) any Liability with respect to deferred compensation, bonuses or commissions or the buy-out or earn-out payments or for the deferred purchase price of property or the provision of services with respect to which a Person is liable, contingently or otherwise, as obligor or otherwise, whether accrued or otherwise, (iv) any commitment by which a Person insures a creditor against loss, (v) any outstanding letters of credit, indebtedness guaranteed in any manner by a Person (including guarantees in the form of an agreement to repurchase or reimburse) and any other off-balance sheet indebtedness, (vi) any Liabilities under capitalized leases with respect to which a Person is liable, contingently or otherwise, as obligor, guarantor or otherwise, (vii) bank overdrafts or checks issued in excess of deposits, (viii) any amounts payable by the Seller, including with respect to accrued and unpaid dividends or other amounts due with respect to the equity interests of the Seller, (ix) any costs, fees, expenses or other Liabilities of the Seller (to the extent not paid prior to the Closing Date) incurred in connection with, or otherwise triggered in whole or in part by, the Transactions, (x) any accrued interest (payable or otherwise), prepayment penalties or obligations, premiums or make-whole amounts related to any of the foregoing clauses and (xi) guarantees in respect of any obligations of the type described in the foregoing clauses (i) through (x) of this definition.

 

Indemnifying Party” shall have the meaning set forth in Section 7.5(a).

 

Independent Auditor” shall have the meaning set forth in Section 2.3(d).

 

Independent Contractors” shall have the meaning set forth in Section 3.16(b).

 

Information Privacy Laws” shall have the meaning set forth in Section 3.17(f)

 

Intellectual Property” shall mean all (i) inventions and discoveries (whether or not patentable or reduced to practice), patents, patent applications, invention disclosures and statutory invention registrations, (ii) Trademarks, (iii) published and unpublished works of authorship, whether copyrightable or not, including websites, software programs, programming material and jingles, copyrights therein and thereto, registrations, applications, renewals and extensions therefor and thereof, and any and all rights associated therewith, email addresses, phone and fax numbers, marketing materials, business names, source codes, object codes, computer software programs, databases, (iv) confidential and proprietary information, including trade secrets, know-how, invention rights, methods, designs, processes, procedures and technology, (v) rights of privacy and publicity, and (vi) the entire Business marketing database consisting of all available customer information and all marketing, advertising and promotional materials, including logos, colors, videos, booklet designs, catalogs, solicitations, email templates, advertisements and all other Business marketing materials (whether in draft or final form) (collectively, the “Marketing Materials”) (vii) all domain names and (viii) any and all other proprietary rights, in each case, whether written or unwritten, and all goodwill associated with, and all derivatives, improvements and refinements of, any of the foregoing.

 

Interim Financial Statements” shall have the meaning set forth in Section 3.9(a).

 

Inventory” shall have the meaning set forth in Section 3.28.

 

IRS” shall mean the United States Internal Revenue Service.

 

Knowledge of the Seller” shall mean the actual knowledge, after reasonable inquiry of the affairs, properties and business of the Seller, of Maurice Rasgon and Alison Kohlenstein.

 

Law” shall mean any constitution, treaty, statute, law, ordinance, regulation, judgment, decree, injunction, ruling, Governmental Order, rule, requirement, stipulation or determination issued, promulgated or entered by or with any Governmental Authority (including common law).

 

Leases” shall have the meaning set forth in Section 3.8(b).

 

 
 

 

Liability” shall mean any liability or obligation, whether known or unknown, whether asserted or unasserted, whether absolute, contingent, fixed or otherwise, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due, regardless of when asserted, including any liability arising under any Law, Action or Governmental Order and any liability for Taxes.

 

Lien” shall mean any mortgage, deed of trust, pledge, security interest, encumbrance, adverse claim of ownership or use, lease, option, easement, reversion, violation, adverse claim, servitude, hypothecation, restriction on transfer (such as a right of first refusal or other similar right), defect of title, lien or charge of any kind, whether voluntarily incurred or arising by operation of Law or otherwise, affecting any assets or property.

 

Losses” shall mean all losses, damages, amounts paid in settlement, costs, expenses, fines, deficiencies, Liabilities, obligations, Taxes and Actions (whether or not resulting from Third Party Claims), including interest and penalties with respect thereto and out of pocket expenses and reasonable attorneys’ and accountants’ fees.

 

Marketing Materials” shall have the definition set forth in the definition of Intellectual Property.

 

Material Adverse Effect” shall mean any event, change, circumstance, occurrence, effect or state of facts that has, or could reasonably be expected to have, individually or in the aggregate with all other effects, changes and events, a materially adverse effect or impact on (i) the condition (financial or otherwise), assets, results of operations, customer or employee relations, prospects or cash flow of the Buyer or Seller, as applicable, or (ii) the ability of the Buyer or Seller, as applicable, to perform its obligations under this Agreement.

Material Contracts” shall have the meaning set forth in Section 3.6(a).

 

Member” shall have the meaning set forth in the preamble.

 

Most Recent Balance Sheet” shall have the meaning set forth in Section 3.9(a).

 

Most Recent Fiscal Month End” shall have the meaning set forth in Section 3.9(a).

 

Negotiation Period” shall have the meaning set forth in Section 2.3(d).

 

Net Sales” shall mean total invoiced billing for sales of only Products sold under the “Per-fekt” mark, less (i) freight and transportation (not to exceed 10%), (ii) all trade, quantity and cash discounts, (iii) all credits and allowances actually granted on Products due to returns including warranty replacements, rejections, billing errors, and retroactive price reductions, and (iv) sale, value-added and use taxes, and equivalent taxes actually paid on Products.

 

Notice of Concurrence” shall have the meaning set forth in Section 2.3(b).

 

Notice of Disagreement” shall have the meaning set forth in Section 2.3(b).

 

Organizational Documents” shall mean the legal document(s) by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs. For example, the “Organizational Documents” of a corporation are its articles or certificate of incorporation and bylaws, the “Organizational Documents” of a limited partnership are its certificate of limited partnership and limited partnership agreement and the “Organizational Documents” of a limited liability company are its articles of organization and operating agreement.

 

Buyer” shall have the meaning set forth in the preamble.

 

PDF” shall have the meaning set forth in Section 8.5.

 

Permit” shall mean any franchise, grant, authorization, agreement, license, permit, qualification, registration, easement, variance, exception, consent, clearance, certificate, approval, order, underground storage tank or other trust fund coverage or similar rights issued, granted or obtained by or from any Governmental Authority.

 

 
 

 

Permitted Encumbrance” shall mean: (i) Liens for Taxes not yet due and payable; (ii) materialmen’s, mechanics’, workmen’s, repairmen’s, landlord’s or other like non-consensual Liens arising in the course of construction or in the ordinary course of operations or maintenance and securing amounts not yet due and payable or which are being contested in good faith and by appropriate proceedings, if appropriate reserves or accruals with respect thereto are maintained in accordance with GAAP; and (iii) easements, rights-of-way, zoning, building codes and other encumbrances on Real Property which do not interfere with the business conducted thereon.

 

Person” shall mean any natural person, general or limited partnership, corporation, firm, limited liability company or partnership, association, trust or other entity, group (as such term is used in Section 13 of the Exchange Act) or organization, including a Governmental Authority, or other legal entity.

 

Preliminary Adjustment Amount” has the meaning set forth in Section 2.2(d).

 

Products” shall have the meaning set forth the recitals.

 

Purchase Price” shall have the meaning set forth in Section 2.2(a).

 

Purchased Assets” shall have the meaning set forth in Section 2.1(a).

 

Records” shall mean all books of account, files, databases, documents and other records in the Seller’s possession or control pertaining to the Business.

 

Related Parties” shall have the meaning set forth in Section 3.20.

 

Release” shall mean disposing, discharging, injecting, spilling, leaking, leaching, dumping, emitting, escaping, emptying, seeping, placing and the like into or upon any land or water or air or otherwise entering into the environment.

 

Remedial Action” shall mean all action to (i) clean up, remove, treat or handle in any other way Hazardous Materials in the environment; (ii) restore or reclaim the environment or natural resources; (iii) prevent the Release of Hazardous Materials so that they do not migrate, endanger or threaten to endanger public health or the environment; (iv) abate, encapsulate or remove any Hazardous Materials containing any building material, facility, equipment or transformer; or (v) perform remedial investigations, feasibility studies, corrective actions, closures and postremedial or postclosure studies, investigations, operations, maintenance and monitoring.

 

Royalty Consideration” shall have the meaning set forth in Section 2.2(c).

 

SEC” shall have the meaning set forth in Section 4.4.

 

Schedules” shall have the meaning set forth in the preamble of Article 3 and are hereby incorporated herein and made a part hereof.

 

Securities Act” shall mean the United States Securities Act of 1933, as amended.

 

Self-Insured Employee Plan” shall have the meaning set forth in Section 3.17(l).

 

Seller” shall have the meaning set forth in the preamble.

 

Seller Equity Interests” shall have the meaning set forth in Section 3.4.

 

Seller Indebtedness Amount” shall have the mening set forth in Section 2.2(b)(i).

 

Seller Indemnifiable Matters” shall have the meaning set forth in Section 7.2.

 

 
 

 

Seller Indemnified Persons” shall have the meaning set forth in Section 7.3.

 

Seller Intellectual Property” shall have the meaning set forth in Section 3.7(a).

 

Seller Leased Real Property” shall have the meaning set forth in Section 3.8(a).

 

Seller Related Agreements” shall have the meaning set forth in Section 3.2.

 

Subsidiary” of any party shall mean any Person of which (i) 50% or more of the outstanding voting securities are directly or indirectly owned by such party or one of its Subsidiaries; (ii) such party or any Subsidiary of such party is a general partner, managing member or managing director; or (iii) such party and/or one or more of its Subsidiaries holds voting power to elect a majority of the board of directors or any similar governing body.

 

Survival Period” shall have the meaning set forth in Section 7.1.

 

Tax” shall mean any federal, state, provincial, local or foreign income, gross receipts, license, payroll, employment, excise, customs, severance, stamp, occupation, premium, windfall profit, environmental (including taxes under Code Section 59A), capital stock, franchise, profits, inventory, withholding, social security (or similar), unemployment, disability, real property, personal property, ad valorem, sales, use, transfer, registration, value-added, alternative or add on minimum, estimated or other tax levy, duty, impost, fee or similar charge of any kind whatsoever imposed by any Governmental Authority, including any interest, penalty, fine or addition thereto or imposed in connection therewith, whether disputed or not.

 

Tax Return” shall mean any return, report, claim for refund, estimate, statement, form or other document (including elections, declarations, amendments, schedules, information returns or attachments thereto) relating to or required to be filed with a Governmental Authority or other Person with respect to Taxes.

 

Third Party Claim” shall have the meaning set forth in Section 7.5(a).

 

Trademarks” shall mean trademarks, service marks, domain names, uniform resource locators, websites, trade dress, slogans, logos, symbols, trade names, brand names and other identifiers of source or goodwill, including registrations and applications for registration thereof and including the goodwill symbolized thereby or associated therewith.

 

Transactions” shall have the meaning set forth in Section 3.2.

 

Treasury Regulations” shall mean the final and temporary regulations promulgated by the United States Department of the Treasury under and pursuant to the Code.

 

WARN Act” shall have the meaning set forth in Section 3.16(g).

 

 

 

Exhibit 10.18

 

AMENDED AND RESTATED LOAN AGREEMENT

 

Dated as of August 9, 2017

 

between

 

KNIGHT THERAPEUTICS (BARBADOS) INC.

 

as Lender

 

– and –

 

SYNERGY CHC CORP.

 

as Borrower

 

 
 

 

Table of Contents

 

    Page
     
ARTICLE 1 - DEFINITIONS 1
   
1.1 General Definitions. 1
1.2 Schedules and Exhibits. 19
1.3 Accounting Terms and Definitions. 20
1.4 Supplements, Re-enactments, Etc. 20
1.5 Headings of Subdivisions. 20
1.6 Gender and Number. 20
1.7 Monetary References. 20
1.8 Actions on Days Other Than Business Days. 21
     
ARTICLE 2 - TERMS OF THE LOAN 21
   
2.1 The Loan. 21
2.2 Additional Tranches 21
     
ARTICLE 3 - PAYMENT 23
   
3.1 Payments on Principal 23
3.2 Prepayments. 23
3.3 General Matters 24
     
ARTICLE 4 - INTEREST, FEES AND CHARGES 24
   
4.1 Rate of Interest. 24
4.2 Payment of Interest. 24
4.3 Default Rate of Interest. 25
4.4 Computation of Interest and Fees. 25
4.5 Maximum Interest. 25
4.6 Origination Fee. 25
4.7 Work Fee 25
4.8 Success Fees 25
4.9 Lender’s Expenses. 26
4.10 Illegality. 26
4.11 Increased Costs. 27
     
ARTICLE 5 - TERMINATION AND REDUCTION 27
   
5.1 Termination. 27
5.2 Continuing Obligations. 27
     
ARTICLE 6 - SECURITY AND COLLATERAL 28
   
6.1 Security Delivered on or Prior to the Closing Date. 28
6.2 Further Assurances 29
6.3 Security Effective Notwithstanding Date of Loan. 29
6.4 No Merger. 29
6.5 Release of Security. 29

 

i
 

 

Table of Contents (continued)

 

    Page
     
ARTICLE 7 - REPRESENTATIONS AND WARRANTIES 30
   
7.1 Representations and Warranties 30
7.2 Survival of Representations and Warranties. 41
     
ARTICLE 8 - SCHEDULES AND REPORTS 41
   
8.1 Financial Information 41
8.2 Compliance Certificate. 42
8.3 Other Matters. 42
     
ARTICLE 9 - COVENANTS 43
   
9.1 Covenants 43
9.2 Negative Covenants. 49
9.3 Entitled to Perform Covenants. 52
     
ARTICLE 10 - CONDITIONS PRECEDENT 52
   
10.1 Conditions Precedent to Loan. 52
     
ARTICLE 11 - EVENTS OF DEFAULT 54
   
11.1 Events of Default. 54
11.2 Acceleration and Termination of Rights 57
11.3 Remedies Cumulative and Waivers. 57
11.4 Saving. 58
11.5 Third Parties 58
11.6 Set-Off or Compensation. 58
     
ARTICLE 12 - INDEMNIFICATION, ETC 59
   
12.1 General Indemnity. 59
12.2 Taxes. 59
     
ARTICLE 13 - GENERAL PROVISIONS 60
   
13.1 Notice. 60
13.2 Choice of Governing Law and Construction. 61
13.3 Attornment. 61
13.4 Press Releases. 62
13.5 Modification and Benefit of Agreement. 62
13.6 Power of Attorney. 62
13.7 Waivers, Confidentiality, Information Sharing. 62
13.8 Timing of Payments. 63
13.9 Judgment Currency. 63
13.10 Severability. 63
13.11 Conflicts. 63
13.12 Entire Agreement. 63
13.13 Counterpart Execution/Electronic Delivery 63
13.14 Interpretation. 63

 

ii
 

 

AMENDED AND RESTATED LOAN AGREEMENT

 

THIS AMENDED AND RESTATED LOAN AGREEMENT is made with effect as of the ninth (9th) day of August, 2017, by and between SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada (the “Borrower”) and KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados, and one or more Persons to whom the foregoing or its permitted assigns may from time to time assign an interest in the Loan Documents (as defined below) (collectively, the “Lender”);

 

RECITALS:

 

WHEREAS the Borrower (then “known as Synergy Strips Corp.) and Lender entered into that certain loan agreement made as of January 21, 2015 (the “Initial Loan Agreement”), pursuant to which Lender extended a loan to the Borrower in the principal amount of $6,000,000 (the “First Tranche”);

 

WHEREAS the Borrower and Lender entered into that certain first amendment to the Initial Loan Agreement made as of the November 12, 2015, as amended by an amendment on December 3, 2015 (collectively with the Initial Loan Agreement, the “Existing Loan Agreement”), pursuant to which Lender extended an additional loan to the Borrower in the principal amount of $5,500,000 (the “Second Tranche”);

 

WHEREAS the Borrower has requested (i) an additional loan in the principal amount of $10,000,000 (the “Third Tranche”) and (ii) an ongoing credit facility for Additional Tranches (as defined below) for an aggregate of up to $20,000,000, and Lender has indicated its willingness to lend on the terms and conditions set forth herein;

 

WHEREAS Lender and the Borrower desire to amend and restate the Existing Loan Agreement, without novation, in order to, inter alia, provide for the Third Tranche and the Additional Tranches (as hereinafter defined) on the terms and conditions set forth herein;

 

NOW THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE 1 - DEFINITIONS

 

1.1 General Definitions.

 

In this Agreement the following terms shall have the following meanings:

 

Acquisition” means, with respect to any Person, any purchase or other acquisition by such Person, regardless of how accomplished or effected (including any such purchase or other acquisition effected by way of amalgamation, merger, arrangement, business combination or other form of corporate reorganization or by way of purchase, lease or other acquisition arrangements), of (i) any other Person (including any purchase or acquisition of such number of the issued and outstanding securities of, or such portion of an Equity Interest in, such other Person so that such other Person becomes a Subsidiary of the purchaser or of any of its Affiliates) or of all or substantially all of the Property of any other Person, or (ii) any division, business, operation or undertaking of any other Person or of all or substantially all of the Property of any division, business, operation or undertaking of any other Person.

 

1
 

 

Action Request” means any request from any Governmental Authority under any Applicable Law whereby such body or agency requests that the Person requested takes action or steps or does acts or things in respect of any Property in its charge, management or control to remediate a matter which is not or is alleged not to be in compliance with all Applicable Laws.

 

Affiliate” means: (i) any Person which, directly or indirectly, controls, is controlled by or is under common control with any other Person; (ii) any Person which beneficially owns or holds, directly or indirectly, fifty percent (50%) or more of any class of voting stock or Equity Interest (including partnership interests) of any other Person; or (iii) any Person, fifty percent (50%) or more of any class of the voting stock (or if such Person is not a corporation, fifty percent (50%) or more of the Equity Interest, including partnership interests) of which is beneficially owned or held, directly or indirectly, by any other Person. For the purposes of this definition, control of any Person (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to elect or appoint a majority of the board of directors of, or persons performing similar functions in respect of, such Person, whether through the ownership of voting securities, by contract, or otherwise.

 

Agreement” means this agreement and all schedules attached hereto; the expressions “hereof”, “herein”, “hereto”, “hereunder”, “hereby” and similar expressions refer to this Agreement, as amended, restated or supplemented from time to time, as a whole and not to any particular Article, Section, Schedule, or other portion hereof or thereof.

 

Annual Business Plan” means the annual business plan of the Borrower, prepared on a Consolidated basis, with detailed financial projections and budgets on a quarter to quarter basis for the following one (1) Fiscal Year, in each case consisting of a balance sheet, statement of income, retained earnings, statement of cash flows, proposed Capital Expenditures and a list of assumptions upon which such projections are based.

 

Applicable Law” means (i) any domestic or foreign statute, law (including common and civil law), treaty, code, ordinance, rule, regulation, restriction or by-law (zoning or otherwise), including all Health Care Laws and Privacy Laws, (ii) any judgment, order, writ, injunction, decision, ruling, decree or award; (iii) any regulatory policy, practice, guideline or directive; or (iv) any franchise, license, qualification, authorization, consent, exemption, waiver, right, permit or other approval of any Governmental Authority, binding on or affecting the Person referred to in the context in which the term is used or binding on or affecting the property of such Person, in each case whether or not having the force of law.

 

Arm’s Length” has the meaning specified in the definition of “Non-Arm’s Length”.

 

Associate” with respect to Lender means an “associate” as defined in the Canada Business Corporations Act.

 

Audited Financial Statements” means the audited Consolidated statement of financial position of the Borrower for the Fiscal Year ended December 31, including, without limitation, balance sheet, statement of income and retained earnings and statements of cash flows for such Fiscal Year prepared in accordance with GAAP.

 

2
 

 

Auditor” means the Borrower’s auditor and includes its successor which needs be an auditor of recognized national standing from time to time.

 

Board” means the Borrower’s board of directors.

 

Borrower” means Synergy CHC Corp. (formerly known as Synergy Strips Corp.) a corporation incorporated under the laws of the State of Nevada, and its permitted successors and assigns.

 

Breakthrough” means Breakthrough Products, Inc.

 

Breakthrough Acquisition” means the acquisition by the Borrower that occurred on or about November 12, 2015 of all the issued and outstanding shares of Breakthrough Products, Inc.

 

Business” means the business of the Borrower as of the date hereof, being the manufacture, distribution, sale of consumer health, wellness and beauty products, including the products known as Synergy Strips, Flat Tummy Tea, UrgentRX Products, FOCUSfactor, FOCUSfactor Kids, Hand MD, Neuragen, Perfekt Beauty, Sneaky Vaunt and The Queen Pegasus.

 

Business Day” means a day (other than Saturday or Sunday) on which banks are generally open for business in Bridgetown, Barbados and New York, New York.

 

Capital Expenditures” means, for any period, any expenditure made by any Person for the purchase, lease, acquisition, license, erection, development, improvement, construction, repair or replacement of capital assets, and any expenditure related to a Capital Lease or any other expenditure required to be capitalized, all as determined in accordance with GAAP.

 

Capital Lease” means, with respect to any Person, any lease of (or other agreement conveying the right to use) any real or personal property by such Person that, in conformity with GAAP, is or should be accounted for as a capital lease on the balance sheet of that Person.

 

Cash Balance Statement” shall have the meaning ascribed to it in Section 9.1(z)(iii).

 

Change of Control” means, with respect to the Borrower, the acquisition by any Person or group of Persons who act together in concert for such purpose of (i) shares or other voting Equity Interests of the Borrower to which are attached more than fifty percent (50%) of the votes that may be cast to elect directors or other Persons charged with the direction of the management the Borrower and which, if exercised, are sufficient to elect a majority of such directors or other management Persons, or (ii) any other right to appoint a majority of such directors or other management Persons or with respect to any Person who from time to time has previously met the foregoing test the further acquisition by such Person or group of Persons who act together in concert for such purpose of any further units or other voting Equity Interests of any Loan Party.

 

Closing Date” means August 9, 2017 or such other date on which the Third Tranche is advanced.

 

3
 

 

Collateral” means all of the undertaking and Property, present and future, real, immovable, personal and movable, of the Loan Parties, now or hereafter pledged, hypothecated, granted or assigned to Lender to secure, either directly or indirectly, repayment on account of payment of any of the Obligations.

 

Compliance Certificate” means the certificate required pursuant to Section 8.2, substantially in the form annexed as Schedule 8.2 and signed by the Chief Executive Officer and Chief Financial Officer of the Borrower.

 

Consolidated” means, when used to modify a financial term, test, statement, or report of a Person, the application or preparation of such term, test, statement or report (as applicable) based upon the consolidation, in accordance with GAAP, of the financial condition or operating results of such Person.

 

Consolidated Net Income” means, for any period, the Consolidated net income after tax of the Borrower for such period.

 

Contingent Obligation” means, as to any Person, any obligation, whether secured or unsecured, of such Person guaranteeing or indemnifying, or in effect guaranteeing or indemnifying, any indebtedness, leases, dividends, letters of credit or other monetary obligations (the “primary obligations”) of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, including any obligation of such Person as an account party in respect of a letter of credit or letter of guarantee issued to assure payment by the primary obligor of any such primary obligation and any obligations of such Person, whether or not contingent, (i) to purchase any such primary obligation or any Property constituting direct or indirect security therefor, (ii) to advance or supply funds for the purchase or payment of any such primary obligation or to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (iii) to purchase Property, Equity Interests or services primarily for the purpose of assuring the obligee under any such primary obligation of the ability of the primary obligor to make payment of such primary obligation, or (iv) otherwise to assure or hold harmless the obligee under such primary obligation against loss in respect of such primary obligation; provided, however, that the term “Contingent Obligation” shall not include endorsements of instruments for deposit or collection in the ordinary course of business.

 

Control Agreement” means a control agreement, in form and substance satisfactory to Lender, executed and delivered by any Loan Party, Lender and the applicable securities intermediary with respect to a Securities Account or a deposit-taking institution with respect to a Deposit Account.

 

Controlled Group” means, in respect of a Loan Party operating in the United States, all members of a controlled group of corporations and all trades or businesses (whether or not incorporated) under common control which, together such Loan Party or any of its Subsidiaries, are treated as a single employer under Section 414(b) or (c) of the Revenue Code.

 

Current Market Price” means the thirty (30) day volume weighted average of the closing sales price of the common shares of the Borrower for a given day on all domestic securities exchanges on which such security may at the time be listed.

 

4
 

 

Data Breach” has the meaning set forth in Section 7.1(e)

 

Debt” means, with respect to any Person, without duplication, the aggregate of the following amounts, at the date of determination: (i) all indebtedness of such Person for borrowed money; (ii) all obligations of such Person for the deferred purchase price of Property or services which constitute indebtedness; (iii) all obligations of such Person evidenced by notes, bonds, debentures or other similar instruments; (iv) all obligations of such Person created or arising under any conditional sale or other title retention agreement with respect to Property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such Property); (v) all obligations of such Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as Capital Leases; (vi) all reimbursement obligations, contingent or otherwise, of such Person under acceptance, letter of credit and similar facilities; (vii) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any partnership or shareholder or other Equity Interests of such Person (for greater certainty, not including obligations with respect to unexercised options and rights of first refusal and where conditions precedent to the purchase, redemption, retirement, defeasance or other acquisition of such obligations have not occurred); (viii) all Contingent Obligations of such Person in respect of Debt of another Person; and (ix) any other obligation arising under arrangements or agreements that, in substance, provide financing to such Person.

 

Deemed Interest Rate” means the interest rate applicable to the Loan as set out in Section 4.1 or 4.3, as the case may be, from time to time.

 

Default” means any event or condition which, with the giving of notice, the lapse of time or both, would constitute an Event of Default.

 

Deposit Account” means any “deposit account” as such term is defined in the UCC.

 

Depreciation Expense” means, for any period with respect to any Person, depreciation, amortization, depletion and other like reductions to income of such Person for such period not involving any outlay of cash, determined, without duplication and determined on a Consolidated basis, in accordance with GAAP.

 

Disposition” means any sale, assignment, transfer, conveyance, lease or other disposition of any asset of any Loan Party in a single transaction or a series of related transactions and the word “Dispose” or “Disposed” shall have a correlative meaning.

 

Distribution” means, with respect to any Person, any payment, directly or indirectly, by such Person: (i) of any dividends on any shares of its capital, other than dividends payable in shares; (ii) on account of, or for the purpose of setting apart any property for a sinking or other analogous fund for, the purchase, redemption, retirement or other acquisition of any Equity Interests; (iii) of any other distribution in respect of any Equity Interests; or (iv) of any management, consulting or similar fee or compensation or any bonus payment or comparable payment, or by way of gift or other gratuity, to any Affiliate of such Person or to any director, officer or member of the management of such Person or an Affiliate of such Person or to any Person not dealing at Arm’s Length with such first Person.

 

5
 

 

EBITDA” means, for any period, Consolidated Net Income for the Borrower earned during such period, plus, to the extent deducted in calculating Consolidated Net Income (without duplication):

 

(i) Interest Expense for such period;

 

(ii) Income Tax Expense for such period; and

 

(iii) Depreciation Expense for such period;

 

decreased by the sum (without duplication) of:

 

(iv)  extraordinary, unusual or non-recurring items for such period; and

 

(v) dividend and interest income earned or received for such period.

 

Employment Arrangement” means any written or oral employment agreement with any executive employee or key employee, or any consulting services contract, management services contract, labor services contract or similar agreement or arrangement pursuant to which any Person will, directly or indirectly, provide any services similar to executive employee or key employee services to the Borrower or any of its Subsidiaries.

 

Environmental Laws” means all Applicable Laws relating to Materials of Environmental Concern, pollution or protection of health, safety or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including without limitation, laws and regulations relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern, or otherwise relating to the manufacturing, processing, distribution, use, treatment, storage, disposal or transport of Materials of Environmental Concern.

 

Equipment” means all machinery, apparatus, equipment, fittings, furniture, fixtures, motor vehicles and other tangible personal or movable Property (other than Inventory) of every kind and description used in a Person’s operations or owned by such Person or in which such Person has an interest, whether now owned or hereafter acquired by such Person and wherever located, and all parts, accessories and tools and all increases and accessories thereto and substitutions and replacements therefor.

 

Equity Financing” means the completion of an offering or offerings of the Borrower’s Equity Interests or securities convertible into Equity Interests with proceeds of at least $1,000,000 in the aggregate.

 

Equity Interests” means (i) in the case of any corporation or company, all shares or capital stock and any securities exchangeable for or convertible into shares or capital stock, (ii) in the case of an association or business entity, any and all shares, interests, participation rights or other equivalents of corporate stock (however designated) in or to such association or entity, (iii) in the case of a partnership, limited liability company or unlimited liability company, partnership or membership interests (whether general or limited and regardless of whether denoted as units or shares), as applicable, and (iv) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distribution of assets of, the issuing Person, and including, in all of the foregoing cases described in clauses (i), (ii), (iii) or (iv), any warrants, rights or other options to purchase or otherwise acquire any of the interests described in any of the foregoing cases.

 

6
 

 

ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, together with the regulations thereunder as the same may be amended from time to time.

 

ERISA Plan” means any employee pension benefit plan covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Revenue Code (other than a multiemployer plan) that either (i) is maintained by a Loan Party, or (ii) with respect to which a Loan Party has or may have liability.

 

Event of Default” shall have the meaning ascribed to it in Section 11.1 hereof.

 

Existing Loan Agreement” shall have the meaning ascribed to it in the recitals hereof.

 

FDA” means the Food and Drug Administration of the United States of America or any successor entity thereto.

 

Financial Statements” means the Consolidated or combined statements of financial position of the Borrower, including without limitation, the balance sheet, statement of income and retained earnings and statement of cash flows of the Borrower, the Cash Balance Statement, all prepared in accordance with GAAP and consistent with the approach used by the Borrower in its Audited Financial Statements.

 

First Tranche” shall have the meaning ascribed to it in the recitals hereof.

 

Fiscal Quarter” means any of the quarterly accounting periods of the Borrower ending on March 31, June 30, September 30, and December 31 of each year.

 

Fiscal Year” means any period of twelve consecutive months ending on December 31 of any calendar year.

 

FNL” means Factor Nutrition Labs, LLC, a Delaware limited liability company and its permitted successors and assigns.

 

FNL Asset Purchase Agreement” means that certain Agreement for Purchase and Sale of Assets dated as of January __, 2015, by and among FNL and Borrower.

 

GAAP” means United States generally accepted accounting principles, as amended, supplemented or replaced from time to time.

 

Governmental Authority” means the government of Canada, the United States, Australia or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government, including the FDA and any supranational bodies such as the European Union or the European Central Bank and including a Minister of the Crown, Superintendent of Financial Institutions or other comparable authority or agency.

 

7
 

 

Health Care Laws” has the meaning set forth in Section 7.1(kk)

 

Income Tax Expense” means, with respect to the Borrower, for any period, the aggregate, without duplication and on a Consolidated basis, of all current Taxes on the income of the Borrower for such period, determined in accordance with GAAP.

 

Independent Director” means an individual who is not at the time of initial appointment, or at any time while serving as a director, and has not been at any time during the preceding five years: (a) a shareholder holding more than 10% of the shares of the Borrower, director (with the exception of serving as an Independent Director), officer, employee, consultant, partner, attorney or counsel of the Borrower or any of its Subsidiaries; (b) a material customer, supplier or creditor of the Borrower or any of its Subsidiaries or any Affiliate of any of them; (c) a person controlling or under common control with any such shareholder, director, officer, consultant, partner, customer, supplier or other person; or (d) a member of the immediate family of any such shareholder, director, officer, employee, partner, customer, supplier or other person (as used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of management, policies or activities of a person, whether through ownership of voting securities, by contract or otherwise).

 

Intellectual Property” means the intellectual property in patents, patent applications, trade-marks, trade-mark applications, trade names, service marks, copyrights, copyright registrations and trade secrets including, without limitation, customer lists and information and business opportunities, industrial designs, proprietary software, technology, recipes and formulae and other similar intellectual property rights.

 

Interest Expense” of the Borrower means, for any period, without duplication and on a Consolidated basis, the aggregate amount of interest and other financing charges paid or payable by the Borrower, on account of such period with respect to Debt including interest, amortization of discount and financing fees, commissions, discounts, the interest or time value of money component of costs related to factoring or securitizing receivables or monetizing inventory and other fees and charges payable with respect to letters of credit, letters of guarantee and bankers’ acceptance financing, standby fees, the interest component of Capital Leases, all as determined in accordance with GAAP.

 

Interest Payment Date” means March 31, June 30, September 30 and December 31 in each year.

 

Inventory” means, with respect to any Person, all inventory of such Person, whether now owned or hereafter acquired including, but not limited to, all goods intended for sale or lease by such Person, or for display or demonstration; all work in process; all raw materials and other materials and supplies of every nature and description used or which might be used in connection with the manufacture, printing, packing, shipping, advertising, selling, leasing or furnishing of such goods or otherwise used or consumed in such Person’s business.

 

8
 

 

Lender Distribution Agreements” means, collectively, any license and distribution agreement between the Borrower or any other Loan Party (or any of their respective Affiliates) and Lender (or any of its Affiliates).

 

Lender Option” means the option granted to Lender pursuant to that certain distribution option agreement dated as of January 22, 2015 whereby Lender acquired the option to negotiate an exclusive distribution agreement for the Borrower’s Products for Canada, Russia, Sub-Sahara Africa and Israel.

 

Lender’s Nominee” shall have the meaning ascribed to it in Section 9.1(aa) hereof.

 

License” or “License Agreement” shall have the meaning ascribed to it in Section 7.1(g) hereof.

 

Lien” means: (i) any interest in Property securing an obligation owed to, or a claim by, a Person, whether such interest is based on the common law, civil law, statute, or contract, and including, without limitation, a security interest, charge, claim, hypothec or lien arising from a mortgage, deed of trust, hypothec, encumbrance, pledge, hypothecation, assignment, deposit arrangement, agreement, security agreement, conditional sale or trust receipt or a lease, consignment or bailment for security purposes; and (ii) to the extent not included under clause (i), (A) any rights of repossession or similar rights of unpaid suppliers, (B) any reservation, exception, encroachment, easement, right-of-way, covenant, condition, restriction, lease or other title exception or encumbrance affecting Property, and (C) any other lien, hypothec, charge, privilege, secured claim, title retention, garnishment right, deemed trust, encumbrance or other right affecting Property, choate or inchoate, whether or not crystallized or fixed, whether or not for amounts due or accruing due, arising by any statute or law of any jurisdiction, at law, in equity or by any agreement.

 

Loan” means, collectively or individually, as the context requires, the First Tranche, the Second Tranche, the Third Tranche and any Additional Tranches.

 

Loan Documents” means (i) this Agreement and the Security Documents delivered by the Loan Parties pursuant to this Agreement and the Existing Loan Agreement or otherwise in connection with this Agreement and the Existing Loan Agreement, including any Loan Document delivered to Lender as general continuing collateral security for the payment and performance of the present and future Obligations (including obligations relating to the Second Tranche, the Third Tranche and any Additional Tranche), as well as any amendments, replacements, supplements or other modifications hereto or thereto or any other documents or instruments contemplated hereby or thereby, (ii) all present and future security, agreements and documents labelled by the parties thereto as a Loan Document, (iii) all confirmation agreements delivered by the Loan Parties confirming the validity of any of the foregoing Loan Documents and (iv) Lender Distribution Agreements, in each case as the same may from time to time be supplemented, amended or restated, and “Loan Document” shall mean any one of the Loan Documents.

 

Loan Parties” means the Borrower and its Subsidiaries.

 

Losses” shall have the meaning ascribed to it in Section 12.1 hereof.

 

9
 

 

Material Adverse Effect” shall mean (i) a material adverse effect on the business, prospects, operations, properties, assets, or condition (financial or otherwise) of the Borrower on a consolidated basis, (ii) an adverse effect on the legality, validity or enforceability of any of the Loan Documents which could reasonably be considered material having regard to the Loan Documents considered as a whole, including the validity, enforceability, perfection or priority of any Lien created under any of the Security which could reasonably be considered material having regard to the Security considered as a whole, (iii) a material adverse effect on the ability of any Loan Party, to pay or perform any of its debts, liabilities or obligations under any of the Loan Documents, which could reasonably be considered material having regard to Borrower and the other Loan Parties as a whole, or (iv) an adverse effect on the right, entitlement or ability of Lender to enforce its rights or remedies under any of the Loan Documents which could reasonably be considered material having regard to the Loan Documents taken as a whole.

 

Material Contract” means any agreement (whether written or oral), or multiple agreements with the same Person, arrangement or understanding entered into by any Loan Party or assigned to any Loan Party, (i) which could reasonably be expected to be material to the financial condition, property, assets, operations or business of any Loan Party, (ii) involving payments by or to any Loan Party (or all of them) in excess of $500,000 in the aggregate, or (iii) contracts relating to Employment Arrangements.

 

Material Licenses” means, collectively, each license, certificates, certification, concession, grant, franchise, variance, exemption or permission from, accreditations, product clearances or approvals, provider numbers or provider authorizations, marketing authorizations, other authorizations, establishment licenses, registrations, permits, consents and approvals issued by any Governmental Authority or any applicable stock exchange or securities commission to any Loan Party or assigned to any Loan Party issued or required (i) in connection with the conduct of any of the Borrower’s or any Subsidiary’s Business (ii) required for the research, development, manufacture, distribution, marketing, storage, transportation, use and sale of Products, or (iii) to comply with Applicable Laws, including without limitation new drug applications, abbreviated new drug applications, biologics license applications, investigational new drug applications, over-the-counter drug monograph, device pre-market approval applications, device pre-market notifications, investigational device exemptions, product recertifications, manufacturing approvals and authorizations, CE Marks, pricing and reimbursement approvals, labeling approvals or their foreign equivalent, controlled substance registrations, and wholesale distributor permits.

 

Materials of Environmental Concern” means any chemicals, pollutants, contaminants, wastes, toxic substances, petroleum, petroleum products, together with any hazardous, toxic or dangerous substances, materials and wastes, including, without limitation, hydrocarbons (including naturally occurring or man-made petroleum and hydrocarbons), flammable explosives, asbestos, urea formaldehyde insulation, radioactive materials, biological substances, polychlorinated biphenyls, pesticides, herbicides and any other kind and/or type of pollutants or contaminants (including, without limitation, materials which include hazardous constituents), sewage, sludge, industrial slag, solvents and/or any other similar substances, materials or wastes and including any other substances, materials or wastes that are or become regulated under any laws relating to the protection of the environment or maintenance of occupational safety (including, without limitation, any that are or become classified as hazardous or toxic under any such laws).

 

10
 

 

Maturity Date(s)” means: (i) with respect to the First Tranche, January 20, 2018, (ii) with respect to the Second Tranche, November 11, 2017, (iii) with respect to the Third Tranche, the third anniversary of the Closing Date and (iv) with respect to any Additional Tranche, the third anniversary of the date of the advance thereof.

 

Net Debt” means, as of any date of determination, (i) Consolidated Debt of the Borrower outstanding on such date minus (ii) the aggregate amount of cash and cash equivalents included in the cash accounts listed on the Consolidated statement of financial position of the Borrower as of such date, to the extent the use thereof for application to payment of Debt is not prohibited by law or contract.

 

Nomad” means Nomadchoice Pty Ltd (ABN 41 160 729 939).

 

Nomad Acquisition” means the acquisition by the Borrower of all the issued and outstanding shares of Nomad, which occurred on or about November 12, 2015.

 

Nomad Purchase Agreement” means that certain Stock Purchase Agreement dated November 12, 2015 among the Borrower, Nomad, TPR Investments Pty Ltd CAN 128 396 654, as trustee for Polmear Family Trust, Timothy Polmear and Rebecca Polmear, effecting the Nomad Acquisition.

 

Non-Arm’s Length” and similar phrases have the meaning attributed thereto for the purposes of the Income Tax Act (Canada); and “Arm’s Length” shall have the opposite meaning.

 

Obligations” means all present and future obligations and indebtedness, of any and every kind and nature, of the Loan Parties to Lender arising under this Agreement and the other Loan Documents, whether now or hereafter existing, whether now due or to become due, whether primary, secondary, direct, indirect, absolute, contingent or otherwise (including without limitation, obligations of performance), whether several or joint or joint and several.

 

OFAC” means the Office of Foreign Assets Control of the US Department of the Treasury.

 

Organizational Documents” means, with respect to any applicable Person, such Person’s articles or other charter or constitutional documents, by-laws, shareholder agreement, partnership agreement, joint venture agreement, limited liability company agreement or trust agreement, as applicable, and any and all other similar agreements, documents and instruments relative to such Person.

 

PBGC” means the Pension Benefit Guaranty Corporation or any Person succeeding to any or all of its functions under ERISA.

 

Pension Plan” means (i) a “pension plan” or “plan” which is subject to the funding requirements of applicable pension benefit legislation in any jurisdiction as is applicable to the employees of any Loan Party; or (ii) any pension benefit plan or similar agreement applicable to employees of the Loan Parties (other than a plan sponsored by a Governmental Authority) which, for greater certainty, includes an ERISA Plan.

 

11
 

 

Perfection Certificate” means a certificate in the form of Exhibit 1, or any other form approved by Lender.

 

Permitted Cash Investments” means an investment in any of the following:

 

(i) direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the Government of the United States or of any state thereof, as applicable (or by any agency or instrumentality of any of the foregoing to the extent such obligations are backed by the full faith and credit of the Government of the United States or of such state, as applicable);

 

(ii) investments in certificates of deposit, bankers’ acceptances and time deposits maturing within 180 days from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the United States or federal state in the United States having combined capital and surplus of not less than $300,000,000 or the equivalent in any other currency; and

 

(iii) commercial paper of an issuer rated at least A-1+ or the equivalent thereof by a rating agency satisfactory to Lender, and in each case maturing within six months from the date of acquisition.

 

Permitted Debt” means:

 

(i) Debt under this Agreement;

 

(ii) Debt in respect of Purchase Money Security Interests and Capital Leases in an outstanding amount not to exceed $250,000 in aggregate at any time;

 

(iii) Debt consented to in writing by Lender from time to time and subject to the terms imposed by Lender in connection with such consent;

 

(iv) to the extent included as Debt, accounts payable that arise, and accrued expenses incurred in, the ordinary course of business; and

 

(v) Debt incurred by a Subsidiary of the Borrower in accordance Section 2.2(d).

 

Permitted Disposition” means (i) the Disposition of Inventory in the ordinary course of business; (ii) the Disposition of used, worn-out or surplus Equipment in the ordinary course of business; (iii) other Dispositions to the extent that no Default or Event of Default exists and the fair market value of the assets Disposed of pursuant to this clause (iii) does not exceed during any Fiscal Year $150,000; and (iv) a Disposition under a distribution agreement contemplated by Lender Option.

 

Permitted Distribution” means, so long as there exists no Default or Event of Default (i) fees paid by the Borrower to Independent Directors in an aggregate amount in any Fiscal Year not to exceed $100,000, provided such directors’ fees are customary and reasonable for directors in a similar business to the Business; (ii) bonuses paid or other comparable payments made to Borrower’s officers and members of management by the Borrower in amounts materially consistent with the past compensation practice of the Borrower and customary and reasonable for officers and members of management in a business similar to the Business, provided that the aggregate amount in respect of all such bonuses and comparable payments in any Fiscal Year (for certainty, including any payments contemplated by (iii) below) shall not exceed 5% of TTM EBITDA (the “Management Bonus Limit”), (iii) subject to the Management Bonus Limit, bonuses and other comparable payments paid, directly or indirectly, to any one Person pursuant to any employment agreements, consulting services contracts (including agreements between the Borrower and Kenek Brands Inc.), management services contracts, labor services contracts or similar agreements or arrangements for the services of such Person (whether pursuant to one agreement or multiple agreements) of no more than $695,000 per Fiscal Year (for certainty, in excess of any base compensation payable to such Person), provided that any such payments paid to any such Person shall also be determined and paid strictly in accordance with the relevant Employment Arrangement(s) (the terms of which shall have been disclosed to the Lender) and (iv) any distribution by the Subsidiaries of the Borrower (other than a Special Purposes Entity) to the Borrower.

 

12
 

 

Permitted Liens” means, with respect to any Person, the following:

 

(i) liens for Taxes not yet due or for which installments have been paid based on reasonable estimates pending final assessments, or if due, the validity of which is being contested diligently and in good faith by appropriate proceedings by that Person for which reasonable reserves under GAAP are maintained;

 

(ii) undetermined or inchoate liens, rights of distress and charges incidental to current operations which have not at such time been filed or exercised and of which Lender has been given notice, or which relate to obligations not due or payable, or if due, the validity of which is being contested diligently and in good faith by appropriate proceedings by that Person;

 

(iii) reservations, limitations, provisos and conditions expressed in any original grants from the Crown or other grants of real or immovable property, or interests therein;

 

(iv) zoning, land use and building restrictions, by-laws, regulations and ordinances of federal, provincial, state, municipal and other Governmental Authorities, licenses, easements, servitudes, rights-of-way and rights in the nature of easements (including, without limiting the generality of the foregoing, licenses, easements, servitudes, rights-of-way and rights in the nature of easements for railways, sidewalks, public ways, sewers, drains, gas, steam and water mains or electric light and power, or telephone and telegraph conduits, poles, wires and cables) which do not materially impair the use of the affected land for the purpose for which it is used by that Person;

 

(v) title defects, encroachments or irregularities or other matters relating to title which are of a minor nature and which in the aggregate do not materially impair the use of the affected property for the purpose for which it is used by that Person;

 

(vi) the right reserved to or vested in any municipality or governmental or other public authority by the terms of any lease, license, contract, franchise, grant or permit acquired by that Person or by any statutory provision to terminate any such lease, license, contract, franchise, grant or permit, or to require annual or other payments as a condition to the continuance thereof;

 

13
 

 

(vi) the Lien resulting from the deposit of cash or securities in connection with contracts, tenders or expropriation proceedings, or to secure workers compensation, employment insurance, surety or appeal bonds, costs of litigation when required by law not to exceed $100,000 in aggregate outstanding at any time, liens and claims incidental to current construction, mechanics’, warehousemen’s, carriers’ and other similar liens, and public, statutory and other like obligations incurred in the ordinary course of business;

 

(vii) security given to a public utility or any municipality or Governmental Authority when required by such utility or authority in connection with the operations of that Person in the ordinary course of its business provided that such security does not materially impair the use of the affected property for the purpose for which it is used by that Person;

 

(viii) the Lien created by a judgment of a court of competent jurisdiction, as long as the judgment is being contested diligently and in good faith by appropriate proceedings by that Person and does not result in an Event of Default;

 

(ix) the Security;

 

(x) Purchase Money Security Interests and Capital Leases, provided that such Liens secure Permitted Debt;

 

(xi) such other Liens as agreed to in writing by Lender in accordance with this Agreement;

 

(xii) any other Liens securing Debt the principal amount of which (when aggregated with the outstanding principal of any other such Debt secured by Borrower) does not exceed $100,000 (or its equivalent));

 

(xiii) any Lien in favour of Knight Therapeutics, Inc. perfected by the UCC financing statement filed on July 31, 2015 against Neuragen Corp. in favour of Knight Therapeutics, Inc. under original file number 20153327714 at the Delaware Secretary of State; and

 

(xiv) Liens granted by Special Purpose Entities in order to secure Qualified Acquisitions otherwise permitted hereby.

 

“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, institution, entity, party or foreign or local government (whether federal, provincial, state, county, city, municipal or otherwise), including, without limitation, any instrumentality, division, agency, body or department thereof.

 

Privacy Law” has the meaning set forth in Section 7.1(e)

 

14
 

 

“Product” means each current and future product, process or service under development, developed, manufactured, tested, licensed, distributed, marketed or sold by any Loan Party and any other current or future products or services in which any Loan Party has any proprietary rights or beneficial interests.

 

Prohibited Transaction” means any transaction set forth in Section 406 of ERISA, or Section 4975 of the Revenue Code, to the extent that such transaction is not otherwise exempt by Applicable Law.

 

Property” means, with respect to any Person, all or any portion of its undertaking, property or asset, whether real, immovable, personal, movable, or mixed, tangible or intangible, including for greater certainty any Equity Interests of a corporation or ownership interest in any other Person.

 

Purchase Money Security Interest” means a Lien created or assumed by a Loan Party securing Debt incurred to finance the unpaid acquisition price of personal Property provided that (i) such Lien is created concurrently with or prior to the acquisition of such personal Property, (  ) such Lien does not at any time encumber any Property other than the Property financed or refinanced (to the extent the principal amount is not increased) by such Debt, (iii) the principal amount of Debt secured thereby is not increased subsequent to such acquisition, and (iv) the principal amount of Debt secured by any such Lien at no time exceeds 100% of the original purchase price of such personal Property at the time it was acquired, and for the purposes of this definition the term “acquisition” shall include a Capital Lease and the term “acquire” shall have a corresponding meaning.

 

Qualified Acquisition” means any Acquisition by the Borrower or any other Loan Party, whether by purchase, merger or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business line or unit or a division of, any Person (the “Target”), provided that:

 

(i) the Target shall be a profitable, cash-positive business that is in the same business as or in a business complementary to the Business;

 

(ii) immediately prior to, and after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or would result therefrom;

 

(iii) immediately prior to, and after giving effect thereto, all representations and warranties herein and in any other Loan Document shall be true and correct in all material respects;

 

(iv) the Target and all of its assets shall be located only in one or more of the countries in which the Loan Parties operate as of the Closing Date, or such other country as may be approved by Lender in its sole discretion, all transactions in connection therewith shall be consummated, in all material respects, in accordance with all Applicable Laws and in conformity with all applicable governmental approvals and the consummation of such transaction shall not subject Lender to any additional regulatory or other requirements;

 

15
 

 

(xv) simultaneously with the consummation of such acquisition or, to the extent restricted under Applicable Law, as soon as legally permissible in the relevant jurisdiction, Lender shall be granted a first priority, perfected Lien in the Target (subject only to Permitted Liens) which shall be in form and substance satisfactory to Lender and shall not subject Lender to any additional regulatory or other requirements;

 

(xvi) in the case of the Acquisition of Equity Interests, the Acquisition shall be of all of the Equity Interests (except for any such Equity Interests in the nature of directors’ qualifying shares required pursuant to Applicable Laws) of the Target, and the Equity Interest so acquired or otherwise issued by such Target or any newly formed Subsidiary of a Loan Party in connection with such acquisition shall be owned 100% by a Loan Party and such Loan Party shall have taken, or caused to be granted Lender a duly perfected first-priority Lien, subject only to Permitted Liens, in all of the present and after-acquired assets, property and undertaking of the Target or Subsidiary as security for the Obligations, and shall have delivered to Lender all supporting documents and opinions, as reasonably required by Lender;

 

(xvii) both before and after giving effect to the Acquisition, the Borrower and the other Loan Parties shall be in compliance with all of the covenants (including, for certainty, the financial covenants) set forth herein;

 

(xviii) the Acquisition shall have been approved by the board of directors or other governing body or controlling Person of the Target or the Person from whom such assets or division is acquired; and

 

(xix) on or prior to the date of such acquisition, Lender shall have received, each in form and substance satisfactory to, certified copies of the acquisition agreement and all material related agreements and instruments, and all opinions, certificates, lien search results and other credit documents in respect thereof in form and substance acceptable to Lender;

 

(xx) Lender shall have received copies of, and shall have been satisfied with, all legal and business due diligence reports prepared for the benefit of the Loan Parties in respect of such acquisitions, as well as its own legal and business due diligence (if any);

 

(xxi) the Borrower shall have certified to Lender that it has obtained all necessary or required material consents or approvals of any Governmental Authority or other Person in connection with the completion of the Acquisition; and

 

(xxii) Lender shall have received a source and use of funds statement (which shall, among other things, demonstrate that all of the proceeds of the Acquisition will be used to fund the Acquisition) and an outline of the flow of funds with respect to the Acquisition shall have been delivered to Lender; and

 

(xxiii) Lender shall (in its sole discretion) otherwise be satisfied in all respects with the proposed Acquisition.

 

16
 

 

Regulatory Authority” means any Governmental Authority that has responsibility in any country or group of countries over the development, manufacture or commercialization of a Product, including the FDA, Health Canada and the European Medicines Agency, and any successor agency thereof.

 

Repayment Schedule” means the Amended and Restated Schedule of Repayment of principal for each Loan, attached hereto as Schedule 3.1(b).

 

Reportable Event” means any of the events set forth in Section 4043 of ERISA, other than an event for which the provision of notice has been waived.

 

Requirements of Law” means, as to any Person, the Organizational Documents of such Person and any Applicable Law, or determination of a Governmental Authority, in each case, applicable to or binding upon such Person or any of its business or Property or to which such Person or any of its business or Property is subject.

 

Revenue Code” means the United States Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and the regulations and published interpretations thereof.

 

Revenues” means, for any period, consolidated gross income for such period.

 

Sanctioned Entity” means (i) a country or a government of a country, (ii) an agency of the government of a country, (iii) an organization directly or indirectly controlled by a country or its government, (iv) a Person resident in, or determined to be resident in, a country, in each case, that is subject to a country sanctions program administered and enforced by OFAC.

 

Sanctioned Person” means a person named on the list of Specially Designated Nationals maintained by OFAC (including on account of its membership in a Controlled Group).

 

Second Tranche” shall have the meaning ascribed to it in the recitals hereof.

 

Securities Account” means any “securities account” as such term is defined in the Personal Property Security Act (Ontario) and the UCC.

 

Security” means the Liens created by the Security Documents.

 

Security Documents” means the documents set out in Section 6.1.

 

17
 

 

Special Purpose Entity” means a Person that at all times since its formation and at all times thereafter (unless otherwise expressly agreed to by the Lender in writing): (i) was and will be organized solely for the purpose of owning, developing or operating the business acquired pursuant to a particular Qualified Acquisition (the “Specific Business”) and activities which are related and ancillary thereto; (ii) has not engaged and will not engage in any business unrelated to the Specific Business, (iii) has not had and will not have any assets other than those related to the Specific Business, (iv) has not engaged, sought or consented to and will not engage in, seek or consent to any dissolution, winding up, liquidation, consolidation, merger, asset sale, transfer of Equity Interests or the like, or amendment of its limited partnership agreement, articles of incorporation, articles of organization, certificate of formation or operating agreement (as applicable); (v) has remained and will remain solvent; and has maintained and will maintain adequate capital in light of its contemplated business operations; provided, however, that the foregoing shall not require the contribution of additional capital or any other advance of funds by the Borrower or any other Loan Party or any other Person, (vi) has not failed and will not fail to use commercially reasonably efforts to correct any known misunderstanding regarding the separate identity of such Person; (vii) has maintained and will maintain its accounts, books and records separate from any other Person and will file its own tax returns and maintain its own appropriate insurance coverage; (viii) has not commingled and will not commingle its funds or assets with those of any other Person; (ix) has held and will hold its assets in its own name; (x) has conducted and will conduct the Specific Business in its name only; (xi) has maintained and will maintain its financial statements, accounting records and other entity documents separate from any other Person; (xii) has paid and will pay its own liabilities, including the salaries of its own employees, if any, out of its own funds and assets; (xiii) has observed and will observe all material partnership, corporate or limited liability company formalities, as applicable; (xiv) has maintained and will maintain an arm’s-length relationship with its Affiliates; (xiv) has not entered into or been a party to, and will not enter into or be a party to, any transaction with any other Loan Party except (I) with the prior written consent of Lender and (II) in the ordinary course of its business and on terms which are intrinsically fair and are no less favorable to it than would be obtained in a comparable arm’s-length transaction with an unrelated third party, provided that any consideration paid by any Loan Party to such Special Purpose Entity pursuant to any commercial arrangement shall be on terms no more beneficial to such Special Purpose Entity than terms paid by any Loan Party to any other Loan Party under similar commercial arrangements; (xv) has no and will have no indebtedness other than the indebtedness permitted pursuant to Section 2.2(d) hereof (“Specific Business Financing”); (xvi) has not and will not assume or guarantee or become obligated for the debts of any other Person or hold out its credit as being available to satisfy the obligations of any other Person, (xvii) has not and will not acquire obligations or securities of any other Loan Party, (xvii) except in connection with the Specific Business Financing, has not pledged and will not pledge its assets for the benefit of any other Person; (xviii) has held itself out and identified itself, and will hold itself out and identify itself, as a separate and distinct entity under its own name and not as a division or part of any other Person; (xix) has maintained and will maintain its assets in such a manner that it will not be costly or difficult to segregate, ascertain or identify its individual assets from those of any other Person; (xx) has not made and will not make loans to any Person; (xxi) has not identified and will not identify any other Loan Party, or any Affiliate of any of them, as a division or part of it; (xxii) will consider the interests of its creditors in connection with all corporate, partnership or limited liability company actions, as applicable; (xxiii) for certainty, has not done and will not do any of the following: (I) file a bankruptcy, insolvency or reorganization petition or otherwise seek any relief under any laws relating to the relief from debts or the protection of debtors generally; (II) seek or consent to the appointment of a receiver, liquidator, assignee, trustee, custodian or any similar official for such entity or all or any portion of such entity’s properties; (III) make any assignment for the benefit of such entity’s creditors’ or (IV) take any action that might cause such entity to become insolvent; and (xxiv) satisfies such other criteria as required by Lender in its sole discretion.

 

Subsidiary” means, with respect to a Person, any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether at the time stock of any other class of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned by the Person or by any partnership or other corporate entity of which more than fifty percent (50%) of the outstanding Equity Interests are at the time, directly or indirectly, owned by the Person.

 

18
 

 

Taxes” shall have the meaning ascribed to it in Section 12.2 hereof.

 

Termination Date” means the fifth anniversary of the Closing Date.

 

Third Tranche” shall have the meaning ascribed to it in the recitals hereof.

 

TTM EBITDA” means, at any particular time, EBITDA for the twelve (12) month period immediately preceding the last day of the period reported upon in the most recent Financial Statements.

 

UCC” means the Uniform Commercial Code as in effect from time to time in the State of New York or any other state the laws of which are required to be applied in connection with the issue of perfection of security interests.

 

Unfunded Qualified Acquisition” means a Qualified Acquisition that is financed by the Borrower’s cash flow.

 

Violation Notice” means any notice received by a Person, from any Governmental Authority under any Applicable Law that such Person or any of its Property is not in compliance with the requirements of any Applicable Law, including any notice that the FDA, Health Canada or any other similar Governmental Authority is limiting, suspending or revoking any Material License, changing the market classification, distribution pathway or parameters, or labeling of the Products, or considering any of the foregoing.

 

Welfare Plan” means any medical, health, hospitalization, insurance or other employee benefit or welfare plan, agreement or arrangement subject to ERISA and applicable to employees of the Loan Parties and includes a “welfare plan” as defined in Section 3(1) of ERISA.

 

1.2 Schedules and Exhibits.

 

The following are the Schedules and Exhibits to this Agreement, which are deemed to be a part of this Agreement:

 

Exhibit 1 Perfection Certificate 
Schedule 3.1(b) Repayment Schedule
Schedule 7.1(g) Intellectual Property
Schedule 7.1(h) Current and Prior Names
Schedule 7.1(i) Subsidiaries
Schedule 7.1(j) Litigation
Schedule 7.1(k) Material Contracts and Material Licenses
Schedule 7.1(p) Taxes
Schedule 7.1(s) Location of Collateral
Schedule 7.1(t) Owned Real Property
Schedule 7.1(u) Leased Real Property

 

19
 

 

Schedule 7.1(x) Labor Matters
Schedule 7.1(y) Pension Plans
Schedule 7.1(bb) Insurance
Schedule 7.1(kk) Regulatory Matters
Schedule 8.2 Officer’s Compliance Certificate 

 

1.3 Accounting Terms and Definitions.

 

Unless otherwise defined or specified herein, all defined terms in Section 1.1 as used in this Agreement shall have the meanings set out in such paragraph, and all accounting terms used in this Agreement shall be construed in accordance with GAAP, applied on a basis consistent in all material respects with the annual Audited Financial Statements, except as otherwise specifically prescribed herein. All accounting determinations for purposes of determining compliance with the financial covenants contained herein shall be made in accordance with GAAP as in effect on the Closing Date (unless and to the extent otherwise stipulated herein) and applied on a basis consistent in all material respects with the Audited Financial Statements, except as otherwise specifically prescribed herein. Except as otherwise specified herein, the financial statements required to be delivered hereunder from and after the Closing Date, and all financial records, shall be maintained in accordance with sound accounting practices including, if applicable, GAAP. If GAAP shall change from the basis used in preparing the Audited Financial Statements, the Compliance Certificates required to be delivered pursuant to Section 8.2 demonstrating compliance with the covenants contained herein shall include, at the election of the Borrower or upon the request of Lender, calculations setting forth the adjustments necessary to demonstrate how the Borrower is in compliance with the financial covenants based upon GAAP as in effect on the Closing Date.

 

1.4 Supplements, Re-enactments, Etc.

 

References herein to any agreement, document or legislation are, unless otherwise stated, to be construed as references to such agreement, document or legislation as amended, restated or supplemented from time to time and references to any enactment include re-enactments, amendments and extensions thereof.

 

1.5 Headings of Subdivisions.

 

The headings of subdivisions in this Agreement are for convenience of reference only, and shall not govern the interpretation of any of the provisions of this Agreement.

 

1.6 Gender and Number.

 

Words importing the singular include the plural and vice versa and words importing gender include all genders.

 

1.7 Monetary References.

 

Any reference in this Agreement to “Dollars”, “dollars” or the sign “$” shall be deemed to be a reference to lawful money of the United States, unless otherwise expressly stated.

 

20
 

 

1.8 Actions on Days Other Than Business Days.

 

Except as otherwise specifically provided herein, where any payment is required to be made or any other action is required to be taken on a particular day and such day is not a Business Day and, as a result, such payment cannot be made or action cannot be taken on such day, then this Agreement shall be deemed to provide that such payment shall be made or such action shall be taken on the first Business Day after such day.

 

ARTICLE 2 - TERMS OF THE LOAN

 

2.1 The Loan.

 

(a) First Tranche. As of the date hereof, the aggregate outstanding principal amount of the First Tranche is $1,687,500 and the Borrower acknowledges that the First Tranche shall for all purposes hereunder constitute and be referred to as a portion of the Loan, without constituting a novation, but in all cases subject to the terms and conditions applicable to Loans hereunder. The Borrower shall not be permitted to reborrow any amount of the First Tranche once repaid.

 

(b) Second Tranche. As of the date hereof, the aggregate outstanding principal amount of the Second Tranche is $1,375,000 and the Borrower acknowledges that the Second Tranche shall for all purposes hereunder constitute and be referred to as a portion of the Loan, without constituting a novation, but in all cases subject to the terms and conditions applicable to Loans hereunder. The Borrower shall not be permitted to reborrow any amount of the Second Tranche once repaid.

 

(c) Third Tranche. Subject to the terms and conditions of this Agreement and the other Loan Documents, Lender agrees to loan to the Borrower the Third Tranche to or for the account of the Borrower on the Closing Date and the Borrower hereby irrevocably authorizes Lender to advance the Third Tranche on the Closing Date.

 

2.2 Additional Tranches.

 

(a) Additional Tranches. Subject to the terms and conditions contained in this Agreement, from the Closing Date until the Termination Date, and provided that no Event of Default and no Default then exists, the Borrower may from time to time request additional advances of One Million Dollars or more (from Lender to support one or more Qualified Acquisitions (“Additional Tranches”), it being agreed and understood that (i) each request by the Borrower for an Additional Tranche shall be in a minimum amount of One Million Dollars ($1,000,000) and (ii) the maximum aggregate principal amount of all Additional Tranches made by Lender hereunder shall not exceed Twenty Million Dollars ($20,000,000). For certainty, Additional Tranches may only be used to finance Qualified Acquisitions.

 

21
 

 

(b) Additional Tranche Request. Whenever Borrower desires an Additional Tranche, Borrower shall notify Lender of the proposed Qualified Acquisition and the proposed borrowing (an “Additional Tranche Request”). Any Additional Tranche Request shall, inter alia: (i) specify the proposed closing date of the Qualified Acquisition, (ii) specify the purchase price of the Qualified Acquisition, including a breakdown of all details relating to the purchase price and any other consideration (e.g., cash vs. other consideration, upfront vs. deferred, consideration in the form or royalties and equity, etc.), (iii) the principal amount of the Additional Tranche requested and a summary of expected uses and sources of funds for the Qualified Acquisition, (iv) be accompanied by a certificate signed by the Chief Executive Officer and Chief Financial Officer of the Borrower, stating that no Default or Event of Default exists or, after giving effect to the Qualified Acquisition and the advance of the requested Additional Tranche, will exist, and (iv) include an appropriate and comprehensive information package relating to the proposed transaction, including a full set of business and legal due diligence materials relating thereto. Lender shall thereafter have ten (10) Business Days following its confirmed receipt of an Additional Tranche Request to notify the Borrower whether it agrees to make an Additional Tranche (the “Review Period”), provided, however, that should Lender fail to respond before the expiry of the Review Period it shall be deemed to have declined the Additional Tranche Request. Lender shall be entitled to request such additional information about the proposed Qualified Acquisition (including any additional due diligence materials) as necessary or useful, in the opinion of the Lender, to properly assess the Qualified Acquisition, and if the Lender makes any such requests before the expiry of the Review Period then a new Review Period shall begin upon Lender’s receipt of such additional information in order to allow Lender to consider the Additional Tranche Request. For certainty, Lender shall not be obligated to make a requested Additional Tranche and Lender, in its sole and absolute discretion, may decline to issue an Additional Tranche even if Borrower is in compliance with this Agreement. The refusal of any proposed Additional Tranche by Lender shall not affect the Borrower’s right to request an Additional Tranche at a future date.

 

(c) Additional Tranche Terms: In the event that Lender agrees, in its sole discretion, to grant any Additional Tranche, and without limiting anything else set forth herein or in any other Loan Document or any other provisions herein which apply to Loans (which, for certainty, apply to Additional Tranches unless otherwise provided), the following shall apply to such Additional Tranche(s)

 

(i) Amendments; Additional Documents. Lender shall provide Borrower with such amendment documents, if any, to the Loan Documents as may be required to give effect to the Additional Tranche (including a duly updated Repayment Schedule), as well as a list of such additional documents and deliverables (including Security Documents) as Lender may require in its sole discretion in connection with such Additional Tranche and the execution and delivery of such documents and any other customary documents and deliverables so required by the Lender shall be conditions precedent to the advance of any Additional Tranche.

 

(ii) Additional Tranche Work Fee. The Borrower will pay to Lender a work fee equal to 1% of the amount of any Additional Tranche that the Lender agrees to advance in accordance with 2.2(b) above, which amount will be fully earned and payable on the date that the Lender notifies the Borrower of its acceptance to advance such Additional Tranche (for certainty, whether or not the Qualified Acquisition is effected and/or such Additional Tranche is ultimately advanced).

 

22
 

 

  (  ) Additional Tranche Origination Fee. Concurrently with the advance of any Additional Tranche, the Borrower will pay to Lender an origination fee equal to 2% of the amount of such Additional Tranche, which amount will be fully earned and payable on the date of the advance of such Additional Tranche.

 

(i) Success Fee. For certainty, any Additional Tranche made by Lender shall entitle Lender to additional common shares or cash consideration pursuant to Section 4.8 hereof in accordance with the terms thereof.

 

(ii) Expenses. For certainty, the Borrower shall reimburse Lender for its expenses incurred in connection with its consideration of any Additional Tranche Requests (whether or not agreed to) and any Additional Tranches (whether or not advanced) in accordance with Section 4.9 hereof.

 

(d) If Lender declines an Additional Tranche Request on the terms described herein, and notwithstanding Sections 9.2(d) and 9.2(r) hereof, then the Borrower shall be entitled to effect the Qualified Acquisition through a Special Purpose Entity which Special Purpose Entity shall be entitled to obtain secured financing or other financing from third parties to finance the proposed Qualified Acquisition, on the strict condition that no Loan Party other than such Special Purpose Entity shall be a party to or otherwise involved in or affected by such transactions and that such transactions shall not, in the opinion of the Lender, otherwise adversely affect Lender or its rights hereunder.

 

ARTICLE 3 - PAYMENT

 

3.1 Payments on Principal.

 

(a) The Borrower shall pay in full to Lender the outstanding principal amount on each Loan, together with all accrued and unpaid interest thereon and any other accrued and unpaid Obligations, on the earliest to occur of: (i) the applicable Maturity Date; and (ii) the date of the acceleration of the Obligations pursuant to Section 11.2 of this Agreement.

 

(b) In addition to the interest payments set forth in Section 4.2, the Borrower shall pay to Lender on account of principal of each Loan the amounts set forth on the Repayment Schedule.

 

(c) All payments to be made by the Borrower to Lender hereunder shall be made to Lender by wire transfer in accordance with the wire instructions given by Lender to the Borrower in writing from time to time.

 

3.2 Prepayments.

 

Without the prior written consent of Lender, which may be withheld or conditioned by Lender in its sole discretion, the outstanding principal of Loans shall not be prepaid prior to the applicable Maturity Date of such Loans. Any amounts prepaid or repaid (to the extent permitted by Lender) shall not be re-borrowed and shall be applied (i) firstly in reduction of accrued and unpaid interest and all other amounts then outstanding (other than the principal amount of the relevant Loan), and (ii) thereafter, in reduction of the principal amount of such Loan.

 

23
 

 

3.3 General Matters.

 

All payments made by the Borrower shall be made without set-off, recoupment or counterclaim. The Loan shall, if requested by Lender, in Lender’s sole discretion, be evidenced by one or more promissory notes in form and substance satisfactory to Lender. However, if such Loan is not so evidenced, the Loan made by Lender, including rates of interest, fees and other charges, may be evidenced by entries upon the books and records maintained by Lender which books and records shall constitute conclusive evidence thereof in the absence of manifest error.

 

ARTICLE 4 - INTEREST, FEES AND CHARGES

 

4.1 Rate of Interest.

 

(a) First Tranche and Second Tranche. Subject to Section 4.3, the principal amount of the First Tranche and the Second Tranche and other outstanding Obligations relating to the First Tranche and the Second Tranche shall bear interest at a rate equal to 15% per annum compounded quarterly; provided, however, that upon the occurrence of an Equity Financing interest on the First Tranche only shall thereafter be calculated at a rate equal to 13% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4(a).

 

(b) Third Tranche. Subject to Section 4.3, the principal amount of the Third Tranche and other outstanding Obligations relating to the Third Tranche shall bear interest from the Closing Date to the date paid, at a rate equal to 10.5% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4(b).

 

(c) Additional Tranches. Subject to Section 4.3, the principal amount of each Additional Tranche and other outstanding Obligations relating to such Additional Tranche shall bear interest from the date of the advance thereof to the date paid, at a rate equal to 10.5% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4(b).

 

4.2 Payment of Interest.

 

The Borrower shall pay Lender all accrued and unpaid interest on the principal amount of the Second Tranche then outstanding monthly in arrears in cash on the eleventh (11th) day of each month and pay Lender all accrued and unpaid interest on the principal amount of all other Loans (including, for certainty, any Additional Tranches) then outstanding and the outstanding amount of other Obligations quarterly in arrears in cash on each Interest Payment Date, starting with the Interest Payment Date falling on September 30, 2017. For certainty, the final payment date with respect to interest and principal owing under the First Tranche shall be January 20, 2018.

 

24
 

 

4.3 Default Rate of Interest.

 

Upon and after the occurrence of an Event of Default under Section 11.1, and during the continuation thereof, the principal amount of the Loan and the other Obligations shall bear interest at a rate per annum equal to the interest rate otherwise payable pursuant to Section 4.1 plus five percent (5%) and such interest shall be calculated daily and compounded quarterly and shall be payable on demand by Lender.

 

4.4 Computation of Interest and Fees.

 

(a) First Tranche and Second Tranche. With respect to the First Tranche, interest shall be determined daily and compounded quarterly not in advance, and with respect to the Second Tranche, interest shall be determined daily and compounded monthly not in advance, in each case both before and after demand, default and judgment and shall be computed on the actual number of days elapsed over a year of three hundred and sixty-five (365) days or three hundred and sixty-six (366) days, as the case may be.

 

(b) Third Tranche and Additional Tranches. With respect to the Third Tranche and any Additional Tranches, interest shall be determined daily and compounded quarterly not in advance, both before and after demand, default and judgment and shall be computed on a 360-day basis.

 

4.5 Maximum Interest.

 

It is the intent of the parties that the rate of interest and the other charges to the Borrower under this Agreement shall be lawful; therefore, if for any reason the interest or other charges payable under this Agreement are found by a court of competent jurisdiction, in a final determination, to exceed the limit which Lender may lawfully charge the Borrower, then the obligation to pay interest and other charges shall automatically be reduced with retroactive effect to such limit and, if any amount in excess of such limit shall have been paid, then such amount shall be refunded to the Borrower.

 

4.6 Origination Fee.

 

The Borrower will pay to Lender an origination fee equal to $200,000 (the “Origination Fee”), being 2% of the Third Tranche amount, which will be fully earned and payable on the date hereof.

 

4.7 Work Fee.

 

The Borrower will pay to Lender a work fee equal to $100,000 (the “Work Fee”), being 1% of the Third Tranche amount, which will be fully earned and payable at the earlier of August 1, 2017 and the Closing Date. For greater certainty, the said fee is payable whether or not the Third Tranche is advanced.

 

4.8 Success Fees.

 

On (i) the Maturity Date of each Loan advanced hereunder on or after the date hereof (including, for certainty, the Third Tranche and every Additional Tranche), or (ii) at the option of the Lender, on the date of the acceleration by Lender of each such Loan advanced hereunder on or after the date hereof pursuant to Section 11.2 hereof (each, a “Calculation Date”) the Borrower shall pay the Lender a success fee payable with respect to each Loan so advanced by issuance and delivery by the Borrower to the Lender of such number of common shares being equal 10% of such Loan, divided by the lesser of (A) $1.50, (B) the lowest price at which any common shares were issued by the Borrower in any offering or equity financing or other transaction between the Closing Date and the Calculation Date of the relevant Loan, and (C) the Current Market Price on the Calculation Date of the relevant Loan (“Success Fee Shares”). Within five (5) Business Days of each Calculation Date, the Borrower shall, at its option, either: (X) issue and deliver the relevant number of Success Fee Shares to the Lender or (Y) make a cash payment to the Lender in an amount equal to the number of Success Fee Shares otherwise issuable multiplied by the Current Market Price as of the relevant Calculation Date.

 

25
 

 

4.9 Lender’s Expenses.

 

The Borrower shall reimburse Lender for all reasonable costs and expenses (including without limitation, reasonable accounting, valuation and consultant fees and expenses and reasonable legal fees and expenses in each applicable jurisdiction) incurred by Lender before or after the Closing Date in connection with: (a) the preparation, negotiation, execution and delivery of this Agreement and the other Loan Documents and the documentation and consummation of the transactions contemplated hereby and thereby (whether or not a given Loan transaction is consummated and whether such transactions are effected concurrently with the funding of a Loan or subsequently), including matters relating to the post-closing deliverables contemplated by this Agreement, to Lender’s Distribution Agreements and, for certainty, to Qualified Acquisitions (including the consideration thereof) and Additional Tranches (whether or not advanced), as well as any amendments, modifications or waivers of the provisions hereof or thereof, including, without limitation, security and other public record searches, lien filings, express mail or similar express or messenger delivery, due diligence costs and expenses, (b) its administration and interpretation of this Agreement and the other Loan Documents and its seeking to collect, protect or enforce any rights in or to the Collateral or incurred by Lender in seeking to collect any Obligations and to administer and enforce any of its rights under this Agreement and the other Loan Documents. All such costs, expenses and charges incurred on or prior to August 1, 2017 or the Closing Date, as applicable, shall be paid on such date, and all such costs, expenses and charges incurred after the Closing Date will constitute Obligations hereunder, shall be payable by the Borrower to or to the order of Lender on demand and, if overdue by 30 days or more, until paid, will bear interest at the Deemed Interest Rate.

 

4.10 Illegality.

 

If any Applicable Law coming into force after the Closing Date, or if any change in any existing Applicable Law or in the interpretation or application thereof by any court or Governmental Authority, now or hereafter makes it unlawful for Lender to have advanced or acquired interest in the Loan or to give effect to its obligations in respect thereof, Lender may, by written notice thereof to the Borrower, declare its obligations under this Agreement to be terminated, and the Borrower shall prepay, within the time required by such law, the principal amount of the Loan together with accrued interest thereon and any other amounts owing under this Agreement as may be applicable to the date of such payment. If any such event shall, in the opinion of Lender, only affect part of its obligations under this Agreement, the remainder of this Agreement shall be unaffected and the obligations of the Loan Parties under the Loan Documents shall continue.

 

26
 

 

4.11 Increased Costs.

 

Notwithstanding any other provision herein, in the event that the introduction of or any change in any Applicable Law or in the interpretation or application thereof, or compliance by Lender with any request or directive (whether or not having the force of law) from any Governmental Authority:

 

(a) subjects Lender to any new tax of any kind whatsoever with respect to this Agreement, the other Loan Documents or the Loan, or changes the basis of taxation of payments to Lender of principal, interest or any other amount payable hereunder (except for changes in the rate of tax imposed on the overall net income of Lender); or

 

(b) imposes, modifies, holds applicable any reserve, special deposit, compulsory loan or similar requirement against Property held by, or deposits or other obligations in or for the account of, advances or loans by, or other credit extended by, or any other acquisition of funds by, any office of Lender;

 

and the result of any of the foregoing is to materially increase the cost to Lender of agreeing to make, making, continuing or maintaining or participating in the Loan, or to materially reduce any amount receivable thereunder or to materially increase the withholding taxes payable then, in any such case, the Borrower shall pay Lender, after demand by Lender, any additional amounts necessary to compensate Lender on an after-tax basis for such additional cost or reduced amount receivable or increased withholding taxes payable with respect to any Loan Document or the Loan made hereunder.

 

ARTICLE 5 - TERMINATION AND REDUCTION

 

5.1 Termination.

 

This Agreement shall be in effect from the date hereof until the later of (i) the indefeasible repayment and performance in full of the Obligations and (ii) the Termination Date. At such time:

 

(a) the Borrower shall provide a release of any obligations and obligations of Lender and its Affiliates, in form and substance reasonably satisfactory to Lender; and

 

(b) Lender shall, at the Borrower’s cost and expense, deliver to the Borrower a termination, discharge and release of all security in form and substance reasonably satisfactory to the Borrower and such other documents and instruments as the Borrower may reasonably request in order to effect or evidence the termination of this Agreement and the security.

 

5.2 Continuing Obligations.

 

Nothing in Section 5.1 shall affect any rights, liabilities and obligations of Borrower or Lender set out in this Agreement or in any other Loan Document which are stated to survive payment of the Obligations and termination of this Agreement or the Loan Documents, as the case may be.

 

27
 

 

ARTICLE 6 - SECURITY AND COLLATERAL

 

6.1 Security Delivered on or Prior to the Closing Date.

 

On or prior to the Closing Date (subject to the post-closing delays noted below), as continuing collateral security for the payment and satisfaction of all Obligations, the Loan Parties shall deliver or cause to be delivered to Lender Security on the Collateral, including the following Security Documents, all of which shall be in form and substance satisfactory to Lender:

 

(a) a general security agreement from each Loan Party in favour of Lender constituting a first-priority Lien (subject only to Permitted Liens) on all of the present and future Property of each Loan Party in all relevant jurisdictions;

 

(b) the shares of the Subsidiaries, duly pledged and endorsed for transfer in blank (to be delivered within 10 days of the Closing Date);

 

(c) a collateral assignment from each Loan Party of its interests in all Material Contracts and Material Licenses;

 

(d) such Control Agreements as Lender may require (to be delivered within 60 days of the Closing Date);

 

(e) landlord access agreement with the landlord of any leased premises of any Loan Party (to be delivered within 30 days of the Closing Date);

 

(f) Intellectual Property security agreement from each Loan Party in favour of Lender, duly filed in such intellectual property registries as the Lender shall require (Borrower shall effect the necessary filings in the appropriate intellectual property registries in Canada, the United, the European Union, Australia and with the World Intellectual Property Organization (and any other registries designated by Knight) within 30 days of the Closing Date).

 

(g) Waivers from bailees or warehouseman with respect to any premises where Property of the Borrower or any other Loan Party having a book value in excess of $25,000 may be located from time to time (to be delivered within 30 days of the Closing Date);

 

(h) a guarantee agreement of the Obligations from each Subsidiary of the Borrower in favour of Lender;

 

(i) specific security agreement granted by the Borrower in respect of the issued share capital in Nomad;

 

(j) confirmation agreements from the Borrower, Nomad and Breakthrough in favour of Lender in relation to the Security Documents delivered prior to the Closing Date, including those delivered pursuant to the Existing Loan Agreement; and

 

(k) such other agreements as Lender may require from time to time. 28

 

28
 

 

6.2 Further Assurances.

 

The Borrower shall take or cause to be taken such action and execute and deliver or cause to be executed and delivered to Lender such agreements, documents and instruments as Lender shall request, and register, file or record the same (or a notice or financing statement in respect thereof) in all offices where such registration, filing or recording is, in the opinion of Lender or Lender’s counsel, necessary or advisable to constitute, perfect and maintain the Security Documents referred to in Section 6.1 as first-ranking Liens of Borrower or the Person granting such Liens, subject only to the Permitted Liens, in all jurisdictions reasonably required by Lender, in each case within a reasonable time after the request therefor by Lender or Lender’s counsel, and in each case in form and substance satisfactory to Lender and Lender’s counsel, acting reasonably.

 

6.3 Security Effective Notwithstanding Date of Loan.

 

The Security and the Security Documents shall be effective and the undertakings in this Agreement and the other Loan Documents with respect thereto shall be continuing, whether the monies hereby or thereby secured or any part thereof shall be advanced before or after or at the same time as the creation of any such Security or before or after or upon the date of execution of this Agreement. The Security shall not be affected by any payments on this Agreement or any of the other Loan Documents, but shall constitute continuing security to and in favour of Lender for the Obligations from time to time.

 

6.4 No Merger.

 

The Security and the Security Documents shall not merge in any other security granted by the Borrower. No judgment obtained by or on behalf of Lender shall in any way affect any of the provisions of this Agreement, the Security Documents or the other Loan Documents. For greater certainty, no judgment obtained by or on behalf of Lender shall in any way affect the obligation of the Borrower to pay interest or other amounts at the rates, times and in the manner provided in this Agreement, or the obligations of the other Loan Parties under the Security.

 

6.5 Release of Security.

 

At the later of (i) the due payment and performance in full of all Obligations and (ii) the Termination Date, Lender will, at the cost and expense of the Borrower, release and discharge the right and interest of Lender in the Collateral, following indefeasible payment and performance in full of all Obligations.

 

In addition, if any Property of any of the Loan Parties is Disposed of as permitted by this Agreement or is otherwise released from the Security at the direction or with the consent of Lender, at the request, cost and expense of the Borrower (on satisfaction, or on being assured of concurrent satisfaction, of any condition to or obligation imposed with respect to such Disposition), Lender shall discharge such Property from the Security and deliver and re-assign to the Borrower or its Subsidiaries (without any representation or warranty) any of such Property as is then in the possession of Lender.

 

29
 

 

ARTICLE 7 - REPRESENTATIONS AND WARRANTIES

 

7.1 Representations and Warranties.

 

The Borrower hereby makes the following representations:

 

(a) Existence and Qualification. Each Loan Party (i) has been duly incorporated, amalgamated, formed, merged or continued, as the case may be, and is validly subsisting and in good standing as a corporation, company or partnership, under the laws of its jurisdiction of incorporation, amalgamation, merger, formation or continuance, as the case may be, (ii) is duly qualified to carry on its business in each jurisdiction in which it carries on business except for non-qualification which has no adverse effect on the Business, and (iii) has all required Material Licenses.

 

(b) Power and Authority. Each Loan Party has the corporate, company or partnership power, capacity and authority, as the case may be, (i) to enter into, and to exercise its rights and perform its obligations under, the Loan Documents to which it is a party and all other instruments and agreements delivered by it pursuant to any of the Loan Documents, and (ii) to own its Property and carry on its business as currently conducted.

 

(c) Execution, Delivery, Performance and Enforceability of Documents. The execution, delivery and performance of each of the Loan Documents to which each Loan Party is a party has been duly authorized by all corporate or limited liability company, as the case may be, actions required, and each of such documents has been duly executed and delivered by it. Each Loan Document to which each Loan Party is a party constitutes the legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity).

 

(d) Compliance with Applicable Laws, Organizational Documents and Contractual Obligations. None of the execution or delivery of, the consummation of the transactions contemplated in, or the compliance with the terms, conditions and provisions of any of, the Loan Documents conflicts with or will conflict with, or results or will result in any breach of, or constitutes a default under or contravention of, any Applicable Law, the Loan Parties’ respective Organizational Documents or any Material Contract or Material License, or results or will result in the creation or imposition of any Liens upon any of its Property except for Permitted Liens.

 

(e) Privacy Laws. Without in any way limiting anything else set forth herein, the Borrower and the other Loan Parties have established policies and procedures with respect to the collection, use, transfer and disclosure of information (including health information) about identifiable individuals including with respect to employees, customers, patients and health care professionals (“Personal Data”) compliant with Applicable Law relating to privacy and data protection (“Privacy Law”), and have been and are operating at all times in compliance in all material respects with all such Applicable Law. None of the Loan Parties has had any breach, misappropriation, or unauthorized collection, use or disclosure of any Personal Data (a “Data Breach”) or are a party to any Action Request or Violation Notice which has been instituted or threatened involving a claim against them for any breach, misappropriation or unauthorized collection, use, transfer or disclosure or any breach of any Applicable Law relating to privacy and data protection of Personal Data. Without limiting the foregoing, (i) the Loan Parties have obtained all necessary and required consents with respect to the collection, use and disclosure of Personal Data; (ii) the transfers of any Personal Data by the Borrower to the Lender arising from or pursuant to this Agreement or any other Loan Document will comply in all material respects with any Applicable Law relating to privacy law and data protection law in all relevant jurisdictions (iii) the Loan Parties have obtained all necessary and required consents with respect to the sending of commercial electronic messages to third parties; and (d) the Borrower has full records of all privacy law consents or such other consents so required obtained in writing, including the record of the date, time, purpose, and manner of each consent so as to demonstrate the context in which the consenting party provided consent, with such records including full copies of any materials the consenting party may have encountered in providing such consent.

 

30
 

 

(f) Consent Respecting Loan Documents. Each Loan Party has obtained, made or taken all consents, approvals, authorizations, declarations, registrations, filings, notices and other actions whatsoever required (except for registrations or filings which may be required in respect of the Security Documents) to enable it to execute and deliver each of the Loan Documents to which it is a party and to consummate the transactions contemplated in the Loan Documents, except where the failure to do so is immaterial considering the nature of the Loan Documents.

 

(g) Intellectual Property/License Agreements. Each Loan Party owns or licenses or otherwise has the right to use all Intellectual Property that is material and necessary and useful to continue to conduct its Business as heretofore conducted by it or proposed to be conducted, details of all of which as of the Closing Date are described in Schedule 7.1(g). As of the date hereof, no Loan Party has any Intellectual Property registered, or subject to pending applications, in the United States Patent and Trademark Office, the Canadian Intellectual Property Office or any similar office or agency in the United States, Canada, Australia, any State or Province thereof, any political subdivision thereof or in any other country, other than those described in Schedule 7.1(g). and has not granted any licenses with respect thereto other than as set forth in Schedule 7.1(g). No event has occurred which permits or would permit after notice or passage of time or both, the revocation, suspension or termination of such rights and each Loan Party will be entitled to continue to use, practice and exercise rights in all of the Intellectual Property. To the Borrower’s knowledge, no slogan or other advertising device, product, process, method, substance or other Intellectual Property or goods bearing or using any Intellectual Property presently contemplated to be sold by or employed by any Loan Party infringes any patent, trademark, servicemark, tradename, copyright, license or other Intellectual Property owned by any other Person presently and no claim or litigation is pending or, to the Borrower’s knowledge, threatened against or affecting any Loan Party contesting its right to sell or use any such Intellectual Property. Schedule 7.1(g) sets forth all of the agreements or other arrangements of the Loan Parties pursuant to which any Loan Party has a license or other right to use any trademarks, logos, designs, representations or other Intellectual Property owned by another person as in effect on the date hereof and the dates of the expiration of such agreements or other arrangements of any Loan Party as in effect on the date hereof (collectively, together with such agreements or other arrangements as may be entered into by a Loan Party after the date hereof, collectively, the “Licenses” or “License Agreements” and individually, a “License” or “License Agreement”).

 

31
 

 

(h) Jurisdiction, Current and Prior Names. Each Loan Parties jurisdiction of organization, chief executive office, legal name and prior names, trade-names and division names are described on Schedule 7.1(h) as of the date hereof, and such schedule also lists all jurisdictions of organization and legal names of such Loan Party for the six (6) months preceding the date hereof, if different.

 

(i) Corporate Structure. The Loan Parties have no Subsidiaries, other than the Subsidiaries described in Schedule 7.1(i). The Loan Parties are not engaged in any joint venture or partnership with any other Person.

 

(j) Litigation. Except as described in Schedule 7.1(j), to the best of Borrower’s knowledge after due inquiry, there are no actions, suits, counterclaims or proceedings which are pending or threatened against the Loan Parties where more than $100,000 is at issue.

 

(k) Material Contracts and Material Licenses. Schedule 7.1(k) (as amended from time to time and updated with the delivery of each Compliance Certificate pursuant to Section 8.2), accurately sets out all Material Contracts and Material Licenses. A true and complete certified copy of each Material Contract and Material License existing at the Closing Date has been delivered to Lender and each Material Contract and Material License is in full force and effect. No event has occurred and is continuing which would constitute a material breach of or a default under any such Material Contract or Material License. Each Material Contract to which the Loan Parties are a party is binding upon such Loan Party and, to Borrower’s knowledge, is a binding agreement of each other Person who is a party to the Material Contract. It has obtained, as of the Closing Date, all necessary consents, including consents of landlords, licensees, Government Authorities and other third parties to the granting of a security interest in each Material Contract and Material License pursuant to the Security Documents.

 

(l) No Liens. No security agreement, financing statement or analogous instrument exists as at the Closing Date with respect to any of the Collateral other than any security agreement, financing statement or analogous instrument evidencing Permitted Liens.

 

(m) Title to Collateral. The Loan Parties are the lawful owners of all Collateral now purportedly owned or hereafter purportedly acquired by them, free from all Liens, whether voluntarily or involuntarily created and whether or not perfected, other than Permitted Liens.

 

(n) Financial Information. All of the quarterly and annual Financial Statements or other financial information which have been furnished to Lender, in connection with this Agreement are complete in all material respects and such Financial Statements or other financial information fairly present the results of operations and financial position of the Borrower as of the dates referred to therein and have been prepared in accordance with GAAP. All other financial information provided to Lender (including, without limitation, the Annual Business Plan) are complete in all material respects and based on reasonable assumptions and expectations.

 

32
 

 

(o) Permitted Debt. As of the Closing Date (giving effect to the making of the Third Tranche), the Loan Parties are not obligated, whether directly or indirectly, for any Debt other than the Permitted Debt.

 

(p) Taxes. Except as disclosed in Schedule 7.1(p), each Loan Party has duly and timely filed all tax returns required to be filed by it and has paid or made adequate provision for the payment of all Taxes levied on its Property or income which are showing therein as due and payable, including interest and penalties, or has accrued such amounts in its financial statements for the payment of such Taxes except for Taxes which are not material in amount or which are not delinquent or if delinquent are being contested, and there is no material action (except, after the date of this Agreement, as is disclosed to Lender in writing), suit, proceeding, investigation, audit or claim now pending, or to its knowledge, threatened by any Governmental Authority regarding any Taxes nor has it agreed to waive or extend any statute of limitations with respect to the payment or collection of Taxes.

 

(q) Full Disclosure. All information provided or to be provided to Lender by or on behalf of the Loan Parties in connection with the Loan is, to Borrower’s or such Loan Party’s knowledge, true and correct in all material respects and none of the documentation furnished to Lender by or on behalf of it, to Borrower’s knowledge, omits or will omit as of such time, a material fact necessary to make the statements contained therein not misleading in any material way, and all expressions of expectation, intention, belief and opinion contained therein were honestly made on reasonable grounds (and any other Person who furnished such material on behalf of it).

 

(r) Insolvency. Each Loan Party (i) has not committed any act of bankruptcy, (ii) is not insolvent, will not be rendered insolvent hereby, nor has proposed, nor given notice of its intention to propose, a compromise or arrangement to its creditors generally, nor (iii) has any petition for a receiving order in bankruptcy filed against it, made a voluntary assignment in bankruptcy, taken any proceeding with respect to any compromise or arrangement, taken any proceeding to have itself declared bankrupt or wound-up, taken any proceeding to have a receiver appointed of any part of its Property.

 

(s) Location of Collateral. The offices where each Loan Party keeps its books, records and accounts (or copies thereof) concerning the Collateral, each Loan Party’s principal place of business and each Loan Party’s other significant places of business and significant locations of Collateral are as set forth in Schedule 7.1(s).

 

(t) Owned Real Property. A list of each Loan Party’s owned real property is as set forth in Schedule 7.1(t).

 

(u) Leased Real Property. A list of each Loan Party’s leased real property is as set forth in Schedule 7.1(u).

 

33
 

 

(v) Deposit Accounts and Security Accounts. A list of the Borrower’s Deposit Accounts and Securities Accounts as of the Closing Date is set forth in Schedule 7.1(v), including in each case the name and address of each depository, the name in which the account is held, a general description of the purpose of the account and the complete account number therefor.

 

(w) Environmental Laws. Each Loan Party complied with all Environmental Laws applicable to the construction and operation of its Property and businesses, except where any non-compliance would not reasonably be expected to have a Material Adverse Effect; each Loan Party has no material contingent liability with respect to non-compliance with Environmental Laws or the generation, handling, use, storage, or disposal of Materials of Environmental Concern; and, without limiting the generality of the foregoing, except as would not reasonably be expected to have a Material Adverse Effect, the Loan Parties:

 

(i) have not received any Action Request, Violation Notice, summons, complaint, order or other notice that it is not in compliance with, or that any Governmental Authority is investigating its compliance with, Environmental Laws:

 

(ii) have no knowledge or reason to believe that operations or any Property of or occupied by the Loan Parties or in the Loan Parties’ charge, management or control are not in compliance with all applicable Environmental Laws and each of their Properties is free:

 

(A) from contamination by, and there has not been thereon a release, discharge or emission of, any Materials of Environmental Concern which is prohibited, controlled or regulated under any Environmental Law; and

 

(B) of underground storage tanks, landfills, land disposals and dumps;

 

(iii) have not filed any notice, or received notice, under any Applicable Law, including any Environmental Law, indicating past or present treatment, storage or disposal of a Material of Environmental Concern or reporting any spill or release of a Material of Environmental Concern into the environment;

 

(iv) have no contingent liability of which the Borrower has knowledge or reasonably should have knowledge in connection with any release of any Material of Environmental Concern;

 

(v) do not generate, transport, treat or dispose of any Material of Environmental Concern in any manner which is not in compliance with all applicable Environmental Laws; and

 

(vi) have not disposed of any Material of Environmental Concern in or on the ground of the Loan Parties’ real properties or premises leased by the Loan Parties.

 

(x) Labor Matters. Except as provided on Schedule 7.1(x):

 

(i) there is no collective bargaining agreement or other labour contract covering employees of the Loan Parties;

 

34
 

 

(ii) there is no pending or, to the best of its knowledge, threatened strike, work stoppage, material unfair labour practice claims, or other material labour dispute against or affecting the Loan Parties or their employees which would reasonably be expected to have a Material Adverse Effect;

 

(iii) there are no controversies pending or threatened between the Loan Parties and any of their employees, other than employee grievances arising in the ordinary course of business which would not reasonably be expected to have a Material Adverse Effect; and

 

(iv) no employee of the Borrower or any of its Subsidiaries, and no consultant, independent contractor or agent engaged by the Borrower or any of its Subsidiaries (and no employee of such consultant or independent contractor) is an illegal or undocumented worker. All employees, consultants, independent contractors or agents have all work permits, visas, authorizations or status, as the case may be, required to perform work or provide services in the United States (or in the case of non-US subsidiaries, such other relevant jurisdiction in which a Subsidiary resides); and

 

(v) each Loan Party is in compliance in all material respects with all Applicable Laws respecting employment and employment terms, conditions and practices.

 

(y) Pension Plans. Except as disclosed on Schedule 7.1(y), the Loan Parties do not sponsor or maintain or contribute to a Pension Plan. With respect to any Pension Plan adopted or to which the Loan Parties may become obliged to contribute, no failure to remit contributions (other than immaterial amounts) has occurred with respect to any such Pension Plan, that is sufficient to give rise to a Lien under any Applicable Laws of any jurisdiction (other than a Permitted Lien), and no condition exists and no event or transaction has occurred with respect to any such Pension Plan which could result in the incurrence by a Loan Party of any material liability, fine or penalty. Each Pension Plan is in compliance in all material respects with all Applicable Laws pertaining to pension benefits and Tax laws, (i) all contributions (including employee contributions made by authorized payroll deductions or other withholdings) required to be made to the appropriate funding agency in accordance with all Applicable Laws and the terms of such Pension Plan have been made in accordance with all Applicable Laws and the terms of such Pension Plan, except for amounts which are immaterial, (ii) all liabilities under such Pension Plan are fully funded, on a going concern and solvency basis, in accordance with the terms of the respective Pension Plans, the requirements of applicable pension benefits laws and of applicable regulatory authorities and the most recent actuarial report filed with respect to the Pension Plan. No event has occurred and no conditions exist with respect to any such Pension Plan that has resulted or could reasonably be expected to result in such Pension Plan having its registration revoked or refused for the purposes of any applicable pension benefits or tax laws or being placed under the administration of any relevant pension benefits regulatory authority or being required to pay any taxes or penalties under any applicable pension benefits or tax laws.

 

(z) ERISA. (i) With respect to each ERISA Plan, each Loan Party and each other member of its Controlled Group has fulfilled its obligations under the minimum funding standards of and is in compliance in all material respects with ERISA and the Revenue Code to the extent applicable to it and has not incurred any liability to the PBGC or under Title IV of ERISA, other than a liability to the PBGC for premiums under Section 4007 of ERISA; (ii) it does not have any contingent liabilities with respect to any post-retirement benefits under a Welfare Plan, other than liability for continuation coverage described in Part 6 of Title I of ERISA or as required under Applicable Law requirements for health continuation coverage, (iii) neither a Reportable Event nor a Prohibited Transaction has occurred and is continuing with respect to any ERISA Plan; (iv) no notice of intent to terminate an ERISA Plan has been filed, nor has any ERISA Plan been terminated; (v) no circumstances exist which constitute grounds entitling the PBGC to institute proceedings to terminate, or appoint a trustee to administer, ERISA Plan, nor has the PBGC instituted any such proceedings; (vi) neither it nor any member of its Controlled Group has completely or partially withdrawn from a multiemployer plan; (vii) it and all members of its Controlled Group have met their minimum funding requirements under ERISA with respect to all of their ERISA Plans and the present value of all vested benefits under each ERISA Plan exceeds the fair market value of all such ERISA Plan assets allocable to such benefits, as determined on the most recent valuation date of such ERISA Plan and in accordance with the provisions of ERISA; and neither it nor any member of its Controlled Group has incurred any liability to the PBGC under ERISA.

 

35
 

 

(aa) Computer Software. Each Loan Party owns or has licensed for use or otherwise has the right to use or to acquire or License all of the material software necessary to conduct its businesses. All computer equipment owned or used by the Loan Parties and necessary for the conduct of business has been properly maintained and is in good working order for the purposes of on-going operation, subject to ordinary wear and tear for computer equipment of comparable age.

 

(bb) Insurance. Each Loan Party has maintained and maintains insurance which is in full force and effect that complies with all of the requirements of this Agreement. Each Loan Party has maintained and maintains product liability insurance which is in full force and effect covering at least $5,000,000 per claim and $5,000,000 in the aggregate. Schedule 7.1(bb) lists all existing insurance policies maintained by the Loan Parties as of the Closing Date.

 

(cc) OFAC. The Loan Parties are not in violation of any of the country or list based economic and trade sanctions administered and enforced by OFAC or any of the United States Department of State, the United States Department of Commerce or any other government authority or pursuant to any Executive Order of the President of the United States of America. The Borrower (i) is not a Sanctioned Person or a Sanctioned Entity or named on any other list of terrorists, terrorist organizations or narcotics traffickers maintained pursuant to any of the Rules and Regulations of OFAC or any similar lists maintained by the aforementioned Governmental Authorities, (ii) has no more than ten percent (10%) of its assets located in Sanctioned Entities or by Sanctioned Persons, or (iii) derives no more than ten percent (10%) of its revenues from investments in, or transactions with Sanctioned Persons or Sanctioned Entities. or other Persons described in clause (i).

 

(dd) Anti-Money Laundering, Etc. Each Loan Party has conducted all transactions, negotiations, discussions and dealings in full compliance with anti-bribery and anti-corruption laws and regulations applicable in any jurisdiction in which they are located or conducting business. No Loan Party has made any offer, payment, promise to pay or authorization of payment of money or anything of value to any government official, or any other person while having reasonable grounds to believe that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a government official, for the purpose of (i) assisting the parties in obtaining, retaining or directing business; (ii) influencing any act or decision of a government official in his or its official capacity; (iii) inducing a government official to do or omit to do any act in violation of his or its lawful duty, or to use his or its influence with a government or instrumentality thereof to affect or influence any act or decision of such government or department, agency, instrumentality or entity thereof; (iv) securing any improper advantage; or (v) otherwise violating the U.S. Foreign Corrupt Practices Act of 1977, as amended from time to time, including any replacement legislation; The operations of each of the Loan Parties are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively, the “Applicable Money Laundering Laws”) and no action, suit or proceeding by or before any Governmental Authority involving the Borrower with respect to Applicable Money Laundering Laws is pending or threatened;

 

36
 

 

(ee) Investment Company. No Loan Party is an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940 of the United Sates, as amended.

 

(ff) No Margin Stock. No Loan Party is engaged in the business of extending credit for the purpose of purchasing or carrying margin stock. None of the proceeds of the Loan shall be used to purchase or carry, or to reduce or retire or refinance any credit incurred to purchase or carry, any margin stock (within the meaning of Regulations U and X of the Board of Governors of the Federal Reserve System of the United States) or to extend credit to others for the purpose of purchasing or carrying any margin stock.

 

(gg) Perfection Certificate. The information set forth in the Perfection Certificate (and each Perfection Certificate delivered in accordance herewith) is true, correct and complete as of the date set forth therein and will be true, correct and complete on the Closing Date.

 

(hh) Purchase Agreements. The accuracy and completeness of each of the representations and warranties set out in the Nomad Purchase Agreement, the share purchase agreement concerning the Breakthrough Acquisition and Section 5 of the FNL Asset Purchase Agreement, including the definitions used therein and all such representations, warranties and definitions are hereby incorporated into this Agreement by reference as if same were herewith recited at length and made directly by the Borrower for the benefit of Lender. Such representations and warranties shall survive for so long as the Obligations remain outstanding, notwithstanding any shorter survival period under agreements.

 

(ii) No Material Adverse Effect. No event has occurred which has had or could reasonably be expected to have a Material Adverse Effect.

 

(jj) No Default or Event of Default. No Default or Event of Default has occurred and is continuing.

 

37
 

 

(kk) Regulatory Matters.

 

(i) Except as set forth on Schedule 7.1(kk) and (i) each Loan Party has obtained and holds in its name all Material Licenses required by the FDA, Health Canada or any other Governmental Authority, for the conduct of their Business as currently conducted, to permit any manufacturing, distribution, sales, testing, marketing or research and development activities of such Loan Party to date (the “Activities to Date”) with respect to each Product; (B) all such Material Licenses are in full force and effect and no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of the holder of any Material License; (C) each Loan Party in compliance in all respects with all terms and conditions of each Material License, and with all Applicable Laws and requirements pertaining to the Activities to Date with respect to each Product; (D) each Loan Party is in compliance with all Applicable Laws regarding registration or notification for the site at which the Products are manufactured, processed, packed, held for distribution or from which and into which they are distributed; (ii) all manufacturing operations performed by or on behalf of each Loan Party are in compliance with current good manufacturing practice requirements and Applicable Laws and Material Licenses; and (iii) each Loan Party is in compliance with all reporting requirements for all Material Licenses, including, without limitation plant registrations.

 

(ii) All applications, notifications, submissions, information, claims, reports and statistics, and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Material License from the FDA, Health Canada, or other Governmental Authority relating to the Loan Parties or the Business or Products, when submitted to the FDA, Health Canada, United States Department of Agriculture or other Governmental Authority were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes, corrections or modification have been submitted to the FDA, Health Canada, or other Governmental Authority. The claims for the Products are valid and supported by proper research, design, testing, analysis and disclosure.

 

(iii) Except as set out in Schedule 7.1(kk), each Product that is subject to the Applicable Laws promulgated by a Regulatory Authority, is manufactured, packaged, labelled, imported, exported, stored, distributed, sold (whether or not for consideration), advertised and marketed in compliance with all such Applicable Laws, (except for immaterial non-compliance) as well as all material terms and conditions imposed in any Licenses and permits issued in respect of the Products.

 

(iv) None of the Loan Parties nor, to the knowledge of the Borrower, any officer, employee, contractor or agent of the Loan Parties has ever made an untrue statement of material fact or fraudulent statement to a Regulatory Authority or failed to disclose a material fact required to be disclosed to a Regulatory Authority, or committed any act, made any statement, or failed to make any statement, that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (September 10, 1991) or Health Canada or other Governmental Authority to invoke any similar policy or law.

 

38
 

 

(xxiv) No Loan Party has ever entered into a consent decree with the FDA, Health Canada or other Regulatory Authority or has been otherwise subject to a consent decree entered into by the FDA, Health Canada or other Governmental Authority.

 

(xxv) Except as set out in Schedule 7.1(kk), no Product has been recalled, withdrawn, suspended or discontinued (other than for commercial or business reasons), the subject of warnings, “dear doctor” letters, investigator notices, safety alerts, “serious adverse event” reports or other notice of action relating to an alleged lack of safety or regulatory compliance of any Products by any Loan Party at any time, any clinical investigator and/or other third party, and the Loan Parties have not received any information or report from any Governmental Authority, indicating that any of the Products, or ingredients therein, are unsafe or unsuitable for its intended use or pose an unacceptable health risk.

 

(xxvi) To the knowledge of Borrower after due inquiry, none of the Products or ingredients therein have been the subject of a warning, consumer alert or other cautionary statement issued by any Governmental Authority nor is there any ongoing complaint or investigation by any Governmental Authority relating to the advertising or marketing practices used for any Product. Other than as provided for in Schedule 7.1(kk), Borrower is not aware of any facts that would indicate that any Governmental Authority has or will prohibit or materially restrict the marketing, sale, distribution or use in the United States, Canada or Europe of any Product or the operation or use of any facility currently used to produce, manufacture or distribute the Products. Without limiting the foregoing, no Loan Party (i) has had any Product or manufacturing site subject to a Regulatory Authority (including Health Canada, FDA or the DEA) shutdown or import or export prohibition, (ii) has received any FDA Form 483 or other Regulatory Authority written notice of inspectional observations, “warning letters,” “untitled letters” or written requests or requirements to make changes to any Products or any Loan Party’s manufacturing facilities, processes or procedures (including, but not limited to, packaging and labeling) that if not complied with could, individually or in the aggregate, reasonably be expected to materially affect the Borrower, (iii) has received similar correspondence or notice from the FDA, DEA, Health Canada or other Regulatory Authority in respect of their respective Businesses alleging or asserting material noncompliance with any applicable Law, Material License or such requests or requirements of a Regulatory Authority, nor (iv) has received written notice from any applicable Regulatory Authority that such Regulatory Authority is conducting an investigation or review of any Material License or that such Permit has been revoked or withdrawn, nor has any such Regulatory Authority issued any order or recommendation stating that the development, testing, sale, marketing and/or manufacturing of such product should cease. As of the date hereof, to the knowledge of the Borrower or any of its Subsidiaries, neither the FDA, nor the DEA, Health Canada or any Governmental Authority is considering any such action described in this paragraph.

 

(xxvii) As of the date hereof, none of the Loan Parties or, to the knowledge of Borrower or any of its Subsidiaries, any of their respective officers, key employees or agents has been convicted of any crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under Applicable Law, including, without limitation, 21 U.S.C. Section 335a. No claims, actions, proceedings or investigations that would reasonably be expected to result in such a material debarment or exclusion are pending, or to the knowledge of Borrower or any of its Subsidiaries, threatened, against Borrower or its Subsidiaries or any of their respective officers, employees or agents.

 

39
 

 

(ix) Each Loan Party and each of their respective directors, officers, employees, and agents (while acting in such capacity) is, and at all times has been, in compliance with all health care Applicable Laws applicable to Borrower and its Subsidiaries or by which any or their respective properties, businesses (including the Business), Products or other assets is bound or affected, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Federal Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), all criminal laws relating to health care fraud and abuse including, without limitation, 18 U.S.C. §§ 286, 287, 1001 and 1347, the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. § 17921 et seq.), the Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h), the exclusion laws (42 U.S.C. § 1320a-7), the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), the Public Health Service Act (42 U.S.C. §§ 201 et seq.), the Medicare Program (Title XVIII of the Social Security Act), the Medicaid Program (Title XIX of the Social Security Act), the Controlled Substances Act (21 U.S.C. §§ 801 et seq.), the Criminal Code (Canada), the Corruption of Foreign Public Officials Act (Canada), the Personal Information Protection and Electronic Documents Act (Canada) and any other federal or provincial law regulating privacy of individually identifiable personal and personal health information, the Food and Drugs Act (Canada), the Controlled Drugs and Substances Act (Canada), the Consumer Packaging and Labelling Act (Canada), the Natural Health Products Regulations (Canada), the Medical Devices Regulations (Canada), the Ontario Drug Benefit Act (Ontario), the Drug Interchangeability and Dispensing Fee Act (Ontario) (“DIDFA”), and any similar law and all the regulations promulgated pursuant to all such laws, and any policy statement or written guidance document relating to all such laws, including, without limitation, the requirements for collection, reporting, and processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8) and any state, provincial or territorial supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the VA Federal Supply Schedule (38 U.S.C. § 8126) or under any state, provincial or territorial pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs (collectively, the “Health Care Laws”). None of Loan Parties have received any pending or threatened claim, suit, proceeding, hearing, enforcement, audit, investigation, arbitration or other action or any other notification, correspondence or written or oral communication from any Governmental Authority, including, without limitation, FDA, Health Canada, the Executive Officer appointed under DIDFA, DEA, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services Office of Inspector General, of potential or actual non-compliance by, or liability of, the Borrower or any of its Subsidiaries, under any Health Care Laws, in any such case which could reasonably be expected to have be material to the financial condition, property, assets, operations or business of any Loan Party, no Loan Party has engaged in activities which are, as applicable, cause for false claims liability, civil penalties or mandatory or permissive exclusion from Medicare, Medicaid or any other federal or state healthcare program. Borrower and its Subsidiaries have filed, obtained, maintained, and submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Law (“Filings”), and all such Filings were true, complete, correct and not misleading on the date filed and any necessary or required updates, changes, corrections or modification have been submitted. Neither Borrower nor any of its Subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement agreements, or similar agreements related to any Health Care Law imposed by any Governmental Authority. None of Borrower, its Subsidiaries, or their respective directors, officers, employees, and agents has been or is currently suspended or excluded from participation in any federal health care program (as defined in Section 1128B(f) of the Social Security Act).

 

40
 

 

(ll) None of the foregoing representations and warranties and no document furnished by or on behalf of Borrower or any other Loan Party to Lender in connection with the negotiation of the transactions contemplated by this Agreement contain any untrue statement of a material fact or omit to state any material fact necessary to make any such statement or representation (taken as a whole) not materially misleading at such time in light of the circumstances under which such information or data was furnished.

 

7.2 Survival of Representations and Warranties.

 

The Borrower, for itself and on behalf of the other Loan Parties, represents, warrants and covenants that all representations, warranties and covenants contained in this Agreement (whether appearing in Article 7 or elsewhere) shall be true, correct and complete at the time of the Borrower’s execution of this Agreement, shall survive the execution, delivery and acceptance hereof by the parties hereto and the closing of the transactions described herein or related hereto, shall, except for representations and warranties that relate solely to an earlier date, remain true, correct and complete until the indefeasible repayment and performance in full of all of the Obligations and termination of this Agreement.

 

ARTICLE 8 - SCHEDULES AND REPORTS

 

8.1 Financial Information.

 

The Borrower shall be subject to the following obligations with respect to the delivery or disclosure of financial information:

 

(a) the Borrower shall publicly-file copies of its internally prepared Consolidated Financial Statements as required by Applicable Law no later than forty-five (45) days after the end of the Borrower’s first three Fiscal Quarters each year,

 

41
 

 

(b) the Borrower shall publicly-file copies of its annual Consolidated Audited Financial Statements as required by Applicable Law no later than ninety (90) days after the end of each Fiscal Year,

 

(c) beginning with the 2018 Fiscal Year of the Borrower, no later than thirty (30) days prior to the commencement of each Fiscal Year of the Borrower, a copy of the Annual Business Plan (in form and substance satisfactory to Lender) approved by the board of directors of the Borrower, and, within twenty (20) days of any material modification thereto, a copy of the Annual Business Plan previously delivered, as modified; and

 

(d) The Borrower shall deliver to Lender copies of the Cash Balance Statements no later than twenty-five (25) days after the end of each calendar month.

 

8.2 Compliance Certificate.

 

The Borrower shall deliver to the Lender a Compliance Certificate (containing supporting calculations) confirming, inter alia, that it has maintained the financial covenants set forth in Section 9.1(z)(i) and 9.1(z)(iv) concurrently with the public filing of each Financial Statement filed pursuant to Sections 8.1(a) and 8.1(b) and, concurrently with the public filing of each Financial Statement filed pursuant to Section 8.1(b), commencing with the 2018 Fiscal Year of the Borrower, the Borrower shall also provide a comparison to the budget set forth in the Annual Business Plan and the previous year. Together with the Cash Balance Statement delivered pursuant to 8.1(d), the Borrower shall deliver to the Lender a Compliance Certificate (containing supporting calculations) confirming that it has maintained the financial covenants set forth in Section 9.1(z)(ii) and 9.1(z)(iii).

 

8.3 Other Matters.

 

At such times as may be requested by Lender from time to time hereafter, the Borrower shall deliver to Lender (i) without limiting Borrower’s obligations in Section 8.2 and 9.1(o), such additional schedules, certificates, reports and information with respect to the Collateral as Lender may from time to time reasonably require, including, but not limited to, non-consolidated Financial Statements of the Borrower; (ii) a collateral assignment of any or all items of property held by the Loan Parties, from time to time, to Lender or as Lender may direct in order to perfect and further establish the security interests in favour of Lender in such property in accordance with this Agreement (to the extent not otherwise previously perfected under a Loan Document). All schedules, certificates, reports and assignments and other items delivered by the Loan Parties to Lender hereunder shall be executed by an authorized representative of the Loan Parties, and shall be in such form and contain such information as Lender shall reasonably request. Lender, through its officers, employees or agents, shall have the right, upon reasonable notice at any time and from time to time in Lender’s name, in the name of a nominee of Lender or in Borrower’s name, to verify the validity, amount or any other matter relating to any of the Collateral, by mail, telephone, telegraph or otherwise. The Borrower shall reimburse Lender, on demand, for all reasonable receipted costs, fees and expenses incurred by Lender in this regard.

 

42
 

 

ARTICLE 9 - COVENANTS

 

9.1 Covenants.

 

Until indefeasible payment and performance in full of all Obligations and termination of this Agreement, unless the Borrower obtains the prior written consent of Lender waiving or modifying any covenants hereunder in any specific instance, the Borrower shall and shall cause each Loan Party to (as applicable):

 

(a) Timely Payment. Make due and timely payment of the Obligations required to be paid by it hereunder.

 

(b) Conduct of Business, Maintenance of Existence, Compliance with Laws. Carry on and conduct its business and operations in a proper, efficient and businesslike manner, in accordance with good business practice except for non-compliance which would not have a Material Adverse Effect; preserve, renew and keep in full force and effect its existence, will ensure that each Loan Party that is a Special Purpose Entity continues to maintain itself in all respects as a Special Purpose Entity, and take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business and to comply in all material respects with all Material Contracts, Material Licenses, material Licenses and Requirements of Law, including Health Care Law, Privacy Law, applicable consumer protection legislation and any other Applicable Law.

 

(c) Regulatory Compliance. Without limiting the generality of the foregoing (i) in connection with the development, testing, manufacture, marketing or sale of each and any Product by any Loan Party, such Loan Party shall comply fully and completely in all respects Material Licenses at all times issued by any Government Authority, specifically including the FDA and Health Canada, with respect to such development, testing, manufacture, marketing or sales of such Product by the Loan Parties as such activities are at any such time being conducted by the Loan Parties and (ii) the Loan Parties shall not permit any event or occurrence to occur or to take or to fail to take any action if the result of any of the forgoing would be that any of the representations and warranties set forth in Section 7.1(kk) to become untrue in any respect as of any date.

 

(d) Further Assurances. Provide Lender with such other documents, opinions, consents, acknowledgements and agreements as are reasonably necessary to implement this Agreement and the other Loan Documents from time to time.

 

(e) Access to Information. Promptly provide Lender with all information reasonably requested by Lender from time to time concerning its financial condition and Property, and during normal business hours and from time to time upon reasonable notice, permit representatives of Lender to inspect any of its Property and to examine and take extracts from its financial books, accounts and records including but not limited to accounts and records stored in computer data banks and computer software systems, and to discuss its financial affairs, its business or any part of its Property with its senior officers and (in the presence of such of its representatives as it may designate) its Auditor. Provided that a Default or Event of Default is then continuing (or Lender reasonably expects that that is the case), the Borrower will pay all reasonable expenses incurred by such representatives in order to visit Borrower’s premises or attend at the Borrower’s principal office, as applicable, for such purposes.

 

43
 

 

(f) Obligations and Taxes. Pay or discharge or cause to be paid or discharged, before the same shall become delinquent (i) all Taxes imposed upon it or upon its income or profits or in respect of its business or Property and file all tax returns in respect thereof; (ii) all lawful claims for labour, materials and supplies; (iii) all required payments under any of its Debt, and (iv) all other obligations; provided, however that it shall not be required to pay or discharge or to cause to be paid or discharged any such amount so long as the validity or amount thereof shall be contested in good faith by appropriate proceedings and, in the case of clause (i) above, an adequate reserve in accordance with GAAP has been established in its books and records.

 

(g) Use of Loan. Use the proceeds of the Third Tranche for general working capital for the Business and to fund Unfunded Qualified Acquisitions and use the proceeds of the Additional Tranches to fund Qualified Acquisitions.

 

(h) Insurance. Maintain or cause to be maintained with reputable insurers coverage against risk of loss or damage to its Property (including public liability and damage to property of third parties) and business interruption insurance of such types as is customary for and would be maintained by a corporation with an established reputation engaged in the same or similar business in similar locations and provide to Lender, as requested (acting reasonably), evidence of such coverage. The Borrower shall, prior to the expiry or replacement of any insurance policy, notify Lender of the replacement and at Lender’s request send copies of all replacement policies to Lender. Without limiting the generality of the foregoing, the Borrower will maintain product liability insurance covering at least $5,000,000 per claim and $5,000,000 in the aggregate. Without limiting the generality of the foregoing, the Borrower shall maintain in effect all insurance coverage reasonable and prudent for a business similar to the Business conducted in similar locations. Lender shall be indicated in all insurance policies, as applicable, as first loss payee and additional insured, and all policies shall contain such standard mortgage clauses as Lender shall reasonably require for Lender’s protection.

 

(i) Notice of Default or Event of Default. Promptly and, in any event within two (2) Business Days, notify Lender of any Default or Event of Default that would apply to it or to any Loan Party of which it becomes aware along with the action to be taken by such Loan Party to remedy any such Default or Event of Default.

 

(j) Notice of Material Adverse Effect. Promptly notify Lender of any Material Adverse Effect of which it becomes aware.

 

(k) Notice of Litigation. Promptly notify Lender on becoming aware of the occurrence of any litigation, dispute, arbitration, proceeding or other circumstance the result of which if determined adversely would or could reasonably be expected to result in (a) a judgment or award against a Loan Party in excess of $100,000 or (b) a Material Adverse Effect, and from time to time provide Lender with all reasonable information requested by it concerning the status of any such proceeding.

 

44
 

 

(l) Other Notices. Promptly, upon having knowledge, give notice to Lender of:

 

(i) any Loan Party becoming aware that any of the representations and warranties set forth herein are untrue in any material respect;

 

(ii) any notice of expropriation affecting any Loan Party;

 

(iii) any Action Request or Violation Notice;

 

(iv) any Data Breach;

 

(v) any Loan Party becoming subject to any administrative or regulatory action, inspection, Form FDA 483 observation, warning letter, notice of violation letter, or other notice, response or commitment made to or with the FDA, Health Canada or any comparable Governmental Authority, or any Product of any Loan Party being seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing, or the commencement of any proceedings in the United States, Canada or any other jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any Product are pending or threatened against the Loan Parties;

 

(vi) any violation of any Applicable Law, including Privacy Laws, Health Care Laws and consumer protection legislation;

 

(vii) any default under any Debt in a principal amount greater than $100,000 of any Loan Party;

 

(viii) any termination prior to maturity of or default under a Material Contract or any termination, lapse, rescission or default under a Material License;

 

(ix) any damage to or destruction of any Property, of any Loan Party having a replacement cost in excess of $100,000;

 

(x) the acquisition of any real property by any Loan Party;

 

(xi) the receipt of insurance proceeds by any Loan Party in excess of $100,000;

 

(xii) any Lien registered against any Property of any Loan Party, other than a Permitted Lien;

 

(xiii) the occurrence of any event referred to in Section 7.1(y);

 

(xiv) a Product being recalled, withdrawn, suspended or discontinued or is under consideration of being recalled, withdrawn, suspended or discontinued;

 

(xv) a Product or any Loan Party being the subject of a warning, consumer alert or other cautionary statement issued by any Governmental Authority;

 

45
 

 

(xvi) any information or report from any Governmental Authority, indicating that any of the Products are, unsafe or unsuitable for its intended use or pose an unacceptable health risk;

 

(xvii) any entering into of a Material Contract or Material License; and

 

(xviii) any material adverse change in, or material adverse amendment to, or termination of a Material Contract or Material License.

 

(m) Environmental Compliance. Operate its business in compliance with Requirements of Environmental Laws (except where the failure to do so would not have a Material Adverse Effect) and operate all Property owned, leased or otherwise used by it such that no obligation, including a clean-up or remedial obligation, will arise under any Requirements of Environmental Law; provided, however, that if any such claim is made or any such obligation arises, the Borrower shall, or shall cause the applicable Loan Party to, promptly satisfy, address or contest such claim or obligation at its own cost and expense. Borrower shall promptly notify Lender upon: (i) learning of the existence of any Materials of Environmental Concern located on, above or below the surface of any land which it owns, leases, operates, occupies or controls (except those being stored, used or otherwise handled in compliance with Requirements of Environmental Law), or contained in the soil or water constituting such land; and (ii) the occurrence of any reportable release, spill, leak, emission, discharge, leaching, dumping or disposal of Materials of Environmental Concern that has occurred on or from such land, which, in either the case of (i) or (ii), is likely to result in liability under Requirements of Environmental Law in excess of $100,000.

 

(n) Security. With respect to the Security:

 

(i) provide to Lender the Security required from time to time pursuant to Article 6 in accordance with the provisions of such Article, accompanied by supporting resolutions, certificates and opinions in form and substance satisfactory to Lender; and

 

(ii) do, execute and deliver all such things, documents, security, agreements and assurances as may from time to time be requested by Lender to ensure that Lender holds at all times valid, enforceable, perfected first-priority Liens (subject only to Permitted Liens) on the Collateral from the Loan Parties meeting the requirements of Article 6.

 

(o) Perfection Certificate. The Borrower shall provide Lender with an updated Perfection Certificate upon any material change to the information set forth therein and in any event at least once per calendar year.

 

(p) Maintenance of Property. Keep all Property useful and necessary in its business in good working order and condition, normal wear and tear excepted, and maintain all Intellectual Property necessary to carry on its business.

 

(q) Landlord Consents. Use its best commercial efforts to obtain, in favour of Lender, a consent agreement from a landlord of premises that are leased at any time and from time to time by Borrower.

 

46
 

 

(r) Material Contracts, Material Licenses and Material License Agreements. Ensure that any Material Contract, Material License and material License Agreement is assigned by way of security in favour of Lender by the applicable Loan Party and to obtain, in favour of Lender, if requested by Lender or if reasonably necessary for a valid assignment of or grant of a security interest in such Material Contract, Material License or material License Agreement, or for the enforcement by Lender of the Security with respect thereto following an Event of Default (including the transfer upon foreclosure to Lender or to third parties), an acknowledgement of a Person or Governmental Authority to such assignment.

 

(s) Employee Benefit and Welfare Plans. Maintain all employee benefit, Pension Plans and Welfare Plans relating to its business in compliance with all Applicable Laws except for immaterial non-compliance.

 

(t) Additional Information. Promptly provide Lender, after the sending or filing thereof, with copies of all reports, notices, prospectuses and registration statements which Borrower or any other Loan Party files with a securities commission or securities regulatory authority in any Province of Canada or any other securities commission.

 

(u) Material Contracts and Material Licenses. At the request of Lender from time to time, provide to Lender certified copies of all Material Contracts and Material Licenses.

 

(v) Regulatory Matters. Ensure that (i) all non-compliance (other than immaterial non-compliance) with regulatory matters as identified in Schedule 7.1(kk) is remedied within a reasonable period of time following the Closing Date, and (ii) all existing and future Products are licensed and/or registered, as applicable, in compliance with Applicable Laws.

 

(w) ERISA. Promptly pay and discharge all obligations and liabilities arising under ERISA of a character which if unpaid or unperformed could result in the imposition of a Lien other than a Permitted Lien against any of its Properties; promptly notify Lender of (i) the occurrence of any Reportable Event with respect to an ERISA Plan that could reasonably be expected to result in material liability, (ii) receipt of any notice from the PBGC of its intention to seek termination of any ERISA Plan or appointment of a trustee therefor, (iii) its intention to terminate or withdraw from any ERISA Plan or multiemployer plan that could reasonably be expected to result in material liability, and (iv) the occurrence of any event with respect to any ERISA Plan or multiemployer plan which would result in the incurrence by it or any Subsidiary of any material liability, fine or penalty, and (v) any material increase in its contingent liability with respect to any post-retirement Welfare Plan benefit.

 

(x) Patriot Act. In the case of Borrower, the Borrower acknowledges and agrees that pursuant to the provisions of the USA Patriot Act (Title III of the Pub. L. 107-56) signed into law October 26, 2001 (the “Patriot Act”) or any analogous or corresponding provision of applicable Australian law, Lender may be required to obtain, verify and record information with respect to Borrower; and the Borrower hereby agrees to cooperate with Lender and provide them with all information that may be required in order to fulfil their obligations under the Patriot Act; and without limiting the generality of the foregoing, the Borrower agrees to use commercially reasonable efforts to obtain the consent of any of their respective officers, directors and employees whose consent to the disclosure of any such information is required under applicable privacy legislation in Canada.

 

47
 

 

(y) Books and Records. At all times keep accurate and complete books, records and accounts with respect to all of its business activities, in accordance with sound accounting practices and, where applicable, GAAP consistently applied, and shall keep such books, records and accounts, and any copies thereof, only at the addresses indicated for such purpose on Schedule 7.1(s).

 

(  ) Financial Covenants.

 

(i) Minimum EBITDA. The Borrower shall maintain a minimum EBITDA of Five Million Dollars ($5,000,000) for the twelve (12) months ending on September 30, 2017 and for the twelve (12) month period ending on the last day of each Fiscal Quarter thereafter, provided that the minimum EBITDA amount shall be increased by an amount equal to 50% of any Additional Tranche advanced to Borrower hereunder.

 

(ii) Net Debt to TTM EBITDA Ratio. At all times, the Borrower shall maintain a Net Debt to TTM EBITDA Ratio of no more than 6:1.

 

(iii) Cash Balance. The Borrower will maintain at all times a minimum positive cash balance equal to (i) One Million Dollars ($1,000,000), if the aggregate principal amount of the Third Tranche and all Additional Tranches advanced to Borrower hereunder (whether or not then outstanding) is below $15,000,000, (ii) or Two Million Dollars ($2,000,000), if the aggregate principal amount of the Third Tranche and all Additional Tranches advanced to Borrower hereunder (whether or not then outstanding) is $15,000,000 or above, and shall prepare a statement in accordance with GAAP setting forth the aggregate amount of cash and cash equivalents held by the Borrower, which statement shall be certified by the Chief Executive Officer and Chief Financial Officer of the Borrower (the “Cash Balance Statement”).

 

(iv) Minimum Revenues. The Borrower will maintain minimum Consolidated gross income of Twenty Million Dollars ($20,000,000) for the twelve (12) months ending on September 30, 2017 and for the twelve (12) month period ending on the last day of each Fiscal Quarter thereafter, provided that the required minimum Consolidated gross income amount shall be increased by an amount equal to 200% of any Additional Tranche advanced to Borrower hereunder (whether or not then outstanding).

 

(aa) Observer Rights. Until the repayment and performance in full of all of the Obligations and the termination of this Agreement Lender shall be entitled to designate one individual (the “Lender’s Nominee”), to be an observer to the Borrower’s board of directors (the “Board”), and so long as Lender’s Nominee serves as an observer of the Board, to observe the Board’s Audit and Compensation Committee.

 

48
 

 

9.2 Negative Covenants.

 

So long as this Agreement is in force and except as otherwise permitted by the prior written consent of Lender, the Borrower shall not and shall ensure that the Loan Parties (individually or collectively) shall not:

 

(a) Disposition of Property. Except for Permitted Dispositions, dispose of, in one transaction or a series of transactions, all or any part of its Property, whether now owned or hereafter acquired.

 

(b) No Consolidation, Amalgamation, Merger, etc. Consolidate, amalgamate or merge with any other Person, export a corporation into a jurisdiction outside of the United States, enter into any corporate reorganization or other transaction intended to effect or otherwise permit a change in its existing corporate or capital structure, liquidate, wind-up or dissolve itself, or permit any liquidation, winding-up or dissolution unless prior written approval has been received by Lender and such documentation as is required by counsel to Lender is delivered concurrently with such transaction.

 

(c) No Change of Name. Change its name or change its jurisdiction of incorporation or formation in each case without providing Lender with fifteen (15) days’ prior written notice thereof.

 

(d) No Debt. Create, incur, assume or permit any Debt to remain outstanding, other than Permitted Debt.

 

(e) Operating Leases. Create, incur, assume or permit obligations outstanding in respect to operating leases (which, for greater certainty, does not include leases of real property) such that the aggregate annual payments due on such leases exceeds $250,000.

 

(f) No Distributions. Make any Distribution except Permitted Distributions.

 

(g) No Lien. Create, incur, assume or permit to exist any Lien upon any of its Property except a Permitted Lien.

 

(h) Acquisitions. Make any Acquisitions except:

 

(a) provided that no Event of Default has occurred and is continuing (or would result from such Acquisition), an Acquisition of any other Person or of all or part of the Property of any other Person or of all or part of any division, business, operation or undertaking of any other Person where the business of such Person is the same or substantially the same as, similar, complementary or related to, the Business and the aggregate consideration payable in respect of such Acquisition (including, without limitation, any deferred consideration) is not more than $100,000, and further provided that any Person acquired becomes a guarantor (and a “Loan Party”) hereunder and otherwise complies with Section 9.2(r)) and any property acquired pursuant to such Acquisition becomes Collateral subject to the Security (including, without limitation, any shares of any Subsidiary); or

 

49
 

 

(ii) exercise of the Borrower’s right to repurchase Lender Option as permitted under Lender Option; or

 

(iii) a Qualified Acquisition that is financed by the Lender pursuant to an Additional Tranche in accordance with Section 2.2 or a third party financing in accordance with Section 2.2(d), or

 

(iv) subject to the written consent of the Lender (not to be unreasonably withheld), Unfunded Qualified Acquisitions, provided that the aggregate value of the consideration payable for all Unfunded Qualified Acquisitions in the 365 days preceding any Unfunded Qualified Acquisition (including, for certainty, consideration payable for the proposed Unfunded Qualified Acquisition) fifty percent (50%) or less of TTM EBITDA.

 

(i) No Change to Year End. Make any change to its Fiscal Year.

 

(j) Location of Assets in Other Jurisdictions. Except for any Property in transit in the ordinary course of business, acquire any Property outside of the jurisdictions identified in Schedule 7.1(s) or move any Property from one jurisdiction to another jurisdiction where the movement of such Property would cause the Lien of the Security over such Property to cease to be perfected under Applicable Law, or suffer or permit in any other manner any of its Property to not be subject to the Lien of the Security or to be or become located in a jurisdiction as a result of which the Lien of Security over such Property is not perfected, unless (i) Borrower has first given thirty (30) days’ prior written notice thereof to Lender, and (ii) the applicable Loan Party has first executed and delivered to Lender all Security and all financing or registration statements in form and substance satisfactory to Lender which Lender or its counsel, acting reasonably, from time to time deem necessary or advisable to ensure that the Security at all times constitutes a perfected first-priority Lien (subject only to Permitted Liens) over such Property notwithstanding the movement or location of such Property as aforesaid together with such supporting certificates, resolutions, opinions and other documents as Lender may deem necessary or desirable in connection with such security and registrations.

 

(k) Amendments to Organizational Documents. Amend any of its Organizational Documents in a manner that would be prejudicial to the interests of Lender under the Loan Documents.

 

(l) Amendments to other Documents. Amend, vary or alter any Material Contract, Material License or material License Agreement or any other contract or agreement in any manner which could reasonably be expected to be material to the financial condition, property, assets, operations or business of any Loan Party.

 

(m) Non-Arm’s Length Transactions. Except as contemplated by Section 9.2(f), effect any transactions with any Person not dealing at Arm’s Length unless such transaction is on market terms and consistent with transactions with Persons at Arm’s Length.

 

(n) Employment Arrangements. Without limiting anything else set forth herein or in any other Loan Document, not (i) enter into any one or more Employment Arrangement with any Person where after the entering into of such Employment Arrangement(s) the aggregate base compensation payable to such Person by the Borrower and the Subsidiaries is more than $500,000 per Fiscal Year, or (ii) increase the compensation payable (directly or indirectly) to any Person pursuant to any Employment Arrangement(s), or make any other changes to any Employment Arrangement(s), where the aggregate base compensation payable (directly or indirectly) to any Person by the Borrower and the Subsidiaries after such increase or change will be more than $500,000 per Fiscal Year (including, for certainty, increases to the base compensation payable where the amount payable prior to any increase or change is already above $500,000 per Fiscal Year), in each case without the prior written consent of the Lender, such consent not to be unreasonably withheld.

 

50
 

 

(o) Sale and Leaseback. Enter into any arrangement with any Person providing for the leasing by any Loan Party, as lessee, of Property which has been or is to be sold or transferred by such Loan Party to such Person or to any other Person to whom funds have been or are to be advanced by such Person on the security of such Property or the lease obligation of such Loan Party.

 

(p) Employee Loans. Make any loans or advances to an employee of any Loan Party other than loans in an aggregate amount (for all Loan Parties) not to exceed $100,000 provided that such loans are used to purchase Equity Interests in Borrower and at the time of the loan no Default or Event of Default exists.

 

(q) Deposit Accounts and Securities Accounts. The Loan Parties will not have any Permitted Cash Investments, cash or Equity Interests in any single Deposit Account or Securities Account located in the United States, Canada or any other jurisdiction where security interests in such accounts can be perfected by agreement (other than payroll accounts), where the balance in such Deposit Account or Securities Account is in excess of $100,000 at any one time unless such Loan Party and the applicable securities intermediary or deposit-taking institution have entered into a Control Agreement or similar agreement governing such Deposit Account or Securities Account in order to perfect (and further establish) the security interests in favour of Lender under the Security Documents in such Permitted Cash Investments, cash or Equity Interests, except that (i) in the case of any Permitted Cash Investments, cash or Equity Interests in any single Deposit Account or Securities Account in existence on the Closing Date, such Loan Party will within sixty (60) days of the Closing Date enter into a Control Agreement or similar agreement governing such Deposit Account or Securities Account in order to perfect (and further establish) the security interests in favour of Lender under the Security Documents in such Permitted Cash Investments, cash or Equity Interests; and (ii) the requirements of this proviso will not apply to any Deposit Account or Securities Account that is required in connection with a Qualified Acquisition until sixty (60) days following the date such acquisition is consummated. The aggregate amount of all Permitted Cash Investments, cash and Equity Interests in all Deposit Accounts and all Securities Accounts owned by the Loan Parties for which a Control Agreement has not been delivered shall not exceed $200,000 at any time. Notwithstanding the foregoing, the proceeds of the Third Tranche advanced by the Lender on the Closing Date and any Additional Tranches advanced thereafter shall be immediately deposited in and at all times thereafter held only in Deposit Accounts that are subject to Control Agreements and, for certainty, the transfer of all or any portion of the proceeds of the Third Tranche or any Additional Tranches to any other Deposit Account at any time shall constitute an Event of Default hereunder.

 

51
 

 

(r) New Subsidiaries. Create or acquire any Subsidiary after the date of this Agreement (other than Special Purpose Entities otherwise permitted hereunder), including in respect of any Subsidiaries acquired as part of an Acquisition permitted under this Agreement, unless: (i) such Subsidiary exists pursuant to the laws of a state of the United States of America or of a province of Canada; (ii) all of the issued and outstanding Equity Interests of such Subsidiary is owned by a Loan Party and pledged to the Lender as security for the Obligations; (iii) such new Subsidiary provides a legal, valid and enforceable guarantee in favour of Lender and first-ranking security in all relevant jurisdictions; supported in each case by appropriate certificates, estoppels, consents, corporate deliverables and legal opinions, the whole in form and substance satisfactory to Lender.

 

(s) Capital Expenditures. Without prior written consent of Lender, which consent will not be unreasonably withheld, the Loan Parties may not make any Capital Expenditures which exceed in any Fiscal Year an aggregate of $500,000.

 

(t) Compensation. Make any material changes to employee or management compensation practices other than changes which are customary and reasonable in a business similar to the Business.

 

9.3 Entitled to Perform Covenants.

 

If any of the Loan Parties fails to perform any covenant contained in this Article 9, or in any other provision hereof or of any of the other Loan Documents, Lender may perform in any manner deemed fit by it without thereby waiving any rights to enforce this Agreement or the other Loan Documents, any such covenant capable of being performed by it and if any such covenant requires the payment of money, Lender may make such payments. All sums so expended by Lender shall be deemed to form part of the Obligations, shall bear interest at the same rate as the Loan and shall be payable by the Borrower on demand.

 

ARTICLE 10 - CONDITIONS PRECEDENT

 

10.1 Conditions Precedent to Loan.

 

The effectiveness of this Agreement and Lender’s obligation to fund the Third Tranche amount shall be subject to the following conditions precedent having been met to the satisfaction of Lender, or, alternatively, waived in writing by Lender:

 

(a) this Agreement shall have been executed and delivered by all parties hereto;

 

(b) the Loan Parties shall have executed and delivered to Lender the Loan Documents to which each is a party including, without limitation, the Security Documents;

 

(c) Lender shall have received certified copies of the Organizational Documents of the Loan Parties, the resolutions authorizing the execution, delivery and performance of the Loan Parties’ respective obligations under the Loan Documents to which they are a party and the transactions contemplated therein, and the incumbency of the officers of each Loan Party;

 

52
 

 

(d) copies of all shareholder, limited liability and partnership agreements, if any, applicable to the Loan Parties, certified by Borrower to be true, shall have been delivered to Lender’s satisfaction;

 

(e) certificates of status or good standing, as applicable, for all relevant jurisdictions of each Loan Party shall have been delivered to Lender;

 

(f) Borrower shall be in compliance in all material respects with all (if any) Material Contracts and Material Licenses to the satisfaction of Lender and copies of all Material Contracts and Material Licenses if any, applicable to Borrower, shall have been delivered to Lender;

 

(g) evidence of repayment in full of all Debt that is not Permitted Debt owing by the Loan Parties to any third party lenders to the Loan Parties concurrent with the Loan shall have been delivered to Lender;

 

(h) releases, discharges, estoppels and postponements with respect to all Liens which are not Permitted Liens, if any, shall have been delivered to Lender;

 

(i) payment of all amounts and fees payable to Lender;

 

(j) duly executed copies of the Security shall have been delivered to Lender and such financing statements or other registrations of such Security, or notice thereof, shall have been filed, registered, entered or recorded in all offices of public record necessary or desirable in the opinion of Lender to preserve or protect the charges and security interests created thereby;

 

(k) the share certificates of the Subsidiaries pledged in favour of the Lender pursuant to the Security Documents shall have been delivered to the Lender, duly endorsed in blank (to be delivered within 10 days of the Closing Date);

 

(l) a letter of opinion of counsel to the Borrower along with the opinions of local counsel for Borrower shall have been delivered to Lender. Such opinions shall, amongst other things, confirm that the existing Security and any additional Security delivered in connection with the Loan is first ranking security in favour of Lender in respect to all of the Obligations;

 

(m) the Borrower shall have delivered to Lender certificates of insurance acceptable to Lender showing, inter alia, Lender as a first loss payee as its interest may appear on all insurance policies that insure the assets to be secured by the Security;

 

(n) no Default or Event of Default has occurred and is continuing on the Closing Date or would result from making the Third Tranche;

 

(o) all representations and warranties made by the Loan Parties in the Loan Documents are true and correct in all material respects;

 

(p) no Material Adverse Effect has occurred;

 

53
 

 

(q) all outstanding obligations following the acquisitions of Nomad and FNL have been satisfied;

 

(r) Lender shall have received such additional evidence, documents or undertakings as Lender shall reasonably request to establish the consummation of the transactions contemplated hereby and be satisfied, acting reasonably, as to the taking of all proceedings in connection herewith in compliance with the conditions set forth in this Agreement;

 

(s) Lender shall have completed all due diligence which it considers necessary or appropriate in its discretion in regard to the Loan Parties and their Property, books and records, operations, prospects and condition (financial or otherwise), including, without limitation, in regards to past and ongoing compliance with Applicable Laws (including Environmental Laws), union and labour relations and pension matters;

 

(t) Lender shall have received a duly completed Perfection Certificate with respect to all of the Loan Parties; and

 

(u) Lender shall have received the Origination Fee (Section 4.6) and the Work Fee (Section 4.7).

 

10.2 Additional Condition Precedent to Loan in favour of Borrower

 

At the request of the Borrower, and as a condition precedent to the effectiveness of the Borrower’s obligations hereunder (unless waived by the Borrower), the Lender shall have executed and delivered the Irrevocable Proxy to be dated as of the date hereof with respect to the common shares of the Borrower, duly countersigned by the Chief Executive Officer of the Borrower.

 

ARTICLE 11 – EVENTS OF DEFAULT

 

11.1 Events of Default.

 

The occurrence of any one or more of the following events shall constitute an “Event of Default” hereunder:

 

(a) the failure of the Borrower to pay any principal hereunder when due; or

 

(b) the failure of the Borrower or any other Loan Party to pay any interest or other Obligations (other than principal hereunder) when due, which failure continues unremedied for three (3) Business Days; or

 

(c) the failure of (i) Borrower or any other Loan Party to perform, keep or observe in a material respect any of the financial covenants in Section 9.1(z) of this Agreement, (ii) a Loan Party to perform, keep or observe any of the other covenants, conditions, promises, agreements or obligations under this Agreement (other than as described in Sections 11.1(a) and (b) and other than those covenants, conditions, promises, agreements or obligations referred to in (i) above) or in any of the Loan Documents, in each case which failure is not cured within thirty (30) days of receipt of written notice from Lender of such failure; or

 

54
 

 

(d) the making or furnishing by a Loan Party or any director or officer thereof to Lender of any representation, warranty, certificate, schedule, report or other communication of a material nature within or in connection with this Agreement or the Loan Documents, which is untrue or misleading in any material respect when made; provided that, no Event of Default under this Section 11.1(d) will occur if such representation, warranty or other communication was not intentionally untrue or misleading, is capable of being corrected within thirty (30) days of being made and is diligently corrected within such thirty (30) day period; or

 

(e) if a Loan Party ceases or threatens to cease to carry on business generally or admits it inability or fails to pay its debts generally; or

 

(f) if (i) the Debt under any subordinated loan agreement is accelerated by lender thereunder, (ii) a Loan Party fails to make any payment when such payment is due and payable to any Person in relation to any indebtedness for borrowed money or other indebtedness or liabilities arising in respect of any other Debt which in the aggregate principal amount then outstanding is in excess of $100,000 and such payment is not made within any applicable cure or grace period; or (iii) a Loan Party defaults in the observance or performance of any other agreement or condition in relation to any such indebtedness to any Person which in the aggregate principal amount then outstanding is in excess of $100,000 or contained in any instrument or agreement evidencing, securing or relating thereto and such default is not waived or cured within any applicable cure or grace period; or

 

(g) if a Loan Party denies its obligations under any Loan Document or claims any of the Loan Documents to be invalid or withdrawn in whole or in part; or

 

(h) any of the Loan Documents or any material provision of any of them becomes unenforceable, unlawful or is changed by virtue of legislation or by a court, statutory board or commission, in each case in a manner that is adverse to Lender, if a Loan Party does not, within fifteen (15) Business Days of receipt of notice of such Loan Document or material provision becoming unenforceable, unlawful or being changed and being provided with any required new agreement or amendment for execution by Lender (acting reasonably), replace such Loan Document with a new agreement that is in form and substance satisfactory to Lender or amend such Loan Document to the satisfaction of Lender; or

 

(i) if a decree or order of a court of competent jurisdiction is entered adjudging a Loan Party a bankrupt or insolvent or approving a petition seeking the winding-up of a Loan Party under the United States Bankruptcy Code, the Companies’ Creditors Arrangement Act (Canada), the Bankruptcy and Insolvency Act (Canada) or any other bankruptcy, insolvency or analogous laws, including any analogous or corresponding provision of applicable Australian law, or issuing sequestration or process of execution against any substantial part of the Property of a Loan Party or ordering the winding up or liquidation of its affairs; or

 

(j) if a Loan Party becomes insolvent, makes any assignment in bankruptcy or makes any other similar assignment for the benefit of creditors, makes any proposal under the United States Bankruptcy Code, the Companies’ Creditors Arrangement Act (Canada), the Bankruptcy and Insolvency Act (Canada), the Corporations Act 2001 (Cth) or any comparable law, including any analogous or corresponding provision of applicable Australian law, seeks relief under any other bankruptcy, insolvency or analogous law, is adjudged bankrupt, files a petition or proposal to take advantage of any act of insolvency, consents to or acquiesces in the appointment of a trustee, receiver, receiver and manager, interim receiver, custodian, sequestrator or other Person with similar powers of itself or of all or any substantial portion of its assets, or files a petition or otherwise commences any proceeding seeking any reorganization, arrangement, composition or readjustment under any applicable bankruptcy, insolvency, moratorium, reorganization or other similar law affecting creditors’ rights or consents to, or acquiesces in, the filing of such a petition; or

 

55
 

 

(k) if any proceeding or filing shall be instituted or made against a Loan Party seeking to have an order for relief entered against a Loan Party as debtor or to adjudicate it bankrupt or insolvent, or seeking liquidation, winding-up, reorganization, arrangement, adjustment or composition under any law relating to bankruptcy, insolvency, reorganization or relief or debtors (including, without limitation, the United States Bankruptcy Code the Companies’ Creditors Arrangement Act (Canada), the Bankruptcy and Insolvency Act (Canada), the Corporations Act 2001 (Cth) or any comparable law, including any analogous or corresponding provision of applicable Australian law) or seeking appointment of a receiver, trustee, custodian or other similar official for a Loan Party and the Winding-Up and Restructuring Act (Canada) or for any substantial part of its properties or assets unless the same is being contested actively and diligently in good faith by appropriate and timely proceedings and is dismissed, vacated or permanently stayed within thirty (30) days of institution; or

 

(l) if a Person takes possession by appointment of a receiver, receiver and manager, or otherwise of any material portion of the Property of a Loan Party; or

 

(m) if a final judgment, execution, writ of seizure and sale, sequestration or decree for the payment of money due shall have been obtained or entered against a Loan Party in an amount in excess of $100,000 and such judgment, execution, writ of seizure and sale, sequestration or decree shall not have been and remain vacated, satisfied, discharged or stayed pending appeal within the applicable appeal period; or

 

(n) if any of the Security shall cease to be a valid and perfected first-priority security interest subject only to Permitted Liens and the Borrower or the applicable Loan Party shall have failed to remedy such default within fifteen (15) Business Days of the Borrower becoming aware of such fact; or

 

(o) if an event of default occurs under any Material Contract or Material License of Borrower and which is committed by a Loan Party (other than an event of default specifically dealt with in this Section) and such event of default has or would reasonably be expected to have a Material Adverse Effect and is not remedied within fifteen (15) days after the Borrower becomes aware of such event of default; or

 

(p) if any of the following events shall occur with respect to any Pension Plan:

 

(i) the institution of any steps by a Loan Party or any member of its Controlled Group or any applicable regulatory authority to terminate a Pension Plan (wholly or in part) if, as a result of such termination, a Loan Party may be required to make an additional contribution to such Pension Plan, or to incur an additional liability or obligation to such Pension Plan or ERISA Plan, equal to or in excess of $100,000 or the equivalent thereof in another currency; or

 

56
 

 

(ii) any Reportable Event or Prohibited Transaction occurs; or

 

(iii) a contribution failure occurs with respect to any ERISA Plan maintained by a Loan Party or any member of its Controlled Group sufficient to give rise to a lien or charge under Section 302(f) of ERISA or under any applicable pension benefits legislation in any other jurisdiction; or

 

(q) if a Change of Control occurs; or

 

(r) all or any material part of the Property of a Loan Party shall be nationalized, expropriated or condemned, seized or otherwise appropriated, or custody or control of such Property of a Loan Party shall be assumed by any Governmental Authority or any court of competent jurisdiction at the instance of any Governmental Authority, in each case which has or would reasonably be expected to have a Material Adverse Effect except where contested in good faith by proper proceedings diligently pursued where a stay of enforcement is in effect; or

 

(s) if any order is made by any Governmental Authority in relation to the Borrower, or there is any change of law, or the interpretation or administration therefore, in each case, which in the reasonable opinion of Lender, operates to prevent or restrict the trading of the common shares of the Borrower.

 

11.2 Acceleration and Termination of Rights.

 

If any Event of Default shall occur and be continuing, all Obligations owing by the Borrower under the Loan Documents shall, at the option of Lender, become immediately due and payable, all without notice, presentment, protest, demand, notice of dishonour or any other demand or notice whatsoever, all of which are hereby expressly waived by Borrower; provided, if any Event of Default described in Section 11.1(e), 11.1(i) through 11.1(k) with respect to the Loan Parties shall occur, the outstanding principal amount of the Loan and all other Obligations shall automatically be and become immediately due and payable. In such event Lender may, in its discretion, exercise any right or recourse and/or proceed by any action, suit, remedy or proceeding against the Loan Parties authorized or permitted by law for the recovery of all the Obligations of the Loan Parties to Lender and proceed to exercise any and all rights hereunder and under the Security and no such remedy for the enforcement of the rights of Lender shall be exclusive of or dependent on any other remedy but any one or more of such remedies may from time to time be exercised independently or in combination.

 

11.3 Remedies Cumulative and Waivers.

 

For greater certainty, it is expressly understood and agreed that the rights and remedies of Lender hereunder or under any other Loan Document or instrument executed pursuant to this Agreement are cumulative and are in addition to and not in substitution for any rights or remedies provided by law or by equity; and any single or partial exercise by Lender of any right or remedy for a default or breach of any term, covenant, condition or agreement contained in this Agreement or any other Loan Document shall not be deemed to be a waiver of or to alter, affect or prejudice any other right or remedy or other rights or remedies to which Lender may be lawfully entitled for such default or breach. Any waiver by Lender of the strict observance, performance or compliance with any term, covenant, condition or other matter contained herein and any indulgence granted, either expressly or by course of conduct, by Lender shall be effective only in the specific instance and for the purpose for which it was given and shall be deemed not to be a waiver of any rights and remedies of Lender under this Agreement or any other Loan Document as a result of any other default or breach hereunder or thereunder.

 

57
 

 

11.4 Saving.

 

Lender shall not be under any obligation to the Loan Parties or any other Person to realize any Collateral or enforce the Security or any part thereof or to allow any of the Collateral to be sold, dealt with or otherwise disposed of. Lender shall not be responsible or liable to the Loan Parties or any other Person for any loss or damage upon the realization or enforcement of, the failure to realize or enforce the Collateral or any part thereof or the failure to allow any of the Collateral to be sold, dealt with or otherwise disposed of or for any act or omission on their respective parts or on the part of any director, officer, agent, servant or adviser in connection with any of the foregoing, except that Lender may be responsible or liable for any loss or damage arising from the wilful misconduct or gross negligence of Lender.

 

11.5 Third Parties.

 

No Person dealing with Lender or any agent of Lender shall be required to inquire whether the Security has become enforceable, or whether the powers which Lender is purporting to exercise have been exercisable, or whether any Obligations remain outstanding upon the security thereof, or as to the necessity or expediency of the stipulations and conditions subject to which any sale shall be made, or otherwise as to the propriety or regularity of any sale or other disposition or any other dealing with the Collateral charged by such Security or any part thereof.

 

11.6 Set-Off or Compensation.

 

In addition to and not in limitation of any rights now or hereafter granted under Applicable Law, if repayment is accelerated pursuant to Section 11.2, Lender may at any time and from time to time without notice to the Borrower or any other Loan Party or any other Person, any notice being expressly waived by the Borrower or any Loan Party, set-off and compensate and apply any and all deposits, general or special, time or demand, provisional or final, matured or unmatured, and any other indebtedness at any time owing by Lender, to or for the credit of or the account of the Borrower, against and on account of the Obligations notwithstanding that any of them are contingent or unmatured.

 

58
 

 

ARTICLE 12 - INDEMNIFICATION, ETC.

 

12.1 General Indemnity.

 

The Borrower agrees to (and to cause the other Loan Parties to) defend (with counsel satisfactory to Lender), protect, indemnify and hold harmless Lender, and each of its Affiliates, and Subsidiaries, and its respective officers, directors, employees, legal counsel and agents (each an “Indemnified Party”) from and against any and all obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature (including, without limitation, the disbursements and the fees (on a solicitor-client basis) of one legal counsel (unless it would be inappropriate for one counsel to represent all Indemnified Parties due to a conflict of interest or otherwise in which case, all legal counsel for each Indemnified Party) in connection with any investigative, administrative or judicial proceedings, whether or not any Indemnified Party shall be designated a party thereto), (collectively, “Losses”) which may be imposed on, incurred by, or asserted against, any Indemnified Party (whether direct, indirect or consequential and whether based on any federal, provincial, state or local laws or regulations, including, without limitation, securities, environmental and commercial laws and regulations, under common law or in equity, or based on contract or otherwise) in any manner relating to or arising out of this Agreement or any other Loan Document, or any act, event or transaction related or attendant thereto, the making and/or the management of the Loan or the use or intended use of the proceeds of the Loan; provided, however that the Borrower shall have no obligation hereunder to any Indemnified Party to the extent that such Losses were caused by or resulted from the wilful misconduct or gross negligence of such Indemnified Party. To the extent that the undertaking to indemnify set forth in the preceding sentence may be unenforceable against the Borrower because it violates any law or public policy, the Borrower shall satisfy such undertaking to the maximum extent permitted by Applicable Law. Any Losses covered by this indemnity shall be paid to each Indemnified Party on demand, and, failing prompt payment, shall, together with interest thereon at the Deemed Interest Rate from the date incurred by each Indemnified Party until paid in full, be added to the Obligations and be secured by the Collateral. The provisions of this Section 12.1 shall survive the satisfaction and payment of all Obligations and the termination of this Agreement.

 

12.2 Taxes.

 

All payments made by any other Loan Party under this Agreement and the Loan Documents shall be made free and clear of, and without deduction or withholding for or on account of, any present or future income, stamp or other taxes, levies, assessments, imposts, deductions, charges, or withholdings imposed by any foreign, federal, provincial, state, local or other jurisdiction or any Governmental Authority thereof or political subdivision or taxing authority therein, excluding taxes imposed on the net income or the capital of Lender (all such non-excluded taxes being hereinafter called “Taxes”). If any Taxes are required to be withheld from any amounts so payable to Lender hereunder or under any Loan Documents the amounts so payable shall be increased to the extent necessary to yield to the recipient (after payment of all Taxes) interest or any such other amounts payable hereunder at the rates or in the amounts specified in this Agreement or any other Loan Documents. If the Borrower is required by Applicable Law to make any deduction or withholding on account of any Taxes or other amount from any sum paid or expressed to be payable to Lender under this Agreement or any other Loan Document, then: (i) such Loan Party shall notify Lender of any such requirement or any change in any such requirement as soon as it becomes aware of it; (ii) such Loan Party shall pay any such Taxes or other amount before the date on which penalties attached thereto become due and payable; (iii) the sum payable by the Borrower in respect of which the relevant deduction, withholding or payment is required shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding or payment, the recipient receives on the due date and retains (free from any liability in respect of any such deduction, withholding or payment) a sum equal to that which it would have received and so retained had no such deduction, withholding or payment been required or made; and (iv) within thirty (30) days after payment of any sum from which the Borrower is required by Applicable Law to make any deduction or withholding, and within thirty (30) days after the due date of payment of any Taxes or other amount which it is required by clause (ii) above to pay, it shall deliver to Lender all such certified documents and other evidence as to the making of such deduction, withholding or payment as (A) are reasonably satisfactory to Lender as proof of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other authority and (B) are reasonably required by Lender to enable it to claim a tax credit with respect to such deduction, withholding or payment. If a Loan Party fails to pay any Taxes when due to the appropriate taxing authority, such Loan Party shall indemnify Lender for any incremental taxes, interest or penalties that may become payable by Lender as a result of any such failure. The provisions of this Section 12.2 shall survive the satisfaction and payment of all Obligations and the termination of this Agreement.

 

59
 

 

ARTICLE 13 - GENERAL PROVISIONS

 

13.1 Notice.

 

Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 13.1. Notices and other communications shall be addressed as follows:

 

  (a) if to the Borrower:

 

Synergy CHC Corp.

c/o Jack Ross

865 Spring Street

Westbrook, Maine 04092

Fax:

  E-mail: jack.ross@purebrands.ca

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

  Attention: W. David Mannheim, Esq.
  Fax No. (919) 781-4865
  E-mail: dmannheim@wyrick.com

 

60
 

 

  (b) if to Lender:

 

Knight Therapeutics (Barbados) Inc.

The Business Center

Upton, St. Michael

BB11103

Barbados, WI

  Attention: Michel Loustric, President
  E-mail mloustric@gudknight.com

 

with a copy to:

 

Knight Therapeutics Inc.

3400 De Maisonneuve W., Suite 1055

Montreal Quebec

Canada H3Z 3B8

  Attention: Samira Sakhia, President
  E-mail ssakhia@gud-knight.com

 

and with a copy to:

 

Davies Ward Phillips & Vineberg LLP

900 Third Avenue

24th Floor

New York, NY 10022

U.S.A.

  Attention: Dan Wolfensohn
  Telecopier: (212) 308-0132
  E-mail dwolfensohn@dwpv.com

 

13.2 Choice of Governing Law and Construction.

 

Except as expressly set forth therein, pursuant to Section 5-1401 of the New York General Obligations Law, this Agreement and the other Loan Documents (unless expressly stated otherwise in the other Loan Documents) shall be governed by the laws of the State of New York therein as to interpretation, enforcement, validity, construction, effect, and in all other respects, including, without limitation, the legality of the interest rate and other charges, but excluding perfection and realization of the security interests and hypothecs in the Collateral, which shall be governed and controlled by the laws of the relevant jurisdiction.

 

13.3 Attornment.

 

Pursuant to Section 5-1402 of the New York General Obligations Law, the parties hereto irrevocably submit and attorn to the non-exclusive jurisdiction of the courts of the State of New York for all matters arising out of, or in connection with, this Agreement and the other Loan Documents.

 

61
 

 

13.4 Press Releases.

 

Each party hereto agrees that it will promptly provide the other party with drafts of any press releases relating to the subject matter hereof, including the entering into of this Agreement, for review and comment prior to the issuance thereof, such review and comments not to be unreasonably withheld or delayed.

 

13.5 Modification and Benefit of Agreement.

 

This Agreement and the other Loan Documents may not be modified, altered or amended except by an agreement in writing signed by the Borrower and Lender. The Borrower may not sell, assign or transfer this Agreement, or the other Loan Documents or any portion thereof including, without limitation, the Borrower’s right, title, interest, remedies, powers or duties thereunder. The sale, assignment, transfer or other disposition by Lender, at any time and from time to time hereafter, of this Agreement, or the other Loan Documents, or of any portion thereof, or participation therein including, without limitation, the right, title, interest, remedies, powers and/or duties of Lender thereunder will require the prior written consent of the Borrower (not to be unreasonably withheld or delayed), unless an Event of Default is continuing or unless such sale, assignment, transfer or other disposition is to an Affiliate or Associate of Lender. The Borrower agrees that it shall execute and deliver such documents as Lender may request in connection with any such sale, assignment, transfer or other disposition. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their successors and permitted assigns.

 

13.6 Power of Attorney.

 

The Borrower acknowledges and agrees that its appointment of Lender as its attorney and agent for the purposes specified in this Agreement is an appointment coupled with an interest and shall be irrevocable until all of the Obligations are paid in full and this Agreement is terminated.

 

13.7 Waivers, Confidentiality, Information Sharing.

 

(a) In no event shall any party hereto be liable for lost profits or other special or consequential damages.

 

(b) To the maximum extent permitted by Applicable Law, the Borrower hereby waives all rights to a hearing of any kind prior to the exercise by Lender of its rights to repossess the Collateral without judicial process or to reply, attach or levy upon such Collateral without prior notice or hearing.

 

(c) To the maximum extent permitted by Applicable Law, the Borrower hereby waives demand, presentment, protest and notice of nonpayment.

 

(d) Failure of Lender, at any time or times hereafter, to require strict performance by any Loan Party of any provision of this Agreement or any of the other Loan Documents shall not waive, affect or diminish any right of Lender thereafter to demand strict compliance and performance therewith. Any suspension or waiver by Lender of a Default or Event of Default under this Agreement or any default under any of the Loan Documents shall not suspend, waive or affect any other Default or Event of Default under this Agreement or any other default under any of other Loan Documents, whether the same is prior or subsequent thereto and whether of the same or of a different kind or character. No delay on the part of Lender in the exercise of any right or remedy under this Agreement or any other Loan Documents shall preclude any other or further exercise thereof or the exercise of any right or remedy. None of the undertakings, agreements, warranties, covenants and representations of the Loan Parties contained in this Agreement or any of the other Loan Documents and no Default or Event of Default under this Agreement or default under any of the other Loan Documents shall be deemed to have been suspended or waived by Lender unless such suspension or waiver is in writing, signed by duly authorized officer(s) of Lender and directed to the Loan Parties specifying such suspension or waiver.

 

62
 

 

(e) The Borrower hereby agrees and acknowledges that Lender shall be permitted to share with any of its Affiliates, any information concerning the Loan Parties, this Agreement and all other Loan Documents, and the subject matter thereof, that Lender has or will have in its possession.

 

13.8 Timing of Payments.

 

Any payment received by Lender after 3:00 p.m. (New York time) on a Business Day, or on any day that is not a Business Day, shall be credited to the account of the Borrower on the following Business Day.

 

13.9 Judgment Currency.

 

If in the recovery by Lender of any amount owing hereunder in any currency, judgment can only be obtained in another currency and because of changes in the exchange rate of such currencies between the date of judgment and payment in full of the amount of such judgment, the amount of recovery under the judgment differs from the full amount owing hereunder, the Borrower shall pay any such shortfall to Lender, and such shortfall can be claimed by Lender against the Borrower as an alternative or additional cause of action and any surplus received by Lender will be repaid to the Borrower.

 

13.10 Severability.

 

If any provision of this Agreement is held to be prohibited by or invalid under Applicable Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or remaining provisions of this Agreement.

 

13.11 Conflicts.

 

In the event there occurs any conflict or inconsistency between any provision hereof and any provision of the other Loan Documents, the provision hereof, to the extent of any such conflict or inconsistency, shall govern.

 

13.12 Entire Agreement.

 

This Agreement and the other Loan Documents embody the entire agreement and understanding between the parties hereto and thereto and supersede all prior agreements and understandings between such parties relating to the subject matter hereof and thereof and may not be contradicted by evidence of prior or contemporaneous agreements of the parties. There are no unwritten oral agreements between the parties related to the subject matter of this Agreement and the other Loan Documents.

 

13.13 Counterpart Execution/Electronic Delivery.

 

This Agreement may be executed in counterpart and delivered by fax or other electronic means of delivery.

 

13.14 Interpretation.

 

From and after the date hereof, all references in the Loan Documents to the “Loan Agreement” (or words of similar import) shall be deemed to be references to this Amended and Restated Loan Agreement, as may otherwise be amended, restated, supplemented or otherwise modified from time to time. All references in any of the Loan Documents to the “Loan Documents” shall mean the Loan Documents as amended by this Amended and Restated Loan Agreement, as may otherwise be amended, restated, supplemented, confirmed or otherwise modified from time to time.

 

[Remainder of page intentionally left blank.]

 

63
 

 

IN WITNESS WHEREOF, the Borrower has duly executed this Agreement as of the date set out on the first page hereof.

 

  KNIGHT THERAPEUTICS (BARBADOS) INC.
     
  Per: /s/ Michel Loustric
  Name:  Michel Loustric
  Title: President
     
  SYNERGY CHC CORP.
     
  Per: /s/ Jack Ross
  Name: Jack Ross
  Title: CFO and Corporate Secretary
     
  Per: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

Signature Page – Loan Agreement

 

 
 

 

SCHEDULE 8.2

 

COMPLIANCE CERTIFICATE

 

TO: KNIGHT THERAPEUTICS (BARBADOS) INC.

Chancery House, High Street

Bridgetown, St. Michael

BB 11128, Barbados WI

 

  Attention: Michel Loustric
  Telecopier: 1-246-431-0076

 

FROM: SYNERGY CHC CORP.

 

DATE: ●, 201●

 

1. This Compliance Certificate is delivered to you, as Lender, pursuant to the Amended and Restated Loan Agreement made as of ●, 2017 between the Borrower and Lender, as amended, supplemented, restated or replaced from time to time (the “Loan Agreement”). All defined terms set forth, but not otherwise defined, in this notice shall have the respective meanings set forth in the Loan Agreement, unless the context requires otherwise.

 

2. I am the duly appointed • of the Borrower and am providing this Certificate pursuant to the Loan Agreement.

 

3. I am familiar with the Loan Agreement for purposes of delivering this Certificate.

 

4. The Borrower is in compliance with the Financial Covenants set forth in Section 9.1(z) of the Loan Agreement, namely:

 

(a) EBITDA for the twelve (12) months ending • was $•;

 

(b) for the Fiscal Quarter ending •, Net Debt to TTM EBITDA Ratio was •;

 

(c) as at ●, the cash balance was $•; and

 

(d) as at ●, the minimum Consolidated gross income was $•.

 

5. Attached as Schedule A is a list of additional Material Contracts and Material Licenses entered into since the date of the prior Compliance Certificate.

 

6. All rent payable to any landlord of leased real premises is up to date and there is no default by the Borrower under any such lease.

 

 
 

 

7. As of the date hereof, the Borrower is and will be in compliance with all of the terms and conditions of the Loan Agreement to which it is a party and no Default or Event of Default is continuing under the Loan Agreement.

 

IN WITNESS WHEREOF, I have signed this Certificate.

 

  SYNERGY CHC CORP.
     
  Per:  
  Name: 
  Title: Chief Executive Officer
     
  Per:  
  Name:
  Title: Chief Financial Officer

 

 
 

 

Schedule 3.1(b)

 

Repayment Schedule

 

First Tranche Repayment Schedule1

 

Date   Amount  
       
30/09/2017     562.5  
31/12/2017     562.5  
20/01/2018     562.5  

 

 

1 ($k)

 

Second Tranche Repayment Schedule1

 

Date   Amount  
       
11/8/2017     343.75  
11/9/2017     343.75  
11/10/2017     343.75  
11/11/2017     343.75  

 

Third Tranche Repayment Schedule2

 

Date   Amount  
       
8/11/2017     500  
8/2/2018     500  
8/5/2018     500  
8/8/2018     500  
8/11/2018     500  
8/2/2019     500  
8/5/2019     500  
8/8/2019     500  
8/11/2019     500  
8/2/2020     500  
8/5/2020     500  
8/8/2020     4,500  

 

 

1 ($k)

2 ($k)

 

Additional Tranche Repayment Schedule

 

sixty percent (60%) of the principal amount of any Additional Tranche shall be repaid in equal quarterly payments over the term of such Additional Tranche; and
     
forty percent (40%) of the principal amount of any Additional Tranche shall be repaid at the applicable Maturity Date of such Additional Tranche;

 

 

 

Exhibit 10.19

 

LOAN AMENDMENT AGREEMENT

 

LOAN AMENDMENT AGREEMENT TO AMENDED AND RESTATED LOAN AGREEMENT entered into as of the 14th day of May 2018 (the “First Amendment Agreement”),

 

BETWEEN: KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados;

 

(hereinafter called the “Lender”)

 

AND: SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada;

 

(hereinafter called the “Synergy”)

 

WHEREAS Synergy and the Lender are parties to that certain loan agreement (the “Amended and Restated Loan Agreement”) made as of the 9th day of August 2017, pursuant to which the Lender has extended a loan to Synergy in the principal amount of Ten Million United States Dollars ($10,000,000) (the “Loan”);

 

WHEREAS, per the March 31, 2018 statements, Synergy did not meet the Five Million Dollars ($5,000,000) Minimum EBITDA covenant as per Clause 9.1(z)(i) to the Amended and Restated Loan Agreement (“Event of Default”);

 

WHEREAS, Due to the Event of Default, the Lender and Synergy agree to the following;

 

In this Loan Amendment Agreement, the following terms shall have the following meanings:

 

“FF Net Sales” means, with respect to any period, the total amount billed or invoiced on sales of FF Products and any royalties or milestone payments received or accrued during such period in any jurisdiction by the Borrower or any of its Affiliates, their associated parties and any licensees to unaffiliated third parties in bona fide arm’s length transactions, less the following deductions, in each case to the extent reasonable and customarily provided to unaffiliated entities and actually allowed and taken or accrued with respect to such sales:

 

(a) credits, price adjustments or allowances for damaged products, returns or rejections of any FF Products;

 

(b) normal and customary trade, cash and quantity discounts, allowances and credits (other than price discounts granted at the time of invoicing which have already been included in the gross amount invoiced);

 

(c) chargeback payments, repayments and rebates (or the equivalent thereof) granted to or imposed by group purchasing organizations, managed health care organizations or federal, state/provincial, local and other governments, including any or all of their regulatory authorities, agencies, review boards or tribunals, or trade customers;

 

(d) sales, value-added (to the extent not refundable in accordance with Applicable Law), and excise Taxes and other Taxes directly related to the sale (but not including Taxes assessed against the income derived from such sale).

 

(e) stocking allowances; and

 

 
 

 

(f) any other payment which reduces gross revenue and is permitted to be deducted in calculating net sales in accordance with GAAP,

 

the whole of which shall at all times be calculated in accordance with GAAP.”

 

FF Products” means, collectively, the products known as FOCUSfactor, FOCUSfactor Kids and any other products of Borrower or its Subsidiaries now or hereafter marketed or sold under the FOCUSfactor brand, and any improvements thereon.

 

Synergy and the Lender agree to the following amendments to the Amended and Restated Loan Agreement:

 

  1. Synergy and the Lender hereby agree to replace clause 9.1(z)(i) of the Amended and Restated Loan Agreement with the following:
     
    The Borrower shall maintain a minimum EBITDA of Two Million Dollars ($2,000,000) for the twelve (12) months ending on September 30, 2017 and for each twelve (12) month period ending on the last day of each Fiscal Quarter until September 30th, 2018 and the borrower shall maintain a minimum EBITDA of Five Million Dollars ($5,000,000) for the twelve (12) month period ending on the last day of each Fiscal Quarter thereafter, provided that the minimum EBITDA amount shall be increased by an amount equal to 50% of any Additional Tranche advanced to Borrower hereunder;
     
  2. An additional default interest rate of 5% (“Default Interest Rate”) will apply as from April 1st, 2018 up to later of i) September 30th, 2018 or ii) when Event of Default is cured;
     
  3. The Default Interest Rate will be reduced to 13% if Synergy amends its employment agreement for each and every employee earning $250,000 or more annually through a reduction of individual salary by at least $60,000 in exchange for bonus of no more than $75,000 payable upon Synergy achieving an EBITDA of $13.887 million for calendar year 2018;
     
  4. Synergy and the Lender hereby agree to add clause 9.1(z)(v) of the Amended and Restated Loan Agreement with the following:
     
    Synergy shall maintain FF Net Sales as measured on a year-end basis of at least USD$15 million for each fiscal year starting with December 31st, 2017

 

▪▪▪▪▪▪▪▪▪

 

 
 

 

In witness whereof, the parties have duly executed this amendment as of May 14th, 2018.

 

/s/ Jack Ross   /s/ Michel Loustric
Jack Ross, CEO – Synergy CHC Corp   Michel Loustric, President – Knight Therapeutics (Barbados) Inc.

 

 

 

Exhibit 10.20

 

SECOND AMENDMENT TO AMENDED & RESTATED LOAN AGREEMENT

 

The SECOND AMENDMENT to the AMENDED AND RESTATED LOAN AGREEMENT is entered into as of the 27th day of March 2019 (the “Second Amendment Agreement”),

 

BETWEEN: KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados;

 

(hereinafter called the “Lender”)

 

AND: SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada;

 

(hereinafter called the “Synergy”)

 

WHEREAS Synergy and the Lender are parties to that certain loan agreement (the “Amended and Restated Loan Agreement”) made as of the 9th day of August 2017, pursuant to which the Lender has extended a loan to Synergy in the principal amount of Ten Million United States Dollars ($10,000,000) (the “Loan”);

 

WHEREAS, per the audited financial statements for the year ended December 31”, 2018, Synergy failed to achieve (1) the Five Million Dollars ($5,000,000) Minimum EBITDA covenant in accordance with Clause 9.1(z)(i) of the Amended and Restated Loan Agreement, (2) the Net Debt to TTM EBITDA ratio of 6:1 in accordance with Clause 9.1(z)(ii) and (3) the Cash Balance in accordance with Clause 9.1(z)(iii). In accordance with Article 11.1 of the Amended and Restated Loan Agreement such failure is an Event of Default.

 

WHEREAS, Due to the Event of Default, the Lender and Synergy agree to the following;

 

In this Second Amendment Agreement, the following terms shall have the following meanings:

 

“FF Net Sales” means, with respect to any period, the total amount billed or invoiced on sales of Focus Factor Products and any royalties or milestone payments received or accrued during such period in any jurisdiction by the Borrower or any of its Affiliates, their associated parties and any licensees to unaffiliated third parties in bona fide arm’s length transactions, less the following deductions, in each case to the extent reasonable and customarily provided to unaffiliated entities and actually allowed and taken or accrued with respect to such sales:

 

  a) Credits, price adjustments or allowances for damaged products, returns or rejections of any FF products;
     
  b) Normal and customary trade, cash and quantity discount, allowances and credits (other than price discounts granted at the time of invoicing which have already been included in the gross amount invoiced);
     
  c) Chargeback payments, repayments and rebates (or the equivalent thereof) granted to or imposed by group purchasing organizations, managed health care organizations or federal, state/provincial, local and other governments, including any or all of their regulatory authorities, agencies, review boards or tribunals, or trade customers;
     
  d) Sales, value-added (to the extent not refundable in accordance with Applicable Law), and excise Taxes and other Taxes directly related to the sale to the extent included in amount invoiced (but not including Taxes assessed against the income derived from such sale).

 

 
 

 

  e) Stocking allowances; and

 

The whole of which shall at all times be calculated in accordance with GAAP

 

“FF Products” means, collectively, the products known as FOCUSfactor, FOCUSfactor Kids and any other products of Borrower or its Subsidiaries now or here after marketed or sold under the FOCUSfactor brand, and any improvements thereon.

 

Synergy and the Lender agree to the following amendments to the Amended and Restated Loan Agreement:

 

  1. Synergy and the Lender hereby agree to replace clause 9.1(z)(i) of the Amended and Restated Loan agreement with the following:

 

The Borrower shall maintain a minimum EBITDA of One Million and Nine Hundred Thousand Dollars ($1,900,000) for the twelve (12) months ending on December 31$t, 2018. For each twelve (12) month period ending on the last day of each Fiscal Quarter until September 30th, 2019, the minimum EBITDA shall be maintained pursuant to Schedule “A” herein attached but for clarity to be:

 

The Borrower shall maintain a minimum EBITDA of Two Million Five Hundred Thousand Dollars ($2,500,000) for the twelve (12) months ending on March 31, 2019

 

The Borrower shall maintain a minimum EBITDA of Three Million Five Hundred Thousand Dollars ($3,500,000) for the twelve (12) months ending on June 30th, 2019

 

Following thereafter, the borrower shall maintain a minimum EBITDA of Five Million Dollars ($5,000,000) for the twelve (12) month period ending on the last day of each Fiscal Quarter thereafter, provided that the minimum EBITDA amount shall be increased by an amount equal to 50% of any Additional Tranche advanced to Borrower hereunder;

 

  2. Synergy and the Lender hereby agree to replace clause 9.1(z)(ii) of the Amended and Restated Loan agreement with the following:

 

The Borrower shall maintain a Net Debt to TIM EBITDA Ratio of no more than 8:1 for the twelve (12) month period ending on December 31, 2018 until March 31, 2019 and shall maintain a Net Debt to TTM EBITDA Ratio of no more than 6:1

 

  3. Synergy and the Lender hereby agree to replace clause 9.1(z)(iii) of the Amended and Restated Loan agreement with the following:

 

The Borrower shall maintain at all times a minimum positive cash balance equal to Five Hundred and Seventy-Five Thousand Dollars ($575,000) for the three (3) months ending on December 31, 2018.

 

The Borrower shall maintain at all times a minimum positive cash balance equal to Seven Hundred and Fifty Thousand Dollars ($750,000) for the three (3) months ending on March 31, 2019

 

The Borrower shall maintain at all times a minimum positive cash balance equal to One Million Dollars ($1,000,000) after March 31, 2019.

 

  4. The default interest rate of 15.5% will apply as from October 1, 2018 to June 30, 2019. The interest shall be calculated daily, compounded quarterly and payable in accordance with the terms of the Amended and Restated Loan Agreement.
     
  5. The borrower has included one-time adjustments of approximately $4.4 million (“Adjustments”) in the 2018 EBITDA calculation. For clarity purposes, the Adjustments are subject to the review and approval by Lender. The borrower will provide necessary support and documentation of the Adjustments within 15 days of execution of Second Amendment Agreement.

 

 
 

 

In witness whereof, the parties have duly executed this amendment as of March 27th, 2019.

 

/s/ Jack Ross   /s/ Michel Loustric
Jack Ross, CEO – Synergy CHC Corp   Michel Loustric, President – Knight Therapeutics (Barbados) Inc.

 

 
 

 

Schedule “A”

 

Covenant   Current
Dec’18
  Q1   Q2   Q3   Q4
Minimum TTM EBITDA   1,900,000   2,500,000   3,500,000   5,000,000   5,000,000
Minimum Cash Balance   575,000   750,000   1,000,000   1,000,000   1,000,000
Minimum UM Revenues   20,000,000   20,000,000   20,000,000   20,000,000   20,000,000
Minimum FF Net Sales   15,000,000   15,000,000   15,000,000   15,000,000   15,000,000
Net Debt to UM EBITDA   8:1   6:1   6:1   6:1   6:1

 

 

 

Exhibit 10.21

 

THIRD AMENDMENT AGREEMENT entered into as of the May 8, 2020 (the “Third Amendment”),

 

BETWEEN: KNIGHT THERAPEUTICS (BARBADOS) INC., a corporation formed under the laws of Barbados;

 

(hereinafter called the “Lender”)

 

AND: SYNERGY CHC CORP., a corporation formed under the laws of the State of Nevada;

 

(hereinafter called the “Borrower”)

 

WHEREAS the Borrower and the Lender are parties to that certain loan agreement made as of the 21st day of January, 2015, as amended by a first amending agreement dated November 12, 2015, as amended and restated as of the 9th day of August, 2017, as amended by a loan amendment agreement to the amended and restated loan agreement dated May 14, 2018 and as amended by a second amendment to the amended and restated loan agreement dated March 27, 2019 (such agreement, as amended, restated, amended and restated or otherwise modified from time to time as of the date hereof, the “Loan Agreement”);

 

WHEREAS the Borrower has requested (i) that the Lender advance an additional loan in the principal amount of Two Million Five Hundred Thousand United States Dollars (US$2,500,000) in order to fund working capital needs (the “Additional Loan”) and (ii) certain amendments to the Loan Agreement, including with respect to Maturity Date and the payment of the Third Tranche Success Fee (as hereinafter defined);

 

WHEREAS the Lender and the Borrower desire to amend the Loan Agreement to, inter alia, provide for the Additional Loan on the terms and conditions set forth herein and to amend certain terms and conditions in the Loan Agreement;

 

NOW, THEREFORE, IN CONSIDERATION of these presents and of the mutual covenants hereinafter contained, the parties have agreed as follows:

 

 

 

 

ARTICLE 1

INTERPRETATION

 

1.1 Capitalized Terms

 

In this Third Amendment (including the recitals), capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement as if amended to include the amendments set out in this Third Amendment.

 

1.2 To be Read with Loan Agreement

 

This Third Amendment is an amendment to the Loan Agreement. Unless the context of the Third Amendment otherwise requires, the Loan Agreement and this Third Amendment shall be read together and shall have effect as if the provisions of the Loan Agreement and this Third Amendment were contained in one agreement.

 

ARTICLE 2

AMENDMENTS

 

2.1 Amendments to the Loan Agreement

 

The Borrower and the Lender hereby agree to amend the Loan Agreement as follows:

 

  2.1.1  Section 1.1 of the Loan Agreement is amended by inserting or restating the following definitions (as the case may be):
     
    Additional Loan” means the loan to the Borrower by the Lender in the principal amount of Two Million Five Hundred Thousand United States Dollars (US$2,500,000) pursuant to the Third Amendment.
     
    Additional Loan Success Fee” has the meaning set forth in Section 4.8. “Third Tranche Success Fee” has the meaning set forth in Section 4.8.
     
    Loan” means, collectively or individually, as the context requires, the First Tranche, the Second Tranche, the Third Tranche, the Additional Loan, any Additional Tranches and, starting August 9, 2020, the Third Tranche Success Fee.
     
    Loan Documents” means (i) this Agreement and the Loan Agreement, as amended hereby, and the Security Documents delivered by the Loan Parties pursuant to this Agreement and the Existing Loan Agreement or otherwise in connection with this Agreement and the Existing Loan Agreement, including any Loan Document delivered to Lender as general continuing collateral security for the payment and performance of the present and future Obligations (including obligations relating to the Second Tranche, the Third Tranche, the Additional Loan, any Additional Tranche and the Third Tranche Success Fee), as well as any amendments, replacements, supplements or other modifications hereto or thereto or any other documents or instruments contemplated hereby or thereby, (ii) all present and future security, agreements and documents labelled by the parties thereto as a Loan Document, (iii) all confirmation agreements delivered by the Loan Parties confirming the validity of any of the foregoing Loan Documents and (iv) Lender Distribution Agreements, in each case as the same may from time to time be supplemented, amended or restated, and “Loan Document” shall mean any one of the Loan Documents.

 

 
- 2 -

 

    Maturity Date(s)” means: (i) with respect to the First Tranche, January 20, 2018, (ii) with respect to the Second Tranche, November 11, 2017, (iii) with respect to the Third Tranche, December 31, 2020, (iv) with respect to the Additional Loan, the first anniversary of the Second Closing Date and (v) with respect to the Third Tranche Success Fee, August 31, 2022.
     
    Projected Sales Schedule” means the target revenues and projected sales of the Borrower attached to the Third Amendment as Schedule B.
     
    Repayment Schedule” means the Amended and Restated Schedule of Repayment of principal of the Loan attached to the Third Amendment as Schedule A.
     
    Second Closing Date” means May 8, 2020 or such other date on which the Additional Loan is advanced to the Borrower.
     
    Termination Date” means August 31, 2022.
     
    Third Amendment” means that certain Third Amendment to Loan Agreement dated as of May 8, 2020.

 

  2.1.2 The following shall be added as Section 2.1(d) immediately following Section 2.1(c) in respect of the Additional Loan:
     
    “(d) Additional Loan. Subject to the terms and conditions of this Agreement and the other Loan Documents, the Lender agrees to loan to the Borrower in lawful money of the United States the Additional Loan on the terms hereof and the Borrower hereby irrevocably authorizes the Lender to advance the Additional Loan on the terms hereof. The Additional Loan shall bear interest as set forth in Section 4.1 of this Agreement.”
     
  2.1.3  Section 4.1 (b) is hereby amended and restated as follows:
     
    “(b) Third Tranche and Additional Loan. Subject to Section 4.3, the principal amount of the Third Tranche, the Additional Loan and other outstanding Obligations relating to the Third Tranche and the Additional Loan shall bear interest from the Second Closing Date to the date paid in full, at a rate equal to 12.5% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4(b).

 

 
- 3 -

 

  2.1.4 Section 4.1 is hereby amended by adding the following immediately after 4.1(c):
     
    “(d) Third Tranche Success Fee. Subject to Section 4.3, the principal amount of the Third Tranche Success Fee and other outstanding Obligations relating to the Third Tranche Success Fee shall bear interest from August 9, 2020 to the date paid, at a rate equal to 12.5% per annum compounded quarterly. In each case such interest shall be payable in arrears in accordance with Section 4.2 and calculated in accordance with Section 4.4(b).
     
  2.1.5 Section 4.4 is hereby amended by adding the following after 4.4(b):
     
    “(c) Additional Loan and the Third Tranche Success Fee. With respect to the Additional Loan and the Third Tranche Success Fee, interest shall be determined daily and compounded quarterly not in advance, both before and after demand, default and judgment and shall be computed on a 360-day basis.”
     
  2.1.6 Section 4.8 is hereby amended and restated as follows:
     
    The Borrower will pay to Lender (i) a success fee in the amount of US$1,000,000 with respect to the Third Tranche (the “Third Tranche Success Fee”), which amount shall be fully earned as of the Second Closing Date and payable no later than the Termination Date and (ii) a success fee in the amount of US$83,250 with respect to the Additional Loan (the “Additional Loan Success Fee”), which shall be fully no later than the Second Closing Date and payable on the first anniversary of the Second Closing Date. The Third Tranche Success Fee shall bear interest as set forth in Section 4.1 of this Loan Agreement and, for certainty, the Third Tranche Success Fee and the Additional Loan Success Fee shall be “Obligations” as defined in this Agreement and in the other Loan Documents.
     
  2.1.7 The following shall be added as Section 9.1 (bb) immediately following Section 9.1 (aa):
     
    9.1 (bb) Weekly Sweep. Without limiting in any way the provisions of Section 9.2(q), the Loan Parties undertake and agree that any funds, Permitted Cash Investments, cash or Equity Interests deposited or held in a Deposit Account or a Security Account not subject to a Control Agreement shall be transferred to a Deposit Account or a Security Account subject to a Control Agreement on no less than a weekly basis.

 

 
- 4 -

 

  2.1.8 The following shall be added as Section 9.4 immediately following Section 9.3:
     
    9.4. Agreements and other deliverables to be delivered following the Second Closing Date.
     
    (a) Within thirty (30) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall enter into, and provide the Lender with an executed copy of, a third party logistics services agreement with Moulton Logistics, which agreement shall be on terms and conditions consistent with the current arrangements between the Borrower and Moulton Logistics as disclosed by the Borrower to the Lender prior to the date hereof (the “3PL Agreement”;
     
    (b) Within thirty (30) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall obtain a consent, waiver and acknowledgement from Moulton Logistics, in form, scope and substance reasonably acceptable to the Lender;
     
    (c) Within sixty (60) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall enter into, and provide the Lender with executed copies of, master quality agreements between the Borrower and each of its two principal suppliers with respect to FF Products, which agreements shall be in form, scope and substance satisfactory to the Lender, acting reasonably;
     
    (d) Within fifteen (15) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall deliver evidence of the perfection of the Lender’s security in the State of Maine;
     
    (e) Within ten (15) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall deliver a certificate of status or good standing, as applicable, for the State of Maine;
     
    (f) Within twenty (20) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall deliver a certificate of insurance to the Lender evidencing appropriate property insurance, in form and substance satisfactory to the Lender, acting reasonably; and
     
    (h) Within thirty (30) days of the Second Closing Date (or such later date agreed to by the Lender), the Borrower shall provide the Lender with evidence that notices of the Liens granted to the Lender have been duly filed with the United States Patent and Trademark Office and the Canadian Intellectual Property Office.

 

 
- 5 -

 

  2.1.9 Section 9.1(z)(i) of the Loan Agreement is hereby amended and restated as follows:
     
    “(i) Minimum EBITDA. The Borrower shall maintain a minimum EBITDA of Three Million Dollars (US$3,000,000) for the twelve (12) months ending on June 30, 2020 and Four Million Dollars (US$4,000,000) for the twelve (12) month period ending on the last day of each Fiscal Quarter thereafter.”
     
  2.1.10 Section 9.1(z)(iii) of the Loan Agreement is hereby amended and restated as follows:
     
    “(iii) Cash Balance. The Borrower will maintain at all times a minimum positive cash balance equal to Six Hundred Thousand Dollars (US$600,000), and the Borrower shall prepare a statement in accordance with GAAP setting forth the aggregate amount of cash and cash equivalents so held by the Borrower, which statement shall be certified by the Chief Executive Officer and Chief Financial Officer of the Borrower (the “Cash Balance Statement”).”
     
  2.1.11 Section 9.2(q) of the Loan Agreement is amended by adding the following text at the end thereof.
     
    “Notwithstanding the foregoing, the proceeds of the Additional Loan advanced by the Lender on the Second Closing Date shall be immediately deposited in and at all times thereafter held only in Deposit Accounts that are subject to Control Agreements and, for certainty, the transfer of all or any portion of the proceeds of the Additional Loan to any other Deposit Account, or any other account at any financial institution or any other institution (including securities firms) and brokerage accounts, at any time shall constitute an Event of Default hereunder.”
     
  2.1.12 Section 9.2 of the Loan Agreement is amended by adding the following text after subsection (t):
     
    “(u) Covid-19 Covenant. Notwithstanding anything else set forth in this Agreement or in any other Loan Document, if the monthly Consolidated net revenues of the Borrower fall below the monthly revenue targets and projected sales set forth in the Projected Sales Schedule by an amount of more than 18%, then the Borrower shall immediately: (i) cease all consulting service payments otherwise payable to Kenek Brands Inc. pursuant to any written or oral employment service or consulting agreements (the “Suspension of Compensation”), (ii) implement such other cost-cutting measures proposed by the Borrower and approved by and satisfactory to the Lender, acting reasonably (the “Acceptable Cost-Cutting Measures”) and, unless otherwise confirmed by the Lender to the Borrower in writing, the Suspension of Compensation and Acceptable Cost-Cutting Measures shall remain in effect until the earlier of (i) the indefeasible repayment and performance in full of the Obligations and (ii) the Termination Date. For certainty, the failure of the Borrower to implement and maintain the Suspension of Compensation or establish, implement and maintain Acceptable Cost-Cutting Measures shall be an Event of Default.

 

 
- 6 -

 

  2.1.13 From and as of the Second Closing Date, (i) all references in the Loan Agreement to “this Agreement” shall mean the Loan Agreement as amended by this Third Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time, and (ii) all references in the other Loan Documents to the “Loan Agreement” (or words of similar import) shall be deemed to be references to the Loan Agreement as amended by this Third Amendment, and as may otherwise be amended, restated, supplemented or otherwise modified from time to time. All references in any of the Loan Documents to the “Loan Documents” shall mean the Loan Documents as amended by this Third Amendment and as may otherwise be amended restated, supplemented or otherwise modified from time to time and, for certainty, shall include any security, agreements and documents executed and delivered by the Borrower or any of its Subsidiaries in connection with this Third Amendment.
     
  2.1.14 Except as expressly amended by this Third Amendment, all other provisions of the Loan Agreement and the Loan Documents not specifically amended hereby shall remain unchanged and in full force and effect.

 

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

 

3.1 Representations and Warranties

 

In order to induce the Lender to enter into this Third Amendment, the Borrower represents and warrants to the Lender as of the Second Closing Date as follows, which representations and warranties shall survive the execution and delivery hereof:

 

  3.1.1 after giving effect to the updated disclosure schedules contemplated in subsection 3.1.4 of this Third Amendment, the representations and warranties set forth in Article 7 of the Loan Agreement are true and correct as of the Second Closing Date;
     
  3.1.2 all consents and approvals required in connection with the execution and delivery by the Loan Parties of this Third Amendment and the other Loan Documents contemplated hereby have been obtained;
     
  3.1.3 the execution and delivery of this Third Amendment and the other Loan Documents contemplated hereby do not conflict with or contravene any agreement to which any Loan Party is a party;
     
 
- 7 -

 

  3.1.4 attached to this Third Amendment are updated disclosure schedules to the Loan Agreement in connection with each representation set forth in Section 11 of the Loan Agreement, which schedules reflect such representations being current to the Second Closing Date (as contrasted to the Closing Date);
     
  3.1.5 all necessary action, corporate or otherwise, has been taken to authorize the execution, delivery and performance of this Third Amendment and the other Loan Documents contemplated hereby by the Loan Parties;
     
  3.1.6 as of the Second Closing Date, no Default or Event of Default exists.

 

ARTICLE 4

CONDITIONS PRECEDENT & CLOSING DATE

 

4.1 Conditions to Loan by the Lender

 

The effectiveness of this Third Amendment and the Lender’s obligation to fund the Additional Loan amount shall be subject to the following conditions precedent having been met to the satisfaction of the Lender, or, alternatively, waived in writing by the Lender:

 

  4.1.1 the Borrower will pay to the Lender Thirty Six Thousand United States Dollars (US$36,000) as payment of the Work Fee in respect of the Additional Loan amount, (which, for certainty, shall be fully earned and payable on the date hereof, whether or not the Additional Loan is advanced);
     
  4.1.2 the Borrower will pay to the Lender Five Hundred Thousand United States Dollars (US$500,000) as a partial repayment of the outstanding principal amount of the Third Tranche;
     
  4.1.3 this Agreement shall have been executed and delivered by all parties hereto;
     
  4.1.4  the Borrower and its Subsidiaries shall have executed and delivered to the Lender a confirmation of guarantee and security agreement;
     
  4.1.5 the Lender shall have received certified copies of the resolutions authorizing the execution, delivery and performance of Borrower’s obligations hereunder and copies of the resolutions of the Borrower authorizing the confirmation of guarantee and security agreement regarding the Loan Documents to which they are a party and the transactions contemplated therein, and the incumbency of the officers of Borrower;
     
  4.1.6 certificates of status or good standing, as applicable, for all relevant jurisdictions of Borrower shall have been delivered to the Lender;
     
  4.1.7 the Loan Parties shall be in compliance in all material respects with all (if any) Material Contracts and Material Licences to the satisfaction of the Lender and copies of all Material Contracts and Material Licences if any, applicable to the Loan Parties, shall have been delivered to the Lender;

 

 
- 8 -

 

  4.1.8 evidence that all necessary or required consents or approvals of any Governmental Authority or other Person in connection the delivery of the Loan Documents have been obtained;
     
  4.1.9 US and Canadian Lien searches and reports thereon, and releases, discharges, estoppels and postponements with respect to all Liens which are not Permitted Liens, if any, shall have been delivered to the Lender;
     
  4.1.10 payment of all amounts and fees payable to the Lender (for certainty, including fees of counsel to the Lender);
     
  4.1.11 duly executed copies of the Security (including any additional Security required by the Lender further to the merger of the Borrower or otherwise) shall have been delivered to the Lender and such financing statements or other registrations of such Security, or notice thereof, shall have been filed, registered, entered or recorded in all offices of public record necessary or desirable in the opinion of the Lender to preserve or protect the charges and security interests created thereby;
     
  4.1.12 a currently dated letter of opinion of US counsel to the Borrower shall have been delivered to the Lender. Such opinions shall, amongst other things, opine as to the enforceability of this Agreement and the Loan Agreement as amended hereby, that the existing Security delivered in connection with the Loan Agreement is first ranking perfected security in favour of the Lender in respect to all of the Obligations, including without limitation, the Additional Loan, and shall also address other customary enforceability, security and corporate matters;
     
  4.1.13  the Borrower shall have delivered to the Lender certificates of insurance acceptable to the Lender showing, inter alia, the Lender as a first loss payee as its interest may appear on all insurance policies that insure the assets to be secured by the Security;
     
  4.1.14  no Default or Event of Default shall have occurred and be continuing on the Second Closing Date or would result from making the Additional Loan and a senior officer of the Borrower shall have certified the same to the Lender;
     
  4.1.15 no Material Adverse Effect shall have occurred;
     
  4.1.16 the Lender shall have received such additional evidence, documents or undertakings as the Lender shall reasonably request to establish the consummation of the transactions contemplated hereby and be satisfied, acting reasonably, as to the taking of all proceedings in connection herewith in compliance with the conditions set forth in this Third Amendment; and
     
  4.1.17 the Lender shall have completed all due diligence which it considers necessary or appropriate in its discretion in regard to the Loan Parties and their Property, books and records, operations, prospects and condition (financial or otherwise), including, without limitation, in regards to past and ongoing compliance with Applicable Laws (including Environmental Laws), union and labour relations and pension matters.

 

 
- 9 -

 

ARTICLE 5

MISCELLANEOUS

 

5.1 Further Assurances

 

Each of the Borrower and the Lender shall, from time to time hereafter and upon any reasonable request of the other party, execute and deliver such further agreements and documents and do all such other acts and things as may be necessary or appropriate to give effect to the foregoing.

 

5.2 Time of the Essence

 

Time shall be of the essence of this Third Amendment.

 

5.3 Severability

 

If any provision of this Third Amendment is found by final judgment of a court of competent jurisdiction to be invalid or unenforceable in whole or in part, such provision (or part thereof, as the case may be) shall be severable and such finding shall not affect the validity or enforceability of the remainder of such provision or of any other provision hereof.

 

5.4 Enurement

 

This Third Amendment shall enure to the benefit of and be binding upon the parties hereto and their permitted assigns.

 

5.5 Counterparts

 

This Third Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

 

5.6 Paramountcy

 

In the event of any conflict or inconsistency between the terms and conditions of this Third Amendment and the terms and conditions of any other Loan Document, including the Loan Agreement, the terms and conditions of this Third Amendment shall prevail and be paramount to the extent of such conflict or inconsistency.

 

5.7 Continuance of Loan Agreement and Security

 

The Loan Agreement, as changed, altered, amended or modified by this Third Amendment, shall be and continue in full force and effect and is hereby confirmed and the rights and obligations of all parties thereunder shall not be affected or prejudiced in any manner except as specifically provided for herein. Nothing in this Third Amendment shall constitute a release, settlement, extinguishment, rescission or novation of any indebtedness or Loan outstanding under the Loan Agreement and all advances outstanding under the Loan Agreement shall continue as advances following the execution and delivery of this Third Amendment.

 

 
- 10 -

 

5.8 Performance; No Lender Defaults.

 

The Borrower confirms that the Lender has fully and timely performed all of its respective obligations and duties in compliance with the Loan Documents and applicable law, and has acted reasonably and in good faith. In further consideration of the Lender’s execution of this Third Amendment, the Borrower, on behalf of itself, its successors, assigns, affiliates, members, officers, directors, employees, agents and attorneys hereby forever, fully, unconditionally and irrevocably waive and release the Lender, and the respective successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, attorneys and agents of each (each a “Releasee”) from any and all claims, liabilities, obligations, debts, causes of action (whether at law or in equity or otherwise), defenses, counterclaims, setoffs, of any kind, whether known or (to the maximum extent permitted by applicable law) unknown, whether liquidated or unliquidated, matured or unmatured, fixed or contingent, directly or indirectly arising out of, connected with, resulting from or related to any act or omission by the Lender, or any other Releasee, with respect to the Loan Documents and any collateral, other than Lender’s or any Releasee’s gross negligence or willful misconduct, on or before the date of this Third Amendment (collectively, the “Claims”). Borrower further agrees that it shall not commence, institute, or prosecute any lawsuit, action or other proceeding, whether judicial, administrative or otherwise, to collect or enforce any Claim.

 

5.9 Governing Law

 

This Third Amendment will be governed by and construed in accordance with the laws of the Province of Quebec and the laws of Canada applicable therein.

 

5.10 Language

 

The parties acknowledge that they have requested that this Third Amendment and all ancillary documents be drawn up in the English language only. Les parties reconnaissent avoir exigé que cette convention ainsi que tous les documents y reliés soient rédigés en anglais seulement.

 

(signature page follows)

 

 
- 11 -

 

IN WITNESS WHEREOF the parties hereto have duly executed this Third Amendment as of the date and at the place first hereinabove set forth.

 

  KNIGHT THERAPEUTICS (BARBADOS) INC.
     
  by /s/ Michel Loustric
  Name: Michel Loustric
  Title: President
     
  SYNERGY CHC CORP.
     
  by /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

Exhibit 10.22

 

DISTRIBUTION AGREEMENT
(Canada)

 

THIS AGREEMENT, effective February 15, 2016, by and among KNIGHT THERAPEUTICS INC. (“Knight”), a corporation incorporated under the laws of Canada, and NOMAD CHOICE PTY LTD. (“Nomad”), a corporation formed under the laws of Australia.

 

WHEREAS Synergy CHC Corp. (“Synergy”) and Knight Therapeutics (Barbados) Inc. (“KB”) are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time, including by amendment and confirmation agreement dated December 3, 2015 to which amendment Nomad and Breakthrough Products, Inc. were also parties (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named KB its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS Synergy has acquired all of the shares of Nomad effective November 16, 2015 and, as and from that date, Nomad became an Affiliate;

 

WHEREAS pursuant to the amendment and confirmation agreement dated December 3, 2015 and referred to above, Nomad confirmed that the terms and conditions of the DLS Agreement apply to it and its products;

 

WHEREAS KB assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight;

 

WHEREAS FT Products (as herein defined) are included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with Nomad in respect of Direct Channel Sales of FT Products in Canada;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS
   
1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
   
1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:
   
  “Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of FT Products and supply of same to Nomad under this Agreement. For greater certainty, where Knight purchases FT Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer.

 

 
2

 

Direct Channels Sales” means the Commercialization of FT Products in Canada directly to consumers from a website or any other direct-to-consumer sales channel.

 

FT Products” means the “Flat Tummy Tea” line of products as now or may in the future be Commercialized by Nomad or its Affiliates (including future line extensions relating thereto) and other tea or beverage products and related accessories Commercialized from time to time by Nomad or any company or entity controlled by Nomad. For greater certainty, the “Flat Tummy Tea” line of products shall include any products and accessories that are Commercialized under the “Flat Tummy” trademark and/or tradename (or any variations thereof) together with any tea products and related accessories, or any beverage products that are marketed to reduce bloating.

 

Gross Sales” means the gross invoiced sales price for FT Products sold by Nomad or its Affiliates, as applicable, to Third Parties throughout Canada during each Calendar Quarter, less only (1) the shipping and handling charges that are actually incurred by Nomad or its Affiliates in delivering such FT Products to the end users in Canada and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of FT Products. Sales between or among Nomad and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where (a) FT Products are sold by Nomad or its Affiliates other than in an arm’s length sale, (b) FT Products are sold as one of a number of items without a separate invoiced price; or (c) consideration for FT Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be Nomad’s average Gross Sales to Third Parties for the applicable quantity of FT Products at that time.

 

1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 Canadian Dollars. References in this Agreement to “Dollars” or “s” shall mean the legal tender of Canada, unless otherwise noted.
   
1.7 Gender. Words of one gender include the other gender.
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

 

 
3

 

1.9 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.
   
1.10  Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.11 Party References. Reference to any Party includes the successors and permitted assigns of that Party.
   
1.12 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.
   
2 DISTRIBUTION TERMS
   
2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and its Affiliates, hereby appoints Nomad as its exclusive Third Party distributor of FT Products for Canada solely and exclusively in respect of Direct Channel Sales and further grants to Nomad and Nomad hereby accepts for Canada and solely and exclusively in respect of Direct Channel Sales a non-exclusive sublicense under the Synergy Marks used in association with FT Products to Commercialize FT Products through Direct Channel Sales in Canada. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute FT Products in Canada through Direct Channel Sales. In the event that Knight determines to create and operate a website or uses other social media to promote and sell FT Products in Canada, it shall consult with Nomad and each of Nomad and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the FT Products in Canada through Direct Channel Sales, Knight shall not pursue a brand strategy that Nomad, acting reasonably, determines is materially adverse to the brand equity of FT Products in Canada.
   
2.2 Sublicensing. Nomad may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Nomad assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.
   
2.3 Interim Period. Section 3.2 below contemplates that Knight shall enter into an agreement with the Manufacturer. Knight shall advise Nomad by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, Nomad shall be permitted to source FT Products directly from the Manufacturer. Nomad will make payments to Knight equal to sixty percent (60%) of Gross Sales in respect of the period from November 1, 2015 and until Nomad exhausts sales of FT Products sourced from such directly acquired inventory. The first such payment in respect of Gross Sales made during the period from November 1, 2015 to and including December 31, 2015 shall be made within ten (10) Business Days from the date hereof A further payment in respect of the Gross Sales made during the period from January 1, 2016 to and including the Notice Date shall be made within ten (10) Business Days of the Notice Date for Gross Sales made during such period. Thereafter, payments shall be made on a monthly basis (on or before the fifteenth (15th) day of each month) from all Gross Sales of such inventory and until such inventory is exhausted.

 

 
4

 

3 SUPPLY
   
3.1 Exclusivity. Except as set forth otherwise in Section 2.3, Nomad will purchase all of its requirements of FT Products for Canada and in respect of Direct Channel Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. Nomad acknowledges that Knight may from time to time enter into an agreement with a contract manufacturer (the “Manufacturer”) for the supply of FT Products under this Agreement. In such instances, Knight and Nomad shall determine mutually acceptable procedures that will allow Nomad to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that Nomad shall acquire FT Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at Nomad’s request, facilitate any claims, demands, complaints or similar actions that Nomad wishes to assert against the Manufacturer in respect of FT Products purchased by Nomad from Knight.
   
3.3 Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the packaging for the FT Products, Knight shall not be obliged to supply packaging to Nomad. Nomad will continue to source such packaging itself and will make arrangements with the Manufacturer to fill bulk product into the packaging provided.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of FT Products that are on order or unpaid from time to time.
   
3.5 Liability. Nomad acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of FT Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.
   
3.6 Regulatory Submissions. Knight shall be solely responsible, at its expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the FT Products in Canada. Nomad shall provide reasonable assistance to Knight in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Knight. Knight shall notify Nomad of all Regulatory Submissions that it submits.
   
3.7 Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in Canada. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.

 

 
5

 

3.8 Other Covenants. In addition to its other obligations, commitments and undertakings set out in this Agreement, Knight agrees to assume the reasonable costs of intellectual property filings, procurement and maintenance for all intellectual property applications and registrations associated with the FT Products in Canada.
   
3.9 Additional Terms.
     
  3.9.1 A Party shall promptly notify the other Party in writing of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority in Canada, concerning the quality of FT Products and/or documentation or other items for such changes relating to the quality of the FT Products. The Parties shall negotiate in good faith towards an appropriate response to such a Governmental Authority in respect of each proposed change in the quality of the FT Products including any costs associated with implementing said changes.
     
  3.9.2 Minor changes in the procedures for manufacture or quality control that do not require approval from a Governmental Authority in Canada or that will not affect Regulatory Approvals in Canada will be communicated by Knight to Nomad in an annual review,
     
  3.9.3 Knight will maintain complete and accurate books, records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.
     
  3.9.4 During the Term of this Agreement and for three (3) years thereafter, Nomad will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Knight as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.

 

 
6

 

  3.9.5 If, based on the results of any audit under Section 3.9.4, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.
     
3.10 Responsibility. Nomad acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of FT Products in Canada through Direct Channel Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.
     
4 PAYMENT AND FINANCIAL TERMS
     
  4.1 Product Price. Knight will supply FT Products to Nomad at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) sixty percent (60%) of the Gross Sales. Knight shall initially invoice Nomad for the Cost of Goods for FT Products supplied hereunder. Nomad shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of FT Products relating thereto.
     
  4.2 Report. Within sixty (60) days following the end of each Calendar Quarter, Nomad shall render a written report to Knight setting forth the following information and calculations in which sales of FT Products occurred as permitted pursuant to Section 2.1 above in the Calendar Quarter covered by such report:

 

  4.2.1 the Gross Sales, if any, in Canadian dollars; and
     
  4.2.2 the calculation of the balance of the Product Price for FT Products (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.

     
4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by Nomad within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.
   
4.4 Currency. The Product Price shall be paid by Nomad in Canadian dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than Canadian dollars, the Cost of Goods shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to Nomad in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than Canadian dollars, Gross Sales shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.5 Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty- four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.

 

 
7

 

4.6 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
4.7 Withholding Tax. Nomad will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Nomad under this Agreement will be timely paid by Nomad on behalf of Knight to the appropriate Governmental Authority, and Nomad will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Nomad and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
4.8 VAT and Similar Taxes. All amounts paid by Nomad to Knight under this Agreement are exclusive of, and Nomad shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.
   
5 TERM
   
5.1 Initial Term. The appointment set forth in Section 2.1 shall be for the duration of five (5) years commencing on the date hereof, and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.
   
5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:
     
  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Nomad’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

 
8

 

5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and Nomad undertakes to except as provided for in Section 5.4, cease any Commercialization of the FT Products in Canada.
   
5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, Nomad shall be entitled to sell off any inventory of the FT Products in Nomad’s possession or control or which are subject to binding purchase orders on the date such termination is effective.
   
6 LIMITATION OF LIABILITY
   
  WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.
   
7 OTHER PROVISIONS
   
7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.

 

 
9

 

7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of Canada.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.
   
7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:

 

  (a) In the case of the Nomad:

 

NOMAD CHOICE PTY LTD.

c/o Synergy Strips Corp.

865 Spring Street

Westbrook, Maine 04092

Attention: Jack Ross

E-mail:          jack.ross@purebrands.ca

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax:               (919) 781-4865

E-mail:          dmannheim@wyrick.com

 

 
10

 

  (b) In the case of Knight:

 

KNIGHT THERAPEUTICS INC.

376 Victoria Avenue

Suite 220

Westmount, Quebec H3Z 1C3

Attention: Jeff Kadanoff, Chief Financial Officer

Fax: (514) 481-4116

E-mail:          jkadanoff@gud-laiight.com

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

1501 McGill College Ave.

Suite 2600

Montreal, Quebec H3A 3N9

Attention: Hillel W. Rosen

Fax:               (514) 841-6499

E-mail:          hrosen@dwpv.com

 

73 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances
   
7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.
   
7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.

 

 
11

 

7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof
   
7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision..

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
     
  By: /s/ Jeffrey Kadanoff
  Name: Jeffrey Kadanoff
  Title: CFO
     
  NOMAD CHOICE PTY LTD.
     
  By:                         
  Name:  
  Title:  

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
     
  By:                         
  Name:
  Title:
     
  NOMAD CHOICE PTY LTD.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

Exhibit 10.23

 

DISTRIBUTION AGREEMENT
(Remaining Territories)

 

THIS AGREEMENT, effective February 15, 2016, by and among KNIGHT THERAPEUTICS (BARBADOS) INC. (“Knight”), a corporation incorporated under the laws of Barbados, and NOMAD CHOICE PTY LTD. (“Nomad”), a corporation formed under the laws of Australia.

 

WHEREAS Synergy CHC Corp. (“Synergy”) and Knight are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time, including by amendment and confirmation agreement dated December 3, 2015 to which amendment Nomad and Breakthrough Products, Inc. were also parties (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named Knight its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS Synergy has acquired all of the shares of Nomad effective November 16, 2015 and, as and from that date, Nomad became an Affiliate;

 

WHEREAS pursuant to the amendment and confirmation agreement dated December 3, 2015 and referred to above, Nomad confirmed that the terms and conditions of the DLS Agreement apply to it and its products;

 

WHEREAS FT Products (as herein defined) are included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with. Nomad in respect of Direct Channel Sales of FT Products in all countries of the Territory other than Canada (collectively, the “Remaining Territories”);

 

WHEREAS Knight assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight Therapeutics Inc. (“KTI”);

 

WHEREAS, contemporaneously herewith, Nomad and KTI are entering into a similar distribution agreement with respect to Canada.

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS
   
1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.

 

 
2

 

1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:
   
  “Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of FT Products and supply of same to Nomad under this Agreement. For greater certainty, where Knight purchases FT Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer.
   
  “Direct Channels Sales” means the Commercialization of FT Products in the Remaining Territories directly to consumers from a website or any other direct-to-consumer sales channel.
   
  “FT Products” means the “Flat Tummy Tea” line of products as now or may in the future be Commercialized by Nomad or its Affiliates (including future line extensions relating thereto) and other tea or beverage products and related accessories Commercialized from time to time by Nomad or any company or entity controlled by Nomad. For greater certainty, the “Flat Tummy Tea” line of products shall include any products and accessories that are Commercialized under the “Flat Tummy” trademark and/or tradename (or any variations thereof) together with any tea products and related accessories, or any beverage products that are marketed to reduce bloating.
   
  “Gross Sales” means the gross invoiced sales price for FT Products sold by Nomad or its Affiliates, as applicable, to Third Parties throughout the Remaining Territories during each Calendar Quarter, less only (i) the shipping and handling charges that are actually incurred by Nomad or its Affiliates in delivering such FT Products to the end users in the Remaining Territories and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of FT Products. Sales between or among Nomad and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where
   
  (a) FT Products are sold by Nomad or its Affiliates other than in an arm’s length sale,
  (b) FT Products are sold as one of a number of items without a separate invoiced price; or
  (c) consideration for FT Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be Nomad’s average Gross Sales to Third Parties for the applicable quantity of FT Products at that time.
   
1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 Gender. Words of one gender include the other gender.

 

 
3

 

1.7 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.
   
1.8 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.
   
1.9 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.10 Party References. Reference to any Party includes the successors and permitted assigns of that Party.
   
1.11 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.
   
1.12 United States Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of the United States, unless otherwise noted.
   
2 DISTRIBUTION TERMS
   
2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and its Affiliates, hereby appoints Nomad as its exclusive Third Party distributor of FT Products for the Remaining Territories solely and exclusively in respect of Direct Channel Sales and further grants to Nomad and Nomad hereby accepts for the Remaining Territories and solely and exclusively in respect of Direct Channel Sales a non-exclusive sublicense under the Synergy Marks used in association with FT Products to Commercialize FT Products through Direct Channel Sales in the Remaining Territories. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute FT Products in the Remaining Territories through Direct Channel Sales. In the event that Knight determines to create and operate a website or uses other social media to promote and sell FT Products in the Remaining Territories, it shall consult with Nomad and each of Nomad and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the FT Products in the Remaining Territories through Direct Channel Sales, Knight shall not pursue a brand strategy that Nomad, acting reasonably, determines is materially adverse to the brand equity of FT Products in the Remaining Territories.
   
2.2 Sublicensing. Nomad may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and Nomad assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.

 

 
4

 

2.3 Interim Period. Section 3.2 below contemplates that Knight shall enter into an agreement with the Manufacturer. Knight shall advise Nomad by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, Nomad shall be permitted to source FT Products directly from the Manufacturer. Nomad will make payments to Knight equal to sixty percent (60%) of Gross Sales in respect of the period from November 1, 2015 and until Nomad exhausts sales of FT Products sourced from such directly acquired inventory. The first such payment in respect of Gross Sales made during the period from November 1, 2015 to and including December 31, 2015 shall be made within ten (10) Business Days from the date hereof. A further payment in respect of the Gross Sales made during the period from January 1, 2016 to and including the Notice Date shall be made within ten (10) Business Days of the Notice Date for Gross Sales made during such period. Thereafter, payments shall be made on a monthly basis (on or before the fifteenth (15th) day of each month) from all Gross Sales of such inventory and until such inventory is exhausted.
   
3 SUPPLY
   
3.1 Exclusivity. Except as set forth otherwise in Section 2.3, Nomad will purchase all of its requirements of FT Products for the Remaining Territories and in respect of Direct Channel Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. Nomad acknowledges that Knight may from time to time enter into an agreement with a contract manufacturer (the “Manufacturer”) for the supply of FT Products under this Agreement. In such instances, Knight and Nomad shall determine mutually acceptable procedures that will allow Nomad to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that Nomad shall acquire FT Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at Nomad’s request, facilitate any claims, demands, complaints or similar actions that Nomad wishes to assert against the Manufacturer in respect of FT Products purchased by Nomad from Knight.
   
3.3 Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the packaging for the FT Products, Knight shall not be obliged to supply packaging to Nomad. Nomad will continue to source such packaging itself and will make arrangements with the Manufacturer to fill bulk product into the packaging provided.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of FT Products that are on order or unpaid from time to time.
   
3.5 Liability. Nomad acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of FT Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.
   
3.6 Regulatory Submissions. Knight shall be solely responsible, at its expense, for preparing, filing, and managing any Regulatory Submission and for maintaining any Regulatory Approval for the FT Products in the Remaining Territories. Nomad shall provide reasonable assistance to Knight in making submissions to Governmental Authorities and maintaining such Regulatory Approvals. Unless otherwise required by Applicable Law, any Regulatory Approvals shall be filed, owned and held in the name of Knight. Knight shall notify Nomad of all Regulatory Submissions that it submits.

 

 
5

 

3.7 Regulatory Correspondence. Each Party shall promptly (and in any event, within five (5) Business Days of the date of receipt of notice) notify the other Party in writing of, and shall provide the other Party with copies of, any material correspondence received from a Governmental Authority in the Remaining Territories. In the event that a Party receives any material regulatory letter requiring a response, the other Party will cooperate fully with the receiving Party in preparing such response and will promptly provide the receiving Party with any data or information required by the Receiving Party in preparing any such response.
   
3.8 Other Covenants. In addition to its other obligations, commitments and undertakings set out in this Agreement, Knight agrees to assume the reasonable costs of intellectual property filings, procurement and maintenance for all intellectual property applications and registrations associated with the FT Products in the Remaining Territories.
   
3.9 Additional Terms.
     
  3.9.1 A Party shall promptly notify the other Party in writing of all proposed changes, whether voluntary or involuntary, including those arising from a request from a Governmental Authority in the Remaining Territories, concerning the quality of FT Products and/or documentation or other items for such changes relating to the quality of the FT Products. The Parties shall negotiate in good faith towards an appropriate response to such a Governmental Authority in respect of each proposed change in the quality of the FT Products including any costs associated with implementing said changes.
     
  3.9.2 Minor changes in the procedures for manufacture or quality control that do not require approval from a Governmental Authority in the Remaining Territories or that will not affect Regulatory Approvals in the Remaining Territories will be communicated by Knight to Nomad in an annual review.
     
  3.9.3 Knight will maintain complete and accurate books, records, and accounts used for the determination of expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.

 

 
6

 

  3.9.4 During the Term of this Agreement and for three (3) years thereafter, Nomad will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of Knight as may be reasonably necessary to verify the accuracy of Cost of Goods for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.
     
  3.9.5 If, based on the results of any audit under Section 3.9.4, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.
     
3.10 Responsibility. Nomad acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of FT Products in the Remaining Territories through Direct Channel Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.
   
4 PAYMENT AND FINANCIAL TERMS
   
4.1 Product Price. Knight will supply FT Products to Nomad at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) sixty percent (60%) of the Gross Sales. Knight shall initially invoice Nomad for the Cost of Goods for FT Products supplied hereunder. Nomad shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of FT Products relating thereto.
   
4.2 Report. Within sixty (60) days following the end of each Calendar Quarter, Nomad shall render a written report to Knight setting forth the following information and calculations in which sales of FT Products occurred as permitted pursuant to Section 2.1 above in the Calendar Quarter covered by such report:
     
  4.2.1 the Gross Sales, if any, in United States dollars; and
     
  4.2.2 the calculation of the balance of the Product Price for FT Products (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.
     
4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by Nomad within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.

 

 
7

 

4.4 Currency. The Product Price shall be paid by Nomad in United States dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than United States dollars, the Cost of Goods shall be converted into United States dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to Nomad in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than United States dollars, Gross Sales shall be converted into United States dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.5 Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty-four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.
   
4.6 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
4.7 Withholding Tax. Nomad will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by Nomad under this Agreement will be timely paid by Nomad on behalf of Knight to the appropriate Governmental Authority, and Nomad will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction. of the withheld amount, or to otherwise comply with its duties. Nomad and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
4.8 VAT and Similar Taxes. All amounts paid by Nomad to Knight under this Agreement are exclusive of, and Nomad shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, Ievies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.
   
5 TERM
   
5.1 Initial Term. The appointment set forth in Section 2.1 shall be for the duration of five (5) years commencing on the date hereof, and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.

 

 
8

 

5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:
     
  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Nomad’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.
     
5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and Nomad undertakes to except as provided for in Section 5.4, cease any Commercialization of the FT Products in the Remaining Territories.
   
5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, Nomad shall be entitled to sell off any inventory of the FT Products in Nomad’s possession or control or which are subject to binding purchase orders on the date such termination is effective.
     
6 LIMITATION OF LIABILITY
   
  WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.
     
7 OTHER PROVISIONS
   
7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.

 

 
9

 

7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.
   
7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of the Remaining Territories.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.
   
7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:

 

  (a) In the case of the Nomad:

 

NOMAD CHOICE PTY LTD.

do Synergy Strips Corp.

865 Spring Street

Westbrook, Maine 04092

Attention: Jack Ross

E-mail:          jack.ross@purebrands.ca

 

 
10

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax:               (919) 781.4865

E-mail:          dmannheim@wyrick.com

 

  (b) In the case of Knight:

 

KNIGHT THERAPEUTICS (BARBADOS) INC.

The Business Centre

Upton, St-Michael

BB11103 Barbados

Attention: Michel Loustric, President

E-mail:          mloustric@gud-knight.com

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

900 Third Avenue - 24th Floor

New York, New York 10022

U.S.A.

Attention: Hillel W. Rosen

Fax:              (212) 308-0132

E-mail:          hrosen@dwpv.com

 

7.7 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances
   
7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

 
11

 

7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof
   
7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision.

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
  (BARBADOS) INC.
     
  By: /s/ Michael Loustric
  Name: Michael Loustric
  Title: President
     
  NOMAD CHOICE PTY LTD.
     
  By:
  Name:
  Title:

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
  (BARBADOS) INC.
     
  By:                        
  Name:
  Title:
     
  NOMAD CHOICE PTY LTD.
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

Exhibit 10.24

 

DISTRIBUTION AGREEMENT
(Canada)

 

THIS AGREEMENT, effective January 1, 2017, by and among KNIGHT THERAPEUTICS INC. (“Knight”), a corporation incorporated under the laws of Canada, and SNEAKY VAUNT CORP. (“SVC”), a corporation formed under the laws of Delaware.

 

WHEREAS Synergy CHC Corp (“Synergy”) and Knight Therapeutics (Barbados) Inc. (“KB”) are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time, including by amendment and confirmation agreement dated December 3, 2015 to which. amendment Nomad Choice pty Ltd and Breakthrough Products, Inc. were also parties and that certain Amendment Agreement dated December 22, 2016 (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named KB its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS KB assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight;

 

WHEREAS SVC is a subsidiary of Synergy and markets and sells SV Products (as herein defined);

 

WHEREAS SV Products are accordingly included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with SVC in respect of Direct Channel Sales of SV Products in Canada;

 

WHEREAS contemporaneously herewith, KB and SVC are entering into a similar distribution agreement with respect to Countries in the Territory other than Canada;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS
   
1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
   
1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:
   
  “Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of SV Products and supply of same to SVC under this Agreement. For greater certainty, where Knight purchases SV Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer.

 

 
2

 

  “Direct Channels Sales” means the Commercialization of SV Products in Canada directly to consumers from a website or any other direct-to-consumer sales channel.
   
  “Gross Sales” means the gross invoiced sales price for SV Products sold by SVC or its Affiliates, as applicable, to Third Parties throughout Canada during each Calendar Quarter, less only (i) the shipping and handling charges that are actually incurred by SVC or its Affiliates in delivering such SV Products to the end users in Canada and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of SV Products. Sales between or among SVC and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where (a) SV Products are sold by SVC or its Affiliates other than in an arm’s length sale, (b) SV Products are sold as one of a number of items without a separate invoiced price; or (c) consideration for SV Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be SVC’s average Gross Sales to Third Parties for the applicable quantity of SV Products at that time.
   
  “SV Products” means the “Sneaky Vaunt” line of products as now or may in the future be Commercialized by SVC or its Affiliates (including future line extensions relating thereto) and lingerie and other apparel products and related accessories Commercialized from time to time by SVC or any company or entity controlled by SVC. For greater certainty, the “Sneaky Vaunt” line of products shall include any products and accessories that are Commercialized under the “Sneaky Vaunt” trademark and/or tradename (or any variations thereof).
   
  “Threshold Amount” means $1,096,497.07.
   
1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 Canadian Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of Canada, unless otherwise noted.
   
1.7 Gender. Words of one gender include the other gender.
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

 

 
3

 

1.9 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.
   
1.10 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.11  Party References. Reference to any Party includes the successors and permitted assigns of that Party.
   
1.12 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.
   
2 DISTRIBUTION TERMS
   
2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and  its Affiliates, hereby appoints SVC as its exclusive Third Party distributor of SV Products for Canada solely and exclusively in respect of Direct Channel Sales and further grants to SVC and SVC hereby accepts for Canada and solely and exclusively in respect of Direct Channel Sales a non-exclusive sublicense under the SVC Marks used in association with SV Products to Commercialize SV Products through Direct Channel Sales in Canada. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute SV Products in Canada through Direct Channel Sales. In the event that Knight determines to create and operate a website or uses other social media to promote and sell SV Products in Canada, it shall consult with SVC and each of SVC and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the SV Products in Canada through Direct Channel Sales, Knight shall not pursue a brand strategy that SVC, acting reasonably, determines is materially adverse to the brand equity of SV Products in Canada.
   
2.2 Sublicensing. SVC may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and SVC assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.
   
2.3 Interim Period. Section 3.2 below contemplates that Knight shall enter into an agreement with the Manufacturer. Knight shall advise SVC by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, SVC shall be permitted to source SV Products directly from the Manufacturer. With respect to SV Products not purchased from Knight and commencing January 1, 2017 and for each Calendar Year thereafter, SVC will make payments to Knight equal to sixty percent (60%) of Gross Sales from sales of SV Products until Gross Sales in such Calendar Year equal the Threshold Amount and then forty percent (40%) of Gross Sales in that same Calendar Year in excess of the Threshold Amount. Payments shall be made (i) initially within 2 Business Days of the execution of this Agreement in respect to all Calendar Quarters prior to the date hereof and (ii) within thirty (30) days following the end of each subsequent Calendar Quarter. Such payments shall be accompanied by the report to Knight as per Section 4.2.1.

 

 
4

 

3 SUPPLY
   
3.1 Exclusivity. Except as set forth otherwise in Section 2.3, SVC will purchase all of its requirements of SV Products for Canada and in respect of Direct Channel Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. SVC acknowledges that Knight may from time to time enter into an agreement with a contract manufacturer (the “Manufacturer”) for the supply of SV Products under this Agreement. In such instances, Knight and SVC shall determine mutually acceptable procedures that will allow SVC to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that SVC shall acquire SV Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at SVC’s request, facilitate any claims, demands, complaints or similar actions that SVC wishes to assert against the Manufacturer in respect of SV Products purchased by SVC from Knight.
   
3.3 Labelling and Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the labelling and/or packaging for the SV Products, Knight shall not be obliged to supply labelling and/or packaging to SVC. SVC will continue to source such labelling and/or packaging itself.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of SV Products that are on order or unpaid from time to time.
   
3.5 Liability. SVC acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of SV Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.
     
3.6 Additional Terms
     
  3.6.1 Each party will maintain complete and accurate books, records, and accounts used for the determination of (i) in the case of Knight, expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods, and (ii) in the case of SVC, the determination of Gross Sales in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.

 

 
5

 

  3.6.2 During the Term of this Agreement and for three (3) years thereafter, each Party will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of the other Party as may be reasonably necessary to verify the accuracy of Cost of Goods or Gross Sales (as the case may be) for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight or Gross Sales reported by SVC (as applicable) is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.
     
  3.6.3 If, based on the results of any audit under Section 3.6.2, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.
     
3.7 Responsibility. SVC acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of SV Products in Canada through Direct Channel Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.
     
4 PAYMENT AND FINANCIAL TERMS
   
4.1 Product Price. Knight will supply SV Products to SVC at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) for each Calendar Year, sixty percent (60%) of the Gross Sales until the Gross Sales in such Calendar Year equal the Threshold Amount and then forty percent (40%) of all Gross Sales in that same Calendar Year in excess of the Threshold Amount. Knight shall initially invoice SVC for the Cost of Goods for SV Products supplied hereunder. SVC shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of SV Products relating thereto.
   
4.2 Report. Within twenty-five (25) days following the end of each Calendar Quarter, SVC shall render a written report to Knight setting forth the following information and calculations in which sales of SV Products occurred as permitted pursuant to Section 2.1 above in the Calendar Quarter covered by such report:
     
  4.2.1 the Gross Sales, if any, in Canadian dollars; and
     
  4.2.2 the calculation of the balance of the Product Price for SV Products (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.

 

 
6

 

4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by SVC within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.
   
4.4 Currency. The Product Price shall be paid by SVC in Canadian dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than Canadian dollars, the Cost of Goods shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to SVC in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than Canadian dollars, Gross Sales shall be converted into Canadian dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.5

Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty-four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.

   
4.6

Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.

   
4.7 Withholding Tax. SVC will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by SVC under this Agreement will be timely paid by SVC on behalf of Knight to the appropriate Governmental Authority, and SVC will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. SVC and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
4.8 VAT and Similar Taxes. All amounts paid by SVC to Knight under this Agreement are exclusive of, and SVC shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.

 

 
7

 

5 TERM
   
5.1 Initial Term. The appointment set forth in Section 2.1 shall be for an initial period terminating on February 15, 2021 and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.
     
5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:
     
     
  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of SVC’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and SVC undertakes to except as provided for in Section 5.4, cease any Commercialization of the SV Products in Canada.
   
5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, SVC shall be entitled to sell off any inventory of the SV Products in SVC’s possession or control or which are subject to binding purchase orders on the date such termination is effective.

 

 
8

 

6 LIMITATION OF LIABILITY
   
  WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.
   
7 OTHER PROVISIONS
   
7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.
   
7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.
   
7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of Canada.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.

 

 
9

 

7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:
     
  (a) In the case of the SVC:

 

SNEAKY VAUNT CORP.

do Synergy CI-IC Corp

865 Spring Street

Westbrook, Maine 04092

Attention: Jack Ross

E-mail:          jack@synergychc.com

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax:               (919) 781-4865

E-mail:          dmannheim@wyrick.com

 

  (b) In the case of Knight:

 

KNIGHT THERAPEUTICS INC.

3400 De Maisonneuve Blvd. West

Suite 1055

Montreal, Quebec H3Z 3B8

Attention: Jeffrey Kadanoff, Chief Financial Officer

Fax:              (514) 481-4116

E-mail:          jkadanoff@gudknight.com

 

 
10

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

1501 McGill College Ave.

Suite 2600

Montreal, Quebec H3A 3N9

Attention: Hillel W. Rosen

Fax:              (514) 841-6499

E-mail:          hrosen@dwpv.com

 

7.7 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof. Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances
   
7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof. Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.
   
7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof
   
7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision.

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
   
  By: /s/ Jeffrey Kadanoff
  Name: Jeffrey Kadanoff
  Title: CFO
                                   
  SNEAKY VAUNT
   
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

Exhibit 10.25

 

DISTRIBUTION AGREEMENT

(Remaining Territories)

 

THIS AGREEMENT, effective January 1, 2017, by and among KNIGHT THERAPEUTICS (BARBADOS) INC. (“Knight”), a corporation incorporated under the laws of Barbados, and SNEAKY VAUNT CORP (“SVC”), a corporation fowled under the laws of Delaware.

 

WHEREAS Synergy CHC Corp. (“Synergy”) and Knight are parties to that certain distribution, license and supply agreement dated January 22, 2015 as may be amended, supplemented or restated from time to time, including by amendment and confirmation agreement dated December 3, 2015 to which amendment Nomad Choice Pty Ltd. and Breakthrough Products, Inc. were also parties and that certain Amendment Agreement dated December 22, 2016 (collectively the “DLS Agreement”);

 

WHEREAS pursuant to the DLS Agreement, Synergy, for itself and on behalf of its Affiliates, has named Knight its exclusive distributor of Licensed Products in the Territory;

 

WHEREAS SVC is a subsidiary of Synergy and markets and sells SV Products (as herein defined);

 

WHEREAS SV Products accordingly are included amongst the Licensed Products;

 

WHEREAS Knight wishes to enter into this distribution agreement with SVC in respect of Direct Channel Sales of SV Products in all countries of the Territory other than Canada (the “Remaining Territories”);

 

WHEREAS Knight assigned all of its rights under the DLS Agreement in respect of Licensed Products in Canada to Knight Therapeutics Inc (“KTI”);

 

WHEREAS contemporaneously herewith, KTI and SVC are entering into a similar distribution agreement with respect to Canada;

 

NOW THEREFORE in consideration of the mutual promises and covenants contained herein, the Parties, intending to be legally bound, agree as follows:

 

1 DEFINITIONS
   
1.1 Definitions. Unless the context otherwise indicates, defined terms used in this Agreement shall have the meaning ascribed thereto in the DLS Agreement.
   
1.2 The following terms as used hereinafter in this Agreement shall have the meaning set forth in this Section:

 

“Cost of Goods” means Knight’s cost of manufacture, packaging and/or purchase of SV Products and supply of same to SVC under this Agreement. For greater certainty, where Knight purchases SV Products from a Manufacturer, the Cost of Goods will be the amount paid by Knight to the Manufacturer.

 

 
2

 

“Direct Channel Sales” means the Commercialization of SV Products in the Remaining Territories directly to consumers from a website or any other direct-to-consumer sales channel.

 

“Gross Sales” means the gross invoiced sales price for SV Products sold by SVC or its Affiliates, as applicable, to Third Parties throughout the Remaining Territories during each Calendar Quarter, less only (i) the shipping and handling charges that are actually incurred by SVC or its Affiliates in delivering such SV Products to the end users in the Remaining Territories and (ii) sales, value added and other similar taxes that are included in the gross invoiced sales price of SV Products. Sales between or among SVC and its Affiliates shall be excluded from the computation of Gross Sales, but Gross Sales shall include the subsequent final sales to Third Parties by any such Affiliates. Where (a) SV Products are sold by SVC or its Affiliates other than in an arm’s length sale, (b) SV Products are sold as one of a number of items without a separate invoiced price; or (c) consideration for SV Products shall include any non-cash element, the Gross Sales applicable to any such transaction shall be deemed to be SVC’s average Gross Sales to Third Parties for the applicable quantity of SV Products at that time.

 

“SV Products” means the “Sneaky Vaunt” line of products as now or may in the future be Commercialized by SVC or its Affiliates (including future line extensions relating thereto) and lingerie and other apparel products and related accessories Commercialized from time to time by SVC or any company or entity controlled by SVC. For greater certainty, the “Sneaky Vaunt” line of products shall include any products and accessories that are Commercialized under the “Sneaky Vaunt” trademark and/or tradename (or any variations thereof).

 

1.3 Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof.
   
1.4 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.
   
1.5 Sections and Headings. The term “Section” refers to the specified Section of this Agreement, unless otherwise specified. Headings and captions of the Sections hereof are for convenience only and are not to be used in the interpretation of this Agreement.
   
1.6 United States Dollars. References in this Agreement to “Dollars” or “$” shall mean the legal tender of United States, unless otherwise noted.
   
1.7 Gender. Words of one gender include the other gender.
   
1.8 Include, Includes, Including. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import.

 

 
3

 

1.9 Joint and Several Obligations. Unless specified otherwise in this Agreement, the obligations of any Party consisting of more than one person are joint and several.
   
1.10 Number of Days. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days.
   
1.11 Party References.’ Reference to any Party includes the successors and permitted assigns of that Party.
   
1.12 Singular/Plural. Words using the singular or plural number also include the plural or singular number, respectively.

 

2 DISTRIBUTION TERMS
   
2.1 Distribution. Subject to the terms of the Agreement, Knight on behalf of itself and its Affiliates, hereby appoints SVC as its exclusive Third Party distributor of SV Products for the Remaining Territories solely and exclusively in respect of Direct Channel Sales and further grants to SVC and SVC hereby accepts for the Remaining Territories and solely and exclusively in respect of Direct Channel Sales a non-exclusive sublicense under the Synergy Marks used in association with SV Products to Commercialize SV Products through Direct Channel Sales in the Remaining Territories. For greater certainty, the said appointment shall not limit the right of Knight (directly or through its Affiliates) to distribute SV Products in the Remaining Territories through Direct Channel Sales. In the event that Knight determines to create and operate a website or uses other social media to promote and sell SV Products in the Remaining Territories, it shall consult with SVC and each of SVC and Knight shall coordinate and cooperate with respect to their web and social media initiatives. In commercializing the SV Products in the Remaining Territories through Direct Channel Sales, Knight shall not pursue a brand strategy that SVC, acting reasonably, determines is materially adverse to the brand equity of SV Products in the Remaining Territories.
   
2.2 Sublicensing. SVC may sublicense its rights granted hereunder or use sub-distributors or third party service providers to exercise its right or fulfill its obligations hereunder. All sublicense agreements, distribution or other arrangements or agreements shall be consistent with the terms and conditions of this Agreement, and SVC assumes full responsibility for any actions taken by any sublicensee, distributor or other party and any of the expenses, costs, or fees incurred by any sublicensee, distributor or other party.
   
2.3 Interim Period. Section 3.2 below contemplates that Knight shall enter into an agreement with the Manufacturer. Knight shall advise SVC by notice in writing when such agreement is in place (the “Notice Date”). Notwithstanding Section 3.1, until the Notice Date, SVC shall be permitted to source SV Products directly from the Manufacturer. With respect to SV Products not purchased from Knight, effective January 1, 2017, SVC will make payments to Knight equal to sixty percent (60%) of Gross Sales from sales of SV Products. Payments shall be made (i) initially within 2 Business Days of the execution of this Agreement in respect to all Calendar Quarters prior to the date hereof and (ii) within thirty (30) days following the end of each subsequent Calendar Quarter. Such payments shall be accompanied by the report to Knight as per Section 4.2.1.

 

 
4

 

3 SUPPLY
   
3.1 Exclusivity. Except as set forth otherwise in Section 2.3, SVC will purchase all of its requirements of SV Products for the Remaining Territories and in respect of Direct Channel Sales exclusively from Knight, subject to the terms and conditions of this Agreement.
   
3.2 Manufacturer. SVC acknowledges that Knight may from time to time enter into an agreement with a contract manufacturer (the “Manufacturer”) for the supply of SV Products under this Agreement. In such instances, Knight and SVC shall determine mutually acceptable procedures that will allow SVC to liaise directly with the Manufacturer in respect of order entry, logistics, delivery and other related matters; provided that SVC shall acquire SV Products exclusively from Knight as stated in Section 3.1 above. Subject to Section 3.5 below, Knight will, at SVC’s request, facilitate any claims, demands, complaints or similar actions that SVC wishes to assert against the Manufacturer in respect of SV Products purchased by SVC from Knight.
   
3.3 Labelling and Packaging. The parties acknowledge that to the extent that the Manufacturer does not supply the labelling and/or packaging for the SV Products, Knight shall not be obliged to supply labelling and/or packaging to SVC. SVC will continue to source such labelling and/or packaging itself.
   
3.4 Credit Limit. Knight may impose reasonable credit limits on the amount of SV Products that are on order or unpaid from time to time.
   
3.5 Liability. SVC acknowledges that Knight’s liability for any and all claims arising from or in connection with the supply of SV Products under this Agreement shall be limited to the amounts that Knight may itself recover from the Manufacturer less all amounts incurred by Knight to recover such amounts.

 

3.6 Additional Terms.

 

  3.6.1 Each Party will maintain complete and accurate books, records, and accounts used for the determination of (i) in the case of Knight expenses, deductions, credits, or other relevant factors in connection with the calculation of Cost of Goods and (ii) in the case of SVC, the determination of Gross Sales, in sufficient detail to confirm the accuracy of any payments required under this Agreement, which books, records, and accounts will be retained until three (3) years after the end of the period to which such books, records, and accounts pertain.

 

 
5

 

  3.6.2 During the Term of this Agreement and for three (3) years thereafter, each Party will have the right to have an independent certified public accounting firm of internationally recognized standing access during normal business hours, and upon reasonable prior written notice, to such of the records of the other Party as may be reasonably necessary to verify the accuracy of Cost of Goods or Gross Sales (as the case may be) for any Calendar Quarter. The accounting firm will disclose to the Parties only whether the Cost of Goods reported by Knight or Gross Sales reported by SVC (as applicable) is correct or incorrect and the specific details concerning any discrepancies. The auditing Party will bear all costs of such audit, unless the audit reveals a discrepancy in the auditing Party’s favor of more than five percent (5%), in which case the other Party will bear the cost of the audit. Each Party will treat all information subject to review under this Section as Confidential Information and will cause its accounting firm to enter into a reasonably acceptable confidentiality agreement obligating such firm to maintain all such financial information in confidence pursuant to such confidentiality agreement.
     
  3.6.3 If, based on the results of any audit under Section 3.6.2, payments are owed by one Party to the other under this Agreement, then the Party having such obligation will make such payment promptly after the accounting firm’s written report is delivered by courier or registered mail to both Parties.

 

3.7 Responsibility. SVC acknowledges the terms and conditions of the DLS Agreement and agrees that, except as set forth in this Agreement, it shall be solely liable and responsible for all obligations, liabilities and requirements under the DLS Agreement and under Applicable Law relating to the Commercialization of SV Products in the Remaining Territories through Direct Channel Sales as permitted pursuant to Section 2.1 and shall indemnify and hold Knight harmless in respect of same.

 

4 PAYMENT AND FINANCIAL TERMS
   
4.1 Product Price. Knight will supply SV Products to SVC at a price (the “Product Price”) equal to the aggregate of (i) the Cost of Goods and (ii) sixty percent (60%) of the Gross Sales. Knight shall initially invoice SVC for the Cost of Goods for SV Products supplied hereunder. SVC shall pay Knight’s invoice for the Cost of Goods no later than thirty (30) days after delivery of SV Products relating thereto.
   
4.2 Report. Within twenty-five (25) days following the end of each Calendar Quarter, SVC shall render a written report to Knight setting forth the following information and calculations in which sales of SV Products occurred as permitted pursuant to Section 2.1 above in the Calendar Quarter covered by such report:
   

 

  4.2.1 the Gross Sales, if any, in United States dollars; and
     
  4.2.2 the calculation of the balance of the Product Price for SV Products (having regard to the Cost of Goods previously invoiced) based on that Calendar Quarter’s actual Gross Sales.

 

4.3 Balance of Product Price. The payment of the balance of the Product Price shall be made by SVC within thirty (30) days from the end of each Calendar Quarter in which such payment accrues.

 

 
6

 

4.4 Currency. The Product Price shall be paid by SVC in United States dollars. For the purposes of determining the Cost of Goods, if incurred by Knight in a currency other than United States dollars, the Cost of Goods shall be converted into United States dollars using the closing conversion rate of the Bank of Canada on the business date prior to the date of the invoice to SVC in respect thereof, and with respect to the balance of the Product Price, if Gross Sales were invoiced in a currency other than United States dollars, Gross Sales shall be converted into United States dollars using the closing conversion rate of the Bank of Canada on the last business day of the calendar quarter preceding the applicable calendar quarter.
   
4.5 Procedures. All sums due under this Agreement shall be paid by wire transfer of immediately available funds, or such other method mutually agreed upon by the Parties, in each case at the expense of the payer, no later than the due date thereof (with twenty-four (24) hours advance notice of each wire transfer) to the bank accounts or such other bank accounts as the payee shall designate in writing within reasonable period of time prior to such due date.
   
4.6 Interest. In the event that any payment due hereunder is not made when due, interest shall accrue at a rate per annum equal to the lesser of one point twenty-five percent (1.25%) per month or the highest rate permitted by Law, calculated on the number of days such payments are paid after the date such payments are due and compounded monthly.
   
4.7 Withholding Tax. SVC will make all payments to Knight under this Agreement without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Any tax required to be withheld on amounts payable by SVC under this Agreement will be timely paid by SVC on behalf of Knight to the appropriate Governmental Authority, and SVC will furnish Knight with the corresponding proof of payment of such tax, as may be required in order to enable Knight to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. SVC and Knight agree to cooperate to legally minimize and reduce such withholding taxes and provide any information or documentation required by any taxing authority.
   
4.8 VAT and Similar Taxes. All amounts paid by SVC to Knight under this Agreement are exclusive of, and SVC shall pay any sales, use, rental, custom, excise, stamp documentary, value added, consumption or other similar Taxes, duties, levies, fees or charges that may be assessed in any jurisdiction resulting from or arising under this Agreement. Knight shall collect and remit such taxes, duties, levies, fees or charges as required under Law.
   
5 TERM
   
5.1 Initial Term. The appointment set forth in Section 2.1 shall be for an initial period
   
  terminating on February 15, 2021 and this Agreement shall automatically renewal for additional one (1) year terms unless either Party gives notice of nonrenewal at least one hundred and eighty (180) days prior to the end of the then-current term.

 

 
7

 

5.2 Termination for Breach. Either Party may terminate this Agreement by written notice to the other Party with immediate effect in the following cases:

 

  (a) In the event of a petition in bankruptcy or insolvency of the other Party, or in case of the filing by the other Party of any petition or answer seeking reorganization, readjustment, or rearrangement of its business under any law or any government regulation relating to bankruptcy or insolvency, or in case of the institution by the other Party of any proceedings for the liquidation or winding up of its business, or for the termination of its corporate charter.
     
  (b) If the other Party is otherwise in material default or breach of this Agreement and such default or breach is not cured within (i) sixty (60) days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of SVC’s failure to pay any amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days, within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting or breaching Party.

 

5.3 Effect of Termination. Upon expiry or termination of this Agreement, all rights granted by Knight hereunder shall terminate and SVC undertakes to except as provided for in Section 5.4, cease any Commercialization of the SV Products in the Remaining Territories.
   
5.4 Sell-Off of Inventory. Subject to compliance with Section 4 hereof, upon termination of this Agreement, SVC shall be entitled to sell off any inventory of the SV Products in SVC’s possession or control or which are subject to binding purchase orders on the date such termination is effective.
   
6 LIMITATION OF LIABILITY
   
  WITHOUT LIMITING THE PARTIES’ OBLIGATIONS REGARDING INDEMNIFICATION, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY WHO MAY BENEFIT FROM ANY PROVISION OF THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.
   
7 OTHER PROVISIONS
   
7.1 Further Assurances. Upon request by either Party and at such Party’s expense, the other Party shall do such further acts and execute such additional agreements and instruments as may be reasonably necessary to give effect to the purposes of this Agreement.

 

 
8

 

7.2 Independent Status. Each Party shall act as an independent contractor and shall not bind nor attempt to bind the other Party to any contract, nor any performance of obligations outside of the license agreement. Nothing contained or done under the Agreement shall be interpreted as constituting either Party the agent of the other in any sense of the term whatsoever or in the relationship of partners or joint venturers.
   
7.3 Assignment. Except in connection with the acquisition of a Party or the sale of all or substantially all of the assets of such Party, this Agreement may not be, directly or indirectly, assigned or transferred, in whole or in part, by a Party to a Third Party without the prior written consent of the other Party. The rights and obligations contained herein shall inure to the benefit of each Party’s successors and permitted assigns, and shall be binding on and enforceable against the relevant Party’s successors and permitted assigns. Any reference in this Agreement to any Party shall be construed accordingly.
   
7.4 Compliance with Law. Each Party shall comply with, and shall not be in violation of any valid applicable international, national, provincial or local statutes, laws, ordinances, rules, regulations, or other governmental orders of the Remaining Territories.
   
7.5 Force Majeure. No Party shall be responsible for a failure or delay in performance of any of the obligations hereunder due wars, insurrections, strikes, acts of God, power outages, storms, or actions of regulatory agencies (such events being defined as “Force Majeure”), provided that the Party seeking relief from its obligations advises the other Party forthwith of the Force Majeure. A Party whose performance of obligations has been delayed by force majeure shall use commercially reasonable efforts to overcome the effect of the Force Majeure as soon as possible. The other Party will have no right to demand indemnity for damage or assert a breach against such Party, provided, however, that if the event of Force Majeure preventing performance shall continue for more than six (6) months and such underlying cause would not also prevent other parties from performing such obligations, then the Party not subject to the event of Force Majeure may terminate this Agreement with a written notice to the other without any liability hereunder, except the obligation to make payments due to such date.
   
7.6 Notices and Amendments. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be given by facsimile or other means of electronic communication or by hand delivery as hereinafter provided. Any such notice, if sent by fax or other means of electronic communication, shall be deemed to have been received on the day of sending, or if delivered by hand shall be deemed to have been received at the time it is delivered to the applicable address noted below. Notices of change of address shall also be governed by this Section 7.6. Notices and other communications shall be addressed as follows:

 

  (a) In the case of the Sneaky Vaunt Corp

 

SNEAKY VAUNT CORP

c/o Synergy CHC Corp.

865 Spring Street

Westbrook, Maine 04092

Attention: Jack Ross

E-mail:          jack@synergychc.com

 

 
9

 

with a copy to:

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

U.S.A.

Attention: W. David Mannheim, Esq.

Fax:                 (919) 781-4865

E-mail:             dmannheim@wyrick.com

 

  (b) In the case of Knight:

 

KNIGHT THERAPEUTICS (BARBADOS) INC.

The Business Centre

Upton, St-Michael

BB11103 Barbados

Attention: Michel Loustric, President

E-mail:            mloustric@gudknight.com

 

With a copy to:

 

Davies Ward Phillips & Vineberg LLP

900 Third Avenue 24th Floor

New York, New York 10022

U.S.A.

Attention: Hillel W. Rosen

Fax:                  (212) 308-0132

E-mail:             hrosen@dwpv.com

 

7.7 Waiver. No failure to exercise and no delay in exercising any right or remedy hereunder shall operate as a waiver thereof Any waiver granted hereunder shall only be applicable the specific acts covered thereby and shall not apply to any subsequent events, acts, or circumstances
   
7.8 Complete Agreement. This Agreement embodies all of the understandings and obligations between the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof Any amendments or supplements to this Agreement shall not be valid unless executed in writing by duly authorized officers of both parties.
   
7.9 Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portion hereof shall remain in full force and effect. If any of the terns or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law.

 

 
10

 

7.10 Governing Law. This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of the State of New York.
   
7.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be considered one and the same Agreement and shall become effective when a counterpart hereof has been signed by each of the Parties and delivered to the other Party.
   
7.12 Time of Essence. Time shall be of the essence of this Agreement and of each provision hereof
   
7.13 Arbitration. Except as otherwise expressly provided herein, any dispute or claim arising out of or relating to this Agreement, or to the breach, termination, or validity of this Agreement, will be resolved as follows: each Party shall discuss the matter and make reasonable efforts to attempt to resolve the dispute. If the Parties are unable to resolve, the dispute a CEO or President of each Party will meet within thirty days (30) of a request to attempt to resolve such dispute being made by a Party. If the CEOs or Presidents cannot resolve the dispute through good faith negotiations within sixty (60) days after a Party requests such meeting, then the Parties shall resort to binding arbitration before a single arbitrator using the arbitration procedures set forth under the American Arbitration Association under its Commercial Arbitration Rules. Any hearing in the course of the arbitration shall be held New York, New York in the English language. The decision of the arbitrator shall be final and not subject to appeal and the arbitrator may apportion the costs of the arbitration, including the reasonable fees and disbursements of the parties, between or among the parties in such manner as the arbitrator considers reasonable. All matters in relation to the arbitration shall be kept confidential to the full extent permitted by law, and no individual shall be appointed as an arbitrator unless he or she agrees in writing to be bound by this provision.

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, the Parties have signed this Agreement,

 

  KNIGHT THERAPEUTICICS
  (BARBADOS) INC.
                                
  By: /s/ Michael Loustric
  Name: Michael Loustric
  Title: President
     
  SNEAKY VAUNT
     
  By: /s/ Jack Ross
  Name: Jack Ross
  Title: CEO

 

 

 

Exhibit 10.26

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

 

Date: October 9, 2009    Vendor A/P No.
      Dept. No  

 

COSTCO WHOLESALE

BASIC VENDOR AGREEMENT

United States (2004)

 

Factor Nutrition Labs LLC (“Vendor”) and Costco
Wholesale Corporation (referred to as “Costco Wholesale”) agree that:  

 

A. Agreement Documents. All sales and deliveries of all merchandise by Vendor to Costco Wholesale (or other purchaser under paragraph C below), and all purchase orders by Costco Wholesale (or other purchaser under paragraph C below) to Vendor, will be covered by and subject to the terms of each of the following documents (collectively the “Agreement Documents”):

 

  ●  This Basic Vendor Agreement;
     
  ●  The attached Costco Wholesale Standard Terms United States (2004), as they may be amended in writing by Costco Wholesale from time to time (“Standard Terms”); and
     
  ●  Each Vendor Purchase Program Agreement, Item Agreement, or any other agreements (such as warehouse displays, promotions or rebates) that have been or will be signed between Vendor and Costco Wholesale.

 

B. Inconsistency. The above Agreement Documents collectively are an agreement between us, are part of this Basic Vendor Agreement and are incorporated herein by reference. In case of any inconsistency among any Agreement Documents, the lowest such document in the above list will take priority over any document higher on the list.
   
C. Purchaser. Each purchase will be made in the name of “Costco Wholesale,” but may be for the account of its affiliates or licensees.
   
D. Insurance. The insurance requirements are set forth in Section 16 of the Standard Terms.
   
E. Disputes. Disputes shall be resolved under Sections 20 and 21 of the Standard Terms.
   
F. Relationship of the Parties. The relationship between Costco Wholesale and Vendor is that of an independent contractor and Vendor agrees that it has not and shall not hold itself out as, nor shall Vendor be deemed to be, an agent of Costco Wholesale.

 

Page 1
 

 

G. Vendor Code of Conduct. Vendor agrees to comply with Costco Wholesale’s Vendor Code of Conduct (December 2003), as it may be amended in writing by Costco Wholesale from time to time.
   
H. Other Forms. The Agreement Documents supersede all terms in Vendor’s invoices and other forms, and all prior oral or written communications between us. No party is entering into these Agreement Documents in reliance on any oral or written promises, representations or understandings other than those in the Agreement Documents.

 

COSTCO WHOLESALE CORPORATION VENDOR:
       
By By /s/ Annie L Hodgdon
  (Buyer)   (Signature of Owner, Officer or other Authorized Employee)
       
By   Annie L. Hodgdon Retail Coordinator
  (GMM)   (Print Name and Title

 

Page 2
 

 

 

 
 

 

 

 
 

 

 

 

 
 

 

      Vendor A/P No. __________________________________________
Date:  

Sept. 23, 2009

Dept. No. ____________________________________________________

 

COSTCO.COM DROP-SHIP VENDOR AGREEMENT

United States (2004)

 

Factor Nutrition Labs LLC (“Vendor”) and Costco Wholesale Corporation (referred to hereinafter as “costco.com” unless specifically stated otherwise agree that:

 

1. Agreement Documents. All sales and deliveries of all Merchandise by Vendor to costco.com’s Customers purchased by costco.com from Vendor, and sold through the Internet e-commerce site(s) of costco.com or its Affiliate Purchasers (as defined below), will be covered by and subject to the definitions in the Drop-Ship E-Standard Terms and the terms of each of the following documents (collectively the “Drop-Ship Agreement Documents”):

 

(a) This costco.com Drop-Ship Vendor Agreement;
   
(b) The attached costco.com Drop-Ship E-Standard Terms (United States 2004), as they may be amended in writing by costco.com from time to time (the “Drop-Ship E-Standard Terms”); and
   
(c) Each Vendor Purchase Program Agreement, costco.com E-Item Agreement or any other agreement that has been or will be signed between Vendor and costco.com.

 

2. Inconsistency. The above Drop-Ship Agreement Documents collectively are an agreement between us, are part of this costco.com Drop-Ship Vendor Agreement and are incorporated herein by reference. In case of any inconsistency among any Drop-Ship Agreement Documents, the lowest such document on the list in Section 1 above will take priority over any document higher on the list.

 

3. Purchaser. Each purchase will be made in the trade name of “costco.com,” but may be for the account of Costco Wholesale or of its affiliates or licensees that operate online e-commerce sites and for whom Costco Wholesale acts as purchasing agent (“Affiliate Purchasers”).

 

4. Insurance. Vendor shall comply with the insurance requirements set forth in Section 27 of the Drop-Ship E-Standard Terms.

 

5. Disputes. Disputes shall be resolved as provided in Sections 32, 33 and 34 of the Drop-Ship E- Standard Terms.

 

6. Relationship of the Parties. The relationship between costco.com and Vendor is that of an independent contractor and Vendor agrees that it has not and shall not hold itself out as, nor shall Vendor be deemed to be, an agent of costco.com.

 

 
 

 

7. Assigned Numbers. Vendor acknowledges that the Vendor A/P number and department number referenced on page 1 of this costco.com Drop-Ship Vendor Agreement, as well as any vendor number assigned to Vendor by costco.com, are included for the sole benefit of costco.com and may be changed by costco.com at any time and from time to time. Costco.com will notify Vendor of any such change(s) and Vendor will thereafter use the revised number(s) as and when required by costco.com.

 

8. Vendor Code of Conduct. Vendor agrees to comply with Costco Wholesale’s Vendor Code of Conduct (December 2003), as it may be amended in writing by Costco Wholesale from time to time.

 

9. Other Forms. The Agreement Documents supersede all terms in Vendor’s invoices and other forms, and all prior oral or written communications between us. Costco.com shall not be bound by, and specifically objects to, any term, condition or other provision that is different or in addition to the provisions of the Agreement Documents and is offered by Vendor and otherwise appears in any email, invoice, receipt, acceptance, confirmation, correspondence or otherwise, unless costco.com specifically agrees to such provision in a writing signed by costco.com. No party is entering into these Agreement Documents in reliance on any oral or written promises, representations or understandings other than those in the Agreement Documents.

 

Costco. com :

Vendor:

   
Costco Wholesale Corporation Factor Nutrition Labs LLC
     
Signature of GMM: _____________________________ Signature: /s/ Annie L Hodgon
     
Printed Name: _____________________________ Printed Name: Annie L. Hodgdon
     
Signature of Buyer: _____________________________ Title: Retail Coordinator
     
Printed Name: _____________________________    

 

 

 

Exhibit 10.27

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

 

SUPPLIER AGREEMENT

 

Supplier Number: −40− Effective Date: //

 

This Supplier Agreement (“Agreement”) between the party listed below (“Supplier”) and Wal−Mart Stores, Inc., Wal−Mart Stores East, LP, Wal−Mart Stores East, Inc., Wal−Mart Stores Texas, LP, Sam’s West, Inc., Sam’s East, Inc. and affiliates (hereinafter referred to collectively as “Company”) sets forth Supplier’s qualifications and the general terms of the business relationship between Company and Supplier. The parties agree that all sales and deliveries of all Merchandise (as defined below) by Supplier to Company and all Orders (as defined below) by Company will be covered by and subject to the terms of this Agreement, the Standards for Suppliers (which is attached and incorporated by reference) and any Order signed or initialed (electronically or otherwise) by an Authorized Buyer (as defined below) for Company. This Agreement becomes effective on the date shown above and remains effective for the term set forth herein. The execution and submission of this Agreement does not impose upon Company any obligation to purchase Merchandise.

 

 

 

General Supplier Information

 

Supplier’s Business Classification: (Please disregard this section if Supplier is not a female or minority−owned business)

 

Woman−Owned? Minority Owned?

BLACK ASIAN−PACIFIC AMERICAN INDIAN ESKIMO HISPANIC NATIVE AMERICAN ALEUT NATIVE HAWAIIAN

 

If Supplier falls within any of the above classes, and has been certified as minority−owned by a government agency or purchasing council, Supplier is qualified for the first step in the Wal−Mart Minority/Female Owned Business Development Program (the “Supplier Development Program”). Supplier agrees to provide to Company a copy of its certification as a prerequisite to qualification in the Supplier Development Program. For further information, please contact the Wal−Mart Supplier Development Office at 1−800−604−4555.

 

 

 

Enter the Federal Taxpayer Identification Number (TIN) of the Supplier Named Below.

If a TIN has not been issued, enter the Employer’s Social Security Number.

TIN: *****0274

Type of Payee (Check Only One): _Individual/Sole Proprietorship _Corporation _Partnership X Other

 

Supplier Information: FACTOR NUTRITION LABS   President : PAUL LEVINSHOHN Phone: 2073212309
Address: 100 COMMERCIAL STREET   Acct. Executive or V.P. Sales: MICHAEL WILSON Phone: 2073212303
Address 2:            
City/State/Zip: PORTLAND, ME 04101   Acct. Contact:   Phone:  

 

ADDRESS TO MAIL PAYMENT:     ADDRESS TO SEND ORDERS:
         
Supplier Name: FACTOR NUTRITION LABS    Supplier Name: FACTOR NUTRITION LABS
         
Address: 100 COMMERCIAL STREET SUITE 200    Attention: JAIME UNDERWOOD
         
Address 2:   Address: 100 COMMERCIAL STREET
         
City/State/Zip: PORTLAND, ME 04101   City/State/Zip: PORTLAND, ME 04101
         
Factor Name:     Street Address for use by delivery services other than the U.S.
         
Supplier Also Doing Business As: (Attach a list to Agreement if space below is insufficient):     Mail, if not already shown in the Purchase Order address above.:
        Room:
Supplier Number:     Expedite Orders: Phone: Extension #:
      2073212337  
         
ADDRESS TO MAIL CLAIM DOCUMENTATION:      
      ADDRESS TO SEND
Attention: JAIME UNDERWOOD   PRICING TICKETS:
Address: 100 COMMERCIAL STREET   Supplier Name: FACTOR NUTRITION LABS
City/State/Zip: PORTLAND, ME 04101   Attention: JAIME UNDERWOOD
Accounting Phone Number: 2073212337 Extension #: 0   Address: 100 COMMERCIAL STREET
Toll Free Number: Fax Number: 2073212397   City/State/Zip: PORTLAND, ME 04101

 

Has Supplier or any related entity previously conducted business with Company? Yes No X If so, under what name(s)?

 

STANDARD TERMS AND CONDITIONS

 

1. DEFINITIONS. As used in this Agreement or any Company issued Order, the following capitalized words shall have the following meanings:

 

(a) “Account” shall mean any right to receive payments arising under this Agreement.

(b) “Anticipation” shall mean the intentional or unintentional payment of obligations prior to the due date which results in a monetary adjustment in amounts payable to Supplier.

(c) “Authorized Buyer” shall mean any General Merchandise Manager, Divisional Merchandise Manager, Buyer 1, 2 or 3 and replenishment manager assigned to the Wal−Mart category/department corresponding to the purchased Merchandise.

(d) “Merchandise” shall mean all products, goods, materials, equipment, articles, and tangible items supplied by Supplier to Company and all packaging, instructions, warnings, warranties, advertising and other services included therewith.

(e) “Electronic Data Interchange” (“EDI”) shall mean the moving of information regarding specific business processes (invoicing, ordering, reporting, etc.) electronically between two or more businesses. The information is transmitted electronically structured according to standards mandated by Company.

 

 
 

 

( ) “End of Month Dating” shall mean payment terms beginning at the first of the following month rather than from the receipt of merchandise, if the merchandise is received on or after the 24th of the month.

(a) “High Risk Supplier” shall mean a Supplier identified as such by Company in view of the nature of the Supplier’s products, the severity of claims made against Supplier’s products, the frequency of claims made, past litigation involving the Supplier’s products and other factors deemed relevant by Company.

(b) “Order” shall mean any written or electronic purchase order issued by Company.

(c) “Recall” shall mean any removal of Merchandise from the stream of commerce initiated by Supplier, a government entity or Company.

(d) “Standards” shall mean the Wal−Mart Stores, Inc. Standards for Suppliers, attached hereto.

(e) “Vendor Master” shall mean the accounting department of Company responsible for control and processing of new supplier agreements and updates to existing agreements.

 

2. ORDERS; CANCELLATION. Supplier may ship only after receipt of an Order. Acceptance of an Order may be made only by shipment of the Merchandise in accordance herewith. Acceptance is expressly limited to all of the terms and conditions of such Order, including, all shipping, routing and billing instructions and all attachments and supplemental instructions delivered therewith. Shipments made contrary to Company’s routing instructions will be deemed F.O.B. Destination (either store, club or warehouse). Supplier’s invoice, confirmation memorandum or other writing may not vary the terms of any Order. Supplier’s failure to comply with one or more terms of an Order shall constitute an event of default and shall be grounds for the exercise by Company of any of the remedies provided for in this Agreement or by applicable law. Projections, past purchasing history and representations about quantities to be purchased are not binding, and Company shall not be liable for any act or expenditure (including but not limited to expenditures for equipment, materials, packaging or other capital expenditures) by Supplier in reliance on them. Company may cancel all or any part of an Order at any time prior to shipment.

 

3. SUPPLIER FINANCIAL INFORMATION; SALES TO COMPANY. Supplier shall submit to Company with this Agreement one of the following: (1) a complete set of audited current financial statements, (2) a current Dun & Bradstreet financial report, or (3) if publicly held, Supplier’s most recent annual report to shareholders and management proxy information. If Company’s purchases from Supplier are anticipated by Supplier to constitute twenty percent (20%) or more of Supplier’s gross annual sales on a calendar year basis, Supplier agrees to notify Company of this fact, in writing, within thirty (30) days of Supplier becoming aware of such possibility.

 

4. PAYMENT TERMS; CASH DISCOUNT; ANTICIPATION. Supplier shall transmit invoices on the same day Merchandise is shipped, but payment terms shall date from Company’s receipt of the Merchandise. If Supplier selects End of Month Dating on Appendix 1 hereto, Merchandise received after the 24th of any month shall be payable as if received on the first day of the following month. Any cash discount selected by Supplier on Appendix 1 will be calculated on the gross amount of Supplier’s invoice. Anticipation may be taken upon the mutual consent of the parties.

 

5. SET−OFF; RESERVATION OF ACCOUNT; CREDIT BALANCE. Company may set off against amounts payable under any Order all present and future indebtedness of Supplier to Company arising from this or any other transaction whether or not related hereto. If Company determines that Supplier’s performance under an Order and/or this Agreement is likely to be impaired, Company may establish a reserve on Supplier’s Account to satisfy Supplier’s actual or anticipated obligations to Company arising from any such Order or this Agreement, by withholding payment of Supplier’s invoices. Supplier agrees that any credit balance will be paid in cash to Company upon written request.

 

IMPORTANT NOTICE: ALL PAYMENTS OF MONIES OWED PURSUANT TO THIS SUPPLIER AGREEMENT AND PURCHASE ORDERS MUST BE MAILED TO THE FOLLOWING ADDRESS:

 

WAL−MART STORES, INC./SAM’S CLUB, C/O CORPORATE ACCOUNTING, P.O. BOX 500787, ST. LOUIS, MISSOURI 63150−0787.

 

Note: Any payments on your Wal−Mart or SAM’S CLUB Credit Card should be mailed to the billing address indicated on your credit card statement, not the address above.

 

6. NOTICE REGARDING ASSIGNMENT OF ACCOUNTS; ACCOUNT DISPUTES. Supplier shall provide Company written notice of an assignment, factoring, or other transfer of its Account at least 30 days prior to such assignment, factoring, or other transfer taking legal effect. Such written notice shall include the name and address of the assignee/transferee, the date the assignment is to begin, and terms of the assignment, and shall be considered delivered upon receipt of such written notice by Vendor Master. Supplier may have only one assignment, factoring or transfer of its Account effective at any time. The assignment of any Account hereunder shall not affect Company’s rights set forth in Section 5 of this Agreement. Supplier shall defend indemnify and hold Company harmless from any and all lawsuits, claims, demands, actions, damages (including reasonable attorney fees, court costs, obligations, liabilities or liens) arising from or related to the assignment, transfer or factoring of its Account. Supplier releases and waives any right, claim or action against Company for amounts due and owing under this Agreement where Supplier has not complied with the notice requirements of this provision. Notices required pursuant to this Section shall be mailed to: Wal−Mart Stores, Inc., Attn: Vendor Master, 1108 S.E. 10th St. Bentonville, AR 72716−0680.

 

Notwithstanding the foregoing, any dispute or any other circumstance, Company reserves the right to remit payment to Supplier.

 

7. TAXES. The prices set forth in any Order are deemed to include all taxes. If any manufacturer’s excise or other similar or different taxes are paid on the Merchandise described in any Order and if such tax, or any part thereof, is refunded to Supplier, then Supplier shall immediately pay Company the amount of such refund.

 

8. PRICE PROTECTION; PRICE GUARANTEE AND NOTICE OF PRICE INCREASES. Supplier guarantees its prices against manufacturer’s or Supplier’s own price decline. If Supplier reduces its price on any Merchandise sold to Company, which Merchandise has not yet been delivered to Company by Supplier or, if consistent with Supplier’s practice, which Merchandise is currently in Company’s inventory (including Merchandise on hand, in warehouses and in transit), Supplier shall at Company’s discretion either issue a check or give Company a credit equal to the price difference for such Merchandise, multiplied by the units of such Merchandise to be delivered by Supplier and/or currently in Company’s inventory. For all Merchandise not yet shipped to Company, Supplier agrees to meet the price of any of its competitors selling comparable merchandise. If a court, regulatory agency or other government entity with jurisdiction finds that the prices on an Order are in excess of that allowed by any law or regulation of any governmental agency, the prices shall be automatically revised to equal a price which is not in violation of said law or regulation. If Company shall have made payment before it is determined that there has been a violation of this section, Supplier shall promptly refund an amount of money equal to the difference between the price paid for the Merchandise and the price which is not in violation of this section. If contemporaneously with Supplier’s sale of Merchandise to the Company, Supplier sells or offers to any competitor of Company any merchandise of like grade and quality at lower prices and/or on terms more favorable than those stated on the Order, the prices and/or terms of the Order shall be deemed automatically revised to equal the lowest prices and most favorable terms at which Supplier shall have sold or shall have offered such merchandise and payment shall be made accordingly. If Company shall become entitled to such lower prices, but shall have made payment at any prices in excess thereof, Supplier shall promptly refund the difference in price to Company. If there is a price increase, Supplier shall give Company written notice of any such increase at least sixty (60) days prior to the effective date of the increase.

 

 
 

 

9. SUPPLIER EDI RESPONSIBILITIES.

 

(a) Supplier shall electronically receive Orders and send Company invoices via EDI unless otherwise agreed to by Company in writing.

(b) Supplier shall assure that access by its employees to the EDI interchange is restricted by password to those persons authorized to contractually bind Supplier.

(c) Supplier’s use of the EDI interchange acknowledges Supplier’s review and acceptance of the terms and requirements for using the EDI system to contract electronically.

(d) Supplier will establish a user I.D. to identify itself, and the presence of this user I.D. in the EDI interchange will be sufficient to verify the source of the data and the authenticity of the document.

(e) Documents containing the user I.D. will constitute a signed writing, and neither party shall contest the validity or enforceability of the document on the basis of lack of a signature or sufficient identification of the parties.

(f) EDI documents or printouts thereof shall constitute originals.

(g) EDI documents will be retained by both Company and Supplier in a form that is accessible and reproducible.

(h) If Company agrees to waive the EDI requirements of this section of this Agreement, Orders may be sent via overnight mail at Supplier’s expense.

 

10. PURCHASE COSTS AND CONDITIONS. Supplier is responsible for verifying the accuracy of costs, discounts, allowances and all other terms of sale on all Orders. If incorrect information exists, Supplier shall notify Company not less than twenty−four (24) hours prior to shipment. If a change is necessary, no shipment is to commence without written confirmation of the change from an authorized member of Company’s merchandising department. If Merchandise ships prior to discovery of an error on the Order, the parties shall confer within forty−eight (48) hours of such discovery to determine the actions to be taken regarding the erroneous Order.

 

11. SHIPPER LOAD AND COUNT RESPONSIBILITIES. Supplier who is shipping a full truckload collect, or full truckload under Company control, to Company will be responsible for monitoring its shipping process. Supplier is required to close the trailer, seal it with a Supplier−provided seal, and document the seal number on all copies of the Bill of Lading. All such shipments will be considered Shipper Load and Shipper Count, whether or not so notated. If Supplier fails to seal the trailer, or fails to reference and identify the seal on all copies of the Bill of Lading, and shortages occur, Supplier shall be liable for such shortage. The Shipper expressly agrees that the contractual provision herein shall supersede any contrary Bill of Lading term, clause, notation, other provision, or any other writing.

 

12. DELIVERY TIME. THE TIME SPECIFIED IN AN ORDER FOR SHIPMENT OF MERCHANDISE IS OF THE ESSENCE OF THIS AGREEMENT AND IF SUCH MERCHANDISE IS NOT SHIPPED WITHIN THE TIME SPECIFIED, COMPANY RESERVES THE RIGHT, AT ITS OPTION AND WITHOUT LIMITATION, TO CANCEL THE ORDER AND/OR REJECT ANY MERCHANDISE DELIVERED AFTER THE TIME SPECIFIED. In addition to the aforementioned remedy, Company may exercise any other remedies provided for in this Agreement or provided by applicable law, including but not limited to those remedies provided by the Uniform Commercial Code. Notwithstanding Company’s right to cancel shipment, or to reject or revoke acceptance of Merchandise, Supplier agrees to inform Company immediately of any actual or anticipated failure to ship all or any part of an Order or the exact Merchandise called for in an Order on the shipment date specified. Acceptance of any Merchandise shipped after the specified shipment date shall not be construed as a waiver of any of Company’s rights or remedies resulting from the late shipment.

 

13. REPRESENTATIONS, WARRANTIES AND GUARANTEES. By acceptance of an Order, Supplier represents, warrants and guarantees that:

 

(a) The Merchandise will be new and not used, remanufactured, reconditioned or refurbished, and will comply with all specifications contained in such Order and will be of equal or better quality as all samples delivered to Company;

(b) The Merchandise is genuine and is not counterfeit, adulterated, misbranded, falsely labeled or advertised or falsely invoiced within the meaning of any applicable local, state or federal laws or regulations;

(c) The Merchandise has been labeled, advertised and invoiced in accordance with the requirements (if applicable) of the Wool Products Labeling Act of 1939, the Fur Products Labeling Act, the Textile Fiber Products Identification Act and any other applicable local, state or federal laws or regulations, and the sale of the Merchandise by Company does not and will not violate any such laws;

(d) Reasonable and representative tests made in accordance with the requirements of the Flammable Fabrics Act (if applicable) show that the Merchandise is not so highly flammable as to be dangerous when worn by individuals;

(e) The Merchandise is properly labeled as to content as required by applicable Federal Trade Commission Trade Practice Rules, the Fair Labor Standards Act, the Federal Food, Drug and Cosmetics Act and similar local, state or federal laws, rules or regulations;

(f) The Merchandise shall be delivered in good and undamaged condition and shall, when delivered, be merchantable and fit and safe for the purposes for which the same are intended to be used, including but not limited to consumer use;

(g) The Merchandise does not infringe upon or violate any patent, copyright, trademark, trade name, trade dress, trade secret or, without limitation, any other rights belonging to others, and all royalties owed by Supplier, if any, have been paid to the appropriate licensor;

(h) All weights, measures, sizes, legends or descriptions printed, stamped, attached or otherwise indicated with regard to the Merchandise are true and correct, and conform and comply with all laws, rules, regulations, ordinances, codes and/or standards of federal, state and local governments relating to said Merchandise;

(i) The Merchandise is not in violation of any other laws, ordinances, statutes, rules or regulations of the United States or any state or local government or any subdivision or agency thereof, including but not limited to all laws and regulations relating to health, safety, environment, serial and identification numbers, labeling and country of origin designation, toxic substances, OSHA and EPA regulations, Federal Meat Inspection Act or Poultry Products Inspections Act (or any other food safety statute) and the requirements of California Proposition 65, and such Merchandise or the sale thereof by Company do not and will not violate any such laws;

(j) All Merchandise shall have an accurate twelve (12) digit manufacturer−assigned UPC number that complies with Companys UPC requirements, as amended from time to time;

(k) There is no other impediment or restriction, legal or otherwise, that limits, prohibits or prevents Supplier from selling and delivering the Merchandise to Company or limits, prohibits or prevents Company from reselling the Merchandise to its customers;

(l) The Merchandise is mined, produced, manufactured, assembled and packaged in compliance with the Standards; and

 

 
 

 

(m) The Merchandise is not transshipped for the purpose of mislabeling, evading quota or country of origin restrictions or avoiding compliance with the Standards. Where applicable, Supplier agrees to provide Company with a current, complete and accurate Material Safety Data Sheet (“MSDS”) for said Merchandise;

(n)if any particular item of Merchandise under this Agreement contains a powder, liquid, gel or paste that is not intended for human consumption; a compressed gas or propellant (such as an aerosol); or a flammable solid (such as matches), Supplier shall notify Company. If the item Merchandise contains such properties, Companys Chemicals Return Policy shall govern all returns of such Merchandise and Supplier shall promptly elect return options under that policy.

 

It shall be within the sole discretion of Company to determine if Supplier has breached the above−mentioned representations, warranties and guarantees. In addition to the representations, warranties and guarantees contained in this paragraph, all other representations, warranties and guarantees provided by law, including but not limited to any warranties provided by the Uniform Commercial Code, are specifically incorporated herein. Nothing contained in this Agreement or an Order shall be deemed a waiver of any representations, warranties or guarantees implied by law.

 

14. INDEMNIFICATION. Supplier shall protect, defend, hold harmless and indemnify Company, including its officers, directors, employees and agents, from and against any and all lawsuits, claims, demands, actions, liabilities, losses, damages, costs and expenses (including attorneys’ fees and court costs), regardless of the cause or alleged cause thereof, and regardless of whether such matters are groundless, fraudulent or false, arising out of any actual or alleged:

 

(a) Misappropriation or infringement of any patent, trademark, trade dress, trade secret, copyright or other right relating to any Merchandise;

(b) Death of or injury to any person, damage to any property, or any other damage or loss, by whomsoever suffered, resulting or claimed to result in whole or in part from any actual or alleged use of or latent or patent defect in, such Merchandise, including but not limited to (i) any actual or alleged failure to provide adequate warnings, labelings or instructions, (ii) any actual or alleged improper construction or design of said Merchandise, or (iii) any actual or alleged failure of said merchandise to comply with specifications or with any express or implied warranties of Supplier;

(c) Violation of any law, statute, ordinance, governmental administrative order, rule or regulation relating to the merchandise, or to any of its components or ingredients, or to its manufacture, shipment, labeling, use or sale, or to any failure to provide a Material Safety Data Sheet or certification;

(d) Act, activity or omission of Supplier or any of its employees, representatives or agents, including but not limited to activities on Company’s premises and the use of any vehicle, equipment, fixture or material of Supplier in connection with any sale to or service for the Company; and

(e) Any installation by Supplier of Merchandise covered by this Agreement.

 

Supplier shall promptly notify Company of the assertion, filing or service of any lawsuit, claim, demand, action, liability or other matter that is or may be covered by this indemnity, and shall immediately take such action as may be necessary or appropriate to protect the interests of Company, its officers, directors, employees and agents. Any and all counsel selected or provided by Supplier to represent or defend Company or any of its officers, directors, employees or agents shall accept and acknowledge receipt of Company’s Indemnity Counsel Guidelines, and shall conduct such representation or defense strictly in accordance with such Guidelines. If Company in its sole discretion shall determine that such counsel has not done so, or appears unwilling or unable to do so, Company may replace such counsel with other counsel of Company’s own choosing. In such event, any and all fees and expenses of Company’s new counsel, together with any and all expenses or costs incurred on account of the change of counsel, shall be paid or reimbursed by Supplier as part of its indemnity obligation hereunder. Company shall at all times have the right to direct the defense of, and to accept or reject any offer to compromise or settle, any lawsuit, claim, demand or liability asserted against Company or any of its officers, directors, employees or agents. The duties and obligations of Supplier created hereby shall not be affected or limited in any way by Company’s extension of express or implied warranties to its customers.

 

15. RECALLS. If Merchandise is the subject of a Recall, whether initiated by Supplier, Company or a government entity (including the issuance of safety notices), Supplier shall be responsible for all matters and costs associated with the Recall, including but not limited to:

 

(a) Consumer notification and contact;

(b) All expenses and losses incurred by Company in connection with such Recall (and where applicable, any products with which the Recalled Merchandise has been packaged, consolidated or commingled), including but not limited to refunds to customers, lost profits, transportation costs and all other costs associated therewith; and

(c) Initial contact and reporting of the Recall to any government agency having jurisdiction over the affected Merchandise.

 

If a government agency initiates any inquiry or investigation relating to the Merchandise or similar goods manufactured or supplied by Supplier, Supplier shall notify Company immediately thereof and take reasonable steps to resolve the matter without exposing Company to any liability or risk.

 

16. LIMITATION OF DAMAGES. In no event shall Company be liable for any punitive, special, incidental or consequential damages of any kind (including but not limited to loss of profits, business revenues, business interruption and the like), arising from or relating to the relationship between Supplier and Company, including all prior dealings and agreements, or the conduct of business under or breach of this Agreement or any Order, Company’s cancellation of any Order or Orders or the termination of business relations with Supplier, regardless of whether the claim under which such damages are sought is based upon breach of warranty, breach of contract, negligence, tort, strict liability, statute, regulation or any other legal theory or law, even if Company has been advised by Supplier of the possibility of such damages.

 

17. REMEDIES. Supplier’s failure to comply with any of the terms and conditions of this Agreement or any Order shall be grounds for the exercise by Company of any one or more of the following remedies:

 

(a) Cancellation of all or any part of any undelivered Order without notice, including but not limited to the balance of any remaining installments on a multiple−shipment Order;

(b) Rejection (or revocation of acceptance) of all or any part of any delivered shipment. Upon rejection or revocation of acceptance of any part of or all of a shipment, Company may return the Merchandise or hold it at Supplier’s risk and expense. Payment of any invoice shall not limit Company’s right to reject or revoke acceptance. Company’s right to reject and return or hold Merchandise at Supplier’s expense and risk shall also extend to Merchandise which is returned by Company’s customers. Company may, at its option, require Supplier to grant a full refund or credit to Company of the price actually paid by any customer of Company for any such item in lieu of replacement with respect to any item. Company shall be under no duty to inspect the Merchandise, and notice to Supplier of rejection shall be deemed given within a reasonable time if given within a reasonable time after notice of defects or deficiencies has been given to Company by its customers. In respect of any Merchandise rejected (or acceptance revoked) by Company, there shall be charged to Supplier all expenses incurred by Company in (i) unpacking, examining, repacking and storing such Merchandise (it being agreed that in the absence of proof of a higher expense that the Company shall claim an allowance for each rejection at the rate of 10% of the price for each rejection made by Company) and (ii) landing and reshipping such Merchandise. Unless Company otherwise agrees in writing, Supplier shall not have the right to make a conforming delivery within the contract time;

 

 
 

 

(c) Termination of all current and future business relationships;

(d) Assessment of monetary fines as determined in Company’s reasonable discretion;

(e) Recovery from Supplier of any damages sustained by Company as a result of Supplier’s breach or default; and

(f) Buyer’s remedies under the Uniform Commercial Code and such other remedies as are provided under applicable law.

 

These remedies are not exclusive and are in addition to all other remedies available to Company at law or in equity.

 

18. INSURANCE REQUIREMENTS. Supplier is required to obtain and maintain the following insurance coverage from a carrier acceptable to Company in the amounts and with the conditions listed below:

 

a) Commercial General Liability, including Contractual, Personal & Advertising Injury, Products and Completed Operations coverage, with certificate holder named as Additional Insured as evidenced by attached endorsement or blanket additional insured coverage provided by the policy. Policy shall be occurrence based with limits of no less than $5,000,000 per occurrence, without any aggregate limits or $50,000,000 in the aggregate. Defense costs shall not apply against coverage limits. High Risk Suppliers (as defined by Company) shall maintain policy limits of not less than $10,000,000 per occurrence without any aggregate limits or $100,000,000 in the aggregate.

b) Statutory Workers’ Compensation Coverage for a Supplier whose employees will be entering Company’s premises, with $1,000,000 in employers’ liability coverage and a waiver of subrogation where Permitted By Law.

c) Automobile Coverage, with certificate holder named as Additional Insured as evidenced by attached endorsement or blanket additional insured coverage provided by the policy, for a Supplier whose employees or agents will be driving on Company’s premises or making delivery to Company’s premises shall be occurrence based with limits of no less than $5,000,000 per occurrence, without any aggregate limits or $50,000,000 in the aggregate. Defense costs shall not apply against coverage limits.

d) Supplier shall provide at least thirty (30) days’ written notice prior to any cancellation of any policy of insurance maintained hereunder, and each such policy shall obligate the insurer to provide at least thirty (30) days’ written notice to Company in advance of any contemplated cancellation or termination thereof.

e) Supplier’s insurance shall be considered primary, non−contributory and not excess coverage.

 

A copy of Supplier’s current Certificate of Insurance with the following requirements must be submitted with this Agreement:

 

●Certificate Holder should read: WAL−MART STORES, INC., ITS SUBSIDIARIES & ITS AFFILIATES, 702 SW 8th Street, Bentonville, AR 72716−0145, Attn: Risk Management

●Renewals of Certificates of Insurance must be submitted prior to expiration of insurance coverage

●Existing Suppliers must include Supplier Number on Certificate of Insurance.

●Please direct any questions regarding your insurance to Risk Management at (479) 277−1658 or (479) 277−2890.

 

SUPPLIER CONTACT FOR PRODUCT LIABILITY CLAIMS:

 

Name: FACTOR NUTRITION LABS   Insuring Company: FEDERAL INSURANCE COMPANY
Address: 100 COMMERCIAL STREET   Telephone: 5163333000 Extension #: 0
City/State/Zip: PORTLAND, ME 04101        
Telephone: 2073212300   Extension #: 109  
Fax Number: 2077754349   e−mail: PLEVINSOHN@FACTORNUTRITION.COM

 

19. FORCE MAJEURE. If any place of business or other premises of Company shall be affected by lockouts, strikes, riots, war, acts of terrorism, fire, civil insurrection, flood, earthquake or any other casualty or cause beyond Company’s control, which might reasonably tend to impede or delay the reception, handling, inspecting, processing or marketing of the Merchandise covered by this Agreement, Company may, at its option, cancel all or any part of the undelivered Order hereunder by giving written notice to Supplier which notice shall be effective upon mailing.

 

20. ASSIGNMENT. Except as specifically set forth in Section 6, no part of this Agreement or of any Order shall be assignable by Supplier without the written consent of Company, and Company shall not be obligated to accept a tender of performance by any assignee, unless Company shall have previously expressly consented in writing to such an assignment.

 

21. PUBLICITY; USE OF NAME AND INTELLECTUAL PROPERTY. Supplier shall not refer to Company in any advertising or published communication without the prior written approval of Company. Supplier shall not use, or allow to be used, Company’s name, logo, trademarks, service marks, patents, copyrights or trade dress without the prior written approval of Company. Company may use Supplier’s name, logo, trademarks, service marks, patents, copyrights and trade dress in connection with Company’s marketing of the Merchandise.

 

22. COMPLIANCE WITH STANDARDS FOR SUPPLIER. Supplier warrants that it has read and understands and will comply with the requirements set forth in the Standards located at http://www.walmartstores.com/Files/SupplierStandards.pdf, or attached, as may be reasonably amended from time to time by Company. If the Supplier is not able to view the Standards on−line they may request a current copy from Supplier Development, their local Global Procurement office or from the Direct Imports Division. Company reserves the right to cancel any outstanding Order, refuse any shipments and otherwise cease to do business with Supplier if Supplier fails to comply with any terms of the Standards or if Company reasonably believes Supplier has failed to do so.

 

23. SEVERABILITY; WAIVER. At the option of Company, no finding that a part of this Agreement is invalid or unenforceable shall affect the validity of any other part hereof. Company’s failure to enforce at any time any provision of this Agreement will not be construed as a waiver of such provision or of any rights thereafter to enforce such provision. Any waiver by Company of any of the terms and conditions of this Agreement or any Order must be in writing signed by an authorized representative of Company.

 

 
 

 

24. FORUM SELECTION; CHOICE OF LAW; STATUTE OF LIMITATIONS. This Agreement, any and all Orders, and any and all disputes arising thereunder or relating thereto, whether sounding in contract or tort, shall be governed by and construed in accordance with the laws of the State of Arkansas without regard to the internal law of Arkansas regarding conflicts of law, and the federal and/or state courts of Benton and Washington County, Arkansas, shall have exclusive jurisdiction over any actions or suits relating thereto. The parties mutually acknowledge and agree that they shall not raise, and hereby waive, any defenses based upon venue, inconvenience of forum or lack of personal jurisdiction in any action or suit brought in accordance with the foregoing. Any legal action brought by Supplier against Company with respect to this Agreement or any Orders shall be filed in one of the above referenced jurisdictions within two (2) years after the cause of action arises or it shall be deemed forever waived. The parties acknowledge that they have read and understand this clause and agree willingly to its terms.

 

25. ATTORNEY FEES AND INTEREST OBLIGATIONS. Company reserves the right to charge Supplier interest at the rate of 12% per annum or such lower rate as may be permitted under applicable law for any obligations owed by Supplier to Company, including debit balances not paid within thirty (30) days after due, until such amounts are paid in full, and Company will be entitled to recover from Supplier its attorneys’ fees and costs incurred in collecting any past−due obligation.

 

26. NOTICES. Unless otherwise specifically provided for herein, any notice or demand which under the terms of this Agreement or under any statute must or may be given or made shall be in writing and shall be given or made by overnight express service addressed as follows: if to Company: Wal−Mart Stores, Inc., Attn: General Merchandise Manager (identify department or category), 702 SW 8th Street, Bentonville, AR 72716. If to Supplier: to Supplier’s address set forth above. Such notice or demand shall be deemed given on the second (2nd) business day after deposit of such notice or demand with the overnight express service. The above addresses may be changed at any time by giving prior written notice as provided above.

 

27. TERM OF AGREEMENT. This Agreement ends one year after the Effective Date. This Agreement may only be renewed or extended by an agreement signed by an authorized officer of Company and Supplier. Supplier and Company are under no obligation to extend the term of this Agreement or to renew this Agreement. Neither Supplier nor Company should take any actions in reliance upon this Agreement being extended or renewed. Neither party shall be responsible for any costs incurred by the other in anticipation of the extension or renewal of this Agreement.

 

28. INFORMATION SECURITY. Supplier represents that it currently follows industry best practices as a means to prevent any compromise of its information systems, computer networks, or data files (“Systems”) by unauthorized users, viruses, or malicious computer programs which could in turn be propagated via computer networks, email, magnetic media or other means to Company. Supplier agrees to immediately give Company notice if the security of its Systems are breached or compromised in any way.

 

Supplier agrees to apply appropriate internal information security practices, including, but not limited to, using appropriate firewall and anti−virus software; maintaining said countermeasures, operating systems, and other applications with up−to−date virus definitions and security patches; installing and operation security mechanisms in the manner in which they were intended sufficient to ensure the Company will not be impacted nor operations disrupted; and permitting only authorized users access to computer systems, applications, and Retail Link.

 

Supplier specifically agrees to: use up−to−date anti−virus tools to remove known viruses and malware from any email message or data transmitted to Company; prevent the transmission of attacks on Company via the network connections between Company and the Supplier; and prevent unauthorized access to Company systems via the Supplier’s networks and access codes.

 

In accordance with all applicable US and International privacy laws, Supplier agrees to safeguard confidential protected individually identifiable personal information (health, financial, identity) which are received, transmitted, managed, processed, etc. and to require subcontractor or agent to meet these same security agreements.

 

Financial service suppliers, who handle personally identifiable financial information of our customers agree to maintain a current SAS70 Type II audit.

 

29. SURVIVAL OF PROVISIONS. The provisions of this Agreement which by their nature are intended to survive termination of this Agreement (including but not limited to representations, warranties, guarantees, indemnifications, payment of obligations, remedies, forum selection and statute of limitations) shall survive its termination.

 

The parties hereto agree that this Agreement, the Standards and any Order constitute the full understanding of the parties, a complete allocation of risks between them and a complete and exclusive statement of the terms and conditions of their agreement. All prior agreements, negotiations, dealings and understandings, whether written (including any electronic record) or oral, regarding the subject matter hereof, are superseded by this Agreement. Any changes in this Agreement shall be in writing and executed by both parties. Furthermore, if there is a conflict of terms between this Agreement and an Order, this Agreement shall be the controlling document.

 

We (Company) will never assume that you (Supplier) will be willing to extend or renew this Agreement or to accept any specific volume of Orders. Conversely, we urge you never to assume that this Agreement will be renewed or extended by us or that we will issue Orders for specific volume of Merchandise, even if your impression is based on discussions you may have had with Company representatives. No Company representative has authority to renew or extend this Agreement except in a writing signed by an authorized officer of Company, and no Company representative has authority to order Merchandise except an Authorized Buyer through an Order issued pursuant to and subject to the terms of this Agreement.

 

 
 

 

Supplier No. Department No. 40 Effective Date: //

 

WAL−MART STORES, INC.

 

STANDARDS FOR SUPPLIERS

 

Wal−Mart Stores, Inc. (“Wal−Mart”) has enjoyed success by adhering to three basic beliefs since its founding in 1962:

 

1. Respect for the Individual

2. Service to our Customers

3. Strive for Excellence

 

Wal−Mart strives to conduct its business in a manner that reflects these three basic beliefs. Our suppliers are expected to conform to these beliefs and the values inherent therein and to assure these beliefs and values are reflected in their contracting, subcontracting or other relationships.

 

Since Wal−Mart believes that the conduct of its suppliers can be attributed to Wal−Mart and affect its reputation, Wal−Mart requires its suppliers to conform to standards of business practices which are consistent with the three beliefs described above. More specifically, Wal−Mart requires conformity from its suppliers with the following standards, and hereby reserves the right to make periodic, unannounced inspections of supplier’s facilities to satisfy itself of supplier’s compliance with these standards:

 

1. COMPLIANCE WITH APPLICABLE LAWS. All Suppliers shall comply with the legal requirements and standards of their industry under the national laws of the countries in which the Suppliers are doing business, including the labor and employment laws of those countries, and any applicable U.S. laws. Should the legal requirements and standards of the industry conflict, Suppliers must, at a minimum, be in compliance with the legal requirements of the country in which the products are manufactured. If, however, the industry standards exceed the country’s legal requirements, Wal−Mart will favor Suppliers who meet such industry standards. Suppliers shall comply with all requirements of all applicable governmental agencies. Necessary invoices and required documentation must be provided in compliance with the applicable law. Suppliers shall warrant to Wal−Mart that no merchandise sold to Wal−Mart infringes the patents, trademarks or copyrights of others and shall provide to Wal−Mart all necessary licenses for selling merchandise sold to Wal−Mart, which is under license from a third party. All merchandise shall be accurately marked or labeled with its country of origin in compliance with applicable laws and including those of the country of manufacture. All shipments of merchandise will be accompanied by the requisite documentation issued by the proper governmental authorities, including but not limited to Form A’s, import licenses, quota allocations and visas and shall comply with orderly marketing agreements, voluntary restraint agreements and other such agreements in accordance with applicable law. The commercial invoice shall, in English and in any other language deemed appropriate, accurately describe all the merchandise contained in the shipment, identify the country of origin of each article contained in the shipment, and shall list all payments, whether direct or indirect, to be made for the merchandise, including, but not limited to any assists, selling commissions or royalty payments. Backup documentation, and any Wal−Mart required changes to any documentation, will be provided by Suppliers promptly. Failure to supply complete and accurate information may result in cancellation or rejection of the goods.

 

2. EMPLOYMENT. At a minimum, Wal−Mart expects its “suppliers” to meet the following terms and conditions of employment:

 

Compensation. Suppliers shall fairly compensate their employees by providing wages and benefits, which are in compliance with the local and national laws of the jurisdictions in which the suppliers are doing business or which are consistent with the prevailing local standards in the jurisdictions in which the suppliers are doing business, if the prevailing local standards are higher.

 

Hours of Labor. Suppliers shall maintain reasonable employee work hours in compliance with local standards and applicable laws of the jurisdictions in which the suppliers are doing business. Employees shall not work more than 72 hours per 6 days or work more than a maximum total working hours of 14 hours per calendar day (midnight to midnight). The factory should be working toward achieving a 60−hour work week. Wal−Mart will not use suppliers who, on a regularly scheduled basis, require employees to work in excess of the statutory requirements without proper compensation as required by applicable law. Employees should be permitted reasonable days off (at least one day off for every seven−day period) and leave privileges.

 

Forced Labor/Prison Labor. Forced or prison labor will not be tolerated by Wal−Mart. Suppliers shall maintain employment on a voluntary basis. Wal−Mart will not accept products from suppliers who utilize in any manner forced labor or prison labor in the manufacture or in their contracting, subcontracting or other relationships for the manufacture of their products.

 

Child Labor. Wal−Mart will not tolerate the use of child labor. Wal−Mart will not accept products from suppliers who utilize in any manner child labor in the manufacture or in the contracting, subcontracting or other relationships for the manufacture of their products. No person shall be employed at an age younger than the law of the jurisdiction of manufacture allows. Where country laws allow children below the age of 14 years to work, Wal−Mart will only recognize the minimum working age of 14 years, regardless of the law of the jurisdiction.

 

Discrimination/Human Rights. Wal−Mart recognizes that cultural differences exist and different standards apply in various jurisdictions, however, we believe that all terms and conditions of employment should be based on an individual’s ability to do the job, not on the basis of personal characteristics or beliefs. Wal−Mart favors suppliers who have a social and political commitment to basic principles of human rights and who do not discriminate against their employees in hiring practices or any other term or condition of work, on the basis of race, color, national origin, gender, sexual orientation, religion, disability, or other similar factors.

 

3. WORKPLACE ENVIRONMENT. Wal−Mart expects its suppliers to maintain a safe, clean, healthy and productive environment for its employees. Factories producing merchandise to be sold by Wal−Mart shall provide adequate medical facilities, fire exits and safety equipment, well−lighted and comfortable workstations, clean restrooms, and adequate living quarters where necessary. Workers should be adequately trained to perform their jobs safely. Wal−Mart will not do business with any supplier that provides an unhealthy or hazardous work environment or which utilizes mental or physical disciplinary practices.

 

 
 

 

4. CONCERN FOR THE ENVIRONMENT. We believe it is our role to be a leader in protecting our environment. We encourage our customers and associates to always reduce, reuse, and recycle. We also encourage our suppliers to reduce excess packaging and to use recycled and non−toxic materials whenever possible. We will favor suppliers who share our commitment to the environment.

 

9. FACTORY INSPECTION REQUIREMENTS. Scheduled inspections should typically be conducted a maximum of three times per year to ensure compliance with the standards, terms, and conditions set forth herein. Wal−Mart reserves the right to conduct unannounced factory inspections.

 

In the case of domestic suppliers, factory audits shall typically be conducted by Wal−Mart approved third party audit firms. All charges related to the third party inspection and certification of such facilities shall be paid fully by the supplier. Any supplier who fails or refuses to comply with these standards is subject to immediate cancellation of any and all outstanding orders, refusal or return of any shipment, and termination of its business relationship with Wal−Mart. In the case of suppliers working through Global Procurement Direct Imports, audits should be conducted by Wal−Mart’s internal auditors. Once a factory has been audited and assessed either green or yellow by either Wal−Mart’s internal auditors or an approved third party audit firm, the factory is valid for any supplier to use for Wal−Mart business.

 

10. RIGHT OF INSPECTION. To further assure proper implementation of and compliance with the standards set forth herein, Wal−Mart or a third party designated by Wal−Mart will undertake affirmative measures, such as on−site inspection of production facilities, to implement and monitor said standards. Any supplier which fails or refuses to comply with these standards or does not allow inspection of production facilities is subject to immediate cancellation of any and all outstanding orders, refuse or return any shipment, and otherwise cease doing business with Wal−Mart.

 

11. CONFIDENTIALITY. Supplier shall not at any time, during or after the term of this Agreement, disclose to others and will not take or use for its own purposes or the purpose of others any trade secrets, confidential information, knowledge, designs, data, know−how, or any other information reasonably considered “confidential.” Supplier recognizes that this obligation applies not only to technical information, designs and marketing, but also to any business information that Wal−Mart treats as confidential. Any information that is not readily available to the public shall be considered to be a trade secret and confidential. Upon termination of this Agreement, for any cause, supplier shall return all items belonging to Wal−Mart and all copies of documents containing Wal−Mart’s trade secrets, confidential information, knowledge, data or know−how in supplier’s possession or under supplier’s control.

 

12. WAL−MART GIFT AND GRATUITY POLICY. Wal−Mart Stores, Inc. has a very strict policy which forbids and prohibits the solicitation, offering or acceptance of any gifts, gratuities or any form of “pay off” or facilitation fee as a condition of doing business with Wal−Mart; as a form of gratitude, or as an attempt to gain favor or accept merchandise or services at a lesser degree than what was agreed. Wal−Mart believes in delivering and receiving only the total quantity agreed.

 

Any supplier, factory or manufacturer who violates this policy by offering or accepting any form of gift or gratuity to/from any associate, employee, agent or affiliate of Wal−Mart Stores, Inc. will be subject to all loss of existing and future business, regardless of whether the gift or gratuity was accepted. In addition, a supplier, factory or manufacturer who violates this policy, will be reported to the appropriate governmental authorities of the supplier’s respective and affiliated jurisdictions.

 

Failure to report such information will result in severe action against such supplier, trading company or factory including but not limited to termination of all existing and future business relationships and monetary damages.

 

STANDARDS FOR SUPPLIERS A copy of these Standards for Suppliers shall be posted in a location visible to all employees at all facilities that manufacture products for Wal−Mart Stores, Inc. and its affiliates. Any person with knowledge of a violation of any of these standards by a Supplier or a Wal−Mart associate should call 1−800−WM−ETHIC (1−800−963−8442) (in countries other than the United States, dial AT&T’s U.S.A. Direct Number first) or write to: Wal−Mart Stores, Inc., Business Ethics Committee, 702 SW 8th St., Bentonville, AR 72716−8095.

 

13. ACKNOWLEDGMENT OF STANDARDS. As an officer or duly authorized representative of my company, a Supplier of Wal−Mart, I have read the principles and terms described in this document and understand my company’s business relationship with Wal−Mart is based upon said company being in full compliance with these principles and terms. I further understand that failure by a Supplier to abide by any of the terms and conditions stated herein may result in the immediate cancellation by Wal−Mart of all outstanding orders with that Supplier and refusal by Wal−Mart to continue to do business in any manner with said Supplier. I am signing this Supplier Agreement as a corporate representative of my company, to acknowledge, accept and agree to abide by the standards, terms and conditions set forth herein between my company and Wal−Mart. I hereby affirm that all actions, legal and corporate, to make this Standards for Suppliers binding and enforceable against my company have been completed.

 

 
 

 

Supplier No. Department No. 40 Effective Date: //

 

APPENDIX

 

This Appendix constitutes and is part and parcel of the Supplier Agreement. The terms of the Supplier Agreement are binding and enforceable as to this Appendix.

 

STANDARD PURCHASE ORDER ALLOWANCE

 

These allowances apply to each Purchase Order issued, unless otherwise agreed to by the parties.

 

    DISC       HOW PAID   WHEN PAID
CODE ALLOWANCE   %   SPECIAL INSTRUCTIONS   OI   CM   CK   EI   M   Q   S   A
SA New Store/Club Discount (% Applied to each line item for each new store P.O.)                                        
OL New Store/Club Discount (% Represents contribution of total business to New Store Program.)                                        
NW New Distribution Center                                        
WA Warehouse Allowance                                        
QD Warehouse Distribution Allowance                                        
DM Defective/Returned Mdse. Allowance − Not applicable in Puerto Rico. (When selected must mark option 3 under warranty policy.)                                        
SD Soft Goods Defective Allow                                        
PA Promotional Allowance                                        
VD Volume Discount                                        
FA Freight Allowance                                        
AA Advertising Allowance                                        
TR TV/Radio Media Allowance                                        
DA Display/Endcap Allowance                                        
EB Early Buy Allowance                                        
HA Handling Allowance                                        

 

OI−Off Invoice; CM−Credit Memo; CK−Check; EI−Each Invoice; M−Monthly; Q−Quarterly; S−Semi−Annually; A−Annually;

 

IMPORTANT NOTICE: ALL PAYMENTS OF MONIES OWED PURSUANT TO THIS SUPPLIER AGREEMENT AND PURCHASE ORDERS MUST BE MAILED TO THE FOLLOWING ADDRESS:WAL−MART STORES, INC./SAM’S CLUB, C/O CORPORATE ACCOUNTING, P.O. BOX 500787, ST. LOUIS, MISSOURI 63150−0787. Note: Any payments on your Wal−Mart or SAM’S CLUB Credit Card should be mailed to the billing address indicated on your credit card statement, not the address above.

 

PAYMENT TERMS

 

[***] Cash Discount −−Enter whole percents

 

[***] Cash Discount Days Available(Must be filled in if a Cash Discount is used)

 

[***] Net Payment Days Available(Must be at least one day more than Cash Discount Days Available)

 

End Of Month Dating__ Yes X No

  NEW STORE/WHSE TERMS IF DIFFERENT THAN REGULAR TERMS:

 

SHIPPING TERMS
       
FREIGHT TERMS   MINIMUM FOR PREPAID FREIGHT TERMS
       
__ Collect − F.O.B Supplier     0  Pounds
       
X Prepaid − F.O.B Company     1 Cases/Units
       
__Prepaid To consolidator − F.O.B. Company’s Consolidator     0 Whole Dollars

 

No freight charges are to be added to invoices. Refer to the current Routing Guide for detailed instructions.

 

CONDITION OF SALE

 

X Guaranteed Sales      __Consignment     __ Preticketing     __ Prepricing     __ Stock Balancing     __ Shelf Labels

 

__ Point of Sale (Pay from Scan)           __ Other

 

 
 

 

Product Chemical Information

 

Does Supplier currently sell, or anticipate selling, to Company under this Agreement any item of Merchandise that is or contains a powder, liquid, gel or paste that is not intended for human consumption; a compressed gas or propellant (such as an aerosol); or a flammable solid (such as matches)?

__Yes X No

 

RETURN POLICY.(SUPPLIER MUST CHOOSE ONE OPTION BELOW AND COMPLETE THE NECESSARY INFORMATION.)

 

Supplier will be charged current merchandise costs plus a 10% handling charge for all returned merchandise. Returned merchandise will be shipped with return freight charges billed back to Supplier. Returns are F.O.B. Purchaser.

 

__SUPPLIER OPTION #1: SUPPLIER WANTS RETURNED MERCHANDISE SENT TO THEM:

 

__A. Returned merchandise will be sent to Supplier direct from each store.

 Permanent return authorization #: _______________ , if required for shipment. If automatic return is not possible, a toll free number should be provided or Supplier must accept Purchaser’s collect calls to secure return authorization over the phone.

Phone: Extension #: Contact:

 

__B. Returned merchandise will be sent from store locations to the Return Center and sent to Supplier.

 Permanent return authorization #: _______________ , if required for shipment. If automatic return is not possible, a toll free number must be provided or Supplier must provide a fax number and a contact name.

Phone:                          Extension #:                          Contact:

 

Permanent return authorization #:___________

RETURN SHIPPING ADDRESS: Address:___________ City:___________ State: ____Zip:

 

Special Instructions:

 

X SUPPLIER OPTION #2: SUPPLIER DOES NOT WANT RETURNED MERCHANDISE SENT TO THEM.

 

__A. Returned merchandise must be disposed of by the individual store; OR

 

X B. Returned merchandise will be sent from store locations to the Return Center for disposal.[Choose one of the following

three.]

__ i. Return Center may dispose of returned merchandise through salvage outlets or recycling operations, without accounting for the proceeds of such disposal;

 

__ii. Return Center must destroy returned merchandise. (Supplier may be charged for any additional costs of destruction.);

 

X iii. Return Center may donate returned merchandise to charity.

 

Special Instructions:

 

__SUPPLIER OPTION #3: CUSTOMER SATISFACTION MERCHANDISE ALLOWANCE:

 

Supplier will allow the Customer Satisfaction Merchandise Allowance stated in this agreement. The percentage must be adequate to cover all costs associated with returned merchandise, including but not limited to defective/returned merchandise and handling costs, or additional claims will be filed by the Return Center at our fiscal year end.

 

A.       Return Center may dispose of returned merchandise through salvage outlets or recycling operations, without accounting for the proceeds of such disposal;

B.       Return Center must destroy returned merchandise. (Supplier may incur additional handling charges to cover costs of destruction.);

C.       Returned merchandise will be sent from store locations to the Return Center and sent to Supplier. If Supplier requests the returned merchandise be sent to them, in addition to the Customer Satisfaction Allowance, the merchandise will be shipped with return freight charges billed back to Supplier; OR

D.       Return Center may donate Return Merchandise to charity.

 

Permanent return authorization #:___________

RETURN SHIPPING ADDRESS: Address:___________ City:___________ State: ____Zip:

 

Special Instructions:

 

In electing SUPPLIER OPTION 2.B.iii. or SUPPLIER OPTION 3.D. above, Supplier acknowledges and agrees that not all returned merchandise is suitable for donation. If the returned merchandise is deemed by Company to be unsuitable for donation, Supplier agrees that Company may either (i) destroy such returned merchandise (and Supplier may be charged for any additional costs of destruction) or (ii) dispose of such returned merchandise through recycling operations, without accounting for the proceeds of such disposal. Provided however, Company agrees to retain documentation of returned merchandise for a period of one (1) year after the date on such documentation. Supplier shall have the right, upon reasonable prior notice to Company, to examine and make copies of such documentation related to Supplier’s returned merchandise. Supplier shall be responsible for any and all expenses related to the examination or copies of such records.

 

SHIPPING INSTRUCTIONS

 

Supplier will ship all merchandise in accordance with the then current Shipping and Routing Instructions, Wal−Mart Stores, Inc. (the “Routing Instructions”). Supplier acknowledges it has received a copy of the Routing Instructions. The current Routing Instructions, as may be reasonably amended by Company from time to time, shall be available on Retail Link. Each purchase order will show a routing, which is determined by Company’s Traffic Department. Supplier is liable for the excess transportation cost if the designated routing is not followed. If Supplier has a question concerning the routing selected, Supplier must call Company’s Traffic Department before releasing the shipment at the following number: (479) 273−6359.

 

SHIPPING POINT   SHIPPING STATE
PITTSBURGH   PA

 

 
 

 

AMENDMENT TO SUPPLIER AGREEMENT

 

This Amendment is to the Supplier Agreement dated // between WAL−MART with its corporate offices at 702 SW 8th St., Bentonville, AR 72716 (hereinafter “Company”) and FACTOR NUTRITION LABS with its corporate offices at 100 COMMERCIAL STREET (hereinafter “Supplier”).

 

This Amendment shall be fully incorporated into the Supplier Agreement and any conflict between the Supplier Agreement and this Amendment shall be resolved in favor of this Amendment. Subsequent modifications, amendments, or addenda shall not change or affect this Amendment in any way unless this Amendment is specifically referenced therein and executed by Supplier and Company.

 

Pursuant to the foregoing, Company and Supplier specifically agree to the following changes to the Agreement:

 

Except as modified by this Amendment or by any other written agreement between the parties executed after the date of this Amendment, the sale and purchase of merchandise or goods by the parties will be controlled by the terms of the Supplier Agreement. This Amendment and the Supplier Agreement constitute the entire agreement between the parties with respect to its subject matter and no modification, change or alteration shall be effective unless in writing and executed by both parties.

 

 

 

Exhibit 10.28

 

Shopify Capital Agreement

 

Total owed:     Loan amount:     Repayment rate:
$ 565,000.00 USD     $ 500,000.00 USD     14% of daily sales

 

Every 60 days you’ll be expected to repay at least $94,167.00 USD. These are your 60-day milestones:

 

July 16,
2021
  September 14,
2021
 

November 13,

2021

  January 12,
2022
  March 13,
2022
  May 12,
2022

 

This Loan Agreement (“Agreement”), dated as of the Funding Date (as defined below) is between Shopify Capital Inc., a Virginia Corporation (“Lender,” “We,” “Us” or “Our”), which is an affiliate of Shopify Inc., a Canadian Corporation, and Synergy CHC Corp (“Borrower,” “You,” or “Your”). The parties hereto, intending to be legally bound hereby, agree to the following terms and conditions:

 

I. Definitions.

 

As used in this Agreement, the following words have the meanings as specified below:

 

  Account has the meaning set forth in Section IV.2(i).
     
  ACH Failure Fee has the meaning set forth in Section IV.2(ii) and the maximum amount permitted by applicable law.
     
  Activation Date means the day after the Funding Date or such later date as Lender may, in its sole and absolute discretion, designate in writing to Borrower.
     
  Arbitration Provision has the meaning set forth in Section XII.1.
     
  Authorized Representative means each Owner or any individual who has been authorized by Borrower to obtain the Loan, access the Shopify Services Account and SMBA and any other Account and has authority to accept agreements on behalf of Borrower.
     
  Bi-Monthly Adjustment has the meaning set forth in Section IV.1(ii).
     
  Payment Bi-Monthly Payment Date means the last day of every Bi-Monthly Period.
     
  Bi-Monthly Period   means every 60-day period, commencing on the Activation Date and ending on the day the Total Payment Amount is received by Lender.
     
  Claims has the meaning set forth in Section XII.1.
     
  Collateral has the meaning set forth in Section V.1.
     
  Daily Payment means the daily payments due to Lender, which shall be an amount equal to the Shopify Account Credits attributed to Borrower’s Shopify Services Account for such day multiplied by the Daily Payment Percentage. If Borrower does not have any Shopify Account Credits for any given day, then there shall be no Daily Payment for such day.
     
  Daily Payment Percentage means 14%.
     
  Event of Default means the occurrence of an event described in Section VIII.
     
  Funding Date means the date on or after the date of this Agreement when Lender funds the Loan into the SMBA.
     
  Lender Information has the meaning set forth in Section X.16.
     
  Loan has the meaning set forth in Section II.
     
  Make-up Payments  means deductions from Your Account, as applicable, initiated by Lender or the Processor or any Other Processor for the benefit of Lender if any of Lender, Processor or Other Processor, as applicable, was unable to effect a transfer for any payment due hereunder on a particular day, because of insufficient funds in Your Account or any other reason.
     
  Manual Payment has the meaning set forth in Section IV.1.(iii).

 

 

 

 

  Maturity Date means the one year anniversary of the Activation Date or such later date as Lender may,in its sole and absolute discretion, designate in writing to Borrower.
     
  Minimum Bi-Monthly Payment Amount means 16.7% of the Total Payment Amount.
     
  Obligations means, collectively, Borrower’s obligations under this Agreement, including Your obligation to pay the Total Payment Amount, and any other fees or expenses due hereunder (including, without limitation, any ACH Failure Fee and the reasonable attorney’s fees and expenses that arise upon an Event of Default, including after the filing of a bankruptcy or other insolvency proceeding, regardless of whether allowed or allowable in whole or in part as a claim in such bankruptcy or other insolvency proceeding); and Borrower’s obligation to pay all other obligations and liabilities owed to Lender under any other document or agreement now or hereafter entered into between Lender and Borrower.
     
  Other Business Account means, collectively, all bank accounts associated with Shopify Services accounts of Borrower, or principals, subsidiaries or affiliates of Borrower, and into which funds related to Other Business Receivables are deposited.
     
  Other Business Receivables means the receivables of a business owned or operated by Borrower or the principals, subsidiaries or affiliates of Borrower, other than the Shopify Store, including any funds that are credited to one or more Accounts or Shopify Services accounts of Borrower or the principals, subsidiaries or affiliates of Borrower (other than the Shopify Services Account), regardless of source.
     
  Other Processor means, collectively and individually, any processor, acquirer, service provider or financial institution taking custody of, holding, possessing or issuing payment instructions with respect to any Other Business Receivables.
     
  Outstanding Total means the Total Payment Amount, less the aggregate amounts of Payments received by
     
  Payment Amount Lender.
     
  Owner means any parent company, controlling shareholder, sole proprietor, principal or member of Borrower.
     
  Payments means, collectively, the Daily Payments, Bi-Monthly Adjustment Payments and any Manual Payments
     
  Processor means, collectively and individually, any processor, acquirer, service provider or financial institution taking custody of, holding, possessing or issuing payment instructions with respect to the Shopify Account Credits.
     
  Processor Terms of Service means the agreement, as it may be amended from time to time, under which Processor or Other Processor (along with other applicable third parties) provides Borrower with payment services.
     
  Register has the meaning set forth in Section XIII.
     
  Shopify Account Credits  means all funds from transactions associated with Your Shopify Services Account while you have a Loan with Us, regardless of source, whether those funds are credited through cash, bank checks, credit, debit, and other types of payment cards, electronic money transfers, such as Automated Clearing House or “ACH” debits and PayPal® money transfers or other forms of payment, excluding only the Loan.
     
  Shopify Admin     means the administrative dashboard associated with Borrower’s Shopify Services Account.
     
  Shopify Merchant Bank means the bank account of Borrower set out in the Shopify Admin, and into which (1) the
     
  Account or SMBA Shopify Account Credits settle (less any transaction or other related fees); and (2) the Loan would be funded.
     
  Shopify Services means the ecommerce software and services provided to Borrower by Lender’s affiliate Shopify Inc.
     
  Shopify Services Account  means the account provisioned by Shopify Inc. to Borrower in respect of the Shopify Services.
     
  Shopify Store means Synergy CHC Corp.
     
  Shopify Terms of Service  means the agreement, including the Shopify Acceptable Use Policy and any other documents incorporated by reference, as may be amended from time to time, under which Shopify Inc. provides Borrower with the Shopify Services.
     
  Total Payment Amount means 565000.00, which is the total amount (except for any costs, fees or other damages payable upon an Event of Default or any amounts due under Borrower’s indemnification obligations under this Agreement) that Borrower promises to pay Lender as consideration for the Loan.

 

 

 

 

II. Loan Funding.

 

By clicking on “Accept Terms,” You are making a request for Lender to complete its diligence and to make the Loan (as defined below). For this diligence, and for purposes of any further lending requests, We may obtain and review any information on the Borrower or the individual executing this Agreement on behalf of the Borrower that We are permitted by applicable law or your consent to obtain and review for this purpose, including (1) Your Shopify Services Account history; (2) the credit history of the Borrower and the individual executing this Agreement on behalf of the Borrower; and (3) information about any financial accounts Borrower and the individual executing this Agreement on behalf of the Borrower have with third-party institutions, including transaction data with respect to such accounts, which We may obtain directly or through third-party services. You authorize Us to obtain account information from third-party services for the purpose of authenticating or obtaining information about accounts You have with financial institutions, and acknowledge that You may be required to provide such authorization directly to such third parties. If You do not provide the required authorization to the third-party services described above, Lender may decline to proceed with Your request for funding. We also may decline to proceed with Your request for funding if a financial institution prevents us or our service provider to access Your account, even if you did not instruct the financial institution to do so. If Lender is satisfied with the results of its diligence, in its sole and absolute discretion, Lender shall accept the Agreement and lend to Borrower, in a single payment to be made on a date determined by Lender to the SMBA, the sum of $500,000.00 USD (the “Loan”). This Agreement will not take effect unless We accept it by funding the Loan. THE LOAN SHALL BE MADE BY LENDER IN ITS SOLE AND ABSOLUTE DISCRETION, AND BORROWER’S ACCEPTANCE OF THIS AGREEMENT SHALL NOT BE CONSTRUED TO OBLIGATE LENDER TO MAKE THE LOAN

 

III. Business Purpose, Business Account and Arbitration.

 

1. Business Purpose. You represent and warrant that You are obtaining this Loan and will use the funds received in connection with this Loan for business purposes only. You will not use this Loan for personal, family or household purposes. You understand that You are not receiving a consumer loan and that statutory and regulatory protections for consumers will not apply to Your Loan. You also understand that We are not obligated to confirm whether the use of any funds provided conforms to this section. You agree that Your breach of this section will not affect Lender’s right to (a) enforce Your promise to pay all Obligations and amounts owed under this Agreement, regardless of the purpose for which the funds are in fact obtained, or (b) use any remedy legally available to Lender, even if that remedy would not have been available had the funds been provided for consumer purposes.
   
2. Business Account. You represent, warrant, acknowledge and agree that the SMBA, any substitute Account and the Shopify Services Account are each business accounts used solely for business purposes only and that the Account(s) named above are not and will not be used for personal, family, consumer or household purposes.
   
3. Arbitration. This Agreement requires the use of arbitration on an individual basis to resolve disputes rather than jury trials or class actions (as discussed in Section XII).

 

IV. Repayment of the Loan; Authorizations.

 

1. Repayment Terms.
   
  i. Borrower promises to pay Lender the Total Payment Amount by making Daily Payments to Lender, starting on the Activation Date until the Total Payment Amount is received by Lender.
     
  ii. In addition to the Daily Payments, Borrower agrees that every Bi-Monthly Payment Date, to the extent that the aggregate amount of Payments paid prior to the current Bi-Monthly Payment Date were less than the Minimum Bi-Monthly Payment Amount multiplied by the number of Bi-Monthly Periods that have occurred from the Activation Date to the current Bi-Monthly Payment Date, Borrower will pay Lender the difference between the Minimum Bi-Monthly Payment Amount and the aggregate amount of Payments during the current Bi-Monthly Period (the “Bi-Monthly Adjustment Payment”).
     
  iii. In addition to the Daily Payments and Bi-Monthly Adjustment Payments, You may make one or more additional payments for any amount, up to and including the then-remaining Outstanding Total Payment Amount (“Manual Payments”). Manual Payments may be made only by ACH, or such other method that Shopify permits, in its sole discretion, from time to time. Shopify may refuse any attempted Manual Payment or impose limits on the frequency or amounts of Manual Payments at any time if Shopify suspects fraud or has any other concerns about the payment. If You make a Manual Payment that is less than the Outstanding Total Payment Amount and We successfully take delivery of the Manual Payment, the Outstanding Total Payment Amount will be adjusted by the amount of such Manual Payment. If You select to pay the entire Outstanding Total Payment Amount, and We successfully take delivery of the Manual Payment in such amount, You will have no further obligations to Us under the Agreement. If We do not successfully take delivery of the Manual Payment or the Manual Payment is reversed or disputed, then any credit to the Outstanding Total Payment Amount applied as a result of the Manual Payment will be reversed as of the date it was applied and You will continue to be obligated to repay Your Loan under the Agreement until the Total Payment Amount has been repaid.
     
  iv. In addition to the Daily Payments, the Bi-Monthly Adjustment Payments and, as applicable, any Manual Payments, to the extent that there is an Outstanding Total Payment Amount on the Maturity Date, Borrower agrees to pay the Outstanding Total Payment Amount on the Maturity Date.

 

2. Fund Transfers. To the extent that Processor or Other Processor, if applicable, is not acting on behalf of Lender pursuant to clause (i) below or as Lender may otherwise determine, Lender may act in accordance with clause (ii) below.
     
  i. Processing Arrangement. Borrower explicitly authorizes and directs Processor or Other Processor to transfer to Lender from the SMBA, any Other Business Account and/or any other account containing Your Shopify Account Credits or Other Business Receivables (collectively, the “Account”) (a) each Daily Payment on a daily basis until the Total Payment Amount has been delivered to Lender, (b) each Bi-Monthly Adjustment Payment on each Bi-Monthly Payment Date, if any, until the Total Payment Amount has been delivered to Lender, (c) the Outstanding Total Payment Amount on the Maturity Date, and (d) in the event that We declare the entire Outstanding Total Payment Amount (plus any other amounts due under this Agreement) to be immediately due and payable upon an Event of Default, to deliver to Us the then Outstanding Total Payment Amount plus the amount of any other outstanding Obligations, together with any other amounts due under this Agreement. Upon an Event of Default, You irrevocably authorize Processor and any Other Processor to deliver all funds on deposit in any Account to Us until We have received the Outstanding Total Payment Amount (plus any other amounts due under this Agreement). You agree that any Processor and Other Processor may rely on any instructions issued by Us with respect to the delivery of funds on deposit in any Account, including, but not limited to, an instruction to deliver to Us all Shopify Account Credits, Other Business Receivables, and funds on deposit in any such Accounts to Us until the then Outstanding Total Payment Amount (plus any other amounts due under this Agreement) are delivered to Us after an Event of Default. You agree that You do not have the right to revoke or otherwise seek to override the authorization set forth herein and that this authorization may only be revoked by Us. If there has been no Event of Default, no Processor or Other Processor will deliver to Us any particular payment owed hereunder if such payment has already been delivered to Us by Processor or Other Processor, as applicable, or We have taken such amount via clause 2(ii) below.
     

 

 

 

 

  ii. Shopify Electronic Fund Transfer Authorization. You irrevocably authorize Us (which includes, for the purposes of this authorization, Our agents, service providers, successors and assigns) to take delivery of any payment required under this Agreement by initiating an electronic fund transfer via the ACH network from any Account. You authorize Us, to initiate a single ACH for the combined amounts of different Payments owed hereunder (e.g. initiate a single ACH on Monday for Daily Payments that were created on Friday, Saturday and Sunday, or initiate a single ACH which combines a Daily Payment and a Bi-Monthly Adjustment Payment) or to initiate individual ACHs for any such Payments. We will not initiate an ACH for any Payments delivered to Us via clause 2(i). After the occurrence of an Event of Default, You irrevocably authorize Us to initiate ACHs from any Account until We have received the Outstanding Total Payment Amount (plus any other Obligations or amounts due under this Agreement). You also authorize Us to initiate ACH credits or debits to any Account to correct any errors We may make in processing a payment. In the event that an ACH is returned unpaid, You authorize Us to re-initiate the ACH until it is paid and to initiate a separate ACH or to add to a reinitiated ACH the amount of any ACH Failure Fee. You agree that You will not cancel this authorization or instruct any depository holding Shopify Account Credits (or, after an Event of Default, any other depository holding Other Business Receivables) to reject Our ACHs. You promise that the Account is used for business purposes and not for personal, family, consumer or household purposes and that You are an authorized signor on the Accounts. You agree to be bound by the rules and regulations of any applicable payment networks as may be required to effect any of the transactions authorized under this section. We are entitled to receive from You and You agree to pay the ACH Failure Fee for each rejected or dishonored ACH attempt, check, or wire transfer withdrawal, as the case may be.
     
3. Make-up Payments; Transfer Size/Timing. If any of Lender, Processor or Other Processor is unable to effect a transfer for any payment due hereunder, You authorize and direct Lender, Processor or Other Processor, as applicable, to deduct any available funds from Your Account, as applicable, to make up any deficit on subsequent days through additional transfers in excess of the payment amounts then due on such subsequent days until the full amount due (that was initially insufficient) has been delivered to Lender in full. You authorize and direct any of Lender, Processor or Other Processor to initiate transfers for Make-up Payments in combination with any Payments due on subsequent days or as separate transfers. You agree that any transfers may be split into multiple, smaller transfers and/or initiated the moment funds are credited to the Account, as applicable.
     
V. Security Interest; Collateral.
     
1. As security for all Obligations, Borrower hereby grants, assigns and pledges to Lender a continuing and unconditional lien on and security interest in and to the following, whether now owned or hereafter acquired or arising and wherever located (collectively, the “Collateral”): (a) all Accounts , and all balances in such Accounts and any other businesses owned or operated by Borrower, (b) all general intangibles (as that term is defined in Article 9 of the Uniform Commercial Code as in effect in the state referred to in the Borrower’s address as set out in the Shopify Admin), all payment intangibles, all rights to payment, all accounts receivable (including the Other Business Receivables), and all other rights (whether arising under common law, statutes, regulations, or otherwise), of Borrower, in each case, arising with respect to, or in connection with, the Accounts, (c) all money, cash equivalents, and other assets of Borrower that now or hereafter come into the possession, custody, or control of Lender, Processor or Other Processor (or any of their respective agents or designees) and (d) all of the proceeds (as such term is defined in the applicable UCC) and products, whether tangible or intangible, of any of the foregoing.
   
2. In furtherance of the intentions of the parties hereto, this Agreement shall constitute written notice to all interested parties of Lender’s security interest in the Collateral. Borrower acknowledges and agrees that so long as any of the Obligations remain outstanding, all Accounts and any funds on deposit from time to time therein shall be under the sole dominion and control of Lender. Neither Borrower nor any other person or entity, acting by, through or under Borrower, shall have any control over the use of, or any right to withdraw any amount from such Accounts without the consent of Lender, provided that Lender shall be deemed to have granted such consent until such time as the occurrence of an Event of Default. In addition, Lender shall have the exclusive rights (i) to require that any bank or securities intermediary at which any Collateral may be located acknowledge Lender’s security interest in and control of the Collateral for purposes of perfecting Lender’s security interest therein and (ii) to direct and provide instructions to such bank or securities intermediary as to the disposition of the Collateral to fulfill Borrower’s Obligations herein. Borrower agrees that Borrower shall execute and deliver any document requested by Lender to perfect and continue its security interest in the Collateral, including, but not limited to, any account control agreements.
   
3. You authorize Us to file one or more UCC-1 financing statements to memorialize and perfect on the security interest granted to Us hereunder. Any financing statements may include notice that You have given a negative pledge of the Collateral.
     
VI. Representations and Warranties.
     
Borrower represents and warrants that, as of the date of this Agreement and during the term of this Agreement:
     
1. Your form of organization is correctly set forth in the Shopify Admin. Unless You are an individual or sole proprietorship, You were duly incorporated or formed and are validly existing and in good standing under the laws of the state of the business address reflected in Your Shopify Admin. You further represent and warrant that: (i) You are duly qualified, licensed and in good standing in every state in which You are doing business; (ii) Your principal office and the location where You keep Your records concerning Your accounts, contract rights and other property, are accurately reflected in Your Shopify Admin; (iii) Your exact legal name is accurately set forth in the Your Shopify Admin and in this Agreement; (iv) You have provided Us with any fictitious names; (v) You have the requisite power and authority, and the legal right, to own, lease and operate Your properties and assets and to conduct Your business as it is now being conducted and to enter into this Agreement; (vi) You are complying and will comply with all laws, statutes, regulations and ordinances pertaining to the conduct of Your business; (vii) all of Your organization papers and all amendments thereto have been duly filed and are in proper order, and any capital stock, member interest or other equity issued by You and outstanding was and is properly issued; and (viii) all Your books and records are accurate and up to date and will be so maintained.

 

 

 

 

2. No consent or authorization of, filing with, notice to or other act by, or in respect of, any governmental authority or any other individual or entity is required in order for You to execute, deliver, or perform any of Your obligations under this Agreement. The execution, delivery and performance of the Agreement and any other document executed in connection therewith are within Your powers, have been duly authorized, and are not in contravention of law or the terms of Your charter, by-laws or other organization papers, if any, or of any indenture, contract, agreement or undertaking to which You are a party. You are not subject to any charter, corporate or other legal restriction, or any judgment, award, decree, order, governmental rule or regulation or contractual restriction that could have a material adverse effect on Your financial condition, business or prospects. You are in compliance with Your organization documents and by-laws, if any, and all contractual requirements by which You may be bound and where the failure to comply might materially adversely affect Your financial condition, business or prospects or Your ability to perform Your obligations under this Agreement.
   
3. There is no action, suit, proceeding or investigation pending or, to Your knowledge, threatened against or affecting You, Your Shopify Store or any of Your assets that, if determined adversely, could have a material adverse effect on Your financial condition, business or prospects or Your ability to perform Your obligations under this Agreement.
   
4. This Agreement is Borrower’s valid, legal and binding obligation, enforceable against Borrower in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).
   
5. You have not sold nor are subject to any other contract or agreement that provides for the sale, assignment or any other transfer of any interest in the Collateral as of the date of this Agreement. You have good, complete and marketable title to the Collateral, free and clear of any claims, charges, liens, restrictions, encumbrances or security interests of any nature whatsoever, other than in favor of Lender. The Shopify Account Credits are and will be the proceeds of bona fide transactions with Borrower’s customers arising out of the Shopify Store.
   
6. Borrower does not presently intend to cease to operate the Shopify Store, either permanently or temporarily. Borrower is solvent and does not contemplate bankruptcy or insolvency proceedings. Borrower has not filed any petition for bankruptcy protection and there has been no involuntary petition threatened or filed against Borrower. Borrower does not anticipate the voluntary or involuntary filing of any such bankruptcy petition.
   
7. All federal, state, local and foreign tax returns and tax reports, and all taxes due and payable that are required to be filed by Borrower have been or will be filed and paid, on a timely basis (including any extensions). All such returns and reports are and will be true, correct and complete. Borrower has no material liabilities and, to the best of its knowledge, knows of no material contingent liabilities, except current liabilities incurred in the ordinary course of business.
   
8. You are entering into this Agreement for business purposes and not as a consumer or for personal, family, consumer or household purposes. Any credit extended under this Agreement, including the Loan, is solely for business purposes and not for personal, family, consumer or household use.
   
9. Any attempt to receive the Loan or pay Your Daily Payment, Bi-Monthly Adjustment Payment, Manual Payment or Outstanding Total Payment Amount through any account other than the SMBA will entitle Processor, any Other Processor and Lender to consider any such account as part of Your SMBA for purposes of this Agreement.
   
10. Each Authorized Representative is at least 18 years of age and has the legal capacity and all necessary authority to bind You to this Agreement.
   
VII. Covenants.
 
Borrower agrees to comply with the covenants in this Agreement and to be bound by the terms and conditions of this Agreement. In this regard, Borrower irrevocably agrees that, during the term of this Agreement, Borrower shall:
   
1. Cause the SMBA and any substitute Accounts to remain in good standing.
   
2. Comply with the Processor or Other Processor Terms of Service in connection with all payments Borrower accepts and processes during the term of this Agreement.
   
3. Provide account statements for any account into which Shopify Account Credits are deposited or transferred, any bank account reflected in Borrower’s Shopify Admin, and any account opened without Lender’s permission at any time during the performance of this Agreement (including, but not limited to, any other bank accounts associated with other Shopify Services account(s) of Borrower), no later than five (5) business days after Our request. You agree that if You own or operate any other business other than the Shopify Store, You will keep separate accounting records for each business.
   
4. Not take any action that would discourage those making payments to Borrower from paying via a method that settles into the SMBA or permit any event to occur that could have an adverse effect on the making of such payments into the SMBA.
   
5. Not withdraw funds from the SMBA prior to Lender receiving the Daily Payment for such day.
   
6. Not, without Our prior written consent (i) change Your name (including any d/b/a name), place of business, chief executive office (if applicable), or organizational identification number, if any, (ii) change Your type of organization, jurisdiction of organization or other legal structure, (iii) materially change the goods or services sold by the Shopify Store, (iv) materially change the nature of the Shopify Store, (v) change the methods by which You accept or process payments, (vi) close the Shopify Store or cease operations (either permanently or temporarily).

 

 

 

 

7. (i) preserve, renew and maintain in full force and effect Your corporate or organizational existence, (ii) take all reasonable action to maintain all rights, privileges and franchises necessary or desirable for the normal conduct of Your business, and (iii) remain duly qualified, licensed and in good standing in Your state of organization (if any) and every other state in which You are doing business.
   
8. Not create, incur or assume any indebtedness or borrow money, except for the Loan and trade debt incurred in the ordinary course of Borrower’s business.
   
9. Not create or permit any lien or other encumbrance to be placed on the Collateral, other than in favor of Lender.
   
10. Not permit any event to occur that could cause diversion of (i) any amounts payable to or from any Account or (ii) the Shopify Account Credits from Lender.
   
11. Maintain all of Your contact information current, including primary electronic mail address for Your Shopify Services Account and SMBA, Your phone number, and physical address, and notify Lender promptly of any change to Your phone number or physical, electronic mail and/or website address(es).
   
12. Cooperate fully with Lender to take all necessary actions required to effectuate Borrower’s obligations hereunder, including, but not limited to, signing any and all documents Lender deems necessary or appropriate.
   
13. Only use the Loan, the SMBA, any substitute Account and the Shopify Services Account for commercial or business purposes, in the ordinary course of business, and not for personal, family, consumer or household purposes.
   
14. Not, without Our prior written consent, merge or consolidate with or into any other business entity or enter into any joint venture or partnership with any person, firm or corporation.
   
15. Be solely responsible for the payment of any fees and charges imposed with respect to the Accounts, or any processing agreement with the Processor or Other Processor. The Total Payment Amount, any fees payable for Shopify Services, any Obligations owing hereunder and any other amount payable to Lender under this Agreement, do not include processing fees, charges, or any other amounts payable to Processor or Other Processor deducted from the Shopify Account Credits.
   
16. Provide promptly to Lender, from time to time at Lender’s request, purchase transaction files maintained by Borrower, and any other information related to past purchases, Shopify Account Credits, or the transactions contemplated by this Agreement, whether created for the purpose of audit or otherwise, and such information about Your financial condition and operations as We may from time to time reasonably request.
   
17. Maintain on Your property insurance of responsible and reputable companies in such amounts and covering such risks as is prudent and is usually carried by companies engaged in businesses similar to that of Borrower; Borrower shall furnish Lender, on request, with certified copies of insurance policies or other appropriate evidence of compliance with the foregoing covenant.
   
18. Promptly provide notice to Us in writing upon becoming aware of any Event of Default, the occurrence or existence of an event which, with the passage of time or the giving of notice or both, would constitute an Event of Default, or any material adverse change in Your cash flow, business operation or business ownership.
   
19. Provide to Lender, upon request, documentation confirming the authority of any Authorized Representative.
   
20. Settle or “batch out” Your receipts with Processor or Other Processor on a daily basis.
   
21. Not make any changes to the SMBA, any other Account or the Shopify Services Account that would adversely effect Lender.
   
VIII. Events of Default.
   
In addition to the events of default identified elsewhere in this Agreement, You will be in default under this Agreement, and an “Event of Default” will be deemed to have occurred, if:
   
1. You fail to pay any of the Outstanding Total Payment Amount or the Bi-Monthly Adjustment Payment as and when due.
   
2. During the term of the Loan, Processor, Other Processor or Lender initiates transfers for Make-up Payments in connection with more than three separate Daily Payments.
   
3. You materially breach any of the representations or warranties made in this Agreement.
   
4. You fail to perform or complete any covenant in this Agreement.
   
5. You seek to close or terminate Your Shopify Services Account, SMBA or any substitute Account while there is an Outstanding Total Payment Amount.
   
6. You become insolvent, file for bankruptcy protection, dissolve, die or become incapacitated.
   
7. You attempt to terminate this Agreement while there is an Outstanding Total Payment Amount.
   
8. You authorize any third party, without Our prior written consent, to make transfers out of Your SMBA or substitute Account or divert payments away from Your SMBA or substitute Account.

 

 

 

 

9. You sell, transfer or otherwise encumber or attempt to sell, transfer or otherwise encumber Collateral without Our prior written consent.
   
10. You sell all or substantially all of Your assets used in the operation of Your business to a third party without Our prior written consent.
   
11. You become a party to or the subject of any agreement pursuant to or as a result of which any person or group of persons acquires control, directly or indirectly, of Your business without Our prior written consent.
   
12. You materially change the operation of Your business (including, without limitation, shutting down or ceasing operations or changing industry, concept, size, etc.) without Our prior written consent.
   
13. You stop accepting a particular method of payment while You remain open for business.
   
14. You change Your legal name or jurisdiction of formation or carry on business through a different business entity.
   
15. A default or other similar event occurs under any other loan agreement or merchant cash advance agreement You have with Lender or an affiliate of Lender.
   
16. You breach the Processor or Other Processor Terms of Service or the Shopify Terms of Service, including the Shopify Acceptable Use Policy.
   
17. You close or suspend your Shopify Services Account.
   
18. You decide, for whatever reason, to cease doing business.
   
IX. Consequences of Event of Default.
   
Upon an Event of Default, Lender in its sole and absolute discretion may:
   
1. Declare the Outstanding Total Payment Amount and any other Obligations or liabilities of Borrower to Lender to be forthwith due and payable immediately. At Our option (subject to any applicable law to the contrary), You agree to pay Lender any and all damages Lender incurs, including, without limitation, reasonable attorney’s fees and court costs if permitted by applicable law, in any way relating to the Loan, this Agreement, the Account, any substitute account, or an Event of Default, and agree to hold Lender harmless from any liability it may have to any other person(s) as a result of the Event of Default, the Loan or any Obligation.
   
2. Take any of the following actions, or direct Processor or any Other Processor to take any or all of the following actions on Lender’s behalf in order to enforce Lender’s rights to collect from Borrower any funds due and owing as a result of such Event of Default (in addition to exercising all rights and remedies available under applicable law and as otherwise set forth in this Agreement and without waiver of any such rights and remedies):

 

  i. Place limitations on, and/or deduct funds owed to Lender from, any Account; and/or
     
  ii. Offset any amounts You owe under this Agreement against amounts to which You may be entitled under any agreement You have entered into with Us or an affiliate, including, but not limited to, agreements for payment processing services; and/or
     
  iii. Freeze, suspend, halt, terminate, or otherwise cease in any manner, any services We or an affiliate of Ours may provide You or Your affiliates.

 

X. Miscellaneous.
   
1. Modifications; Amendments. No modification, amendment or waiver of, or consent to any departure by Borrower from, any provision of this Agreement will be effective unless made in a writing signed by each of Lender and the party to be charged, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Notwithstanding the foregoing, Lender may modify this Agreement for the purposes of completing missing content or correcting erroneous content, without the need for a written amendment, provided that Lender shall send a copy of any such modification to Borrower (which notice may be given by electronic mail).
   
2. Assignment. We may assign, transfer or sell Our rights to receive the Total Payment Amount or any other rights hereunder or delegate Our duties hereunder, either in whole or in part, without prior notice to You, and without Your consent. Borrower may not assign or transfer its rights and obligations hereunder, either in whole or in part, without prior written consent from Us, which consent We may withhold in Our sole and absolute discretion.
   
3. Governing Law/Forum. Except as set forth in the Arbitration Provision, (i) this Agreement, any transactions it contemplates, the construction of the terms of the Agreement and all transactions, and the interpretation, performance and enforcement of the rights and duties of You and Us, will be governed by and construed in accordance with the laws of Maine, except to the extent inconsistent with or pre-empted by federal law, without regards to conflicts of law principles; and (ii) the parties agree that the laws of Maine govern the entire relationship between the parties, including, without limitation, all issues or claims arising out of, relating to, in connection with or incident to this Agreement and any transaction it contemplates, whether such claims are based in tort or contract, or arise under statute or in equity. The parties acknowledge and agree that this Agreement is made and performed in Maine.
   
4. Survival. Except as set forth in the Arbitration provisions, (i) all provisions of this Agreement, including Section XII, that, by their nature, are intended to survive Your performance of all obligations hereunder will survive and remain in full force and effect and (ii) all representations, warranties and covenants herein will survive the execution and delivery of this Agreement and will continue in full force until all obligations under this Agreement have been satisfied in full and this Agreement is as a
result terminated.

 

 

 

 

5. Waiver; Remedies. We reserve the right, at any time and in Our sole and absolute discretion, not to exercise any of Our other rights under this Agreement, and should We do so, We will not waive Our right to exercise the right as set forth in this Agreement in the future. Without limiting the foregoing, We may, at Our option accept partial payments without notifying You and without releasing You from Your obligation to pay all amounts owing under this Agreement in full or to otherwise perform the terms and conditions of this Agreement. You understand and agree that Your obligation to pay all amounts owing under this Agreement and otherwise to perform the terms and conditions of this Agreement are absolute and unconditional. No failure on Our part to exercise, and no delay in exercising, any right under this Agreement constitutes a waiver of such right, nor will any single or partial exercise of any right under this Agreement preclude any other or further exercise of that right or the exercise of any other right. The remedies provided in this Agreement are cumulative and not exclusive of any remedies provided by law or equity.
   
6. Severability. In case any of the provisions in this Agreement are found to be invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, the validity, legality and enforceability of any other provision contained herein will not in any way be affected or impaired, and that court will have the power to rewrite that provision to the maximum extent enforceable and the remainder of this Agreement will continue in full force and effect.
   
7. Counterparts; Electronic Signatures. This Agreement may be signed in one or more counterparts, each of which constitutes an original and all of which when taken together constitute the same agreement. Electronic signatures will be deemed manual signatures, and each party to this Agreement may rely on an electronic signature as an original for purposes of enforcing this Agreement. For the avoidance of doubt, Borrower’s acceptance of the Agreement by clicking “Accept terms” will be deemed to constitute such party’s electronic signature and effective as a manual signature of each such party.
   
8. Entire Agreement. This Agreement constitutes the entire agreement between Borrower and Lender relating to this Loan and supersedes any other prior or contemporaneous agreement between You and Us relating to this Loan. The terms of Your use of the Shopify Services and Shopify Services Account are unaffected by this Agreement.
   
9. Inspection of Place of Borrower. We or Our designated representatives and agents have the right, during Your normal business hours and at other reasonable times, to examine Your business where located, including the interior and exterior. Any such examination may include, among other things whether You have a place of business that is separate from any personal residence, are open for business, have sufficient inventory to conduct Your business and have one or more point-of-sale terminals to process payment transactions. When performing an examination, We or Our designated representatives and agents may photograph the interior and exterior of any of Your places of business, including any signage, and may photograph any principals.
   
10. Publicity. You and each Owner authorize Us to use Your, his or her name in a listing of clients and in advertising and marketing materials.
   
11. Notices. All notices, requests, consents, demands and other communications hereunder must be in writing and delivered by electronic mail or certified mail, return receipt requested, to the respective parties to this Agreement, in the case of the Borrower, at the Borrower’s addresses set forth in the Shopify Admin, and in the case of the Lender, at 33 Montgomery St. Suite 750, San Francisco, CA 94105, and in each case will become effective only upon receipt.
   
12. Binding Effect. This Agreement is binding upon and inures to the benefit of You and Us and Our respective successors and permitted assigns. Shopify Inc., Shopify Payments (USA) Inc., Processor and any Other Processor shall be third-party beneficiaries of this Agreement.
   
13. Maximum Interest Rate. Regardless of any provisions contained in this Agreement or in any of the other Loan documents, Lender shall never be deemed to have contracted for or be entitled to receive, collect or apply as interest (whether explicit or deemed to be interest by judicial determination or operation of law) on the Loan, any amount in excess of the maximum rate of interest permitted to be charged by applicable law, and in the event Lender ever receives, collects or applies as interest any such excess, such amount that would be excessive interest shall be deemed to be a partial prepayment of principal and treated hereunder as such, and if the principal balance of the Loan is paid in full, any remaining excess shall forthwith be paid to Borrower. In determining whether or not the interest paid or payable under any specific contingency exceeds the highest lawful rate, Borrower and Lender shall, to the maximum extent permitted under applicable law, (i) characterize any non-principal payment (other than payments that are expressly designated as interest payments hereunder) as an expense, fee or premium, rather than as interest, (ii) exclude voluntary prepayments and the effect thereof and (iii) spread the total amount of interest throughout the entire contemplated term of the Loan so that the interest rate is uniform throughout such term.
   
14. Headings. Section headings are for convenience of reference only and shall in no way affect the interpretation of this Agreement.
   
15. Information Sharing between Lender, Processor and Other Processor. You authorize Lender to share with its affiliates, Processor and Other Processor any information in Lender’s records related to this Loan, including information about Your Shopify Services Account and Your payment history. You also authorize Lender’s affiliates and Processor or Other Processor to share with Lender any information in their records related to Your Shopify Services Account or any Account and any services Borrower obtains pursuant to the Processor or Other Processor. You also authorize Other Processor to share with Lender any information in its records related to any Other Business Receivables, any Shopify Services account, and any Account. You agree that there is no limitation on the purpose for which Lender may share such information with its affiliates, Processor or Other Processor or for which Lender’s affiliates, Processor or Other Processor may share such information with Lender. You further agree that Lender, Processor and Other Processor may use such information in their sole and absolute discretion.

 

16. Disclosure.  
     
  i. Neither party will disclose the other’s confidential information to any third parties, except that Lender may make any disclosures (i) contemplated by this Agreement, (ii) that are reasonably necessary for consummation of this Agreement, (iii) to its affiliates, members, managers, investors, prospective investors, financing sources and equity holders and any external accountants, agents, attorneys and other advisors, (iv) to Processor or Other Processor, (v) as required or requested by any regulatory authority or examiner or any insurance association, (vi) as required by any applicable law, court decree, subpoena, or legal or administrative order or process, (vii) in connection with the exercise of any remedy hereunder or (viii) as agreed by Borrower.

 

 

 

 

  ii. Borrower understands and agrees that the terms and conditions of the products and services offered hereunder, including this Agreement and any other agreement related hereto (“Lender Information”), are proprietary and confidential information of Lender. Accordingly, unless disclosure is required by law or court order, Borrower shall not disclose any Lender Information to any other person other than an attorney, accountant or financial advisor who needs to know such information for purposes of advising Borrower; provided such person uses such Lender Information solely for the purposes of advising Borrower and first agrees not to disclose any Lender Information to any person.

 

17. Credit Reports. Borrower agrees that a consumer report about Borrower may be obtained in connection with this Agreement. Any such report may contain information, including public record information, information about creditworthiness, credit standing, credit capacity, character, general reputation, personal characteristics, or mode of living, such as criminal history, age verification information, citizenship status or fraudulent activity. If adverse action is taken, based in whole or in part on the information contained in the consumer report, Borrower, as applicable, will be provided with the name, address, and telephone number of the consumer reporting agency as well as a summary of Borrower’s rights under the Fair Credit Reporting Act. Borrower voluntarily and knowingly authorizes and requests any consumer reporting agency engaged by Us to furnish the above-mentioned information. Borrower understands that the above-mentioned information may be obtained from a variety of sources, including, but not limited to, public records, credit bureaus and financial institutions. Borrower further authorizes Us to obtain the above-mentioned reports at any time during which this Agreement is in effect. Borrower acknowledges that We may report information about Borrower’s obligation under this Agreement to credit bureaus. A default under this Agreement may be reflected in Borrower’s credit report. You authorize Us to obtain reports regarding Your business at any time during which this Agreement is in effect. For the avoidance of doubt, Lender reserves the right to seek the consent of individual principals of the Borrower to obtain a consumer report about such principals in connection with this Agreement.
   
18. Right To Cancel. Within three (3) business days of the Funding Date, You may cancel this Agreement by notifying Us in writing and returning to Lender the full amount advanced by Lender to Your SMBA on the Funding Date. Such notice and return of the amount of the Loan must be received by Us prior to midnight on the third business day after the Funding Date.
   
19. Waiver. You waive and release any and all claims You may have against Processor or Other Processor that are in any way related to its respective duties as a processor.
   
20. Indemnity; Limitation of Liability. YOU, YOUR SUCCESSORS AND PERMITTED ASSIGNEES AND AFFILIATES, AGREE TO FOREVER PROTECT, INDEMNIFY AND “HOLD HARMLESS” US, PROCESSOR, OTHER PROCESSOR(S), AND THEIR AND OUR RESPECTIVE SUCCESSORS, ASSIGNS, OFFICERS, DIRECTORS, EMPLOYEES, MANAGERS, MEMBERS, AGENTS AND AFFILIATES, AGAINST ALL DAMAGES, EXPENSES, CLAIMS, SUITS, DEMANDS, COSTS, ATTORNEYS’ FEES OR LOSSES ARISING OUT OF OR ALLEGED TO HAVE ARISEN OUT OF OR IN CONNECTION WITH YOUR CONDUCT OF YOUR BUSINESS, YOUR PERFORMANCE OR NON-PERFORMANCE UNDER THIS AGREEMENT, THE DELIVERING OF ANY PAYMENTS TO US AS DESCRIBED IN THIS AGREEMENT, AND THE EXERCISE OF ANY OF OUR RIGHTS AS DESCRIBED IN THIS AGREEMENT. IN NO EVENT WILL WE, OUR AFFILIATES, PROCESSOR OR OTHER PROCESSOR(S) BE LIABLE TO YOU OR TO ANY THIRD PARTY FOR ANY LOSS OF USE, REVENUE OR PROFIT OR LOSS OF DATA OR FOR ANY DIRECT, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL OR PUNITIVE DAMAGES, WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, REGARDLESS OF WHETHER SUCH DAMAGE WAS FORESEEABLE AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. Borrower agrees that any amounts due to Processor or Other Processor under Your agreement with Processor or Other Processor takes priority over amounts to be delivered to Us under this Agreement.
   
21. Power of Attorney. You grant to Us an irrevocable power of attorney, coupled with an interest, and appoint Us and Our designees as Your attorney-in-fact to take any and all actions necessary or appropriate to direct new or additional processors to make payment to Us as contemplated by this Agreement.
   
XI. Communications Between You and Lender.
   
1. Automatic Reminders. We may use automated telephone dialling, text messaging systems and electronic mail to provide messages to You about the Loan. The telephone messages may be played by a machine automatically when the telephone is answered, whether answered by You or another party. These messages may also be recorded by Your answering machine or voicemail. You give Us permission to call or send a text message to any telephone number that You or Your Authorized Representative have given Us and to play pre-recorded messages or send text messages with information about this Agreement, the SMBA or Your Loan over the phone. You also give Us permission to communicate such information to You via electronic mail. You agree that We will not be liable to You for any such calls or electronic communications, even if information is communicated to an unintended recipient. You understand that, when You receive such calls or electronic communications, You may incur a charge from the company that provides You with telecommunications, wireless and/or Internet services. You agree that We have no liability for such charges. You agree to immediately notify Us if You change telephone numbers or are otherwise no longer the subscriber or customary user of a telephone number You have previously provided to Us.
   
2. Monitoring and Recording. We may monitor, tape, or electronically record Our telephone calls with You, including, without limitation, any calls with Our and/or Processor’s or Other Processor’s customer service department, collection department, and any other department.
   

 

 

 

 

 

XII. Arbitration Provision with Class Action Waiver.

 

1. You and We agree to resolve any and all claims and disputes relating in any way to this Agreement or Our dealings with You (“Claims”), except for Claims concerning the validity, scope or enforceability of this Section XII (“Arbitration Provision”), through BINDING INDIVIDUAL ARBITRATION. Notwithstanding the foregoing, You or We may bring an individualized action in small claims court for Claims within the jurisdiction of that court. This Arbitration Provision is made with respect to transactions involving interstate commerce and shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the “FAA”), and not by state law.
   
2. Individual Arbitration. By entering into this Arbitration Provision, neither You nor We will be able to have the dispute settled by a court or jury trial or to participate in a class action, collective action, class arbitration, or other representative action or proceeding. Other rights that You and We would have if You or We went to court will not be available or will be more limited in arbitration, including the right to appeal. You and We each understand that by agreeing to resolve any dispute through individual arbitration, WE ARE EACH WAIVING THE RIGHT TO A COURT OR JURY TRIAL. YOU AND WE AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN YOUR OR OUR INDIVIDUAL CAPACITY AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING. The arbitrator(s) may not consolidate more than one party’s claims and may not otherwise preside over any form of a representative or class proceeding. Further, the arbitrator may award declaratory or injunctive relief only in favor of the individual party seeking relief and only to the extent necessary to provide relief warranted by that party’s individual claim. If applicable law precludes enforcement of any of this paragraph’s limitations as to a particular claim for relief, then that claim (and only that claim) must be severed from arbitration and may be brought in court. If any portion of this Arbitration Provision other than this paragraph’s limitations is deemed invalid or unenforceable, it shall not invalidate the remaining portions of this Arbitration Provision.
   
3. Arbitration Rules. Arbitration of any dispute under this Arbitration Provision shall be administered by JAMS pursuant to the applicable rules of JAMS in effect at the time the arbitration is initiated. You may contact JAMS to obtain information about arbitration, by calling 800-352-5267 or visiting www.jamsadr.com. If JAMS is unable or unwilling to administer the arbitration of a dispute, then a dispute may be referred to any other arbitration organization You and We agree upon or to an arbitration organization or arbitrator appointed pursuant to section 5 of the FAA. Arbitrations shall be conducted before a single arbitrator. Any in-person arbitration shall take place in the federal judicial district in which Your physical address is located, unless otherwise agreed by You and Us in writing. If Your claim is for $10,000 or less, We agree that You may choose whether the arbitration will be conducted solely on the basis of documents submitted to the arbitrator, through a telephonic hearing, or by an in-person hearing as established by the JAMS rules. If Your claim exceeds $10,000, the right to a hearing will be determined by the JAMS rules.
   
4. Regardless of the manner in which the arbitration is conducted, the arbitrator shall issue a reasoned written decision sufficient to explain the essential findings and conclusions on which the award is based. The arbitrator shall apply applicable substantive law consistent with the FAA and applicable statutes of limitations and shall be authorized to award any relief that would have been available in court, provided that the arbitrator’s authority to resolve claims and make awards is limited to You and Us alone except as otherwise specifically stated herein. The decision by the arbitrator shall be final and binding. You and We agree that this Arbitration Provision extends to any other parties involved in any Claims, including but not limited to Your and Our employees, affiliated companies, and vendors. In the event of any conflict between this Arbitration Provision and the JAMS arbitration rules or the rules of any other arbitration organization or arbitrator, this Arbitration Provision shall govern.
   
5. Arbitration Fees and Costs. Except as otherwise provided for herein, We will pay all JAMS filing, administration, and arbitrator fees. If, however, the arbitrator finds that either the substance of Your claim or the relief sought in Your arbitration demand is frivolous or brought for an improper purpose (as measured by the standards set forth in Federal Rule of Civil Procedure 11(b)), then the payment of such fees will be governed by the JAMS rules. In such case, You agree to reimburse Us for all monies previously disbursed by Us that are otherwise Your obligation to pay under the JAMS rules. In addition, if You initiate an arbitration in which You seek more than $75,000 in damages, the payment of these fees will be governed by the JAMS rules.
   
6. Arbitration Provision Is Optional. YOU HAVE THE RIGHT TO REJECT THIS ARBITRATION PROVISION, BUT YOU MUST EXERCISE THIS RIGHT PROMPTLY. If You do not wish to be bound by this agreement to arbitrate, You must notify Us in writing within sixty (60) days after the date of this Agreement. You must send Your request to: 33 New Montgomery St. Suite 750 San Francisco, CA 94105. The request must include Your full name, address, Shopify Store name, d/b/a name (if applicable), and the statement “I reject the Arbitration Provision contained in my Shopify Loan Agreement.” If You exercise Your right under this Section XII to reject arbitration, the other terms of this Agreement shall remain in full force and effect as if You had not rejected arbitration. Opting out of this Arbitration Provision has no effect on any other or future arbitration agreements that You may have with Us.

 

XIII. Register.

 

You agree that Lender, on Your behalf, may maintain a register in order to record the amount of Your Loan and the current or future owner of Your Loan (including any assignee, participant or transferee, if any, who becomes the subsequent owner of any portion of Your Loan) (the “Register”). The parties hereto agree that the entity whose name is recorded in the Register as the current owner of Your Loan is treated as the owner of Your Loan. The Register must be updated for any transfer of ownership of Your Loan to occur.

 

By clicking on “Accept terms,” You agree, on behalf of Your business Synergy CHC Corp, as Borrower, to the terms of this Agreement, which includes an arbitration and waiver of class action provision, and You represent that You are an Authorized Representative of Borrower and acknowledge that You received a copy of this Agreement.

 

 

 

 

Exhibit 10.29

 

INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (the “Agreement”) is made and entered into as of              , 2021 between Synergy CHC Corp., a Nevada corporation (the “Company”), and ____________ (“Indemnitee”).

 

WITNESSETH THAT:

 

WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. Chapter 78 of the Nevada Revised Statutes (the “NRS”) and the Amended and Restated Articles of Incorporation of the Company (the “Articles”) authorize indemnification of the directors, officers, employees, fiduciaries and agents of the Company. The Amended and Restated Bylaws of the Company (the “Bylaws”) provide that the Company will indemnify the directors and officers of the Company. The NRS expressly provides that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and persons acting on behalf of the Company with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company’s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to and in furtherance of any indemnification provisions in the Articles and/or the Bylaws of the Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee does not regard the protection available under the NRS, the Bylaws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or a director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified.

 

NOW, THEREFORE, in consideration of Indemnitee’s agreement to serve as an officer and/or a director from and after the date of this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1. Indemnity of Indemnitee. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof.

 

 

 

 

(a) Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section l(a) if, by reason of his or her Corporate Status (as hereinafter defined), Indemnitee was or is a party, or is threatened to be made a party, to any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company. Pursuant to this Section 1(a), the Company shall indemnify Indemnitee against all Expenses (as hereinafter defined), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee either (i) is not liable pursuant to NRS 78.138 or (ii) acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful.

 

(b) Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 1(b) if, by reason of his or her Corporate Status, Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 1(b), the Company shall indemnify Indemnitee against all Expenses and amounts paid in settlement actually and reasonably incurred by Indemnitee, or on Indemnitee’s behalf, in connection with such Proceeding or any claim, issue or matters therein, if Indemnitee either (i) is not liable pursuant to NRS 78.138 or (ii) acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, if applicable law so provides, no indemnification against such Expenses or other amounts shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Company or for amounts paid in settlement to the Company, unless and only to the extent that the court in which the Proceeding was brought or other court of competent jurisdiction shall determine that in view of all the circumstances in the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

 

(c) Termination of Proceeding. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, adversely affect the right of Indemnitee to indemnification or create an inference or presumption either that Indemnitee is liable pursuant to NRS 78.138, that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to believe that the conduct was unlawful. The Company acknowledges that such a resolution, short of final judgment, may be successful on the merits if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such Proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

(d) Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, the Company shall indemnify Indemnitee to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or her on his or her behalf in connection with the defense of the Proceeding. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

2. Additional Indemnity. In addition to, and without regard to any limitations on, the indemnification provided for in Section 1 of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee, to the fullest extent permitted by law, as may be amended from time to time, against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf, if, by reason of his or her Corporate Status, he or she was or is a party, or is threatened to be made a party, to any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the simple or gross negligence, recklessness, or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company’s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in Section 6 and Section 7 hereof) to be unlawful.

 

 

 

 

3. Contribution.

 

(a) Whether or not the indemnification provided in Section 1 and Section 2 hereof is available, in respect of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall pay the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.

 

(b) Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction from which such Proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.

 

(c) The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors, or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.

 

(d) To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

(e) The Company hereby acknowledges that Indemnitee may have rights to indemnification for payment of the judgment or settlement amount provided by another entity (“Other Indemnitor(s)”). The Company agrees with Indemnitee that the Company is the indemnitor of first resort of Indemnitee with respect to matters for which indemnification is provided under this Agreement and that the Company will be obligated to make all payments due to or for the benefit of Indemnitee under this agreement without regard to any rights that Indemnitee may have against the Other Indemnitor(s). The Company hereby waives any equitable rights to contribution or indemnification from the Other Indemnitor in respect of any amounts paid to Indemnitee hereunder until such time as the Indemnitee has been fully and finally indemnified. The Company further agrees that no payment of Expenses or losses by the Other Indemnitor(s) to or for the benefit of Indemnitee shall affect the obligations of the Company hereunder.

 

 

 

 

4. Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, is a witness, or is made (or asked) to respond to discovery requests or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection therewith.

 

5. Advancement of Expenses. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with defending any Proceeding within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and Indemnitee shall also submit a written undertaking to repay any Expenses advanced if it shall ultimately be determined by a court of competent jurisdiction that Indemnitee is not entitled to be indemnified by the Company against such Expenses. Any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest free. In furtherance of the foregoing, Indemnitee hereby undertakes to repay such amounts advanced if, and to the extent that, it shall ultimately be determined by a court of competent jurisdiction that Indemnitee is not entitled to be indemnified by the Company pursuant to the terms of this Agreement.

 

6. Procedures and Presumptions for Determination of Entitlement to Indemnification. It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the NRS and public policy of the State of Nevada. Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement:

 

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, the Company is actually and materially prejudiced as a result of such failure.

 

(b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 6(a) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following three methods, which shall be at the election of the Board (i) by a majority vote of a quorum consisting of Disinterested Directors (as defined below), (ii) if a majority vote of a quorum consisting of Disinterested Directors so orders, or if a quorum of Disinterested Directors cannot be obtained, by Independent Counsel (as defined below) in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (iii) by the stockholders of the Company.

 

(c) Notwithstanding anything to the contrary set forth in this Agreement, if a request for indemnification is made after a Change in Control, at the election of Indemnitee made in writing to the Company, and if the Board by a majority vote of a quorum consisting of Disinterested Directors orders the determination of Indemnitee’s entitlement to indemnification to be made by an Independent Counsel, or if a quorum of Disinterested Directors cannot be obtained, any determination required to be made pursuant to Section 6(b) above as to whether Indemnitee is entitled to indemnification shall be made by Independent Counsel selected as provided in this Section 6(c). The Independent Counsel shall be selected by Indemnitee, unless Indemnitee shall request that such selection be made by the Board. The party making the selection shall give written notice to the other party advising it of the identity of the Independent Counsel so selected. The party receiving such notice may, within seven (7) days after such written notice of selection shall have been given, deliver to the other party a written objection to such selection. Such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 13 hereof, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made, the Independent Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected (or, if selected, such selection shall have been objected to) in accordance with this paragraph, then either the Company or Indemnitee may petition the courts of the State of Nevada or other court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom an objection is favorably resolved or the person so appointed shall act as Independent Counsel under Section 6(c) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 6(b) hereof. The Company shall pay any and all reasonable and necessary fees and expenses incident to the procedures of this Section 6(c), regardless of the manner in which such Independent Counsel was selected or appointed.

 

 

 

 

(d) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this Section 6(d). The Independent Counsel shall be selected by the Board. Indemnitee may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 13 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected (or, if selected, such selection shall have been objected to) in accordance with this paragraph, then either the Company or Indemnitee may petition the appropriate courts of the State of Nevada or other court of competent jurisdiction for resolution of any objection which shall have been made by Indemnitee to the Company’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom an objection is favorably resolved or the person so appointed shall act as Independent Counsel under Section 6(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel in connection with acting pursuant to Section 6(b) hereof, and the Company shall pay any and all reasonable fees and expenses incident to the procedures of this Section 6(d), regardless of the manner in which such Independent Counsel was selected or appointed.

 

(e) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(f) Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise (as hereinafter defined), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(f) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. The Company will promptly advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.

 

 

 

 

(g) Notwithstanding anything to the contrary set forth in this Agreement, if the person, persons or entity empowered or selected under Section 6 to determine whether Indemnitee is entitled to indemnification shall not have been appointed or shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, unless the Company establishes by written opinion of Independent Counsel (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 6(g) shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 6(b) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Disinterested Directors resolve as required by Section 6(b)(iii) of this Agreement to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.

 

(h) Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel or member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding Indemnitee’s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

7. Remedies of Indemnitee.

 

(a) In the event that (i) a determination is made pursuant to Section 6 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 5 of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to Section 6(b) or Section 6(c) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification, or such longer period, not to exceed an additional thirty (30) days, to which the period may be extended pursuant to Section 6(g), (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication of Indemnitee’s entitlement to such indemnification or advancement of expenses either, at Indemnitee’s sole option, in (1) an appropriate court of the State of Nevada, or any other court of competent jurisdiction or (2) an arbitration to be conducted by a single arbitrator, selected by mutual agreement of the Company and Indemnitee, pursuant to the rules of the American Arbitration Association. The Company shall not oppose Indemnitee’s right to seek any such adjudication.

 

(b) In the event that a determination shall have been made pursuant to Section 6(b) or Section 6(c) of this Agreement that Indemnitee is not entitled to indemnification, (i) any judicial proceeding or arbitration commenced pursuant to this Section 7 shall be conducted in all respects de novo on the merits, and Indemnitee shall not be prejudiced by reason of any adverse determination under Section 6(b) or Section 6(c); and (ii) in any such judicial proceeding or arbitration, the Company shall have the burden of proving that Indemnitee is not entitled to indemnification under this Agreement.

 

 

 

 

(c) If a determination shall have been made pursuant to Section 6(b) or Section 6(c), or shall have been deemed to have been made pursuant to Section 6(g), of this Agreement that Indemnitee is entitled to indemnification, the Company shall be obligated to pay the amounts constituting such indemnification within five (5) days after such determination has been made or has been deemed to have been made and shall be conclusively bound by such determination in any judicial proceeding commenced pursuant to this Section 7, unless the Company establishes by written opinion of Independent Counsel (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s misstatement not materially misleading in connection with the request for indemnification or (ii) a prohibition of such indemnification under applicable law.

 

(d) In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of, or an award in arbitration to enforce, his or her rights under, or to recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the Company, the Company shall pay to him or her, or on his or her behalf, in advance, and shall indemnify him or her against, any and all expenses (of the types described in the definition of Expenses in Section 13 of this Agreement) actually and reasonably incurred by him or her in such judicial adjudication or arbitration, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery.

 

(e) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.

 

8. Non-Exclusivity; Survival of Rights; Insurance; Subrogation.

 

(a) The rights of indemnification and advancement of expenses as provided by this Agreement shall not be deemed exclusive of, and shall be in addition to, any other rights to which Indemnitee may at any time be entitled under applicable law, the Articles or the Bylaws of the Company, any agreement, a vote of stockholders, a resolution of directors of the Company, or otherwise, and nothing in this Agreement shall diminish or otherwise restrict Indemnitee’s rights to indemnification or advancement of expenses under any of the foregoing. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in the NRS, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Articles, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change and Indemnitee shall be deemed to have such greater benefits hereunder. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. The Company shall not adopt any amendments to its Articles or Bylaws, the effect of which would be to deny, diminish or encumber Indemnitee’s right to indemnification or advancement of expenses under this Agreement, any other agreement or otherwise, without the prior written consent of the Indemnitee.

 

(b) The Company shall use commercially reasonable efforts to obtain and maintain in effect one or more policies of insurance with reputable insurance companies to provide the officers/directors of the Company with coverage for losses from wrongful acts and omissions and to ensure the Company’s performance of its indemnification obligations under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director or officer under such policy or policies. In all such insurance policies, the Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same rights and benefits as are accorded to the most favorably insured of the Company’s directors and officers.

 

 

 

 

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights (with all of Indemnitee’s reasonable expenses, including, without limitation, attorneys’ fees and charges, related thereto to be reimbursed by or, at the option of Indemnitee, advanced by the Company).

 

(d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e) The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

 

9. Exception to Right of Indemnification. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:

 

(a) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or similar provisions of state statutory law or common law; or

 

(c) for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or

 

(d) for any reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act; or

 

(e) in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company (other than to enforce Indemnitee’s rights under this Agreement) or its directors, officers, employees or other indemnitees, unless (i) the Board of the Company authorized the Proceeding (or such part of the Proceeding) prior to its initiation, or (ii) the Company indemnifies Indemnitee, in its sole discretion, independently of this Agreement pursuant to the powers vested in the Company under applicable law.

 

10. Retroactive Effect; Duration of Agreement; Successors and Binding Agreement. All agreements and obligations of the Company contained herein shall be deemed to have become effective upon the date Indemnitee first had Corporate Status; shall continue during the period Indemnitee has Corporate Status; and shall continue thereafter so long as Indemnitee may be subject to any Proceeding (or any action commenced under Section 7 hereof) by reason of his or her Corporate Status, whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation, reorganization or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives. The Company shall require any such successor to all or substantially all of the business or assets of the Company, by agreement in form and substance satisfactory to Indemnitee and his or her counsel, expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would be required to perform if no such succession had taken place. Except as otherwise set forth in this Section 10, this Agreement shall not be assignable or delegable by the Company.

 

 

 

 

11. Security. To the extent requested by Indemnitee and approved by the Board of the Company, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee.

 

12. Enforcement.

 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve, or continue to serve, as an officer or a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving or continuing to serve as an officer or a director of the Company.

 

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

13. Definitions. For purposes of this Agreement:

 

(a) “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

(i) Acquisition of Stock by Third Party. Other than Jack Ross and Knight Therapeutics (Barbados) Inc., any Person (as defined below) is or becomes the “beneficial owner” as defined in Rule 13d-3 under the Exchange Act (a “Beneficial Owner”), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors, unless (1) the change in the relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, or (2) such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute a Change in Control under part (iii) of this definition;

 

(ii) Change in Board of Directors. Individuals who, as of the date hereof, constitute the Board, and any new director whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two thirds of the directors then still in office who were directors on the date hereof or whose election for nomination for election was previously so approved (collectively, the “Continuing Directors”), cease for any reason to constitute at least a majority of the members of the Board;

 

(iii) Corporate Transactions. The effective date of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses or assets (a “Business Combination”), in each case, unless, following such Business Combination: (1) all or substantially all of the individuals and entities who were the Beneficial Owners of securities entitled to vote generally in the election of directors immediately prior to such Business Combination beneficially own, directly or indirectly, more than 51% of the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more Subsidiaries (as defined below)) in substantially the same proportions as their ownership immediately prior to such Business Combination, of the securities entitled to vote generally in the election of directors; (2) other than the Sponsor or an affiliate thereof, no Person (excluding any corporation resulting from such Business Combination) is the Beneficial Owner, directly or indirectly, of fifteen percent (15%) or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of directors of the surviving corporation except to the extent that such ownership existed prior to the Business Combination; and (3) at least a majority of the Board of Directors of the corporation resulting from such Business Combination were Continuing Directors at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;

 

 

 

 

(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement or series of agreements for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than factoring the Company’s current receivables or escrows due (or, if such stockholder approval is not required, the decision by the Board to proceed with such a liquidation, sale, or disposition in one transaction or a series of related transactions); or

 

(v) Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or any successor rule) (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement.

 

(b) “Corporate Status” means the fact that a person is or was a director, officer, employee, agent or fiduciary of the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise.

 

(c) “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(d) “Enterprise” shall mean the Company, and any other corporation, constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger to which the Company (or any of its wholly owned subsidiaries) is a party, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, trustee, partner, manager, managing member, employee, agent or fiduciary.

 

(e) “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred or actually incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in a Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding, including, without limitation, the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent. Should any payments by the Company to or for the account of Indemnitee under this Agreement be determined to be subject to any federal, state or local income or excise tax, Expenses shall also include such amounts as are necessary to place Indemnitee in the same after-tax position (after giving effect to all applicable taxes) Indemnitee would have been in had no such tax been determined to apply to those payments. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable in the good faith judgment of such counsel shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(f) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

 

 

 

(g) “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act as in effect on the date hereof; provided, however, that “Person” shall exclude: (i) the Company; (ii) any Subsidiaries (as defined below) of the Company; (iii) any employment benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; and (iv) any trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a Subsidiary (as defined below) of the Company or of a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(h) “Proceeding” includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative, legislative or investigative (formal or informal); in each case whether or not Indemnitee’s Corporate Status existed at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to Section 7 of this Agreement to enforce his or her rights under this Agreement.

 

(i) “Subsidiary,” with respect to any Person, shall mean any corporation, limited liability company, partnership, joint venture, trust or other entity of which a majority of the voting power of the voting equity securities or equity interest is owned, directly or indirectly, by that Person.

 

14. Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.

 

15. Modification and Waiver. No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

 

16. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement unless, and only to the extent that, the Company is actually and materially prejudiced as a result of such delay or failure.

 

17. Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile, or (c) upon delivery when sent by a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent:

 

(a) To Indemnitee at the address set forth below Indemnitee’s signature hereto.

 

(b) To the Company at:

    Synergy CHC Corp.
    865 Spring Street
    Westbrook, Maine 04092

 

or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.

 

 

 

 

18. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

19. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

20. Successors and Assigns. The terms of this Agreement shall be binding upon the Company and its successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company) and shall inure to the benefit of Indemnitee and Indemnitee’s spouse, assigns, heirs, devisees, executors, administrators and other legal representatives.

 

21. Governing Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Nevada, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement (other than an arbitration pursuant to Section 7 hereof) shall be brought only in the Eighth Judicial District Court of Clark County (the “Nevada Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Nevada Court for purposes of such action or proceeding, (iii) waive any objection to the laying of venue of any such action or proceeding in the Nevada Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Nevada Court has been brought in an improper or inconvenient forum.

 

22. Waiver of Claims to Trust Account. Notwithstanding anything contained herein to the contrary, Indemnitee hereby agrees that it does not have any right, title, interest or claim of any kind (each, a “Claim”) in or to any monies in the trust account established in connection with the Company’s initial public offering for the benefit of the Company and holders of shares issued in such offering, and hereby waives any Claim it may have in the future as a result of, or arising out of, any services provided to the Company and will not seek recourse against such trust account for any reason whatsoever.

 

[Remainder of page intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and year first above written.

 

  COMPANY
   
  SYNERGY CHC CORP.
     
  By:  
  Name:  
  Title:  
     
  INDEMNITEE
              
  Name:  
  Address:  

 

[Signature Page to Indemnification Agreement]

 

 

 

 

 

 

Exhibit 14.1

 

Synergy CHC Corp.

CODE OF BUSINESS ETHICS AND CONDUCT

(Effective as of              , 2021)

Introduction

 

Consistent ethical business conduct by all Directors, employees, agents, consultants, contractors and business partners is critical to the preservation and enhancement of the business reputation of Synergy CHC Corp., and its wholly-owned subsidiaries, hereafter referred to as the “Company”, conducting business currently in the United States and Canada.

 

Contained within this code of business ethics and conduct, hereafter referred to as the “Code”, are fundamental values and principles that are nonnegotiable. These include, but are not limited to:

 

Respect for:

 

  one another,
     
  our shareholders, and
     
  the environment,

 

and a commitment to:

 

  the health and safety of employees, contractors, and the communities in which we work and live.

 

Employees are expected to accept certain responsibilities, adhere to acceptable legal business principles and exhibit a high degree of personal integrity at all times. Employees are expected to refrain from actions that might be harmful to themselves, co-workers, our business associates or the Company. The intent of the Code is not to place unreasonable restrictions on personal actions, but to set out the minimum standards of conduct expected as an employee of the Company.

 

The Company requires all employees to conduct themselves in accordance with the Code and will hold all employees accountable for their conduct. Those who engage in any conduct contrary to the Code may be terminated summarily for just cause.

 

Fundamental Principles

 

The Code will describe the minimum standards of business conduct that the Company expects from every employee at every level of responsibility and to the extent feasible and applicable, to our agents, consultants, contractors and business partners. Furthermore, these principles will apply to every part of the Company, whether operating domestically or internationally.

 

Confidential 1  

 

 

Section 1.

 

1.0 Definitions

 

Employee

 

For the purposes of the Code, employee will be defined as all directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions for the Company.

 

Company

 

For the purposes of the Code, the Company will be defined as Synergy CHC Corp., and all of its wholly owned subsidiaries conducting business currently in the United States and Canada.

 

Company Resources

 

Company resources include Company time, materials, supplies, equipment, information, intellectual property, electronic mail and computer systems.

 

Compliance Officer

 

Shall be defined as the acting chair of the Corporate Governance Committee.

 

Gifts and Hospitality

 

In the Code the term(s) “gifts and hospitality” shall include, but will not be limited to such items as meals, beverages, and invitations to social or recreational outings, accommodation, and travel.

 

Insider Trading

 

For the purposes of the Code, insider trading will be defined as the illegal buying or selling of the Company’s securities on the basis of Material Information that is Nonpublic.

 

Material Information

 

Information about the Company is “material” if it would be expected to affect the investment or voting decisions of a reasonable shareholder or investor, or if the disclosure of the information would be expected to alter significantly the total mix of information in the marketplace about the Company. Examples of material information include, but are not limited to:

 

  Financial performance and significant changes in financial performance or liquidity.
     
  Potential material mergers and acquisitions or material sales of Company assets or subsidiaries.
     
  Stock splits, public or private securities/debt offerings, or changes in Company dividend policies or amounts.
     
  Significant changes in senior management.
     
  New major contracts or customers, or the loss of a major customer.
     
  Initiation of a significant lawsuit.

 

Confidential 2  

 

 

Nonpublic Information

 

Material information is “nonpublic” if it has not been widely disseminated to the public, for example, through major newswire services, national news services, Web casts or financial news services. For the purposes of the Code, information will be considered public, i.e., no longer “nonpublic,” at the opening of trading on the third full trading day following the Company’s widespread public release of the information.

 

Proprietary Confidential Information (PCI)

 

PCI includes, but is not limited to: any information, know-how, patent, copyright, Intangible Property, trade secret, process, technique, program, design or formula; any marketing, advertising, financial, commercial, sales or programming matter; any customer or supplier lists or pricing information; any confidential personal information of customers, suppliers or any other parties to whom the Company has obligations of confidentiality; any budget, plan, model or analysis; any written materials, compositions, drawings, diagrams, computer programs, studies, work in progress, visual demonstrations, ideas or concepts; any other PCI including the terms and conditions of any completed or potential transaction; and any of the forgoing derived in whole or in part from PCI whether in oral, written, graphic, electronic, or any other form or medium whatsoever, of the Company or relating to the Company that may be disclosed to, or in the possession of, the employee in connection with employment with the Company.

 

Intellectual Property

 

Intellectual property includes: computer software programs, technical processes, inventions, research devices, reports or articles containing any form of unique or original innovation or development, whether or not protected by patent, trademark, copyright, or otherwise.

 

Intellectual property that has been created or developed by any employee in the course of employment is the sole property of the Company.

 

Section 2.

 

2.0 Compliance with Laws

 

Employees, and where applicable agents, consultants, contractors and business partners are required to perform their duties on behalf of the Company in compliance with all applicable laws and regulations and with Company policies and procedures that are designed to facilitate compliance. This obligation includes, but is not limited to, compliance with all relevant laws regarding health and safety, fraud, kickbacks, referral fees, false claims, commercial bribery, copyrights, trademarks and trade secrets, information privacy, insider trading, illegal political contributions, antitrust, foreign corrupt practices, employment discrimination or harassment, false or misleading financial information, and misuse of Company assets.

 

The Company’s Compliance Officer and the Company’s General Legal Counsel are available to provide advice and guidance on compliance with applicable laws.

 

Confidential 3  

 

 

Section 3.

 

3.0 Conflict of Interest

 

Definition

 

Any position, circumstance, or situation where an employee’s personal interest conflicts, is perceived to conflict, or could potentially conflict, in any way with the interests of the Company.

 

Guiding Principles for avoiding Conflict of Interest

 

  Business decisions must be based on merit ensuring that the best interest of the Company is kept primary.
     
  Whether direct or indirect, there shall be no personal advantage derived from having made a business decision on behalf of the Company.
     
  Situations that may result in, or may be perceived to result in, a conflict of interest between an employee’s personal interest and those of the Company should be summarily avoided.
     
  Abstain from any decision or situation that may influence a decision related to the Company that could result in any real or perceived financial or other advantage for an employee, his or her family members, or friends.
     
  In most instances, common sense and integrity will identify the best course of action, however, should there be a circumstance, situation or position that causes even the slightest doubt on course to the decision to be made, err on the side of caution and refer the circumstance, situation or position to the Company compliance officer.

 

Declaring Actual, Perceived, or Potential Conflict of Interest Process

 

The responsibility to declare any actual, perceived or potential conflict of interest must be submitted in writing, to the department manager or the Company Compliance Officer, by the employee(s) involved. If in doubt about any circumstance, situation or position it is recommended that a form be completed and provided to the manager of the department, or the Company Compliance Officer to assist in determining the appropriate course of action.

 

3.1 Political Participation

 

As a private citizen, an employee may participate in levels of recognized political activity during non-working hours provided these obligations do not conflict or negatively impact an employee’s duties and responsibilities as an employee of the Company. Participation must always be kept separate from the association with the Company.

 

Prior to participating as a candidate in a federal, state, provincial, or municipal election, an employee must notify his immediate supervisor in writing, no less than two (2) months prior to any election. An employee may be requested to apply for an unprotected leave of absence from his job without pay as a result.

 

It will be considered a violation of the Code should an employee use any supplies, facilities, tools, or other Company assets to support political activities.

 

Confidential 4  

 

 

3.2 Non-Profit and Professional Organizations

 

The Company recognizes that employees may have an interest in contributing in a positive way to non-profit and professional organizations through active participation in a wide variety of organizations. However, this participation must not at any time, interfere with individual performance of job duties during working hours.

 

  For those employees wishing to participate in non-profit or professional organizations the employee’s immediate supervisor must pre-approve such participation.
     
  Should an employee be afforded the opportunity to act as a spokesperson for any organization, professional or otherwise, it must be made clear that the employee is speaking on behalf of that organization, or himself, but not as a spokesperson, agent, or representative of the Company.

 

3.3 Outside Business Activities

 

Acting in a Director or Officer Capacity of an Organization

 

You may not act in the capacity of a Director or Officer of an organization that:

 

  Competes directly or indirectly with the Company
     
  Purchases goods or services from the Company
     
  Supplies goods or services to the Company

 

Exceptions to section 3.3 of the Code must have written pre-approval from the Board of Directors of the Company.

 

Services performed for another organization

 

Employees may choose to provide services for compensation to additional organizations during non-working hours of the Company as they desire.

 

However,

 

  Prior to providing said services for an organization other than the Company, you must obtain written approval from the Company Compliance Officer and your immediate supervisor if the services to be provided conflict, appear to conflict, or may conflict in the future with your ability to perform your duties as an employee of the Company.
     
  The approval process is initiated by the employee by completing the appropriate request for approval form, and submitting this to their immediate supervisor.
     
  Immediate supervisors will then be responsible to provide appropriate comments where required and to submit the completed form to the Company Compliance Officer.
     
  Failure by an employee to disclose information pertaining to the provision of services to another organization that conflicts, appears to conflict, or may conflict in the future, with an employees’ ability to perform their duties as an employee of the Company will not be an acceptable excuse for failing to meet minimum performance standards of their job duties.

 

Set out below is a list of rules to be considered by those employees wishing to provide services to another organization.

 

Confidential 5  

 

 

The absence of a specific rule in this list shall not be considered as a rule condonable by the Company on the premise that it was not identified in this list.

 

Never:

 

  Perform services for the other organization during Company work hours.
     
  Permit customers or colleagues from the other organization to contact you at the Company.
     
  Use any Company resources, supplies, facilities, tools, personnel, or intellectual property in the course of providing service to the other organization.
     
  Participate in an organization that offers products and/or services that could be perceived as competing for business with the Company.
     
  Perform services for a supplier of the Company.
     
  Sell products or services of a supplier of the Company.
     
  Perform services that currently or in future, may have the potential to provide current or future competitors with a competitive advantage over the Company.
     
  Promote the products and/or services of the other organization during your working hours at the Company.
     
  Perform services for an organization that competes with the Company.
     
  Perform services for an organization currently providing services for the Company or any competitors of the organization.
     
  Participate in or in any way influence the Company’s decisions to purchase goods and/or services that relate to an employment interest or business interest that may benefit an employee directly or indirectly.
     
  Perform services for an organization that would by definition result in a conflict of interest as defined by the Code.

 

3.4 Financial Interest

 

Employees and their families, (families will include spouse, children, or spouse equivalent residing together as a family) shall not own, control or direct a material financial interest (greater than 5%) in a contractor, competitor, supplier, or in any business enterprise which currently or in future may, conduct business with the Company.

 

This would include those situations when, although an employee of the Company may not directly hold the investment, the employee does have the ability to control or direct the investment.

 

Confidential 6  

 

 

Section 4.

 

4.0 Business Gifts and Hospitality

 

Employees must be judicious in the offering or acceptance of gifts and/or hospitality to or from a person or entity with which the Company currently does or seeks to do business in the future.

 

Accepting gifts and/or hospitality may compromise or appear to compromise an employees’ ability to make business decisions that are in the best interest of the Company. However, on occasion, it may be acceptable to give or receive a business related gift or hospitality when there is a business benefit to the Company.

 

Employees must consult their immediate supervisor, the department manager or the Company Compliance Officer for advice on the appropriateness of accepting or offering gifts and/or hospitality.

 

Gifts having a monetary value such as cash, gift certificates, loans, services, and discounts are not permitted. Gifts such as unsolicited advertising mementos of nominal value would generally be acceptable. Depending on the circumstances, unacceptable gifts should be returned with thanks and clarification of the Code.

 

These requirements do not change during traditional gift-giving seasons.

 

4.1 Accepting/Offering Gifts or Hospitality

 

General Guideline

 

Prior to offering or accepting anything from a person or entity with which the Company currently does or seeks to do business with in the future, the employee should ask himself:

 

  Is the value of the item nominal, e.g. a pen or a fridge magnet?
     
  What will the business benefit be to the Company versus the employee?
     
  Is the value and the reason for the gift or hospitality appropriate considering the situation, the people involved, and the employee’s role or function within the Company?
     
  Could it compromise or be perceived to compromise the employee’s ability to make a decision in the best interest of the Company?
     
  Would the employee be uncomfortable discussing the situation with his immediate supervisor, peers, or family?
     
  Could this be considered to be a form of bribe or kickback?

 

For all situations regarding the offering of gifts and hospitality on behalf of the Company, employees at all levels must receive appropriate approval prior to the provision of said gifts and/or hospitality. An employee should consult his immediate supervisor, department manager or the Company Compliance Officer.

 

Never offer, ask for, or receive:

 

  Any form of bribe, kickback or any other form of monetary or material gift or hospitality that may be perceived to be a bribe or kickback.
     
  Any gift, gratuity, entertainment, hospitality, or any other benefit that may compromise or be perceived to compromise the ability to make business decisions in the best interest of the Company.

 

Confidential 7  

 

 

Section 5.

 

5.0 Proprietary Confidential Information (PCI)

 

Employees are responsible to the Company to ensure maximum effort is afforded in keeping PCI confidential. This effort is necessary to:

 

  Safeguard assets.
     
  Preserve the privacy of employees, customers, suppliers and business partners.
     
  Comply with all legal, regulatory, or applicable contractual obligations.
     
  Ensure the Company’s competitive advantage.
     
  Safeguard intellectual property of the Company.

 

5.1 Employee Responsibilities

 

  It is every employee’s responsibility to know what PCI must remain in confidence. Should an employee question whether certain PCI would be classified as confidential, he is encouraged to discuss the PCI with his immediate supervisor, or the manager of the department prior to the disclosure of the PCI.
     
  Do not disclose PCI, except where required by law.
     
  Do not disclose PCI to others including colleagues or other current or previous employees of the Company, except as required for current employees to carry out their job duties.
     
  Make every effort to protect PCI against theft, loss, destruction, misuse, or unauthorized access.
     
  Comply with applicable insider-trading laws and regulations that govern the use of certain PCI.
     
  Comply with the terms and conditions as set out in any policies and procedures regarding company and confidential personal information.
     
  Comply with the Company policies and procedures as related to the use of e-mail, and technology systems when storing and transmitting PCI.
     
  An employee should advise his immediate supervisor, the department manager, or the Company Compliance Officer in the event that he is aware of any attempt to obtain or disclose PCI by/to unauthorized individuals.

 

5.2 Insider Trading

 

Securities laws explicitly prohibit any person in a special relationship with the Company from trading with knowledge of “material nonpublic information” or “insider information” which has not been generally disclosed. In addition, securities laws prohibit any person in a special relationship with the Company from informing another person of any “material non-public” or “insider” information which has not been generally disclosed.

 

Confidential 8  

 

 

Employees of the Company, and their immediate family members, will not trade in their personal account in any physical commodity or financial derivative of any physical or financial commodity related to those traded by the Company if that employee holds a position at the Company that would make them privy to detailed or inside information about the Company’s commodity trading activities.

 

5.3 Media

 

Employees contacted by the media, should refer the inquiry to their immediate supervisor who should in turn, contact the Director, Corporate Relations or General Counsel. Employees shall be cordial to the media, but should respectfully decline any questions. Refrain from confirming, denying or otherwise, information related to the Company with representatives from the media unless specifically directed to by the director, corporate relations. Never discuss PCI or matters involved with litigation.

 

5.4 Litigation

 

Employees are responsible to notify their immediate supervisor, department manager or the Company Compliance Officer of any subpoena, summons, complaint, court order, or any audit documents received by any federal, state or provincial agency governing the Company.

 

5.5 Purchasing

 

Employees involved in the purchase of goods and/or services must ensure:

 

  All purchasing policies, procedures and applicable processes are followed for every purchasing transaction.
     
  Purchasing decisions are made honestly and with integrity utilizing criteria that ensure competitive pricing, quality, quantity, delivery and service.
     
  Purchasing decisions are not based on personal gain, prejudice, favoratism, or preferential treatment.
     
  Any real or perceived purchasing decisions that may be questionable when considering the terms of the Code are disclosed to the employee’s immediate supervisor, department manager or the Company Compliance Officer.

 

Section 6.

 

6.0 Suppliers

 

Employees involved with external suppliers of goods and/or services must:

 

  Treat all suppliers with the utmost respect, courtesy and professionalism.
     
  Inform suppliers of the existence of, and the terms and conditions of the Code.
     
  Deal with suppliers that observe the Code.

 

Confidential 9  

 

 

  All supplier contracts contain a provision for the observation of the Code.
     
  Take immediate action to address any concerns with suppliers as related to violations of the Code, or any other applicable law.
     
  Inform their immediate supervisor, department manager or the Company Compliance Officer of any real or perceived violation of the Code as applicable to suppliers.

 

Section 7.

 

7.0 Company Resources

 

General Principles

 

Employees engaged in the use of Company resources will be responsible to:

 

  Protect the Company’s resources, use them appropriately, and for Company business only.
     
  Protect the Company’s resources from theft and destruction whether through vandalism or neglect.
     
  Protect the Company’s intellectual property, and PCI.
     
  Never misuse Company resources entrusted to them.

 

7.1 Use of Company Resources

 

Company resources are generally to be used only in the course of carrying out job duties and for company-defined purposes.

 

7.2 Use of Internet, Voice mail and E-mail

 

The Company’s computer networks and information resources include our electronic mail and messaging systems and the public internet. The Company’s computer resources and networks are provided for company-related business purposes. Excessive personal use is inappropriate. Use of the Company’s computer resources to view, retrieve or send sexually-related or pornographic messages or material; violent or hate-related messages or material; bigoted, racist or other offensive messages or other messages or material related to illegal activities is strictly prohibited.

 

7.3 Use of the Company Name

 

Employees must not use their employment status to obtain personal gain from those doing or seeking to do business with the Company. Employees may not use the Company’s name or purchasing power to obtain personal discounts or rebates.

 

In protecting the Company’s resources, the Company will reserve the right to periodically monitor access and contents of the Company’s computer systems and networks. Employees should not assume they have any right to privacy of PCI residing on the Company’s computer resources.

 

Confidential 10  

 

 

Section 8.

 

8.0 Business Expenses

 

Certain employees may be required to travel for the purposes of conducting business on behalf of the Company. Employees who, in the course of their employment, incur business related expenses must keep the following in mind:

 

  Exercise integrity, prudence, and sound business judgment in the expenses incurred.
     
  Ensure the expenses are for the purposes of good and ethical business purposes and will enhance the business interests of the Company.
     
  Ensure the expenses comply with any Company policies and procedures regarding travel and expenses.

 

Section 9.

 

9.0 Finance, Accounting and Business Reporting

 

No false, artificial or misleading entries in the books, records and documents of the Company shall be made for any reason. No employee shall engage in any arrangement that results in prohibited acts. All reports filed by the Company shall be in accordance with applicable internal reporting practices, in addition to all applicable laws, regulations and statutes applicable to the filing of reports and the keeping of all books and records. Additionally, all disclosure will be full, fair, accurate, complete and understandable.

 

Section 10.

 

10.0 Fair Dealing

 

Employees must deal fairly with the Company’s customers, suppliers, competitors and employees. No one should take advantage of another through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any other unfair dealing practices.

 

Employees must disclose prior to, or at their time of hire with the Company, the existence of any employment agreement, non-compete or non-solicitation agreement, confidentiality agreement or similar agreement with a former employer that in any way restricts or prohibits the performance of any duties or responsibilities of their positions with the Company. In no event shall an employee use any trade secrets, proprietary confidential information, personal confidential information or similar property, acquired in the course of his of her employment with another employer, in the performance of his of her duties for the Company.

 

10.1 Illegal Remuneration

 

The Company is committed to compliance with all laws, statutes, and regulations regarding illegal remuneration (kickbacks, bribes, and improper payments). The Company specifically prohibits employees from engaging in any fraudulent, deceptive or corrupt conduct toward the Company, its customers, suppliers, contractors, employees, representatives or anyone else with whom the Company has current of future business associations. Prohibited actions include kickbacks, inflated billing and offering, accepting or soliciting, directly or indirectly, of money, goods or services where the purpose of the action is to influence a person to act contrary to the interest of his of her own employer. Company employees may not ask for gifts or gratuities from customers or suppliers of the Company. No employee of the Company will ever offer or receive anything of value with the intent to influence or be influenced by any supplier, customer, government official, candidate, or holder of public office.

 

Confidential 11  

 

 

Section 11.

 

11.0 Employment Practices

 

The Company is committed to ensuring a work environment where employees are treated with dignity, fairness and respect. All employees have the right to work in an atmosphere that provides equal employment opportunities and is free of discriminatory practices and illegal harassment.

 

11.1 Diversity

 

The Company values the background, experience, perspectives and talents of every individual, and thus, strives to create a diverse workforce comprised of individuals drawn from the community within which it conducts business.

 

11.2 Discrimination

 

Neither the Company nor any employee of the Company nor any person acting as an agent on behalf of the Company shall refuse to employ or continue to employ, nor shall they discriminate against any person with regard to employment, term or condition of employment, on the grounds of race, ancestry, place of origin, color, ethnic origin, citizenship, creed, sex, sexual orientation, age, record of offences for which a pardon has been granted, marital status, same sex-partnership status, family status,(including pregnancy or child-birth) or handicap, all as defined by applicable Human Rights legislation or other similar applicable law.

 

11.3 Harassment

 

The Company does not condone any form of illegal harassment or any other conduct that interferes with an individual’s work performance or creates an intimidating, hostile, or offensive work environment. The Company will make every reasonable effort to ensure employees, contractors, and persons acting as agents on behalf of the Company conform to the Company’s anti-harassment and anti-sexual harassment policies.

 

11.4 Workplace Violence

 

The Company expects all employees to treat all fellow employees and persons the Company conducts business with currently, or in the future, with dignity and respect. As such, the Company will not tolerate, whether real or implied, threats or acts of abuse, intimidation, or violence against any employee of the Company, or the organizations the Company conducts business with.

 

11.5 Drug and Alcohol Policy

 

The Company is committed to providing a safe and healthy work environment for all employees. As such the use of illicit drugs, the inappropriate use of alcohol and the misuse of medications and other substances is prohibited.

 

11.6 New Hires

 

All new hire offer letters to prospective employees will require prospective employees to disclose any conflict, or potential conflict of interest, prior to the acceptance of employment with the Company.

 

Confidential 12  

 

 

Section 12.

 

12.0 Health Safety and Environment

 

The Company is committed to providing a safe and healthy working environment and protecting the public interest with standards and programs that meet or exceed industry standards and applicable government codes, standards and regulations in all jurisdictions in which it conducts business.

 

All Company operations are to be conducted in a manner that protects the health and safety of its employees and all people in the communities where the Company operates. All Company employees are responsible for understanding, reinforcing and implementing the Company’s commitment to environmental responsibility.

 

Section 13.

 

13.0 Fraud or Criminal Conduct

 

Fraud is defined but not limited to, an intentional deception, maladministration of Company resources, falsification or manipulation of PCI, to the advantage or disadvantage of a person or entity.

 

Management is responsible for the detection and prevention of fraud, misappropriations and other inappropriate conduct: however, all employees have some responsibility in the detection, prevention or reporting of fraudulent activities. Employees who detect or suspect possible fraudulent activity of any employee, supplier, customer or any other party having any association with the Company, must provide a written report containing the details to the Company Compliance Officer immediately. Do not discuss instances of actual or suspected fraud with anyone except those authorized to investigate such conduct.

 

The Company Compliance Officer will investigate and/or engage the services of additional investigative services for all cases of fraud or criminal conduct including local and federal law enforcement agencies. In the event an investigation substantiates that fraudulent activities have occurred, the Company Compliance

 

Officer will issue reports to appropriate designated personnel, The Board of Directors, and appropriate law enforcement agencies.

 

Section 14.

 

14.0 Compliance

 

Employees must complete any required training on the Code as required. Annual training on the Code will be the responsibility of the employee’s immediate supervisor, and shall be substantiated in employee files.

 

All new hires of the Company will be required to complete training on the Code within 30 days of their original hire date and shall be included as part of the new hire induction training.

 

14.1 Reporting Real or Perceived Violations of the Code

 

Employees who are aware or become aware of conduct by others that violates, or appears to violate the Code are required to report the details of the violation or apparent violation to their immediate supervisor, department manager or the Company Compliance Officer. Supervisors and Managers will be responsible to submit the detailed report of the violation or apparent violation to the Company Compliance Officer immediately.

 

Confidential 13  

 

 

14.2 Whistle Blowing

 

The Company strictly prohibits reprisals or retaliation against anyone who reports a violation or perceived violation, in good faith of the Code.

 

In the event that an employee feels he or she have been subjected to retaliatory or disciplinary action as a result of having filed a report in good faith of a violation or perceived violation of the Code, please contact the Company Compliance Officer.

 

14.3 Confidentiality

 

To the extent permissible by applicable law and to the extent that is reasonable, the Company will keep the report of the violation or perceived violation of the Code, confidential. The Company will however, cooperate fully with all external investigative authorities involved with the report of a violation or perceived violation of the Code as required by law, and will provide all information requested by said investigative authorities.

 

14.4 When the Code does NOT Have the Answer

 

There may be occasions when the Code may not have the answer to the ethical question facing an employee, or there may be a difficult judgment call to make with respect to the application of the Code. In these cases, the employee should consult with his or her manager, who will either provide guidance or refer the employee to the relevant policy or to the Company Compliance Officer.

 

14.5 Consequences for non-Compliance

 

Employees who make the unilateral decision to not comply with the Code may be subject to disciplinary actions up to and including dismissal and/or legal action.

 

14.6 Enforcement

 

The Company must ensure prompt and consistent action against violations of this Code.

 

If, after investigating a report of an alleged prohibited action by a director or executive officer, the Audit Committee determines that a violation of this Code has occurred, the Audit Committee will report such determination to the Board of Directors.

 

If, after investigating a report of an alleged prohibited action by any other person, the relevant supervisor or the Compliance Officer determines that a violation of this Code has occurred, the supervisor or the Compliance Officer will report such determination to the General Counsel.

 

Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or the General Counsel will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

 

Section 15.

 

15.0 Waiver

 

Each of the Board of Directors (in the case of a violation by a director or executive officer) and the General Counsel (in the case of a violation by any other person) may, in its discretion, waive any violation of this Code.

 

Any waiver for a director or an executive officer shall be disclosed as required by SEC and Nasdaq rules.

 

Confidential 14  

 

 

EXHIBIT 21.1

 

Subsidiaries

 

Name   State of Incorporation
     
Hand MD Corp.   Delaware
     
NomadChoice Pty Ltd.   Tasmania, Australia
     
Synergy CHC Inc.   Alberta, Canada

 

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of

Synergy CHC Corp.

 

We hereby consent to the reference to our firm under the caption “Experts” and the use of our report dated August 5, 2021 on the consolidated financial statements of Synergy CHC Corp. as of December 31, 2020 and 2019 and for the years then ended, which appears in this Registration Statement on Form S-1.

 

/s/ RBSM LLP

New York, New York

October 21, 2021

 

 

 

 

Exhibit 99.1

 

Consent of Director Nominee

 

Synergy CHC Corp.

 

Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-1 (the “Registration Statement”) of Synergy CHC Corp. (the “Company”), the undersigned hereby consents to being named and described as a director nominee in the Registration Statement and any amendment or supplement to any prospectus included in such Registration Statement, any amendment to such Registration Statement or any subsequent Registration Statement filed pursuant to Rule 462(b) under the Securities Act and to the filing or attachment of this consent with such Registration Statement and any amendment or supplement thereto.

 

IN WITNESS WHEREOF, the undersigned has executed this consent as of July 28, 2021.

 

    /s/ Nitin Kaushal
  Name: Nitin Kaushal